



Effective Health Care Program

Comparative Effectiveness Review
Number 103

Migraine in Adults: Preventive Pharmacologic Treatments



Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

Migraine in Adults: Preventive Pharmacologic Treatments

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. 290-2007-10064-I

Prepared by:

Minnesota Evidence-based Practice Center
Minneapolis, MN

Investigators:

Tatyana A. Shamliyan, M.D., M.S.
Robert L. Kane, M.D.
Frederick R. Taylor, M.D.

This report is based on research conducted by the Minnesota Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10064-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact EffectiveHealthCare@ahrq.hhs.gov.

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.

Suggested citation: Shamliyan TA, Kane RL, Taylor FR. Migraine in Adults: Preventive Pharmacologic Treatments. Comparative Effectiveness Review No. 103. (Prepared by the University of Minnesota Evidence-based Practice Center under Contract No. 290-2007-10064-I) AHRQ Publication No. 13-EHC068-EF. Rockville, MD: Agency for Healthcare Research and Quality; April 2013. www.effectivehealthcare.ahrq.gov/reports/final.cfm.

Preface

The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of systematic reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. These reviews provide comprehensive, science-based information on common, costly medical conditions, and new health care technologies and strategies.

Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews can help clarify whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about AHRQ EPC systematic reviews, see www.effectivehealthcare.ahrq.gov/reference/purpose.cfm

AHRQ expects that these systematic reviews will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an email list to learn about new program products and opportunities for input.

We welcome comments on this systematic review. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to epc@ahrq.hhs.gov.

Carolyn M. Clancy, M.D.
Director
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.
Director, Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.
Director
Evidence-based Practice Program
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Suchitra Iyer, Ph.D.
Task Order Officer
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Acknowledgments

The authors gratefully acknowledge the following individuals for their contributions to this project. We would like to thank the librarians, Judy Stanke, M.A., and Delbert Reed, Ph.D., for their contributions to the literature search; Jae-Young Choi, M.H.P.A., Ph.D., Rema Ramakrishnan, M.P.H., Jennifer Biggs Miller, P.T., M.P.H., C.W.S., and Shi-Yi Wang, M.D., M.S., Ph.D. for their assistance with the literature search and data abstraction; Jeannine Ouellette for her help in writing the report; Marilyn Eells for editing and formatting the report; and Christa Prodzinski, R.N., and Kirsten Johnson B.S., for assistance with data entry, quality control, and formatting tables. We would like to thank Thomas Trikalinos, M.D., Ph.D., and Gerta Rücker, Ph.D., for their statistical advice in arcsine transformation of the data and Hwanhee Hong, Ph.D. candidate, for her help in conducting Bayesian network meta-analyses.

Key Informants

In designing the study questions, the EPC consulted several Key Informants who represent the end-users of research. The EPC sought the Key Informant input on the priority areas for research and synthesis. Key Informants are not involved in the analysis of the evidence or the writing of the report. Therefore, in the end, study questions, design, methodological approaches, and/or conclusions do not necessarily represent the views of individual Key Informants.

Key Informants must disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Because of their role as end-users, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any conflicts of interest.

The list of Key Informants who participated in developing this report follows:

Thomas Becker, M.D., M.B.A.
Medica Health Plans
Minnetonka, MN

Andrew D. Hershey, M.D., Ph.D.
University of Cincinnati College of Medicine
Cincinnati, OH

Roger K. Cady, M.D.
Headache Care Center
Springfield, MO

Brady Patrick-Lake, M.F.S.
Consumer representative
Erie, CO

Robert Dalton
National Headache Foundation
Chicago, IL

Alan M. Rapoport, M.D.
David Geffen School of Medicine, UCLA
Los Angeles, CA

Lida Etermad, Pharm.D., M.S.
United Healthcare
Edina, MN

Stephen D. Silberstein, M.D., FACP
Jefferson Headache Center
Philadelphia, PA

Technical Expert Panel

In designing the study questions and methodology at the outset of this report, the EPC consulted several technical and content experts. Broad expertise and perspectives were sought. Divergent and conflicted opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Therefore, in the end, study questions, design, methodologic approaches, and/or conclusions do not necessarily represent the views of individual technical and content experts.

Technical Experts must disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential conflicts of interest identified.

The list of Technical Experts who participated in developing this report follows:

Andrew Blumenfeld, M.D.
Kaiser Permanente
San Diego, CA

Alan M. Rapoport, M.D.
David Geffen School of Medicine, UCLA
Los Angeles, CA

Roger K. Cady, M.D.
Headache Care Center
Springfield, MO

Stephen D. Silberstein, M.D., FACP
Jefferson Headache Center
Philadelphia, PA

Andrew D. Hershey, M.D., Ph.D.
University of Cincinnati College of Medicine
Cincinnati, OH

Peer Reviewers

Prior to publication of the final evidence report, EPCs sought input from independent Peer Reviewers without financial conflicts of interest. However, the conclusions and synthesis of the scientific literature presented in this report does not necessarily represent the views of individual reviewers.

Peer Reviewers must disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential nonfinancial conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential nonfinancial conflicts of interest identified.

The list of Peer Reviewers follows:

Andrew Blumenfeld, M.D.
Kaiser Permanente
San Diego, CA

Rochelle Fu, Ph.D.
Oregon Evidence-based Practice Center
Portland, OR

Frederick Freitag, D.O., FAHS
Baylor Research Institute
Dallas, TX

Bray Patrick-Lake, M.F.S.
Consumer representative
Erie, CO

Structured Abstract

Objectives. To assess comparative effectiveness and safety of preventive pharmacologic treatments for community-dwelling adults with episodic or chronic migraine.

Data sources. We searched major electronic bibliographic databases and trial registries up to May 20, 2012.

Review methods. We performed a systematic review of published, English-language original studies of pharmacologic treatments for prevention of episodic or chronic migraine. Studies that compared drugs with inactive controls, nonpharmacologic interventions, or other drugs were eligible. Outcomes evaluated included rates of complete migraine cessation, ≥ 50 percent reduction in monthly migraine frequency, reduction in migraine-related disability, and improvement in quality of life. We calculated absolute risk differences, pooled them with random-effects models and with Bayesian network meta-analysis, and calculated numbers of outcome events attributable to treatments per 1,000 participants treated.

Results. Of 5,244 retrieved references, 245 publications of randomized controlled clinical trials (RCTs) and 76 publications of nonrandomized therapeutic studies met eligibility criteria. Most enrollees were middle-aged Caucasian women, with an average of five monthly migraine attacks. Few trials reported the proportion of obese subjects, but many subjects were overweight. More than half of the RCTs defined migraine according to the International Headache Society criteria. Studies excluded adults with severe medical or psychiatric illnesses or contraindications to examined drugs. Strength of evidence was mostly low due to risk of bias and imprecision in individual RCTs and pooled estimates.

For chronic migraine, botulinum toxin formulations were examined in 20 RCTs of 4,237 adults. Onabotulinumtoxin A was more effective than placebo in reducing monthly chronic migraine attacks by ≥ 50 percent (low-strength evidence from 3 RCTs of 459 adults) with inconsistent improvement in quality of life. Pooled analyses demonstrated that per 1,000 treated adults, 170 (95% confidence interval [CI], 82 to 258) would experience ≥ 50 percent reduction in migraine frequency, 155 (95% CI, 90 to 220) would experience adverse effects, and 26 (95% CI, 10 to 43) would discontinue treatments due to bothersome adverse effects. Topiramate reduced disability in patients with chronic migraine but failed to decrease monthly migraine frequency by ≥ 50 percent (low-strength evidence from one RCT of 328 adults). Individual RCTs examined the comparative effectiveness of onabotulinumtoxin A with topiramate or divalproex and found no differences in chronic migraine prevention. Propranolol combined with topiramate treatment demonstrated no benefits in nonresponders to topiramate monotherapy (low-strength evidence from one RCT of 191 adults).

For episodic migraine, RCTs examined 59 drugs from 14 drug classes. All approved drugs (topiramate, divalproex, timolol, and propranolol), some off-label beta blockers, ACE inhibitors, and the angiotensin II receptor antagonist candesartan were better than placebo in reducing episodic monthly migraine frequency by ≥ 50 percent. Drugs would result in clinical improvement in 200 to 400 patients per 1,000 treated. Adverse effects leading to treatment discontinuation were examined in 68 RCTs. Topiramate, off-label antiepileptics, and

antidepressants resulted in bothersome adverse effects leading to treatment discontinuation more often than placebo.

Limited direct evidence of comparative effectiveness from head-to-head RCTs demonstrated no consistent significant differences in outcomes with examined drugs in patients with episodic migraine. Exploratory indirect adjusted frequentist analysis offered low-strength evidence that the angiotensin II receptor blocker candesartan was more effective than approved drugs including topiramate, propranolol, timolol, and divalproex. Exploratory network Bayesian meta-analysis offered low-strength evidence that angiotensin inhibiting drugs (captopril, lisinopril, candesartan) were the most effective and tolerable for episodic migraine prevention in adults who have no contraindications to examined drugs.

Individual RCTs of drug-management interventions for episodic migraine offered low-strength evidence that compared with usual care, multidisciplinary team care improved quality of life and reduced migraine-related disability; a headache management program resulted in complete cessation of migraine; a minimal-contact cognitive-behavioral program improved patient satisfaction with treatments; headache school decreased overuse of drugs for acute headache attacks and reduced migraine disability; pharmaceutical care improved self-efficacy; and an intensive pharmaceutical care campaign had no statistically significant impact on use of acute drugs.

Conclusions. For chronic migraine, onabotulinumtoxin A reduced migraine attacks but increased the risk of adverse effects and treatment discontinuation due to adverse effects. For episodic migraine, approved drugs are effective but increase risk of adverse effects and treatment discontinuation due to adverse effects. Some off-label beta blockers and angiotensin inhibiting drugs are effective without bothersome harms and therefore offer the best benefits-to-harms ratio. We could not determine the long-term (i.e., trials of more than 3 months' duration), preventive benefits and adherence with drugs. Evidence on improving quality of life was inconsistent across individual drugs. Evidence for individualized treatment decisions is very limited. Future research should examine the role of patient characteristics on drug benefits and safety.

Contents

Executive Summary	ES-1
Introduction	1
Topic Refinement and Review Prototocol	2
Key Questions	2
Methods	4
Literature Search Strategy	4
Search Strategy	4
Inclusion Criteria	4
Exclusion Criteria	5
Study Selection	6
Data Extraction	6
Risk of Bias Assessment	6
Data Synthesis	7
Grading the Evidence for Each Key Question	9
Assessing Applicability	10
Peer Review and Public Commentary	10
Results	11
Publication Bias	12
Applicability	16
Risk of Bias	16
KQ 1. What are the efficacy and comparative effectiveness of pharmacologic treatments for preventing migraine attacks in adults?	21
KQ 1a. How do preventative pharmacologic treatments affect patient-centered and intermediate outcomes when compared with placebo or no active treatment?	21
Prevention of Chronic Migraine	28
Prevention of Episodic Migraine	29
KQ 1b. How do preventive pharmacologic treatments affect patient-centered and intermediate outcomes when compared with active pharmacologic treatments?	35
Indirect Evidence of Comparative Effectiveness of Preventive Drugs for Episodic Migraine	38
KQ 1c. How do preventive pharmacologic treatments affect patient-centered and intermediate outcomes when compared with active nonpharmacologic treatments?	47
KQ 1d. How do preventive pharmacologic treatments combined with nondrug treatments affect patient-centered and intermediate outcomes when compared with pharmacologic treatments alone?	47
KQ 1e1. How might dosing regimens or duration of treatments influence the effects of the treatments on patient-centered outcomes?	51
KQ 1e2. How might approaches to drug management (such as patient-care teams, integrated care, coordinated care, patient education, drug surveillance, or interactive drug monitoring) influence results?	54
KQ 2. What are the comparative harms from pharmacologic treatments for preventing migraine attacks in adults?	57
KQ 2a. What are the harms from preventive pharmacologic treatments when compared with placebo or no active treatment?	57

KQ 2b. What are the harms from preventive pharmacologic treatments when compared with active pharmacologic treatments?	62
Indirect Evidence of Comparative Safety of Drugs for Episodic Migraine Prevention in Adults	65
KQ 2c. How might approaches to drug management (such as patient-care teams, integrated care, coordinated care, patient education, drug surveillance, or interactive drug monitoring) influence results?	65
KQ 3. Which patient characteristics predict the effectiveness and safety of pharmacologic treatments for preventing migraine attacks in adults?.....	77
Discussion	81
Future Research Needs	83
Key Messages	84
Efficacy and Comparative Effectiveness of Pharmacologic Treatments for Preventing Migraine Attacks in Adults	84
References	91

Tables

Table A. Efficacy of migraine preventive pharmacological treatments, evidence from meta-analyzed randomized controlled clinical trials that compared active drugs with placebo.....	ES-10
Table B. Comparative effectiveness with migraine preventive drugs in adults, direct evidence from head-to-head randomized controlled clinical trials.....	ES-13
Table C. Treatment discontinuation due to adverse effects with migraine preventive drugs in adults, evidence from meta-analyzed randomized controlled clinical trials.....	ES-17
Table 1. Strength of evidence ranks and definitions.....	10
Table 2. Registration, publication, and cost of the NIH-funded grants aimed at migraine prevention (as of May 2012).....	13
Table 3. Years between the NIH-funded project end dates and the publication dates of the results.....	13
Table 4. Publication and posting of the results of migraine prevention studies registered in ClinicalTrials.gov.....	14
Table 5. Odds of publication and posting of results in ClinicalTrials.gov among all studies registered in ClinicalTrials.gov.....	15
Table 6. Total number randomized, weeks of followup, and loss of followup in randomized controlled clinical trials of migraine prevention in adults	17
Table 7. Reporting of patient baseline characteristics in randomized controlled clinical trials of migraine prevention drugs in adults.....	18
Table 8. Number of randomized controlled clinical trials of migraine prevention in adults that met risk of bias criteria.....	20
Table 9. 100 percent reduction in monthly migraine frequency with pharmacologic preventive treatments versus placebo in adults with episodic migraine, results from randomized controlled clinical trials	22
Table 10. Migraine prevention with approved pharmacologic preventive treatments versus placebo in adults, results from randomized controlled clinical trials (pooled with random effects models)	23

Table 11. Migraine prevention with pharmacologic treatments versus placebo in adults with episodic migraine (pooled with random effects model results from randomized controlled clinical trials)	25
Table 12. Migraine prevention (50% or more reduction) with off-label pharmacologic treatments versus placebo in adults with episodic migraine, results from individual randomized controlled clinical trials	26
Table 13. Comparative effectiveness of approved and off-label drugs on migraine prevention (50% or more reduction) in adults with episodic migraine, results from individual head-to-head randomized controlled clinical trials	40
Table 14. Comparative effectiveness of drugs for migraine prevention in adults with episodic migraine, direct evidence from head-to-head randomized controlled clinical trials (pooled with random effects model)	42
Table 15. Indirect adjusted comparative effectiveness of clinical response (defined as ≥ 50 percent reduction in monthly migraine frequency or self-reported substantial reduction in monthly migraine frequency) in RCTs of approved drugs for the prophylaxis of episodic migraine (odds ratios of each drug vs. placebo were compared with each other to calculate presented odds ratios with 95% CI)	43
Table 16. Indirect adjusted comparative effectiveness of clinical response (defined as ≥ 50 percent reduction in monthly migraine frequency or self reported substantial reduction in monthly migraine frequency) in RCTs of approved drugs versus off-label drugs for the prophylaxis of episodic migraine (odds ratios of each drug vs. placebo were compared with each other to calculate presented odds ratios with 95% CI)	44
Table 17. Odds ratio of clinical response (defined as ≥ 50 percent reduction in monthly episodic migraine frequency or self-reported substantial reduction in monthly migraine frequency) with preventive drugs, results from exploratory Bayesian network meta-analysis	45
Table 18. Comparative effectiveness of beta blockers combined with behavioral therapy (orientation +relaxation training; migraine warning signs and triggers; effectively using migraine medication, and reducing impact of migraines; stress management or biofeedback training; migraine management plan) for episodic migraine prevention in adults, results from individual low risk of bias randomized controlled clinical trial	49
Table 19. Comparative effectiveness of antidepressant amitriptyline and spinal manipulation for episodic migraine prevention in adults, individual medium risk of bias randomized controlled clinical trial	50
Table 20. Dose response reduction in migraine attacks by $\geq 50\%$ from baseline with topiramate in adults	53
Table 21. Prevention of migraine with drug management programs, results from individual randomized controlled clinical trials	56
Table 22. Treatment discontinuation due to adverse effects with migraine preventive drugs in adults, evidence from meta-analyzed randomized controlled clinical trials	66
Table 23. Adverse effect with onabotulinumtoxin A versus placebo for chronic migraine prevention in adults (magnitude of the effect and strength of evidence from randomized controlled clinical trials)	67

Table 24. Adverse effects with onabotulinumtoxin A versus placebo in adults with chronic migraine, meta-regression by study level factors (log of relative risk in randomized controlled clinical trials)	68
Table 25. Treatment discontinuation due to adverse effects with topiramate versus placebo in adults, pooled with random effects results from randomized controlled clinical trials	69
Table 26. Adverse effects with topiramate in adults with migraine, significant results from pooled analysis of randomized controlled clinical trials	70
Table 27. Treatment discontinuation due to bothersome adverse effects and adverse effects with divalproex versus placebo for episodic migraine prevention in adults, results from randomized controlled clinical trials	71
Table 28. Treatment discontinuation due to adverse effects with propranolol or timolol for episodic migraine prevention in adults, results from randomized controlled clinical trials	73
Table 29. Treatment discontinuation due to any adverse effects with topiramate versus other drugs for episodic migraine prevention in adults	74
Table 30. Comparative safety of beta blockers for episodic migraine prevention in adults, treatment discontinuation due to bothersome adverse effects in randomized controlled clinical trials	75
Table 31. Treatment adherence and discontinuation due to adverse effects with antidepressant amitriptyline and spinal manipulation for migraine prevention in adults, individual medium risk of bias randomized controlled clinical trial	76
Table 32. Future research needs	87

Figures

Figure A. Analytical framework	ES-4
Figure B. Bayesian network meta-analysis of clinical response to drugs versus placebo (66 RCTs of 14,774 adults) in randomized controlled clinical trials that aimed to prevent migraine in adults	ES-14
Figure C. Bayesian network meta-analysis of treatment discontinuation due to intolerable adverse effects with drugs versus placebo (47 RCTs of 3,054 adults) in randomized controlled clinical trials that aimed to prevent migraine in adults	ES-19
Figure 1. Analytical framework	5
Figure 2. Study flow	11
Figure 3. Bayesian network meta-analysis of clinical response to drugs versus placebo (66 RCTs of 14,774 adults) in randomized controlled clinical trials that aimed to prevent migraine in adults	46
Figure 4. Bayesian network meta-analysis of treatment discontinuation due to intolerable adverse effects with drugs versus placebo (47 RCTs of 3,054 adults) in randomized controlled clinical trials that aimed episodic migraine prevention in adults	77
Figure 5. Change from baseline in Migraine Specific Quality of Life	80

Appendixes

Appendix A. Literature Search
Appendix B. Analytical Framework
Appendix C. Excluded Studies
Appendix D. Evidence Tables

Executive Summary

Introduction

According to the International Classification of Headache Disorder, migraine is a common disabling primary headache disorder manifesting in attacks lasting 4 to 72 hours.^{1,2} Migraine headaches range from moderate to very severe³ and are sometimes debilitating.⁴ Episodic migraine affects 17 percent of women and 6 percent of men.⁵⁻⁸

Migraine frequency is divided into episodic and chronic.² Episodic migraine is characterized by <15 migraine days and chronic migraine by ≥ 15 headache days per month. Sometimes migraine may be described as chronic simply because the attacks recur over long periods of time. Chronic migraine affects 1.4 to 2.2 percent of adults.⁹ All migraine types significantly affect the physical, psychological, and social well-being of patients, and can impose serious lifestyle restrictions. Each year lost work time and diminished productivity from migraine costs American employers \$225.8 billion.¹⁰

Forty percent of adults with episodic migraine and all patients with chronic migraine might benefit from preventive medication; yet, only about 12 percent of adults with frequent migraines take preventive medication.⁵ Preventive medications from several drug classes are thought to affect various aspects of migraine pathophysiology.^{11,12} The U.S. Food and Drug Administration (FDA) has approved four drugs for *episodic* migraine prevention in adults: the beta blockers propranolol and timolol, and the antiepileptic drugs topiramate and divalproex sodium.¹³ For prevention of *chronic* migraine, the FDA has approved only one drug, onabotulinumtoxin A. Doctors also prescribe off-label drugs (approved for clinical conditions other than migraine prevention), including novel antiepileptic drugs, calcium channel blockers, serotonin and noradrenaline reuptake inhibitors, glutamate blockers, and drugs from several other classes.¹³

Preventive treatments aim to eliminate headache pain without intolerable harms. Often, however, some degree of pain persists; therefore, treatment success is usually defined by a decrease in migraine frequency of ≥ 50 percent.³ Preventive treatments are also expected to reduce use of acute drugs and improve quality of life.⁶ Treatment safety is defined by the total rates of adverse effects and adverse effects that lead to treatment discontinuation. Between 17 and 29 percent of patients discontinue preventive migraine medication because of adverse effects such as anxiety, nausea, vomiting, sleep time reduction, drowsiness, or weakness.^{14,15} Drug choices in clinical practice are based on many drug-related factors such as familiarity, efficacy, and adverse effects, as well as many patient characteristics such as headache frequency, presence of aura, comorbid conditions, and patient preference.

Indications for preventive treatments differ. The American Migraine Prevalence and Prevention expert advisory group recommends preventive treatment for those who experience two or more monthly headache attacks accompanied by disability, and for those who experience four or more monthly attacks with or without accompanying disability.¹⁶ Some guidelines recommend preventive treatments for patients who have five or more migraine attacks per month, but others suggest it only for those who experience a headache on most days of the month.^{17,18} Often, preventive treatment is recommended for only 6 to 9 months; however, very limited research has examined migraine frequency after discontinuation of preventive treatments.^{3,19}

Several gaps remain in the published literature on preventive treatments for migraines. Systematic reviews have focused on the efficacy of specific drugs rather than on the comparative effectiveness of all available pharmacologic and nonpharmacologic treatments.²⁰ Little attention

has been paid to the comparative effectiveness of off-label drugs to prevent migraine. Published reviews have not examined quality of life. Clinical reviews have compared the safety of only a few drugs.^{20,21}

Scope

Our review focuses on the comparative effectiveness and safety of the drugs for preventing migraine attacks in adults; our results can help inform treatment and policy recommendations. By the nature of the question, our review focuses on outpatient care.

During the topic refinement stage, we solicited input from Key Informants representing medical professional societies/clinicians in the areas of neurology, primary care, consumers, scientific experts, and payers, to help define the Key Questions (KQs).²² The KQs were then posted for public comment for 4 weeks, and the comments received were considered in the development of the research protocol. We next convened a Technical Expert Panel (TEP) comprising clinical, content, and methodological experts to provide input in defining populations, interventions, comparisons, and outcomes, and in identifying particular studies or databases to search. The Key Informants and members of the TEP were required to disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts. Any potential conflicts of interest were balanced or mitigated. Neither Key Informants nor members of the TEP performed analysis of any kind, nor did any of them contribute to the writing of this report. Members of the TEP were invited to provide feedback on an initial draft of the review protocol, which was then refined based on their input, reviewed by AHRQ, and posted for public access from April 12, 2012, to May 10, 2012, at the AHRQ Effective Health Care Web site.

We chose not to synthesize studies of the drug flunarizine, which is commonly used for adults in Europe, because the FDA has not approved it. Efficacy of nonpharmacologic preventive treatments was beyond our scope. We conducted a comprehensive literature review following the principles in the “Methods Guide for Effectiveness and Comparative Effectiveness Reviews” (hereafter the Methods Guide) developed by the Agency for Healthcare Research and Quality (AHRQ) Evidence-based Practice Center Program^{23,24} and PRISMA guidelines (protocol registration number is CRD42012001918, available at www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42012001918).

Key Questions

KQ 1

What are the efficacy and comparative effectiveness of pharmacologic treatments for preventing migraine attacks in adults?

- a. How do preventive pharmacologic treatments affect patient-centered and intermediate outcomes when compared with placebo or no active treatment?
- b. How do preventive pharmacologic treatments affect patient-centered and intermediate outcomes when compared with active pharmacologic treatments?
- c. How do preventive pharmacologic treatments affect patient-centered and intermediate outcomes when compared with active nonpharmacologic treatments?
- d. How do preventive pharmacologic treatments combined with nondrug treatments affect patient-centered and intermediate outcomes when compared with pharmacologic treatments alone?

- e. How might dosing regimens or duration of treatments influence the effects of the treatments on patient-centered outcomes? How might approaches to drug management (such as patient-care teams, integrated care, coordinated care, patient education, drug surveillance, or interactive drug monitoring) influence results?

KQ 2

What are the comparative harms from pharmacologic treatments for preventing migraine attacks in adults?

- a. What are the harms from preventive pharmacologic treatments when compared with placebo or no active treatment?
- b. What are the harms from preventive pharmacologic treatments when compared with active pharmacologic treatments?
- c. How might approaches to drug management (such as patient-care teams, integrated care, coordinated care, patient education, drug surveillance, or interactive drug monitoring) influence results?

KQ 3

Which patient characteristics predict the effectiveness and safety of pharmacologic treatments for preventing migraine attacks in adults?

Methods

We followed an a priori research protocol that we developed with the clinical and methodological input of a technical expert panel. The protocol followed the Effective Health Care Program's Methods Guide.

Literature Search Strategy

We searched several databases including MEDLINE[®] (via Ovid and PubMed[®]), the Cochrane Library, and the SCIRUS bibliographic database to find original studies published in English up to May 20, 2012. To search the grey literature, we accessed the FDA Web site to find medical and statistical reviews of the eligible drugs and we searched several trial registries to find ongoing, completed, and published trials of migraine prevention.

Eligibility

Three investigators independently determined study eligibility, resolving disagreements through discussions until consensus was achieved.²⁵ To assess the effectiveness of drugs, we analyzed all included RCTs. To assess adverse effects and treatment discontinuation due to adverse effects, we analyzed all included RCTs and nonrandomized studies.²⁶ We defined harms as the totality of all possible adverse consequences of an intervention.²⁷ We analyzed harms regardless of how authors perceived causality of treatments.

We determined eligibility according to the PICOTS (Population, Intervention, Comparator, Outcomes, Timing, and Settings) framework. We defined the target population as community-dwelling adults with episodic or chronic migraine. We formulated a list of eligible interventions after discussions with key informants and technical experts and after consideration of public comments. Eligible comparators included pharmacologic, nonpharmacologic, and combined


preventive treatments. We defined eligible intermediate and patient-centered outcomes (presented in the analytical framework, Figure A).

Eligible studies included patients with episodic migraine, chronic daily headache, or chronic migraine defined according to the criteria of the International Headache Society.¹⁷ We reviewed RCTs that included adults with migraine, comorbid headache disorders, or tension headache if they examined prevention of migraine. We excluded studies of treatments aimed at acute migraine attacks. We excluded studies that involved patients with other migraine variants, hospitalized patients, and patients in emergency rooms. We also excluded studies of short-term prevention of migraine, including menstrual migraines.

Data Extraction

Researchers used standardized forms to extract data (available at https://netfiles.umn.edu/xythoswfs/webui/_xy-21041343_1-t_zdhvSpvy). For each trial, one reviewer extracted the data and a second reviewer checked the abstracted data for accuracy. We assessed errors by comparing established ranges for each variable and data charts from the original articles. Any detected discrepancies were discussed.

Figure A. Analytical framework



KQ = Key Question; SES = socioeconomic status

KQ 1: What are the efficacy and comparative effectiveness of pharmacologic treatments for preventing migraine attacks in adults?

KQ 2: What are the comparative harms from pharmacologic treatments for preventing migraine attacks in adults?

KQ 3: Which patient characteristics predict the effectiveness and safety of pharmacologic treatments for preventing migraine attacks in adults?

We abstracted the information relevant to the PICOTS framework. We abstracted minimum datasets to reproduce the results presented by the authors. For categorical variables, we abstracted the number of events among treatment groups to calculate rates, relative risk, and absolute risk differences. We abstracted means and standard deviations of continuous variables to calculate mean differences with a 95% confidence interval (CI).

We abstracted the number randomized to each treatment group as the denominator to calculate estimates by applying intention-to-treat principles assuming that the same proportions apply in the missing data. We abstracted drug regimen and doses and patient characteristics including demographics, baseline frequency and severity, and prior treatment status as factors that can modify treatment effects. We abstracted sponsorship of the studies and conflict of interest by the authors. We incorporated risk of bias in individual studies into the synthesis of evidence by using individual risk of bias criteria rather than a global score or a ranking category of overall risk of bias.

Risk of Bias Assessment

We evaluated the risk of bias in individual studies for benefits and harms using the criteria from the Cochrane risk of bias tool.²⁸ We evaluated: (1) random allocation of the subjects to the treatment groups; (2) masking of the treatment status to the participants and investigators; (3) adequacy of allocation concealment; (4) adequacy of randomization as estimated based on similarity of the subjects in treatment groups by demographics and by frequency and severity of migraine; (5) use of planned and executed intention-to-treat principles; and (6) selective outcome reporting when compared with the protocols (when available) and methods sections in the articles. Since all outcomes in the review were self-reported, masking of outcome assessment was not essential.

We assumed a low risk of bias when RCTs met all of the risk of bias criteria, a medium risk of bias if at least one of the risk of bias criteria was not met, and a high risk of bias if two or more risk of bias criteria were not met. We concluded an unknown risk of bias for studies with poorly reported risk of bias criteria. We examined risk of bias in nonrandomized studies according to adjustment for confounding factors to address selection bias and exclusion of subjects from the analyses to address attrition biases. We evaluated disclosure of conflict of interest by the authors of individual studies and funding sources, but did not use this information to downgrade quality of individual studies.

Data Synthesis

We summarized the results into evidence tables. We focused on patient-centered outcomes, such as reduction in migraine attack rate of ≥ 50 percent from baseline, quality of life, patient satisfaction, and composite measures of response including frequency and severity of migraine.

We synthesized the evidence according to population characteristics that could modify treatment effect, including age, sex, race, and duration of migraine, baseline frequency and severity of acute migraine attacks, presence of aura, previous drug treatments, or history of drug overuse when reported in the original studies. When possible, based on the reporting in original studies, we conducted subgroup and sensitivity analyses according to patient characteristics, drug dose, and timing of followup.

We examined whether the definition of migraine could contribute to differences in trial results. The FDA approved four drugs for prevention of episodic migraine based on trials conducted prior to the recent implementation of the migraine definition proposed by the

International Headache Society.¹⁷ Thus, eligible studies published before 2004 defined classic or common migraine as per previous definitions from the International Headache Society or the Ad Hoc Committee on Classification of Headache.²⁹ We compared baseline patient characteristics and treatment effects depending on the exact migraine definition and report the results when they are significantly different.

Using Meta-Analyst and STATA[®] software, we calculated the relative risk and absolute risk difference from the abstracted events and the mean differences in continuous variables from the reported means and standard deviations. We evaluated statistical significance at a 95 percent confidence level. We used default software continuity coefficients for 0 events and intention to treat as recommended calculations for missing data. We hypothesized superiority of drugs versus placebo and versus each other.

For pooling results from studies addressing KQs 1 and 2, we required that studies included the same active drug treatments and comparators and the same definitions of the outcomes. Cohen standardized mean differences were calculated for different continuous measures of the same outcome. For sparse adverse effects data, we used multiple models to test robustness of inferential statistics.

We tested consistency in the results by comparing the direction and strength of the association and assessed heterogeneity in results with chi-squared and I-squared tests. We explored heterogeneity with meta-regression and sensitivity analysis, reporting only the results from random effects models. We used the random effects model to incorporate into the pooled analysis any differences between trials in patient populations, baseline rates of the outcomes, dosage of drugs, and other factors. We explored heterogeneity by risk of bias criteria, disclosed conflicts of interest, study sponsorship, dose and duration of drug treatments, time of followup, inclusion of minorities, proportion of women and elderly adults, and other patient characteristics described above. To avoid ecological fallacy, we did not use patient-level variables (for example, mean age or body mass index) in meta-regression.

We calculated the number needed to treat to achieve one event of a patient-centered outcome as reciprocal to absolute risk differences (ARD) in rates of outcome events in the active and control groups. We calculated means and 95% CIs for the number needed to treat as reciprocal to pooled ARD when the ARD was significant. The number of avoided or excessive events per population of 1,000 is the difference between the two event rates multiplied by 1,000.

In cases when very few studies were available to provide evidence from direct head-to-head comparisons, we conducted indirect comparisons. To do so, we used statistical techniques to estimate the treatment effects from studies of each given treatment against controls under an assumption of consistency.

- We used adjusted indirect frequentist comparisons for individual drugs that were compared with placebo. This analysis provided pair-wise triangular comparisons for drugs that were compared against placebo rather than network meta-analysis.
- To address the problems with inevitable differences across studies, we used mixed (or multiple) treatment comparisons (MTCs), or so-called Bayesian network meta-analysis. We calculated Bayesian odds ratios with 2.5 to 97.5 percent credible intervals and Bayesian network random effects meta-analysis assuming heterogeneous variances across treatments. We synthesized evidence from drug classes in network meta-analysis when individual drugs from the same class demonstrated no significant differences in outcomes. We concluded no differences in drug effect (hereafter called similar effects) if confidence or credible intervals included one (no effect or no difference). All Bayesian

results were obtained from the WinBUGS software using Markov chain Monte Carlo (MCMC) samples after a 50,000-sample algorithm burn-in.

Grading the Evidence for Each KQ

We assessed strength of evidence according to risk of bias, consistency, directness, and precision for each patient-centered outcome, which included 100 percent or ≥ 50 percent reduction in monthly migraine frequency, patient global assessment of treatment success, rates of clinically important improvement in migraine-related disability and quality of life.³⁰ We also assessed treatment discontinuation due to harms. We based our criteria on published guidelines acknowledging inevitable subjectivity of the assessment. We assigned a medium or high risk of bias in the body of evidence when at least one individual RCT had medium or high risk of bias, respectively. We defined treatment effect estimates as precise when pooled estimates had reasonably narrow 95% CIs, and the pooled sample had ≥ 300 events (using 25% relative effect difference for calculation of optimal information size).³¹ We did not include justification of the sample size into grading of the evidence nor did we conduct post hoc statistical power analysis.

As part of our strength of evidence assessment we looked at dose-response association, strength of association, and reporting bias in nonrandomized studies. We evaluated the strength of the association, defining a priori a large effect when relative risk was >2 and a very large effect when relative risk was >5 .²⁵ We defined low magnitude of the effect when relative risk was significant but <2 .

We defined reporting bias as publication bias, selective outcomes reporting, and multiple publication bias. We did not perform formal statistical tests quantifying reporting biases due to the questionable statistical validity of the available tests.

We defined a high level of evidence on the basis of consistent findings from low risk of bias RCTs. We downgraded strength of evidence to moderate if at least one of the four strength-of-evidence criteria was not met (e.g., the studies had medium risk of bias or the results were inconsistent or imprecise). We downgraded strength of evidence to low if two or more criteria were not met. We assigned a low level of evidence to nonrandomized studies but upgraded strength of evidence for strong or dose response associations. We defined evidence as insufficient if treatment effects or associations were examined by a single study with unclear or high risk of bias. We applied this approach regardless of statistical significance of the results.

Assessing Applicability

We estimated applicability of the population by evaluating baseline subject characteristics in observational studies and clinical trials.³²

Results

Of 5,244 identified references, we included 245 references of RCTs and 76 references of nonrandomized studies (detailed information about the results with references is available in the main body of the full report and in the evidence tables in Appendix D). Most trials were funded by industry but did not disclose conflict of interest by study investigators. Proportions of industry sponsorship and disclosed conflict of interest varied among examined drugs.

More than half of the RCTs had medium risk of bias. Proportions of low risk of bias RCTs varied among examined drugs. Most RCTs (86 percent) were double blind. We concluded unclear adequacy of allocation concealment in 94 percent of RCTs and unclear adequacy of

randomization in 51 percent of RCTs. Planned intention to treat was reported in 24 percent of RCTs.

The results were applicable to the target population. Most RCTs were conducted in the United States and Western countries, used the International Headache Society's definition, and enrolled mostly middle age women with episodic migraine suffering from an average of five monthly migraine attacks. RCTs enrolled on average 210 adults, measured the outcomes at 2 to 3 months of followup, and reported about 14 percent loss of followup (attrition rate).

Studies enrolled mostly adults (average age was 38 years) and adolescents. Few trials reported a proportion of obese subjects, but many participants were overweight according to the average body mass index. Most trials included patients with and without aura. Almost half of the enrolled subjects were naïve to migraine preventive drugs. Patient age and baseline migraine characteristics were similar in most trials. Substantial variability in reporting comorbidities prevented us from using this information in quantitative synthesis of evidence. Most trials, however, excluded patients with severe medical comorbidities or psychiatric illnesses, stroke, and vascular migraine. RCTs rarely reported important patient characteristics that could modify drug effects, including family history of migraine, socioeconomic status, or response to prior preventive treatments.

KQ 1. What are the efficacy and comparative effectiveness of pharmacological treatments for preventing migraine attacks in adults?

The 245 eligible references presented the results from RCTs. RCTs examined four approved drugs for episodic migraine (topiramate, divalproex, propranolol, and timolol), one approved drug for chronic migraine (onabotulinumtoxin A), and various off-label preventive drugs. Most trials examined a monotherapy with one active agent compared with placebo or another drug. RCTs rarely reported specifics of concomitant treatments such as exact drugs and doses. However, most trials disallowed concomitant drugs during the run-in period and after randomization, thus implying no concomitant treatments were used in the RCTs. Strength of evidence was low due to medium or high risk of bias and imprecise estimates from individual or meta-analyzed RCTs (Tables A–B). This executive summary focuses on pooled analyses from RCTs and the results from network meta-analysis. All results can be found in the main body of the full report.

KQ1a. How do preventive pharmacologic treatments affect patient-centered and intermediate outcomes when compared with placebo or no active treatment?

Prevention of Chronic Migraine

Only one drug for chronic migraine, Onabotulinumtoxin A, was examined in more than one RCT. Onabotulinumtoxin A was better than placebo in reducing monthly migraine attack by ≥ 50 percent in patients with baseline ≥ 15 migraine days per month (Table A). Low-strength evidence from individual RCTs suggested a dose-responsive increase in migraine prevention with higher doses of onabotulinumtoxin A.

A single RCT reported that topiramate was better than placebo in achieving: (1) reduction of monthly migraine days from baseline; (2) 25 percent reduction in monthly migraine attacks, and (3) frequency of associated symptoms. Topiramate was not, however, better than placebo in

reducing monthly migraine attacks by ≥ 50 percent. The other individual RCT reported that propranolol added to topiramate did not effectively prevent chronic migraine in patients for whom topiramate monotherapy had failed.

Prevention of Episodic Migraine

All approved drugs were better than placebo in reducing monthly migraine frequency by ≥ 50 percent in patients with baseline < 15 migraine days per month (clinical response) (Table A). Drugs would achieve a clinical response preventing half or more migraine attacks in 200 to 400 patients per 1,000 treated. Clinicians need to treat three to five patients with episodic migraine to prevent half or more migraine attacks in one patient. Low-strength evidence from individual RCTs suggested a dose-responsive increase in migraine prevention with higher doses of topiramate (from 50 to 100 mg/day with no additional benefits with 200 mg/day).

In addition to ≥ 50 percent reduction in monthly migraine frequency, individual RCTs of approved antiepileptic drugs and beta blockers improved other patient-centered outcomes. Topiramate demonstrated significant improvements for general health status, quality of life, and disability, with score improvements on the Medical Outcome Study Short Form 36 (SF-36) of more than 200 percent for self-reported vitality and more than 100 percent for improvement in pain and general health. Divalproex in a larger dose of 1,500 mg/day increased the likelihood of a 50 percent improvement in whether migraine attacks impaired usual activities or necessitated symptomatic medication and in reducing migraine attacks with nausea, vomiting, phonophobia, or photophobia. Topiramate and propranolol decreased use of drugs for acute migraine attacks.

Among *off-label drugs*, pooled analyses demonstrated that antiepileptic gabapentin, beta-blockers metoprolol, and calcium channel blocker nimodipine were better than placebo in reducing monthly migraine attacks by ≥ 50 percent (Table A).

Table A. Efficacy of migraine preventive pharmacological treatments, evidence from meta-analyzed randomized controlled clinical trials that compared active drugs with placebo

Active Preventive Treatment	Outcome	Sample	Rate, Percent With Drug [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed To Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Strength of Evidence (Reasons for Lowering SOE)
Onabotulinumtoxin A for chronic migraine	≥50% decrease in migraine frequency	459	50.6 [34.4]	1.5 (1.2 to 1.8)	0.17 (0.08 to 0.26)	6 (4 to 12)	170 (82 to 258)	Low (medium ROB, imprecision)
Topiramate 50 to 200mg/day for episodic migraine	100% decrease in migraine frequency	1,299	5.1 [2.6]	1.9 (1.0 to 3.4)	0.02 (-0.01 to 0.05)	NS	NS	Low (medium ROB, inconsistency, imprecision)
Topiramate for episodic migraine	≥75% reduction in monthly migraine days	1,086	22.3 [11.0]	1.9 (1.1 to 3.1)	0.10 (-0.01 to 0.20)	NS	NS	Moderate (imprecision)
Topiramate 50 to 200mg for episodic migraine	≥50% reduction in monthly migraine days	1,145	42.2 [23.3]	1.7 (1.0 to 2.9)	0.18 (0.08 to 0.28)	6 (4 to 13)	179 (75 to 284)	Moderate (imprecision)
Topiramate 50 to 200mg/day for episodic migraine	≥50% reduction in monthly migraine frequency	1,422	49.6 [25.1]	2.0 (1.5 to 2.7)	0.29 (0.18 to 0.40)	3 (3 to 6)	288 (176 to 400)	Moderate (medium ROB)
Divalproex for episodic migraine	≥50% decrease in migraine frequency	405	43.0 [23.3]	2.2 (1.1 to 4.2)	0.24 (0.10 to 0.38)	4 (3 to 10)	241 (97 to 384)	Low (medium ROB, imprecision)
Propranolol for episodic migraine	≥50% decrease in migraine frequency	541	45.1 [22.3]	2.0 (1.5 to 2.7)	0.22 (0.14 to 0.30)	4 (3 to 7)	223 (142 to 304)	Low (medium ROB, imprecision)
Timolol for episodic migraine	≥50% decrease in migraine frequency	276	49.4 [23.3]	2.1 (1.5 to 3.1)	0.27 (0.15 to 0.38)	4 (3 to 6)	265 (154 to 377)	Low (medium ROB, imprecision)
Gabapentin for episodic migraine	≥50% decrease in migraine frequency	270	45.9 [31.0]	1.5 (1.1 to 2.0)	0.17 (0.06 to 0.27)	6 (4 to 16)	165 (61 to 269)	Low (medium ROB, imprecision)

Table A. Efficacy of migraine preventive pharmacological treatments, evidence from meta-analyzed randomized controlled clinical trials that compared active drugs with placebo (continued)

Active Preventive Treatment	Outcome	Sample	Rate, Percent With Drug [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Strength of Evidence (Reasons for Lowering SOE)
Metoprolol for episodic migraine	≥50% decrease in migraine frequency	225	39.9 [19.4]	2.0 (1.3 to 3.2)	0.20 (0.09 to 0.3)	5 (3 to 11)	204 (88 to 321)	Low (medium ROB, imprecision)
Nimodipine for episodic migraine	≥50% decrease in migraine frequency	126	28.6 [6.3]	4.5 (0.5 to 40.1)	0.23 (0.06 to 0.39)	4 (3 to 16)	229 (64 to 394)	Low (medium ROB, imprecision)
Magnesium for episodic migraine	≥50% decrease in migraine frequency	137	33.8 [25.8]	1.3 (0.7 to 2.3)	0.08 (-0.09 to 0.26)	NS	NS	Low (inconsistency, imprecision)

CI = confidence interval; NS = Not significant; ROB = risk of bias; SOE = strength of evidence

Bold = significant effects of drugs on treatment response when 95% CI of attributable events per 1,000 treated do not include 0. Number needed to treat and number of attributable events were calculated for statistically significant differences.

Individual RCTs demonstrated that in patients with episodic migraine suffering from an average of five migraine attacks per month the off-label anti-epileptics carbamazepin and valproate (but not acetazolamide, lamotrigine, or oxcarbazepine) were better than placebo in reducing monthly migraine attacks by ≥ 50 percent. Individual RCTs demonstrated that off-label beta blockers acebutolol atenolol and nadolol (but not pindolol or alprenolol) were better than placebo in reducing monthly migraine attacks by ≥ 50 percent.

Individual RCTs of angiotensin inhibiting drugs demonstrated promising results. The angiotensin converting enzyme inhibitor captopril was examined in a single RCT. When tested in adults with comorbid hypertension and depressive symptoms for whom previous antimigraine drugs had been ineffective, the ACE inhibitor captopril was better than placebo in achieving complete cessation of migraine and improvement in headache index by ≥ 50 percent and in reducing depression symptoms. The ACE inhibitor lisinopril was better than placebo in reducing migraine days and migraine severity in patients with episodic migraine with or without hypertension. It reduced pain measured with SF-36, but did not decrease use of drugs for acute migraine attacks.

The angiotensin II antagonist candesartan was better than placebo in achieving a clinical response defined as ≥ 50 percent reduction in migraine days, hours, and severity. Candesartan also decreased migraine-related disability, but it had no effect on use of drugs for acute migraine attacks. In contrast, angiotensin II antagonist telmisartan was not better than placebo in reducing monthly migraine attacks by ≥ 50 percent.

KQ1b. How do preventive pharmacologic treatments affect patient-centered and intermediate outcomes when compared with active pharmacologic treatments?

Pooled analysis was possible only for four paired drug comparisons (Table B). Most low-strength direct comparative effectiveness evidence came from individual head-to-head RCTs that demonstrated few significant differences between individual drugs.

Comparative Effectiveness of Onabotulinumtoxin A on Prevention of Chronic Migraine

Five individual RCTs provided low-strength evidence about the comparative effectiveness of onabotulinumtoxin A versus other drugs for chronic migraine prevention in 350 adults ages 18 to 65 with 12 to 24 monthly migraine days. Individual RCTs examined the comparative effectiveness of onabotulinumtoxin A versus topiramate and found no significant differences in likelihood of migraine prevention or improvement in migraine disability assessment. Absolute scores of the Headache Impact Test were significantly better with topiramate than onabotulinumtoxin A; however, need for acute drugs did not differ between the two. A single RCT examined the comparative effectiveness of onabotulinumtoxin A versus divalproex sodium and found no differences between the two drugs for migraine prevention, migraine-related disability, or quality of life.

Table B. Comparative effectiveness with migraine preventive drugs in adults, direct evidence from head-to-head randomized controlled clinical trials

Active Preventive Treatment	Outcome	Sample	Rate, Percent With Active [Control] Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed To Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Strength of Evidence (Reasons for Lowering SOE)
Timolol vs. propranolol	≥50% decrease in migraine frequency	242	47.9 [52.1]	1.0 (0.7 to 1.2)	-0.03 (-0.15 to 0.10)	NS	NS	Low (medium ROB, imprecision)
Propranolol vs. metoprolol	≥50% decrease in migraine frequency	113	38.2 [50.0]	0.8 (0.5 to 1.2)	-0.12 (-0.30 to 0.06)	NS	NS	Low (medium ROB, imprecision)
Propranolol vs. Nifedipine	≥50% decrease in migraine frequency	76	46.2 [18.9]	2.3 (1.1 to 4.6)	0.27 (0.09 to 0.46)	4 (2 to 11)	274 (89 to 458)	Low (high ROB, imprecision)
Metoprolol vs. Aspirin	≥50% decrease in migraine frequency	326	33.1 [39.3]	1.6 (0.2 to 11.0)	0.11 (-0.43 to 0.65)	NS	NS	Low (medium ROB, imprecision)


CI = confidence interval; NS = not significant; ROB = risk of bias; SOE = strength of evidence

Bold = significant effects of drugs on treatment response when 95% CI of attributable events per 1,000 treated do not include 0. Number needed to treat and number of attributable events were calculated for statistically significant differences. Line 3 is in bold.

Comparative Effectiveness of Approved Drugs on Prevention of Episodic Migraine

Pooled analyses demonstrated that decrease in headache frequency by ≥ 50 percent did not differ with propranolol versus timolol or versus metoprolol (Table B). Propranolol was better than nifedipine in reducing monthly headache intensity by ≥ 50 percent. Indirect adjusted analysis demonstrated no differences among approved drugs in reducing monthly headache frequency by ≥ 50 percent. Exploratory network Bayesian meta-analyses demonstrated that approved drugs were similarly better than placebo. Among off-label drug classes, angiotensin inhibiting drugs demonstrated the largest significant odds of reducing monthly migraine by ≥ 50 percent (Figure B).

Figure B. Bayesian network meta-analysis of clinical response to drugs versus placebo (66 RCTs of 14,774 adults) in randomized controlled clinical trials that aimed to prevent migraine in adults



CrI = credible intervals; NSAID = nonsteroidal anti-inflammatory drugs

Clinical response was defined as $\geq 50\%$ reduction in monthly migraine attacks or perceived clinically important treatment success. We used heterogeneous random effects model that assumes correlation within study ($\rho = 0.5$) and heterogeneous between studies (WinBUG codes are in Appendix B).

KQ1c. How do preventive pharmacologic treatments affect patient-centered and intermediate outcomes when compared with active nonpharmacologic treatments?

One RCT provided low-strength evidence that the likelihood of reducing monthly migraine frequency by ≥ 25 percent did not differ between propranolol and an intervention consisting of diaphragmatic breathing and systematic relaxation assisted by biofeedback and practiced at home. One RCT provided low-strength evidence that the likelihood of reducing monthly migraine frequency by ≥ 50 percent did not differ between exercising for 40 minutes three times a week, relaxation technique, or daily topiramate use.

KQ1d. How do preventive pharmacological treatments combined with nondrug treatments affect patient-centered and intermediate outcomes when compared with pharmacologic treatments alone?

Individual RCTs did not provide sufficient evidence to conclude whether combined therapy was more effective than drugs alone.

KQe1. How might dosing regimens or duration of treatments influence the effects of the treatments on patient-centered outcomes?

Individual RCTs provided low-strength evidence that increasing the dose of onabotulinumtoxin A, topiramate, venlafaxine, pindolol, nadolol, and bisoprolol resulted in a higher response rate. In contrast, higher doses of divalproex, amitriptyline, or propranolol did not result in greater likelihood of clinically important reduction in migraine frequency.

KQe2. How might approaches to drug management (such as patient-care teams, integrated care, coordinated care, patient education, drug surveillance, or interactive drug monitoring) influence results?

Six individual RCTs examined effectiveness of drug management for migraine prevention in 3,825 adults. Four RCTs examined the effectiveness of a multidisciplinary migraine management program compared with usual care. The trials offered low-strength evidence that multidisciplinary team care improved quality of life and reduced migraine-related disability; a headache management program resulted in complete cessation of migraine; a minimal-contact cognitive-behavioral program improved patient satisfaction with treatments; headache school decreased overuse of drugs for acute headache attacks and reduced migraine disability.

Two RCTs examined the effectiveness of pharmacist-led drug management. The studies provided low-strength evidence that pharmaceutical care improved self-efficacy; an intensive pharmaceutical care campaign had no statistically significant impact on use of acute drugs.

KQ 2. What are the comparative harms from pharmacologic treatments for preventing migraine attacks in adults?

We identified 15 RCTs and six nonrandomized studies that examined the safety of onabotulinumtoxin A for chronic migraine prevention in adults. We identified 159 RCTs of 18,134 adults that examined the safety of drugs for episodic migraine prevention in adults. We concluded that the results of these trials, which were a subset of RCTs that examined benefits

with drugs for episodic migraine prevention in adults, are applicable to the target population. The trials enrolled an average of 78 percent women. Mean age of the enrollees varied from 29 to 49 years. Patients had an average 5.5 monthly migraine attacks. On average, followup time for assessing adverse effects was 18 weeks. The sample size averaged 116 adults (range 12 to 818).

RCTs reporting harms were not necessarily powered to detect statistically significant differences in adverse effects. We concluded medium risk of bias in 104 RCTs and low risk of bias in 36 RCTs. Most studies (133 RCTs) were double blind. We focused on treatment discontinuation due to any and specific adverse effects from pooled analyses.

KQ2a. What are the harms from preventive pharmacologic treatments when compared with placebo or no active treatment?

Adverse Effects With Drugs for Chronic Migraine

Onabotulinumtoxin A resulted in adverse effects and treatment discontinuation due to adverse effects more often than placebo (Table C). Increase in risk of adverse effects was dose responsive. Increasing doses of onabotulinumtoxin A to 150 to 225U resulted in greater risk of blepharoptosis, muscle weakness, and neck rigidity. Among specific adverse effects, onabotulinumtoxin A increased risk of back or neck pain, dysphagia, hypertonia, blepharoptosis, and muscle weakness.

Adverse Effects With Drugs for Episodic Migraine

Bothersome adverse effects leading to treatment discontinuation were examined in 68 RCTs.

Topiramate in doses of 100 and 200 mg/day (but not 50 mg/day) resulted in treatment discontinuation due to adverse effects more often than placebo (Table C). Published pooled analysis of individual patient data demonstrated discontinuation of topiramate treatment due to anorexia, anxiety, depression, and hypesthesia. Larger doses of topiramate caused higher risk of anorexia, depression, paresthesia, and difficulty in memory leading to treatment withdrawal. Larger doses of topiramate caused higher risk of dry mouth, paresthesia or fatigue, mood problems, nausea, and weight loss.

In comparisons of divalproex or valproate versus placebo, treatment discontinuation due to any adverse effects did not differ. However, individual RCTs reported that divalproex caused nausea, somnolence, tremor, vomiting, and asthenia, leading to treatment discontinuation.

Propranolol caused bothersome adverse effects leading to treatment discontinuation more often than placebo (Table C). Among specific adverse effects, propranolol increased risk of diarrhea and nausea. Timolol increased risk of any adverse effects but not bothersome harms that led to treatment discontinuation.

Among off-label drugs, pooled analyses demonstrated that the off-label antidepressant amitriptyline caused bothersome adverse effects leading to treatment discontinuation more often than placebo (Table C).

Table C. Treatment discontinuation due to adverse effects with migraine preventive drugs in adults, evidence from meta-analyzed randomized controlled clinical trials

Active Preventive Treatment	Sample	Rate, Percent With Active Drug [Control]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed To Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Strength of Evidence (Reasons for Lowering SOE)
<i>Compared With Placebo</i>							
Onabotulinumtoxin A	1,384	3.8 [1.1]	3.2 (1.4 to 7.1)	0.03 (0.01 to 0.04)	38 (23 to 100)	26 (10 to 43)	Moderate (medium ROB)
Topiramate	2,055	16.6 [8.5]	1.8 (1.3 to 2.4)	0.06 (0.02 to 0.11)	16 (9 to 53)	63 (19 to 107)	Low (medium ROB, imprecise)
Divalproex	346	9.8 [7.8]	1.2 (0.5 to 2.7)	0.02 (-0.05 to 0.10)	NS	NS	Low (medium ROB, imprecise, inconsistent)
Valproate	150	6.7 [5.3]	1.3 (0.3 to 4.9)	0.01 (-0.07 to 0.08)	NS	NS	Low (medium ROB, imprecise)
Propranolol	221	13.2 [5.6]	2.1 (0.6 to 7.7)	0.06 (0.00 to 0.12)	16 (8 to 333)	62 (3 to 120)	Low (medium ROB, imprecise, inconsistent)
Gabapentin	270	17.0 [7.7]	1.9 (0.9 to 4.2)	0.07 (-0.01 to 0.15)	NS	NS	Low (medium ROB, imprecise)
Lamotrigine	178	12.8 [6.0]	2.4 (0.5 to 12.2)	0.14 (-0.17 to 0.44)	NS	NS	Low (imprecise, inconsistent)
Amitriptyline	507	11.2 [5.8]	1.9 (1.0 to 3.5)	0.05 (0.01 to 0.10)	19 (10 to 167)	54 (6 to 102)	Low (medium ROB, imprecise)
Femoxetine	124	11.7 [6.3]	1.9 (0.6 to 6.1)	0.05 (-0.05 to 0.15)	NS	NS	Low (medium ROB, imprecise)
Clonidine	334	2.4 [0.6]	2.8 (0.4 to 18.5)	0.02 (-0.01 to 0.05)	NS	NS	Low (medium ROB, imprecise)
Nimodipine	155	3.9 [6.3]	0.7 (0.2 to 2.6)	-0.03 (-0.09 to 0.04)	NS	NS	Low (medium ROB, imprecise, inconsistent)
Naproxen	172	3.5 [1.2]	2.3 (0.3 to 15.4)	0.02 (-0.03 to 0.07)	NS	NS	Low (high ROB, imprecise, inconsistent)
Magnesium	150	7.7 [1.4]	3.8 (0.7 to 22.4)	0.06 (0.00 to 0.13)	NS	NS	Low (inconsistent, imprecise)
<i>Compared With Active Treatment</i>							
Topiramate vs. amitriptyline	399	18.3 [21.3]	0.9 (0.6 to 1.3)	-0.04 (-0.11 to 0.04)	NS	NS	Low (medium ROB, imprecision)

CI = confidence interval; NS= not significant; ROB = risk of bias; SOE = strength of evidence

Bold = significant effects of drugs on treatment response and discontinuation due to adverse effects when 95% CI of attributable events per 1,000 treated do not include 0. Number needed to treat and number of attributable events were calculated for statistically significant differences. Lines 1, 2, 5, and 8 are in bold.

KQ2b. What are the harms from preventive pharmacologic treatments when compared with active pharmacologic treatments?

Comparative Harms With Drugs for Prevention of Chronic Migraine

Individual RCTs demonstrated less frequent treatment discontinuation due to adverse effects with onabotulinumtoxin A than topiramate or amitriptyline. Onabotulinumtoxin A versus divalproex sodium resulted in a higher risk of ptosis.

Comparative Harms With Drugs for Prevention of Episodic Migraine


Pooled analysis showed no differences in treatment discontinuation with topiramate versus amitriptyline (Table C). Individual unique RCTs provided low-strength direct evidence about adverse effects with specific drugs. We observed no consistent pattern across available drug comparisons.

Indirect adjusted analyses demonstrated no differences in treatment discontinuation due to adverse effects with approved drugs or approved versus off-label drugs. Exploratory Bayesian network meta-analyses demonstrated that topiramate and off-label antiepileptics and antidepressants resulted in bothersome adverse effects leading to treatment discontinuation more often than placebo (Figure C). According to network meta-analysis, off-label angiotensin inhibiting drugs and beta-blockers were the safest treatment option for adults with episodic migraine.

KQ2c. How might approaches to drug management (such as patient-care teams, integrated care, coordinated care, patient education, drug surveillance, or interactive drug monitoring) influence results?

We found no studies that examined adverse effects with drug management interventions.

Figure C. Bayesian network meta-analysis of treatment discontinuation due to intolerable adverse effects with drugs versus placebo (47 RCTs of 3,054 adults) in randomized controlled clinical trials that aimed to prevent migraine in adults



CrI = credible intervals; NSAID = nonsteroidal anti-inflammatory drugs; RCT = randomized controlled trial

KQ 3. Which patient characteristics predict the effectiveness and safety of pharmacological treatments for preventing migraine attacks in adults?

Evidence was limited to individual RCTs that examined the drug effect modification by selected patient characteristics.

Baseline Migraine Frequency

Onabotulinumtoxin A was more effective in patients with a higher mean baseline migraine frequency according to a single RCT from the BOTULINUM TOXIN North American Episodic Migraine Study Group. Onabotulinumtoxin A decreased the likelihood of acute drug use in patients with a baseline of more than 12 monthly migraine days (RR 0.78, 95% CI, 0.66 to 0.92).

Amitriptyline was better than placebo in reducing monthly migraine, but only in patients with depression or with baseline frequent and severe migraine. A higher dose of amitriptyline increased the odds of reducing monthly migraine by ≥ 50 percent, and the response increased in

association with increased baseline migraine days (odds ratio 2.4, 95% CI, 1.45 to 3.8 for every additional day of migraine at baseline).

Concurrent Prophylactic Medication Use

Onabotulinumtoxin A more often than placebo led to adverse effects, blepharoptosis, muscle weakness, and neck pain, regardless of concurrent prophylactic medication use, according to the BOTULINUM TOXIN CDH Study Group.

Sex

Topiramate caused a complete cessation of migraine attacks in women but not in men according to one low-risk-of-bias RCT. Per 1,000 women treated, topiramate would cause a complete cessation of migraine attacks in 37 (95% CI, 8 to 67) and a reduction of monthly migraine attacks by ≥ 50 percent in 249 (95% CI, 178 to 320). However, both men and women experienced a reduction of monthly migraine 75 to 90 percent more often with topiramate than with placebo.

Prior Medication Use

One RCT that examined adding propranolol to topiramate for subjects who had chronic migraine and for whom previous topiramate monotherapy failed. The study separated subgroups by prior topiramate use or overuse of the drugs for acute migraine. Propranolol with topiramate was not better than topiramate alone in reducing migraine frequency, regardless of the prior drug history of the patients. Changes in quality of life score (from baseline) varied depending on prior topiramate use. Patients with prior stable topiramate use experienced worsening in quality of life with combined therapy versus improvement in quality of life with topiramate monotherapy. In contrast, patients without stable prior topiramate use experienced improvement in quality of life with combined therapy versus statistically insignificant changes with topiramate monotherapy.

Presence of Aura

No trials directly compared drug effects in patients with and without aura. Several post hoc subgroup analyses of topiramate versus placebo provided inconsistent evidence of the drug efficacy in respect to aura. Two publications suggested that topiramate was better than placebo in patients with aura. Post hoc subgroup analysis of one RCT found statistically significant reduction in migraine frequency with topiramate versus placebo (-2.43 vs. -0.79 respectively, p value = 0.02) only in subjects with aura. Post hoc subgroup analysis of the other RCT found that in patients with aura, topiramate was better than placebo reducing migraine frequency, number of migraine days, severity and duration of attacks, and photophobia. In contrast, post hoc analysis of the Prolonged Migraine Prevention (PROMPT) found that topiramate efficacy was similar in patients with and without aura.

Gabapentin reduced migraine attack frequency and intensity significantly more than placebo regardless of the presence of aura (insignificant interaction test). Patients with aura experienced slightly greater reduction in migraine frequency (mean difference -2.2, 95% CI, -2.7 to -1.7) than patients without aura (mean difference -1.6, 95% CI, -2.2 to -0.9). Patients with aura experienced slightly greater reduction in migraine intensity (mean difference -0.83, 95% CI, -1.12 to -0.54) than patients without aura (mean difference -0.42, 95% CI, -0.77 to -0.07).

Discussion

All approved drugs, some off-label beta blockers, and the angiotensin inhibiting drugs were better than placebo in reducing monthly migraine frequency by ≥ 50 percent (clinical response). The relative effect size of drugs was moderate: drugs would result in to 200 to 400 cases of clinical response (≥ 50 percent reduction in monthly migraine frequency) per 1,000 treated.

Critical assessment of the strength of the available evidence suggested low risk of bias in one third of included RCTs and medium risk of bias in more than half of included RCTs. Strength of evidence was moderate only for topiramate, and low for other drugs due to risk of bias and imprecise estimates. Many authors of individual trials did not provide sufficient details about allocation concealment methods or about planned measurements of clinically important changes in quality of life scores and did not use intention-to-treat principles for all examined outcomes. We incorporated risk of bias in our evaluation of strength of evidence, but we could not estimate the effect of risk of bias criteria on drug benefits or safety because most evidence came from individual RCTs. We found it difficult to evaluate the role of financial conflict of interest and industry sponsor participation in data analyses and interpretation because many studies were conducted prior to mandatory requirements for financial disclosure, leading to inconsistent reporting and insufficient detail from individual studies.³³ For instance, the same authors disclosed no or different relationships with industry in multiple publications. Subjects' baseline severity and frequency of migraine attacks as well as comorbidities and concomitant treatments were also inconsistently reported.

The results were applicable to the target population since trials enrolled predominantly middle-aged Caucasian women. However, average treatment effects in a clinically diverse population may not reflect the actual effects for a specific subgroup.³⁴ Very few studies provided evidence for individualized treatment decisions with clear descriptions of planned stratified randomization and subgroup analyses. Published RCTs rarely reported important patient characteristics that could modify drug effects (family history of migraine, socioeconomic status, or a response to prior preventive treatments).^{35,36} No trials examined the role of genetic polymorphism in drug metabolism and effects. Migraine prevention trials did not address teratogenic effects, anorgasmia, impotence, and other harms of anti-epileptic drugs that can deter long-term adherence to preventive drugs.

Few RCTs reported treatment effects in patient subgroups. Low strength of evidence suggested that onabotulinumtoxin A and amitriptyline were more effective in patients with frequent baseline migraine suffering from ≥ 15 monthly migraine days. Our review demonstrated that a relative risk of adverse effects with onabotulinumtoxin A was lower in trials with higher placebo rates of adverse effects. Previous research demonstrated that compared with patients with epilepsy, patients with migraine more often quit taking topiramate due to bothersome adverse effects.¹⁵ Most trials in our review excluded patients with severe medical or psychiatric illnesses, stroke, and vascular migraine. Substantial variability in reporting comorbidities prevented us from using this information in quantitative synthesis of evidence.

Comparative effectiveness and safety with preventive drugs were examined in individual RCTs that failed to meet pooling criteria. Variability in examined drug comparisons in head-to-head RCTs precluded meta-analysis of direct evidence. However, because we found no differences across RCTs in baseline patient characteristics, indirect comparisons were feasible. Thus, we conducted Bayesian network meta-analyses, which indicated that angiotensin inhibiting drugs and beta blockers were the most effective and tolerable drugs. Head-to-head trials were not designed to test safety with migraine preventive drugs. Network meta-analysis demonstrated that

patients stopped taking active drugs more often than placebo with topiramate, off-label antiepileptics, antidepressants, and ergot alkaloids. Individual adverse effects varied depending on the pharmacodynamic properties of the drugs. Multidisciplinary drug management programs demonstrated improvement in migraine-related disability and patient satisfaction, but long-term adherence and benefits are unclear.

The few RCTs that examined quality of life provided no consistent evidence of improvement with examined drugs. The authors rarely measured quality of life using the disease-specific Migraine Specific Questionnaire, Migraine Disability Assessment, or the Headache Impact Test. We could not determine the clinical importance of statistically different changes in scores.

Our review has implications for clinical practice. Informed decisions in clinical settings should take into account the rates of benefits and harms attributable to specific drugs.³⁷ The most recent guidelines from the American Academy of Neurology and the American Headache Society recommend the four FDA-approved drugs—the antiepileptics topiramate and divalproex and the beta-blockers propranolol and timolol—for adult migraine prevention.³⁸

The aforementioned guidelines, which focused on published evidence, differed in regard to recommending off-label drugs. Further, current guidelines do not include consideration of the balance between benefits and harms of drugs as a basis for clinical decisionmaking.³⁹ Our review analyzed benefits and harms of drugs and provided evidence for using effective and relatively safe off-label angiotensin inhibiting drugs and off-label beta-blockers as alternatives based on patient preferences, comorbidities, and contraindications to the medications.

The most effective and safest drugs should be the first choice in adult migraine prevention. We found no published controlled observational studies about preventive drug use or about comparative effectiveness of approved versus off-label drugs. We found no studies that examined use of medical treatment for adverse effects with drugs.

Some evidence suggests that off-label drug use is common in the United States, with little or no scientific support.⁴⁰ For instance, the Institute for Healthcare Informatics Health National Disease and Therapeutic Index analysis suggested that 20 percent of all outpatient drug prescriptions for adults were for off-label uses, with the most common being anticonvulsants, gabapentin, and amitriptyline hydrochloride.⁴¹ We found that off-label antiepileptics and antidepressants demonstrated worse benefits and safety profiles than beta blockers or angiotensin inhibiting drugs. Evidence of off-label drug use and associated adverse effects has been evaluated with prospective pharmacovigilance surveys in European countries.^{42,43} Routine monitoring of harms with off-label drugs via collecting and analyzing evidence of comparative safety in clinical settings is needed in the United States.

Our review found poor results availability from all conducted studies and possible reporting bias in outcomes reporting from completed and published studies. We restricted our review to studies published in English in journals, reviewed by the FDA, or reported on the ClinicalTrials.gov Web site. Even after such a comprehensive review of evidence, we do not know how many funded but unregistered studies we may have missed in our review. Published articles rarely provided unique trial registration numbers from ClinicalTrials.gov. We concluded multiple reports of the same data based on available information and did not contact the authors for further clarification. We suspected selective harms reporting because published articles reported common and expected adverse effects. In contrast, few RCTs that posted results on the ClinicalTrials.gov Web site reported all harms regardless of rates or assumed causal association with active drugs.

Our report has limitations. We did not contact the authors requesting unreported benefits and harms. In cases of poor reporting of risk of bias criteria, we did not contact the authors for additional details about methodological quality. Vast variability in examined treatment options, risk of bias, and imprecise estimates from small individual RCTs hampered synthesis of evidence. We found no evidence of consistent baseline differences in enrolled populations by age, proportion of women, and baseline frequency of migraine. We used indirect network meta-analysis to synthesize treatment effects of several pharmacologic classes. However, indirect comparisons did not address unreported baseline differences in comorbidities or in socioeconomic status. We did not grade strength of evidence for flunarizine, a drug widely used in other countries, because the FDA has not approved it.

Future Research Needs

We identified gaps and biases in available evidence that should direct future research. Well-designed randomized clinical trials should examine the comparative effectiveness of the approved drugs and the most effective off-label ACE inhibitors, angiotensin II blockers, and off-label beta blockers. Future trials should examine the potential treatment-modifying effects of patient age, sex, race, migraine family history, comorbidities, and prior treatment with migraine preventive drugs. Observational studies should analyze off-label drug use and comparative effectiveness and safety with migraine preventive drugs. Analysis of administrative databases should examine emergency and doctor visits among adults taking migraine preventive drugs. Prospective pharmacovigilance methods should be used for routine monitoring of off-label drug use and associated adverse effects with migraine preventive drugs. The long-term preventive benefits of and adherence to drugs are unknown. Evidence on improving quality of life was inconsistent across individual drugs. Evidence for individualized treatment decisions is very limited. Future research is needed for identifying the treatment modifying effects of patient characteristics on long-term drug benefits and safety.

Our review provides a comprehensive network analysis of comparative effectiveness and harms with migraine preventive drugs in adults. We concluded that angiotensin inhibiting drugs demonstrated the most effective migraine prevention without bothersome adverse effects leading to treatment discontinuation. All approved drugs (onabotulinumtoxin A, topiramate, divalproex, timolol, and propranolol) and off-label beta blockers were better than placebo in reducing monthly migraine frequency by ≥ 50 percent. However, topiramate and off-label antiepileptics and antidepressants resulted in bothersome adverse effects leading to treatment discontinuation more often than placebo.

Key Messages

Efficacy and Comparative Effectiveness of Pharmacologic Treatments for Preventing Migraine Attacks in Adults

Effect of Preventive Pharmacologic Treatments on Patient-Centered and Intermediate Outcomes Compared With Placebo or no Active Treatment

- For chronic migraine, onabotulinumtoxin A was more effective than placebo in reducing monthly chronic migraine attacks by ≥ 50 percent with inconsistent improvement in quality of life.
- For episodic migraine, all approved drugs (topiramate, divalproex, propranolol, and timolol) were better than placebo in reducing monthly migraine frequency by ≥ 50 percent (clinical response).
- Relative effect of drugs was moderate: drugs would result in clinical response in 200 to 400 patients per 1,000 treated.
- Strength of evidence was low due to medium risk of bias and imprecise estimates.
- Low-strength evidence from individual RCTs suggested a dose-responsive increase in migraine prevention with higher doses of onabotulinumtoxin A and topiramate (from 50 to 100 mg with no additional benefits with 200 mg/day).
- Among off-label drugs, pooled analyses offered low-strength evidence that the antiepileptic gabapentin, beta-blocker metoprolol, and the calcium channel blocker nimodipine were better than placebo in reducing monthly migraine attacks by ≥ 50 percent.
- Individual RCTs offered low-strength evidence that the off-label beta blockers acebutolol and nadolol were better than placebo in reducing monthly migraine attacks by ≥ 50 percent. Individual RCTs demonstrated that angiotensin converting enzyme inhibitors captopril and lisinopril and angiotensin II antagonist candesartan were better than placebo in reducing monthly migraine attacks by ≥ 50 percent.

Effect of Preventive Pharmacological Treatments on Patient-Centered and Intermediate Outcomes Compared With Active Pharmacological Treatments

- Individual RCTs provided low-strength direct evidence about the comparative effectiveness of drugs and demonstrated few significant differences between drugs.
- Indirect adjusted analysis demonstrated no differences between approved drugs and greater odds of a clinical response with the angiotensin II antagonist candesartan.
- Exploratory network Bayesian meta-analyses demonstrated that approved drugs were similarly better than placebo. Among off-label drug classes, angiotensin inhibiting drugs demonstrated the largest significant odds of reducing monthly migraine by ≥ 50 percent.

Effect of Preventive Pharmacologic Treatments on Patient-Centered and Intermediate Outcomes Compared With Active Nonpharmacologic Treatments

- Individual RCTs provided low-strength evidence of no difference between propranolol and biofeedback for achieving a ≥ 50 percent reduction in monthly migraine attacks.

Influence of Approaches to Drug Management Versus Usual Care (Such as Patient-Care Teams, Integrated Care, Coordinated Care, Patient Education, Drug Surveillance, or Interactive Drug Monitoring)

- Multidisciplinary team care improved quality of life and reduced migraine-related disability.
- A headache management program resulted in complete cessation of migraine (100 percent reduction in monthly migraine attacks).
- A cognitive-behavioral minimal contact program improved patient satisfaction with treatments.
- Headache school decreased overuse of acute drugs and reduced migraine disability.
- An intensive pharmaceutical care campaign had no statistically significant impact on use of drugs for acute attacks.

Comparative Harms From Pharmacological Treatments for Preventing Migraine Attacks in Adults

- Among approved drugs, onabotulinumtoxin A, topiramate, and propranolol resulted in bothersome adverse effects leading to treatment discontinuation more often than placebo.
- The association was dose responsive for topiramate. Larger doses of topiramate caused higher risk of anorexia, depression, paresthesia, and difficulty in memory leading to treatment withdrawal. Larger doses of topiramate caused higher risk of dry mouth, paresthesia or fatigue, mood problems, nausea, and weight loss.
- Individual RCTs showed that divalproex led to treatment discontinuation due to adverse effects that included nausea, somnolence, tremor, vomiting, and asthenia.
- Among other drugs, pooled analyses demonstrated that off-label antidepressant amitriptyline caused bothersome adverse effects leading to treatment discontinuation more often than placebo.
- Limited low-strength evidence from individual head-to-head RCTs suggested that treatment discontinuation due to adverse effects was less frequent with onabotulinumtoxin A than topiramate or amitriptyline.
- Individual unique RCTs provided low-strength direct evidence about adverse effects with specific drugs, with no consistent pattern across available drug comparisons.
- Indirect adjusted analyses demonstrated no differences in treatment discontinuation due to adverse effects with approved drugs or approved versus off-label drugs. Exploratory Bayesian network meta-analyses demonstrated that topiramate, off-label antiepileptics, and antidepressants resulted in bothersome adverse effects leading to treatment discontinuation more often than placebo. According to network meta-analysis, off-label angiotensin inhibiting drugs and beta-blockers were the safest treatment option for adults with episodic migraine.

Influence of Patient Characteristics on the Effectiveness and Safety of Pharmacological Treatments for Preventing Migraine Attacks in Adults

- Evidence was limited to individual RCTs that examined the drug effect modification by selected patient characteristics.
- Onabotulinumtoxin A was more effective in patients with a higher mean baseline migraine frequency.
- Amitriptyline was better than placebo in reducing monthly migraine, but only in patients with frequent migraine attacks and in depressed patients with baseline severe migraine.

Glossary

AHRQ	Agency for Healthcare Research and Quality
ARD	Absolute risk difference
CI	Confidence interval
FDA	Food and Drug Administration
PICOTS	Population(s), Intervention, Comparators, Outcomes, Timing, Settings
RCT	Randomized controlled trial

References

1. Goadsby PJ, Raskin NH. Chapter 15. Headache. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., eds. Harrison's principles of internal medicine. 17th ed. New York: The McGraw-Hill Companies; 2008.
2. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9-160. PMID: 14979299.
3. Silberstein SD. Preventive migraine treatment. Neurol Clin. 2009 May;27(2):429-43. PMID: 19289224.
4. Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology. 2000;55(9 Suppl 2):S29-35. PMID: 11089517.
5. Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007 Mar;47(3):355-63. PMID: 17371352.
6. Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002 Mar 26;58(6):885-94. PMID: 11914403.
7. Bigal ME, Lipton RB, Winner P, et al. Migraine in adolescents: association with socioeconomic status and family history. Neurology. 2007 Jul 3;69(1):16-25. PMID: 17606878.
8. Hernandez-Latorre MA, Roig M. Natural history of migraine in childhood. Cephalalgia. 2000 Jul;20(6):573-9. PMID: 11075841.
9. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010 May;30(5):599-609. PMID: 19614702.
10. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999 Apr 26;159(8):813-8. PMID: 10219926.

11. Sprenger T, Goadsby PJ. Migraine pathogenesis and state of pharmacological treatment options. *BMC Medicine*. 2009;7:71. PMID: 19917094.
12. Sanchez-Del-Rio M, Reuter U, Moskowitz MA. New insights into migraine pathophysiology. *Curr Opin Neurol*. 2006 Jun;19(3):294-8. PMID: 16702838.
13. Rapoport AM. Acute and prophylactic treatments for migraine: present and future. *Neurol Sci*. 2008 May;29 Suppl 1:S110-22. PMID: 18545911.
14. Lainez MJ, Freitag FG, Pfeil J, et al. Time course of adverse events most commonly associated with topiramate for migraine prevention. *Eur J Neurol*. 2007 Aug;14(8):900-6. PMID: 17662012.
15. Luykx J, Mason M, Ferrari MD, et al. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. *Clin Pharmacol Ther*. 2009 Mar;85(3):283-8. PMID: 18987621.
16. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. *Neurology*. 2007 Jan 30;68(5):343-9. PMID: 17261680.
17. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. *Cephalalgia*. 2006 Jun;26(6):742-6. PMID: 16686915.
18. U.S. Food and Drug Administration. FDA News Release: FDA Approves Botox to Treat Chronic Migraine. 2010. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229782.htm.
19. Pascual J, El Berdei Y, Gomez-Sanchez JC. How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate. *J Headache Pain*. 2007 Apr;8(2):90-3. PMID: 17221343.
20. Amanzio M, Corazzini LL, Vase L, et al. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. *Pain*. 2009 Dec;146(3):261-9. PMID: 19781854.
21. Whyte CA, Tepper SJ. Adverse effects of medications commonly used in the treatment of migraine. *Expert Rev Neurother*. 2009 Sep;9(9):1379-91. PMID: 19769452.
22. Whitlock EP, Lopez SA, Chang S, et al. AHRQ Series Paper 3: identifying, selecting, and refining topics for comparative effectiveness systematic reviews: AHRQ and the Effective Health-Care Program. *J Clin Epidemiol*. 2010 May;63(5):491-501. PMID: 19540721.
23. Slutsky J, Atkins D, Chang S, et al. Comparing medical interventions: AHRQ and the Effective Health Care Program. *Methods Guide for Effectiveness and Comparative Effectiveness Reviews*. AHRQ Publication No. 10(11)-EHC063-EF. 2011/03/25 ed. Vol. March 2011. Rockville, MD: Agency for Healthcare Research and Quality; 2008:1-4. www.effectivehealthcare.ahrq.gov.
24. Helfand M, Balshem H. AHRQ Series Paper 2: Principles for developing guidance: AHRQ and the Effective Health Care Program. *J Clin Epidemiol* 2010 May;63(5):484-490. PMID: 19716268.
25. Higgins J, Green S, eds. *Cochrane handbook for systematic reviews of interventions*. Version 5.1.0. London: The Cochrane Collaboration; 2011.
26. Norris S, Atkins D, Bruening W, et al. Selecting observational studies for comparing medical interventions. Chapter 4. *Methods Guide for Effectiveness and Comparative Reviews*. AHRQ Publication No. 10(11)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2011:56-68. www.effectivehealthcare.ahrq.gov.
27. Chou R, Aronson N, Atkins D, et al. AHRQ Series Paper 4: assessing harms when comparing medical interventions: AHRQ and the Effective Health-Care Program. *J Clin Epidemiol*. 2008 Sep 25;63(5):502-12. PMID: 18823754.
28. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928. PMID: 22008217.
29. Ad Hoc Committee on Classification of Headache. Classification of headache. *JAMA*. 1962;179(9):717-8. doi:10.1001/jama.1962.03050090045008.

30. Owens DK, Lohr KN, Atkins D, et al. AHRQ Series Paper 5: grading the strength of a body of evidence when comparing medical interventions. Agency for Healthcare Research and Quality and the Effective Health-Care Program. *J Clin Epidemiol*. 2010 May;63(5):513-23. PMID: 19595577.
31. Guyatt G, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence-imprecision. *J Clin Epidemiol*. Epub 2011 Aug 11. PMID: 21839614.
32. Atkins D, Chang SM, Gartlehner G, et al. Assessing applicability when comparing medical interventions. AHRQ and the Effective Health Care Program. *J Clin Epidemiol*. 2011 Nov;64(11):1198-207. PMID: 21463926.
33. Barden J, Derry S, McQuay HJ, et al. Bias from industry trial funding? A framework, a suggested approach, and a negative result. *Pain*. 2006 Apr;121(3):207-18. PMID: 16495012.
34. Arends LR, Hoes AW, Lubsen J, et al. Baseline risk as predictor of treatment benefit: three clinical meta-re-analyses. *Stat Med*. 2000 Dec 30;19(24):3497-518. PMID: 11122510.
35. Hazard E, Munakata J, Bigal ME, et al. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. *Value in Health*. 2009 Jan;12(1):55-64. PMID: 18671771.
36. Russell MB, Hilden J, Sorensen SA, et al. Familial occurrence of migraine without aura and migraine with aura. *Neurology*. 1993 Jul;43(7):1369-73. PMID: 8392151.
37. Bingham MF, Johnson FR, Miller D. Modeling choice behavior for new pharmaceutical products. *Value in Health*. 2001 Jan-Feb;4(1):32-44. PMID: 11704970.
38. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2012 Apr 24;78(17):1337-45. PMID: 22529202.
39. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. *J Clin Epidemiol*. 2010 Dec;63(12):1308-11. PMID: 20656455.
40. Stafford RS. Regulating off-label drug use—rethinking the role of the FDA. *N Engl J Med*. 2008 Apr 3;358(14):1427-9. PMID: 18385495.
41. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. *Arch Intern Med*. 2006 May 8;166(9):1021-6. PMID: 16682577.
42. Edwards IR. Off-label pharmacovigilance. *Drug Safety*. 2011 Oct 1;34(10):795-7. PMID: 21879775.
43. Layton D, Hazell L, Shakir SA. Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management. *Drug Safety*. 2011 Dec 1;34(12):e1-9. PMID: 22077508.

Introduction

Migraine is a central nervous system disorder characterized by vascular headaches.¹ Migraine headaches range from moderate to very severe, can cause debilitating pain, and can last from 4 to 72 hours.^{2,3} In the United States, migraine affects 17 percent of women and 6 percent of men.⁴⁻⁷ The cumulative lifetime incidence of migraine in the U.S. population is 43 percent for women and 18 percent for men.⁸

Although the frequency and severity of migraine vary considerably, the American Migraine Prevalence and Prevention expert advisory group recommends that prevention for episodic migraine defined as ≥ 4 monthly migraine days with normal functioning or ≥ 2 migraine days with severe impairment.⁹ For 1.4 to 2.2 percent of those who experience migraine, the condition is chronic¹⁰ as defined by the National Headache Foundation (i.e., headache that occurs >15 days per month for at least 3 months).^{11,12} Both migraine types significantly affect patients' physical, psychological, and social well-being and can impose serious lifestyle restrictions.

Migraine also exacts a heavy economic toll. Each year, lost work time and diminished productivity from migraines cost American employers \$225.8 billion.¹³⁻¹⁵ Forty percent of adults with episodic migraine and all adults with chronic migraine might benefit from preventive medication,^{5,16,17} thus reducing lost productivity and work time. Yet, results from several studies demonstrate that only 12.4 percent of adults who experience migraine take preventive medication.^{4,5,16,17}

Migraine pain results primarily from increased activity of several agents that regulate blood vessels and sensory function of the brain.¹ In about 15 percent of patients, migraine attacks may be accompanied by aura (visual, sensory, or language symptoms). Other accompanying symptoms may include photophobia (excessive sensitivity to light), phonophobia (fear of loud sounds), osmophobia (hypersensitivity to smells), nausea, or vomiting.²

Preventive medications from several drug classes presumably affect various aspects of migraine pathophysiology.^{18,19} The four drugs approved by the U.S. Food and Drug Administration (FDA) for episodic migraine prevention in adults are propranolol, timolol, topiramate, and divalproex sodium.²⁰ For chronic migraine, the FDA has approved only one drug, onabotulinumtoxin A. Doctors also prescribe off-label drugs (approved for clinical conditions other than migraine prevention) for migraine prevention, including novel antiepileptic drugs, calcium channel blockers, serotonin and noradrenaline reuptake inhibitors, glutamate blockers, and drugs from several other classes.^{20,21}

Preventive treatment aims to eliminate headache pain without intolerable harms.²²⁻²⁴ However, some degree of pain often persists; therefore, treatment success is usually defined by a decrease in migraine frequency by ≥ 50 percent after 3 months.² In addition to relieving pain, preventive drugs can decrease severity of migraine attacks, reduce use of acute drugs, improve quality of life, normalize brain activity, and eliminate photophobia, phonophobia, nausea, and vomiting.^{25,26}

Long-term adherence to preventive treatments is low. Between 17 and 29 percent of patients discontinue medication because of adverse effects such as anxiety, nausea, vomiting, reduced sleep time, drowsiness, and weakness.^{27,28} Drug choices are based on efficacy and adverse effects as well as headache frequency, presence of aura, and comorbid conditions.^{11,22,23,29,30} Some guidelines recommend preventive treatments for patients who have five or more migraine attacks per month,¹ while others suggest it for those who experience a headache on most days of the month.^{11,12,31} Often, preventive treatment is recommended for only 6 to 9 months; however, very

limited research exists regarding migraine frequency after discontinuation of preventive treatment.²

Several gaps remain in published literature on preventive treatments for migraines. Systematic reviews have focused on the efficacy of specific drugs rather than comparative effectiveness of all pharmacologic and nonpharmacologic treatment options.³² Little attention has been paid to the comparative effectiveness of off-label drugs used for migraine prevention. Published reviews have not examined quality of life. Clinical reviews have compared the safety with only a few drugs.^{32,33} The majority of patients seen in headache specialty clinics that practice multidisciplinary coordinated care had chronic migraine.⁸

Our review focuses on the comparative effectiveness and safety of the drugs used for migraine prevention in adults; our results may help inform treatment recommendations. By the nature of the question, this review focuses on outpatient care.

Topic Refinement and Review Protocol

The topic was anonymously nominated via the public domain. During the topic refinement stage, we solicited input from Key Informants representing medical professional societies/clinicians in the areas of neurology, primary care, consumers, scientific experts, and payers, to help define the Key Questions (KQs).³⁴ The KQs were then posted for public comment for 4 weeks, and the comments received were considered in the development of the research protocol. We next convened a Technical Expert Panel (TEP) comprising clinical, content, and methodological experts to provide input in defining populations, interventions, comparisons, and outcomes, and in identifying particular studies or databases to search. The Key Informants and members of the TEP were required to disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts. Any potential conflicts of interest were balanced or mitigated. Neither Key Informants nor members of the TEP performed analysis of any kind, nor did any of them contribute to the writing of this report. Members of the TEP were invited to provide feedback on an initial draft of the review protocol, which was then refined based on their input, reviewed by AHRQ, and posted for public access from April 12, 2012, to May 10, 2012, at the AHRQ Effective Health Care Web site.

We conducted a comprehensive literature review following the principles in the “Methods Guide for Effectiveness and Comparative Effectiveness Reviews” (hereafter Methods Guide) developed by the Agency for Healthcare Research and Quality (AHRQ) Evidence-based Practice Center Program^{35,36} and PRISMA guidelines.³⁷ The protocol is posted in the systematic review registry (protocol registration number is CRD42012001918, available at www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42012001918).³⁸

Key Questions

KQ 1. What are the efficacy and comparative effectiveness of pharmacologic treatments for preventing migraine attacks in adults?

- a. How do preventive pharmacologic treatments affect patient-centered and intermediate outcomes when compared with placebo or no active treatment?
- b. How do preventive pharmacologic treatments affect patient-centered and intermediate outcomes when compared with active pharmacologic treatments?

- c. How do preventive pharmacologic treatments affect patient-centered and intermediate outcomes when compared with active nonpharmacologic treatments?
- d. How do preventive pharmacologic treatments combined with nondrug treatments affect patient-centered and intermediate outcomes when compared with pharmacologic treatments alone?
- e. How might dosing regimens or duration of treatments influence the effects of the treatments on patient-centered outcomes? How might approaches to drug management (such as patient-care teams, integrated care, coordinated care, patient education, drug surveillance, or interactive drug monitoring) influence results?

KQ 2. What are the comparative harms from pharmacologic treatments for preventing migraine attacks in adults?

- a. What are the harms from preventive pharmacologic treatments when compared with placebo or no active treatment?
- b. What are the harms from preventive pharmacologic treatments when compared with active pharmacologic treatments?
- c. How might approaches to drug management (such as patient-care teams, integrated care, coordinated care, patient education, drug surveillance, or interactive drug monitoring) influence results?

KQ 3. Which patient characteristics predict the effectiveness and safety of pharmacologic treatments for preventing migraine attacks in adults?

Methods

We followed an a priori research protocol that we developed with the clinical and methodological input of a technical expert panel. The protocol followed the Effective Health Care Program's "Methods Guide for Effectiveness and Comparative Effectiveness Review."

Literature Search Strategy

Search Strategy

We searched for published studies in several databases including MEDLINE[®] (via Ovid and PubMed[®]), the Cochrane Library, and the SCIRUS bibliographic database to find original studies published in English up to May 20, 2012. We searched the FDA Web site for medical and statistical reviews of eligible drugs. We searched clinical trial registries, including ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry, to find ongoing, completed, and published trials of migraine prevention. The Scientific Resource Center requested Scientific Information Packets from appropriate manufacturers (Appendix A) per usual procedures. We did not contact the investigators of the primary studies for missing data or clarifications.

To identify related articles, we developed an a priori search strategy based on relevant medical subject heading (MeSH[®]) terms, text words, and weighted word-frequency algorithms. Exact search strategies are shown in Appendix A.


Searches for relevant literature involved several steps: (1) evaluating previously published systematic reviews,³⁹ (2) conducting a comprehensive literature search in the databases listed above to retrieve identified references, (3) screening abstracts against the inclusion/exclusion criteria, and (4) reviewing full text articles of eligible studies to determine potential inclusion in the synthesis.

Inclusion Criteria

- Original epidemiologic studies that aimed to examine preventive pharmacologic treatments for migraine.
- Publication in English.
- Target population of community-dwelling adults with episodic migraine, chronic daily headache, or chronic migraine defined according to International Headache Society criteria for chronic migraine (Appendix B).¹¹
- Eligible intermediate and patient-centered outcomes as listed in Figure 1.
- Drugs approved by the FDA for migraine prevention and off-label drugs examined in clinical trials (Appendix B Table 1).

We reviewed RCTs that included adults with migraine, comorbid headache disorders, or tension headache if they examined prevention of migraine.

Figure 1. Analytical framework^{35,36,40}



KQ = Key Question; SES = socioeconomic status

K1 What are the efficacy and comparative effectiveness of pharmacologic treatments for preventing migraine attacks in adults?

K2 What are the comparative harms from pharmacologic treatments for preventing migraine attacks in adults?

K3 Which patient characteristics predict the effectiveness and safety of pharmacologic treatments for preventing migraine attacks in adults?

Exclusion Criteria

- Studies of treatments aimed at acute migraine attacks.
- Studies that involved patients with migraine variants, such as hemiplegic migraines, basilar migraine, retinal migraine, complicated migraines, and ophthalmoplegic migraine; hospitalized patients; or patients in emergency rooms.^{41,42,43} Studies of short-term prevention of migraine, including menstrual migraines.
- Studies that included some patients with migraine but did not separately report those outcomes.
- Studies that involved surgical treatments for migraine.
- Preclinical pharmacokinetic studies of eligible drugs; studies that examined the pathophysiology of migraine and reported instrumental measurements or biochemical outcomes.
- Studies that examined eligible drugs on populations with other diseases.

Study Selection

We followed the AHRQ Methods Guide to select evidence from controlled trials and observational studies.⁴⁴ Three investigators worked independently to determine study eligibility resolving disagreements through discussion.⁴⁵ We used all included randomized controlled trials (RCTs) to assess effectiveness with drugs. We used all included RCTs and nonrandomized studies to assess adverse effects and treatment discontinuation due to adverse effects.⁴⁴ To assess harms of treatments, we included published and unpublished evidence of the adverse effects of drugs in patients with migraine.⁴⁶ We defined harms as a totality of all possible adverse consequences of an intervention⁴⁶ and analyzed all harms, regardless of how authors perceived causality of treatments.

We defined eligible preventive treatments, outcomes, time, and outpatient setting following the analytical PICOTS framework (Population, Intervention, Comparator, Outcomes, Timing, and Settings). We defined the target population as community-dwelling adults with episodic or chronic migraine. We formulated a list of eligible interventions after discussions with key informants and technical experts and after consideration of public comments (Appendix B Table 1). Eligible comparators included pharmacologic, nonpharmacologic, and combined preventive treatments. We defined eligible intermediate and patient-centered outcomes (presented in the analytical framework in Figure 1).

Data Extraction

Researchers used standardized forms to extract data (available at https://netfiles.umn.edu/xythoswfs/webui/_xy-21041343_1-t_zdhvSpvy). One reviewer abstracted an article and a second reviewed the abstracted data for accuracy. We assessed errors by comparing established ranges for each variable with data charts from the original articles and discussed detected discrepancies. We abstracted the information relevant to the PICOTS framework. We abstracted minimum datasets to reproduce the results presented by the authors. For categorical variables we abstracted the number of events among treatment groups to calculate rates, relative risk, and absolute risk differences. We abstracted means and standard deviations of continuous variables to calculate mean differences with a 95% confidence interval (CI).

For RCTs in the quantitative analysis set we abstracted the number randomized to each treatment group as the denominator and calculated estimates by applying intention-to-treat principles assuming that the same proportions apply in the missing data.⁴⁵ We abstracted the time when the outcomes were assessed as weeks from randomization and the time of followup after treatments.

We abstracted inclusion and exclusion criteria, drug regimen and doses, and patient characteristics (demographics, baseline frequency, severity, and prior treatment status) as factors that can modify treatment effects. We abstracted the definition of migraine used in each study. We abstracted sponsorship of the studies, sponsor participation in study design and in analysis and presentation of data, and conflict of interest by the authors.

Risk of Bias Assessment

We evaluated the risk of bias in individual studies of benefits and harms according to recommendations from the “Cochrane Handbook for Systematic Reviews of Interventions.”⁴⁵ First, we classified studies by their design as either interventional (RCTs, nonrandomized

controlled clinical trials, and nonrandomized uncontrolled clinical trials) or observational (cohort or case-control studies, cross-sectional studies, or case series).

Then, using the criteria from the Cochrane risk of bias tool in interventional studies,⁴⁷ we evaluated: (1) random allocation of the subjects to the treatment groups; (2) masking of the treatment status to the participants and investigators; (3) adequacy of allocation concealment; (4) adequacy of randomization as similarity of the subjects in treatment groups by demographics, migraine frequency and severity, and response to previous treatments; (5) intention-to-treat principles; and (6) selective outcome reporting when compared with methods section in the articles. Since all outcomes in the review were self-reported, masking of outcome assessment was not essential in evaluating risk of bias, but masking of treatment was. Masking of treatment status was not feasible for RCTs that examined nondrug therapies as comparators; therefore, we did not include it in risk-of-bias assessment for those studies.

We assumed a low risk of bias when RCTs met all the risk of bias criteria, a medium risk of bias if at least one of the risk of bias criteria was not met, and a high risk of bias if two or more risk of bias criteria were not met.⁴⁸ We concluded an unknown risk of bias for the studies with poorly reported risk of bias criteria. We assessed risk of bias in nonrandomized studies according to adjustment for confounding factors to address selection bias and exclusion of subjects from the analyses to address attrition biases.⁴⁹

We evaluated disclosure of conflict of interest by the authors of individual studies and funding sources, but we did not use this information to downgrade quality of individual studies.

Data Synthesis

We categorized drugs according to The Anatomical Therapeutic Chemical Classification System of the World Health Organization. Accordingly, we categorized botulinum toxin treatments under one category-M03AX01. We analyzed together and separately the effects of onabotulinumtoxin A (approved by the FDA), botulinum neurotoxin type A, and abobotulinumtoxin A.

We focused on patient-centered outcomes, such as ≥ 50 percent reduction in migraine attacks from baseline, quality of life, patient satisfaction, and composite measures of response, including frequency and severity of migraine. We incorporated risk of bias in individual studies into the synthesis of evidence by using individual risk of bias criteria rather than a global score or a ranking category of overall risk of bias.^{50,51} Synthesis of evidence about comparative benefits and safety with drugs from individual RCTs was restricted to studies with low or medium risk of bias.²²

We synthesized the evidence according to patient characteristics that could modify treatment effect, including age, sex, race, and duration of migraine, baseline frequency and severity of acute migraine attacks, presence of aura, previous drug treatments, history of drug overuse, and others described in the PICOTS framework. We addressed the role of comorbidities and concomitant treatments in association with patient-centered outcomes. When possible, based on the reporting in original studies, we conducted subgroup and sensitivity analyses according to patient characteristics, drug dose, and timing of followup.

We examined whether the definition of migraine could contribute to the differences in trial results. The FDA approved four drugs for prevention of episodic migraine based on trials conducted before the implementation of the most recent migraine definition proposed by the International Headache Society.¹¹ Thus, older eligible studies published before 2004 defined migraine according to previous definitions of the International Headache Society or according

to definitions of the Ad Hoc Committee on Classification of Headache.⁵² We compared baseline patient characteristics and treatment effects depending on the exact migraine definition and here we report the results when they differed significantly.

Using Meta-Analyst⁵³ and STATA^{®54} software, we calculated the relative risk and absolute risk difference from the abstracted events. We evaluated statistical significance at a 95 percent confidence level. We used default software continuity coefficients for 0 events and intention to treat as recommended calculations for missing data. We hypothesized superiority of drugs versus placebo and versus each other.⁵⁵

For continuous outcomes we calculated the mean differences from the reported means and standard deviations. We also calculated ratios of means that describe clinically interpretable percentage differences in outcomes with active versus control treatments.⁵⁶ We calculated Cohen standardized mean differences for different measures of the same outcome.

We used a logarithmic scale to analyze the adjusted regression coefficient with a standard error of association between treatments and patient-centered outcomes. We used correction coefficients (0.5 as a default option in both software applications) and intention to treat as recommended calculations for missing data.⁴⁵

For sparse adverse effects data, we used multiple models to test robustness of inferential statistics. Models included random and fixed effects inverse variance methods, maximum likelihood methods, Peto odds ratio,⁵⁷ double arcsine transformation for comparing two proportions, and odds ratios from random-effects generalized nonlinear mixed-effect models.^{53,58-61}

Pooling criteria for Key Questions 1 and 2 included the same active drug treatments and comparators and the same definitions of the outcomes. We calculated and pooled Cohen standardized mean differences for different continuous measures of the same outcome. In cases of multiarm trials, we created a single pair-wise comparison.⁴⁷ To avoid the spurious increase in precision in multiarm trials, we divided placebo arms approximately evenly among the comparisons according to randomization ratio.^{45,62}

We tested consistency in the results by comparing the direction and strength of the association.⁶³ We assessed heterogeneity in results with Chi-squared and I-squared tests.^{64,65} We explored heterogeneity with meta-regression and sensitivity analysis; we report the results from random effects models only.⁶⁶ We used the random effects model to incorporate in the pooled analysis any differences across trials in patient populations, baseline rates of the outcomes, dosage of drugs, and other factors.⁵⁷ We explored heterogeneity by risk-of-bias criteria, disclosed conflicts of interest, study sponsorship, dose and duration of drug treatments, time of followup, inclusion of minorities, proportion of women and elderly adults, and other patient characteristics described above. To avoid ecological fallacy, we did not use patient level variables (for example, mean age or body mass index) in meta-regression.⁶⁶

We calculated the number needed to treat to achieve one event of a patient-centered outcome as reciprocal to absolute risk differences (ARD) in rates of outcome events in the active and control groups.^{54,67} We calculated means and 95% CIs for the number needed to treat as reciprocal to pooled ARD when ARD was significant.⁶⁸ The number of avoided or excess events (respectively) per population of 1,000 is the difference between the two event rates multiplied by 1,000.

In cases when very few studies were available to provide evidence from direct head-to-head comparisons, we conducted indirect comparisons. To conduct indirect comparisons, we used

statistical techniques to estimate the treatment effects from studies of each given treatment against controls under an assumption of consistency.⁶⁹⁻⁷³

- We used adjusted indirect frequentist comparisons for individual drugs that were compared with placebo.⁷¹ This analysis provided pair-wise triangular comparisons for drugs that were compared with placebo rather than network meta-analysis.
- To address the problems with inevitable differences across studies, we used mixed (or multiple) treatment comparisons (MTCs), or so-called network meta-analysis.⁷¹⁻⁷³ Network meta-analysis refers to methods that, in the absence of head-to-head comparisons, compare treatments by combining all available evidence from studies that form a network of evidence (including studies that compare three or more treatment arms).

By synthesizing direct and indirect comparisons, we improved the precision of estimates for treatment effects. A Bayesian analysis can easily construct complicated models with fewer assumptions. Bayesian analysis also permits explicit posterior inference regarding the probability that each treatment is “best” for a specific outcome.⁷⁴⁻⁷⁶ We calculated Bayesian odds ratios^{53,61} with 2.5 to 97.5 percent credible intervals. We conducted exploratory Bayesian network random effects meta-analysis assuming heterogeneous variances across treatments (Appendix B Table 2).⁷⁷ We synthesized evidence from drug classes in network meta-analysis when individual drugs from the same class demonstrated no significant differences in outcomes. We compared odds ratios from network meta-analyses with odds ratios from direct head-to-head RCTs to examine consistency of the estimates.⁷⁸ We concluded no differences in drug effect (hereafter called similar effects) if confidence or credible intervals included one (no effect or no difference).⁷⁹ All Bayesian results were obtained from the WinBUGS software,⁸⁰ using Markov chain Monte Carlo (MCMC) samples after a 50,000-sample algorithm burn-in. WinBUG codes are presented in Appendix B Table 3.

Grading the Evidence for Each Key Question

We assessed strength of evidence according to risk of bias, consistency, directness, and precision for each patient-centered outcome including reduction in monthly migraine frequency by 100 percent or ≥ 50 percent, patient global assessment of treatment success, rates of clinically important improvement in migraine-related disability and quality of life. We also assessed treatment discontinuation due to harms.⁶³ We based our criteria on published guidelines acknowledging inevitable subjectivity of the assessment.^{47,81} We assigned a medium or high risk of bias in the body of evidence when at least one individual RCT had medium or high risk of bias, respectively.

We defined treatment effect estimates as precise when pooled estimates had reasonably narrow 95% CIs, and pooled sample size was greater than 300 (using 25% relative effect difference for calculation of optimal information size).⁸² We did not include justification of the sample size into grading of the evidence nor did we conduct post hoc statistical power analysis.

We defined reporting bias as publication bias, selective outcomes reporting, and multiple publication bias. We did not perform formal statistical tests quantifying reporting biases due to the questionable statistical validity of the available tests.⁸³ We assess publication bias by analyses of the publication rates of the registered studies and the NIH funded studies. We assess selective reporting of the patient centered outcomes by comparing protocols with published results.

In assessing strength of evidence, we looked at dose-response association, strength of association, and reporting bias in nonrandomized studies. We evaluated the strength of the association, defining a priori a large effect when relative risk was >2 and a very large effect when relative risk was >5 .⁴⁵ We defined low magnitude of the effect when relative risk is significant but <2 .

We defined high level of evidence on the basis of consistent findings from well-designed RCTs (Table 1). We downgraded strength of evidence to moderate if at least one of the four strength-of-evidence criteria was not met; for example, the studies had medium risk of bias or the results were not consistent or precise. We downgraded strength of evidence to low if two or more criteria were not met. We assigned a low level of evidence to nonrandomized studies and upgraded strength of evidence for strong or dose response associations. We defined evidence as insufficient when a single study with high risk of bias examined treatment effects or associations. We applied this approach regardless of whether the results were statistically significant.

Table 1. Strength of evidence ranks and definitions

Grade	Definition
High	High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect.
Moderate	Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.
Low	Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and is likely to change the estimate.
Insufficient	Evidence either is unavailable or does not permit a conclusion.

Assessing Applicability

We estimated applicability of the population by evaluating the selection of adults with migraine in observational studies and clinical trials.⁷⁹ Studies of community-dwelling adults receiving drug treatments with 6 or more months of followup had high applicability, as did large observational cohorts based on national registries, population-based effectiveness trials, and nationally representative administrative and clinical databases.


Peer Review and Public Commentary

We invited external peer review of this Comparative Effectiveness Review (CER) from experts in migraine management fields and individuals representing stakeholder and user communities; AHRQ and an associate editor also provided comments. The draft report was posted on the AHRQ Web site for 4 weeks to elicit public comment. We addressed all reviewer comments, revised the text as appropriate, and documented everything in a disposition of comments report that will be made available 3 months after the Agency posts the final CER on the AHRQ Web site.

Results

Of 5,244 identified references, we included 245 references of RCTs and 76 nonrandomized studies (Figure 2). All excluded references are presented in Appendix C.

Figure 2. Study flow



Publication Bias

By analyzing the NIH-funded and registered studies, we found that the results are available from only a small proportion of migraine prevention studies. However, we could not determine exact reasons for low availability of results based on available data. Both, posting of results and publication rates, varied by individual sponsors.

We found 18 NIH funded grants that aimed to examine migraine prevention. Six grant projects funded three RCTs. Two of those three RCTs were registered in ClinicalTrials.gov (Table 2). Overall publication rate was 44 percent (eight of 18 funded projects). The National Institute of Neurological Disorders and Stroke funded nine studies (the largest number among the agencies), and published the results from four of these projects (Table 2). We could not explain why the studies have not been published because the NIH grant database does not allow the analysis of the exact reasons for the low publication rates of the projects. Results from the NIH-funded projects were published after 1.9 to 3 years from the end dates of the projects (Table 3). Time intervals between project end dates and publication did not differ among the funding agencies.

Searching trial registries, we found 67 studies in ClinicalTrials.gov and 24 studies in other registries. Publication rates of study results were slightly lower for the studies registered in ClinicalTrials.gov (21 percent; 14/67) than in other registries (33 percent; 8/24). Among the studies registered in ClinicalTrials.gov most studies examined drugs (61/67). A placebo control was used by 64 percent (43/67). Most studies were completed (70 percent; 47/67) and four studies were terminated. Termination due to harms with treatments was clearly indicated in two terminated studies. The results were posted for nine studies (13 percent).

Publication rates varied depending on subjects and study characteristics (Table 4). Only 28 percent of all completed studies, 50 percent of biologics studies, and 18 percent of drug studies were published. Only 33 percent of Phase III and 50 percent of Phase IV studies were published. No terminated studies were published. Publications occurred an average of 2 years after study completion (0.5 to 6.6 years). Publication time varied among individual sponsors. Odds of publication did not reach statistical significance, probably due to the small number of studies (Table 5).

The rates of the posting of the results also varied depending on subjects and study characteristics (Table 4). Half of biologics studies and 12 percent of drug studies posted the result in ClinicalTrials.gov. Only 13 percent of Phase III and 29 percent of Phase IV trials posted the results in ClinicalTrials.gov. Trials that were terminated for safety reasons did not post the results. Results were posted an average of 2.6 years after study completion dates (0.9 to 5.2 years). Biologic studies posted the results an average of 3 years after completion dates, and drug studies posted results an average of 2.6 years after completion dates. Placebo-controlled studies posted results an average of 2.5 years after completion dates, and comparative effectiveness studies 3.4 years after completion dates. Terminated studies posted the results an average of 5 years after study termination. Odds of posting the results did not reach statistical significance, probably due to the small number of studies (Table 5).

Table 2. Registration, publication, and cost of the NIH-funded grants aimed at migraine prevention (as of May 2012)

Agency	Not Registered	Registered	Total	% Registered	Unpublished	Published	Total	% Published	Sum/Cost of Studies With No Results Available	Minimum Cost	Maximum Cost
NCCAM	1	2	3	67	1	2	3	67	\$675,532/ \$222,925	\$100,000	\$292,000
NCI	2	0	2	0	2	0	2	0	\$176,000/ \$176,000	\$88,000	\$88,000
NIDA	2	0	2	0	0	2	2	100	\$791,080	\$283,941	\$507,139
NIMH	1	0	1	0	1	0	1	0	Not reported		
NINDS	7	2	9	22	5	4	9	44	\$1,159,146/ \$649,121	\$155,568	\$210,668
NINR	1	0	1	0	1	0	1	0	\$159,480/ \$159,480	\$159,480	\$159,480

NCCAM = National Center for Complementary and Alternative Medicine; NCI = National Cancer Institute; NIDA = National Institute on Drug Abuse; NIMH = National Institute of Mental Health; NINDS = National Institute of Neurological Disorders and Stroke; NINR= National Institute of Nursing Research

Table 3. Years between the NIH-funded project end dates and the publication dates of the results

NIH Agency	Interval Time Point	Mean	Minimum	Maximum	Standard Deviation
NCCAM	Project End Date	1.9	1.4	2.4	0.7
NCCAM	Budget End Date	2.4	1.4	3.4	1.4
NIDA	Project End Date	2.3	1.8	2.8	0.7
NIDA	Budget End Date	2.8	1.8	3.8	1.4
NINDS	Project End Date	2.3	0.6	3.7	1.6
NINDS	Budget End Date	3.0	1.6	4.7	1.6

NCCAM = National Center for Complementary and Alternative Medicine; NIDA = National Institute on Drug Abuse; NIMH = National Institute of Mental Health; NINDS = National Institute of Neurological Disorders and Stroke

Table 4. Publication and posting of the results of migraine prevention studies registered in ClinicalTrials.gov

		Published	Not Published	Total	% Published	Has Results	No Results Available	Total	% Posted
Category	Total	14	53	67	20.9	9	58	67	13.4
Age	Adult	8	29	37	21.6	6	31	37	16.2
Age	Adult Senior	3	18	21	14.3	3	18	21	14.3
Age	Child	0	6	6	0.0	0	6	6	0.0
Age	Child Adult	3	0	3	100.0	0	3	3	0.0
Gender	Both	13	46	59	22.0	9	50	59	15.3
Gender	Female	0	1	1	0.0	0	1	1	0.0
Type	Interventional	14	51	65	21.5	9	56	65	13.8
Type	Observational	0	2	2	0.0	0	2	2	0.0
Intervention	Behavioral	0	1	1	0.0	0	1	1	0.0
Intervention	Biological	2	2	4	50.0	2	2	4	50.0
Intervention	Drug	11	50	61	18.0	7	54	61	11.5
Intervention	Procedure	1	0	1	100.0	0	1	1	0.0
Phases	Phase 1 Phase 2	0	1	1	0.0	0	1	1	0.0
Phases	Phase 2	2	17	19	10.5	2	17	19	10.5
Phases	Phase 2 Phase 3	0	1	1	0.0	0	1	1	0.0
Phases	Phase 3	8	16	24	33.3	3	21	24	12.5
Phases	Phase 4	2	5	7	28.6	2	5	7	28.6
Phases	Phase 1	0	1	1	0.0	0	1	1	0.0
Phases	Phase 2	0	3	3	0.0	0	3	3	0.0
Phases	Phase 4	1	1	2	50.0	0	2	2	0.0
Placebo	No	3	21	24	12.5	2	22	24	8.3
Placebo	Yes	11	32	43	25.6	7	36	43	16.3
Recruitment	Active, not recruiting	0	2	2	0.0	0	2	2	0.0
Recruitment	Completed	13	34	47	27.7	8	39	47	17.0
Recruitment	Not yet recruiting	0	2	2	0.0	0	2	2	0.0
Recruitment	Recruiting	1	9	10	10.0	0	10	10	0.0
Recruitment	Terminated	0	4	4	0.0	1	3	4	25.0
Recruitment	Withdrawn	0	2	2	0.0	0	2	2	0.0
Reason for termination	Administrative	0	1	1	0.0	1	0	1	100.0
Reason for termination	Other	0	1	1	0.0	0	1	1	0.0
Reason for termination	Safety related	0	2	2	0.0	0	2	2	0.0
Funding	Industry	9	34	43	20.9	4	39	43	9.3
Funding	Industry NIH	0	1	1	0.0	1	0	1	100.0
Funding	Industry Other	1	1	2	50.0	0	2	2	0.0

Table 4. Publication and posting of the results of migraine prevention studies registered in ClinicalTrials.gov (continued)

		Published	Not Published	Total	% Published	Has Results	No Results Available	Total	% Posted
Funding	Other	1	8	9	11.1	0	9	9	0.0
Funding	Other Industry	2	6	8	25.0	3	5	8	37.5
Funding	Other NIH	0	1	1	0.0	0	1	1	0.0
Funding	Other NIH Industry	1	0	1	100.0	1	0	1	100.0
Funding	Other U.S. Fed Industry	0	1	1	0.0	0	1	1	0.0
Funding	U.S. Fed Other	0	1	1	0.0	0	1	1	0.0

Table 5. Odds of publication and posting of results in ClinicalTrials.gov among all studies registered in ClinicalTrials.gov

Outcome	Active	Control	Active With Outcome	Active Without Outcome	Control With Outcome	Control Without Outcome	Odds Ratio	Lower 95% CI	Upper 95% CI
Publication	Interventional	Observational	14	51	0	2	1.41	0.06	30.99
Publication	Drug studies	All other studies	11	50	3	3	0.22	0.04	1.24
Publication	Placebo control	No placebo control (active treatments comparison)	11	32	3	21	2.41	0.60	9.66
Publication	Has results	No results available	4	5	10	48	3.84	0.87	16.88
Publication	Funded by industry	Funded by other sources	9	34	1	10	2.65	0.30	23.49
Posting results	Drug studies	All other studies	7	54	2	4	0.26	0.04	1.68
Posting results	Phase 3-4 trials	Phase 1-2 trials	5	28	2	23	2.05	0.36	11.58
Posting results	Placebo control	No placebo control (active treatments comparison)	7	36	2	22	2.14	0.41	11.23
Posting results	Terminated for safety reasons	Terminated for other reasons	0	2	1	1	0.20	0.00	8.82
Posting results	Funded by Industry	Funded by other sources	9	47	0	11	4.60	0.25	84.94

Abstracted data are available in Appendix D with evidence tables (available at https://netfiles.umn.edu/xythoswfs/webui/_xy-21041343_1-t_zdhvSpvy). Randomized trials examined 59 drugs from 14 pharmacologic drug classes (Appendix Table D1).

Most trials were funded by industry but did not disclose conflict of interest by study investigators (Appendix Table D2). Proportions of industry sponsorship and disclosed conflict of interest varied among drugs (Appendix Table D2).

Applicability

The results from eligible studies were applicable to the target population. Most RCTs were conducted in the United States and Western countries and used the International Headache Society's definition (Appendix Table D3). Older publications used the definition of migraine developed by the Ad Hoc Committee on Classification of Headache, and about 34 RCTs did not specify a migraine definition.

Investigators recruited patients in clinics in almost half of RCTs. Half did not report this information, and eight RCTs clearly indicated community-based recruitment. RCTs enrolled an average of 210 adults, measured the outcomes at 2 to 3 months of followup, and reported about 14 percent loss of followup (Table 6 and Appendix Table D4).

Studies enrolled mostly adults (average age, 38 years) and adolescents (Table 7). Women made up the majority of enrolled subjects (Appendix Table D5). Few trials reported a proportion of obese subjects, but many participants were overweight according to the average body mass index. Most trials included patients with and without aura (Appendix Table D5). Enrolled patients had an average of five monthly migraine attacks. Almost half of the enrolled subjects were naïve to migraine preventive drugs (Table 7). Patient age and baseline migraine characteristics were similar in most trials (Appendix Table D6).

Substantial variability in reporting comorbidities prevented us from using this information in quantitative synthesis of evidence. Most trials, however, excluded patients with severe medical comorbidities or psychiatric illnesses, stroke, and vascular migraine. RCTs rarely reported important patient characteristics that could modify drug effects, including family history of migraine, socioeconomic status, or response to prior preventive treatments

Risk of Bias

More than half of the RCTs had medium risk of bias and about 21 percent had low risk of bias (Table 8). Proportions of RCTs with low risk of bias varied among drugs (Appendix Table D7). Among approved drugs, the percent of low-risk-of-bias RCTs was as follows: topiramate, 45 percent; divalproex, 67 percent; and propranolol, 13 percent (Appendix Table D7). Most RCTs (86 percent) were double blind. Timolol was examined in two RCTs of medium risk of bias. We concluded unclear adequacy of allocation concealment in 94 percent of RCTs and adequacy of randomization in 51 percent of RCTs (Table 8). Planned intention to treat was reported in 24 percent of RCTs.

Published RCTs rarely presented subject flows. Nor did RCTs report why some eligible subjects were not randomized and therefore excluded from the trials. Proportions of eligible subjects excluded from randomization varied among trials. Investigators excluded an average of 5 percent of randomized subjects from the analyses, with substantial variability among the drugs.

Table 6. Total number randomized, weeks of followup, and loss of followup in randomized controlled clinical trials of migraine prevention in adults

	Total Sample	# RCTs That Reported Sample	Sample Assigned to Treatment Mean [Min to Max]	# RCTs That Reported Length of Followup	Total Length of Followup, Weeks Mean [Min to Max]	# RCTs That Reported % Loss of Followup	% Loss of Followup Mean [Min to Max]
Antiepileptics	7656	42	182.3 [23 to 818]	43	17.6 [8.0 to 28.0]	28	5.5 [0.0 to 36.0]
Antidepressants	1701	21	83.0 [17 to 391]	21	13.5 [4.0 to 27.0]	19	22.6 [0.0 to 48.0]
Beta blockers	6006	62	96.9 [14 to 810]	65	18.1 [4.0 to 60.0]	36	12.3 [0.0 to 37.5]
ACE inhibitors	72	2	36.0 [12 to 60]	2	37.8 [7.5 to 68.0]	1	22.0
Angiotensin II receptor blockers	144	2	72.0 [60 to 84]	2	22.0 [12.0 to 32.0]	2	11.0 [5.0 to 17.0]
Calcium channel blockers	2602	33	78.8 [20 to 521]	33	18.8 [8.0 to 36.0]	30	15.4 [0.0 to 48.3]
Antiadrenergics	711	15	47.4 [20 to 133]	15	21.6 [8.0 to 48.0]	11	21.2 [6.0 to 38.0]
Dopaminergic agents	172	3	57.3 [30 to 102]	3	28.0 [16.0 to 40.0]		Not reported
Ergot alkaloids	1040	9	115.6 [18 to 384]	9	13.6 [6.0 to 24.0]	8	11.6 [0.0 to 32.4]
NSAIDs	23993	16	1499.6 [26 to 22071]	16	26.0 [4.0 to 144.0]	6	15.2 [0.0 to 29.6]
Magnesium	174	3	58.0 [24 to 81]	3	17.3 [12.0 to 24.0]	3	23.0 [11.0 to 42.0]
Nondrugs vs. drugs	632	4	158.0 [114 to 218]	4	20.0 [16.0 to 24.0]		Not reported
Cortical spreading depression inhibitor	124	1	124.0	1	13.0	1	5.1
Muscle relaxants	136	1	136.0	1	12.0		Not reported
Montelukast	177	1	177.0	1	20.0	1	2.2
Total	45340	215	210.9 [12 to 22071]	219	18.6 [4.0 to 144.0]	146	13.9 [0.0 to 48.3]
% RCTs that did not report the variable		2.3		0.5		33.6	

ACE = angiotensin converting enzyme; NSAID = nonsteroidal anti-inflammatory drug; RCT = randomized clinical trial

Table 7. Reporting of patient baseline characteristics in randomized controlled clinical trials of migraine prevention drugs in adults

Drugs	# RCTs	Age Mean [Min to Max]	# RCTs	% Female, Mean [Min to Max]	# RCTs	Obesity , BMI Mean [Min to Max]	# RCTs	Baseline Frequency of Migraine/Mont h Mean [Min to Max]	# RCTs	Duration of Migraine, Years Mean [Min to Max]	# RCTs	% With Aura Mean [Min to Max]	# RCTs	% Naïve to Treatment Mean [Min to Max]
Anti-epileptics	39	39.2 [29.4 to 46.0]	41	76.3 [10.9 to 100.0]	8	27.1 [23.0 to 30.3]	40	6.5 [1.0 to 26.6]	14	13.2 [3.0 to 25.0]	18	24.0 [0.0 to 86.3]	7	43.0 [0.0 to 100.0]
Anti-depressants	17	36.6 [31.0 to 44.4]	19	80.0 [63.5 to 92.3]		Not reported	2	6.0 [5.0 to 7.0]	2	18.4 [16.0 to 20.8]	8	19.2 [0.0 to 45.2]	2	66.7 [0.0 to 100.0]
Beta blockers	50	37.8 [28.6 to 43.5]	61	78.5 [52.0 to 94.5]	2	23.1 [22.8 to 23.4]	44	4.5 [2.0 to 8.4]	27	16.8 [9.0 to 26.0]	46	39.8 [0.0 to 100.0]	7	53.8 [0.0 to 93.2]
ACE inhibitors	2	45.0 [41.0 to 49.0]	2	69.5 [58.0 to 81.0]		Not reported	1	2.3		Not reported		Not reported		Not reported
Angiotensin II receptor blockers	2	40.9 [39.8 to 42.0]	2	81.8 [79.0 to 84.5]	1	24.0	1	6.2		0.0		Not reported		Not reported
Calcium channel blockers	28	35.5 [29.0 to 44.0]	32	73.8 [41.0 to 91.1]	2	23.4 [23.0 to 23.7]	22	5.2 [2.0 to 10.0]	18	14.1 [5.0 to 20.0]	29	25.3 [0.0 to 100.0]	6	54.5 [25.0 to 100.0]
Anti- adrenergics	12	37.8 [32.0 to 48.0]	14	77.4 [30.0 to 92.0]		Not reported	5	5.1 [4.0 to 6.5]	3	16.0 [12.0 to 22.0]		Not reported		Not reported
Dopa- minergic agents	2	34.3 [33.9 to 34.6]	3	74.4 [71.6 to 76.7]		Not reported	3	5.3 [4.3 to 6.0]		Not reported	3	0.0 [0.0 to 0.0]		Not reported
Ergot alkaloids	7	35.9 [30.0 to 42.0]	8	76.3 [60.0 to 95.0]	2	23.7 [23.1 to 24.2]	6	4.8 [3.0 to 8.5]	5	16.2 [14.2 to 20.0]	7	23.1 [0.0 to 67.5]	2	63.3 [60.0 to 66.7]
NSAIDs	15	39.5 [35.0 to 53.2]	15	73.9 [0.0 to 100.0]	2	25.6 [25.0 to 26.1]	6	4.7 [1.3 to 8.2]	4	17.2 [15.0 to 20.0]	2	4.4 [0.0 to 8.7]		Not reported
Magnesium	2	42.4 [41.0 to 43.8]	2	89.5 [86.0 to 93.0]		Not reported	2	5.0 [4.0 to 6.0]	1	4.2	2	50.0 [0.0 to 100.0]		Not reported

Table 7. Reporting of patient baseline characteristics in randomized controlled clinical trials of migraine prevention drugs in adults (continued)

Drugs	# RCTs	Age Mean [Min to Max]	# RCTs	% Female, Mean [Min to Max]	# RCTs	Obesity , BMI Mean [Min to Max]	# RCTs	Baseline Frequency of Migraine/Mont h Mean [Min to Max]	# RCTs	Duration of Migraine, Years Mean [Min to Max]	# RCTs	% With Aura Mean [Min to Max]	# RCTs	% Naïve to Treatment Mean [Min to Max]
Nondrug vs. drugs	4	38.9 [37.8 to 40.1]	4	87.9 [78.9 to 100.0]	1	23.5	3	4.7 [2.0 to 6.3]	1	15.9	3	38.9 [0.0 to 100.0]	1	46.5 [0.0 to 0.0]
Cortical spreading depression inhibitor	1	36.0	1	92.3		Not reported		Not reported		Not reported		Not reported	1	100.0
Muscle relaxants	1	40.3	1	79.0		Not reported		Not reported		Not reported		Not reported		Not reported
Montelukast	1	40.0	1	88.0		Not reported	1	5.1 [0.0 to 0.0]		Not reported		Not reported		Not reported
Total	183	37.9 [28.6 to 53.2]	206	77.2 [0.0 to 100.0]	18	25.3 [22.8 to 30.3]	136	5.3 [1.0 to 26.6]	75	15.3 [3.0 to 26.0]	118	30.0 [0.0 to 100.0]	26	53.0 [0.0 to 100.0]
%RCTs that did not report the variable	17		6		92		38		66		46		88	

ACE = angiotensin converting enzyme; BMI = body mass index; NSAID = nonsteroidal anti-inflammatory drug; RCT = randomized clinical trial

Table 8. Number of randomized controlled clinical trials of migraine prevention in adults that met risk of bias criteria

Drug Classes	Double Blind	Open Label	Single Blind	Adequate Allocation Concealment	Unclear Allocation Concealment	Adequate Randomization	Not Adequate Randomization	Unclear Adequacy of Randomization	Planned Intention to Treat Analysis	Low Risk of Bias	Medium Risk of Bias	High Risk of Bias	Unclear Risk of Bias	Total
Anti-epileptics	40	3	0	9	34	23	6	14	23	19	22	2	0	43
Anti-depressants	19	3	0	0	22	14	3	5	3	1	18	3	0	22
Beta blockers	59	4	2	1	64	18	2	45	11	8	52	5	0	65
ACE inhibitors	2	0	0	1	1	0	0	2	1	2	0	0	0	2
Angiotensin II receptor blockers	2	0	0	1	1	0	1	1	1	1	0	1	0	2
Calcium channel blockers	29	3	2	0	34	15	4	15	3	2	24	8	0	34
Anti-adrenergics	14	1	0	0	15	1	0	14	1	4	9	1	1	15
Dopa-minergic agents	3	0	0	0	3	0	1	2	0	0	2	1	0	3
Ergot alkaloids	8	1	0	0	9	4	0	5	1	1	8	0	0	9
Muscle relaxants	1	0	0	0	1	1	0	0	0	0	1	0	0	1
Montelukast	1	0	0	0	1	1	0	0	1	1	0	0	0	1
NSAIDs	7	9	0	0	16	5	3	8	3	3	10	2	1	16
Magnesium	3	0	0	0	3	2	1	0	2	2	0	1	0	3
Nondrugs compared with drugs	0	3	1	2	2	3	1	0	3	1	2	1	0	4
Total	188	27	5	14	206	87	22	111	53	45	148	25	2	220
Percent	85.5	12.3	2.3	6.4	93.6	39.5	10.0	50.5	24.1	20.5	67.3	11.4	0.9	

ACE = angiotensin converting enzyme; NSAID = nonsteroidal anti-inflammatory drug

Key Question 1. What is the efficacy and comparative effectiveness of pharmacologic treatments for preventing migraine attacks in adults?

Results from RCTs were available in 245 references. RCTs examined four approved drugs for episodic migraine (topiramate, divalproex, propranolol, and timolol), one approved drug for chronic migraine (onabotulinumtoxin A), and various off-label preventive drugs. Most trials examined a monotherapy with one active agent compared with placebo or to another drug. RCTs rarely reported exact drugs and doses of concomitant treatments. However, we surmise there were no concomitant treatments because most trials disallowed concomitant drugs during the run-in period and after randomization. Strength of evidence was low due to medium or high risk of bias and imprecise estimates from individual or meta-analyzed RCTs.

KQ1a. How do preventive pharmacologic treatments affect patient-centered and intermediate outcomes when compared with placebo or no active treatment?

All approved drugs were better than placebo in reducing monthly migraine frequency by ≥ 50 percent in patients with episodic migraine and baseline < 15 migraine days per month (clinical response). The relative effect of drugs was moderate: drugs resulted in clinical response in 200 to 400 patients per 1,000 treated. Clinicians need to treat three to five patients with episodic migraine to prevent half or more migraine attacks in one patient.

Strength of evidence was lowered due to medium risk of bias and imprecise estimates. Low-strength evidence from individual RCTs suggested a dose-responsive increase in migraine prevention with higher doses of onabotulinumtoxin A and topiramate (from 50-100 mg/day with no additional benefits with 200 mg/day).

Among off-label drugs, pooled analyses offered low-strength evidence that antiepileptic gabapentin, beta-blocker metoprolol, and calcium channel blocker nimodipine were better than placebo in reducing monthly migraine attacks by ≥ 50 percent. Individual RCTs offered low-strength evidence that off-label beta blockers, acebutolol, atenolol, and nadolol, were better than placebo in reducing monthly migraine attacks by ≥ 50 percent. Individual RCTs demonstrated that the angiotensin converting enzyme inhibitors captopril and lisinopril and the angiotensin II antagonist candesartan were better than placebo in reducing monthly migraine attacks by ≥ 50 percent.

We present strength of evidence for patient-centered outcomes, including complete migraine cessation (Table 9) and migraine prevention with approved (Table 10) and off-label drugs (Tables 11 and 12).

Only a few RCTs examined quality of life, and they provided no consistent evidence of improvement with examined drugs. The studies rarely assess clinical importance of the changes in quality of life or disability scales. We describe those effects as well as changes in intermediate outcomes in the text and appendix tables.

Table 9. 100% reduction in monthly migraine frequency with pharmacologic preventive treatments versus placebo in adults with episodic migraine, results from randomized controlled clinical trials

Active Drug, Weeks From Randomization to Time to Measure Outcome	References	Sample	% With Outcome in Active [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Risk of Bias	Directness	Consistency	Precision	Strength of Evidence
Topiramate, 16-26 weeks	Pooled Bussone, 2005 ⁸⁴ Silberstein 2006 ⁸⁵ Silberstein, 2009 ⁸⁶	1299	5.1 [2.6]	1.9 (1.0 to 3.4)	0.02 (-0.01 to 0.05)	NS	NS	Medium	Yes	No	No	Low
	p value			0.499	0.067							
	I squared			0.00%	63.00%							
Gabapentin 17 weeks of treatment	NCT00742209, 2010 ⁸⁷	82	25.8 [20.9]	1.3 (0.5 to 3.4)	0.06 (-0.15 to 0.26)	NS	NS	Low	Yes	Not applicable	Imprecise	Low
Captopril 32 weeks of treatment	Minervini, 1987⁸⁸	24	66.7 [0.0]	17.0 (1.1 to 265.0)	0.67 (0.39 to 0.95)	1 (1 to 3)	667 (388 to 946)	Low	Yes	Not applicable	Imprecise	Low
Nimodipine 12 weeks of treatment	Gelmers, 1983⁸⁹	60	50.0 [6.7]	7.5 (1.9 to 30.0)	0.43 (0.23 to 0.63)	2 (2 to 4)	433 (233 to 633)	Medium	Yes	Not applicable	Imprecise	Low
Dihydro-ergotamine 20 weeks of treatment	Pradalier, 2004 ⁹⁰	384	37.5 [30.0]	1.3 (0.9 to 1.7)	0.08 (-0.02 to 0.17)	NS	NS	Low	Yes	Not applicable	Imprecise	Low
Indomethacin 4 weeks of treatment	Anthony, 1968 ⁹¹	38	5.3 [10.5]	0.5 (0.0 to 5.1)	-0.05 (-0.22 to 0.12)	NS	NS	Medium	Yes	Not applicable	Imprecise	Low

Bold = significant differences when 95% CI of absolute risk differences do not include 0; CI = confidence interval; NS = not significant;

Number needed to treat and number of attributable events were calculated for statistically significant differences

Table 10. Migraine prevention with approved pharmacologic treatments versus placebo in adults, results from randomized controlled clinical trials (pooled with random effects models)

Active Drug	References	Sample	% With Outcome With Active Drug [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Risk of Bias	Direct	Consistency	Precision	Strength of Evidence
Chronic Migraine												
Onabotulinumtoxin A ≥50% decrease in migraine frequency	Pooled⁹²⁻⁹⁴	459	50.6 [34.4]	1.5 (1.2 to 1.8)	0.17 (0.08 to 0.26)	6 (4 to 12)	170 (82 to 258)	Medium	Yes	Yes	No	Low
	p value			0.7	0.9							
	I squared			0.00%	0.00%							
Episodic Migraine												
Topiramate 100% reduction in migraine frequency	Pooled⁸⁴⁻⁸⁶	1299	5.1 [2.6]	1.9 (1.0 to 3.4)	0.02 (-0.01 to 0.05)	NS	NS	Medium	Yes	No	No	Low
	p value			0.499	0.067							
	I squared			0.00	0.63							
Topiramate on >50% reduction on migraine frequency	Pooled^{84,85, 95-99}	1422	49.6 [25.1]	2.0 (1.5 to 2.7)	0.29 (0.18 to 0.40)	3 (3 to 6)	288 (176 to 400)	Medium	Yes	Yes	Yes	Moderate
	P value			0.036	0.001							
	I squared			0.555	0.736							
Topiramate on >50% reduction on migraine days	Pooled^{84,86, 100}	1145	42.2 [23.3]	1.7 (1.0 to 2.9)	0.18 (0.08 to 0.28)	6 (4 to 13)	179 (75 to 284)	Low	Yes	Yes	No	Moderate
	P value			0.012	0.042							
	I squared			0.772	0.684							
Topiramate on ≥75% reduction in migraine days	Pooled^{84,86}	1086	22.3 [11.0]	1.9 (1.1 to 3.1)	0.10 (-0.01 to 0.20)	NS	NS	Low	Yes	Yes	No	Moderate
	P value			0.123	0.026							
	I squared			0.58	0.797							
Divalproex	Pooled¹⁰¹⁻¹⁰³	405	43.0 [23.3]	2.2 (1.1 to 4.2)	0.24 (0.10 to 0.38)	4 (3 to 10)	241 (97 to 384)	Medium	Yes	Yes	No	Low
	P value			0.123	0.098							
	I squared			0.523	0.569							

Table 10. Migraine prevention with approved pharmacologic treatments versus placebo in adults, results from randomized controlled clinical trials (pooled with random effects models) (continued)

Active Drug	References	Sample	% With Outcome With Active Drug [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Risk of Bias	Direct	Consistency	Precision	Strength of Evidence
Propranolol	Pooled¹⁰⁴⁻¹⁰⁷	541	45.1 [22.3]	2.0 (1.5 to 2.7)	0.22 (0.14 to 0.30)	4 (3 to 7)	223 (142 to 304)	Medium	Yes	Yes	No	Low
	P value			0.995	0.936							
	I squared			0	0							
Timolol 100% reduction in migraine frequency	Single RCT ¹⁰⁸	28	14.3 [0.0]	5.0 (0.3 to 95.6)	0.14 (-0.07 to 0.35)	NS	NS	Medium	Yes	Not applicable	No	Low
Timolol ≥50% reduction in migraine frequency	Pooled^{104,107,109}	276	49.4 [23.3]	2.1 (1.5 to 3.1)	0.27 (0.15 to 0.38)	4 (3 to 6)	265 (154 to 377)	Medium	Yes	Yes	No	Low
	P value			0.732	0.606							
	I squared			0	0							

Bold = significant differences when 95% CI of absolute risk difference do not include 0; CI = confidence interval; RCT = randomized controlled trial; NS = not significant; Number needed to treat and number of attributable events were calculated for statistically significant differences

Table 11. Migraine prevention with pharmacologic treatments versus placebo in adults with episodic migraine (pooled with random effects model results from randomized controlled clinical trials)

Active Drug	References	Sample	% With Outcome With Active Drug [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Risk of Bias	Direct	Consistency	Precision	Strength of Evidence
Gabapentin	Pooled^{87,110,111}	270	45.9 [31.0]	1.5 (1.1 to 2.0)	0.17 (0.06 to 0.27)	6 (4 to 16)	165 (61 to 269)	Medium	Yes	Yes	No	Low
	P value			0.487	0.847							
	I squared			0	0							
Metoprolol	Pooled^{89,112-114}	225	39.9 [19.4]	2.0 (1.3 to 3.2)	0.20 (0.09 to 0.3)	5 (3 to 11)	204 (88 to 321)	Medium	Yes	Yes	No	Low
	P value			0.415	0.385							
	I squared			0	0							
Nimodipine	Pooled^{89,112}	126	28.6 [6.3]	4.5 (0.5 to 40.1)	0.23 (0.06 to 0.39)	4 (3 to 16)	229 (64 to 394)	Medium	Yes	No	No	Low
	P value			0.125	0.194							
	I squared			0.576	0.407							
Magnesium	Pooled^{115,116}	137	33.8 [25.8]	1.3 (0.7 to 2.3)	0.08 (-0.09 to 0.26)	NS	NS	Low	Yes	No	No	Low
	P value			0.268	0.248							
	I squared			0.186	0.251							

CI = confidence interval; NS= not significant

Number needed to treat and number of attributable events were calculated for statistically significant differences

Bold = significant differences when 95% CI of absolute risk difference do not include 0.

Table 12. Migraine prevention (50% or more reduction) with off-label pharmacologic treatments versus placebo in adults with episodic migraine, results from individual randomized controlled clinical trials

Active Drug, Weeks From Randomization to Time to Measure Outcome	Reference	Sample	% With Outcome With Active Drug [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Risk of Bias	Direct	Consistency	Precision	Strength of Evidence
Acetazolamide 12 weeks	Vahedi, 2002 ¹¹⁷	53	30.8 [33.3]	0.9 (0.4 to 2.0)	-0.03 (-0.28 to 0.23)	NS	NS	Low	Yes	NA	Imprecise	Low
Carbamazepin 6 weeks	Rompel, 1970¹¹⁸	96	54.2 [10.4]	5.2 (2.2 to 12.4)	0.44 (0.27 to 0.60)	2 (2 to 4)	438 (272 to 603)	Medium	Yes	NA	Imprecise	Low
Lamotrigine 20 weeks	Gupta, 2007 ⁹⁹	120	46.0 [34.0]	1.4 (0.9 to 2.2)	0.13 (-0.04 to 0.31)	NS	NS	Low	Yes	NA	Imprecise	Low
Oxcarbazepine 15 weeks	Silberstein, 2008 ¹¹⁹	170	32.9 [36.5]	0.9 (0.6 to 1.4)	-0.04 (-0.18 to 0.11)	NS	NS	Low	Yes	NA	Imprecise	Low
Valproate 12 weeks	Jensen, 1994¹²⁰	86	39.5 [14.0]	2.8 (1.2 to 6.5)	0.26 (0.08 to 0.43)	4 (2 to 13)	256 (77 to 435)	Medium	Yes	NA	Imprecise	Low
Acebutolol 12 weeks	Nanda, 1978¹²¹	86	30.2 [4.7]	6.5 (1.6 to 27.1)	0.26 (0.10 to 0.41)	4 (2 to 10)	256 (105 to 407)	Medium	Yes	NA	Imprecise	Low
Alprenolol 6 weeks	Ekbom, 1975 ¹²²	66	33.3 [36.4]	0.9 (0.5 to 1.8)	-0.03 (-0.26 to 0.20)	NS	NS	Medium	Yes	NA	Imprecise	Low
Atenolol 12 weeks	Forssman, 1983¹²³	48	33.3 [0.0]	17.0 (1.0 to 278.9)	0.33 (0.14 to 0.53)	3 (2 to 7)	333 (140 to 527)	Medium	Yes	NA	Imprecise	Low
Nadolol 12 weeks	Freitag, 1984¹²⁴	32	25.0 [0.0]	4.7 (0.3 to 75.0)	0.25 (0.02 to 0.48)	4 (2 to 45)	250 (22 to 478)	Low	Yes	NA	Imprecise	Low
Amitriptyline 16 weeks	Couch, 2011 ¹²⁵	391	24.2 [24.4]	1.0 (0.7 to 1.4)	0.00 (-0.09 to 0.08)	NS	NS	Medium	Yes	NA	Imprecise	Low
Amitriptyline 4 weeks (≥75% improvement in headache)	Couch, 1976¹²⁶	73	43.2 [19.4]	2.2 (1.0 to 4.8)	0.24 (0.03 to 0.44)	4 (2 to 31)	238 (33 to 443)	Medium	Yes	NA	Imprecise	Low
Tonabersat 12 weeks	Goadsby, 2009 ¹²⁷	124	40.7 [36.9]	1.1 (0.7 to 1.7)	0.04 (-0.13 to 0.21)	NS	NS	Low	Yes	NA	Imprecise	Low
Lisinopril 12 weeks	Schrader, 2001 ¹²⁸	120	23.3 [0.0]	29.0 (1.8 to 475.4)	0.23 (0.12 to 0.34)	4 (3 to 8)	233 (124 to 343)	Low	Yes	NA	Imprecise	Low
Candesartan 12 weeks	Tronvik, 2003 ¹²⁹	120	38.3 [3.3]	11.5 (2.8 to 46.6)	0.35 (0.22 to 0.48)	3 (2 to 5)	350 (219 to 481)	Low	Yes	NA	Imprecise	Low

Table 12. Migraine prevention (50% or more reduction) with off-label pharmacologic treatments versus placebo in adults with episodic migraine, results from individual randomized controlled clinical trials (continued)

Active Drug, Weeks From Randomization to Time to Measure Outcome	Reference	Sample	% With Outcome With Active Drug [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Risk of Bias	Direct	Consistency	Precision	Strength of Evidence
Nifedipine 4 weeks	Shukla, 1995 ¹³⁰	72	55.6 [11.1]	5.0 (1.9 to 13.2)	0.44 (0.25 to 0.64)	2 (2 to 4)	444 (252 to 637)	Medium	Yes	NA	Imprecise	Low
Dihydro-ergotamine 20 weeks	Pradalier, 2004 ⁹⁰	384	60.9 [56.0]	1.1 (0.9 to 1.3)	0.05 (-0.05 to 0.15)	NS	NS	Low	Yes	NA	Imprecise	Low
Lisuride 12 weeks	Somerville, 1976 ¹³¹	150	37.3 [25.3]	1.5 (0.9 to 2.4)	0.12 (-0.03 to 0.27)	NS	NS	Medium	Yes	NA	Imprecise	Low
Flurbiprofen 8 weeks	Solomon, 1993 ¹³²	46	69.6 [30.4]	2.3 (1.2 to 4.5)	0.39 (0.13 to 0.66)	3 (2 to 8)	391 (125 to 657)	Medium	Yes	NA	Imprecise	Low
Indomethacin 4 weeks	Anthony, 1968 ⁹¹	38	31.6 [26.3]	1.2 (0.4 to 3.3)	0.05 (-0.24 to 0.34)	NS	NS	Medium	Yes	NA	Imprecise	Low
Rofecoxib 12 weeks	Visser, 2004 ¹³³	175	22.0 [9.5]	2.3 (1.1 to 5.0)	0.12 (0.02 to 0.23)	8 (4 to 53)	125 (19 to 230)	Medium	Yes	NA	Imprecise	Low
Tolfenamic Acid 10 weeks	Mikkelsen, 1982 ¹³⁴	62	45.2 [6.5]	7.0 (1.7 to 28.3)	0.39 (0.19 to 0.58)	3 (2 to 5)	387 (192 to 582)	Medium	Yes	NA	Imprecise	Low
Aspirin 240 weeks (ever having migraine attack)	Buring, 1990 ¹³⁵	22071	6.0 [7.4]	0.8 (0.7 to 0.9)	-0.01 (-0.02 to -0.01)	-70 (48 to 131)	-14 (8 to 21)	Low	Yes	NA	Imprecise	Low
Montelukast 12 weeks	Brandes, 2004 ¹³⁶	177	24.2 [21.8]	1.2 (0.7 to 2.0)	0.0 (-0.09 to 0.16)	NS	NS	Low	Yes	NA	Imprecise	Low

CI = confidence interval; NA = Not applicable; NS= not significant

Number needed to treat and number of attributable events were calculated for statistically significant differences

Bold = significant differences when 95% CI of absolute risk difference do not include 0.

Prevention of Chronic Migraine

Muscle Relaxants

Onabotulinumtoxin A

We identified 15 RCTs that examined the efficacy of botulinum toxin for migraine prevention; 13 RCTs examined onabotulinumtoxin A and two RCTs examined abobotulinumtoxin A (Appendix Table D8). The studies enrolled an average of 285 patients aged 18 to 65 years with four to 12 migraine attacks/month. Most trials included patients with 10 or more years of migraine experience. Women made up 85 percent of participants. More than half of enrolled patients had been previously treated with preventive medications for migraine. Most RCTs were industry funded and reported conflict of interest by study investigators (Appendix Table D9). All RCTs were double blind and most had low risk of bias (Appendix Table D10).

Onabotulinumtoxin A was better than placebo in reducing monthly migraine attacks by ≥ 50 percent (three RCTs of 459 adults, low-strength evidence) (Appendix Table D11).⁹²⁻⁹⁴ Onabotulinumtoxin A tended to increase the likelihood of ≥ 50 percent reduction in migraine frequency compared with placebo in all RCTs (Appendix Table D12). Pooled relative increase by 50 percent achieved statistical significance (pooled RR 1.5, 95% CI, 1.2 to 1.8). Pooled analyses demonstrated that 170 adults per 1,000 treated (95% CI, 82 to 258) would experience ≥ 50 percent reduction in migraine frequency with onabotulinumtoxin A (Table 10). No RCTs of abobotulinumtoxin A reported rates of ≥ 50 percent reduction in monthly migraine attacks.

A reduction in migraine days was considered as a primary outcome in the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) RCT that reported statistically significant reduction in frequency of headache days relative to 20 headache days at baseline (-9.0 days with onabotulinumtoxin A versus -6.7 days with placebo, $p < .001$).¹³⁷ The same trial reported a statistically significant reduction in frequency of migraine days relative to 19 migraine days at baseline (mean difference with placebo -2.4 with 95% CI -3.3 to -1.4).¹³⁷ We could not pool the results from other RCTs that examined a reduction in migraine days or hours because the trials failed to report data needed for reproducible results.¹³⁷⁻¹³⁹

For intermediate outcomes, the absolute number of migraine attacks did not differ between onabotulinumtoxin A and placebo (Appendix Table D13). Improvement in migraine severity was inconsistent across four RCTs (Appendix Table D14).^{92,139-141} Improvement in migraine disability assessment was inconsistent across two RCTs (Appendix Table D14).^{93,142} A single RCT of patients who had not benefitted from previous oral prophylactic treatment demonstrated significant improvement in most domains of quality of life as assessed by the Migraine Impact Questionnaire (Appendix Table D14).¹⁴² The PREEMPT clinical program RCT demonstrated statistically significant improvement in all domains of the Migraine-Specific Quality of Life Questionnaire.¹⁴³ Significant improvement was demonstrated in global assessment, severity of migraine symptoms, self-management of migraine, and ability to work and participate in recreational activities (Appendix Table D14).¹⁴²

In our separate analysis of RCTs of abobotulinumtoxin A we found inconsistent effects on patient global evaluation of treatment success. The Dysport Migraine Study Group reported a statistically significant increase in patient's global evaluation of treatment efficacy.¹⁴⁴ Slightly or much improved migraine frequency was reported in 281 patients per 1,000 treated (95% CI 46 to 516).¹⁴⁴ In contrast, the Dysport® In Migraine Without Aura Prophylaxis trial found no

differences in patient or investigators' perception of global assessment with the active drug versus placebo.¹³⁹ Neither trial showed statistically significant reduction in absolute number of migraine attacks with abobotulinumtoxin A versus placebo.^{139,144}

Tizanidine

Tizanidine was better than placebo in reducing migraine severity (one RCT of 136 adults) but had no effect on migraine frequency.¹⁴⁵

Antiepileptics

The Topiramate Chronic Migraine Study Group RCT offered low-strength evidence that topiramate was better than placebo in reducing from baseline monthly migraine days, rates of 25 percent reduction in monthly migraine attacks, and frequency of associated symptoms.^{86,146,147} Topiramate was not better than placebo in reducing monthly migraine attacks by ≥ 50 percent.⁸⁶ Topiramate did not decrease treatment discontinuation due to failure.¹⁴⁶

The drug improved quality of life and migraine related disability in adult with chronic migraine. We estimated that 133 patients (95% CI, 27 to 239) per 1,000 treated would experience improvement in quality of life measured using the SGIC instrument (Subject's Global Impression of Change). We estimated that 72 patients (95% CI, 7 to 137) per 1,000 treated experienced reduction in migraine related disability.¹⁴⁷ Improvement in disability scale score was large and clinically important.¹⁰⁰

Prevention of Episodic Migraine

Antiepileptics

Topiramate

Individual RCTs and two pooled analyses of individual patient data from RCTs examined efficacy of topiramate versus placebo for migraine prevention in adults (Appendix Table D15). Most trials were funded by industry (Appendix Table D16). All trials were double blind and most had low risk of bias (Appendix Table D17).

Topiramate was not better than placebo in achieving complete cessation of migraine (Table 9).⁸⁴⁻⁸⁶ Topiramate in doses of 50, 100, or 200 mg/day was better than placebo in reducing monthly migraine frequency by ≥ 50 percent (Table 10 and Appendix Table D18). The results were consistent across the studies and robust regardless of pooling methods (Appendix Table D19). Topiramate was also better than placebo in reducing monthly migraine days by ≥ 50 percent (Table 10). Topiramate tended to reduce treatment discontinuation due to lack of efficacy with borderline statistical significance in pooled analyses (pooled absolute risk difference -0.04 95% CI -0.07 to 0).^{84,85,96,99,146,148-150}

Topiramate, 100 mg/day, decreased the absolute number of migraine days by 5 days/month in pooled analyses of RCTs (Appendix Table D20). The reduction in migraine severity scores was inconsistent across the studies (Appendix Table D21). Individual RCTs demonstrated significant improvement in quality of life as measured by scores on the Headache Impact Test,¹⁴⁹ Migraine Specific Questionnaire,¹⁵¹ and Migraine Disability Assessment¹⁰⁰ (Appendix Table D22). Topiramate was better than placebo in improving general health status in a previously published pooled analysis of individual patient data from RCTs (Appendix Table D23).¹⁵² Medical Outcome Study Short Form 36 (SF-36) scores improved by more than 200 percent for

self-reported vitality and more than 100 percent for pain and general health (Appendix Table D23).¹⁵²

Topiramate was better than placebo in reducing use of acute drugs (Appendix Table D24). Most individual RCTs demonstrated a small but significant reduction in the number of medications taken or in the reduction of days when drugs for acute attacks were needed (Appendix Table D24).

Divalproex

Three RCTs examined the efficacy of divalproex for migraine prevention in adults (Appendix Table D25).¹⁰¹⁻¹⁰³ All three RCTs were funded by industry (Appendix Table D26) and all were double blind (Appendix Table D27).

Divalproex was better than placebo in reducing monthly migraine frequency by ≥ 50 percent (Table 10 and Appendix Table D28).^{101,102} A larger dose of divalproex (1500 mg/day) was effective in achieving a ≥ 50 percent reduction in migraine-related effects, including impairment of usual activities, need for symptomatic medication, and nausea, vomiting, phonophobia, or photophobia (Appendix Table D29).¹⁰³ Evidence was low-strength due to imprecise treatment effects.¹⁰³

Valproate

Small RCTs examined the efficacy of valproate for migraine prevention in adults (Appendix Table D25).^{120,153} The trials were double blind and had medium risk of bias because the investigators did not use planned intention-to-treat principles (Appendix Table D27).

Valproate was better than placebo in reducing monthly migraine frequency by ≥ 50 percent (Table 12).¹²⁰ We estimated that 256 patients per 1,000 treated (95% CI, 77 to 435) would experience clinically important reduction in migraine attacks attributable to valproate.¹²⁰ Valproate decreased the frequency of migraine attacks and severe attacks,¹⁵³ duration of attacks,¹⁵³ and the use of drugs for acute attacks¹²⁰ (Appendix Table D30).

Beta Blockers

Propranolol

Most RCTs that examined the efficacy of propranolol versus placebo for migraine prevention in adults (Appendix Table D31) failed to report funding sources (Appendix Table D32). All trials were double blind but did not analyze the data according to planned intention-to-treat principles (Appendix Table D33).

Propranolol was better than placebo in reducing migraine monthly frequency by ≥ 50 percent (Table 10 and Appendix Table D34). The preventive effects of propranolol were consistent across the studies (Appendix Table D35). Propranolol caused a small but significant decrease in the absolute number of monthly migraine attacks (mean difference -1, 95% CI, -2 to -0.3).^{104, 105, 154,155} A single RCT demonstrated that propranolol decreased use of drugs for acute attacks, both analgesics (mean difference -0.3, 95% CI, -0.4 to -0.1 doses per patient day) and the acute drug ergotamine (mean difference -0.1, 95% CI, -0.3 to -0.1 doses per patient day).¹⁵⁶

Timolol

Timolol was not better than placebo in achieving complete migraine cessation (Table 9).¹⁰⁸ Timolol was better than placebo in reducing migraine monthly frequency by ≥ 50 percent (Table

10 and Appendix Table D36).^{104,107,109} Evidence was low-strength due to medium risk of bias and estimate imprecision (Appendix Table D37) Timolol also decreased absolute number of migraine attacks and severity of headaches (Appendix Table D38).

Off-Label Drugs

Off-Label Antiepileptic Drugs

Most RCTs that examined six off-label antiepileptic drugs: acetazolamide, gabapentin, vigabatrin, oxcarbazepine, carbamazepin, and lamotrigine (Appendix Table D39) were sponsored by industry (Appendix Table D40), and all were double blind (Appendix Table D41).

Gabapentin was not better than placebo in achieving complete cessation of migraine attacks (Table 9).⁸⁷ Gabapentin was, however, better than placebo in reducing monthly migraine attacks by ≥ 50 percent (Table 11).^{87,110,111} Individual RCTs found that carbamazepin¹¹⁸ but not oxcarbazepine¹¹⁹ and acetazolamide¹¹⁷ were better than placebo in preventing migraine attacks (Table 11).

In addition to off-label antiepileptic drugs examined in RCTs, pregabalin was examined in one open-label uncontrolled trial.¹⁵⁷ Pregabalin was associated with a significant decrease from baseline in headache frequency and severity and with global improvement defined as ≥ 50 in visual analog scale (VAS) score in 40 percent of patients.¹⁵⁷

Beta Blockers

Most RCTs that examined the effects of off-label beta blockers versus placebo for migraine prevention in adults (Appendix Table D42) failed to report funding and conflict of interest (Appendix Table D43). All trials were double blind with medium risk of bias because the investigators did not use planned intention-to-treat principles (Appendix Table D44).

Metoprolol

Metoprolol was better than placebo in improving patient perception of marked reduction in migraine attacks (Appendix Tables D45).^{113,114} Pooled analysis found a significant increase in the likelihood of a clinical response (Appendix Table D46)^{113,114} but no effect on absolute number of migraine attacks (Appendix Table D47).^{113,114,158}

Metoprolol reduced severity of migraine attacks in a single RCT (Appendix Table D48).¹¹⁴ Regarding use of drugs for acute attacks, evidence with metoprolol was mixed; one trial reported reduced use of such drugs and a second reported increased use of analgesics (Appendix Table D47).^{113,114}

Atenolol

Atenolol was better than placebo in reducing monthly migraine attacks by ≥ 50 percent (Table 12 and Appendix Table D46).¹⁵⁹ Atenolol significantly reduced use of ergotamine drugs in a single RCT (Appendix Table D46).¹⁵⁹

Nadolol

Nadolol was better than placebo in reducing monthly migraine attacks by ≥ 50 percent (Table 12).¹²⁴ In a single RCT, nadolol improved perceived relief in frequency, intensity, and severity of migraine attacks (Appendix Table D46).¹²⁴

Alprenolol

Alprenolol was not better than placebo in achieving perceived treatment success (Table 12 and Appendix Table D46).¹²² Alprenolol did not reduce the absolute number of monthly migraine attacks or Headache Index scores (Appendix Table D47).¹²²

Pindolol

Pindolol was not better than placebo in reducing headache indices by ≥ 50 percent (Appendix Table D48).¹⁶⁰ Pindolol did not reduce the absolute number of monthly migraine attacks or Headache Index scores (Appendix Table D47).¹⁶⁰

Acebutolol

Acebutolol was better than placebo in achieving patient perception of clinical response (Table 12).¹²¹

Antidepressants

Most RCTs that examined the effectiveness of off-label antidepressants for migraine prevention in adults (Appendix Table D49) were sponsored by industry (Appendix Table D50). Most trials were double blind with medium risk of bias (Appendix Table D51).

Amitriptyline

Amitriptyline was better than placebo in reducing monthly migraine attacks by ≥ 75 percent (Table 12).¹²⁶ RCTs demonstrated inconsistent improvement in migraine days and intensity.^{126,161}

Fluoxetine

Fluoxetine was not better than placebo in achieving an excellent self-reported clinical response.¹⁶² Improvement in pain indexes was inconsistent in RCTs.¹⁶²⁻¹⁶⁴

Venlafaxine

Venlafaxine in a dose of 150 but not 75 mg/day was better than placebo in achieving an excellent self-reported clinical response.¹⁶⁵

Femoxetine

Femoxetine was not better than placebo in achieving patient satisfaction with treatment effect or migraine frequency and severity.¹⁶⁶⁻¹⁶⁸

Mianserin

Mianserin was not better than placebo in improving migraine index or reducing migraine frequency.¹⁶⁹

Cortical Spreading Depression Inhibitor

Tonabersat

Tonabersat (one RCT of 124 adults, low strength of evidence) (Table 12) was not better than placebo in reducing monthly migraine attacks by ≥ 50 percent.¹²⁷

Calcium Channel Antagonists

Most RCTs that examined calcium channel blockers for migraine prevention in adults (Appendix Table D52) were sponsored by industry and failed to disclose conflict of interest (Appendix Table D53). All trials were double blind, with medium risk of bias (Appendix Table D54).

Nimodipine

Nimodipine was better than placebo in complete cessation of migraine attacks (Table 9)⁸⁹ Nimodipine was better than placebo in reducing monthly migraine attacks by ≥ 50 percent (Table 11).^{89,112}

Nicardipine

Nicardipine was better than placebo in reducing migraine intensity and absolute number of migraine attacks.¹⁷⁰

Verapamil

Verapamil was better than placebo in reducing composite migraine score and achieving patient satisfaction.^{171,172} Verapamil also reduced use of drugs for acute attacks.¹⁷¹

Angiotensin Converting Enzyme Inhibitors

Two RCTs examined the effects of ACE inhibitors for migraine prevention in adults (Appendix Table D55).^{88,128} One industry-funded RCT examined lisinopril (Appendix Table D56).¹²⁸ One RCT of captopril reported neither funding source nor conflict of interest.⁸⁸ Both trials were double blind with low risk of bias (Appendix Table D57).

Captopril

Captopril was examined in one small RCT that enrolled adults with comorbid hypertension and depressive symptoms for whom drugs had previously failed to prevent migraines.⁸⁸ Captopril was better than placebo in achieving complete cessation of migraine (Table 9) and improvement in Headache Index scores by more than 60 percent.⁸⁸ The effect was large. We estimated that 667 patients per 1,000 treated experienced no migraine (95% CI, 388 to 946).⁸⁸ Captopril was also better than placebo in reducing depression symptoms.⁸⁸

Lisinopril

Lisinopril was better than placebo in reducing migraine days and severity of symptoms in a single RCTs of 60 adults with episodic migraine.¹²⁸ Lisinopril also reduced the absolute number of migraine days and body pain measured with SF-36 but did not decrease use of drugs for acute attacks.¹²⁸

Angiotensin II Receptor Antagonists

Two RCTs examined the effects of angiotensin II receptor antagonists for migraine prevention in adults (Appendix Table D55).^{129,173} Both trials were funded by industry and reported conflict of interest (Appendix Table D56).^{129,173} Both trials were double blind (Appendix Table D57).

Candesartan

Candesartan was better than placebo in achieving ≥ 50 percent reduction in migraine days, hours, and severity (Table 12).¹²⁹ Candesartan also decreased migraine-related disability but had no effect on use of drugs for acute attacks.¹²⁹

Telmisartan

Telmisartan was not better than placebo in reducing monthly migraine days by ≥ 50 percent.¹⁷³ Telmisartan reduced the absolute number of migraine days but had no effect on use of drugs for acute attacks.¹⁷³

Antiadrenergics

Clonidine

Most RCTs that examined clonidine for its effects on migraine prevention in adults (Appendix Table D58) failed to report funding and conflict of interest (Appendix Table D59). Most trials were double blind but did not use intention-to-treat principles (Appendix Table D60).

Clonidine was better than placebo in ≥ 50 percent reduction in headache index¹⁷⁴ but not in increasing the number of patients considered better according to self-reported global assessment.¹⁷⁵ Clonidine also failed to achieve clinically noticeable reduction in migraine frequency.¹⁷⁶ Clonidine was better than placebo in reducing migraine duration¹⁷⁷ and use of drugs for acute attacks.¹⁷⁸

Guanfacine

Guanfacine was better than placebo in reducing monthly migraine days and migraine days with nausea or vomiting in one small RCT.¹⁷⁹

Ergot Alkaloids

All RCTs that examined effectiveness of ergot alkaloids for migraine prevention in adults (Appendix Table D61) failed to report funding and conflict of interest (Appendix Table D62). Most trials were double blind with medium risk of bias (Appendix Table D63).

Dihydroergotamine

Dihydroergotamine was not better than placebo in achieving complete cessation of migraine attacks⁹⁰ (Table 9) or in reducing monthly migraine attacks by ≥ 50 percent (Table 12).⁹⁰

Leukotriene Receptor Antagonists

Montelukast

Montelukast was not better than placebo in reducing monthly migraine attacks by ≥ 50 percent.¹³⁶

Nonsteroid Anti-Inflammatory Drugs

Individual RCTs demonstrated that aspirin, flurbiprofen, rofecoxib, and tolafenamic acid were better than placebo in reducing migraine frequency by ≥ 50 percent (Table 12).

Antipsychotic Drugs

Published RCTs did not examine antipsychotic drugs for migraine prevention. Quetiapine was examined in one uncontrolled trial of refractory migraine, defined as migraine that was previously unresponsive to the combination of atenolol, nortriptyline, and flunarizine.¹⁸⁰ Adult patients with <15 days of headache per month who were not overusing drugs for acute attacks were treated with quetiapine (75mg/day) for 10 weeks. Reduction in migraine frequency by ≥ 50 percent was achieved in 65 percent of the patients.¹⁸⁰ Patients also experienced a significant reduction in migraine days (from 10.2 to 6.2 per month), and use of drugs for acute attacks (from 2.3 to 1.2 days/week).¹⁸⁰

Antidementia Drugs

Published RCTs did not examine antidementia drugs. Retrospective review of case series and case reports demonstrated that with memantine treatment, 60 percent of the patients experienced ≥ 50 percent reduction in monthly migraine frequency, and 80 percent experienced a significant reduction in frequency of aura.^{181,182}

KQ1b. How do preventive pharmacologic treatments affect patient-centered and intermediate outcomes when compared with active pharmacologic treatments?

Individual RCTs provided low-strength direct evidence about the comparative effectiveness of drugs and demonstrated few significant differences. Indirect adjusted analysis demonstrated no differences between approved drugs and greater odds of clinical response with the angiotensin II antagonist candesartan.

Exploratory network Bayesian meta-analyses demonstrated that approved drugs were similarly better than placebo. Among off-label drug classes; however, angiotensin inhibiting drugs demonstrated the largest significant odds of reducing monthly migraine by ≥ 50 percent.

Approved Drugs

Muscle Relaxants for Chronic Migraine

Onabotulinumtoxin A

Five RCTs of 350 adults examined comparative effectiveness of onabotulinumtoxin A versus other drugs for migraine prevention (Appendix Table D64). Trials enrolled an average of 70 ± 18 patients ages 18 to 65. Subjects experienced 12 to 24 monthly migraine days. Women made up 91 percent of enrollees. Trials were funded by industry^{183,184} or grants,¹⁸⁵ with most investigators disclosing conflict of interest (Appendix Table D65). All RCTs but one¹⁸⁵ were double blind, with medium or high risk of bias due to inadequacy of randomization or unplanned intention-to-treat analyses (Appendix Table D66). The trials often concluded that both active treatments were successful based on statistically significant reduction from baseline in absolute number of migraine days or hours.

We focus on differences in outcomes at the end of the treatment with active and control drugs.

Comparative effectiveness of onabotulinumtoxin A versus topiramate was examined in two RCTs that found no significant differences in likelihood of migraine prevention or improvement in migraine disability assessment (Appendix Table D67).^{183,186} Physicians found marked

improvement in migraine frequency more often with topiramate than onabotulinumtoxin A (ARD 0.33, 95% CI, 0.10 to 0.57) (Appendix Table D67).¹⁸³ Absolute scores on the Headache Impact Test were significantly better with topiramate than onabotulinumtoxin A;¹⁸³ however, use of drugs for acute attacks did not differ between the two.¹⁸³

A single RCT examined the comparative effectiveness of onabotulinumtoxin A versus divalproex sodium and found no differences in migraine prevention with two drugs (Appendix Table D68).¹⁴² Neither did the two drugs differ for absolute number of migraine days or changes in scores from baseline in the migraine Disability Assessment Scores and/or Headache Impact Test.¹⁴²

A single RCT examined the comparative effectiveness of onabotulinumtoxin A versus amitriptyline and found no differences in migraine prevention with the two drugs (Appendix Table D69).¹⁸⁵ Evidence was insufficient due to a high risk of bias in this individual RCT.¹⁸⁵

Beta Blockers for Chronic Migraine

The National Institute of Neurological Disorders and Stroke Clinical Research Collaboration trial demonstrated no benefits from combined propranolol and topiramate treatment on migraine prevention in adults with chronic migraine for whom previous topiramate monotherapy had failed.¹⁸⁷ Propranolol combined with the antidepressant nortriptyline was no better than propranolol alone or nortriptyline in reducing the number of days with headache by ≥ 50 percent.¹⁸⁸

Antiepileptics for Episodic Migraine

Topiramate

Nine RCTs of 872 adults examined the comparative effectiveness of topiramate and other drugs for migraine prevention (Appendix Table D70). Most trials did not report funding source or conflict of interest (Appendix Table D71). All trials but one were double blind with low or medium risk of bias (Appendix Table D72).

Individual RCTs provided low-strength evidence that topiramate was more effective than amitriptyline in reducing monthly headache days by ≥ 50 percent with no differences in monthly migraine days (Table 13).¹⁸⁹ Topiramate was more effective than lamotrigine in reducing monthly headache intensity by ≥ 50 percent.⁹⁹ Differences were small (less than 20 percent absolute risk difference) but statistically significant (Appendix Table D73). Decrease in headache frequency by ≥ 50 percent did not differ between topiramate and zonisamide,¹⁹⁰ valproate,¹⁹¹ levetiracetam,¹⁹² or lamotrigine.⁹⁹ Topiramate was more effective than propranolol in reducing absolute migraine frequency, duration, and intensity.¹⁹³

Beta Blockers for Episodic Migraine

Propranolol

Most RCTs that examined the comparative effectiveness of propranolol for migraine prevention in adults (Appendix Table D74) failed to report funding (Appendix Table D75). Most trials were double blind but did not analyze the data according to planned intention-to-treat principles (Appendix Table D76). Few trials met pooling criteria (Table 14).

Propranolol Versus Topiramate

The likelihood of ≥ 50 percent reduction in monthly migraine frequency did not differ between topiramate and propranolol (Table 13 and Appendix Table D35).¹⁰⁵ Topiramate was more effective than propranolol in reducing absolute migraine frequency, duration, and intensity.¹⁹³ Use of drugs for acute attacks did not differ between the two drugs.¹⁰⁵

Propranolol Versus Timolol

The likelihood of ≥ 50 percent reduction in monthly migraine frequency did not differ between propranolol and timolol (Table 14).^{104,107}

Propranolol Versus Metoprolol

The likelihood of ≥ 50 percent reduction of the sum of severity scores or clinically important reduction in migraine days did not differ between propranolol and metoprolol (Table 14).^{194,195}

Propranolol Versus Nifedipine

Propranolol was more effective than nifedipine in reducing monthly migraine frequency by ≥ 50 percent (Table 14).^{195,196}

Propranolol Versus Clonidine

The likelihood of ≥ 50 percent reduction in migraine days did not differ between propranolol and clonidine (Table 13).¹⁹⁷

Propranolol Versus Nadolol

Nadolol, 160 mg/day, was more effective than propranolol in achieving a reduction of ≥ 50 percent in migraine frequency, duration, and intensity (Table 13).¹⁹⁸ Differences between a lower dose of nadolol (80 mg/day) and propranolol (160 mg/day) were not significant.^{198,199}

Propranolol Versus Antidepressants

The likelihood of ≥ 50 percent reduction in monthly migraine attacks did not differ between propranolol and amitriptyline²⁰⁰ nortriptyline,¹⁸⁸ or femoxetine.²⁰¹ The likelihood of ≥ 50 percent reduction in the number of migraine days did not differ between a combined therapy using both drugs and propranolol alone.¹⁸⁸

Off-Label Drugs

Off-Label Beta Blockers

RCTs that examined comparative effectiveness of off-label beta blockers for migraine prevention in adults (Appendix Table D77) failed to report funding and conflict of interest (Appendix Table D78). All trials were double blind (Appendix Table D79). All RCTs examined unique drug comparisons except two RCTs that compared the effects of metoprolol and aspirin.

Metoprolol Versus Aspirin

In pooled analyses, metoprolol and aspirin resulted in similar rates of ≥ 50 percent reduction in monthly migraine attacks (Table 14).^{202,203} Individual RCTs reported that metoprolol was more effective than aspirin, 300 mg/day,²⁰² but less effective than aspirin, 1,500 mg/day.²⁰³

Metoprolol Versus Nifedipine

Metoprolol was more effective than nifedipine in reducing monthly migraine attacks by ≥ 50 percent (Table 13).¹⁹⁵

Metoprolol Versus Bisoprolol (Appendix Table D80)

Metoprolol and bisoprolol did not differ for reduction in monthly migraine attacks by ≥ 50 percent nor absolute number of migraine days (Appendix Table D81).^{204,205}

Metoprolol Versus Nebivolol (Evidence Table D80)

Reduction in monthly migraine attacks by ≥ 50 percent did not differ between metoprolol and nebivolol.²⁰⁶ Neither migraine-related disability, use of drugs for acute attacks (Appendix Table D82), nor quality of life (Appendix Table D80) differed between metoprolol and nebivolol.²⁰⁶

Metoprolol Versus Clonidine

Reduction in monthly migraine attacks by ≥ 50 percent did not differ between metoprolol and clonidine.²⁰⁷ However, more patients noticed a reduction in migraine days with metoprolol than clonidine (Appendix Table D82).²⁰⁷

Antidepressants

Individual RCTs found no differences in the comparative effectiveness of antidepressants for migraine prevention. The likelihood of reducing monthly migraine attacks by ≥ 50 percent did not differ between fluoxetine and propranolol, nor did the duration or intensity of attacks or use of acute drugs differ.²⁰¹ Fluoxetine combined with amitriptyline versus amitriptyline alone resulted in similar migraine frequency and severity.²⁰⁸ Fluvoxamine versus amitriptyline resulted in similar migraine frequency and severity.²⁰⁹ Venlafaxine versus amitriptyline resulted in similar migraine frequency and severity.²¹⁰

Indirect Evidence of Comparative Effectiveness of Preventive Drugs for Episodic Migraine

Among all included RCTs, 97 percent examined the outcome of clinically important reduction in migraine frequency by ≥ 50 percent. We found no consistent differences in baseline patient characteristics in RCTs that examined the efficacy of various drugs for migraine prevention. We conducted exploratory Bayesian network meta-analysis (Appendix Table D83) and indirect adjusted analysis of such drugs (Appendix Table D84). We found no differences among approved drugs (Table 15). Approved drugs were more effective than off-label drugs except for the angiotensin II receptor blocker candesartan, which was more effective than topiramate, divalproex, and propranolol (Table 16). Exploratory Bayesian network meta-analysis demonstrated that the approved drugs topiramate, divalproex, and propranolol, and off-label drug classes except ergot alkaloids were better than placebo (Figure 3). The strength of the association was the largest with angiotensin inhibiting drugs (Table 17).

Next, we analyzed the comparative effectiveness of nine treatments including propranolol, timolol, metoprolol, all other off-label beta blockers (atenolol, nadolol, pindolol, bisoprolol, or nebivolol), all off-label antidepressants, all approved and off-label antiepileptics, ACE inhibitors, or angiotensin II antagonists, and all other off-label drugs. This analysis clearly demonstrated that angiotensin inhibiting drugs were more effective than all other treatments. Propranolol,

timolol, metoprolol, and all other off-label beta blockers resulted in significantly greater odds of migraine prevention than antiepileptics, antidepressants, and other off-label drugs.

Table 13. Comparative effectiveness of approved and off-label drugs on migraine prevention (50% or more reduction) in adults with episodic migraine, results from individual head-to-head randomized controlled clinical trials

Active vs. Control Drug Weeks From Randomization to Time to Measure Outcome	Reference	Sample	% With Outcome With Active [Control] Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Risk of Bias	Direct	Consistency	Precision	Strength of Evidence
Topiramate vs. Amitriptyline 26 weeks	Dodick, 2009 ¹⁸⁹	347	55.6 [45.9]	1.2 (1.0 to 1.5)	0.09 (-0.01 to 0.20)	NS	NS	Low	Yes	NA	Imprecise	Low
Topiramate vs. Lamotrigine 20 weeks	Gupta, 2007 ⁹⁹	120	63.0 [46.0]	1.4 (1.0 to 1.9)	0.17 (-0.01 to 0.34)	NS	NS	Low	Yes	NA	Imprecise	Low
Topiramate vs. Propranolol 26 weeks	Diener, 2004 ¹⁰⁵	288	34.7 [43.1]	0.8 (0.6 to 1.1)	-0.08 (-0.20 to 0.03)	NS	NS	Low	Yes	NA	Imprecise	Low
Topiramate vs. Levetiracetam 8 weeks	de Tommaso, 2007 ¹⁹²	28	61.5 [53.3]	1.2 (0.6 to 2.2)	0.08 (-0.28 to 0.45)	NS	NS	Medium	Yes	NA	Imprecise	Low
Propranolol vs. Clonidine 16 weeks	Kass, 1980 ¹⁹⁷	46	56.5 [34.8]	1.6 (0.8 to 3.2)	0.22 (-0.06 to 0.50)	NS	NS	Medium	Yes	NA	Imprecise	Low
Propranolol vs. Femoxetine 12 weeks	Kangasniemi, 1983 ²⁰¹	29	20.0 [7.1]	2.8 (0.3 to 23.9)	0.13 (-0.11 to 0.37)	NS	NS	Medium	Yes	NA	Imprecise	Low
Propranolol vs. Nadolol 12 weeks	Sudilovsky, 1987²¹¹	91	11.4 [38.3]	0.3 (0.1 to 0.7)	-0.27 (-0.44 to -0.10)	-4 (2 to 10)	-269 (102 to 437)	Medium	Yes	NA	Imprecise	Low
Femoxetine vs. Propranolol 12 weeks	Kangasniemi, 1983 ²⁰¹	24	27.3 [7.7]	3.5 (0.4 to 29.4)	0.20 (-0.10 to 0.50)	NS	NS	Medium	Yes	NA	Imprecise	Low
Nortriptyline vs. Propranolol 8 weeks	Domingues, 2009 ¹⁸⁸	49	29.2 [44.0]	0.7 (0.3 to 1.4)	-0.15 (-0.41 to 0.12)	NS	NS	Medium	Yes	NA	Imprecise	Low
Metoprolol vs. Bisoprolol 12 weeks	Worz, 1992 ²⁰⁵	250	8.8 [9.6]	0.9 (0.4 to 2.0)	-0.01 (-0.08 to 0.06)	NS	NS	Medium	Yes	NA	Imprecise	Low
Metoprolol vs. Nebivolol 18 weeks	Schellenberg, 2008 ²⁰⁶	30	57.0 [50.0]	1.1 (0.6 to 2.2)	0.07 (-0.29 to 0.43)	NS	NS	Medium	Yes	NA	Imprecise	Low

Table 13. Comparative effectiveness of approved and off-label drugs on migraine prevention (50% or more reduction) in adults with episodic migraine, results from individual head-to-head randomized controlled clinical trials (continued)

Active vs. Control Drug Weeks From Randomization to Time to Measure Outcome	Reference	Sample	% With Outcome With Active [Control] Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Risk of Bias	Direct	Consistency	Precision	Strength of Evidence
Metoprolol vs. Nifedipine 28 weeks	Gerber, 1991¹⁹⁵	39	27.3 [0.0]	10.2 (0.6 to 168.9)	0.27 (0.07 to 0.47)	4 (2 to 14)	273 (74 to 472)	Medium	Yes	NA	Imprecise	Low
Metoprolol vs. Clonidine 8 weeks	Louis, 1985 ²⁰⁷	62	32.3 [25.8]	1.3 (0.6 to 2.7)	0.06 (-0.16 to 0.29)	NS	NS	Medium	Yes	NA	Imprecise	Low
Nadolol vs. Propranolol 24 weeks	Olerud, 1986 ¹⁹⁹	28	38.5 [60.0]	0.6 (0.3 to 1.4)	-0.22 (-0.58 to 0.15)	NS	NS	Medium	Yes	NA	Imprecise	Low
Lisuride vs. Methysergide 12 weeks	Hermann, 1977 ²¹²	253	53.1 [51.2]	1.0 (0.8 to 1.3)	0.02 (-0.10 to 0.14)	NS	NS	Medium	Yes	NA	Imprecise	Low

CI = confidence interval; NA = not applicable; NS= not significant

Number needed to treat and number of attributable events were calculated for statistically significant differences.

Bold = significant differences when 95% CI of absolute risk difference do not include 0.

Table 14. Comparative effectiveness of drugs for migraine prevention in adults with episodic migraine, direct evidence from head-to-head randomized controlled clinical trials (pooled with random effects model)

Active Preventive Treatment References	Outcome	Sample	Rate, Percent With Active [Control] Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Strength of Evidence Reasons for Lowering SOE
Timolol vs. Propranolol ^{104,107}	≥50% decrease in migraine frequency	242	47.9 [52.1]	1.0 (0.7 to 1.2)	-0.03(-0.15 to 0.10)	NS	NS	Low (medium ROB, imprecision)
	p value			0.593	0.606			
	I squared			0	0			
Propranolol vs. Metoprolol ^{194,195}	≥50% decrease in migraine frequency	113	38.2 [50.0]	0.8 (0.5 to 1.2)	-0.12 (-0.30 to 0.06)	NS	NS	Low (medium ROB, imprecision)
	p value			p = 0.371	p = 0.361			
	I squared			0	0			
Propranolol vs. Nifedipine ^{195,196}	≥50% decrease in migraine frequency	76	46.2 [18.9]	2.3 (1.1 to 4.6)	0.27 (0.09 to 0.46)	4 (2 to 11)	274 (89 to 458)	Low (high ROB, imprecision)
Metoprolol vs. Aspirin ^{202,203}	≥50% decrease in migraine frequency	326	33.1 [39.3]	1.6 (0.2 to 11.0)	0.11 (-0.43 to 0.65)	NS	NS	Low (medium ROB, imprecision)
	p value			0.001	0			
	I squared			0.907	0.948			

ROB = risk of bias; SOE = strength of evidence; NS= not significant; CI = confidence interval

Bold = significant effects of drugs on treatment response when 95% CI of attributable events per 1,000 treated do not include 0. Number needed to treat and number of attributable events were calculated for statistically significant differences

Table 15. Indirect adjusted comparative effectiveness of clinical response* in RCTs of approved drugs for the prophylaxis of episodic migraine

Active	Control -- Propranolol	Control -- Timolol	Control -- Topiramate	Control -- Divalproex
Divalproex	1.1 (0.4 to 2.9)	1.0 (0.4 to 2.7)	0.9 (0.3 to 2.5)	1
Propranolol	1	0.9 (0.4 to 1.7)	0.8 (0.4 to 1.6)	0.9(0.3;2.3)
Timolol	1.2(0.6;2.3)	1	1.0 (0.5 to 2.0)	1.0(0.4;2.9)
Valproate	1.4 (0.5 to 4.5)	1.2 (0.4 to 4.1)	1.2 (0.4 to 3.8)	1.3 (0.3 to 5.0)

CI = confidence interval; RCT = randomized controlled trial

*Clinical response was defined as ≥ 50 percent reduction in monthly migraine frequency or self-reported substantial reduction in monthly migraine frequency Differences are significant when 95% CI of odds ratios do not include 1; odds ratios of each drug versus placebo were compared with each other to calculate presented odds ratios with 95% CI.

Table 16. Indirect adjusted comparative effectiveness of clinical response* in RCTs of approved drugs versus off-label drugs for the prophylaxis of episodic migraine

Active	Control -- Divalproex	Control Propranolol	Control -- Timolol	Control -- Topiramate	Control -- Valproate
Acebutolol	2.8 (0.5;16.7)	3.2 (0.6;15.9)	2.7 (0.5;14.2)	2.6 (0.5;13.5)	2.2 (0.3;14.5)
Acetazolamide	0.3 (0.1;1.2)	0.3 (0.1;1.1)	0.3 (0.1;1.0)	0.3 (0.1;0.9)	0.2 (0.0;1.1)
Amitriptyline	1.0 (0.3;3.9)	1.1 (0.4;3.5)	1.0 (0.3;3.2)	0.9 (0.3;3.0)	0.8 (0.2;3.5)
Aspirin	0.3 (0.1;0.6)	0.3 (0.2;0.4)	0.2 (0.1;0.4)	0.2 (0.1;0.4)	0.2 (0.1;0.6)
Atenolol	8.0 (0.4;167.6)	9.0 (0.5;171.2)	7.7 (0.4;150.9)	7.5 (0.4;144.4)	6.3 (0.3;139.7)
Candesartan	5.7 (1.0;32.2)	6.4 (1.4;30.4)	5.5 (1.1;27.3)	5.3 (1.1;26.0)	4.5 (0.7;28.1)
Clonidine	0.7 (0.2;2.4)	0.8 (0.3;2.0)	0.7 (0.3;1.9)	0.7 (0.2;1.8)	0.6 (0.1;2.1)
Dihydroergotamine	0.4 (0.1;1.0)	0.4 (0.2;0.8)	0.4 (0.2;0.7)	0.4 (0.2;0.7)	0.3 (0.1;0.9)
Fenoprofen	0.2 (0.1;0.9)	0.3 (0.1;0.8)	0.2 (0.1;0.8)	0.2 (0.1;0.7)	0.2 (0.0;0.8)
Flurbiprofen	1.7 (0.4;7.6)	1.9 (0.5;7.0)	1.6 (0.4;6.3)	1.5 (0.4;6.0)	1.3 (0.3;6.7)
Indomethacin	0.4 (0.1;2.1)	0.5 (0.1;2.0)	0.4 (0.1;1.8)	0.4 (0.1;1.7)	0.3 (0.1;1.9)
Lamotrigine	0.6 (0.2;1.7)	0.6 (0.3;1.4)	0.5 (0.2;1.3)	0.5 (0.2;1.3)	0.4 (0.1;1.6)
Lisinopril	11.9 (0.6;233.2)	13.4 (0.8;237.7)	11.6 (0.6;209.6)	11.2 (0.6;200.5)	9.4 (0.4;194.7)
Lisuride	0.6 (0.2;1.7)	0.6 (0.3;1.4)	0.5 (0.2;1.3)	0.5 (0.2;1.2)	0.4 (0.1;1.5)
Montelukast	0.4 (0.1;1.2)	0.4 (0.2;1.0)	0.4 (0.2;0.9)	0.4 (0.2;0.8)	0.3 (0.1;1.1)
Nadolol	1.9 (0.1;42.4)	2.1 (0.1;43.4)	1.8 (0.1;38.2)	1.8 (0.1;36.6)	1.5 (0.1;35.3)
Nifedipine	3.2 (0.7;14.2)	3.6 (1.0;13.0)	3.1 (0.8;11.8)	3.0 (0.8;11.2)	2.5 (0.5;12.6)
Oxcarbazepine	0.3 (0.1;0.8)	Not able to calculate	0.3 (0.1;0.6)	0.3 (0.1;0.6)	0.2 (0.1;0.7)
Rofecoxib	0.8 (0.2;2.9)	0.3 (0.1;0.6)	0.8 (0.3;2.3)	0.8 (0.3;2.2)	0.7 (0.2;2.6)
Telmisartan	0.5 (0.1;1.8)	0.6 (0.2;1.6)	0.5 (0.2;1.4)	0.5 (0.2;1.4)	0.4 (0.1;1.6)
Tolfenamic Acid	3.8 (0.6;23.2)	4.2 (0.8;22.1)	3.7 (0.7;19.8)	3.5 (0.7;18.8)	3.0 (0.4;20.1)
Tonabersat	0.4 (0.1;1.1)	0.4 (0.2;1.0)	0.4 (0.1;0.9)	0.3 (0.1;0.8)	0.3 (0.1;1.0)
Gabapentin	0.8 (0.3;2.5)	0.9 (0.4;1.8)	0.7 (0.3;1.7)	0.7 (0.3;1.6)	.59 (0.2;2.0)
Mg	0.5 (0.1;1.7)	0.5 (0.2;1.3)	0.4 (0.2;1.2)	0.4 (0.2;1.2)	0.4 (0.1;1.4)
Nimodipine	2.0 (0.2;0.0)	2.1 (0.2;24.3)	1.8 (0.2;21.6)	1.8 (0.2;20.6)	1.42 (0.1;0.0)

CI = confidence interval; RCT = randomized controlled trial

*Clinical response was defined as ≥ 50 percent reduction in monthly migraine frequency or self-reported substantial reduction in monthly migraine frequency Bold = differences are significant when 95% CI of odds ratios do not include 1; odds ratios of each drug vs. placebo were compared with each other to calculate presented odds ratios with 95% CI

Table 17. Odds ratio of clinical response with preventive drugs, results from exploratory Bayesian network meta-analysis


Active	Subjects	Control -- Divalproex	Control -- Propranolol	Control -- Angiotensin Inhibiting Drugs	Control -- NSAID	Control -- Beta Blockers	Control -- Antidepressants	Control -- Antiepileptics	Control -- Ergot Alkaloids	Control -- Clonidine	Control -- Ca ++ Blockers
Topiramate 16 RCTs	1,812	0.8 (0.4 to 1.4)	0.9 (0.5 to 1.4)	0.4 (0.2 to 1.1)	1.0 (0.5 to 1.9)	0.7 (0.4 to 1.2)	1.2 (0.6 to 2.0)	1.2 (0.7 to 2.0)	1.7 (0.6 to 4.2)	0.7 (0.3 to 1.3)	0.9 (0.4 to 2.7)
Divalproex 8 RCTs	419	1	1.1 (0.6 to 2.0)	0.6 (0.2 to 1.6)	1.3 (0.6 to 2.8)	1.0 (0.5 to 1.9)	1.5 (0.7 to 3.1)	1.5 (0.8 to 3.1)	2.2 (0.8 to 5.9)	0.9 (0.4 to 1.9)	1.2 (0.5 to 3.6)
Propranolol 24 RCTs	1,172	0.9 (0.5 to 1.5)	1	0.5 (0.2 to 1.2)	1.1 (0.6 to 2.2)	0.8 (0.5 to 1.3)	1.3 (0.8 to 2.3)	1.3 (0.8 to 2.4)	1.9 (0.7 to 4.8)	0.8 (0.4 to 1.4)	1.0 (0.4 to 2.9)
Angiotensin inhibiting drugs 5 RCTs	180	1.8 (0.6 to 5.2)	2.1 (0.8 to 5.2)	1	2.3 (0.8 to 6.6)	1.7 (0.7 to 4.6)	2.8 (1.0 to 7.5)	2.7 (1.0 to 7.5)	3.9 (1.2 to 13.8)	1.6 (0.6 to 4.5)	2.1 (0.7 to 8.2)
NSAID 9 RCTs	11,442	0.8 (0.4 to 1.7)	0.9 (0.5 to 1.7)	0.4 (0.2 to 1.2)	1	0.7 (0.4 to 1.4)	1.2 (0.6 to 2.5)	1.2 (0.6 to 2.6)	1.7 (0.6 to 4.6)	0.7 (0.3 to 1.6)	0.9 (0.3 to 2.9)
Beta blockers 17 RCTs	714	1.0 (0.5 to 2.0)	1.2 (0.7 to 1.9)	0.6 (0.2 to 1.5)	1.3 (0.7 to 2.6)	1	1.6 (0.9 to 2.9)	1.6 (0.9 to 3.1)	2.3 (0.9 to 5.9)	0.9 (0.5 to 1.7)	1.2 (0.5 to 3.6)
Antidepressants 10 RCTs	595	0.7 (0.3 to 1.4)	0.7 (0.4 to 1.3)	0.4 (0.1 to 1.0)	0.8 (0.4 to 1.8)	0.6 (0.3 to 1.2)	1	1.0 (0.5 to 2.0)	1.4 (0.5 to 3.8)	0.6 (0.3 to 1.2)	0.8 (0.3 to 2.3)
Antiepileptics 9 RCTs	457	0.7 (0.3 to 1.3)	0.8 (0.4 to 1.3)	0.4 (0.1 to 1.0)	0.9 (0.4 to 1.8)	0.6 (0.3 to 1.2)	1.0 (0.5 to 2.0)	1	1.4 (0.5 to 3.9)	0.6 (0.3 to 1.3)	0.8 (0.3 to 2.3)
Ergot alkaloids 2 RCTs	259	0.5 (0.2 to 1.3)	0.5 (0.2 to 1.4)	0.3 (0.1 to 0.9)	0.6 (0.2 to 1.7)	0.4 (0.2 to 1.2)	0.7 (0.3 to 1.9)	0.7 (0.3 to 2.0)	1	0.4 (0.1 to 1.2)	0.5 (0.2 to 2.1)
Clonidine 7 RCTs	271	1.1 (0.5 to 2.4)	1.3 (0.7 to 2.3)	0.6 (0.2 to 1.7)	1.4 (0.6 to 3.2)	1.1 (0.6 to 2.0)	1.7 (0.8 to 3.6)	1.7 (0.8 to 3.7)	2.4 (0.8 to 6.7)	1	1.3 (0.5 to 4.1)
Ca++ blockers 4 RCTs	136	0.9 (0.3 to 2.2)	1.0 (0.4 to 2.3)	0.5 (0.1 to 1.5)	1.1 (0.3 to 2.9)	0.8 (0.3 to 2.0)	1.3 (0.4 to 3.2)	1.3 (0.4 to 3.4)	1.8 (0.5 to 6.0)	0.8 (0.2 to 2.1)	1

NSAID = nonsteroidal anti-inflammatory drugs; RCT = randomized controlled trial

*Clinical response (defined as ≥50 percent reduction in monthly episodic migraine frequency or self-reported substantial reduction in monthly migraine frequency Bold = differences are significant when 2.5 to 97.5% credible intervals of odds ratios do not include 1.

We used heterogeneous random effects model that assumes correlation within study ($\rho = 0.5$) and heterogeneous between studies (WinBUG codes are in Appendix B) NSAID nonsteroidal anti-inflammatory drugs.

Figure 3. Bayesian network meta-analysis of clinical response to drugs versus placebo (66 RCTs of 14,774 adults) in randomized controlled clinical trials that aimed to prevent migraine in adults



CrI = credible intervals; NSAID = nonsteroidal anti-inflammatory drugs

Clinical response was defined as $\geq 50\%$ reduction in monthly migraine attacks or perceived clinically important treatment success. We used heterogeneous random effects model that assumes correlation within study ($\rho = 0.5$) and heterogeneous between studies (WinBUG codes are in Appendix B).

KQ1c. How do preventive pharmacologic treatments affect patient-centered and intermediate outcomes when compared with active nonpharmacologic treatments?

Antiepileptics

Topiramate Versus Exercise or Relaxation

The likelihood of ≥ 50 percent reduction in monthly migraine frequency did not differ between topiramate and aerobic exercise or common forms of relaxation, breathing, and stress-management techniques.²¹³ Migraine days, pain intensity, quality of life, or acute drug use did not differ between topiramate and aerobic exercise or relaxation.²¹³

Beta Blockers

Propranolol Versus Biofeedback

The likelihood of a reduction in monthly migraine frequency of ≥ 25 percent did not differ between propranolol and diaphragmatic breathing and systematic relaxation that was assisted by biofeedback and also practiced at home.²¹⁴

Antidepressants

Amitriptyline Versus Spinal Manipulation

Amitriptyline was more effective than spinal manipulation for reducing monthly migraine attacks during the trial but less effective during post-treatment followup period.²¹⁵ Evidence was low-strength due to risk of bias and imprecision (Appendix Table D85). Evidence from a single high-risk-of-bias RCT was insufficient to conclude the comparative effectiveness of amitriptyline versus biofeedback.²¹⁶

KQ1d. How do preventive pharmacologic treatments combined with nondrug treatments affect patient-centered and intermediate outcomes when compared with pharmacologic treatments alone?

Five RCTs compared the effectiveness of drugs combined with nondrug treatments with placebo or pharmacologic treatments alone (Appendix Table D86). Most trials were funded by nonprofit grants (Appendix Table D87). Risk of bias was low in one trial, medium in two, and high in two (Appendix Table D88).

Beta Blockers

Behavioral migraine management and relaxation combined with propranolol (maximum dose 240 mg/day) or nadolol (maximum dose 120 mg/day) was more effective than placebo in reducing monthly migraine frequency by ≥ 50 percent (Appendix Table D89). However, effects of the combined therapy did not differ from the effects of drugs alone.²¹⁷ Evidence of effectiveness and safety was low due to imprecise estimates from a single RCT (Appendix Table D90).²¹⁷ We estimated that 387 adults per 1,000 treated would experience a reduction in migraine frequency by ≥ 50 percent (95% CI, 157 to 618) with combined therapy (Table 18).²¹⁷

Propranolol (240 mg/day) or nadolol (120 mg/day) combined with behavioral therapy (orientation plus relaxation training, migraine warning signs and triggers, effectively using migraine medication, reducing impact of migraines, stress management or biofeedback training, and migraine management plan) was more effective than placebo in improving self-efficacy (Appendix Table D91).²¹⁸

Evidence was insufficient from a single high-risk-of-bias RCT that compared the effectiveness of propranolol combined with biofeedback and propranolol alone for migraine prevention in adults.²¹⁶

Antidepressants

Amitriptyline Combined With Spinal Manipulation Versus Amitriptyline Alone or Spinal Manipulation Alone (Table 19)²¹⁵

Spinal manipulation was more effective than combined treatment in reducing Headache Index scores.²¹⁵ Combined treatment was not more effective than amitriptyline alone in improving general health status or reducing use of drugs for acute attacks (Appendix Table D92).²¹⁵ Evidence from a single high-risk-of-bias RCT was insufficient to conclude comparative effectiveness between amitriptyline combined with biofeedback and the drug alone.²¹⁶

Table 18. Comparative effectiveness of beta blockers combined with behavioral therapy* for episodic migraine prevention in adults, results from individual low risk of bias randomized controlled clinical trial²¹⁷

Outcome	Active Treatment	Control	Sample	Rate % in Active [Control] Group	Number Needed To Treat (95% CI)	Attributable Events (95% CI)	Strength of Evidence
Clinically improved (≥50% reduction in migraines) at month 10	Behavioral migraine management + propranolol/nadolol	Placebo	90	76.8 [40.0]	3 (2 to 6)	387 (157 to 618)	Low
Clinically improved (≥50% reduction in migraines) at month 10	Behavioral migraine management + placebo	Propranolol/nadolol	108	34.5 [34.0]	NS	NS	Low
Clinically improved (≥50% reduction in migraines) at month 10	Behavioral migraine management + propranolol/nadolol	Propranolol/nadolol	122	76.8 [34.0]	2 (2 to 4)	428 (267 to 590)	Low
Clinically improved (≥50% reduction in migraines) at month 10	Behavioral migraine management + placebo	Behavioral migraine management + Propranolol/nadolol	124	34.5 [76.8]	-2 (2 to 4)	-423 (262 to 583)	Low

CI = confidence interval; NS= not significant

*Behavioral therapy included orientation+relaxation training; migraine warning signs and triggers; effectively using migraine medication, and reducing impact of migraines; stress management or biofeedback training; migraine management plan; Bold = significant at 95% confidence limit when 95% CI of attributable events per 1,000 treated do not include 0. Number needed to treat and number of attributable events were calculated for statistically significant differences.

Table 19. Comparative effectiveness of antidepressant amitriptyline and spinal manipulation for episodic migraine prevention in adults, individual medium risk of bias randomized controlled clinical trial²¹⁵

Definition of the Outcome	Active Treatment	Control Treatment	Sample	Rate, % With Active vs. [Control] Treatment	Number Needed To Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Strength of Evidence
>60% reduction in HI in last 4 weeks of treatment phase	Spinal manipulation	Amitriptyline 100 mg/day	147	22.1 [48.6]	-4 (-9 to -2)	-265 (-414 to -116)	Low
>60% reduction in HI during the 4-week post-treatment followup phase	Spinal manipulation	Amitriptyline 100 mg/day	147	22.1 [15.7]	NS	NS	Low
Reduction in HI (headache index) scores during treatment compared with baseline	Spinal manipulation	Spinal manipulation + amitriptyline 100 mg/day	148	40.3 [40.8]	NS	NS	Low
Reduction in HI from baseline during the post-treatment followup period	Spinal manipulation	Spinal manipulation + amitriptyline 100 mg/day	148	41.6 [25.4]	6 (3 to 80)	162 (13 to 312)	Low
Reduction in HI (headache index) scores during treatment compared with baseline	Spinal manipulation	Spinal manipulation + amitriptyline 100 mg/day	148	40.3 [40.8]	NS	NS	Low
Reduction in HI from baseline during the post-treatment followup period	Spinal manipulation	Spinal manipulation + amitriptyline 100 mg/day	148	41.6 [25.4]	6 (3 to 80)	162 (13 to 312)	Low

CI = confidence interval; HI = Headache Index; NS = not significant

Number needed to treat and number of attributable events were calculated for statistically significant differences.

Bold = significant differences at 95% confidence limit when 95% CI of attributable events per 1,000 treated do not include 0.

KQ1e1. How might dosing regimens or duration of treatments influence the effects of the treatments on patient-centered outcomes?

Muscle Relaxants

Onabotulinumtoxin A

Dose Response Migraine Prevention With Onabotulinumtoxin A

Higher doses of onabotulinumtoxin A resulted in a greater decrease in absolute migraine frequency according to the BoNTA-024-026-036 Study Group in adults with chronic migraine.²¹⁹ Higher doses of onabotulinumtoxin A resulted in less frequent use and overuse of acute pain medications at 1 and 3 months of followup according to the BoNTA-039 Study Group (Appendix Table D93).¹³⁸ However, neither patients nor investigators found differences in global assessment of improvement with higher doses of onabotulinumtoxin A (Appendix Table D94).¹³⁹

Higher doses of abobotulinumtoxin A did not increase the rates of positive global assessment of the treatment effect in the Dysport[®] In Migraine Without Aura Prophylaxis trial.¹³⁹ Higher doses of abobotulinumtoxin A did not reduce migraine duration or intensity¹³⁹ or depression scores.¹⁴⁴

Antiepileptics

Topiramate

Increase in topiramate dose from 50 to 100 mg/day resulted in a higher response rate (≥ 50 percent reduction in monthly migraine frequency) without additional benefit from increasing the dose to 200 mg/day (Appendix Table D95). Higher topiramate doses (50 to 100 mg) resulted in significant migraine prevention of ≥ 50 percent in one patient for every six treated (Table 20).

Divalproex

Higher doses of divalproex did not result in a greater likelihood of clinically important migraine frequency reduction (Appendix Table D96).¹⁰³

Beta Blockers

Propranolol

Increasing propranolol dose did not result in a greater likelihood of clinically important reduction in migraine frequency.²²⁰⁻²²³

Off-Label Beta Blockers

Individual RCTs examined dose response effects with pindolol,²²⁴ nadolol,^{225,226} and bisoprolol.²²⁷

Pindolol

Pindolol, 15 mg/day, was more effective than 7.5 mg in reducing migraine days and duration.²²⁴

Nadolol

Nadolol, 160 to 240 mg/day, was more effective than 80 mg/day in reducing migraine frequency and severity.^{225,226}

Bisoprolol

Bisoprolol, 10 mg/day, was more effective than 5 mg/day in reducing migraine duration but not frequency.²²⁷

Antidepressants

Amitriptyline

Amitriptyline, 50 mg/day, was not more effective than 25 mg/day in reducing migraine frequency or severity.²²⁸

Venlafaxine

Venlafaxine, 150 mg/day, resulted in excellent global self-reported efficacy more often than 75 mg/day.¹⁶⁵

Table 20. Dose response reduction in migraine attacks by ≥50% from baseline with topiramate in adults

Reference Risk of Bias	Topiramate Daily Doses	Events/Randomized With Larger vs. Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed To Treat (95% CI)	Attributable Events (95% CI)
Brandes, 2004 ²²⁹ Risk of bias: Low	100mg vs. 50mg/day	60/122 47/120	1.3 (0.9 to 1.7)	0.10 (-0.02 to 0.23)	NS	NS
Silberstein, 2003⁹⁷ Risk of bias: Medium	100mg vs. 50mg/day	68/125 41/117	1.5 (1.1 to 2.1)	0.19 (0.07 to 0.31)	5 (3 to 15)	189 (67 to 312)
Silberstein, 2004²³⁰ Risk of bias: Low	100mg vs. 50mg/day	69/128 45/125	1.5 (1.1 to 2.0)	0.18 (0.06 to 0.30)	6 (3 to 17)	179 (58 to 300)
Pooled	100mg vs. 50mg/day	196/375 133/362	1.4 (1.2 to 1.7)	0.16 (0.09 to 0.23)	6 (4 to 12)	157 (86 to 228)
Brandes, 2004 ²²⁹ Risk of bias: Low	100mg vs. 50mg/day	57/121 47/120	1.2 (0.9 to 1.6)	0.08 (-0.05 to 0.20)	NS	NS
Silberstein, 2003⁹⁷ Risk of bias: Medium	200mg/day vs. 50mg/day	58/112 41/117	1.5 (1.1 to 2.0)	0.17 (0.04 to 0.29)	6 (3 to 24)	167 (41 to 294)
Silberstein, 2004²³⁰ Risk of bias: Low	200mg/day vs. 50mg/day	61/117 45/125	1.4 (1.1 to 1.9)	0.16 (0.04 to 0.29)	6 (4 to 26)	161 (38 to 285)
Pooled	200mg/day vs. 50mg/day	176/350 133/362	1.4 (1.2 to 1.6)	0.14 (0.06 to 0.21)	7 (5 to 16)	136 (64 to 208)
Brandes, 2004 ²²⁹ Risk of bias: Low	200mg/day vs. 100mg/day	57/121 60/122	1.0 (0.7 to 1.2)	-0.02 (-0.15 to 0.11)	NS	NS
Silberstein, 2003 ⁹⁷ Risk of bias: Medium	200mg/day vs. 100mg/day	58/112 68/125	1.0 (0.8 to 1.2)	-0.02 (-0.15 to 0.11)	NS	NS
Silberstein, 2004 ²³⁰ Risk of bias: Low	200mg/day vs. 100mg/day	61/117 69/128	1.0 (0.8 to 1.2)	-0.02 (-0.14 to 0.11)	NS	NS
Pooled	200mg/day vs. 100mg/day	176/350 196/375	1.0 (0.8 to 1.1)	-0.02 (-0.09 to 0.05)	NS	NS

CI = confidence interval; NS = not significant

Bold = significant at 95% confidence limit when 95% CI of attributable events per 1,000 treated do not include 0.

Number needed to treat and number of attributable events were calculated for statistically significant differences.

KQ1e2. How might approaches to drug management (such as patient-care teams, integrated care, coordinated care, patient education, drug surveillance, or interactive drug monitoring) influence results?

Six RCTs of 3,825 adults examined the effectiveness of drug management for migraine prevention in adults (Table 21 and Appendix Table D97). Most trials were sponsored by nonprofit organizations (Appendix Table D98). Half of the trials had low risk of bias, and the other half had medium risk of bias due to inadequacy of randomization (Appendix Table D99). Four RCTs examined the effectiveness of multidisciplinary migraine management programs and two examined the effectiveness of pharmacist-led drug management (Appendix Table D100).

Multidisciplinary Intervention Versus Standard Care

The community-based multidisciplinary intervention included intake by a neurologist, physical therapist, and a psychologist, with group-supervised exercise therapy sessions, massage therapy sessions, and group lectures with a dietitian²³¹ (Appendix Table D100). Adherence did not differ between the multidisciplinary intervention and standard medical care with the patient's primary physician (Appendix Table D101).²³¹ The multidisciplinary intervention was more effective in improving quality of life and reducing migraine-related disability (Appendix Table D102).²³¹ We found no statistically significant changes in medication use or work status.²³¹

Migraine Management Program Versus Usual Care

A multidisciplinary migraine management program was administered by a midlevel provider (e.g., nurse practitioner or physician assistant) with expertise in migraine evaluation and management.²³² The program included an educational session in which patients received materials that described: migraine types and etiologies, triggers, sleep hygiene, pharmacologic treatment, and relaxation techniques.²³² Patients in the control group continued with their current clinician, without access to the migraine management program. Fewer adults had migraine-related disability at 6 months of followup with the migraine management program (Appendix Table D103).²³² We estimated that 196 adults per 1,000 treated (95% CI, 125 to 258) would have no migraine-related disability with the migraine management intervention.²³² The program was also more effective than usual care in improving quality of life and treatment satisfaction (Appendix Table D104).²³²

Cognitive Behavioral Minimal Contact Program Versus Usual Care

The cognitive-behavioral minimal contact program consisted of five sessions that provided information about migraine and progressive muscle relaxation, acute and prophylactic migraine medications, and triggers for medication overuse (e.g., availability of drugs, fear of attack and loss of social functioning, and stress level in private and professional life). Participants also established individualized goals for future drug intake and improving quality of life.²³³ The cognitive-behavioral minimal contact program did not decrease migraine frequency or duration of migraine related disability (Appendix Table D105),²³³ nor did it improve engagement in social activity, self-management of pain, migraine-related anxiety, or depression.²³³ However, patient satisfaction with treatment was significantly greater with the cognitive-behavioral minimal contact program than with usual care.²³³

Headache School Versus Usual Care

Headache school involved a standardized curriculum of didactic instructions regarding migraine biogenesis and management. It consisted of classes taught by neurologists and migraine sufferers who previously had undergone intensive classroom training. Headache school classes focused mostly on acute preventive drug treatments.²³⁴ Patients in the control group received routine drug management.²³⁴ Patients who attended headache school less often overused drugs for acute attacks than patients receiving routine drug management (Appendix Table D106).²³⁴ Attending headache school also reduced migraine disability (Appendix Table D107).²³⁴

Pharmaceutical Care for Migraine Versus Standard Counseling

Pharmaceutical care intervention was defined as intensified structured counseling between patient and pharmacist and the use of drug databases. German pharmacists worked with patients individually to prioritize problems, define goals, and devise plans to work toward goals.²³⁵ Patients in the control group received standard counseling that included general information about benefits and possible adverse drug effects.²³⁵ Pharmaceutical care resulted in a statistically significant improvement from baseline in mental health and self-efficacy.²³⁶ However, the likelihood of complete migraine cessation did not differ between active and control interventions (Appendix Table D108)²³⁵ nor did the absolute number of migraine attacks or quality of life (Appendix Table D109).²³⁵

Intensive Pharmaceutical Care Campaign Versus Control Pharmacy

Danish pharmacists and pharmacy assistants provided the intervention according to the manual developed by the Danish College of Pharmacy Practice.²³⁶ The campaign targeted inappropriate use of triptans. Intervention pharmacy staff received information about migraine, detection of inappropriate triptan use and other drug-related problems, and techniques for establishing a private dialogue with patients.²³⁶ The campaign had no statistically significant impact on use of triptans (Appendix Table D110).²³⁶

Table 21. Prevention of migraine with drug management programs, results from individual randomized controlled clinical trials

Reference/Treatment vs. Control Sample/Risk of Bias	Description	Results
Lemstra, 2002 ²³¹ Multidisciplinary intervention vs. standard medical care with the patient's family physician Sample: 80 Risk of bias: Medium	Multidisciplinary intervention consisted of a neurologist intake, physical therapist intake, 18 group-supervised exercise therapy sessions with an exercise therapist, 2 group lectures with a registered psychologist 1 group lecture with a dietitian, 2 massage therapy sessions, and a neurologist and physical therapist.	More effective in improving quality of life and reducing migraine related disability with no statistically significant changes in the use of acute drugs or work status.
Matchar, 2008 ²³² Headache management program vs. continue with current clinician Sample: 614 Risk of bias: Medium	Headache management program consisting of: (1) a class specifically designed to inform patients about headache types, triggers, and treatment options; (2) diagnosis and treatment by a professional especially trained in headache care (based on U.S. Headache Consortium guidelines); and (3) proactive followup by a case-manager.	More effective in improving quality of life and satisfaction with care; 196 adults per 1,000 treated (95% CI, 125 to 258) had no migraine-related disability with the headache management program.
Fritsche, 2010 ²³³ Cognitive-behavioral minimal contact program (MCT) vs. two brochures Sample: 158 Risk of bias: Low	The program consisted of 5 sessions with six participants and lasting 2 hours each: (1) Introduction and syndrome education; (2) Medication rules and the risk of medication overuse headache, including information about prophylactic migraine medication and medication overuse; (3) Medication intake behavior, aimed at raising awareness for "external" and "internal" influences on patient's medication intake behavior; (4) General and personal risk factors for drug intake; and (5) Everyday transfer aimed at establishing individual goals for future drug intake and learning how to make use of social support to control intake behavior.	More effective in patient satisfaction. No effects on migraine frequency or duration of migraine related disability, social activity engagement, pain self-management, or migraine related anxiety and depression.
Rothrock, 2006 ²³⁴ Standardized course of didactic instructions regarding migraine biogenesis and management ("headache school") Sample: 100 Risk of bias: Medium	The curriculum consisted of 3 90-minute classes held on evenings and weekends and taught by lay migraineurs who previously had undergone intensive classroom and in-clinic training by neurology investigators. All individuals serving as patient instructors underwent 12 hours of classroom instruction in headache theory and treatment, received and reviewed a related course syllabus, were required to pass a written examination based on that didactic instruction, and then served a minimum of 12 hours as observers in the headache clinics.	Decreased overuse of acute drugs and reduced migraine disability.
Hoffmann, 2008 ²³⁵ Pharmaceutical care for migraine vs. regular pharmaceutical consultation Sample: 410 Risk of bias: Low	Pharmacists from the intervention pharmacies participated in a 2-day central training program conducted by a physician and a pharmacist. Together with the patient, the intervention pharmacist prioritized problems, defined goals, and devised a plan to work toward them. The training was based on a comprehensive standard operation manual developed by the Federal Union of German Associations of Pharmacists, in cooperation with the principal.	Complete migraine cessation did not differ between active and control intervention.
Sondergaard, 2006 ²³⁶ Intensive pharmaceutical care campaign Sample: 2463 Risk of bias: Low	Pharmacists from the intervention pharmacies identified inappropriate triptan use, established a dialogue with individual patients and offered advice about migraine management with preventive drugs to reduce triptan overuse. The training package was developed in cooperation with the Danish College of Pharmacy Practice.	Significant improvement in mental health and self-efficacy; no statistically significant impact on use of triptans.

Key Question 2. What are the comparative harms from pharmacologic treatments for preventing migraine attacks in adults?

We identified 15 RCTs and six nonrandomized studies that examined the safety of onabotulinumtoxin A for chronic migraine prevention in adults. We identified 159 RCTs of 18,134 adults that examined the safety of drugs for episodic migraine prevention in adults.

Among approved drugs, onabotulinumtoxin A, topiramate, and propranolol resulted in bothersome adverse effects leading to treatment discontinuation more often than placebo.

The association was dose responsive for topiramate. Larger doses of topiramate caused higher risk of anorexia, depression, paresthesia, and difficulty in memory leading to treatment withdrawal. Larger doses of topiramate caused higher risk dry mouth, paresthesia or fatigue, mood problems, nausea, and weight loss.

Individual RCTs showed that divalproex caused adverse effects that led to treatment discontinuation, including nausea, somnolence, tremor, vomiting, and asthenia.

Among other drugs, pooled analyses demonstrated that off-label antidepressant amitriptyline caused bothersome adverse effects leading to treatment discontinuation more often than placebo.

Limited low-strength direct comparative evidence from individual head-to-head RCTs suggested that treatment discontinuation due to adverse effects was less frequent with onabotulinumtoxin A than topiramate or amitriptyline. Individual unique RCTs provided low-strength direct evidence about adverse effects with specific drugs with no consistent pattern across available drug comparisons.

Indirect adjusted analyses demonstrated no differences in treatment discontinuation due to adverse effects with approved drugs or approved versus off-label drugs. Exploratory Bayesian network meta-analyses demonstrated that topiramate and off-label antiepileptics and antidepressants resulted in bothersome adverse effects leading to treatment discontinuation more often than placebo. According to network meta-analysis, off-label angiotensin inhibiting drugs and beta blockers were the safest treatment option for adults with episodic migraine.

KQ2a. What are the harms from preventive pharmacologic treatments when compared with placebo or no active treatment?

We identified 83 RCTs that compared adverse drug effects with placebo. Most studies failed to disclose conflict of interest by trial investigators (Appendix Table D111). The results from these 83 trials that were a subset of RCTs that examined benefits with drugs for episodic migraine prevention in adults were applicable to the target population (Appendix Table D112). Women made up an average of 78 percent of all enrollees. Mean age of the enrollees varied from 29 to 49 years. Patients had an average 5.5 monthly migraine attacks. The trials followed for an average 18 weeks to assess adverse effects (Appendix Table D113). Sample size averaged 116 adults (range 12 to 818). RCTs reporting harms were not necessarily powered to detect statistically significant differences in adverse effects.

We concluded medium risk of bias in 54 RCTs and low risk of bias in 22 RCTs (Appendix Table D114). Most studies were double blind. Nonrandomized studies with high risk of bias suggested that 10 to 20 percent of patients discontinued antiepileptic drug treatments at one year or longer of followup (Appendix Table D115).

We focused on treatment discontinuation due to any and specific adverse effects from pooled analyses (Table 22).

Muscle Relaxants

Onabotulinumtoxin A

Fifteen RCTs examined the safety of botulinum toxin for chronic migraine prevention in adults including 13 RCTs of onabotulinumtoxin A and two RCTs of abobotulinumtoxin A (Appendix Table D8). Onabotulinumtoxin A resulted in adverse effects and treatment discontinuation due to adverse effects more often than placebo (Table 22). Pooled analyses demonstrated that per 1,000 patients treated, 155 experienced adverse effects and 26 discontinued treatments due to bothersome adverse effects (Table 23). The results were robust and remained significant with different methods of pooling (Appendix Tables D116 and D117). Abobotulinumtoxin A RCTs did not report treatment discontinuation due to adverse effects.^{139,144}

Among individual adverse effects, neck pain and muscle weakness were the most common (Table 23). Increase in risk of adverse effects with onabotulinumtoxin A was lower in trials with higher placebo rates of adverse effects (Table 24). Increase in risk of adverse effects was dose responsive (Appendix Table D118). Patients experienced eyelid edema with 50U of onabotulinumtoxin A more often than with 25U.²¹⁹ Higher doses of 150 to 225U of onabotulinumtoxin A resulted in greater risk of blepharoptosis, muscle weakness, and neck rigidity (Appendix Table D118).

Abobotulinumtoxin A

Abobotulinumtoxin A RCTs reported increased risk of neck weakness in 109 patients per 1,000 treated (95% CI, 22 to 196).^{139,144} The rates of the total adverse effects were statistically higher with the increased dose of the drug (210U versus 80U).¹⁴⁴ The rates of specific adverse effects did not differ between the active drug and placebo.^{139,144}

Antiepileptics

Topiramate

Most RCTs that examined safety with topiramate versus placebo for episodic migraine prevention in adults (Appendix Table D119) were funded by industry and reported conflict of interest by principal investigators (Appendix Table D120). All trials were double blind (Appendix Table D121).

Patients stopped taking topiramate more often than placebo because of intolerable adverse effects including fatigue, paresthesia, and taste perversion (Table 25). Topiramate in doses of 100 and 200 mg/day (but not 50 mg/day) resulted in treatment discontinuation due to adverse effects more often than placebo (Appendix Table D122). Compared with placebo, topiramate more often resulted in bothersome taste perversion, paresthesia, and fatigue leading to withdrawal (Appendix Table D123).

Pooled estimates were consistent with imprecision that decreased strength of evidence. Per 1,000 treated, topiramate resulted in bothersome adverse effects leading to treatment discontinuation in 36 (with 100 mg/day) or 146 (with 200 mg/day) patients. Published pooled analysis of individual patient data demonstrated topiramate discontinuation due to anorexia, anxiety, depression, hypoesthesia, and nausea (Appendix Table D124).²³⁷ Some adverse effects leading to treatment discontinuation were reported in individual RCTs that failed to show statistically significant increase in risk of specific harms with topiramate (Appendix Table D125).

Topiramate increased risk of specific adverse effects. Individual RCTs reported small numbers of events. Pooled analyses demonstrated a statistically significant increase in risk of any adverse effect, paresthesia, cognitive difficulties, diarrhea, dry mouth, fatigue, nausea, taste alteration or perversion, and weight loss (Appendix Table D126). Topiramate caused adverse effects in one patient for every eight treated. Taste alteration, weight loss, and paresthesia were the most common adverse effects (Table 26). Individual RCTs reported increased risk of severe anorexia and mood problems (Table D127).

Risk of adverse effects was dose responsive according to the published pooled analyses of individual patient data (Appendix Table D128).²³⁷ Larger doses of topiramate increased risk of anorexia, depression, paresthesia, and difficulty in memory leading to treatment withdrawal.²³⁷ Larger doses of topiramate increased risk of dry mouth, paresthesia or fatigue, mood problems, nausea, and weight loss.²³⁷

Divalproex

Adverse effects with divalproex versus placebo were examined in three RCTs that examined efficacy of divalproex for episodic migraine prevention in adults (Appendix Table D25). All three RCTs were funded by industry (Appendix Table D26) and all were double blind (Appendix Table D27).

Treatment discontinuation due to adverse effects did not differ with divalproex versus placebo (Table 22 and Appendix Table D122).^{101,102} Divalproex caused alopecia, asthenia, nausea, and tremor more often than placebo (Table 27). Strength of evidence was low because of risk of bias and imprecision of the treatment effects. Larger doses of divalproex did not increase risk of bothersome adverse effects leading to treatment discontinuation (Appendix Table D129).¹⁰³ Larger doses of divalproex increased risk of nausea and tremor (Appendix Table D130).¹⁰³

Valproate

Adverse effects of valproate were examined in two small double-blind RCTs of 75 adults that examined efficacy of valproate for episodic migraine prevention in adults (Appendix Tables D25-D27).

Treatment discontinuation due to adverse effects did not differ with valproate versus placebo (Table 22).¹⁵³ Rates of combined adverse effects did not differ between valproate and placebo (Appendix Table D131).^{120,153}

Beta Blockers

Propranolol

All RCTs that examined safety with propranolol versus placebo in adults with episodic migraine (Appendix Table D31) were double blind but did not analyze the data according to planned intention-to-treat principles (Appendix Table D33). Propranolol increased risk of bothersome adverse effects leading to treatment discontinuation more often than placebo (Table 22).^{106,238}

Propranolol resulted in adverse effects more often than placebo (Appendix Table D132). Among individual adverse effects, propranolol more often than placebo resulted in diarrhea (pooled 89 attributable events per 1,000 treated; 95% CI, 14 to 164) and nausea (pooled 43 attributable events per 1,000 treated 95% CI, 9 to 77).

Timolol

Treatment discontinuation due to bothersome adverse effects did not differ with timolol and placebo in adults with episodic migraine (low-strength evidence from individual RCT) (Table 28). Timolol increased risk of overall adverse effects but not of any specific examined adverse effects more often than placebo (Appendix Tables D133 and D134).

Off-Label Drugs

Antiepileptics

All RCTs that examined the safety of six off-label antiepileptic drugs for episodic migraine, including acetazolamide, gabapentin, vigabatrin, oxcarbazepine, carbamazepin, and lamotrigine (Appendix Table D39) were double blind (Appendix Table D41). Pooled analyses demonstrated no differences in treatment discontinuation due to adverse effects with gabapentin or lamotrigine versus placebo (Table 22 and Appendix Table D135) but increase in risk of the total adverse effects with gabapentin (Appendix Table D136). Antiepileptic drugs increased risk of the specific adverse effects as follows.

Acetazolamide

Acetazolamide caused paresthesia, drowsiness, memory impairment, malaise, and fasciculation more often than placebo in adults with episodic migraine (Appendix Table D137).¹¹⁷

Carbamazepin

Carbamazepin caused adverse effects that led to dose reductions more often than placebo in adults with episodic migraine. Specific adverse effects included vertigo and drowsiness. (Appendix Table D138).¹¹⁸

Gabapentin

Gabapentin caused somnolence and dizziness more often than placebo in adults with episodic migraine (Appendix Table D139)¹¹¹; however, the validity of the results was questioned due to exclusion of patients from the analyses and biased tolerability conclusions.²³⁹

Lamotrigine

Treatment discontinuation due to the specific side effects, including rash, occurred more frequently with lamotrigine than placebo in adults with episodic migraine (Appendix Table D140).²⁴⁰ A fixed dose of 200 mg/day of lamotrigine caused skin rash more often than placebo. In contrast, a gradually escalated dose of lamotrigine starting with 25 mg/day did not cause skin rash.²⁴⁰

Oxcarbazepine

Oxcarbazepine caused adverse effects including fatigue, dizziness, and nausea more often than placebo in adults with episodic migraine (Appendix Table D141).¹¹⁹

Antidepressants

Pooled analyses demonstrated that amitriptyline but not femoxetine caused adverse effects leading to treatment discontinuation more often than placebo in adults with episodic migraine (Table 22). Amitriptyline increased the risk of dizziness, drowsiness, and constipation (Appendix

Table D142). Femoxetine and fluoxetine increased the risk of any adverse effects (Appendix Table D142).

Cortical Spreading Depression Inhibitor

Individual RCTs demonstrated no differences between placebo and tonabersat in treatment discontinuation due to bothersome adverse effects in adults with episodic migraine.¹²⁷

Beta Blockers

Atenolol

Treatment discontinuation due to bothersome adverse effects did not differ between atenolol and placebo in adults with episodic migraine (Appendix Table D143).^{123,159,241} Less than 1 percent of participants discontinued atenolol due to bothersome side effects (Appendix Table D144).^{123,159,241} Among all examined adverse effects, only rates of slight orthostatic dizziness during the first week of treatments were greater with atenolol than with placebo.

Bisoprolol

Treatment discontinuation due to bothersome adverse effects did not differ between bisoprolol and placebo in adults with episodic migraine.²²⁷ In fact, side effects occurred no more often from bisoprolol than from placebo (Appendix Table D144). A higher dose of bisoprolol did not result in greater rates of adverse effects or treatment discontinuation due to adverse effects.²²⁷ Bisoprolol, 10 mg/day, decreased heart rate when compared with 5 mg/day.²²⁷ Systolic and diastolic blood pressure did not differ with two doses of bisoprolol.²²⁷

Metoprolol

Treatment discontinuation due to bothersome adverse effects did not differ between metoprolol and placebo in adults with episodic migraine.¹¹⁴ Rates of total adverse effects were greater with metoprolol than with placebo in a single RCT.¹¹³ Metoprolol caused fatigue and sleep disturbances more often than placebo (Appendix Table D145).¹¹³

Nadolol

Treatment discontinuation due to bothersome adverse effects did not differ between nadolol and placebo in adults with episodic migraine.¹²⁴ In fact, nadolol caused adverse effects no more often than placebo. An increased dose of nadolol did not result in greater rates of adverse effects.^{225,226}

Pindolol

Treatment discontinuation due to bothersome adverse effects did not differ with pindolol and placebo in adults with episodic migraine.¹⁶⁰ Patients experienced orthostatic dizziness and faintness more often with pindolol than with placebo.¹⁶⁰

Ergot Alkaloids

In individual underpowered RCTs, treatment discontinuation due to bothersome adverse effects did not differ with placebo, lisuride, or methysergide in adults with episodic migraine.^{131,242}

Angiotensin Converting Enzyme Inhibitors

Individual RCTs of adults with episodic migraine did not examine treatment discontinuation to bothersome adverse effects with lisinopril¹²⁸ or captopril.⁸⁸ Captopril caused adverse effects no more often than placebo.⁸⁸ The rates of any adverse effects were greater with lisinopril than placebo; however, rates of the most common adverse effects with ACE inhibitors (coughing, fatigue, dizziness, or tendency to faint) did not differ between lisinopril and placebo.¹²⁸

Angiotensin II Antagonists

Individual RCTs did not examine treatment discontinuation to bothersome adverse effects with candesartan¹²⁹ or telmisartan in adults with episodic migraine.¹⁷³ Neither drug caused any adverse effect more often than placebo.^{129,173}

Calcium Channel Antagonists

Treatment discontinuation due to bothersome adverse effects did not differ between placebo and nifedipine,²⁴³ nimodipine,^{112,244} or verapamil in adults with episodic migraine.¹⁷¹

Compared with placebo, verapamil more often caused tolerable constipation that did not result in treatment discontinuation.¹⁷¹ Nifedipine resulted in adverse effects more often than placebo.²⁴³ Among individual adverse effects, nifedipine increased rates of headache, dizziness, and edema.²⁴³ Nimodipine increased rates of abdominal cramps but no other examined adverse effects.⁸⁹

NSAID

Individual RCTs found no differences in bothersome adverse effects leading to treatment discontinuation with fenoprofen,²⁴⁵ naproxen sodium,²⁴⁶ or tolafenamic acid in adults with episodic migraine.¹³⁴ Among individual adverse effects, fenoprofen increased rates of fatigue and somnolence.²⁴⁵

KQ2b. What are the harms from preventive pharmacologic treatments when compared with active pharmacologic treatments?

There was low-strength evidence from individual RCTs that examined comparative safety with migraine preventive drugs.

Muscle Relaxants

Onabotulinumtoxin A for Chronic Migraine

Comparative safety of onabotulinumtoxin A versus topiramate was examined in two RCTs that demonstrated better safety with onabotulinumtoxin A than topiramate (Appendix Table D146).^{183,186} Patients experienced depression or mood disturbance, weight loss, paresthesias, or cognitive deficits more often with topiramate (Appendix Table D146).^{183,186}

A single RCT examined the comparative safety of onabotulinumtoxin A versus divalproex sodium and found a higher risk of ptosis with onabotulinumtoxin A (Appendix Table D147).¹⁸⁴ In contrast, risk of fatigue, nausea, and total adverse effects was higher with divalproex (Appendix Table D147).

A single RCT examined the comparative safety of onabotulinumtoxin A versus amitriptyline and concluded better safety with onabotulinumtoxin A (Appendix Table D148).¹⁸⁵ Patients

experienced dry mouth, constipation, somnolence, and weight gain several times more often with amitriptyline than with onabotulinumtoxin A.¹⁸⁵

Topiramate

Treatment discontinuation due to adverse effects did not differ between topiramate and amitriptyline in adults with episodic migraine (Table 22).^{189,247} Comparative safety of topiramate with other drugs was examined in individual RCTs. Treatment discontinuation due to any adverse effects did not differ between topiramate and zonisamide or valproate (Table 29). Treatment discontinuation due to specific adverse effects differed with topiramate and other drugs according to individual RCTs (Appendix Table D149). Somnolence or weight increase leading to withdrawal was less common with topiramate than amitriptyline (Table 29).^{189,247} Treatment discontinuation to treatment failure, however, did not differ between topiramate and amitriptyline or lamotrigine (Appendix Table D150).

Risk of specific adverse effects differed between topiramate and other drugs in individual RCTs in adults with episodic migraine (Appendix Table D151). Topiramate increased risk of weight loss when compared with amitriptyline,¹⁸⁹ levetiracetam,¹⁹² and valproate²⁴⁸ (Appendix Table D151). Topiramate increased risk of paresthesia when compared with amitriptyline^{189,247} (Appendix Table D151). Risk of dry mouth and constipation was lower with topiramate than amitriptyline (Appendix Table D152).^{189,247} Individual RCTs demonstrated higher risk of headache with topiramate than amitriptyline (Appendix Table D153).

Comparative safety of topiramate combined with amitriptyline versus monotherapy was examined in one small RCT.²⁴⁷ Treatment discontinuation due to adverse effects did not differ between topiramate combined with amitriptyline and monotherapy.²⁴⁷ The risk of adverse effects was lower with combined therapy when compared with amitriptyline alone but not topiramate alone (Appendix Table D154).²⁴⁷

Beta Blockers for Episodic Migraine

Propranolol

Treatment discontinuation due to bothersome adverse effects did not differ between propranolol and aspirin (Table 28).²⁴⁹ Evidence of comparative safety with propranolol ergotamine intake was insufficient due to high risk of bias in individual RCT (Appendix Table D155).

Treatment discontinuation due to adverse effects did not differ between behavioral migraine management and propranolol (Appendix Table D156).²¹⁷ Treatment discontinuation due to bothersome adverse effects did not differ between combined behavioral migraine management with propranolol versus propranolol alone.²¹⁷ Combined therapy was more effective than propranolol alone in having self-efficacy and internal control over headache (Appendix Table D157).²¹⁸

Off-Label Drugs for Episodic Migraine

Off-Label Beta Blockers

Metoprolol Versus Clonidine

Metoprolol resulted in treatment discontinuation due to bothersome adverse effects or treatment failure less often than clonidine (Table 30 and Appendix Table D158).²⁰⁷

Metoprolol Versus Bisoprolol

Treatment discontinuation due to adverse effects did not differ between the two drugs (Table 30 and Appendix Table D158)²⁰⁴ nor did rates of individual examined adverse effects differ between the drugs (Appendix Table D159).

Metoprolol Versus Nebivolol

Treatment discontinuation due to adverse effects did not differ between the two drugs (Table 30).²⁰⁶ Patients experienced moderate adverse effects, fatigue, and bradycardia more often with metoprolol than with nebivolol (Appendix Table D159).²⁰⁶

Metoprolol Versus Aspirin

Gastrointestinal side effects leading to withdrawal were more common with aspirin than metoprolol (Table 30 and Appendix Table D158).²⁰² However, autonomic nervous system and psychiatric disorders were more common with metoprolol than aspirin (Appendix Table D159).²⁰³

Metoprolol Versus Clomipramine

Treatment discontinuation because of severe adverse reactions was more common with clomipramine than metoprolol (Table 30).²⁵⁰ Clomipramine caused insomnia and sweating more often than metoprolol (Appendix Table D159).²⁵⁰

Antidepressants

Clomipramine Versus Metoprolol

Clomipramine resulted in treatment discontinuation due to bothersome adverse effects more often than metoprolol (Table 30).²⁵⁰

Femoxetine Versus Propranolol

Treatment discontinuation due to bothersome adverse effects did not differ between femoxetine and propranolol.²⁰¹

Amitriptyline Versus Spinal Manipulation

Treatment discontinuation due to adverse effects occurred less with spinal stimulation than with amitriptyline (Table 31).²¹⁵ Strength of evidence was low due to risk of bias and imprecise estimate (Appendix Table D160).²¹⁵

Treatment discontinuation due to adverse effects did not differ between combined treatment using spinal manipulation with amitriptyline and amitriptyline alone (Appendix Table D161).²¹⁵

Ergot Alkaloids

A single RCT of 253 adults (low-strength evidence) found that treatment discontinuation due to adverse effects was less common with lisuride than with methysergide.²¹²

Indirect Evidence of Comparative Safety of Drugs for Episodic Migraine Prevention in Adults

Bothersome adverse effects leading to treatment discontinuation were examined in 68 RCTs. Indirect adjusted analyses demonstrated no differences in treatment discontinuation due to adverse effects with approved drugs or approved versus off-label drugs (Appendix Table D162). Exploratory Bayesian network meta-analyses demonstrated that topiramate, off-label antiepileptics, and antidepressants resulted in bothersome adverse effects leading to treatment discontinuation more often than placebo (Figure 4). According to network meta-analysis, off-label angiotensin inhibiting drugs and beta blockers were the safest treatment option for adults with episodic migraine (Appendix Table D163)

KQ2c. How might approaches to drug management (such as patient-care teams, integrated care, coordinated care, patient education, drug surveillance, or interactive drug monitoring) influence results?

We found no studies that examined adverse effects with different approaches to drug management (such as patient-care teams, integrated care, coordinated care, patient education, drug surveillance, or interactive drug monitoring).

Table 22. Treatment discontinuation due to adverse effects with migraine preventive drugs in adults, evidence from meta-analyzed randomized controlled clinical trials

Active Preventive Treatment	Sample	Rate, Percent With Drug [Control]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed To Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Strength of Evidence Reasons for Lowering SOE
<i>Compared With Placebo</i>							
<i>Chronic Migraine</i>							
Onabotulinumtoxin A ^{137,251}	1384	3.8 [1.1]	3.2 (1.4 to 7.1)	0.03 (0.01 to 0.04)	38 (23 to 100)	26 (10 to 43)	Moderate (medium ROB)
<i>Episodic Migraine</i>							
Topiramate ^{27,85,96,99,146,148,150,252}	2055	16.6 [8.5]	1.8 (1.3 to 2.4)	0.06 (0.02 to 0.11)	16 (9 to 53)	63 (19 to 107)	Low (medium ROB, Imprecise)
Divalproex ^{101,102}	346	9.8 [7.8]	1.2 (0.5 to 2.7)	0.02 (-0.05 to 0.10)	NS	NS	Low (medium ROB, Imprecise , Inconsistent)
Valproate ^{120,153}	150	6.7 [5.3]	1.3 (0.3 to 4.9)	0.01 (-0.07 to 0.08)	NS	NS	Low (medium ROB, Imprecise)
Propranolol ^{106,238}	221	13.2 [5.6]	2.1 (0.6 to 7.7)	0.06 (0.00 to 0.12)	16 (8 to 333)	62 (3 to 120)	Low (medium ROB, Imprecise, Inconsistent)
Gabapentin ^{87,110,111}	270	17.0 [7.7]	1.9 (0.9 to 4.2)	0.07 (-0.01 to 0.15)	NS	NS	Low (medium ROB, Imprecise)
Lamotrigine ^{99,240}	178	12.8 [6.0]	2.4 (0.5 to 12.2)	0.14 (-0.17 to 0.44)	NS	NS	Low (Imprecise , Inconsistent)
Amitriptyline ^{125,253}	507	11.2 [5.8]	1.9 (1.0 to 3.5)	0.05 (0.01 to 0.10)	19 (10 to 167)	54 (6 to 102)	Low (medium ROB, Imprecise)
Femoxetine ^{167,168}	124	11.7 [6.3]	1.9 (0.6 to 6.1)	0.05 (-0.05 to 0.15)	NS	NS	Low (medium ROB, Imprecise)
Clonidine ^{177,254}	334	2.4 [0.6]	2.8 (0.4 to 18.5)	0.02 (-0.01 to 0.05)	NS	NS	Low (medium ROB, Imprecise)
Nimodipine ^{112,244}	155	3.9 [6.3]	0.7 (0.2 to 2.6)	-0.03 (-0.09 to 0.04)	NS	NS	Low (medium ROB, Imprecise , Inconsistent)
Naproxen ^{246,255}	172	3.5 [1.2]	2.3 (0.3 to 15.4)	0.02 (-0.03 to 0.07)	NS	NS	Low (High ROB, Imprecise , Inconsistent)
Magnesium ^{115,116}	150	7.7 [1.4]	3.8 (0.7 to 22.4)	0.06 (0.00 to 0.13)	NS	NS	Low (Inconsistent Imprecise)

Table 22. Treatment discontinuation due to adverse effects with migraine preventive drugs in adults, evidence from meta-analyzed randomized controlled clinical trials (continued)

Active Preventive Treatment	Sample	Rate, Percent With Drug [Control]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed To Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Strength of Evidence Reasons for Lowering SOE
<i>Compared With Active Treatment, Episodic Migraine</i>							
Topiramate vs. amitriptyline ^{189,247}	399	18.3 [21.3]	0.9 (0.6 to 1.3)	-0.04 (-0.11 to 0.04)	NS	NS	Low (medium ROB, imprecision)

CI = confidence interval; ROB = risk of bias; SOE = strength of evidence; NS = not significant

Number needed to treat and number of attributable events were calculated for statistically significant differences.

Table 23. Adverse effect with onabotulinumtoxin A versus placebo for chronic migraine prevention in adults (magnitude of the effect and strength of evidence from randomized controlled clinical trials)

Adverse Effect	Sample, References	Rate, Percent With Onabotulinumtoxin A [Placebo]	Number Needed To Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Strength of Evidence
Any adverse effect	5031 ^{94,137,138,142,144,219,251,256,257}	47.5 [29.4]	6 (5 to 11)	155 (90 to 220)	Moderate
Back pain	1112 ^{93,138,257}	2.2 [0.5]	59 (32 to 333)	17 (3 to 31)	High
Discontinuations related to adverse effect	1384 ^{137,251}	3.8 [1.1]	38 (23 to 100)	26 (10 to 43)	Moderate
Dizziness	893 ^{93,94,139,257}	1.7 [0.9]	NS	NS	Moderate
Dysphagia	1057 ^{94,138}	3.3 [0.3]	36 (23 to 83)	28 (12 to 44)	High
Eyelid edema	915 ^{139,219,257}	3.6 [0.3]	NS	NS	High
Headache	2204 ^{94,138,139,219,256,257}	5.2 [4.5]	NS	NS	High
Hypertonia	1426 ^{94,138,257}	7.1 [1.3]	16 (12 to 24)	62 (42 to 82)	High
Neck pain	2233 ^{94,139,251,257}	14.1 [1.4]	9 (6 to 17)	111 (58 to 164)	Moderate
Neck rigidity	1467 ^{93,94,138,257}	9.2 [1.8]	13 (9 to 24)	75 (41 to 110)	Moderate
Pain	2319 ^{93,94,138,139,257}	3.6 [2.1]	NS	NS	Moderate
Blepharoptosis	2454 ^{92,94,138,139,144,219,256,257}	6.4 [0.8]	20 (14 to 34)	49 (29 to 69)	High
Muscle weakness	1968 ^{94,138,251,256}	15.8 [0.1]	8 (5 to 18)	132 (56 to 209)	Moderate
Fever	587 ^{93,139,219}	5.3 [7.1]	NS	NS	Moderate

CI = confidence interval; NS = not significant

Bold = Differences were significant when 95% CI of attributable events per 1,000 treated do not include 0.

Number needed to treat and number of attributable events were calculated for statistically significant differences.

Table 24. Adverse effects with onabotulinumtoxin A versus placebo in adults with chronic migraine, meta-regression by study level factors (log of relative risk in randomized controlled clinical trials)

Contributing Factor	Adverse Effect	Contributing Variable	Meta-Regression Coefficient	Lower 95% CI	Upper 95% CI
Drug	Blepharoptosis	Dose	0.00	-0.01	0.01
Patient	Blepharoptosis	Age	0.22	-0.30	0.74
Patient	Blepharoptosis	Years of migraine	-0.05	-0.11	0.01
Study	Blepharoptosis	Percent of women	-0.02	-0.15	0.11
Study	Blepharoptosis	Control rate	0.99	-102.24	104.22
Study	Blepharoptosis	Loss of followup	-0.04	-0.10	0.03
Study	Blepharoptosis	Risk of bias	-0.56	-1.79	0.67
Drug	Adverse effects	Dose	0.00	0.00	0.01
Patient	Adverse effects	Age	0.04	-0.12	0.20
Patient	Adverse effects	Years of migraine	-0.05	-0.11	0.01
Study	Adverse effects	Percent of women	-0.02	-0.15	0.11
Study	Adverse effects	Control rate	-1.92	-2.46	-1.37
Study	Adverse effects	Loss of followup	0.02	0.00	0.04
Study	Adverse effects	Risk of bias	0.06	-0.34	0.47
Drug	Headache	Dose	0.00	0.00	0.01
Patient	Headache	Age	0.25	-0.16	0.67
Patient	Headache	Years of migraine	0.01	-0.10	0.11
Study	Headache	Percent of women	-0.08	-0.25	0.08
Study	Headache	Control rate	8.52	-34.54	51.59
Study	Headache	Loss of followup	0.01	-0.03	0.06
Study	Headache	Risk of bias	-0.11	-1.24	1.02

CI = confidence interval

Bold = significant differences at 95% confidence limit when 95% CI do not include 0.

Table 25. Treatment discontinuation due to adverse effects with topiramate versus placebo in adults, pooled with random effects results from randomized controlled clinical trials

Reason for Treatment Discontinuation References	Sample	Rate with Topiramate [Placebo]	Pooled Relative Risk (95% CI)	Pooled Absolute Risk Difference (95% CI)	Number Needed To Treat To Harm (95% CI)	Attributable Events per 1,000 Treated (95% CI)
Cognitive difficulties ^{27,96,252}	939	7.3 [2.0]	2.8 (0.5 to 15.3)	0.05 (-0.02 to 0.12)	NS	NS
Difficulty with memory ^{237,252}	765	1.7 [1.1]	1.2 (0.1 to 16.3)	0.01 (-0.01 to 0.03)	NS	NS
Dizziness ^{27,252}	824	1.9 [2.0]	0.7 (0.1 to 5.1)	-0.02 (-0.11 to 0.07)	NS	NS
Fatigue^{27, 105,252}	824	4.5 [0.9]	2.8 (0.4 to 21.2)	0.04 (0.01 to 0.06)	28 (17 to 71)	36 (14 to 58)
Insomnia ^{27,252}	824	3.1 [1.2]	1.3 (0.1 to 15.1)	0.01 (-0.04 to 0.06)	NS	NS
Language problems ^{237,252}	766	2.2 [0.4]	3.7 (0.7 to 20.3)	0.02 (0.00 to 0.03)	NS	15 (0 to 31)
Paresthesia ^{27,96,252}	939	8.4 [0.7]	9.6 (3.5 to 26.5)	0.08 (0.05 to 0.10)	13 (10 to 20)	75 (49 to 101)
Somnolence ^{96,237}	831	2.1 [1.8]	1.1 (0.4 to 3.2)	0.00 (-0.02 to 0.02)	NS	NS
Taste perversion^{96,237,252}	881	1.5 [0.0]	3.8 (0.7 to 21.4)	0.01 (0.00 to 0.02)	77 (42 to 1000)	13 (1 to 24)

CI = confidence interval; NS = not significant

Bold = significant differences when 95% CI of absolute risk difference do not include 0.

Number needed to treat and number of attributable events were calculated for statistically significant differences.

Table 26. Adverse effects with topiramate in adults with migraine, significant results from pooled analysis of randomized controlled clinical trials

Outcome, Reference	Sample	Rate With Topiramate [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed To Treat To Harm (95% CI)	Attributable Events per 1,000 Treated (95% CI)
Adverse events ^{85,99,100,146,148,237}	1700	59.9 [56.1]	1.2 (1.0 to 1.3)	0.12 (0.02 to 0.22)	8 (4 to 42)	124 (24 to 223)
Paresthesia ^{85,95,96,98-100,146,148,237,252}	1876	24.0 [5.5]	4. 7(3.4 to 6.3)	0.24 (0.14 to 0.33)	4 (3 to 7)	235 (142 to 328)
Weight decrease ^{85,95,96,149,237,252}	1648	12.3 [4.4]	3.6 (1.5 to 8.3)	0.10 (0.05 to 0.15)	10 (6 to 19)	104 (53 to 154)
Cognitive difficulties ^{96,100,105,146,149,237,52}	1782	8[3]	2.2 (1.1 to 4.4)	0.045 (0.01 to 0.08)	22(13 to 100)	45 (10 to 80)
Diarrhea ^{148,150,237}	1170	9.8 [3.6]	2.7 (1.5 to 4.7)	0.06 (0.01 to 0.10)	18 (10 to 71)	57 (14 to 100)
Dry mouth ^{86,148,237}	1429	6.1 [2.7]	2.5 (1.4 to 4.3)	0.04 (0.01 to 0.06)	29 (18 to 71)	35 (14 to 57)
Fatigue ^{100,237}	1857	9.6 [4.6]	1.7 (1.3 to 2.3)	0.05 (0.03 to 0.08)	20 (13 to 38)	50 (26 to 75)
Hyperesthesia ^{146,148,237}	1756	7.4 [1.6]	3.5 (1.8 to 6.5)	0.06 (0.03 to 0.08)	18 (13 to 30)	57 (33 to 80)
Insomnia ^{84,105,150,252}	878	4 [2]	1.6 (0.5 to 4.7)	0.02 (0.001 to 0.04)	NS	21 (1 to 42)
Memory impairment ^{85,86,100,105,150,237,252}	1436	10.4 [3.9]	2.4 (1.2 to 4.6)	0.058 (0.017 to 0.099)	17 (10 to 59)	58 (17 to 99)
Nausea ^{85,105,146,148,149,237}	2156	11[6]	1.5 (1.1 to 2.0)	0.034 (0.003 to 0.065)	29 (15 to 333)	34 (3 to 65)
Taste perversion ^{86,95,96,105,148,237,252}	1634	5.9 [1.3]	4.9 (2.5 to 9.8)	0.083 (0.025 to 0.14)	12 (7 to 40)	83 (25 to 140)
Abdominal pain ^{149,237}	1229	2.0 [2.3]	0.9 (0.4 to 2.0)	0.00 (-0.02 to 0.02)	NS	NS
Anorexia ^{85,95,99,100,146,148,149,237,252}	2424	5.6 [3.3]	1.8 (1.2 to 2.7)	0.03 (0.00 to 0.05)	NS	NS
Back pain ^{148,237}	1100	4.6 [5.1]	0.9 (0.5 to 1.6)	0.00 (-0.03 to 0.02)	NS	NS
Giddiness ^{85,99,100,146,148,237,252}	1871	10.1 [7.8]	1.2 (0.8 to 1.7)	0.01 (-0.02 to 0.04)	NS	NS
Dyspepsia ^{100,237}	1018	1.5 [1.1]	1.3 (0.4 to 3.8)	0.01 (-0.03 to 0.05)	NS	NS
Infection, viral ^{100,148}	444	8.2 [8.0]	1.0 (0.6 to 1.9)	0.00 (-0.05 to 0.05)	NS	NS
Injury ^{146,148,237}	1672	5.0 [6.1]	0.8 (0.2 to 3.2)	-0.01 (-0.07 to 0.04)	NS	NS
Adverse events: Serious ^{86,149}	842	7.9 [6.6]	1.1 (0.6 to 2.1)	0.01 (-0.05 to 0.06)	NS	NS
Sinusitis ^{146,148,237}	1429	7.4 [6.4]	1.1 (0.7 to 1.7)	0.01 (-0.02 to 0.03)	NS	NS
Sleepiness ^{85,86,96,98,100,148,237,252}	1893	4.4 [3.4]	1.5 (0.8 to 3.0)	0.02 (-0.01 to 0.04)	NS	NS
Language problems ^{150,237,252}	657	3.6 [0.5]	4.8 (1.1 to 20.5)	0.09 (-0.03 to 0.21)	NS	NS
Upper respiratory tract infection ^{85,86,148,237}	1641	8.7 [9.0]	1.0 (0.7 to 1.4)	0.00 (-0.03 to 0.03)	NS	NS
Vision, abnormal ^{95,237}	756	7.7 [2.2]	3.3 (1.4 to 7.8)	0.07 (-0.01 to 0.15)	NS	NS

CI = confidence interval; NS = not significant

Number needed to treat and number of attributable events were calculated for statistically significant differences.

Bold = significant differences when 95% CI of absolute risk difference do not include 0.

Table 27. Treatment discontinuation due to bothersome adverse effects and adverse effects with divalproex versus placebo for episodic migraine prevention in adults, results from randomized controlled clinical trials

Outcome	Daily Dose	Reference	Sample	Rate, Percent With Divalproex [Placebo]	Number Needed To Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Strength of Evidence
Discontinuations due to intolerance	Mean average dose 1087 mg/d	Mathew, 1995 ¹⁰¹	107	12.9 [5.4]	NS	NS	
Discontinuations due to intolerance	Mean average dose 871 mg/d	Freitag, 2002 ¹⁰²	239	8.1 [8.6]	NS	NS	
Discontinuations due to intolerance	Pooled		346	9.8 [7.8]	NS	NS	Low
Abdominal pain	Mean average dose 871 mg/d	Freitag, 2002 ¹⁰²	239	6.5 [5.2]	NS	NS	Low
Alopecia	Mean average dose 1087 mg/d	Mathew, 1995¹⁰¹	107	12.9 [0.0]	8 (5 to 24)	129 (41 to 216)	Low
Any	Mean average dose 871 mg/d	Freitag, 2002 ¹⁰²	239	67.5 [69.8]	NS	NS	Low
Asthenia	Mean average dose 1087 mg/d	Mathew, 1995¹⁰¹	107	31.4 [8.1]	4 (3 to 11)	233 (93 to 373)	Low
Asthenia	500 mg	Klapper, 1997 ¹⁰³	60	8.9 [9.1]	NS	NS	Low
Asthenia	1000 mg	Klapper, 1997 ¹⁰³	57	9.3 [9.1]	NS	NS	Low
Asthenia	1500 mg	Klapper, 1997 ¹⁰³	58	22.7 [9.3]	NS	NS	Low
Asthenia	Mean average dose 871 mg/d	Freitag, 2002 ¹⁰²	239	7.3 [10.3]	NS	NS	Low
Back pain	500 mg	Klapper, 1997 ¹⁰³	60	6.7 [9.1]	NS	NS	Low
Back pain	1000 mg	Klapper, 1997 ¹⁰³	57	4.7 [9.1]	NS	NS	Low
Back pain	1500 mg	Klapper, 1997 ¹⁰³	58	13.6 [9.3]	NS	NS	Low
Diarrhea	500 mg	Klapper, 1997 ¹⁰³	60	6.7 [4.5]	NS	NS	Low
Diarrhea	1000 mg	Klapper, 1997 ¹⁰³	58	4.7 [4.5]	NS	NS	Low
Diarrhea	1500 mg	Klapper, 1997 ¹⁰³	59	18.2 [4.6]	NS	NS	Low
Diarrhea	Mean average dose 871 mg/d	Freitag, 2002 ¹⁰²	239	7.3 [3.4]	NS	NS	Low
Dizziness	500 mg	Klapper, 1997 ¹⁰³	60	6.7 [4.5]	NS	NS	Low
Dizziness	1000 mg	Klapper, 1997 ¹⁰³	58	7.0 [4.5]	NS	NS	Low
Dizziness	1500 mg	Klapper, 1997 ¹⁰³	59	20.5 [4.6]	NS	NS	Low
Dyspepsia	500 mg	Klapper, 1997 ¹⁰³	60	6.7 [9.1]	NS	NS	Low
Dyspepsia	1000 mg	Klapper, 1997 ¹⁰³	57	18.6 [9.1]	NS	NS	Low
Dyspepsia	1500 mg	Klapper, 1997 ¹⁰³	58	15.9 [9.3]	NS	NS	Low
Dyspepsia	Mean average dose of study: 871 mg/d	Freitag, 2002 ¹⁰²	239	6.5 [4.3]	NS	NS	Low
Flu syndrome	Mean average dose of study: 871 mg/d	Freitag, 2002 ¹⁰²	239	8.1 [8.6]	NS	NS	Low
Infection	500 mg	Klapper, 1997 ¹⁰³	60	17.8 [18.2]	NS	NS	Low
Infection	1000 mg	Klapper, 1997 ¹⁰³	58	16.3 [18.2]	NS	NS	Low
Infection	1500 mg	Klapper, 1997 ¹⁰³	59	20.5 [18.6]	NS	NS	Low

Table 27. Treatment discontinuation due to bothersome adverse effects and adverse effects with divalproex versus placebo for episodic migraine prevention in adults, results from randomized controlled clinical trials (continued)

Outcome	Daily Dose	Reference	Sample	Rate, Percent With Divalproex [Placebo]	Number Needed To Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Strength of Evidence
Infection	Mean average dose of study: 871 mg/d	Freitag, 2002 ¹⁰²	239	14.6 [13.8]	NS	NS	Low
Nausea	Mean average dose of divalproex sodium was 1087 mg/d	Mathew, 1995¹⁰¹	107	45.7 [13.5]	3 (2 to 6)	322 (162 to 482)	Low
Nausea	500 mg	Klapper, 1997¹⁰³	60	26.7 [6.8]	5 (3 to 52)	200 (19 to 381)	Low
Nausea	1000 mg	Klapper, 1997 ¹⁰³	57	9.3 [6.8]	NS	NS	Low
Nausea	1500 mg	Klapper, 1997¹⁰³	59	34.1 [7.0]	4 (2 to 12)	274 (86 to 463)	Low
Nausea	Mean average dose of study: 871 mg/d	Freitag, 2002 ¹⁰²	239	14.6 [8.6]	NS	NS	Low
Pain	500 mg	Klapper, 1997 ¹⁰³	60	8.9 [6.8]	NS	NS	Low
Pain	1000 mg	Klapper, 1997 ¹⁰³	57	7.0 [6.8]	NS	NS	Low
Pain	1500 mg	Klapper, 1997 ¹⁰³	59	11.4 [7.0]	NS	NS	Low
Sinusitis	Mean average dose of study: 871 mg/d	Freitag, 2002 ¹⁰²	239	3.3 [7.8]	NS	NS	Low
Somnolence	Mean average dose 1087 mg/d	Mathew, 1995¹⁰¹	107	30.0 [5.4]	4 (3 to 9)	246 (116 to 376)	Low
Somnolence	500 mg	Klapper, 1997 ¹⁰³	60	6.7 [4.5]	NS	NS	Low
Somnolence	1000 mg	Klapper, 1997 ¹⁰³	58	7.0 [4.5]	NS	NS	Low
Somnolence	1500 mg	Klapper, 1997 ¹⁰³	59	18.2 [4.6]	NS	NS	Low
Somnolence	Mean average dose of study: 871 mg/d	Freitag, 2002 ¹⁰²	239	6.5 [1.7]	NS	NS	Low
Tremor	Mean average dose 1087 mg/d	Mathew, 1995¹⁰¹	107	12.9 [0.0]	8 (5 to 24)	129 (41 to 216)	Low
Tremor	500 mg	Klapper, 1997 ¹⁰³	60	0.0 [0.0]	NS	NS	Low
Tremor	1000 mg	Klapper, 1997 ¹⁰³	57	7.0 [0.0]	NS	NS	Low
Tremor	1500 mg	Mathew, 1995¹⁰¹	59	15.9 [0.0]	6 (3 to 48)	159 (21 to 297)	Low
Vomiting	Mean average dose 1087 mg/d	Mathew, 1995¹⁰¹	107	18.6 [0.0]	5 (4 to 11)	186 (88 to 284)	Low
Vomiting	500 mg	Klapper, 1997 ¹⁰³	60	4.4 [2.3]	NS	NS	Low
Vomiting	1000 mg	Klapper, 1997 ¹⁰³	57	4.7 [2.3]	NS	NS	Low
Vomiting	1500 mg	Klapper, 1997 ¹⁰³	58	11.4 [2.3]	NS	NS	Low
Vomiting	Mean average dose of study: 871 mg/d	Freitag, 2002 ¹⁰²	239	6.5 [1.7]	NS	NS	Low

CI = confidence interval; NS = not significant

Bold = significant difference at 95% confidence limit when 95% CI of attributable events per 1,000 treated do not include 0.

Number needed to treat and number of attributable events were calculated for statistically significant differences.

Table 28. Treatment discontinuation due to adverse effects with propranolol or timolol for episodic migraine prevention in adults, results from randomized controlled clinical trials

	Active Treatment	Control Treatment	Reference	Sample	Rate With Active Treatment, Percent	Rate With Control Treatment, Percent	Number Needed To Treat (95% CI)	Attributable Events (95% CI)	Strength of Evidence
Treatment discontinuation due to adverse effects	Propranolol	Aspirin	Baldrati, 1983 ²⁴⁹	36	11.1	16.7	NS	NS	Low
Moderate chest pain on day 28 leading to discontinuation	Timolol	Placebo	Stellar, 1984 ¹⁰⁹	94	2.1	0	NS	NS	Low
Discontinued therapy because of severe epigastric distress and fecal impaction	Timolol	Placebo	Stellar, 1984 ¹⁰⁹	94	2.1	0	NS	NS	Low
Withdrew due to adverse experiences	Timolol	Placebo	Stellar, 1984 ¹⁰⁹	94	4.3	0	NS	NS	Low

CI = Confidence interval; NS = not significant

Bold = significant at 95% confidence limit when 95% CI of attributable events per 1,000 treated do not include 0.

Number needed to treat and number of attributable events were calculated for statistically significant differences.

Table 29. Treatment discontinuation due to any adverse effects with topiramate versus other drugs for episodic migraine prevention in adults

Adverse Effects Leading to Withdrawal	Active	Control	Reference	Sample	Rate, Percent With Topiramate [Control Drug]	Number Needed To Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Strength of Evidence
Aggravation of migraine leading to withdrawal	Topiramate	Amitriptyline	Dodick, 2009 ¹⁸⁹	347	0.0 [1.8]	NS	NS	Low
Anxiety leading to withdrawal	Topiramate	Amitriptyline	Dodick, 2009 ¹⁸⁹	347	1.7 [0.0]	NS	NS	Low
Confusion leading to withdrawal	Topiramate	Amitriptyline	Dodick, 2009 ¹⁸⁹	347	1.7 [0.0]	NS	NS	Low
Dizziness leading to withdrawal	Topiramate	Amitriptyline	Dodick, 2009 ¹⁸⁹	347	1.7 [0.0]	NS	NS	Low
Dry mouth leading to withdrawal	Topiramate	Amitriptyline	Dodick, 2009 ¹⁸⁹	347	0.0 [1.8]	NS	NS	Low
Fatigue leading to withdrawal	Topiramate	Amitriptyline	Dodick, 2009 ¹⁸⁹	347	3.4 [2.4]	NS	NS	Low
Hypoesthesia leading to withdrawal	Topiramate	Amitriptyline	Dodick, 2009 ¹⁸⁹	347	1.7 [0.0]			Low
Somnolence leading to withdrawal	Topiramate	Amitriptyline	Dodick, 2009¹⁸⁹	347	0.0 [4.1]	-24 (14 to 104)	-41 (10 to 73)	Low
Weight increase leading to withdrawal	Topiramate	Amitriptyline	Dodick, 2009¹⁸⁹	347	0.0 [4.7]	-21 (12 to 73)	-47 (14 to 81)	Low
Withdrew due to drowsiness	Topiramate	Valproate (slow-release)	Bartolini, 2005 ¹⁹¹	44	9.1 [13.6]	NS	NS	Low
Left the study due to impaired concentration	Topiramate	Zonasamide	Mohammadiani nejad, 2011 ¹⁹⁰	80	0.0 [2.5]	NS	NS	Low
Left the study due to intolerable paresthesia	Topiramate	Zonasamide	Mohammadiani nejad, 2011 ¹⁹⁰	80	5.0 [0.0]	NS	NS	Low
Left the study due to unbearable restless leg syndrome	Topiramate	Zonasamide	Mohammadiani nejad, 2011 ¹⁹⁰	80	0.0 [2.5]	NS	NS	Low
Discontinued due to adverse effects	Topiramate 100mg	Amitriptyline 100mg	Dodick, 2009 ¹⁸⁹	347	19.7 [22.5]	NS	NS	Low
Discontinued due to adverse effects	Topiramate + Amitriptyline amitriptyline	Amitriptyline	Keskinbora, 2008 ²⁴⁷	51	4.3 [14.3]	NS	NS	Low
Discontinued due to adverse effects	Topiramate 200mg	Amitriptyline 150mg	Keskinbora, 2008 ²⁴⁷	52	8.3 [14.3]	NS	NS	Low

Table 29. Treatment discontinuation due to any adverse effects with topiramate versus other drugs for episodic migraine prevention in adults (continued)

Adverse Effects Leading to Withdrawal	Active	Control	Reference	Sample	Rate, Percent With Topiramate [Control Drug]	Number Needed To Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Strength of Evidence
Discontinued due to adverse effects	Topiramate 200mg)	Topiramate + Amitriptyline	Keskinbora, 2008 ²⁴⁷	47	8.3 [4.3]	NS	NS	Low
Discontinued due to adverse effects	Topiramate 25mg BD	Lamotrigine 25mg BD	Gupta, 2007 ⁹⁹	120	5.0 [5.0]	NS	NS	Low
Discontinued due to adverse effects	Topiramate 100mg BD	Levetiracetam 1000mg BD	de Tommaso, 2007 ¹⁹²	28	7.7 [0.0]	NS	NS	Low

CI = confidence interval; NS = not significant

Bold = significant at 95% confidence limit when 95% CI of attributable events per 1,000 treated do not include 0.

Number needed to treat and number of attributable events were calculated for statistically significant differences.

Table 30. Comparative safety of beta blockers for episodic migraine prevention in adults, treatment discontinuation due to bothersome adverse effects in randomized controlled clinical trials

Definition of the Outcome	Reference	Active Drug	Control Drug	Sample	Rate of Outcome in Active Group [Rate of Outcome in Control Group], Percent	Number Needed To Treat To Harm One Patient (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Strength of Evidence
Withdrew because of side effects and/or lack of efficacy	Louis, 1985²⁰⁷	Metoprolol	Clonidine	62	0.0 [12.9]	-8 (4 to 870)	-129 (1 to 257)	Low
Discontinued due to side-effects	Worz, 1991 ²⁰⁴	Metoprolol	Bisoprolol	156	6.4 [10.3]	NS	NS	Low
Patient withdrawal due to events	Schellenberg, 2008 ²⁰⁶	Metoprolol	Nebivolol	30	7. [6.3]	NS	NS	Low
Drowsiness leading to withdrawal	Grotemeyer, 1990 ²⁰²	Metoprolol	Aspirin	56	7.1 [0.0]	NS	NS	Low
Gastrointestinal side-effects leading to withdrawal	Grotemeyer, 1990²⁰²	Metoprolol	Aspirin	56	0.0 [17.9]	-6 (3 to 35)	-179 (28 to 329)	Low
Discontinued treatment because of severe adverse reactions	Langohr, 1985²⁵⁰	Clomipramine	Metoprolol	126	28.6 [0.0]	3 (3 to 6)	286 (173 to 399)	Low

CI = confidence interval; NS = not significant

Bold = significant differences at 95% confidence limit when 95% CI of attributable events per 1,000 treated do not include 0.

Number needed to treat and number of attributable events were calculated for statistically significant differences.

Table 31. Treatment adherence and discontinuation due to adverse effects with antidepressant amitriptyline and spinal manipulation for migraine prevention in adults, individual medium risk of bias randomized controlled clinical trial²¹⁵


Definition of the Outcome	Active Treatment	Control Treatment	Sample	Rate With Active, Percent [Control] Treatments	Number Needed To Treat (95% CI)	Attributable Events per 1,000 Treated (95% CI)	Strength of Evidence
Withdrawn due to side-effects	Spinal Manipulation	Amitriptyline 100mg/day	147	0.0 [10.0]	-10 (-38 to -6)	-100 (-174 to -26)	Low
Withdrawn due to side effects	Spinal Manipulation + Amitriptyline 100 mg/day	Amitriptyline 100 mg/days	141	5.6 [10.0]	NS	NS	Low
Withdrawn due to side effects	Spinal Manipulation	Spinal Manipulation + Amitriptyline 100 mg/day	148	0.0 [5.6]	NS	NS	Low

CI = confidence interval; NS = not significant

Bold = significant differences at 95% confidence limit when 95% CI of attributable events per 1,000 treated do not include 0.

Number needed to treat and number of attributable events were calculated for statistically significant differences.

Figure 4. Bayesian network meta-analysis of treatment discontinuation due to intolerable adverse effects with drugs versus placebo (47 RCTs of 3,054 adults) in randomized controlled clinical trials that aimed episodic migraine prevention in adults



CrI = credible intervals; NSAID = nonsteroidal anti-inflammatory drugs

Note: We used heterogeneous random effects model that assumes correlation within study ($\rho = 0.5$) and heterogeneous between studies (WinBUG codes are in the Appendix B). RCTs of angiotensin inhibiting drugs do not report intolerable adverse effects.

Key Question 3. Which patient characteristics predict the effectiveness and safety of pharmacologic treatments for preventing migraine attacks in adults?

Muscle Relaxants

Onabotulinumtoxin A for Chronic Migraine

Placebo Responders

Four RCTs examined the efficacy of onabotulinumtoxin A among placebo responders versus nonresponders.^{94,257-259} Onabotulinumtoxin A was better than placebo in preventing migraine attacks/month by ≥ 50 percent, regardless of placebo response, according to the BOTULINUM

TOXIN CDH Study Group.⁹⁴ Magnitude of the effect was slightly larger in placebo nonresponders (RR 2.2, 95% CI, 1.4 to 3.4) than in placebo responders (RR 1.6, 95% CI, 1.1 to 2.4).⁹⁴ The European BoNTA Headache Study Group demonstrated no additional benefits from increasing onabotulinumtoxin A dose, regardless of placebo response.²⁵⁹ The number of migraine days did not differ by dose of onabotulinumtoxin A (75, 15, or 225U).²⁵⁹

Baseline Migraine Frequency

Onabotulinumtoxin A was more effective in patients with a higher mean baseline migraine frequency in a single RCT from the BOTULINUM TOXIN North American Episodic Migraine Study Group.²⁵⁷ Onabotulinumtoxin A decreased the likelihood of use of drugs for acute attacks in patients with more than 12 migraine days per month at baseline (RR 0.78, 95% CI, 0.66 to 0.92).²⁵⁷

Concurrent Prophylactic Medication Use

Onabotulinumtoxin A caused adverse effects more often than placebo (blepharoptosis, muscle weakness, and neck pain, regardless of concurrent prophylactic medication use) according to the BOTULINUM TOXIN CDH Study Group.²⁵⁸

Antiepileptics for Episodic Migraine

Topiramate

Presence of Aura

No trials directly compared drug effects in patients with and without aura. Several post hoc subgroup analysis of topiramate versus placebo trials provided conflicting evidence of the drug efficacy in respect to aura. Two publications suggested that topiramate was better than placebo in patients with aura. Post hoc subgroup analysis of one RCT found a statistically significant reduction in migraine frequency with topiramate versus placebo (-2.43 vs. -0.79 respectively, p value=0.02) only in subjects with aura.⁸⁵ Post hoc subgroup analysis of the other RCTs found that in patients with aura, topiramate was better than placebo in reducing migraine frequency, number of migraine days, severity and duration of attacks, and photophobia.²⁶⁰ In contrast, however, post hoc analysis of the Prolonged Migraine Prevention found that topiramate efficacy was similar in patients with and without aura.²⁶¹

Beta Blockers for Episodic Migraine

Propranolol

Prior Medication Use

Subgroup analysis in chronic migraine patients by prior topiramate use or overuse of the drugs for acute migraine was conducted in a single RCT.¹⁸⁷ This study examined adding propranolol to topiramate treatment for chronic migraine subjects for whom topiramate monotherapy had failed.¹⁸⁷ Propranolol with topiramate was no better than topiramate alone in reducing migraine frequency, regardless of patients' prior drug histories.¹⁸⁷ Quality of life score changes from baseline difference depend on prior topiramate use (Figure 5). Patients with prior stable topiramate use experienced worsening in quality of life with combined therapy versus improvement in quality of life with topiramate monotherapy. In contrast, patients without stable

prior topiramate use experienced improvement in quality of life with combined therapy versus insignificant changes with topiramate monotherapy.¹⁸⁷

Sex

Topiramate caused a complete cessation of migraine attacks and a reduction of monthly migraine attacks by 50 percent in women but not men according to one low-risk-of-bias RCT.⁸⁴ Topiramate would cause a complete cessation of migraine attacks in 37 (95% CI, 8 to 67) and a reduction of monthly migraine attacks by 50 percent in 249 (95% CI, 178 to 320) per 1,000 treated women.⁸⁴ However, both men and women experienced a reduction of monthly migraine 75 to 90 percent more often with topiramate than with placebo.⁸⁴

Gabapentin for Episodic Migraine

Presence of Aura

Gabapentin reduced the frequency and intensity of migraine attacks significantly more than placebo, regardless of aura.²⁶² Patients with aura experienced a slightly greater reduction in migraine frequency (mean difference -2.2, 95% CI, -2.7 to -1.7) than patients without aura (mean difference -1.6, 95% CI, -2.2 to -0.9). Patients with aura experienced a slightly greater reduction in migraine intensity (mean difference -0.83, 95% CI, -1.12 to -0.54) than patients without aura (mean difference -0.42, 95% CI, -0.77 to -0.07).

Prior Medication Use

In a single, low-risk-of-bias RCT, gabapentin was not better than placebo in reducing acute drug use, regardless of prior use of triptans, opioids, or prescription or over-the-counter acute medications.⁸⁷

Antidepressants for Episodic Migraine

Amitriptyline

Baseline Migraine Frequency

Amitriptyline was better than placebo in reducing monthly migraine but only in patients with baseline frequent and severe migraine (Appendix Table D164).¹²⁵ Amitriptyline was better than placebo in reducing monthly migraine only in depressed patients whose baseline migraine was frequent and severe (Appendix Table D165).²⁵³

A higher dose of amitriptyline increased the odds of reducing monthly migraine by ≥ 50 percent in accordance with increased baseline migraine days (odds ratio 2.35, 95% CI 1.45 to 3.8 for every additional day of baseline migraine) (Appendix Table D166).²²⁸


Selective Calcium Channel Blockers for Episodic Migraine

Nimodipine

Presence of Aura

A higher dose of nimodipine was not associated with increased response rates regardless of aura.²⁶³ Nimodipine, 40 mg/day versus 20 mg/day, reduced use of drugs for acute attacks but only in patients with classic and not common migraine.²⁶³

Figure 5. Change from baseline in Migraine Specific Quality of Life



Migraine Specific Quality of Life = MSQL scale, an increase in MSQL indicates an improvement) with combined propranolol with topiramate or topiramate monotherapy in patients with chronic migraine for whom topiramate monotherapy failed, results from a single randomized controlled trial.¹⁸⁷

Discussion

Our report, in accordance with previously published reviews,^{23,24} demonstrated that all approved drugs were better than placebo in reducing monthly migraine frequency by ≥ 50 percent. In addition, we found that, compared with approved drugs, some off-label beta blockers and angiotensin inhibiting drugs are more effective and safer for preventing adult migraine. The relative effect of drugs was moderate, with drugs resulting in 200 to 400 cases of clinical response (of ≥ 50 percent reduction in monthly migraine frequency) per 1,000 treated.

Critical assessment of the strength of the available evidence suggested low risk of bias in one-third and medium risk of bias in more than half of included RCTs. We relied on direct evidence from head-to-head RCTs. We also analyzed previously published meta-analyses of individual patient data that provided valid estimation of dose response effects with drugs. However, strength of evidence was moderate only for topiramate and low for other drugs due to risk of bias and imprecise estimates. Many authors of individual trials did not provide sufficient details about allocation concealment methods or about planned measurements of clinically important changes in quality of life scores. In addition, many investigators failed to use intention-to-treat principles for all examined outcomes. Finally, many trials did not fully adhere to the recommendations from the Task Force of the International Headache Society Clinical Trials Subcommittee in design and reporting of the controlled clinical trials for preventing migraine in adults.²²

We incorporated risk of bias in our evaluation of the strength of evidence, but we could not estimate the effect of risk of bias criteria on drug benefits or safety because most evidence came from individual RCTs. The role of financial conflict of interest and industry sponsor participation in data analyses and interpretation was difficult to evaluate due to inconsistent reporting in individual studies and insufficient reporting of details.²⁶⁴ For instance, the same authors disclosed no or different relationships with industry in multiple publications. Studies inconsistently reported subjects' baseline severity and frequency of migraine attacks as well as comorbidities and concomitant treatments.^{2,265}

The results from eligible studies were applicable to the target population. The trials enrolled predominantly middle-aged Caucasian women. However, average treatment effects in a clinically diverse population may not reflect the actual effects for a specific subgroup.²⁶⁶ Very few studies provided evidence for individualized treatment decisions with clear descriptions of planned stratified randomization and subgroup analyses. Published RCTs rarely reported important patient characteristics that could modify drug effects (history of migraine, socioeconomic status, or response to prior preventive treatments).^{267,268} No trials examined the role of genetic polymorphism in drug metabolism and effects.²⁶⁹⁻²⁷¹ Migraine prevention trials did not address teratogenic effects, anorgasmia, impotence, and other harms of anti-epileptic drugs that can deter long-term adherence to preventive drugs.^{272,273,274}

A few RCTs reported treatment effects in patient subpopulations by baseline migraine frequency of placebo response. Low-strength evidence suggested that onabotulinumtoxin A²⁵⁷ and amitriptyline²²⁸ were more effective in patients with frequent baseline migraine. Rates of migraine prevention in placebo arms ranged from 6 to 30 percent in examined RCTs. Previous research demonstrated a high placebo response in trials aimed to treat acute migraine attacks.^{28,275} Our review demonstrated that a relative risk of adverse effects with onabotulinumtoxin A was lower in trials with higher placebo rates of adverse effects.⁹⁴ Previous research has demonstrated that patients with migraine quit taking topiramate due to bothersome adverse effects more often than patients with epilepsy.²⁸ Most trials in our review excluded

patients with severe medical or psychiatric illnesses, stroke, and vascular migraine. Substantial variability in reporting comorbidities precluded using this information in quantitative synthesis of evidence.

Comparative effectiveness and safety with preventive drugs were examined in individual RCTs that failed to meet pooling criteria. Variability in examined drug comparisons in head-to-head RCTs precluded meta-analysis of direct evidence. However, indirect comparisons were feasible because we found no evident differences in baseline patient characteristics across RCTs. Thus, we conducted Bayesian network meta-analyses, which indicated that angiotensin inhibiting drugs and beta blockers were the most effective and safe drugs. Head-to-head trials were not designed to test safety with migraine preventive drugs. Very few trials were designed to detect significant increase in rates of bothersome adverse effects leading to treatment discontinuation when compared with placebo. In contrast, network meta-analysis demonstrated that patients stopped taking drugs more often with topiramate, off-label antiepileptics, and antidepressants than with placebo. Individual adverse effects varied depending on the pharmacodynamic properties of the drugs.

Multidisciplinary drug management programs demonstrated improvement in migraine-related disability and patient satisfaction, but long-term adherence and benefits are unclear.

Only a few RCTs examined quality of life, providing no consistent evidence of improvement with examined drugs. The authors rarely measured quality of life using disease-specific instruments such as the Migraine Specific Questionnaire, Migraine Disability Assessment, or the Headache Impact Test. We could not determine the clinical importance of statistically different changes in scores.

Our review has implications for clinical practice. Informed decisions in clinical settings should take into account exact rates of benefits and harms with specific drugs.²⁷⁶

The most recent guidelines from the American Academy of Neurology and the American Headache Society recommend the four FDA-approved drugs—the antiepileptics topiramate and divalproex and the beta-blockers propranolol and timolol—for adult migraine prevention.²⁷⁷ The aforementioned guidelines, which focused on published evidence, differed regarding their recommendations for off-label drugs. Further, current guidelines do not include consideration of the balance between benefits and harms of drugs as a basis for clinical decisionmaking.²⁷⁸ Our review analyzed benefits and harms of drugs and provided evidence for using effective and relatively safe off-label angiotensin inhibiting drugs and other off-label beta-blockers as alternatives based on patient preferences, comorbidities, and contraindications to the medications.

We could not find published controlled observational studies about preventive drug use or about the comparative effectiveness of approved versus off-label drugs. A single retrospective administrative database study found that migraine prophylaxis medications (tricyclic antidepressants, serotonin reuptake inhibitors antidepressants, mirtazapine, venlafaxine, phenelzine, beta blockers, calcium channel blockers, valproic acid and derivatives, gabapentin, tiagabine, topiramate, and carbamazepine) were associated with a significant reduction in migraine-related costs.²⁷⁹ Large observational studies of health care use for migraine did not analyze comparative effectiveness of preventive drugs.^{5,16}

Some evidence suggested that use of off-label drugs is common in the United States, despite having little or no scientific support.²¹ For instance, the Institute of Medical Informatics Health National Disease and Therapeutic Index analysis suggested that 20 percent of all outpatient drug prescriptions for adults were for off-label drugs. The most commonly prescribed off-label drugs

were anticonvulsants, gabapentin, and amitriptyline hydrochloride.²⁸⁰ We found that off-label antiepileptics and antidepressants demonstrated worse benefits and safety profiles than beta blockers or angiotensin inhibiting drugs. Evidence of off-label drug use and associated adverse effects has been evaluated with prospective pharmacovigilance surveys in European countries.^{281,282} Routine monitoring of harms with off-label drugs is needed in the United States in order to collect and analyze evidence of comparative safety in clinical settings.

Our report has limitations, including possible reporting bias. We restricted our review to studies published in English in journals, reviewed by the FDA, or reported on the ClinicalTrials.gov Web site. Even after such a comprehensive review of evidence, we do not know how many funded but unregistered studies we may have missed. Published articles rarely provided unique trial registration numbers from Clinicaltrials.gov. We concluded multiple reports of the same data based on available information and did not contact the authors for further clarifications. We suspected selective harms reporting because published articles reported common and expected adverse effects. In contrast, few RCTs that posted results in Clinicaltrials.gov reported all harms regardless of the rate or the assumed association with active drugs. We did not contact the authors requesting unreported benefits and harms; the cost-effectiveness of this pursuit is still being debated.^{283,284} For studies in which methodological quality criteria were poorly reported, we did not contact the authors for additional details. Vast variability in examined treatment option, risk of bias, and imprecise estimates from small individual RCTs hampered synthesis of evidence.

Future Research Needs

We identified gaps and biases in available evidence that can direct future research (Table 32). Future randomized well-designed clinical trials should examine comparative effectiveness of the approved drugs and the most effective off-label ACE inhibitors, angiotensin II blockers, and off-label beta blockers. Future trials should examine the potential modification of treatment effects by factors such as patient age, sex, race, migraine family history, comorbidities, and prior treatment response. Observational studies should analyze off-label drug use as well as the comparative effectiveness and safety of migraine preventive drugs. Analysis of administrative databases should examine visits to doctors and emergency rooms among adults taking migraine preventive drugs. Prospective pharmacovigilance methods should be used for routine monitoring of off-label drug utilization and associated adverse effects with migraine preventive drugs. All interventional studies should be registered in ClinicalTrials.gov. All clinical trials of migraine preventive drugs should be required to post their results in ClinicalTrials.gov.

Key Messages

Efficacy and Comparative Effectiveness of Pharmacologic Treatments for Preventing Migraine Attacks in Adults

Effect of Preventive Pharmacologic Treatments on Patient-centered and Intermediate Outcomes Compared With Placebo or No Active Treatment

- For chronic migraine, onabotulinumtoxin A was more effective than placebo in reducing monthly chronic migraine attacks by ≥ 50 percent with inconsistent improvement in quality of life.
- For episodic migraine, all approved drugs were better than placebo in reducing monthly migraine frequency by ≥ 50 percent (clinical response).
- Relative effect of drugs was moderate: drugs would result in clinical response in 200 to 400 patients per 1,000 treated.
- Strength of evidence was lowered due to medium risk of bias and imprecise estimates.
- Low-strength evidence from individual RCTs suggested a dose-responsive increase in migraine prevention with higher doses of onabotulinumtoxin A and topiramate (from 50-100 mg with no additional benefits with 200 mg/day).
- Among off-label drugs, pooled analyses offered low-strength evidence that the antiepileptic gabapentin, the beta-blocker metoprolol, and the calcium channel blocker nimodipine were better than placebo in reducing monthly migraine attacks by ≥ 50 percent.
- Individual RCTs offered low-strength evidence that off-label beta blockers acebutolol, atenolol, and nadolol were better than placebo in reducing monthly migraine attacks by ≥ 50 percent. Individual RCTs demonstrated that compared with placebo, the angiotensin converting enzyme inhibitors captopril and lisinopril and the angiotensin II antagonist candesartan were better in reducing monthly migraine attacks by ≥ 50 percent.

Effect of Preventive Pharmacologic Treatments on Patient-Centered and Intermediate Outcomes Compared With Active Pharmacologic Treatments

- Individual RCTs provided low-strength direct evidence about the comparative effectiveness of drugs and demonstrated few significant differences.
- Indirect adjusted analysis demonstrated no differences between approved drugs and greater odds of clinical response with angiotensin II antagonist candesartan.
- Exploratory network Bayesian meta-analyses demonstrated that approved drugs were similarly better than placebo. Among off-label drug classes, angiotensin inhibiting drugs demonstrated the largest significant odds of reducing monthly migraine by ≥ 50 percent.

Effect of Preventive Pharmacologic Treatments on Patient-centered and Intermediate Outcomes Compared With Active Nonpharmacologic Treatments

- Individual RCTs provided low-strength evidence that a ≥ 50 percent reduction in monthly migraine attacks did not differ with propranolol versus biofeedback.

Influence of Approaches to Drug Management Versus Usual Care (Such as Patient-Care Teams, Integrated Care, Coordinated Care, Patient Education, Drug Surveillance, or Interactive Drug Monitoring)

- Multidisciplinary team care improved quality of life and reduced migraine-related disability.
- Headache management program resulted in complete cessation of migraine (100 percent reduction in monthly migraine attacks).
- A cognitive-behavioral minimal contact program improved patient satisfaction with treatments.
- Headache school decreased overuse of acute drugs and reduced migraine disability.
- An intensive pharmaceutical care campaign had no statistically significant impact on use of drugs for acute attacks.

Comparative Harms From Pharmacologic Treatments for Preventing Migraine Attacks in Adults

- Among approved drugs, onabotulinumtoxin A, topiramate, and propranolol resulted in bothersome adverse effects leading to treatment discontinuation more often than placebo.
- The association was dose responsive for topiramate. Larger doses of topiramate caused higher risk of anorexia, depression, paresthesia, and difficulty in memory leading to treatment withdrawal. Larger doses of topiramate caused higher risk dry mouth, paresthesia or fatigue, mood problems, nausea, and weight loss.
- Individual RCTs showed that divalproex led to treatment discontinuation, nausea, somnolence, tremor, vomiting, and asthenia.
- Among other drugs, pooled analyses demonstrated that the off-label antidepressant amitriptyline caused bothersome adverse effects leading to treatment discontinuation more often than placebo.
- Limited low-strength evidence from individual head-to-head RCTs suggested that treatment discontinuation due to adverse effects was less frequent with onabotulinumtoxin A than topiramate or amitriptyline.
- Individual unique RCTs provided low-strength direct evidence about adverse effects with specific drugs with no consistent pattern across available drug comparisons.
- Indirect adjusted analyses demonstrated no differences in treatment discontinuation due to adverse effects with approved drugs or approved versus off-label drugs. Exploratory Bayesian network meta-analyses demonstrated that topiramate, off-label antiepileptics and antidepressants resulted in bothersome adverse effects leading to treatment discontinuation more often than placebo. According to network meta-analysis, off-label angiotensin inhibiting drugs and beta blockers were the safest treatment option for adults with episodic migraine.

Influence of Patient Characteristics on the Effectiveness and Safety of Pharmacologic Treatments for Preventing Migraine Attacks in Adults

- Evidence was limited to individual RCTs that examined the drug effect modification by selected patient characteristics.
- Onabotulinumtoxin A was more effective in patients with a higher mean baseline migraine frequency.
- Amitriptyline was better than placebo in reducing monthly migraine only in patients with frequent and severe baseline migraine and in depressed patients with baseline severe migraine.

Table 32. Future research needs

Key Question	Findings	Types of Studies Needed To Answer Question	Future Research Recommendation
KQ 1: What are the efficacy and comparative effectiveness of pharmacologic treatments for preventing migraine attacks in adults?	<ul style="list-style-type: none"> • All approved drugs, some off-label beta blockers, and ACE inhibitors were better than placebo in reducing monthly migraine frequency by $\geq 50\%$ (clinical response). • Individual RCTs provided low strength of evidence about comparative effectiveness of drugs with few significant differences. • Network Bayesian meta-analysis of 59 drugs from 14 drug classes demonstrated that all approved drugs were similarly better than placebo. Among off-label drugs angiotensin inhibiting drugs, and some off-label beta blockers are more effective than all other drugs. 	<ul style="list-style-type: none"> • Randomized clinical trials. • Creating of migraine registry with individual patient data from electronic medical records and quarterly completed migraine diaries. • Analysis of health insurance, Medicare, and Medicaid databases. • Prospective pharmacovigilance surveys. 	<ul style="list-style-type: none"> • Design low-risk-of-bias RCTs following recommendations from the International Headache Society about migraine definitions, inclusion, and exclusion criteria of the subjects, assessments of patient centered outcomes at the end of the treatments and at 6 months or more of followup. • Conduct observational studies reducing risk of bias by matching, adjustment, and propensity score. • Examine comparative effectiveness of the most effective and safe angiotensin inhibiting drugs and beta blockers with approved antiepileptics and beta blockers. • Examine comparative effectiveness of combined treatments with approved and off-label Angiotensin inhibiting drugs vs. monotherapy. • Examine treatment effects in patient subpopulations by age, sex, race, socioeconomic status, prior treatment history, comorbidity, family history of migraine, and baseline migraine type, severity, and frequency. • Focus on validated measures of quality of life and migraine related disability. • Examined preventive drug utilization and the effects on health care utilization (emergency visits, hospitalizations, abortive drug utilization and overuse). • Examine which patient and provider characteristics are associated with preventive drug utilization. • Examine the benefits with multidisciplinary migraine management programs and combined pharmacologic and self-administrated migraine management interventions.

Table 32. Future research needs (continued)

Key Question	Findings	Types of Studies Needed To Answer Question	Future Research Recommendation
KQ 2: What are the comparative harms from pharmacologic treatments for preventing migraine attacks in adults?	<ul style="list-style-type: none"> • Among approved drugs, onabotulinumtoxin A, topiramate, and propranolol resulted in bothersome adverse effects leading to treatment discontinuation more often than placebo. • The association was dose responsive for topiramate. Larger doses of topiramate caused higher risk of anorexia, depression, paresthesia, and difficulty in memory leading to treatment withdrawal. Larger doses of topiramate caused higher risk dry mouth, paresthesia or fatigue, mood problems, nausea, and weight loss. • Individual RCTs showed that divalproex led to treatment discontinuation due to adverse effects that included nausea, somnolence, tremor, vomiting, and asthenia. • Among other drugs, pooled analyses demonstrated that off-label antidepressant amitriptyline caused bothersome adverse effects leading to treatment discontinuation more often than placebo. 	<ul style="list-style-type: none"> • Randomized clinical trials. • Creating migraine registry with individual patient data from electronic medical records and quarterly completed migraine diaries. • Analysis of health insurance, Medicare, and Medicaid databases. • Prospective pharmacovigilance surveys 	<ul style="list-style-type: none"> • Design low-risk-of-bias fully powered to assess harms RCTs following recommendations from the HIS about migraine definitions, inclusion, and exclusion criteria of the subjects, comorbidities, assessments of patient centered outcomes at the end of the treatments and at 6 months or more of followup. • Conduct observational studies reducing risk of bias by matching, adjustment, and propensity score. • Examine comparative safety of the commonly used approved and off-label drugs with the most effective and safe angiotensin inhibiting drugs and beta blockers. • Examine treatment harms in patient subpopulations by age, sex, race, socioeconomic status, prior treatment history, comorbidity, concomitant treatments, family history of migraine, and doses of the drugs. • Analyze all harms the patient experienced irrespective of investigator determination about causality between drugs and harms. • Examine preventive drug utilization and the effects on health care utilization (treatments for adverse effects, hospitalizations for drug harms). • Examine the effects of multidisciplinary migraine management programs on patient safety. • Routinely analyze all harms in patients with migraine taking preventive drugs.

Table 32. Future research needs (continued)

Key Question	Findings	Types of Studies Needed To Answer Question	Future Research Recommendation
KQ 2: What are the comparative harms from pharmacologic treatments for preventing migraine attacks in adults? (continued)	<ul style="list-style-type: none"> • Limited low-strength evidence from individual head-to-head RCTs suggested that treatment discontinuation due to adverse effects was less frequent with onabotulinumtoxin A than topiramate or amitriptyline. • Individual unique RCTs provided low-strength direct evidence about adverse effects with specific drugs, with no consistent pattern across available drug comparisons. • Indirect adjusted analyses demonstrated no differences in treatment discontinuation due to adverse effects with approved drugs or approved versus off-label drugs. Exploratory Bayesian network meta-analyses demonstrated that topiramate, off-label antiepileptics, and antidepressants resulted in bothersome adverse effects leading to treatment discontinuation more often than placebo. According to network meta-analysis, off-label angiotensin inhibiting drugs and beta-blockers were the safest treatment option for adults with episodic migraine 		

Table 32. Future research needs (continued)

Key Question	Findings	Types of Studies Needed To Answer Question	Future Research Recommendation
KQ 3: Which patient characteristics predict the effectiveness and safety of pharmacologic treatments for preventing migraine attacks in adults?	<ul style="list-style-type: none"> Evidence was limited to individual RCTs that examined the drug effect modification by selected patient characteristics. 	<ul style="list-style-type: none"> Randomized clinical trials. Creating of migraine registry with individual patient data from electronic medical records and quarterly completed migraine diaries. Analysis of health insurance, Medicare, and Medicaid databases; prospective pharmacovigilance surveys. 	<ul style="list-style-type: none"> Conduct low-risk-of-bias RCTs with planned subgroup analysis of treatment benefits by age, sex, race, socioeconomic status, prior treatment history, comorbidity, family history of migraine, and baseline migraine type, severity, and frequency. Conduct low-risk-of-bias powered RCTs with planned subgroup analysis of treatment harms by age, sex, race, socioeconomic status, prior treatment history, comorbidity, concomitant treatments, family history of migraine, and doses of the drugs. Conduct pharmacogenomic studies to examine the effects of genetically predisposed drug metabolism on treatment benefits and harms. Evaluate treatment effects in patient subpopulations by age, sex, race, socioeconomic status, prior treatment history, comorbidity, family history of migraine, and baseline migraine type, severity, and frequency. Examine treatment harms in patient subpopulations by age, sex, race, socioeconomic status, prior treatment history, comorbidity, concomitant treatments, family history of migraine, and doses of the drugs. Routinely analyze which patient and provider characteristics are associated with drug adverse effects in patients with migraine taking preventive drugs. Routinely analyze which patient and provider characteristics are associated with treatment discontinuation in patients with migraine taking preventive drugs.

RCT = randomized controlled trial

References

1. Goadsby PJ, Raskin NH. Chapter 15. Headache. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., eds. *Harrison's principles of internal medicine*. 17th ed. New York: The McGraw-Hill Companies; 2008.
2. Silberstein SD. Preventive migraine treatment. *Neurol Clin*. 2009 May;27(2):429-43. PMID 19289224.
3. Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. *Neurology*. 2000;55(9 Suppl 2):S29-35. PMID 11089517.
4. Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. *Headache*. 2007 Mar;47(3):355-63. PMID 17371352.
5. Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. *Neurology*. 2002 Mar 26;58(6):885-94. PMID 11914403.
6. Bigal ME, Lipton RB, Winner P, et al. Migraine in adolescents: association with socioeconomic status and family history. *Neurology*. 2007 Jul 3;69(1):16-25. PMID 17606878.
7. Hernandez-Latorre MA, Roig M. Natural history of migraine in childhood. *Cephalalgia*. 2000 Jul;20(6):573-9. PMID 11075841.
8. Charles A. Advances in the basic and clinical science of migraine. *Ann Neurol*. 2009 May;65(5):491-8. PMID 19479724.
9. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. *Neurology*. 2007 Jan 30;68(5):343-9. PMID 17261680.
10. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. *Cephalalgia*. 2010 May;30(5):599-609. PMID 19614702.
11. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. *Cephalalgia*. 2006 Jun;26(6):742-6. PMID 16686915.
12. Solomon S. New appendix criteria open for a broader concept of chronic migraine (Comment on: *Cephalalgia* 2006 Jun;26(6):742-6). *Cephalalgia*. 2007 May;27(5):469; author reply -70. PMID 17448186.
13. Stewart WF, Ricci JA, Chee E, et al. Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. *J Occup Environ Med*. 2003 Dec;45(12):1234-46. PMID 14665809.
14. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. *Arch Intern Med*. 1999 Apr 26;159(8):813-8. PMID 10219926.
15. Burton WN, Landy SH, Downs KE, et al. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. *Mayo Clin Proc*. 2009 May;84(5):436-45. PMID 19411440.
16. Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. *Neurology*. 2003 Feb 11;60(3):441-8. PMID 12578925.
17. Lipton RB, Stewart WF. The epidemiology of migraine. *Eur Neurol*. 1994;34 Suppl 2:6-11. PMID 7835383.
18. Sprenger T, Goadsby PJ. Migraine pathogenesis and state of pharmacological treatment options. *BMC Medicine*. 2009;7:71. PMID 19917094.
19. Sanchez-Del-Rio M, Reuter U, Moskowitz MA. New insights into migraine pathophysiology. *Curr Opin Neurol*. 2006 Jun;19(3):294-8. PMID 16702838.
20. Rapoport AM. Acute and prophylactic treatments for migraine: present and future. *Neurol Sci*. 2008 May;29 Suppl 1:S110-22. PMID 18545911.

21. Stafford RS. Regulating off-label drug use--rethinking the role of the FDA. *N Engl J Med*. 2008 Apr 3;358(14):1427-9. PMID 18385495.
22. Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. *Cephalalgia*. 2008 May;28(5):484-95. PMID 18294250.
23. Schroeder BM. AAFP/ACP-ASIM release guidelines on the management and prevention of migraines. *Am Fam Physician*. 2003 Mar 15;67(6):1392, 5-7. PMID 12674472.
24. Morey SS. Guidelines on migraine: part 4. General principles of preventive therapy. *Am Fam Physician*. 2000 2000 Nov 15;62(10):2359-60. PMID 11126860.
25. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2000 Sep 26;55(6):754-62. PMID 10993991.
26. Schuurmans A, van Weel C. Pharmacologic treatment of migraine. Comparison of guidelines. *Can Fam Physician*. 2005 Jun;51:838-43. PMID 15986940.
27. Lainez MJ, Freitag FG, Pfeil J, et al. Time course of adverse events most commonly associated with topiramate for migraine prevention. *Eur J Neurol*. 2007 Aug;14(8):900-6. PMID 17662012.
28. Luykx J, Mason M, Ferrari MD, et al. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. *Clin Pharmacol Ther*. 2009 Mar;85(3):283-8. PMID 18987621.
29. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. *Eur J Neurol*. 2009 Sep;16(9):968-81. PMID 19708964.
30. Dowson AJ, Lipscombe S, Sender J, et al. New guidelines for the management of migraine in primary care. *Curr Med Res Opin*. 2002;18(7):414-39. PMID 12487508.
31. U.S. Food and Drug Administration. FDA News Release: FDA Approves Botox to Treat Chronic Migraine. 2010. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229782.htm. Accessed on July 25 2012.
32. Amanzio M, Corazzini LL, Vase L, et al. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. *Pain*. 2009 Dec;146(3):261-9. PMID 19781854.
33. Whyte CA, Tepper SJ. Adverse effects of medications commonly used in the treatment of migraine. *Expert Rev Neurother*. 2009 Sep;9(9):1379-91. PMID 19769452.
34. Whitlock EP, Lopez SA, Chang S, et al. AHRQ series paper 3: identifying, selecting, and refining topics for comparative effectiveness systematic reviews: AHRQ and the effective health-care program. *J Clin Epidemiol*. 2010 May;63(5):491-501. PMID 19540721.
35. Slutsky J, Atkins D, Chang S, et al. AHRQ series paper 1: comparing medical interventions: AHRQ and the Effective Health-Care Program. *J Clin Epidemiol*. 2010 May;63(5):481-3. PMID 18834715.
36. Helfand M, Balshem H. AHRQ series paper 2: principles for developing guidance: AHRQ and the Effective Health-Care Program. *J Clin Epidemiol*. 2010 May;63(5):484-90. PMID 19716268.
37. Shamilyan T. Comparative effectiveness of preventive pharmacological treatments for migraine in adults. *Prospero*. 2011;CRD42012001918.
38. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Annals of Internal Medicine*. 2009 Aug 18;151(4):W65-94. PMID 19622512.

39. White CM, Ip S, McPheeters ML, et al. Chapter 11. Using existing systematic reviews to replace de novo processes in conducting comparative effectiveness reviews. *Methods Guide for Effectiveness and Comparative Reviews*. AHRQ Publication No. 10(11)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality; March 2011; 2009:136-51. www.effectivehealthcare.ahrq.gov.
40. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. *Am J Prev Med*. 2001 Apr;20(3 Suppl):21-35. PMID 11306229.
41. Rothner AD. Complicated migraine and migraine variants. *Curr Pain Headache Rep*. 2002 Jun;6(3):233-9. PMID 12003695.
42. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. *Cephalalgia*. 2004;24 Suppl 1:9-160. PMID 14979299.
43. Hansen JM, Thomsen LL, Olesen J, et al. Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype. *Neurology*. 2008 Sep 9;71(11):841-7. PMID 18779512.
44. Norris S, Atkins D, Bruening W, et al. Chapter 4. Selecting observational studies for comparing medical interventions. *Methods Guide for Effectiveness and Comparative Reviews*. AHRQ Publication No. 10(11)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2011:56-68. www.effectivehealthcare.ahrq.gov.
45. Higgins J, Green S, eds. *Cochrane handbook for systematic reviews of interventions*. Version 5.1.0. London: The Cochrane Collaboration; 2011.
46. Chou R, Aronson N, Atkins D, et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the Effective Health-Care Program. *J Clin Epidemiol*. 2008 Sep 25;63(5):502-12. PMID 18823754.
47. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928. PMID 22008217.
48. Viswanathan M AM, Berkman ND, Chang S, Hartling L, McPheeters LM, Santaguida PL, Shamliyan T, Singh K, Tsertsvadze A, Treadwell JR. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. Agency for Healthcare Research and Quality Methods Guide for Comparative Effectiveness Reviews. 2012;AHRQ Publication No. 12-EHC047-EF. www.effectivehealthcare.ahrq.gov/.
49. Viswanathan M BN. Development of the RTI Item Bank on Risk of Bias and Precision of Observational Studies. Methods Research Report. (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-0056-I.) 2011;AHRQ Publication No. 11-EHC028-EF. Rockville, MD: Agency for Healthcare Research and Quality www.effectivehealthcare.ahrq.gov/reports/final.cfm).
50. van der Velde G, van Tulder M, Cote P, et al. The sensitivity of review results to methods used to appraise and incorporate trial quality into data synthesis. *Spine (Phila Pa 1976)*. 2007 Apr 1;32(7):796-806. PMID 17414916.
51. Herbison P, Hay-Smith J, Gillespie WJ. Adjustment of meta-analyses on the basis of quality scores should be abandoned. *J Clin Epidemiol*. 2006 Dec;59(12):1249-56. PMID 17098567.
52. Ad Hoc Committee on Classification of Headache. Classification of headache. *JAMA*. 1962;179(9):717-8.
53. Wallace BC, Schmid CH, Lau J, et al. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. *BMC Med Res Methodol*. 2009;9:80. PMID 19961608.
54. Egger M, Smith GD, Altman DG. *Systematic reviews in health care: meta-analysis in context*. 2nd ed. London: BMJ Books; 2001.
55. Treadwell JR, Uhl S, Tipton K, et al. Assessing equivalence and noninferiority. *J Clin Epidemiol*. 2012 Nov;65(11):1144-9. PMID 22732455.

56. Friedrich JO, Adhikari NK, Beyene J. Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods. *Journal of Clinical Epidemiology*. 2011 May;64(5):556-64. PMID 21447428.
57. Fu R, Gartlehner G, Grant M, et al. Chapter 9. Conducting quantitative synthesis when comparing medical interventions. *Methods Guide for Effectiveness and Comparative Effectiveness Reviews*. AHRQ Publication No. 10(11)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2011:104-19. www.effectivehealthcare.ahrq.gov/reports/final.cfm.
58. Rucker G, Schwarzer G, Carpenter J, et al. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells. *Stat Med*. 2009 Feb 28;28(5):721-38. PMID 19072749.
59. Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. *Stat Med*. 2007 Jan 15;26(1):53-77. PMID 16596572.
60. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Stat Med*. 2004 May 15;23(9):1351-75. PMID 15116347.
61. Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. *Stat Med*. 2010 Dec 20;29(29):3046-67. PMID 20827667.
62. White IR. Multivariate random-effects meta-regression: Updates to mvmeta. *The Stata Journal*. 2011;11(2) PMID ocn746827598.
63. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the Effective Health-Care Program. *J Clin Epidemiol*. 2010 May;63(5):513-23. PMID 19595577.
64. Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis. *Stat Med*. 2007 Jan 15;26(1):37-52. PMID 16463355.
65. Knapp G, Biggerstaff BJ, Hartung J. Assessing the amount of heterogeneity in random-effects meta-analysis. *Biom J*. 2006 Apr;48(2):271-85. PMID 16708778.
66. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986 Sep;7(3):177-88. PMID 3802833.
67. Ebrahim S. The use of numbers needed to treat derived from systematic reviews and meta-analysis. Caveats and pitfalls. *Eval Health Prof*. 2001 Jun;24(2):152-64. PMID 11523384.
68. Altman DG. Confidence intervals for the number needed to treat. *BMJ*. 1998 Nov 7;317(7168):1309-12. PMID 9804726.
69. Coory M, Jordan S. Frequency of treatment-effect modification affecting indirect comparisons: a systematic review. *Pharmacoeconomics*. 2010;28(9):723-32.
70. Wells G, Sultan S, Chen L, et al. Indirect evidence: Indirect treatment comparisons in meta-analysis. *Canadian Agency for Drugs and Technologies in Health*. 2009;Ottawa.
71. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. *Health Technol Assess*. 2005 Jul;9(26):1-134, iii-iv. PMID 16014203.
72. Song F, Loke YK, Walsh T, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. *BMJ*. 2009;338:b1147. PMID 19346285.
73. Donegan S, Williamson P, Gamble C, et al. Indirect comparisons: a review of reporting and methodological quality. *PLoS One*. 2010;5(11):e11054. PMID 21085712.
74. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. *Value Health*. 2011 Jun;14(4):417-28. PMID 21669366.

75. Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. *Value Health*. 2011 Jun;14(4):429-37. PMID 21669367.
76. Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. *Stat Med*. 2010 Mar 30;29(7-8):932-44. PMID 20213715.
77. Carlin BP, Louis TA. *Bayesian Methods for Data Analysis*. Boca Raton, Fla.: Chapman & Hall/CRC; 2009.
78. Higgins JPT, Jackson D, Barrett JK, et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. *Research Synthesis Methods*. 2012;3(2):98-110.
79. Aschengrau A, Seage GR. *Essentials of epidemiology in public health*. Sudbury, MA: Jones and Bartlett; 2003.
80. Lunn D, Thomas A, Best N, et al. WinBUGS- a Bayesian modelling framework: concepts, structure, and extensibility. *Statistics and Computing*. 2000;10:325-37.
81. Berkman ND, Lohr KN, Morgan LC, et al. Reliability Testing of the AHRQ EPC Approach to Grading the Strength of Evidence in Comparative Effectiveness Reviews. Rockville (MD); 2012.
82. Guyatt G, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence-imprecision. *J Clin Epidemiol*. 2011 Aug 10; PMID 21839614.
83. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ*. 2011;343:d4002. PMID 21784880.
84. Bussone G, Diener HC, Pfeil J, et al. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. *Int J Clin Pract*. 2005 Aug;59(8):961-8. PMID 16033621.
85. Silberstein SD, Hulihan J, Karim MR, et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. *Clin Ther*. 2006 Jul;28(7):1002-11. PMID 16990078.
86. Silberstein S, Lipton R, Dodick D, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. *Headache*. 2009 Sep;49(8):1153-62. PMID 19719543.
87. NCT00742209. Prevention Study in Adult Patients Suffering From Migraine Headaches. 2010.
88. Minervini MG, Pinto K. Captopril relieves pain and improves mood depression in depressed patients with classical migraine. *Cephalalgia*; 1987. p. 485-6.
89. Gelmers HJ. Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine. *Headache*; 1983. p. 106-9.
90. Pradalier A, Lanteri-Minet M, Geraud G, et al. The PROMISE study: PROphylaxis of MIGraine with SEglor (dihydroergotamine mesilate) in French primary care. *CNS Drugs*. 2004;18(15):1149-63. PMID 15581385.
91. Anthony M, Lance JW. Indomethacin in migraine. *Med J Aust*. 1968 Jan 13;1(2):56-7. PMID 4867513.
92. Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. *Headache*. 2000 Jun;40(6):445-50. PMID 10849039.
93. Freitag FG, Diamond S, Diamond M, et al. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. *Headache*. 2008 Feb;48(2):201-9. PMID 18042229.
94. Mathew NT, Frishberg BM, Gawel M, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. *Headache*. 2005 Apr;45(4):293-307. PMID 15836565.

95. Storey JR, Calder CS, Hart DE, et al. Topiramate in migraine prevention: a double-blind, placebo-controlled study. *Headache*. 2001 Nov-Dec;41(10):968-75. PMID 11903524.
96. Mei D, Capuano A, Vollono C, et al. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. *Neurol Sci*. 2004 Dec;25(5):245-50. PMID 15624081.
97. Silberstein S. Efficacy and safety of topiramate in migraine prevention: a dose-ranging, placebo-controlled, double-blind, multicenter study. *Advanced Studies in Medicine*. 2003;3(6C):S565-8.
98. Silvestrini M, Bartolini M, Coccia M, et al. Topiramate in the treatment of chronic migraine. *Cephalalgia*. 2003 Oct;23(8):820-4. PMID 14510929.
99. Gupta P, Singh S, Goyal V, et al. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). *Headache*. 2007 Mar;47(3):402-12. PMID 17371357.
100. Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. *Cephalalgia*. 2007 Jul;27(7):814-23. PMID 17441971.
101. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. *Arch Neurol*. 1995 Mar;52(3):281-6. PMID 7872882.
102. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. *Neurology*. 2002 Jun 11;58(11):1652-9. PMID 12058094.
103. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. *Cephalalgia*. 1997 Apr;17(2):103-8. PMID 9137847.
104. Tfelt-Hansen P, Standnes B, Kangasneimi P, et al. Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. *Acta Neurol Scand*. 1984 Jan;69(1):1-8. PMID 6367336.
105. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control. *J Neurol*. 2004 Aug;251(8):943-50. PMID 15316798.
106. Diamond S, Medina JL. Double blind study of propranolol for migraine prophylaxis. *Headache*; 1976. p. 24-7.
107. Standnes B. The prophylactic effect of timolol versus propranolol and placebo in common migraine: Beta-blockers in migraine. *Cephalalgia*; 1982. p. 165-70.
108. Briggs RS, Millac PA. Timolol in migraine prophylaxis. *Headache*. 1979 Nov;19(7):379-81. PMID 511540.
109. Stellar S, Ahrens SP, Meibohm AR, et al. Migraine prevention with timolol. A double-blind crossover study. *JAMA*. 1984 Nov 9;252(18):2576-80. PMID 6387197.
110. Wessely P, Baumgartner C, Klingler D, et al. Preliminary results of a double-blind study with the new migraine prophylactic drug Gabapentin. *Cephalalgia*; 1987. p. 477-8.
111. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. *Headache*. 2001 Feb;41(2):119-28. PMID 11251695.
112. Havanka-Kanniainen H, Hokkanen E, Myllylä VV. Efficacy of nimodipine in the prophylaxis of migraine. *Cephalalgia : an international journal of headache*; 1985. p. 39-43.
113. Kangasniemi P, Andersen AR, Andersson PG, et al. Classic migraine: effective prophylaxis with metoprolol. *Cephalalgia*. 1987 Dec;7(4):231-8. PMID 3322569.
114. Andersson PG, Dahl S, Hansen JH, et al. Prophylactic treatment of classical and non-classical migraine with metoprolol--a comparison with placebo. *Cephalalgia*. 1983 Dec;3(4):207-12. PMID 6640652.
115. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. *Cephalalgia*. 1996 Jun;16(4):257-63. PMID 8792038.

116. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine--a double-blind placebo-controlled study. *Cephalalgia*. 1996 Oct;16(6):436-40. PMID 8902254.
117. Vahedi K, Taupin P, Djomby R, et al. Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial. *J Neurol*. 2002 Feb;249(2):206-11. PMID 11985388.
118. Rompel H, Bauermeister PW. Aetiology of migraine and prevention with carbamazepine (Tegretol): results of a double-blind, cross-over study. *S Afr Med J*. 1970 Jan 24;44(4):75-80. PMID 4905910.
119. Silberstein S, Saper J, Berenson F, et al. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. *Neurology*. 2008 Feb 12;70(7):548-55. PMID 18268247.
120. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. *Neurology*. 1994 Apr;44(4):647-51. PMID 8164818.
121. Nanda RN, Johnson RH, Gray J, et al. A double blind trial of acebutolol for migraine prophylaxis. *Headache*; 1978. p. 20-2.
122. Ekblom K. Alprenolol for migraine prophylaxis. *Headache*; 1975. p. 129-32.
123. Forssman B, Lindblad CJ, Zbornikova V. Atenolol for migraine prophylaxis. *Headache*; 1983. p. 188-90.
124. Freitag FG, Diamond S. Nadolol and placebo comparison study in the prophylactic treatment of migraine. *The Journal of the American Osteopathic Association*; 1984. p. 343-7.
125. Couch JR. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. *Headache*. 2011 Jan;51(1):33-51. PMID 21070231.
126. Couch JR, Hassanein RS. Migraine and depression: effect of amitriptyline prophylaxis. *Trans Am Neurol Assoc*; 1976. p. 234-7.
127. Goadsby PJ, Ferrari MD, Csanyi A, et al. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. *Cephalalgia*. 2009 Jul;29(7):742-50. PMID 19222510.
128. Schrader H, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. *BMJ*. 2001 Jan 6;322(7277):19-22. PMID 11141144.
129. Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. *JAMA*. 2003 Jan 1;289(1):65-9. PMID 12503978.
130. Shukla R, Garg RK, Nag D, et al. Nifedipine in migraine and tension headache: a randomised double blind crossover study. *J Assoc Physicians India*. 1995 Nov;43(11):770-2. PMID 8773038.
131. Somerville BW, Herrmann WM. Migraine prophylaxis with lisuride. A double blind study of lisuride versus placebo. *Headache*; 1976. p. 85-6.
132. Solomon GD, Kunkel RS. Flurbiprofen in the prophylaxis of migraine. *Cleve Clin J Med*. 1993 Jan-Feb;60(1):43-8. PMID 8443934.
133. Visser WH, Malbecq W, Strohmaier K, et al. Preventive treatment of migraine headache with rofecoxib. In: Olesen J, Silberstein SD, Tfelt Hansen P, eds. *Preventive Pharmacotherapy of Headache Disorders*. Oxford: Oxford University Press; 2004:44-9.
134. Mikkelsen BM, Falk JV. Prophylactic treatment of migraine with tolafenamic acid. A comparative double-blind crossover study between tolafenamic acid and placebo. *Acta neurologica Scandinavica*; 1982. p. 105-11.
135. Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. *JAMA*. 1990 Oct 3;264(13):1711-3. PMID 2204739.

136. Brandes JL, Visser WH, Farmer MV, et al. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study. *Headache*. 2004 Jun;44(6):581-6. PMID 15186302.
137. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. *Cephalalgia*. 2010 Jul;30(7):804-14. PMID 20647171.
138. Silberstein SD, Stark SR, Lucas SM, et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. *Mayo Clin Proc*. 2005 Sep;80(9):1126-37. PMID 16178492.
139. Chankrachang S, Arayawichanont A, Pongvarin N, et al. Prophylactic botulinum type A toxin complex (Dysport(R)) for migraine without aura. *Headache*. 2011 Jan;51(1):52-63. PMID 21083558.
140. Anand KS, Prasad A, Singh MM, et al. Botulinum toxin type A in prophylactic treatment of migraine. *Am J Ther*. 2006 May-Jun;13(3):183-7. PMID 16772757.
141. Vo AH, Satori R, Jabbari B, et al. Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial. *Aviat Space Environ Med*. 2007 May;78(5 Suppl):B113-8. PMID 17547312.
142. Cady R, Schreiber C. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. *Headache*. 2008 Jun;48(6):900-13. PMID 18047501.
143. Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. *Neurology*. 2011 Oct 11;77(15):1465-72. PMID 21956721.
144. Petri S, Tolle T, Straube A, et al. Botulinum toxin as preventive treatment for migraine: a randomized double-blind study. *Eur Neurol*. 2009;62(4):204-11. PMID 19622887.
145. Saper JR, Lake AE, 3rd, Cantrell DT, et al. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. *Headache*. 2002 Jun;42(6):470-82. PMID 12167135.
146. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. *Headache*. 2007 Feb;47(2):170-80. PMID 17300356.
147. Dodick DW, Silberstein S, Saper J, et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. *Headache*. 2007 Nov-Dec;47(10):1398-408. PMID 18052949.
148. Lipton RB, Silberstein S, Dodick D, et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. *Cephalalgia*. 2011 Jan;31(1):18-30. PMID 20974598.
149. Diener HC, Agosti R, Allais G, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2007 Dec;6(12):1054-62. PMID 17988947.
150. Edwards KR, Potter DL, Wu SC, et al. Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials. *CNS Spectr*. 2003 Jun;8(6):428-32. PMID 12858132.
151. Brandes JL, Kudrow DB, Rothrock JF, et al. Assessing the ability of topiramate to improve the daily activities of patients with migraine. *Mayo Clin Proc*. 2006 Oct;81(10):1311-9. PMID 17036556.
152. Dahlof C, Loder E, Diamond M, et al. The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. *Health Qual Life Outcomes*. 2007;5:56. PMID 17916258.
153. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. *Cephalalgia*. 1992 Apr;12(2):81-4. PMID 1576648.

154. Wideroe TE, Vigander T. Propranolol in the treatment of migraine. *Br Med J.* 1974 Jun 29;2(5921):699-701. PMID 4604977.
155. Ahuja GK, Verma AK. Propranolol in prophylaxis of migraine. *Indian J Med Res.* 1985 Sep;82:263-5. PMID 3908306.
156. Forssman B, Henriksson KG, Johannsson V, et al. Propranolol for migraine prophylaxis. *Headache*; 1976. p. 238-45.
157. Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, et al. Pregabalin in the treatment of chronic migraine: an open-label study. *Clinical Neuropharmacology.* 2010 Jan-Feb;33(1):35-9. PMID 19935409.
158. Siniatchkin M, Andrasik F, Kropp P, et al. Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study. *Cephalalgia.* 2007 Sep;27(9):1024-32. PMID 17680819.
159. Forssman B. Atenolol for Migraine Prophylaxis. *Acta Neurologica Scandinavica.* 1982;65(S90):75-6.
160. Sjaastad O, Stensrud P. Clinical trial of a beta-receptor blocking agent (LB 46) in migraine prophylaxis. *Acta neurologica Scandinavica*; 1972. p. 124-8.
161. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. *J Neurol Neurosurg Psychiatry.* 1973 Aug;36(4):684-90. PMID 4731336.
162. Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. *Headache.* 1992 Feb;32(2):101-4. PMID 1551787.
163. d'Amato CC, Pizza V, Marmolo T, et al. Fluoxetine for migraine prophylaxis: a double-blind trial. *Headache.* 1999 Nov-Dec;39(10):716-9. PMID 11279947.
164. Steiner TJ, Ahmed F, Findley LJ, et al. S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. *Cephalalgia.* 1998 Jun;18(5):283-6. PMID 9673809.
165. Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. *Headache.* 2005 Feb;45(2):144-52. PMID 15705120.
166. Zeeberg I, Orholm M, Nielsen JD, et al. Femoxetine in the prophylaxis of migraine: A randomized comparison with placebo. *Acta-Neurol-Scand*; 1981. p. 452-9.
167. Orholm M, Le Fevre P. Prophylactic treatment of migraine with femoxetine - a randomized comparison with placebo. *Cephalalgia*; 1985. p. 516-7.
168. Orholm M, Honore PF, Zeeberg I. A randomized general practice group-comparative study of femoxetine and placebo in the prophylaxis of migraine. *Acta Neurol Scand.* 1986 Sep;74(3):235-9. PMID 3538753.
169. Monro P, Swade C, Coppen A. Mianserin in the prophylaxis of migraine: a double-blind study. *Acta psychiatrica Scandinavica. Supplementum*; 1985. p. 98-103.
170. Leandri M, Rigardo S, Schizzi R, et al. Migraine treatment with nicardipine. *Cephalalgia.* 1990 Jun;10(3):111-6. PMID 2245455.
171. Markley HG, Cheronis JC, Piepho RW. Verapamil in prophylactic therapy of migraine. *Neurology*; 1984. p. 973-6.
172. Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. *JAMA.* 1983 Nov 11;250(18):2500-2. PMID 6355533.
173. Diener HC, Gendolla A, Feuersenger A, et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. *Cephalalgia.* 2009 Sep;29(9):921-7. PMID 19250283.
174. Behan PO. Prophylactic treatment for migraine - a comparison of pizotifen and clonidine. *Cephalalgia*; 1985. p. 524-5.
175. Ryan RE, Diamond S. Double blind study of clonidine and placebo for the prophylactic treatment of migraine. *Headache*; 1975. p. 202-10.
176. Kallanranta T, Hakkarainen H, Hokkanen E, et al. Clonidine in migraine prophylaxis. *Headache*; 1977. p. 169-72.
177. Adam EI, Gore SM, Price WH. Double blind trial of clonidine in the treatment of migraine in a general practice. *J R Coll Gen Pract.* 1978 Oct;28(195):587-90. PMID 368333.

178. Bredfeldt RC, Sutherland JE, Kruse JE. Efficacy of transdermal clonidine for headache prophylaxis and reduction of narcotic use in migraine patients. A randomized crossover trial. *J Fam Pract.* 1989 Aug;29(2):153-6; discussion 7-8. PMID 2666565.
179. Elkind AH, Webster C, Herbertson Jr RK. Efficacy of guanfacine in a double blind parallel study for migraine prophylaxis. *Cephalalgia*; 1989. p. 369-70.
180. Krymchantowski AV, Jevoux C, Moreira PF. An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine. *Pain Med.* 2010 Jan;11(1):48-52. PMID 20002594.
181. Charles A, Flippen C, Romero Reyes M, et al. Memantine for prevention of migraine: a retrospective study of 60 cases. *J Headache Pain.* 2007 Sep;8(4):248-50. PMID 17901918.
182. Spengos K, Theleritis C, Paparrigopoulos T. Memantine and NMDA antagonism for chronic migraine: a potentially novel therapeutic approach? *Headache.* 2008 Feb;48(2):284-6. PMID 18194287.
183. Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxinA (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. *Headache.* 2009 Nov-Dec;49(10):1466-78. PMID 19912346.
184. Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. *Headache.* 2008 Feb;48(2):210-20. PMID 18047502.
185. Magalhaes E, Menezes C, Cardeal M, et al. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. *Clin Neurol Neurosurg.* 2010 Jul;112(6):463-6. PMID 20399553.
186. Cady RK, Schreiber CP, Porter JA, et al. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. *Headache.* 2011 Jan;51(1):21-32. PMID 21070228.
187. Silberstein SD, Dodick DW, Lindblad AS, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. *Neurology.* 2012 Mar 27;78(13):976-84. PMID 22377815.
188. Domingues RB, Silva AL, Domingues SA, et al. A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine. *Arq Neuropsiquiatr.* 2009 Dec;67(4):973-7. PMID 20069203.
189. Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. *Clin Ther.* 2009 Mar;31(3):542-59. PMID 19393844.
190. Mohammadianinejad SE, Abbasi V, Sajedi SA, et al. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. *Clin Neuropharmacol.* 2011 Jul-Aug;34(4):174-7. PMID 21738025.
191. Bartolini M, Silvestrini M, Taffi R, et al. Efficacy of topiramate and valproate in chronic migraine. *Clin Neuropharmacol.* 2005 Nov-Dec;28(6):277-9. PMID 16340383.
192. de Tommaso M, Marinazzo D, Nitti L, et al. Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine. *Clin Neurophysiol.* 2007 Oct;118(10):2297-304. PMID 17709295.
193. Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. *Acta Neurol Scand.* 2008 Nov;118(5):301-5. PMID 18713156.
194. Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. *Cephalalgia.* 1984 Jun;4(2):91-6. PMID 6428749.

195. Gerber WD, Diener HC, Scholz E, et al. Responders and non-responders to metoprolol, propranolol and nifedipine treatment in migraine prophylaxis: a dose-range study based on time-series analysis. *Cephalalgia*. 1991 Feb;11(1):37-45. PMID 2036669.
196. Albers GW, Simon LT, Hamik A, et al. Nifedipine versus propranolol for the initial prophylaxis of migraine. *Headache*. 1989 Apr;29(4):215-8. PMID 2654067.
197. Kass B, Nestvold K. Propranolol (Inderal) and clonidine (Catapressan) in the prophylactic treatment of migraine. A comparative trial. *Acta Neurol Scand*. 1980 Jun;61(6):351-6. PMID 6998250.
198. Sudilovsky A, Elkind AH, Ryan RES, et al. Comparative efficacy of nadolol and propranolol in the management of migraine. *Headache*; 1987. p. 421-6.
199. Olerud B, Gustavsson CL, Furberg B. Nadolol and propranolol in migraine management. *Headache*; 1986. p. 490-3.
200. Ziegler DK, Hurwitz A, Hassanein RS, et al. Migraine prophylaxis. A comparison of propranolol and amitriptyline. *Arch Neurol*. 1987 May;44(5):486-9. PMID 3579659.
201. Kangasniemi PJ, Nyrke T, Lang AH, et al. Femoxetine - a new 5-HT uptake inhibitor - and propranolol in the prophylactic treatment of migraine. *Acta Neurol Scand*; 1983. p. 262-7.
202. Grotemeyer KH, Scharafinski HW, Schlake HP, et al. Acetylsalicylic acid vs. metoprolol in migraine prophylaxis--a double-blind cross-over study. *Headache*. 1990 Oct;30(10):639-41. PMID 2272812.
203. Diener HC, Hartung E, Chrubasik J, et al. A comparative study of oral acetylsalicylic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study. *Cephalalgia*. 2001 Mar;21(2):120-8. PMID 11422094.
204. Worz R, Reinhardt-Benmalek B, Grotemeyer KH, et al. Bisoprolol and metoprolol in the prophylactic treatment of migraine with and without aura - A randomized double-blind cross-over multicenter study. *Cephalalgia*; 1991. p. 152-3.
205. Worz R, Reinhardt-Benmalek B, Foeh M, et al. Migraine prophylaxis with bisoprolol. *Headache Quarterly*; 1992. p. 64-72.
206. Schellenberg R, Lichtenthal A, Wohling H, et al. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment? *Headache*. 2008 Jan;48(1):118-25. PMID 18184294.
207. Louis P, Schoenen J, Hedman C. Metoprolol v. clonidine in the prophylactic treatment of migraine. *Cephalalgia*. 1985 Sep;5(3):159-65. PMID 3899370.
208. Krymchantowski AV, Silva MT, Barbosa JS, et al. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. *Headache*. 2002 Jun;42(6):510-4. PMID 12167139.
209. Bank J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. *Headache*. 1994 Sep;34(8):476-8. PMID 7960733.
210. Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. *Clin Neurol Neurosurg*. 2004 Dec;107(1):44-8. PMID 15567552.
211. Sudilovsky A, Elkind AH, Ryan RE, Sr., et al. Comparative efficacy of nadolol and propranolol in the management of migraine. *Headache*. 1987 Sep;27(8):421-6. PMID 3312113.
212. Herrmann WM, Horowski R, Dannehl K, et al. Clinical effectiveness of lisuride hydrogen maleate: a double-blind trial versus methysergide. *Headache*. 1977 May;17(2):54-60. PMID 324950.
213. Varkey E, Cider A, Carlsson J, et al. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. *Cephalalgia*. 2011 Oct;31(14):1428-38. PMID 21890526.
214. Kaushik R, Kaushik RM, Mahajan SK, et al. Biofeedback assisted diaphragmatic breathing and systematic relaxation versus propranolol in long term prophylaxis of migraine. *Complement Ther Med*. 2005 Sep;13(3):165-74. PMID 16150370.

215. Nelson CF, Bronfort G, Evans R, et al. The efficacy of spinal manipulation, amitriptyline and the combination of both therapies for the prophylaxis of migraine headache. *J Manipulative Physiol Ther.* 1998 Oct;21(8):511-9. PMID 9798179.
216. Mathew NT. Prophylaxis of migraine and mixed headache. A randomized controlled study. *Headache.* 1981 May;21(3):105-9. PMID 7021472.
217. Holroyd KA, Cottrell CK, O'Donnell FJ, et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. *BMJ.* 2010;341:c4871. PMID 20880898.
218. Seng EK, Holroyd KA. Dynamics of changes in self-efficacy and locus of control expectancies in the behavioral and drug treatment of severe migraine. *Annals of behavioral medicine : a publication of the Society of Behavioral Medicine;* 2010. p. 235-47.
219. Elkind AH, O'Carroll P, Blumenfeld A, et al. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. *J Pain.* 2006 Oct;7(10):688-96. PMID 17018329.
220. Stensrud P, Sjaastad O. Short-term clinical trial of phopranolol in racemic form (Inderal), D-propranolol and placebo in migraine. *Acta neurologica Scandinavica;* 1976. p. 229-32.
221. Carroll JD, Reidy M, Savundra PA, et al. Long-acting propranolol in the prophylaxis of migraine: a comparative study of two doses. *Cephalalgia.* 1990 Apr;10(2):101-5. PMID 2193712.
222. Havanka-Kanniainen H, Hokkanen E, Myllyla VV. Long acting propranolol in the prophylaxis of migraine. Comparison of the daily doses of 80 mg and 160 mg. *Headache;* 1988. p. 607-11.
223. al-Qassab HK, Findley LJ. Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study. *Cephalalgia.* 1993 Apr;13(2):128-31. PMID 8495455.
224. Ekbom K, Lundberg PO. Clinical trial of LB-46 (d, 1-4-(2-hydroxy-3-isopropylaminopropoxy)indol. An adrenergic beta-receptor blocking agent in migraine prophylaxis. *Headache;* 1972. p. 15-7.
225. Ryan R, Ryan R, Sudilovsky A. Nadolol and placebo comparison study in the prophylactic treatment of migraine. *Panminerva Med;* 1982. p. 89-94.
226. Ryan R, Ryan R, Sudilovsky A. Nadolol: Its use in the prophylactic treatment of migraine. *Headache;* 1983. p. 26-31.
227. van de Ven LL, Franke CL, Koehler PJ. Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study. *Cephalalgia.* 1997 Aug;17(5):596-9. PMID 9251876.
228. Lampl C, Huber G, Adl J, et al. Two different doses of amitriptyline ER in the prophylaxis of migraine: long-term results and predictive factors. *Eur J Neurol.* 2009 Aug;16(8):943-8. PMID 19456855.
229. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. *JAMA.* 2004 Feb 25;291(8):965-73. PMID 14982912.
230. Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial. *Arch Neurol.* 2004 Apr;61(4):490-5. PMID 15096395.
231. Lemstra M, Stewart B, Olszynski WP. Effectiveness of multidisciplinary intervention in the treatment of migraine: a randomized clinical trial. *Headache.* 2002 Oct;42(9):845-54. PMID 12390609.
232. Matchar DB, Harpole L, Samsa GP, et al. The headache management trial: a randomized study of coordinated care. *Headache.* 2008 Oct;48(9):1294-310. PMID 18547268.
233. Fritsche G, Frettlöh J, Hüppe M, et al. Prevention of medication overuse in patients with migraine. *Pain;* 2010. p. 404-13.
234. Rothrock JF, Parada VA, Sims C, et al. The impact of intensive patient education on clinical outcome in a clinic-based migraine population. *Headache.* 2006 May;46(5):726-31. PMID 16643574.

235. Hoffmann W, Herzog B, Muhlig S, et al. Pharmaceutical care for migraine and headache patients: a community-based, randomized intervention. *Ann Pharmacother*. 2008 Dec;42(12):1804-13. PMID 19001531.
236. Sondergaard J, Foged A, Kragstrup J, et al. Intensive community pharmacy intervention had little impact on triptan consumption: a randomized controlled trial. *Scand J Prim Health Care*. 2006 Mar;24(1):16-21. PMID 16464810.
237. Adelman J, Freitag FG, Lainez M, et al. Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials. *Pain Med*. 2008 Mar;9(2):175-85. PMID 18298700.
238. Pradalier A, Serratrice G, Collard M, et al. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. *Cephalalgia*. 1989 Dec;9(4):247-53. PMID 2692838.
239. Schoonman GG, Wiendels NJ, Ferrari MD. Gabapentin in migraine prophylaxis: is it effective and well tolerated? *Headache*. 2002 Mar;42(3):235. PMID 11903552.
240. Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. *Cephalalgia*. 1997 Apr;17(2):109-12. PMID 9137848.
241. Johannsson V, Nilsson LR, Widelius T, et al. Atenolol in migraine prophylaxis: a double-blind cross-over multicenter study. *Headache*; 1987. p. 372-4.
242. Whewell J. Methysergide in prophylaxis of migraine: a clinical trial in general practice. *Br Med J*. 1966 Aug 13;2(5510):394-5. PMID 5331176.
243. McArthur JC, Marek K, Pestronk A, et al. Nifedipine in the prophylaxis of classic migraine: a crossover, double-masked, placebo-controlled study of headache frequency and side effects. *Neurology*; 1989. p. 284-6.
244. (MINES) M-NESG. European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). *Headache*. 1989 Nov;29(10):639-42. PMID 2693406.
245. Diamond S, Solomon GD, Freitag FG, et al. Fenoprofen in the prophylaxis of migraine: a double-blind, placebo controlled study. *Headache*; 1987. p. 246-9.
246. Welch KMA, Ellis DJ, and Keenan PA. Successful migraine prophylaxis with naproxen sodium. *Neurology*; 1985.
247. Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. *Clin Neurol Neurosurg*. 2008 Dec;110(10):979-84. PMID 18620801.
248. Shaygannejad V, Janghorbani M, Ghorbani A, et al. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. *Headache*. 2006 Apr;46(4):642-8. PMID 16643559.
249. Baldrati A, Cortelli P, Procaccianti G, et al. Propranolol and acetylsalicylic acid in migraine prophylaxis. Double-blind crossover study. *Acta Neurol Scand*; 1983. p. 181-6.
250. Langohr HD, Gerber WD, Koletzki E, et al. Clomipramine and metoprolol in migraine prophylaxis--a double-blind crossover study. *Headache*. 1985 Mar;25(2):107-13. PMID 3886599.
251. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. *Cephalalgia*. 2010 Jul;30(7):793-803. PMID 20647170.
252. Mei D, Ferraro D, Zelano G, et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. *Clin Neuropharmacol*. 2006 Sep-Oct;29(5):269-75. PMID 16960472.
253. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. *Arch Neurol*. 1979 Nov;36(11):695-9. PMID 508127.
254. Boisen E, Deth S, Hübbe P, et al. Clonidine in the prophylaxis of migraine. *Acta neurologica Scandinavica*; 1978. p. 288-95.
255. Ziegler DK, Ellis DJ. Naproxen in prophylaxis of migraine. *Archives of neurology*; 1985. p. 582-4.

256. Saper JR, Mathew NT, Loder EW, et al. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. *Pain Med.* 2007 Sep;8(6):478-85. PMID 17716321.
257. Aurora SK, Gawel M, Brandes JL, et al. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. *Headache.* 2007 Apr;47(4):486-99. PMID 17445098.
258. Dodick DW, Mauskop A, Elkind AH, et al. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. *Headache.* 2005 Apr;45(4):315-24. PMID 15836567.
259. Relja M, Poole AC, Schoenen J, et al. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. *Cephalalgia.* 2007 Jun;27(6):492-503. PMID 17428299.
260. Freitag FG. Topiramate prophylaxis in patients suffering from migraine with aura: results from a randomized, double-blind, placebo-controlled trial. *Advanced Studies in Medicine;* 2003. p. S562-s4.
261. Reuter U, Del Rio MS, Diener HC, et al. Migraines with and without aura and their response to preventive therapy with topiramate. *Cephalalgia: an international journal of headache;* 2010. p. 543-51.
262. Di Trapani G, Mei D, Marra C, et al. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. *Clin Ter.* 2000 May-Jun;151(3):145-8. PMID 10958046.
263. Meyer JS, Hardenberg J. Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headaches. *Headache;* 1983. p. 266-77.
264. Barden J, Derry S, McQuay HJ, et al. Bias from industry trial funding? A framework, a suggested approach, and a negative result. *Pain.* 2006 Apr;121(3):207-18. PMID 16495012.
265. Fox AW. Disease modification in migraine: study design and sample size implications. *Headache.* 2008 Sep;48(8):1169-75. PMID 18819175.
266. Arends LR, Hoes AW, Lubsen J, et al. Baseline risk as predictor of treatment benefit: three clinical = meta-re-analyses. *Stat Med.* 2000;19:3497-518.
267. Hazard E, Munakata J, Bigal ME, et al. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. *Value in Health.* 2009 Jan;12(1):55-64. PMID 18671771.
268. Russell MB, Hilden J, Sorensen SA, et al. Familial occurrence of migraine without aura and migraine with aura. *Neurology.* 1993 Jul;43(7):1369-73. PMID 8392151.
269. Gentile G, Missori S, Borro M, et al. Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. *Journal of Headache & Pain.* 2010 Apr;11(2):151-6. PMID 20213484.
270. Schurks M, Zee RY, Buring JE, et al. ACE D/I polymorphism, migraine, and cardiovascular disease in women. *Neurology.* 2009 Feb 17;72(7):650-6. PMID 19221299.
271. Feldman HL. Pushing drugs: genomics and genetics, the pharmaceutical industry, and the law of negligence. *Washburn Law Journal.* 2003;42(3):575-99. PMID 15115000.
272. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. *Lancet Neurol.* 2012 Sep;11(9):803-13. PMID 22805351.
273. Coebergh JA, Waldinger MD. Reversible anorgasmia with topiramate for migraine prophylaxis. *J Neuropsychiatry Clin Neurosci.* 2012 Mar 1;24(2):E30-1. PMID 22772690.
274. Huang CY, Keller JJ, Sheu JJ, et al. Migraine and erectile dysfunction: evidence from a population-based case-control study. *Cephalalgia.* 2012 Apr;32(5):366-72. PMID 22407657.
275. Antonaci F, Chimento P, Diener H-C, et al. Lessons from placebo effects in migraine treatment. *Journal of Headache & Pain.* 2007 Feb;8(1):63-6. PMID 17361384.

276. Bingham MF, Johnson FR, Miller D. Modeling choice behavior for new pharmaceutical products. *Value in Health*. 2001 Jan-Feb;4(1):32-44. PMID 11704970.
277. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2012 Apr 24;78(17):1337-45. PMID 22529202.
278. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. *J Clin Epidemiol*. 2010 Dec;63(12):1308-11. PMID 20656455.
279. Etemad LR, Yang W, Globe D, et al. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. *Journal of Managed Care Pharmacy*. 2005 Mar;11(2):137-44. PMID 15766320.
280. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. *Arch Intern Med*. 2006 May 8;166(9):1021-6. PMID 16682577.
281. Edwards IR. Off-label pharmacovigilance. *Drug Safety*. 2011 Oct 1;34(10):795-7. PMID 21879775.
282. Layton D, Hazell L, Shakir SA. Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management. *Drug Safety*. 2011 Dec 1;34(12):e1-9. PMID 22077508.
283. Mullan RJ, Flynn DN, Carlberg B, et al. Systematic reviewers commonly contact study authors but do so with limited rigor. *J Clin Epidemiol*. 2009 Feb;62(2):138-42. PMID 19013767.
284. Agency for Healthcare Research and Quality Finding Evidence and Assessing for Reporting Biases when Comparing Medical Interventions: AHRQ and the Effective Health Care Program. In press. 2012.

Appendix A. Literature Search

January, 2011
PubMed

#	Strings	N
8	Search "Migraine Disorders"[Mesh] AND "Migraine Disorders"[Mesh] Limits: Humans, Meta-Analysis, English	97
7	Search "Migraine Disorders"[Mesh] AND "Migraine Disorders"[Mesh] Limits: Humans, Randomized Controlled Trial, English	907

#	Strings	N
71	Search migraine NOT acute Limits: Humans, Randomized Controlled Trial, English	655
70	Search migraine Limits: Humans, Randomized Controlled Trial, English	1040
66	Search melatonin AND migraine	55
67	Search melatonin AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	7
64	Search "Brain-Derived Neurotrophic Factor"[Mesh] AND migraine	6
63	Search "Brain-Derived Neurotrophic Factor"[Mesh] AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	1
62	Search "Brain-Derived Neurotrophic Factor"[Mesh] Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	94
58	Search Risperidone AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
57	Search Paliperidone AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
56	Search Methiothepin AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
55	Search Metergoline AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
53	Search Lisuride AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	5
51	Search Bromocriptine AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	4
50	Search Zotepine AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
49	Search Ziprasidone AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
48	Search Trifluoperazine AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
47	Search Tenilapine AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
46	Search Sulpiride AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	1
45	Search Spiperone AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
44	Search Sertindole AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
43	Search Olanzapine AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
42	Search Loxapine AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
41	Search Ketanserin AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
40	Search Imipramine AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
39	Search Fluperlapine AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
38	Search Fluphenazine AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
36	Search Cyproheptadine AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	9
35	Search Clozapine AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
33	Search Clomipramine AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	2
32	Search Aripiprazole AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
31	Search Amoxapine AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
29	Search Amitriptyline AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	34
28	Search Amitriptyline AND migraine Limits: Humans, English	150
27	Search 5-HT7 AND migraine Limits: Humans, English	12
24	Search 5-HT7 Limits: Humans, English	150
13	Search Quetiapine AND migraine Limits: Humans, English	5
21	Search "Antipsychotic Agents "[Pharmacological Action] AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	41

20	Search "Antipsychotic Agents "[Pharmacological Action] AND migraine Limits: Humans, English	206
19	Search "Antipsychotic Agents "[Pharmacological Action] Limits: Humans, English	51308
11	Search 5-HT2A AND migraine Limits: Humans, English	14
10	Search 5-HT2A antagonists AND migraine Limits: Humans, English	3
7	Search 5-HT2A antagonists Limits: Humans, English	394
5	Search Alpha-2 agonists AND migraine Limits: Humans, English	6
4	Search Alpha-2 agonists AND migraine	17

84	Search telcagepant AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	4
83	Search olcegepant AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
82	Search Arachidonic cascade modulators Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
80	Search tonabersat) AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	6
79	Search dextromethorphan AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
78	Search dextromethorphan AND migraine NOT acute Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
77	Search loxapine AND migraine NOT acute Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	0
76	Search prochlorperazine AND migraine NOT acute Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	8
75	Search prochlorperazine AND migraine Limits: Humans, Clinical Trial, Randomized Controlled Trial, English	20

August, 2011

#	Strings	N
15	Search Phenelzine AND migraine Limits: Humans, Journal Article, English	11
14	Search Bupropion AND migraine Limits: Humans, Journal Article, English	1
13	Search Imipramine AND migraine Limits: Humans, Journal Article, English	15
12	Search Imipramine AND headache Limits: Humans, Journal Article, English	60
11	Search Doxepin AND headache Limits: Humans, Journal Article, English	15
9	Search Desipramine AND headache Limits: Humans, Journal Article, English	13
10	Search Desipramine AND migraine Limits: Humans, Journal Article, English	1
7	Search Protriptyline AND headache Limits: Humans, Journal Article, English	4
6	Search Protriptyline AND migraine Limits: Humans, Journal Article, English	0

Updated search in Ovid; 1948 to November Week 3 2011

#	Searches	Results
1	exp migraine disorders/dt	5944
2	exp migraine disorders/pc	1669
3	ad.fs.	998247
4	2 and 3	286
5	1 or 4	6112
6	1 or 2	7065
7	exp "off-label use"/	519
8	off label.mp.	2412
9	7 or 8	2412
10	6 and 9	14
11	exp calcium channel blockers/	68976
12	exp antihypertensive agents/	216956
13	exp antidepressive agents/	113058
14	exp anticonvulsants/	111349
15	exp botulinum toxin type a/	4832
16	exp alzheimer disease/dt	8107

17	11 or 12 or 13 or 14 or 15 or 16	476372
18	6 and 17	1675
19	5 or 10 or 18	6489
20	limit 19 to (humans and yr="2000 -Current")	3195
21	limit 20 to updatetype="mesz(20111121020154-20111121091315]"	0

Ovid MEDLINE(R) 1946 to December Week 4 2011

#	Searches	Results
1	exp migraine disorders/dt	5882
2	exp migraine disorders/pc	1659
3	ad.fs.	975844
4	2 and 3	284
5	1 or 4	6048
6	1 or 2	6996
7	exp "off-label use"/	510
8	off label.mp.	2358
9	7 or 8	2358
10	6 and 9	13
11	exp calcium channel blockers/	67571
12	exp antihypertensive agents/	1420023
13	exp antidepressive agents/	110836
14	exp anticonvulsants/	1012405
15	exp botulinum toxin type a/	4648
16	exp alzheimer disease/dt	7829
17	11 or 12 or 13 or 14 or 15 or 16	2510533
18	6 and 17	1831
19	5 or 10 or 18	6431

Database(s): **Ovid MEDLINE(R) 1946 to May Week 2 2012**

Search Strategy:

#	Searches	Results
1	drug management.mp.	467
2	exp patient care team/	49789
3	exp delivery of health care, integrated/	7185
4	integrated care.mp.	1087
5	exp managed care programs/	38113
6	(managed care or coordinated care).mp.	28360
7	exp Patient Education as Topic/	64554
8	exp Health Education/	125606
9	drug surveillance.mp.	432
10	exp drug monitoring/	12104
11	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10	231287
12	exp patient compliance/	46268
13	exp patient satisfaction/	52327
14	exp patient care management/	475066
15	12 or 13 or 14	555310
16	exp migraine disorders/dt	5965
17	11 and 16	111
18	15 and 16	360

Ovid Technologies, Inc.

Search for: limit 19 to (humans and yr="2000 -Current")
Results: 100

Database: Ovid MEDLINE(R) <1946 to May Week 2 2012> Search Strategy:

- 1 exp migraine disorders/dt (5965)
- 2 exp migraine disorders/pc (1692)
- 3 ad.fs. (1002489)
- 4 2 and 3 (291)
- 5 1 or 4 (6136)
- 6 1 or 2 (7101)
- 7 exp "off-label use"/ (628)
- 8 off label.mp. (2572)
- 9 7 or 8 (2572)
- 10 6 and 9 (14)
- 11 exp calcium channel blockers/ (68722)
- 12 exp antihypertensive agents/ (217035)
- 13 exp antidepressive agents/ (113333)
- 14 exp anticonvulsants/ (112028)
- 15 exp botulinum toxin type a/ (4853)
- 16 exp alzheimer disease/dt (8211)
- 17 11 or 12 or 13 or 14 or 15 or 16 (477138)
- 18 6 and 17 (1689)
- 19 5 or 10 or 18 (6514)
- 20 limit 19 to (humans and yr="2000 -Current") (3226)

Scientific Information Package requests and responses

Company Name	Date Responded
Abbott Laboratories	No response
Alexza Pharmaceuticals, Inc.	No response
Allergan, Inc.	No response
Almirall, S.A.	No response
AstraZeneca Pharmaceuticals, LP	No response
Beth Israel Deaconess Medical Center	No response
Boston Scientific	No response
BTG International, Ltd.	No response
Capnia, Inc.	No response
Centre Hospitalier Universitaire de Saint Etienne	No response
Cephalon, Inc	No response
Chengdu University of Traditional Chinese Medicine	No response
Clinvest	No response
CoLucid Pharmaceuticals, Inc.	No response
D-Pharm Ltd.	No response
Eisai Inc.	No response
Eli Lilly & Co	No response
Endo Pharmaceuticals	No response
eNeura	No response
Eurohead	No response
GlaxoSmithKline	Submitted
HaEmek Medical Center	No response
Ipsen Biopharm, Ltd	No response
Janssen Cilag Pharmaceutica S.A.C.I.	No response
Janssen EMEA	No response
Janssen Pharmaceutica NV	Submitted
Janssen-Ortho, Inc.	No response
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	No response
Kowa Pharmaceuticals America	No response
Lotus Pharmaceuticals, Inc.	No response
Luitpold Pharmaceuticals, Inc.	No response
Manhattan Pharmaceuticals, Inc.	No response
MAP Pharmaceuticals, Inc.	No response
Medtronic, Inc.	No response
Merck & Co., Inc.	Submitted
Nektar	Nothing to submit 11/16/2011
NeurAxon	No response
Nordlandssykehuset HF	No response
Novartis Pharmaceuticals Corporation	No response
NPS Pharmaceuticals	No response
Ortho-McNeil Janssen Scientific Affairs, LLC	No response
Ortho-McNeil Neurologics	No response
Ortho-McNeil-Janssen Pharmaceuticals, Inc	No response
Pfizer Inc	No response
Pozen	No response
PriCara® (Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.)	No response
Raptor Pharmaceutical Corp.	No response
Roxane Laboratories	No response
SK Chemicals	No response
Sorlandet Hospital HF	No response
Takeda Global Research & Development Center, Inc.	No response
Takeda Pharmaceuticals North America, Inc.	No response
The EMMES Corporation	No response
UCB, Inc.	No response
Valeant Pharmaceuticals International	No response
Zogenix	No response

Appendix B. Analytical Framework

PICOTS Framework

Population(s)

Adults with episodic migraine, chronic daily headache, or chronic migraine as defined by the Headache Classification Subcommittee of the International Headache Society¹ (see below for definitions).

Patient characteristics that can modify the effects of pharmacological treatments for preventing migraine attacks in children and adults:

- Age
- Sex
- Pregnancy
- Hormone-based birth control and hormone replacement
- The onset of menarche and menopause
- Race and ethnicity
- Socioeconomic status
- Education
- Family history
- Access to care, type of care, and residence in rural or urban areas
- Definition of migraine
- Presence of aura
- Headache frequency
- Prior treatments; overuse of drugs for acute migraine
- Obesity
- Nutritional and dietary factors, specifically caffeine
- Aerobic fitness
- Previous head injury
- Psychological factors and social/family support system
- Comorbidities (depression, bipolar disorder, anxiety, diabetes, hypertension, cardiovascular diseases, others)
- Concomitant medications for comorbid conditions

Interventions

Drugs approved by the FDA (such as propranolol, timolol, topiramate, and divalproex sodium) to prevent episodic migraine and to treat chronic migraine (such as Botox).

Off-label medications available in the United States and previously examined in clinical trials for preventing migraine.

Monotherapy.

Multidrug interventions.

Combined pharmacological with nonpharmacological modalities: behavioral interventions with education, exercise, biofeedback, relaxation techniques, yoga, massage, acupuncture, and dietary supplements.

Comparators

Placebo.

Drug treatments (comparative effectiveness).

Nonpharmacological treatments: behavioral interventions with education, exercise, biofeedback, relaxation techniques, yoga, massage, acupuncture, and dietary supplements.

Outcomes

Patient-centered outcomes:

Reduction of migraine attacks by >50 percent from baseline; primary outcome for the review.

Quality of life.

Patient satisfaction.

Composite patient centered outcomes defined as an aggregate improvement of the aforementioned outcomes.

Emergency visits, loss of work days; treatment failure.

Intermediate outcomes:

Number of headache days.

Number of moderate to severe headache days.

Improvement in associated symptoms.

Use of drugs for acute migraine (prescribed or over-counter).

Physician/healthcare professional (HCP) visits.

Harms:

All reported adverse reactions and effects (such as anxiety, nausea, vomiting, sleep time reduction, drowsiness, or weakness).

Treatment discontinuation due to adverse effects.

Additional medical resource utilization to manage adverse effects (e.g., prescription medication, urgent care/emergency services, physician/HCP visits).

Timing

6 months or more; optimally 12 months.

Any time of occurrence for the harms.

Setting

Outpatient settings

Definition of Terms

Migraine (as defined by the Headache Classification Subcommittee of the International Headache Society):¹

Repeated attacks of headache lasting 4 to 72 hours in patients with a normal physical examination, no other reasonable cause for the headache, and:

At least two of the following features:

- Unilateral pain
- Throbbing pain

- Aggravation by movement
 - Moderate or severe intensity
- Plus at least one of the following features:

- Nausea/vomiting
- Photophobia and phonophobia

Episodic migraine as an indication for preventive treatment:

Five or more attacks a month²

Three or more attacks a month²

Definitions of chronic migraine (can be chronic from onset or transformed from episodic migraine):

FDA:

- Chronic migraine is defined as having a history of migraine and experiencing a headache on most days of the month.³

Revised International Headache Society criteria for chronic migraine:¹

1.5.1. Chronic migraine

A. Headache (tension-type and/or migraine) on ≥ 15 days per month for at least 3 months

* Characterization of a frequently recurring headache generally requires a headache diary to record information on pain and associated symptoms day by day for at least 1 month.

B. Occurring in a patient who has had at least five attacks.

C. On ≥ 8 days per month for at least 3 months headache has fulfilled C.1 and/or C.2 below, that is, has fulfilled criteria for pain and associated symptoms of migraine without aura.

1. Has at least two of a–d

- a. Unilateral location
- b. Pulsating quality
- c. Moderate or severe pain intensity
- d. Aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) and at least one of (1) or (2):
 - (1). Nausea and/or vomiting
 - (2). Photophobia and phonophobia

2. Treated and relieved by triptan(s) or ergot before the expected development of C.1 above

D. No medication overuse[†] and not attributed to another causative disorder
[†]Headache Classification Committee criteria for a medication overuse headache (A8.2)¹

References

1. Olesen J, Boussier MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. *Cephalalgia*. 2006 Jun;26(6):742-6. PMID 16686915.
2. Goadsby PJ, Raskin NH. Chapter 15. Headache. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., eds. *Harrison's principles of internal medicine*. 17th ed. New York: The McGraw-Hill Companies; 2008.
3. Administration USFaD. FDA News Release: FDA approves Botox to treat chronic migraine. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229782.htm>. Accessed on February 1 2011.

Table 1. Pharmacological classes for migraine prevention

Drug, ATC Code*	Class of Drug
ANTIEPILEPTICS	
Topiramate, N03AX11	N03 ANTIEPILEPTICS N03AX Other antiepileptics
Lamotrigine, N03AX09	N03A ANTIEPILEPTICS
Levetiracetam, N03AX14	N03A ANTIEPILEPTICS
Pregabalin, N03AX16	N03A ANTIEPILEPTICS alpha2-delta agonist
Carbamazepine , N03AF01	N03A ANTIEPILEPTICS N03AF Carboxamide derivatives
Valproic acid, N03AG01	N03A ANTIEPILEPTICS N03AG Fatty acid derivatives, Gamma-aminobutyric acid (GABA) enhancer and analog
Vigabatrin, N03AG04	N03A ANTIEPILEPTICS N03AG Fatty acid derivatives, GABA transaminase inhibitor
Tiagabine, N03AG06	N03A ANTIEPILEPTICS N03AG Fatty acid derivatives, gamma aminobutyric acid (GABA) enhancer
Zonisamide, N03AX15	N03A ANTIEPILEPTICS N03AX Other antiepileptics
Valproate	N03A ANTIEPILEPTICS N03AG Fatty acid derivatives
Divalproex	Gamma-aminobutyric acid (GABA) enhancer and analog
Gabapentin, N03AX12	N03A ANTIEPILEPTICS
Acetazolamide, S01EC01	S01EC, carbonic anhydrase inhibitor
ANTIDEPRESSANTS	
Nortriptyline , N06AA10	N06A ANTIDEPRESSANTS N06AA nonselective monoamine reuptake inhibitors
Clomipramine, N06AA04	N06A ANTIDEPRESSANTS N06AA nonselective monoamine reuptake inhibitors
Citalopram, N06AB04	N06A ANTIDEPRESSANTS N06AB selective serotonin reuptake inhibitors
Venlafaxine, N06AX16	N06A ANTIDEPRESSANTS N06AX Other antidepressants
Amitriptyline	N06A ANTIDEPRESSANTS N06AA nonselective monoamine reuptake inhibitors
Mirtazapine, N06AX11	N06A ANTIDEPRESSANTS tricyclic antidepressants
BETA BLOCKERS	
Timolol, C07AA06	C07AA , Beta blocking agents, nonselective
Nadolol , C07AA12	C07AA Beta blocking agents, nonselective
Propranolol,C07AA05	C07AA Beta blocking agents, nonselective
Metoprolol,C07AB02	C07AB Beta blocking agents, selective
Atenolol, C07AB03	C07AB Beta blocking agents, selective
Bisoprolol,C07AB07	C07AB Beta blocking agents, selective
Acebutolol,C07AB04	C07AB Beta blocking agents, selective
Alprenolol, C07AA01	C07A BETA BLOCKING AGENTS
Oxprenolol, C07AA02 (discontinued in the FDA)	C07AA Beta blocking agents, nonselective
Pindolol, C07AA03	C07AA Beta blocking agents, nonselective
ACE INHIBITORS	
Trandolapril, C09AA10	C09AA ACE inhibitors
Enalapril,C09AA02	C09AA ACE inhibitors
Captopril,C09AA01	C09AA ACE inhibitors
Lisinopril, C09AA03	C09AA ACE inhibitors
ANGIOTENSIN II ANTAGONISTS	
Telmisartan,C09CA07	C09CA Angiotensin II antagonists
Candesartan, C09CA06	C09CA Angiotensin II antagonists
CALCIUM CHANNEL ANTAGONIST	
Dotarizine	SELECTIVE CALCIUM CHANNEL ANTAGONIST; 5-HT receptors ANTAGONIST
Flunarizine, N07CA03; Sibelium	SELECTIVE CALCIUM CHANNEL ANTAGONISTN07C ANTIVERTIGO PREPARATIONS

Drug, ATC Code*	Class of Drug
SELECTIVE CALCIUM CHANNEL BLOCKERS	
Nimodipine, C08CA06	C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS C08CA Dihydropyridine derivatives
Verapamil, C08DA01	C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS C08DA Phenylalkylamine derivatives
Nicardipine, C08CA04	C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS C08CA Dihydropyridine derivatives
Nifedipine, C08CA05	C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS C08CA Dihydropyridine derivatives
ANTIADRENERGICS	
Clonidine, C02AC01	C02A ANTIADRENERGIC AGENTS, CENTRALLY ACTING C02AC Imidazoline receptor agonists
Labetalol, C07AG01	C07AG , Alpha and beta blocking agents
Dixarit (clonidine, C02AC01) Guanfacine, C02AC02	C02A ANTIADRENERGIC AGENTS, CENTRALLY ACTING C02A ANTIADRENERGIC AGENTS, CENTRALLY ACTING C02AC Imidazoline receptor agonists
ANTI-DEMENTIA	
Donepezil, N06DA02	N06 PSYCHOANALEPTICS
Memantine, N06DX01	N06D ANTI-DEMENTIA DRUGS N-methyl-D-aspartate (NMDA) receptor inhibitor
ANTIPSYCHOTICS	
Aripiprazole, N05AX12	N05A ANTIPSYCHOTICS
Olanzapine, N05AH03	N05A ANTIPSYCHOTICS N05AH Diazepines, oxazepines, thiazepines and oxepines
Quetiapine, N05AH04	N05A ANTIPSYCHOTICS N05AH Diazepines, oxazepines, thiazepines and oxepines
Deanxit (Flupentixol, N05AF01)	N05A ANTIPSYCHOTICS N05AF Thioxanthene derivatives
Sulpiride, N05AL01 (antipsychotic)	N05A ANTIPSYCHOTICS N05AL Benzamides
Prochlorperazine, N05AB04	N05A ANTIPSYCHOTICS
DOPAMINERGIC AGENTS	
Amantadine, N04BB01	N04B DOPAMINERGIC AGENTS N04BB Adamantane derivatives N-methyl-D-aspartate (NMDA) receptor inhibitor
Dihydroergocryptine, N04BC03	N04B DOPAMINERGIC AGENTS N04BC Dopamine agonists
ERGOT ALKALOIDS	
Dihydroergotamine, N02CA01	N02C ANTIMIGRAINE PREPARATIONS N02CA Ergot alkaloids
Lisuride, N02CA07	N02C ANTIMIGRAINE PREPARATIONS
Ergotamine, N02CA02	N02C ANTIMIGRAINE PREPARATIONS N02CA Ergot alkaloids
Methysergide, N02CA04	N02C ANTIMIGRAINE PREPARATIONS N02CA Ergot alkaloids
MUSCLE RELAXANTS	
Botulinum Toxin Type A, M03AX01	M03A MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS M03AX Other muscle relaxants, peripherally acting agents
Tizanidine, M03BX02	M03B MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
SYSTEMIC DRUGS	
Montelukast, R03DC03	R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03DC Leukotriene receptor antagonists

ATC code - The Anatomical Therapeutic Chemical classification

Table 2 Bayesian models summary under the noninformative prior

Fixed effect model	Random effect model (homogeneous)	Random effect model (heterogeneous)	Random effect model (inconsistency)
<p>Data</p> $r_{ik} \sim \text{Bin}(n_{ik}, p_{ik})$ $i = 1, \dots, \text{NS}; k = 1, \dots, \text{NT}$ (NS = number of study; NT = number of trt) <p>Model</p> $\text{logit}(p_{ik}) = \mu_{iB} + \Delta_{Bk}$ where B is for the baseline treatment, μ_{iB} is the log odds of the baseline treatment and Δ_{Bk} is the fixed effect of the k^{th} drug versus the baseline treatment defined by $d_k - d_B$ with the fixed effect of the k^{th} drug versus placebo, d_k ($d_B = 0$) <p>Prior</p> $d_k \sim N(0, 10000)$ $\mu_{iB} \sim N(0, 10000)$	<p>Data</p> $r_{ik} \sim \text{Bin}(n_{ik}, p_{ik})$ <p>Model</p> $\text{logit}(p_{ik}) = \mu_{iB} + \delta_{iBk}$ where δ_{iBk} is the random effect of the k^{th} drug versus the baseline treatment in the i^{th} study <p>Prior</p> $\delta_{iBk} \sim N(d_k - d_B, \sigma^2)$ $d_k \sim N(0, 10000)$ $\mu_{iB} \sim N(0, 10000)$ $\sigma \sim \text{Unif}(0.01, 2)$	<p>Data</p> $r_{ik} \sim \text{Bin}(n_{ik}, p_{ik})$ <p>Model</p> $\text{logit}(p_{ik}) = \mu_{iB} + \delta_{iBk}$ where δ_{iBk} is the random effect of the k^{th} drug versus the baseline treatment in the i^{th} study <p>Prior</p> $\delta_{iBk} \sim N(d_k - d_B, \sigma_{Bk}^2)$ $d_k \sim N(0, 10000)$ $\mu_{iB} \sim N(0, 10000)$ $\log \sigma_{xy} = \log \sigma_0 + v_{xy}$ $\sigma_0 \sim \text{Unif}(0.01, 2)$ $v_{xy} \sim N(0, \psi^2)$	<p>Data</p> $r_{ik} \sim \text{Bin}(n_{ik}, p_{ik})$ <p>Model</p> $\text{logit}(p_{ik}) = \mu_{iB} + \delta_{iBk}$ where δ_{ik} is the random effect of the k^{th} drug versus the placebo in the i^{th} study <p>1. $d_{BC} = d_{AC} - d_{AB} + w_{ABC}$ w_{ABC} is the amount of inconsistency between direct and indirect comparisons</p> <p>Prior</p> $\delta_{iBk} \sim N(d_k - d_B, \sigma^2)$ $d_k \sim N(0, 10000)$ $\mu_{iB} \sim N(0, 10000)$ $w_{ABC} \sim N(0, \sigma_w^2)$ $\sigma, \sigma_w \sim \text{Unif}(0.01, 2)$
[Example] Study 1: Drugs 1 vs. 2 vs. 3 trial (drug 1 is the baseline treatment)			
Fixed effect model	Random effect model (homogeneous)	Random effect model (heterogeneous)	Random effect model (inconsistency)
<p>Data</p> $r_{11} \sim \text{Bin}(n_{11}, p_{11})$ $r_{12} \sim \text{Bin}(n_{12}, p_{12})$ $r_{13} \sim \text{Bin}(n_{13}, p_{13})$ <p>Model</p> 2. $\text{logit}(p_{11}) = \mu_{11}$ 3. $\text{logit}(p_{12}) = \mu_{11} + d_2$ 4. $\text{logit}(p_{13}) = \mu_{11} + d_3$ <p>Prior</p> $d_2, d_3 \sim N(0, 10000)$ $\mu_{11} \sim N(0, 10000)$	<p>Model</p> 5. $\text{logit}(p_{11}) = \mu_{11}$ 6. $\text{logit}(p_{12}) = \mu_{11} + \delta_{12}$ 7. $\text{logit}(p_{13}) = \mu_{11} + \delta_{13}$ <p>Prior (assume $\rho=0.5$)</p> $\begin{pmatrix} \delta_{12} \\ \delta_{13} \end{pmatrix} \sim \text{MVN}\left(\begin{pmatrix} d_2 \\ d_3 \end{pmatrix}, \sigma^2 \begin{pmatrix} 1 & 0.5 \\ 0.5 & 1 \end{pmatrix}\right)$ → $\delta_{12} \sim N(d_2, \sigma^2)$ → $\delta_{13} \delta_{12} \sim N(d_3 + \frac{1}{2}(\delta_{12} - d_2), \frac{3}{4}\sigma^2)$ <p>$d_2, d_3 \sim N(0, 10000)$ $\mu_{11} \sim N(0, 10000)$ $\sigma \sim \text{Unif}(0.01, 2)$</p>	<p>Model</p> 8. $\text{logit}(p_{11}) = \mu_{11}$ 9. $\text{logit}(p_{12}) = \mu_{11} + \delta_{12}$ 10. $\text{logit}(p_{13}) = \mu_{11} + \delta_{13}$ <p>Prior (assume $\rho=0.5$)</p> $\begin{pmatrix} \delta_{12} \\ \delta_{13} \end{pmatrix} \sim \text{MVN}\left(\begin{pmatrix} d_2 \\ d_3 \end{pmatrix}, \begin{pmatrix} \sigma_{11}^2 & 0.5\sigma_{12} \\ 0.5\sigma_{12} & \sigma_{22}^2 \end{pmatrix}\right)$ → $\delta_{12} \sim N(d_2, \sigma_1^2)$ → $\delta_{13} \delta_{12} \sim N(d_3 + \frac{1}{2}(\delta_{12} - d_2), \frac{3}{4}\sigma_2^2)$ <p>$d_2, d_3 \sim N(0, 10000)$ $\mu_{11} \sim N(0, 10000)$ $\log \sigma_{11} = \log \sigma_0 + v_{11}$ $\log \sigma_{12} = \log \sigma_0 + v_{12}$ $\log \sigma_{22} = \log \sigma_0 + v_{22}$ $\sigma_0 \sim \text{Unif}(0.01, 2)$ $v_{11}, v_{12}, v_{22} \sim \text{Unif}(0.01, \psi^2)$</p>	<p>Study 1: 1 vs. 2 vs. 3 trial 11. Study 2: 1 vs. 2 12. Study 3: 1 vs. 3 → We can estimate w_{123} because the data permit estimation via the equation $d_{23} = d_{13} - d_{12} + w_{123}$</p> <p>Model and priors are similarly defined as in Model2. Additional prior is $w_{123} \sim N(0, \sigma_w^2)$ $\sigma_w \sim \text{Unif}(0.01, 2)$</p>

Table 3. Winbug Code for Bayesian network meta analysis

Outcome – reduction in monthly migraine by $\geq 50\%$ or perceived clinically important treatment success

Model - heterogeneous random effects model

Assume correlation within study ($\rho = 0.5$)

Assume heterogeneous between studies

```

model {
  for (i in 1:NS) {
    s[i,1] <- 0
    delta[i, t[i,1]] <- 0
    mu[i] ~ dnorm(mmu[t[i,1]], tau_mu) # handle different baseline treatments

    for (k in 1:na[i]) {
      r[i,k] ~ dbin(p[i,t[i,k]], n[i,k])
      logit(p[i,t[i,k]]) <- mu[i] + delta[i,t[i,k]]
    }

    for (k in 2:na[i]) {
      delta[i,t[i,k]] ~ dnorm(md[i,t[i,k]], tau_d[i,t[i,k]])
      md[i,t[i,k]] <- d[t[i,k]] - d[t[i,1]] + ss[i,k]
      tau_d[i,t[i,k]] <- tau[t[i,1],t[i,k]]*2*(k-1)/k
      s[i,k] <- (delta[i, t[i,k]] - d[t[i,k]] + d[t[i,1]])
      ss[i,k] <- sum(s[i, 1:k-1])/(k-1)
    }
  }

  mmu[5] <- 0 #Treatments 1,2,3,4,6,7 are one of baseline treatments.
  mmu[8] <- 0 # other treatments should be assigned to 0.
  mmu[9] <- 0
  mmu[10] <- 0
  mmu[11] <- 0
  mmu[12] <- 0
  mmu[13] <- 0
  mmu[14] <- 0
  mmu[1] ~ dnorm(0, 0.0001)
  mmu[2] ~ dnorm(0, 0.0001)
  mmu[3] ~ dnorm(0, 0.0001)
  mmu[4] ~ dnorm(0, 0.0001)
  mmu[6] ~ dnorm(0, 0.0001)
  mmu[7] ~ dnorm(0, 0.0001)
  sdmu ~ dunif(0.01, 2)
  tau_mu <- 1/pow(sdmu,2)

  d[1] <- 0
  for (k in 2:NT) {
    d[k] ~ dnorm(0,0.0001)
    ed[k] <- exp(d[k]) # ed is odds ratio against placebo
  }

  for(i in 1:(NT-1)) {
    for(j in (i+1):NT) {
      v[i,j] ~ dnorm(0, 8.32)
      log(sd[i,j]) <- log(sd0) + v[i,j]
      tau[i,j] <- 1/pow(sd[i,j],2)
      var[i,j] <- pow(sd[i,j],2)
    }
  }
  sd0 ~ dunif(0.01, 2)
  var0 <- pow(sd0,2)

```


5	48	26	48	NA	1	1	9	NA	2
4	18	10	17	NA	1	1	14	NA	2
12	48	48	96	NA	1	1	4	NA	2
10	47	25	47	NA	1	1	4	NA	2
15	36	17	36	NA	1	4	7	NA	2
3	15	1	14	NA	1	4	8	NA	2
4	37	10	34	NA	1	1	7	NA	2
3	13	13	25	NA	1	1	4	NA	2
13	23	8	23	NA	1	4	11	NA	2
5	37	33	70	NA	1	1	3	NA	2
6	43	17	43	NA	1	1	3	NA	2
7	23	16	23	NA	1	1	6	NA	2
7	32	14	36	NA	1	1	13	NA	2
10	34	10	35	NA	1	1	13	NA	2
2	15	19	44	NA	1	1	3	NA	2
24	37	25	37	NA	1	3	4	NA	2
0	60	14	60	NA	1	1	5	NA	2
5	45	26	98	NA	1	1	9	NA	2
34	69	32	66	NA	1	11	14	NA	2
61	135	40	135	NA	1	6	7	NA	2
2	21	5	19	NA	1	1	2	NA	2
9	27	8	26	NA	1	1	9	NA	2
125	270	141	275	NA	1	4	14	NA	2
32	116	50	123	NA	1	1	3	NA	2
2	60	23	60	NA	1	1	5	NA	2
1	14	10	14	NA	1	1	2	NA	2
18	84	23	93	NA	1	1	13	NA	2
112	200	112	184	NA	1	1	10	NA	2
12	57	37	58	NA	1	1	2	NA	2
0	19	9	21	NA	1	1	8	NA	2
93	372	188	386	NA	1	1	2	NA	2
20	22	21	22	NA	1	2	3	NA	2
25	73	55	140	NA	1	1	2	NA	2
16	372	8	384	NA	1	1	2	NA	2
0	27	7	32	NA	1	1	2	NA	2
8	13	8	15	NA	1	2	9	NA	2
27	45	30	45	NA	1	2	13	NA	2
31	85	28	85	NA	1	1	9	NA	2
37	58	41	67	NA	1	3	13	NA	2
24	65	24	59	NA	1	1	13	NA	2
99	178	78	169	NA	1	2	8	NA	2

50	163	64	165	NA	1	1	2	NA	2
11	25	7	24	NA	1	4	8	NA	2
6	16	18	53	NA	1	1	4	NA	2
48	197	47	194	NA	1	1	8	NA	2
16	40	15	40	NA	1	2	9	NA	2
8	84	20	91	NA	1	1	6	NA	2
0	11	5	8	NA	1	1	4	NA	2
0	28	3	28	NA	1	1	7	NA	2
2	43	13	43	NA	1	1	7	NA	2
2	31	14	31	NA	1	1	6	NA	2
0	8	6	24	NA	1	1	7	NA	2
0	33	10	33	NA	1	1	12	NA	2
8	34	12	35	NA	1	4	14	NA	2
2	29	8	29	NA	1	1	14	NA	2
17	71	20	72	NA	1	1	14	NA	2
4	36	20	36	NA	1	1	12	NA	2
0	17	5	17	NA	1	4	14	NA	2
4	30	8	30	NA	1	1	12	NA	2
19	75	28	75	NA	1	1	10	NA	2
24	54	14	48	NA	1	11	14	NA	2
7	36	16	37	NA	1	1	8	NA	2
12	33	11	33	NA	1	1	7	NA	2
1	13	3	11	NA	1	4	8	NA	2
0	29	5	29	NA	1	1	14	NA	2
1	40	17	40	NA	1	1	6	NA	2
0	12	8	12	NA	1	1	5	NA	2
1	14	2	14	NA	1	4	13	NA	2
0	30	10	30	NA	1	1	11	NA	2
11	35	10	38	NA	1	1	6	NA	2
6	14	6	18	NA	1	11	14	NA	2
12	22	18	23	NA	1	1	9	NA	2
16	32	13	27	NA	1	4	14	NA	2
11	47	16	48	NA	1	1	5	NA	2
0	24	8	24	NA	1	1	7	NA	2
10	20	40	62	NA	1	1	9	NA	2
8	36	58	112	NA	1	1	2	NA	2
0	19	6	22	0	17	4	7	12	3
11	49	50	144	62	144	1	2	4	3
18	60	38	60	28	60	1	2	9	3
13	50	21	50	22	50	1	7	11	3

END

node	mean	sd	MC error	2.5%	median	97.5%	start	sample
best1[1]	0.0	0.0	1.414E-12	0.0	0.0	0.0	50001	5000
best1[2]	0.0018	0.04239	7.992E-4	0.0	0.0	0.0	50001	5000
best1[3]	0.053	0.224	0.004245	0.0	0.0	1.0	50001	5000
best1[4]	0.0014	0.03739	5.815E-4	0.0	0.0	0.0	50001	5000
best1[5]	0.7118	0.4529	0.01115	0.0	1.0	1.0	50001	5000
best1[6]	0.01	0.0995	0.001563	0.0	0.0	0.0	50001	5000
best1[7]	0.027	0.1621	0.002892	0.0	0.0	1.0	50001	5000
best1[8]	0.0018	0.04239	5.62E-4	0.0	0.0	0.0	50001	5000
best1[9]	0.0016	0.03997	6.033E-4	0.0	0.0	0.0	50001	5000
best1[10]	0.0048	0.06912	0.001058	0.0	0.0	0.0	50001	5000
best1[11]	0.1004	0.3005	0.006587	0.0	0.0	1.0	50001	5000
best1[12]	0.0584	0.2345	0.007058	0.0	0.0	1.0	50001	5000
best1[13]	4.0E-4	0.02	2.817E-4	0.0	0.0	0.0	50001	5000
best1[14]	0.0276	0.1638	0.003541	0.0	0.0	1.0	50001	5000
best2[1]	0.0	0.0	1.414E-12	0.0	0.0	0.0	50001	5000
best2[2]	0.0096	0.09751	0.001736	0.0	0.0	0.0	50001	5000
best2[3]	0.1468	0.3539	0.007527	0.0	0.0	1.0	50001	5000
best2[4]	0.0162	0.1262	0.002781	0.0	0.0	0.0	50001	5000
best2[5]	0.117	0.3214	0.005758	0.0	0.0	1.0	50001	5000
best2[6]	0.0454	0.2082	0.003424	0.0	0.0	1.0	50001	5000
best2[7]	0.149	0.3561	0.009166	0.0	0.0	1.0	50001	5000
best2[8]	0.0074	0.0857	0.001582	0.0	0.0	0.0	50001	5000
best2[9]	0.008	0.08908	0.001439	0.0	0.0	0.0	50001	5000
best2[10]	0.011	0.1043	0.001426	0.0	0.0	0.0	50001	5000
best2[11]	0.2504	0.4332	0.009641	0.0	0.0	1.0	50001	5000
best2[12]	0.12	0.325	0.008177	0.0	0.0	1.0	50001	5000
best2[13]	0.0028	0.05284	0.001012	0.0	0.0	0.0	50001	5000
best2[14]	0.1164	0.3207	0.006902	0.0	0.0	1.0	50001	5000
d[2]	0.9084	0.1925	0.004303	0.5261	0.9094	1.281	50001	5000
d[3]	1.185	0.2705	0.009589	0.6785	1.175	1.726	50001	5000
d[4]	1.055	0.1783	0.006629	0.712	1.054	1.422	50001	5000
d[5]	1.776	0.4397	0.01533	0.9306	1.767	2.685	50001	5000
d[6]	0.9348	0.2981	0.007378	0.3516	0.9321	1.54	50001	5000
d[7]	1.226	0.2077	0.007711	0.8384	1.216	1.668	50001	5000
d[8]	0.7579	0.2531	0.007698	0.2864	0.7527	1.279	50001	5000
d[9]	0.7709	0.2503	0.007164	0.2765	0.7705	1.26	50001	5000
d[10]	0.4083	0.4418	0.008455	-0.4678	0.4051	1.321	50001	5000
d[11]	1.297	0.2976	0.009451	0.7107	1.297	1.87	50001	5000
d[12]	0.9983	0.4622	0.01963	-0.003467	1.02	1.843	50001	5000
d[13]	0.6217	0.2782	0.008488	0.09102	0.6165	1.194	50001	5000
d[14]	1.202	0.2302	0.008453	0.7564	1.2	1.667	50001	5000
or[1,2]	0.4107	0.07978	0.001746	0.2779	0.4029	0.5916	50001	5000
or[1,3]	0.3171	0.08641	0.003069	0.1781	0.309	0.5075	50001	5000
or[1,4]	0.3536	0.06348	0.002347	0.2412	0.3486	0.4908	50001	5000
or[1,5]	0.1861	0.08501	0.002623	0.06825	0.1709	0.3954	50001	5000
or[1,6]	0.4104	0.1244	0.003053	0.2145	0.3938	0.704	50001	5000
or[1,7]	0.2999	0.06137	0.002257	0.1887	0.2966	0.433	50001	5000
or[1,8]	0.4837	0.122	0.003743	0.2787	0.4711	0.7515	50001	5000
or[1,9]	0.4774	0.1225	0.003379	0.2838	0.4628	0.7587	50001	5000
or[1,10]	0.7342	0.3754	0.006939	0.2674	0.667	1.6	50001	5000
or[1,11]	0.2859	0.08863	0.002711	0.1542	0.2734	0.4914	50001	5000
or[1,12]	0.4132	0.2282	0.009619	0.1588	0.3605	1.013	50001	5000
or[1,13]	0.558	0.1563	0.004771	0.3033	0.5399	0.9146	50001	5000
or[1,14]	0.3087	0.07165	0.002561	0.1891	0.3013	0.4694	50001	5000
or[2,1]	2.527	0.4929	0.01111	1.692	2.483	3.599	50001	5000
or[2,2]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[2,3]	0.7985	0.2637	0.007936	0.3947	0.7568	1.417	50001	5000
or[2,4]	0.8887	0.2173	0.005923	0.5373	0.8614	1.39	50001	5000
or[2,5]	0.4699	0.2374	0.006563	0.1602	0.4235	1.076	50001	5000

or[2,6]	1.037	0.3772	0.00904	0.4744	0.975	1.946	50001	5000
or[2,7]	0.7558	0.2085	0.006392	0.4223	0.7321	1.239	50001	5000
or[2,8]	1.211	0.3508	0.009806	0.6492	1.172	2.017	50001	5000
or[2,9]	1.193	0.3377	0.008759	0.6598	1.15	1.954	50001	5000
or[2,10]	1.855	1.019	0.0183	0.6082	1.652	4.231	50001	5000
or[2,11]	0.7203	0.2607	0.007358	0.3401	0.678	1.341	50001	5000
or[2,12]	1.044	0.6237	0.02546	0.3598	0.9035	2.669	50001	5000
or[2,13]	1.403	0.4644	0.01297	0.7018	1.337	2.49	50001	5000
or[2,14]	0.7778	0.2281	0.006172	0.4194	0.7468	1.309	50001	5000
or[3,1]	3.393	0.9489	0.03265	1.971	3.237	5.616	50001	5000
or[3,2]	1.388	0.4632	0.0145	0.7068	1.321	2.534	50001	5000
or[3,3]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[3,4]	1.189	0.3607	0.01263	0.6474	1.142	2.01	50001	5000
or[3,5]	0.6321	0.3542	0.01034	0.1933	0.5518	1.558	50001	5000
or[3,6]	1.393	0.589	0.01761	0.5745	1.285	2.834	50001	5000
or[3,7]	1.013	0.3406	0.01221	0.5044	0.9566	1.854	50001	5000
or[3,8]	1.635	0.6102	0.01852	0.7315	1.534	3.121	50001	5000
or[3,9]	1.612	0.5991	0.01972	0.7551	1.507	3.099	50001	5000
or[3,10]	2.483	1.45	0.02967	0.762	2.195	5.918	50001	5000
or[3,11]	0.965	0.3987	0.012	0.4189	0.8921	1.94	50001	5000
or[3,12]	1.398	0.8712	0.03537	0.456	1.177	3.648	50001	5000
or[3,13]	1.872	0.7018	0.02272	0.885	1.745	3.534	50001	5000
or[3,14]	1.037	0.3468	0.01144	0.5139	0.9821	1.84	50001	5000
or[4,1]	2.919	0.5273	0.01958	2.038	2.869	4.147	50001	5000
or[4,2]	1.192	0.2909	0.007924	0.7213	1.161	1.862	50001	5000
or[4,3]	0.918	0.279	0.009932	0.4985	0.876	1.546	50001	5000
or[4,4]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[4,5]	0.5406	0.2626	0.008061	0.1915	0.4879	1.182	50001	5000
or[4,6]	1.194	0.4135	0.01059	0.5746	1.133	2.19	50001	5000
or[4,7]	0.8661	0.2015	0.007501	0.5302	0.8462	1.334	50001	5000
or[4,8]	1.398	0.3899	0.01264	0.7829	1.339	2.297	50001	5000
or[4,9]	1.39	0.4264	0.01383	0.7506	1.327	2.418	50001	5000
or[4,10]	2.142	1.163	0.02307	0.73	1.919	4.846	50001	5000
or[4,11]	0.8228	0.2601	0.007328	0.4335	0.7845	1.434	50001	5000
or[4,12]	1.19	0.649	0.02738	0.4413	1.043	2.855	50001	5000
or[4,13]	1.622	0.526	0.01662	0.8185	1.556	2.871	50001	5000
or[4,14]	0.8858	0.2016	0.006694	0.5573	0.8596	1.336	50001	5000
or[5,1]	6.531	3.288	0.1157	2.536	5.852	14.66	50001	5000
or[5,2]	2.677	1.456	0.04636	0.9294	2.362	6.308	50001	5000
or[5,3]	2.07	1.221	0.03897	0.6437	1.812	5.204	50001	5000
or[5,4]	2.295	1.197	0.03874	0.848	2.05	5.231	50001	5000
or[5,5]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[5,6]	2.672	1.621	0.04912	0.8174	2.316	6.636	50001	5000
or[5,7]	1.955	1.066	0.03516	0.6719	1.717	4.553	50001	5000
or[5,8]	3.15	1.794	0.05298	1.026	2.755	7.529	50001	5000
or[5,9]	3.11	1.795	0.05865	1.037	2.723	7.501	50001	5000
or[5,10]	4.801	3.679	0.1041	1.181	3.869	13.77	50001	5000
or[5,11]	1.851	1.08	0.03124	0.5856	1.612	4.51	50001	5000
or[5,12]	2.688	2.076	0.07465	0.6582	2.121	8.163	50001	5000
or[5,13]	3.622	2.123	0.06779	1.202	3.129	8.84	50001	5000
or[5,14]	2.012	1.125	0.03638	0.6848	1.772	4.766	50001	5000
or[6,1]	2.664	0.8302	0.02023	1.421	2.54	4.664	50001	5000
or[6,2]	1.094	0.4074	0.009772	0.5144	1.026	2.118	50001	5000
or[6,3]	0.8444	0.3539	0.0103	0.3536	0.7785	1.742	50001	5000
or[6,4]	0.9382	0.3281	0.007893	0.4569	0.8826	1.742	50001	5000
or[6,5]	0.4947	0.2848	0.007716	0.1509	0.4319	1.228	50001	5000
or[6,6]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[6,7]	0.789	0.2674	0.007402	0.392	0.7476	1.431	50001	5000
or[6,8]	1.287	0.5236	0.01269	0.5518	1.193	2.541	50001	5000
or[6,9]	1.273	0.5417	0.01404	0.5703	1.167	2.605	50001	5000
or[6,10]	1.949	1.22	0.02262	0.5963	1.715	4.644	50001	5000
or[6,11]	0.7575	0.3323	0.009191	0.3127	0.6934	1.566	50001	5000

or[6,12]	1.095	0.7089	0.02537	0.3425	0.9217	2.939	50001	5000
or[6,13]	1.485	0.6386	0.01708	0.6241	1.355	3.133	50001	5000
or[6,14]	0.818	0.3116	0.008111	0.3773	0.7668	1.595	50001	5000
or[7,1]	3.482	0.7557	0.02785	2.313	3.372	5.3	50001	5000
or[7,2]	1.426	0.4009	0.01212	0.8085	1.366	2.369	50001	5000
or[7,3]	1.098	0.3688	0.01338	0.5396	1.045	1.984	50001	5000
or[7,4]	1.217	0.2859	0.0103	0.7494	1.182	1.887	50001	5000
or[7,5]	0.647	0.3291	0.009561	0.2199	0.5826	1.49	50001	5000
or[7,6]	1.411	0.4764	0.01345	0.7015	1.338	2.553	50001	5000
or[7,7]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[7,8]	1.674	0.5254	0.01659	0.8696	1.597	2.905	50001	5000
or[7,9]	1.661	0.5657	0.01858	0.8533	1.575	3.051	50001	5000
or[7,10]	2.553	1.428	0.03081	0.8536	2.273	5.905	50001	5000
or[7,11]	0.9766	0.3159	0.01037	0.508	0.9282	1.727	50001	5000
or[7,12]	1.423	0.8003	0.03107	0.5094	1.232	3.579	50001	5000
or[7,13]	1.934	0.665	0.01738	0.9433	1.829	3.519	50001	5000
or[7,14]	1.06	0.2863	0.009835	0.6117	1.019	1.733	50001	5000
or[8,1]	2.204	0.5772	0.01709	1.332	2.123	3.592	50001	5000
or[8,2]	0.8973	0.2697	0.007155	0.4966	0.8536	1.544	50001	5000
or[8,3]	0.6965	0.262	0.008014	0.322	0.6517	1.368	50001	5000
or[8,4]	0.7711	0.2161	0.006836	0.4358	0.7467	1.278	50001	5000
or[8,5]	0.4094	0.2198	0.005581	0.1328	0.3629	0.9753	50001	5000
or[8,6]	0.9033	0.3641	0.008663	0.3937	0.8381	1.813	50001	5000
or[8,7]	0.6574	0.2102	0.006771	0.3444	0.6262	1.151	50001	5000
or[8,8]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[8,9]	1.05	0.3833	0.01143	0.5071	0.9863	1.984	50001	5000
or[8,10]	1.615	0.9471	0.01815	0.5219	1.422	3.789	50001	5000
or[8,11]	0.6274	0.2537	0.00778	0.2803	0.5797	1.24	50001	5000
or[8,12]	0.9054	0.5685	0.02015	0.3116	0.7661	2.349	50001	5000
or[8,13]	1.228	0.4812	0.01452	0.5566	1.135	2.364	50001	5000
or[8,14]	0.6759	0.2259	0.00673	0.3414	0.6409	1.227	50001	5000
or[9,1]	2.231	0.5692	0.01642	1.319	2.161	3.525	50001	5000
or[9,2]	0.9062	0.2606	0.007071	0.5122	0.8695	1.517	50001	5000
or[9,3]	0.704	0.2577	0.008228	0.3233	0.6636	1.326	50001	5000
or[9,4]	0.7865	0.2391	0.008152	0.4155	0.7538	1.333	50001	5000
or[9,5]	0.4144	0.2211	0.006359	0.1334	0.3675	0.9641	50001	5000
or[9,6]	0.9146	0.3637	0.009147	0.384	0.8571	1.758	50001	5000
or[9,7]	0.6685	0.2209	0.008138	0.3281	0.6354	1.172	50001	5000
or[9,8]	1.076	0.3838	0.01124	0.5047	1.014	1.976	50001	5000
or[9,9]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[9,10]	1.641	0.9597	0.02114	0.5108	1.434	3.911	50001	5000
or[9,11]	0.6371	0.2566	0.008304	0.2724	0.5923	1.292	50001	5000
or[9,12]	0.9237	0.6074	0.02518	0.2976	0.7858	2.318	50001	5000
or[9,13]	1.244	0.4858	0.01515	0.5491	1.161	2.416	50001	5000
or[9,14]	0.6879	0.2382	0.007871	0.3344	0.6507	1.257	50001	5000
or[10,1]	1.664	0.8586	0.01569	0.6264	1.499	3.749	50001	5000
or[10,2]	0.6836	0.3811	0.006752	0.237	0.6054	1.657	50001	5000
or[10,3]	0.5274	0.3216	0.006715	0.169	0.4556	1.318	50001	5000
or[10,4]	0.5883	0.3268	0.006384	0.2064	0.5211	1.37	50001	5000
or[10,5]	0.3081	0.2156	0.005047	0.07301	0.2585	0.8507	50001	5000
or[10,6]	0.6783	0.3953	0.008176	0.2154	0.5832	1.683	50001	5000
or[10,7]	0.4985	0.2829	0.005705	0.1705	0.44	1.176	50001	5000
or[10,8]	0.8022	0.462	0.008587	0.264	0.7034	1.917	50001	5000
or[10,9]	0.7965	0.4792	0.01012	0.2557	0.698	1.959	50001	5000
or[10,10]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[10,11]	0.4751	0.2925	0.005487	0.1491	0.4092	1.201	50001	5000
or[10,12]	0.6889	0.5654	0.01655	0.1683	0.5466	2.14	50001	5000
or[10,13]	0.9306	0.5706	0.01091	0.2922	0.8073	2.271	50001	5000
or[10,14]	0.5118	0.2882	0.005148	0.1727	0.4544	1.236	50001	5000
or[11,1]	3.823	1.157	0.03686	2.035	3.658	6.489	50001	5000
or[11,2]	1.566	0.5627	0.01629	0.7472	1.475	2.942	50001	5000
or[11,3]	1.206	0.4829	0.01596	0.5155	1.121	2.388	50001	5000

or[11,4]	1.333	0.4115	0.0127	0.6975	1.275	2.31	50001	5000
or[11,5]	0.7085	0.4024	0.01146	0.2226	0.6203	1.712	50001	5000
or[11,6]	1.56	0.6583	0.01923	0.6386	1.442	3.207	50001	5000
or[11,7]	1.125	0.3488	0.01153	0.5795	1.078	1.969	50001	5000
or[11,8]	1.841	0.7114	0.02138	0.8076	1.726	3.575	50001	5000
or[11,9]	1.825	0.7421	0.02217	0.7768	1.689	3.682	50001	5000
or[11,10]	2.807	1.726	0.03829	0.8325	2.444	6.721	50001	5000
or[11,11]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[11,12]	1.569	1.0	0.03958	0.4864	1.325	4.072	50001	5000
or[11,13]	2.121	0.8682	0.02563	0.9066	1.971	4.26	50001	5000
or[11,14]	1.148	0.339	0.01027	0.6072	1.11	1.922	50001	5000
or[12,1]	3.002	1.347	0.05696	0.9965	2.774	6.314	50001	5000
or[12,2]	1.233	0.617	0.02324	0.3769	1.107	2.787	50001	5000
or[12,3]	0.9494	0.5025	0.01938	0.2742	0.85	2.193	50001	5000
or[12,4]	1.052	0.4949	0.0216	0.3509	0.9586	2.268	50001	5000
or[12,5]	0.5581	0.3784	0.01416	0.1234	0.4716	1.521	50001	5000
or[12,6]	1.228	0.6887	0.0251	0.3419	1.085	2.922	50001	5000
or[12,7]	0.8941	0.4358	0.01756	0.2797	0.8115	1.965	50001	5000
or[12,8]	1.442	0.7342	0.02749	0.4283	1.305	3.211	50001	5000
or[12,9]	1.435	0.7677	0.02954	0.4343	1.273	3.367	50001	5000
or[12,10]	2.208	1.646	0.04919	0.4683	1.83	5.988	50001	5000
or[12,11]	0.8539	0.4768	0.01929	0.2462	0.7546	2.066	50001	5000
or[12,12]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[12,13]	1.666	0.888	0.0304	0.4791	1.496	3.9	50001	5000
or[12,14]	0.9191	0.4596	0.01937	0.2843	0.8234	2.085	50001	5000
or[13,1]	1.937	0.5627	0.01684	1.095	1.852	3.301	50001	5000
or[13,2]	0.7908	0.2642	0.006907	0.402	0.7482	1.426	50001	5000
or[13,3]	0.6063	0.22	0.00689	0.2831	0.5731	1.134	50001	5000
or[13,4]	0.6818	0.2255	0.007283	0.3488	0.6429	1.224	50001	5000
or[13,5]	0.3578	0.1932	0.005586	0.1133	0.3196	0.8332	50001	5000
or[13,6]	0.7931	0.3321	0.008216	0.3198	0.7383	1.61	50001	5000
or[13,7]	0.5785	0.2018	0.005565	0.2843	0.547	1.061	50001	5000
or[13,8]	0.9342	0.3532	0.01031	0.4232	0.8808	1.804	50001	5000
or[13,9]	0.923	0.358	0.0105	0.4142	0.8613	1.823	50001	5000
or[13,10]	1.425	0.8753	0.01622	0.4407	1.239	3.434	50001	5000
or[13,11]	0.55	0.2271	0.006472	0.2353	0.5074	1.106	50001	5000
or[13,12]	0.7932	0.4827	0.01752	0.2565	0.6683	2.088	50001	5000
or[13,13]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[13,14]	0.5942	0.2104	0.005893	0.2814	0.5593	1.11	50001	5000
or[14,1]	3.415	0.8001	0.02964	2.131	3.319	5.296	50001	5000
or[14,2]	1.399	0.4212	0.01226	0.7642	1.339	2.387	50001	5000
or[14,3]	1.073	0.3607	0.01288	0.5439	1.018	1.948	50001	5000
or[14,4]	1.187	0.2673	0.008836	0.7488	1.163	1.794	50001	5000
or[14,5]	0.6355	0.3385	0.01012	0.2099	0.5646	1.461	50001	5000
or[14,6]	1.394	0.5189	0.01313	0.6273	1.304	2.652	50001	5000
or[14,7]	1.011	0.2683	0.009559	0.5773	0.9814	1.635	50001	5000
or[14,8]	1.641	0.5367	0.01665	0.8154	1.561	2.93	50001	5000
or[14,9]	1.629	0.5675	0.0181	0.7982	1.537	2.996	50001	5000
or[14,10]	2.501	1.404	0.0271	0.8112	2.201	5.796	50001	5000
or[14,11]	0.9504	0.298	0.009145	0.5211	0.9005	1.651	50001	5000
or[14,12]	1.393	0.7883	0.03157	0.4801	1.214	3.526	50001	5000
or[14,13]	1.896	0.6794	0.02013	0.9021	1.788	3.557	50001	5000
or[14,14]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000

```

# Model - heterogeneous random effects model
# Assume correlation within study (rho = 0.5)
# Assume heterogeneous between studies ; "sdmu" is (0.01, 5)

model {
  for (i in 1:NS) {
    s[i,1] <- 0
    delta[i, t[i,1]] <- 0
    mu[i] ~ dnorm(mmu[t[i,1]], taumu) # handle different baseline treatments

    for (k in 1:na[i]) {
      r[i,k] ~ dbin(p[i,t[i,k]], n[i,k])
      logit(p[i,t[i,k]]) <- mu[i] + delta[i,t[i,k]]
    }

    for (k in 2:na[i]) {
      delta[i,t[i,k]] ~ dnorm(md[i,t[i,k]], tau[i,t[i,k]])
      md[i,t[i,k]] <- d[t[i,k]] - d[t[i,1]] + ss[i,k]
      tau[i,t[i,k]] <- tau[t[i,1],t[i,k]]*2*(k-1)/k
      s[i,k] <- (delta[i, t[i,k]] - d[t[i,k]] + d[t[i,1]])
      ss[i,k] <- sum(s[i, 1:k-1])/(k-1)
    }
  }

  mmu[5] <- 0 #Treatments 1,2,3,4,6,7 are one of baseline treatments.
  mmu[8] <- 0 # other treatments should be assigned to 0.
  mmu[9] <- 0
  mmu[10] <- 0
  mmu[11] <- 0
  mmu[12] <- 0
  mmu[13] <- 0
  mmu[14] <- 0
  mmu[1] ~ dnorm(0, 0.0001)
  mmu[2] ~ dnorm(0, 0.0001)
  mmu[3] ~ dnorm(0, 0.0001)
  mmu[4] ~ dnorm(0, 0.0001)
  mmu[6] ~ dnorm(0, 0.0001)
  mmu[7] ~ dnorm(0, 0.0001)
  sdmu ~ dunif(0.01, 5)
  taumu <- 1/pow(sdmu,2)

  d[1] <- 0
  for (k in 2:NT) {
    d[k] ~ dnorm(0,0.0001)
    ed[k] <- exp(d[k]) # ed is odds ratio against placebo
  }

  for(i in 1:(NT-1)) {
    for(j in (i+1):NT) {
      v[i,j] ~ dnorm(0, 8.32)
      log(sd[i,j]) <- log(sd0) + v[i,j]
      tau[i,j] <- 1/pow(sd[i,j],2)
      var[i,j] <- pow(sd[i,j],2)
    }
  }
  sd0 ~ dunif(0.01, 2)
  var0 <- pow(sd0,2)

```


5	48	26	48	NA	1	1	9	NA	2
4	18	10	17	NA	1	1	14	NA	2
12	48	48	96	NA	1	1	4	NA	2
10	47	25	47	NA	1	1	4	NA	2
15	36	17	36	NA	1	4	7	NA	2
3	15	1	14	NA	1	4	8	NA	2
4	37	10	34	NA	1	1	7	NA	2
3	13	13	25	NA	1	1	4	NA	2
13	23	8	23	NA	1	4	11	NA	2
5	37	33	70	NA	1	1	3	NA	2
6	43	17	43	NA	1	1	3	NA	2
7	23	16	23	NA	1	1	6	NA	2
7	32	14	36	NA	1	1	13	NA	2
10	34	10	35	NA	1	1	13	NA	2
2	15	19	44	NA	1	1	3	NA	2
24	37	25	37	NA	1	3	4	NA	2
0	60	14	60	NA	1	1	5	NA	2
5	45	26	98	NA	1	1	9	NA	2
34	69	32	66	NA	1	11	14	NA	2
61	135	40	135	NA	1	6	7	NA	2
2	21	5	19	NA	1	1	2	NA	2
9	27	8	26	NA	1	1	9	NA	2
125	270	141	275	NA	1	4	14	NA	2
32	116	50	123	NA	1	1	3	NA	2
2	60	23	60	NA	1	1	5	NA	2
1	14	10	14	NA	1	1	2	NA	2
18	84	23	93	NA	1	1	13	NA	2
112	200	112	184	NA	1	1	10	NA	2
12	57	37	58	NA	1	1	2	NA	2
0	19	9	21	NA	1	1	8	NA	2
93	372	188	386	NA	1	1	2	NA	2
20	22	21	22	NA	1	2	3	NA	2
25	73	55	140	NA	1	1	2	NA	2
16	372	8	384	NA	1	1	2	NA	2
0	27	7	32	NA	1	1	2	NA	2
8	13	8	15	NA	1	2	9	NA	2
27	45	30	45	NA	1	2	13	NA	2
31	85	28	85	NA	1	1	9	NA	2
37	58	41	67	NA	1	3	13	NA	2
24	65	24	59	NA	1	1	13	NA	2
99	178	78	169	NA	1	2	8	NA	2

50	163	64	165	NA	1	1	2	NA	2
11	25	7	24	NA	1	4	8	NA	2
6	16	18	53	NA	1	1	4	NA	2
48	197	47	194	NA	1	1	8	NA	2
16	40	15	40	NA	1	2	9	NA	2
8	84	20	91	NA	1	1	6	NA	2
0	11	5	8	NA	1	1	4	NA	2
0	28	3	28	NA	1	1	7	NA	2
2	43	13	43	NA	1	1	7	NA	2
2	31	14	31	NA	1	1	6	NA	2
0	8	6	24	NA	1	1	7	NA	2
0	33	10	33	NA	1	1	12	NA	2
8	34	12	35	NA	1	4	14	NA	2
2	29	8	29	NA	1	1	14	NA	2
17	71	20	72	NA	1	1	14	NA	2
4	36	20	36	NA	1	1	12	NA	2
0	17	5	17	NA	1	4	14	NA	2
4	30	8	30	NA	1	1	12	NA	2
19	75	28	75	NA	1	1	10	NA	2
24	54	14	48	NA	1	11	14	NA	2
7	36	16	37	NA	1	1	8	NA	2
12	33	11	33	NA	1	1	7	NA	2
1	13	3	11	NA	1	4	8	NA	2
0	29	5	29	NA	1	1	14	NA	2
1	40	17	40	NA	1	1	6	NA	2
0	12	8	12	NA	1	1	5	NA	2
1	14	2	14	NA	1	4	13	NA	2
0	30	10	30	NA	1	1	11	NA	2
11	35	10	38	NA	1	1	6	NA	2
6	14	6	18	NA	1	11	14	NA	2
12	22	18	23	NA	1	1	9	NA	2
16	32	13	27	NA	1	4	14	NA	2
11	47	16	48	NA	1	1	5	NA	2
0	24	8	24	NA	1	1	7	NA	2
10	20	40	62	NA	1	1	9	NA	2
8	36	58	112	NA	1	1	2	NA	2
0	19	6	22	0	17	4	7	12	3
11	49	50	144	62	144	1	2	4	3
18	60	38	60	28	60	1	2	9	3
13	50	21	50	22	50	1	7	11	3

END

node	mean	sd	MC error	2.5%	median	97.5%	start	sample
best1[1]	0.0	0.0	1.414E-12	0.0	0.0	0.0	50001	5000
best1[2]	0.0018	0.04239	7.992E-4	0.0	0.0	0.0	50001	5000
best1[3]	0.053	0.224	0.004245	0.0	0.0	1.0	50001	5000
best1[4]	0.0014	0.03739	5.815E-4	0.0	0.0	0.0	50001	5000
best1[5]	0.7118	0.4529	0.01115	0.0	1.0	1.0	50001	5000
best1[6]	0.01	0.0995	0.001563	0.0	0.0	0.0	50001	5000
best1[7]	0.027	0.1621	0.002892	0.0	0.0	1.0	50001	5000
best1[8]	0.0018	0.04239	5.62E-4	0.0	0.0	0.0	50001	5000
best1[9]	0.0016	0.03997	6.033E-4	0.0	0.0	0.0	50001	5000
best1[10]	0.0048	0.06912	0.001058	0.0	0.0	0.0	50001	5000
best1[11]	0.1004	0.3005	0.006587	0.0	0.0	1.0	50001	5000
best1[12]	0.0584	0.2345	0.007058	0.0	0.0	1.0	50001	5000
best1[13]	4.0E-4	0.02	2.817E-4	0.0	0.0	0.0	50001	5000
best1[14]	0.0276	0.1638	0.003541	0.0	0.0	1.0	50001	5000
best2[1]	0.0	0.0	1.414E-12	0.0	0.0	0.0	50001	5000
best2[2]	0.0096	0.09751	0.001736	0.0	0.0	0.0	50001	5000
best2[3]	0.1468	0.3539	0.007527	0.0	0.0	1.0	50001	5000
best2[4]	0.0162	0.1262	0.002781	0.0	0.0	0.0	50001	5000
best2[5]	0.117	0.3214	0.005758	0.0	0.0	1.0	50001	5000
best2[6]	0.0454	0.2082	0.003424	0.0	0.0	1.0	50001	5000
best2[7]	0.149	0.3561	0.009166	0.0	0.0	1.0	50001	5000
best2[8]	0.0074	0.0857	0.001582	0.0	0.0	0.0	50001	5000
best2[9]	0.008	0.08908	0.001439	0.0	0.0	0.0	50001	5000
best2[10]	0.011	0.1043	0.001426	0.0	0.0	0.0	50001	5000
best2[11]	0.2504	0.4332	0.009641	0.0	0.0	1.0	50001	5000
best2[12]	0.12	0.325	0.008177	0.0	0.0	1.0	50001	5000
best2[13]	0.0028	0.05284	0.001012	0.0	0.0	0.0	50001	5000
best2[14]	0.1164	0.3207	0.006902	0.0	0.0	1.0	50001	5000
d[2]	0.9084	0.1925	0.004303	0.5261	0.9094	1.281	50001	5000
d[3]	1.185	0.2705	0.009589	0.6785	1.175	1.726	50001	5000
d[4]	1.055	0.1783	0.006629	0.712	1.054	1.422	50001	5000
d[5]	1.776	0.4397	0.01533	0.9306	1.767	2.685	50001	5000
d[6]	0.9348	0.2981	0.007378	0.3516	0.9321	1.54	50001	5000
d[7]	1.226	0.2077	0.007711	0.8384	1.216	1.668	50001	5000
d[8]	0.7579	0.2531	0.007698	0.2864	0.7527	1.279	50001	5000
d[9]	0.7709	0.2503	0.007164	0.2765	0.7705	1.26	50001	5000
d[10]	0.4083	0.4418	0.008455	-0.4678	0.4051	1.321	50001	5000
d[11]	1.297	0.2976	0.009451	0.7107	1.297	1.87	50001	5000
d[12]	0.9983	0.4622	0.01963	-0.003467	1.02	1.843	50001	5000
d[13]	0.6217	0.2782	0.008488	0.09102	0.6165	1.194	50001	5000
d[14]	1.202	0.2302	0.008453	0.7564	1.2	1.667	50001	5000
or[1,2]	0.4107	0.07978	0.001746	0.2779	0.4029	0.5916	50001	5000
or[1,3]	0.3171	0.08641	0.003069	0.1781	0.309	0.5075	50001	5000
or[1,4]	0.3536	0.06348	0.002347	0.2412	0.3486	0.4908	50001	5000
or[1,5]	0.1861	0.08501	0.002623	0.06825	0.1709	0.3954	50001	5000
or[1,6]	0.4104	0.1244	0.003053	0.2145	0.3938	0.704	50001	5000
or[1,7]	0.2999	0.06137	0.002257	0.1887	0.2966	0.433	50001	5000
or[1,8]	0.4837	0.122	0.003743	0.2787	0.4711	0.7515	50001	5000
or[1,9]	0.4774	0.1225	0.003379	0.2838	0.4628	0.7587	50001	5000
or[1,10]	0.7342	0.3754	0.006939	0.2674	0.667	1.6	50001	5000
or[1,11]	0.2859	0.08863	0.002711	0.1542	0.2734	0.4914	50001	5000
or[1,12]	0.4132	0.2282	0.009619	0.1588	0.3605	1.013	50001	5000
or[1,13]	0.558	0.1563	0.004771	0.3033	0.5399	0.9146	50001	5000
or[1,14]	0.3087	0.07165	0.002561	0.1891	0.3013	0.4694	50001	5000
or[2,1]	2.527	0.4929	0.01111	1.692	2.483	3.599	50001	5000
or[2,2]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[2,3]	0.7985	0.2637	0.007936	0.3947	0.7568	1.417	50001	5000
or[2,4]	0.8887	0.2173	0.005923	0.5373	0.8614	1.39	50001	5000
or[2,5]	0.4699	0.2374	0.006563	0.1602	0.4235	1.076	50001	5000

or[2,6]	1.037	0.3772	0.00904	0.4744	0.975	1.946	50001	5000
or[2,7]	0.7558	0.2085	0.006392	0.4223	0.7321	1.239	50001	5000
or[2,8]	1.211	0.3508	0.009806	0.6492	1.172	2.017	50001	5000
or[2,9]	1.193	0.3377	0.008759	0.6598	1.15	1.954	50001	5000
or[2,10]	1.855	1.019	0.0183	0.6082	1.652	4.231	50001	5000
or[2,11]	0.7203	0.2607	0.007358	0.3401	0.678	1.341	50001	5000
or[2,12]	1.044	0.6237	0.02546	0.3598	0.9035	2.669	50001	5000
or[2,13]	1.403	0.4644	0.01297	0.7018	1.337	2.49	50001	5000
or[2,14]	0.7778	0.2281	0.006172	0.4194	0.7468	1.309	50001	5000
or[3,1]	3.393	0.9489	0.03265	1.971	3.237	5.616	50001	5000
or[3,2]	1.388	0.4632	0.0145	0.7068	1.321	2.534	50001	5000
or[3,3]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[3,4]	1.189	0.3607	0.01263	0.6474	1.142	2.01	50001	5000
or[3,5]	0.6321	0.3542	0.01034	0.1933	0.5518	1.558	50001	5000
or[3,6]	1.393	0.589	0.01761	0.5745	1.285	2.834	50001	5000
or[3,7]	1.013	0.3406	0.01221	0.5044	0.9566	1.854	50001	5000
or[3,8]	1.635	0.6102	0.01852	0.7315	1.534	3.121	50001	5000
or[3,9]	1.612	0.5991	0.01972	0.7551	1.507	3.099	50001	5000
or[3,10]	2.483	1.45	0.02967	0.762	2.195	5.918	50001	5000
or[3,11]	0.965	0.3987	0.012	0.4189	0.8921	1.94	50001	5000
or[3,12]	1.398	0.8712	0.03537	0.456	1.177	3.648	50001	5000
or[3,13]	1.872	0.7018	0.02272	0.885	1.745	3.534	50001	5000
or[3,14]	1.037	0.3468	0.01144	0.5139	0.9821	1.84	50001	5000
or[4,1]	2.919	0.5273	0.01958	2.038	2.869	4.147	50001	5000
or[4,2]	1.192	0.2909	0.007924	0.7213	1.161	1.862	50001	5000
or[4,3]	0.918	0.279	0.009932	0.4985	0.876	1.546	50001	5000
or[4,4]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[4,5]	0.5406	0.2626	0.008061	0.1915	0.4879	1.182	50001	5000
or[4,6]	1.194	0.4135	0.01059	0.5746	1.133	2.19	50001	5000
or[4,7]	0.8661	0.2015	0.007501	0.5302	0.8462	1.334	50001	5000
or[4,8]	1.398	0.3899	0.01264	0.7829	1.339	2.297	50001	5000
or[4,9]	1.39	0.4264	0.01383	0.7506	1.327	2.418	50001	5000
or[4,10]	2.142	1.163	0.02307	0.73	1.919	4.846	50001	5000
or[4,11]	0.8228	0.2601	0.007328	0.4335	0.7845	1.434	50001	5000
or[4,12]	1.19	0.649	0.02738	0.4413	1.043	2.855	50001	5000
or[4,13]	1.622	0.526	0.01662	0.8185	1.556	2.871	50001	5000
or[4,14]	0.8858	0.2016	0.006694	0.5573	0.8596	1.336	50001	5000
or[5,1]	6.531	3.288	0.1157	2.536	5.852	14.66	50001	5000
or[5,2]	2.677	1.456	0.04636	0.9294	2.362	6.308	50001	5000
or[5,3]	2.07	1.221	0.03897	0.6437	1.812	5.204	50001	5000
or[5,4]	2.295	1.197	0.03874	0.848	2.05	5.231	50001	5000
or[5,5]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[5,6]	2.672	1.621	0.04912	0.8174	2.316	6.636	50001	5000
or[5,7]	1.955	1.066	0.03516	0.6719	1.717	4.553	50001	5000
or[5,8]	3.15	1.794	0.05298	1.026	2.755	7.529	50001	5000
or[5,9]	3.11	1.795	0.05865	1.037	2.723	7.501	50001	5000
or[5,10]	4.801	3.679	0.1041	1.181	3.869	13.77	50001	5000
or[5,11]	1.851	1.08	0.03124	0.5856	1.612	4.51	50001	5000
or[5,12]	2.688	2.076	0.07465	0.6582	2.121	8.163	50001	5000
or[5,13]	3.622	2.123	0.06779	1.202	3.129	8.84	50001	5000
or[5,14]	2.012	1.125	0.03638	0.6848	1.772	4.766	50001	5000
or[6,1]	2.664	0.8302	0.02023	1.421	2.54	4.664	50001	5000
or[6,2]	1.094	0.4074	0.009772	0.5144	1.026	2.118	50001	5000
or[6,3]	0.8444	0.3539	0.0103	0.3536	0.7785	1.742	50001	5000
or[6,4]	0.9382	0.3281	0.007893	0.4569	0.8826	1.742	50001	5000
or[6,5]	0.4947	0.2848	0.007716	0.1509	0.4319	1.228	50001	5000
or[6,6]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[6,7]	0.789	0.2674	0.007402	0.392	0.7476	1.431	50001	5000
or[6,8]	1.287	0.5236	0.01269	0.5518	1.193	2.541	50001	5000
or[6,9]	1.273	0.5417	0.01404	0.5703	1.167	2.605	50001	5000
or[6,10]	1.949	1.22	0.02262	0.5963	1.715	4.644	50001	5000
or[6,11]	0.7575	0.3323	0.009191	0.3127	0.6934	1.566	50001	5000

or[6,12]	1.095	0.7089	0.02537	0.3425	0.9217	2.939	50001	5000
or[6,13]	1.485	0.6386	0.01708	0.6241	1.355	3.133	50001	5000
or[6,14]	0.818	0.3116	0.008111	0.3773	0.7668	1.595	50001	5000
or[7,1]	3.482	0.7557	0.02785	2.313	3.372	5.3	50001	5000
or[7,2]	1.426	0.4009	0.01212	0.8085	1.366	2.369	50001	5000
or[7,3]	1.098	0.3688	0.01338	0.5396	1.045	1.984	50001	5000
or[7,4]	1.217	0.2859	0.0103	0.7494	1.182	1.887	50001	5000
or[7,5]	0.647	0.3291	0.009561	0.2199	0.5826	1.49	50001	5000
or[7,6]	1.411	0.4764	0.01345	0.7015	1.338	2.553	50001	5000
or[7,7]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[7,8]	1.674	0.5254	0.01659	0.8696	1.597	2.905	50001	5000
or[7,9]	1.661	0.5657	0.01858	0.8533	1.575	3.051	50001	5000
or[7,10]	2.553	1.428	0.03081	0.8536	2.273	5.905	50001	5000
or[7,11]	0.9766	0.3159	0.01037	0.508	0.9282	1.727	50001	5000
or[7,12]	1.423	0.8003	0.03107	0.5094	1.232	3.579	50001	5000
or[7,13]	1.934	0.665	0.01738	0.9433	1.829	3.519	50001	5000
or[7,14]	1.06	0.2863	0.009835	0.6117	1.019	1.733	50001	5000
or[8,1]	2.204	0.5772	0.01709	1.332	2.123	3.592	50001	5000
or[8,2]	0.8973	0.2697	0.007155	0.4966	0.8536	1.544	50001	5000
or[8,3]	0.6965	0.262	0.008014	0.322	0.6517	1.368	50001	5000
or[8,4]	0.7711	0.2161	0.006836	0.4358	0.7467	1.278	50001	5000
or[8,5]	0.4094	0.2198	0.005581	0.1328	0.3629	0.9753	50001	5000
or[8,6]	0.9033	0.3641	0.008663	0.3937	0.8381	1.813	50001	5000
or[8,7]	0.6574	0.2102	0.006771	0.3444	0.6262	1.151	50001	5000
or[8,8]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[8,9]	1.05	0.3833	0.01143	0.5071	0.9863	1.984	50001	5000
or[8,10]	1.615	0.9471	0.01815	0.5219	1.422	3.789	50001	5000
or[8,11]	0.6274	0.2537	0.00778	0.2803	0.5797	1.24	50001	5000
or[8,12]	0.9054	0.5685	0.02015	0.3116	0.7661	2.349	50001	5000
or[8,13]	1.228	0.4812	0.01452	0.5566	1.135	2.364	50001	5000
or[8,14]	0.6759	0.2259	0.00673	0.3414	0.6409	1.227	50001	5000
or[9,1]	2.231	0.5692	0.01642	1.319	2.161	3.525	50001	5000
or[9,2]	0.9062	0.2606	0.007071	0.5122	0.8695	1.517	50001	5000
or[9,3]	0.704	0.2577	0.008228	0.3233	0.6636	1.326	50001	5000
or[9,4]	0.7865	0.2391	0.008152	0.4155	0.7538	1.333	50001	5000
or[9,5]	0.4144	0.2211	0.006359	0.1334	0.3675	0.9641	50001	5000
or[9,6]	0.9146	0.3637	0.009147	0.384	0.8571	1.758	50001	5000
or[9,7]	0.6685	0.2209	0.008138	0.3281	0.6354	1.172	50001	5000
or[9,8]	1.076	0.3838	0.01124	0.5047	1.014	1.976	50001	5000
or[9,9]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[9,10]	1.641	0.9597	0.02114	0.5108	1.434	3.911	50001	5000
or[9,11]	0.6371	0.2566	0.008304	0.2724	0.5923	1.292	50001	5000
or[9,12]	0.9237	0.6074	0.02518	0.2976	0.7858	2.318	50001	5000
or[9,13]	1.244	0.4858	0.01515	0.5491	1.161	2.416	50001	5000
or[9,14]	0.6879	0.2382	0.007871	0.3344	0.6507	1.257	50001	5000
or[10,1]	1.664	0.8586	0.01569	0.6264	1.499	3.749	50001	5000
or[10,2]	0.6836	0.3811	0.006752	0.237	0.6054	1.657	50001	5000
or[10,3]	0.5274	0.3216	0.006715	0.169	0.4556	1.318	50001	5000
or[10,4]	0.5883	0.3268	0.006384	0.2064	0.5211	1.37	50001	5000
or[10,5]	0.3081	0.2156	0.005047	0.07301	0.2585	0.8507	50001	5000
or[10,6]	0.6783	0.3953	0.008176	0.2154	0.5832	1.683	50001	5000
or[10,7]	0.4985	0.2829	0.005705	0.1705	0.44	1.176	50001	5000
or[10,8]	0.8022	0.462	0.008587	0.264	0.7034	1.917	50001	5000
or[10,9]	0.7965	0.4792	0.01012	0.2557	0.698	1.959	50001	5000
or[10,10]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[10,11]	0.4751	0.2925	0.005487	0.1491	0.4092	1.201	50001	5000
or[10,12]	0.6889	0.5654	0.01655	0.1683	0.5466	2.14	50001	5000
or[10,13]	0.9306	0.5706	0.01091	0.2922	0.8073	2.271	50001	5000
or[10,14]	0.5118	0.2882	0.005148	0.1727	0.4544	1.236	50001	5000
or[11,1]	3.823	1.157	0.03686	2.035	3.658	6.489	50001	5000
or[11,2]	1.566	0.5627	0.01629	0.7472	1.475	2.942	50001	5000
or[11,3]	1.206	0.4829	0.01596	0.5155	1.121	2.388	50001	5000

or[11,4]	1.333	0.4115	0.0127	0.6975	1.275	2.31	50001	5000
or[11,5]	0.7085	0.4024	0.01146	0.2226	0.6203	1.712	50001	5000
or[11,6]	1.56	0.6583	0.01923	0.6386	1.442	3.207	50001	5000
or[11,7]	1.125	0.3488	0.01153	0.5795	1.078	1.969	50001	5000
or[11,8]	1.841	0.7114	0.02138	0.8076	1.726	3.575	50001	5000
or[11,9]	1.825	0.7421	0.02217	0.7768	1.689	3.682	50001	5000
or[11,10]	2.807	1.726	0.03829	0.8325	2.444	6.721	50001	5000
or[11,11]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[11,12]	1.569	1.0	0.03958	0.4864	1.325	4.072	50001	5000
or[11,13]	2.121	0.8682	0.02563	0.9066	1.971	4.26	50001	5000
or[11,14]	1.148	0.339	0.01027	0.6072	1.11	1.922	50001	5000
or[12,1]	3.002	1.347	0.05696	0.9965	2.774	6.314	50001	5000
or[12,2]	1.233	0.617	0.02324	0.3769	1.107	2.787	50001	5000
or[12,3]	0.9494	0.5025	0.01938	0.2742	0.85	2.193	50001	5000
or[12,4]	1.052	0.4949	0.0216	0.3509	0.9586	2.268	50001	5000
or[12,5]	0.5581	0.3784	0.01416	0.1234	0.4716	1.521	50001	5000
or[12,6]	1.228	0.6887	0.0251	0.3419	1.085	2.922	50001	5000
or[12,7]	0.8941	0.4358	0.01756	0.2797	0.8115	1.965	50001	5000
or[12,8]	1.442	0.7342	0.02749	0.4283	1.305	3.211	50001	5000
or[12,9]	1.435	0.7677	0.02954	0.4343	1.273	3.367	50001	5000
or[12,10]	2.208	1.646	0.04919	0.4683	1.83	5.988	50001	5000
or[12,11]	0.8539	0.4768	0.01929	0.2462	0.7546	2.066	50001	5000
or[12,12]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[12,13]	1.666	0.888	0.0304	0.4791	1.496	3.9	50001	5000
or[12,14]	0.9191	0.4596	0.01937	0.2843	0.8234	2.085	50001	5000
or[13,1]	1.937	0.5627	0.01684	1.095	1.852	3.301	50001	5000
or[13,2]	0.7908	0.2642	0.006907	0.402	0.7482	1.426	50001	5000
or[13,3]	0.6063	0.22	0.00689	0.2831	0.5731	1.134	50001	5000
or[13,4]	0.6818	0.2255	0.007283	0.3488	0.6429	1.224	50001	5000
or[13,5]	0.3578	0.1932	0.005586	0.1133	0.3196	0.8332	50001	5000
or[13,6]	0.7931	0.3321	0.008216	0.3198	0.7383	1.61	50001	5000
or[13,7]	0.5785	0.2018	0.005565	0.2843	0.547	1.061	50001	5000
or[13,8]	0.9342	0.3532	0.01031	0.4232	0.8808	1.804	50001	5000
or[13,9]	0.923	0.358	0.0105	0.4142	0.8613	1.823	50001	5000
or[13,10]	1.425	0.8753	0.01622	0.4407	1.239	3.434	50001	5000
or[13,11]	0.55	0.2271	0.006472	0.2353	0.5074	1.106	50001	5000
or[13,12]	0.7932	0.4827	0.01752	0.2565	0.6683	2.088	50001	5000
or[13,13]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[13,14]	0.5942	0.2104	0.005893	0.2814	0.5593	1.11	50001	5000
or[14,1]	3.415	0.8001	0.02964	2.131	3.319	5.296	50001	5000
or[14,2]	1.399	0.4212	0.01226	0.7642	1.339	2.387	50001	5000
or[14,3]	1.073	0.3607	0.01288	0.5439	1.018	1.948	50001	5000
or[14,4]	1.187	0.2673	0.008836	0.7488	1.163	1.794	50001	5000
or[14,5]	0.6355	0.3385	0.01012	0.2099	0.5646	1.461	50001	5000
or[14,6]	1.394	0.5189	0.01313	0.6273	1.304	2.652	50001	5000
or[14,7]	1.011	0.2683	0.009559	0.5773	0.9814	1.635	50001	5000
or[14,8]	1.641	0.5367	0.01665	0.8154	1.561	2.93	50001	5000
or[14,9]	1.629	0.5675	0.0181	0.7982	1.537	2.996	50001	5000
or[14,10]	2.501	1.404	0.0271	0.8112	2.201	5.796	50001	5000
or[14,11]	0.9504	0.298	0.009145	0.5211	0.9005	1.651	50001	5000
or[14,12]	1.393	0.7883	0.03157	0.4801	1.214	3.526	50001	5000
or[14,13]	1.896	0.6794	0.02013	0.9021	1.788	3.557	50001	5000
or[14,14]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000

Outcome- treatment discontinuation due to intolerable adverse effects

```
# Model - heterogeneous random effects model
# Assume correlation within study (rho = 0.5)
# Assume heterogeneous between

model {
  for (i in 1:NS) {
    s[i,1] <- 0
    delta[i, t[i,1]] <- 0
    mu[i] ~ dnorm(mmu[t[i,1]], tau_mu) # handle different baseline treatments

    for (k in 1:na[i]) {
      r[i,k] ~ dbin(p[i,t[i,k]], n[i,k])
      logit(p[i,t[i,k]]) <- mu[i] + delta[i,t[i,k]]
    }

    for (k in 2:na[i]) {
      delta[i,t[i,k]] ~ dnorm(md[i,t[i,k]], tau_d[i,t[i,k]])
      md[i,t[i,k]] <- d[t[i,k]] - d[t[i,1]] + ss[i,k]
      tau_d[i,t[i,k]] <- tau[t[i,1],t[i,k]]*2*(k-1)/k
      s[i,k] <- (delta[i, t[i,k]] - d[t[i,k]] + d[t[i,1]])
      ss[i,k] <- sum(s[i, 1:k-1])/(k-1)
    }
  }

  mmu[5] <- 0 #Treatments 1,2,3,4,6,7 are one of baseline treatments.
  mmu[8] <- 0 # other treatments should be assigned to 0.
  mmu[9] <- 0
  mmu[10] <- 0
  mmu[11] <- 0
  mmu[12] <- 0
  mmu[13] <- 0
  mmu[14] <- 0
  mmu[1] ~ dnorm(0, 0.0001)
  mmu[2] ~ dnorm(0, 0.0001)
  mmu[3] ~ dnorm(0, 0.0001)
  mmu[4] ~ dnorm(0, 0.0001)
  mmu[6] ~ dnorm(0, 0.0001)
  mmu[7] ~ dnorm(0, 0.0001)
  sd_mu ~ dunif(0.01, 2)
  tau_mu <- 1/pow(sd_mu,2)

  d[1] <- 0
  for (k in 2:NT) {
    d[k] ~ dnorm(0,0.0001)
    ed[k] <- exp(d[k]) # ed is odds ratio against placebo
  }

  for(i in 1:(NT-1)) {
    for(j in (i+1):NT) {
      v[i,j] ~ dnorm(0, 8.32)
      log(sd[i,j]) <- log(sd0) + v[i,j]
      tau[i,j] <- 1/pow(sd[i,j],2)
      var[i,j] <- pow(sd[i,j],2)
    }
  }
  sd0 ~ dunif(0.01, 2)
  var0 <- pow(sd0,2)

  # pairwise ORs
```

```

# Example: or[2,3] = odds ratio of active(2) vs. control(3)
for (k in 1:NT) {
  for (c in 1:NT) {
    lor[k,c] <- d[k] - d[c]
    log(or[k,c]) <- lor[k,c]
  }
}

# ranking
mP <- mmu[1] # "mP" means the odds of placebo.

for (k in 1:NT) { logit(T[k]) <- mP + d[k] }
for (k in 1:NT) {
  rk[k] <- NT + 1 - rank(T[,k])
  best1[k] <- equals(rk[k],1)
  best2[k] <- equals(rk[k],2)
  best12[k] <- best1[k] + best2[k]
}
}

#Init
list(
d=c(NA,0,0,0,0, 0,0,0,0,0, 0,0,0,0),
sd0=1,
mu=c(0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0,
0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0, 0,0,0),
mmu=c(0,0,0,0,NA, 0,0,NA,NA,NA, NA,NA,NA,NA), sdmu=1
)

```

#Data

```

#Data
list(NT=14, NS=68)

```

r[,1]	n[,1]	r[,2]	n[,2]	r[,3]	n[,3]	t[,1]	t[,2]	t[,3]	na[]
1	96	2	96	NA	1	1	12	NA	2
2	61	5	55	NA	1	1	8	NA	2
1	83	6	83	NA	1	1	5	NA	2
3	48	5	46	NA	1	5	14	NA	2
2	32	1	32	NA	1	1	3	NA	2
1	75	10	74	NA	1	7	14	NA	2
5	20	13	20	NA	1	5	9	NA	2
5	24	9	31	NA	1	1	5	NA	2
4	46	3	43	NA	1	1	9	NA	2
4	44	2	47	NA	1	5	7	NA	2
2	34	4	31	NA	1	1	8	NA	2
0	31	4	31	NA	1	7	12	NA	2
0	48	1	48	NA	1	1	4	NA	2
2	74	1	74	NA	1	1	10	NA	2
0	47	2	47	NA	1	1	6	NA	2
1	37	1	34	NA	1	1	7	NA	2
2	37	9	70	NA	1	1	3	NA	2

2	43	4	43	NA	1	1	3	NA	2
0	38	3	43	NA	1	1	13	NA	2
1	34	3	35	NA	1	1	13	NA	2
3	40	7	18	NA	1	1	4	NA	2
2	38	7	77	NA	1	1	7	NA	2
4	37	1	37	NA	1	3	5	NA	2
4	26	4	27	NA	1	1	8	NA	2
4	45	16	98	NA	1	1	4	NA	2
6	69	1	66	NA	1	13	14	NA	2
5	20	4	20	NA	1	5	10	NA	2
2	27	9	26	NA	1	1	4	NA	2
18	270	19	275	NA	1	5	14	NA	2
10	116	10	123	NA	1	1	3	NA	2
4	64	9	72	NA	1	1	13	NA	2
0	36	6	34	NA	1	1	2	NA	2
2	84	2	93	NA	1	1	13	NA	2
2	57	3	58	NA	1	1	2	NA	2
6	20	9	30	NA	1	1	2	NA	2
4	73	21	140	NA	1	1	2	NA	2
10	163	18	165	NA	1	1	2	NA	2
3	60	3	60	3	60	1	2	4	3
41	383	96	391	NA	1	1	2	NA	2
10	45	0	45	NA	1	2	13	NA	2
4	85	8	85	NA	1	1	4	NA	2
3	58	2	67	NA	1	3	13	NA	2
2	24	4	28	NA	1	2	8	NA	2
1	65	2	59	NA	1	1	13	NA	2
35	178	38	169	NA	1	2	8	NA	2
18	197	21	188	NA	1	1	2	NA	2
13	197	23	194	NA	1	1	8	NA	2
0	28	3	28	NA	1	1	7	NA	2
0	71	2	71	NA	1	1	12	NA	2
1	38	2	38	NA	1	1	11	NA	2
1	33	0	33	NA	1	1	9	NA	2
0	40	1	40	NA	1	1	11	NA	2
3	72	0	72	NA	1	1	7	NA	2
3	45	0	45	NA	1	1	10	NA	2
1	24	5	24	NA	1	1	9	NA	2
5	75	12	75	NA	1	1	10	NA	2
4	54	0	48	NA	1	13	14	NA	2
3	21	2	20	NA	1	8	10	NA	2

0	29	3	29	NA	1	5	8	NA	2
2	30	3	29	NA	1	1	8	NA	2
1	14	2	18	NA	1	9	14	NA	2
1	22	2	23	NA	1	1	4	NA	2
1	46	2	46	NA	1	1	11	NA	2
3	32	2	27	NA	1	5	14	NA	2
2	20	13	62	NA	1	1	4	NA	2
1	13	0	15	NA	1	2	4	NA	2
0	63	18	63	NA	1	7	8	NA	2
3	48	3	44	9	49	5	8	10	3

END

node	mean	sd	MC error	2.5%	median	97.5%	start	sample
best1[1]	0.0	0.0	1.414E-12	0.0	0.0	0.0	50001	5000
best1[2]	0.0516	0.2212	0.005231	0.0	0.0	1.0	50001	5000
best1[3]	0.0342	0.1817	0.005157	0.0	0.0	1.0	50001	5000
best1[4]	0.141	0.348	0.01226	0.0	0.0	1.0	50001	5000
best1[5]	4.0E-4	0.02	2.777E-4	0.0	0.0	0.0	50001	5000
best1[6]	0.3646	0.4813	0.02054	0.0	0.0	1.0	50001	5000
best1[7]	0.0	0.0	1.414E-12	0.0	0.0	0.0	50001	5000
best1[8]	0.0412	0.1988	0.005382	0.0	0.0	1.0	50001	5000
best1[9]	0.086	0.2804	0.008756	0.0	0.0	1.0	50001	5000
best1[10]	0.0072	0.08455	0.001747	0.0	0.0	0.0	50001	5000
best1[11]	0.0628	0.2426	0.006461	0.0	0.0	1.0	50001	5000
best1[12]	0.1846	0.388	0.01594	0.0	0.0	1.0	50001	5000
best1[13]	0.0258	0.1585	0.004967	0.0	0.0	1.0	50001	5000
best1[14]	6.0E-4	0.02449	3.425E-4	0.0	0.0	0.0	50001	5000
best2[1]	0.0	0.0	1.414E-12	0.0	0.0	0.0	50001	5000
best2[2]	0.1248	0.3305	0.0074	0.0	0.0	1.0	50001	5000
best2[3]	0.0636	0.244	0.006352	0.0	0.0	1.0	50001	5000
best2[4]	0.217	0.4122	0.009941	0.0	0.0	1.0	50001	5000
best2[5]	0.0018	0.04239	7.449E-4	0.0	0.0	0.0	50001	5000
best2[6]	0.0896	0.2856	0.006711	0.0	0.0	1.0	50001	5000
best2[7]	0.0	0.0	1.414E-12	0.0	0.0	0.0	50001	5000
best2[8]	0.1068	0.3089	0.007261	0.0	0.0	1.0	50001	5000
best2[9]	0.1178	0.3224	0.007583	0.0	0.0	1.0	50001	5000
best2[10]	0.0202	0.1407	0.0025	0.0	0.0	0.0	50001	5000
best2[11]	0.0754	0.264	0.007277	0.0	0.0	1.0	50001	5000
best2[12]	0.1272	0.3332	0.007916	0.0	0.0	1.0	50001	5000
best2[13]	0.0546	0.2272	0.006064	0.0	0.0	1.0	50001	5000
best2[14]	0.0012	0.03462	6.173E-4	0.0	0.0	0.0	50001	5000
d[2]	0.8963	0.2501	0.009435	0.4273	0.89	1.407	50001	5000
d[3]	0.6082	0.4409	0.0188	-0.2297	0.6022	1.511	50001	5000
d[4]	1.027	0.3391	0.01314	0.3538	1.028	1.68	50001	5000
d[5]	0.1538	0.3677	0.01435	-0.6101	0.1626	0.8581	50001	5000
d[6]	0.9581	1.389	0.06647	-1.836	0.9836	3.633	50001	5000
d[7]	-1.279	0.5862	0.03166	-2.576	-1.248	-0.2382	50001	5000
d[8]	0.835	0.2937	0.01077	0.2566	0.8366	1.412	50001	5000
d[9]	0.7311	0.5374	0.02237	-0.4009	0.7564	1.73	50001	5000
d[10]	0.3228	0.4516	0.01741	-0.6187	0.3393	1.142	50001	5000
d[11]	0.3754	0.7572	0.03379	-1.117	0.3614	1.872	50001	5000
d[12]	0.8049	0.774	0.0374	-0.7337	0.7941	2.314	50001	5000
d[13]	0.6026	0.3885	0.01581	-0.1822	0.6048	1.338	50001	5000
d[14]	-0.1252	0.4832	0.01961	-1.104	-0.1081	0.8008	50001	5000
or[1,2]	0.4209	0.1051	0.003949	0.2449	0.4107	0.6522	50001	5000
or[1,3]	0.5994	0.2768	0.01133	0.2221	0.5476	1.259	50001	5000
or[1,4]	0.3793	0.134	0.005079	0.1865	0.3577	0.7047	50001	5000

or[1,5]	0.9189	0.3654	0.01358	0.4247	0.8499	1.842	50001	5000
or[1,6]	1.084	3.244	0.09586	0.02646	0.374	6.29	50001	5000
or[1,7]	4.363	3.563	0.1932	1.271	3.485	13.19	50001	5000
or[1,8]	0.453	0.136	0.004874	0.2438	0.4334	0.7739	50001	5000
or[1,9]	0.5604	0.3592	0.01455	0.1777	0.4695	1.493	50001	5000
or[1,10]	0.8048	0.4076	0.01548	0.3192	0.7124	1.859	50001	5000
or[1,11]	0.9148	0.8	0.03459	0.1547	0.6974	3.076	50001	5000
or[1,12]	0.6052	0.5691	0.02506	0.09896	0.4524	2.094	50001	5000
or[1,13]	0.5906	0.2411	0.00919	0.2624	0.5463	1.2	50001	5000
or[1,14]	1.28	0.7213	0.02903	0.4519	1.114	3.018	50001	5000
or[2,1]	2.53	0.6745	0.02498	1.533	2.435	4.085	50001	5000
or[2,2]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[2,3]	1.51	0.7924	0.03196	0.4867	1.342	3.517	50001	5000
or[2,4]	0.9466	0.3925	0.01426	0.414	0.8789	1.923	50001	5000
or[2,5]	2.31	1.1	0.04071	0.9095	2.085	4.987	50001	5000
or[2,6]	2.707	7.211	0.226	0.06141	0.9095	16.66	50001	5000
or[2,7]	11.02	9.848	0.4998	2.897	8.453	34.61	50001	5000
or[2,8]	1.13	0.422	0.01554	0.5463	1.054	2.162	50001	5000
or[2,9]	1.423	1.063	0.04281	0.3974	1.158	4.178	50001	5000
or[2,10]	2.036	1.211	0.04509	0.6819	1.746	5.162	50001	5000
or[2,11]	2.333	2.279	0.09269	0.3442	1.704	8.29	50001	5000
or[2,12]	1.532	1.555	0.06726	0.2188	1.105	5.5	50001	5000
or[2,13]	1.488	0.7274	0.03013	0.5534	1.35	3.315	50001	5000
or[2,14]	3.228	2.05	0.07553	0.9813	2.722	8.458	50001	5000
or[3,1]	2.029	0.9873	0.04067	0.7948	1.826	4.53	50001	5000
or[3,2]	0.8534	0.4911	0.02012	0.2849	0.7452	2.055	50001	5000
or[3,3]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[3,4]	0.7713	0.4993	0.01918	0.23	0.6577	2.072	50001	5000
or[3,5]	1.822	1.115	0.04282	0.5741	1.552	4.89	50001	5000
or[3,6]	2.101	6.734	0.1831	0.04494	0.6867	12.55	50001	5000
or[3,7]	8.794	9.033	0.4293	1.779	6.295	30.62	50001	5000
or[3,8]	0.9127	0.5196	0.0201	0.2967	0.787	2.253	50001	5000
or[3,9]	1.124	0.932	0.03152	0.2441	0.8571	3.513	50001	5000
or[3,10]	1.625	1.191	0.04517	0.4179	1.31	4.691	50001	5000
or[3,11]	1.871	2.119	0.08808	0.2115	1.262	7.458	50001	5000
or[3,12]	1.21	1.407	0.05683	0.1496	0.8272	4.563	50001	5000
or[3,13]	1.165	0.7054	0.02566	0.3549	0.9926	2.982	50001	5000
or[3,14]	2.542	1.936	0.06991	0.6406	2.041	7.402	50001	5000
or[4,1]	2.959	1.048	0.03958	1.424	2.796	5.368	50001	5000
or[4,2]	1.228	0.4945	0.01842	0.5208	1.138	2.417	50001	5000
or[4,3]	1.773	1.08	0.04335	0.485	1.521	4.362	50001	5000
or[4,4]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[4,5]	2.701	1.453	0.0521	0.9572	2.37	6.358	50001	5000
or[4,6]	3.143	10.12	0.2869	0.0697	1.057	17.98	50001	5000
or[4,7]	12.89	12.09	0.6136	2.881	9.684	43.23	50001	5000
or[4,8]	1.33	0.5986	0.02199	0.5087	1.219	2.773	50001	5000
or[4,9]	1.648	1.235	0.04849	0.3987	1.339	4.824	50001	5000
or[4,10]	2.379	1.528	0.05204	0.7001	2.005	6.377	50001	5000
or[4,11]	2.688	2.664	0.1115	0.3824	1.911	9.943	50001	5000
or[4,12]	1.812	2.094	0.09474	0.2362	1.285	6.719	50001	5000
or[4,13]	1.742	0.9673	0.03607	0.565	1.535	4.161	50001	5000
or[4,14]	3.763	2.503	0.09802	1.048	3.126	10.24	50001	5000
or[5,1]	1.246	0.4618	0.0177	0.5433	1.177	2.359	50001	5000
or[5,2]	0.5213	0.2299	0.008892	0.2009	0.4797	1.105	50001	5000
or[5,3]	0.7281	0.4019	0.01537	0.2047	0.6445	1.742	50001	5000
or[5,4]	0.4689	0.2387	0.00845	0.1574	0.4219	1.046	50001	5000
or[5,5]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[5,6]	1.329	4.924	0.1203	0.02814	0.4363	8.032	50001	5000
or[5,7]	5.09	4.004	0.2086	1.452	4.053	14.57	50001	5000
or[5,8]	0.5502	0.2302	0.007781	0.2138	0.5144	1.115	50001	5000
or[5,9]	0.6607	0.4615	0.01614	0.1991	0.5547	1.72	50001	5000
or[5,10]	0.9541	0.5144	0.01831	0.3298	0.8341	2.3	50001	5000

or[5,11]	1.142	1.22	0.05539	0.1486	0.8099	4.217	50001	5000
or[5,12]	0.736	0.7612	0.03315	0.09378	0.5302	2.577	50001	5000
or[5,13]	0.7199	0.3685	0.01425	0.2314	0.6431	1.664	50001	5000
or[5,14]	1.453	0.718	0.0272	0.5855	1.303	3.194	50001	5000
or[6,1]	6.687	14.58	0.5624	0.1595	2.674	37.81	50001	5000
or[6,2]	2.825	6.383	0.2363	0.06025	1.1	16.3	50001	5000
or[6,3]	3.872	8.558	0.3288	0.07971	1.458	22.76	50001	5000
or[6,4]	2.558	6.361	0.233	0.05573	0.9466	14.42	50001	5000
or[6,5]	5.961	13.61	0.4665	0.125	2.296	36.1	50001	5000
or[6,6]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[6,7]	27.46	75.76	1.991	0.4817	9.548	159.9	50001	5000
or[6,8]	3.039	6.884	0.2493	0.06875	1.162	18.2	50001	5000
or[6,9]	3.781	9.956	0.3078	0.06009	1.241	24.97	50001	5000
or[6,10]	5.148	12.65	0.3837	0.1034	1.96	29.1	50001	5000
or[6,11]	5.679	15.12	0.5558	0.07721	1.88	33.31	50001	5000
or[6,12]	3.737	9.803	0.3142	0.04831	1.182	23.58	50001	5000
or[6,13]	3.985	9.449	0.3627	0.07632	1.479	24.63	50001	5000
or[6,14]	8.049	18.16	0.6391	0.1501	3.041	47.71	50001	5000
or[7,1]	0.3258	0.1848	0.008788	0.07605	0.2871	0.788	50001	5000
or[7,2]	0.1364	0.08471	0.003891	0.02902	0.1183	0.3469	50001	5000
or[7,3]	0.193	0.1465	0.006358	0.03282	0.1589	0.5631	50001	5000
or[7,4]	0.1232	0.08512	0.003776	0.02317	0.1033	0.3472	50001	5000
or[7,5]	0.2819	0.1701	0.007441	0.06881	0.2468	0.6891	50001	5000
or[7,6]	0.3295	0.917	0.02434	0.006258	0.1049	2.086	50001	5000
or[7,7]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[7,8]	0.1447	0.09074	0.004176	0.03113	0.1258	0.366	50001	5000
or[7,9]	0.1757	0.1553	0.005676	0.02997	0.1334	0.576	50001	5000
or[7,10]	0.254	0.1983	0.007711	0.04845	0.2028	0.7786	50001	5000
or[7,11]	0.3001	0.3727	0.01662	0.0277	0.1919	1.247	50001	5000
or[7,12]	0.1791	0.1829	0.007472	0.02183	0.1285	0.6609	50001	5000
or[7,13]	0.1914	0.1367	0.005824	0.03242	0.1604	0.5276	50001	5000
or[7,14]	0.3864	0.2802	0.01095	0.08454	0.3188	1.061	50001	5000
or[8,1]	2.407	0.7311	0.02678	1.293	2.308	4.103	50001	5000
or[8,2]	0.9971	0.348	0.01264	0.464	0.9488	1.834	50001	5000
or[8,3]	1.432	0.7873	0.02904	0.444	1.271	3.372	50001	5000
or[8,4]	0.9084	0.4339	0.01697	0.3611	0.8206	1.968	50001	5000
or[8,5]	2.158	0.9743	0.03447	0.8973	1.945	4.684	50001	5000
or[8,6]	2.576	9.39	0.2404	0.05526	0.8615	14.55	50001	5000
or[8,7]	10.3	9.012	0.4909	2.741	7.952	32.24	50001	5000
or[8,8]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[8,9]	1.342	0.967	0.03611	0.3583	1.1	3.829	50001	5000
or[8,10]	1.889	1.073	0.0413	0.6721	1.634	4.593	50001	5000
or[8,11]	2.194	2.142	0.08761	0.3251	1.602	7.909	50001	5000
or[8,12]	1.448	1.494	0.06267	0.2047	1.031	5.177	50001	5000
or[8,13]	1.412	0.7162	0.02844	0.5042	1.263	3.19	50001	5000
or[8,14]	3.023	1.962	0.07545	0.9764	2.558	7.846	50001	5000
or[9,1]	2.389	1.337	0.05126	0.6697	2.131	5.638	50001	5000
or[9,2]	1.005	0.6335	0.02332	0.2398	0.8635	2.52	50001	5000
or[9,3]	1.419	1.117	0.04034	0.2855	1.167	4.097	50001	5000
or[9,4]	0.9031	0.6194	0.02453	0.2074	0.7467	2.509	50001	5000
or[9,5]	2.066	1.203	0.04032	0.583	1.803	5.03	50001	5000
or[9,6]	2.583	10.63	0.2691	0.04035	0.8058	16.64	50001	5000
or[9,7]	9.884	9.62	0.4089	1.748	7.496	33.38	50001	5000
or[9,8]	1.079	0.7072	0.02503	0.2613	0.9092	2.795	50001	5000
or[9,9]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[9,10]	1.886	1.465	0.04698	0.3927	1.51	5.813	50001	5000
or[9,11]	2.17	2.512	0.1081	0.2257	1.458	8.505	50001	5000
or[9,12]	1.385	1.495	0.05898	0.1437	0.9514	5.051	50001	5000
or[9,13]	1.376	0.8986	0.03282	0.3154	1.184	3.818	50001	5000
or[9,14]	2.84	1.933	0.06731	0.6867	2.349	7.86	50001	5000
or[10,1]	1.524	0.6921	0.02479	0.5387	1.404	3.135	50001	5000
or[10,2]	0.6398	0.3306	0.01231	0.1946	0.5727	1.468	50001	5000

or[10,3]	0.908	0.5991	0.02261	0.2135	0.7637	2.402	50001	5000
or[10,4]	0.5781	0.3509	0.01119	0.1583	0.4992	1.432	50001	5000
or[10,5]	1.334	0.7006	0.02231	0.4359	1.199	3.037	50001	5000
or[10,6]	1.651	5.83	0.1717	0.03448	0.5107	9.68	50001	5000
or[10,7]	6.392	6.034	0.2966	1.285	4.932	20.74	50001	5000
or[10,8]	0.6712	0.3283	0.01224	0.2182	0.6122	1.488	50001	5000
or[10,9]	0.839	0.7273	0.02277	0.1725	0.6622	2.551	50001	5000
or[10,10]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[10,11]	1.399	1.534	0.0626	0.169	0.9511	5.604	50001	5000
or[10,12]	0.9059	0.9913	0.03709	0.1022	0.6357	3.323	50001	5000
or[10,13]	0.8891	0.5405	0.01875	0.2292	0.7699	2.227	50001	5000
or[10,14]	1.875	1.31	0.03939	0.4782	1.582	5.116	50001	5000
or[11,1]	1.94	1.742	0.06864	0.3272	1.435	6.501	50001	5000
or[11,2]	0.8255	0.8313	0.03436	0.1209	0.5869	2.922	50001	5000
or[11,3]	1.171	1.324	0.05152	0.1353	0.7928	4.744	50001	5000
or[11,4]	0.7306	0.7523	0.02825	0.1006	0.5235	2.619	50001	5000
or[11,5]	1.779	1.852	0.07447	0.2375	1.235	6.738	50001	5000
or[11,6]	2.202	12.7	0.3005	0.0302	0.5321	13.01	50001	5000
or[11,7]	8.319	10.72	0.4271	0.8039	5.213	36.16	50001	5000
or[11,8]	0.8745	0.8281	0.03216	0.1265	0.6249	3.087	50001	5000
or[11,9]	1.096	1.468	0.05678	0.1177	0.6859	4.433	50001	5000
or[11,10]	1.554	1.695	0.06203	0.1787	1.052	5.918	50001	5000
or[11,11]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[11,12]	1.099	1.426	0.05324	0.08756	0.6519	4.922	50001	5000
or[11,13]	1.164	1.396	0.05161	0.1438	0.7964	4.275	50001	5000
or[11,14]	2.464	2.823	0.1087	0.2957	1.641	9.584	50001	5000
or[12,1]	3.019	2.728	0.122	0.4801	2.212	10.12	50001	5000
or[12,2]	1.272	1.247	0.05361	0.182	0.9053	4.576	50001	5000
or[12,3]	1.771	1.842	0.07722	0.2205	1.209	6.703	50001	5000
or[12,4]	1.148	1.187	0.05144	0.1496	0.7785	4.246	50001	5000
or[12,5]	2.732	2.809	0.1241	0.3908	1.887	10.69	50001	5000
or[12,6]	3.247	12.43	0.3681	0.04243	0.8466	20.73	50001	5000
or[12,7]	12.06	20.13	0.8092	1.517	7.784	46.0	50001	5000
or[12,8]	1.365	1.367	0.05698	0.1942	0.9702	4.889	50001	5000
or[12,9]	1.664	2.343	0.08221	0.1985	1.051	7.055	50001	5000
or[12,10]	2.402	2.635	0.1056	0.3011	1.575	9.789	50001	5000
or[12,11]	2.605	3.606	0.1499	0.205	1.535	11.44	50001	5000
or[12,12]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[12,13]	1.788	1.989	0.08766	0.2447	1.196	6.787	50001	5000
or[12,14]	3.767	5.174	0.1768	0.4726	2.493	14.93	50001	5000
or[13,1]	1.969	0.7901	0.03229	0.8334	1.831	3.811	50001	5000
or[13,2]	0.827	0.4029	0.01727	0.3024	0.741	1.812	50001	5000
or[13,3]	1.146	0.6514	0.02321	0.3371	1.008	2.82	50001	5000
or[13,4]	0.7436	0.3973	0.01534	0.243	0.6513	1.771	50001	5000
or[13,5]	1.776	0.9796	0.03893	0.6011	1.555	4.323	50001	5000
or[13,6]	2.227	8.874	0.2376	0.04068	0.6789	13.16	50001	5000
or[13,7]	8.643	8.352	0.4695	1.896	6.236	30.91	50001	5000
or[13,8]	0.8868	0.4481	0.01865	0.3142	0.7922	1.986	50001	5000
or[13,9]	1.08	0.7962	0.0327	0.262	0.8449	3.176	50001	5000
or[13,10]	1.571	1.043	0.03929	0.4518	1.299	4.367	50001	5000
or[13,11]	1.831	1.998	0.08443	0.2344	1.256	6.957	50001	5000
or[13,12]	1.168	1.202	0.04993	0.1475	0.8366	4.09	50001	5000
or[13,13]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[13,14]	2.433	1.612	0.06847	0.719	2.038	6.54	50001	5000
or[14,1]	0.9897	0.5043	0.01855	0.3315	0.8975	2.227	50001	5000
or[14,2]	0.4149	0.2382	0.008061	0.1186	0.3675	1.021	50001	5000
or[14,3]	0.5776	0.3821	0.01402	0.1355	0.4899	1.565	50001	5000
or[14,4]	0.3748	0.272	0.008874	0.09782	0.3199	0.9563	50001	5000
or[14,5]	0.8267	0.3658	0.01397	0.3137	0.768	1.712	50001	5000
or[14,6]	1.029	2.929	0.08762	0.021	0.3293	6.694	50001	5000
or[14,7]	3.921	3.07	0.1389	0.945	3.138	11.86	50001	5000
or[14,8]	0.4377	0.2405	0.008284	0.1282	0.391	1.025	50001	5000

or[14,9]	0.5165	0.3895	0.01389	0.1272	0.4258	1.467	50001	5000
or[14,10]	0.768	0.5631	0.01839	0.1955	0.6322	2.094	50001	5000
or[14,11]	0.9033	1.052	0.04219	0.1048	0.6098	3.382	50001	5000
or[14,12]	0.5724	0.609	0.02446	0.06724	0.4011	2.117	50001	5000
or[14,13]	0.5625	0.3377	0.01329	0.153	0.4908	1.393	50001	5000
or[14,14]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000

```
# Model - heterogeneous random effects model
# Assume correlation within study (rho = 0.5)
# Assume heterogeneous between studies ; "sdmu" is (0.01, 5)
```

```
model {
  for (i in 1:NS) {
    s[i,1] <- 0
    delta[i, t[i,1]] <- 0
    mu[i] ~ dnorm(mmu[t[i,1]], tau_mu) # handle different baseline treatments

    for (k in 1:na[i]) {
      r[i,k] ~ dbin(p[i,t[i,k]], n[i,k])
      logit(p[i,t[i,k]]) <- mu[i] + delta[i,t[i,k]]
    }

    for (k in 2:na[i]) {
      delta[i,t[i,k]] ~ dnorm(md[i,t[i,k]], tau_d[i,t[i,k]])
      md[i,t[i,k]] <- d[t[i,k]] - d[t[i,1]] + ss[i,k]
      tau_d[i,t[i,k]] <- tau[t[i,1],t[i,k]]*2*(k-1)/k
      s[i,k] <- (delta[i, t[i,k]] - d[t[i,k]] + d[t[i,1]])
      ss[i,k] <- sum(s[i, 1:k-1])/(k-1)
    }
  }

  mmu[5] <- 0 #Treatments 1,2,3,4,6,7 are one of baseline treatments.
  mmu[8] <- 0 # other treatments should be assigned to 0.
  mmu[9] <- 0
  mmu[10] <- 0
  mmu[11] <- 0
  mmu[12] <- 0
  mmu[13] <- 0
  mmu[14] <- 0
  mmu[1] ~ dnorm(0, 0.0001)
  mmu[2] ~ dnorm(0, 0.0001)
  mmu[3] ~ dnorm(0, 0.0001)
  mmu[4] ~ dnorm(0, 0.0001)
  mmu[6] ~ dnorm(0, 0.0001)
  mmu[7] ~ dnorm(0, 0.0001)
  sdmu ~ dunif(0.01, 5)
  tau_mu <- 1/pow(sdmu,2)

  d[1] <- 0
  for (k in 2:NT) {
    d[k] ~ dnorm(0,0.0001)
    ed[k] <- exp(d[k]) # ed is odds ratio against placebo
  }

  for(i in 1:(NT-1)) {
    for(j in (i+1):NT) {
      v[i,j] ~ dnorm(0, 8.32)
      log(sd[i,j]) <- log(sd0) + v[i,j]
      tau[i,j] <- 1/pow(sd[i,j],2)
      var[i,j] <- pow(sd[i,j],2)
    }
  }
}
```


0	47	2	47	NA	1	1	6	NA	2
1	37	1	34	NA	1	1	7	NA	2
2	37	9	70	NA	1	1	3	NA	2
2	43	4	43	NA	1	1	3	NA	2
0	38	3	43	NA	1	1	13	NA	2
1	34	3	35	NA	1	1	13	NA	2
3	40	7	18	NA	1	1	4	NA	2
2	38	7	77	NA	1	1	7	NA	2
4	37	1	37	NA	1	3	5	NA	2
4	26	4	27	NA	1	1	8	NA	2
4	45	16	98	NA	1	1	4	NA	2
6	69	1	66	NA	1	13	14	NA	2
5	20	4	20	NA	1	5	10	NA	2
2	27	9	26	NA	1	1	4	NA	2
18	270	19	275	NA	1	5	14	NA	2
10	116	10	123	NA	1	1	3	NA	2
4	64	9	72	NA	1	1	13	NA	2
0	36	6	34	NA	1	1	2	NA	2
2	84	2	93	NA	1	1	13	NA	2
2	57	3	58	NA	1	1	2	NA	2
6	20	9	30	NA	1	1	2	NA	2
4	73	21	140	NA	1	1	2	NA	2
10	163	18	165	NA	1	1	2	NA	2
3	60	3	60	3	60	1	2	4	3
41	383	96	391	NA	1	1	2	NA	2
10	45	0	45	NA	1	2	13	NA	2
4	85	8	85	NA	1	1	4	NA	2
3	58	2	67	NA	1	3	13	NA	2
2	24	4	28	NA	1	2	8	NA	2
1	65	2	59	NA	1	1	13	NA	2
35	178	38	169	NA	1	2	8	NA	2
18	197	21	188	NA	1	1	2	NA	2
13	197	23	194	NA	1	1	8	NA	2
0	28	3	28	NA	1	1	7	NA	2
0	71	2	71	NA	1	1	12	NA	2
1	38	2	38	NA	1	1	11	NA	2
1	33	0	33	NA	1	1	9	NA	2
0	40	1	40	NA	1	1	11	NA	2
3	72	0	72	NA	1	1	7	NA	2
3	45	0	45	NA	1	1	10	NA	2
1	24	5	24	NA	1	1	9	NA	2

5	75	12	75	NA	1	1	10	NA	2
4	54	0	48	NA	1	13	14	NA	2
3	21	2	20	NA	1	8	10	NA	2
0	29	3	29	NA	1	5	8	NA	2
2	30	3	29	NA	1	1	8	NA	2
1	14	2	18	NA	1	9	14	NA	2
1	22	2	23	NA	1	1	4	NA	2
1	46	2	46	NA	1	1	11	NA	2
3	32	2	27	NA	1	5	14	NA	2
2	20	13	62	NA	1	1	4	NA	2
1	13	0	15	NA	1	2	4	NA	2
0	63	18	63	NA	1	7	8	NA	2
3	48	3	44	9	49	5	8	10	3

END

node	mean	sd	MC error	2.5%	median	97.5%	start	sample
best1[1]	0.0	0.0	1.414E-12	0.0	0.0	0.0	50001	5000
best1[2]	0.048	0.2138	0.005892	0.0	0.0	1.0	50001	5000
best1[3]	0.0462	0.2099	0.005419	0.0	0.0	1.0	50001	5000
best1[4]	0.1536	0.3606	0.01422	0.0	0.0	1.0	50001	5000
best1[5]	2.0E-4	0.01414	2.006E-4	0.0	0.0	0.0	50001	5000
best1[6]	0.3488	0.4766	0.02233	0.0	0.0	1.0	50001	5000
best1[7]	0.0	0.0	1.414E-12	0.0	0.0	0.0	50001	5000
best1[8]	0.0428	0.2024	0.005105	0.0	0.0	1.0	50001	5000
best1[9]	0.0978	0.297	0.009791	0.0	0.0	1.0	50001	5000
best1[10]	0.0078	0.08797	0.001628	0.0	0.0	0.0	50001	5000
best1[11]	0.0828	0.2756	0.008454	0.0	0.0	1.0	50001	5000
best1[12]	0.1458	0.3529	0.01337	0.0	0.0	1.0	50001	5000
best1[13]	0.0252	0.1567	0.003928	0.0	0.0	1.0	50001	5000
best1[14]	0.001	0.03161	4.331E-4	0.0	0.0	0.0	50001	5000
best2[1]	0.0	0.0	1.414E-12	0.0	0.0	0.0	50001	5000
best2[2]	0.1408	0.3478	0.008127	0.0	0.0	1.0	50001	5000
best2[3]	0.075	0.2634	0.006685	0.0	0.0	1.0	50001	5000
best2[4]	0.203	0.4022	0.008737	0.0	0.0	1.0	50001	5000
best2[5]	0.0038	0.06153	0.001243	0.0	0.0	0.0	50001	5000
best2[6]	0.0808	0.2725	0.006052	0.0	0.0	1.0	50001	5000
best2[7]	0.0	0.0	1.414E-12	0.0	0.0	0.0	50001	5000
best2[8]	0.108	0.3104	0.007817	0.0	0.0	1.0	50001	5000
best2[9]	0.1238	0.3294	0.007522	0.0	0.0	1.0	50001	5000
best2[10]	0.0182	0.1337	0.002555	0.0	0.0	0.0	50001	5000
best2[11]	0.084	0.2774	0.007281	0.0	0.0	1.0	50001	5000
best2[12]	0.1032	0.3042	0.006101	0.0	0.0	1.0	50001	5000
best2[13]	0.0586	0.2349	0.005443	0.0	0.0	1.0	50001	5000
best2[14]	8.0E-4	0.02827	3.884E-4	0.0	0.0	0.0	50001	5000
d[2]	0.8884	0.2447	0.008527	0.4178	0.8806	1.405	50001	5000
d[3]	0.6419	0.4462	0.0205	-0.1735	0.6181	1.559	50001	5000
d[4]	1.007	0.3599	0.01703	0.3205	1.005	1.705	50001	5000
d[5]	0.1856	0.3805	0.01226	-0.5701	0.1883	0.9327	50001	5000
d[6]	0.8932	1.431	0.06919	-1.87	0.9052	3.751	50001	5000
d[7]	-1.255	0.6031	0.03536	-2.619	-1.213	-0.1867	50001	5000
d[8]	0.8291	0.297	0.01152	0.2442	0.8268	1.423	50001	5000
d[9]	0.7334	0.5474	0.02262	-0.3835	0.7485	1.79	50001	5000
d[10]	0.3362	0.4494	0.01653	-0.5891	0.3491	1.185	50001	5000
d[11]	0.4371	0.7837	0.03416	-1.104	0.4526	1.968	50001	5000
d[12]	0.6907	0.7517	0.03829	-0.7297	0.6485	2.29	50001	5000
d[13]	0.628	0.408	0.01746	-0.1904	0.6351	1.439	50001	5000

d[14]	-0.1063	0.4735	0.01603	-1.091	-0.08985	0.7978	50001	5000
or[1,2]	0.4237	0.1035	0.003432	0.2458	0.4146	0.6585	50001	5000
or[1,3]	0.5796	0.2609	0.01139	0.2108	0.5391	1.19	50001	5000
or[1,4]	0.3904	0.1586	0.006856	0.1827	0.3661	0.7261	50001	5000
or[1,5]	0.8941	0.3665	0.01132	0.3939	0.8284	1.769	50001	5000
or[1,6]	1.162	3.709	0.08424	0.02351	0.4052	6.59	50001	5000
or[1,7]	4.286	3.394	0.1849	1.206	3.367	13.75	50001	5000
or[1,8]	0.4561	0.1398	0.005236	0.2411	0.4375	0.7836	50001	5000
or[1,9]	0.5608	0.356	0.01477	0.1671	0.4732	1.471	50001	5000
or[1,10]	0.7924	0.3933	0.01398	0.3062	0.7055	1.802	50001	5000
or[1,11]	0.912	1.343	0.05316	0.1404	0.6364	3.074	50001	5000
or[1,12]	0.6551	0.5299	0.02391	0.1014	0.5228	2.081	50001	5000
or[1,13]	0.5803	0.251	0.01071	0.2379	0.5299	1.211	50001	5000
or[1,14]	1.248	0.6642	0.02216	0.4505	1.095	2.978	50001	5000
or[2,1]	2.506	0.6435	0.02315	1.519	2.412	4.075	50001	5000
or[2,2]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[2,3]	1.454	0.7815	0.0324	0.4617	1.301	3.444	50001	5000
or[2,4]	0.9714	0.4664	0.01974	0.396	0.8869	2.027	50001	5000
or[2,5]	2.22	1.037	0.03343	0.8734	2.014	4.776	50001	5000
or[2,6]	2.924	8.867	0.2072	0.05464	0.9733	16.59	50001	5000
or[2,7]	10.63	8.71	0.4469	2.691	8.196	34.34	50001	5000
or[2,8]	1.126	0.4092	0.01374	0.5473	1.056	2.154	50001	5000
or[2,9]	1.403	0.996	0.03809	0.3775	1.141	4.104	50001	5000
or[2,10]	1.979	1.141	0.03941	0.6801	1.719	4.933	50001	5000
or[2,11]	2.322	3.883	0.1484	0.2986	1.55	8.424	50001	5000
or[2,12]	1.636	1.416	0.05834	0.2371	1.271	5.365	50001	5000
or[2,13]	1.435	0.6778	0.02578	0.5232	1.299	3.142	50001	5000
or[2,14]	3.107	1.816	0.06276	0.9814	2.662	7.901	50001	5000
or[3,1]	2.107	1.054	0.04751	0.8407	1.855	4.753	50001	5000
or[3,2]	0.8942	0.5264	0.02137	0.2916	0.7691	2.169	50001	5000
or[3,3]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[3,4]	0.817	0.5401	0.01969	0.2476	0.6791	2.186	50001	5000
or[3,5]	1.85	1.214	0.04808	0.553	1.561	4.954	50001	5000
or[3,6]	2.571	9.575	0.2364	0.04141	0.7706	15.43	50001	5000
or[3,7]	8.957	8.736	0.4769	1.691	6.465	33.01	50001	5000
or[3,8]	0.9575	0.5823	0.02467	0.2998	0.823	2.394	50001	5000
or[3,9]	1.193	1.108	0.05082	0.245	0.8856	3.944	50001	5000
or[3,10]	1.655	1.205	0.05222	0.422	1.333	4.984	50001	5000
or[3,11]	1.925	2.915	0.1106	0.2249	1.188	7.52	50001	5000
or[3,12]	1.346	1.333	0.05546	0.1723	0.9671	4.549	50001	5000
or[3,13]	1.184	0.7383	0.03288	0.3596	1.009	3.083	50001	5000
or[3,14]	2.591	1.989	0.07751	0.673	2.045	7.561	50001	5000
or[4,1]	2.92	1.081	0.05138	1.378	2.732	5.503	50001	5000
or[4,2]	1.228	0.5373	0.02447	0.4934	1.128	2.529	50001	5000
or[4,3]	1.674	0.9534	0.03791	0.4579	1.473	4.047	50001	5000
or[4,4]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[4,5]	2.597	1.466	0.05993	0.8501	2.25	6.507	50001	5000
or[4,6]	3.364	9.847	0.2425	0.0588	1.134	19.33	50001	5000
or[4,7]	12.52	11.76	0.5937	2.786	9.249	42.29	50001	5000
or[4,8]	1.33	0.6604	0.0291	0.503	1.177	3.03	50001	5000
or[4,9]	1.638	1.351	0.05941	0.3833	1.291	4.924	50001	5000
or[4,10]	2.311	1.511	0.0619	0.6503	1.912	6.247	50001	5000
or[4,11]	2.638	4.659	0.1637	0.339	1.755	9.104	50001	5000
or[4,12]	1.921	1.897	0.08342	0.2371	1.406	6.604	50001	5000
or[4,13]	1.683	0.9775	0.04343	0.5341	1.438	4.191	50001	5000
or[4,14]	3.618	2.412	0.08986	0.986	3.019	9.827	50001	5000
or[5,1]	1.293	0.5076	0.01625	0.5655	1.207	2.541	50001	5000
or[5,2]	0.5437	0.2488	0.008208	0.2096	0.4965	1.148	50001	5000
or[5,3]	0.7363	0.435	0.0186	0.2024	0.6408	1.811	50001	5000
or[5,4]	0.5009	0.2826	0.01052	0.1544	0.4446	1.177	50001	5000
or[5,5]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[5,6]	1.543	5.359	0.1199	0.02631	0.4881	9.104	50001	5000

or[5,7]	5.152	3.869	0.1929	1.374	4.09	15.81	50001	5000
or[5,8]	0.5709	0.244	0.00831	0.2345	0.5258	1.163	50001	5000
or[5,9]	0.6798	0.4572	0.01635	0.1995	0.5773	1.847	50001	5000
or[5,10]	0.9744	0.55	0.02149	0.3534	0.8456	2.304	50001	5000
or[5,11]	1.17	1.69	0.06378	0.1385	0.7688	4.46	50001	5000
or[5,12]	0.8274	0.7658	0.03029	0.109	0.6223	2.857	50001	5000
or[5,13]	0.7321	0.402	0.01582	0.2287	0.6449	1.767	50001	5000
or[5,14]	1.458	0.6572	0.0222	0.6313	1.315	3.176	50001	5000
or[6,1]	7.504	38.38	0.9885	0.1541	2.473	42.56	50001	5000
or[6,2]	3.182	15.66	0.4102	0.0603	1.028	18.31	50001	5000
or[6,3]	4.054	13.49	0.4374	0.06494	1.3	24.17	50001	5000
or[6,4]	3.074	18.56	0.4447	0.05255	0.8825	17.05	50001	5000
or[6,5]	6.506	22.45	0.7846	0.1111	2.049	38.19	50001	5000
or[6,6]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[6,7]	35.7	220.7	6.824	0.4368	8.754	205.9	50001	5000
or[6,8]	3.34	16.34	0.4179	0.06119	1.1	19.23	50001	5000
or[6,9]	4.584	28.8	0.8018	0.06188	1.144	24.2	50001	5000
or[6,10]	5.836	27.5	0.7544	0.09604	1.758	34.52	50001	5000
or[6,11]	7.185	58.91	1.288	0.06919	1.586	41.01	50001	5000
or[6,12]	4.867	18.32	0.5596	0.05313	1.19	30.0	50001	5000
or[6,13]	4.38	28.4	0.6474	0.0725	1.34	23.36	50001	5000
or[6,14]	8.697	29.33	0.9367	0.1499	2.758	51.76	50001	5000
or[7,1]	0.3372	0.1988	0.01084	0.07289	0.2972	0.8297	50001	5000
or[7,2]	0.1419	0.09073	0.004796	0.02916	0.1221	0.372	50001	5000
or[7,3]	0.1943	0.1519	0.008551	0.0304	0.1547	0.5939	50001	5000
or[7,4]	0.1303	0.09098	0.004251	0.02377	0.1081	0.3591	50001	5000
or[7,5]	0.2829	0.1787	0.008634	0.06351	0.2446	0.7281	50001	5000
or[7,6]	0.391	1.269	0.0295	0.004867	0.1143	2.294	50001	5000
or[7,7]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[7,8]	0.1497	0.09705	0.005185	0.03278	0.1283	0.3936	50001	5000
or[7,9]	0.1781	0.1458	0.006522	0.03062	0.1402	0.5419	50001	5000
or[7,10]	0.2589	0.2069	0.009831	0.04803	0.2047	0.7741	50001	5000
or[7,11]	0.2922	0.3652	0.01436	0.02506	0.1839	1.149	50001	5000
or[7,12]	0.2086	0.198	0.009478	0.01845	0.1514	0.7039	50001	5000
or[7,13]	0.1902	0.1384	0.006839	0.03512	0.1561	0.5519	50001	5000
or[7,14]	0.3862	0.2732	0.01226	0.08535	0.3224	1.097	50001	5000
or[8,1]	2.396	0.7441	0.02871	1.277	2.286	4.149	50001	5000
or[8,2]	0.9985	0.3517	0.01185	0.4662	0.9467	1.829	50001	5000
or[8,3]	1.383	0.7698	0.03313	0.4208	1.216	3.344	50001	5000
or[8,4]	0.9293	0.452	0.01896	0.3303	0.8496	1.989	50001	5000
or[8,5]	2.072	0.9183	0.0318	0.8601	1.903	4.264	50001	5000
or[8,6]	2.862	11.56	0.2297	0.05218	0.9094	16.35	50001	5000
or[8,7]	9.889	7.63	0.4251	2.546	7.798	30.6	50001	5000
or[8,8]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[8,9]	1.316	0.9113	0.03563	0.3493	1.085	3.722	50001	5000
or[8,10]	1.842	0.9964	0.03721	0.6556	1.62	4.357	50001	5000
or[8,11]	2.183	3.392	0.1356	0.2906	1.454	7.751	50001	5000
or[8,12]	1.546	1.324	0.0551	0.2174	1.191	5.178	50001	5000
or[8,13]	1.377	0.7219	0.02917	0.4723	1.22	3.327	50001	5000
or[8,14]	2.907	1.659	0.05733	0.9608	2.529	7.386	50001	5000
or[9,1]	2.41	1.383	0.05116	0.6814	2.114	5.992	50001	5000
or[9,2]	1.013	0.6203	0.0216	0.244	0.877	2.655	50001	5000
or[9,3]	1.4	1.127	0.04397	0.2552	1.13	4.085	50001	5000
or[9,4]	0.9295	0.655	0.02357	0.2034	0.7748	2.613	50001	5000
or[9,5]	2.016	1.217	0.04308	0.5418	1.733	5.032	50001	5000
or[9,6]	2.775	10.69	0.2339	0.04137	0.8762	16.42	50001	5000
or[9,7]	9.74	9.157	0.4377	1.851	7.135	32.9	50001	5000
or[9,8]	1.077	0.6784	0.02428	0.2698	0.9217	2.871	50001	5000
or[9,9]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[9,10]	1.844	1.402	0.05056	0.4228	1.497	5.535	50001	5000
or[9,11]	2.153	3.17	0.1244	0.2086	1.318	8.975	50001	5000
or[9,12]	1.545	1.607	0.06097	0.1568	1.083	5.726	50001	5000

or[9,13]	1.368	0.966	0.03683	0.2864	1.123	3.913	50001	5000
or[9,14]	2.773	1.866	0.06669	0.7011	2.323	7.591	50001	5000
or[10,1]	1.546	0.7207	0.02484	0.5549	1.418	3.271	50001	5000
or[10,2]	0.6505	0.3346	0.01126	0.2029	0.5818	1.475	50001	5000
or[10,3]	0.8877	0.5926	0.02422	0.2011	0.7503	2.381	50001	5000
or[10,4]	0.6001	0.3803	0.01313	0.161	0.523	1.538	50001	5000
or[10,5]	1.303	0.6333	0.02443	0.4376	1.183	2.83	50001	5000
or[10,6]	1.715	4.617	0.1106	0.02904	0.5706	10.54	50001	5000
or[10,7]	6.297	5.347	0.2482	1.293	4.885	20.84	50001	5000
or[10,8]	0.684	0.3436	0.0126	0.2298	0.6175	1.527	50001	5000
or[10,9]	0.8325	0.6297	0.024	0.1814	0.6683	2.39	50001	5000
or[10,10]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[10,11]	1.394	2.209	0.07881	0.1517	0.8892	5.307	50001	5000
or[10,12]	0.9935	0.94	0.04193	0.1137	0.7385	3.569	50001	5000
or[10,13]	0.8766	0.5291	0.01964	0.2223	0.7625	2.186	50001	5000
or[10,14]	1.837	1.182	0.04017	0.4724	1.563	4.747	50001	5000
or[11,1]	2.089	1.882	0.07924	0.3314	1.572	7.157	50001	5000
or[11,2]	0.8902	0.8863	0.03657	0.119	0.6453	3.352	50001	5000
or[11,3]	1.195	1.204	0.04714	0.133	0.842	4.462	50001	5000
or[11,4]	0.8042	0.8367	0.03145	0.1099	0.57	2.956	50001	5000
or[11,5]	1.864	1.943	0.07894	0.2244	1.301	7.254	50001	5000
or[11,6]	2.303	6.956	0.1805	0.02448	0.6307	14.52	50001	5000
or[11,7]	8.994	13.37	0.5397	0.871	5.444	39.92	50001	5000
or[11,8]	0.9484	0.9645	0.04113	0.129	0.6879	3.46	50001	5000
or[11,9]	1.161	1.394	0.05339	0.1117	0.7589	4.817	50001	5000
or[11,10]	1.647	1.882	0.07385	0.1888	1.125	6.638	50001	5000
or[11,11]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[11,12]	1.34	1.796	0.06115	0.07952	0.8094	6.135	50001	5000
or[11,13]	1.209	1.281	0.05074	0.1422	0.8254	4.524	50001	5000
or[11,14]	2.609	3.286	0.1205	0.2914	1.746	10.43	50001	5000
or[12,1]	2.713	2.801	0.1351	0.482	1.913	9.874	50001	5000
or[12,2]	1.15	1.316	0.0608	0.1871	0.7867	4.219	50001	5000
or[12,3]	1.526	1.743	0.08473	0.2206	1.034	5.814	50001	5000
or[12,4]	1.07	1.334	0.06243	0.1523	0.7112	4.23	50001	5000
or[12,5]	2.363	2.669	0.115	0.3501	1.609	9.172	50001	5000
or[12,6]	3.296	17.54	0.4395	0.0335	0.8405	18.89	50001	5000
or[12,7]	11.34	16.71	0.779	1.424	6.608	54.21	50001	5000
or[12,8]	1.225	1.386	0.05917	0.1932	0.8399	4.613	50001	5000
or[12,9]	1.529	2.363	0.09219	0.1758	0.9239	6.383	50001	5000
or[12,10]	2.125	2.574	0.1034	0.2815	1.354	8.815	50001	5000
or[12,11]	2.489	5.524	0.1886	0.1633	1.236	12.61	50001	5000
or[12,12]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[12,13]	1.568	1.89	0.09652	0.2179	1.04	6.292	50001	5000
or[12,14]	3.292	4.58	0.1919	0.4555	2.142	13.35	50001	5000
or[13,1]	2.037	0.8763	0.03607	0.8266	1.887	4.216	50001	5000
or[13,2]	0.8543	0.417	0.01586	0.3188	0.7698	1.92	50001	5000
or[13,3]	1.144	0.6579	0.0282	0.3245	0.9923	2.788	50001	5000
or[13,4]	0.7862	0.4515	0.01745	0.2389	0.6954	1.878	50001	5000
or[13,5]	1.781	1.033	0.03877	0.566	1.551	4.382	50001	5000
or[13,6]	2.323	6.847	0.1606	0.04297	0.7478	13.82	50001	5000
or[13,7]	8.419	7.119	0.3595	1.812	6.407	28.47	50001	5000
or[13,8]	0.9197	0.4795	0.01828	0.3015	0.8195	2.118	50001	5000
or[13,9]	1.124	0.9055	0.03878	0.2557	0.8902	3.494	50001	5000
or[13,10]	1.589	1.061	0.03495	0.4587	1.312	4.5	50001	5000
or[13,11]	1.849	3.026	0.1235	0.2216	1.214	7.113	50001	5000
or[13,12]	1.319	1.248	0.05894	0.1594	0.962	4.598	50001	5000
or[13,13]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000
or[13,14]	2.435	1.558	0.06049	0.7364	2.06	6.715	50001	5000
or[14,1]	1.004	0.4964	0.01563	0.3358	0.9141	2.221	50001	5000
or[14,2]	0.4223	0.2284	0.007802	0.127	0.3757	1.02	50001	5000
or[14,3]	0.569	0.3634	0.01498	0.1326	0.4891	1.487	50001	5000
or[14,4]	0.3876	0.2434	0.008838	0.1019	0.3312	1.015	50001	5000

or[14,5]	0.8089	0.3324	0.01133	0.3149	0.7606	1.589	50001	5000
or[14,6]	1.165	4.4	0.1012	0.01933	0.3631	6.706	50001	5000
or[14,7]	3.878	2.904	0.1498	0.9141	3.102	11.73	50001	5000
or[14,8]	0.4451	0.2371	0.007788	0.1358	0.3954	1.042	50001	5000
or[14,9]	0.5176	0.3545	0.0131	0.1322	0.4306	1.428	50001	5000
or[14,10]	0.7604	0.4965	0.01762	0.2127	0.6404	2.128	50001	5000
or[14,11]	0.8778	1.068	0.03709	0.09612	0.5728	3.446	50001	5000
or[14,12]	0.6302	0.5992	0.02359	0.07555	0.4671	2.198	50001	5000
or[14,13]	0.5553	0.322	0.01296	0.1495	0.4855	1.359	50001	5000
or[14,14]	1.0	0.0	1.414E-12	1.0	1.0	1.0	50001	5000

Appendix C. Excluded Studies

Not Eligible Exposure

1. Pharmacological prevention of migraine: to be considered case by case. *Prescrire International* 2006 Oct; 15(85):184-8; PMID: 17128528.
2. Topiramate: new indication. Migraine prevention: best avoided. *Prescrire International* 2006 Aug; 15(84):132-3; PMID: 16989025.
3. Molecule of the month. Lasmiditan hydrochloride. *Drug News Perspect* 2010 Sep; 23(7):455; PMID: 20862397.
4. Agnoli A, Bussone G, Manzoni GC, et al. Dihydroergokryptine (DEK) versus flunarizine (FLU) in common migraine. A multicentre double-blind study. *Cephalalgia*; 1989: 373-5.
5. Agro F, Liguori A, Petti FB, et al. Acupuncture versus pharmacological therapy in the treatment of migraine without aura: Clinical results. *Pain Clinic*; 2005: 245-7.
6. Ahmed HE, White PF, Craig WF, et al. Use of percutaneous electrical nerve stimulation (PENS) in the short-term management of headache. *Headache* 2000 Apr; 40(4):311-5; PMID: 10759936.
7. Ahonen K, Hamalainen ML, Eerola M, et al. A randomized trial of rizatriptan in migraine attacks in children. *Neurology* 2006 Oct 10; 67(7):1135-40; PMID: 16943370.
8. Alecrim-Andrade J, Maciel-Junior JA, Carne X, et al. Acupuncture in migraine prevention: a randomized sham controlled study with 6-months posttreatment follow-up. *Clin J Pain* 2008 Feb; 24(2):98-105; PMID: 18209514.
9. Alecrim-Andrade J, Maciel-Junior JA, Cladellas XC, et al. Acupuncture in migraine prophylaxis: a randomized sham-controlled trial. *Cephalalgia* 2006 May; 26(5):520-9; PMID: 16674760.
10. Allais G, D'Andrea G, Moschiano F, et al. A randomized, prospective, cross-over, double blind, placebo-controlled multicentre study to assess the efficacy and tolerability of almotriptan 12.5 mg in menstrually-related migraine. *Cephalalgia*; 2009: 13.
11. Allais G, De Lorenzo C, Quirico PE, et al. Non-pharmacological approaches to chronic headaches: transcutaneous electrical nerve stimulation, lasertherapy and acupuncture in transformed migraine treatment. *Neurol Sci* 2003 May; 24 Suppl 2:S138-42; PMID: 12811613.
12. Allen RA, Mills GK. The effects of unilateral plethysmographic feedback of temporal artery activity during migraine head pain. *J-Psychosom-Res*; 1982: 133-40.
13. Almaraz AC, Dilli E, Dodick DW. The effect of prophylactic medications on TMS for migraine aura. *Headache* 2010 Nov; 50(10):1630-3; PMID: 21198566.
14. Alpay K, Ertas M, Orhan EK, et al. Diet restriction in migraine, based on IgG against foods: a clinical double-blind, randomised, cross-over trial. *Cephalalgia : an international journal of headache*; 2010: 829-37.
15. Alstadhaug KB, Odeh F, Salvesen R, et al. Prophylaxis of migraine with melatonin: a randomized controlled trial. *Neurology* 2010 Oct 26; 75(17):1527-32; PMID: 20975054.
16. Altieri M, Di Giambattista R, Di Clemente L, et al. Combined pharmacological and short-term psychodynamic psychotherapy for probable medication overuse headache: a pilot study. *Cephalalgia* 2009 Mar; 29(3):293-9; PMID: 19220310.
17. Alzoubi KH, Mhaidat N, Azzam SA, et al. Prevalence of migraine and tension-type headache among adults in Jordan. *Journal of Headache & Pain* 2009 Aug; 10(4):265-70; PMID: 19387792.
18. Amery WK, Waelkens J. Prevention of the last chance: An alternative pharmacologic treatment of migraine. *Headache*; 1983: 37-8.
19. Andersson PG. Flunarizine and propranolol in the treatment of migraine. *Journal Of Neurology* Vol 232; 1985: 220.
20. Andrasik F, Blanchard EB, Neff DF, et al. Biofeedback and relaxation training for chronic headache: a controlled comparison of booster treatments and regular contacts for long-term maintenance. *J Consult Clin Psychol* 1984 Aug; 52(4):609-15; PMID: 6381563.

21. Archambault ME. Do triptans increase the risk of thromboembolic stroke? JAAPA 2006 Jul; 19(7):57-8; PMID: 16869155.
22. Arora A, Arora S. Spontaneous splenic infarction associated with sumatriptan use. Journal of Headache & Pain 2006 Sep; 7(4):214-6; PMID: 16767537.
23. Arruda MA, Guidetti V, Galli F, et al. Primary headaches in childhood--a population-based study. Cephalalgia 2010 Sep; 30(9):1056-64; PMID: 20713556.
24. Arthur GP, Hornabrook RW. The treatment of migraine with BC 105 (pizotifen): a double blind trial. The New Zealand medical journal; 1971: 5-9.
25. Ashkenazi A, Mushtaq A, Yang I, et al. Ictal and interictal phonophobia in migraine-a quantitative controlled study. Cephalalgia : an international journal of headache; 2009: 1042-8.
26. Aurora SK, Barrodale PM, McDonald SA, et al. Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Headache 2009 Jul; 49(7):1001-4; PMID: 19438735.
27. Aurora SK, Barrodale PM, Vermaas AR, et al. Topiramate modulates excitability of the occipital cortex when measured by transcranial magnetic stimulation. Cephalalgia 2010 Jun; 30(6):648-54; PMID: 19732073.
28. Ausband SC, Goodman PE. An unusual case of clarithromycin associated ergotism. Journal of Emergency Medicine 2001 Nov; 21(4):411-3; PMID: 11728770.
29. Baars MAE, van Boxtel MPJ, Jolles J. Migraine does not affect cognitive decline: results from the Maastricht aging study. Headache 2010 Feb; 50(2):176-84; PMID: 19925622.
30. Backer M, Grossman P, Schneider J, et al. Acupuncture in migraine: investigation of autonomic effects. Clin J Pain 2008 Feb; 24(2):106-15; PMID: 18209515.
31. Bademosi O, Osuntokun BO. Pizotifen in the management of migraine. Practitioner 1978 Feb; 220(1316):325-7; PMID: 345259.
32. Bakker MK, Kerstjens-Frederikse WS, Buys CH, et al. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010 Feb; 88(2):94-100; PMID: 19937603.
33. Barbanti P, Fabbrini G, Aurilia C, et al. A case-control study on excessive daytime sleepiness in episodic migraine. Cephalalgia 2007 Oct; 27(10):1115-9; PMID: 17725651.
34. Barbanti P, Fabbrini G, Pesare M, et al. Unilateral cranial autonomic symptoms in migraine. Cephalalgia 2002 May; 22(4):256-9; PMID: 12100086.
35. Barry J, von Baeyer CL. Brief cognitive-behavioral group treatment for children's headache. Clin J Pain 1997 Sep; 13(3):215-20; PMID: 9303253.
36. Baser O, Palmer L, Stephenson J. The estimation power of alternative comorbidity indices. Value in Health 2008 Sep-Oct; 11(5):946-55; PMID: 18489502.
37. Bassi S, Amersey R, Henderson R, et al. Thyrotoxicosis, sumatriptan and coronary artery spasm. Journal of the Royal Society of Medicine 2004 Jun; 97(6):285-7; PMID: 15173333.
38. Baykal B, Alpay KEM, Orhan EK. Diet restriction in migraine based on IgG antibodies against food antigens: a clinical double-blind, randomized crossover trial. Neurology; 2009: A182, Abstract no: P04.070.
39. Becker C, Brobert GP, Almqvist PM, et al. The risk of newly diagnosed asthma in migraineurs with or without previous triptan prescriptions. Headache 2008 Apr; 48(4):606-10; PMID: 18194300.
40. Becker WJ. Zolmitriptan versus sumatriptan comparison trial. Headache 2001 Mar; 41(3):321-3; PMID: 11264695.
41. Beckmann-Reinhold A, Schauer U, Wellensiek B, et al. A homeopathic complex remedy proves efficacious in migraine therapy: a randomized, double blind, parallel group clinical trial. Headache World; 2000 Sep 3-7; London, England; 2000.
42. Behan PO. Pizotifen in the treatment of severe recurrent headache single and divided dose therapy compared. The British journal of clinical practice; 1982: 13-7.
43. Behan PO. Prophylactic treatment for migraine - a comparison of pizotifen and clonidine. Cephalalgia; 1985: 524-5.
44. Behan PO, Connelly K. Prophylaxis of migraine: a comparison between naproxen sodium and pizotifen. Headache; 1986: 237-9.

45. Bellavance AJ, Meloche JP. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. *Headache* 1990 Nov; 30(11):710-5; PMID: 2074163.
46. Beorchia S, Loisy C. Randomized, double-blind, placebo-controlled study of vasobral in the treatment of migraine. <ORIGINAL> ETUDE RANDOMISEE, EN DOUBLE AVEUGLE CONTRE PLACEBO, DU VASOBAL (R) DANS LE TRAITEMENT DE LA MIGRAINE. *J Med Lyon*; 1989: 71-7.
47. Beorchia S, Loisy C. Dihydrortgocryptine plus caffeine in treatment of migraine: A randomized double-blind trial against placebo. <ORIGINAL> ETUDE RANDOMISEE EN DOUBLE AVEUGLE CONTRE PLACEBO, DU VASOBAL (R) DANS LE TRAITEMENT DE LA MIGRAINE. *Gaz Med*; 1989: 69-75.
48. Bermejo PE, Dorado R, Gomez-Arguelles JM. Variation in almotriptan effectiveness according to different prophylactic treatments. *Headache* 2009 Oct; 49(9):1277-82; PMID: 19788470.
49. Bernhardt M. Zentramine in migraine-like states. *Die Medizinische Welt*; 1984: 772-3.
50. Besser RE, Stern CM. Raynaud phenomena and migraine in two children: inclusion within a family of related disorders. *Acta Paediatrica* 2005 Dec; 94(12):1860-2; PMID: 16421056.
51. Beyer D. Clinical experiences with a new migraine-preparation HM 72 (Migraeflux). *Munchener Medizinische Wochenschrift*; 1975: 733-4.
52. Bigal ME, Golden W, Buse D, et al. Triptan use as a function of cardiovascular risk. A population-based study. *Headache* 2010 Feb; 50(2):256-63; PMID: 20039953.
53. Bigal ME, Rapoport AM, Lipton RB, et al. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. *Headache* 2003 Apr; 43(4):336-42; PMID: 12656704.
54. Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes. *Cephalalgia* 2004 Jun; 24(6):483-90; PMID: 15154858.
55. Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. *Neurology* 2008 Aug 19; 71(8):559-66; PMID: 18711108.
56. Bild R, Adams HE. Modification of migraine headaches by cephalic blood volume pulse and EMG biofeedback. *J Consult Clin Psychol* 1980 Feb; 48(1):51-7; PMID: 7365042.
57. Bille B, Ludvigsson J, Sanner G. Prophylaxis of migraine in children. *Headache*; 1977: 61-3.
58. Black KJ, Sheline YI. Paroxetine as migraine prophylaxis. *Journal of Clinical Psychiatry* 1995 Jul; 56(7):330-1; PMID: 7615489.
59. Black L, Jones M, Boswell D, et al. Naratriptan compared with nonspecific/nonselective therapies reduces migraine-associated lost workplace productivity. *European Journal of Neurology* (Abstracts of the 4th Congress of the European Federation of Neurological Sciences, September 7-11, Lisbon, Portugal 1999); 1999: 21.
60. Blanchard EB, Andrasik F, Neff DF, et al. Biofeedback and relaxation training with three kinds of headache: treatment effects and their prediction. *J Consult Clin Psychol* 1982 Aug; 50(4):562-75; PMID: 6749918.
61. Blanchard EB, Theobald DE, Williamson DA, et al. Temperature biofeedback in the treatment of migraine headaches: a controlled evaluation. *Arch Gen Psychiatry* 1978 May; 35(5):581-8; PMID: 365125.
62. Boccia G, Del Giudice E, Crisanti AF, et al. Functional gastrointestinal disorders in migrainous children: efficacy of flunarizine. *Cephalalgia* 2006 Oct; 26(10):1214-9; PMID: 16961789.
63. Boehnke C, Reuter U, Flach U, et al. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. *European Journal of Neurology* 2004 Jul; 11(7):475-7; PMID: 15257686.
64. Bonetto N, Santelli L, Battistin L, et al. Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and hypericum. *Cephalalgia* 2007 Dec; 27(12):1421-3; PMID: 17868285.
65. Bono G, Criscuoli M, Martignoni E, et al. Serotonin precursors in migraine prophylaxis. *Adv Neurol*; 1982: 357-63.

66. Bonuso S, Di Stasio E, Marano E, et al. Long-term outcome of migraine therapy: predictive value of the frontotemporal nitroglycerin test. *Neurology* 1998 Nov; 51(5):1475-8; PMID: 9818888.
67. Bonuso S, Di Stasio E, Marano E, et al. Sublingual flunarizine: a new effective management of the migraine attack. A comparison versus ergotamine. *Headache* 1986 May; 26(5):227-30; PMID: 3087910.
68. Bonuso S, Marano E, Di Stasio E, et al. The frontotemporal region plays a role in the genesis of migraine without aura. *Headache* 1995 Mar; 35(3):154-7; PMID: 7721576.
69. Borgesen SE, Nielsen JL, Moller CE. Letter: Propranolol in migraine. *Lancet*; 1974: 58.
70. Borhani Haghighi A, Motazedian S, Rezaii R, et al. Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: a randomised, double-blind, placebo-controlled, crossed-over study. *Int J Clin Pract* 2010 Mar; 64(4):451-6; PMID: 20456191.
71. Bottini F, Celle ME, Calevo MG, et al. Metabolic and genetic risk factors for migraine in children. *Cephalalgia : an international journal of headache*; 2006: 731-7.
72. Bou J, Gras J, Cortijo J, et al. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. *Cephalalgia* 2001 Oct; 21(8):804-12; PMID: 11737005.
73. Brandes JL, Cady RK, Freitag FG, et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. *Headache* 2009 Nov-Dec; 49(10):1435-44; PMID: 19849720.
74. Brandes JL, Poole A, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. *Cephalalgia* 2009 Nov; 29(11):1133-48; PMID: 19811503.
75. Brandes JL, Smith T, Diamond M, et al. Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine. *Headache* 2007 Jun; 47(6):886-94; PMID: 17578540.
76. Brescia-Morra V, De Marinis T, Gentile S, et al. Flunarizine versus indobuphene: Open study in the prophylaxis of migraine. *Rassegna Internazionale di Clinica e Terapia*; 1990: 260-4.
77. Briars GL, Travis SE, Anand B, et al. Weight gain with pizotifen therapy. *Archives of Disease in Childhood* 2008 Jul; 93(7):590-3; PMID: 18381348.
78. Brighina F, Piazza A, Vitello G, et al. rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study. *J Neurol Sci* 2004 Dec 15; 227(1):67-71; PMID: 15546593.
79. Brigo B, Serpelloni G. Homeopathic treatment of migraines: a randomized double-blind controlled study of sixty cases (homeopathic remedy versus placebo). *Berlin Journal of Research in Homeopathy*; 1991: 1(2)98-106.
80. Brigo B, Serpelloni G, Bosco O. Homeopathic treatment of migraine: a sixty case; double-blind; controlled study (homeopathic remedy vs placebo). (In French). *Proceedings of the 42nd Congress of the Liga Medicorum Homoeopathica Internationalis (Arlington) (Unpublished)*; 1987: 318-29.
81. Brun J, Claustrat B, Saddier P, et al. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. *Cephalalgia* 1995 Apr; 15(2):136-9; discussion 79; PMID: 7641249.
82. Bryson J, Buse DC, Lipton RB. Assessment and treatment of the burden of migraine: a case series. *Neurologist* 2010 Jul; 16(4):254-61; PMID: 20592569.
83. Burns C. Migraine in a rural practice (1958-1963). A five-year study of a controlled clinical trial. *J Coll Gen Pract*; 1965: 230-8.
84. Bussone G, Baldini S, D'Andrea G, et al. Nimodipine versus flunarizine in common migraine: a controlled pilot trial. *Headache* Vol 27; 1987: 76-9.
85. Bussone G, Manzoni GC, Cortelli P, et al. Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks. *Neurol Sci* 2000 Oct; 21(5):272-8; PMID: 11286039.
86. Cabanas A, Rodriguez R, Rosado F, et al. Subcutaneous sumatriptan comparative study versus placebo in migraine attacks. *Journal of The Neurological Sciences*; 1997: S303.
87. Cabarrocas X, Esbri R, Peris F, et al. Long-term efficacy and safety of oral almotriptan: interim analysis of a 1-year open study. *Headache* 2001 Jan; 41(1):57-62; PMID: 11168604.

88. Cady R. Looking forward: the expanding utility of sumatriptan and naratriptan. *Cephalalgia* 2001; 21 Suppl 1:35-8; PMID: 11678821.
89. Cady R, Elkind A, Goldstein J, et al. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. *Curr Med Res Opin* 2004 Sep; 20(9):1465-72; PMID: 15383196.
90. Cady RC, Ryan R, Jhingran P, et al. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. *Neurology*; 1997: A121.
91. Cady RK, Farmer KU, Altura BT, et al. The effect of magnesium on the responsiveness of migraine sufferers to a 5-HT₁ agonist [abstract]. *Neurology*; 1998: A340.
92. Cady RK, Mathew N, Diener HC, et al. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. *Headache* 2009 Feb; 49(2):216-26; PMID: 19222595.
93. Calhoun A, Ford S. Elimination of menstrual-related migraine beneficially impacts chronification and medication overuse. *Headache* 2008 Sep; 48(8):1186-93; PMID: 18819179.
94. Cano A, Sanz P, Palomeras E, et al. Low doses of flunarizine in the prophylaxis treatment of migraine. *Neurologia*; 1998: 480.
95. Capildeo R, Clifford RF. Single-dose pizotifen, 1.5 mg nocte: a new approach in the prophylaxis of migraine. *Headache* Vol 22; 1982: 272-5.
96. Capildeo R, Rose FC. Single-dose pizotifen, 1.5 mg nocte: a new approach in the prophylaxis of migraine. *Headache*; 1982: 272-5.
97. Carasso RL, Yehuda S. The prevention and treatment of migraine with an analgesic combination. *Br J Clin Pract* 1984 Jan; 38(1):25-7; PMID: 6367797.
98. Caro G, Getsios D, Caro JJ, et al. Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis. *Cephalalgia* 2001 Feb; 21(1):12-9; PMID: 11298658.
99. Caro JJ, Getsios D, Raggio G, et al. Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis. *Headache* 2001 May; 41(5):456-64; PMID: 11380643.
100. Carroll JD, Maclay WP. Pizotifen (BC 105) in migraine prophylaxis. *Curr Med Res Opin* 1975; 3(2):68-71; PMID: 1095308.
101. Castellana M, Carini C, Caprici G, et al. Calcium entry blockers in the treatment of primary headachd in childhood: our experiecne with flunarizine and nimodipine. Paper presented at, 1989; *Headache in children and adolescents. Proceedings of the First International Symposium on Headache in Children and Adolescents*; 1988 May 19-20; Pavia Italy.
102. Ceccherelli F, Ambrosio F, Avila M, et al. Acupuncture vs. placebo in the common migraine: a double blind study [abstract]. *Cephalalgia*; 1987: 499-500.
103. Cerbo R, Casacchia M, Formisano R, et al. Double-blind clinical trial of flunarizine against pizotifen in a single evening dose in patients with migraine. *Rivista di Neurologia*; 1985: 139-46.
104. Cerbo R, Casacchia M, Formisano R, et al. Flunarizine-pizotifen single-dose double-blind cross-over trial in migraine prophylaxis. *Cephalalgia* 1986 Mar; 6(1):15-8; PMID: 3516406.
105. Chan KY, Baun M, de Vries R, et al. Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. *Cephalalgia* 2011 Jan; 31(2):181-9; PMID: 20974589.
106. Chappell AS, Bay JM, Botzum GD. Sergolexole maleate and placebo for migraine prophylaxis. *Cephalalgia*; 1991: 170-1.
107. Chappell AS, Bay JM, Cohen ML. A multicentre trial of sergolexole maleate, a 5HT₂ receptor antagonist, and placebo for migraine prophylaxis. *J Drug Dev*; 1992: 75-81.
108. Chayasirisobhon S. Use of a pine bark extract and antioxidant vitamin combination product as therapy for migraine in patients refractory to pharmacologic medication. *Headache* 2006 May; 46(5):788-93; PMID: 16643582.
109. Christensen MF. Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine. *Archives of disease in childhood*; 1995: 183.

110. Christoph-Diener H, Ferrari M, Mansbach H, et al. Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database. *Neurology* 2004 Aug 10; 63(3):520-4; PMID: 15304585.
111. Ciancarelli I, Tozzi-Ciancarelli MG, Di Massimo C, et al. Flunarizine effects on oxidative stress in migraine patients. *Cephalalgia* 2004 Jul; 24(7):528-32; PMID: 15196294.
112. Cianchetti C, Serici MC, Pisano T, et al. Compression of superficial temporal arteries by a handmade device: a simple way to block or attenuate migraine attacks in children and adolescents. *Journal of Child Neurology* 2010 Jan; 25(1):67-70; PMID: 19525492.
113. Claghorn JL, Mathew RJ, Largent JW, et al. Directional effects of skin temperature self-regulation on regional cerebral blood flow in normal subjects and migraine patients. *Am J Psychiatry* 1981 Sep; 138(9):1182-7; PMID: 7270721.
114. Clayton AH, West SG, McGarvey E, et al. Biochemical evidence of the placebo effect during the treatment of menstrual migraines. *Journal of Clinical Psychopharmacology* 2005 Aug; 25(4):400-1; PMID: 16012294.
115. Cockey CD. Relief for menstruation-related migraines. *AWHONN Lifelines* 2002 Dec; 6(6):497; PMID: 12593251.
116. Colman SS, Brod MI, Krishnamurthy A, et al. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. *Clin Ther* 2001 Jan; 23(1):127-45; PMID: 11219473.
117. Colman SS, Rothermich BA, Rowland CR, et al. Application of the extended Q-Twist methodology among migraine sufferers: results from a clinical trial [abstract]. *Quality of Life Research*; 2000: 258.
118. Colucci D'Amato C, Pizza V, Marmolo T, et al. Paroxetine versus flunarizine in the preventive treatment of migraine. *Headache Quarterly* 1998; 9(3):266-7; PMID.
119. Combremont PC, Marcus EM. Intracranial hemorrhages associated with sumatriptan. *Neurology* 2001 May 8; 56(9):1243-4; PMID: 11342701.
120. Connor HE. Building on the sumatriptan experience: the development of naratriptan. *Cephalalgia* 2001; 21 Suppl 1:32-4; PMID: 11678820.
121. Cooke LJ, Becker WJ. Migraine prevalence, treatment and impact: the Canadian women and migraine study. *Can J Neurol Sci* 2010 Sep; 37(5):580-7; PMID: 21059502.
122. Cooper PE. The optimal use of triptans--sooner is better. *Canadian Journal of Neurological Sciences* 2006 Feb; 33(1):3-4; PMID: 16583715.
123. Coulam CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives? *Epilepsia* 1979 Oct; 20(5):519-25; PMID: 477641.
124. Cruz A, Buhling M, Seibel K. Double-blind study on migraine therapy with etilefrine pivalate. <ORIGINAL> DOPPELBLINDSTUDIE ZUR MIGRANETHERAPIE MIT ETILEFRINPIVALAT. *Arzneim-Forsch/Drug Res*; 1985: 1086-9.
125. Cunnington M, Ephross S, Churchill P. The safety of sumatriptan and naratriptan in pregnancy: what have we learned? *Headache* 2009 Nov-Dec; 49(10):1414-22; PMID: 19804390.
126. Cupini LM, Santorelli FM, Iani C, et al. Cyclic vomiting syndrome, migraine, and epilepsy: a common underlying disorder? *Headache* 2003 Apr; 43(4):407-9; PMID: 12656714.
127. Cupini LM, Troisi E, Placidi F, et al. Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study. *Cephalalgia* 1999 Jan; 19(1):27-31; PMID: 10099857.
128. Cutler NR, Salazar DE, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of avitriptan in patients with migraine after oral dosing. *Headache* 1998 Jun; 38(6):446-52; PMID: 9664749.
129. Cuvellier J-C, Donnet A, Gu, et al. Treatment of primary headache in children: a multicenter hospital-based study in France. *Journal of Headache & Pain* 2009 Dec; 10(6):447-53; PMID: 19771388.
130. Dahlof C. How to assess patient preference of migraine treatments. *Cephalalgia* 1999 Jul; 19 Suppl 24:2-5; discussion -6; PMID: 10526675.

131. Dalla Volta G, Griffini S, Pezzini A. Influence of sumatriptan on the autonomic system during migraine attacks. *Journal of Headache & Pain* 2006 Apr; 7(2):116-7; PMID: 16688414.
132. Dalsgaard-Nielsen T. Therapeutic results of prophylactic treatment for "classic" migraine with antaminic substance (B P 400 Sandoz). *Headache*; 1968: 6-15.
133. D'Andrea G, Cananzi AR, Grigoletto F, et al. The effect of dopamine receptor agonists on prolactin secretion in childhood migraine. *Headache*; 1988: 354-9.
134. D'Arcy Y. Going the distance. New pain treatment provide longer stronger relief. *Advance for Nurse Practitioners* 2007 Jun; 15(6):32-6; quiz 7; PMID: 19999007.
135. Dash S, Bogdanova O, Xavier A, et al. Cerebral vasospasm from sumatriptan. *Neurology* 2004 Dec 14; 63(11):2128; PMID: 15596760.
136. de Almeida R, x00E, o F, et al. Migraine with persistent visual aura: response to furosemide. *Clinics (Sao Paulo, Brazil)* 2009; 64(4):375-6; PMID: 19488599.
137. De Benedittis G, Massei R. Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytryptophan vs. placebo. *Journal of neurosurgical sciences*; 1985: 239-48.
138. de Weerd CJ, Bootsma HPR, Hendriks H. Herbal medicines in migraine prevention. Randomized double-blind placebo-controlled crossover trial of a feverfew preparation. *Phytomedicine*; 1996: 225-30.
139. Del Bene E, Poggioni M, Michelacci S. Lisuride as a migraine prophylactic in children: an open clinical trial. *Int J Clin Pharmacol Res* 1983; 3(2):137-41; PMID: 6679514.
140. Deleu D, Khan MA, Humaidan H, et al. Prevalence and clinical characteristics of headache in medical students in oman. *Headache* 2001 Sep; 41(8):798-804; PMID: 11576205.
141. Demarquay G, Lothe A, Royet JP, et al. Brainstem changes in 5-HT1A receptor availability during migraine attack. *Cephalalgia* 2011 Jan; 31(1):84-94; PMID: 21036859.
142. Denaro A, Martucci N, Ruggieri S, et al. Headache and noradrenergic involvement: the effects of alpha 2-stimulants and alpha 2-antagonists. *Acta Psychiatr Scand Suppl* 1985; 320:20-5; PMID: 3901672.
143. Denuelle M, Fabre N, Payoux P, et al. Hypothalamic activation in spontaneous migraine attacks. *Headache* 2007 Nov-Dec; 47(10):1418-26; PMID: 18052951.
144. Devic M. Comparative trial of 3 migraine remedies. *Lyon Medical*; 1985: 245-50.
145. Di Rosa G, Attin, x00E, et al. Efficacy of folic acid in children with migraine, hyperhomocysteinemia and MTHFR polymorphisms. *Headache* 2007 Oct; 47(9):1342-4; PMID: 17927652.
146. Diamond ML, Cady RK, Mao L, et al. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines. *Headache* 2008 Feb; 48(2):248-58; PMID: 18234046.
147. Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. *Headache* 2007 Mar; 47(3):355-63; PMID: 17371352.
148. Diamond S, Freitag FG, Diamond ML. Flunarizine in migraine therapy. *Clin Pharmacol Ther*; 1990: 165.
149. Diener H. Efficacy and tolerability of flunarizine and propranolol in the prophylactic treatment of migraine. *Cephalalgia* 1999; 19(4):374; PMID.
150. Diener HC, Foh M, Iaccarino C, et al. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. The Study group. *Cephalalgia* 1996 Oct; 16(6):441-7; PMID: 8902255.
151. Diener HC, Kronfeld K, Boewing G, et al. Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial. *Lancet Neurol* 2006 Apr; 5(4):310-6; PMID: 16545747.
152. Diener HC, Krupp P, Schmitt T, et al. Cyclandelate in the prophylaxis of migraine: a placebo-controlled study. *Cephalalgia* 2001 Feb; 21(1):66-70; PMID: 11298666.

153. Diener HC, Louis P, Schellens R, et al. Treatment of migraine attacks with intranasal alniditan: an open study. *Cephalalgia* 2001 Mar; 21(2):140-4; PMID: 11422097.
154. Diener HC, Pfaffenrath V, Schnitker J, et al. Efficacy and safety of 6.25 mg t.i.d. feverfew CO₂-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study. *Cephalalgia* 2005 Nov; 25(11):1031-41; PMID: 16232154.
155. Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. *Eur Neurol* 2004; 51(2):89-97; PMID: 14752215.
156. Diener H-C, Dowson A, Whicker S, et al. Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan. *Journal of Headache & Pain* 2008 Dec; 9(6):359-65; PMID: 18953489.
157. Diez-Tejedor FA. Assessment of response consistency to oral sumatriptan in migraine attacks. *Journal of The Neurological Sciences*; 1997.
158. Dodick D, Blumenfeld A, Silberstein SD. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. *Clinics in Dermatology* 2004 Jan-Feb; 22(1):76-81; PMID: 15158549.
159. Dora B, x00Fc, Balkan S, et al. Normalization of high interictal cerebrovascular reactivity in migraine without aura by treatment with flunarizine. *Headache* 2003 May; 43(5):464-9; PMID: 12752751.
160. Dowson A. Can oral 311C90, a novel 5-HT_{1D} agonist, prevent migraine headache when taken during an aura? *Eur Neurol* 1996; 36 Suppl 2:28-31; PMID: 8791030.
161. Dowson A. Bringing sumatriptan to primary care. *Cephalalgia* 2001; 21 Suppl 1:29-31; PMID: 11678819.
162. Dowson A, Ball K, Haworth D. Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study. *Curr Med Res Opin* 2000; 16(3):190-7; PMID: 11191009.
163. Dowson AJ, Fuat A, Gruffydd-Jones K. Clinical and economic issues associated with switching between triptans in clinical practice. *Current Medical Research & Opinion* 2005 Mar; 21(3):375-9; PMID: 15811206.
164. Dowson AJ, Muir K, Mullen M, et al. A prospective, multicenter, randomised, placebo-controlled trial to evaluate the efficacy of PFO closure with the STARFlex implant to prevent refractory migraine: the MIST trial. 15th European Stroke Conference; 2006.
165. Dowson AJ, Wilmshurst P, Muir KW, et al. A prospective, multicentre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy of PFO closure with the STARFLEX device to prevent refractory migraine: the MIST trial. *European Journal of Neurology*; 2006: 22.
166. Drake ME, Jr., Greathouse NI, Renner JB, et al. Open-label zonisamide for refractory migraine. *Clinical Neuropharmacology* 2004 Nov-Dec; 27(6):278-80; PMID: 15613932.
167. Drillis C, Girke W. Therapeutic results of cinnarizine and flunarizine in patients suffering from migraine. *Medizinische Welt*; 1980: 1870-2.
168. D'Souza PJ, Lumley MA, Kraft CA, et al. Relaxation training and written emotional disclosure for tension or migraine headaches: a randomized, controlled trial. *Ann Behav Med* 2008 Aug; 36(1):21-32; PMID: 18696172.
169. Duckmanton L. Drug information incorrect. *Canadian Family Physician* 2000 Apr; 46:780; PMID: 10790808.
170. Ebinger F. Exteroceptive suppression of masseter muscle activity in juvenile migraineurs. *Cephalalgia : an international journal of headache*; 2006: 722-30.
171. Egger J, Carter CM, Wilson J, et al. Is migraine food allergy? A double-blind controlled trial of oligoantigenic diet treatment. *Lancet* 1983 Oct 15; 2(8355):865-9; PMID: 6137694.
172. Elbarbry FA, Mabrouk MM, El-Dawy MA. Determination of the analgesic components of Spasmomigraine tablet by liquid chromatography with ultraviolet detection. *Journal of AOAC International* 2007 Jan-Feb; 90(1):94-101; PMID: 17373440.

173. Elkind A, Laurenza A, Austin R, et al. Efficacy and tolerability of naratriptan tablets in the treatment of migraine: Results of a double-blind, placebo-controlled, parallel group trial. (Abstract). *Journal of the Neurological Sciences*; 1997: S262.
174. Elkind A, McDaris HL, Satin L, et al. The cardiovascular safety of frovatriptan during a migraine attack in patients with known or at high risk of coronary artery disease. *European Journal of Neurology (Abstracts of the 4th Congress of the European Federation of Neurological Sciences, September 7-11, Lisbon, Portugal 1999)*; 1999: 141.
175. Elkind AH, Satin LZ, Nila A, et al. Frovatriptan use in migraineurs with or at high risk of coronary artery disease. *Headache* 2004 May; 44(5):403-10; PMID: 15147247.
176. Elouni B, Ben Salem C, Zamy M, et al. Fulminant hepatitis possibly related to pizotifen therapy. *Annals of Pharmacotherapy* 2010 Jul-Aug; 44(7-8):1348-9; PMID: 20571104.
177. Elser Jm WRC. Migraine headache in the infant and young child. *Headache*; 1990: 366-8.
178. Endres HG, Böwing G, Diener HC, et al. Acupuncture for tension-type headache: a multicentre, sham-controlled, patient-and observer-blinded, randomised trial. *The journal of headache and pain*; 2007: 306-14.
179. Esposito SB, Gherpelli JL. Chronic daily headaches in children and adolescents: a study of clinical characteristics. *Cephalalgia : an international journal of headache*; 2004: 476-82.
180. Etemad LR, Yang W, Globe D, et al. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. *Journal of Managed Care Pharmacy* 2005 Mar; 11(2):137-44; PMID: 15766320.
181. Evans BJ, Patel R, Wilkins AJ. Optometric function in visually sensitive migraine before and after treatment with tinted spectacles. *Ophthalmic Physiol Opt* 2002 Mar; 22(2):130-42; PMID: 12014487.
182. Evans RW, Baskin SM. Why do migraineurs abuse butalbital-containing combination analgesics? *Headache* 2010 Jul; 50(7):1194-7; PMID: 20649651.
183. Evans RW, Davenport RJ. Benign or sinister? Distinguishing migraine from subarachnoid hemorrhage. *Headache* 2007 Mar; 47(3):433-5; PMID: 17371361.
184. Evans RW, Diamond ML. Is sumatriptan use safe during pregnancy? *Headache* 2000 Nov-Dec; 40(10):856-7; PMID: 11135034.
185. Evans RW, Mannix LK. Triptans for migraine prodrome. *Headache* 2002 Jan; 42(1):83-4; PMID: 12005282.
186. Evans RW, Pascual J, x00E, et al. Bending the rule of monotherapy for migraine prevention? *Headache* 2005 Jun; 45(6):748-50; PMID: 15953308.
187. Evans RW, Seifert T, Mathew NT. Are triptans effective and safe when taken during the aura phase of migraine? *Headache* 2005 May; 45(5):601-3; PMID: 15953281.
188. Evans RW, Solomon S. Is it migraine or cluster? *Headache* 2000 Sep; 40(8):694-5; PMID: 10971670.
189. Evans RW, Tepper SJ, Shapiro RE, et al. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper.[Summary for patients in *Headache*. 2010 Jun;50(6):1101-2; PMID: 20618824]. *Headache* 2010 Jun; 50(6):1089-99; PMID: 20618823.
190. Ferrari A, Leone S, Vergoni AV, et al. Similarities and differences between chronic migraine and episodic migraine. *Headache* 2007 Jan; 47(1):65-72; PMID: 17355496.
191. Ferrari A, Pinetti D, Bertolini A, et al. Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients. *European Journal of Clinical Pharmacology* 2008 May; 64(5):489-95; PMID: 18180912.
192. Ferrari MD. Sumatriptan by injection. *Cephalalgia* 2001; 21 Suppl 1:6-8; PMID: 11678812.
193. Ferrari MD, Haan J, Blokland JA, et al. Cerebral blood flow during migraine attacks without aura and effect of sumatriptan. *Arch Neurol* 1995 Feb; 52(2):135-9; PMID: 7848120.

194. Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. *Cephalalgia* 1994 Oct; 14(5):330-8; PMID: 7828190.
195. Ferrari MD, Wilkinson M, Hirt D, et al. Efficacy of ICS 205-930, a novel 5-hydroxytryptamine₃ (5-HT₃) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question. ICS 205-930 Migraine Study Group. *Pain* 1991 Jun; 45(3):283-91; PMID: 1876437.
196. Ferrigno V, Scaffidi L, Russo S, et al. Comparison of buflomedil and verapamil as alternatives in prophylaxis of essential migraine. *Rassegna di Medicina Interna*; 1985: 279-86.
197. Fichtel A. Recurrent Headache among Swedish Adolescents. Uppsala: Social Sciences, Universitatis Upsaliensis; 2003.
198. Fichtel A, Larsson B. Does relaxation treatment have differential effects on migraine and tension-type headache in adolescents? *Headache* 2001 Mar; 41(3):290-6; PMID: 11264690.
199. Fichtel A, Larsson B. Relaxation treatment administered by school nurses to adolescents with recurrent headaches. *Headache* 2004 Jun; 44(6):545-54; PMID: 15186298.
200. Fiseau E, Webster C, Asgharnejad M, et al. Naratriptan oral pharmacokinetics in migraine subjects [Abstract]. *Journal of the Neurological Sciences*; 1997: S33.
201. Flanagan M. Thermography in migraine: a pilot study. [abstract]. *Australian & New Zealand Journal of Medicine*; 1989: 639.
202. Flexman AM, Del Vicario G, Schwarz SKW. Dark green blood in the operating theatre. *Lancet* 2007 Jun 9; 369(9577):1972; PMID: 17560450.
203. Forcelini CM, Dantas DC, Luz C, et al. Analysis of leukocytes in medication-overuse headache, chronic migraine, and episodic migraine. *Headache* 2011 Sep; 51(8):1228-38; PMID: 21649652.
204. Forssman B, Henriksson KG, Kihlstrand S. A comparison between BC 105 and methysergide in the prophylaxis of migraine. *Acta neurologica Scandinavica*; 1972: 204-12.
205. Forsythe WI, Redmond A. Two controlled trials of tyramine in children with migraine. *Developmedchild Neurol*; 1974: 794-9.
206. Fox AW. Onset of effect of 5-HT_{1B/1D} agonists: a model with pharmacokinetic validation. *Headache* 2004 Feb; 44(2):142-7; PMID: 14756852.
207. Fox AW. Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect. *Headache* 2010 Feb; 50(2):249-55; PMID: 19925626.
208. Frediani F, Cannat, x00E, et al. The patient with medication overuse: clinical management problems. *Neurological Sciences* 2003 May; 24 Suppl 2:S108-11; PMID: 12811605.
209. Freitag FG, Finlayson G, Rapoport AM, et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS). *Headache* 2007 Apr; 47(4):519-30; PMID: 17445101.
210. French DJ, Gauthier JO, Roberge C, et al. Self-efficacy in the thermal biofeedback treatment of migraine sufferers. *Behavior Therapy*; 1997: 109-25.
211. Fumio G, Kunio T, Naoyuki K, et al. Clinical Evaluation of KB-2796 (lomerizine hydrochloride) on Migraine. Late Phase II Study. *Rinsho Hyoka (Clinical Evaluation)*; 1995: 13-37.
212. Fumio G, Kunio T, Naoyuki K, et al. Clinical Evaluation of Lomerizine on Migraine. Double-blind Study in Comparison with Dimetotiazine. *Rinsho Hyoka (Clinical Evaluation)*; 1995: 183-214.
213. Furman JM, Marcus DA. A pilot study of rizatriptan and visually-induced motion sickness in migraineurs. *Int J Med Sci* 2009; 6(4):212-7; PMID: 19680473.
214. Furman JM, Marcus DA, Balaban CD. Rizatriptan reduces vestibular-induced motion sickness in migraineurs. *J Headache Pain* 2011 Feb; 12(1):81-8; PMID: 20862509.
215. Fuseau E, Webster C, Asgharnejad M, et al. Naratriptan oral pharmacokinetic-pharmacodynamic modelling of pain relief in migraine subjects [Abstract]. *Journal of the Neurological Sciences*; 1997: S167.

216. Fuseau E, Webster M, Aspharnejad M, et al. Factors affecting oral naratriptan pharmacokinetics in migraine subjects [abstract]. *Journal of the Neurological Sciences*; 1997: S33.
217. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. *Headache* 2003 Jan; 43(1):36-43; PMID: 12864756.
218. Gallagher RM, Mueller L. Managing intractable migraine with naratriptan. *Headache* 2003 Oct; 43(9):991-3; PMID: 14511276.
219. Gamzu Elkan Pradalier A, Guerard DLA, Scheck F, et al. The Pharmacology of CERETATÍ (CNS1102) and Early Clinical Results: The association of calcium carbasalate-metoclopramide versus dihydroergotamine in the treatment of migraine attacks. 8th-ECNP-(European-College-of-Neuropsychopharmacology)-Congress,- Venice,-Italy: Pathologie Biologie.; 1995: 806-13.
220. Gao S, Zhao D, Xie Y. A comparative study on the treatment of migraine headache with combined distant and local acupuncture points versus conventional drug therapy. *Am J Acupunct* 1999; 27(1-2):27-30; PMID: 10513096.
221. Garc, x00Ed, a-del-Pozo J, et al. Antimigraine drug consumption in Spain (1990-2000). *Acta Neurologica Scandinavica* 2003 Feb; 107(2):158-60; PMID: 12580869.
222. Garza I. Tonabersat: a cortical spreading depression inhibitor as potential pharmacologic prophylaxis in migraine with aura. *Curr Neurol Neurosci Rep* 2010 Jan; 10(1):7-9; PMID: 20425219.
223. Gauthier J, Cote G, French D. The role of home practice in the thermal biofeedback treatment of migraine headache. *J Consult Clin Psychol* 1994 Feb; 62(1):180-4; PMID: 8034821.
224. Gawel M, Kreeft J, Nelson R, et al. Flunarizine is comparable to propranolol in the prophylaxis of migraine with and without aura. *Cephalalgia*; 1991: 156.
225. Gentile G, Borro M, Lala N, et al. Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. *J Headache Pain* 2010 Oct; 11(5):431-5; PMID: 20652353.
226. Gerber WD, Diener HC, Kropp P, et al. The efficacy of flunarizine and etilefrinepivalate in migraine: An empirical double-blind and placebo controlled study. *Cephalalgia*; 1989: 450-1.
227. Gerber WD, Schellenberg R, Thom M, et al. Cyclandelate versus propranolol in the prophylaxis of migraine--a double-blind placebo-controlled study. *Funct Neurol* 1995 Jan-Feb; 10(1):27-35; PMID: 7649498.
228. Gerth WC, Dasback EJ, Musser BJ. Impact of migraine symptoms on health care utilization and work loss [abstract]. *Neurology*; 1997: A123.
229. Gibb CM, Davies PT, Glover V, et al. Chocolate is a migraine-provoking agent. *Cephalalgia : an international journal of headache*; 1991: 93-5.
230. Gillies D, Sills M, Forsythe I. Pizotifen (Sanomigran) in childhood migraine. A double-blind controlled trial. *European neurology*; 1986: 32-5.
231. Gneccchi-Ruscione T, Bernard X, Pierre P, et al. Effect of naratriptan on myocardial blood flow and coronary vasodilator reserve in migraineurs. *Neurology* 2000 Jul 12; 55(1):95-9; PMID: 10891912.
232. Goadsby PJ, Winter P, Asgharnejad M. Twenty-four hour maintenance of headache relief after treatment of migraine with naratriptan tablets: a review of data from controlled clinical trials [abstract]. *Neurology*; 1998: A340-1.
233. Göbel H, Heinze A, Kuhn K, et al. Effect of operationalized computer diagnosis on the therapeutic results of sumatriptan in general practice. *Cephalalgia : an international journal of headache*; 1998: 481-6.
234. Göbel H, Krapat S, Dworschak M, et al. Exteroceptive suppression of temporalis muscle activity during migraine attack and migraine interval before and after treatment with sumatriptan. *Cephalalgia : an international journal of headache*; 1994: 143-8.
235. Gobel H, Krapat S, Soyka D. Effect of sumatriptan on psychological status during migraine attack and migraine interval [abstract]. 1993 Meeting of the European Federation of Neurological Societies (Berlin, Dec 1993); 1993.

236. Goldstein DJ, Offen WW, Klein EG, et al. Lanepitant, an NK-1 antagonist, in migraine prevention. *Cephalalgia* 2001 Mar; 21(2):102-6; PMID: 11422091.
237. Goldstein J, Keywood C, Hutchison J. 24-hour migraine recurrence was low during treatment with frovatriptan. *European Journal of Neurology* (Abstracts of the 4th Congress of the European Federation of Neurological Sciences, September 7-11, Lisbon, Portugal 1999); 1999: 139.
238. Goldstein J, Mathew N, Rapoport A. The safety and tolerability of Frovatriptan, a selective 5HT_{1B/1D} agonist, used for prophylaxis of menstrually associated migraine. *American Academy of Neurology Annual Meeting*, 29 March-5 April, 2003.; 2003: P06.141.
239. Good PA, Taylor RH, Mortimer MJ. The use of tinted glasses in childhood migraine. *Headache* 1991 Sep; 31(8):533-6; PMID: 1960058.
240. Gottschling S, Meyer S, Gribova I, et al. Laser acupuncture in children with headache: a double-blind, randomized, bicenter, placebo-controlled trial. *Pain*; 2008: 405-12.
241. Gottschling S, Meyer S, Gribova I, et al. Laser acupuncture in children with headache: a double-blind, randomized, bicenter, placebo-controlled trial. *Deutsche Zeitschrift für Akupunktur*; 2009: 52.
242. Grazzi L, Andrasik F, D'Amico D, et al. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. *Headache* 2002 Jun; 42(6):483-90; PMID: 12167136.
243. Grazzi L, Bussone G. Effect of biofeedback treatment on sympathetic function in common migraine and tension-type headache. *Cephalalgia* 1993 Jun; 13(3):197-200; PMID: 8358778.
244. Grazzi L, Bussone G. Italian experience of electromyographic-biofeedback treatment of episodic common migraine: preliminary results. *Headache* 1993 Sep; 33(8):439-41; PMID: 8262785.
245. Grottemeyer KH, Schlake HP, Husstedt IW. Normalization of platelet-reactivity under successful migraine-prophylaxis with metoprolol or flunarizine. *Cephalalgia*; 1989: 435-6.
246. Grottemeyer KH, Schlake HP, Husstedt IW. Etilefrine pivalate vs. dihydroergotamine and flunarizine in prophylactic treatment of migraine in patients with low blood pressure - a randomized double blind study. *Cephalalgia*; 1989: 433-4.
247. Grottemeyer KH, Schlake HP, Husstedt IW. Etilefrine pivalate VS. Dihydroergotamin and flunarizin in prophylactic treatment of migraine in patients with low blood pressure - A randomized double-blind-study. *Cephalalgia*; 1989: 433-4.
248. Gueorguieva I, Nestorov IA, Aarons L, et al. Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan. *Pharmaceutical Research* 2005 Oct; 22(10):1614-26; PMID: 16180118.
249. Guerrero RO, Cardenas MA, Ocampo AA, et al. Histamine as a therapeutic alternative in migraine prophylaxis: a randomized, placebo-controlled, double-blind study. *Headache* 1999 Sep; 39(8):576-80; PMID: 11279974.
250. Guidotti M, Mauri M, Barril, et al. Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine. *Journal of Headache & Pain* 2007 Oct; 8(5):283-8; PMID: 17955167.
251. Guidotti M, Zanasi S, Garagiola U. Pirprofen in the treatment of migraine and episodic headache attacks: a placebo-controlled crossover clinical trial. *J Int Med Res* 1989 Jan-Feb; 17(1):48-54; PMID: 2651177.
252. Guyuron B, Kriegler JS, Davis J, et al. Comprehensive surgical treatment of migraine headaches. *Plast Reconstr Surg* 2005 Jan; 115(1):1-9; PMID: 15622223.
253. Guyuron B, Tucker T, Kriegler J. Botulinum toxin A and migraine surgery. *Plastic & Reconstructive Surgery* 2003 Oct; 112(5 Suppl):171S-3S; discussion 4S-6S; PMID: 14504501.
254. Gysin TZC. Clinical hypnosis therapy/self hypnosis for aspecific and episodic headache or migraine and other defined types of headaches in children and adolescents. *Schweizerische Medizinische Wochenschrift Supplementum*; 1994: 64-6.
255. Habek D, Habek JC, Barbir A. Using acupuncture to treat premenstrual syndrome. *Archives of gynecology and obstetrics*; 2002: 23-6.

256. Haddock CK, Rowan AB, Andrasik F, et al. Home-based behavioral treatments for chronic benign headache: a meta-analysis of controlled trials. *Cephalalgia* 1997 Apr; 17(2):113-8; PMID: 9137849.
257. Hadjiloizou N, Rakhit R. Frovatriptan, a probable cause of coronary vasoconstriction. *International Journal of Clinical Practice* 2008 Jul; 62(7):1121-2; PMID: 18564276.
258. Hagen K, Vatten L, Stovner LJ, et al. Low socio-economic status is associated with increased risk of frequent headache: a prospective study of 22718 adults in Norway. *Cephalalgia* 2002 Oct; 22(8):672-9; PMID: 12383064.
259. Hall GC, Brown MM, Mo J, et al. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. *Neurology* 2004 Feb 24; 62(4):563-8; PMID: 14981171.
260. Hansen TM, Hansen B. The effect of aromatherapy on health complaints. A randomised, controlled trial. *International Journal of Essential Oil Therapeutics*; 2007: 67-71.
261. Hardten DR, Hira NK, Lombardo AJ. Triptans and the incidence of epithelial defects during laser in situ keratomileusis. *Journal of Refractive Surgery* 2005 Jan-Feb; 21(1):72-6; PMID: 15724687.
262. Harizanov M, Neykova L, Márquez M, et al. Efficacy and safety of dotarizine versus flunarizine in the prophylaxis of migraine. *Neurología*; 1997: 211.
263. Hauge AW, Asghar MS, Schytz HW, et al. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. *Lancet Neurol* 2009 Aug; 8(8):718-23; PMID: 19570717.
264. Havanka-Kanniainen H, Hokkanen E, Myllylä V. Efficacy of nimodipine in comparison with pizotifen (Sandomigrin) in the prophylaxis of migraine. *Cephalalgia*; 1985: 530-31.
265. Havanka-Kanniainen H, Hokkanen E, Myllylä VV. Efficacy of nimodipine in comparison with pizotifen in the prophylaxis of migraine. *Cephalalgia : an international journal of headache*; 1987: 7-13.
266. Helseth EK, Erickson JC. The prevalence and impact of migraine on US Military officer trainees. *Headache* 2008 Jun; 48(6):883-9; PMID: 18005047.
267. Herrmann WM, Kristof M, Sastre M. Preventive treatment of migraine headache with a new isoergolenyl derivative. *J Int Med Res* 1978; 6(6):476-82; PMID: 363486.
268. Hershey AD, Powers SW, Vockell A-LB, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. *Headache* 2007 Jan; 47(1):73-80; PMID: 17355497.
269. Ho AP, Dahlof CG, Silberstein SD, et al. Randomized, controlled trial of telcagepant over four migraine attacks. *Cephalalgia* 2010 Dec; 30(12):1443-57; PMID: 20974601.
270. Hodge JA, Hodge KD. Ischemic colitis related to sumatriptan overuse. *Journal of the American Board of Family Medicine: JABFM* 2010 Jan-Feb; 23(1):124-7; PMID: 20051552.
271. Hoffman L, Mayzell G, Pedan A, et al. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray. *Journal of Managed Care Pharmacy* 2003 Jul-Aug; 9(4):335-45; PMID: 14613452.
272. Hoivik HO, Laurijssens BE, Harnisch LO, et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. *Cephalalgia* 2010 Dec; 30(12):1458-67; PMID: 20974604.
273. Horga J, Matias-Guiu J, Castillo J, et al. Comparison of dotarizine and pizotifen in prophylactic treatment of migraine - a crossover double blind multicentre study [abstract]. *Journal of Neurology*; 1996: S97.
274. Houghton LA, Foster JM, Whorwell PJ, et al. Is chest pain after sumatriptan oesophageal in origin? *Lancet*; 1994: 985-6.
275. Hu XH, Ng-Mak D, Cady R. Does early migraine treatment shorten time to headache peak and reduce its severity? *Headache* 2008 Jun; 48(6):914-20; PMID: 18005142.
276. Hubbe P. The prophylactic treatment of migraine with an antiserotonin pizotifen. *Acta Neurol Scand*; 1973: 108-14.
277. Hudgson P, Foster JB, Newell DJ. Controlled trial of demigran in the prophylaxis of migraine. *Br Med J* 1967 Apr 8; 2(5544):91-3; PMID: 6020856.
278. Hui JS. Migraines. *Clinical Neuropharmacology* 2001 Nov-Dec; 24(6):307-12; PMID: 11801805.

279. Humphrey PP. How it started. *Cephalalgia* 2001; 21 Suppl 1:2-5; PMID: 11678811.
280. Humphrey PPA. The discovery and development of the triptans, a major therapeutic breakthrough. *Headache* 2008 May; 48(5):685-7; PMID: 18471110.
281. Hutchison J. Efficacy of frovatriptan. *Headache* 2007 Sep; 47(8):1227; PMID: 17883538.
282. Imai N, Konishi T, Serizawa M, et al. Do the effects of long-term lomerizine administration differ with age? *Intern Med* 2007; 46(10):683-4; PMID: 17527044.
283. Innes GD, Macphail I, Dillon EC, et al. Dexamethasone prevents relapse after emergency department treatment of acute migraine: a randomized clinical trial. *CJEM* 1999 Apr; 1(1):26-33; PMID: 17659098.
284. Ishida K, Sato H. Kampo medicines as alternatives for treatment of migraine: six case studies. *Complementary Therapies in Clinical Practice* 2006 Nov; 12(4):276-80; PMID: 17030300.
285. Ivers H, McGrath PJ, Purdy RA, et al. Decision making in migraine patients taking sumatriptan: an exploratory study. *Headache* 2000 Feb; 40(2):129-36; PMID: 10759912.
286. Iwasaki S, Ushio M, Chihara Y, et al. Migraine-associated vertigo: clinical characteristics of Japanese patients and effect of lomerizine, a calcium channel antagonist. *Acta Otolaryngol Suppl* 2007 Dec; (559):45-9; PMID: 18340570.
287. Jacobs H. A trial of opipramol in the treatment of migraine. *Journal of neurology, neurosurgery, and psychiatry*; 1972: 500-4.
288. Jacobson JA, Call NB, Kasworm EM, et al. Safety and efficacy of topical norfloxacin versus tobramycin in the treatment of external ocular infections. *Antimicrob Agents Chemother* 1988 Dec; 32(12):1820-4; PMID: 3072923.
289. Jensen K, Bulow P, Hansen H. Experimental toothclenching in common migraine. *Cephalalgia* 1985 Dec; 5(4):245-51; PMID: 4084979.
290. Jeske AH. Migraine drug therapy: dental implications. *Texas Dental Journal* 2006 Feb; 123(2):190-7; PMID: 16579506.
291. Jessup, and B, et al. Autogenic training and hand temperature biofeedback in the treatment of migraine: a preliminary analysis; 1976: 22.
292. Johnson N, Fethke C. Postdischarge outcomes and care planning for the elderly hospitalized. In: McClelland E, Kelly K, Buckwalter K, eds. *Continuity of Care*. New York: Grune & Stratton; 1985.
293. Johnson RH, Hornabrook RW, Lambie DG. Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis. *Acta neurologica Scandinavica*; 1986: 490-2.
294. Joish VN, Cady PS. Effect of sumatriptan on health care resource use among patients with migraine. *Managed Care Interface* 2001 Jan; 14(1):68-72; PMID: 11214537.
295. Jurgens TP, Busch V, Schmidt-Wilcke T, et al. Migraine-like headache in intracranial haemorrhage is alleviated by sumatriptan and almotriptan. *Cephalalgia* 2008 Mar; 28(3):302-4; PMID: 18201253.
296. Kakisaka Y, Wakusawa K, Haginoya K, et al. Abdominal migraine associated with ecchymosis of the legs and buttocks: does the symptom imply an unknown mechanism of migraine? *Tohoku Journal of Experimental Medicine* 2010; 221(1):49-51; PMID: 20453457.
297. Kallen B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. *Headache* 2001 Apr; 41(4):351-6; PMID: 11318881.
298. Kang EH, Park JE, Chung CS, et al. Effect of biofeedback-assisted autogenic training on headache activity and mood states in Korean female migraine patients. *J Korean Med Sci* 2009 Oct; 24(5):936-40; PMID: 19794995.
299. Kangasniemi P. Placebo, 1-isopropylnoradrenochrome-5-monosemicarbazono and pizotifen in migraine prophylaxis. *Headache*; 1979: 219-22.
300. Kangasniemi P, Tokola R. Flunarizine in the prophylaxis of migraine patients without aura. *Cephalalgia*; 1989: 425.
301. Kaniecki R. Bringing closure to the triptan grab bag. *Headache* 2002 Sep; 42(8):838-9; PMID: 12390656.
302. Karam B, Farah E, Ashoush R, et al. Ergotism precipitated by erythromycin: a rare case of vasospasm. *European Journal of Vascular & Endovascular Surgery* 2000 Jan; 19(1):96-8; PMID: 10706847.

303. Katsarava Z, Limmroth V, Finke M, et al. Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. *Neurology* 2003 May 27; 60(10):1682-3; PMID: 12771266.
304. Kaube H, May A, Pfaffenrath V. Sumatriptan. *BMJ (Clinical research ed.)*; 1994: 1573-4.
305. Kinnunen E, Erkinjuntti T, Farkkila M, et al. Placebo-controlled double-blind trial of pirofen and an ergotamine tartrate compound in migraine attacks. *Cephalalgia* 1988 Sep; 8(3):175-9; PMID: 3143482.
306. Kjaersgard Rasmussen MJ, Holt Larsen B, Borg L, et al. Tolfenamic acid versus propranolol in the prophylactic treatment of migraine. *Acta Neurol Scand* 1994 Jun; 89(6):446-50; PMID: 7976233.
307. Klein AW. Introduction. *Botox. Disease-A-Month* 2002 May; 48(5):296-8; PMID: 12195261.
308. Koehler SM, Glaros A. The effect of aspartame on migraine headache. *Headache*; 1988: 10-4.
309. Kohlenberg RJ, Cahn T. Self-help treatment for migraine headaches: a controlled outcome study. *Headache*; 1981: 196-200.
310. Kosinski M, Bjorner JB, Ware JE, Jr., et al. The responsiveness of headache impact scales scored using 'classical' and 'modern' psychometric methods: a re-analysis of three clinical trials. *Quality of Life Research* 2003 Dec; 12(8):903-12; PMID: 14651411.
311. Kothare SV. Efficacy of flunarizine in the prophylaxis of cyclical vomiting syndrome and abdominal migraine. *European Journal of Paediatric Neurology* 2005; 9(1):23-6; PMID: 15701563.
312. Kraft CA, Lumley MA, D'Souza PJ, et al. Emotional approach coping and self-efficacy moderate the effects of written emotional disclosure and relaxation training for people with migraine headaches. *Br J Health Psychol* 2008 Feb; 13(Pt 1):67-71; PMID: 18230235.
313. Krobot KJ, Kaufman JS, Christensen DB, et al. Accessing a new medication in Germany: a novel approach to assess a health insurance-related barrier. *Annals of Epidemiology* 2005 Nov; 15(10):756-61; PMID: 15961317.
314. Krobot KJ, Miller WC, Kaufman JS, et al. The disparity in access to new medication by type of health insurance: lessons from Germany. *Medical Care* 2004 May; 42(5):487-91; PMID: 15083110.
315. Krobot KJ, Schroder-Bernhardi D, Pfaffenrath V. Migraine consultation patterns in primary care. Results from the PCAOM study 1994-96. *Cephalalgia* 1999 Nov; 19(9):831-40; PMID: 10595294.
316. Kroener-Herwig B, Denecke H. Cognitive-behavioral therapy of pediatric headache: are there differences in efficacy between a therapist-administered group training and a self-help format? *J Psychosom Res* 2002 Dec; 53(6):1107-14; PMID: 12479993.
317. Kroner Herwig B, Diergarten D, Seeger Siewert R. Psychophysiological reactivity of migraine sufferers in conditions of stress and relaxation. *J-Psychosom-Res*; 1988: 483-92.
318. Kroner-Herwig B, Fritsche G, Brauer H. The physiological stress response and the role of cognitive coping in migraine patients and non-headache controls. *J Psychosom Res* 1993 Jul; 37(5):467-80; PMID: 8350289.
319. Krusz JC, Nett R. Naratriptan prevents migraine recurrence after initial relief with sumatriptan. *Jns*; 2001.
320. Krymchantowski AV, Moreira PF. Out-patient detoxification in chronic migraine: comparison of strategies. *Cephalalgia* 2003 Dec; 23(10):982-93; PMID: 14984232.
321. Kutluhan S, Incekara F, Sozen A, et al. Temporary confusion depending on the usage of naratriptan. *Journal of Headache & Pain* 2007 Dec; 8(6):340-1; PMID: 18071630.
322. Kwong WJ, Taylor FR, Adelman JU. The effect of early intervention with sumatriptan tablets on migraine-associated productivity loss. *Journal of Occupational & Environmental Medicine* 2005 Nov; 47(11):1167-73; PMID: 16282878.
323. Labbe E, Williamson DA. Temperature biofeedback in the treatment of children with migraine headaches. *J Pediatr Psychol*; 1983: 317-26.
324. Labbe EE. Treatment of childhood migraine with autogenic training and skin temperature biofeedback: a component analysis. *Headache* 1995 Jan; 35(1):10-3; PMID: 7868327.

325. Labbe EL, Williamson DA. Treatment of childhood migraine using autogenic feedback training. *J Consult Clin Psychol* 1984 Dec; 52(6):968-76; PMID: 6520289.
326. Lake A, Rainey J, Papsdorf JD. Biofeedback and rational-emotive therapy in the management of migraine headache. *J Appl Behav Anal* 1979 Spring; 12(1):127-40; PMID: 468745.
327. Lampl C, Buzath A, Baumhackl U, et al. One-year prevalence of migraine in Austria: a nation-wide survey. *Cephalalgia* 2003 May; 23(4):280-6; PMID: 12716346.
328. Lampl C, Yazdi K, Buzath A, et al. Migraine-like headache in bacterial meningitis. *Cephalalgia* 2000 Oct; 20(8):738-9; PMID: 11167904.
329. Lance JW, Anthony M. Clinical trial of a new serotonin antagonist, BC105, in the prevention of migraine. *Med J Aust* 1968 Jan 13; 1(2):54-5; PMID: 4867512.
330. Landy S, McGinnis J, Curlin D, et al. Selective serotonin reuptake inhibitors for migraine prophylaxis. *Headache* 1999 Jan; 39(1):28-32; PMID: 15613191.
331. Landy S, Savani N, Shackelford S, et al. Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. *Int J Clin Pract* 2004 Oct; 58(10):913-9; PMID: 15587768.
332. Landy SH, McGinnis JE, McDonald SA. Clarification of developing and established clinical allodynia and pain-free outcomes. *Headache* 2007 Feb; 47(2):247-52; PMID: 17300364.
333. Lanfranconi S, Corti S, Bersano A, et al. Aphasic and visual aura with increased vasogenic leakage: an atypical migrainous status. *Journal of the Neurological Sciences* 2009 Oct 15; 285(1-2):227-9; PMID: 19573879.
334. Lant, x00E, ri-Minet M, et al. Evaluating patient satisfaction with specific migraine therapy based on initial treatment expectations: the PAX study. *Current Medical Research & Opinion* 2010 Feb; 26(2):465-72; PMID: 20001575.
335. LaPorta LD. Relief from migraine headache with aripiprazole treatment. *Headache* 2007 Jun; 47(6):922-6; PMID: 17578547.
336. Larsson B, Carlsson J, Fichtel A, et al. Relaxation treatment of adolescent headache sufferers: results from a school-based replication series. *Headache* 2005 Jun; 45(6):692-704; PMID: 15953302.
337. Larsson B, Melin L. Chronic headaches in adolescents: treatment in a school setting with relaxation training as compared with information-contact and self-registration. *Pain* 1986 Jun; 25(3):325-36; PMID: 3528989.
338. Lassen LH, Jacobsen VB, Haderslev PA, et al. Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients. *J Headache Pain* 2008 Jun; 9(3):151-7; PMID: 18437288.
339. Lawler SP, Cameron LD. A randomized, controlled trial of massage therapy as a treatment for migraine. *Ann Behav Med* 2006 Aug; 32(1):50-9; PMID: 16827629.
340. Lawrence ER, Hossain M, Littlestone W. Sanomigran for migraine prophylaxis, controlled multicenter trial in general practice. *Headache*; 1977: 109-12.
341. Levitan BS, Andrews EB, Gilsenan A, et al. Application of the BRAT framework to case studies: observations and insights. *Clin Pharmacol Ther* 2011 Feb; 89(2):217-24; PMID: 21178990.
342. Li ZF, Wu ZD, Chen JX, et al. Curative effect observation of fluoxetine used combining with flunarizine in treatment of 86 cases of migraine. *Modern Hospital*; 2003: 33-4.
343. Lidegaard O. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. *Br J Obstet Gynaecol* 1995 Feb; 102(2):153-9; PMID: 7756208.
344. Liguori A, Petti F, Bangrazi A, et al. Comparison of pharmacological treatment versus acupuncture treatment for migraine without aura--analysis of socio-medical parameters. *J Tradit Chin Med* 2000 Sep; 20(3):231-40; PMID: 11038990.
345. Linde M, Mellberg A, Dahl, et al. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. *Cephalalgia* 2006 Feb; 26(2):113-21; PMID: 16426264.

346. Linde M, Mellberg A, Dahlof C. The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan. *Cephalalgia* 2006 Jun; 26(6):712-21; PMID: 16686911.
347. Lipton RB, Dodick DW, Adelman JU, et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. *Cephalalgia* 2009 Aug; 29(8):826-36; PMID: 19220307.
348. Lipton RB, Gobel H, Einhaupl KM, et al. *Petasites hybridus* root (butterbur) is an effective preventive treatment for migraine. *Neurology* 2004 Dec 28; 63(12):2240-4; PMID: 15623680.
349. Lipton RB, Stewart WF, Cady R, et al. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. (2000 Wolfe Award.). *Headache*; 2000: 783-91.
350. Lisotto C, Mainardi F, Maggioni F, et al. Hemicrania continua with contralateral episodic cluster headache: a case report. *Cephalalgia* 2003 Nov; 23(9):929-30; PMID: 14616936.
351. Liu JG, Yan PJ, Li YX, et al. Metoclopramide in the treatment of 40 cases of migraine. *Herald of Medicine*; 2003: 88-9.
352. Lofland JH, Locklear JC, Frick KD. Different approaches to valuing the lost productivity of patients with migraine. *Pharmacoeconomics* 2001; 19(9):917-25; PMID: 11700778.
353. Loh L, Nathan PW, Schott GD, et al. Acupuncture versus medical treatment for migraine and muscle tension headaches. *J Neurol Neurosurg Psychiatry*; 1984: 333-7.
354. Lohman JJHM, van der Kuy-de Ree MM, Group of Co-operating Pharmacists S-G, et al. Patterns of specific antimigraine drug use--a study based on the records of 18 community pharmacies. *Cephalalgia* 2005 Mar; 25(3):214-8; PMID: 15689197.
355. Low NCP, Du Fort GG, Cervantes P. Prevalence, clinical correlates, and treatment of migraine in bipolar disorder. *Headache* 2003 Oct; 43(9):940-9; PMID: 14511270.
356. Lucas C, Auray JP, Gaudin AF, et al. Use and misuse of triptans in France: data from the GRIM2000 population survey. *Cephalalgia* 2004 Mar; 24(3):197-205; PMID: 15009013.
357. Lucas C, x00E, raud G, et al. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. *Headache* 2006 May; 46(5):715-25; PMID: 16643573.
358. Luciani RJ, Osterhaus JT, Gutterman DL. Patient preferences for migraine therapy: subcutaneous sumatriptan compared with other medications. *The Journal of family practice*; 1995: 147-52.
359. Ludin HP. A comparative trial with flunarizine and propranolol in migraine. *Cephalalgia*; 1987: 469-70.
360. Lugardon S, Roussel H, Sciortino V, et al. Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database. *European Journal of Clinical Pharmacology* 2007 Aug; 63(8):801-7; PMID: 17576547.
361. Lundberg PO. Prophylactic treatment of migraine with flumetazone. *Acta neurologica Scandinavica*; 1969: 309-26.
362. Lynch JJ, Jr., Regan CP, Edvinsson L, et al. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries. *Journal of Cardiovascular Pharmacology* 2010 May; 55(5):518-21; PMID: 20164785.
363. Maas HJ, Spruit MAH, Danhof M, et al. Relevance of absorption rate and lag time to the onset of action in migraine. *Clinical Pharmacokinetics* 2008; 47(2):139-46; PMID: 18193920.
364. MacGregor EA, Brandes JL, Silberstein S, et al. Safety and tolerability of short-term preventive frovatriptan: a combined analysis. *Headache* 2009 Oct; 49(9):1298-314; PMID: 19788471.
365. MacGregor EA, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. *Cephalalgia* 1993 Apr; 13(2):124-7; PMID: 8495454.
366. MacLennan SC, Wade FM, Forrest KM, et al. High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. *J Child Neurol* 2008 Nov; 23(11):1300-4; PMID: 18984840.

367. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. *Headache* 2004 Oct; 44(9):885-90; PMID: 15447697.
368. Maneyapanda SB, Venkatasubramanian A. Relationship between significant perinatal events and migraine severity. *Pediatrics* 2005 Oct; 116(4):e555-8; PMID: 16199683.
369. Mannix LK, Martin VT, Cady RK, et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. *Obstet Gynecol* 2009 Jul; 114(1):106-13; PMID: 19546766.
370. Mannix LK, Savani N, Landy S, et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. *Headache* 2007 Jul-Aug; 47(7):1037-49; PMID: 17635595.
371. Martin PR. How do trigger factors acquire the capacity to precipitate headaches? *Behaviour research and therapy*; 2001: 545-54.
372. Martin PR, Nathan PR, Milech D, et al. Cognitive therapy vs. self-management training in the treatment of chronic headaches. *The British journal of clinical psychology / the British Psychological Society*; 1989: 347-61.
373. Martin VT, Wernke S, Mandell K, et al. Defining the relationship between ovarian hormones and migraine headache. *Headache* 2005 Oct; 45(9):1190-201; PMID: 16178949.
374. Martucci N, Manna V, Porto C, et al. Migraine and the noradrenergic control of vasomotricity: a study with alpha-2 stimulant and alpha-2 blocker drugs. *Headache* 1985 Mar; 25(2):95-100; PMID: 3886600.
375. Marziniak M, Herzog AL, Mossner R, et al. Investigation of the functional brain-derived neurotrophic factor gene variant Val66MET in migraine. *J Neural Transm* 2008 Sep; 115(9):1321-5; PMID: 18478177.
376. Mastro Simone F, Iaccarino C, de Caterina G. Efficacy and tolerance of cyclandelate versus pizotifen in the prophylaxis of migraine. *J Med* 1992; 23(1):1-16; PMID: 1573338.
377. Mathew NT. 5-Hydroxytryptophane in the prophylaxis of migraine: a double blind study. *Headache*; 1978: 111.
378. Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. *Neurology* 2004 Sep 14; 63(5):848-52; PMID: 15365135.
379. Mathew NT, Peykamian M, Laurenza A, et al. Efficacy and tolerability of naratriptan tablets in the treatment of migraine: Results of a double-blind placebo controlled, crossover trial. *Journal of the Neurological Sciences*; 1997: S35.
380. Matias-Guiu J, Horga J, Asensio M, et al. Comparison of dotarizine and pizotifen in prophylactic treatment of migraine: a crossover double-blind multicentre study. *Functional Neurology*; 1996: 155.
381. Matías-Guiu J, Horga J, Asensio M, et al. Comparison of dotarizine and pizotifen in the prophylaxis treatment of migraine: double-blind, cross-over and multicenter study. *Neurología*; 1996: 379.
382. Mattimoe D, Newton W. High-dose riboflavin for migraine prophylaxis. *J Fam Pract* 1998 Jul; 47(1):11; PMID: 9673596.
383. Matts SG. Metoclopramide in the treatment of migraine. *The Practitioner*; 1974: 887-90.
384. Mattsson P. The name of a drug used for the treatment of migraine. *European Journal of Public Health* 2002 Jun; 12(2):155; PMID: 12073756.
385. Mavromichalis I, Zaramboukas T, Giala MM. Migraine of gastrointestinal origin. *European journal of pediatrics*; 1995: 406-10.
386. Mazzoleni R, Kreisler A, Lucas C, et al. Seizure after use of almotriptan. *Clinical Neurology & Neurosurgery* 2008 Sep; 110(8):850-1; PMID: 18599194.
387. Mazzone L, Vitiello B, Incorpora G, et al. Behavioural and temperamental characteristics of children and adolescents suffering from primary headache. *Cephalalgia : an international journal of headache*; 2006: 194-201.
388. McGrath PJ, Humphreys P, Goodman JT, et al. Relaxation prophylaxis for childhood migraine: a randomized placebo-controlled trial. *Dev Med Child Neurol* 1988 Oct; 30(5):626-31; PMID: 3229560.

389. Meckling SK, Becker WJ, Rose MS, et al. Sumatriptan responsiveness and clinical, psychiatric and psychologic features in migraine patients. *Canadian Journal of Neurological Sciences* 2001 Nov; 28(4):313-8; PMID: 11766775.
390. Mehrotra S, Vanmolkot KRJ, Frants RR, et al. The phe-124-Cys and A-161T variants of the human 5-HT_{1B} receptor gene are not major determinants of the clinical response to sumatriptan. *Headache* 2007 May; 47(5):711-6; PMID: 17501853.
391. Mehvari J, Rafieian-Kopaei M. Prophylactic activity of cyproheptadine and Bellergal on migraine headache. *Iranian Journal of Medical Sciences*; 2005: 84-7.
392. Melchart D, Hager S, Hager U, et al. Treatment of patients with chronic headaches in a hospital for traditional Chinese medicine in Germany. A randomised, waiting list controlled trial. *Complementary therapies in medicine*; 2004: 71-8.
393. Merelle SY, Sorbi MJ, van Doornen LJ, et al. Lay trainers with migraine for a home-based behavioral training: a 6-month follow-up study. *Headache* 2008 Oct; 48(9):1311-25; PMID: 19031498.
394. Merelle SY, Sorbi MJ, van Doornen LJ, et al. Migraine patients as trainers of their fellow patients in non-pharmacological preventive attack management: short-term effects of a randomized controlled trial. *Cephalalgia* 2008 Feb; 28(2):127-38; PMID: 18197883.
395. Meskunas CA, Tepper SJ, Rapoport AM, et al. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. *Headache* 2006 May; 46(5):766-72; PMID: 16643579.
396. Miano S, Parisi P, Pelliccia A, et al. Melatonin to prevent migraine or tension-type headache in children. *Neurol Sci* 2008 Sep; 29(4):285-7; PMID: 18810607.
397. Micieli G, Tassorelli C, Bosone D, et al. Increased cerebral blood flow velocity induced by cold pressor test in migraine: a possible basis for pathogenesis? *Cephalalgia* 1995 Dec; 15(6):494-8; PMID: 8706113.
398. Micieli G, Trucco M, Agostinis C, et al. Nimodipine vs. pizotifen in common migraine: results of a double-blind cross-over trial. *Cephalalgia*; 1985: 532-3.
399. Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, et al. Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, double-blind study. *Eur J Neurol* 2007 Oct; 14(10):1079-84; PMID: 17880560.
400. Millan-Guerrero RO, Pineda-Lucatero AG, Hernandez-Benjamin T, et al. Na-methylhistamine safety and efficacy in migraine prophylaxis: Phase I and Phase II studies. *Headache*; 2003: 389-94.
401. Miranda H, Ortiz G, Figueroa S, et al. Depression scores following migraine treatment in patients attending a specialized center for headache and neurology. *Headache* 2001 Jul-Aug; 41(7):680-4; PMID: 11554955.
402. Monro P, Swade C, Coppen A. Double blind comparative study of mianserin vs placebo in the prophylaxis of migraine. *Clin Neuropharmacol* Vol 7; 1984: 654-5.
403. Moore EL, Burgey CS, Paone DV, et al. Examining the binding properties of MK-0974: a CGRP receptor antagonist for the acute treatment of migraine. *European Journal of Pharmacology* 2009 Jan 14; 602(2-3):250-4; PMID: 19084002.
404. Morillo LE, Alarcon F, Aranaga N, et al. Clinical characteristics and patterns of medication use of migraineurs in Latin America from 12 cities in 6 countries. *Headache* 2005 Feb; 45(2):118-26; PMID: 15705116.
405. Moschiano F, Allais G, Grazzi L, et al. Naratriptan in the short-term prophylaxis of pure menstrual migraine. *Neurol Sci* 2005 May; 26 Suppl 2:s162-6; PMID: 15926020.
406. Muiesan ML, Padovani A, Salvetti M, et al. Headache: Prevalence and relationship with office or ambulatory blood pressure in a general population sample (the Vobarno Study). *Blood pressure*; 2006: 14-9.
407. Mullally WJ, Hall K, Goldstein R. Efficacy of biofeedback in the treatment of migraine and tension type headaches. *Pain Physician* 2009 Nov-Dec; 12(6):1005-11; PMID: 19935987.

408. Munno I, Marinaro M, Bassi A, et al. Immunological aspects in migraine: increase of IL-10 plasma levels during attack. *Headache* 2001 Sep; 41(8):764-7; PMID: 11576199.
409. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. *Lancet* 1988 Jul 23; 2(8604):189-92; PMID: 2899663.
410. Mushet GR, Cady RK, Baker CC, et al. Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose System. *Clin Ther* 1996 Jul-Aug; 18(4):687-99; PMID: 8879897.
411. Nagata E, Moriguchi H, Takizawa S, et al. The middle meningeal artery during a migraine attack: 3T magnetic resonance angiography study. *Internal Medicine* 2009; 48(24):2133-5; PMID: 20009407.
412. Nagy AJ, Gandhi S, Bhola R, et al. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. *Neurology* 2011 Nov 15; 77(20):1827-32; PMID: 22049203.
413. Naik M, Potluri R, Almasri E, et al. Sumatriptan-associated ischemic colitis. *Digestive Diseases & Sciences* 2002 Sep; 47(9):2015-6; PMID: 12353847.
414. Nappi G, Sandrini G, Granella F, et al. A new 5-HT₂ antagonist (ritanserine) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline. *Headache* 1990 Jun; 30(7):439-44; PMID: 2119355.
415. Nappi G, Sandrini G, Savoini G, et al. Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine. *Drugs* 1987; 33 Suppl 2:103-9; PMID: 3304950.
416. Nardin R. Randomized, controlled trial of telcagepant for the acute treatment of migraine. *Neurology* 2010 Mar 23; 74(12):1007; author reply -8; PMID: 20308688.
417. Natarajan S, Jabbour JT, Webster CJ, et al. Long-term tolerability of sumatriptan nasal spray in adolescent patients with migraine. *Headache* 2004 Nov-Dec; 44(10):969-77; PMID: 15546259.
418. Nattero G, Biale L, Savi L. Lisuride and pizotifen in the treatment of migraine without aura. *Cephalalgia*; 1991: 218-9.
419. Nattero G, Lisino F, Brandi G, et al. Dimethothiazine in the prevention of migraine. *Minerva-Med*; 1977: 839-46.
420. Nett R, Landy S, Shackelford S, et al. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. *Obstet Gynecol* 2003 Oct; 102(4):835-42; PMID: 14551015.
421. Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. *Headache* 2001 Mar; 41(3):248-56; PMID: 11264684.
422. Newman LC, Cady RK, Landy S, et al. Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan. *International Journal of Clinical Practice* 2008 Dec; 62(12):1889-99; PMID: 19166436.
423. Newman LC, Lipton RB, Lay CL, et al. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. *Neurology* 1998 Jul; 51(1):307-9; PMID: 9674831.
424. Nicholson NL, Blanchard EB. A controlled evaluation of behavioral treatment of chronic headache in the elderly. *Behav Ther* 1993; 24:395-408; PMID.
425. Nickel AK, Hillecke T, Argstatter H, et al. Outcome research in music therapy: a step on the long road to an evidence-based treatment. *Ann N Y Acad Sci* 2005 Dec; 1060:283-93; PMID: 16597777.
426. Nicolodi M, Del Bianco PL, Sicuteri F. The way to serotonergic use and abuse in migraine. *International journal of clinical pharmacology research*; 1997: 79-84.
427. Nicolodi M, Galeotti N, Ghelardini C, et al. Central cholinergic challenging of migraine by testing second-generation anticholinesterase drugs. *Headache* 2002 Jul-Aug; 42(7):596-602; PMID: 12482211.
428. Nicolodi M, Sicuteri F. Exploration of NMDA receptors in migraine: therapeutic and theoretic implications. *Int J Clin Pharmacol Res* 1995; 15(5-6):181-9; PMID: 8835616.

429. Noronha MJ. Double-blind randomised cross-over trial of timolol in migraine prophylaxis in children. *Cephalalgia*; 1985: 174-5.
430. Nyrke T, Kangasniemi P, Lang AH, et al. Steady-state visual evoked potentials during migraine prophylaxis by propranolol and femoxetine. *Acta Neurol Scand* 1984 Jan; 69(1):9-14; PMID: 6608203.
431. Obermann M, Mueller D, Yoon MS, et al. Migraine with isolated facial pain: a diagnostic challenge. *Cephalalgia* 2007 Nov; 27(11):1278-82; PMID: 17850354.
432. Oedegaard KJ, Riise T, Dilsaver SC, et al. A pharmaco-epidemiological study of migraine and antidepressant medications: complete one year data from the Norwegian population. *J Affect Disord* 2011 Mar; 129(1-3):198-204; PMID: 20889212.
433. Oelkers-Ax R, Leins A, Parzer P, et al. Butterbur root extract and music therapy in the prevention of childhood migraine: an explorative study. *Eur J Pain* 2008 Apr; 12(3):301-13; PMID: 17659990.
434. Ohbu S, Igarashi H, Okayasu H, et al. Development and testing of the Japanese version of the migraine-specific quality of life instrument. *Quality of Life Research* 2004 Oct; 13(8):1489-93; PMID: 15503844.
435. Olesen C, Steffensen FH, Sorensen HT, et al. Pregnancy outcome following prescription for sumatriptan. *Headache* 2000 Jan; 40(1):20-4; PMID: 10759898.
436. Olness K, Hall H, Rozniecki JJ, et al. Mast cell activation in children with migraine before and after training in self-regulation. *Headache* 1999 Feb; 39(2):101-7; PMID: 15613202.
437. Olness K, Hall H, Schmidt W, et al. Mast cell activation in child migraine patients before and after training in self regulation. *Alternative therapies in health and medicine*; 1997: 100-1.
438. Olness K, MacDonald J. Self-hypnosis and biofeedback in the management of juvenile migraine. *J Dev Behav Pediatr* 1981 Dec; 2(4):168-70; PMID: 7033294.
439. O'Quinn S, Jhingran P, Pait DG, et al. Relationships between productivity and clinical efficacy measures in a double-blind, placebo-controlled trial of sumatriptan in migraine [abstract]. *Neurology*; 1997: A236-7.
440. Orlando LA, Matchar DB. When to stress over triptans: a Markov analysis of cardiovascular risk in migraine treatment. *Headache* 2004 Jul-Aug; 44(7):652-60; PMID: 15209686.
441. Osterhaus SO, Passchier J, van der Helm-Hylkema H, et al. Effects of behavioral psychophysiological treatment on schoolchildren with migraine in a nonclinical setting: predictors and process variables. *J Pediatr Psychol* 1993 Dec; 18(6):697-715; PMID: 8138865.
442. Osterman PO. A comparison between placebo, pizotifen and 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2.3.5.6-tetrahydroindol (Divascan) in migraine prophylaxis. *Acta neurologica Scandinavica*; 1977: 17-28.
443. Ottman R, Lipton RB. Is the comorbidity of epilepsy and migraine due to a shared genetic susceptibility? *Neurology* 1996 Oct; 47(4):918-24; PMID: 8857719.
444. Palevitch D, Earon G, Carasso R. Feverfew (*Tanacetum parthenium*) as a prophylactic treatment for migraine: A double-blind placebo-controlled study. *Phytotherapy Research*; 1997: 508-11.
445. Panconesi A, Pavone E, Franchini M, et al. Triptans: low utilization and high turnover in the general population. *Cephalalgia* 2010 May; 30(5):576-81; PMID: 19732070.
446. Panconesi A, Pavone E, Vacca F, et al. Triptans in the Italian population: a drug utilization study and a literature review. *Journal of Headache & Pain* 2008 Apr; 9(2):71-6; PMID: 18317865.
447. Parker GB, Pryor DS, Tupling H. Why does migraine improve during a clinical trial? Further results from a trial of cervical manipulation for migraine. *Aust N Z J Med* 1980 Apr; 10(2):192-8; PMID: 6992760.
448. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. *Headache* 2002 Jan; 42(1):28-31; PMID: 12005272.
449. Pascual J, Diener H-C, Massiou H, et al. Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example. *Journal of Headache & Pain* 2006 Feb; 7(1):27-33; PMID: 16440139.

450. Pascual J, Falk R, Docekal R, et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. *European Neurology* 2001; 45(4):206-13; PMID: 11385257.
451. Paterna S, Martino SG, Campisi D, et al. Evaluation of the effects of verapamil, flunarizine, diltiazem, nimodipine and placebo for migraine prophylaxis. A double-blind randomized cross-over study. <ORIGINAL> VALUTAZIONE DEGLI EFFETTI INDOTTI DALL'USO DI VERAPAMILE, FLUNARIZINA, DILTIAZEM, NIMODIPINA E PLACEBO NELLA PROFILASSI DELL'EMICRANIA. STUDIO A DOPPIO CIECO RANDOMIZZATO CROSS-OVER. *Clin Ter*; 1990: 119-25.
452. Paterson C, Zheng Z, Xue C, et al. "Playing their parts": the experiences of participants in a randomized sham-controlled acupuncture trial. *J Altern Complement Med* 2008 Mar; 14(2):199-208; PMID: 18315508.
453. Pelka RB, Jaenicke C, Gruenwald J. Impulse magnetic-field therapy for migraine and other headaches: a double-blind, placebo-controlled study. *Adv Ther* 2001 May-Jun; 18(3):101-9; PMID: 11571822.
454. Perego R. Alpiropride: A new antimigraine drug. A multicenter double-blind crossed trial. *Folha Medica*; 1989: 405-7.
455. Peters EW, de Bruijn SFTM. Migraine treated with acyclovir. *Headache* 2005 Apr; 45(4):396-7; PMID: 15836587.
456. Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study. *Cephalalgia* 2002 Sep; 22(7):523-32; PMID: 12230594.
457. Pfaffenrath V, Rehm M. Migraine in pregnancy: what are the safest treatment options? *Drug Safety* 1998 Nov; 19(5):383-8; PMID: 9825951.
458. Phongphua CH. Feasibility study for a clinical trial of chiropractic care for patients with migraine headaches using different chiropractic techniques. *J Chiropr Edu*; 1999: 75.
459. Pieterse H, Kuster JA, Van Bortel LM. Is the Migraid device an asset in the non-pharmacologic treatment of migraine? *Acta Neurol Belg* 2007 Jun; 107(2):40-6; PMID: 17710839.
460. Pilgrim AJ, Lloyd DK. Migraine. *Lancet* 1992 Jul 4; 340(8810):62; PMID: 1351649.
461. Pini LA, Fabbri L, Di P, et al. Efficacy and safety of sumatriptan 50 mg in patients not responding to standard care, in the treatment of mild to moderate migraine. *International Journal of Clinical Pharmacology Research*; 1999: 57-64.
462. Pini LA, Ferrari A, Guidetti G, et al. Influence of flunarizine on the altered electronystagmographic (ENG) recordings in migraine. *Cephalalgia : an international journal of headache*; 1985: 173-5.
463. Pintov S, Lahat E, Alstein M, et al. Acupuncture and the opioid system: implications in management of migraine. *Pediatr Neurol* 1997 Sep; 17(2):129-33; PMID: 9367292.
464. Piovesan EJ, Young Blood MR, Kowacs PA, et al. Prevalence of migraine in Noonan syndrome. *Cephalalgia* 2007 Apr; 27(4):330-5; PMID: 17376109.
465. Pothmann R. Calcium-antagonist flunarizine vs. low-dose acetylsalicylic acid in childhood migraine: a double-blind study. *Cephalalgia*; 1985: 385-56.
466. Pothmann R, Danesch U. Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. *Headache* 2005 Mar; 45(3):196-203; PMID: 15836592.
467. Powers C, Szeto S, Pangtay D, et al. Evaluation of migraineurs' preferences for naratriptan over conventional first-line agents. *Archives of Family Medicine* 2000 Aug; 9(8):753-8; PMID: 10927717.
468. Pradalier A, Bakouche P, Baudesson G, et al. Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: a double-blind study versus placebo. *Cephalalgia* 2001 Oct; 21(8):818-22; PMID: 11737007.
469. Pradalier A, Lutz G, Vincent D. Transient global amnesia, migraine, thalamic infarct, dihydroergotamine, and sumatriptan. *Headache* 2000 Apr; 40(4):324-7; PMID: 10759939.
470. Presthus J. BC 105 and methysergide (Deseril) in migraine prophylaxis. *Acta neurologica Scandinavica*; 1971: 514-8.

471. Prisinzano T, Law H, Dukat M, et al. Imidazoline-modified benzyimidazolines as h5-HT(1D/1B) serotonergic ligands. *Bioorganic & Medicinal Chemistry* 2001 Mar; 9(3):613-9; PMID: 11310595.
472. Putnam GP, O'Quinn S, Bolden-Watson CP, et al. Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. *Cephalalgia* 1999 Sep; 19(7):668-75; PMID: 10524661.
473. Rahimtoola H, Buurma H, Tijssen CC, et al. Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy--a pilot study. *Pharmacoepidemiology & Drug Safety* 2004 Jan; 13(1):41-7; PMID: 14971122.
474. Rahimtoola H, Buurma H, Tijssen CC, et al. Single use of sumatriptan: a patient interview study. *Headache* 2003 Feb; 43(2):109-16; PMID: 12558764.
475. Rahimtoola H, Egberts AC, Buurma H, et al. Patterns of ergotamine and sumatriptan use in the Netherlands from 1991 to 1997. *Cephalalgia* 2001 Jun; 21(5):596-603; PMID: 11472386.
476. Rahimtoola H, Egberts AC, Buurma H, et al. Reduction in the intensity of abortive migraine drug use during coumarin therapy. *Headache* 2001 Sep; 41(8):768-73; PMID: 11576200.
477. Rand MK, White RG. Behavioral self-management: An application to the problem of migraine headaches. *Behav-Ther*; 1977: 213-21.
478. Rapoport AM, Sheftell FD, Tepper SJ, et al. Levetiracetam in the preventive treatment of transformed migraine: a prospective, open-label, pilot study. *Current therapeutic research* 2005; 66(3):212-21; PMID.
479. Rapoport AM, Visser WH, Cutler NR, et al. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. *Neurology* 1995 Aug; 45(8):1505-9; PMID: 7644049.
480. Rascol A, Montastruc JL, Rascol O. Flunarizine versus pizotifen: a double blind study in the prophylaxis of migraine. *Cephalalgia*; 1985: 542.
481. Rascol A, Montastruc JL, Rascol O. Flunarizine versus pizotifen: a double-blind study in the prophylaxis of migraine. *Headache* 1986 Feb; 26(2):83-5; PMID: 3514549.
482. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. *Cephalalgia* 1992 Aug; 12(4):221-8; discussion 186; PMID: 1525797.
483. Ravindran MK, Zheng Y, Timbol C, et al. Migraine headaches in chronic fatigue syndrome (CFS): comparison of two prospective cross-sectional studies. *BMC Neurol* 2011; 11:30; PMID: 21375763.
484. Reisman M. Evaluate safety/effectiveness of PFO closure with the STARFlex system to resolve refractory migraine with aura. *ClinicalTrials.gov*; 2006.
485. Repaka A, Wenger J, Sitaraman SV. A case of sumatriptan-induced intestinal ischemia. *Journal of Gastroenterology* 2006 Feb; 41(2):177-8; PMID: 16568377.
486. Riadh H, Mohamed G, Salah Y, et al. Pediatric case of ophthalmoplegic migraine with recurrent oculomotor nerve palsy. *Canadian Journal of Ophthalmology* 2010 Dec; 45(6):643; PMID: 21135898.
487. Richardson GM, McGrath PJ. Cognitive-behavioral therapy for migraine headaches: a minimal-therapist-contact approach versus a clinic-based approach. *Headache* 1989 Jun; 29(6):352-7; PMID: 2759842.
488. Richter IL, McGrath PJ, Humphreys PJ, et al. Cognitive and relaxation treatment of paediatric migraine. *Pain*; 1986: 195-203.
489. Ringel G, Taubert K. The efficacy of transcutaneous electrical nerve stimulation with migraine. *Zeitschrift Physiotherapie*; 1991: 8-11.
490. Robbins L. Triptans versus analgesics. *Headache* 2002 Oct; 42(9):903-7; PMID: 12390618.
491. Robbins L. Frequent triptan use: observations on safety issues. *Headache* 2004 Feb; 44(2):178-82; PMID: 14756859.
492. Roebuck-Spencer T, Sun W, Cernich AN, et al. Assessing change with the Automated Neuropsychological Assessment Metrics (ANAM): issues and challenges. *Archives of Clinical Neuropsychology* 2007 Feb; 22 Suppl 1:S79-87; PMID: 17118623.

493. Roon KI, Soons PA, Uitendaal MP, et al. Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks. *Br J Clin Pharmacol* 1999 Mar; 47(3):285-90; PMID: 10215753.
494. Rothner A, Edwards K, Kerr L, et al. Efficacy and safety of Naratriptan Tablets in adolescent migraine. *Journal of the Neurological Sciences*; 1997.
495. Rothrock J, Lopez I, Zweilfer R, et al. Borderline personality disorder and migraine. *Headache* 2007 Jan; 47(1):22-6; PMID: 17355490.
496. Rothrock JF. The price of pain. *Headache* 2006 Jun; 46(6):1011; PMID: 16732848.
497. Rothrock JF, Morey V. "Mixing triptans": patient satisfaction. *Headache* 2011 Jan; 51(1):135-40; PMID: 21198574.
498. Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. *Cephalalgia* 2002 Mar; 22(2):137-41; PMID: 11972582.
499. Ryan JRE. A clinical study of tyramine as an etiological factor in migraine. *Headache*; 1974: 43-8.
500. Saberi A, Esmaealzadeh K, Ghayeghran AR, et al. Assessment the effectiveness of omega 3 on migraine headache severity in migraineurs. *Jornal of Neurology*; 2010: S61, Abstract no: P190.
501. Safar HA, Alanezi KH, Cin, et al. Successful treatment of threatening limb loss ischemia of the upper limb caused by ergotamine. A case report and review of the literature. *Journal of Cardiovascular Surgery* 2002 Apr; 43(2):245-9; PMID: 11887064.
502. Saiers J, Jones M, Kane K, et al. Naratriptan tablets 2.5 Mg exhibit prolonged action and are well-tolerated in non-severe migraine attacks: data from a comparator study with sumatriptan. *European Journal of Neurology (Abstracts of the 4th Congress of the European Federation of Neurological Sciences, September 7-11, Lisbon, Portugal 1999)*; 1999: 105.
503. Salfield SA, Wardley BL, Houlsby WT, et al. Controlled study of exclusion of dietary vasoactive amines in migraine. *Arch Dis Child* 1987 May; 62(5):458-60; PMID: 3038036.
504. Salmon M. Pizotifen (BC.105. Sanomigran) in the prophylaxis of childhood migraine. *Cephalalgia* 1985; 5(Suppl 3):178; PMID.
505. Salonen R. The sumatriptan difference. *Cephalalgia* 2001; 21 Suppl 1:18-20; PMID: 11678816.
506. Sandor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. *Neurology* 2005 Feb 22; 64(4):713-5; PMID: 15728298.
507. Sandrini G, Savoini G, Cavallini A, et al. Efficacy of cyclandelate in migraine prophylaxis. *Cephalalgia*; 1987: 481-2.
508. Santucci M, Cortelli P, Rossi PG, et al. L-5-hydroxytryptophan versus placebo in childhood migraine prophylaxis: a double-blind crossover study. *Cephalalgia : an international journal of headache*; 1986: 155-7.
509. Saper J, Goadsby P, Dodick D, et al. Occipital nerve stiulation (ONS) for treatment of intractable chronic migraine (ICM): 3-month results from the ONSTIM feasibility study. *Neurology Vol 72*; 2009: A252, Abstract no: IN4-2.005.
510. Saper JR, Lake AE, Tepper SJ. Nefazodone for chronic daily headache prophylaxis: an open-label study. *Headache* 2001 May; 41(5):465-74; PMID: 11380644.
511. Sarens T, Herroelen L, Van Deyk K, et al. Patent foramen ovale closure and migraine: are we following the wrong pathway? *J Neurol* 2009 Jan; 256(1):143-4; PMID: 19172218.
512. Savani N, Martin A, Browning D. Switching patients with migraine from sumatriptan to other triptans increases primary care costs. *International Journal of Clinical Practice* 2004 Aug; 58(8):758-63; PMID: 15372848.
513. Schabert E, Crow WT. Impact of osteopathic manipulative treatment on cost of care for patients with migraine headache: a retrospective review of patient records. *Journal of the American Osteopathic Association* 2009 Aug; 109(8):403-7; PMID: 19706829.
514. Scharff L, Marcus DA, Masek BJ. A controlled study of minimal-contact thermal biofeedback treatment in children with migraine. *J Pediatr Psychol* 2002 Mar; 27(2):109-19; PMID: 11821495.

515. Schellenberg R, Schwarz A, Niederberger U, et al. Long-time efficacy of cyclandelate and propranolol in prophylaxis of migraine following four months of treatment. <ORIGINAL> ZUR LANGZEITWIRKUNG VON CYCLANDELAT UND PROPRANOLOL BEI MIGRANE NACH BEENDIGUNG EINER VIERMONATIGEN MEDIKAMENTÖSEN PROPHYLAXE. Nervenheilkunde; 1997: 183-7.
516. Schellenberg R, Schwarz A, Neiderberger U, et al. 1-year-follow-up effects after migraine prophylaxis with cyclandelate and propanolol. Functional Neurology; 1996: 155.
517. Scher AI, Stewart WF, Liberman J, et al. Prevalence of frequent headache in a population sample. Headache; 1998: 497-506.
518. Schmidt R, Oestreich W. Flunarizine in migraine prophylaxis: the clinical experience. Journal of Cardiovascular Pharmacology 1991; 18 Suppl 8:S21-6; PMID: 1726732.
519. Schoenen J, Coppola G. Headache: spreading from molecules to patients. Lancet Neurology 2010 Jan; 9(1):11-2; PMID: 20083026.
520. Schoenen J, De Klippel N, Giurgea S, et al. Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. Cephalalgia 2008 Oct; 28(10):1095-105; PMID: 18644036.
521. Schoenen J, Jacqy J, Lenaerts M. High-dose riboflavin is effective in migraine prophylaxis: results from a double-blind, randomised, placebo-controlled trial [abstract]. Neurology; 1997: A86-7.
522. Schoenen J, Jacqy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998 Feb; 50(2):466-70; PMID: 9484373.
523. Schoonman GG, van der Grond J, Kortmann C, et al. Migraine headache is not associated with cerebral or meningeal vasodilatation--a 3T magnetic resonance angiography study. Brain 2008 Aug; 131(Pt 8):2192-200; PMID: 18502781.
524. Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2000 Aug; 75(8):782-9; PMID: 10943230.
525. Schwartz TH, Karpitskiy VV, Sohn RS. Intravenous valproate sodium in the treatment of daily headache. Headache 2002 Jun; 42(6):519-22; PMID: 12167141.
526. Schwerzmann M, Wiher S, Nedeltchev K, et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology 2004 Apr 27; 62(8):1399-401; PMID: 15111681.
527. Sedighi B, Ghaderi-Sohi S, Emami S. Evaluation of self-medication prevalence, diagnosis and prescription in migraine in Kerman, Iran. Saudi Medical Journal 2006 Mar; 27(3):377-80; PMID: 16532101.
528. Shankland WE. Nociceptive trigeminal inhibition--tension suppression system: a method of preventing migraine and tension headaches. Compend Contin Educ Dent 2001 Dec; 22(12):1075-80, 82; quiz 84; PMID: 11887670.
529. Shankland WE, 2nd. Migraine and tension-type headache reduction through pericranial muscular suppression: a preliminary report. Cranio 2001 Oct; 19(4):269-78; PMID: 11725851.
530. Shepherd AJ. Increased visual after-effects following pattern adaptation in migraine: a lack of intracortical excitation? Brain 2001 Nov; 124(Pt 11):2310-8; PMID: 11673331.
531. Sherman RA, Acosta NM, Robson L. Treatment of migraine with pulsing electromagnetic fields: a double-blind, placebo-controlled study. Headache 1999 Sep; 39(8):567-75; PMID: 11279973.
532. Sherman RA, Robson L, Marden LA. Initial exploration of pulsing electromagnetic fields for treatment of migraine. Headache 1998 Mar; 38(3):208-13; PMID: 9563212.
533. Shrivastava R, Pechadre JC, John GW. Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study. Clin Drug Investig 2006; 26(5):287-96; PMID: 17163262.

534. Shuhaiber S, Pastuszak A, Schick B, et al. Pregnancy outcome following first trimester exposure to sumatriptan. *Neurology* 1998 Aug; 51(2):581-3; PMID: 9710039.
535. Sicuteri F. Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine. *Int Arch Allergy Appl Immunol*; 1959: 300-7.
536. Sicuteri F. The ingestion of serotonin precursors (L-5-hydroxytryptophan and L-tryptophan) improves migraine headache. *Headache*; 1973: 19-22.
537. Siegel SJ, O'Neill C, Dube LM, et al. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. *Pharm Res* 2007 Oct; 24(10):1919-26; PMID: 17577644.
538. Silberstein S, Elkind A, Schreiber C. Frovatriptan, a selective 5HT_{1B/1D} Agonist, is effective for prophylaxis of menstrually associated migraine. American Academy of Neurology Annual Meeting, 29 March-5 April, 2003.; 2003: S15.004.
539. Silberstein SD, Berner T, Tobin J, et al. Scheduled short-term prevention with frovatriptan for migraine occurring exclusively in association with menstruation. *Headache* 2009 Oct; 49(9):1283-97; PMID: 19751371.
540. Silberstein SD, Elkind AH, Schreiber C, et al. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. *Neurology* 2004 Jul 27; 63(2):261-9; PMID: 15277618.
541. Silberstein SD, Young WB, Hopkins MM, et al. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial. *Headache* 2007 Jun; 47(6):878-85; PMID: 17578539.
542. Silcocks P, Whitham D, Whitehouse WP. P3MC: a double blind parallel group randomised placebo controlled trial of Propranolol and Pizotifen in preventing migraine in children. *Trials* 2010; 11:71; PMID: 20553601.
543. Sillanpää M, Koponen M. Papaverine in the prophylaxis of migraine and other vascular headache in children. *Acta paediatrica Scandinavica*; 1978: 209-12.
544. Siniatchkin M, Gerber WD, Vein A. Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study. *Funct Neurol* 1998 Jan-Mar; 13(1):47-56; PMID: 9584874.
545. Smith M, Cros D, Sheen V. Hyperperfusion with vasogenic leakage by fMRI in migraine with prolonged aura. *Neurology* 2002 Apr 23; 58(8):1308-10; PMID: 11971111.
546. Smith T, Blumenthal H, Diamond M, et al. Sumatriptan/Naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes. *Headache* 2007 May; 47(5):683-92; PMID: 17501849.
547. Society NNAAM. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. *Menopause* 2010; 27(2):242-55; PMID.
548. Solomon S. The hazards of medication refills by telephone. *Headache* 2002 Sep; 42(8):835; PMID: 12390654.
549. Somerville BW, Herrmann WM. Migraine prophylaxis with Lisuride hydrogen maleate--a double blind study of Lisuride versus placebo. *Headache* 1978 May; 18(2):75-9; PMID: 348647.
550. Soon YY, Siow HC, Tan CY. Assessment of migraineurs referred to a specialist headache clinic in Singapore: diagnosis, treatment strategies, outcomes, knowledge of migraine treatments and satisfaction. *Cephalalgia : an international journal of headache*; 2005: 1122-32.
551. Sorbi M, Tellegen B. Differential effects of training in relaxation and stress-coping in patients with migraine. *Headache*; 1986: 473-81.
552. Sorbi M, Tellegen B, Du Long A. Long-term effects of training in relaxation and stress-coping in patients with migraine: a 3-year follow-up. *Headache*; 1989: 111-21.
553. Sorensen PS. Prophylactic effect of flunarizine versus metoprolol in migraine. *Cephalalgia*; 1989: 355-6.
554. Sorensen PS, Hansen K, Olesen J. Flunarizine in common migraine prophylaxis, a double-blind cross-over study. *Cephalalgia Vol 5*; 1985: 540-1.

555. Sorge F, De Simone R, Marano E, et al. Efficacy of flunarizine in the prophylaxis of migraine in children: a double-blind, cross-over, controlled study. *Cephalalgia*; 1985: 174.
556. Soyka D, Oestreich W. Therapeutic effectiveness of flunarizine and propranolol in the interval therapy of migraine. *Cephalalgia* Vol 7; 1987: 467-8.
557. Soyka D, Oestreich W. Flunarizine versus propranolol in interval treatment of migraine. *Nervenheilkunde*; 1990: 45-51.
558. Spigt MG, Kuijper EC, Schayck CP, et al. Increasing the daily water intake for the prophylactic treatment of headache: a pilot trial. *European journal of neurology : the official journal of the European Federation of Neurological Societies*; 2005: 715-8.
559. Standal JE. Pizotifen as an antidepressant. *Acta psychiatrica Scandinavica*; 1977: 276-9.
560. Stead M, Josephs KA. Successful treatment of status migrainosus after electroconvulsive therapy with dihydroergotamine. *Headache* 2005 Apr; 45(4):378-80; PMID: 15836577.
561. Stensrud P, Sjaastad O. Clonazepam (rivotril) in migraine prophylaxis. *Headache* 1979 Sep; 19(6):333-4; PMID: 511533.
562. Stensrud P, Skaug OE, Sjaastad O. Clinical trial of MY-25 (1-methyl-ergotamine-bitartrate) in migraine prophylaxis. *Headache*; 1971: 128-31.
563. Stone K. NerveCenter: Sumatriptan's evolution from brand drug to best buy of 2010. *Annals of Neurology* 2010 Sep; 68(3):A10-1; PMID: 20818778.
564. Stout MA. Homeostatic reconditioning in stress-related disorders: A preliminary study of migraine headaches. *Psychotherapy*; 1985: 531-41.
565. Stovner LJ, Hagen K, Waage A, et al. Hereditary haemochromatosis in two cousins with cluster headache. *Cephalalgia* 2002 May; 22(4):317-9; PMID: 12100096.
566. Straumsheim P, Borchgrevink C, Mowinckel P, et al. Homeopathic treatment of migraine: a double blind, placebo controlled trial of 68 patients [see comment]. *Br Homeopath J* 2000 Jan; 89(1):4-7; PMID: 10703903.
567. Straumsheim PA, Borchgrevink C, Mowinckel P, et al. Homeopathic treatment of migraine. A double-blind placebo controlled trial of 68 patients. *Dynamis*; 1997.
568. Strom L, Pettersson R, Andersson G. A controlled trial of self-help treatment of recurrent headache conducted via the Internet. *J Consult Clin Psychol* 2000 Aug; 68(4):722-7; PMID: 10965647.
569. Stronks DL, Tulen JH, Verheij R, et al. Serotonergic, catecholaminergic, and cardiovascular reactions to mental stress in female migraine patients. A controlled study. *Headache* 1998 Apr; 38(4):270-80; PMID: 9595866.
570. Sulman FG, Pfeifer Y, Superstine E. Preventive treatment of migraine with enzyme induction by proxibarbal in a "double-blind" trial. *Headache*; 1980: 269-73.
571. Symon DN, Russell G. Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine. *Arch Dis Child* 1995 Jan; 72(1):48-50; PMID: 7717738.
572. Tassorelli C, Cavallini A, Iannacchero R, et al. Treatment and prophylaxis of migraine-type headache: Effectiveness of indomethacin-caffeine-prochlorperazine (Difmetre). A double-blind controlled trial comparing indomethacin alone. *Clin Trials J*; 1989: 345-55.
573. Teixido M, Seymour P, Kung B, et al. Otagia associated with migraine. *Otol Neurotol* 2011 Feb; 32(2):322-5; PMID: 21178808.
574. Tfelt-Hansen P, Daugaard D, Lassen LH, et al. Prednisolone reduces nitric oxide-induced migraine. *Eur J Neurol* 2009 Oct; 16(10):1106-11; PMID: 19614965.
575. Tfelt-Hansen P, Steiner TJ. Sumatriptan vs dihydroergotamine: patient preference. *International Journal of Clinical Practice* 2001 Mar; 55(2):151; PMID: 11321860.
576. Theeler BJ, Mercer R, Erickson JC. Prevalence and impact of migraine among US Army soldiers deployed in support of Operation Iraqi Freedom. *Headache* 2008 Jun; 48(6):876-82; PMID: 18549370.
577. Thomaidis T, Karapanayiotides T, Kerezoudi E, et al. Intravenous valproate aborts glyceryl trinitrate-induced migraine attacks: a clinical and quantitative EEG study. *Cephalalgia* 2008 Mar; 28(3):250-6; PMID: 18201252.
578. Thompson CA. Frovatriptan approved as migraine treatment. *American Journal of Health-System Pharmacy* 2002 Jan 15; 59(2):116; PMID: 11826560.

579. Titus F, Davalos A, Alom J, et al. 5-Hydroxytryptophan versus methysergide in the prophylaxis of migraine. Randomized clinical trial. *Eur Neurol* 1986; 25(5):327-9; PMID: 3536521.
580. Tokola RA, Anttila VJ, Neuvonen PJ. The effect of metoclopramide on the absorption of tolfenamic acid. *International journal of clinical pharmacology, therapy, and toxicology*; 1982: 465-8.
581. Tokola RA, Neuvonen PJ. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. *Br J Clin Pharmacol*; 1984: 67-75.
582. Tomita M, Suzuki N, Igarashi H, et al. Evidence against strong correlation between chest symptoms and ischemic coronary changes after subcutaneous sumatriptan injection. *Internal Medicine* 2002 Aug; 41(8):622-5; PMID: 12211529.
583. Torelli P, Cologno D, Manzoni GC. Weekend headache: a retrospective study in migraine without aura and episodic tension-type headache. *Headache* 1999 Jan; 39(1):11-20; PMID: 15613189.
584. Torgovnick J, Sethi NK, Arsura E. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled cross-over study. *Cephalalgia* 2010 Oct; 30(10):1277; author reply -9; PMID: 20855373.
585. Trentman TL, Rosenfeld DM, Vargas BB, et al. Greater occipital nerve stimulation via the Bion microstimulator: implantation technique and stimulation parameters. Clinical trial: NCT00205894. *Pain Physician* 2009 May-Jun; 12(3):621-8; PMID: 19461827.
586. Trinka E, Unterrainer J, Luthringshausen G, et al. An auditory electrophysiological intervention in migraine: A randomized placebo controlled add on trial. *Journal of Neurotherapy*; 2002: 21-30.
587. Trucco M, Meineri P, Ruiz L, et al. Preliminary results of a withdrawal and detoxification therapeutic regimen in patients with probable chronic migraine and probable medication overuse headache. *Journal of Headache & Pain* 2005 Sep; 6(4):334-7; PMID: 16362704.
588. Tuchin P. The Effect of Spinal Manipulative Therapy (SMT) on the Cervical Spine for Migraine With Aura. A Randomised Control Trial. *Australasian Chiropractic & Osteopathy*; 1997: 96-7.
589. Tuchin PJ. The Efficacy of Chiropractic Spinal Manipulative Therapy (SMT) in the Treatment of Migraine. A Pilot Study. *Australasian Chiropractic & Osteopathy*; 1997: 41-7.
590. Tuchin PJ. A Twelve Month Clinical Trial of Chiropractic Spinal Manipulative Therapy for Migraine. *Australasian Chiropractic & Osteopathy*; 1999: 61-5.
591. Tulen JH, Stronks DL, Bussmann JB, et al. Towards an objective quantitative assessment of daily functioning in migraine: a feasibility study. *Pain* 2000 May; 86(1-2):139-49; PMID: 10779671.
592. Turin A, Johnson WG. Biofeedback therapy for migraine headaches. *Arch Gen Psychiatry* 1976 Apr; 33(4):517-9; PMID: 938188.
593. Ueberall M. Sumatriptan in paediatric and adolescent migraine. *Cephalalgia* 2001; 21 Suppl 1:21-4; PMID: 11678817.
594. van der Kuy PHM, Merkus FWHM, Lohman JJHM, et al. Hydroxocobalamin, a nitric oxide scavenger, in the prophylaxis of migraine: an open, pilot study. *Cephalalgia* 2002 Sep; 22(7):513-9; PMID: 12230592.
595. Velentgas P, Cole JA, Mo J, et al. Severe vascular events in migraine patients. *Headache* 2004 Jul-Aug; 44(7):642-51; PMID: 15209685.
596. Verspeelt J, De Locht P, Amery WK. Post-marketing cohort study comparing the safety and efficacy of flunarizine and propranolol in the prophylaxis of migraine. *Cephalalgia* 1996 Aug; 16(5):328-36; discussion 288; PMID: 8869768.
597. Vickers A, Rees R, Zollman C, et al. Acupuncture for migraine and headache in primary care: A protocol for a pragmatic, randomized trial. *Complementary Therapies in Medicine*; 1999: 3-18.
598. Vickers AJ, McCarney R. Use of a single global assessment to reduce missing data in a clinical trial with follow-up at one year. *Control Clin Trials* 2003 Dec; 24(6):731-5; PMID: 14662279.

599. Vickers AJ, Rees RW, Zollman CE, et al. Acupuncture for chronic headache in primary care: large, pragmatic, randomised trial. *BMJ* 2004 Mar 27; 328(7442):744; PMID: 15023828.
600. Vieira J, x00E, Pedro, et al. Ophthalmoplegic migraine and infundibular dilatation of a cerebral artery. *Headache* 2008 Oct; 48(9):1372-4; PMID: 18631189.
601. Vilming S, Standnes B, Hedman C. Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine. A double-blind investigation. *Cephalalgia : an international journal of headache*; 1985: 17-23.
602. Vincent CA. A controlled trial of the treatment of migraine by acupuncture. *Clin J Pain* 1989 Dec; 5(4):305-12; PMID: 2520420.
603. Visser EJ. Is migraine a complex regional pain syndrome of the brain? Migraine prophylaxis with vitamin C? *Pain Pract* 2011 Mar; 11(2):199-200; PMID: 21371256.
604. Visudtibhan A, Lusawat A, Chiemchanya S, et al. Flunarizine for prophylactic treatment of childhood migraine. *Journal of the Medical Association of Thailand* 2004 Dec; 87(12):1466-70; PMID: 15822542.
605. Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. *Cephalalgia* 1998 Dec; 18(10):704-8; PMID: 9950629.
606. Vonderheid-Guth B, Todorova A, Wedekind W, et al. Evidence for neuronal dysfunction in migraine: concurrence between specific qEEG findings and clinical drug response--a retrospective analysis. *European Journal of Medical Research* 2000 Nov 30; 5(11):473-83; PMID: 11121368.
607. Vos J, Passchier J. Reduced impact of migraine in everyday life: an observational study in the Dutch Society of Headache Patients. *Headache* 2003 Jun; 43(6):645-50; PMID: 12786925.
608. Wachholtz AB, Pargament KI. Migraines and meditation: does spirituality matter? *J Behav Med* 2008 Aug; 31(4):351-66; PMID: 18551362.
609. Waelkens J. Domperidone in the prevention of complete classical migraine. *Br Med J (Clin Res Ed)* 1982 Mar 27; 284(6320):944; PMID: 6802362.
610. Waelkens J. Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. *Cephalalgia* 1984 Jun; 4(2):85-90; PMID: 6375874.
611. Wainscott G, Sullivan FM, Volans GN, et al. The outcome of pregnancy in women suffering from migraine. *Postgrad Med J* 1978 Feb; 54(628):98-102; PMID: 634879.
612. Walach H, Lowes T, Mussbach D, et al. The long-term effects of homeopathic treatment of chronic headaches: 1 Year follow up. *Cephalalgia*; 2000: 835-7.
613. Walker JE. QEEG-guided neurofeedback for recurrent migraine headaches. *Clinical EEG and neuroscience : official journal of the EEG and Clinical Neuroscience Society (ENCS)*; 2011: 59-61.
614. Walling A, Woolley DC, Molgaard C, et al. Do family physicians fail to provide triptans for patients with migraine? *Journal of Family Practice* 2006 Dec; 55(12):1057-62; PMID: 17137542.
615. Wammes-van der Heijden EA, Rahimtoola H, Leufkens HGM, et al. Risk of ischemic complications related to the intensity of triptan and ergotamine use. *Neurology* 2006 Oct 10; 67(7):1128-34; PMID: 17030745.
616. Wammes-van der Heijden EA, Smidt MH, Tijssen CC, et al. Effect of low-intensity acenocoumarol on frequency and severity of migraine attacks. *Headache* 2005 Feb; 45(2):137-43; PMID: 15705119.
617. Wammes-van der Heijden EA, Tijssen CC, Egberts ACG. Treatment choices and patterns in migraine patients with and without a cardiovascular risk profile. *Cephalalgia* 2009 Mar; 29(3):322-30; PMID: 19220314.
618. Wang JT, Barr CE, Goldfarb SD. Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan. *Headache* 2002 Jan; 42 Suppl 1:38-43; PMID: 11966863.
619. Wang JT, Barr CE, Torigoe Y, et al. Cost savings in migraine associated with less chest pain on new triptan therapy. *American Journal of Managed Care* 2002 Feb; 8(3 Suppl):S102-7; PMID: 11859905.
620. Wang L. Efficacy and safety of acupuncture for migraine prophylaxis - a multicenter, randomized controlled trial. *ISRCTN Register* 2007; PMID.

621. Wang W, Schoenen J. Reduction of temporalis exteroceptive suppression by peripheral electrical stimulation in migraine and tension-type headaches. *Pain* 1994 Dec; 59(3):327-34; PMID: 7708406.
622. Wauquier A, McGrady A, Aloe L, et al. Changes in cerebral blood flow velocity associated with biofeedback-assisted relaxation treatment of migraine headaches are specific for the middle cerebral artery. *Headache* 1995 Jun; 35(6):358-62; PMID: 7635723.
623. Weidmann E, Unger J, Blair S, et al. An open-label study to assess changes in efficacy and satisfaction with migraine care when patients have access to multiple sumatriptan succinate formulations. *Clinical Therapeutics* 2003 Jan; 25(1):235-46; PMID: 12637123.
624. Weinschutz TK, Niederberger U. Relevance of acupuncture in migraine therapy.
<ORIGINAL> ZUM STELLENWERT DER AKUPUNKTUR IN DER MIGRANETHERAPIE. *Nervenheilkunde*; 1995: 295-301.
625. Welch KM. Sumatriptan and naratriptan tolerability and safety: an update of post-marketing experience. *Cephalalgia* 2001; 21 Suppl 1:25-8; PMID: 11678818.
626. Westgeest HM, Akol H, Schreuder TCMA. Pure naratriptan-induced ischemic colitis: a case report. *Turkish Journal of Gastroenterology* 2010 Mar; 21(1):42-4; PMID: 20533112.
627. Whitmarsh TE, Coleston-Shields DM, Steiner TJ. Double-blind randomized placebo-controlled study of homoeopathic prophylaxis of migraine. *Cephalalgia* 1997 Aug; 17(5):600-4; PMID: 9251877.
628. Wilkins AJ, Patel R, Adjamian P, et al. Tinted spectacles and visually sensitive migraine. *Cephalalgia* 2002 Nov; 22(9):711-9; PMID: 12421156.
629. Williams D, Cahill T, Dowson A, et al. Usage of triptans among migraine patients: an audit in nine GP practices. *Current Medical Research & Opinion* 2002; 18(1):1-9; PMID: 11999139.
630. Williamson DA, Monguillot JE, Jarrell MP, et al. Relaxation for the treatment of headache. Controlled evaluation of two group programs. *Behav Modif*; 1984: 407-24.
631. Winner P. Triptans for migraine management in adolescents. *Headache* 2002 Jul-Aug; 42(7):675-9; PMID: 12482222.
632. Winner P, Prensky A, Linder S, et al. Adolescent migraine: efficacy and safety of sumatriptan tablets. *Journal of the Neurological Sciences*; 1997: S172.
633. Witt CM, Reinhold T, Jena S, et al. Cost-effectiveness of acupuncture treatment in patients with headache. *Cephalalgia* 2008 Apr; 28(4):334-45; PMID: 18315686.
634. Wober C, Wober-Bingol C, Koch G, et al. Long-term results of migraine prophylaxis with flunarizine and beta-blockers. *Cephalalgia* 1991 Dec; 11(6):251-6; PMID: 1790569.
635. Wolthausen J, Sternberg S, Gerloff C, et al. Are cortical spreading depression and headache in migraine causally linked? *Cephalalgia* 2009 Feb; 29(2):244-9; PMID: 19025548.
636. Wooltorton E. Triptan migraine treatments and antidepressants: risk of serotonin syndrome. *CMAJ Canadian Medical Association Journal* 2006 Oct 10; 175(8):874; PMID: 16988028.
637. Wright W. Neurostabilizers for migraine prevention. From dosage administration to patient expectations. *Advance for Nurse Practitioners* 85, 2007 Feb; 15(2):52-4; PMID: 19998927.
638. Wylie KR, Jackson C, Crawford PM. Does psychological testing help to predict the response to acupuncture or massage/relaxation therapy in patients presenting to a general neurology clinic with headache? *J Tradit Chin Med* 1997 Jun; 17(2):130-9; PMID: 10437184.
639. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. *Neurology* 2005 Mar 22; 64(6):961-5; PMID: 15781808.
640. Xu Z, Lv JM. Efficacy analysis of qi-promoting method for migraine. *Shanghai Journal of Acupuncture and Moxibustion [Shang Hai Zhen Jiu Za Zhi]*; 1993: 97-100.
641. Yarangumeli A, Comoglu S, Koz O, et al. Effects of betaxolol and flunarizine on visual fields and intraocular pressure in patients with migraine. *Documenta Ophthalmologica* 2003 May; 106(3):265-70; PMID: 12737504.

642. Young WB, Mannix L, Adelman JU, et al. Cardiac risk factors and the use of triptans: a survey study. *Headache* 2000 Jul-Aug; 40(7):587-91; PMID: 10940098.
643. Zeller JA, Lindner V, Frahm K, et al. Platelet activation and platelet-leucocyte interaction in patients with migraine. Subtype differences and influence of triptans. *Cephalalgia* 2005 Jul; 25(7):536-41; PMID: 15955041.
644. Zhao L, Zhang FW, Li Y, et al. Adverse events associated with acupuncture: three multicentre randomized controlled trials of 1968 cases in China. *Trials* 2011; 12:87; PMID: 21435214.
645. Ziegler DK, Batnitzky S, Barter R, et al. Magnetic resonance image abnormality in migraine with aura. *Cephalalgia* 1991 Jul; 11(3):147-50; PMID: 1889071.
646. Zimmermann WJ, Heinisch C, Majunke N, et al. Patent foramen ovale closure with the SeptRx device initial experience with the first "In-Tunnel" device. *JACC. Cardiovascular interventions*; 2010: 963-7.
647. Zsombok T, Juhasz G, Budavari A, et al. Effect of autogenic training on drug consumption in patients with primary headache: an 8-month follow-up study. *Headache* 2003 Mar; 43(3):251-7; PMID: 12603644.
648. Zsombok T, Juhasz G, Budavari A, et al. Effect of autogenic training on drug consumption in patients with primary headache: an 8-month follow-up study. *Headache*; 2004: 251-7.

Not Eligible Target Population

1. Treatment of migraine. The Practitioner; 1971: 551-4.
2. Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med 1991 Aug 1; 325(5):316-21; PMID: 1647495.
3. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group. Eur Neurol 1991; 31(5):323-31; PMID: 1653140.
4. Sumatriptan--an oral dose-defining study. The Oral Sumatriptan Dose-Defining Study Group. Eur Neurol 1991; 31(5):300-5; PMID: 1653137.
5. Treatment of acute cluster headache with sumatriptan. The Sumatriptan Cluster Headache Study Group. The New England journal of medicine; 1991: 322-6.
6. Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs. Cephalalgia 2002 Jul; 22(6):416-23; PMID: 12133040.
7. MT 300. Dihydroergotamine mesylate injection - POZEN. Drugs R D 2003; 4(2):133-4; PMID: 12718573.
8. Abstracts of the 12th International Congress on Schizophrenia Research (ICOSR). March 28-April 1, 2009. San Diego, California, USA. Schizophr Bull 2009 Mar; 35 Suppl 1:1-377; PMID: 19252181.
9. A one-two punch to ward off migraines. Johns Hopkins Med Lett Health After 50 2011 Dec; 23(10):4-5; PMID: 22216467.
10. Adelman JU, Adelman LC, Freeman MC, et al. Cost considerations of acute migraine treatment. Headache 2004 Mar; 44(3):271-85; PMID: 15012668.
11. Adelman JU, Belsey J. Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. J Manag Care Pharm 2003 Jan-Feb; 9(1):45-52; PMID: 14613361.
12. Adelman JU, Lipton RB, Ferrari MD, et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 2001 Oct 23; 57(8):1377-83; PMID: 11673575.
13. Adelman LC, Adelman JU, Von Seggern R, et al. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache 2000 Jul-Aug; 40(7):572-80; PMID: 10940096.
14. Agha-Hosseini F, Mirzaii-Dizgah I, Ghavamzadeh L, et al. Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplantation; 2007: 431-4.
15. Ahn AH. Chronic pain and migraine. Headache 2007 Sep; 47(8):1259-61; PMID: 17883548.
16. Ahonen K, Hamalainen ML, Rantala H, et al. Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial. Neurology 2004 Mar 23; 62(6):883-7; PMID: 15037686.
17. Ahrens SP, Farmer MV, Williams DL, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia 1999 Jun; 19(5):525-30; PMID: 10403069.
18. Ahrens SP, Farmer MV, Williams DL, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia; 1999: 525-30.
19. Alam M, Arndt KA, Dover JS. Severe, intractable headache after injection with botulinum a exotoxin: report of 5 cases. J Am Acad Dermatol 2002 Jan; 46(1):62-5; PMID: 11756947.
20. Albsoul-Younes AM, Salem HA, Ajlouni SF, et al. Topiramate slow dose titration: improved efficacy and tolerability. Pediatr Neurol 2004 Nov; 31(5):349-52; PMID: 15519117.
21. Allais G, Bussone G, Airola G, et al. Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan. Neurological Sciences 2008 May; 29 Suppl 1:S186-90; PMID: 18545931.
22. Allais G, Bussone G, D'Andrea G, et al. Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2011 Jan; 31(2):144-51; PMID: 20660540.

23. Allais G, Sanchez del Rio M, Diener HC, et al. Perimenstrual migraines and their response to preventive therapy with topiramate. *Cephalalgia* 2011 Jan; 31(2):152-60; PMID: 20650999.
24. Allais G, Tullo V, Benedetto C, et al. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. *Neurol Sci* 2011 May; 32 Suppl 1:S99-104; PMID: 21533723.
25. Allen C, Dayno J, Lines C, et al. Rizatriptan wafer--sublingual vs. placebo at the onset of acute migraine. *Cephalalgia* 2001 Feb; 21(1):77; PMID: 11298669.
26. Al-Shekhlee A, Reed R. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. *Neurology* 2000 Sep 12; 55(5):735-6; PMID: 11041768.
27. Altinok D, Agarwal A, Ascadi G, et al. Pediatric hemiplegic migraine: susceptibility weighted and MR perfusion imaging abnormality. *Pediatr Radiol* 2010 Dec; 40(12):1958-61; PMID: 20821201.
28. Al-Waili NS. Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo. *European Journal of Medical Research* 2000 Apr 19; 5(4):176-82; PMID: 10799353.
29. Ampar, x00E, n-Estrada S, et al. Management of acute migraine headache with lidocaine. *Plastic & Reconstructive Surgery* 2005 Jul; 116(1):335; author reply -6; PMID: 15988292.
30. Anderson DR, Drance SM, Schulzer M, et al. Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. *American journal of ophthalmology*; 2003: 820-9.
31. Andersson PG, Hinge HH, Johansen O, et al. Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. *Cephalalgia : an international journal of headache*; 1989: 29-32.
32. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. *Pharmacoepidemiol Drug Saf* 2009 Mar; 18(3):246-52; PMID: 19148882.
33. Andre C, Gillon J, Moulinier B, et al. Randomised placebo-controlled double-blind trial of two dosages of sodium cromoglycate in treatment of varioliform gastritis: Comparison with cimetidine. *Gut*; 1982: 348-52.
34. Andreou AP, Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonists in migraine. *Expert Opinion on Investigational Drugs* 2009 Jun; 18(6):789-803; PMID: 19426123.
35. Anon. Treximet in acute migraine headache: assessing cognitive function. *Clinicaltrials.gov* [www.clinicaltrials.gov]; 2009.
36. Anonymous. Prochlorperazine more effective than ketorolac for pediatric migraine. *Journal of Family Practice*; 2004: 444.
37. Anthony M. Cervicogenic headache: prevalence and response to local steroid therapy. *Clinical & Experimental Rheumatology* 2000 Mar-Apr; 18(2 Suppl 19):S59-64; PMID: 10824289.
38. Antoniazzi AL, Bigal ME, Bordini CA, et al. Headache and hemodialysis: a prospective study. *Headache*; 2003: 99-102.
39. Archambault AP, Hunt RH, Cleator IGM, et al. Comparison of omeprazole with ranitidine for treatment of symptoms associated with gastroesophageal reflux disease and uncomplicated duodenal ulcer. *Canadian Journal of Gastroenterology.*; 1996: 156-62.
40. Arnold LE, Amato A, Bozzolo H, et al. Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial. *Journal of child and adolescent psychopharmacology*; 2007: 791-802.
41. Artto V, Nissil, x00E, et al. Treatment of hemiplegic migraine with triptans. *European Journal of Neurology* 2007 Sep; 14(9):1053-6; PMID: 17718700.
42. Asgharnejad M, DeBussey S. Clinical efficacy of sumatriptan nasal spray in the acute treatment of migraine: a review of data from clinical trials [abstract]. *Neurology*; 1998: A340.
43. Ashford E, Salonen R, Saiers J, et al. Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. *Cephalalgia* 1998 Jun; 18(5):273-7; PMID: 9673807.

44. Ashkenazi A, Matro R, Shaw JW, et al. Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: a randomised comparative study. *J Neurol Neurosurg Psychiatry* 2008 Apr; 79(4):415-7; PMID: 17682008.
45. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. *Health & Quality of Life Outcomes*; 2004: 12.
46. Aurora SK, Rozen TD, Kori SH, et al. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. *Headache* 2009 Jun; 49(6):826-37; PMID: 19545249.
47. Autret A, De Chasteigner C. DHE methane sulfonate with programmed liberation: preliminary results of a controlled study in common migraine. *Cephalalgia*; 1987: 451-2.
48. Awidi A. Efficacy of flurbiprofen in the treatment of acute migraine attacks: A double-blind cross-over study. *Curr-Ther-Res,-Clin-Exp*; 1982: 492-7.
49. Aydin M, Kabakus N, Bozdog S, et al. Profile of children with migraine. *Indian Journal of Pediatrics* 2010 Nov; 77(11):1247-51; PMID: 20886317.
50. Baden EY, Hunter CJ. Intravenous dexamethasone to prevent the recurrence of benign headache after discharge from the emergency department: a randomized, double-blind, placebo-controlled clinical trial. *CJEM* 2006 Nov; 8(6):393-400; PMID: 17209488.
51. Bakhru A, Atlas RO. A case of postpartum cerebral angiitis and review of the literature. *Arch Gynecol Obstet* 2011 Mar; 283(3):663-8; PMID: 20419307.
52. Baldwin ZK, Ceraldi CC. Ergotism associated with HIV antiviral protease inhibitor therapy. *Journal of Vascular Surgery* 2003 Mar; 37(3):676-8; PMID: 12618710.
53. Banerjee M, Findley L. Propranolol in the treatment of acute migraine attacks. *Cephalalgia* : an international journal of headache; 1991: 193-6.
54. Banhidly F, Acs N, Horvath-Puho E, et al. Pregnancy complications and delivery outcomes in pregnant women with severe migraine. *European Journal of Obstetrics, Gynecology, & Reproductive Biology* 2007 Oct; 134(2):157-63; PMID: 17097212.
55. Barbanti P, Carpay JA, Kwong WJ, et al. Effects of a fast disintegrating/rapid release oral formulation of sumatriptan on functional ability in patients with migraine. *Curr Med Res Opin* 2004 Dec; 20(12):2021-9; PMID: 15701219.
56. Barbanti P, Fabbrini G, Vanacore N, et al. Sumatriptan in migraine with unilateral cranial autonomic symptoms: an open study. *Headache* 2003 Apr; 43(4):400-3; PMID: 12656712.
57. Bartolini M, Giamberardino MA, Lisotto C, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. *J Headache Pain* 2011 Jun; 12(3):361-8; PMID: 21437714.
58. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. *Neurology* 1994 Sep; 44(9):1587-92; PMID: 7936279.
59. Beau-Salinas F, x00E, rique, et al. Drug dependence associated with triptans and ergot derivatives: a case/non-case study. *European Journal of Clinical Pharmacology* 2010 Apr; 66(4):413-7; PMID: 20024536.
60. Bell CF, Foley KA, Barlas S, et al. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study. *Clinical Therapeutics* 2006 Jun; 28(6):872-80; PMID: 16860170.
61. Belsey JD. Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials. *Curr Med Res Opin* 2004 May; 20(5):659-69; PMID: 15140331.
62. Belvis R, Ramos R, Villa C, et al. Brain apparent water diffusion coefficient magnetic resonance image during a prolonged visual aura. *Headache* 2010 Jun; 50(6):1045-9; PMID: 20408884.

63. Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. *J Neurol Neurosurg Psychiatry* 1996 Sep; 61(3):285-90; PMID: 8795600.
64. Benito-Ruiz P, Camacho-Zambrano MM, Carrillo-Arcentales JN, et al. A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort. *International Journal of Food Sciences and Nutrition*; 2009: 99-113.
65. Berges A, Walls C, Lener SE, et al. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers. *Clinical therapeutics*; 2010: 1165-77.
66. Biddle AK, Shih YC, Kwong WJ. Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine. *Pharmacotherapy* 2000 Nov; 20(11):1356-64; PMID: 11079284.
67. Bigal M, Rapoport A, Aurora S, et al. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. *Headache* 2007 Apr; 47(4):475-9; PMID: 17445096.
68. Bigal M, Rapoport A, Sheftell F, et al. Memantine in the preventive treatment of refractory migraine. *Headache* 2008 Oct; 48(9):1337-42; PMID: 19031499.
69. Bigal M, Sheftell F, Tepper S, et al. A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine: research submission. *Headache*; 2008: 1286-93.
70. Bigal ME, Bordini CA, Sheftell FD, et al. Migraine with aura versus migraine without aura: pain intensity and associated symptom intensities after placebo. *Headache* 2002 Oct; 42(9):872-7; PMID: 12390612.
71. Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. *J Emerg Med* 2002 Aug; 23(2):141-8; PMID: 12359281.
72. Bigal ME, Borucho S, Serrano D, et al. The acute treatment of episodic and chronic migraine in the USA. *Cephalalgia* 2009 Aug; 29(8):891-7; PMID: 19222509.
73. Bigal ME, Ho TW. Is there an inherent limit to acute migraine treatment efficacy? *Journal of Headache & Pain* 2009 Dec; 10(6):393-4; PMID: 19820895.
74. Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. *Headache* 2008 Sep; 48(8):1157-68; PMID: 18808500.
75. Bigal ME, Sheftell FD, Tepper SJ, et al. Migraine days decline with duration of illness in adolescents with transformed migraine. *Cephalalgia : an international journal of headache*; 2005: 482-7.
76. Bigal ME, Tsang A, Loder E, et al. Body mass index and episodic headaches: a population-based study. *Archives of Internal Medicine* 2007 Oct 8; 167(18):1964-70; PMID: 17923596.
77. Biton V, Edwards KR, Montouris GD, et al. Topiramate titration and tolerability. *Ann Pharmacother* 2001 Feb; 35(2):173-9; PMID: 11215835.
78. Blanchard EB, Appelbaum KA, Radnitz CL, et al. A controlled evaluation of thermal biofeedback and thermal biofeedback combined with cognitive therapy in the treatment of vascular headache. *J Consult Clin Psychol* 1990 Apr; 58(2):216-24; PMID: 2186067.
79. Blanchard EB, Nicholson NL, Radnitz CL, et al. The role of home practice in thermal biofeedback. *J Consult Clin Psychol* 1991 Aug; 59(4):507-12; PMID: 1918553.
80. Blanchard EB, Peters ML, Hermann C, et al. Direction of temperature control in the thermal biofeedback treatment of vascular headache. *Appl Psychophysiol Biofeedback* 1997 Dec; 22(4):227-45; PMID: 9595177.

81. Blanda M, Rench T, Gerson LW, et al. Intranasal lidocaine for the treatment of migraine headache: a randomized, controlled trial. *Acad Emerg Med* 2001 Apr; 8(4):337-42; PMID: 11282668.
82. Blau JN, Engel HO. Individualizing treatment with verapamil for cluster headache patients. *Headache* 2004 Nov-Dec; 44(10):1013-8; PMID: 15546265.
83. Block GA, Goldstein J, Polis A, et al. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups. *Headache* 1998 Nov-Dec; 38(10):764-71; PMID: 11284464.
84. Block GA, Smith M, Jiang K, et al. Rizatriptan (MK-0462) for the acute treatment of migraine and migraine recurrence [abstract]. *Neurology*; 1997: A68.
85. Blumenthal HJ. Butterscotch masks the bitter taste of sumatriptan nasal spray. *Headache* 2001 Feb; 41(2):210; PMID: 11251713.
86. Blumenthal HJ, Weisz MA, Kelly KM, et al. Treatment of primary headache in the emergency department. *Headache* 2003 Nov-Dec; 43(10):1026-31; PMID: 14629236.
87. Boe MG, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache: a randomized, double-blind study. *Neurology* 2007 Jul 3; 69(1):26-31; PMID: 17475943.
88. Bogousslavsky J, Garazi S, Jeanrenaud X, et al. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. *Neurology*; 1996: 1301-5.
89. Bollig G, Pothmann R, Thoiss W, et al. One-point-acupuncture for the treatment of acute headache - First results. *Deutsche Zeitschrift fur Akupunktur*; 2000: 172-4.
90. Bomhof M, Paz J, Legg N, et al. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. *Eur Neurol* 1999; 42(3):173-9; PMID: 10529545.
91. Bonuso S, Marano E, di Stasio E, et al. Source of pain and primitive dysfunction in migraine: an identical site? *J Neurol Neurosurg Psychiatry* 1989 Dec; 52(12):1351-4; PMID: 2515254.
92. Borgesen SE, Nielsen JL, Moller CE. Prophylactic treatment of migraine with propranolol. A clinical trial. *Acta neurologica Scandinavica*; 1974: 651-6.
93. Bosco D, Belfiore A, Fava A, et al. Relationship between high prolactin levels and migraine attacks in patients with microprolactinoma. *Journal of Headache & Pain* 2008 Apr; 9(2):103-7; PMID: 18256782.
94. Boska MD, Welch KM, Schultz L, et al. Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects. *Cephalalgia* 2000 Feb; 20(1):39-44; PMID: 10817445.
95. Boureau F, Chazot G, Emile J, et al. Sumatriptan vs usual acute treatment of migraine [abstract]. *Canadian Journal of Neurological Sciences*; 1993.
96. Bousser MG, Loria Y. Efficacy of dihydroergotamine nasal spray in the acute treatment of migraine attacks. *Cephalalgia*; 1985: 554-5.
97. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. *JAMA* 1994 Mar 23-30; 271(12):918-24; PMID: 8120960.
98. Boyce M, Dunn K, Warrington S. Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers. *Journal of cardiovascular pharmacology*; 2001: 280-9.
99. Boz C, Altunayoglu V, Velioglu S, et al. Sertraline versus amitriptyline in the prophylactic therapy of non-depressed chronic tension-type headache patients. *Journal of Headache & Pain* 2003; 4(2):72-8; PMID.
100. Brain SD, Poyner DR, Hill RG. CGRP receptors: a headache to study, but will antagonists prove therapeutic in migraine? *Trends in Pharmacological Sciences* 2002 Feb; 23(2):51-3; PMID: 11830255.
101. Brennum J, Brinck T, Schriver L, et al. Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. *European Journal of Neurology*.; 1996: 23-8.
102. Brousseau D, Duffy S, Anderson A, et al. Migraines in the pediatric emergency department: A randomized, double blind trial of IV ketorolac versus IV prochlorperazine. *Pediatric research*; 2002: 101a.

103. Brousseau DC, Duffy SJ, Anderson AC, et al. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. *Ann Emerg Med* 2004 Feb; 43(2):256-62; PMID: 14747817.
104. Bruni O, Galli F, Guidetti V. Sleep hygiene and migraine in children and adolescents. *Cephalalgia* 1999 Dec; 19 Suppl 25:57-9; PMID: 10668125.
105. Burgey CS, Stump CA, Nguyen DN, et al. Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine. *Bioorganic & Medicinal Chemistry Letters* 2006 Oct 1; 16(19):5052-6; PMID: 16889959.
106. Burk CT, Gilderman A, Salas J, et al. The impact of an over-the-counter migraine medication program on quality of life. *Headache* 2003 Mar; 43(3):191-201; PMID: 12603637.
107. Burke R, C PW, Laurenza A, et al. Efficacy of sumatriptan injection for the acute treatment of migraine in a primarily non-caucasian group of patients. *Functional Neurology*; 1998: 182.
108. Bussone G, D'Amico D, McCarroll KA, et al. Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials. *European Neurology* 2002; 48(3):172-7; PMID: 12373035.
109. Bussone G, Grazzi L, D'Amico D, et al. Acute treatment of migraine attacks: Efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. *Cephalalgia*; 1999: 232-40.
110. Cabarrocas X, Salva M, Pavesi M, et al. Ethanol does not significantly affect the bioavailability of almotriptan: an open, randomized, crossover, single-dose, phase I clinical trial in healthy volunteers. *International journal of clinical pharmacology and therapeutics*; 2006: 443-8.
111. Cady R. Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis. *Headache* 2002 Jan; 42 Suppl 1:26-31; PMID: 11966861.
112. Cady R, Crawford G, Ahrens S, et al. Long-term efficacy and tolerability of rizatriptan wafers in migraine. *MedGenMed* 2001 Jun 1; 3(3):1; PMID: 11549974.
113. Cady R, Martin V, Adelman J, et al. Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study. *Headache* 2004 Oct; 44(9):900-7; PMID: 15447699.
114. Cady R, Martin V, Mauskop A, et al. Efficacy of Rizatriptan 10 mg administered early in a migraine attack. *Headache* 2006 Jun; 46(6):914-24; PMID: 16732837.
115. Cady R, Martin V, Mauskop A, et al. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. *Cephalalgia* 2007 Sep; 27(9):1055-60; PMID: 17681023.
116. Cady RC, Ryan R, Jhingran P, et al. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. *Arch Intern Med* 1998 May 11; 158(9):1013-8; PMID: 9588435.
117. Cady RK. Treating an acute attack of migraine. *Headache* 2008 Oct; 48(9):1415-6; PMID: 19006560.
118. Cady RK, Banks J, Jones BA, et al. Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination. *Current Medical Research & Opinion* 2009 Nov; 25(11):2711-21; PMID: 19778164.
119. Cady RK, Dexter J, Sargent JD, et al. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. *Neurology* 1993 Jul; 43(7):1363-8; PMID: 8392150.
120. Cady RK, Diamond ML, Diamond MP, et al. Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. *Headache* 2011 May; 51(5):664-73; PMID: 21521204.
121. Cady RK, Goldstein J, Silberstein S, et al. Expanding access to triptans: assessment of clinical outcome. *Headache* 2009 Nov-Dec; 49(10):1402-13; PMID: 19817885.
122. Cady RK, Gutterman D, Saiers JA, et al. Responsiveness of non-IHS migraine and tension-type headache to sumatriptan. *Cephalalgia* 1997 Aug; 17(5):588-90; PMID: 9251874.

123. Cady RK, Lipton RB, Hall C, et al. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. *Headache* 2000 Nov-Dec; 40(10):792-7; PMID: 11135022.
124. Cady RK, Martin VT, Geraud G, et al. Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response. *Headache* 2009 May; 49(5):687-96; PMID: 19472447.
125. Cady RK, Rubino J, Crummett D, et al. Oral sumatriptan in the treatment of recurrent headache. *Arch Fam Med* 1994 Sep; 3(9):766-72; PMID: 7987510.
126. Cady RK, Schreiber CP, Beach ME, et al. Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase. *Medical Science Monitor* 2005 Sep; 11(9):PI65-9; PMID: 16127373.
127. Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. *Clin Ther* 2000 Sep; 22(9):1035-48; PMID: 11048903.
128. Cady RK, Vause CV, Ho TW, et al. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. *Headache* 2009 Oct; 49(9):1258-66; PMID: 19788468.
129. Caekebeke JF, Ferrari MD, Zwetsloot CP, et al. Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. *Neurology* 1992 Aug; 42(8):1522-6; PMID: 1322512.
130. Callahan M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. *Headache*; 1986: 168-71.
131. Campos L, Diaz Gomez M, Ondiviela R, et al. Naproxen sodium in the treatment of otitis. *Atencion Primaria*; 1992: 314, 6-7.
132. Canadian Glaucoma Study G. Canadian Glaucoma Study: 1. Study design, baseline characteristics, and preliminary analyses. *Canadian journal of ophthalmology. Journal canadien d'ophtalmologie*; 2006: 566-75.
133. Caputi L, Carriero MR, Parati EA, et al. Postural dependency of right to left shunt: role of contrast-enhanced transcranial Doppler and its potential clinical implications. *Stroke* 2008 Aug; 39(8):2380-1; PMID: 18535277.
134. Carasso RL, Peled O, Yehuda S. Flufenamic acid in prostaglandin migraine. *Int-J-Neurosci*; 1985: 67-71.
135. Carlsson J, Rosenhall U. Oculomotor disturbances in patients with tension headache treated with acupuncture or physiotherapy. *Cephalalgia* 1990 Jun; 10(3):123-9; PMID: 2245457.
136. Carmona S, Settecase N. Use of topiramate (topamax) in a subgroup of migraine-vertigo patients with auditory symptoms. *Annals of the New York Academy of Sciences* 2005 Apr; 1039:517-20; PMID: 15827012.
137. Carpay JA, Linssen WHJP, Koehler PJJ, et al. Efficacy of sumatriptan nasal spray in recurrent migrainous headache: an open prospective study. *Headache* 2003 Apr; 43(4):395-9; PMID: 12656711.
138. Casale TB, Romero FA, Spierings EL. Intranasal noninhaled carbon dioxide for the symptomatic treatment of seasonal allergic rhinitis. *The Journal of allergy and clinical immunology*; 2008: 105-9.
139. Cates C. Triptan medications to treat acute migraine. *Lancet* 2002 Mar 30; 359(9312):1152; author reply -3; PMID: 11943288.
140. Ceballos Hernansanz MA, Sanchez Roy R, Cano Orgaz A, et al. Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness. *Clinical Therapeutics* 2003 Jul; 25(7):2053-69; PMID: 12946550.
141. Centonze V, Bassi A, Causarano V, et al. Simultaneous occurrence of ipsilateral cluster headache and chronic paroxysmal hemicrania: a case report. *Headache* 2000 Jan; 40(1):54-6; PMID: 10759906.
142. Centonze V, Polito MB, Di BM, et al. Evaluation of the efficacy of oral sumatriptan in the therapy of acute migraine. <ORIGINAL> VALUTAZIONE DELL'EFFICACIA DI SUMATRIPTAN NELLA TERAPIA ORALE DELL'ATTACCO DI EMICRANIA. *Clinica Terapeutica*; 1995: 721-8.
143. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med* 2006 Feb 9; 354(6):579-87; PMID: 16467545.

144. Chan WS, Koren G, Barrera M, et al. Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database. *Hypertens Pregnancy* 2010; 29(3):271-83; PMID: 20670152.
145. Chang L, Henley E. Which oral triptans are effective for the treatment of acute migraine? *Journal of Family Practice* 2002 Feb; 51(2):176; PMID: 11978220.
146. Check JH, Cohen R. Marked improvement of headaches and vasomotor symptoms with sympathomimetic amines in a woman with sympathetic hyperalgesia-edema syndrome. *Clinical & Experimental Obstetrics & Gynecology* 2011; 38(1):88-9; PMID: 21485736.
147. Chen J, Jiang XG, Jiang WM, et al. Intranasal absorption of rizatriptan--in vivo pharmacokinetics and bioavailability study in humans. *Die Pharmazie*; 2005: 39-41.
148. Chengappa KN, Gershon S, Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. *Bipolar disorders*; 2001: 215-32.
149. Chia Y-C, Lim S-H, Wang S-J, et al. Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatory drugs. *Headache* 2003 Oct; 43(9):984-90; PMID: 14511275.
150. Chopra HK, Sami RS, Krishna CK, et al. Peri-operative cardiac assessment & rationale for use of beta-blockers. *Indian Heart J* 2010 Mar-Apr; 62(2):158-67; PMID: 21180310.
151. Christie S, Gobel H, Mateos V, et al. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/cafeine in migraine. *Eur Neurol* 2003; 49(1):20-9; PMID: 12464714.
152. Chun-Fai-Chan B, Koren G, Favez I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. *Am J Obstet Gynecol* 2005 Mar; 192(3):932-6; PMID: 15746694.
153. Cianchetti C. Capsaicin jelly against migraine pain. *Int J Clin Pract* 2010 Mar; 64(4):457-9; PMID: 20456192.
154. Citera G, Arias MA, Maldonado-Cocco JA, et al. The effect of melatonin in patients with fibromyalgia: a pilot study. *Clinical rheumatology*; 2000: 9-13.
155. Cleland PG, Barnes D, Elrington GM, et al. Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone. *Eur Neurol* 1997; 38(1):31-8; PMID: 9252796.
156. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1(MN) gp120, HIV-1(SF2) recombinant gp120, or both vaccines in seronegative adults. *Journal of Infectious Diseases*; 1998: 1230-46.
157. Codispoti JR, Prior MJ, Fu M, et al. Efficacy of nonprescription doses of ibuprofen for treating migraine headache. a randomized controlled trial. *Headache* 2001 Jul-Aug; 41(7):665-79; PMID: 11554954.
158. Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. *BMJ* 2008 Jun 14; 336(7657):1359-61; PMID: 18541610.
159. Cologno D, Torelli P, Manzoni GC. Migraine with aura: a review of 81 patients at 10-20 years' follow-up. *Cephalalgia : an international journal of headache*; 1998: 690-6.
160. Comoglu T, Dogan A, Comoglu S, et al. Formulation and evaluation of diclofenac potassium fast-disintegrating tablets and their clinical application in migraine patients. *Drug Dev Ind Pharm* 2011 Mar; 37(3):260-7; PMID: 20704458.
161. Conte HR, Karasu TB. Psychotherapy for medically ill patients: review and critique of controlled studies. Review 35 refs. *Psychosomatics*; 1981: 285-90.
162. Corbey MP, Bach AB, Lech K, et al. Grading of severity of postdural puncture headache after 27-gauge Quincke and Whitacre needles. *Acta anaesthesiologica Scandinavica*; 1997: 779-84.
163. Cortelli P, Allais G, Tullo V, et al. Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies. *Neurol Sci* 2011 May; 32 Suppl 1:S95-8; PMID: 21533722.

164. Couch JR, Jr., Saper J, Meloche JP. Treatment of migraine with BMS180048: response at 2 hours. North American BMS180048 Study Group. *Headache* 1996 Oct; 36(9):523-30; PMID: 8916559.
165. Cull RE, Price WH, Dunbar A. The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache. *J Neurol Neurosurg Psychiatry* 1997 May; 62(5):490-5; PMID: 9153607.
166. Curro G, Baccarani U, Adani GL, et al. Transient ischemic attack after rizatriptan administration in a liver transplant recipient: a case report. *Transplantation Proceedings* 2006 Nov; 38(9):3138-9; PMID: 17112920.
167. Cutler NR, Claghorn J, Sramek JJ, et al. Pilot study of MK-462 in migraine. *Cephalalgia* 1996 Apr; 16(2):113-6; PMID: 8665577.
168. Dahlof C. Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies. *Cephalalgia* 1999 Nov; 19(9):769-78; PMID: 10595285.
169. Dahlöf C, Tfelt-Hansen P, Massiou H, et al. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. *Neurology*; 2001: 1811-7.
170. Dahlof C, Winter P, Ludlow S. Oral GR43175, a 5HT₁-like agonist, for treatment of the acute migraine attack: an international study - preliminary results. *Cephalalgia*; 1989: 351-2.
171. Dahlof C, Winter P, Whitehouse H, et al. Randomized, double-blind, placebo-controlled comparison of oral naratriptan and oral sumatriptan in the acute treatment of migraine [abstract]. *Neurology*; 1997: A85-6.
172. Dahlöf CG, Jacobs LD. Ketoprofen, paracetamol and placebo in the treatment of episodic tension-type headache. *Cephalalgia : an international journal of headache*; 1996: 117-23.
173. Dahlof CG, Lipton RB, McCarroll KA, et al. Within-patient consistency of response of rizatriptan for treating migraine. *Neurology* 2000 Nov 28; 55(10):1511-6; PMID: 11094106.
174. D'Alessio C, Ambrosini A, Colonnese C, et al. Indomethacin-responsive hemicrania associated with an extracranial vascular malformation: report of two cases. *Cephalalgia* 2004 Nov; 24(11):997-1000; PMID: 15482365.
175. D'Andrea G, Nordera GP, Allais G. Treatment of aura: solving the puzzle. *Neurological Sciences* 2006 May; 27 Suppl 2:S96-9; PMID: 16688638.
176. Dasbach EJ, Carides GW, Gerth WC, et al. Work and productivity loss in the rizatriptan multiple attack study. *Cephalalgia* 2000 Nov; 20(9):830-4; PMID: 11167913.
177. Daugaard D, Thomsen LL, Olesen J. No relation between cephalic venous dilatation and pain in migraine. *J Neurol Neurosurg Psychiatry* 1998 Aug; 65(2):260-2; PMID: 9703185.
178. Davis CP, Torre PR, Williams C, et al. Ketorolac versus meperidine-plus-promethazine treatment of migraine headache: evaluations by patients. *Am J Emerg Med* 1995 Mar; 13(2):146-50; PMID: 7893296.
179. De Marinis M, Giraldi JP, de Feo A, et al. Migraine and ocular pain in "glaucoma suspect". *Cephalalgia : an international journal of headache*; 1999: 243-7.
180. De Sanctis S, Grieco GS, Breda L, et al. Prolonged sporadic hemiplegic migraine associated with a novel de novo missense ATP1A2 gene mutation. *Headache* 2011 Mar; 51(3):447-50; PMID: 21352219.
181. de Tommaso M, Losito L, Libro G, et al. Effects of symptomatic treatments on cutaneous hyperalgesia and laser evoked potentials during migraine attack. *Cephalalgia* 2005 May; 25(5):359-68; PMID: 15839851.
182. Del Bene E, Poggioni M, De Tommasi F. Video assessment of yawning induced by sublingual apomorphine in migraine. *Headache* 1994 Oct; 34(9):536-8; PMID: 8002329.
183. Del Bene E, Poggioni M, Garagiola U, et al. Intramuscular treatment of migraine attacks using diclofenac sodium: a crossover clinical trial. *J Int Med Res* 1987 Jan-Feb; 15(1):44-8; PMID: 3545942.
184. Demailly P, Allaire C, Bron V, et al. Effectiveness and tolerance of beta-blocker/pilocarpine combination eye drops in primary open-angle glaucoma and high intraocular pressure. *Journal of Glaucoma*; 1995: 235-41.
185. Derriennic M, Voi M, Thoren LM, et al. Cefaclor AF in the treatment of streptococcal pharyngitis/tonsillitis. *Postgraduate medical journal*; 1992: S43-6; discussion S6-8.

186. Devineni T, Blanchard EB. A randomized controlled trial of an internet-based treatment for chronic headache. *Behav Res Ther* 2005 Mar; 43(3):277-92; PMID: 15680926.
187. Di Monda V, Nicolodi M, Aloisio A, et al. Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial. *Headache* 2003 Sep; 43(8):835-44; PMID: 12940804.
188. Di Rosa G, Span, x00F, et al. Alternating hemiplegia of childhood successfully treated with topiramate: 18 months of follow-up. *Neurology* 2006 Jan 10; 66(1):146; PMID: 16401872.
189. Diamond ML. Migraine: a diagnostic dilemma in the emergency department. *Headache* 2001 Jun; 41(6):533; PMID: 11437885.
190. Diamond S, Elkind A, Jackson RT, et al. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. *Arch Fam Med* 1998 May-Jun; 7(3):234-40; PMID: 9596457.
191. Diamond S, Freitag FG. Cold as an adjunctive therapy for headache. *Postgrad Med*; 1986: 305-9.
192. Diamond S, Freitag FG. Analgesic efficacy and safety of TNB in the acute treatment of migraine. *Clin Pharmacol Ther*; 1990: 135.
193. Diamond S, Freitag FG, Feoktistov A, et al. Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients with cutaneous allodynia who historically fail to respond to oral triptans. *Journal of Headache & Pain* 2007 Feb; 8(1):13-8; PMID: 17221340.
194. Diamond S, Freitag FG, Gallagher RM, et al. The analgesic efficacy of transnasal butorphanol (TNB) in the acute treatment of migraine. *Cephalalgia*; 1989: 357.
195. Diamond S, Freitag Frederick G, Diamond Merle L, et al. Transnasal butorphanol in the treatment of migraine headache pain. *Headache Quarterly*; 1992: 164-71.
196. Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. *Lancet* 2005 Jul 30-Aug 5; 366(9483):371-7; PMID: 16054936.
197. Diener H-C. Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice. *Headache* 2005 Jun; 45(6):624-31; PMID: 15953293.
198. Diener HC. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. *Cephalalgia* 2003 Apr; 23(3):183-5; PMID: 12662184.
199. Diener HC. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg. *Curr Med Res Opin* 2005 Oct; 21(10):1603-10; PMID: 16238900.
200. Diener HC, Barbanti P, Dahlof C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. *Cephalalgia* 2011 Apr; 31(5):573-84; PMID: 21172952.
201. Diener HC, Bussone G, de Liano H, et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. *Cephalalgia* 2004 Nov; 24(11):947-54; PMID: 15482357.
202. Diener HC, Eikermann A, Gessner U, et al. Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. *Eur Neurol* 2004; 52(1):50-6; PMID: 15240983.
203. Diener HC, Gendolla A, Gebert I, et al. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. *Headache* 2005 Jul-Aug; 45(7):874-82; PMID: 15985104.
204. Diener HC, McHarg A. Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. *International Journal of Clinical Practice* 2000 Dec; 54(10):670-4; PMID: 11221281.
205. Diener HC, Peil H, Aicher B. The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: a post-hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. *Cephalalgia* 2011 Oct; 31(14):1466-76; PMID: 21908446.

206. Diener HC, Pfaffenrath V, Pageler L, et al. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. *Cephalalgia* 2005 Oct; 25(10):776-87; PMID: 16162254.
207. Diener H-C, Evers S. Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing surveillance study. *Clinical Drug Investigation* 2007; 27(1):59-66; PMID: 17177580.
208. Diener H-C, Gendolla A. Part IV: effects of zolmitriptan orally disintegrating tablet on migraine symptoms and ability to perform normal activities: a post-marketing surveillance study in Germany. *Current Medical Research & Opinion* 2005; 21 Suppl 3:S18-24; PMID: 16083520.
209. Diener H-C, Ryan R, Sun W, et al. The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. *European Journal of Neurology* 2004 Feb; 11(2):125-34; PMID: 14748774.
210. Dikel W, Olness K. Self-hypnosis, biofeedback, and voluntary peripheral temperature control in children. *Pediatrics*; 1980: 335-40.
211. Dilli E, Dodick DW. Extracerebral cluster (cluster sine headache). *Neurology* 2008 Apr 15; 70(16):1362-3; PMID: 18413592.
212. Dilone E, Bergstrom D, Cabana B, et al. Rapid oral transmucosal absorption of sumatriptan, and pharmacodynamics in acute migraine. *Headache* 2009 Nov-Dec; 49(10):1445-53; PMID: 19549162.
213. Dimitriou V, Iatrou C, Malefaki A, et al. Blockade of branches of the ophthalmic nerve in the management of acute attack of migraine. *Middle East Journal of Anesthesiology* 2002 Jun; 16(5):499-504; PMID: 12138513.
214. Diomedes M, Sallustio F, Rizzato B, et al. Sildenafil increases cerebrovascular reactivity: a transcranial Doppler study. *Neurology* 2005 Sep 27; 65(6):919-21; PMID: 16051646.
215. DiSerio F, Patin J, Friedman A. U.S.A. trials of dihydroergotamine nasal spray in the acute treatment of migraine headache. *Cephalalgia*; 1989: 344-5.
216. DiSerio FJ, Singer JM, Friedman AP. An evaluation of proquazone in the acute treatment of migraine headache. *Cephalalgia*; 1985: 146-7.
217. Djupesland PG, Docekal P. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study. *Cephalalgia* 2010 2010 Mar 17; 30(8):933-42; PMID.
218. Dodick DW. Epidemiology and acute care of migraine headache. *Managed Care Interface* 2004; 17 Suppl D:6-10; discussion 1-3; PMID: 15506040.
219. Dodick DW. Introduction: cardiovascular safety and triptans in the acute treatment of migraine. *Headache* 2004 May; 44 Suppl 1:S1-4; PMID: 15149487.
220. Dodick DW, Lipsy RJ. Advances in migraine management: implications for managed care organizations. *Managed Care* 2004 May; 13(5):45-51; PMID: 15181689.
221. Doepp F, Schreiber SJ, Dreier JP, et al. Migraine aggravation caused by cephalic venous congestion. *Headache*; 2003: 96-8.
222. d'Onofrio F, Cologno D, Petretta V, et al. Basilar-type migraine responsive to lamotrigine: three case reports. *Neurological Sciences* 2007 May; 28 Suppl 2:S239-41; PMID: 17508181.
223. Dowson AJ, Charlesworth BR, Green J, et al. Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial. *Headache* 2005 Jan; 45(1):17-24; PMID: 15663608.
224. Dowson AJ, D'Amico D, Tepper SJ, et al. Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire. *Neurological Sciences* 2004 Oct; 25 Suppl 3:S276-8; PMID: 15549559.
225. Dowson AJ, Gross MLP, Couch J, Jr. Functional improvement and patient acceptability of BMS-180048 in the treatment of patients with acute migraine. *Functional Neurology*; 1996: 147.

226. Dowson AJ, Massiou H, Aurora SK. Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan. *J Headache Pain* 2005 Apr; 6(2):81-7; PMID: 16362647.
227. Dowson AJ, Massiou H, Lainez JM, et al. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. *Cephalalgia* 2002 Jul; 22(6):453-61; PMID: 12133045.
228. Dowson AJ, Massiou H, Lainez JM, et al. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. *Headache* 2004 Apr; 44(4):318-22; PMID: 15109355.
229. Drance SM. Some clinical implications of the collaborative normal tension glaucoma study. *Klinika oczna*; 2004: 588-92.
230. Drummond PD. Effect of tryptophan depletion on symptoms of motion sickness in migraineurs. *Neurology* 2005 Aug 23; 65(4):620-2; PMID: 16116130.
231. Drury RL, DeRisi WJ, Liberman RP. Temperature biofeedback treatment for migraine headache: a controlled multiple baseline study. *Headache*; 1979: 278-84.
232. Duley L. Pre-eclampsia, eclampsia, and hypertension. *Clin Evid (Online)* 2011; 2011; PMID: 21718554.
233. Dyb G, Holmen TL, Zwart J-A. Analgesic overuse among adolescents with headache: the Head-HUNT-Youth Study. *Neurology* 2006 Jan 24; 66(2):198-201; PMID: 16434653.
234. Earl NL. Clinical safety of 311C90: aggregated data from patients and volunteers to date. *Eur Neurol* 1996; 36 Suppl 2:8-12; PMID: 8791026.
235. Egger J, Carter CH, Soothill JF, et al. Effect of diet treatment on enuresis in children with migraine or hyperkinetic behavior. *Clin Pediatr (Phila)* 1992 May; 31(5):302-7; PMID: 1582098.
236. Egger J, Carter CM, Soothill JF, et al. Oligoantigenic diet treatment of children with epilepsy and migraine. *The Journal of pediatrics*; 1989: 51-8.
237. Ehrenberg BL. Acute migraine treatment with droperidol. *Neurology* 2003 Dec 23; 61(12):1826; author reply PMID: 14694067.
238. Eikermann A, Diener HC. Effect of active treatment is lower when using placebo control in clinical trials on acute therapy of migraine. *Cephalalgia*; 2004: 344-7.
239. Ellis GL, Delaney J, DeHart DA, et al. The efficacy of metoclopramide in the treatment of migraine headache. *Ann Emerg Med* 1993 Feb; 22(2):191-5; PMID: 8427430.
240. Ensink FBM, Dahlof C, Tournilhac M, et al. Evaluation of a multiple-dose regiment of oral sumatriptan for the acute treatment of migraine. *Eur. Neurol.*; 1991: 306-13.
241. Evans RW. Treating migraine in the emergency department. *BMJ* 2008 Jun 14; 336(7657):1320; PMID: 18541609.
242. Evans RW, Lipton RB, Ritz KA. A survey of neurologists on self-treatment and treatment of their families. *Headache* 2007 Jan; 47(1):58-64; PMID: 17355495.
243. Evans RW, Young WB. Droperidol and other neuroleptics/antiemetics for the management of migraine. *Headache* 2003 Jul-Aug; 43(7):811-3; PMID: 12890142.
244. Evers S, Rahmann A, Kraemer C, et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. *Neurology* 2006 Aug 8; 67(3):497-9; PMID: 16775229.
245. Evers S, Vollmer-Haase J, Schwaag S, et al. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study. *Cephalalgia* 2004 Oct; 24(10):838-43; PMID: 15377314.
246. Facchinetti F, Allais G, Nappi RE, et al. Sumatriptan (50 mg tablets vs. 25 mg suppositories) in the acute treatment of menstrually related migraine and oral contraceptive-induced menstrual migraine: a pilot study. *Gynecol Endocrinol* 2010 Oct; 26(10):773-9; PMID: 20528213.
247. Facchinetti F, Bonellie G, Kangasniemi P, et al. The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group. *Obstetrics and gynecology*; 1995: 911-6.
248. Fadeyi MO, Adams QM. Use of botulinum toxin type B for migraine and tension headaches. *American Journal of Health-System Pharmacy* 2002 Oct 1; 59(19):1860-2; PMID: 12374073.

249. Farmer K, Cady R, Bleiberg J, et al. Sumatriptan nasal spray and cognitive function during migraine: results of an open-label study. *Headache* 2001 Apr; 41(4):377-84; PMID: 11318884.
250. Featherstone HJ. Low-dose propranolol therapy for aborting migraine. *Western Journal of Medicine* 1983 Mar; 138(3):416-7; PMID: 6858129.
251. Feleppa M, Apice G, D'Alessio A, et al. Tolerability of acute migraine medications: influence of methods of assessment and relationship with headache attributes. *Cephalalgia* 2008 Oct; 28(10):1012-6; PMID: 18727650.
252. Ferrari A, Leone S, Tacchi R, et al. The link between pain patient and analgesic medication is greater in migraine than in rheumatic disease patients. *Cephalalgia* 2009 Jan; 29(1):31-7; PMID: 18771492.
253. Ferrari A, Spaccapelo L, Sternieri E. Pharmacoepidemiology of triptans in a headache centre. *Cephalalgia* 2010 Jul; 30(7):847-54; PMID: 20647176.
254. Ferrari M, Bayliss EM, Ludlow S, et al. Subcutaneous Gr43175 in the treatment of acute migraine: an international study. *Cephalalgia*; 1989: 348.
255. Ferrari MD. Subcutaneous sumatriptan in the acute treatment of migraine [abstract]. *Canadian Journal of Neurological Sciences*; 1993.
256. Ferrari MD. Subcutaneous sumatriptan in the acute treatment of migraine. *Can-J-Neurological-Sci*; 1994: S37.
257. Ferrari MD. The clinical effectiveness of 311C90 in the acute treatment of migraine. *Eur Neurol* 1996; 36 Suppl 2:4-7; PMID: 8791025.
258. Ferrari MD. Triptstar: a comprehensive patient-based approach to compare triptans. *Headache* 2002 Jan; 42 Suppl 1:18-25; PMID: 11966860.
259. Ferrari MD, Gijsman H, Block GA, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-0462) in acute migraine. *Functional Neurology*; 1996: 149.
260. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT_{1B/1D} agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. *Cephalalgia* 2002 Oct; 22(8):633-58; PMID: 12383060.
261. Ferriere G. Flunarizine in the prophylactic treatment of paediatric migraine. *Cephalalgia* 1985; 5(Suppl 3):176-7; PMID.
262. Fiesseler FW, Shih R, Szucs P, et al. Steroids for migraine headaches: a randomized double-blind, two-armed, placebo-controlled trial. *J Emerg Med* 2011 Apr; 40(4):463-8; PMID: 19846269.
263. Findley LJ, Abbas A, Bayliss E. The acute treatment of migraine with aura with sumatriptan. *Cephalalgia*; 1991: 226-7.
264. Fioroni L, Sances G, Martignoni E, et al. Perimenstrual headache prophylaxis with dihydroergokriptine. *Cephalalgia* 1991; 11(Suppl. 11):199-200; PMID.
265. Fleishaker JC, Pearson LK, Knuth DW, et al. Pharmacokinetics and tolerability of a novel 5-HT_{1D} agonist, PNU-142633F. *International journal of clinical pharmacology and therapeutics*; 1999: 487-92.
266. Fleishaker JC, Ryan KK, Carel BJ, et al. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. *Journal of clinical pharmacology*; 2001: 217-23.
267. Fletcher PE, McDonald S, Lowy MT. Long-term safety, efficacy and pattern of usage of 311C90 in the acute oral treatments of migraine. *Functional Neurology*; 1996: 153.
268. Foley KA, Cady R, Martin V, et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. *Headache* 2005 May; 45(5):538-45; PMID: 15953272.
269. Forteza AM, Brozman B, Rabinstein AA, et al. Acetazolamide for the treatment of migraine with aura in CADASIL. *Neurology* 2001 Dec 11; 57(11):2144-5; PMID: 11739850.
270. Fox AW, Keywood C, Sheftell FD, et al. Comparison of therapeutic gain with therapeutic ratio for the assessment of selective 5HT_{1B/1D} agonist efficacy in migraine. *Headache* 2002 Jul-Aug; 42(7):680-8; PMID: 12482223.
271. Freitag F, Smith T, Mathew N, et al. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. *Headache* 2008 Mar; 48(3):341-54; PMID: 18302700.

272. Freitag FG, Cady R, DiSerio F, et al. Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. *Headache* 2001 Apr; 41(4):391-8; PMID: 11318886.
273. Freitag-Frederick G. The acute treatment of migraine with transnasal butorphanol (TNB). *Headache Quarterly*; 1993: 22-8.
274. Friedenbergs S, Dodick DW. Migraine-associated seizure: a case of reversible MRI abnormalities and persistent nondominant hemisphere syndrome. *Headache* 2000 Jun; 40(6):487-90; PMID: 10849047.
275. Friedman AP, Di SFJ, Hwang DS. Symptomatic relief of migraine: Multicenter comparison of Cafergot((R)) P-B, Cafergot((R)), and placebo. *Clin Ther*; 1989: 170-82.
276. Friedman BW, Bijur PE, Lipton RB. Standardizing emergency department-based migraine research: an analysis of commonly used clinical trial outcome measures. *Academic Emergency Medicine* 2010 Jan; 17(1):72-9; PMID: 20078439.
277. Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. *Neurology* 2005 Feb 8; 64(3):463-8; PMID: 15699376.
278. Friedman BW, Mulvey L, Esses D, et al. Metoclopramide for acute migraine: a dose-finding randomized clinical trial. *Ann Emerg Med* 2011 May; 57(5):475-82 e1; PMID: 21227540.
279. Friedman BW, Solorzano C, Esses D, et al. Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan. *Ann Emerg Med* 2010 Jul; 56(1):7-17; PMID: 20303198.
280. Friedman MH. Migraine, tension-type headache and facial pain. A common intraoral etiology and treatment. *New York State Dental Journal* 2002 Jun-Jul; 68(6):24-6; PMID: 12149787.
281. Friedman MH. Local inflammation as a mediator of migraine and tension-type headache. *Headache* 2004 Sep; 44(8):767-71; PMID: 15330822.
282. Fulton JA, Kahn J, Nelson LS, et al. Renal infarction during the use of rizatriptan and zolmitriptan: two case reports. *Clinical Toxicology: The Official Journal of the American Academy of Clinical Toxicology & European Association of Poisons Centres & Clinical Toxicologists* 2006; 44(2):177-80; PMID: 16615676.
283. Furlan AJ, Reisman M, Massaro J, et al. Study design of the CLOSURE I Trial: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFlex septal closure system versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. *Stroke; a journal of cerebral circulation*; 2010: 2872-83.
284. Gaby AR. Intravenous nutrient therapy: the "Myers' cocktail". *Alternative Medicine Review* 2002 Oct; 7(5):389-403; PMID: 12410623.
285. Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. *Archives of neurology*; 1996: 1285-91.
286. Gandolfi SA, Cimino L. Shortterm effect of brimonidine and apraclonidine on central visual function and iop in humans. a cross-over study. *Iovs*; 1998: ARVO Abstract 2195.
287. Gauthier J, Bois R, Allaire D, et al. Evaluation of skin temperature biofeedback training at two different sites for migraine. *J Behav Med* 1981 Dec; 4(4):407-19; PMID: 7338895.
288. Gendolla A. Part I: what do patients really need and want from migraine treatment? *Current Medical Research & Opinion* 2005; 21 Suppl 3:S3-7; PMID: 16083517.
289. Geraud G, Olesen J, Pfaffenrath V, et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. *Cephalalgia* 2000 Feb; 20(1):30-8; PMID: 10817444.
290. Geraud G, Spierings ELH, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002 Apr; 42 Suppl 2:S93-9; PMID: 12028325.

291. Gerber WD, Haag G, Grotemeyer KH, et al. Differential efficacy of ergotamine, paracetamol and ergotamine-paracetamol-combination in the treatment of acute migraine attacks: A multicenter doubleblind study. *Cephalalgia*; 1991: 174.
292. Gerhardt RT, Hermstad E, Crawford DM, et al. Postdischarge secobarbital after ED migraine treatment decreases pain and improves resolution. *Am J Emerg Med* 2011 Jan; 29(1):86-90; PMID: 20825791.
293. Gerth WC, McCarroll KA, Santanello NC, et al. Patient satisfaction with rizatriptan versus other triptans: direct head-to-head comparisons. *Int J Clin Pract* 2001 Oct; 55(8):552-6; PMID: 11695077.
294. Ghose K, Coppen A, Carrol D. Intravenous tyramine response in migraine before and during treatment with indoramin. *Br Med J* 1977 May 7; 1(6070):1191-3; PMID: 324566.
295. Ghossaini SN, Spitzer JB, Mackins CC, et al. High-frequency pulsed electromagnetic energy in tinnitus treatment. *The Laryngoscope*; 2004: 495-500.
296. Gillman MA, Lichtigfeld FJ. Analgesic nitrous oxide: an opioid treatment for migraine. *American Journal of Emergency Medicine* 2000 Jul; 18(4):501; PMID: 10919548.
297. Ginsburg R, Schroeder JS. The short and long-term efficacy of diltiazem for the treatment of variant angina pectoris. *Archives des maladies du coeur et des vaisseaux*; 1983: 149-52.
298. Glauser T, Sachdeo R, Ritter F, et al. Topiramate in Lennox-Gastaut syndrome: a double blind trial. *Neurology* 1997; 48:1729; PMID.
299. Goadsby PJ. 311C90, a novel 5-HT_{1B/1D} receptor agonist: the assessment of efficacy and tolerability in the acute treatment of migraine [abstract]. *Neurology*; 1997: A86.
300. Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan. *Neurology*; 2000: 156-63.
301. Goadsby PJ, Keywood CG. Investigation of the role of mGluR5 inhibition in migraine: a proof of concept study of ADX10059 in acute treatment of migraine. *Neurology*; 2009: A285, Abstract no: P06.006.
302. Gobel H, Heinze A. The Migraine Intervention Score - a tool to improve efficacy of triptans in acute migraine therapy: the ALADIN study. *Int J Clin Pract* 2011 Aug; 65(8):879-86; PMID: 21762313.
303. Gobel H, Heinze A, Dworschak M, et al. Analgesic efficacy and tolerability of locally applied oleum menthae piperitae preparation LI 170 in patients with migraine or tension-type headache. *Zeitschrift fur Allgemeinmedizin*; 2001: 287-95.
304. Gobel H, Krapat S. Psychological status during migraine attack and interval before and after treatment with a selective 5-HT₁-agonist. *Headache*; 1993: 118-20.
305. Gobel H, Krapat S, Ensink FB, et al. Comparison of contingent negative variation between migraine interval and migraine attack before and after treatment with sumatriptan. *Headache* 1993 Nov-Dec; 33(10):570-2; PMID: 8294198.
306. Gobel H, Schenkl S. Post-lumbar puncture headache: The relation between experimental suprathreshold pain sensitivity and a quasi-experimental clinical pain syndrome. *Pain*; 1990: 267-78.
307. Gobel H, Winter P, Boswell D, et al. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group. *Clin Ther* 2000 Aug; 22(8):981-9; PMID: 10972634.
308. Gobel H, Winter P, Boswell D, et al. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. *Clinical Therapeutics*; 2000: 981-9.
309. Gode S, Celebisoy N, Kirazli T, et al. Clinical assessment of topiramate therapy in patients with migrainous vertigo. *Headache* 2010 Jan; 50(1):77-84; PMID: 19656221.
310. Goldberg MR, Lowry RC, Musson DG, et al. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. *Journal of clinical pharmacology*; 1999: 192-9.
311. Goldberg MR, Sciberras D, De Smet M, et al. Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT_{1B/1D} agonist: differential effects of propranolol, nadolol and metoprolol. *British journal of clinical pharmacology*; 2001: 69-76.

312. Goldstein J, Gawel MJ, Winner P, et al. Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine. *Headache* 1998 Jul-Aug; 38(7):516-22; PMID: 15613167.
313. Goldstein J, Hoffman HD, Armellino JJ, et al. Successful treatment of severe, disabling migraine headache with non-prescription combination of acetaminophen, aspirin and caffeine. Results from three randomized, placebo-controlled studies. *Functional Neurology*; 1998: 187-8.
314. Goldstein J, Hoffman HD, Armellino JJ, et al. Successful treatment of severe, disabling migraine headache with a non-prescription combination of acetaminophen, aspirin and caffeine: results from three randomised, placebo-controlled studies [abstract]. *Neurology*; 1998: A377-8.
315. Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. *Headache* 1998 Nov-Dec; 38(10):737-47; PMID: 11284462.
316. Goldstein J, Ryan RE, Elkind AH. A double-blind trial of BMS-180048 at 75 mg, 150 mg and 200 mg in the acute treatment of migraine headaches. *Functional Neurology*; 1996: 147.
317. Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. *Headache* 2005 Sep; 45(8):973-82; PMID: 16109110.
318. Gomez-Mancilla B, Cutler NR, Leibowitz MT, et al. Safety and efficacy of PNU-142633, a selective 5-HT_{1D} agonist, in patients with acute migraine. *Cephalalgia*; 2001: 727-32.
319. Gordon ML, Lipton RB, Brown SL, et al. Headache and cortisol responses to m-chlorophenylpiperazine are highly correlated. *Cephalalgia*; 1993: 400-5.
320. Gross ML, Kay J, Turner AM, et al. Long-term efficacy of subcutaneous sumatriptan using a novel self-injector. *Headache* 1995 Nov-Dec; 35(10):601-6; PMID: 8550361.
321. Gruppo LQ, Jr. Intravenous Zofran for headache. *Journal of Emergency Medicine* 2006 Aug; 31(2):228-9; PMID: 17044590.
322. Gupta R, Gernsheimer J. Treating headache in the emergency ward: avoiding the migraine-meperidine trap. *Annals of Emergency Medicine* 2003 Jul; 42(1):161; author reply -2; PMID: 12852415.
323. Guttuso TJ, Jr. Gabapentin's effects on hot flashes and hypothermia. *Neurology* 2000 Jun 13; 54(11):2161-3; PMID: 10851385.
324. Haake M, Boddeker IR, Decker T, et al. Side-effects of extracorporeal shock wave therapy (ESWT) in the treatment of tennis elbow. *Arch Orthop Trauma Surg* 2002 May; 122(4):222-8; PMID: 12029512.
325. Haas DC, Sheehe PR. Dextroamphetamine pilot crossover trials and n of 1 trials in patients with chronic tension-type and migraine headache. *Headache* 2004 Nov-Dec; 44(10):1029-37; PMID: 15546268.
326. Hagen K, Albretsen C, Vilming ST, et al. Management of medication overuse headache: 1-year randomized multicentre open-label trial. *Cephalalgia* 2009 Feb; 29(2):221-32; PMID: 18823363.
327. Hakkarainen H, Gustafsson B, Stockman O. A comparative trial of ergotamine tartrate, acetyl salicylic acid and a dextropropoxyphene compound in acute migraine attacks. *Headache*; 1978: 35-9.
328. Hakkarainen H, Parantainen J, Gothoni G, et al. Tolfenamic acid and caffeine: a useful combination in migraine. *Cephalalgia* 1982 Dec; 2(4):173-7; PMID: 6984358.
329. Hakkarainen H, Quiding H, Stockman O. Mild analgesics as an alternative to ergotamine in migraine. A comparative trial with acetylsalicylic acid, ergotamine tartrate, and a dextropropoxyphene compound. *J Clin Pharmacol*; 1980: 590-5.
330. Hakkarainen H, Vapaatalo H, Gothoni G, et al. Tolfenamic acid is as effective as ergotamine during migraine attacks. *Lancet* 1979 Aug 18; 2(8138):326-8; PMID: 89390.
331. Hakkarainen H AH. Ergotamine vs. metoclopramide vs. their combination in acute migraine attacks. *Headache*; 1982: 10-2.
332. Halloul Z, Meyer F, Lippert H, et al. Ergotamine-induced acute vascular insufficiency of the lower limb--a case report. *Angiology* 2001 Mar; 52(3):217-21; PMID: 11269787.

333. Halpern MT, Lipton RB, Cady RK, et al. Costs and outcomes of early versus delayed migraine treatment with sumatriptan. *Headache* 2002 Nov-Dec; 42(10):984-99; PMID: 12453030.
334. Hamalainen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults? *Neurology* 1997 Apr; 48(4):1100-3; PMID: 9109909.
335. Hamalainen ML, Hoppu K, Santavuori PR. Oral dihydroergotamine for therapy-resistant migraine attacks in children. *Pediatr Neurol* 1997 Feb; 16(2):114-7; PMID: 9090684.
336. Harle DE, Shepherd AJ, Evans BJW. Visual stimuli are common triggers of migraine and are associated with pattern glare. *Headache* 2006 Oct; 46(9):1431-40; PMID: 17040340.
337. Havanka H, Dahlof C, Pop PHM, et al. Efficacy of naratriptan tablets in the acute treatment of migraine: A dose-ranging study. *Clinical Therapeutics*; 2000: 970-80.
338. Havanka-Kanniainen H. Acute migraine attack therapy: ibuprofen and placebo compared [abstract]. *International journal of clinical pharmacology and therapeutics.*; 1988: 171.
339. Havanka-Kanniainen H. Treatment of acute migraine attack: ibuprofen and placebo compared. *Headache*; 1989: 507-9.
340. Hawken ER, Delva NJ, Lawson JS. Successful use of propranolol in migraine associated with electroconvulsive therapy. *Headache* 2001 Jan; 41(1):92-6; PMID: 11168610.
341. Hay E, Rodrig J, Hussain A, et al. Rizatriptan RPD for severe migraine in the emergency department--a multicenter study. *Journal of Emergency Medicine* 2003 Oct; 25(3):245-9; PMID: 14585450.
342. Heikkila M. Puerperal insertion of a copper-releasing and a levonorgestrel-releasing intrauterine contraceptive device. *Contraception* 1982 Jun; 25(6):561-72; PMID: 6811195.
343. Heikkinen J, Vaheri R, Timonen U. Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses. *The journal of the British Menopause Society*; 2004: 95-102.
344. Hellings JA, Barth FX, Logan M, et al. Overnight versus progressive conversion of multiple daily-dose divalproex to once-daily divalproex extended release: which strategy is better tolerated by adults with intellectual disabilities? *Journal of clinical psychopharmacology*; 2009: 492-5.
345. Henry KA. Memantine for the prophylaxis of chronic tension-type headache. *Curr Pain Headache Rep* 2009 Dec; 13(6):423-4; PMID: 19889282.
346. Henry P, Hiesse PO, Dillenschneider A, et al. Efficacy and tolerance of effervescent aspirin-metoclopramide association in the treatment of migraine attack. A randomized, double blind, placebo controlled study. *Presse Medicale.*; 1995: 254-8.
347. Hering-Hanit R, Yavetz A, Dagan Y. Effect of withdrawal of misused medication on sleep disturbances in migraine sufferers with chronic daily headache. *Headache* 2000 Nov-Dec; 40(10):809-12; PMID: 11135024.
348. Hershey AD, Powers SW, LeCates S, et al. Effectiveness of nasal sumatriptan in 5- to 12-year-old children. *Headache* 2001 Jul-Aug; 41(7):693-7; PMID: 11554957.
349. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. *Cephalalgia* 2011 Apr; 31(6):712-22; PMID: 21383045.
350. Hirata K, Kubo J, Arai M, et al. Alternate numbness in the upper extremities as the initial symptom of basilar migraine: an electrophysiological evaluation using EEG power topography. *Internal Medicine* 2000 Oct; 39(10):852-5; PMID: 11030214.
351. Hirt D, Lataste X, Taylor P. A comparison of DHE nasal spray and Cafergot(TM) in acute migraine. *Cephalalgia*; 1989: 410-1.
352. Ho TW. Clinical profile of the novel oral CGRP receptor antagonist telcagepant for the acute treatment of migraine in phase 3 studies. *Journal of the Neurological Sciences*; 2009: S149, Abstract no: FP58-FR-04.
353. Ho TW, Ferrari MD, Dodick DW, et al. Clinical profile of the novel oral CGRP receptor antagonist telcagepant for the acute treatment of migraine in two phase 3 randomized placebo controlled trials. *Neurology*; 2009: A250, Abstract no: IN4-1.006.

354. Ho TW, Olesen J, Dodick DW, et al. Antimigraine efficacy of telcagepant based on patient's historical triptan response. *Headache* 2011 Jan; 51(1):64-72; PMID: 21054362.
355. Ho TW, Rodgers A, Bigal ME. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. *Headache* 2009 Mar; 49(3):395-403; PMID: 19222588.
356. Holroyd KA, Cordingley GE, Pingel JD, et al. Enhancing the effectiveness of abortive therapy: a controlled evaluation of self-management training. *Headache* 1989 Mar; 29(3):148-53; PMID: 2496052.
357. Holroyd KA, Holm JE, Hursey KG, et al. Recurrent vascular headache: home-based behavioral treatment versus abortive pharmacological treatment. *J Consult Clin Psychol* 1988 Apr; 56(2):218-23; PMID: 3286705.
358. Hsu DA, Stafstrom CE, Rowley HA, et al. Hemiplegic migraine: hyperperfusion and abortive therapy with intravenous verapamil. *Brain & Development* 2008 Jan; 30(1):86-90; PMID: 17614229.
359. Hu HQ, Zhou YH, Wang XL. Clinical study on effect of Xiaoyao Nose Drops in stopping episode of migraine. *Chin J Integr Med* 2006 Jun; 12(2):112-7; PMID: 16800989.
360. Hu XH, Raskin NH, Cowan R, et al. Treatment of migraine with rizatriptan: when to take the medication. *Headache* 2002 Jan; 42(1):16-20; PMID: 12005270.
361. Humbert H, Cabiatic MD, Dubray C, et al. Human pharmacokinetics of dihydroergotamine administered by nasal spray. *Clinical pharmacology and therapeutics*; 1996: 265-75.
362. Hunninghake DB, Davidson M, Knapp HR, et al. Extended-release fluvastatin 80 mg shows greater efficacy, with comparable tolerability, versus immediate-release fluvastatin 40 mg for once daily treatment of primary hypercholesterolaemia. *British Journal of Cardiology*; 2002: 469-75.
363. Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. *Neurology* 2008 Jul 22; 71(4):272-6; PMID: 18645165.
364. Hurtado TR, Vinson DR, Vandenberg JT. ED treatment of migraine headache: factors influencing pharmacotherapeutic choices. *Headache* 2007 Sep; 47(8):1134-43; PMID: 17883518.
365. Hyson MI. Anticephalgic photoprotective premedicated mask. A report of a successful double-blind placebo-controlled study of a new treatment for headaches with associated frontalis pain and photophobia. *Headache*; 1998: 475-7.
366. Ifergane G, Wirguin I, Shvartzman P. Triptans--why once? *Headache* 2006 Sep; 46(8):1261-3; PMID: 16942470.
367. Ikeda Y, Jimbo H, Shimazu M, et al. Sumatriptan scavenges superoxide, hydroxyl, and nitric oxide radicals: in vitro electron spin resonance study. *Headache* 2002 Oct; 42(9):888-92; PMID: 12390615.
368. Ilacqua GE. Migraine headaches: coping efficacy of guided imagery training. *Headache* 1994 Feb; 34(2):99-102; PMID: 8163375.
369. Irimia P, Palma JA, Fernandez-Torron R, et al. Refractory migraine in a headache clinic population. *BMC Neurol* 2011; 11:94; PMID: 21806790.
370. Ishkanian G, Blumenthal H, Webster CJ, et al. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study. *Clin Ther* 2007 Jan; 29(1):99-109; PMID: 17379050.
371. Itil TM, Herrmann WM, Akpınar S. Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmacoelectroencephalogram. *Int J Clin Pharmacol Biopharm* 1975 Jul; 12(1-2):221-33; PMID: 1100539.
372. Iversen HK, Olesen J. Nitroglycerin-induced headache is not dependent on histamine release: support for a direct nociceptive action of nitric oxide. *Cephalalgia : an international journal of headache*; 1994: 437-42.
373. Jackson NC. Clinical measures of efficacy, safety and tolerability for the acute treatment of migraine: a comparison of eletriptan (20-80mg), sumatriptan (100mg) and placebo [abstract]. *Neurology*; 1998: A376.

374. Jamieson D, Cutrer FM, Goldstein J, et al. Real-world experiences in migraine therapy with rizatriptan. *Headache* 2003 Mar; 43(3):223-30; PMID: 12603640.
375. Jamieson DG. Rizatriptan. Comparative trial results. *Postgraduate Medicine* 2000 Sep; 108(3 Suppl):22-8; PMID: 19667527.
376. Janssen K, Neutgens J. Autogenic training and progressive relaxation in the treatment of three kinds of headache. *Behav Res Ther* 1986; 24(2):199-208; PMID: 3964184.
377. Jeavons PM, Clark JE, Maheshwari MC. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate ("epilim"). *Dev Med Child Neurol* 1977 Feb; 19(1):9-25; PMID: 403104.
378. Jelinski SE, Becker WJ, Christie SN, et al. Pain free efficacy of sumatriptan in the early treatment of migraine. *Can J Neurol Sci* 2006 Feb; 33(1):73-9; PMID: 16583726.
379. Jensen K, Tfelt-Hansen P, Hansen EW, et al. Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice. *Cephalalgia* 1995 Oct; 15(5):423-9; PMID: 8536304.
380. Jensen K, Tfelt-Hansen P, Lauritzen M, et al. Clinical trial of nimodipine for single attacks of classic migraine. *Cephalalgia* 1985 Sep; 5(3):125-31; PMID: 3899368.
381. Jhee SS, Salazar DE, Ford NF, et al. A double-blind, randomized, crossover assessment of blood pressure following administration of avitriptan, sumatriptan, or placebo to patients with mild to moderate hypertension. *Cephalalgia : an international journal of headache*; 1999: 95-9.
382. Johannessen Landmark C, Larsson PG, Rytter E, et al. Antiepileptic drugs in epilepsy and other disorders--a population-based study of prescriptions. *Epilepsy Research* 2009 Nov; 87(1):31-9; PMID: 19679449.
383. Johnson CA, Sample PA, Trick GL, et al. Short Wavelength Automated Perimetry (swap) In The Ocular Hypertension Treatment Study (ohts). *Iovs*; 2002: ARVO E-abstract 2136.
384. Johnson ES, Ratcliffe DM, Wilkinson M. Naproxen sodium in the treatment of migraine. *Cephalalgia* 1985 Mar; 5(1):5-10; PMID: 3886154.
385. Joish VN, Cady PS, Shaw JW. Health care utilization by migraine patients: a 1998 Medicaid population study. *Clinical Therapeutics* 2000 Nov; 22(11):1346-56; PMID: 11117659.
386. Jouvent R. Dihydrergocryptine plus caffeine in treatment of migraine: A randomized double-blind trial against placebo. <ORIGINAL> STRATEGIES THERAPEUTIQUES. *Gaz Med*; 1989: 41-6.
387. Jovicic A, Maric D, Ilic T. Treatment of the acute migraine attacks. *Vojnosanitetski Pregled.*; 1995: 44-8.
388. Jurish SE, Blanchard EB, Andrasik F, et al. Home- versus clinic-based treatment of vascular headache. *J Consult Clin Psychol* 1983 Oct; 51(5):743-51; PMID: 6630689.
389. Kabbouche MA, Powers SW, Segers A, et al. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. *Headache* 2009 Jan; 49(1):106-9; PMID: 19125879.
390. Kabbouche MA, Powers SW, Vockell A-LB, et al. Carnitine palmityltransferase II (CPT2) deficiency and migraine headache: two case reports. *Headache* 2003 May; 43(5):490-5; PMID: 12752755.
391. Kabbouche MA, Vockell AL, LeCates SL, et al. Tolerability and effectiveness of prochlorperazine for intractable migraine in children. *Pediatrics* 2001 Apr; 107(4):E62; PMID: 11335783.
392. Kallen B, Nilsson E, Otterblad Olausson P. Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. *Drug Safety* 2011 Aug 1; 34(8):691-703; PMID: 21751829.
393. Kaniecki R, Ruoff G, Smith T, et al. Prevalence of migraine and response to sumatriptan in patients self-reporting tension/stress headache. *Curr Med Res Opin* 2006 Aug; 22(8):1535-44; PMID: 16870078.
394. Kaniecki RG. Mixing sumatriptan: a prospective study of stratified care using multiple formulations. *Headache* 2001 Oct; 41(9):862-6; PMID: 11703472.

395. Kanwar VS, Pearce J. Acute renal failure in a 17-year-old female with ALL receiving escalating intravenous methotrexate without leukovorin. *Pediatric Blood & Cancer* 2007 Aug; 49(2):216;author reply 9; PMID: 16786587.
396. Kapicioglu S, Gokce E, Kapicioglu Z, et al. Treatment of migraine attacks with a long-acting somatostatin analogue (octreotide, SMS 201-995). *Cephalalgia* 1997 Feb; 17(1):27-30; PMID: 9051332.
397. Karagiannis DA, Venkatesh P, Kirkpatrick N. Cessation of migraines in a woman with low-tension glaucoma following the use of latanoprost: a favourable side effect? *Eye* 2007 Feb; 21(2):293-5; PMID: 16946757.
398. Katic BJ, Rajagopalan S, Ho TW, et al. Triptan persistency among newly initiated users in a pharmacy claims database. *Cephalalgia* 2011 Mar; 31(4):488-500; PMID: 20937605.
399. Katsarava Z, Limmroth V. Is a combination of tramadol and acetaminophen effective for the treatment of acute migraine pain? *Nature Clinical Practice Neurology* 2006 Jul; 2(7):360-1; PMID: 16932584.
400. Kaube H, Herzog J, x00E, et al. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. *Neurology* 2000 Jul 12; 55(1):139-41; PMID: 10891926.
401. Kaube H, Katsarava Z, Przywara S, et al. Acute migraine headache: possible sensitization of neurons in the spinal trigeminal nucleus? *Neurology* 2002 Apr 23; 58(8):1234-8; PMID: 11971092.
402. Kellstein DE, Lipton RB, Geetha R, et al. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. *Cephalalgia* 2000 May; 20(4):233-43; PMID: 10999673.
403. Kelly AM, Kerr D, Clooney M. Impact of oral dexamethasone versus placebo after ED treatment of migraine with phenothiazines on the rate of recurrent headache: a randomised controlled trial. *Emerg Med J* 2008 Jan; 25(1):26-9; PMID: 18156535.
404. Kelly A-M, Knott J, Bennetts S, et al. Treatment of migraine in Australian Emergency Departments. *Emergency Medicine Australasia* 2009 Aug; 21(4):333-4; PMID: 19682021.
405. Kelman L, Harper SQ, Hu X, et al. Treatment response and tolerability of frovatriptan in patients reporting short- or long-duration migraines at baseline. *Curr Med Res Opin* 2010 Sep; 26(9):2097-104; PMID: 20642390.
406. Kemp JP, Cook DA, Incaudo GA, et al. Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. *Journal of Allergy and Clinical Immunology*; 1998: 188-95.
407. Keyvan G, Abolfazl MB. Comparison of treatment effect of sodium valproate, propranolol and tricyclic antidepressants in migraine. *Pak J Biol Sci* 2009 Aug 1; 12(15):1098-101; PMID: 19943469.
408. Keywood C, Baggish J, Blumenthal HJ, et al. Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study. *Pain Medicine*; 2009: 633-8.
409. Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. *Clin Pharmacol Ther* 1990 Mar; 47(3):305-12; PMID: 2178851.
410. Kitley JL, Lachmann HJ, Pinto A, et al. Neurologic manifestations of the cryopyrin-associated periodic syndrome. *Neurology*; 2010: 1267-70.
411. Klapper J, Stanton J. The emergency treatment of acute migraine headache: A comparison of intravenous dihydroergotamine, dexamethasone, and placebo. *Cephalalgia*; 1991: 159-60.
412. Klapper JA, O'Connor S. Rizatriptan wafer--sublingual vs. placebo at the onset of acute migraine. *Cephalalgia : an international journal of headache*; 2000: 585-7.
413. Klapper JA, Stanton J. Current emergency treatment of severe migraine headaches. *Headache* 1993 Nov-Dec; 33(10):560-2; PMID: 8294195.
414. Klassen A, Webster C, Laurenza A, et al. Naratriptan tablets are effective and well-tolerated in the acute treatment of migraine: results of a double-blind placebo-controlled parallel-group trial [abstract]. *Neurology*; 1997: A66-7.
415. Kolodny A, Polis A, Battisti WP, et al. Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets. *Cephalalgia* 2004 Jul; 24(7):540-6; PMID: 15196296.

416. Korostenskaja M, Pardos M, Kujala T, et al. Impaired auditory information processing during acute migraine: a magnetoencephalography study. *Int J Neurosci* 2011 Jul; 121(7):355-65; PMID: 21425948.
417. Koudstaal PJ, Algra A, Pop GA, et al. Risk of cardiac events in atypical transient ischaemic attack or minor stroke. The Dutch TIA Study Group. *Lancet*; 1992: 630-3.
418. Kozubski W. Metamizole and hydrocortisone for the interruption of a migraine attack--preliminary study. *Headache Quarterly*; 1992: 326-8.
419. Krämer HH, Lundblad L, Birklein F, et al. Activation of the cortical pain network by soft tactile stimulation after injection of sumatriptan. *Pain*; 2007: 72-8.
420. Kramer MS, Matzura-Wolf D, Getson A, et al. Placebo-controlled double-blind study of Rizatriptan in multiple attacks of acute migraine [abstract]. *Neurology*; 1997: A68-9.
421. Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. *Neurology* 1998 Sep; 51(3):773-81; PMID: 9748025.
422. Krusz JC, Scott V, Belanger J. Intravenous propofol: unique effectiveness in treating intractable migraine. *Headache* 2000 Mar; 40(3):224-30; PMID: 10759925.
423. Kruuse C, Thomsen LL, Birk S, et al. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. *Brain* 2003 Jan; 126(Pt 1):241-7; PMID: 12477710.
424. Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. *Arq Neuropsiquiatr* 2000 Jun; 58(2B):428-30; PMID: 10920403.
425. Krymchantowski AV. Monitoring patients' response to acute migraine treatment: a headache attack report form. *Headache* 2006 Feb; 46(2):346-7; PMID: 16492255.
426. Krymchantowski AV, Barbosa JS. Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with a nonsteroidal anti-inflammatory drug. *Arquivos de Neuro-Psiquiatria* 2001 Sep; 59(3-B):708-11; PMID: 11593269.
427. Krymchantowski AV, Silva MTT. Intravenous Lysine Clonixinate for the acute treatment of severe migraine attacks: a double-blind, randomized, placebo-controlled study. *Current Therapeutic Research, Clinical & Experimental*; 2003: 505-13.
428. Kunka RL, Hussey EK, Shaw S, et al. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers. *Cephalalgia : an international journal of headache*; 1997: 532-40.
429. Kwong WJ. Determinants of migraine emergency department utilization in the georgia medicaid population. *Headache* 2007 Oct; 47(9):1326-33; PMID: 17927649.
430. Lainez MJA, Lopez A, Pascual AM. Effects on productivity and quality of life of rizatriptan for acute migraine: a workplace study. *Headache* 2005 Jul-Aug; 45(7):883-90; PMID: 15985105.
431. Laloux P, Vakaet A, Monseu G, et al. Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation. *Acta Neurol Belg* 1998 Dec; 98(4):332-41; PMID: 9922821.
432. Lampl C, Marecek S, May A, et al. A prospective, open-label, long-term study of the efficacy and tolerability of topiramate in the prophylaxis of chronic tension-type headache. *Cephalalgia* 2006 Oct; 26(10):1203-8; PMID: 16961787.
433. Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. *J Neurol* 2007 Jun; 254(6):705-12; PMID: 17406776.
434. Lance JW, Fine RD, Curran DA. An evaluation of methysergide in the prevention of migraine and other vascular headaches. *Med J Aust*; 1963: 814-8.
435. Landy SH. Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: a case series. *Headache* 2004 Sep; 44(8):762-6; PMID: 15330821.
436. Landy SH, McGinnis JE, McDonald SA. Pilot study evaluating preference for 3-mg versus 6-mg subcutaneous sumatriptan. *Headache* 2005 Apr; 45(4):346-9; PMID: 15836571.

437. Lane PL, McLellan BA, Baggoley CJ. Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache. *Ann Emerg Med* 1989 Apr; 18(4):360-5; PMID: 2705667.
438. Lanteri-Minet M, Diaz-Insa S, Leone M, et al. Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study. *Int J Clin Pract* 2010 Jun; 64(7):936-43; PMID: 20584227.
439. Lanteri-Minet M, Radat F, Chautard MH, et al. Anxiety and depression associated with migraine: influence on migraine subjects' disability and quality of life, and acute migraine management. *Pain*; 2005: 319-26.
440. Lanzi G, D'Arrigo S, Termine C, et al. The effectiveness of hospitalization in the treatment of paediatric idiopathic headache patients. *Psychopathology*; 2007: 1-7.
441. Larkin GL, Prescott JE. A randomized, double-blind, comparative study of the efficacy of ketorolac tromethamine versus meperidine in the treatment of severe migraine. *Ann Emerg Med* 1992 Aug; 21(8):919-24; PMID: 1497157.
442. Latsko M, Silberstein S, Rosen N. Frovatriptan as preemptive treatment for fasting-induced migraine. *Headache* 2011 Mar; 51(3):369-74; PMID: 21269298.
443. Levin M, Ward TN, Larson E. Migraine-tic syndrome: a case report of a new headache type. *Cephalalgia* 2004 Jan; 24(1):72-3; PMID: 14687017.
444. Lewis DW, Winner P, Hershey AD, et al. Efficacy of zolmitriptan nasal spray in adolescent migraine. *Pediatrics* 2007 Aug; 120(2):390-6; PMID: 17671066.
445. Li Q, Tan G, Zhou J. Basilar-type migraine with coma: case reports and literature review. *Pain Med* 2011 Apr; 12(4):654-6; PMID: 21463463.
446. Limmroth V, May A, Auerbach P, et al. Changes in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine. *J Neurol Sci* 1996 Jun; 138(1-2):60-5; PMID: 8791240.
447. Linder SL, Dowson AJ. Zolmitriptan provides effective migraine relief in adolescents. *International Journal of Clinical Practice* 2000 Sep; 54(7):466-9; PMID: 11070573.
448. Linder SL, Mathew NT, Cady RK, et al. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. *Headache* 2008 Oct; 48(9):1326-36; PMID: 18484981.
449. Lindkvist J, Airaksinen M, Kaukonen AM, et al. Evolution of paediatric off-label use after new significant medicines become available for adults: a study on triptans in Finnish children 1994-2007. *Br J Clin Pharmacol* 2011 Jun; 71(6):929-35; PMID: 21564161.
450. Lines CR, Vandormael K, Malbecq W. A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients. *Pain* 2001 Aug; 93(2):185-90; PMID: 11427330.
451. Lipton RB, Baggish JS, Stewart WF, et al. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. *Arch Intern Med* 2000 Dec 11-25; 160(22):3486-92; PMID: 11112243.
452. Lipton RB, Bigal ME. Opioid therapy and headache: a cause and a cure. *Neurology* 2004 May 25; 62(10):1662-3; PMID: 15159457.
453. Lipton RB, Cutrer FM, Goadsby PJ, et al. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians. *Current Medical Research & Opinion* 2005 Mar; 21(3):413-24; PMID: 15811210.
454. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. *Lancet Neurol* 2010 Apr; 9(4):373-80; PMID: 20206581.
455. Lipton RB, Pascual J, Goadsby PJ, et al. Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. *Headache* 2001 Sep; 41(8):754-63; PMID: 11576198.
456. Lipton RB, Stewart WF, Ryan RE, Jr., et al. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. *Arch Neurol* 1998 Feb; 55(2):210-7; PMID: 9482363.

457. Lipton RB, Stewart WF, Stone AM, et al. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. *JAMA* 2000 Nov 22-29; 284(20):2599-605; PMID: 11086366.
458. Liu AS, Wang JN, Zhang JY. Treatment of migraine by "head triple needle" acupuncture: a report of 30 Cases. *New Journal of Traditional Chinese Medicine*; 1997: 25-6.
459. Lloyd DK, Pilgrim AJ. Sumatriptan and recurrence of migraine. *Lancet* 1992 Oct 31; 340(8827):1110; PMID: 1357515.
460. Loder E, Boyle D, Wang L, et al. Comparison of preference for rizatriptan 10 mg or sumatriptan 50 mg tablet for the acute treatment of migraine. *Jns*; 2001.
461. Loder E, Brandes JL, Silberstein S, et al. Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine. *Headache* 2001 Sep; 41(8):745-53; PMID: 11576197.
462. Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. *Cephalalgia* 2005 Feb; 25(2):124-31; PMID: 15658949.
463. Loder E, Silberstein SD, Abu-Shakra S, et al. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. *Headache* 2004 Feb; 44(2):120-30; PMID: 14756849.
464. Loder EW, Dowson AJ, Spierings ELH. Part II: clinical efficacy and tolerability of zolmitriptan orally disintegrating tablet in the acute treatment of migraine. *Current Medical Research & Opinion* 2005; 21 Suppl 3:S8-12; PMID: 16083518.
465. Lofland JH, Kim SS, Batenhorst AS, et al. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. *Mayo Clinic Proceedings* 2001 Nov; 76(11):1093-101; PMID: 11702897.
466. Loisy C, Beorchia S, Centonze V, et al. Effects on migraine headache of MDL 72,222, an antagonist at neuronal 5-HT receptors. Double-blind, placebo-controlled study. *Cephalalgia : an international journal of headache*; 1985: 79-82.
467. Lomia M, Tchelidze T, Pruidze M. Bronchial asthma as neurogenic paroxysmal inflammatory disease: a randomized trial with carbamazepine. *Respiratory medicine*; 2006: 1988-96.
468. Longmore J, Hargreaves RJ, Boulanger CM, et al. Comparison of the vasoconstrictor properties of the 5-HT(1D)-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: Outcome of two independent studies using different experimental protocols. *Functional Neurology*; 1997: 3-9.
469. Lowy MT. 2.5 mg 311C in the acute treatment of migraine: efficacy and safety [abstract]. *European Journal of Neurology*; 1996: 152.
470. Lu SR, Fuh JL, Juang KD, et al. Migraine prevalence in adolescents aged 13-15: a student population-based study in Taiwan. *Cephalalgia* 2000 Jun; 20(5):479-85; PMID: 11037745.
471. Lumme P, Tuulonen A, Airaksinen PJ. Treatment and no treatment in low-tension glaucoma. *Investigative Ophthalmology and Visual Science*; 1990: Abstract number 2467.
472. Luthringer R, Djupesland PG, Sheldrake CD, et al. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. *J Pharm Pharmacol* 2009 Sep; 61(9):1219-28; PMID: 19703372.
473. Maas HJ, Danhof M, Della Pasqua O. A model-based approach to treatment comparison in acute migraine. *British Journal of Clinical Pharmacology* 2006 Nov; 62(5):591-600; PMID: 17061965.
474. Maas HJ, Danhof M, Della Pasqua OE. Prediction of headache response in migraine treatment. *Cephalalgia* 2006 Apr; 26(4):416-22; PMID: 16556242.
475. MacGregor EA, Dowson A, Davies PT. Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. *Headache* 2002 Apr; 42(4):249-55; PMID: 12010380.
476. MacGregor EA, Frith A, Ellis J, et al. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. *Neurology* 2006 Dec 26; 67(12):2154-8; PMID: 16971700.
477. MacGregor EA, Frith AA, Hackshaw A. Efficacy, safety, and tolerability of sertraline on depressive symptoms in women with comorbid migraine: an open-label study. *Journal of Clinical Psychopharmacology* 2011 Jun; 31(3):392-3; PMID: 21532361.

478. Maggioni F, Mainardi F, Dainese F, et al. Migraine secondary to superior oblique myokymia. *Cephalalgia* 2007 Nov; 27(11):1283-5; PMID: 17692104.
479. Maizels M. Headache evaluation and treatment by primary care physicians in an emergency department in the era of triptans. *Archives of Internal Medicine* 2001 Sep 10; 161(16):1969-73; PMID: 11525699.
480. Maizels M. Rizatriptan 5mg is not efficacious for migraine in adolescents. *Headache* 2002 Sep; 42(8):839-40; author reply 40; PMID: 12390657.
481. Maizels M, Geiger AM. Intranasal lidocaine for migraine: a randomized trial and open-label follow-up. *Headache* 1999 Sep; 39(8):543-51; PMID: 11279969.
482. Maizels M, Scott B, Cohen W, et al. Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial. *JAMA* 1996 Jul 24-31; 276(4):319-21; PMID: 8656545.
483. Malik SN, Hopkins M, Young WB, et al. Acute migraine treatment: patterns of use and satisfaction in a clinical population. *Headache* 2006 May; 46(5):773-80; PMID: 16643580.
484. Malmberg I. Evaluation of the cost effectiveness of zolmitriptan for the acute treatment of migraine [abstract]. 15th Annual Meeting of the International Society of Technology Assessment in Health Care; 1999 Jun 20-23; 1999: 145.
485. Mandema JW, Cox E, Alderman J. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation. *Cephalalgia* 2005 Sep; 25(9):715-25; PMID: 16109054.
486. Manna V. Effects of piroxicam-beta-cyclodextrin in the treatment of spontaneous migraine attacks and reserpine-induced headache: Putative serotonergic involvement in antinociceptive drug activity. *Advances in Therapy*; 1998: 75-84.
487. Marcus DA, Scharff L, Turk D, et al. A double-blind provocative study of chocolate as a trigger of headache. *Cephalalgia : an international journal of headache*; 1997: 855-62; discussion 00.
488. Mariano Da Silva H, Alcantara MC, Bordini CA, et al. Strictly unilateral headache reminiscent of hemicrania continua resistant to indomethacin but responsive to gabapentin. *Cephalalgia* 2002 Jun; 22(5):409-10; PMID: 12110117.
489. Marino C. Acute migraine treatment guideline. *Annals of Internal Medicine* 2003 Oct 7; 139(7):603; author reply -4; PMID: 14530242.
490. Marschner NW, Adler M, Nagel GA, et al. Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. *European journal of cancer (Oxford, England : 1990)*; 1991: 1137-40.
491. Martin C, Bonneru JJ, Brun JP, et al. Vecuronium or suxamethonium for rapid sequence intubation: which is better? *Br J Anaesth* 1987 Oct; 59(10):1240-4; PMID: 2890365.
492. Martin PR, Seneviratne HM. Effects of food deprivation and a stressor on head pain. *Health Psychol* 1997 Jul; 16(4):310-8; PMID: 9237082.
493. Martin PR, Todd J, Reece J. Effects of noise and a stressor on head pain. *Headache* 2005 Nov-Dec; 45(10):1353-64; PMID: 16324168.
494. Marty J, Benhamou D, Chassard D, et al. Effects of single-dose injectable paracetamol versus propacetamol in pain management after minor gynecologic surgery: a multicenter, randomized, double-blind, active-controlled, two-parallel-group study. *Current Therapeutic Research, Clinical & Experimental*; 2005: 294-306.
495. Massiou H. A comparison os sumatriptan nasal spray and intranasal dhydroergotamine (DHE) in the acute treatment of migraine. *Functional Neurology*; 1996: 151.
496. Massiou H, Jamin C, Hinzelin G, et al. Efficacy of oral naratriptan in the treatment of menstrually related migraine. *Eur J Neurol* 2005 Oct; 12(10):774-81; PMID: 16190915.
497. Massiou H, x00E, ne, et al. Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks. The migraine--satisfaction with treatment: reality with Almogran study. *European Neurology* 2006; 55(4):198-203; PMID: 16772716.

498. Matharu MS, Cohen AS, McGonigle DJ, et al. Posterior hypothalamic and brainstem activation in hemicrania continua. *Headache* 2004 Sep; 44(8):747-61; PMID: 15330820.
499. Mathew NT. Indomethacin responsive headache syndromes. *Headache*; 1981: 147-50.
500. Mathew NT. Early intervention with almotriptan improves sustained pain-free response in acute migraine. *Headache* 2003 Nov-Dec; 43(10):1075-9; PMID: 14629242.
501. Mathew NT, Finlayson G, Smith TR, et al. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). *Headache* 2007 Feb; 47(2):189-98; PMID: 17300358.
502. Mathew NT, Kailasam J, Meadors L, et al. Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. *Headache* 2000 Oct; 40(9):720-3; PMID: 11091289.
503. Mathew NT, Landy S, Stark S, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. *Headache* 2009 Jul; 49(7):971-82; PMID: 19486178.
504. Mathew NT, Schoenen J, Winner P, et al. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. *Headache* 2003 Mar; 43(3):214-22; PMID: 12603639.
505. Matta AP, Ribas MC, Moreira Filho PF. Postmeningitis headache: case report. *Arquivos de Neuro-Psiquiatria* 2007 Jun; 65(2B):521-3; PMID: 17665028.
506. Mauskop A, Farkkila M, Hering-Hanit R, et al. Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache. *Curr Med Res Opin* 1999; 15(4):282-9; PMID: 10640260.
507. May A, Gijsman HJ, Wallnöfer A, et al. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. *Pain*; 1996: 375-8.
508. Mazza A, Zamboni S, Cuppini S, et al. Internal carotid artery fibromuscular dysplasia in arterial hypertension: management in clinical practice. *Blood Pressure* 2008; 17(5-6):274-7; PMID: 18825547.
509. McBeath JG, Nanda A. Roller coaster migraine: an underreported injury? *Headache* 2000 Oct; 40(9):745-7; PMID: 11091294.
510. McCall RB, Huff R, Chio CL, et al. Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT_{1D} receptor agonist PNU-142633. *Cephalalgia* 2002 Dec; 22(10):799-806; PMID: 12485205.
511. McCarty J, Ruoff GE, Jacobson KD. Loracarbef (LY163892) versus cefaclor in the treatment of bacterial skin and skin-structure infections in an adult population. *The American journal of medicine*; 1992: 80s-5s.
512. McCrory P, Heywood J, Ugoni A. Open label study of intranasal sumatriptan (Imigran) for footballer's headache. *British Journal of Sports Medicine* 2005 Aug; 39(8):552-4; PMID: 16046342.
513. McEwen JI, O'Connor HM, Dinsdale HB. Treatment of migraine with intramuscular chlorpromazine. *Ann Emerg Med* 1987 Jul; 16(7):758-63; PMID: 3592329.
514. McEwen JI, O'Connor HM, Dinsdale HB. Treating migraine with chlorpromazine. *Nurses Drug Alert*; 1987: 87.
515. McGrath PJ, Humphreys P, Keene D, et al. The efficacy and efficiency of a self-administered treatment for adolescent migraine. *Pain* 1992 Jun; 49(3):321-4; PMID: 1408297.
516. Melchart D, Thormaehlen J, Hager S, et al. Acupuncture versus placebo versus sumatriptan for early treatment of migraine attacks: a randomized controlled trial. *J Intern Med* 2003 Feb; 253(2):181-8; PMID: 12542558.
517. Melchart De. Acupuncture versus sumatriptan for early treatment of acute migraine attacks - a randomised controlled clinical trial. *Deutsche Zeitschrift Fur Akupunktur*; 2000: 39.
518. Mellick LB, Mellick GA. Treatment of primary headache in the emergency department. *Headache* 2004 Sep; 44(8):840-1; PMID: 15330841.
519. Mendhekar DN, Andrade C. Prochlorperazine-induced tardive dystonia and its worsening with clozapine in a non-mentally ill patient with migraine. *Ann Pharmacother* 2011 Apr; 45(4):545-6; PMID: 21487079.
520. Mercer AJ, Lamb RJ, Rolan PE, et al. Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers. *Psychopharmacology*; 1998: 398-404.

521. Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. *Am J Emerg Med* 2003 May; 21(3):173-5; PMID: 12811706.
522. Micieli G, Piazza D, Sinforiani E, et al. Antimigraine drugs in the management of daily chronic headaches: clinical profiles of responsive patients. *Cephalalgia : an international journal of headache*; 1985: 219-24.
523. Miller FG. Treatment of acute migraine. *Lancet* 2002 Mar 2; 359(9308):802; PMID: 11888631.
524. Miller MA, Levsky ME, Enslow W, et al. Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache. *Am J Emerg Med* 2009 Feb; 27(2):160-4; PMID: 19371522.
525. Million R, Finlay BR, Whittington JR. Clinical trial of flupirtine maleate in patients with migraine. *Curr Med Res Opin* 1984; 9(3):204-12; PMID: 6389014.
526. Millson D, Frischer M, Croft P, et al. Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness? *Cephalalgia* 2000 Oct; 20(8):732-7; PMID: 11167903.
527. Milton KA, Kleinermans D, Scott N, et al. The bioequivalence of standard sumatriptan tablets and two encapsulated forms of sumatriptan. *International Journal of Pharmaceutical Medicine*; 2001: 21-6.
528. Miner JR, Smith SW, Moore J, et al. Sumatriptan for the treatment of undifferentiated primary headaches in the ED. *American Journal of Emergency Medicine* 2007 Jan; 25(1):60-4; PMID: 17157685.
529. Misra UK, Jose M, Kalita J. Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial. *Postgraduate Medical Journal*; 2004: 720-3.
530. Misra UK, Kalita J, Yadav RK. Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial. *J Headache Pain* 2007 Jun; 8(3):175-9; PMID: 17563841.
531. Mitsikostas DD, Vikelis M, Kodounis A, et al. Migraine recurrence is not associated with depressive or anxiety symptoms. Results of a randomized controlled trial. *Cephalalgia : an international journal of headache*; 2010: 690-5.
532. Mjaset C, Russell MB. Intravenous nimodipine worsening prolonged attack of familial hemiplegic migraine. *Journal of Headache & Pain* 2008 Dec; 9(6):381-4; PMID: 18846413.
533. Moghadam AH, Zarei H, Seifaddini R, et al. Outpatient treatment of migraine headache, can we use a dexamethasone containing regimen? *Journal of Research in Medical Sciences*; 2008: 264-7.
534. Molaie M, Olson CM, Koch J. The effect of intravenous verapamil on acute migraine headache. *Headache*; 1987: 51-3.
535. Moldofsky H, Lue FA, Mously C, et al. The effect of zolpidem in patients with fibromyalgia: a dose ranging, double blind, placebo controlled, modified crossover study. *The Journal of rheumatology*; 1996: 529-33.
536. Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. *Epilepsy & Behavior* 2003 Jun; 4(3):310-7; PMID: 12791334.
537. Moore KH, Leese PT, McNeal S, et al. The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. *Clinical therapeutics*; 2002: 583-94.
538. Moorjani BI, Rothner AD. Indomethacin-responsive headaches in children and adolescents. *Seminars in Pediatric Neurology* 2001 Mar; 8(1):40-5; PMID: 11332865.
539. Morello F, Ronzani G, Cappellari F. Migraine, cortical blindness, multiple cerebral infarctions and hypocoagulopathy in celiac disease. *Neurological Sciences* 2003 Jun; 24(2):85-9; PMID: 12827546.
540. Morrato EH, Nicol GE, Maahs D, et al. Metabolic screening in children receiving antipsychotic drug treatment. *Arch Pediatr Adolesc Med* 2010 Apr; 164(4):344-51; PMID: 20368487.
541. Mortimer PS, Badger C, Clarke I, et al. A double-blind, randomized, parallel-group, placebo-controlled trial of O-(beta-hydroxyethyl)-rutosides in chronic arm oedema resulting from breast cancer treatment. *Phlebology.*; 1995: 51-5.
542. Mullins CD, Subedi PR, Healey PJ, et al. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective. *Pharmacotherapy* 2007 Aug; 27(8):1092-101; PMID: 17655509.

543. Mullins CD, Weis KA, Perfetto EM, et al. Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat. *Journal of Managed Care Pharmacy* 2005 Jun; 11(5):394-402; PMID: 15934798.
544. Musson DG, Birk KL, Panebianco DL, et al. Pharmacokinetics of rizatriptan in healthy elderly subjects. *International journal of clinical pharmacology and therapeutics*; 2001: 447-52.
545. Myers DE, Myers RA. A preliminary report on hyperbaric oxygen in the relief of migraine headache. *Headache* 1995 Apr; 35(4):197-9; PMID: 7775175.
546. Nagtegaal JE, Smits MG, Swart AC, et al. Melatonin-responsive headache in delayed sleep phase syndrome: preliminary observations. *Headache* 1998 Apr; 38(4):303-7; PMID: 9595871.
547. Nappi G, Micieli G, Tassorelli C, et al. Effectiveness of a piroxicam fast dissolving formulation sublingually administered in the symptomatic treatment of migraine without aura. *Headache*; 1993: 296-300.
548. Nappi RE, Cagnacci A, Granella F, et al. Course of primary headaches during hormone replacement therapy. *Maturitas* 2001 Apr 20; 38(2):157-63; PMID: 11306204.
549. Nappi RE, Sances G, Brundu B, et al. Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. *Human Reproduction* 2005 Dec; 20(12):3423-8; PMID: 16123089.
550. Nestvold K. Naproxen and naproxen sodium in acute migraine attacks. *Cephalalgia*; 1986: 81-4.
551. Nett RB, Tiseo PJ, Almas M, et al. Patient satisfaction with eletriptan in the acute treatment of migraine in primary care. *International Journal of Clinical Practice* 2007 Oct; 61(10):1677-85; PMID: 17877653.
552. Neuhauser H, Radtke A, von Brevern M, et al. Zolmitriptan for treatment of migrainous vertigo: a pilot randomized placebo-controlled trial. *Neurology* 2003 Mar 11; 60(5):882-3; PMID: 12629256.
553. Newman LC, Harper S, Jones BA, et al. Frovatriptan for acute treatment of migraine associated with menstruation: results from an open-label postmarketing surveillance study. *Journal of Women's Health* 2009 Aug; 18(8):1265-73; PMID: 19627225.
554. Newman LC, Lipton RB. Migraine MLT-down: an unusual presentation of migraine in patients with aspartame-triggered headaches. *Headache* 2001 Oct; 41(9):899-901; PMID: 11703479.
555. Nezvalov, x00E, Henriksen K, et al. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study. *Headache* 2010 Apr; 50(4):563-75; PMID: 20132339.
556. Ng TM, Kohli A, Fagan SC, et al. The effect of intravenous verapamil on cerebral hemodynamics in a migraine patient with hemiplegia. *Annals of Pharmacotherapy* 2000 Jan; 34(1):39-43; PMID: 10669185.
557. Ng-Mak DS, Hu XH, Bigal M. Migraine treatment with rizatriptan and almotriptan: a crossover study. *Headache* 2009 May; 49(5):655-62; PMID: 19456878.
558. Ng-Mak DS, Hu XH, Chen Y, et al. Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans. *International Journal of Clinical Practice* 2007 Jul; 61(7):1091-111; PMID: 17537184.
559. Ni, x00F, o-Maldonado AI, et al. Efficacy and tolerability of intravenous methylergonovine in migraine female patients attending the emergency department: a pilot open-label study. *Head & Face Medicine* 2009; 5:21; PMID: 19895705.
560. Nicolodi M, Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. *Adv Exp Med Biol* 1996; 398:373-9; PMID: 8906292.
561. Nicolodi M, Sicuteri F. L-5-hydroxytryptophan can prevent nociceptive disorders in man. *Adv Exp Med Biol* 1999; 467:177-82; PMID: 10721054.
562. Norman BA, Block GA, Jiang K, et al. Two-period crossover comparison of rizatriptan 5 mg and 10 mg to sumatriptan 25 mg and 50 mg for the acute treatment of migraine [abstract]. *Neurology*; 1998: A341.

563. Norton J. Use of intravenous valproate sodium in status migraine. *Headache* 2000 Oct; 40(9):755-7; PMID: 11091297.
564. O BP, Cuddy L, Taylor DW, et al. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice. *Canadian Respiratory Journal*; 1996: 169-75.
565. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport (R) and Botox (R) in the treatment of cervical dystonia. *Journal of Neurology Neurosurgery and Psychiatry*; 1998: 6-12.
566. Okuma H, Kitagawa Y, Takagi S. Clinical efficacy of rizatriptan for patients with migraine: efficacy of drug therapy for migraine accompanied by tension headache-like symptoms, focusing on neck stiffness. *Journal of Headache & Pain* 2005 Dec; 6(6):455-8; PMID: 16388340.
567. Okuyucu E, Melek IM, Duman T, et al. Hypomania complicating topiramate therapy for migraine prophylaxis. *European Journal of Neurology* 2007 Mar; 14(3):e6; PMID: 17355539.
568. Olesen J. 5-Hydroxytryptamine 1F (5-HT_{1F}) receptor agonism. A possible new treatment principle for acute migraine attacks. *Cephalalgia* 2010 Oct; 30(10):1157-8; PMID: 20855360.
569. Olesen J, Diener HC, Schoenen J, et al. No effect of eletriptan administration during the aura phase of migraine. *Eur J Neurol* 2004 Oct; 11(10):671-7; PMID: 15469451.
570. Olson AD, Li BUK. The diagnostic evaluation of children with cyclic vomiting: a cost-effectiveness assessment. *Journal of Pediatrics* 2002 Nov; 141(5):724-8; PMID: 12410206.
571. Omata T, Takanashi J, Wada T, et al. Genetic diagnosis and acetazolamide treatment of familial hemiplegic migraine. *Brain & Development* 2011 Apr; 33(4):332-4; PMID: 20542393.
572. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. *Cephalalgia* 2004 Jan; 24(1):60-5; PMID: 14687015.
573. O'Quinn S, DeBussey S, Saiers JA. Sumatriptan injection and nasal spray: onset of efficacy in the acute treatment of migraine [abstract]. *Neurology*; 1998: A264-5.
574. O'Quinn S, Ephross SA, Williams V, et al. Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. *Arch Gynecol Obstet* 1999 Nov; 263(1-2):7-12; PMID: 10728620.
575. Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. *Eur Neurol*; 1991: 306-13.
576. Orlikowski CE, Dickinson JE, Paech MJ, et al. Intrapartum analgesia and its association with post-partum back pain and headache in nulliparous women. *Aust N Z J Obstet Gynaecol* 2006 Oct; 46(5):395-401; PMID: 16953853.
577. Ozkul Y, Bozlar S. Effects of fluoxetine on habituation of pattern reversal visually evoked potentials in migraine prophylaxis. *Headache* 2002 Jul-Aug; 42(7):582-7; PMID: 12482209.
578. Padma MV, Jain S, Maheshwari MC, et al. Efficacy and tolerability of oral Sumatriptan in Indian patients with acute migraine; a multicentre study. *Neurology India*; 1998: 105-8.
579. Pakalnis A, Kring D, Paolicchi J. Parental satisfaction with sumatriptan nasal spray in childhood migraine. *Journal of Child Neurology* 2003 Nov; 18(11):772-5; PMID: 14696905.
580. Palikh GM, Vaughn BV. Topiramate responsive exploding head syndrome. *Journal of Clinical Sleep Medicine* 2010 Aug 15; 6(4):382-3; PMID: 20726288.
581. Panagiotopoulos C, Ronsley R, Elbe D, et al. First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. *J Can Acad Child Adolesc Psychiatry* 2010 May; 19(2):124-37; PMID: 20467549.
582. Panerai AE, Monza G, Movilia P, et al. A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. *Acta Neurol Scand* 1990 Jul; 82(1):34-8; PMID: 2239134.

583. Parisi P, Kasteleijn-Nolst T, x00E, et al. A case with atypical childhood occipital epilepsy "Gastaut type": an ictal migraine manifestation with a good response to intravenous diazepam. *Epilepsia* 2007 Nov; 48(11):2181-6; PMID: 17711460.
584. Parisi P, Pagani J, Galiffa S, et al. Migrainous vertigo unresponsive to antimigraine therapy in a child with "asymptomatic" cerebellar lesion: casual or causal association? *Cephalalgia* 2005 Oct; 25(10):831-5; PMID: 16162262.
585. Parker GB, Tupling H, Pryor DS. A controlled trial of cervical manipulation of migraine. *Aust N Z J Med* 1978 Dec; 8(6):589-93; PMID: 373735.
586. Pascual J. Clinical benefits of early triptan therapy for migraine. *Headache* 2002 Jan; 42 Suppl 1:10-7; PMID: 11966859.
587. Pascual J, Bussone G, Hernandez JF, et al. Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine. *Eur Neurol* 2001; 45(4):275-83; PMID: 11385269.
588. Pascual J, Diener H-C. Use of almotriptan in triptan-experienced and triptan-naïve patients. *Current Medical Research & Opinion* 2007 Oct; 23(10):2433-40; PMID: 17723158.
589. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. *Cephalalgia* 2000 Jul; 20(6):588-96; PMID: 11075844.
590. Pascual J, Fit, x00E, et al. Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. *Headache* 2002 Feb; 42(2):93-8; PMID: 12005301.
591. Pascual J, Garc, x00Ed, et al. Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: analysis of return to function and patient preference. *Headache* 2005 Oct; 45(9):1140-50; PMID: 16178944.
592. Pascual J, Mu, x00F, et al. Correlation between lipophilicity and triptan outcomes. *Headache* 2005 Jan; 45(1):3-6; PMID: 15663606.
593. Pascual J, Vega P, Diener HC, et al. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. *Cephalalgia*; 2000: 455-61.
594. Patrick DL, Hurst BC, Hughes J. Further development and testing of the migraine-specific quality of life (MSQOL) measure. *Headache* 2000 Jul-Aug; 40(7):550-60; PMID: 10940093.
595. Patten JP. Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study. Oral Sumatriptan Dose-defining Study Group. *Journal of neurology*; 1991: S62-5.
596. Peck RW, Seaber EJ, Dixon R, et al. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). *British journal of clinical pharmacology*; 1997: 595-9.
597. Peck RW, Seaber EJ, Dixon RM, et al. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women. *Clinical pharmacology and therapeutics*; 1998: 342-53.
598. Penzien D, Johnson C, Carpenter D, et al. Drug vs. behavioral treatment of migraine: long-acting propranolol vs. home-based self-management training. *Headache*; 1990: 300.
599. Perfetto EM, Weis KA, Mullins CD, et al. An economic evaluation of triptan products for migraine. *Value in Health* 2005 Nov-Dec; 8(6):647-55; PMID: 16283865.
600. Perino M, Famularo G, Tarroni P. Acquired transient stuttering during a migraine attack. *Headache* 2000 Feb; 40(2):170-2; PMID: 10759918.
601. Peroutka SJ, Lyon JA, Swarbrick J, et al. Efficacy of diclofenac sodium softgel 100 mg with or without caffeine 100 mg in migraine without aura: a randomized, double-blind, crossover study. *Headache* 2004 Feb; 44(2):136-41; PMID: 14756851.
602. Perrin VL, Farkkila M, Goasguen J, et al. Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine. *Cephalalgia*; 1989: 63-72.
603. Perrotta A, Serrao M, Tassorelli C, et al. Oral nitric-oxide donor glyceryl-trinitrate induces sensitization in spinal cord pain processing in migraineurs: a double-blind, placebo-controlled, cross-over study. *Eur J Pain* 2011 May; 15(5):482-90; PMID: 20965755.

604. Pfadenhauer K, Sch, x00F, et al. The risks of sumatriptan administration in patients with unrecognized subarachnoid haemorrhage (SAH). *Cephalalgia* 2006 Mar; 26(3):320-3; PMID: 16472339.
605. Pfaffenrath V. Efficacy and safety of sumatriptan tablets (25mg, 50mg, 100mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. *Journal of the Neurological Sciences*; 1997: S41.
606. Pfaffenrath V, Diener HC, Isler H, et al. Efficacy and tolerability of amitriptyline in the treatment of chronic tension-type headache: a multi-centre controlled study. *Cephalalgia* 1994 Apr; 14(2):149-55; PMID: 8062354.
607. Pichard-Garcia L, Hyland R, Baulieu J, et al. Human hepatocytes in primary culture predict lack of cytochrome P-450 3A4 induction by eletriptan in vivo. *Drug Metab Dispos* 2000 Jan; 28(1):51-7; PMID: 10611140.
608. Pini LA, Sternieri E, Fabbri L, et al. High efficacy and low frequency of headache recurrence after oral sumatriptan. The Oral Sumatriptan Italian Study Group. *J Int Med Res* 1995 Mar-Apr; 23(2):96-105; PMID: 7601299.
609. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. *Drugs* 1994 Apr; 47(4):622-51; PMID: 7516861.
610. Poston S, Dickson M, Johnsrud M, et al. Topiramate prescribing patterns among medicare patients: diagnosis, comorbidities, and dosing. *Clinical Therapeutics* 2007 Mar; 29(3):504-18; PMID: 17577471.
611. Pothmann R, Lobisch M. Acute treatment of episodic childhood tension-type headache with flupirtine and paracetamol - A double-blind crossover-study. *Schmerz*; 2000: 1-4.
612. Pongvarin N. The first world report of botulinum A toxin injection for status migrainosus. *Journal of the Medical Association of Thailand* 2001 Aug; 84(8):1199-203; PMID: 11758858.
613. Pradalier A, Guerard DLA, Scheck F, et al. The association of calcium carbasalate-metoclopramide versus dihydroergotamine in the treatment of migraine attacks. *Pathologie Biologie*; 1995: 806-13.
614. Pradel FG, Subedi P, Varghese AA, et al. Does earlier headache response equate to earlier return to functioning in patients suffering from migraine? *Cephalalgia* 2006 Apr; 26(4):428-35; PMID: 16556244.
615. Pryse-Phillips W. Oral eletriptan (40-80 mg) versus oral sumatriptan (50-100 mg) for the treatment of acute migraine in sumatriptan-naïve patients. *European Journal of Neurology (Abstracts of the 4th Congress of the European Federation of Neurological Sciences, September 7-11, Lisbon, Portugal 1999)*; 1999: 21.
616. Rabinowitz JD, Lloyd PM, Munzar P, et al. Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation. *Journal of pharmaceutical sciences*; 2006: 2438-51.
617. Ragot JP, Giorgi M, Marinoni M, et al. Acute activity of nimesulide in the treatment of pain after oral surgery - Double blind, placebo and mefenamic acid controlled study. *European Journal of Clinical Research*; 1994: 39-50.
618. Rahimdel A, Eslami MH, Zeinali A. A randomized controlled study of magnesium sulfate versus dihydroergotamine in the management of acute migraine attacks. *Pak J Neurological Sci*; 2007: 92-5.
619. Rahman A, Yildiz M, Dadas E, et al. Reversal of ergotamine-induced vasospasm following methylprednisolone. *Clinical Toxicology: The Official Journal of the American Academy of Clinical Toxicology & European Association of Poisons Centres & Clinical Toxicologists* 2008 Dec; 46(10):1074-6; PMID: 18763151.
620. Rahmann A, Wienecke T, Hansen JM, et al. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. *Cephalalgia* 2008 Mar; 28(3):226-36; PMID: 18254893.
621. Rampello L, Alvano A, Chiechio S, et al. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. *Neuropsychobiology* 2004; 50(4):322-8; PMID: 15539864.
622. Ramsberg J, Henriksson M. The cost-effectiveness of oral triptan therapy in Sweden. *Cephalalgia* 2007 Jan; 27(1):54-62; PMID: 17212684.

623. Rankin LM. Migraine in the emergency department: not a win-win situation. *Headache* 2003 Nov-Dec; 43(10):1032-3; PMID: 14629237.
624. Reches A. Comparison of the efficacy, safety and tolerability of oral eletriptan and cafergot(r) in the acute treatment of migraine. *European Journal of Neurology (Abstracts of the 4th Congress of the European Federation of Neurological Sciences, September 7-11, Lisbon, Portugal 1999)*; 1999: 57.
625. Rederich G, Rapoport A, Cutler N, et al. Oral sumatriptan for the long-term treatment of migraine: clinical findings. *Neurology* 1995 Aug; 45(8 Suppl 7):S15-20; PMID: 7644080.
626. Regan LA, Hoffman RS, Nelson LS. Slower infusion of metoclopramide decreases the rate of akathisia. *The American journal of emergency medicine*; 2009: 475-80.
627. Reutens D, Fatovich D, Stewart-Wynne E, et al. Is intravenous lignocaine clinically effective in acute migraine? [abstract]. *Australian & New Zealand Journal of Medicine*; 1991: 172.
628. Richer LP, Laycock K, Millar K, et al. Treatment of children with migraine in emergency departments: national practice variation study. *Pediatrics* 2010 Jul; 126(1):e150-5; PMID: 20530076.
629. Rimaitis K, Svitojute A, Macas A. The influence of dexamethasone and ketolgan on postoperative nausea and vomiting and estimation of risk factors in women undergoing gynecologic laparoscopic surgeries. *Medicina (Kaunas)* 2010; 46(4):261-7; PMID: 20571294.
630. Roberts RB, Shirley MA. The obstetrician's role in reducing the risk of aspiration pneumonitis. With particular reference to the use of oral antacids. *Am J Obstet Gynecol* 1976 Mar 15; 124(6):611-7; PMID: 943944.
631. Rodgers AJ, Hustad CM, Cady RK, et al. Total migraine freedom, a potential primary endpoint to assess acute treatment in migraine: comparison to the current FDA requirement using the complete rizatriptan study database. *Headache* 2011 Mar; 51(3):356-68; PMID: 21039453.
632. Roon KI, Olesen J, Diener HC, et al. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. *Ann Neurol* 2000 Feb; 47(2):238-41; PMID: 10665496.
633. Rossi P, Di Lorenzo C, Faroni J, et al. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. *Cephalalgia* 2006 Sep; 26(9):1097-105; PMID: 16919060.
634. Ross-Lee LM, Eadie MJ, Heazlewood V, et al. Aspirin pharmacokinetics in migraine. The effect of metoclopramide. *Eur J Clin Pharmacol* 1983; 24(6):777-85; PMID: 6884416.
635. Rostoff P, Gajos G, Latacz P, et al. Ergotamine-induced cardiovascular toxicity: mechanisms and clinical significance. *International Journal of Cardiology* 2010 May 14; 141(1):111-4; PMID: 19135734.
636. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. *Clinical therapeutics*; 2006: 689-706.
637. Rothner AD, Wasiewski W, Winner P, et al. Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. *Headache* 2006 Jan; 46(1):101-9; PMID: 16412157.
638. Rothner AD, Winner P, Nett R, et al. One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study. *Clinical Therapeutics* 2000 Dec; 22(12):1533-46; PMID: 11192144.
639. Rothrock JF. Compound medications for acute migraine treatment. *Headache* 2008 Sep; 48(8):1283; PMID: 18808510.
640. Rothrock JF. Treatment-refractory migraine: the case for opioid therapy. *Headache* 2008 Jun; 48(6):850-4; PMID: 18549362.
641. Rothrock JF. Injectable sumatriptan: now needle-based or needle-free. *Headache* 2010 Feb; 50(2):343-4; PMID: 20456140.

642. Rothrock JF. Opiate and opioid ("narcotic") therapy for acute migraine headache. *Headache* 2010 Jul; 50(7):1255-6; PMID: 20649661.
643. Rothrock JF. Membership survey: use of oral triptans and injectable sumatriptan within the same 24-hour period. *Headache* 2011 Jan; 51(1):141; PMID: 21198575.
644. Rothrock JF, Cady RK, Aurora SK, et al. Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence. *Curr Med Res Opin* 2011 Sep 26; PMID: 21942531.
645. Rowe BH, Colman I, Edmonds ML, et al. Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache. *Headache* 2008 Mar; 48(3):333-40; PMID: 18047499.
646. Rozen T. Cessation of hemiplegic migraine auras with greater occipital nerve blockade. *Headache* 2007 Jun; 47(6):917-9; PMID: 17578545.
647. Ruiz C, Gener B, Garaizar C, et al. Episodic spontaneous hypothermia: a periodic childhood syndrome. *Pediatric Neurology* 2003 Apr; 28(4):304-6; PMID: 12849886.
648. Ruiz RS, Saathoff K, Villanueva M, et al. Red Contact Lens Therapy for the Reduction of Migraine Severity. *Iovs*; 2004: ARVO E-abstract 5610.
649. Russell MB, Holm TOE, Nielsen MR, et al. Subcutaneous sumatriptan in general practice: A randomized double-blind placebo-controlled cross-over study. *Ugeskrift for Laeger*; 1995: 2320-3.
650. Russell MB, Holm-Thomsen OE, Rishoj Nielsen M, et al. A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice. *Cephalalgia* 1994 Aug; 14(4):291-6; PMID: 7954759.
651. Ryan R, Geraud G, Goldstein J, et al. Clinical efficacy of frovatriptan: placebo-controlled studies. *Headache* 2002 Apr; 42 Suppl 2:S84-92; PMID: 12028324.
652. Ryan RE, Jr., Diamond S, Giammarco RAM, et al. Efficacy of zolmitriptan at early time-points for the acute treatment of migraine and treatment of recurrence: A randomised, placebo-controlled trial. *CNS Drugs*; 2000: 215-26.
653. Ryan RE, Elkind AH, Goldstein J. Twenty four hour response rate and incidence of recurrence of BMS-180048 in the acute treatment of migraine headaches. *Functional Neurology*; 1996: 148.
654. Sakai F, Diener HC, Ryan R, et al. Eletriptan for the acute treatment of migraine: results of bridging a Japanese study to Western clinical trials. *Curr Med Res Opin* 2004 Mar; 20(3):269-77; PMID: 15025836.
655. Sakai F, Iwata M, Tashiro K, et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose-response study. *Cephalalgia* 2002 Jun; 22(5):376-83; PMID: 12110113.
656. Sakai Y, Dobson C, Diksic M, et al. Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis. *Neurology* 2008 Feb 5; 70(6):431-9; PMID: 18250288.
657. Salazar G, Fragoso M, Vergez L, et al. Metoclopramide as an analgesic in severe migraine attacks: an open, single-blind, parallel control study. *Recent Pat CNS Drug Discov* 2011 May 1; 6(2):141-5; PMID: 21585330.
658. Salonen R. Speed of onset of sumatriptan injection, nasal spray, and tablets in the acute treatment of migraine. *Functional Neurology*; 1998: 179.
659. Salonen R, Dawson R. Intranasal sumatriptan in the acute treatment of migraine [abstract]. *Canadian Journal of Neurological Sciences*; 1993.
660. Sandrini G, Farkkila M, Burgess G, et al. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. *Neurology* 2002 Oct 22; 59(8):1210-7; PMID: 12391349.
661. Sanger MD. The treatment of anxiety and depression in the allergic patient. *Annals of allergy*; 1969: 506-10.
662. Santanello NC, Davies G, Allen C, et al. Determinants of migraine-specific quality of life. *Cephalalgia* 2002 Oct; 22(8):680-5; PMID: 12383065.
663. Santanello NC, Polis AB, Hartmaier SL, et al. Improvement in migraine-specific quality of life in a clinical trial of rizatriptan. *Cephalalgia* 1997 Dec; 17(8):867-72; discussion 00; PMID: 9453276.

664. Santone G, Ricchi G, Rocchetti D, et al. Is the exposure to antidepressant drugs in early pregnancy a risk factor for spontaneous abortion? A review of available evidences. *Epidemiol Psichiatri Soc* 2009 Jul-Sep; 18(3):240-7; PMID: 20034202.
665. Saracco MG, Valfre W, Cavallini M, et al. Greater occipital nerve block in chronic migraine. *Neurol Sci* 2010 Jun; 31 Suppl 1:S179-80; PMID: 20464617.
666. Savani N, Pfaffenrath V, Rice L, et al. Efficacy, tolerability, and patient satisfaction with 50- and 100-mg sumatriptan tablets in those initially dissatisfied with the efficacy of 50-mg sumatriptan tablets. *Clin Ther* 2001 Feb; 23(2):260-71; PMID: 11293559.
667. Schmitt WJ, Slowey E, Fravi N, et al. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. *Headache* 2001 Jul-Aug; 41(7):658-64; PMID: 11554953.
668. Schoenen J, Bulcke J, Caekebeke J, et al. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study. *Cephalalgia*; 1994: 55-63.
669. Schoenen J, Pascual J, Rasmussen S, et al. Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan. *Eur J Neurol* 2005 Feb; 12(2):108-17; PMID: 15679698.
670. Scholpp J, Schellenberg R, Moeckesch B, et al. Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. *Cephalalgia* 2004 Nov; 24(11):925-33; PMID: 15482353.
671. Schrader A, Bene J. Results in the therapy of bronchial asthma using histaglobine. *Zeitschrift für Erkrankungen der Atmungsorgane, Mit Folia Bronchologica*; 1972: 337-45.
672. Schreiber CP, Cady RK. Diagnosis of menstrual headache and an open-label study among those with previously undiagnosed menstrually related migraine to evaluate the efficacy of sumatriptan 100 mg. *Clinical Therapeutics* 2007; 29 Suppl:2511-9; PMID: 18164918.
673. Schulman EA, Dermott KF. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. *Headache* 2003 Jul-Aug; 43(7):729-33; PMID: 12890127.
674. Schulte-Mattler WJ, Krack P. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. *Pain* 2004 May; 109(1-2):110-4; PMID: 15082132.
675. Seaber E, On N, Dixon RM, et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). *Br J Clin Pharmacol* 1997 Jun; 43(6):579-87; PMID: 9205817.
676. Seaber EJ, Peck RW, Smith DA, et al. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. *British journal of clinical pharmacology*; 1998: 433-9.
677. Seeburger JL, Taylor FR, Friedman D, et al. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. *Cephalalgia* 2011 May; 31(7):786-96; PMID: 21078681.
678. Seidel WT, Mitchell WG. Cognitive and behavioral effects of carbamazepine in children: data from benign rolandic epilepsy. *Journal of child neurology*; 1999: 716-23.
679. Shadle CR, Liu G, Goldberg MR. A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers. *Journal of clinical pharmacology*; 2000: 309-15.
680. Shah A, Johnson BF, Milton KA. The pharmacokinetics of eletriptan - a new oral agent for the acute treatment of migraine [abstract]. *Neurology*; 1998: A377.
681. Shahien R, Saleh SA, Bowirrat A. Intravenous sodium valproate aborts migraine headaches rapidly. *Acta Neurol Scand* 2011 Apr; 123(4):257-65; PMID: 20569223.
682. Shankland WE. Nociceptive trigeminal inhibition--tension suppression system: a method of preventing migraine and tension headaches. *Compend Contin Educ Dent* 2002 Feb; 23(2):105-8, 10, 12-3; quiz 14; PMID: 11915652.

683. Sharma A, Jusko WJ, Fulmor IE, et al. Pharmacokinetics and pharmacodynamics of avitriptan during intravenous administration in healthy subjects. *Journal of clinical pharmacology*; 1999: 685-94.
684. Sheftell F, Almas M, Weeks R, et al. Quantifying the return of headache in triptan-treated migraineurs: an observational study. *Cephalalgia* 2010 Jul; 30(7):838-46; PMID: 20647175.
685. Sheftell F, O'Quinn S, Watson C, et al. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. *Headache* 2000 Feb; 40(2):103-10; PMID: 10759909.
686. Sheftell FD, Byer J, Couch J, et al. Dihydroergotamine nasal spray in the acute treatment of migraine headache. *Headache*; 1989: 314.
687. Sheftell FD, Feleppa M, Tepper SJ, et al. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. *Headache* 2004 Jul-Aug; 44(7):661-8; PMID: 15209687.
688. Sheftell FD, Fox AW, Weeks RE, et al. Differentiating the efficacy of 5-HT(1B/1D) agonists. *Headache* 2001 Mar; 41(3):257-63; PMID: 11264685.
689. Sheftell FD, Rapoport AM, Marriott J, et al. Comparison of meclomen, ergotamine tartrate with caffeine and placebo for the treatment of acute headaches: a double-blind parallel-group multi-center study. *Headache*; 1988: 299.
690. Shrikanth V, Vanderheiden A, Simha V. Spontaneous intracerebral hemorrhage associated with ingestion of isometheptine containing anti-migraine medication. *Clin Neurol Neurosurg* 2011 Feb; 113(2):167-9; PMID: 21075510.
691. Shuster LT, Faubion SS, Sood R, et al. Hormonal manipulation strategies in the management of menstrual migraine and other hormonally related headaches. *Curr Neurol Neurosci Rep* 2011 Apr; 11(2):131-8; PMID: 21207200.
692. Sicuteri F, Del Bene E. The influence of tryptophan and parachlorophenylalanine on the sexual activity in man. *Acta vitaminologica et enzymologica*; 1975: 100-2.
693. Siitonen S, Uusitalo A. Angiotensin converting enzyme activity and blood pressure during treatment and after discontinuation of Ramipril and Enalapril in hypertensive patients. *Journal of Clinical Research*; 1998: 63-74.
694. Silberstein SD. Rizatriptan versus usual care in long-term treatment of migraine. *Neurology* 2000; 55(9 Suppl 2):S25-8; PMID: 11089516.
695. Silberstein SD. Pharmacological profile and clinical characteristics of frovatriptan in the acute treatment of migraine: introduction. *Headache* 2002 Apr; 42 Suppl 2:S45-6; PMID: 12028319.
696. Silberstein SD, Cady RK, Sheftell FD, et al. Efficacy of eletriptan in migraine-related functional impairment: functional and work productivity outcomes. *Headache* 2007 May; 47(5):673-82; PMID: 17501848.
697. Silberstein SD, Gobel H, Jensen R, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. *Cephalalgia* 2006 Jul; 26(7):790-800; PMID: 16776693.
698. Siniatchkin M, Hierundar A, Kropp P, et al. Self-regulation of slow cortical potentials in children with migraine: an exploratory study. *Applied Psychophysiology and Biofeedback*; 2000: 13-32.
699. Smith DA, Cleary EW, Watkins S, et al. Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study. *Journal of clinical pharmacology*; 1998: 685-93.
700. Smith DA, Cleary EW, Watkins S, et al. Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. *International journal of clinical pharmacology and therapeutics*; 1998: 301-5.
701. Smith M, Golwala H, Lozano P. Zolmitriptan induced acute coronary syndrome: a unique case. *Am J Ther* 2011 Sep; 18(5):e153-6; PMID: 21869671.
702. Smythe GA, Lazarus L. Suppression of human growth hormone secretion by melatonin and cyproheptadine. *J Clin Invest* 1974 Jul; 54(1):116-21; PMID: 4600047.

703. Sobaniec W, Kulak W, Smigielska-Kuzia J, et al. A multicenter, placebo-controlled, double-blind study of efficacy of a new form of carbamazepine (CarbatrolR) in refractory epileptic patients. *Polish Journal of Pharmacology*; 2004: 195-201.
704. Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. *Obstet Gynecol* 1993 Nov; 82(5):769-72; PMID: 8414324.
705. Solomon S, Frishberg B, Hu XH, et al. Migraine treatment outcomes with rizatriptan in triptan-naïve patients: a naturalistic study. *Clinical Therapeutics* 2001 Jun; 23(6):886-900; PMID: 11440288.
706. Somerville BW. Treatment of migraine attacks with an analgesic combination (Mersyndol). *The Medical journal of Australia*; 1976: 865-6.
707. Soriani S, Battistella PA, Naccarella C, et al. Nimesulide and acetaminophen for the treatment of juvenile migraine: A study for comparison of efficacy, safety, and tolerability. *Headache Quarterly*; 2001: 233-6.
708. Soyka D. Treatment of acute migraine attacks with intravenous flunarizine. *Cephalalgia*; 1987: 529.
709. Soyka D, Taneri Z, Oestreich W, et al. Flunarizine i.v. in the acute treatment of the migraine attack. A double-blind placebo-controlled study. *Cephalalgia : an international journal of headache*; 1988: 35-40.
710. Spears RC. Is gabapentin an effective treatment choice for hemicrania continua? *Journal of Headache & Pain* 2009 Aug; 10(4):271-5; PMID: 19437100.
711. Spierings EL. Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan. *Neurology* 2000 Sep 12; 55(5):735; author reply 6; PMID: 10980753.
712. Spierings ELH, Keywood C. Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study. *Pain Medicine* 2009 May-Jun; 10(4):633-8; PMID: 19453958.
713. Spira PJ, Beran RG. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. *Neurology* 2003 Dec 23; 61(12):1753-9; PMID: 14694042.
714. Sramek JJ, Hussey EK, Clements B, et al. Oral sumatriptan pharmacokinetics in the migraine state. *Clinical Drug Investigation*; 1999: 137-44.
715. Srinivasu P, Rambhau D, Rao BR, et al. Lack of pharmacokinetic interaction between sumatriptan and naproxen. *Journal of clinical pharmacology*; 2000: 99-104.
716. Sriraman R, Indu S, Chari P. Is granisetron-dexamethasone combination better than ondansetron - dexamethasone in the prevention of postoperative nausea and vomiting in outpatient gynaecological laparoscopy? *Journal of Anaesthesiology Clinical Pharmacology*; 2007: 365-72.
717. Stark S, Spierings EL, McNeal S, et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. *Headache* 2000 Jul-Aug; 40(7):513-20; PMID: 10940089.
718. Stegall MD, Simon M, Wachs ME, et al. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. *Transplantation*; 1997: 1695-700.
719. Steiner TJ, Lange R, Voelker M. Aspirin in episodic tension-type headache: placebo-controlled dose-ranging comparison with paracetamol. *Cephalalgia : an international journal of headache*; 2003: 59-66.
720. Sternieri E, Pinetti D, Coccia CPR, et al. Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients. *Journal of Headache & Pain* 2005 Sep; 6(4):319-21; PMID: 16362699.
721. Stiell IG, Dufour DG, Moher D, et al. Methotrimeprazine versus meperidine and dimenhydrinate in the treatment of severe migraine: a randomized, controlled trial. *Ann Emerg Med* 1991 Nov; 20(11):1201-5; PMID: 1952306.
722. Stillman MJ, Zajac D, Rybicki LA. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience. *Headache* 2004 Jan; 44(1):65-9; PMID: 14979885.
723. Striano P, Zara F, Santorelli FM, et al. Topiramate-associated worsening symptoms in a patient with familial hemiplegic migraine. *Journal of the Neurological Sciences* 2008 Sep 15; 272(1-2):194-5; PMID: 18603263.

724. Sullivan JT, Preston KL, Testa MP, et al. Psychoactivity and abuse potential of sumatriptan. *Clinical pharmacology and therapeutics*; 1992: 635-42.
725. Sunshine A, Mulhern SA, Olson N, et al. Comparative sensitivity of stopwatch methodology and conventional pain assessment measures for detecting early response to triptans in migraine: results of a randomized, open-label pilot study. *Clin Ther* 2006 Aug; 28(8):1107-15; PMID: 16982287.
726. Syrett N, Abu-Shakra S, Yates R. Zolmitriptan nasal spray: advances in migraine treatment. *Neurology* 2003 Oct 28; 61(8 Suppl 4):S27-30; PMID: 14581655.
727. Szekely B, Merryman S, Croft H, et al. Prophylactic effects of naproxen sodium on perimenstrual headache: a double-blind, placebo-controlled study. *Cephalalgia* 1989; 9(Suppl. 10):452-3; PMID.
728. Tamayo-Sarver JH, Dawson NV, Cydulka RK, et al. Variability in emergency physician decision making about prescribing opioid analgesics. *Annals of Emergency Medicine* 2004 Apr; 43(4):483-93; PMID: 15039692.
729. Tamayo-Sarver JH, Dawson NV, Hinze SW, et al. The effect of race/ethnicity and desirable social characteristics on physicians' decisions to prescribe opioid analgesics. *Academic emergency medicine : official journal of the Society for Academic Emergency Medicine*; 2003: 1239-48.
730. Tamayo-Sarver JH, Dawson NV, Hinze SW, et al. The effect of race/ethnicity and desirable social characteristics on physicians' decisions to prescribe opioid analgesics. *Academic emergency medicine : official journal of the Society for Academic Emergency Medicine*; 2004: 1239-48.
731. Tamura BM, Chang B. Botulinum toxin: application into acupuncture points for migraine. *Dermatologic Surgery* 2003 Jul; 29(7):749-54; PMID: 12828700.
732. Taylor FR, Heiring JO, Messina E, et al. Sumatriptan/naproxen sodium as early intervention for migraine: Effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. *Journal of Clinical Outcomes Management*; 2007: 195-204.
733. Taylor M, Silva S, Cottrell C. Botulinum toxin type-A (BOTOX) in the treatment of occipital neuralgia: a pilot study. *Headache* 2008 Nov-Dec; 48(10):1476-81; PMID: 19076646.
734. Tedeschi G, Casucci G, Di Costanzo A, et al. Acute effect of flunarizine on saccadic eye movements. *Acta neurologica*; 1992: 326-32.
735. Teixeira AL, Meira FC, Maia DP, et al. Migraine headache in patients with Sydenham's chorea. *Cephalalgia : an international journal of headache*; 2005: 542-4.
736. Tek D, Mellon M. The effectiveness of nalbuphine and hydroxyzine for the emergency treatment of severe headache. *Annals of emergency medicine*; 1987: 308-13.
737. Tek DS, McClellan DS, Olshaker JS, et al. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. *Ann Emerg Med* 1990 Oct; 19(10):1083-7; PMID: 2221512.
738. ten Berg K, van Oppen ACC, Nikkels PGJ, et al. Complex cardiac defect with hypoplastic right ventricle in a fetus with valproate exposure. *Prenatal Diagnosis* 2005 Feb; 25(2):156-8; PMID: 15712340.
739. Tepper SJ, Bigal ME, Sheftell FD, et al. Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases. *Headache* 2004 Sep; 44(8):794-800; PMID: 15330826.
740. Tepper SJ, Cochran A, Hobbs S, et al. Sumatriptan suppositories for the acute treatment of migraine. *International Journal of Clinical Practice*; 1998: 31-5.
741. Tepper SJ, Donnan GA, Dowson AJ, et al. A long-term study to maximise migraine relief with zolmitriptan. *Curr Med Res Opin* 1999; 15(4):254-71; PMID: 10640258.
742. Terrazzino S, Viana M, Floriddia E, et al. The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. *European Journal of Pharmacology* 2010 Sep 1; 641(2-3):82-7; PMID: 20488209.
743. Terwindt GM, Ophoff RA, Haan J, et al. Familial hemiplegic migraine: a clinical comparison of families linked and unlinked to chromosome 19.DMG RG. *Cephalalgia : an international journal of headache*; 1996: 153-5.

744. Tfelt-Hansen P. Pain freedom at 2 hours in migraine after telcagepant 300 mg. *CNS Drugs* 2011 Mar 1; 25(3):269-70; PMID: 21323397.
745. Tfelt-Hansen P. Low efficacy of transdermal sumatriptan in migraine. *CNS Drugs* 2011 Feb 1; 25(2):171; author reply -3; PMID: 21254793.
746. Tfelt-Hansen P, Bach FW, Daugaard D, et al. Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study. *J Headache Pain* 2006 Dec; 7(6):389-94; PMID: 17164991.
747. Tfelt-Hansen P, Goadsby PJ. Naratriptan is effective and well tolerated in the acute treatment of migraine.[comment]. *Neurology*; 1999: 1300-1.
748. Tfelt-Hansen P, Henry P, Mulder LJ, et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. *Lancet* 1995 Oct 7; 346(8980):923-6; PMID: 7564725.
749. Tfelt-Hansen P, Jensen K, Vendsborg P, et al. Chlormezanone in the treatment of migraine attacks: A double blind comparison with diazepam and placebo. *Cephalalgia*; 1982: 205-10.
750. Tfelt-Hansen P, Olesen J, Aebelholt-Krabbe A, et al. A double blind study of metoclopramide in the treatment of migraine attacks. *J Neurol Neurosurg Psychiatry*; 1980: 369-71.
751. Tfelt-Hansen P, Ryan RE, Jr. Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials. *Neurology* 2000; 55(9 Suppl 2):S19-24; PMID: 11089515.
752. Tfelt-Hansen P, Seidelin K, Stepanavage M, et al. The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects. *Br J Clin Pharmacol* 2002 Jul; 54(1):38-44; PMID: 12100223.
753. Tfelt-Hansen PC. Unpublished clinical trials with sumatriptan. *Lancet* 2009 Oct 31; 374(9700):1501-2; PMID: 19880018.
754. Than M, Bidwell S, Davison C, et al. Evidence-based emergency medicine at the 'coal face'. *Emergency Medicine Australasia* 2005 Aug; 17(4):330-40; PMID: 16091095.
755. The SBMSG. The efficacy, tolerability and safety of oral sumatriptan 50 mg in the acute treatment of migraine [abstract]. *European Journal of Neurology*; 1996: 149.
756. The SBMSG. A study comparing the efficiency, safety and tolerability of oral sumatriptan 25, 50 and 100 mg doses in the acute treatment of migraine [abstract]. *European Journal of Neurology*; 1996: 149-50.
757. Thomas J, Tomb E, Thomas E, et al. Migraine treatment by oral magnesium intake and correction of the irritation of buccofacial and cervical muscles as a side effect of mandibular imbalance. *Magnes Res* 1994 Jun; 7(2):123-7; PMID: 7999526.
758. Thompson I, Williams G, Caldwell B, et al. Randomised double-blind, placebo-controlled trial of the effects of the 'party pills' BZP/TFMPP alone and in combination with alcohol. *Journal of psychopharmacology (Oxford, England)*; 2010: 1299-308.
759. Thompson M, Gawel M, Desjardins B, et al. An economic evaluation of rizatriptan in the treatment of migraine. *Pharmacoeconomics* 2005; 23(8):837-50; PMID: 16097844.
760. Tiller JW, Johnson GF, Burrows GD. Moclobemide for depression: an Australian psychiatric practice study. *Journal of clinical psychopharmacology*; 1995: 31s-4s.
761. Titus F, Escamilla C, Gomes Da Costa Palmeira MM, et al. A double-blind comparison of lysine acetylsalicylate plus metoclopramide vs ergotamine plus caffeine in migraine: Effects on nausea, vomiting and headache symptoms. *Clinical Drug Investigation*; 2001: 87-94.
762. Tobin J, Flitman S. Treatment of migraine with occipital nerve blocks using only corticosteroids. *Headache* 2011 Jan; 51(1):155-9; PMID: 21198577.
763. Tokola R, Hokkanen E. Propranolol for acute migraine. *Br Med J* 1978 Oct 14; 2(6144):1089; PMID: 709242.
764. Tokola RA. Tolfenamic acid in combination with caffeine: absorption during acute migraine. Methods and findings in experimental and clinical pharmacology; 1985: 545-50.
765. Tokola RA. The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine. *Cephalalgia : an international journal of headache*; 1988: 139-47.

766. Tokola RA, Kangasniemi P, Neuvonen PJ, et al. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. *Cephalalgia* 1984 Dec; 4(4):253-63; PMID: 6394143.
767. Troconiz IF, Wolters JM, Tillmann C, et al. Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist. *Clin Pharmacokinet* 2006; 45(7):715-28; PMID: 16802852.
768. Tronvik E, Stovner LJ, Bovim G, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. *BMC Neurology* 2008; 8:4; PMID: 18366776.
769. Trottier ED, Bailey B, Dauphin-Pierre S, et al. Practice variation after implementation of a protocol for migraines in children. *European Journal of Emergency Medicine* 2010 Oct; 17(5):290-2; PMID: 19864956.
770. Trottier ED, Bailey B, Dauphin-Pierre S, et al. Clinical outcomes of children treated with intravenous prochlorperazine for migraine in a pediatric emergency department. *J Emerg Med* 2010 Aug; 39(2):166-73; PMID: 19150192.
771. Tuchin PJ, Pollard H, Bonello R. A randomized controlled trial of chiropractic spinal manipulative therapy for migraine. *J Manipulative Physiol Ther* 2000 Feb; 23(2):91-5; PMID: 10714533.
772. Tuchman M, Edvinsson L, Geraud G, et al. Zolmitriptan provides consistent migraine relief when used in the long-term. *Curr Med Res Opin* 1999; 15(4):272-81; PMID: 10640259.
773. Turcani P, Farkasova D, Marcek T, et al. Real-life experiences in migraine therapy. *Bratislavske Lekarske Listy* 2010; 111(2):74-8; PMID: 20429318.
774. Türk U, İlhan S, Alp R, et al. Botulinum toxin and intractable trigeminal neuralgia. *Clinical neuropharmacology*; 2005: 161-2.
775. Turner IM, Agrillo T. Migraine, botulinum toxin type-A, and the disappearing sebaceous cyst. *Headache* 2005 Feb; 45(2):166-7; PMID: 15705125.
776. Tvedskov JF, Iversen HK, Olesen J. A double-blind study of SB-220453 (Tonerbasat) in the glyceryltrinitrate (GTN) model of migraine. *Cephalalgia* 2004 Oct; 24(10):875-82; PMID: 15377319.
777. Tvedskov JF, Iversen HK, Olesen J, et al. Nitroglycerin provocation in normal subjects is not a useful human migraine model? *Cephalalgia* 2010 Aug; 30(8):928-32; PMID: 19740120.
778. Tvedskov JF, Thomsen LL, Iversen HK, et al. The prophylactic effect of valproate on glyceryltrinitrate induced migraine. *Cephalalgia* 2004 Jul; 24(7):576-85; PMID: 15196300.
779. U.S. Food and Drug Administration. Clinical Pharmacology Review of Inderal® (propranolol hydrochloride).1-18; PMID.
780. U.S. Food and Drug Administration. Public Health Advisory: treatment challenges of depression in pregnancy and the possibility of persistent pulmonary hypertension in newborns. *Public Health Advisories* 2006; 2006 Public Health Advisories; PMID.
781. U.S. Food and Drug Administration. Office of Clinical Pharmacology and Biopharmaceutics/Pharmacometrics Review of Olanzapine October 30, 2006 2006.
782. U.S. Food and Drug Administration. Clinical Executive Summary of Olanzapine 10/31/06 2006.
783. U.S. Food and Drug Administration. Clinical Pharmacology/Biopharmaceutics Review of Divalproex Sodium. 2007:1-10; PMID: NDA 21-168/SE5-015.
784. U.S. Food and Drug Administration. Clinical Pharmacology/Biopharmaceutics Review of Aripiprazole. 2007:1-73; PMID: NDA 21436/S018.
785. U.S. Food and Drug Administration. Clinical Pharmacology Review of Guanfacine Hydrochloride 2007.
786. U.S. Food and Drug Administration. Clinical Review of Guanfacine Hydrochloride 2007.
787. U.S. Food and Drug Administration. Clinical Review of Combigan (brimonidine tartrate-timolol maleate) 2007.
788. U.S. Food and Drug Administration. Clinical Pharmacology Review of Combigan May 3, 2007 2007.
789. U.S. Food and Drug Administration. Statistical Review and Evaluation of Combigan: Clinical Studies 2007.
790. U.S. Food and Drug Administration. Clinical Pharmacology Review of Simvastatin 2007.

791. U.S. Food and Drug Administration. Clinical Review of Olanzapine 4/06/2007 2007.
792. U.S. Food and Drug Administration. Clinical Pharmacology/Biopharmaceutics Review of AXERT® (almotriptan malate) 2008.
793. U.S. Food and Drug Administration. Clinical Pharmacology Review of KEPPRA® (levetiracetam) 2008.
794. U.S. Food and Drug Administration. Safety Review: sNDA for Levetiracetam Use in Pediatric Patients With Refractory Partial Onset Seizures 2008.
795. U.S. Food and Drug Administration. Clinical Review of Divalproex Sodium 2008.
796. U.S. Food and Drug Administration. Clinical Pharmacology/Biopharmaceutics Review of Escitalopram 2008.
797. U.S. Food and Drug Administration. Clinical Review of Abilify® (aripiprazole) 2008.
798. U.S. Food and Drug Administration. Memorandum of Lamictal XR July 10, 2008 2008.
799. U.S. Food and Drug Administration. Clinical Review of Divalproex Sodium 2008.
800. U.S. Food and Drug Administration. Joint Clinical and Statistical Review of Levetiracetam. March 18, 2008.
801. U.S. Food and Drug Administration. Clinical Review of Simvastatin 2008.
802. U.S. Food and Drug Administration. Clinical Pharmacology and Biopharmaceutics Review of Zolmitriptan 2008.
803. U.S. Food and Drug Administration. Clinical Review of Olanzapine 7/14/2008 2008.
804. U.S. Food and Drug Administration. Clinical Review of Candesartan Cilexetil 2009.
805. U.S. Food and Drug Administration. Clinical Review of Almotriptan 2009.
806. U.S. Food and Drug Administration. Statistical Review of Almotriptan 2009.
807. U.S. Food and Drug Administration. Clinical Review of Escitalopram 2009.
808. U.S. Food and Drug Administration. Memorandum of Guanfacine September 1, 2009 2009.
809. U.S. Food and Drug Administration. Memorandum of Lamotrigine. 2009 May 6, 2009:1-4; PMID: NDA 22-115.
810. U.S. Food and Drug Administration. Statistical Review and Evaluation of CLONICEL® (clonidine HCl modified release): Clinical Studies. 2009:1-32; PMID: NDA 22-331/S-001.
811. U.S. Food and Drug Administration. Clinical Review of Lamotrigine XR March 6, 2009 2009.
812. U.S. Food and Drug Administration. Statistical Review and Evaluation of Lamotrigine March 31, 2009 2009.
813. U.S. Food and Drug Administration. Clinical Review of Topiramate 2009.
814. U.S. Food and Drug Administration. Clinical Pharmacology Review of Topiramate 2009.
815. U.S. Food and Drug Administration. Clinical Review of Quetiapine 8/10/2009 2009.
816. U.S. Food and Drug Administration. Clinical Pharmacology and Biopharmaceutics Review of Quetiapine 2009.
817. U.S. Food and Drug Administration. Statistical Review and Evaluation of Seroquel (quetiapine fumarate): Clinical Studies 2009.
818. U.S. Food and Drug Administration. Clinical Pharmacology Review of Guanfacine 2010.
819. U.S. Food and Drug Administration. Statistical Review and Evaluation of Guanfacine: Clinical Studies 2010.
820. U.S. Food and Drug Administration. Statistical Review and Evaluation of Guanfacine 2010.
821. U.S. Food and Drug Administration. Clinical Review of Clonidine Hydrochloride 2010.
822. U.S. Food and Drug Administration. Pharmacometrics Review of Clonidine 2010.
823. U.S. Food and Drug Administration. Clinical Review of Norethindrone October 4, 2010 2010.
824. U.S. Food and Drug Administration. Clinical Review: Second Review of Prenatal Valproic Acid Exposure and Neurdevelopmental Delay 2010.
825. U.S. Food and Drug Administration. Clinical Review of Guanfacine 2011.
826. U.S. Food and Drug Administration. Clinical Review of Lamotrigine 2011.

827. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Clinical Review of Topamax (topiramate): Division of Neuropharmacological Drug Products; 1998.
828. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Statistical Review and Evaluation of Topiramate: The R.W. Johnson Pharmaceutical Research Institute; 1998.
829. U.S. Food and Drug Administration, Department of Health and Human Service, Public Health Service, et al. Memorandum of Divalproex Sodium 2008.
830. U.S. Food and Drug Administration, Department of Health and Human Services, Public Health Service, et al. Memorandum of Olanzapine April 29, 2007 2007.
831. U.S. Food and Drug Administration, Department of Health and Human Services, Public Health Service, et al. Memorandum of Olanzapine July 18, 2008 2008.
832. U.S. Food and Drug Administration, Department of Health and Human Services, Public Health Service, et al. Memorandum of Guanfacine July 27, 2009 2009.
833. U.S. Food and Drug Administration, Johnson and Johnson Pharmaceutical Research and Development L.L.C. Clinical Review of Topiramate: Johnson and Johnson Pharmaceutical Research and Development L.L.C.; 2009.
834. U.S. Food and Drug Administration, Office of Clinical Pharmacology Review. Clinical Pharmacology Review of Candesartan Cilexetil 2009.
835. U.S. Food and Drug Administration, U.S. Department of Health and Human Services, Center For Drug Evaluation and Research, et al. Statistical Review and Evaluation of Zomig® (zolmitriptan nasal spray) October 14, 2008 2008.
836. U.S. Food and Drug Administration, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research, et al. Statistical Review and Evaluation of Olanzapine: Clinical Studies December 29, 2006 2006.
837. U.S. Food and Drug Administration, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research, et al. Statistical Review and Evaluation: Antiepileptic Drugs and Suicidality 2008.
838. U.S. Food and Drug Administration, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research, et al. Statistical Review and Evaluation of Escitalopram: Clinical Studies 2008.
839. U.S. Food and Drug Administration, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research, et al. Statistical Review and Evaluation of Aripiprazole: Clinical Studies. 2008:1-13; PMID: NDA 21-463/S-021.
840. U.S. Food and Drug Administration, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research, et al. Statistical Review and Evaluation of Simvastatin: Pediatric Study 2008.
841. U.S. Food and Drug Administration, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research, et al. Statistical Review and Evaluation of Candesartan Cilexetil: Clinical Studies 2009.
842. Uldall P, Bulteau C, Pedersen S, et al. Single-blind study of safety, tolerability, and preliminary efficacy of tiagabine as adjunctive treatment of children with epilepsy. *Epilepsia* 1995; 36(Suppl 3):S147-S8; PMID.
843. Utiger D, Eichenberger U, Bernasch D, et al. Transient minor improvement of high altitude headache by sumatriptan. *High altitude medicine & biology*; 2002: 387-93.
844. Uzogara E, Sheehan DV, Manschreck TC, et al. A combination drug treatment for acute common migraine. *Headache*; 1986: 231-6.
845. Vachharajani NN, Shyu WC, Nichola PS, et al. A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration. *Cephalalgia : an international journal of headache*; 2002: 282-7.
846. Vakil N, Kianifard F, Bottoli I. Exploratory study of tegaserod for dyspepsia in women receiving PPIs for heartburn. *Archives of Drug Information*; 2008: 79-88TN: NCT00171470/ClinicalTrials.gov.

847. Van Haarst AD, Van Gerven JM, Cohen AF, et al. The effects of moclobemide on the pharmacokinetics of the 5-HT_{1B/1D} agonist rizatriptan in healthy volunteers. *British journal of clinical pharmacology*; 1999: 190-6.
848. Vasconcellos E, Pina-Garza JE, Millan EJ, et al. Analgesic rebound headache in children and adolescents. *J Child Neurol* 1998 Sep; 13(9):443-7; PMID: 9733291.
849. Vasudeva S, Claggett AL, Tietjen GE, et al. Biofeedback-assisted relaxation in migraine headache: relationship to cerebral blood flow velocity in the middle cerebral artery. *Headache* 2003 Mar; 43(3):245-50; PMID: 12603643.
850. Vaughan D, Speed J, Medve R, et al. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers. *Clinical therapeutics*; 2010: 146-60.
851. Vernon H, Jansz G, Goldsmith CH, et al. A randomized, placebo-controlled clinical trial of chiropractic and medical prophylactic treatment of adults with tension-type headache: results from a stopped trial. *J Manipulative Physiol Ther* 2009 Jun; 32(5):344-51; PMID: 19539116.
852. Vestergaard P, Hermann AP, Gram J, et al. Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. *Maturitas*; 1997: 137-45.
853. Vikelis M, Rapoport AM. New drug delivery options for migraine. *Expert Rev Neurother* 2011 Jun; 11(6):771-3; PMID: 21651323.
854. Vinson DR. Emergency department treatment of migraine headaches. *Archives of Internal Medicine* 2002 Apr 8; 162(7):845; author reply 6; PMID: 11926869.
855. Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. *Annals of Emergency Medicine* 2002 Mar; 39(3):215-22; PMID: 11867972.
856. Vinson DR, Hurtado TR, Vandenberg JT, et al. Variations among emergency departments in the treatment of benign headache. *Annals of Emergency Medicine* 2003 Jan; 41(1):90-7; PMID: 12514688.
857. Visser WH, Ferrari MD, Bayliss EM, et al. Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group. *Cephalalgia* 1992 Oct; 12(5):308-13; PMID: 1330318.
858. Visser WH, Winner P, Strohmaier K, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. *Headache* 2004 Oct; 44(9):891-9; PMID: 15447698.
859. Vollono C, Capuano A, Mei D, et al. Multiple attack study on the available triptans in Italy versus placebo. *Eur J Neurol* 2005 Jul; 12(7):557-63; PMID: 15958097.
860. Vollono C, Ferraro D, Miliucci R, et al. The abnormal recovery cycle of somatosensory evoked potential components in children with migraine can be reversed by topiramate. *Cephalalgia* 2010 Jan; 30(1):17-26; PMID: 19489886.
861. Vukovic-Cvetkovic V, Plavec D, Lovrencic-Huzjan A, et al. Is iron deficiency anemia related to menstrual migraine? Post hoc analysis of an observational study evaluating clinical characteristics of patients with menstrual migraine. *Acta Clin Croat* 2010 Dec; 49(4):389-94; PMID: 21830449.
862. Walach H, Betz HD, Schweickhardt A. Sferics and headache: a prospective study. *Cephalalgia* 2001 Jul; 21(6):685-90; PMID: 11531901.
863. Walker Z, Walker RW, Robertson MM, et al. Antidepressant treatment of chronic tension-type headache: a comparison between fluoxetine and desipramine. *Headache* 1998 Jul-Aug; 38(7):523-8; PMID: 15613168.
864. Wallasch T-M. Frovatriptan in the practice of office-based neurologists/pain therapists: Results of postmarketing surveillance study ALADIN. *Advances in Therapy* 2010 Jan; 27(1):56-62; PMID: 20140543.
865. Wang SJ, Fuh JL, Wu ZA. Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine. *J Chin Med Assoc* 2007 Feb; 70(2):39-46; PMID: 17339143.

866. Wasiak J, Anderson JN. Is dexamethasone effective in treating acute migraine headache? *Medical Journal of Australia* 2002 Jan 21; 176(2):83; PMID: 11936293.
867. Watanabe Y, Tanaka H, Dan I, et al. Monitoring cortical hemodynamic changes after sumatriptan injection during migraine attack by near-infrared spectroscopy. *Neurosci Res* 2011 Jan; 69(1):60-6; PMID: 20875464.
868. Waters WE. Controlled clinical trial of ergotamine tartrate. *Br Med J* 1970 May 9; 2(5705):325-7; PMID: 4913961.
869. Weaver MB, Mackowiak JI, Solari PG. Triptan therapy impacts health and productivity. *Journal of Occupational & Environmental Medicine* 2004 Aug; 46(8):812-7; PMID: 15300133.
870. Weder CR, Schneemann M. Triptans and troponin: a case report. *Orphanet Journal Of Rare Diseases* 2009; 4:15; PMID: 19538745.
871. Wells NE, Steiner TJ. Effectiveness of eletriptan in reducing time loss caused by migraine attacks. *Pharmacoeconomics* 2000 Dec; 18(6):557-66; PMID: 11227394.
872. Wheeler SD. Donepezil treatment of topiramate-related cognitive dysfunction. *Headache* 2006 Feb; 46(2):332-5; PMID: 16492246.
873. White JR, Bell WL. Dysphonia associated with carotidynia and migraine responding to dihydroergotamine. *Headache* 2003 Jan; 43(1):69-71; PMID: 12864762.
874. Wiklund IK, Mattsson LA, Lindgren R, et al. Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: A double-blind, placebo-controlled trial. *International Journal of Clinical Pharmacology Research*; 1999: 89-99.
875. Wilkinson M. L-ASA compared to sumatriptan and parenteral placebo in the acute treatment of migraine. *Cephalalgia*; 1999: 542.
876. Willer L, Jensen RH, Juhler M. Medication overuse as a cause of chronic headache in shunted hydrocephalus patients. *J Neurol Neurosurg Psychiatry* 2010 Nov; 81(11):1261-4; PMID: 20660917.
877. Wilson AJ, Baum M, Brinkley DM, et al. Six-year results of a controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. *World-J-Surg*; 1985: 756-64.
878. Wilson JR, Foresman BH, Gamber RG, et al. Hyperbaric oxygen in the treatment of migraine with aura. *Headache* 1998 Feb; 38(2):112-5; PMID: 9529766.
879. Winner P, Adelman J, Aurora S, et al. Efficacy and tolerability of sumatriptan injection for the treatment of morning migraine: two multicenter, prospective, randomized, double-blind, controlled studies in adults. *Clinical therapeutics*; 2006: 1582-91.
880. Winner P, Dalessio D, Mathew N, et al. Concomitant administration of antiemetics is not necessary with intramuscular dihydroergotamine. *The American journal of emergency medicine*; 1994: 138-41.
881. Winner P, Landy S, Richardson M, et al. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. *Clin Ther* 2005 Nov; 27(11):1785-94; PMID: 16368449.
882. Winner P, Mannix LK, Putnam DG, et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. *Mayo Clin Proc* 2003 Oct; 78(10):1214-22; PMID: 14531480.
883. Winner P, Rothner AD, Wooten JD, et al. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. *Headache* 2006 Feb; 46(2):212-22; PMID: 16492230.
884. Winner P, Saper JR, Nett R, et al. Sumatriptan nasal spray in the acute treatment of migraine in adolescent migraineurs. *Pediatrics*; 1999: 694-5.
885. Wober C, Wober-Bingol C. Intranasal sumatriptan for the acute treatment of migraine in children. *Neurology* 2000 Mar 14; 54(5):1209-10; PMID: 10720311.
886. Wonderling D, Vickers AJ, Grieve R, et al. Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care. *BMJ (Clinical research ed.)*; 2004: 747.
887. Wynn RL. The sugar-loaded fentanyl lollipop (Actiq) and the risk for tooth decay. *Gen Dent* 2011 May-Jun; 59(3):168-70; PMID: 21903538.
888. Wynne AG, Romanski SA, Klee GG, et al. Nifedipine, but not verapamil, acutely elevates parathyroid hormone levels in premenopausal women. *Clinical endocrinology*; 1995: 9-15.

889. Yamaki T, Nozaki M, Sakurai H, et al. Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. *European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery*; 2009: 343-8.
890. Yang TY, Jang TY. The effects of one botulinum toxin type A (BTX-A) injection after UPPP. *European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery*; 2008: 1269-73.
891. Yurekli VA, Akhan G, Kutluhan S, et al. The effect of sodium valproate on chronic daily headache and its subgroups. *J Headache Pain* 2008 Feb; 9(1):37-41; PMID: 18231713.
892. Zafeiriou DI, Vargiami E. Childhood steroid-responsive painful ophthalmoplegia: clues to ophthalmoplegic migraine. *Journal of Pediatrics* 2006 Dec; 149(6):881; PMID: 17137913.
893. Zangaladze A, Asadi-Pooya AA, Ashkenazi A, et al. Sporadic hemiplegic migraine and epilepsy associated with CACNA1A gene mutation. *Epilepsy & Behavior* 2010 Feb; 17(2):293-5; PMID: 20071244.
894. Zank R, Strehl U, Larbig W, et al. Effects of rizatriptan on the contingent negative variation in healthy women. *Cephalalgia : an international journal of headache*; 2008: 922-32.
895. Zhao YB, Zhang GP, Chen QT, et al. [A clinical trial with sumatriptan in patients with acute migraine]. *The Chinese Journal of Clinical Pharmacology*; 1994: 143-7.
896. Zito G, Jull G, Story I. Clinical tests of musculoskeletal dysfunction in the diagnosis of cervicogenic headache. *Manual therapy*; 2006: 118-29.
897. Zukerman E, Negro MHS, Nothen MR. Comparative study on the efficacy and tolerability of different formulations for Tonopan versus placebo in migraine. <ORIGINAL> ESTUDO COMPARATIVO DA EFICACIA E TOLERABILIDADE DE DIFERENTES FORMULACOES DO TONOPAN VERSUS PLACEBO NAS ENXAQUECAS. *Rev Bras Neurol*; 1990: 57-60.
898. Zwart JA, Dyb G, Hagen K, et al. Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. *Neurology* 2003 Jul 22; 61(2):160-4; PMID: 12874392.

Not Eligible Outcomes

1. Alberici A, Borroni B, Manelli F, et al. Topiramate weight loss in migraine patients. *Journal of the Neurological Sciences* 2009 Mar 15; 278(1-2):64-5; PMID: 19084843.
2. Bigal ME, Kolodner KB, Lafata JE, et al. Patterns of medical diagnosis and treatment of migraine and probable migraine in a health plan. *Cephalalgia* 2006 Jan; 26(1):43-9; PMID: 16396665.
3. Binder WJ, Brin MF, Blitzner A, et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. *Otolaryngology - Head & Neck Surgery* 2000 Dec; 123(6):669-76; PMID: 11112955.
4. Bowyer SM, Mason KM, Moran JE, et al. Cortical hyperexcitability in migraine patients before and after sodium valproate treatment. *J Clin Neurophysiol* 2005 Jan-Feb; 22(1):65-7; PMID: 15689715.
5. Brown JS, Papadopoulos G, Neumann PJ, et al. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. *Headache* 2005 Sep; 45(8):1012-22; PMID: 16109115.
6. Brown JS, Papadopoulos G, Neumann PJ, et al. Cost-effectiveness of migraine prevention: the case of topiramate in the UK. *Cephalalgia* 2006 Dec; 26(12):1473-82; PMID: 17116098.
7. Brown JS, Rupnow MFT, Neumann P, et al. Cost effectiveness of topiramate in the prevention of migraines in the United States: an update. *Managed Care Interface* 2006 Dec; 19(12):31-8; PMID: 17274479.
8. Busch V, Kaube S, Schulte-Mattler W, et al. Sumatriptan and corneal reflexes in headache-free migraine patients: a randomized and placebo-controlled crossover study. *Cephalalgia* 2007 Feb; 27(2):165-72; PMID: 17257238.
9. Caproni S, Corbelli I, Pini LA, et al. Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: the results of a pilot study. *Cephalalgia* 2011 Apr; 31(5):543-9; PMID: 21216871.
10. Caruso JM, Brown WD, Exil G, et al. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. *Headache* 2000 Sep; 40(8):672-6; PMID: 10971664.
11. Cassidy EM, Tomkins E, Sharifi N, et al. Differing central amine receptor sensitivity in different migraine subtypes? A neuroendocrine study using buspirone. *Pain* 2003 Feb; 101(3):283-90; PMID: 12583871.
12. Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. *BMJ (Clinical research ed.)*; 1999: 13-8.
13. Charles JA, Jotkowitz S. Observations of the "carry-over effect" following successful termination of chronic migraine in the adolescent with short-term dihydroergotamine, dexamethasone and hydroxyzine: a pilot study. *Journal of Headache & Pain* 2005 Feb; 6(1):51-4; PMID: 16362192.
14. Christensen ML, Eades SK, Fuseau E, et al. Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine. *Journal of Clinical Pharmacology* 2001 Feb; 41(2):170-5; PMID: 11210397.
15. Christensen ML, Mottern RK, Jabbour JT, et al. Pharmacokinetics of sumatriptan nasal spray in children. *Journal of Clinical Pharmacology* 2004 Apr; 44(4):359-67; PMID: 15051742.
16. Claustrat B, Brun J, Chiquet C, et al. Melatonin secretion is supersensitive to light in migraine. *Cephalalgia* 2004 Feb; 24(2):128-33; PMID: 14728708.
17. Colucci D'Amato C, Pizza V, Marmolo T, et al. Migraine prophylactic therapy: citalopram versus flunarizine. *Headache Quarterly* 2000; 11(3):213-5; PMID.
18. Crooks J, Stephen SA, Brass W. Clinical trial of inhaled ergotamine tartrate in migraine. *Br Med J*; 1964: 221-4.
19. De Ciantis A, Muti M, Piccolini C, et al. A functional MRI study of language disturbances in subjects with migraine headache during treatment with topiramate. *Neurological Sciences* 2008 May; 29 Suppl 1:S141-3; PMID: 18545916.
20. Dey R, Khan S, Akhouri V, et al. Labetalol for prophylactic treatment of intractable migraine during pregnancy. *Headache* 2002 Jul-Aug; 42(7):642-5; PMID: 12482217.

21. Diener HC, Scholz E, Dichgans J, et al. Central effects of drugs used in migraine prophylaxis evaluated by visual evoked potentials. *Ann Neurol* 1989 Feb; 25(2):125-30; PMID: 2645824.
22. Dowson AJ. Analysis of the patients attending a specialist UK headache clinic over a 3-year period. *Headache* 2003 Jan; 43(1):14-8; PMID: 12864753.
23. Duquesnoy C, Mamet JP, Sumner D, et al. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*; 1998: 99-104.
24. Elkind AH, Wade A, Ishkanian G. Pharmacokinetics of frovatriptan in adolescent migraineurs. *Journal of Clinical Pharmacology* 2004 Oct; 44(10):1158-65; PMID: 15342617.
25. Ergun H, Gulmez SE, Tulunay FC. Cost-minimization analysis comparing topiramate with standard treatments in migraine prophylaxis. *Eur Neurol* 2007; 58(4):215-7; PMID: 17827966.
26. Evers S, Heuel T, Frese A, et al. The impact of different antimigraine compounds on platelet and erythrocyte aggregation. *Cephalalgia* 2006 Aug; 26(8):920-4; PMID: 16886927.
27. Fanciullacci M, Alessandri M, Nicolodi M, et al. Possible long-lasting inhibition of converting enzyme by enalapril in human cerebrospinal fluid. *Clin Sci (Lond)* 1993 Mar; 84(3):313-7; PMID: 8384953.
28. Feliu AL, Rupnow MFT, Blount A, et al. Resource use associated with topiramate in migraine prophylaxis. *American Journal of Health-System Pharmacy* 2007 Jul 15; 64(14):1483-91; PMID: 17617498.
29. Garcia-Monco JC, Foncea N, Bilbao A, et al. Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients. *Cephalalgia* 2007 Aug; 27(8):920-8; PMID: 17645757.
30. Gerwig M, Niehaus L, Stude P, et al. Beta-blocker migraine prophylaxis affects the excitability of the visual cortex as revealed by transcranial magnetic stimulation. *J Headache Pain* 2012 Jan; 13(1):83-9; PMID: 22089539.
31. Gneocchi-Ruscione T, Lorenzoni R, Anderson D, et al. Effects of ergotamine on myocardial blood flow in migraineurs without evidence of atherosclerotic coronary artery disease. *Am J Cardiol* 1998 May 1; 81(9):1165-8; PMID: 9605061.
32. Gordon CR, Kuritzky A, Doweck I, et al. Vestibulo-ocular reflex in migraine patients: the effect of sodium valproate. *Headache* 1993 Mar; 33(3):129-32; PMID: 8486508.
33. Green MW, Giordano S, Jiang P, et al. Effect of divalproex on metabolic parameters is dose related in migraine prophylaxis. *Headache* 2005 Sep; 45(8):1031-7; PMID: 16109117.
34. Greenlee CR, Puri V. Pediatric migraines: a case report. *Journal of the Kentucky Medical Association* 2003 Nov; 101(11):498-504; PMID: 14635578.
35. Hedman C, Andersen AR. Effects of the B1-selective adrenoceptor antagonist metoprolol on the symptomatology of classic migraine attacks. *Cephalalgia*; 1987: 461-2.
36. Hedman C, Andersen AR, Andersson PG, et al. Symptoms of classic migraine attacks: modifications brought about by metoprolol. *Cephalalgia : an international journal of headache*; 1988: 279-84.
37. Hedman C, Winther K, Knudsen JB. The difference between non-selective and beta 1-selective beta-blockers in their effect on platelet function in migraine patients. *Acta Neurol Scand* 1986 Dec; 74(6):475-8; PMID: 3030039.
38. Hershey AD, Powers SW, Benti AL, et al. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. *Headache* 2000 Jul-Aug; 40(7):539-49; PMID: 10940092.
39. Hirfanoglu T, Serdaroglu A, Gulbahar O, et al. Prophylactic drugs and cytokine and leptin levels in children with migraine. *Pediatric Neurology* 2009 Oct; 41(4):281-7; PMID: 19748048.
40. Hughes HE, Goldstein DA. Birth defects following maternal exposure to ergotamine, beta blockers, and caffeine. *J Med Genet* 1988 Jun; 25(6):396-9; PMID: 3398007.
41. Iannetti P, Spalice A, Iannetti L, et al. Residual and persistent Adie's pupil after pediatric ophthalmoplegic migraine. *Pediatric Neurology* 2009 Sep; 41(3):204-6; PMID: 19664538.

42. Javanmard SH, Sonbolestan SA, Heshmat-Ghahdarjani K, et al. Enalapril improves endothelial function in patients with migraine: A randomized, double-blind, placebo-controlled trial. *J Res Med Sci* 2011 Jan; 16(1):26-32; PMID: 21448379.
43. Joseph R, Steiner TJ, Schultz LU, et al. Platelet activity and selective beta-blockade in migraine prophylaxis. *Stroke*; 1988: 704-8.
44. Kececi H, Atakay S. Effects of topiramate on neurophysiological and neuropsychological tests in migraine patients. *Journal of Clinical Neuroscience* 2009 Dec; 16(12):1588-91; PMID: 19793661.
45. Kowacs PA, Piovesan EJ, Werneck LC, et al. Critical flicker frequency in migraine. A controlled study in patients without prophylactic therapy. *Cephalalgia* 2005 May; 25(5):339-43; PMID: 15839848.
46. Kung TA, Totonchi A, Eshraghi Y, et al. Review of pediatric migraine headaches refractory to medical management. *Journal of Craniofacial Surgery* 2009 Jan; 20(1):125-8; PMID: 19165008.
47. Matharu MS, Boes CJ, Goadsby PJ. SUNCT syndrome: prolonged attacks, refractoriness and response to topiramate. *Neurology* 2002 Apr 23; 58(8):1307; PMID: 11971110.
48. Matthews M, Flatt S. The efficacy of hypnotherapy in the treatment of migraine. *Nursing standard (Royal College of Nursing (Great Britain))* : 1987); 1999: 33-6.
49. Mulleners WM, Chronicle EP, Vredevelde JW, et al. Visual cortex excitability in migraine before and after valproate prophylaxis: a pilot study using TMS. *Eur J Neurol* 2002 Jan; 9(1):35-40; PMID: 11784374.
50. Music M, Babic N, Fajkic A, et al. Analysis of the electroencephalogram and pain characteristic in patients before and after carbamazepine treatment. *Medicinski Arhiv* 2008; 62(5-6):256-8; PMID: 19469263.
51. Ortiz A, Alda M. Treatment of bipolar disorder with comorbid migraine. *Journal of Psychiatry & Neuroscience* 2010 Jan; 35(1):E1-2; PMID: 20040250.
52. Owada K. Efficacy of candesartan in the treatment of migraine in hypertensive patients. *Hypertension Research - Clinical & Experimental* 2004 Jun; 27(6):441-6; PMID: 15253110.
53. Paisley RD, Arora HS, Nazeri A, et al. Migraine and vasodepressor syncope in a large family. *Texas Heart Institute Journal* 2009; 36(5):468-9; PMID: 19876431.
54. Palermo A, Fierro B, Giglia G, et al. Modulation of visual cortex excitability in migraine with aura: effects of valproate therapy. *Neuroscience Letters* 2009 Dec 18; 467(1):26-9; PMID: 19800389.
55. Palmer JE, Chronicle EP, Rolan P, et al. Cortical hyperexcitability is cortical under-inhibition: evidence from a novel functional test of migraine patients. *Cephalalgia* 2000 Jul; 20(6):525-32; PMID: 11075834.
56. Pentland B, Anderson DA, Critchley JA. Failure of ejaculation with indoramin. *Br Med J (Clin Res Ed)* 1981 May 2; 282(6274):1433-4; PMID: 6784854.
57. Pini LA, Ferrari A, Guidetti G, et al. Effectiveness of flunarizine in altering electronystagmographic patterns in migraine patients: a preliminary report. *International journal of clinical pharmacology research*; 1986: 27-32.
58. Pothmann R, Winter K. Migraine prophylaxis with dihydroergotamine - A double-blind placebo-controlled study. *Cephalalgia* Vol 9; 1989: 428-9.
59. Rahimtoola H, Buurma H, Tijssen CC, et al. Incidence and determinants of migraine prophylactic medication in the Netherlands. *European Journal of Clinical Pharmacology* 2002 May; 58(2):149-55; PMID: 12012149.
60. Rosenberg MD, Strassels SA. Serotonin-active drugs. *Journal of the Massachusetts Dental Society* 2000; 48(4):48-50; PMID: 11819931.
61. Rothrock JF, Parada VA, Drinkard R, et al. Predictors of a negative response to topiramate therapy in patients with chronic migraine. *Headache* 2005 Jul-Aug; 45(7):932-5; PMID: 15985112.
62. Rozen TD. Aborting a prolonged migrainous aura with intravenous prochlorperazine and magnesium sulfate. *Headache* 2003 Sep; 43(8):901-3; PMID: 12940813.
63. Saper JR, Winner PK, Lake AE, 3rd. An open-label dose-titration study of the efficacy and tolerability of tizanidine hydrochloride tablets in the prophylaxis of chronic daily headache. *Headache* 2001 Apr; 41(4):357-68; PMID: 11318882.

64. Sargent JD, Baumel B, Peters K, et al. Aborting a migraine attack: naproxen sodium v ergotamine plus caffeine. *Headache*; 1988; 263-6.
65. Scher AI, Stewart WF, Ricci JA, et al. Factors associated with the onset and remission of chronic daily headache in a population-based study. *Pain* 2003 Nov; 106(1-2):81-9; PMID: 14581114.
66. Sciamanna CN, Nicholson RA, Lofland JH, et al. Effects of a Website designed to improve the management of migraines. *Headache* 2006 Jan; 46(1):92-100; PMID: 16412156.
67. Serdaroglu G, Erhan E, Tekgul H, et al. Sodium valproate prophylaxis in childhood migraine. *Headache* 2002 Sep; 42(8):819-22; PMID: 12390647.
68. Silberstein SD. Control of topiramate-induced paresthesias with supplemental potassium. *Headache* 2002 Jan; 42(1):85; PMID: 12005283.
69. Silberstein SD, Feliu AL, Rupnow MF, et al. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost. *Headache* 2007 Apr; 47(4):500-10; PMID: 17445099.
70. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. *Headache* 2003 Mar; 43(3):171-8; PMID: 12603635.
71. Sri-udomkajorn S, Ruangsuwan S. Short-term outcomes of tension type and migraine headache in children. *Journal of the Medical Association of Thailand* 2008 Oct; 91 Suppl 3:S104-8; PMID: 19253504.
72. Storey JR, Calder CS, Potter DL. Potential role of topiramate (TPM) in the treatment of intractable daily headache: a retrospective pilot study (abstract). *Neurology* 1999; 52:A211; PMID.
73. Tietjen GE, Athanas K, Utley C, et al. The combination of naratriptan and prochlorperazine in migraine treatment. *Headache* 2005 Jun; 45(6):751-3; PMID: 15953309.
74. Truter I. Prescribing for migraine with the focus on selective 5HT1-receptor agonists: a pharmacy database analysis. *International Journal of Clinical Pharmacology & Therapeutics* 2010 May; 48(5):319-26; PMID: 20420788.
75. Velati D, Viana M, Cresta S, et al. 5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms. *European Journal of Pharmacology* 2008 Feb 2; 580(1-2):43-7; PMID: 18035351.
76. Vieira DS, x00E, vio d, et al. Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine. *Headache* 2007 Jun; 47(6):842-7; PMID: 17578532.
77. Virtanen R, Aromaa M, Rautava P, et al. Changing headache from preschool age to puberty. A controlled study. *Cephalalgia : an international journal of headache*; 2007: 294-303.
78. Visudtibhan A, Thampratankul L, Khongkhatithum C, et al. Migraine in junior high-school students: A prospective 3-academic-year cohort study. *Brain & Development* 2010 Nov; 32(10):855-62; PMID: 20060252.
79. Wang S-J, Fuh J-L, Lu S-R, et al. Outcomes and predictors of chronic daily headache in adolescents: a 2-year longitudinal study. *Neurology* 2007 Feb 20; 68(8):591-6; PMID: 17182975.
80. Warner BW, LaGrange CA, Tucker T, et al. Induction of progressive profound hypocitratemia with increasing doses of topiramate. *Urology* 2008 Jul; 72(1):29-32; discussion -3; PMID: 18436283.
81. Welch BJ, Graybeal D, Moe OW, et al. Biochemical and stone-risk profiles with topiramate treatment. *Am J Kidney Dis* 2006 Oct; 48(4):555-63; PMID: 16997051.
82. Wilper A, Woolhandler S, Himmelstein D, et al. Impact of insurance status on migraine care in the United States: a population-based study. *Neurology* 2010 Apr 13; 74(15):1178-83; PMID: 20385889.
83. Winther K, Hedman C, Flodgaard H. Platelet P1, P4-Di (adenosine-51) tetraphosphate (AP4A) in migraine patients before and during beta-adrenoceptor blockade. *Eur J Clin Invest* 1990 Jun; 20(3):336-8; PMID: 2164477.
84. Yaldo AZ, Wertz DA, Rupnow MFT, et al. Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting. *Clinical Therapeutics* 2008 Dec; 30(12):2452-60; PMID: 19167603.

85. Yogendran L, Boswell D, Nacci P, et al. Effect of subcutaneous naratriptan on forearm blood flow. *Cephalalgia : an international journal of headache*; 1998; 476-80.
86. Young W, Shaw J, Bloom M, et al. Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects. *Headache* 2008 Nov-Dec; 48(10):1490-8; PMID: 19076647.
87. Ziegler DK, Hurwitz A, Preskorn S, et al. Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. *Arch Neurol* 1993 Aug; 50(8):825-30; PMID: 8352668.

Other

1. Almotriptan joins migraine market. *American Journal of Health-System Pharmacy* 2001 Aug 1; 58(15):1386; PMID: 11494779.
2. Summaries for patients. Guidelines for the treatment and prevention of migraine headaches.[Original report in *Ann Intern Med*. 2002 Nov 19;137(10):840-9; PMID: 12435222]. *Annals of Internal Medicine* 2002 Nov 19; 137(10):I50; PMID: 12435232.
3. New medications show promise for migraine sufferers. *Dentistry Today* 2002 Oct; 21(10):70; PMID: 12382492.
4. Nurse addicted to stadol sues manufacturer. Case on point: *Uhiren v. Bristol-Myers Squibb Company, Inc.*, 346 F.3d 824--AR (2003). *Nursing Law's Regan Report* 2003 Dec; 44(7):2; PMID: 14730828.
5. New drug curbs migraine pain. *Health News* 2004 May; 10(5):7; PMID: 15132108.
6. Migraine drugs not linked with heart attack, stroke risk. *Mayo Clinic Women's Healthsource* 2005 Jan; 9(1):3; PMID: 15592163.
7. Over-the-counter triptans--making the switch. *Lancet Neurology* 2005 Oct; 4(10):587; PMID: 16168921.
8. Ibuprofen: new indication. Migraine attacks: don't begin with 400 mg! *Prescrire International* 2007 Dec; 16(92):244; PMID: 18092409.
9. ... Why do placebos work in some kids with migraine. *Child Health Alert* 2008 Apr; 26:5; PMID: 18828187.
10. Addex starts a phase IIB trial of ADX10059 for migraine prevention 2008.
11. Acin MP, Bono MC, Rodrigo MD, et al. [Preventive analgesia with pregabalin in mesh hernia repair. Review at 1 year]. *Revista de la Sociedad Espanola del Dolor*; 2009: 215-21.
12. Adelman JU, Calhoun A. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. *Neurology* 2005 Mar 8; 64(5):931; author reply PMID: 15753451.
13. Aguirre Tellaeche R, Plata Toledo L, Lopez-Aguado Mario Z, et al. Reports on seven cases of migraine headache treated with biofeedback. [Spanish]. *Salud Mental*; 1987: 77-82.
14. Ahmed DS, Fecik S. MAOIs: still here, still dangerous. *American Journal of Nursing* 2000 Feb; 100(2):29-30; PMID: 10683640.
15. Alemdar M, Selekler HM. Migraine with aura triggered by citalopram. *Neuropsychobiology* 2007; 55(2):121-2; PMID: 17596740.
16. Al-Hassan N. Menstrual migraine. *Journal of Family Planning & Reproductive Health Care* 2007 Oct; 33(4):289; author reply PMID: 17925127.
17. Alkhatib AA, Gangotena F, Peterson KA. Rizatriptan induced acute on top of chronic ischemic colitis. *American Journal of Gastroenterology* 2009 Oct; 104(10):2643-4; PMID: 19806107.
18. Allen C, Cady R, Lines C, et al. Effect of rizatriptan in the spectrum of headache. *Headache* 2001 Jun; 41(6):607-8; PMID: 11437904.
19. Allen C, Dayno J. Tolerability of sumatriptan: clinical trials and postmarketing experience. *Cephalalgia* 2001 Oct; 21(8):855-6; PMID: 11737014.
20. Ambrosini A, Pierelli F, Schoenen J. Acetazolamide acts on neuromuscular transmission abnormalities found in some migraineurs. *Cephalalgia* 2003 Mar; 23(2):75-8; PMID: 12603362.
21. Amelin AV, Skoromets AA, Gonchar MA, et al. [Comparative efficacy of betaserc and cinnarizine of vertigo in patients with migraine]. *Zhurnal nevrologii i psikiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinsko i promyshlennosti Rossijskoj Federatsii, Vserossijskoe obshchestvo nevrologov [i] Vserossijskoe obshchestvo psikiatrov*; 2003: 43-8.
22. Anon. [A further step in migraine prevention] Ein weiterer schritt in der migraneprophylaxe. [German]. *Fortschr Med*; 1985: 11-3.
23. Anon. [Observation Sur L'Efficacite du Traitement Par Acupuncture de 35 Cas de Migraines]. *Shanghai journal of acupuncture and moxibustion*; 2000: 19.
24. Anselmi B, Del Bianco PL, Knor K, et al. [The antihistaminic Sandomigran as the treatment of choice in anxious, thin, and anorexic patients with migraine]. *Schweizerische medizinische Wochenschrift*; 1972: 487-91.

25. Antonello R, Cazzato G, Capizzi A, et al. Randomized, double-blind trial on the therapeutic effect of the complex beta-cyclodextrin-piroxicam in migraine attacks. [Italian]. *Giornale di Neuropsicofarmacologia*; 1992: 21-4.
26. Aronson SM. One man's poison. *Medicine & Health, Rhode Island* 2008 Dec; 91(12):359; PMID: 19170308.
27. Artemenko AR, Kurenkov AL, Nikitin SS. [Treatment of chronic migraine]. *Zhurnal Nevrologii i Psikiatrii Imeni S S Korsakova* 2011; 111(5):85-9; PMID: 21905333.
28. Ault J. Teaching case: migraine and pupil dilation. *Headache* 2011 Feb; 51(2):324-6; PMID: 21284618.
29. Ayata C, Jin H, Kudo C, et al. Suppression of cortical spreading depression in migraine prophylaxis. *Ann Neurol* 2006 Apr; 59(4):652-61; PMID: 16450381.
30. Aylward M, Chazot G, Maddock J, et al. [Treatment of morning migraine. Clinical and biokinetic correlation of programmed-release dihydroergotamine]. *Presse médicale (Paris, France : 1983); 1984: 1617-9.*
31. Bajard A, Chabaud S, Perol D, et al. Revisiting the level of evidence in randomized controlled clinical trials: A simulation approach. *Contemporary Clinical Trials* 2009 Sep; 30(5):400-10; PMID: 19576298.
32. Bana DS, MacNeal PS, LeCompte PM, et al. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. *Am Heart J* 1974 Nov; 88(5):640-55; PMID: 4420941.
33. Barnett R. Migraine in women. *Practitioner* 2002 Jun; 246(1635):455; author reply PMID: 12073705.
34. Bartleson JD. Triptans to the rescue: effective therapy for migraine headaches in the workplace. *Mayo Clinic Proceedings* 2000 Aug; 75(8):780-1; PMID: 10943229.
35. Bartley J, Watkins LR. Comment on: excessive opioid use and the development of chronic migraine. *Pain* 2009 Sep; 145(1-2):262-3; PMID: 19553017.
36. Basquin S, Dubois M, Loukakis G, et al. [The treatment of headaches: an open randomized comparative therapeutic study (author's transl)]. *La semaine des hôpitaux : organe fondé par l'Association d'enseignement médical des hôpitaux de Paris*; 1979: 806-9.
37. Bateman DN. Triptans and migraine. *Lancet* 2000 Mar 11; 355(9207):860-1; PMID: 10752697.
38. Baust W, Stürtzbecher KH. [Management of migraine using acupuncture in a double-blind study]. *Die Medizinische Welt*; 1978: 669-73.
39. Baxter RC, Marsden CD, Parkes JD, et al. Amantadine in migraine. *Lancet*; 1972: 429.
40. Baykan B, x00Fc, Erta, et al. Hypnic headache associated with medication overuse: case report. *Agri Dergisi* 2008 Jul; 20(3):40-3; PMID: 19085181.
41. Bento MS, Esperan, x00E, et al. Migraine with prolonged aura. *Headache* 2000 Jan; 40(1):52-3; PMID: 10759905.
42. Bernik V, Maia E. The use of propranolol on prophylaxis of migraine: A double-blind clinical trial comparing propranolol with an analgesic drug (acetaminophen) and placebo. <ORIGINAL> USO DO PROPRANOLOL NA PROFILAXIA DA ENXAQUECA: ESTUDO DUPLO-CEGO COMPARANDO PROPRANOLOL A UM ANALGESICO (ACETAMINOFEN) E PLACEBO. *Folha Med Vol 77; 1978: 501-8.*
43. Bernik V, Maia E. [The use of propranolol on prophylaxis of migraine: A double-blind clinical trial comparing propranolol with an analgesic drug (acetaminophen) and placebo.]. *Folha Med Vol 77; 1978: 501-8.*
44. Bes A, Geraud G, Guell A, et al. [Dopaminergic hypersensitivity in migraine: a diagnostic test?]. *Nouvelle Presse Médicale*; 1982: 1475-8.
45. Bès A, Géraud G, Güell A, et al. [Dopaminergic hypersensitivity in migraine: a diagnostic test? (author's transl)]. *La Nouvelle presse médicale*; 1982: 1475-8.
46. Bhagey J, James B. Topical timolol prevented migraine attacks. *Eye* 2004 Jul; 18(7):751; PMID: 14765100.

47. Bhindi R, Ormerod OJ. Letter by Bhindi and Ormerod regarding article, "Lack of association between migraine headache and patent foramen ovale: results of a case-control study". *Circulation* 2010 Dec 14; 122(24):e581; author reply e3; PMID: 21156652.
48. Bigal ME. To use or not to use dipyrone? *Sao Paulo Medical Journal = Revista Paulista de Medicina* 2002 Mar 7; 120(2):63; PMID: 11994777.
49. Bigal ME, Lipton RB, Biondi DM, et al. Weight change and clinical markers of cardiovascular disease risk during preventive treatment of migraine. *Cephalalgia* 2009 Nov; 29(11):1188-96; PMID: 19558539.
50. Bisdorff AR. Treatment of migraine related vertigo with lamotrigine an observational study. *Bulletin de la Societe des Sciences Medicales du Grand-Duché de Luxembourg* 2004; (2):103-8; PMID: 15641316.
51. Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. *Headache* 2003 Sep; 43(8):853-60; PMID: 12940806.
52. Blumenfeld A. Does single-file botox injection really work for primary headache? *Headache* 2004 Sep; 44(8):838-9; PMID: 15330839.
53. Blumenkron D, Rivera C, Cuevas C. [Efficacy of botulinum toxin type A in patients with migraine]. *Medicina Interna de Mexico*; 2006: 25-31.
54. Blumenthal HJ, Diamond ML. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial--a comment. *Headache* 2006 Feb; 46(2):340; author reply 1; PMID: 16492249.
55. Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. *Nature Medicine* 2002 Feb; 8(2):136-42; PMID: 11821897.
56. Borgesen SE. Treatment of migraine with propranolol. *Postgrad Med J* 1976; 52 Suppl 4:163-5; PMID: 787958.
57. Bradley DP, Smith MI, Netsiri C, et al. Diffusion-weighted MRI used to detect in vivo modulation of cortical spreading depression: comparison of sumatriptan and tonabersat. *Exp Neurol* 2001 Dec; 172(2):342-53; PMID: 11716558.
58. Brain SD. Calcitonin gene-related peptide (CGRP) antagonists: blockers of neuronal transmission in migraine. *British Journal of Pharmacology* 2004 Aug; 142(7):1053-4; PMID: 15237096.
59. Brannon GE, Rolland PD, Gary JM. Use of mirtazapine as prophylactic treatment for migraine headache. *Psychosomatics* 2000 Mar-Apr; 41(2):153-4; PMID: 10749956.
60. Brauneis S, Marzano M, Collini S, et al. [The administration of sumatriptan in the treatment of migraine and cluster headache.]. *Confin Cephalalgica*; 1994: 159-64.
61. Brennan KC. Turn down the lights!: an irritable occipital cortex in migraine without aura. *Neurology* 2011 Jan 18; 76(3):206-7; PMID: 21148117.
62. Brenner SR. Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. *Neurology* 2010 Jan 12; 74(2):182-3; author reply 3; PMID: 20065258.
63. Brigo B. [Homeopathic treatment of migraine: a sixty case double-blind controlled study.]. *Journal of Liga Medicorum Homoeopathica Internationalis*; 1987: 18-25.
64. Brügger A. [Differential diagnosis of headache and experiences with a new preparation in the treatment of migraine]. *Schweizerische Rundschau für Medizin Praxis = Revue suisse de médecine Praxis*; 1970: 1360-5.
65. Burstein R, Dodick D, Silberstein S. Migraine prophylaxis with botulinum toxin A is associated with perception of headache. *Toxicon* 2009 Oct; 54(5):624-7; PMID: 19344670.
66. Burstein R, Jakubowski M. Almotriptan efficacy in migraine with allodynia: a critique of Schoenen et al. *Cephalalgia* 2009 Oct; 29(10):1019-20; PMID: 19366354.
67. Bussone G, Boiardi A, Merati B, et al. [Tiapride in the treatment of chronic headache (author's transl)]. *Rivista di patologia nervosa e mentale*; 1981: 247-53.
68. Canario JR, Jr., Shenenberger DW. Sumatriptan use in patients with migraine. *Mayo Clinic Proceedings* 2002 Feb; 77(2):201; PMID: 11838657.

69. Canepari C, Riva M, Erminio F. Effectiveness of flunarizine in chronic headache. A double-blind comparison with placebo and amitriptyline. <ORIGINAL> EFFICACIA DELLA FLUNARIZINA NELLE CEFALEE CRONICHE. STUDIO IN DOPPIO CIECO VERSO PLACEBO E AMITRIPTILINA. Clin Ter; 1985: 463-8.
70. Cano A, Sanz P, Fossas P. Comparison between flunarizine, nifedipine and nimodipine in the preventive treatment of migraine. Neurología; 1997: 486.
71. Caputi CA. Effectiveness of BoNT-A in the treatment of migraine and its ability to repress CGRP release. Headache 2004 Sep; 44(8):837-8; PMID: 15330838.
72. Carpay HA, Dowson AJ. Sumatriptan fast-disintegrating/rapid-release tablets: viewpoints. Drugs 2006; 66(6):891-2; PMID: 16706566.
73. Carvalho DDS, Rabello GD, Figueiro JAB. [Dipyron plus caffeine versus dipyron alone to acute treatment of mild to moderate primary headache attacks: A double blind, randomized, compared clinical study]. Revista Brasileira de Medicina; 2007: 273-8.
74. Cattin T. Botulinum toxin as a preventive treatment for migraine and chronic tension headache. New Zealand Medical Journal 2003 May 16; 116(1174):U440; PMID: 12766786.
75. Celiker A, Bir LS, Ardic N. Effects of valproate on vestibular symptoms and electronystagmographic findings in migraine patients. Clin Neuropharmacol 2007 Jul-Aug; 30(4):213-7; PMID: 17762318.
76. Centonze V, Macinagrossa G, Attolini E, et al. Migraine prophylaxis: Flunarizine vs. verapamil. <ORIGINAL> TERAPIA PREVENTIVA DELL'EMICRANIA: FLUNARIZINA VERSUS VERAPAMIL. Clin. Ter.; 1985: 333-9.
77. Centonze V, Polito MB, Di Bari M, et al. [Evaluation of the efficacy of oral sumatriptan in the management of migraine attacks. Clinical results]. La Clinica terapeutica; 1995: 721-8.
78. Cerbo R, Casacchia M, Formisano R, et al. [Double-blind clinical study: flunarizine versus pizotifen in a single nightly dose in hemispheric patients]. Rivista di neurologia; 1985: 139-46.
79. Chang JJ, Liu X, Fai CP, et al. Lysine-aspirin plus metoclopramide in treatment of migraine. Chinese Journal of New Drugs and Clinical Remedies; 2000: 387-8.
80. Charles A, Brennan KC. A touch of increased pain: cutaneous allodynia in migraine. Annals of Neurology 2008 Feb; 63(2):130-2; PMID: 18306413.
81. Charles JA, Peterlin BL, Rapoport AM, et al. Chronic daily headache in adolescents: an 8-year follow-up study. Neurology 2010 Mar 2; 74(9):780; author reply -1; PMID: 20194921.
82. Charles JA, Pullicino PM, Stoopack PM, et al. Ischemic colitis associated with naratriptan and oral contraceptive use. Headache 2005 Apr; 45(4):386-9; PMID: 15836580.
83. Chazot G, Chauplannaz G, Biron A, et al. [Migraine: treatment by lithium (letter)]. Nouv-Presse-Med; 1979: 2836-7.
84. Chen FJ, Ye CS, Zhang H, et al. [74 cases of vascular migraine treated by low frequency square-wave pulse current therapy]. Chinese Journal of Physical Therapy; 1993: 92-3.
85. Chen WT, Fuh JL, Lu SR, et al. Persistent migrainous visual phenomena might be responsive to lamotrigine. Headache 2001 Sep; 41(8):823-5; PMID: 11576209.
86. Chen Z. [Migraine treated by acupuncture with the points on both the upper and lower body parts]. Shaanxi journal of tcm; 2004: 155.
87. Christiani K. [The interval treatment of migraine with nocertone]. Die Medizinische Welt; 1978: 1293-5.
88. Christie SN, Giammarco R, Gawel M, et al. Botulinum toxin type A and acute drug costs in migraine with triptan overuse. Can J Neurol Sci 2010 Sep; 37(5):588-94; PMID: 21059503.
89. Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004; (3):CD003226; PMID: 15266476.
90. Cochran JW. Levetiracetam as migraine prophylaxis. Clinical Journal of Pain 2004 May-Jun; 20(3):198-9; PMID: 15100599.
91. Cohen D, Huinink S. Atypical antipsychotic-induced diabetes mellitus in child and adolescent psychiatry. CNS Drugs 2007; 21(12):1035-8; PMID: 18020482.

92. Cohen GL. Dubious about Depakote. *Headache* 2001 May; 41(5):515-7; PMID: 11380652.
93. Corbat F. [Clonidin in the treatment of migraine (author's transl)]. *Schweizerische Rundschau für Medizin Praxis = Revue suisse de médecine Praxis*; 1976: 82-3.
94. Cortelli P, Sacquegna T, Albani F, et al. Propranolol plasma levels and relief of migraine. Relationship between plasma propranolol and 4-hydroxypropranolol concentrations and clinical effects. *Arch Neurol* 1985 Jan; 42(1):46-8; PMID: 3966884.
95. Couch JR, Bearss CM, Verhulst S. Fenoprofen in migraine prophylaxis. *Headache*; 1987: 289.
96. Couch JR, Ziegler DK, Hassanein R. Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects. *Neurology* 1976 Feb; 26(2):121-7; PMID: 943066.
97. Cruz A, Bühling M, Seibel K. [Double blind study of migraine therapy with etilefrine pivalate]. *Arzneimittel-Forschung*; 1985: 1086-9.
98. Cucherat M, Dib M. Letter to the editor concerning: Pascual J, Mateos V, Roig C, Sanchez-Del-Rio M, Jimenez D. Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability. *Headache*. 2007;47(8):1152-1168. *Headache* 2008 Oct; 48(9):1379-80; PMID: 19031501.
99. Curtis-Brown R. A PROTEIN POISON THEORY: Its Application to the Treatment of Headache and Especially Migraine. *Br Med J* 1925 Jan 24; 1(3343):155-6; PMID: 20771881.
100. Curtiss FR. Clinical, service, and cost outcomes of drug coverage edits and quantity limits. *Journal of Managed Care Pharmacy* 2003 Jul-Aug; 9(4):368-9; PMID: 14613458.
101. Curtiss FR. Best value for money in triptans. *Journal of Managed Care Pharmacy* 2005 Jun; 11(5):419-21; PMID: 15934803.
102. Dahl, x00F, f C. Assessing patient preference in migraine treatment. *Cephalalgia* 2001 Oct; 21(8):791-5; PMID: 11737002.
103. Dalsgaard-Nielsen T, Trautmann J. [Prophylactic treatment of migraine with vitamin B 12]. *Ugeskrift for læger*; 1970: 339-41.
104. Damen L, Bruijn JK, Verhagen AP, et al. Symptomatic treatment of migraine in children: a systematic review of medication trials. *Pediatrics* 2005 Aug; 116(2):e295-302; PMID: 16061583.
105. D'Amico D. Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials. *Neurological Sciences* 2010 Jun; 31 Suppl 1:S23-8; PMID: 20464578.
106. D'Amico D, Solari A, Usai S, et al. Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study. *Cephalalgia : an international journal of headache*; 2006: 691-6.
107. Danesch U, Rittinghausen R. Safety of a patented special butterbur root extract for migraine prevention. *Headache*; 2003: 76-8.
108. Danilov AB, Glembotskaia GT, Kozub OV. [Pharmacoeconomic aspects of migraine]. *Zhurnal Nevrologii i Psikiatrii Imeni S S Korsakova* 2011; 111(4):79-81; PMID: 21898951.
109. Davis JS. High-dose riboflavin for the prevention of migraine: can we afford to ignore it? *Internal Medicine Journal* 2004 Jun; 34(6):372-3; author reply 3; PMID: 15228409.
110. De Simone R, Marano E, Di Stasio E, et al. Acetazolamide efficacy and tolerability in migraine with aura: a pilot study. *Headache* 2005 Apr; 45(4):385-6; PMID: 15836579.
111. DeDea L. Metoclopramide for migraines; how to stock a first aid kit. *JAAPA* 2010 Nov; 23(11):16; PMID: 21086883.
112. Degnan AP, Chaturvedula PV, Conway CM, et al. Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure. *Journal of Medicinal Chemistry* 2008 Aug 28; 51(16):4858-61; PMID: 18665579.
113. Deleu D, Hanssens Y. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. *Neurology* 2003 Apr 8; 60(7):1221-2; author reply -2; PMID: 12682349.

114. Delva NJ, Horgan SA, Hawken ER. Valproate prophylaxis for migraine induced by selective serotonin reuptake inhibitors. *Headache* 2000 Mar; 40(3):248-51; PMID: 10759929.
115. Derosier FJ, Kori SH. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial--a comment. *Headache* 2007 Apr; 47(4):623; author reply -5; PMID: 17445117.
116. Devor WN, Napoli R, Sacc, et al. Vascular smooth muscle cell dysfunction in patients with migraine. *Neurology* 2010 Jan 5; 74(1):94; author reply PMID: 20038783.
117. Di Legge S, Bruti G, Di Piero V, et al. Topiramate versus migraine: which is the cause of glaucomatous visual field defects? *Headache* 2002 Sep; 42(8):837-8; PMID: 12390655.
118. Di Lorenzo C, Pierelli F, Coppola G, et al. Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. *Neurology* 2009 May 5; 72(18):1588-94; PMID: 19414726.
119. Di Sabato F. [Comparison of treatment with STRESSEN and arginine glutamate on homocysteine blood levels]. *La Clinica terapeutica*; 2004: 17-20.
120. Diamond S, Kudrow L, Stevens J, et al. Long-term study of propranolol in the treatment of migraine. *Headache*; 1982: 268-71.
121. Diamond S, Solomon GD, Freitag FG, et al. Long-acting propranolol in the prophylaxis of migraine. *Headache* 1987 Feb; 27(2):70-2; PMID: 3553068.
122. Diener H-C. Placebo effects in treating migraine and other headaches. *Current Opinion in Investigational Drugs* 2010 Jul; 11(7):735-9; PMID: 20597189.
123. Diener HC, Pfaffenrath V, Pageler L, et al. [Triple combination (Thomapyrin) is more efficient for the treatment of headache than mono substances and dual combination]. *Nervenheilkunde*; 2005: 626-39.
124. Dimitriadou V, Buzzi MG, Theoharides TC, et al. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. *Neuroscience* 1992; 48(1):187-203; PMID: 1374861.
125. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. *Headache* 2010 Jun; 50(6):921-36; PMID: 20487038.
126. Doerr-Proske H, Wittchen HU. [A muscle and vascular oriented relaxation program for the treatment of chronic migraine patients. A randomized clinical comparative study]. *Zeitschrift für Psychosomatische Medizin und Psychoanalyse*; 1985: 247-66.
127. Dowson AJ, Cady RK, Tepper SJ, et al. Pharmacologic management of migraine. *Annals of Internal Medicine* 2004 Mar 16; 140(6):W26; PMID: 15023737.
128. Drillisch C, Girke W. [Results of treatment of migraine patients with cinnarizine and flunarizine]. *Die Medizinische Welt*; 1980: 1870-2.
129. Dufresne JJ. [Double-blind study of oxetorone in patients with migraine or migrainous headache (author's transl)]. *Schweizerische Rundschau für Medizin Praxis = Revue suisse de médecine Praxis*; 1978: 1148-52.
130. Dufresne JJ, Muggler J. [Trials with the new preparation cephatac in the attack treatment of migraine (author's transl)]. *Schweizerische Rundschau für Medizin Praxis = Revue suisse de médecine Praxis*; 1975: 1514-8.
131. Dukat M. Donitriptan (Pierre Fabre). *Current Opinion in Investigational Drugs* 2001 Mar; 2(3):415-8; PMID: 11575714.
132. Durham PL. CGRP-receptor antagonists--a fresh approach to migraine therapy? *New England Journal of Medicine* 2004 Mar 11; 350(11):1073-5; PMID: 15014178.
133. Ebihara A, Ohashi K, Fujimura A, et al. [Phase I Study of Sumatriptan Tablet (The 1st Report): Single- and Multiple-Oral Dose Study in Japanese Subjects]. *Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)*; 1993: 757-65.
134. Ebihara A, Ohashi K, Fujimura A, et al. [Phase I Study of Sumatriptan Injection (The 2nd Report): Single- and Multiple-Subcutaneous Dose Study in Japanese Healthy Subjects]. *Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)*; 1993: 767-76.

135. Edvinsson L. CGRP-receptor antagonism in migraine treatment. *Lancet* 2008 Dec 20; 372(9656):2089-90; PMID: 19036426.
136. Edvinsson L. CGRP blockers in migraine therapy: where do they act? *British Journal of Pharmacology* 2008 Dec; 155(7):967-9; PMID: 18776915.
137. Egger J, Carter C, Wilson J, et al. Food allergies and migraine in children. *Monatsschrift fur Kinderheilkunde*; 1983: 686.
138. Egger J, McEwen L. Controlled study on the effectivity of hyposensitisation in children with food-induced migraine. *Monatsschrift fur Kinderheilkunde*; 1997: S21.
139. Egger J, Stolla A, McEwen L. Controlled study on the effectivity of hyposensibilisation due to enzyme potency in children with food-induced migraine. *Monatsschrift fur Kinderheilkunde*; 1992: 707.
140. Eom KS, Kim TY. Greater occipital nerve block by using transcranial Doppler ultrasonography. *Pain Physician* 2010 Jul; 13(4):395-6; PMID: 20648209.
141. Erbguth F, Brittner W, Fogel W, et al. Botulinum toxin in migraine. *Journal of Neurology* 2004 Feb; 251 Suppl 1:I31-2; PMID: 14991340.
142. Erdemoglu AK, Ozbakir S. Valproic acid in prophylaxis of refractory migraine. *Acta Neurol Scand* 2000 Dec; 102(6):354-8; PMID: 11125749.
143. Eross EJ. Patient page. Chronic migraine and medication-overuse headache. *Neurology* 2006 Jun 27; 66(12):E43-4; PMID: 16801636.
144. Eross EJ, Gladstone JP, Lewis S, et al. Duration of migraine is a predictor for response to botulinum toxin type A. *Headache* 2005 Apr; 45(4):308-14; PMID: 15836566.
145. Evans RW. Rizatriptan. Convenience and consistency. *Postgraduate Medicine* 2000 Sep; 108(3 Suppl):10-5; PMID: 19667525.
146. Evans RW. The non-nocebo response: can migraine medication efficacy be enhanced? *Headache* 2003 Jun; 43(6):693; PMID: 12786934.
147. Evans RW. Triptans and serotonin syndrome. *Cephalalgia* 2008 May; 28(5):573-4; author reply 4-5; PMID: 18355351.
148. Evans RW, Atriham AR. QT prolongation with migraine medications. *Headache* 2003 Jul-Aug; 43(7):809-10; PMID: 12890141.
149. Evans RW, Blumenfeld A. Botulinum toxin injections for headache. *Headache* 2003 Jun; 43(6):682-5; PMID: 12786931.
150. Evans RW, Dahl, x00F, et al. Determining triptan preference for the individual patient. *Headache* 2004 Jul-Aug; 44(7):723-5; PMID: 15209698.
151. Evans RW, Johnston JC. Migraine and medical malpractice. *Headache* 2011 Mar; 51(3):434-40; PMID: 21352217.
152. Evans RW, Linde M. Expert opinion: adherence to prophylactic migraine medication. *Headache* 2009 Jul; 49(7):1054-8; PMID: 19583596.
153. Evans RW, Loder E, Biondi DM. When can successful migraine prophylaxis be discontinued? *Headache* 2004 Nov-Dec; 44(10):1040-2; PMID: 15546270.
154. Evans RW, Rosen N. Expert opinion: migraine, psychiatric comorbidities, and treatment. *Headache* 2008 Jun; 48(6):952-8; PMID: 18572433.
155. Farinelli I, Coloprisko G, De Filippis S, et al. Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. *J Headache Pain* 2006 Dec; 7(6):407-12; PMID: 17149565.
156. Feng SHU, He XIN, Li SUH. [Clinical observation of migraine by the temporal three acupoints]. *Journal of clinical acupuncture and moxibustion*; 2003: 23.
157. Fern, x00E, ndez de las P, et al. Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A. *Pain* 2007 Jun; 129(3):363-4; author reply 4-5; PMID: 17360120.
158. Fernandez D, Wilkins AJ. Uncomfortable images in art and nature. *Perception* 2008; 37(7):1098-113; PMID: 18773732.
159. Fernandez-Rodriguez CM, Lledo JL, Lopez-Serrano P, et al. [Effect of pentoxifylline on survival, cardiac function, and portal and systemic hemodynamics in advanced alcoholic cirrhosis]. *Revista Espanola de Enfermedades Digestivas*; 2008: 481-9.
160. Ferrante E. Ophthalmoplegic migraine. *Cephalalgia* 2006 Mar; 26(3):357; author reply -8; PMID: 16472350.

161. Ferrari MD. Re: Gomez-Mancilla et al. Safety and efficacy of PNU-142633, a selective 5-HT_{1D} agonist, in patients with acute migraine. *Cephalalgia* 2001;21:727-32. *Cephalalgia* 2001 Sep; 21(7):711; PMID: 11603382.
162. Ferrari MD. Should we advise patients to treat migraine attacks early? *Cephalalgia* 2004 Nov; 24(11):915-7; PMID: 15482351.
163. Ferrari MD, Farkkila M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT_{1F} receptor agonist lasmiditan--a randomised proof-of-concept trial. *Cephalalgia* 2010 Oct; 30(10):1170-8; PMID: 20855362.
164. Fitch MT, Jones AE. Adjunctive therapy for migraine headaches: can we teach an old dog a new trick? *Academic Emergency Medicine* 2008 Dec; 15(12):1310-1; PMID: 18945233.
165. Florence J. [Clinical study of oxetorone in catamenial migraine. Comparison of two posological diagrams (author's transl)]. *Schweizerische Rundschau für Medizin Praxis* = *Revue suisse de médecine Praxis*; 1978: 1323-7.
166. Fox AW. 5HT_{1B/1D} agonists. *Journal of Clinical Pharmacology* 2002 Nov; 42(11):1281-2; author reply 2-3; PMID: 12412829.
167. Fox AW. Metoclopramide and sumatriptan. *Headache* 2004 May; 44(5):446-7; PMID: 15147257.
168. Fox AW. Revised estimates for probability of successful outcome of pregnancy after sumatriptan exposure. *Headache* 2004 Mar; 44(3):293-4; PMID: 15012675.
169. Fox AW. Clinical trial ethics. *Headache* 2005 Sep; 45(8):1090-1; author reply 1; PMID: 16109130.
170. Fox AW. 5-HT_{1B/1D} agonists, oral contraceptives, and ischemic colitis. *Headache* 2006 Jun; 46(6):1021-2; author reply 2-3; PMID: 16732852.
171. Fox AW, Spierings EL. Sumatriptan and pregnancy outcome. *Headache* 2000 Nov-Dec; 40(10):860-1; PMID: 11135036.
172. Fragoso YD. Low dose of sodium divalproate for the treatment of migraine. *Medgenmed [Computer File]: Medscape General Medicine* 2003 Mar 12; 5(1):32; PMID: 12827093.
173. Freitag FG. Importance of botulinum toxin for prevention of migraine. *Expert Review of Neurotherapeutics* 2010 Mar; 10(3):339-40; PMID: 20187855.
174. Freitag FG, Diamond S, Diamond ML, et al. Divalproex in the long-term treatment of chronic daily headache. *Headache* 2001 Mar; 41(3):271-8; PMID: 11264687.
175. Frenken CW, Nuijten ST. [Flunarizine--a new agent for migraine prevention. Results of a double-blind comparison with placebo]. *Fortschritte der Medizin*; 1984: 349-51.
176. Frenken CW, Nuijten ST. [Flunarizine - a new agent for migraine prevention. Results of a double blind comparison with placebo] Flunarizin - ein neues Mittel zur Migraneprophylaxe. Ergebnisse eines Doppelblindvergleichs mit Plazebo. [German]. *Fortschr Med*; 1984: 349-51.
177. Friedrich MJ. Studies suggest new approaches to pain. *JAMA* 2007 Jul 4; 298(1):27-8; PMID: 17609482.
178. Fujita M, Fujiwara J, Maki T, et al. The efficacy of sodium valproate and a MRA finding in confusional migraine. *Brain & Development* 2007 Apr; 29(3):178-81; PMID: 16973324.
179. Fukuuchi Y, et al. [Clinical Evaluation of BAY e 9736 (Nimodipine) on Migraine: Pilot Study and Open Study]. *Yakuri to Chiryo (Japanese Pharmacology and Therapeutics)*; 1986: 1561-86.
180. Fumal A, Laureys S, Di Clemente L, et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. *Brain* 2006 Feb; 129(Pt 2):543-50; PMID: 16330505.
181. Fumal A, Schoenen J. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open study [abstract]. *Cephalalgia* 2006; 26:1369-70; PMID.
182. Gallagher RM, Mueller LL, Freitag FG. Divalproex sodium in the treatment of migraine and cluster headaches. *Journal of the American Osteopathic Association* 2002 Feb; 102(2):92-4; PMID: 11866398.

183. Galvez-Jimenez N, Hanson MR. Re: "Botulinum toxin type A as a migraine preventive treatment" (Silberstein S, Mathew N, Saper J, Jenkins S, for the BOTOX Migraine Clinical Research Group. *Headache*. 2000;40:445-450). *Headache* 2001 Jun; 41(6):607; PMID: 11437903.
184. Garaizar C, Prats JM, Zuazo E. [Results of prophylactic treatment for common childhood headaches]. *Revista de Neurología*; 1998.
185. Garaizar C, Prats JM, Zuazo E. [Response to prophylactic treatment of benign headache in children]. *Revista de neurologia*; 1998: 380-5.
186. Garcia Garcia C, Casanovas N, Recasens L, et al. Spontaneous coronary artery dissection in ergotamine abuse. *International Journal of Cardiology* 2007 Jun 12; 118(3):410-1; PMID: 17049384.
187. Garcia GD, Goff JM, Jr., Hadro NC, et al. Chronic ergot toxicity: A rare cause of lower extremity ischemia. *Journal of Vascular Surgery* 2000 Jun; 31(6):1245-7; PMID: 10842162.
188. Gasbarri A, Arnone B, Pompili A, et al. Emotional memory and migraine: effects of amitriptyline and sex related difference. *Behav Brain Res* 2008 May 16; 189(1):220-5; PMID: 18242724.
189. Gebauer R, Hoffmann J, Kuhl ED, et al. About migraine therapy. *Die Medizinische Welt*; 1985: 550-6.
190. Genefke IK, Bryndum B, Dalsgaard-Nielsen T, et al. [The action of reserpine on the concentration of 5-hydroxytryptamine, epinephrine and norepinephrine in the venous blood of migraine patients]. *Minerva medica*; 1976: 1876-82.
191. Gerber WD, Kropp P, Speckenbach U, et al. [BVP and MCA training in migraine: sensible procedures for acute treatment]. *Verhaltenstherapie*; 1995: A28.
192. Gerhards F, Florin I, Rojahn J. [Biofeedback in vasomotor control and cognitive overcoming of stress in the treatment of migraine. Comparison of 2 training programs]. *Fortschritte der Medizin*; 1985: 861-4.
193. Gherpelli J, x00E, Luiz D. New migraine prophylactic drug options. *Revista do Hospital das Clinicas; Faculdade de Medicina Da Universidade de Sao Paulo* 2002 Nov-Dec; 57(6):249-50; PMID: 12612755.
194. Ghose K, Niven B. Prophylactic sodium valproate therapy in patients with drug-resistant migraine. *Methods Find Exp Clin Pharmacol* 1998 May; 20(4):353-9; PMID: 9658386.
195. Gilbert GJ. Cerebral vasoconstriction and stroke after use of serotonergic drugs. *Neurology* 2002 Aug 27; 59(4):651-2; author reply 2; PMID: 12196679.
196. Goadsby PJ. Migraine: selecting treatments now and making requests for the future? *Current Medical Research & Opinion* 2001; 17 Suppl 1:s98-9; PMID: 12463287.
197. Goadsby PJ. Squeezing life into botulinum toxin A in migraine: imploding versus exploding pain. *Pain* 2006 Dec 5; 125(3):206-7; PMID: 17069974.
198. Goadsby PJ. Calcitonin gene-related peptide (CGRP) antagonists and migraine: is this a new era? *Neurology* 2008 Apr 15; 70(16):1300-1; PMID: 18413584.
199. Goadsby PJ, Edvinsson L. Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. *Headache* 1994 Jul-Aug; 34(7):394-9; PMID: 7928323.
200. Goadsby PJ, Ferrari MD, Lipton RB. Therapeutic gain or therapeutic ratio? *Headache* 2003 Jul-Aug; 43(7):814-5; author reply 5-6; PMID: 12890143.
201. Gobel H, Heinze A, Dworschak M, et al. [Oleum menthae piperitae in the acute therapy of migraine and tension-type headache]. *Zeitschrift fur Phytotherapie*; 2004: 129-39.
202. Gobel H, Pothmann R, Bauer R, et al. Migraine prevention with Petasites (Butterbur): Clinic and pharmacology of a special root extract. [German]. [References]. *Nervenheilkunde: Zeitschrift fur interdisziplinäre Fortbildung*; 2005: 211-6.
203. Goldman MD, Login IS. Misdiagnosis of migraine. *Headache* 2003 Jan; 43(1):85-6; author reply 6; PMID: 12864768.
204. Goldstein J, Tiseo PT, Albert KS, et al. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. *Headache* 2006 Jul-Aug; 46(7):1142-50; PMID: 16866718.

205. Gonzalez-Espinosa LE, Gomez-Viera N, Olivera-Leal I, et al. [Treatment of an acute attack of migraine headache with sumatriptan.]. *Revista De Neurologia*; 1997: 1672-5.
206. González-Espinosa LE, Gómez-Viera N, Olivera-Leal I, et al. [Treatment of acute attack of migraine with sumatriptan]. *Revista de neurologia*; 1997: 1672-5.
207. Gorman C, Park A. The new science of headaches. *Time* 2002 Oct 7; 160(15):76-82; PMID: 12389453.
208. Graham JR. Cardiac and pulmonary fibrosis during methysergide therapy for headache. *Am J Med Sci* 1967 Jul; 254(1):1-12; PMID: 6027684.
209. Granado L, Guillen G. Treatment options for ophthalmoplegic migraine. *Journal of Postgraduate Medicine* 2009 Jul-Sep; 55(3):231; author reply -2; PMID: 19884756.
210. Grigor'eva VN, Gustov AV, Kornilova LE, et al. [Efficacy of combined kinesi- and psychotherapy in the treatment of patients with migraine]. *Zhurnal nevrologii i psikiatrii imeni S.S. Korsakova / Ministerstvo zdavookhraneniia i meditsinsko-promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikiatrov*; 2003: 20-5.
211. Grottemeyer KH, Husstedt IW, Schlake HP. [Betablocker vs placebo in vasomotor headache. A double-blind crossover study]. *Deutsche medizinische Wochenschrift* (1946); 1987: 1740-3.
212. Grottemeyer KH, Scharafinski HW, Schlake HP, et al. Acetylsalicylic acid versus metoprolol in migraine prophylaxis. A double-blind crossover study. *Nervenheilkunde*; 1991: 44-7.
213. Grottemeyer KH, Schlake HP, Husstedt IW. [Prevention of migraine with metoprolol and flunarizine. A double-blind crossover study]. *Der Nervenarzt*; 1988: 549-52.
214. Grzesk G, Szadujkis-Szadurski L, Witkowski W, et al. [The effectiveness of ergotamine treatment in chronic headache disorders: a double-blind, randomized, crossover, placebo controlled trial]. *Przegląd Lekarski*; 2003: 471-4.
215. Guariso G, Bertoli S, Cernetti R, et al. [Migraine and food intolerance: a controlled study in pediatric patients]. *La Pediatria medica e chirurgica : Medical and surgical pediatrics*; 1993: 57-61.
216. Gunner KB, Smith HD, Ferguson LE. Practice guideline for diagnosis and management of migraine headaches in children and adolescents: Part two. *J Pediatr Health Care* 2008 Jan-Feb; 22(1):52-9; PMID: 18174091.
217. Guo S, Chen C, Xue G. [Variation of female migraine after menopause and its prophylaxis and treatment]. *Zhonghua nei ke za zhi [Chinese journal of internal medicine]*; 1997: 454-6.
218. Gupta S. How to prevent a migraine. *Time* 2002 Jul 1; 160(1):69; PMID: 12119734.
219. Gupta VK. Magnesium therapy for migraine: do we need more trials or more reflection? *Headache* 2004 May; 44(5):445-6; PMID: 15147256.
220. Gupta VK. De novo headache and analgesic consumption: pathophysiological insights from nosologic complexity? *Headache* 2004 Apr; 44(4):375; PMID: 15109365.
221. Gupta VK. Pharmacotherapeutics of migraine and the blood-brain barrier: serendipity, empiricism, hope, and hype. *Medgenmed [Computer File]: Medscape General Medicine* 2006; 8(2):89; PMID: 16926828.
222. Gupta VK. Orbitofrontal cortex hypometabolism, medication overuse headache, substance abuse and migraine: key pathophysiological issues. *Brain* 2006 Jul; 129(Pt 7):E52; author reply E3; PMID: 16803837.
223. Gupta VK. Letter regarding article by Law et al, "headaches and the treatment of blood pressure: results from a meta-analysis of 94 randomized placebo-controlled trials with 24,000 participants". *Circulation* 2006 Feb 21; 113(7):e164-5; PMID: 16493784.
224. Gupta VK. Antimigraine action of nicotine: theoretical basis and potential clinical application. *European Journal of Emergency Medicine* 2007 Aug; 14(4):243-4; PMID: 17620924.
225. Gupta VK. Pre-emptive/early intervention with triptans in migraine: hope, hype and hazard. *International Journal of Clinical Practice* 2007 Feb; 61(2):350-2; PMID: 17263726.

226. Gysin T. [Clinical hypnotherapy/self-hypnosis for unspecified, chronic and episodic headache without migraine and other defined headaches in children and adolescents]. *Forschende Komplementärmedizin*; 1999: 44-6.
227. Haag G. A review of evidence-based medicine and meta-analytic reviews in migraine. *Cephalalgia* 2007 Jul; 27(7):862-3; author reply 3; PMID: 17598773.
228. Haag G GWD. The interaction of behavioural treatment and drug reduction in migraine patients. *Clin Pharmacol Ther*; 1987: 202.
229. Haan J, Sluis P, Sluis LH, et al. Acetazolamide treatment for migraine aura status. *Neurology* 2000 Nov 28; 55(10):1588-9; PMID: 11094126.
230. Hakkarainen H, Viukari M. (Sulpiride in the treatment of migraine, tension headache, and associated psychosomatic symptoms). *Duodecim*; 1973: 1504-9.
231. Hanchanale VS, Biyani CS, Browning AJ, et al. Topiramate and the risk of urolithiasis. *BJU Int* 2011 Feb; 107(3):352-4; PMID: 21265983.
232. He WZ, Chen M, Zheng JZ. [Curative effect of fluoxetine for adjuvant treatment of migraine and its effect on serum lipid]. *Zhongguo Linchuang Kangfu*; 2004: 5254-5.
233. Henneicke-von Zepelin H-H. Feverfew for migraine prophylaxis. *Headache* 2006 Mar; 46(3):531; PMID: 16618282.
234. Henry P, Hiesse-Provost O, Dillenschneider A, et al. [Efficacy and tolerance of an effervescent aspirin-metoclopramide combination in the treatment of a migraine attack. Randomized double-blind study using a placebo]. *Presse médicale (Paris, France : 1983)*; 1995: 254-8.
235. Herman LY. The efficacy of a safe, effective non-narcotic treatment of migraine headache. *Journal of Emergency Medicine* 2003 Oct; 25(3):322-3; PMID: 14585464.
236. Hershey AD. Adolescents with migraine: nature vs nurture. *Neurology* 2007 Jul 3; 69(1):12-3; PMID: 17606876.
237. Hettiarachchi J, Sikes C. Eletriptan issues. *Headache* 2003 Jul-Aug; 43(7):816-8; author reply 8-9; PMID: 12945540.
238. Heuser B, Middendorf E. [Migraine prevention with dihydroergotamine]. *Fortschritte der Medizin*; 1985: 966-70.
239. Heydenreich A. [Punctate transcutaneous electrical nerve stimulation in functional vertebrogenic disorders and in migraine]. *Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete*; 1988: 651-3.
240. Heydenreich A. [Single-point transcutaneous electric nerve stimulation in a simple placebo comparison in migraine (a prospective randomized study)]. *Zeitschrift für ärztliche Fortbildung*; 1989: 881-3.
241. Heydenreich A, Thiessen M. [Comparison of the effectiveness of drug therapy, invasive and non-invasive acupuncture in migraine]. *Zeitschrift für ärztliche Fortbildung*; 1989: 877-9.
242. Hill KP, Hope O. Combination of sumatriptan and naproxen for migraine. *JAMA* 2007 Sep 19; 298(11):1276; author reply -7; PMID: 17878418.
243. Hirata K. Sumatriptan-induced chest symptoms in Japanese. *Internal Medicine* 2002 Aug; 41(8):599-600; PMID: 12211521.
244. Hochman MS. The interrelations of migraine, vertigo, and migrainous vertigo. *Neurology* 2001 Oct 23; 57(8):1522; PMID: 11673611.
245. Hoernecke R, Doenicke A. [Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo]. *Medizinische Klinik (Munich, Germany : 1983)*; 1993: 642-8.
246. Holdorff B, Sinn M, Roth G. [Propranolol for prophylaxis of migraine (author's transl)]. *Medizinische Klinik*; 1977: 1115-8.
247. Holroyd KA, Penzien DB. Pharmacological versus non-pharmacological prophylaxis of recurrent migraine headache: a meta-analytic review of clinical trials. *Pain* 1990 Jul; 42(1):1-13; PMID: 2146583.
248. Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. *Headache* 1991 May; 31(5):333-40; PMID: 1830566.
249. Holtmann M, Opp J, Tokarzowski M, et al. Human epilepsy, episodic ataxia type 2, and migraine. *Lancet* 2002 Jan 12; 359(9301):170-1; PMID: 11809294.

250. Hu GC. [The effect of sapogenins from leaves of *panox notoginseng* on migraine]. *Chinese Journal of Integrated Traditional and Western Medicine*; 1988: 726-7.
251. Huang JJ, Pang J, Lei LM, et al. [Observation on therapeutic effect of Jingjin therapy on migraine]. *Zhongguo zhen jiu = Chinese acupuncture & moxibustion*; 2006: 322-4.
252. Hussar DA. New drugs 04, part 1. *Nursing* 2004 Feb; 34(2):56-62; quiz 3-4; PMID: 14758333.
253. Hwang IK, Shih WJ, De Cani JS. Group sequential designs using a family of type I error probability spending functions. *Statistics in Medicine* 1990 Dec; 9(12):1439-45; PMID: 2281231.
254. Jackson M, Barbuto JP. Botox, migraine, and the American Academy of Neurology: an antidote to anecdote. *Journal of Managed Care Pharmacy* 2008 Jun; 14(5):465-7; PMID: 18597576.
255. Jakubowski M, McAllister PJ, Bajwa ZH, et al. Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A. *Pain* 2006 Dec 5; 125(3):286-95; PMID: 17069972.
256. Janssen van Doorn K, Van der Niepen P, van Tussenbroeck F, et al. Acute tubulo-interstitial nephritis and renal infarction secondary to ergotamine therapy. *Nephrology Dialysis Transplantation* 2000 Nov; 15(11):1877-9; PMID: 11071983.
257. Jia CS, Shi J, Ma XS, et al. [Study on the therapeutic effect of electroacupuncture on migraine and influencing factors]. *Zhongguo zhen jiu = Chinese acupuncture & moxibustion*; 2007: 557-61.
258. Jiménez MD, Frieria G, Morales A, et al. Gabapentine in the prophylaxis of migraine. A pilot study. *Neurología*; 1999: 478.
259. Jin DX, Chen XY, Huang H, et al. [The cerebral hemodynamics in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy]. *Zhonghua nei ke za zhi [Chinese journal of internal medicine]*; 2006: 996-9.
260. Jindeel A. Are we ignoring the elephant in the room? *Archives of Internal Medicine* 2007 Nov 12; 167(20):2263-4; PMID: 17998505.
261. Johnsen SV, Kropp P, Niederberger U, et al. [Acupuncture in migraine therapy - Methodological considerations and results of two randomised, controlled clinical and electrophysical studies.]. *Akupunktur*; 1998: 72-82.
262. Jorgensen RS. [BC 105, a new preparation for migraine]. *Ugeskrift for laeger*; 1972: 2266-8.
263. Jovici, A., Mari, et al. [Treatment of acute migraine attacks]. *Vojnosanitetski pregled. Military-medical and pharmaceutical review*; 1995: 44-8.
264. Jurgens TP. [Update migraine therapy]. *MMW Fortschritte der Medizin* 2011 Apr 7; 153(14):49-52; PMID: 21966870.
265. Kaniecki RG. Musing on Mathew et al. *Headache* 2003 Sep; 43(8):922; author reply 4-8; PMID: 14562838.
266. Kanner AM. Are antiepileptic drugs used in the treatment of migraine associated with an increased risk of suicidality? *Curr Pain Headache Rep* 2011 Jun; 15(3):164-9; PMID: 21479999.
267. Kapoor K, Willems EW, Maassen VanDenBrink A, et al. Assessment of anti-migraine potential of a novel alpha-adrenoceptor agonist S19014: effects on porcine carotid and regional haemodynamics and human coronary artery. *Cephalalgia* 2004 Jun; 24(6):425-38; PMID: 15154852.
268. Karceski SC. How migraines affect cognitive function.[Original report in *Neurology*. 2007 Apr 24;68(17):1417-24; PMID: 17452587]. *Neurology* 2007 Apr 24; 68(17):E23-4; PMID: 17452572.
269. Kawamura S, Sakai A, Endo T, et al. Atypical depression as a premonitory symptom of migraine managed by an oral contraceptive. *Psychiatry & Clinical Neurosciences* 2008 Jun; 62(3):365; PMID: 18588602.
270. Kawase Y, Ikeda K, Iwasaki Y. Amantadine for migraine. *Headache* 2008 Oct; 48(9):1380; PMID: 18547263.
271. Khromov A, Segal M, Nissinoff J, et al. Migraines linked to interferon-beta treatment of multiple sclerosis. *American Journal of Physical Medicine & Rehabilitation* 2005 Aug; 84(8):644-7; PMID: 16034235.

272. Kim CC, Bogart MM, Wee SA, et al. Predicting migraine responsiveness to botulinum toxin type A injections. *Archives of Dermatology* 2010 Feb; 146(2):159-63; PMID: 20157026.
273. Kirby M. The importance of getting treatment for headache right. *International Journal of Clinical Practice* 2006 Dec; 60(12):1519-21; PMID: 17109658.
274. Klapetek J. [Neosal, ergotamine tartrate caffeine and placebo in acute migraine attack]. *Die Medizinische Welt*; 1973: 745-7.
275. Klapetek J. [Antidepressive effect of sandomigran]. *Der Nervenarzt*; 1974: 213-4.
276. Klapetek J. [On the effect of the dynamics of Neosal, ergotamintartrate caffeine and placebo in an acute migraine attack.]. *Acta Univpalackiolomucfacmed*; 1975: 235-45.
277. Klapper JA. An open label cross-over comparison of divalproex sodium and propranolol HCl in the prevention of migraine headaches. *Headache Q*; 1994: 50-3.
278. Klimek A, Niewodniczy A, Pozniak-Patewicz E, et al. [Propranolol in the treatment of migraine and similar headaches]. *Pol Tyg Lek* 1978 Jul 10; 33(28):1109-11; PMID: 704408.
279. Kmie, T., Kami, et al. [Usefulness of cerebral SPECT in the children with migraine]. *Neurologia i neurochirurgia polska*; 2005: S36-41.
280. Koehler PJ, Isler H. The early use of ergotamine in migraine. Edward Woakes' report of 1868, its theoretical and practical background and its international reception. *Cephalalgia* 2002 Oct; 22(8):686-91; PMID: 12383066.
281. Koella WP. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. *Eur J Clin Pharmacol* 1985; 28 Suppl:55-63; PMID: 2865151.
282. Kornblau DH. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. *Neurology* 2007 Apr 24; 68(17):1441; PMID: 17452599.
283. Kozubski W, Prusi, ski A. [Controlled study of iprazochrome effectiveness (Divascan) in prophylactic treatment of migraine]. *Neurologia i neurochirurgia polska*; 1999: 369-76.
284. Kozubski W, Prusinski A. [Sodium valproate versus propranolol in the prophylactic treatment of migraine]. *Neurologia i Neurochirurgia Polska* 1995 Nov-Dec; 29(6):937-47; PMID: 8714731.
285. Krabbe AA, Olesen J. [Ferrum quartz in the prevention of migraine. A double-blind study]. *Ugeskrift for laeger*; 1980: 516-8.
286. Krusz JC, Albright JP. Lacosamide in the treatment of chronic headache and migraine disorders. *Headache* 2010; 50(Supplement 1):48; PMID.
287. Kumar S. Preventive therapy of migraine. *Neurology India* 2005 Jun; 53(2):243; author reply PMID: 16010078.
288. Kurth T, Hernandez-Diaz S. Commentary: Triptan use during pregnancy: a safe choice? *Headache* 2010 Apr; 50(4):576-8; PMID: 20456148.
289. La PS, Mandarinini A, Majello L, et al. Migraine prophylaxis: A new approach. Preliminary results of a double-blind study: Flunarizine/versus/placebo. <ORIGINAL> PROFILASSI DELLA EMICRANIA: UN NUOVO APPROCCIO. RISULTATI PRELIMINARI DI UNO STUDIO DOPPIO-CIECO: FLUNARIZINA v/s PLACEBO. *Osp Ital Pediatr Spec Chir*; 1985: 969-79.
290. Lambru G, Manzoni GC, Torelli P, et al. Reversible cerebral vasoconstriction phenomena following indomethacin administration. *Headache* 2011 May; 51(5):813-8; PMID: 21521211.
291. Lampl C, Katsarava Z, Diener HC, et al. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. *Journal of Neurology, Neurosurgery & Psychiatry* 2005 Dec; 76(12):1730-2; PMID: 16291905.
292. Lance JW. Paper bullets of the brain. A neurologist's story. *Medical Journal of Australia* 2003 Dec 1-15; 179(11-12):620-3; PMID: 14636134.
293. Land ST. 20 years ago: British Homoeopathic Journal, January 1984. Homeopathy: the Journal of the Faculty of Homeopathy 2004 Jan; 93(1):54-5; PMID: 14960105.
294. Landy S, Richardson M, O'Quinn S. Migraine, Midrin, and Imitrex. *Headache* 2002 Apr; 42(4):322-3; author reply 3-4; PMID: 12010397.

295. Langohr HD, Reinecke M, Gerber WD, et al. Migraine prophylaxis with dihydroergotamine and flunarizine. *Fortschritte der Medizin*; 1988: 65-70.
296. Langohr HD, Reinecke M, Gerber WD, et al. [Dihydroergotamine and flunarizine in the prevention of migraine. A comparative double-blind study]. *Fortschritte der Medizin*; 1988: 65-6, 9-70.
297. Lastilla M, Achille P, Savarese MA, et al. [Verapamil versus flunarizine in the preventive therapy of hemicrania]. *La Clinica terapeutica*; 1990: 401-4.
298. Lastimosa AC. Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. *Neurology* 2003 Sep 9; 61(5):721-2; author reply 2; PMID: 12963781.
299. Lastra L, Herranz J, Arteaga R. [Flunarizine or dihydroergotamine in the treatment of migraine in childhood. A randomised study of 50 patients.]. *Anales Española de Pediatría*; 1990: 213-18.
300. Lastra Martinez L, Herranz Fernandez J, Arteaga Manjon Cabez R. [Flunarizine and dihydroergotamine in the treatment of migraine in children (published erratum appears in *An Esp Pediatr* 1990 Jun;32(6):566)]. *An-Esp-Pediatr*; 1990: 213-8.
301. Lastra Martínez L, Herranz Fernández J, Arteaga Manjón-Cabez R. [Flunarizine and dihydroergotamine in the treatment of migraine in children]. *Anales españoles de pediatría*; 1990: 213-8.
302. Lehmann V, Banzhaf E, Kunze E, et al. Randomized clinically controlled study of the efficacy of acupuncture in comparison with electroacupuncture as well as drug therapy with propranolol in patients with recurrent migraine. *Deutsche Zeitschrift Für Akupunktur*; 1991: 27-30.
303. Lehmann V, Banzhaf E, Kunze E, et al. Randomized clinically controlled study of the efficacy of acupuncture in comparison with electroacupuncture as well as drug therapy with propranolol in patients with recurrent migraine. *Dtsch. Z. Akupunktur*; 1991: 27-30.
304. Lehrer JF. Cyproheptadine's antiserotonin effects are responsible for its antimigraine activity. *Headache* 2004 Oct; 44(9):935; PMID: 15447711.
305. Lenaerts M, Bastings E, Sianard J, et al. Sodium valproate in severe migraine and tension-type headache: an open study of long-term efficacy and correlation with blood levels. *Acta neurologica Belgica*; 1996: 126-9.
306. Leniger T, Wiemann M, Bingmann D, et al. Different effects of GABAergic anticonvulsants on 4-aminopyridine-induced spontaneous GABAergic hyperpolarizations of hippocampal pyramidal cells--implication for their potency in migraine therapy. *Cephalalgia* 2000 Jul; 20(6):533-7; PMID: 11075835.
307. Leonard L, Phillips WJ. Near-complete migraine prophylaxis with amlodipine: a case report. *Journal of Pain & Symptom Management* 2007 Dec; 34(6):571-3; PMID: 18053876.
308. Levy D, Burstein R. The vascular theory of migraine: leave it or love it? *Ann Neurol* 2011 Apr; 69(4):600-1; PMID: 21520229.
309. Lewis D, Ashwal S, Hershey A, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. *Neurology* 2004 Dec 28; 63(12):2215-24; PMID: 15623677.
310. Lewis DW. Please don't let her suffer like I did! Expert Review of Neurotherapeutics 2005 May; 5(3):291-4; PMID: 15938660.
311. Lewis DW. Headaches in children and adolescents. *Pediatric Annals* 2010 Jul; 39(7):388-90; PMID: 20666342.
312. Li Y, Liang F, Yu S, et al. Randomized controlled trial to treat migraine with acupuncture: design and protocol. *Trials* 2008; 9:57; PMID: 18928574.
313. Li Z, Wang D, Cui Y. The clinical observation of Suxiao Jiuxin pellet on migraine for 42 cases. *Chinese Journal of Integrated Traditional and Western Medicine (Zhong Guo Zhong Xi Yi Jie He Za Zhi)*; 1996: 15.
314. Li ZX, Li XG, Xiong XJ, et al. A clinical study of sibelium combining topiramate in prophylactic treatment of migraine. *The Chinese Journal of Modern Applied Pharmacy*; 2002: 419-21.

315. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. *Cochrane Database of Systematic Reviews* 2004; (2):CD003225; PMID: 15106196.
316. Lines C, Allen C, McCarroll K. Evidence-based migraine therapy. *Cephalalgia* 2001 Nov; 21(9):932-3; author reply 3-4; PMID: 11903292.
317. Lines C, Visser WH. Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. *International Journal of Clinical Practice* 2004 Mar; 58(3):322; author reply -3; PMID: 15117106.
318. Lionetto L, Fiorillo M, Martelletti P. Efficacy and tolerability of almotriptan in menstrual migraine: a comment. *Expert Opinion on Pharmacotherapy* 2011 Oct; 12(15):2279-81; PMID: 21916785.
319. Lipton RB, Cady R. Mixing sumatriptan. *Headache* 2002 Apr; 42(4):325-6; PMID: 12010399.
320. Liu H-C. Botulinum toxin type a as a prophylactic treatment for chronic daily headache: time to conduct a large clinical trial in Taiwan? *Journal of the Chinese Medical Association: JCMA* 2007 Dec; 70(12):519-20; PMID: 18194891.
321. Liu HJ, Huang YQ, Wang XP. [Effects of yanyue qingnao granules on headache symptoms and hemorheology in patients with migraine]. *Zhongguo Linchuang Kangfu*; 2005: 108-9.
322. Liu Y, Zhang X-P, Chen J-L. [Observations on the curative effect of acupuncture on migraine]. *Shanghai journal of acupuncture and moxibustion*; 2002: 24.
323. Liu Y-C, Fuh J-L, Chen R-C, et al. Botulinum toxin type a in the prophylactic treatment of transformed migraine in Taiwanese patients: a review of 30 consecutive cases.[Erratum appears in *J Chin Med Assoc.* 2008 Oct;71(10):549]. *Journal of the Chinese Medical Association: JCMA* 2007 Dec; 70(12):535-40; PMID: 18194894.
324. Loder E. Menstrual migraine: timing is everything. *Neurology* 2004 Jul 27; 63(2):202-3; PMID: 15277607.
325. Loder E. Fixed drug combinations for the acute treatment of migraine : place in therapy. *CNS Drugs* 2005; 19(9):769-84; PMID: 16142992.
326. Loftus BD. Unilateral time-delayed encapsulation does not make for a fair race. *Headache* 2003 Sep; 43(8):921; author reply 4-8; PMID: 12940818.
327. Logroscino G, Lipton RB. Migraine is associated with chest symptoms but not cardiac events: a reassuring paradox. *Neurology* 2004 Dec 28; 63(12):2209-10; PMID: 15623674.
328. Loisy C. [Chenodeoxycholic acid and the Vichy cure]. *Médecine & chirurgie digestives*; 1981: 547-8.
329. Longo G, Rudoi I, Iannuccelli M, et al. [Treatment of essential headache in developmental age with L-5-HTP (cross over double-blind study versus placebo)]. *La Pediatria medica e chirurgica : Medical and surgical pediatrics*; 1984: 241-5.
330. Lopez-Gil A. Evaluating triptan usage: a rebuttal. *Headache* 2004 Oct; 44(9):934-5; PMID: 15447710.
331. Louis P. Migraine prophylaxis: Double-blind trials with flunarizine. <ORIGINAL> **BERICHT ZUR MIGRANEPROPHYLAxe: DOPPELBLINDVERSUCHE MIT FLUNARIZIN.** *Therapiewoche* Vol 34; 1984: 5661-6.
332. Lu SL, Ma YL, Shan SQ. [Blocking astroid sympathetic ganglion to treat migraine by bupivacaine and morphine combined solution]. *Chinese Journal of Anesthesiology*; 1992: 120-1.
333. Ludvigsson J. Letter: Propranolol in treatment of migraine in children. *Lancet* 1973 Oct 6; 2(7832):799; PMID: 4126507.
334. Lutschg J, Vassella F. Flunarizine and propranolol in the treatment of migraine in children. *Schweizerische Medizinische Wochenschrift*; 1990: 1731-6.
335. Lütschg J, Vassella F. [The treatment of juvenile migraine using flunarizine or propranolol]. *Schweizerische medizinische Wochenschrift*; 1990: 1731-6.
336. Lynggaard F, Ostergaard F. [Clonidine in prevention of migraine. Report of a double-blind study of 38 patients referred for neurological assessment]. *Ugeskrift for laeger*; 1975: 149-51.

337. Maggioni F. Revisiting the role of ergots in the treatment of migraine and headache: a comment. *Headache* 2011 May; 51(5):819-20; PMID: 21453328.
338. Mahmood T, Silverstone T. Twin concordance for bipolar disorder and migraines. *American Journal of Psychiatry* 2000 Dec; 157(12):2057; PMID: 11097985.
339. Maissen CP, Ludin HP. [Comparison of the effect of 5-hydroxytryptophan and propranolol in the interval treatment of migraine]. *Schweizerische medizinische Wochenschrift*; 1991: 1585-90.
340. Maissen CP, Ludin HP. [Comparative efficacy of 5-hydroxytryptophan and propranolol in interval treatment of migraine.]. *Schweiz Med Wochenschr*; 1991: 1585-90.
341. Malone TD, Kori SH. Ischemic colitis associated with naratriptan and oral contraceptive use: a response. *Headache* 2005 Nov-Dec; 45(10):1418-9; author reply 9-20; PMID: 16324179.
342. Mann JD, Faurot KR, Wilkinson L, et al. Craniosacral therapy for migraine: protocol development for an exploratory controlled clinical trial. *BMC Complement Altern Med* 2008; 8:28; PMID: 18541041.
343. Mansoor Q, Jain S. Bilateral angle-closure glaucoma following oral topiramate therapy. *Acta Ophthalmologica Scandinavica* 2005 Oct; 83(5):627-8; PMID: 16188011.
344. Manzoni GC, Martucci N, Agnoli A, et al. Multicentric, double-blind, randomized study on the efficacy and tolerance of dothiepin and amitriptyline for the prophylaxis of chronic migraine. [Italian]. *Giornale di Neuropsicofarmacologia*; 1990: 179-84.
345. Marcus DA. Pregnancy and chronic headache. *Expert Opinion on Pharmacotherapy* 2002 Apr; 3(4):389-93; PMID: 11934341.
346. Martelletti P. Dispute settlement understanding on the use of Botox in chronic migraine. *J Headache Pain* 2011 Feb; 12(1):1-2; PMID: 21246242.
347. Martikainen MH, Roine S. Rapid improvement of a complex migrainous episode with sodium valproate in a patient with CADASIL. *J Headache Pain* 2012 Jan; 13(1):95-7; PMID: 22065121.
348. Martinez Collado JH, Alvarado Gay FJ, Danel Beltran JA, et al. [Glucose screening test in pregnant women. A comparison between the traditional glucose load and diet]. *Medicina Interna de Mexico*; 2003: 286-8.
349. Martinez LL, Fernandez JH, Manjon-Cabeza RA. Flunarizine or dihydroergotamine in the treatment of migraine in childhood. A randomised study of 50 patients. <ORIGINAL> FLUNARIZINA O DIHIDROERGOTAMINA EN EL TRATAMIENTO DE LA MIGRANA EN LA INFANCIA. ESTUDIO RANDOMIZADO DE 50 PACIENTES. *An Esp Pediat*; 1990: 213-8.
350. Masdrakis VG, Oulis P, Karakatsanis NA, et al. Remission of migraine attacks in a patient with depression who is taking pregabalin. *Clinical Neuropharmacology* 2008 Jul-Aug; 31(4):238-40; PMID: 18670248.
351. Massiou H. What is lacking in the treatment of paediatric and adolescent migraine? *Cephalalgia* 1997; 17(Suppl 17):21-4; PMID: 9218882.
352. Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache. An open label study. *Headache* 1991 Feb; 31(2):71-4; PMID: 2030076.
353. Mathew NT, Saper JR, Silberstein SD. Safety and efficacy of divalproex sodium in the prophylaxis of migraine headache: a multicenter, double-blind, placebo-controlled trial [abstract]. *Canadian Journal of Neurological Sciences*; 1993.
354. Matsumaru Y, Hayakawa M. [Endovascular treatment for carotid artery stenosis]. *Brain & Nerve / Shinkei Kenkyu no Shinpo* 2010 Dec; 62(12):1291-300; PMID: 21139182.
355. Matthews SC, Miller BP. Auditory hallucinations associated with topiramate. *Journal of Clinical Psychiatry* 2001 Aug; 62(8):653; PMID: 11561939.
356. Mattsson P. Migraine: preventive treatment. *Cephalalgia* 2004 Oct; 24(10):908; author reply -9; PMID: 15377326.
357. Maubach KA, Davis RJ, Clark DE, et al. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. *British Journal of Pharmacology* 2009 Jan; 156(2):316-27; PMID: 19154437.

358. Mauksop A, Basdeo R. Botulinum toxin A is an effective prophylactic therapy for migraines [abstract]. *Cephalalgia* 2000; 20:422, abstract 387; PMID.
359. McCrory DC. Report on gabapentin (Neurontin®) for migraine prophylaxis. 2008; PMID.
360. McDevitt DG. The assessment of beta-adrenoceptor blocking drugs in man. *Br J Clin Pharmacol* 1977 Aug; 4(4):413-25; PMID: 20123.
361. McIntosh E. Anti-emetics, NSAIDs and opiates in migraine. *Practitioner* 2006 Sep; 250(1686):60; author reply PMID: 17036920.
362. McQuay H, Carroll D, Jadad AR, et al. Anticonvulsant drugs for management of pain: a systematic review. *BMJ (Clinical research ed.)*; 1995: 1047-52.
363. Medvedeva LA, Zagorul'ko OI, Gnezdilov AV, et al. [Use of anesthesiological technologies in the complex treatment of cervicocranial pain syndromes]. *Anesteziologija i reanimatologija*; 2008: 92-6.
364. Mehrotra S, Gupta S, Garrelds IM, et al. Effects of current and prospective antimigraine drugs on the porcine isolated meningeal artery. *Naunyn-Schmiedeberg's Archives of Pharmacology* 2006 Dec; 374(3):163-75; PMID: 17103145.
365. Menault F. Maintenance therapy in cranio-facial pain: a controlled trial with tiapride (author's transl). [French]. *Sem Hop*; 1981: 1015-6.
366. Mendizabal JE. Extended-release divalproex sodium improves the quality of life of adolescent migraineurs. *Headache* 2002 Apr; 42(4):327-8; PMID: 12010402.
367. Messerich J. [EMA 3--a phenacetin-free combination with analgesic action]. *Schweizerische Rundschau für Medizin Praxis = Revue suisse de médecine Praxis*; 1973: 774-6.
368. Michel H. Migraine and tiapride. A controlled study (author's transl). [French]. *Sem Hop*; 1980: 1931-5.
369. Midelfart E, Winnem M. [Sumatriptan in the treatment of migraine in general practice]. *Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række*; 1994: 3430-2.
370. Mierzwi, ski J, Pawlak O, et al. [The vestibular system and migraine in children]. *Otolaryngologia polska. The Polish otolaryngology*; 2000: 537-40.
371. Mitchell MP, Schaeffer K, Cannon HE, et al. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization. *Journal of Managed Care Pharmacy* 2008 Jun; 14(5):442-50; PMID: 18597573.
372. Mnie-Filali O, Lambas-Senas L, Scarna H, et al. Therapeutic potential of 5-HT7 receptors in mood disorders. *Current Drug Targets* 2009 Nov; 10(11):1109-17; PMID: 19702552.
373. Moore KL. Valproate in the treatment of refractory recurrent headaches. *Headache Quarterly* 1992; 3(3):323-5; PMID.
374. Moreno MJ, Abounader R, x00E, et al. Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. *Neuropharmacology* 2002 Mar; 42(4):568-76; PMID: 11955527.
375. Morey SS. Guidelines on migraine: Part 3. Recommendations for individual drugs. *American Family Physician* 2000 Nov 1; 62(9):2145-8; PMID: 11087191.
376. Morey SS. Guidelines on migraine: Part 2. General principles of drug therapy. *American Family Physician* 2000 Oct 15; 62(8):1915-7; PMID: 11057843.
377. Morren JA, Galvez-Jimenez N. Where is dihydroergotamine mesylate in the changing landscape of migraine therapy? *Expert Opinion on Pharmacotherapy* 2010 Dec; 11(18):3085-93; PMID: 21080856.
378. Moses LL. Botulinum toxin A. An alternative treatment for migraine. *Advance for Nurse Practitioners* 2009 Dec; 17(12):40-1; PMID: 20014704.
379. Mucke HA. Robalzotan AstraZeneca. *Current Opinion in Investigational Drugs* 2000 Oct; 1(2):236-40; PMID: 11249580.
380. Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. *Cephalalgia* 2008 Jun; 28(6):585-97; PMID: 18454787.

381. Müller KH, Haarmann K, Neff K. [Effect of BC 105 on the depressed mood in migraine]. *Therapeutische Umschau. Revue thérapeutique*; 1972: 628-35.
382. Naess K. [Short piece on a double blind study with Demigran]. *Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række*; 1969: 1658.
383. Nair KG. A pilot study of the value of propranolol in migraine. *Journal of Postgraduate Medicine* 1975 Jul; 21(3):111-3; PMID: 1107526.
384. Nair P. Recent developments in health law. *Wyeth v. Levine: challenging implied pre-emption for drugs. Journal of Law, Medicine & Ethics* 2009; 37(3):527-30; PMID: 19791315.
385. Naprienko MV, Oknin V, Kremenchugskaja MR, et al. [Use of acupuncture in the therapy of chronic daily headache]. *Zhurnal nevrologii i psikiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinsko-promyshlennosti Rossi; promyshlennosti Rossi; Federatsii, Vserossi; skoe obshchestvo nevrologov [i] Vserossi; skoe obshchestvo psikiatrov*; 2003: 40-4.
386. Nascimento ED. [Prophylaxis of migraine: open study with venlafaxine in 42 patients]. *Arq Neuropsiquiatr* 1998 Dec; 56(4):744-6; PMID: 10029876.
387. Nattero G, Lisino F, Brandi G, et al. [Use of dimethothiazine in the prevention of hemicrania]. *Minerva medica*; 1977: 839-45.
388. Nattero G, Lisino F, Brandi G, et al. [Reserpine in the prevention of migraine and in the therapy of tension-vascular headache]. *Minerva medica*; 1976: 1871-5.
389. Ni C. [32 cases of non-premonitory migraine treated by opening "four gates"]. *Acta universitatis traditionis medicalis sinensis pharmacologiaeque shanghai*; 2002: 24.
390. Nørrelund N, Christiansen LV, Plantener S. [Tolfenamic acid versus paracetamol in migraine attacks. A double-blind study in general practice]. *Ugeskrift for læger*; 1989: 2436-8.
391. Novembre E, Dini L, Bernardini R, et al. [Unusual reactions to food additives]. *La Pediatria medica e chirurgica : Medical and surgical pediatrics*; 1992: 39-42.
392. Ogoose T, Manabe T, Abe T. Childhood steroid-responsive painful ophthalmoplegia: clues to ophthalmoplegic migraine. *Journal of Pediatrics* 2007 Aug; 151(2):e8-9; author reply e; PMID: 17643751.
393. Olesen C, Olsen J. Sumatriptan: what do we know about fetal risks? *Headache* 2001 Feb; 41(2):206-7; PMID: 11251709.
394. O'Quinn S, Saiers J, Mansbach H, et al. Comparison of rizatriptan and sumatriptan: a reply to Tfelt-Hansen et al. *Headache* 2000 Jul-Aug; 40(7):605-9; PMID: 10940103.
395. Oshinsky ML, Luo J. Neurochemistry of trigeminal activation in an animal model of migraine. *Headache* 2006 Jun; 46 Suppl 1:S39-44; PMID: 16927963.
396. Oterino A, Ramon C, Pascual J. Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks. *J Headache Pain* 2011 Apr; 12(2):235-8; PMID: 21298315.
397. Overbeek WA, de Vroede MA, Lahuis BE, et al. [Antipsychotics and metabolic abnormalities in children and adolescents: a review of the literature and some recommendations]. *Tijdschr Psychiatr* 2010; 52(5):311-20; PMID: 20458678.
398. Pakalnis A, Couch J. Headache therapy with botulinum toxin: form over substance. *Archives of Neurology* 2008 Jan; 65(1):149-51; PMID: 18195156.
399. Pakalnis A, Kring D. Zonisamide prophylaxis in refractory pediatric headache. *Headache* 2006 May; 46(5):804-7; PMID: 16643584.
400. Palmer JB, Salonen R. Migraine revolution and sumatriptan. *Lancet* 2000 Jun 24; 355(9222):2250-1; PMID: 10881915.
401. Parisi P. Migraine and suicidal ideation in adolescents aged 13 to 15 years. *Neurology* 2009 Nov 17; 73(20):1713; author reply -4; PMID: 19918001.
402. Pascual J. Good news for chronic migraine. *Journal of Headache & Pain* 2006 Sep; 7(4):169-71; PMID: 16897616.
403. Paterna S, di Pasquale P, Martino S, et al. [Captopril versus placebo in the prevention of hemicrania without aura. A randomized double-blind study]. *La Clinica terapeutica*; 1992: 475-81.

404. Paterna S, Martino S, Ingurgio NC, et al. [The effects of terazosin hydrochloride and buflomedil in patients with hemicrania without aura]. *La Clinica terapeutica*; 1994: 307-19.
405. Paterna S, Martino SG, Campisi D, et al. [Evaluation of the effects of verapamil, flunarizine, diltiazem, nimodipine and placebo in the prevention of hemicrania. A double-blind randomized cross-over study]. *La Clinica terapeutica*; 1990: 119-25.
406. Peatfield RC. Importance of headache. *Current Medical Research & Opinion* 2001; 17 Suppl 1:s1-3; PMID: 12463269.
407. Pedersen E, Moller CE. Methysergide in migraine prophylaxis. *Clinical pharmacology and therapeutics*; 1966: 520-6.
408. Pellock JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. *Neurology* 1991 Jul; 41(7):961-4; PMID: 2067658.
409. Perrotta A. [The importance of early symptomatic treatment of the migraine attack]. *Confinia Cephalalgia*; 2006: 83-7.
410. Pfaffenrath V, Diener HC, Isler H, et al. [Effectiveness and tolerance of amitriptyline oxide in chronic tension headache--a multicenter double-blind study versus amitriptyline versus placebo]. *Der Nervenarzt*; 1993: 114-20.
411. Philipp M. [Therapy of migraine. Clinical experience with Migraeflux, a new migraine drug]. *Fortschritte der Medizin*; 1977: 107-10.
412. Pichler E, Strauss A, Wunderlich E. [Ophthalmodynamographic studies in spontaneous and pharmacologically induced vascular headache]. [German]. *Wiener Klinische Wochenschrift*; 1968: 855-61.
413. Pini LA. Future drugs for migraine. *Internal & Emergency Medicine* 2009 Oct; 4(5):361-2; PMID: 19707844.
414. Piovesan EJ, Werneck LC, Kowacs PA, et al. [Anesthetic blockade of the greater occipital nerve in migraine prophylaxis]. *Arquivos de neuro-psiquiatria*; 2001: 545-51.
415. Pita E, Higuera A, Bolaños J, et al. Propranolol and migraine. A clinical trial. *Archivos de farmacología y toxicología*; 1977: 273-8.
416. Pluvinage R. [The treatment of migraine and tension headaches with amitriptyline (author's transl)]. *La semaine des hôpitaux : organe fondé par l'Association d'enseignement médical des hôpitaux de Paris*; 1978: 713-6.
417. Poch GF. [BC 105 in migraine]. *Prensa médica argentina*; 1972: 563-7.
418. Polisca R, Signoretti P, Marchi P. [Fluoxetine in the treatment of migraine with interval headache]. *Rassegna Internazionale di Clinica e Terapia*; 1992: 408-15.
419. Pothmann R. Migraine prophylaxis in children with low dose aspirin and flunarizin. *Journal of Neurology*; 1985: 219.
420. Pothmann R. [Prevention of migraine with flunarizine and acetylsalicylic acid. A double-blind study]. *Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft für Kinderheilkunde*; 1987: 646-9.
421. Pothmann R. Childhood migraine prophylaxis with calcium antagonist flunarizine and acetylsalicylic acid. A double blind study. *Monatsschrift für Kinderheilkunde*; 1987: 646-9.
422. Pradalier A, Dry J, Loisy B, et al. [Comparative study of indoramin versus dihydroergotamine in the preventive treatment of migraine]. *Thérapie*; 1988: 293-7.
423. Pradalier A, Dry J, Maininger V, et al. [Comparative study of indoramin vs dihydroergotamine in in-depth treatment of migraine (with or without aura)]. *Thérapie*; 1990: 364.
424. Pradalier A, Guérard des Lauriers A, Scheck F, et al. [Calcium carbasalate-metoclopramide combination versus dihydroergotamine in the treatment of migraine attacks]. *Pathologie-biologie*; 1995: 806-13.
425. Pradalier A, Serratrice G, Collard M, et al. [Beta-blockers and migraine. Efficacy of time-release propranolol versus placebo]. *Thérapie*; 1990: 441-5.
426. Pradalier A, Serratrice G, Collard M, et al. Betablockers and migraine: Long-acting propranolol in migraine prophylaxis, against placebo. <ORIGINAL> BETA-BLOQUANTS ET MIGRAINE. EFFICACITE, CONTRE PLACEBO, DU PROPRANOLOL A LIBERATION PROLONGEE. *Thérapie*; 1990: 441-5.

427. Pradalier A, Vincent D. [Migraine and non-steroidal anti-inflammatory agents]. *Pathologie-biologie*; 1992: 397-405.
428. Prusinski A, Kozubski W. [Use of verapamil in the treatment of migraine]. *Wiadomosci Lekarskie* 1987 Jun 1; 40(11):734-8; PMID: 3673084.
429. Puzich R, Girke W, Heidrich H, et al. [Doppler ultrasound studies of the extracranial cerebral vessels in migraine patients after ergotamine tartrate administration]. *Deutsche medizinische Wochenschrift* (1946); 1983: 457-61.
430. Rabe K, Katsarava Z, Pageler L, et al. [Efficacy of oral prednisone in the treatment of medication withdrawal headache following medication overuse headache: A placebo-controlled, double-blind and randomised study]. *Aktuelle Neurologie*; 2007: 526-9.
431. Rahimtoola H, Buurma H, Tijssen CC, et al. Migraine prophylactic medication usage patterns in The Netherlands. *Cephalalgia* 2003 May; 23(4):293-301; PMID: 12716348.
432. Ramchandren S, Liebeskind DS. Headache in a patient with Klinefelter's syndrome and hyperostosis frontalis interna. *Journal of Headache & Pain* 2007 Dec; 8(6):342-4; PMID: 18071629.
433. Ramos-Reyna E, Figueroa-Medina MJ, Garcia-Hurtado JP. [Clinical trial of intranasal tetracaine and placebo in an acute migraine attack at the Central Military Hospital]. *Archivos de Neurociencias*; 2008: 237-41.
434. Rapoport A. Antimigraine drugs: new frontiers. *Neurol Sci* 2009 May; 30 Suppl 1:S49-54; PMID: 19415426.
435. Raveau-Landon C, Bousser MG. [Metoprolol, a new effective antimigraine agent]. *Presse médicale* (Paris, France : 1983); 1988: 1805-9.
436. Ravishankar K. Botulinum toxin--role in headache prophylaxis. *Journal of the Association of Physicians of India* 2003 Sep; 51:851-2; PMID: 14710967.
437. Recober A, Russo AF. Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. *Idrugs* 2007 Aug; 10(8):566-74; PMID: 17665333.
438. Regidor PA, Speer K, Regidor M, et al. [Long-term side-effects following cyproterone acetate containing therapy in gynecology]. *Zentralblatt für Gynäkologie*; 2000: 268-73.
439. Richardson MS, Bowers BW, Petrie JL. The comparative clinical and economic benefits of drugs should be established and discussed as part of any formulary decision process. *American Journal of Managed Care* 2002 Aug; 8(8):693-4; author reply 4-5; PMID: 12212757.
440. Ridley-Smith RM. A fatal error. *New Zealand Medical Journal* 2007; 120(1255):U2570; PMID: 17546115.
441. Rieder MJ. Comparison of rizatriptan and other triptans on stringent measures of efficacy. *Neurology* 2002 Sep 10; 59(5):787; author reply 8; PMID: 12229911.
442. Riopelle R, McCans JL. A pilot study of the calcium channel antagonist diltiazem in migraine syndrome prophylaxis. *Can J Neurol Sci* 1982; 9(2):269; PMID.
443. Roach ES. Questioning botulinum toxin for headache: reality or illusion. *Archives of Neurology* 2008 Jan; 65(1):151-2; PMID: 18195157.
444. Robbins L. Stadol nasal spray for headache. *Headache* 2002 May; 42(5):386; PMID: 12047344.
445. Rodgers A, Hustad CM, Ramsey KE, et al. Comment on eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. *Headache* 2007 Mar; 47(3):452; author reply -3; PMID: 17371373.
446. Rollet J. More than skin deep. Botox applications go beyond frown lines. *Advance for Nurse Practitioners* 2004 Dec; 12(12):33-4; PMID: 15615218.
447. Rothrock JF. Clinical studies of valproate for migraine prophylaxis. *Cephalalgia* 1997 Apr; 17(2):81-3; PMID: 9137842.
448. Rothrock JF. Oral triptan therapy. *Headache* 2006 Jun; 46(6):1038; PMID: 16732854.
449. Rothrock JF. Topiramate for chronic migraine. *Headache* 2007 Jan; 47(1):139; PMID: 17355514.
450. Rothrock JF. Lagniappe. *Headache* 2007 Sep; 47(8):1232-3; PMID: 17883544.
451. Rothrock JF. Patient information regarding subcutaneous self-administration of dihydroergotamine (DHE). *Headache* 2007 May; 47(5):740; PMID: 17501862.

452. Rothrock JF. Patient information regarding subcutaneous self-administration of sumatriptan (Imitrex). *Headache* 2007 Apr; 47(4):639; PMID: 17445120.
453. Rothrock JF. Chronic migraine: medication overuse headache. *Headache* 2007 Mar; 47(3):467-8; PMID: 17371376.
454. Rothrock JF. BOTOX for headache treatment. *Headache* 2007 Feb; 47(2):345-6; PMID: 17300388.
455. Rothrock JF. Images from headache: a costly attack of migraine. *Headache* 2008 Jun; 48(6):951; PMID: 18549373.
456. Rothrock JF. Preventive (prophylactic) therapy. *Headache* 2009 Sep; 49(8):1253-5; PMID: 19719547.
457. Rothrock JF. In this issue. *Headache* 2009 Nov-Dec; 49(10):1401; PMID: 19912345.
458. Rothrock JF. Triptans, SSRIs/SNRIs and serotonin syndrome.[Original report in *Headache*. 2010 Jun;50(6):1089-99; PMID: 20618823]. *Headache* 2010 Jun; 50(6):1101-2; PMID: 20618824.
459. Rothrock JF. Non-steroidal anti-inflammatory drugs (NSAIDs) for acute migraine treatment. *Headache* 2010 Nov; 50(10):1635-6; PMID: 21198567.
460. Rothrock JF, Mendizabal JE. An analysis of the "carry-over effect" following successful short-term treatment of transformed migraine with divalproex sodium. *Headache* 2000 Jan; 40(1):17-9; PMID: 10759897.
461. Rozen TD. Worsening of headaches on topiramate? A low cerebrospinal fluid pressure syndrome? *Headache* 2003 Jul-Aug; 43(7):819-20; PMID: 12945541.
462. Russell MB, Holm-Thomsen OE, Nielsen MR, et al. [Sumatriptan treatment of migraine in general practice. A randomized, double-blind, placebo-controlled cross-over study]. *Ugeskrift for læger*; 1995: 2320-3.
463. Sacr, x00E, Anne, et al. Topiramate induces type 3 renal tubular acidosis by inhibiting renal carbonic anhydrase. *Nephrology Dialysis Transplantation* 2006 Oct; 21(10):2995-6; PMID: 16735391.
464. Sánchez-Pérez R, Asensio M, Melchor A, et al. [Clinical features of migraine according to the questionnaire 'Alcoi-92' in the Comtat area]. *Revista de neurologia*; 1999: 459-63.
465. Sandor PS, Morath GP, Hess K, et al. Prosopagnosia as symptom of migraine with aura: a case report. *Cephalalgia* 2006 Mar; 26(3):345-8; PMID: 16472345.
466. Sartory G, Muller B, Metsch J, et al. [Psychological and medicinal treatment of migraine in children and adolescents]. *Verhaltenstherapie*; 1995: A25.
467. Sattin JA, Login IS. Buspirone challenge is not a valid probe of central 5-HT1A receptor function. *Cephalalgia* 2004 Jun; 24(6):510; author reply 1-2; PMID: 15154863.
468. Saurugg D, Hodkewitsch E. [Clinical experiences with an analgesic-acting infusion solution in neurological painful conditions]. *Wiener medizinische Wochenschrift* (1946); 1977: 490-2.
469. Saxena P, Tesar PJ. Vascular obstruction related to mediastinal fibrosis: an interesting clinical entity. *Journal of Thoracic & Cardiovascular Surgery* 2007 Nov; 134(5):1379; author reply -80; PMID: 17976493.
470. Schaerlinger B, Hickel P, Etienne N, et al. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. *British Journal of Pharmacology* 2003 Sep; 140(2):277-84; PMID: 12970106.
471. Schnorrenberger CC, Baust W. [Acupuncture therapy of migraine in a double-blind trial]. *Die Medizinische Welt*; 1979: 425-8.
472. Schoenen J, Vandenheede M. Almotriptan efficacy in migraine with allodynia: a rebuttal to Burstein and Jakubowski's critique of Schoenen et al. *Cephalalgia* 2010 Sep; 30(9):1147-8; PMID: 20713568.
473. Schreiber CP. Building a migraine toolkit for patients: successful management of migraine headache. *Postgraduate Medicine* 2003 Nov; 114(5 Suppl Understanding):27-35; PMID: 19667647.
474. Schulz HD, Taubert K, Falkner R. [Migraine therapy with shortwave]. *Zeitschrift für ärztliche Fortbildung*; 1991: 41-2.
475. Schurks M. Common mechanisms in migraine and epilepsy: a comment. *Archives of Neurology* 2008 Nov; 65(11):1546; author reply -7; PMID: 19001180.

476. Seidel S, x00F, ber C. Numb chin syndrome, migraine-like headache and leptomeningeal spread of a B-cell lymphoma. *Headache* 2010 Jan; 50(1):150-1; PMID: 19804399.
477. Sercl M, Vrcha L. [Clinical experiences with polyantiaminic BC-105 Sandoz in the prevention of vasomotor headaches]. *Schweizerische Rundschau für Medizin Praxis = Revue suisse de médecine Praxis*; 1970: 679-83.
478. Sewell RA, Gottschalk CH. Problem child is no headache. *Headache* 2011 Feb; 51(2):306; author reply -7; PMID: 21083559.
479. Shaffer CR. Triptan therapy in migraine. *New England Journal of Medicine* 2010 Sep 30; 363(14):1377; author reply 8; PMID: 20886673.
480. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of structurally novel anticonvulsant. *Epilepsia* 1994 Mar-Apr; 35(2):450-60; PMID: 8156972.
481. Sharifi M, Burks J. Efficacy of clopidogrel in the treatment of post-ASD closure migraines. *Catheterization & Cardiovascular Interventions* 2004 Oct; 63(2):255; PMID: 15390244.
482. Shimony A, Romem A, Horowitz S, et al. Acute coronary syndrome associated with myocardial bridging due to ergotamine treatment for migraine. *International Journal of Cardiology* 2006 Oct 26; 113(1):E7-8; PMID: 16887217.
483. Shin JI, Lee JS. Can chronic fatigue symptoms associated with nutcracker phenomenon be treated with aspirin? *Medical Hypotheses* 2007; 69(3):704-5; PMID: 17329037.
484. Shulman ST. Headaches! *Pediatric Annals* 2010 Jul; 39(7):386-7; PMID: 20666341.
485. Siegmeth W, Placheta P. [Double-blind comparative trial of lonazolac-Ca versus naproxen in spinal osteoarthritis, coxarthrosis and gonarthrosis (author's transl)]. *Wiener klinische Wochenschrift*; 1982: 145-7.
486. Silberstein SD. Divalproex sodium in headache: literature review and clinical guidelines. *Headache* 1996 Oct; 36(9):547-55; PMID: 8916563.
487. Stovner LJ. Migraine prophylaxis with drugs influencing the renin-angiotensin system. *European Journal of Neurology* 2007 Jul; 14(7):713-4; PMID: 17594324.
488. Strunge P. [MY 25, a peroral prophylactic for migraine]. *Ugeskrift for laeger*; 1971: 1209-13.
489. Sulman FG, Pfeifer Y, Tal E. [Migraine therapy by enzyme induction with proxibarbital]. *Therapie der Gegenwart*; 1976: 2088-103.
490. Sun Zhong-Ren ET. [Research Into Clinical Curative Effect of Acupuncture on Migraine and Its Biochemical Mechanism]. *Shanghai journal of acupuncture and moxibustion*; 2002: 16.
491. Tan LR, Huang SH, Zheng BL. [Observation on integrated Chinese and western medicine therapy on intractable migraine]. *Hubei Journal of Tradional Chinese Medicine*; 2005: 28-9.
492. Taneri Z, Petersen-Braun M. Double blind study of intravenous aspirin vs placebo in the treatment of acute migraine attacks. <ORIGINAL> THERAPIE DES AKUTEN MIGRANEANFALLS MIT INTRAVENOS APPLIZIERTER ACETYLSALICYLSAURE. EINE PLAZEBOKONTROLLIERTE DOPPELBLINDSTUDIE. *Schmerz*; 1995: 124-9.
493. Taneri Z, Petersen-Braun M. [Double blind study of intravenous aspirin vs placebo in the treatment of acute migraine attacks.]. *Schmerz*; 1995: 124-9.
494. Taubert K. [Magnesium in migraine. Results of a multicenter pilot study]. *Fortschritte der Medizin*; 1994: 328-30.
495. Taylor MT. Cautions concerning botox therapy. *Journal of the American Osteopathic Association* 2007 May; 107(5):172-3; author reply 3-4; PMID: 17596584.
496. Tazaki Y, Sakai F, Tashiro K, et al. [Clinical Evaluation of SN-308 (Sumatriptan) Tablet on Migraine: Early Phase II Study]. *Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)*; 1997: 5547-65.
497. Tazaki Y, Sakai F, Tashiro K, et al. [Clinical Evaluation of SN-308 (Sumatriptan) Tablet on Migraine: Double-Blind Parallel-Group Study]. *Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)*; 1993: 2147-65.
498. Tazaki Y, Sakai F, Tashiro K, et al. [Clinical Evaluation of SN-308 (Sumatriptan) Tablet on Migraine: Dose Finding Study by Double-Blind Cross-Over Method]. *Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)*; 1993: 1539-66.

499. Tazaki Y, Sakai F, Tashiro K, et al. [Clinical Evaluation of SN-308 (Sumatriptan) Tablet on Migraine: Dose Finding Study by Double-Blind Cross-Over Method]. *Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)*; 1997: 5567-94.
500. Tazaki Y, Sakai F, Tashiro K, et al. [Study on Clinical Usefulness of SN-308 (Sumatriptan) Subcutaneous Injection in Migraine: Dose Finding Study by Envelope Method]. *Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)*; 1993: 1077-93.
501. Temple RJ, Meyer R. Continued need for placebo in many cases, even when there is effective therapy. *Archives of Internal Medicine* 2003 Feb 10; 163(3):371-3; author reply 3; PMID: 12578526.
502. Tfelt-Hansen P. Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies. *Cephalalgia* 2000 Mar; 20(2):137; PMID: 10961773.
503. Tfelt-Hansen P. Oral triptans vs. other classes of acute migraine medication. *Cephalalgia* 2006 May; 26(5):628; PMID: 16674775.
504. Tfelt-Hansen P. Gastric emptying in migraine. *Headache* 2007 Jun; 47(6):929; author reply - 30; PMID: 17578550.
505. Tfelt-Hansen P. Frovatriptan and data publication. *Headache* 2008 Oct; 48(9):1382-3; PMID: 19006553.
506. Tfelt-Hansen P. Maximum effect of triptans in migraine? A comment. *Cephalalgia* 2008 Jul; 28(7):767-8; PMID: 18547214.
507. Tfelt-Hansen P. Early responses in randomized clinical trials of triptans in acute migraine treatment. Are they clinically relevant? A comment. *Headache* 2010 Jul; 50(7):1198-200; PMID: 19178578.
508. Tfelt-Hansen P, Henry P, Mulder LJ, et al. [The combination of oral lysine-acetylsalicylate and metoclopramide compared with oral sumatriptan in the treatment of migraine attacks. A randomized, double-blind, placebo-controlled clinical trial]. *Ugeskrift for laeger*; 1996: 6435-9.
509. Tfelt-Hansen P, Olesen J. Increasing the effect of triptans in migraine. *Lancet* 2006 Oct 14; 368(9544):1313-4; PMID: 17046449.
510. Tfelt-Hansen P, Steiner T. The truth about frovatriptan. *Headache* 2003 Jun; 43(6):699-700; author reply 697-9; PMID: 12786937.
511. Tfelt-Hansen PC. When to use frovatriptan in migraine? *J Headache Pain* 2011 Jun; 12(3):393-4; author reply 5-6; PMID: 21512776.
512. Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. *Cephalalgia* 2008 Aug; 28(8):877-86; PMID: 18460007.
513. Thygesen P, Klee A, Fog M. [Prophylactic treatment of migraine patients with 6-alpha-trifluoromethyl-17-alpha-acetoxypregnosterone (Demigran Leo, WG 537)]. *Ugeskrift for laeger*; 1969: 144-9.
514. Torgovnick J. OnabotulinumtoxinA for the treatment of chronic migraine not quite there. *Cephalalgia* 2011 Feb; 31(3):377; author reply 8-9; PMID: 21098110.
515. Uzar E, Kutluhan S, x00Fc, et al. Topiramate-induced reversible auditory hallucination. *Epileptic Disorders* 2008 Sep; 10(3):240; PMID: 18833667.
516. Vale S. How migraines impact cognitive function: findings from the Baltimore ECA. *Neurology* 2007 Aug 21; 69(8):810; PMID: 17709720.
517. van de Velde K, Cras P, Helsen G. Acute chorea caused by valproate in an elderly. *Acta Neurol Belg* 2011 Sep; 111(3):220-1; PMID: 22141287.
518. van den Maagdenberg AMJM, Plomp JJ. Neuromuscular synapse function in typical migraine. *Cephalalgia* 2003 Mar; 23(2):73-4; PMID: 12603361.
519. Varkey BM, Varkey LM. Topiramate induced somnambulism and automatic behaviour. *Indian Journal of Medical Sciences* 2003 Nov; 57(11):508-10; PMID: 14646161.
520. Vas J, Rebollo A, Perea-Milla E, et al. Study protocol for a pragmatic randomised controlled trial in general practice investigating the effectiveness of acupuncture against migraine. *BMC Complement Altern Med* 2008; 8:12; PMID: 18410686.

521. Vedula SS, Bero L, Scherer RW, et al. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. *New England Journal of Medicine* 2009 Nov 12; 361(20):1963-71; PMID: 19907043.
522. Victor S, Ryan SW. Drugs for preventing migraine headaches in children. *Cochrane Database of Systematic Reviews* 2003; (4):CD002761; PMID: 14583952.
523. Vitols S, Vetr A, Tomson T. [It's possible to influence prescriptions patterns by producer-independent information]. [Swedish]. *Lakartidningen*; 2004: 2573-5.
524. Wang B. [Nape Multiple Acupuncture Plus Surrounding Acupuncture for Migraine] (in Chinese). *Shanghai journal of acupuncture and moxibustion*; 2004: 14-5.
525. Wang QM, Wang JJ, Hu J, et al. [Study on the best solution of immediate analgesia of acupuncture for migraine]. *Zhongguo zhen jiu = Chinese acupuncture & moxibustion*; 2010: 798-801.
526. Wang S, Cai YY. [The Clinical Effect of Point-through-Point Acupuncture on Migraine and the Investigation into its Mechanism] (in Chinese). *Shanghai journal of acupuncture and moxibustion*; 2003: 18-20.
527. Wang Sa. [Clinical Observation on Treatment of Migraine with Acupuncture Matching Chuanju Capsule]. *Journal of clinical acupuncture and moxibustion*; 2002: 11.
528. Wang Z, Guo ZX, Ma W. [Clinical Observations on Pricking Blood Treatment of Migraine with Three-Edged Needle]. *Shanghai journal of acupuncture and moxibustion*; 2002: 11.
529. Wang ZY, Ma L, Yue CY, et al. [Cold treatment for 77 cases with migraine]. *Chinese Journal of Physical Therapy*; 1995: 166-7.
530. Wasserfallen JM. [Double-blind study with oxetorone in cephalalgia (author's transl)]. *Schweizerische Rundschau für Medizin Praxis = Revue suisse de médecine Praxis*; 1976: 1021-4.
531. Waters WE. A randomized controlled trial of ergotamine tartrate. *Br J Prev Soc Med* 1970 Feb; 24(1):65; PMID: 4908199.
532. Watson DB, Torres-Trejo A, Gutmann L. Altitude induced migraine. *W V Med J* 2011 Jan-Feb; 107(1):22-3; PMID: 21322468.
533. Wears RL. Headaches from practice guidelines. *Annals of Emergency Medicine* 2002 Mar; 39(3):334-7; PMID: 11867993.
534. Weerasuriya K, Patel L, Turner P. Beta-adrenoceptor blockade and migraine. *Cephalalgia* 1982 Mar; 2(1):33-45; PMID: 6126280.
535. Weinschutz TK. [Acupuncture in headache therapy]. [German]. *Schmerz*; 1996: 149-55.
536. Weinschutz TK, Niederberger U. [Relevance of acupuncture in migraine therapy.]. *Nervenheilkunde*; 1995: 295-301.
537. Weinschutz TN. Zum stellenwert der akupunktur in der migranetherapie. *Nervenheilkunde*; 1995: 295-301.
538. Welch KMA. Botulinum toxin type A for the treatment of headache: con. *Headache* 2004 Sep; 44(8):831-3; PMID: 15330835.
539. Wenzel RG. A comment on acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. *Headache* 2006 Feb; 46(2):341; author reply -3; PMID: 16492251.
540. Wilkinson F. Migraine, eating disorders, and triptans: an unrecognized risk? *Headache* 2001 Oct; 41(9):914-5; PMID: 11703486.
541. Williams P, Dowson AJ, Rapoport AM, et al. The cost effectiveness of stratified care in the management of migraine. *Pharmacoeconomics* 2001; 19(8):819-29; PMID: 11596834.
542. Winett B. There is value in anecdotal reports of relief from migraine with botulinum toxin. *Journal of Managed Care Pharmacy* 2009 Jan-Feb; 15(1):78; author reply -9; PMID: 19125554.
543. Worz R, Drillisch C. Migraine prevention by a calcium channel blocker. Results of a double-blind study of flunarizine vs. pizotifen. [German]. *MMW Munch Med Wochenschr*; 1983: 711-14.
544. Worz R, Reinhardt-Benmalek B, Foh M, et al. Migraine prophylaxis by bisoprolol. Results of a double-blind study in comparison with metoprolol. <ORIGINAL> MIGRANEPROPHYLAXE DURCH BISOPROLOL. ERGEBNISSE EINER DOPPELBLINDSTUDIE VERSUS METOPROLOL. *Fortschr Med*; 1992: 80-90.

545. Wörz R, Reinhardt-Benmalek B, Föh M, et al. [Prevention of migraine using bisoprolol. Results of a double-blind study versus metoprolol]. *Fortschritte der Medizin*; 1992: 268-72.
546. Wu WD, Liu YL, Li YQ, et al. Lithium carbonate in the treatment of migraine. *Chinese Journal of New Drugs*; 1997: 370-1.
547. Xu CY, et al. [Analysis of the curative effect of Qi-promoting acupuncture manipulation on migraine]. *Shanghai Journal of Acupuncture and Moxibustion*; 1993: 97-103.
548. Yan XX, Bian SK, Huo JH, et al. [Impulse current therapy for migraine]. *Chinese Journal of Physical Therapy*; 1993: 142-.
549. Yang G. [Observation of Curative Effect of 42 Cases of Migraine Treated by Points Injection]. *Yunnan journal of tcm and materia medica*; 2000: 42.
550. Ye Deba FJSYa. [The Effect of Tens of Pc6 on Acute Migraine Attacked Patients Tcd]. *Journal of zhejiang college of tcm*; 2003: 68.
551. Yetkin E, Turhan H. Is it worthwhile to test statin in migraine? *Headache* 2007 Mar; 47(3):448-50; PMID: 17371368.
552. Young WB. Cessation of hemiplegic migraine auras with greater occipital nerve blockade: a comment. *Headache* 2008 Mar; 48(3):481; PMID: 18205798.
553. Yuan C, Wang JX, Yu JP, et al. [A double-blind trial of 5 calcium channel blockers in prophylaxis of migraine]. *The Chinese Journal of Clinical Pharmacology*; 1998: 14-7.
554. Zgorzalewicz M. [Visual evoked potentials in children and school adolescents with migraine and tension-type headache. Clinical and neurophysiological correlations]. *Neurologia i neurochirurgia polska*; 2005: S26-35.
555. Zhang JT, Kuang PG, Lang SY, et al. Clinical study of the efficacy of flupenthixol/melitracen in treatment of migraine with depression and/or anxiety. *Chinese Journal of New Drugs*; 2001: 605-7.
556. Zhang JT, Lang SY, Wu WP, et al. A randomized controlled trial: Deanxit in treatment of migraine complicated with depression and/or anxiety. *Chinese Journal of Clinical Rehabilitation*; 2003: 2720-21.
557. Zhang Y, Wang L, Liu H, et al. The design and protocol of acupuncture for migraine prophylaxis: a multicenter randomized controlled trial. *Trials* 2009; 10:25; PMID: 19389262.
558. Zhang Y, Zhang L, Li B, et al. [Effects of acupuncture preventive treatment on the quality of life in patients of no-aura migraine]. *Zhongguo zhen jiu = Chinese acupuncture & moxibustion*; 2009: 431-5.
559. Zhong GW, Li W, Luo YH, et al. [Herbs for calming liver and suppressing liver-yang in treatment of migraine with hyperactive liver-yang syndrome and its effects on lymphocyte protein expression: a randomized controlled trial]. *Journal of Chinese Integrative Medicine*; 2009: 25-33.
560. Zhong GW, Li W, Luo YH, et al. [Acupuncture at points of the liver and gallbladder meridians for treatment of migraine: a multi-center randomized and controlled study]. *Zhongguo zhen jiu = Chinese acupuncture & moxibustion*; 2009: 259-63.
561. Zhou JW, Li J, Li N, et al. [Transient analgesic effect of electroacupuncture at Taiyang (EX-HN 5) for treatment of migraine with hyperactivity of the liver-yang]. *Zhongguo zhen jiu = Chinese acupuncture & moxibustion*; 2007: 159-63.
562. Zhu YH, Ju LZ, Dong J. [Current impulse therapy for migraine]. *Chinese Journal of Physical Therapy*; 1992: 110-.
563. Zlotnik G. Ischemic stroke and active migraine. *Neurology* 2002 Jul 9; 59(1):149; author reply 50; PMID: 12105331.
564. Zwozdziak W. [Treatment of migraine with migristin]. *Wiadomości lekarskie (Warsaw, Poland : 1960)*; 1973: 1617-20.
565. Zwozdziak W. [BC-105 preparation in treatment of migraine]. *Wiadomości lekarskie (Warsaw, Poland : 1960)*; 1973: 2207-9.
566. Silberstein SD. Analyses of cost-effectiveness of migraine therapies should consider multiple measures. *Journal of Managed Care Pharmacy* 2003 May-Jun; 9(3):279-80; author reply 80-1; PMID: 14613476.
567. Silberstein SD. Association between restless legs syndrome and migraine. *Journal of Neurology, Neurosurgery & Psychiatry* 2010 May; 81(5):473-5; PMID: 20460586.

568. Silberstein SD. Predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate. *Cephalalgia* 2010 Nov; 30(11):1283; PMID: 20921027.
569. Silberstein SD, Aoki KR. Botulinum toxin type A: myths, facts, and current research. *Headache* 2003 Jul-Aug; 43 Suppl 1:S1; PMID: 12887387.
570. Silberstein SD, Marmura MJ, Shaw J, et al. Headache prophylaxis with BoNTA: patient characteristics. *Headache* 2010 Jan; 50(1):63-70; PMID: 19549156.
571. Silberstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. *Neurology* 2000 Apr 25; 54(8):1553; PMID: 10762491.
572. Smith DG. Cost-effectiveness of migraine treatment: a commentary. *Value in Health* 2003 Jul-Aug; 6(4):436-7; PMID: 12859584.
573. Smith R, Schwartz A. Diltiazem prophylaxis in refractory migraine. *N Engl J Med* 1984 May 17; 310(20):1327-8; PMID: 6144044.
574. Smuts JA, Schultz D, Barnard A. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. *Headache* 2004 Sep; 44(8):801-5; PMID: 15330827.
575. Sold-Darseff J, Leydhecker W. Acupuncture for pain in the cranial region and for blepharospasm without organic cause. [German]. *Klin Monatsbl Augenheilkd*; 1986: 167-9.
576. Solomon GD. Verapamil in migraine prophylaxis--a five-year review. [Review] [16 refs]. *Headache*; 1989: 425-7.
577. Soyka D, Oestreich W. Flunarizine versus propranolol in migraine prophylaxis - A multicenter double-blind study in 12 hospitals. *Nervenheilkunde*; 1987: 177-83.
578. Spierings EL. The (suma)triptan history revisited. *Headache* 2000 Oct; 40(9):766-7; PMID: 11091302.
579. Spierings ELH. Triptan meta-analysis. *Headache* 2002 Oct; 42(9):948; PMID: 12390627.
580. Spierings ELH, Sjaastad O. Hemicrania continua is not that rare. *Neurology* 2002 Aug 13; 59(3):476-7; author reply 7; PMID: 12177400.
581. Steiner T. Triptans vs other drugs for acute migraine. *Headache* 2008 Oct; 48(9):1378-9; PMID: 18793208.
582. Steiner TJ, Cook GE, Joseph R, et al. Double-blind dose-ranging comparison of metoprolol with placebo in the prophylaxis of classical and common migraine. *Cephalalgia* Vol 5; 1985: 558-9.
583. Storer RJ, Goadsby PJ. Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat. *Brain* 1997 Dec; 120 (Pt 12):2171-7; PMID: 9448572.

Appendix D. Evidence Tables

Table D1.	Pharmacological groups and agents examined in randomized controlled trials for migraine prevention in adults.....	D-11
Table D2.	Funding, ethical approval, and disclosure of conflict of interest in randomized controlled clinical trials of drugs for migraine prevention in adults.....	D-13
Table D3.	Definition of migraine in randomized controlled clinical trials that examined drugs for migraine prevention in adults.....	D-15
Table D4.	Total sample, weeks of followup, and percentage of loss of followup in randomized controlled clinical trials that examined drugs for migraine prevention in adults.....	D-16
Table D5.	Reporting of baseline patient characteristics in randomized controlled clinical trials that examined drugs for migraine prevention in adults.....	D-18
Table D6.	Differences in subject characteristics in randomized controlled clinical trials that examined drugs for migraine prevention in adults.....	D-21
Table D7.	Risk of bias in randomized controlled clinical trials of drugs for migraine prevention in adults.....	D-77
Table D8.	Randomized controlled clinical trials that examined efficacy of botulinum toxin for migraine prevention in adults.....	D-79
Table D9.	Funding and conflict of interest in randomized controlled clinical trials that examined efficacy of botulinum toxin for migraine prevention in adults.....	D-82
Table D10.	Risk of bias in randomized controlled clinical trials that examined efficacy of botulinum toxin for migraine prevention in adults.....	D-84
Table D11.	Strength of evidence of decrease in migraine frequency by $\geq 50\%$ with onabotulinumtoxin A.....	D-86
Table D12.	Decrease in migraine frequency by $\geq 50\%$ with onabotulinumtoxin A, pooled results from randomized controlled clinical trials, random effects models with inverse variance weights.....	D-87
Table D13.	Migraine headache frequency (change from baseline) with onabotulinumtoxin A, pooled results from randomized controlled clinical trials, random effects models.....	D-88
Table D14.	Severity, disability, and quality of life with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials).....	D-89
Table D15.	Randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults.....	D-94
Table D16.	Funding, ethical approval, and conflict of interest in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults.....	D-98
Table D17.	Risk of bias in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults.....	D-109
Table D18.	Strength of evidence of migraine prevention with topiramate in adults.....	D-111
Table D19.	Migraine prevention with topiramate vs. placebo in adults (pooled results from randomized controlled clinical trials).....	D-112

Table D20.	Reduction in migraine frequency and duration in randomized controlled clinical trials that examined efficacy of topiramate in adults	D-114
Table D21.	Reduction in migraine severity and symptoms in randomized controlled clinical trials that examined efficacy of topiramate in adults	D-116
Table D22.	Quality of life in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults.....	D-117
Table D23.	General health status in pooled analysis of individual patient data from randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults	D-120
Table D24.	Drug utilization for acute migraine attacks in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults	D-121
Table D25.	Randomized controlled clinical trials that examined efficacy of divalproex or valproate for migraine prevention in adults.....	D-123
Table D26.	Funding and conflict of interest in randomized controlled clinical trials that examined efficacy of divalproex or valproate for migraine prevention in adults	D-124
Table D27.	Risk of bias in randomized controlled clinical trials that examined efficacy of divalproex or valproate for migraine prevention in adults	D-125
Table D28.	Strength of evidence of migraine prevention in adults with divalproex vs. placebo, results from randomized controlled clinical trials	D-126
Table D29.	Migraine prevention in adults with divalproex vs. placebo, results from randomized controlled clinical trials.....	D-127
Table D30.	Migraine frequency, severity, and drug utilization with valproate vs. placebo for migraine prevention in adults, results from medium risk of bias randomized controlled clinical trials.....	D-129
Table D31.	Randomized controlled clinical trials that examined efficacy of propranolol for migraine prevention in adults	D-130
Table D32.	Funding and conflict of interest in randomized controlled clinical trials that examined efficacy of propranolol for migraine prevention in adults	D-133
Table D33.	Risk of bias in randomized controlled clinical trials that examined efficacy of propranolol for migraine prevention in adults	D-135
Table D34.	Strength of evidence of migraine prevention with propranolol (randomized controlled clinical trials)	D-136
Table D35.	Migraine prevention with propranolol, results from randomized controlled clinical trials.....	D-137
Table D36.	Reduction in frequency of migraine attack by at least 50% from baseline with timolol 10mg twice a day (pooled with random effects model results from randomized controlled clinical trials).....	D-143
Table D37.	Strength of evidence of migraine prevention with timolol	D-144
Table D38.	Reduction in migraine attack frequency and severity with timolol 10mg twice a day, results from randomized controlled clinical trials	D-145
Table D39.	Randomized controlled clinical trials that examined off label anti-epileptic drugs for migraine prevention in adults	D-146
Table D40.	Finding and conflict of interest in randomized controlled clinical trials that examined off label anti-epileptic drugs for migraine prevention in adults	D-147

Table D41.	Risk of bias in randomized controlled clinical trials that examined off label anti-epileptic drugs for migraine prevention in adults	D-148
Table D42.	Randomized controlled clinical trials that examined efficacy of beta-blockers for migraine prevention in adults	D-149
Table D43.	Funding and conflict of interest in randomized controlled clinical trials that examined efficacy of beta-blockers for migraine prevention in adults.....	D-152
Table D44.	Risk of bias in randomized controlled clinical trials that examined efficacy of beta-blockers for migraine prevention in adults	D-153
Table D45.	Strength of evidence of migraine prevention with beta-blockers in adults	D-155
Table D46.	Efficacy of beta-blockers in prevention of migraine in adults, results from randomized controlled clinical trials.....	D-156
Table D47.	Efficacy of beta-blockers for migraine prevention in adults on intermediate outcomes of migraine frequency, duration, and severity (results from randomized controlled clinical trials)	D-158
Table D48.	Efficacy of beta-blockers on migraine severity in adults, results from randomized controlled clinical trials.....	D-160
Table D49.	Randomized controlled clinical trials that examined off label antidepressants and tonabersat for migraine prevention in adults.....	D-161
Table D50.	Funding and conflict of interest in randomized controlled clinical trials that examined off label antidepressants and tonabersat for migraine prevention in adults	D-164
Table D51.	Risk of bias in randomized controlled clinical trials that examined off label antidepressants and tonabersat for migraine prevention in adults	D-165
Table D52.	Randomized controlled clinical trials that examined calcium channel antagonists for migraine prevention in adults.....	D-166
Table D53.	Funding and conflict of interest in randomized controlled clinical trials that examined calcium channel antagonists for migraine prevention in adults	D-168
Table D54.	Risk of bias in randomized controlled clinical trials that examined calcium channel antagonists for migraine prevention in adults	D-169
Table D55.	Randomized controlled clinical trials that examined ACE inhibitors of Angiotensin II receptor blockers for migraine prevention in adults	D-170
Table D56.	Funding and conflict of interest in randomized controlled clinical trials that examined ACE inhibitors of Angiotensin II receptor blockers for migraine prevention in adults.....	D-171
Table D57.	Risk of bias in randomized controlled clinical trials that examined ACE inhibitors of Angiotensin II receptor blockers for migraine prevention in adults	D-172
Table D58.	Randomized controlled clinical trials that examined clonidine for migraine prevention in adults.....	D-173
Table D59.	Sponsorship and conflict of interest in randomized controlled clinical trials that examined clonidine for migraine prevention in adults	D-175
Table D60.	Risk of bias in randomized controlled clinical trials that examined clonidine for migraine prevention in adults.....	D-176
Table D61.	Randomized controlled clinical trials that examined ergot alkaloids for migraine prevention in adults.....	D-177

Table D62.	Funding and conflict of interest in randomized controlled clinical trials that examined ergot alkaloids for migraine prevention in adults.....	D-179
Table D63.	Risk of bias in randomized controlled clinical trials that examined ergot alkaloids for migraine prevention in adults	D-180
Table D64.	Randomized controlled clinical trials that examined comparative effectiveness of onabotulinumtoxin A for migraine prevention in adults	D-181
Table D65.	Funding and conflict of interest in randomized controlled clinical trials that examined comparative effectiveness of botulinum toxin for migraine prevention in adults.....	D-183
Table D66.	Risk of bias in randomized controlled clinical trials that examined comparative effectiveness of botulinum toxin for migraine prevention in adults	D-184
Table D67.	Comparative effectiveness of onabotulinumtoxin A vs. topiramate in migraine prevention (results from individual randomized controlled clinical trials)	D-185
Table D68.	Comparative effectiveness of onabotulinumtoxin A vs. divalproex sodium in migraine prevention (results from a single medium risk of bias randomized controlled clinical trial).....	D-186
Table D69.	Comparative effectiveness of onabotulinumtoxin A vs. amitriptyline in migraine prevention (results from a single high risk of bias randomized controlled clinical trial).....	D-187
Table D70.	Randomized controlled clinical trials of comparative effectiveness of topiramate for migraine prevention in adults.....	D-188
Table D71.	Funding and conflict of interest in randomized controlled clinical trials that examined comparative effectiveness of topiramate for migraine prevention in adults.....	D-190
Table D72.	Risk of bias in randomized controlled clinical trials that examined comparative effectiveness of topiramate for migraine prevention in adults.....	D-191
Table D73.	Comparative effectiveness of topiramate for migraine prevention in adults (individual randomized controlled clinical trials).....	D-192
Table D74.	Randomized controlled clinical trials that examined comparative effectiveness of propranolol of migraine prevention in adults	D-194
Table D75.	Funding and conflict of interest in randomized controlled clinical trials that examined comparative effectiveness of propranolol for migraine prevention in adults.....	D-199
Table D76.	Risk of bias in randomized controlled clinical trials that examined comparative effectiveness of propranolol for migraine prevention in adults	D-201
Table D77.	Randomized controlled clinical trials that examined comparative effectiveness of beta-blockers for migraine prevention in adults	D-202
Table D78.	Funding and conflict of interest in randomized controlled clinical trials that examined comparative effectiveness of beta-blockers for migraine prevention in adults.....	D-204
Table D79.	Risk of bias in randomized controlled clinical trials that examined comparative effectiveness of beta-blockers for migraine prevention in adults ...	D-205
Table D80.	Strength of evidence of comparative effectiveness of beta-blockers for migraine prevention in adults.....	D-206

Table D81.	Comparative effectiveness of beta-blockers on migraine frequency, severity, and impact (results from randomized controlled clinical trials)	D-207
Table D82.	Comparative effectiveness of beta-blockers for migraine prevention in adults (results from randomized controlled clinical trials)	D-209
Table D83.	Exploratory network Bayesian Meta-analysis of clinical response (defined as $\geq 50\%$ reduction in migraine or self-reported substantial reduction in monthly migraine frequency) with preventive approved drugs and off label drug classes in adults, results from randomized controlled clinical trials	D-212
Table D84.	Clinical response defined as ≥ 50 percent reduction in monthly migraine frequency or self reported substantial reduction in monthly migraine frequency; indirect adjusted frequentist comparisons of migraine preventive drugs in adults from RCTs (analyzed for drugs that were more effective than placebo).....	D-215
Table D85.	Comparative effectiveness of antidepressant amitriptyline and spinal manipulation for migraine prevention in adults, individual medium risk of bias randomized controlled clinical trial.....	D-226
Table D86.	Comparative effectiveness of drugs with nonpharmacological treatments for migraine prevention in adults, randomized controlled clinical trials.....	D-227
Table D87.	Funding and conflict of interest in randomized controlled clinical trials that examined comparative effectiveness of drugs and non pharmacological migraine preventive treatments in adults	D-228
Table D88.	Risk of bias in randomized controlled clinical trials that examined comparative effectiveness of drugs and nonpharmacological migraine preventive treatments in adults	D-229
Table D89.	Migraine prevention with beta-blockers combined with behavior therapy vs. placebo in adults, results from individual low risk of bias randomized controlled clinical trial	D-230
Table D90.	Strength of evidence - efficacy and safety of beta-blockers combined with behavioral therapy (orientation + relaxation training; migraine warning signs and triggers; effectively using migraine medication and reducing impact of migraines; stress management or biofeedback training; migraine management plan) vs. placebo for migraine prevention in adults, results from individual low risk of bias randomized controlled clinical trial	D-231
Table D91.	Efficacy of beta-blockers combined with behavioral therapy (orientation + relaxation training; migraine warning signs and triggers; effectively using migraine medication and reducing impact of migraines; stress management or biofeedback training; migraine management plan) vs. placebo for migraine prevention in adults, results from individual medium risk of bias randomized controlled clinical trial	D-232
Table D92.	Comparative effectiveness of antidepressant amitriptyline, 100mg/day and spinal manipulation on intermediate outcomes in adults with migraine, individual medium risk of bias randomized controlled clinical trial	D-233
Table D93.	Dose response in acute treatment utilization with onabotulinumtoxin A for migraine prevention in adults (individual low risk of bias RCT)	D-235

Table D94.	Dose response in global assessment of treatment success with onabotulinumtoxin A for migraine prevention in adults (individual low risk of bias RCT).....	D-236
Table D95.	Dose response reduction in migraine attacks by $\geq 50\%$ from baseline with topiramate in adults.....	D-237
Table D96.	Dose response migraine prevention with divalproex in adults, results from low risk of bias randomized controlled clinical trial	D-238
Table D97.	Migraine management programs examined in randomized controlled clinical trials.....	D-239
Table D98.	Funding and conflict of interest in randomized controlled clinical trials that examined migraine management programs in adults.....	D-240
Table D99.	Risk of bias in randomized controlled clinical trials that examined migraine management programs in adults	D-241
Table D100.	Description of disease management programs for migraine prevention in adults	D-242
Table D101.	Adherence to multidisciplinary intervention for migraine prevention in adults compared to standard care, results from medium risk of bias randomized controlled clinical trial	D-246
Table D102.	Effectiveness of multidisciplinary intervention for migraine prevention in adults compared to standard care (results from medium risk of bias randomized controlled clinical trial).....	D-247
Table D103.	Reduction in disability with headache management program for migraine prevention in adults compared to standard care (results from medium risk of bias randomized controlled clinical trial)	D-248
Table D104.	Effectiveness of headache management program for migraine prevention in adults compared to standard care (results from medium risk of bias randomized controlled clinical trial).....	D-249
Table D105.	Effectiveness of cognitive-behavioral minimal contact program for migraine prevention in adults compared to educational brochure (results from medium risk of bias randomized controlled clinical trial)	D-250
Table D106.	Reduction in acute drug overuse with headache school for migraine prevention in adults on acute drug utilization (results from medium risk of bias randomized controlled clinical trial)	D-253
Table D107.	Effectiveness of headache school for migraine prevention in adults (results from medium risk of bias randomized controlled clinical trial)	D-254
Table D108.	Migraine cessation with specialized pharmaceutical care for migraine compared to standard counseling in adults (results from low risk of bias randomized controlled clinical trial).....	D-255
Table D109.	Effectiveness of specialized pharmaceutical care for migraine compared to standard counseling for migraine prevention in adults (results from low risk of bias randomized controlled clinical trial)	D-256
Table D110.	Effectiveness of intensive pharmaceutical care campaign for migraine prevention in adults (results from low risk of bias randomized controlled clinical trial)	D-257

Table D111. Funding, ethical approval, and disclosure of conflict of interest in placebo controlled randomized controlled clinical trials of drugs for migraine prevention that included adverse effects.....	D-258
Table D112. Patient characteristics in placebo controlled randomized controlled clinical trials of adverse effects with drugs for migraine prevention in adults.....	D-259
Table D113. Followup characteristics in placebo controlled randomized controlled clinical trials of adverse effects with drugs for migraine prevention in adults....	D-260
Table D114. Risk of bias in placebo controlled randomized controlled clinical trials of adverse effects with drugs for migraine prevention.....	D-261
Table D115. Adverse effects with drugs for migraine prevention in adults, results from nonrandomized studies.....	D-262
Table D116. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with random effects model, inverse variance weights).....	D-273
Table D117. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with Bayesian odds ratios and maximum likelihood absolute risk difference).....	D-286
Table D118. Dose response adverse effects with onabotulinumtoxin A for migraine prevention in adults (results from individual randomized controlled clinical trials)	D-297
Table D119. Randomized controlled clinical trials that examined adverse effects with topiramate vs. placebo	D-308
Table D120. Funding and conflict of interest in randomized controlled clinical trials that examined adverse effects with topiramate vs. placebo.....	D-311
Table D121. Risk of bias in randomized controlled clinical trials that examined adverse effects with topiramate vs. placebo.....	D-317
Table D122. Treatment discontinuation due to adverse effects with approved drugs vs. placebo (pooled results from randomized controlled clinical trials that examined migraine prevention in adults).....	D-318
Table D123. Treatment discontinuation due to specific adverse effects with topiramate vs. placebo, pooled with random effects model results from individual randomized controlled clinical trials.....	D-320
Table D124. Discontinuation due to adverse effects with topiramate in pooled analysis of individual patient data from three randomized controlled clinical trials of migraine prevention in adults.....	D-323
Table D125. Treatment discontinuation due to adverse effects with approved and off-label drugs vs. placebo, results from individual randomized controlled clinical trials.....	D-326
Table D126. Adverse effects with topiramate in adults with migraine (pooled results from randomized controlled clinical trials)	D-332
Table D127. Significant increase in risk of adverse effects with migraine preventive drugs vs. placebo, results from individual RCTs.....	D-333
Table D128. Dose response adverse effects with topiramate in adults.....	D-336

Table D129. Dose response in treatment discontinuation due to bothersome adverse effects with divalproex for migraine prevention in adults, results from low risk of bias randomized controlled clinical trial	D-339
Table D130. Dose response in adverse effects with divalproex for migraine prevention in adults, results from low risk of bias randomized controlled clinical trial.....	D-341
Table D131. Adverse effects with valproate vs. placebo for migraine prevention in adults, results from medium risk of bias randomized controlled clinical trials.....	D-343
Table D132. Adverse effects with propranolol vs. placebo, pooled results from randomized controlled clinical trials (random effects model)	D-344
Table D133. Adverse effects with timolol 10mg twice a day (results from randomized controlled clinical trials pooled with random effects model)	D-345
Table D134. Adverse effects with timolol 10mg twice a day (results from randomized controlled clinical trials)	D-346
Table D135. Treatment discontinuation due to adverse effects with off label migraine preventive drugs vs. placebo, pooled with random effects model results from randomized controlled clinical trials.....	D-347
Table D136. Adverse effects with antiepileptic drugs vs. placebo, pooled results from randomized controlled clinical trials (random effects model)	D-349
Table D137. Adverse effects with acetazolamide, 500 mg/day vs. placebo for migraine prevention in adults, results from low risk of bias randomized controlled clinical trial	D-350
Table D138. Adverse effects with carbamazepin vs. placebo for migraine prevention in adults, results from medium risk of bias randomized controlled clinical trial....	D-351
Table D139. Adverse effects with gabapentin, titrated up to 2400 mg daily, vs. placebo for migraine prevention in adults, results from medium risk of bias randomized controlled clinical trial	D-352
Table D140. Treatment discontinuation due to bothersome adverse effects with lamotrigine, titrated up to 200 mg daily vs. placebo for migraine prevention in adults, results from low risk of bias randomized controlled clinical trial.....	D-353
Table D141. Adverse effects with oxcarbazepine, titrated to a maximum tolerated dose of 1,200 mg/day, vs. placebo for migraine prevention in adults, results from low risk of bias randomized controlled clinical trial	D-354
Table D142. Adverse effects with off label antidepressants vs. placebo, pooled results from randomized controlled clinical trials (random effects model)	D-355
Table D143. Strength of evidence of treatment discontinuation due to adverse effects with beta-blockers for migraine prevention in adults (evidence from randomized controlled clinical trials)	D-356
Table D144. Treatment discontinuation due to adverse effects with beta-blockers for migraine prevention in adults, results from individual randomized controlled clinical trials.....	D-357
Table D145. Adverse effects with beta-blockers for migraine prevention in adults (results from randomized controlled clinical trials).....	D-358
Table D146. Comparative safety of topiramate vs. onabotulinumtoxin A for migraine prevention in adults (results from individual randomized controlled clinical trials)	D-359

Table D147. Comparative safety of divalproex sodium vs. onabotulinumtoxin A for migraine prevention in adults (results from a single medium risk of bias randomized controlled clinical trial).....	D-361
Table D148. Comparative safety of amitriptyline vs. botulinum toxin type A for migraine prevention in adults (results from a single high risk of bias randomized controlled clinical trial).....	D-362
Table D149. Treatment discontinuation due to adverse effects with migraine preventive drugs compared to each other, results from individual randomized controlled clinical trials.....	D-362
Table D150. Discontinuation due to treatment failure with topiramate vs. other drugs for migraine prevention in adults.....	D-365
Table D151. Adverse effects with preventive drugs compared to each other, pooled with random effects models results from randomized controlled clinical trials.....	D-366
Table D152. Comparative safety of topiramate for migraine prevention in adults (individual randomized controlled clinical trials).....	D-367
Table D153. Adverse effects with migraine preventive drugs compared to each other, significant results from individual randomized controlled clinical trials	D-376
Table D154. Risk of any adverse effects with topiramate vs. amitriptyline for migraine prevention in adults.....	D-380
Table D155. Treatment discontinuation due to adverse effects with propranolol for migraine prevention in adults (results from randomized controlled clinical trials)	D-381
Table D156. Comparative effectiveness and safety of beta-blockers combined with behavioral therapy (orientation + relaxation training; migraine warning signs and triggers; effectively using migraine medication and reducing impact of migraines; stress management or biofeedback training; migraine management plan) vs. beta-blockers alone for migraine prevention in adults, results from individual low risk of bias randomized controlled clinical trial	D-383
Table D157. Headache specific locus of control at month 16 with beta-blockers combined with behavioral therapy (orientation + relaxation training; migraine warning signs and triggers; effectively using migraine medication and reducing impact of migraines; stress management or biofeedback training; migraine management plan) vs. beta-blockers alone for migraine prevention in adults, results from individual medium risk of bias randomized controlled clinical trial	D-385
Table D158. Strength of evidence of comparative safety of beta-blockers for migraine prevention in adults, treatment discontinuation due to bothersome adverse effects in randomized controlled clinical trials.....	D-387
Table D159. Comparative safety beta-blockers for migraine prevention in adults, adverse effects in randomized controlled clinical trials.....	D-388
Table D160. Strength of evidence about treatment adherence and discontinuation due to adverse effects with antidepressant amitriptyline and spinal manipulation for migraine prevention in adults, individual medium risk of bias randomized controlled clinical trial	D-394

Table D161. Treatment adherence and discontinuation due to adverse effects with antidepressant amitriptyline and spinal manipulation for migraine prevention in adults, individual medium risk of bias randomized controlled clinical trial ...	D-395
Table D162. Indirect adjusted analysis of the comparative effects on the treatment discontinuation due to bothersome adverse effects with preventive drugs in adults, results from randomized controlled clinical trials (results with approved drugs and statistically significant results when off label drugs were compared with each other) (strength of evidence is low due to risk of bias and imprecision).....	D-396
Table D163. Exploratory network Bayesian meta-analysis of treatment discontinuation due to bothersome adverse effects with preventive drugs in adults, results from randomized controlled clinical trials	D400
Table D164. Decrease in frequency of migraine >50% with amitriptyline vs. placebo in adults with different baseline migraine frequency, results from medium risk of bias RCT	D-404
Table D165. Improvement of M score >50% with amitriptyline vs. placebo in adults with different baseline M score and depressive symptoms, results from medium risk of bias RCT	D-405
Table D166. Prediction of $\geq 50\%$ in migraine days reduction per month with different doses of amitriptyline (50 vs. 25mg/day) for migraine prevention in adults, results from medium risk of bias RCT.....	D-406
References for Appendix D	D-407

Appendix Table D1. Pharmacological groups and agents examined in randomized controlled trials for migraine prevention in adults

Pharmacological Group of the Drug in Active Group	Name of Drug in Active Group	The Anatomical Therapeutic Chemical (ATC) Classification System
ACE Inhibitors	Captopril	C09AA01
ACE Inhibitors	Lisinopril	C09AA03
Angiotensin II receptor blockers	Candesartan	C09CA06
Angiotensin II receptor blockers	Telmisartan	C09CA07
Antiadrenergic	Clonidine	C02AC01
Antiadrenergic	Guanfacine	C02AC02
Antidepressant	Amitriptyline	N06AA09
Antidepressant	Clomipramine	N06AA04
Antidepressant	Escitalopram	N06AB10
Antidepressant	Femoxetine	N06AB05
Antidepressant	Fluoxetine	N06AB03
Antidepressant	Fluvoxamine	N06AB08
Antidepressant	Mianserin	N06AX03
Antidepressant	Nortriptyline	N06AA10
Antidepressant	Venlafaxine	N06AX16
Antiepileptic	Acetazolamide	S01EC01
Antiepileptic	Carbamazepin	N03AF01
Antiepileptic	Divalproex	N03AG01
Antiepileptic	Gabapentin	N03AX12
Antiepileptic	Lamotrigine	N03AX09
Antiepileptic	Levetiracetam	N03AX14
Antiepileptic	Oxcarbazepine	N03AF02
Antiepileptic	Topiramate	N03AX11
Antiepileptic	Valproate	N03AG01
Antiepileptic	Vigabatrin	N03AG04
Antiepileptic	Zonisamide	N03AX15
Beta-blocker	Acebutolol	C07AB04
Beta-blocker	Alprenolol	C07AA01
Beta-blocker	Atenolol	C07AB03
Beta-blocker	Bisoprolol	C07AB07
Beta-blocker	Metoprolol	C07AB02
Beta-blocker	Nadolol	C07AA12
Beta-blocker	Nebivolol	C07AB12
Beta-blocker	Pindolol	C07AA03
Beta-blocker	Practolol	C07AB01
Beta-blocker	Propranolol	C07AA05
Beta-blocker	Timolol	C07AA06
Cortical spreading depression inhibitor	Tonabersat	Not available
Dopaminergic agent	Dihydroergocryptine	N04BC03
Ergot alkaloid	Dihydroergotamine	N02CA01
Ergot alkaloid	Lisuride	N02CA07
Ergot alkaloid	Methysergide	N02CA04
Magnesium	Magnesium	A12CC
Muscle relaxant	Tizanidine	M03BX02
Antiinflammatory and Antirheumatic Products, Nonsteroids	Aspirin	N02BA01
Antiinflammatory and Antirheumatic Products, Nonsteroids	Fenoprofen	M01AE04
Antiinflammatory and Antirheumatic Products, Nonsteroids	Flurbiprofen	M01AE09
Antiinflammatory and Antirheumatic Products, Nonsteroids	Indobufen	B01AC10
Antiinflammatory and Antirheumatic Products, Nonsteroids	Indomethacin	M01AB01
Antiinflammatory and Antirheumatic Products, Nonsteroids	Induprofen	Not available

Appendix Table D1. Pharmacological groups and agents examined in randomized controlled trials for migraine prevention in adults (continued)

Pharmacological Group of the Drug in Active Group	Name of Drug in Active Group	The Anatomical Therapeutic Chemical (ATC) Classification System
Antiinflammatory and Antirheumatic Products, Nonsteroids	Ketoprofen	M01AE03
Antiinflammatory and Antirheumatic Products, Nonsteroids	Naproxen	M01AE02
Antiinflammatory and Antirheumatic Products, Nonsteroids	Rofecoxib	M01AH02
Antiinflammatory and Antirheumatic Products, Nonsteroids	Tolfenamic Acid	M01AG02
Selective Calcium Channel Blockers	Nicardipine	C08CA04
Selective Calcium Channel Blockers	Nifedipine	C08CA05
Selective Calcium Channel Blockers	Nimodipine	C08CA06
Selective Calcium Channel Blockers	Verapamil	C08DA01
Leukotriene Receptor Antagonists	Montelukast	R03DC03

Appendix Table D2. Funding, ethical approval, and disclosure of conflict of interest in randomized controlled clinical trials of drugs for migraine prevention in adults

	COI not Disclosed	Disclosure of no COI	Disclosed COI	Funded by Grant	Funded by Industry	Funding not Reported	Funding from non Industry, not for Profit Sources	IRB Approval and Consent not Reported	Clear Reporting of IRB Approval and Consent	Total
Topiramate*	15	4	8	0	14	12	1	4	23	27
Divalproex*	0	0	3	0	3	0	0	1	2	3
Propranolol*	39	1	5	3	12	27	3	31	14	45
Timolol*	2	0	0	0	0	2	0	1	1	2
Acetazolamide	1	0	0	0	1	0	0	0	1	1
Gabapentin	4	0	0	0	1	3	0	3	1	4
Lamotrigine	1	0	0	0	0	1	0	0	1	1
Oxcarbazepine	0	0	1	0	1	0	0	0	1	1
Valproate	4	0	0	0	1	3	0	0	4	4
Vigabatrin	1	0	0	0	1	0	0	0	1	1
Carbamazepine	1	0	0	0	1	0	0	1	0	1
Alprenolol	1	0	0	0	0	1	0	1	0	1
Atenolol	2	0	0	0	0	2	0	2	0	2
Bisoprolol	1	0	0	0	1	0	0	0	1	1
Metoprolol	7	1	1	0	2	7	0	3	6	9
Nadolol	2	0	0	0	0	2	0	2	0	2
Pindolol	2	0	0	0	0	2	0	2	0	2
Acebutolol	1	0	0	1	0	0	0	1	0	1
Amitriptyline	3	0	1	0	2	2	0	2	2	4
Femoxetine	6	0	0	0	2	4	0	4	2	6
Fluoxetine	6	0	0	0	2	4	0	3	3	6
Fluvoxamine	1	0	0	0	0	1	0	1	0	1
Venlafaxine	3	0	0	0	2	1	0	1	2	3
Mianserin	1	0	0	0	1	0	0	1	0	1
Captopril	1	0	0	0	0	1	0	1	0	1
Lisinopril	0	0	1	0	1	0	0	0	1	1
Candesartan	0	0	1	0	1	0	0	0	1	1
Telmisartan	0	0	1	0	1	0	0	0	1	1
Nifedipine	1	0	0	0	0	1	0	1	0	1
Nimodipine	6	0	0	1	0	5	0	5	1	6
Verapamil	2	0	0	0	2	0	0	2	0	2
Nicardipine	1	0	0	0	1	0	0	1	0	1
Clonidine	14	0	0	0	7	7	0	13	1	14
Guanfacine	1	0	0	0	0	1	0	1	0	1

Appendix Table D2. Funding, ethical approval, and disclosure of conflict of interest in randomized controlled clinical trials of drugs for migraine prevention in adults (continued)

	COI not Disclosed	Disclosure of no COI	Disclosed COI	Funded by Grant	Funded by Industry	Funding not Reported	Funding from non Industry, not for Profit Sources	IRB Approval and Consent not Reported	Clear Reporting of IRB Approval and Consent	Total
Dihydroergocryptine	3	0	0	0	0	3	0	2	1	3
Dihydroergotamine	3	1	0	0	1	3	0	3	1	4
Lisuride	3	0	0	0	0	3	0	3	0	3
Methysergide	2	0	0	0	0	2	0	2	0	2
Non -drug	2	2	0	1	0	1	2	1	3	4
Aspirin	4	0	1	2	0	3	0	5	0	5
Fenoprofen	1	0	0	0	0	1	0	1	0	1
Flurbiprofen	1	0	0	0	1	0	0	0	1	1
Indobufen	1	0	0	0	0	1	0	1	0	1
Indomethacin	1	0	0	0	1	0	0	1	0	1
Induprofen	1	0	0	0	0	1	0	1	0	1
Ketoprofen	1	0	0	0	1	0	0	1	0	1
Naproxen sodium	3	0	0	1	1	1	0	2	1	3
Rofecoxib	1	0	0	0	0	1	0	1	0	1
Tolfenamic Acid	1	0	0	0	1	0	0	1	0	1
Magnesium	3	0	0	0	1	2	0	1	2	3
Montelukast	0	0	1	0	1	0	0	0	1	1
Tizanidine	1	0	0	0	1	0	0	1	0	1
Tonabersat	1	0	0	0	1	0	0	1	0	1
Total**	187	9	24	10	77	127	6	132	88	220
%	85	4.09	10.91	4.55	35	57.73	2.73	60	40	100

* approved drugs; **- including flunarizine trials COI = conflict of interest; IRB = Institutional Review Board

Appendix Table D3. Definition of migraine in randomized controlled clinical trials that examined drugs for migraine prevention in adults

Drugs	International Headache Society	Ad hoc Committee	Other Definitions	Not Reported	Total
Topiramate*	27	0	0	0	27
Divalproex*	3	0	0	0	3
Propranolol*	13	17	7	8	45
Timolol*	0	2	0	0	2
Acetazolamide	1	0	0	0	1
Gabapentin	3	0	1	0	4
Lamotrigine	1	0	0	0	1
Oxcarbazepine	1	0	0	0	1
Valproate	3	1	0	0	4
Vigabatrin	1	0	0	0	1
Carbamazepine	0	0	0	1	1
Alprenolol	0	1	0	0	1
Atenolol	0	2	0	0	2
Bisoprolol	0	0	0	1	1
Metoprolol	4	2	2	1	9
Nadolol	0	1	0	1	2
Pindolol	0	2	0	0	2
Acebutolol	1	0	0	0	1
Amitriptyline	1	2	0	1	4
Femoxetine	0	2	0	4	6
Fluoxetine	3	1	0	2	6
Fluvoxamine	1	0	0	0	1
Venlafaxine	3	0	0	0	3
Mianserin	0	0	0	1	1
Captopril	0	1	0	0	1
Lisinopril	1	0	0	0	1
Candesartan	1	0	0	0	1
Telmisartan	1	0	0	0	1
Nifedipine	1	0	0	0	1
Nimodipine	1	4	0	1	6
Verapamil	0	1	0	1	2
Nicardipine	1	0	0	0	1
Clonidine	1	7	0	6	14
Guanfacine	0	0	0	1	1
Dihydroergocryptine	2	0	0	1	3
Dihydroergotamine	1	3	0	0	4
Lisuride	2	0	0	1	3
Methysergide	1	1	0	0	2
Non -drug	4	0	0	0	4
Aspirin	1	2	1	1	5
Fenoprofen	0	1	0	0	1
Flurbiprofen	1	0	0	0	1
Indobufen	0	1	0	0	1
Indomethacin	0	0	0	1	1
Induprofen	0	1	0	0	1
Ketoprofen	0	1	0	0	1
Naproxen sodium	0	2	0	1	3
Rofecoxib	1	0	0	0	1
Tolfenamic Acid	0	1	0	0	1
Magnesium	2	1	0	0	3
Montelukast	1	0	0	0	1
Tizanidine	1	0	0	0	1
Tonabersat	1	0	0	0	1
Total	91	60	11	34	196**

* approved drugs; ** 24 flunarizine RCTs are not shown

Appendix Table D4. Total sample, weeks of followup, and percentage of loss of followup in randomized controlled clinical trials that examined drugs for migraine prevention in adults

Drug	Total Sample	# RCTs	Mean [Standard Deviation]	# RCTs	Weeks of Followup Mean [Standard Deviation]	# RCTs	% Loss of Followup Mean [Standard Deviation]
Topiramate*	5788	27	214.4 [209.1]	27	18.6 [6.5]	12	6.8 [5.8]
Divalproex*	522	3	174.0 [66.0]	3	12.0 [0.0]	3	1.2 [1.5]
Propranolol*	4630	42	110.2 [176.2]	45	18.6 [11.1]	36	12.3 [11.7]
Timolol*	121	2	60.5 [65.8]	2	20.0 [5.7]	Not reported	Not reported
Acetazolamide	53	1	53	1	12	1	0
Gabapentin	779	4	194.8 [225.1]	4	17.5 [6.4]	3	2.0 [3.5]
Lamotrigine	77	1	77	1	12	1	0
Oxcarbazepine	170	1	170	1	15	1	3.5
Valproate	244	4	61.0 [43.0]	4	17.0 [7.6]	4	11.9 [16.3]
Vigabatrin	23	1	23	1	28	1	0
Carbamazepine	Not reported	Not reported		1	12.0 [0.0]	1	6.3
Alprenolol	33	1	33	1	13.0 [0.0]	Not reported	Not reported
Atenolol	96	2	48.0 [33.9]	2	27.0 [1.4]	Not reported	Not reported
Bisoprolol	226	1	226	1	12.0 [0.0]	Not reported	Not reported
Metoprolol	687	9	76.3 [76.7]	9	16.7 [5.5]	Not reported	Not reported
Nadolol	112	2	56.0 [33.9]	2	12.0 [0.0]	Not reported	Not reported
Pindolol	58	2	29.0 [1.4]	2	7.5 [4.9]	Not reported	Not reported
Acebutolol	43	1	43	1	28.0 [0.0]	Not reported	Not reported
Amitriptyline	753	4	188.3 [135.4]	4	10.0 [7.7]	3	25.4 [19.6]
Femoxetine	301	6	50.2 [17.7]	6	16.8 [5.5]	5	22.7 [6.3]
Fluoxetine	304	6	50.7 [32.5]	6	13.5 [5.9]	6	22.0 [16.7]
Fluvoxamine	64	1	64	1	12	1	15.6
Venlafaxine	241	3	80.3 [22.8]	3	11.3 [1.2]	3	27.4 [3.7]
Mianserin	38	1	38	1	16	1	10.5
Captopril	12	1	12	1	68.0 [0.0]	Not reported	Not reported
Lisinopril	60	1	60	1	7.5	1	22
Candesartan	60	1	60	1	32	1	5
Telmisartan	84	1	84	1	12	1	17
Nifedipine	36	1	36	1	8	1	22
Nimodipine	426	6	71.0 [61.6]	6	17.7 [5.4]	5	16.8 [12.7]
Verapamil	43	2	21.5 [2.1]	2	22.0 [2.8]	2	34.0 [19.8]
Nicardipine	30	1	30	1	16	1	14
Clonidine	674	14	48.1 [32.9]	14	22.3 [12.2]	10	22.5 [11.5]
Guanfacine	37	1	37	1	12	1	8
Dihydroergocryptine	172	3	57.3 [39.0]	3	28.0 [12.0]	Not reported	Not reported
Dihydroergotamine	605	4	151.3 [156.9]	4	10.5 [6.4]	4	3.9 [7.1]

Appendix Table D4. Total sample, weeks of followup, and percentage of loss of followup in randomized controlled clinical trials that examined drugs for migraine prevention in adults (continued)

Drug	Total Sample	# RCTs	Mean [Standard Deviation]	# RCTs	Weeks of Followup Mean [Standard Deviation]	# RCTs	% Loss of Followup Mean [Standard Deviation]
Lisuride	343	3	114.3 [64.4]	3	15.3 [5.8]	2	13.9 [19.6]
Methysergide	92	2	46.0 [39.6]	2	17.0 [9.9]	2	24.6 [11.1]
Non -drug	632	4	158.0 [44.2]	4	20.0 [4.6]	Not reported	
Aspirin	23315	5	4663.0 [9739.6]	5	50.4 [56.0]	4	17.3 [12.8]
Fenoprofen	110	1	110	1	12	1	6.8
Flurbiprofen	29	1	29	1	20.0 [0.0]	Not reported	Not reported
Indobufen	28	1	28	1	12.0 [0.0]	Not reported	Not reported
Indomethacin	38	1	38	1	4.0 [0.0]	Not reported	Not reported
Induprofen	40	1	40	1	12.0 [0.0]	Not reported	Not reported
Ketoprofen	26	1	26	1	12.0 [0.0]	Not reported	Not reported
Naproxen sodium	101	3	33.7 [6.0]	3	16.7 [4.2]	1	15
Rofecoxib	268	1	268	1	20.0 [0.0]	Not reported	Not reported
Tolfenamic Acid	38	1	38	1	22.0 [0.0]	Not reported	Not reported
Magnesium	174	3	58.0 [30.0]	3	17.3 [6.1]	3	23.0 [16.6]
Montelukast	177	1	177	1	20	1	2.2
Tizanidine	136	1	136	1	12.0 [0.0]	Not reported	Not reported
Tonabersat	124	1	124	1	13	1	5.1

* approved drugs; # RCTs- = number of randomized controlled clinical trials that reported the variable

Appendix Table D5. Reporting of baseline patient characteristics in randomized controlled clinical trials that examined drugs for migraine prevention in adults

Drug	# RCTs	Age Mean [STD]	# RCTs	% Women Mean [STD]	# RCTs	Body Mass Index Mean [STD]	# RCTs	Years with Migraine Mean [STD]	# RCTs	Migraine Attacks/Month Mean [STD]	# RCTs	% with Aura Mean [STD]
Topiramate*	25	38.8 [3.9]	25	77.6 [18.1]	5	28.3 [1.7]	9	9.3 [5.5]	24	8.0 [5.5]	8	16.3 [16.1]
Divalproex*	3	42.3 [2.9]	3	81.9 [6.2]	1	26.7	3	22.3 [2.5]	3	2.9 [2.5]	2	4.0 [1.4]
Propranolol*	35	37.6 [3.6]	41	77.7 [7.9]	Not reported	Not reported	19	16.3 [3.8]	27	4.9 [1.4]	31	44.8 [35.9]
Timolol*	1	43	2	71.7 [0.4]	Not reported	Not reported	Not reported	Not reported	2	3.9[2.6]	2	9.5 [6.8]
Acetazolamide	1	39.2	1	75.5	1	23	Not reported		1	5	1	9.4
Gabapentin	3	40.6 [2.1]	4	60.5 [32.5]	1	25.6	1	20.8	4	4.5 [1.0]	2	46.5 [3.9]
Lamotrigine	1	37.2	1	81.8	Not reported	Not reported	Not reported	Not reported	1	4	1	40.3
Oxcarbazepine	1	40.5	1	84.7	Not reported	Not reported	Not reported	Not reported	1	6	Not reported	
Valproate	4	37.5 [5.7]	4	79.2 [6.5]	Not reported	Not reported	1	14	4	5.6 [1.5]	3	35.9 [44.9]
Vigabatrin	1	43.6	1	73.9	Not reported	Not reported	Not reported	Not reported	1	2	1	43.5
Carbamazepine	Not reported		1	68.8	Not reported	Not reported	Not reported	Not reported	1	3	Not reported	
Alprenolol	1	41.3	1	81.8	Not reported	Not reported	Not reported	Not reported	1	3	1	18.2
Atenolol	2	41.5 [2.1]	2	74.9 [7.2]	Not reported	Not reported	1	26	1	2	2	0.0 [0.0]
Bisoprolol	1	38.7	1	82	1	23.4	Not reported	Not reported	1	5.5	1	23
Metoprolol	7	37.3 [3.3]	9	82.0 [2.9]	1	22.8	7	16.8 [3.9]	8	4.2 [1.4]	6	39.2 [46.7]
Nadolol	1	36.3	2	79.4 [2.7]	Not reported	Not reported	Not reported	Not reported	1	3	1	84.4
Pindolol	2	34.8 [1.5]	2	86.2 [0.7]	Not reported	Not reported	Not reported	Not reported	2	3.0 [1.4]	2	31.7 [25.9]
Acebutolol	Not reported		1	74.4	Not reported	Not reported	Not reported	Not reported	1	4.8	Not reported	0.0 [0.0]
Amitriptyline	2	33.5 [2.1]	4	80.7 [5.4]	Not reported	Not reported	1	16		0.0 [0.0]	1	24

Appendix Table D5. Reporting of baseline patient characteristics in randomized controlled clinical trials that examined drugs for migraine prevention in adults (continued)

Drug	# RCTs	Age Mean [STD]	# RCTs	% Women Mean [STD]	# RCTs	Body Mass Index Mean [STD]	# RCTs	Years with Migraine Mean [STD]	# RCTs	Migraine Attacks/Month Mean [STD]	# RCTs	% with Aura Mean [STD]
Femoxetine	5	40.3 [2.6]	5	79.9 [8.8]	Not reported	Not reported	1	20.8	1	5	1	36.5
Fluoxetine	6	36.6 [3.1]	6	76.1 [9.4]	Not reported	Not reported	Not reported	Not reported	1	7	2	22.6 [32.0]
Fluvoxamine	1	34	1	73.4	Not reported	Not reported	Not reported	Not reported	Not reported	0.0 [0.0]	1	18.8
Venlafaxine	3	33.8 [3.8]	3	85.4 [4.2]	Not reported	Not reported	Not reported	Not reported	Not reported	0.0 [0.0]	3	9.8 [11.9]
Mianserin	Not reported		Not reported	Not reported [0.0]	Not reported	Not reported	Not reported	Not reported	Not reported	0.0 [0.0]	Not reported	
Captopril	1	49	1	58	Not reported	Not reported	Not reported	Not reported	Not reported	0.0 [0.0]	Not reported	
Lisinopril	1	41	1	81	Not reported	Not reported	Not reported	Not reported	1	2.3	Not reported	
Candesartan	1	42	1	79	Not reported	Not reported	Not reported	Not reported	Not reported	0.0 [0.0]	Not reported	
Telmisartan	1	39.8	1	84.5	1	24	Not reported	Not reported	1	6.2	Not reported	
Nifedipine	1	29.8	1	79	Not reported	Not reported	1	8.8	1	10	Not reported	
Nimodipine	5	37.5 [4.5]	5	64.8 [11.6]	1	23	3	18.7 [1.9]	3	5.0 [1.3]	3	21.6 [28.9]
Verapamil	2	36.0 [4.2]	2	80.5 [7.8]	Not reported	Not reported	1	13.4	1	5.3	1	41.7
Nicardipine	Not reported	0.0 [0.0]	1	73	Not reported	Not reported	1	8	1	4.3	1	100
Clonidine	12	37.8 [5.1]	13	76.9 [16.0]	Not reported	Not reported	3	16.0 [5.3]	5	5.1 [1.1]	Not reported	
Guanfacine	Not reported		1	84	Not reported	Not reported	Not reported	Not reported	Not reported		Not reported	
Dihydroergocryptine	2	34.3 [0.5]	3	74.4 [2.6]	Not reported	Not reported	Not reported	Not reported	3	5.3 [0.9]	3	0.0 [0.0]
Dihydroergotamine	3	37.5 [1.4]	4	69.8 [8.5]	2	23.7 [0.8]	2	15.9 [0.1]	2	4.4 [1.6]	4	15.8 [31.6]
Lisuride	2	31.8 [2.5]	2	84.1 [15.4]	Not reported	Not reported	2	14.6 [0.6]	3	5.7 [2.5]	2	43.8 [33.6]

Appendix Table D5. Reporting of baseline patient characteristics in randomized controlled clinical trials that examined drugs for migraine prevention in adults (continued)

Drug	# RCTs	Age Mean [STD]	# RCTs	% Women Mean [STD]	# RCTs	Body Mass Index Mean [STD]	# RCTs	Years with Migraine Mean [STD]	# RCTs	Migraine Attacks/Month Mean [STD]	# RCTs	% with Aura Mean [STD]
Methysergide	2	37.6 [6.2]	2	81.7 [2.3]	Not reported	Not reported	1	20	1	3	1	11.1
Non -drug	4	38.9 [1.2]	4	87.9 [8.9]	1	23.5	1	15.9	3	4.7 [2.4]	3	38.9 [53.6]
Aspirin	4	44.7 [8.8]	4	61.5 [43.1]	2	25.6 [0.8]	Not reported	0.0 [0.0]	2	7.2 [1.5]	Not reported	0.0 [0.0]
Fenoprofen	1	40.5	1	81	Not reported	Not reported	Not reported	0.0 [0.0]	Not reported		Not reported	0.0 [0.0]
Flurbiprofen	1	36	1	80	Not reported	Not reported	1	17	Not reported		1	8.7
Indobufen	1	35	Not reported	Not reported [0.0]	Not reported	Not reported	Not reported	0.0 [0.0]	1	4.8	1	0
Indomethacin	1	40	1	76	Not reported	Not reported	1	20	Not reported		Not reported	Not reported
Induprofen	1	35.8	1	60	Not reported	Not reported	1	15	Not reported		Not reported	Not reported
Ketoprofen	1	36	1	88	Not reported	Not reported	Not reported	0.0 [0.0]	1	2.8	Not reported	Not reported
Naproxen sodium	3	38.8 [0.8]	3	79.3 [10.3]	Not reported	Not reported	1	16.6	1	1.3	Not reported	Not reported
Rofecoxib	1	39.7	1	84.5	Not reported	Not reported	Not reported	Not reported	1	5.2	Not reported	Not reported
Tolfenamic Acid	1	35	1	87	Not reported	Not reported	Not reported	Not reported	Not reported	0.0 [0.0]	Not reported	Not reported
Magnesium	2	42.4 [2.0]	2	89.5 [4.9]	Not reported	Not reported	1	4.2	2	5.0 [1.4]	2	50.0 [70.7]
Montelukast	1	40	1	88	Not reported	Not reported	Not reported	Not reported	1	5.1	Not reported	Not reported
Tizanidine	1	40.3	1	79	Not reported	Not reported	Not reported	Not reported	Not reported	0.0 [0.0]	Not reported	Not reported
Tonabersat	1	36	1	92.3	Not reported	Not reported	Not reported	Not reported	Not reported	0.0 [0.0]	Not reported	Not reported

STD = standard deviation; #RCTs = number of randomized controlled clinical trials that reported baseline variable; * approved drugs

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0)

Baseline Variable	Active drug class	Comparator	Difference in baseline variable (95% CI)
Age	Acetazolamide	Alprenolol	-2.1 (-14.4 to 10.2)
Age	Acetazolamide	Amitriptyline	4.3 (-8.0 to 16.6)
Age	Acetazolamide	Aspirin	-5.5 (-15.2 to 4.2)
Age	Acetazolamide	Atenolol	-2.3 (-12.9 to 8.3)
Age	Acetazolamide	Candesartan	-2.8 (-15.1 to 9.5)
Age	Acetazolamide	Captopril	-9.8 (-22.1 to 2.5)
Age	Acetazolamide	Clonidine	0.9 (-8.2 to 10.0)
Age	Acetazolamide	Dihydroergotamine	1.7 (-8.3 to 11.7)
Age	Acetazolamide	Divalproex	-3.9 (-14.5 to 6.8)
Age	Acetazolamide	Femoxetine	-0.8 (-10.8 to 9.2)
Age	Acetazolamide	Fluoxetine	1.1 (-8.6 to 10.8)
Age	Acetazolamide	Gabapentin	-2.1 (-12.7 to 8.5)
Age	Acetazolamide	Indobufen	4.2 (-8.1 to 16.5)
Age	Acetazolamide	Indomethacin	-0.8 (-13.1 to 11.5)
Age	Acetazolamide	Induprofen	3.5 (-8.8 to 15.7)
Age	Acetazolamide	Induprofen	3.2 (-9.1 to 15.5)
Age	Acetazolamide	Lamotrigine	2.0 (-10.3 to 14.3)
Age	Acetazolamide	Lisinopril	-1.8 (-14.1 to 10.5)
Age	Acetazolamide	Magnesium	-3.2 (-13.8 to 7.4)
Age	Acetazolamide	Methysergide	-2.8 (-15.1 to 9.5)
Age	Acetazolamide	Metoprolol	1.1 (-8.9 to 11.2)
Age	Acetazolamide	Montelukast	-0.8 (-13.1 to 11.5)
Age	Acetazolamide	Nadolol	2.9 (-9.4 to 15.2)
Age	Acetazolamide	Naproxen sodium	0.4 (-9.6 to 10.5)
Age	Acetazolamide	Nifedipine	9.4 (-2.9 to 21.7)
Age	Acetazolamide	Nimodipine	2.5 (-7.5 to 12.6)
Age	Acetazolamide	Oxcarbazepine	-1.3 (-13.6 to 11.0)
Age	Acetazolamide	Pindolol	3.4 (-8.9 to 15.7)
Age	Acetazolamide	Propranolol	-0.3 (-9.5 to 8.9)
Age	Acetazolamide	Rofecoxib	-0.5 (-12.8 to 11.8)
Age	Acetazolamide	Telmisartan	-0.6 (-12.9 to 11.7)
Age	Acetazolamide	Timolol	-3.8 (-16.1 to 8.5)
Age	Acetazolamide	Tizanidine	-1.1 (-13.4 to 11.2)
Age	Acetazolamide	Tolfenamic Acid	4.2 (-8.1 to 16.5)
Age	Acetazolamide	Tonabersat	3.2 (-9.1 to 15.5)
Age	Acetazolamide	Topiramate	-2.1 (-11.3 to 7.0)
Age	Acetazolamide	Valproate	-0.8 (-11.4 to 9.8)
Age	Acetazolamide	Verapamil	3.3 (-7.4 to 13.9)
Age	Acetazolamide	Vigabatrin	-4.4 (-16.7 to 7.9)
Age	Alprenolol	Amitriptyline	6.4 (-5.9 to 18.7)
Age	Alprenolol	Aspirin	-3.4 (-13.1 to 6.3)
Age	Alprenolol	Atenolol	-0.2 (-10.8 to 10.4)
Age	Alprenolol	Candesartan	-0.7 (-13.0 to 11.6)
Age	Alprenolol	Captopril	-7.7 (-20.0 to 4.6)
Age	Alprenolol	Clonidine	3.0 (-6.1 to 12.1)
Age	Alprenolol	Dihydroergotamine	3.8 (-6.2 to 13.8)
Age	Alprenolol	Divalproex	-1.8 (-12.4 to 8.9)
Age	Alprenolol	Femoxetine	1.3 (-8.7 to 11.3)
Age	Alprenolol	Fluoxetine	3.2 (-6.5 to 12.9)
Age	Alprenolol	Gabapentin	0.0 (-10.6 to 10.6)
Age	Alprenolol	Indobufen	6.3 (-6.0 to 18.6)
Age	Alprenolol	Indomethacin	1.3 (-11.0 to 13.6)
Age	Alprenolol	Induprofen	5.6 (-6.7 to 17.8)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Age	Alprenolol	Induprofen	5.3 (-7.0 to 17.6)
Age	Alprenolol	Lamotrigine	4.1 (-8.2 to 16.4)
Age	Alprenolol	Lisinopril	0.3 (-12.0 to 12.6)
Age	Alprenolol	Magnesium	-1.1 (-11.7 to 9.5)
Age	Alprenolol	Methysergide	-0.7 (-13.0 to 11.6)
Age	Alprenolol	Metoprolol	3.2 (-6.8 to 13.3)
Age	Alprenolol	Montelukast	1.3 (-11.0 to 13.6)
Age	Alprenolol	Nadolol	5.0 (-7.3 to 17.3)
Age	Alprenolol	Naproxen sodium	2.5 (-7.5 to 12.6)
Age	Alprenolol	Nifedipine	11.5 (-0.8 to 23.8)
Age	Alprenolol	Nimodipine	4.6 (-5.4 to 14.7)
Age	Alprenolol	Oxcarbazepine	0.8 (-11.5 to 13.1)
Age	Alprenolol	Pindolol	5.5 (-6.8 to 17.8)
Age	Alprenolol	Propranolol	1.8 (-7.4 to 11.0)
Age	Alprenolol	Rofecoxib	1.6 (-10.7 to 13.9)
Age	Alprenolol	Telmisartan	1.5 (-10.8 to 13.8)
Age	Alprenolol	Timolol	-1.7 (-14.0 to 10.6)
Age	Alprenolol	Tizanidine	1.0 (-11.3 to 13.3)
Age	Alprenolol	Tolfenamic Acid	6.3 (-6.0 to 18.6)
Age	Alprenolol	Tonabersat	5.3 (-7.0 to 17.6)
Age	Alprenolol	Topiramate	0.0 (-9.2 to 9.1)
Age	Alprenolol	Valproate	1.3 (-9.3 to 11.9)
Age	Alprenolol	Verapamil	5.4 (-5.3 to 16.0)
Age	Alprenolol	Vigabatrin	-2.3 (-14.6 to 10.0)
Age	Amitriptyline	Aspirin	-9.8 (-19.5 to -0.1)
Age	Amitriptyline	Atenolol	-6.6 (-17.2 to 4.0)
Age	Amitriptyline	Candesartan	-7.1 (-19.4 to 5.2)
Age	Amitriptyline	Captopril	-14.1 (-26.4 to -1.8)
Age	Amitriptyline	Clonidine	-3.4 (-12.5 to 5.7)
Age	Amitriptyline	Dihydroergotamine	-2.6 (-12.6 to 7.4)
Age	Amitriptyline	Divalproex	-8.2 (-18.8 to 2.5)
Age	Amitriptyline	Femoxetine	-5.1 (-15.1 to 4.9)
Age	Amitriptyline	Fluoxetine	-3.2 (-12.9 to 6.5)
Age	Amitriptyline	Gabapentin	-6.4 (-17.0 to 4.2)
Age	Amitriptyline	Indobufen	-0.1 (-12.4 to 12.2)
Age	Amitriptyline	Indomethacin	-5.1 (-17.4 to 7.2)
Age	Amitriptyline	Induprofen	-0.9 (-13.1 to 11.4)
Age	Amitriptyline	Induprofen	-1.1 (-13.4 to 11.2)
Age	Amitriptyline	Lamotrigine	-2.3 (-14.6 to 10.0)
Age	Amitriptyline	Lisinopril	-6.1 (-18.4 to 6.2)
Age	Amitriptyline	Magnesium	-7.5 (-18.1 to 3.1)
Age	Amitriptyline	Methysergide	-7.1 (-19.4 to 5.2)
Age	Amitriptyline	Metoprolol	-3.2 (-13.2 to 6.9)
Age	Amitriptyline	Montelukast	-5.1 (-17.4 to 7.2)
Age	Amitriptyline	Nadolol	-1.4 (-13.7 to 10.9)
Age	Amitriptyline	Naproxen sodium	-3.9 (-13.9 to 6.2)
Age	Amitriptyline	Nifedipine	5.1 (-7.2 to 17.4)
Age	Amitriptyline	Nimodipine	-1.8 (-11.8 to 8.3)
Age	Amitriptyline	Oxcarbazepine	-5.6 (-17.9 to 6.7)
Age	Amitriptyline	Pindolol	-0.9 (-13.2 to 11.4)
Age	Amitriptyline	Propranolol	-4.6 (-13.8 to 4.6)
Age	Amitriptyline	Rofecoxib	-4.8 (-17.1 to 7.5)
Age	Amitriptyline	Telmisartan	-4.9 (-17.2 to 7.4)
Age	Amitriptyline	Timolol	-8.1 (-20.4 to 4.2)
Age	Amitriptyline	Tizanidine	-5.4 (-17.7 to 6.9)
Age	Amitriptyline	Tolfenamic Acid	-0.1 (-12.4 to 12.2)
Age	Amitriptyline	Tonabersat	-1.1 (-13.4 to 11.2)
Age	Amitriptyline	Topiramate	-6.4 (-15.6 to 2.7)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Age	Amitriptyline	Valproate	-5.1 (-15.7 to 5.5)
Age	Amitriptyline	Verapamil	-1.1 (-11.7 to 9.6)
Age	Amitriptyline	Vigabatrin	-8.7 (-21.0 to 3.6)
Age	Aspirin	Atenolol	3.2 (-4.3 to 10.7)
Age	Aspirin	Candesartan	2.7 (-7.0 to 12.4)
Age	Aspirin	Captopril	-4.3 (-14.0 to 5.4)
Age	Aspirin	Clonidine	6.4 (1.4 to 11.5)
Age	Aspirin	Dihydroergotamine	7.2 (0.6 to 13.8)
Age	Aspirin	Divalproex	1.7 (-5.8 to 9.1)
Age	Aspirin	Femoxetine	4.7 (-1.9 to 11.3)
Age	Aspirin	Fluoxetine	6.6 (0.5 to 12.7)
Age	Aspirin	Gabapentin	3.4 (-4.1 to 10.9)
Age	Aspirin	Indobufen	9.7 (0.0 to 19.4)
Age	Aspirin	Indomethacin	4.7 (-5.0 to 14.4)
Age	Aspirin	Induprofen	9.0 (-0.7 to 18.6)
Age	Aspirin	Ketoprofen	8.7 (-1.0 to 18.4)
Age	Aspirin	Lamotrigine	7.5 (-2.2 to 17.2)
Age	Aspirin	Lisinopril	3.7 (-6.0 to 13.4)
Age	Aspirin	Methysergide	2.7 (-7.0 to 12.4)
Age	Aspirin	Metoprolol	6.6 (0.0 to 13.2)
Age	Aspirin	Magnesium	2.3 (-5.2 to 9.8)
Age	Aspirin	Montelukast	4.7 (-5.0 to 14.4)
Age	Aspirin	Nadolol	8.4 (-1.3 to 18.1)
Age	Aspirin	Naproxen sodium	5.9 (-0.7 to 12.5)
Age	Aspirin	Nifedipine	14.9 (5.2 to 24.6)
Age	Aspirin	Nimodipine	8.0 (1.4 to 14.6)
Age	Aspirin	Oxcarbazepine	4.2 (-5.5 to 13.9)
Age	Aspirin	Pindolol	8.9 (-0.8 to 18.6)
Age	Aspirin	Propranolol	5.2 (-0.1 to 10.5)
Age	Aspirin	Rofecoxib	5.0 (-4.7 to 14.7)
Age	Aspirin	Telmisartan	4.9 (-4.8 to 14.6)
Age	Aspirin	Timolol	1.7 (-8.0 to 11.4)
Age	Aspirin	Tizanidine	4.4 (-5.3 to 14.1)
Age	Aspirin	Tolfenamic Acid	9.7 (0.0 to 19.4)
Age	Aspirin	Tonabersat	8.7 (-1.0 to 18.4)
Age	Aspirin	Topiramate	3.4 (-1.8 to 8.6)
Age	Aspirin	Valproate	4.7 (-2.8 to 12.2)
Age	Aspirin	Verapamil	8.8 (1.3 to 16.2)
Age	Aspirin	Vigabatrin	1.1 (-8.6 to 10.8)
Age	Atenolol	Candesartan	-0.5 (-11.1 to 10.1)
Age	Atenolol	Captopril	-7.5 (-18.1 to 3.1)
Age	Atenolol	Clonidine	3.2 (-3.5 to 9.9)
Age	Atenolol	Dihydroergotamine	4.0 (-3.9 to 11.9)
Age	Atenolol	Divalproex	-1.6 (-10.2 to 7.1)
Age	Atenolol	Femoxetine	1.5 (-6.4 to 9.4)
Age	Atenolol	Fluoxetine	3.4 (-4.1 to 10.9)
Age	Atenolol	Gabapentin	0.2 (-8.5 to 8.9)
Age	Atenolol	Indobufen	6.5 (-4.1 to 17.1)
Age	Atenolol	Indomethacin	1.5 (-9.1 to 12.1)
Age	Atenolol	Induprofen	5.8 (-4.9 to 16.4)
Age	Atenolol	Induprofen	5.5 (-5.1 to 16.1)
Age	Atenolol	Lamotrigine	4.3 (-6.3 to 14.9)
Age	Atenolol	Lisinopril	0.5 (-10.1 to 11.1)
Age	Atenolol	Magnesium	-0.9 (-9.6 to 7.8)
Age	Atenolol	Methysergide	-0.5 (-11.1 to 10.1)
Age	Atenolol	Metoprolol	3.4 (-4.5 to 11.4)
Age	Atenolol	Montelukast	1.5 (-9.1 to 12.1)
Age	Atenolol	Nadolol	5.2 (-5.4 to 15.8)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Age	Atenolol	Naproxen sodium	2.7 (-5.2 to 10.7)
Age	Atenolol	Nifedipine	11.7 (1.1 to 22.3)
Age	Atenolol	Nimodipine	4.8 (-3.1 to 12.8)
Age	Atenolol	Oxcarbazepine	1.0 (-9.6 to 11.6)
Age	Atenolol	Pindolol	5.7 (-4.9 to 16.3)
Age	Atenolol	Propranolol	2.0 (-4.8 to 8.9)
Age	Atenolol	Rofecoxib	1.8 (-8.8 to 12.4)
Age	Atenolol	Telmisartan	1.7 (-8.9 to 12.3)
Age	Atenolol	Timolol	-1.5 (-12.1 to 9.1)
Age	Atenolol	Tizanidine	1.2 (-9.4 to 11.8)
Age	Atenolol	Tolfenamic Acid	6.5 (-4.1 to 17.1)
Age	Atenolol	Tonabersat	5.5 (-5.1 to 16.1)
Age	Atenolol	Topiramate	0.2 (-6.6 to 7.0)
Age	Atenolol	Valproate	1.5 (-7.2 to 10.2)
Age	Atenolol	Verapamil	5.6 (-3.1 to 14.2)
Age	Atenolol	Vigabatrin	-2.1 (-12.7 to 8.5)
Age	Candesartan	Captopril	-7.0 (-19.3 to 5.3)
Age	Candesartan	Clonidine	3.7 (-5.4 to 12.8)
Age	Candesartan	Dihydroergotamine	4.5 (-5.5 to 14.5)
Age	Candesartan	Divalproex	-1.1 (-11.7 to 9.6)
Age	Candesartan	Femoxetine	2.0 (-8.0 to 12.0)
Age	Candesartan	Fluoxetine	3.9 (-5.8 to 13.6)
Age	Candesartan	Gabapentin	0.7 (-9.9 to 11.3)
Age	Candesartan	Indobufen	7.0 (-5.3 to 19.3)
Age	Candesartan	Indomethacin	2.0 (-10.3 to 14.3)
Age	Candesartan	Induprofen	6.3 (-6.0 to 18.5)
Age	Candesartan	Induprofen	6.0 (-6.3 to 18.3)
Age	Candesartan	Lamotrigine	4.8 (-7.5 to 17.1)
Age	Candesartan	Lisinopril	1.0 (-11.3 to 13.3)
Age	Candesartan	Magnesium	-0.4 (-11.0 to 10.2)
Age	Candesartan	Methysergide	0.0 (-12.3 to 12.3)
Age	Candesartan	Metoprolol	3.9 (-6.1 to 14.0)
Age	Candesartan	Montelukast	2.0 (-10.3 to 14.3)
Age	Candesartan	Nadolol	5.7 (-6.6 to 18.0)
Age	Candesartan	Naproxen sodium	3.2 (-6.8 to 13.3)
Age	Candesartan	Nifedipine	12.2 (-0.1 to 24.5)
Age	Candesartan	Nimodipine	5.3 (-4.7 to 15.4)
Age	Candesartan	Oxcarbazepine	1.5 (-10.8 to 13.8)
Age	Candesartan	Pindolol	6.2 (-6.1 to 18.5)
Age	Candesartan	Propranolol	2.5 (-6.7 to 11.7)
Age	Candesartan	Rofecoxib	2.3 (-10.0 to 14.6)
Age	Candesartan	Telmisartan	2.2 (-10.1 to 14.5)
Age	Candesartan	Timolol	-1.0 (-13.3 to 11.3)
Age	Candesartan	Tizanidine	1.7 (-10.6 to 14.0)
Age	Candesartan	Tolfenamic Acid	7.0 (-5.3 to 19.3)
Age	Candesartan	Tonabersat	6.0 (-6.3 to 18.3)
Age	Candesartan	Topiramate	0.7 (-8.5 to 9.8)
Age	Candesartan	Valproate	2.0 (-8.6 to 12.6)
Age	Candesartan	Verapamil	6.1 (-4.6 to 16.7)
Age	Candesartan	Vigabatrin	-1.6 (-13.9 to 10.7)
Age	Captopril	Clonidine	10.7 (1.6 to 19.8)
Age	Captopril	Dihydroergotamine	11.5 (1.5 to 21.5)
Age	Captopril	Divalproex	6.0 (-4.7 to 16.6)
Age	Captopril	Femoxetine	9.0 (-1.0 to 19.0)
Age	Captopril	Fluoxetine	10.9 (1.2 to 20.6)
Age	Captopril	Gabapentin	7.7 (-2.9 to 18.3)
Age	Captopril	Indobufen	14.0 (1.7 to 26.3)
Age	Captopril	Indomethacin	9.0 (-3.3 to 21.3)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Age	Captopril	Induprofen	13.3 (1.0 to 25.5)
Age	Captopril	Induprofen	13.0 (0.7 to 25.3)
Age	Captopril	Lamotrigine	11.8 (-0.5 to 24.1)
Age	Captopril	Lisinopril	8.0 (-4.3 to 20.3)
Age	Captopril	Magnesium	6.6 (-4.0 to 17.2)
Age	Captopril	Methysergide	7.0 (-5.3 to 19.3)
Age	Captopril	Metoprolol	10.9 (0.9 to 21.0)
Age	Captopril	Montelukast	9.0 (-3.3 to 21.3)
Age	Captopril	Nadolol	12.7 (0.4 to 25.0)
Age	Captopril	Naproxen sodium	10.2 (0.2 to 20.3)
Age	Captopril	Nifedipine	19.2 (6.9 to 31.5)
Age	Captopril	Nimodipine	12.3 (2.3 to 22.4)
Age	Captopril	Oxcarbazepine	8.5 (-3.8 to 20.8)
Age	Captopril	Pindolol	13.2 (0.9 to 25.5)
Age	Captopril	Propranolol	9.5 (0.3 to 18.7)
Age	Captopril	Rofecoxib	9.3 (-3.0 to 21.6)
Age	Captopril	Telmisartan	9.2 (-3.1 to 21.5)
Age	Captopril	Timolol	6.0 (-6.3 to 18.3)
Age	Captopril	Tizanidine	8.7 (-3.6 to 21.0)
Age	Captopril	Tolfenamic Acid	14.0 (1.7 to 26.3)
Age	Captopril	Tonabersat	13.0 (0.7 to 25.3)
Age	Captopril	Topiramate	7.7 (-1.5 to 16.8)
Age	Captopril	Valproate	9.0 (-1.6 to 19.6)
Age	Captopril	Verapamil	13.1 (2.4 to 23.7)
Age	Captopril	Vigabatrin	5.4 (-6.9 to 17.7)
Age	Clonidine	Dihydroergotamine	0.8 (-4.9 to 6.4)
Age	Clonidine	Divalproex	-4.8 (-11.4 to 1.9)
Age	Clonidine	Femoxetine	-1.7 (-7.4 to 3.9)
Age	Clonidine	Fluoxetine	0.2 (-4.9 to 5.3)
Age	Clonidine	Gabapentin	-3.0 (-9.7 to 3.7)
Age	Clonidine	Indobufen	3.3 (-5.8 to 12.4)
Age	Clonidine	Indomethacin	-1.7 (-10.8 to 7.4)
Age	Clonidine	Induprofen	2.5 (-6.5 to 11.6)
Age	Clonidine	Induprofen	2.3 (-6.8 to 11.4)
Age	Clonidine	Lamotrigine	1.1 (-8.0 to 10.2)
Age	Clonidine	Lisinopril	-2.7 (-11.8 to 6.4)
Age	Clonidine	Magnesium	-4.1 (-10.8 to 2.6)
Age	Clonidine	Methysergide	-3.7 (-12.8 to 5.4)
Age	Clonidine	Metoprolol	0.2 (-5.4 to 5.9)
Age	Clonidine	Montelukast	-1.7 (-10.8 to 7.4)
Age	Clonidine	Nadolol	2.0 (-7.1 to 11.1)
Age	Clonidine	Naproxen sodium	-0.5 (-6.1 to 5.2)
Age	Clonidine	Nifedipine	8.5 (-0.6 to 17.6)
Age	Clonidine	Nimodipine	1.6 (-4.0 to 7.3)
Age	Clonidine	Oxcarbazepine	-2.2 (-11.3 to 6.9)
Age	Clonidine	Pindolol	2.5 (-6.6 to 11.6)
Age	Clonidine	Propranolol	-1.2 (-5.2 to 2.8)
Age	Clonidine	Rofecoxib	-1.4 (-10.5 to 7.7)
Age	Clonidine	Telmisartan	-1.5 (-10.6 to 7.6)
Age	Clonidine	Timolol	-4.7 (-13.8 to 4.4)
Age	Clonidine	Tizanidine	-2.0 (-11.1 to 7.1)
Age	Clonidine	Tolfenamic Acid	3.3 (-5.8 to 12.4)
Age	Clonidine	Tonabersat	2.3 (-6.8 to 11.4)
Age	Clonidine	Topiramate	-3.0 (-6.9 to 0.9)
Age	Clonidine	Valproate	-1.7 (-8.4 to 5.0)
Age	Clonidine	Verapamil	2.3 (-4.3 to 9.0)
Age	Clonidine	Vigabatrin	-5.3 (-14.4 to 3.8)
Age	Dihydroergotamine	Divalproex	-5.6 (-13.5 to 2.4)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Age	Dihydroergotamine	Femoxetine	-2.5 (-9.6 to 4.6)
Age	Dihydroergotamine	Fluoxetine	-0.6 (-7.2 to 6.1)
Age	Dihydroergotamine	Gabapentin	-3.8 (-11.7 to 4.1)
Age	Dihydroergotamine	Indobufen	2.5 (-7.5 to 12.5)
Age	Dihydroergotamine	Indomethacin	-2.5 (-12.5 to 7.5)
Age	Dihydroergotamine	Induprofen	1.8 (-8.3 to 11.8)
Age	Dihydroergotamine	Induprofen	1.5 (-8.5 to 11.5)
Age	Dihydroergotamine	Lamotrigine	0.3 (-9.7 to 10.3)
Age	Dihydroergotamine	Lisinopril	-3.5 (-13.5 to 6.5)
Age	Dihydroergotamine	Magnesium	-4.9 (-12.8 to 3.0)
Age	Dihydroergotamine	Methysergide	-4.5 (-14.5 to 5.5)
Age	Dihydroergotamine	Metoprolol	-0.6 (-7.7 to 6.5)
Age	Dihydroergotamine	Montelukast	-2.5 (-12.5 to 7.5)
Age	Dihydroergotamine	Nadolol	1.2 (-8.8 to 11.2)
Age	Dihydroergotamine	Naproxen sodium	-1.3 (-8.4 to 5.8)
Age	Dihydroergotamine	Nifedipine	7.7 (-2.3 to 17.7)
Age	Dihydroergotamine	Nimodipine	0.8 (-6.3 to 7.9)
Age	Dihydroergotamine	Oxcarbazepine	-3.0 (-13.0 to 7.0)
Age	Dihydroergotamine	Pindolol	1.7 (-8.3 to 11.7)
Age	Dihydroergotamine	Propranolol	-2.0 (-7.9 to 3.9)
Age	Dihydroergotamine	Rofecoxib	-2.2 (-12.2 to 7.8)
Age	Dihydroergotamine	Telmisartan	-2.3 (-12.3 to 7.7)
Age	Dihydroergotamine	Timolol	-5.5 (-15.5 to 4.5)
Age	Dihydroergotamine	Tizanidine	-2.8 (-12.8 to 7.2)
Age	Dihydroergotamine	Tolfenamic Acid	2.5 (-7.5 to 12.5)
Age	Dihydroergotamine	Tonabersat	1.5 (-8.5 to 11.5)
Age	Dihydroergotamine	Topiramate	-3.8 (-9.6 to 2.0)
Age	Dihydroergotamine	Valproate	-2.5 (-10.4 to 5.4)
Age	Dihydroergotamine	Verapamil	1.6 (-6.4 to 9.5)
Age	Dihydroergotamine	Vigabatrin	-6.1 (-16.1 to 3.9)
Age	Divalproex	Femoxetine	3.1 (-4.9 to 11.0)
Age	Divalproex	Fluoxetine	5.0 (-2.5 to 12.5)
Age	Divalproex	Gabapentin	1.8 (-6.9 to 10.4)
Age	Divalproex	Indobufen	8.1 (-2.6 to 18.7)
Age	Divalproex	Indomethacin	3.1 (-7.6 to 13.7)
Age	Divalproex	Induprofen	7.3 (-3.3 to 17.9)
Age	Divalproex	Induprofen	7.1 (-3.6 to 17.7)
Age	Divalproex	Lamotrigine	5.9 (-4.8 to 16.5)
Age	Divalproex	Lisinopril	2.1 (-8.6 to 12.7)
Age	Divalproex	Magnesium	0.7 (-8.0 to 9.3)
Age	Divalproex	Methysergide	1.1 (-9.6 to 11.7)
Age	Divalproex	Metoprolol	5.0 (-2.9 to 12.9)
Age	Divalproex	Montelukast	3.1 (-7.6 to 13.7)
Age	Divalproex	Nadolol	6.8 (-3.9 to 17.4)
Age	Divalproex	Naproxen sodium	4.3 (-3.6 to 12.2)
Age	Divalproex	Nifedipine	13.3 (2.6 to 23.9)
Age	Divalproex	Nimodipine	6.4 (-1.5 to 14.3)
Age	Divalproex	Oxcarbazepine	2.6 (-8.1 to 13.2)
Age	Divalproex	Pindolol	7.3 (-3.4 to 17.9)
Age	Divalproex	Propranolol	3.6 (-3.3 to 10.4)
Age	Divalproex	Rofecoxib	3.4 (-7.3 to 14.0)
Age	Divalproex	Telmisartan	3.3 (-7.4 to 13.9)
Age	Divalproex	Timolol	0.1 (-10.6 to 10.7)
Age	Divalproex	Tizanidine	2.8 (-7.9 to 13.4)
Age	Divalproex	Tolfenamic Acid	8.1 (-2.6 to 18.7)
Age	Divalproex	Tonabersat	7.1 (-3.6 to 17.7)
Age	Divalproex	Topiramate	1.7 (-5.1 to 8.5)
Age	Divalproex	Valproate	3.1 (-5.6 to 11.7)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Age	Divalproex	Verapamil	7.1 (-1.6 to 15.8)
Age	Divalproex	Vigabatrin	-0.6 (-11.2 to 10.1)
Age	Femoxetine	Fluoxetine	1.9 (-4.7 to 8.6)
Age	Femoxetine	Gabapentin	-1.3 (-9.2 to 6.6)
Age	Femoxetine	Indobufen	5.0 (-5.0 to 15.0)
Age	Femoxetine	Indomethacin	0.0 (-10.0 to 10.0)
Age	Femoxetine	Induprofen	4.3 (-5.8 to 14.3)
Age	Femoxetine	Induprofen	4.0 (-6.0 to 14.0)
Age	Femoxetine	Lamotrigine	2.8 (-7.2 to 12.8)
Age	Femoxetine	Lisinopril	-1.0 (-11.0 to 9.0)
Age	Femoxetine	Magnesium	-2.4 (-10.3 to 5.5)
Age	Femoxetine	Methysergide	-2.0 (-12.0 to 8.0)
Age	Femoxetine	Metoprolol	1.9 (-5.2 to 9.0)
Age	Femoxetine	Montelukast	0.0 (-10.0 to 10.0)
Age	Femoxetine	Nadolol	3.7 (-6.3 to 13.7)
Age	Femoxetine	Naproxen sodium	1.2 (-5.9 to 8.3)
Age	Femoxetine	Nifedipine	10.2 (0.2 to 20.2)
Age	Femoxetine	Nimodipine	3.3 (-3.8 to 10.4)
Age	Femoxetine	Oxcarbazepine	-0.5 (-10.5 to 9.5)
Age	Femoxetine	Pindolol	4.2 (-5.8 to 14.2)
Age	Femoxetine	Propranolol	0.5 (-5.4 to 6.4)
Age	Femoxetine	Rofecoxib	0.3 (-9.7 to 10.3)
Age	Femoxetine	Telmisartan	0.2 (-9.8 to 10.2)
Age	Femoxetine	Timolol	-3.0 (-13.0 to 7.0)
Age	Femoxetine	Tizanidine	-0.3 (-10.3 to 9.7)
Age	Femoxetine	Tolfenamic Acid	5.0 (-5.0 to 15.0)
Age	Femoxetine	Tonabersat	4.0 (-6.0 to 14.0)
Age	Femoxetine	Topiramate	-1.3 (-7.1 to 4.5)
Age	Femoxetine	Valproate	0.0 (-7.9 to 7.9)
Age	Femoxetine	Verapamil	4.1 (-3.9 to 12.0)
Age	Femoxetine	Vigabatrin	-3.6 (-13.6 to 6.4)
Age	Fluoxetine	Gabapentin	-3.2 (-10.7 to 4.3)
Age	Fluoxetine	Indobufen	3.1 (-6.6 to 12.8)
Age	Fluoxetine	Indomethacin	-1.9 (-11.6 to 7.8)
Age	Fluoxetine	Induprofen	2.3 (-7.4 to 12.0)
Age	Fluoxetine	Induprofen	2.1 (-7.6 to 11.8)
Age	Fluoxetine	Lamotrigine	0.9 (-8.8 to 10.6)
Age	Fluoxetine	Lisinopril	-2.9 (-12.6 to 6.8)
Age	Fluoxetine	Magnesium	-4.3 (-11.8 to 3.2)
Age	Fluoxetine	Methysergide	-3.9 (-13.6 to 5.8)
Age	Fluoxetine	Metoprolol	0.0 (-6.6 to 6.6)
Age	Fluoxetine	Montelukast	-1.9 (-11.6 to 7.8)
Age	Fluoxetine	Nadolol	1.8 (-7.9 to 11.5)
Age	Fluoxetine	Naproxen sodium	-0.7 (-7.3 to 5.9)
Age	Fluoxetine	Nifedipine	8.3 (-1.4 to 18.0)
Age	Fluoxetine	Nimodipine	1.4 (-5.2 to 8.0)
Age	Fluoxetine	Oxcarbazepine	-2.4 (-12.1 to 7.3)
Age	Fluoxetine	Pindolol	2.3 (-7.4 to 12.0)
Age	Fluoxetine	Propranolol	-1.4 (-6.7 to 3.9)
Age	Fluoxetine	Rofecoxib	-1.6 (-11.3 to 8.1)
Age	Fluoxetine	Telmisartan	-1.7 (-11.4 to 8.0)
Age	Fluoxetine	Timolol	-4.9 (-14.6 to 4.8)
Age	Fluoxetine	Tizanidine	-2.2 (-11.9 to 7.5)
Age	Fluoxetine	Tolfenamic Acid	3.1 (-6.6 to 12.8)
Age	Fluoxetine	Tonabersat	2.1 (-7.6 to 11.8)
Age	Fluoxetine	Topiramate	-3.2 (-8.5 to 2.0)
Age	Fluoxetine	Valproate	-1.9 (-9.4 to 5.6)
Age	Fluoxetine	Verapamil	2.1 (-5.4 to 9.6)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Age	Fluoxetine	Vigabatrin	-5.5 (-15.2 to 4.2)
Age	Gabapentin	Indobufen	6.3 (-4.3 to 16.9)
Age	Gabapentin	Indomethacin	1.3 (-9.3 to 11.9)
Age	Gabapentin	Induprofen	5.6 (-5.1 to 16.2)
Age	Gabapentin	Induprofen	5.3 (-5.3 to 15.9)
Age	Gabapentin	Lamotrigine	4.1 (-6.5 to 14.7)
Age	Gabapentin	Lisinopril	0.3 (-10.3 to 10.9)
Age	Gabapentin	Magnesium	-1.1 (-9.8 to 7.6)
Age	Gabapentin	Methysergide	-0.7 (-11.3 to 9.9)
Age	Gabapentin	Metoprolol	3.2 (-4.7 to 11.2)
Age	Gabapentin	Montelukast	1.3 (-9.3 to 11.9)
Age	Gabapentin	Nadolol	5.0 (-5.6 to 15.6)
Age	Gabapentin	Naproxen sodium	2.5 (-5.4 to 10.5)
Age	Gabapentin	Nifedipine	11.5 (0.9 to 22.1)
Age	Gabapentin	Nimodipine	4.6 (-3.3 to 12.6)
Age	Gabapentin	Oxcarbazepine	0.8 (-9.8 to 11.4)
Age	Gabapentin	Pindolol	5.5 (-5.1 to 16.1)
Age	Gabapentin	Propranolol	1.8 (-5.0 to 8.7)
Age	Gabapentin	Rofecoxib	1.6 (-9.0 to 12.2)
Age	Gabapentin	Telmisartan	1.5 (-9.1 to 12.1)
Age	Gabapentin	Timolol	-1.7 (-12.3 to 8.9)
Age	Gabapentin	Tizanidine	1.0 (-9.6 to 11.6)
Age	Gabapentin	Tolfenamic Acid	6.3 (-4.3 to 16.9)
Age	Gabapentin	Tonabersat	5.3 (-5.3 to 15.9)
Age	Gabapentin	Topiramate	0.0 (-6.8 to 6.8)
Age	Gabapentin	Valproate	1.3 (-7.4 to 10.0)
Age	Gabapentin	Verapamil	5.4 (-3.3 to 14.0)
Age	Gabapentin	Vigabatrin	-2.3 (-12.9 to 8.3)
Age	Indobufen	Indomethacin	-5.0 (-17.3 to 7.3)
Age	Indobufen	Induprofen	-0.8 (-13.0 to 11.5)
Age	Indobufen	Induprofen	-1.0 (-13.3 to 11.3)
Age	Indobufen	Lamotrigine	-2.2 (-14.5 to 10.1)
Age	Indobufen	Lisinopril	-6.0 (-18.3 to 6.3)
Age	Indobufen	Magnesium	-7.4 (-18.0 to 3.2)
Age	Indobufen	Methysergide	-7.0 (-19.3 to 5.3)
Age	Indobufen	Metoprolol	-3.1 (-13.1 to 7.0)
Age	Indobufen	Montelukast	-5.0 (-17.3 to 7.3)
Age	Indobufen	Nadolol	-1.3 (-13.6 to 11.0)
Age	Indobufen	Naproxen sodium	-3.8 (-13.8 to 6.3)
Age	Indobufen	Nifedipine	5.2 (-7.1 to 17.5)
Age	Indobufen	Nimodipine	-1.7 (-11.7 to 8.4)
Age	Indobufen	Oxcarbazepine	-5.5 (-17.8 to 6.8)
Age	Indobufen	Pindolol	-0.8 (-13.1 to 11.5)
Age	Indobufen	Propranolol	-4.5 (-13.7 to 4.7)
Age	Indobufen	Rofecoxib	-4.7 (-17.0 to 7.6)
Age	Indobufen	Telmisartan	-4.8 (-17.1 to 7.5)
Age	Indobufen	Timolol	-8.0 (-20.3 to 4.3)
Age	Indobufen	Tizanidine	-5.3 (-17.6 to 7.0)
Age	Indobufen	Tolfenamic Acid	0.0 (-12.3 to 12.3)
Age	Indobufen	Tonabersat	-1.0 (-13.3 to 11.3)
Age	Indobufen	Topiramate	-6.3 (-15.5 to 2.8)
Age	Indobufen	Valproate	-5.0 (-15.6 to 5.6)
Age	Indobufen	Verapamil	-1.0 (-11.6 to 9.7)
Age	Indobufen	Vigabatrin	-8.6 (-20.9 to 3.7)
Age	Indomethacin	Induprofen	4.3 (-8.0 to 16.5)
Age	Indomethacin	Induprofen	4.0 (-8.3 to 16.3)
Age	Indomethacin	Lamotrigine	2.8 (-9.5 to 15.1)
Age	Indomethacin	Lisinopril	-1.0 (-13.3 to 11.3)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Age	Indomethacin	Magnesium	-2.4 (-13.0 to 8.2)
Age	Indomethacin	Methysergide	-2.0 (-14.3 to 10.3)
Age	Indomethacin	Metoprolol	1.9 (-8.1 to 12.0)
Age	Indomethacin	Montelukast	0.0 (-12.3 to 12.3)
Age	Indomethacin	Nadolol	3.7 (-8.6 to 16.0)
Age	Indomethacin	Naproxen sodium	1.2 (-8.8 to 11.3)
Age	Indomethacin	Nifedipine	10.2 (-2.1 to 22.5)
Age	Indomethacin	Nimodipine	3.3 (-6.7 to 13.4)
Age	Indomethacin	Oxcarbazepine	-0.5 (-12.8 to 11.8)
Age	Indomethacin	Pindolol	4.2 (-8.1 to 16.5)
Age	Indomethacin	Propranolol	0.5 (-8.7 to 9.7)
Age	Indomethacin	Rofecoxib	0.3 (-12.0 to 12.6)
Age	Indomethacin	Telmisartan	0.2 (-12.1 to 12.5)
Age	Indomethacin	Timolol	-3.0 (-15.3 to 9.3)
Age	Indomethacin	Tizanidine	-0.3 (-12.6 to 12.0)
Age	Indomethacin	Tolfenamic Acid	5.0 (-7.3 to 17.3)
Age	Indomethacin	Tonabersat	4.0 (-8.3 to 16.3)
Age	Indomethacin	Topiramate	-1.3 (-10.5 to 7.8)
Age	Indomethacin	Valproate	0.0 (-10.6 to 10.6)
Age	Indomethacin	Verapamil	4.1 (-6.6 to 14.7)
Age	Indomethacin	Vigabatrin	-3.6 (-15.9 to 8.7)
Age	Induprofen	Induprofen	-0.3 (-12.5 to 12.0)
Age	Induprofen	Lamotrigine	-1.5 (-13.7 to 10.8)
Age	Induprofen	Lisinopril	-5.3 (-17.5 to 7.0)
Age	Induprofen	Magnesium	-6.7 (-17.3 to 4.0)
Age	Induprofen	Methysergide	-6.3 (-18.5 to 6.0)
Age	Induprofen	Metoprolol	-2.3 (-12.3 to 7.7)
Age	Induprofen	Montelukast	-4.3 (-16.5 to 8.0)
Age	Induprofen	Nadolol	-0.6 (-12.8 to 11.7)
Age	Induprofen	Naproxen sodium	-3.0 (-13.0 to 7.0)
Age	Induprofen	Nifedipine	6.0 (-6.3 to 18.2)
Age	Induprofen	Nimodipine	-0.9 (-10.9 to 9.1)
Age	Induprofen	Oxcarbazepine	-4.8 (-17.0 to 7.5)
Age	Induprofen	Pindolol	-0.1 (-12.3 to 12.2)
Age	Induprofen	Propranolol	-3.7 (-12.9 to 5.5)
Age	Induprofen	Rofecoxib	-4.0 (-16.2 to 8.3)
Age	Induprofen	Telmisartan	-4.1 (-16.3 to 8.2)
Age	Induprofen	Timolol	-7.3 (-19.5 to 5.0)
Age	Induprofen	Tizanidine	-4.6 (-16.8 to 7.7)
Age	Induprofen	Tolfenamic Acid	0.8 (-11.5 to 13.0)
Age	Induprofen	Tonabersat	-0.3 (-12.5 to 12.0)
Age	Induprofen	Topiramate	-5.6 (-14.7 to 3.6)
Age	Induprofen	Valproate	-4.3 (-14.9 to 6.4)
Age	Induprofen	Verapamil	-0.2 (-10.8 to 10.4)
Age	Induprofen	Vigabatrin	-7.9 (-20.1 to 4.4)
Age	Ketoprofen	Lamotrigine	-1.2 (-13.5 to 11.1)
Age	Ketoprofen	Lisinopril	-5.0 (-17.3 to 7.3)
Age	Ketoprofen	Magnesium	-6.4 (-17.0 to 4.2)
Age	Ketoprofen	Methysergide	-6.0 (-18.3 to 6.3)
Age	Ketoprofen	Metoprolol	-2.1 (-12.1 to 8.0)
Age	Ketoprofen	Montelukast	-4.0 (-16.3 to 8.3)
Age	Ketoprofen	Nadolol	-0.3 (-12.6 to 12.0)
Age	Ketoprofen	Naproxen sodium	-2.8 (-12.8 to 7.3)
Age	Ketoprofen	Nifedipine	6.2 (-6.1 to 18.5)
Age	Ketoprofen	Nimodipine	-0.7 (-10.7 to 9.4)
Age	Ketoprofen	Oxcarbazepine	-4.5 (-16.8 to 7.8)
Age	Ketoprofen	Pindolol	0.2 (-12.1 to 12.5)
Age	Ketoprofen	Propranolol	-3.5 (-12.7 to 5.7)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Age	Ketoprofen	Rofecoxib	-3.7 (-16.0 to 8.6)
Age	Ketoprofen	Telmisartan	-3.8 (-16.1 to 8.5)
Age	Ketoprofen	Timolol	-7.0 (-19.3 to 5.3)
Age	Ketoprofen	Tizanidine	-4.3 (-16.6 to 8.0)
Age	Ketoprofen	Tolfenamic Acid	1.0 (-11.3 to 13.3)
Age	Ketoprofen	Tonabersat	0.0 (-12.3 to 12.3)
Age	Ketoprofen	Topiramate	-5.3 (-14.5 to 3.8)
Age	Ketoprofen	Valproate	-4.0 (-14.6 to 6.6)
Age	Ketoprofen	Verapamil	0.1 (-10.6 to 10.7)
Age	Ketoprofen	Vigabatrin	-7.6 (-19.9 to 4.7)
Age	Lamotrigine	Lisinopril	-3.8 (-16.1 to 8.5)
Age	Lamotrigine	Magnesium	-5.2 (-15.8 to 5.4)
Age	Lamotrigine	Methysergide	-4.8 (-17.1 to 7.5)
Age	Lamotrigine	Metoprolol	-0.9 (-10.9 to 9.2)
Age	Lamotrigine	Montelukast	-2.8 (-15.1 to 9.5)
Age	Lamotrigine	Nadolol	0.9 (-11.4 to 13.2)
Age	Lamotrigine	Naproxen sodium	-1.6 (-11.6 to 8.5)
Age	Lamotrigine	Nifedipine	7.4 (-4.9 to 19.7)
Age	Lamotrigine	Nimodipine	0.5 (-9.5 to 10.6)
Age	Lamotrigine	Oxcarbazepine	-3.3 (-15.6 to 9.0)
Age	Lamotrigine	Pindolol	1.4 (-10.9 to 13.7)
Age	Lamotrigine	Propranolol	-2.3 (-11.5 to 6.9)
Age	Lamotrigine	Rofecoxib	-2.5 (-14.8 to 9.8)
Age	Lamotrigine	Telmisartan	-2.6 (-14.9 to 9.7)
Age	Lamotrigine	Timolol	-5.8 (-18.1 to 6.5)
Age	Lamotrigine	Tizanidine	-3.1 (-15.4 to 9.2)
Age	Lamotrigine	Tolfenamic Acid	2.2 (-10.1 to 14.5)
Age	Lamotrigine	Tonabersat	1.2 (-11.1 to 13.5)
Age	Lamotrigine	Topiramate	-4.1 (-13.3 to 5.0)
Age	Lamotrigine	Valproate	-2.8 (-13.4 to 7.8)
Age	Lamotrigine	Verapamil	1.3 (-9.4 to 11.9)
Age	Lamotrigine	Vigabatrin	-6.4 (-18.7 to 5.9)
Age	Lisinopril	Magnesium	-1.4 (-12.0 to 9.2)
Age	Lisinopril	Methysergide	-1.0 (-13.3 to 11.3)
Age	Lisinopril	Metoprolol	2.9 (-7.1 to 13.0)
Age	Lisinopril	Montelukast	1.0 (-11.3 to 13.3)
Age	Lisinopril	Nadolol	4.7 (-7.6 to 17.0)
Age	Lisinopril	Naproxen sodium	2.2 (-7.8 to 12.3)
Age	Lisinopril	Nifedipine	11.2 (-1.1 to 23.5)
Age	Lisinopril	Nimodipine	4.3 (-5.7 to 14.4)
Age	Lisinopril	Oxcarbazepine	0.5 (-11.8 to 12.8)
Age	Lisinopril	Pindolol	5.2 (-7.1 to 17.5)
Age	Lisinopril	Propranolol	1.5 (-7.7 to 10.7)
Age	Lisinopril	Rofecoxib	1.3 (-11.0 to 13.6)
Age	Lisinopril	Telmisartan	1.2 (-11.1 to 13.5)
Age	Lisinopril	Timolol	-2.0 (-14.3 to 10.3)
Age	Lisinopril	Tizanidine	0.7 (-11.6 to 13.0)
Age	Lisinopril	Tolfenamic Acid	6.0 (-6.3 to 18.3)
Age	Lisinopril	Tonabersat	5.0 (-7.3 to 17.3)
Age	Lisinopril	Topiramate	-0.3 (-9.5 to 8.8)
Age	Lisinopril	Valproate	1.0 (-9.6 to 11.6)
Age	Lisinopril	Verapamil	5.1 (-5.6 to 15.7)
Age	Lisinopril	Vigabatrin	-2.6 (-14.9 to 9.7)
Age	Magnesium	Montelukast	2.4 (-8.2 to 13.0)
Age	Magnesium	Nadolol	6.1 (-4.5 to 16.7)
Age	Magnesium	Naproxen sodium	3.6 (-4.3 to 11.6)
Age	Magnesium	Nifedipine	12.6 (2.0 to 23.2)
Age	Magnesium	Nimodipine	5.7 (-2.2 to 13.7)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Age	Magnesium	Oxcarbazepine	1.9 (-8.7 to 12.5)
Age	Magnesium	Pindolol	6.6 (-4.0 to 17.2)
Age	Magnesium	Propranolol	2.9 (-3.9 to 9.8)
Age	Magnesium	Rofecoxib	2.7 (-7.9 to 13.3)
Age	Magnesium	Telmisartan	2.6 (-8.0 to 13.2)
Age	Magnesium	Timolol	-0.6 (-11.2 to 10.0)
Age	Magnesium	Tizanidine	2.1 (-8.5 to 12.7)
Age	Magnesium	Tolfenamic Acid	7.4 (-3.2 to 18.0)
Age	Magnesium	Tonabersat	6.4 (-4.2 to 17.0)
Age	Magnesium	Topiramate	1.1 (-5.7 to 7.9)
Age	Magnesium	Valproate	2.4 (-6.3 to 11.1)
Age	Magnesium	Verapamil	6.5 (-2.2 to 15.1)
Age	Magnesium	Vigabatrin	-1.2 (-11.8 to 9.4)
Age	Methysergide	Magnesium	-0.4 (-11.0 to 10.2)
Age	Methysergide	Metoprolol	3.9 (-6.1 to 14.0)
Age	Methysergide	Montelukast	2.0 (-10.3 to 14.3)
Age	Methysergide	Nadolol	5.7 (-6.6 to 18.0)
Age	Methysergide	Naproxen sodium	3.2 (-6.8 to 13.3)
Age	Methysergide	Nifedipine	12.2 (-0.1 to 24.5)
Age	Methysergide	Nimodipine	5.3 (-4.7 to 15.4)
Age	Methysergide	Oxcarbazepine	1.5 (-10.8 to 13.8)
Age	Methysergide	Pindolol	6.2 (-6.1 to 18.5)
Age	Methysergide	Propranolol	2.5 (-6.7 to 11.7)
Age	Methysergide	Rofecoxib	2.3 (-10.0 to 14.6)
Age	Methysergide	Telmisartan	2.2 (-10.1 to 14.5)
Age	Methysergide	Timolol	-1.0 (-13.3 to 11.3)
Age	Methysergide	Tizanidine	1.7 (-10.6 to 14.0)
Age	Methysergide	Tolfenamic Acid	7.0 (-5.3 to 19.3)
Age	Methysergide	Tonabersat	6.0 (-6.3 to 18.3)
Age	Methysergide	Topiramate	0.7 (-8.5 to 9.8)
Age	Methysergide	Valproate	2.0 (-8.6 to 12.6)
Age	Methysergide	Verapamil	6.1 (-4.6 to 16.7)
Age	Methysergide	Vigabatrin	-1.6 (-13.9 to 10.7)
Age	Metoprolol	Magnesium	-4.3 (-12.3 to 3.6)
Age	Metoprolol	Montelukast	-1.9 (-12.0 to 8.1)
Age	Metoprolol	Nadolol	1.8 (-8.3 to 11.8)
Age	Metoprolol	Naproxen sodium	-0.7 (-7.8 to 6.4)
Age	Metoprolol	Nifedipine	8.3 (-1.8 to 18.3)
Age	Metoprolol	Nimodipine	1.4 (-5.7 to 8.5)
Age	Metoprolol	Oxcarbazepine	-2.4 (-12.5 to 7.6)
Age	Metoprolol	Pindolol	2.3 (-7.8 to 12.3)
Age	Metoprolol	Propranolol	-1.4 (-7.3 to 4.5)
Age	Metoprolol	Rofecoxib	-1.6 (-11.7 to 8.4)
Age	Metoprolol	Telmisartan	-1.7 (-11.8 to 8.3)
Age	Metoprolol	Timolol	-4.9 (-15.0 to 5.1)
Age	Metoprolol	Tizanidine	-2.2 (-12.3 to 7.8)
Age	Metoprolol	Tolfenamic Acid	3.1 (-7.0 to 13.1)
Age	Metoprolol	Tonabersat	2.1 (-8.0 to 12.1)
Age	Metoprolol	Topiramate	-3.3 (-9.0 to 2.5)
Age	Metoprolol	Valproate	-1.9 (-9.9 to 6.0)
Age	Metoprolol	Verapamil	2.1 (-5.8 to 10.0)
Age	Metoprolol	Vigabatrin	-5.5 (-15.6 to 4.5)
Age	Montelukast	Nadolol	3.7 (-8.6 to 16.0)
Age	Montelukast	Naproxen sodium	1.2 (-8.8 to 11.3)
Age	Montelukast	Nifedipine	10.2 (-2.1 to 22.5)
Age	Montelukast	Nimodipine	3.3 (-6.7 to 13.4)
Age	Montelukast	Oxcarbazepine	-0.5 (-12.8 to 11.8)
Age	Montelukast	Pindolol	4.2 (-8.1 to 16.5)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Age	Montelukast	Propranolol	0.5 (-8.7 to 9.7)
Age	Montelukast	Rofecoxib	0.3 (-12.0 to 12.6)
Age	Montelukast	Telmisartan	0.2 (-12.1 to 12.5)
Age	Montelukast	Timolol	-3.0 (-15.3 to 9.3)
Age	Montelukast	Tizanidine	-0.3 (-12.6 to 12.0)
Age	Montelukast	Tolfenamic Acid	5.0 (-7.3 to 17.3)
Age	Montelukast	Tonabersat	4.0 (-8.3 to 16.3)
Age	Montelukast	Topiramate	-1.3 (-10.5 to 7.8)
Age	Montelukast	Valproate	0.0 (-10.6 to 10.6)
Age	Montelukast	Verapamil	4.1 (-6.6 to 14.7)
Age	Montelukast	Vigabatrin	-3.6 (-15.9 to 8.7)
Age	Nadolol	Naproxen sodium	-2.5 (-12.5 to 7.6)
Age	Nadolol	Nifedipine	6.5 (-5.8 to 18.8)
Age	Nadolol	Nimodipine	-0.4 (-10.4 to 9.7)
Age	Nadolol	Oxcarbazepine	-4.2 (-16.5 to 8.1)
Age	Nadolol	Pindolol	0.5 (-11.8 to 12.8)
Age	Nadolol	Propranolol	-3.2 (-12.4 to 6.0)
Age	Nadolol	Rofecoxib	-3.4 (-15.7 to 8.9)
Age	Nadolol	Telmisartan	-3.5 (-15.8 to 8.8)
Age	Nadolol	Timolol	-6.7 (-19.0 to 5.6)
Age	Nadolol	Tizanidine	-4.0 (-16.3 to 8.3)
Age	Nadolol	Tolfenamic Acid	1.3 (-11.0 to 13.6)
Age	Nadolol	Tonabersat	0.3 (-12.0 to 12.6)
Age	Nadolol	Topiramate	-5.0 (-14.2 to 4.1)
Age	Nadolol	Valproate	-3.7 (-14.3 to 6.9)
Age	Nadolol	Verapamil	0.4 (-10.3 to 11.0)
Age	Nadolol	Vigabatrin	-7.3 (-19.6 to 5.0)
Age	Naproxen sodium	Nifedipine	9.0 (-1.1 to 19.0)
Age	Naproxen sodium	Nimodipine	2.1 (-5.0 to 9.2)
Age	Naproxen sodium	Oxcarbazepine	-1.7 (-11.8 to 8.3)
Age	Naproxen sodium	Pindolol	3.0 (-7.1 to 13.0)
Age	Naproxen sodium	Propranolol	-0.7 (-6.6 to 5.2)
Age	Naproxen sodium	Rofecoxib	-0.9 (-11.0 to 9.1)
Age	Naproxen sodium	Telmisartan	-1.0 (-11.1 to 9.0)
Age	Naproxen sodium	Timolol	-4.2 (-14.3 to 5.8)
Age	Naproxen sodium	Tizanidine	-1.5 (-11.6 to 8.5)
Age	Naproxen sodium	Tolfenamic Acid	3.8 (-6.3 to 13.8)
Age	Naproxen sodium	Tonabersat	2.8 (-7.3 to 12.8)
Age	Naproxen sodium	Topiramate	-2.6 (-8.3 to 3.2)
Age	Naproxen sodium	Valproate	-1.2 (-9.2 to 6.7)
Age	Naproxen sodium	Verapamil	2.8 (-5.1 to 10.7)
Age	Naproxen sodium	Vigabatrin	-4.8 (-14.9 to 5.2)
Age	Nifedipine	Nimodipine	-6.9 (-16.9 to 3.2)
Age	Nifedipine	Oxcarbazepine	-10.7 (-23.0 to 1.6)
Age	Nifedipine	Pindolol	-6.0 (-18.3 to 6.3)
Age	Nifedipine	Propranolol	-9.7 (-18.9 to -0.5)
Age	Nifedipine	Rofecoxib	-9.9 (-22.2 to 2.4)
Age	Nifedipine	Telmisartan	-10.0 (-22.3 to 2.3)
Age	Nifedipine	Timolol	-13.2 (-25.5 to -0.9)
Age	Nifedipine	Tizanidine	-10.5 (-22.8 to 1.8)
Age	Nifedipine	Tolfenamic Acid	-5.2 (-17.5 to 7.1)
Age	Nifedipine	Tonabersat	-6.2 (-18.5 to 6.1)
Age	Nifedipine	Topiramate	-11.5 (-20.7 to -2.4)
Age	Nifedipine	Valproate	-10.2 (-20.8 to 0.4)
Age	Nifedipine	Verapamil	-6.2 (-16.8 to 4.5)
Age	Nifedipine	Vigabatrin	-13.8 (-26.1 to -1.5)
Age	Nimodipine	Oxcarbazepine	-3.8 (-13.9 to 6.2)
Age	Nimodipine	Pindolol	0.9 (-9.2 to 10.9)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Age	Nimodipine	Propranolol	-2.8 (-8.7 to 3.1)
Age	Nimodipine	Rofecoxib	-3.0 (-13.1 to 7.0)
Age	Nimodipine	Telmisartan	-3.1 (-13.2 to 6.9)
Age	Nimodipine	Timolol	-6.3 (-16.4 to 3.7)
Age	Nimodipine	Tizanidine	-3.6 (-13.7 to 6.4)
Age	Nimodipine	Tolfenamic Acid	1.7 (-8.4 to 11.7)
Age	Nimodipine	Tonabersat	0.7 (-9.4 to 10.7)
Age	Nimodipine	Topiramate	-4.7 (-10.4 to 1.1)
Age	Nimodipine	Valproate	-3.3 (-11.3 to 4.6)
Age	Nimodipine	Verapamil	0.7 (-7.2 to 8.6)
Age	Nimodipine	Vigabatrin	-6.9 (-17.0 to 3.1)
Age	Oxcarbazepine	Pindolol	4.7 (-7.6 to 17.0)
Age	Oxcarbazepine	Propranolol	1.0 (-8.2 to 10.2)
Age	Oxcarbazepine	Rofecoxib	0.8 (-11.5 to 13.1)
Age	Oxcarbazepine	Telmisartan	0.7 (-11.6 to 13.0)
Age	Oxcarbazepine	Timolol	-2.5 (-14.8 to 9.8)
Age	Oxcarbazepine	Tizanidine	0.2 (-12.1 to 12.5)
Age	Oxcarbazepine	Tolfenamic Acid	5.5 (-6.8 to 17.8)
Age	Oxcarbazepine	Tonabersat	4.5 (-7.8 to 16.8)
Age	Oxcarbazepine	Topiramate	-0.8 (-10.0 to 8.3)
Age	Oxcarbazepine	Valproate	0.5 (-10.1 to 11.1)
Age	Oxcarbazepine	Verapamil	4.6 (-6.1 to 15.2)
Age	Oxcarbazepine	Vigabatrin	-3.1 (-15.4 to 9.2)
Age	Pindolol	Propranolol	-3.7 (-12.9 to 5.5)
Age	Pindolol	Rofecoxib	-3.9 (-16.2 to 8.4)
Age	Pindolol	Telmisartan	-4.0 (-16.3 to 8.3)
Age	Pindolol	Timolol	-7.2 (-19.5 to 5.1)
Age	Pindolol	Tizanidine	-4.5 (-16.8 to 7.8)
Age	Pindolol	Tolfenamic Acid	0.8 (-11.5 to 13.1)
Age	Pindolol	Tonabersat	-0.2 (-12.5 to 12.1)
Age	Pindolol	Topiramate	-5.5 (-14.7 to 3.6)
Age	Pindolol	Valproate	-4.2 (-14.8 to 6.4)
Age	Pindolol	Verapamil	-0.2 (-10.8 to 10.5)
Age	Pindolol	Vigabatrin	-7.8 (-20.1 to 4.5)
Age	Propranolol	Rofecoxib	-0.2 (-9.4 to 9.0)
Age	Propranolol	Telmisartan	-0.3 (-9.5 to 8.9)
Age	Propranolol	Timolol	-3.5 (-12.7 to 5.7)
Age	Propranolol	Tizanidine	-0.8 (-10.0 to 8.4)
Age	Propranolol	Tolfenamic Acid	4.5 (-4.7 to 13.7)
Age	Propranolol	Tonabersat	3.5 (-5.7 to 12.7)
Age	Propranolol	Topiramate	-1.8 (-6.1 to 2.4)
Age	Propranolol	Valproate	-0.5 (-7.4 to 6.3)
Age	Propranolol	Verapamil	3.5 (-3.3 to 10.4)
Age	Propranolol	Vigabatrin	-4.1 (-13.3 to 5.1)
Age	Rofecoxib	Telmisartan	-0.1 (-12.4 to 12.2)
Age	Rofecoxib	Timolol	-3.3 (-15.6 to 9.0)
Age	Rofecoxib	Tizanidine	-0.6 (-12.9 to 11.7)
Age	Rofecoxib	Tolfenamic Acid	4.7 (-7.6 to 17.0)
Age	Rofecoxib	Tonabersat	3.7 (-8.6 to 16.0)
Age	Rofecoxib	Topiramate	-1.6 (-10.8 to 7.5)
Age	Rofecoxib	Valproate	-0.3 (-10.9 to 10.3)
Age	Rofecoxib	Verapamil	3.8 (-6.9 to 14.4)
Age	Rofecoxib	Vigabatrin	-3.9 (-16.2 to 8.4)
Age	Telmisartan	Timolol	-3.2 (-15.5 to 9.1)
Age	Telmisartan	Tizanidine	-0.5 (-12.8 to 11.8)
Age	Telmisartan	Tolfenamic Acid	4.8 (-7.5 to 17.1)
Age	Telmisartan	Tonabersat	3.8 (-8.5 to 16.1)
Age	Telmisartan	Topiramate	-1.5 (-10.7 to 7.6)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Age	Telmisartan	Valproate	-0.2 (-10.8 to 10.4)
Age	Telmisartan	Verapamil	3.9 (-6.8 to 14.5)
Age	Telmisartan	Vigabatrin	-3.8 (-16.1 to 8.5)
Age	Timolol	Tizanidine	2.7 (-9.6 to 15.0)
Age	Timolol	Tolfenamic Acid	8.0 (-4.3 to 20.3)
Age	Timolol	Tonabersat	7.0 (-5.3 to 19.3)
Age	Timolol	Topiramate	1.7 (-7.5 to 10.8)
Age	Timolol	Valproate	3.0 (-7.6 to 13.6)
Age	Timolol	Verapamil	7.1 (-3.6 to 17.7)
Age	Timolol	Vigabatrin	-0.6 (-12.9 to 11.7)
Age	Tizanidine	Tolfenamic Acid	5.3 (-7.0 to 17.6)
Age	Tizanidine	Tonabersat	4.3 (-8.0 to 16.6)
Age	Tizanidine	Topiramate	-1.0 (-10.2 to 8.1)
Age	Tizanidine	Valproate	0.3 (-10.3 to 10.9)
Age	Tizanidine	Verapamil	4.4 (-6.3 to 15.0)
Age	Tizanidine	Vigabatrin	-3.3 (-15.6 to 9.0)
Age	Tolfenamic Acid	Tonabersat	-1.0 (-13.3 to 11.3)
Age	Tolfenamic Acid	Topiramate	-6.3 (-15.5 to 2.8)
Age	Tolfenamic Acid	Valproate	-5.0 (-15.6 to 5.6)
Age	Tolfenamic Acid	Verapamil	-1.0 (-11.6 to 9.7)
Age	Tolfenamic Acid	Vigabatrin	-8.6 (-20.9 to 3.7)
Age	Tonabersat	Topiramate	-5.3 (-14.5 to 3.8)
Age	Tonabersat	Valproate	-4.0 (-14.6 to 6.6)
Age	Tonabersat	Verapamil	0.1 (-10.6 to 10.7)
Age	Tonabersat	Vigabatrin	-7.6 (-19.9 to 4.7)
Age	Topiramate	Valproate	1.3 (-5.5 to 8.1)
Age	Topiramate	Verapamil	5.4 (-1.4 to 12.2)
Age	Topiramate	Vigabatrin	-2.3 (-11.4 to 6.9)
Age	Valproate	Verapamil	4.1 (-4.6 to 12.7)
Age	Valproate	Vigabatrin	-3.6 (-14.2 to 7.0)
Age	Verapamil	Vigabatrin	-7.7 (-18.3 to 3.0)
% females	Acebutolol	Acetazolamide	-1.1 (-45.6 to 43.4)
% females	Acebutolol	Alprenolol	-7.4 (-51.9 to 37.1)
% females	Acebutolol	Amitriptyline	-8.9 (-45.2 to 27.4)
% females	Acebutolol	Aspirin	12.9 (-25.4 to 51.2)
% females	Acebutolol	Atenolol	-0.5 (-39.0 to 38.0)
% females	Acebutolol	Candesartan	-4.6 (-49.1 to 39.9)
% females	Acebutolol	Captopril	16.4 (-28.1 to 60.9)
% females	Acebutolol	Carbamazepine	5.6 (-38.9 to 50.1)
% females	Acebutolol	Clonidine	-3.1 (-35.8 to 29.6)
% females	Acebutolol	Dihydroergocryptine	2.8 (-41.7 to 47.3)
% females	Acebutolol	Dihydroergotamine	4.2 (-32.1 to 40.5)
% females	Acebutolol	Divalproex	-3.9 (-42.4 to 34.6)
% females	Acebutolol	Femoxetine	-7.8 (-44.1 to 28.5)
% females	Acebutolol	Fluoxetine	-3.0 (-38.2 to 32.1)
% females	Acebutolol	Gabapentin	-0.3 (-36.6 to 36.0)
% females	Acebutolol	Guanfacine	-9.6 (-54.1 to 34.9)
% females	Acebutolol	Indobufen	6.4 (-38.1 to 50.9)
% females	Acebutolol	Indomethacin	-1.6 (-46.1 to 42.9)
% females	Acebutolol	Induprofen	14.4 (-30.1 to 58.9)
% females	Acebutolol	Ketoprofen	-13.6 (-58.1 to 30.9)
% females	Acebutolol	Lamotrigine	-7.4 (-51.9 to 37.1)
% females	Acebutolol	Lisinopril	-6.6 (-51.1 to 37.9)
% females	Acebutolol	Methysergide	-5.6 (-50.1 to 38.9)
% females	Acebutolol	Metoprolol	-8.7 (-45.0 to 27.6)
% females	Acebutolol	Magnesium	-15.1 (-53.6 to 23.4)
% females	Acebutolol	Montelukast	-13.6 (-58.1 to 30.9)
% females	Acebutolol	Nadolol	-6.9 (-51.4 to 37.6)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Acebutolol	Naproxen sodium	-4.9 (-41.2 to 31.4)
% females	Acebutolol	Nicardipine	1.4 (-43.1 to 45.9)
% females	Acebutolol	Nifedipine	-4.6 (-49.1 to 39.9)
% females	Acebutolol	Nimodipine	4.1 (-32.2 to 40.4)
% females	Acebutolol	Oxcarbazepine	-10.3 (-54.8 to 34.2)
% females	Acebutolol	Pindolol	-11.3 (-55.8 to 33.2)
% females	Acebutolol	Propranolol	-3.7 (-36.7 to 29.3)
% females	Acebutolol	Rofecoxib	-10.1 (-54.6 to 34.4)
% females	Acebutolol	Telmisartan	-10.1 (-54.6 to 34.4)
% females	Acebutolol	Timolol	2.7 (-35.8 to 41.2)
% females	Acebutolol	Tizanidine	-4.6 (-49.1 to 39.9)
% females	Acebutolol	Tolfenamic Acid	-12.6 (-57.1 to 31.9)
% females	Acebutolol	Tonabersat	-17.9 (-62.4 to 26.6)
% females	Acebutolol	Topiramate	4.4 (-28.8 to 37.5)
% females	Acebutolol	Valproate	-8.3 (-46.8 to 30.3)
% females	Acebutolol	Verapamil	-6.1 (-44.6 to 32.4)
% females	Acebutolol	Vigabatrin	0.5 (-44.0 to 45.0)
% females	Acetazolamide	Alprenolol	-6.3 (-50.8 to 38.2)
% females	Acetazolamide	Amitriptyline	-7.8 (-44.1 to 28.5)
% females	Acetazolamide	Aspirin	14.0 (-24.3 to 52.3)
% females	Acetazolamide	Atenolol	0.6 (-37.9 to 39.1)
% females	Acetazolamide	Candesartan	-3.5 (-48.0 to 41.0)
% females	Acetazolamide	Captopril	17.5 (-27.0 to 62.0)
% females	Acetazolamide	Carbamazepine	6.7 (-37.8 to 51.2)
% females	Acetazolamide	Clonidine	-2.0 (-34.7 to 30.7)
% females	Acetazolamide	Dihydroergocryptine	3.9 (-40.6 to 48.4)
% females	Acetazolamide	Dihydroergotamine	5.3 (-31.0 to 41.6)
% females	Acetazolamide	Divalproex	-2.8 (-41.3 to 35.7)
% females	Acetazolamide	Femoxetine	-6.7 (-43.0 to 29.6)
% females	Acetazolamide	Fluoxetine	-1.9 (-37.1 to 33.2)
% females	Acetazolamide	Gabapentin	0.8 (-35.5 to 37.1)
% females	Acetazolamide	Guanfacine	-8.5 (-53.0 to 36.0)
% females	Acetazolamide	Indobufen	7.5 (-37.0 to 52.0)
% females	Acetazolamide	Indomethacin	-0.5 (-45.0 to 44.0)
% females	Acetazolamide	Induprofen	15.5 (-29.0 to 60.0)
% females	Acetazolamide	Ketoprofen	-12.5 (-57.0 to 32.0)
% females	Acetazolamide	Lamotrigine	-6.3 (-50.8 to 38.2)
% females	Acetazolamide	Lisinopril	-5.5 (-50.0 to 39.0)
% females	Acetazolamide	Methysergide	-4.5 (-49.0 to 40.0)
% females	Acetazolamide	Metoprolol	-7.6 (-43.9 to 28.7)
% females	Acetazolamide	Magnesium	-14.0 (-52.5 to 24.5)
% females	Acetazolamide	Montelukast	-12.5 (-57.0 to 32.0)
% females	Acetazolamide	Nadolol	-5.8 (-50.3 to 38.7)
% females	Acetazolamide	Naproxen sodium	-3.8 (-40.1 to 32.5)
% females	Acetazolamide	Nicardipine	2.5 (-42.0 to 47.0)
% females	Acetazolamide	Nifedipine	-3.5 (-48.0 to 41.0)
% females	Acetazolamide	Nimodipine	5.2 (-31.1 to 41.5)
% females	Acetazolamide	Oxcarbazepine	-9.2 (-53.7 to 35.3)
% females	Acetazolamide	Pindolol	-10.2 (-54.7 to 34.3)
% females	Acetazolamide	Propranolol	-2.6 (-35.6 to 30.4)
% females	Acetazolamide	Rofecoxib	-9.0 (-53.5 to 35.5)
% females	Acetazolamide	Telmisartan	-9.0 (-53.5 to 35.5)
% females	Acetazolamide	Timolol	3.8 (-34.7 to 42.3)
% females	Acetazolamide	Tizanidine	-3.5 (-48.0 to 41.0)
% females	Acetazolamide	Tolfenamic Acid	-11.5 (-56.0 to 33.0)
% females	Acetazolamide	Tonabersat	-16.8 (-61.3 to 27.7)
% females	Acetazolamide	Topiramate	5.5 (-27.7 to 38.6)
% females	Acetazolamide	Valproate	-7.2 (-45.7 to 31.4)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Acetazolamide	Verapamil	-5.0 (-43.5 to 33.5)
% females	Acetazolamide	Vigabatrin	1.6 (-42.9 to 46.1)
% females	Alprenolol	Amitriptyline	-1.5 (-37.8 to 34.8)
% females	Alprenolol	Aspirin	20.3 (-18.0 to 58.6)
% females	Alprenolol	Atenolol	6.9 (-31.6 to 45.4)
% females	Alprenolol	Candesartan	2.8 (-41.7 to 47.3)
% females	Alprenolol	Captopril	23.8 (-20.7 to 68.3)
% females	Alprenolol	Carbamazepine	13.0 (-31.5 to 57.5)
% females	Alprenolol	Clonidine	4.3 (-28.4 to 37.0)
% females	Alprenolol	Dihydroergocryptine	10.2 (-34.3 to 54.7)
% females	Alprenolol	Dihydroergotamine	11.6 (-24.7 to 47.9)
% females	Alprenolol	Divalproex	3.5 (-35.0 to 42.0)
% females	Alprenolol	Femoxetine	-0.4 (-36.7 to 35.9)
% females	Alprenolol	Fluoxetine	4.4 (-30.8 to 39.5)
% females	Alprenolol	Gabapentin	7.1 (-29.2 to 43.4)
% females	Alprenolol	Guanfacine	-2.2 (-46.7 to 42.3)
% females	Alprenolol	Indobufen	13.8 (-30.7 to 58.3)
% females	Alprenolol	Indomethacin	5.8 (-38.7 to 50.3)
% females	Alprenolol	Induprofen	21.8 (-22.7 to 66.3)
% females	Alprenolol	Ketoprofen	-6.2 (-50.7 to 38.3)
% females	Alprenolol	Lamotrigine	0.0 (-44.5 to 44.5)
% females	Alprenolol	Lisinopril	0.8 (-43.7 to 45.3)
% females	Alprenolol	Methysergide	1.8 (-42.7 to 46.3)
% females	Alprenolol	Metoprolol	-1.3 (-37.6 to 35.0)
% females	Alprenolol	Magnesium	-7.7 (-46.2 to 30.8)
% females	Alprenolol	Montelukast	-6.2 (-50.7 to 38.3)
% females	Alprenolol	Nadolol	0.5 (-44.0 to 45.0)
% females	Alprenolol	Naproxen sodium	2.5 (-33.8 to 38.8)
% females	Alprenolol	Nicardipine	8.8 (-35.7 to 53.3)
% females	Alprenolol	Nifedipine	2.8 (-41.7 to 47.3)
% females	Alprenolol	Nimodipine	11.5 (-24.8 to 47.8)
% females	Alprenolol	Oxcarbazepine	-2.9 (-47.4 to 41.6)
% females	Alprenolol	Pindolol	-3.9 (-48.4 to 40.6)
% females	Alprenolol	Propranolol	3.7 (-29.3 to 36.7)
% females	Alprenolol	Rofecoxib	-2.7 (-47.2 to 41.8)
% females	Alprenolol	Telmisartan	-2.7 (-47.2 to 41.8)
% females	Alprenolol	Timolol	10.1 (-28.4 to 48.6)
% females	Alprenolol	Tizanidine	2.8 (-41.7 to 47.3)
% females	Alprenolol	Tolfenamic Acid	-5.2 (-49.7 to 39.3)
% females	Alprenolol	Tonabersat	-10.5 (-55.0 to 34.0)
% females	Alprenolol	Topiramate	11.8 (-21.4 to 44.9)
% females	Alprenolol	Valproate	-0.9 (-39.4 to 37.7)
% females	Alprenolol	Verapamil	1.3 (-37.2 to 39.8)
% females	Alprenolol	Vigabatrin	7.9 (-36.6 to 52.4)
% females	Amitriptyline	Aspirin	21.8 (-4.3 to 47.9)
% females	Amitriptyline	Atenolol	8.4 (-20.3 to 37.1)
% females	Amitriptyline	Candesartan	4.3 (-32.0 to 40.6)
% females	Amitriptyline	Captopril	25.3 (-11.0 to 61.6)
% females	Amitriptyline	Carbamazepine	14.5 (-21.8 to 50.8)
% females	Amitriptyline	Clonidine	5.8 (-14.5 to 26.1)
% females	Amitriptyline	Dihydroergocryptine	11.7 (-24.6 to 48.0)
% females	Amitriptyline	Dihydroergotamine	13.1 (-12.6 to 38.7)
% females	Amitriptyline	Divalproex	5.0 (-23.7 to 33.7)
% females	Amitriptyline	Femoxetine	1.1 (-24.6 to 26.8)
% females	Amitriptyline	Fluoxetine	5.9 (-18.1 to 29.9)
% females	Amitriptyline	Gabapentin	8.6 (-17.1 to 34.3)
% females	Amitriptyline	Guanfacine	-0.7 (-37.0 to 35.6)
% females	Amitriptyline	Indobufen	15.3 (-21.0 to 51.6)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Amitriptyline	Indomethacin	7.3 (-29.0 to 43.6)
% females	Amitriptyline	Induprofen	23.3 (-13.0 to 59.6)
% females	Amitriptyline	Ketoprofen	-4.7 (-41.0 to 31.6)
% females	Amitriptyline	Lamotrigine	1.5 (-34.8 to 37.8)
% females	Amitriptyline	Lisinopril	2.3 (-34.0 to 38.6)
% females	Amitriptyline	Methysergide	3.3 (-33.0 to 39.6)
% females	Amitriptyline	Metoprolol	0.2 (-25.4 to 25.9)
% females	Amitriptyline	Magnesium	-6.2 (-34.9 to 22.5)
% females	Amitriptyline	Montelukast	-4.7 (-41.0 to 31.6)
% females	Amitriptyline	Nadolol	2.0 (-34.3 to 38.3)
% females	Amitriptyline	Naproxen sodium	4.0 (-21.7 to 29.6)
% females	Amitriptyline	Nicardipine	10.3 (-26.0 to 46.6)
% females	Amitriptyline	Nifedipine	4.3 (-32.0 to 40.6)
% females	Amitriptyline	Nimodipine	13.0 (-12.7 to 38.6)
% females	Amitriptyline	Oxcarbazepine	-1.4 (-37.7 to 34.9)
% females	Amitriptyline	Pindolol	-2.4 (-38.7 to 33.9)
% females	Amitriptyline	Propranolol	5.2 (-15.5 to 25.9)
% females	Amitriptyline	Rofecoxib	-1.2 (-37.5 to 35.1)
% females	Amitriptyline	Telmisartan	-1.2 (-37.5 to 35.1)
% females	Amitriptyline	Timolol	11.6 (-17.1 to 40.3)
% females	Amitriptyline	Tizanidine	4.3 (-32.0 to 40.6)
% females	Amitriptyline	Tolfenamic Acid	-3.7 (-40.0 to 32.6)
% females	Amitriptyline	Tonabersat	-9.0 (-45.3 to 27.3)
% females	Amitriptyline	Topiramate	13.3 (-7.7 to 34.3)
% females	Amitriptyline	Valproate	0.7 (-28.1 to 29.4)
% females	Amitriptyline	Verapamil	2.8 (-25.9 to 31.5)
% females	Amitriptyline	Vigabatrin	9.4 (-26.9 to 45.7)
% females	Aspirin	Atenolol	-13.4 (-43.0 to 16.2)
% females	Aspirin	Candesartan	-17.5 (-55.8 to 20.8)
% females	Aspirin	Captopril	3.5 (-34.8 to 41.8)
% females	Aspirin	Carbamazepine	-7.3 (-45.6 to 31.0)
% females	Aspirin	Clonidine	-16.0 (-35.8 to 3.8)
% females	Aspirin	Dihydroergocryptine	-10.1 (-48.4 to 28.2)
% females	Aspirin	Dihydroergotamine	-8.7 (-34.9 to 17.4)
% females	Aspirin	Divalproex	-16.8 (-46.4 to 12.8)
% females	Aspirin	Femoxetine	-20.7 (-46.8 to 5.4)
% females	Aspirin	Fluoxetine	-15.9 (-40.1 to 8.3)
% females	Aspirin	Gabapentin	-13.2 (-39.3 to 12.9)
% females	Aspirin	Guanfacine	-22.5 (-60.8 to 15.8)
% females	Aspirin	Indobufen	-6.5 (-44.8 to 31.8)
% females	Aspirin	Indomethacin	-14.5 (-52.8 to 23.8)
% females	Aspirin	Induprofen	1.5 (-36.8 to 39.8)
% females	Aspirin	Ketoprofen	-26.5 (-64.8 to 11.8)
% females	Aspirin	Lamotrigine	-20.3 (-58.6 to 18.0)
% females	Aspirin	Lisinopril	-19.5 (-57.8 to 18.8)
% females	Aspirin	Methysergide	-18.5 (-56.8 to 19.8)
% females	Aspirin	Metoprolol	-21.6 (-47.7 to 4.6)
% females	Aspirin	Magnesium	-28.0 (-57.6 to 1.6)
% females	Aspirin	Montelukast	-26.5 (-64.8 to 11.8)
% females	Aspirin	Nadolol	-19.8 (-58.1 to 18.5)
% females	Aspirin	Naproxen sodium	-17.8 (-44.0 to 8.3)
% females	Aspirin	Nicardipine	-11.5 (-49.8 to 26.8)
% females	Aspirin	Nifedipine	-17.5 (-55.8 to 20.8)
% females	Aspirin	Nimodipine	-8.8 (-35.0 to 17.3)
% females	Aspirin	Oxcarbazepine	-23.2 (-61.5 to 15.1)
% females	Aspirin	Pindolol	-24.2 (-62.5 to 14.1)
% females	Aspirin	Propranolol	-16.6 (-36.9 to 3.6)
% females	Aspirin	Rofecoxib	-23.0 (-61.3 to 15.3)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Aspirin	Telmisartan	-23.0 (-61.3 to 15.3)
% females	Aspirin	Timolol	-10.2 (-39.8 to 19.4)
% females	Aspirin	Tizanidine	-17.5 (-55.8 to 20.8)
% females	Aspirin	Tolfenamic Acid	-25.5 (-63.8 to 12.8)
% females	Aspirin	Tonabersat	-30.8 (-69.1 to 7.5)
% females	Aspirin	Topiramate	-8.5 (-29.1 to 12.0)
% females	Aspirin	Valproate	-21.2 (-50.8 to 8.5)
% females	Aspirin	Verapamil	-19.0 (-48.6 to 10.6)
% females	Aspirin	Vigabatrin	-12.4 (-50.7 to 25.9)
% females	Atenolol	Candesartan	-4.1 (-42.6 to 34.4)
% females	Atenolol	Captopril	16.9 (-21.6 to 55.4)
% females	Atenolol	Carbamazepine	6.1 (-32.4 to 44.6)
% females	Atenolol	Clonidine	-2.6 (-26.6 to 21.4)
% females	Atenolol	Dihydroergocryptine	3.3 (-35.2 to 41.8)
% females	Atenolol	Dihydroergotamine	4.7 (-24.0 to 33.4)
% females	Atenolol	Divalproex	-3.4 (-34.8 to 28.0)
% females	Atenolol	Femoxetine	-7.3 (-36.0 to 21.4)
% females	Atenolol	Fluoxetine	-2.5 (-29.8 to 24.7)
% females	Atenolol	Gabapentin	0.2 (-28.5 to 28.9)
% females	Atenolol	Guanfacine	-9.1 (-47.6 to 29.4)
% females	Atenolol	Indobufen	6.9 (-31.6 to 45.4)
% females	Atenolol	Indomethacin	-1.1 (-39.6 to 37.4)
% females	Atenolol	Induprofen	14.9 (-23.6 to 53.4)
% females	Atenolol	Ketoprofen	-13.1 (-51.6 to 25.4)
% females	Atenolol	Lamotrigine	-6.9 (-45.4 to 31.6)
% females	Atenolol	Lisinopril	-6.1 (-44.6 to 32.4)
% females	Atenolol	Methysergide	-5.1 (-43.6 to 33.4)
% females	Atenolol	Metoprolol	-8.2 (-36.9 to 20.5)
% females	Atenolol	Magnesium	-14.6 (-46.0 to 16.8)
% females	Atenolol	Montelukast	-13.1 (-51.6 to 25.4)
% females	Atenolol	Nadolol	-6.4 (-44.9 to 32.1)
% females	Atenolol	Naproxen sodium	-4.4 (-33.1 to 24.3)
% females	Atenolol	Nicardipine	1.9 (-36.6 to 40.4)
% females	Atenolol	Nifedipine	-4.1 (-42.6 to 34.4)
% females	Atenolol	Nimodipine	4.6 (-24.1 to 33.3)
% females	Atenolol	Oxcarbazepine	-9.8 (-48.3 to 28.7)
% females	Atenolol	Pindolol	-10.8 (-49.3 to 27.7)
% females	Atenolol	Propranolol	-3.2 (-27.6 to 21.2)
% females	Atenolol	Rofecoxib	-9.6 (-48.1 to 28.9)
% females	Atenolol	Telmisartan	-9.6 (-48.1 to 28.9)
% females	Atenolol	Timolol	3.2 (-28.2 to 34.6)
% females	Atenolol	Tizanidine	-4.1 (-42.6 to 34.4)
% females	Atenolol	Tolfenamic Acid	-12.1 (-50.6 to 26.4)
% females	Atenolol	Tonabersat	-17.4 (-55.9 to 21.1)
% females	Atenolol	Topiramate	4.9 (-19.7 to 29.5)
% females	Atenolol	Valproate	-7.8 (-39.2 to 23.7)
% females	Atenolol	Verapamil	-5.6 (-37.0 to 25.8)
% females	Atenolol	Vigabatrin	1.0 (-37.5 to 39.5)
% females	Candesartan	Captopril	21.0 (-23.5 to 65.5)
% females	Candesartan	Carbamazepine	10.2 (-34.3 to 54.7)
% females	Candesartan	Clonidine	1.5 (-31.2 to 34.2)
% females	Candesartan	Dihydroergocryptine	7.4 (-37.1 to 51.9)
% females	Candesartan	Dihydroergotamine	8.8 (-27.5 to 45.1)
% females	Candesartan	Divalproex	0.7 (-37.8 to 39.2)
% females	Candesartan	Femoxetine	-3.2 (-39.5 to 33.1)
% females	Candesartan	Fluoxetine	1.6 (-33.6 to 36.7)
% females	Candesartan	Gabapentin	4.3 (-32.0 to 40.6)
% females	Candesartan	Guanfacine	-5.0 (-49.5 to 39.5)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Candesartan	Indobufen	11.0 (-33.5 to 55.5)
% females	Candesartan	Indomethacin	3.0 (-41.5 to 47.5)
% females	Candesartan	Induprofen	19.0 (-25.5 to 63.5)
% females	Candesartan	Ketoprofen	-9.0 (-53.5 to 35.5)
% females	Candesartan	Lamotrigine	-2.8 (-47.3 to 41.7)
% females	Candesartan	Lisinopril	-2.0 (-46.5 to 42.5)
% females	Candesartan	Methysergide	-1.0 (-45.5 to 43.5)
% females	Candesartan	Metoprolol	-4.1 (-40.4 to 32.2)
% females	Candesartan	Magnesium	-10.5 (-49.0 to 28.0)
% females	Candesartan	Montelukast	-9.0 (-53.5 to 35.5)
% females	Candesartan	Nadolol	-2.3 (-46.8 to 42.2)
% females	Candesartan	Naproxen sodium	-0.3 (-36.6 to 36.0)
% females	Candesartan	Nicardipine	6.0 (-38.5 to 50.5)
% females	Candesartan	Nifedipine	0.0 (-44.5 to 44.5)
% females	Candesartan	Nimodipine	8.7 (-27.6 to 45.0)
% females	Candesartan	Oxcarbazepine	-5.7 (-50.2 to 38.8)
% females	Candesartan	Pindolol	-6.7 (-51.2 to 37.8)
% females	Candesartan	Propranolol	0.9 (-32.1 to 33.9)
% females	Candesartan	Rofecoxib	-5.5 (-50.0 to 39.0)
% females	Candesartan	Telmisartan	-5.5 (-50.0 to 39.0)
% females	Candesartan	Timolol	7.3 (-31.2 to 45.8)
% females	Candesartan	Tizanidine	0.0 (-44.5 to 44.5)
% females	Candesartan	Tolfenamic Acid	-8.0 (-52.5 to 36.5)
% females	Candesartan	Tonabersat	-13.3 (-57.8 to 31.2)
% females	Candesartan	Topiramate	9.0 (-24.2 to 42.1)
% females	Candesartan	Valproate	-3.7 (-42.2 to 34.9)
% females	Candesartan	Verapamil	-1.5 (-40.0 to 37.0)
% females	Candesartan	Vigabatrin	5.1 (-39.4 to 49.6)
% females	Captopril	Carbamazepine	-10.8 (-55.3 to 33.7)
% females	Captopril	Clonidine	-19.5 (-52.2 to 13.2)
% females	Captopril	Dihydroergocryptine	-13.6 (-58.1 to 30.9)
% females	Captopril	Dihydroergotamine	-12.2 (-48.5 to 24.1)
% females	Captopril	Divalproex	-20.3 (-58.8 to 18.2)
% females	Captopril	Femoxetine	-24.2 (-60.5 to 12.1)
% females	Captopril	Fluoxetine	-19.4 (-54.6 to 15.7)
% females	Captopril	Gabapentin	-16.7 (-53.0 to 19.6)
% females	Captopril	Guanfacine	-26.0 (-70.5 to 18.5)
% females	Captopril	Indobufen	-10.0 (-54.5 to 34.5)
% females	Captopril	Indomethacin	-18.0 (-62.5 to 26.5)
% females	Captopril	Induprofen	-2.0 (-46.5 to 42.5)
% females	Captopril	Ketoprofen	-30.0 (-74.5 to 14.5)
% females	Captopril	Lamotrigine	-23.8 (-68.3 to 20.7)
% females	Captopril	Lisinopril	-23.0 (-67.5 to 21.5)
% females	Captopril	Methysergide	-22.0 (-66.5 to 22.5)
% females	Captopril	Metoprolol	-25.1 (-61.4 to 11.2)
% females	Captopril	Magnesium	-31.5 (-70.0 to 7.0)
% females	Captopril	Montelukast	-30.0 (-74.5 to 14.5)
% females	Captopril	Nadolol	-23.3 (-67.8 to 21.2)
% females	Captopril	Naproxen sodium	-21.3 (-57.6 to 15.0)
% females	Captopril	Nicardipine	-15.0 (-59.5 to 29.5)
% females	Captopril	Nifedipine	-21.0 (-65.5 to 23.5)
% females	Captopril	Nimodipine	-12.3 (-48.6 to 24.0)
% females	Captopril	Oxcarbazepine	-26.7 (-71.2 to 17.8)
% females	Captopril	Pindolol	-27.7 (-72.2 to 16.8)
% females	Captopril	Propranolol	-20.1 (-53.1 to 12.9)
% females	Captopril	Rofecoxib	-26.5 (-71.0 to 18.0)
% females	Captopril	Telmisartan	-26.5 (-71.0 to 18.0)
% females	Captopril	Timolol	-13.7 (-52.2 to 24.8)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Captopril	Tizanidine	-21.0 (-65.5 to 23.5)
% females	Captopril	Tolfenamic Acid	-29.0 (-73.5 to 15.5)
% females	Captopril	Tonabersat	-34.3 (-78.8 to 10.2)
% females	Captopril	Topiramate	-12.0 (-45.2 to 21.1)
% females	Captopril	Valproate	-24.7 (-63.2 to 13.9)
% females	Captopril	Verapamil	-22.5 (-61.0 to 16.0)
% females	Captopril	Vigabatrin	-15.9 (-60.4 to 28.6)
% females	Carbamazepine	Clonidine	-8.7 (-41.4 to 24.0)
% females	Carbamazepine	Dihydroergocryptine	-2.8 (-47.3 to 41.7)
% females	Carbamazepine	Dihydroergotamine	-1.4 (-37.7 to 34.9)
% females	Carbamazepine	Divalproex	-9.5 (-48.0 to 29.0)
% females	Carbamazepine	Femoxetine	-13.4 (-49.7 to 22.9)
% females	Carbamazepine	Fluoxetine	-8.6 (-43.8 to 26.5)
% females	Carbamazepine	Gabapentin	-5.9 (-42.2 to 30.4)
% females	Carbamazepine	Guanfacine	-15.2 (-59.7 to 29.3)
% females	Carbamazepine	Indobufen	0.8 (-43.7 to 45.3)
% females	Carbamazepine	Indomethacin	-7.2 (-51.7 to 37.3)
% females	Carbamazepine	Induprofen	8.8 (-35.7 to 53.3)
% females	Carbamazepine	Ketoprofen	-19.2 (-63.7 to 25.3)
% females	Carbamazepine	Lamotrigine	-13.0 (-57.5 to 31.5)
% females	Carbamazepine	Lisinopril	-12.2 (-56.7 to 32.3)
% females	Carbamazepine	Methysergide	-11.2 (-55.7 to 33.3)
% females	Carbamazepine	Metoprolol	-14.3 (-50.6 to 22.0)
% females	Carbamazepine	Magnesium	-20.7 (-59.2 to 17.8)
% females	Carbamazepine	Montelukast	-19.2 (-63.7 to 25.3)
% females	Carbamazepine	Nadolol	-12.5 (-57.0 to 32.0)
% females	Carbamazepine	Naproxen sodium	-10.5 (-46.8 to 25.8)
% females	Carbamazepine	Nicardipine	-4.2 (-48.7 to 40.3)
% females	Carbamazepine	Nifedipine	-10.2 (-54.7 to 34.3)
% females	Carbamazepine	Nimodipine	-1.5 (-37.8 to 34.8)
% females	Carbamazepine	Oxcarbazepine	-15.9 (-60.4 to 28.6)
% females	Carbamazepine	Pindolol	-16.9 (-61.4 to 27.6)
% females	Carbamazepine	Propranolol	-9.3 (-42.3 to 23.7)
% females	Carbamazepine	Rofecoxib	-15.7 (-60.2 to 28.8)
% females	Carbamazepine	Telmisartan	-15.7 (-60.2 to 28.8)
% females	Carbamazepine	Timolol	-2.9 (-41.4 to 35.6)
% females	Carbamazepine	Tizanidine	-10.2 (-54.7 to 34.3)
% females	Carbamazepine	Tolfenamic Acid	-18.2 (-62.7 to 26.3)
% females	Carbamazepine	Tonabersat	-23.5 (-68.0 to 21.0)
% females	Carbamazepine	Topiramate	-1.2 (-34.4 to 31.9)
% females	Carbamazepine	Valproate	-13.9 (-52.4 to 24.7)
% females	Carbamazepine	Verapamil	-11.7 (-50.2 to 26.8)
% females	Carbamazepine	Vigabatrin	-5.1 (-49.6 to 39.4)
% females	Clonidine	Dihydroergocryptine	5.9 (-26.8 to 38.6)
% females	Clonidine	Dihydroergotamine	7.3 (-13.0 to 27.6)
% females	Clonidine	Divalproex	-0.8 (-24.8 to 23.2)
% females	Clonidine	Femoxetine	-4.7 (-25.0 to 15.6)
% females	Clonidine	Fluoxetine	0.1 (-18.1 to 18.2)
% females	Clonidine	Gabapentin	2.8 (-17.5 to 23.1)
% females	Clonidine	Guanfacine	-6.5 (-39.2 to 26.2)
% females	Clonidine	Indobufen	9.5 (-23.2 to 42.2)
% females	Clonidine	Indomethacin	1.5 (-31.2 to 34.2)
% females	Clonidine	Induprofen	17.5 (-15.2 to 50.2)
% females	Clonidine	Ketoprofen	-10.5 (-43.2 to 22.2)
% females	Clonidine	Lamotrigine	-4.3 (-37.0 to 28.4)
% females	Clonidine	Lisinopril	-3.5 (-36.2 to 29.2)
% females	Clonidine	Methysergide	-2.5 (-35.2 to 30.2)
% females	Clonidine	Metoprolol	-5.6 (-25.9 to 14.7)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Clonidine	Magnesium	-12.0 (-36.0 to 12.0)
% females	Clonidine	Montelukast	-10.5 (-43.2 to 22.2)
% females	Clonidine	Nadolol	-3.8 (-36.5 to 28.9)
% females	Clonidine	Naproxen sodium	-1.8 (-22.1 to 18.5)
% females	Clonidine	Nicardipine	4.5 (-28.2 to 37.2)
% females	Clonidine	Nifedipine	-1.5 (-34.2 to 31.2)
% females	Clonidine	Nimodipine	7.2 (-13.1 to 27.5)
% females	Clonidine	Oxcarbazepine	-7.2 (-39.9 to 25.5)
% females	Clonidine	Pindolol	-8.2 (-40.9 to 24.5)
% females	Clonidine	Propranolol	-0.6 (-14.1 to 12.9)
% females	Clonidine	Rofecoxib	-7.0 (-39.7 to 25.7)
% females	Clonidine	Telmisartan	-7.0 (-39.7 to 25.7)
% females	Clonidine	Timolol	5.8 (-18.2 to 29.8)
% females	Clonidine	Tizanidine	-1.5 (-34.2 to 31.2)
% females	Clonidine	Tolfenamic Acid	-9.5 (-42.2 to 23.2)
% females	Clonidine	Tonabersat	-14.8 (-47.5 to 17.9)
% females	Clonidine	Topiramate	7.5 (-6.4 to 21.4)
% females	Clonidine	Valproate	-5.2 (-29.2 to 18.9)
% females	Clonidine	Verapamil	-3.0 (-27.0 to 21.0)
% females	Clonidine	Vigabatrin	3.6 (-29.1 to 36.3)
% females	Dihydroergocryptine	Dihydroergotamine	1.4 (-34.9 to 37.7)
% females	Dihydroergocryptine	Divalproex	-6.7 (-45.2 to 31.8)
% females	Dihydroergocryptine	Femoxetine	-10.6 (-46.9 to 25.7)
% females	Dihydroergocryptine	Fluoxetine	-5.8 (-41.0 to 29.3)
% females	Dihydroergocryptine	Gabapentin	-3.1 (-39.4 to 33.2)
% females	Dihydroergocryptine	Guanfacine	-12.4 (-56.9 to 32.1)
% females	Dihydroergocryptine	Indobufen	3.6 (-40.9 to 48.1)
% females	Dihydroergocryptine	Indomethacin	-4.4 (-48.9 to 40.1)
% females	Dihydroergocryptine	Induprofen	11.6 (-32.9 to 56.1)
% females	Dihydroergocryptine	Ketoprofen	-16.4 (-60.9 to 28.1)
% females	Dihydroergocryptine	Lamotrigine	-10.2 (-54.7 to 34.3)
% females	Dihydroergocryptine	Lisinopril	-9.4 (-53.9 to 35.1)
% females	Dihydroergocryptine	Methysergide	-8.4 (-52.9 to 36.1)
% females	Dihydroergocryptine	Metoprolol	-11.5 (-47.8 to 24.8)
% females	Dihydroergocryptine	Magnesium	-17.9 (-56.4 to 20.6)
% females	Dihydroergocryptine	Montelukast	-16.4 (-60.9 to 28.1)
% females	Dihydroergocryptine	Nadolol	-9.7 (-54.2 to 34.8)
% females	Dihydroergocryptine	Naproxen sodium	-7.7 (-44.0 to 28.6)
% females	Dihydroergocryptine	Nicardipine	-1.4 (-45.9 to 43.1)
% females	Dihydroergocryptine	Nifedipine	-7.4 (-51.9 to 37.1)
% females	Dihydroergocryptine	Nimodipine	1.3 (-35.0 to 37.6)
% females	Dihydroergocryptine	Oxcarbazepine	-13.1 (-57.6 to 31.4)
% females	Dihydroergocryptine	Pindolol	-14.1 (-58.6 to 30.4)
% females	Dihydroergocryptine	Propranolol	-6.5 (-39.5 to 26.5)
% females	Dihydroergocryptine	Rofecoxib	-12.9 (-57.4 to 31.6)
% females	Dihydroergocryptine	Telmisartan	-12.9 (-57.4 to 31.6)
% females	Dihydroergocryptine	Timolol	-0.1 (-38.6 to 38.4)
% females	Dihydroergocryptine	Tizanidine	-7.4 (-51.9 to 37.1)
% females	Dihydroergocryptine	Tolfenamic Acid	-15.4 (-59.9 to 29.1)
% females	Dihydroergocryptine	Tonabersat	-20.7 (-65.2 to 23.8)
% females	Dihydroergocryptine	Topiramate	1.6 (-31.6 to 34.7)
% females	Dihydroergocryptine	Valproate	-11.1 (-49.6 to 27.5)
% females	Dihydroergocryptine	Verapamil	-8.9 (-47.4 to 29.6)
% females	Dihydroergocryptine	Vigabatrin	-2.3 (-46.8 to 42.2)
% females	Dihydroergotamine	Divalproex	-8.1 (-36.8 to 20.6)
% females	Dihydroergotamine	Femoxetine	-12.0 (-37.6 to 13.7)
% females	Dihydroergotamine	Fluoxetine	-7.2 (-31.2 to 16.8)
% females	Dihydroergotamine	Gabapentin	-4.5 (-30.1 to 21.2)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Dihydroergotamine	Guanfacine	-13.8 (-50.1 to 22.5)
% females	Dihydroergotamine	Indobufen	2.2 (-34.1 to 38.5)
% females	Dihydroergotamine	Indomethacin	-5.8 (-42.1 to 30.5)
% females	Dihydroergotamine	Induprofen	10.2 (-26.1 to 46.5)
% females	Dihydroergotamine	Ketoprofen	-17.8 (-54.1 to 18.5)
% females	Dihydroergotamine	Lamotrigine	-11.6 (-47.9 to 24.7)
% females	Dihydroergotamine	Lisinopril	-10.8 (-47.1 to 25.5)
% females	Dihydroergotamine	Methysergide	-9.8 (-46.1 to 26.5)
% females	Dihydroergotamine	Metoprolol	-12.8 (-38.5 to 12.8)
% females	Dihydroergotamine	Magnesium	-19.3 (-48.0 to 9.4)
% females	Dihydroergotamine	Montelukast	-17.8 (-54.1 to 18.5)
% females	Dihydroergotamine	Nadolol	-11.1 (-47.4 to 25.2)
% females	Dihydroergotamine	Naproxen sodium	-9.1 (-34.8 to 16.6)
% females	Dihydroergotamine	Nicardipine	-2.8 (-39.1 to 33.5)
% females	Dihydroergotamine	Nifedipine	-8.8 (-45.1 to 27.5)
% females	Dihydroergotamine	Nimodipine	-0.1 (-25.8 to 25.6)
% females	Dihydroergotamine	Oxcarbazepine	-14.5 (-50.8 to 21.8)
% females	Dihydroergotamine	Pindolol	-15.5 (-51.8 to 20.8)
% females	Dihydroergotamine	Propranolol	-7.9 (-28.6 to 12.8)
% females	Dihydroergotamine	Rofecoxib	-14.3 (-50.6 to 22.0)
% females	Dihydroergotamine	Telmisartan	-14.3 (-50.6 to 22.0)
% females	Dihydroergotamine	Timolol	-1.5 (-30.2 to 27.2)
% females	Dihydroergotamine	Tizanidine	-8.8 (-45.1 to 27.5)
% females	Dihydroergotamine	Tolfenamic Acid	-16.8 (-53.1 to 19.5)
% females	Dihydroergotamine	Tonabersat	-22.1 (-58.4 to 14.2)
% females	Dihydroergotamine	Topiramate	0.2 (-20.7 to 21.2)
% females	Dihydroergotamine	Valproate	-12.4 (-41.1 to 16.3)
% females	Dihydroergotamine	Verapamil	-10.3 (-39.0 to 18.4)
% females	Dihydroergotamine	Vigabatrin	-3.7 (-40.0 to 32.6)
% females	Divalproex	Femoxetine	-3.9 (-32.6 to 24.8)
% females	Divalproex	Fluoxetine	0.9 (-26.4 to 28.1)
% females	Divalproex	Gabapentin	3.6 (-25.1 to 32.3)
% females	Divalproex	Guanfacine	-5.7 (-44.2 to 32.8)
% females	Divalproex	Indobufen	10.3 (-28.2 to 48.8)
% females	Divalproex	Indomethacin	2.3 (-36.2 to 40.8)
% females	Divalproex	Induprofen	18.3 (-20.2 to 56.8)
% females	Divalproex	Ketoprofen	-9.7 (-48.2 to 28.8)
% females	Divalproex	Lamotrigine	-3.5 (-42.0 to 35.0)
% females	Divalproex	Lisinopril	-2.7 (-41.2 to 35.8)
% females	Divalproex	Methysergide	-1.7 (-40.2 to 36.8)
% females	Divalproex	Metoprolol	-4.8 (-33.5 to 23.9)
% females	Divalproex	Magnesium	-11.2 (-42.6 to 20.2)
% females	Divalproex	Montelukast	-9.7 (-48.2 to 28.8)
% females	Divalproex	Nadolol	-3.0 (-41.5 to 35.5)
% females	Divalproex	Naproxen sodium	-1.0 (-29.7 to 27.7)
% females	Divalproex	Nicardipine	5.3 (-33.2 to 43.8)
% females	Divalproex	Nifedipine	-0.7 (-39.2 to 37.8)
% females	Divalproex	Nimodipine	8.0 (-20.7 to 36.7)
% females	Divalproex	Oxcarbazepine	-6.4 (-44.9 to 32.1)
% females	Divalproex	Pindolol	-7.4 (-45.9 to 31.1)
% females	Divalproex	Propranolol	0.2 (-24.2 to 24.6)
% females	Divalproex	Rofecoxib	-6.2 (-44.7 to 32.3)
% females	Divalproex	Telmisartan	-6.2 (-44.7 to 32.3)
% females	Divalproex	Timolol	6.6 (-24.8 to 38.0)
% females	Divalproex	Tizanidine	-0.7 (-39.2 to 37.8)
% females	Divalproex	Tolfenamic Acid	-8.7 (-47.2 to 29.8)
% females	Divalproex	Tonabersat	-14.0 (-52.5 to 24.5)
% females	Divalproex	Topiramate	8.3 (-16.3 to 32.9)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Divalproex	Valproate	-4.4 (-35.8 to 27.1)
% females	Divalproex	Verapamil	-2.2 (-33.6 to 29.2)
% females	Divalproex	Vigabatrin	4.4 (-34.1 to 42.9)
% females	Femoxetine	Fluoxetine	4.8 (-19.2 to 28.8)
% females	Femoxetine	Gabapentin	7.5 (-18.2 to 33.2)
% females	Femoxetine	Guanfacine	-1.8 (-38.1 to 34.5)
% females	Femoxetine	Indobufen	14.2 (-22.1 to 50.5)
% females	Femoxetine	Indomethacin	6.2 (-30.1 to 42.5)
% females	Femoxetine	Induprofen	22.2 (-14.1 to 58.5)
% females	Femoxetine	Ketoprofen	-5.8 (-42.1 to 30.5)
% females	Femoxetine	Lamotrigine	0.4 (-35.9 to 36.7)
% females	Femoxetine	Lisinopril	1.2 (-35.1 to 37.5)
% females	Femoxetine	Methysergide	2.2 (-34.1 to 38.5)
% females	Femoxetine	Metoprolol	-0.9 (-26.5 to 24.8)
% females	Femoxetine	Magnesium	-7.3 (-36.0 to 21.4)
% females	Femoxetine	Montelukast	-5.8 (-42.1 to 30.5)
% females	Femoxetine	Nadolol	0.9 (-35.4 to 37.2)
% females	Femoxetine	Naproxen sodium	2.9 (-22.8 to 28.5)
% females	Femoxetine	Nicardipine	9.2 (-27.1 to 45.5)
% females	Femoxetine	Nifedipine	3.2 (-33.1 to 39.5)
% females	Femoxetine	Nimodipine	11.9 (-13.8 to 37.5)
% females	Femoxetine	Oxcarbazepine	-2.5 (-38.8 to 33.8)
% females	Femoxetine	Pindolol	-3.5 (-39.8 to 32.8)
% females	Femoxetine	Propranolol	4.1 (-16.6 to 24.8)
% females	Femoxetine	Rofecoxib	-2.3 (-38.6 to 34.0)
% females	Femoxetine	Telmisartan	-2.3 (-38.6 to 34.0)
% females	Femoxetine	Timolol	10.5 (-18.2 to 39.2)
% females	Femoxetine	Tizanidine	3.2 (-33.1 to 39.5)
% females	Femoxetine	Tolfenamic Acid	-4.8 (-41.1 to 31.5)
% females	Femoxetine	Tonabersat	-10.1 (-46.4 to 26.2)
% females	Femoxetine	Topiramate	12.2 (-8.8 to 33.2)
% females	Femoxetine	Valproate	-0.5 (-29.2 to 28.3)
% females	Femoxetine	Verapamil	1.7 (-27.0 to 30.4)
% females	Femoxetine	Vigabatrin	8.3 (-28.0 to 44.6)
% females	Fluoxetine	Gabapentin	2.7 (-21.3 to 26.7)
% females	Fluoxetine	Guanfacine	-6.6 (-41.7 to 28.6)
% females	Fluoxetine	Indobufen	9.4 (-25.7 to 44.6)
% females	Fluoxetine	Indomethacin	1.4 (-33.7 to 36.6)
% females	Fluoxetine	Induprofen	17.4 (-17.7 to 52.6)
% females	Fluoxetine	Ketoprofen	-10.6 (-45.7 to 24.6)
% females	Fluoxetine	Lamotrigine	-4.4 (-39.5 to 30.8)
% females	Fluoxetine	Lisinopril	-3.6 (-38.7 to 31.6)
% females	Fluoxetine	Methysergide	-2.6 (-37.7 to 32.6)
% females	Fluoxetine	Metoprolol	-5.6 (-29.7 to 18.4)
% females	Fluoxetine	Magnesium	-12.1 (-39.3 to 15.2)
% females	Fluoxetine	Montelukast	-10.6 (-45.7 to 24.6)
% females	Fluoxetine	Nadolol	-3.9 (-39.0 to 31.3)
% females	Fluoxetine	Naproxen sodium	-1.9 (-25.9 to 22.1)
% females	Fluoxetine	Nicardipine	4.4 (-30.7 to 39.6)
% females	Fluoxetine	Nifedipine	-1.6 (-36.7 to 33.6)
% females	Fluoxetine	Nimodipine	7.1 (-16.9 to 31.1)
% females	Fluoxetine	Oxcarbazepine	-7.3 (-42.4 to 27.9)
% females	Fluoxetine	Pindolol	-8.3 (-43.4 to 26.9)
% females	Fluoxetine	Propranolol	-0.7 (-19.3 to 17.9)
% females	Fluoxetine	Rofecoxib	-7.1 (-42.2 to 28.1)
% females	Fluoxetine	Telmisartan	-7.1 (-42.2 to 28.1)
% females	Fluoxetine	Timolol	5.7 (-21.5 to 33.0)
% females	Fluoxetine	Tizanidine	-1.6 (-36.7 to 33.6)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Fluoxetine	Tolfenamic Acid	-9.6 (-44.7 to 25.6)
% females	Fluoxetine	Tonabersat	-14.9 (-50.0 to 20.3)
% females	Fluoxetine	Topiramate	7.4 (-11.5 to 26.3)
% females	Fluoxetine	Valproate	-5.2 (-32.5 to 22.0)
% females	Fluoxetine	Verapamil	-3.1 (-30.3 to 24.2)
% females	Fluoxetine	Vigabatrin	3.5 (-31.6 to 38.7)
% females	Gabapentin	Guanfacine	-9.3 (-45.6 to 27.0)
% females	Gabapentin	Indobufen	6.7 (-29.6 to 43.0)
% females	Gabapentin	Indomethacin	-1.3 (-37.6 to 35.0)
% females	Gabapentin	Induprofen	14.7 (-21.6 to 51.0)
% females	Gabapentin	Ketoprofen	-13.3 (-49.6 to 23.0)
% females	Gabapentin	Lamotrigine	-7.1 (-43.4 to 29.2)
% females	Gabapentin	Lisinopril	-6.3 (-42.6 to 30.0)
% females	Gabapentin	Methysergide	-5.3 (-41.6 to 31.0)
% females	Gabapentin	Metoprolol	-8.4 (-34.0 to 17.3)
% females	Gabapentin	Magnesium	-14.8 (-43.5 to 13.9)
% females	Gabapentin	Montelukast	-13.3 (-49.6 to 23.0)
% females	Gabapentin	Nadolol	-6.6 (-42.9 to 29.7)
% females	Gabapentin	Naproxen sodium	-4.6 (-30.3 to 21.0)
% females	Gabapentin	Nicardipine	1.7 (-34.6 to 38.0)
% females	Gabapentin	Nifedipine	-4.3 (-40.6 to 32.0)
% females	Gabapentin	Nimodipine	4.4 (-21.3 to 30.0)
% females	Gabapentin	Oxcarbazepine	-10.0 (-46.3 to 26.3)
% females	Gabapentin	Pindolol	-11.0 (-47.3 to 25.3)
% females	Gabapentin	Propranolol	-3.4 (-24.1 to 17.3)
% females	Gabapentin	Rofecoxib	-9.8 (-46.1 to 26.5)
% females	Gabapentin	Telmisartan	-9.8 (-46.1 to 26.5)
% females	Gabapentin	Timolol	3.0 (-25.7 to 31.7)
% females	Gabapentin	Tizanidine	-4.3 (-40.6 to 32.0)
% females	Gabapentin	Tolfenamic Acid	-12.3 (-48.6 to 24.0)
% females	Gabapentin	Tonabersat	-17.6 (-53.9 to 18.7)
% females	Gabapentin	Topiramate	4.7 (-16.3 to 25.7)
% females	Gabapentin	Valproate	-8.0 (-36.7 to 20.8)
% females	Gabapentin	Verapamil	-5.8 (-34.5 to 22.9)
% females	Gabapentin	Vigabatrin	0.8 (-35.5 to 37.1)
% females	Guanfacine	Indobufen	16.0 (-28.5 to 60.5)
% females	Guanfacine	Indomethacin	8.0 (-36.5 to 52.5)
% females	Guanfacine	Induprofen	24.0 (-20.5 to 68.5)
% females	Guanfacine	Ketoprofen	-4.0 (-48.5 to 40.5)
% females	Guanfacine	Lamotrigine	2.2 (-42.3 to 46.7)
% females	Guanfacine	Lisinopril	3.0 (-41.5 to 47.5)
% females	Guanfacine	Methysergide	4.0 (-40.5 to 48.5)
% females	Guanfacine	Metoprolol	0.9 (-35.4 to 37.2)
% females	Guanfacine	Magnesium	-5.5 (-44.0 to 33.0)
% females	Guanfacine	Montelukast	-4.0 (-48.5 to 40.5)
% females	Guanfacine	Nadolol	2.7 (-41.8 to 47.2)
% females	Guanfacine	Naproxen sodium	4.7 (-31.6 to 41.0)
% females	Guanfacine	Nicardipine	11.0 (-33.5 to 55.5)
% females	Guanfacine	Nifedipine	5.0 (-39.5 to 49.5)
% females	Guanfacine	Nimodipine	13.7 (-22.6 to 50.0)
% females	Guanfacine	Oxcarbazepine	-0.7 (-45.2 to 43.8)
% females	Guanfacine	Pindolol	-1.7 (-46.2 to 42.8)
% females	Guanfacine	Propranolol	5.9 (-27.1 to 38.9)
% females	Guanfacine	Rofecoxib	-0.5 (-45.0 to 44.0)
% females	Guanfacine	Telmisartan	-0.5 (-45.0 to 44.0)
% females	Guanfacine	Timolol	12.3 (-26.2 to 50.8)
% females	Guanfacine	Tizanidine	5.0 (-39.5 to 49.5)
% females	Guanfacine	Tolfenamic Acid	-3.0 (-47.5 to 41.5)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Guanfacine	Tonabersat	-8.3 (-52.8 to 36.2)
% females	Guanfacine	Topiramate	14.0 (-19.2 to 47.1)
% females	Guanfacine	Valproate	1.4 (-37.2 to 39.9)
% females	Guanfacine	Verapamil	3.5 (-35.0 to 42.0)
% females	Guanfacine	Vigabatrin	10.1 (-34.4 to 54.6)
% females	Indobufen	Indomethacin	-8.0 (-52.5 to 36.5)
% females	Indobufen	Induprofen	8.0 (-36.5 to 52.5)
% females	Indobufen	Ketoprofen	-20.0 (-64.5 to 24.5)
% females	Indobufen	Lamotrigine	-13.8 (-58.3 to 30.7)
% females	Indobufen	Lisinopril	-13.0 (-57.5 to 31.5)
% females	Indobufen	Methysergide	-12.0 (-56.5 to 32.5)
% females	Indobufen	Metoprolol	-15.1 (-51.4 to 21.2)
% females	Indobufen	Magnesium	-21.5 (-60.0 to 17.0)
% females	Indobufen	Montelukast	-20.0 (-64.5 to 24.5)
% females	Indobufen	Nadolol	-13.3 (-57.8 to 31.2)
% females	Indobufen	Naproxen sodium	-11.3 (-47.6 to 25.0)
% females	Indobufen	Nicardipine	-5.0 (-49.5 to 39.5)
% females	Indobufen	Nifedipine	-11.0 (-55.5 to 33.5)
% females	Indobufen	Nimodipine	-2.3 (-38.6 to 34.0)
% females	Indobufen	Oxcarbazepine	-16.7 (-61.2 to 27.8)
% females	Indobufen	Pindolol	-17.7 (-62.2 to 26.8)
% females	Indobufen	Propranolol	-10.1 (-43.1 to 22.9)
% females	Indobufen	Rofecoxib	-16.5 (-61.0 to 28.0)
% females	Indobufen	Telmisartan	-16.5 (-61.0 to 28.0)
% females	Indobufen	Timolol	-3.7 (-42.2 to 34.8)
% females	Indobufen	Tizanidine	-11.0 (-55.5 to 33.5)
% females	Indobufen	Tolfenamic Acid	-19.0 (-63.5 to 25.5)
% females	Indobufen	Tonabersat	-24.3 (-68.8 to 20.2)
% females	Indobufen	Topiramate	-2.0 (-35.2 to 31.1)
% females	Indobufen	Valproate	-14.7 (-53.2 to 23.9)
% females	Indobufen	Verapamil	-12.5 (-51.0 to 26.0)
% females	Indobufen	Vigabatrin	-5.9 (-50.4 to 38.6)
% females	Indomethacin	Induprofen	16.0 (-28.5 to 60.5)
% females	Indomethacin	Ketoprofen	-12.0 (-56.5 to 32.5)
% females	Indomethacin	Lamotrigine	-5.8 (-50.3 to 38.7)
% females	Indomethacin	Lisinopril	-5.0 (-49.5 to 39.5)
% females	Indomethacin	Methysergide	-4.0 (-48.5 to 40.5)
% females	Indomethacin	Metoprolol	-7.1 (-43.4 to 29.2)
% females	Indomethacin	Magnesium	-13.5 (-52.0 to 25.0)
% females	Indomethacin	Montelukast	-12.0 (-56.5 to 32.5)
% females	Indomethacin	Nadolol	-5.3 (-49.8 to 39.2)
% females	Indomethacin	Naproxen sodium	-3.3 (-39.6 to 33.0)
% females	Indomethacin	Nicardipine	3.0 (-41.5 to 47.5)
% females	Indomethacin	Nifedipine	-3.0 (-47.5 to 41.5)
% females	Indomethacin	Nimodipine	5.7 (-30.6 to 42.0)
% females	Indomethacin	Oxcarbazepine	-8.7 (-53.2 to 35.8)
% females	Indomethacin	Pindolol	-9.7 (-54.2 to 34.8)
% females	Indomethacin	Propranolol	-2.1 (-35.1 to 30.9)
% females	Indomethacin	Rofecoxib	-8.5 (-53.0 to 36.0)
% females	Indomethacin	Telmisartan	-8.5 (-53.0 to 36.0)
% females	Indomethacin	Timolol	4.3 (-34.2 to 42.8)
% females	Indomethacin	Tizanidine	-3.0 (-47.5 to 41.5)
% females	Indomethacin	Tolfenamic Acid	-11.0 (-55.5 to 33.5)
% females	Indomethacin	Tonabersat	-16.3 (-60.8 to 28.2)
% females	Indomethacin	Topiramate	6.0 (-27.2 to 39.1)
% females	Indomethacin	Valproate	-6.7 (-45.2 to 31.9)
% females	Indomethacin	Verapamil	-4.5 (-43.0 to 34.0)
% females	Indomethacin	Vigabatrin	2.1 (-42.4 to 46.6)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Induprofen	Ketoprofen	-28.0 (-72.5 to 16.5)
% females	Induprofen	Lamotrigine	-21.8 (-66.3 to 22.7)
% females	Induprofen	Lisinopril	-21.0 (-65.5 to 23.5)
% females	Induprofen	Methysergide	-20.0 (-64.5 to 24.5)
% females	Induprofen	Metoprolol	-23.1 (-59.4 to 13.2)
% females	Induprofen	Magnesium	-29.5 (-68.0 to 9.0)
% females	Induprofen	Montelukast	-28.0 (-72.5 to 16.5)
% females	Induprofen	Nadolol	-21.3 (-65.8 to 23.2)
% females	Induprofen	Naproxen sodium	-19.3 (-55.6 to 17.0)
% females	Induprofen	Nicardipine	-13.0 (-57.5 to 31.5)
% females	Induprofen	Nifedipine	-19.0 (-63.5 to 25.5)
% females	Induprofen	Nimodipine	-10.3 (-46.6 to 26.0)
% females	Induprofen	Oxcarbazepine	-24.7 (-69.2 to 19.8)
% females	Induprofen	Pindolol	-25.7 (-70.2 to 18.8)
% females	Induprofen	Propranolol	-18.1 (-51.1 to 14.9)
% females	Induprofen	Rofecoxib	-24.5 (-69.0 to 20.0)
% females	Induprofen	Telmisartan	-24.5 (-69.0 to 20.0)
% females	Induprofen	Timolol	-11.7 (-50.2 to 26.8)
% females	Induprofen	Tizanidine	-19.0 (-63.5 to 25.5)
% females	Induprofen	Tolfenamic Acid	-27.0 (-71.5 to 17.5)
% females	Induprofen	Tonabersat	-32.3 (-76.8 to 12.2)
% females	Induprofen	Topiramate	-10.0 (-43.2 to 23.1)
% females	Induprofen	Valproate	-22.7 (-61.2 to 15.9)
% females	Induprofen	Verapamil	-20.5 (-59.0 to 18.0)
% females	Induprofen	Vigabatrin	-13.9 (-58.4 to 30.6)
% females	Ketoprofen	Lamotrigine	6.2 (-38.3 to 50.7)
% females	Ketoprofen	Lisinopril	7.0 (-37.5 to 51.5)
% females	Ketoprofen	Methysergide	8.0 (-36.5 to 52.5)
% females	Ketoprofen	Metoprolol	4.9 (-31.4 to 41.2)
% females	Ketoprofen	Magnesium	-1.5 (-40.0 to 37.0)
% females	Ketoprofen	Montelukast	0.0 (-44.5 to 44.5)
% females	Ketoprofen	Nadolol	6.7 (-37.8 to 51.2)
% females	Ketoprofen	Naproxen sodium	8.7 (-27.6 to 45.0)
% females	Ketoprofen	Nicardipine	15.0 (-29.5 to 59.5)
% females	Ketoprofen	Nifedipine	9.0 (-35.5 to 53.5)
% females	Ketoprofen	Nimodipine	17.7 (-18.6 to 54.0)
% females	Ketoprofen	Oxcarbazepine	3.3 (-41.2 to 47.8)
% females	Ketoprofen	Pindolol	2.3 (-42.2 to 46.8)
% females	Ketoprofen	Propranolol	9.9 (-23.1 to 42.9)
% females	Ketoprofen	Rofecoxib	3.5 (-41.0 to 48.0)
% females	Ketoprofen	Telmisartan	3.5 (-41.0 to 48.0)
% females	Ketoprofen	Timolol	16.3 (-22.2 to 54.8)
% females	Ketoprofen	Tizanidine	9.0 (-35.5 to 53.5)
% females	Ketoprofen	Tolfenamic Acid	1.0 (-43.5 to 45.5)
% females	Ketoprofen	Tonabersat	-4.3 (-48.8 to 40.2)
% females	Ketoprofen	Topiramate	18.0 (-15.2 to 51.1)
% females	Ketoprofen	Valproate	5.4 (-33.2 to 43.9)
% females	Ketoprofen	Verapamil	7.5 (-31.0 to 46.0)
% females	Ketoprofen	Vigabatrin	14.1 (-30.4 to 58.6)
% females	Lamotrigine	Lisinopril	0.8 (-43.7 to 45.3)
% females	Lamotrigine	Methysergide	1.8 (-42.7 to 46.3)
% females	Lamotrigine	Metoprolol	-1.3 (-37.6 to 35.0)
% females	Lamotrigine	Magnesium	-7.7 (-46.2 to 30.8)
% females	Lamotrigine	Montelukast	-6.2 (-50.7 to 38.3)
% females	Lamotrigine	Nadolol	0.5 (-44.0 to 45.0)
% females	Lamotrigine	Naproxen sodium	2.5 (-33.8 to 38.8)
% females	Lamotrigine	Nicardipine	8.8 (-35.7 to 53.3)
% females	Lamotrigine	Nifedipine	2.8 (-41.7 to 47.3)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Lamotrigine	Nimodipine	11.5 (-24.8 to 47.8)
% females	Lamotrigine	Oxcarbazepine	-2.9 (-47.4 to 41.6)
% females	Lamotrigine	Pindolol	-3.9 (-48.4 to 40.6)
% females	Lamotrigine	Propranolol	3.7 (-29.3 to 36.7)
% females	Lamotrigine	Rofecoxib	-2.7 (-47.2 to 41.8)
% females	Lamotrigine	Telmisartan	-2.7 (-47.2 to 41.8)
% females	Lamotrigine	Timolol	10.1 (-28.4 to 48.6)
% females	Lamotrigine	Tizanidine	2.8 (-41.7 to 47.3)
% females	Lamotrigine	Tolfenamic Acid	-5.2 (-49.7 to 39.3)
% females	Lamotrigine	Tonabersat	-10.5 (-55.0 to 34.0)
% females	Lamotrigine	Topiramate	11.8 (-21.4 to 44.9)
% females	Lamotrigine	Valproate	-0.9 (-39.4 to 37.7)
% females	Lamotrigine	Verapamil	1.3 (-37.2 to 39.8)
% females	Lamotrigine	Vigabatrin	7.9 (-36.6 to 52.4)
% females	Lisinopril	Methysergide	1.0 (-43.5 to 45.5)
% females	Lisinopril	Metoprolol	-2.1 (-38.4 to 34.2)
% females	Lisinopril	Magnesium	-8.5 (-47.0 to 30.0)
% females	Lisinopril	Montelukast	-7.0 (-51.5 to 37.5)
% females	Lisinopril	Nadolol	-0.3 (-44.8 to 44.2)
% females	Lisinopril	Naproxen sodium	1.7 (-34.6 to 38.0)
% females	Lisinopril	Nicardipine	8.0 (-36.5 to 52.5)
% females	Lisinopril	Nifedipine	2.0 (-42.5 to 46.5)
% females	Lisinopril	Nimodipine	10.7 (-25.6 to 47.0)
% females	Lisinopril	Oxcarbazepine	-3.7 (-48.2 to 40.8)
% females	Lisinopril	Pindolol	-4.7 (-49.2 to 39.8)
% females	Lisinopril	Propranolol	2.9 (-30.1 to 35.9)
% females	Lisinopril	Rofecoxib	-3.5 (-48.0 to 41.0)
% females	Lisinopril	Telmisartan	-3.5 (-48.0 to 41.0)
% females	Lisinopril	Timolol	9.3 (-29.2 to 47.8)
% females	Lisinopril	Tizanidine	2.0 (-42.5 to 46.5)
% females	Lisinopril	Tolfenamic Acid	-6.0 (-50.5 to 38.5)
% females	Lisinopril	Tonabersat	-11.3 (-55.8 to 33.2)
% females	Lisinopril	Topiramate	11.0 (-22.2 to 44.1)
% females	Lisinopril	Valproate	-1.7 (-40.2 to 36.9)
% females	Lisinopril	Verapamil	0.5 (-38.0 to 39.0)
% females	Lisinopril	Vigabatrin	7.1 (-37.4 to 51.6)
% females	Magnesium	Montelukast	1.5 (-37.0 to 40.0)
% females	Magnesium	Nadolol	8.2 (-30.3 to 46.7)
% females	Magnesium	Naproxen sodium	10.2 (-18.5 to 38.9)
% females	Magnesium	Nicardipine	16.5 (-22.0 to 55.0)
% females	Magnesium	Nifedipine	10.5 (-28.0 to 49.0)
% females	Magnesium	Nimodipine	19.2 (-9.5 to 47.9)
% females	Magnesium	Oxcarbazepine	4.8 (-33.7 to 43.3)
% females	Magnesium	Pindolol	3.8 (-34.7 to 42.3)
% females	Magnesium	Propranolol	11.4 (-13.0 to 35.8)
% females	Magnesium	Rofecoxib	5.0 (-33.5 to 43.5)
% females	Magnesium	Telmisartan	5.0 (-33.5 to 43.5)
% females	Magnesium	Timolol	17.8 (-13.6 to 49.2)
% females	Magnesium	Tizanidine	10.5 (-28.0 to 49.0)
% females	Magnesium	Tolfenamic Acid	2.5 (-36.0 to 41.0)
% females	Magnesium	Tonabersat	-2.8 (-41.3 to 35.7)
% females	Magnesium	Topiramate	19.5 (-5.1 to 44.1)
% females	Magnesium	Valproate	6.9 (-24.6 to 38.3)
% females	Magnesium	Verapamil	9.0 (-22.4 to 40.4)
% females	Magnesium	Vigabatrin	15.6 (-22.9 to 54.1)
% females	Methysergide	Metoprolol	-3.1 (-39.4 to 33.2)
% females	Methysergide	Magnesium	-9.5 (-48.0 to 29.0)
% females	Methysergide	Montelukast	-8.0 (-52.5 to 36.5)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Methysergide	Nadolol	-1.3 (-45.8 to 43.2)
% females	Methysergide	Naproxen sodium	0.7 (-35.6 to 37.0)
% females	Methysergide	Nicardipine	7.0 (-37.5 to 51.5)
% females	Methysergide	Nifedipine	1.0 (-43.5 to 45.5)
% females	Methysergide	Nimodipine	9.7 (-26.6 to 46.0)
% females	Methysergide	Oxcarbazepine	-4.7 (-49.2 to 39.8)
% females	Methysergide	Pindolol	-5.7 (-50.2 to 38.8)
% females	Methysergide	Propranolol	1.9 (-31.1 to 34.9)
% females	Methysergide	Rofecoxib	-4.5 (-49.0 to 40.0)
% females	Methysergide	Telmisartan	-4.5 (-49.0 to 40.0)
% females	Methysergide	Timolol	8.3 (-30.2 to 46.8)
% females	Methysergide	Tizanidine	1.0 (-43.5 to 45.5)
% females	Methysergide	Tolfenamic Acid	-7.0 (-51.5 to 37.5)
% females	Methysergide	Tonabersat	-12.3 (-56.8 to 32.2)
% females	Methysergide	Topiramate	10.0 (-23.2 to 43.1)
% females	Methysergide	Valproate	-2.7 (-41.2 to 35.9)
% females	Methysergide	Verapamil	-0.5 (-39.0 to 38.0)
% females	Methysergide	Vigabatrin	6.1 (-38.4 to 50.6)
% females	Metoprolol	Magnesium	-6.4 (-35.1 to 22.3)
% females	Metoprolol	Montelukast	-4.9 (-41.2 to 31.4)
% females	Metoprolol	Nadolol	1.8 (-34.5 to 38.1)
% females	Metoprolol	Naproxen sodium	3.7 (-21.9 to 29.4)
% females	Metoprolol	Nicardipine	10.1 (-26.2 to 46.4)
% females	Metoprolol	Nifedipine	4.1 (-32.2 to 40.4)
% females	Metoprolol	Nimodipine	12.7 (-12.9 to 38.4)
% females	Metoprolol	Oxcarbazepine	-1.6 (-37.9 to 34.7)
% females	Metoprolol	Pindolol	-2.6 (-38.9 to 33.7)
% females	Metoprolol	Propranolol	5.0 (-15.7 to 25.7)
% females	Metoprolol	Rofecoxib	-1.4 (-37.7 to 34.9)
% females	Metoprolol	Telmisartan	-1.4 (-37.7 to 34.9)
% females	Metoprolol	Timolol	11.4 (-17.3 to 40.1)
% females	Metoprolol	Tizanidine	4.1 (-32.2 to 40.4)
% females	Metoprolol	Tolfenamic Acid	-3.9 (-40.2 to 32.4)
% females	Metoprolol	Tonabersat	-9.2 (-45.5 to 27.1)
% females	Metoprolol	Topiramate	13.1 (-7.9 to 34.0)
% females	Metoprolol	Valproate	0.4 (-28.3 to 29.1)
% females	Metoprolol	Verapamil	2.6 (-26.1 to 31.3)
% females	Metoprolol	Vigabatrin	9.2 (-27.1 to 45.5)
% females	Montelukast	Nadolol	6.7 (-37.8 to 51.2)
% females	Montelukast	Naproxen sodium	8.7 (-27.6 to 45.0)
% females	Montelukast	Nicardipine	15.0 (-29.5 to 59.5)
% females	Montelukast	Nifedipine	9.0 (-35.5 to 53.5)
% females	Montelukast	Nimodipine	17.7 (-18.6 to 54.0)
% females	Montelukast	Oxcarbazepine	3.3 (-41.2 to 47.8)
% females	Montelukast	Pindolol	2.3 (-42.2 to 46.8)
% females	Montelukast	Propranolol	9.9 (-23.1 to 42.9)
% females	Montelukast	Rofecoxib	3.5 (-41.0 to 48.0)
% females	Montelukast	Telmisartan	3.5 (-41.0 to 48.0)
% females	Montelukast	Timolol	16.3 (-22.2 to 54.8)
% females	Montelukast	Tizanidine	9.0 (-35.5 to 53.5)
% females	Montelukast	Tolfenamic Acid	1.0 (-43.5 to 45.5)
% females	Montelukast	Tonabersat	-4.3 (-48.8 to 40.2)
% females	Montelukast	Topiramate	18.0 (-15.2 to 51.1)
% females	Montelukast	Valproate	5.4 (-33.2 to 43.9)
% females	Montelukast	Verapamil	7.5 (-31.0 to 46.0)
% females	Montelukast	Vigabatrin	14.1 (-30.4 to 58.6)
% females	Nadolol	Naproxen sodium	2.0 (-34.3 to 38.3)
% females	Nadolol	Nicardipine	8.3 (-36.2 to 52.8)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Nadolol	Nifedipine	2.3 (-42.2 to 46.8)
% females	Nadolol	Nimodipine	11.0 (-25.3 to 47.3)
% females	Nadolol	Oxcarbazepine	-3.4 (-47.9 to 41.1)
% females	Nadolol	Pindolol	-4.4 (-48.9 to 40.1)
% females	Nadolol	Propranolol	3.2 (-29.8 to 36.2)
% females	Nadolol	Rofecoxib	-3.2 (-47.7 to 41.3)
% females	Nadolol	Telmisartan	-3.2 (-47.7 to 41.3)
% females	Nadolol	Timolol	9.6 (-28.9 to 48.1)
% females	Nadolol	Tizanidine	2.3 (-42.2 to 46.8)
% females	Nadolol	Tolfenamic Acid	-5.7 (-50.2 to 38.8)
% females	Nadolol	Tonabersat	-11.0 (-55.5 to 33.5)
% females	Nadolol	Topiramate	11.3 (-21.9 to 44.4)
% females	Nadolol	Valproate	-1.4 (-39.9 to 37.2)
% females	Nadolol	Verapamil	0.8 (-37.7 to 39.3)
% females	Nadolol	Vigabatrin	7.4 (-37.1 to 51.9)
% females	Naproxen sodium	Nicardipine	6.3 (-30.0 to 42.6)
% females	Naproxen sodium	Nifedipine	0.3 (-36.0 to 36.6)
% females	Naproxen sodium	Nimodipine	9.0 (-16.7 to 34.7)
% females	Naproxen sodium	Oxcarbazepine	-5.4 (-41.7 to 30.9)
% females	Naproxen sodium	Pindolol	-6.4 (-42.7 to 29.9)
% females	Naproxen sodium	Propranolol	1.2 (-19.5 to 21.9)
% females	Naproxen sodium	Rofecoxib	-5.2 (-41.5 to 31.1)
% females	Naproxen sodium	Telmisartan	-5.2 (-41.5 to 31.1)
% females	Naproxen sodium	Timolol	7.6 (-21.1 to 36.3)
% females	Naproxen sodium	Tizanidine	0.3 (-36.0 to 36.6)
% females	Naproxen sodium	Tolfenamic Acid	-7.7 (-44.0 to 28.6)
% females	Naproxen sodium	Tonabersat	-13.0 (-49.3 to 23.3)
% females	Naproxen sodium	Topiramate	9.3 (-11.6 to 30.3)
% females	Naproxen sodium	Valproate	-3.3 (-32.0 to 25.4)
% females	Naproxen sodium	Verapamil	-1.2 (-29.9 to 27.5)
% females	Naproxen sodium	Vigabatrin	5.4 (-30.9 to 41.7)
% females	Nicardipine	Nifedipine	-6.0 (-50.5 to 38.5)
% females	Nicardipine	Nimodipine	2.7 (-33.6 to 39.0)
% females	Nicardipine	Oxcarbazepine	-11.7 (-56.2 to 32.8)
% females	Nicardipine	Pindolol	-12.7 (-57.2 to 31.8)
% females	Nicardipine	Propranolol	-5.1 (-38.1 to 27.9)
% females	Nicardipine	Rofecoxib	-11.5 (-56.0 to 33.0)
% females	Nicardipine	Telmisartan	-11.5 (-56.0 to 33.0)
% females	Nicardipine	Timolol	1.3 (-37.2 to 39.8)
% females	Nicardipine	Tizanidine	-6.0 (-50.5 to 38.5)
% females	Nicardipine	Tolfenamic Acid	-14.0 (-58.5 to 30.5)
% females	Nicardipine	Tonabersat	-19.3 (-63.8 to 25.2)
% females	Nicardipine	Topiramate	3.0 (-30.2 to 36.1)
% females	Nicardipine	Valproate	-9.7 (-48.2 to 28.9)
% females	Nicardipine	Verapamil	-7.5 (-46.0 to 31.0)
% females	Nicardipine	Vigabatrin	-0.9 (-45.4 to 43.6)
% females	Nifedipine	Nimodipine	8.7 (-27.6 to 45.0)
% females	Nifedipine	Oxcarbazepine	-5.7 (-50.2 to 38.8)
% females	Nifedipine	Pindolol	-6.7 (-51.2 to 37.8)
% females	Nifedipine	Propranolol	0.9 (-32.1 to 33.9)
% females	Nifedipine	Rofecoxib	-5.5 (-50.0 to 39.0)
% females	Nifedipine	Telmisartan	-5.5 (-50.0 to 39.0)
% females	Nifedipine	Timolol	7.3 (-31.2 to 45.8)
% females	Nifedipine	Tizanidine	0.0 (-44.5 to 44.5)
% females	Nifedipine	Tolfenamic Acid	-8.0 (-52.5 to 36.5)
% females	Nifedipine	Tonabersat	-13.3 (-57.8 to 31.2)
% females	Nifedipine	Topiramate	9.0 (-24.2 to 42.1)
% females	Nifedipine	Valproate	-3.7 (-42.2 to 34.9)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Nifedipine	Verapamil	-1.5 (-40.0 to 37.0)
% females	Nifedipine	Vigabatrin	5.1 (-39.4 to 49.6)
% females	Nimodipine	Oxcarbazepine	-14.4 (-50.7 to 21.9)
% females	Nimodipine	Pindolol	-15.4 (-51.7 to 20.9)
% females	Nimodipine	Propranolol	-7.8 (-28.5 to 12.9)
% females	Nimodipine	Rofecoxib	-14.2 (-50.5 to 22.1)
% females	Nimodipine	Telmisartan	-14.2 (-50.5 to 22.1)
% females	Nimodipine	Timolol	-1.4 (-30.1 to 27.3)
% females	Nimodipine	Tizanidine	-8.7 (-45.0 to 27.6)
% females	Nimodipine	Tolfenamic Acid	-16.7 (-53.0 to 19.6)
% females	Nimodipine	Tonabersat	-22.0 (-58.3 to 14.3)
% females	Nimodipine	Topiramate	0.3 (-20.6 to 21.3)
% females	Nimodipine	Valproate	-12.3 (-41.0 to 16.4)
% females	Nimodipine	Verapamil	-10.2 (-38.9 to 18.5)
% females	Nimodipine	Vigabatrin	-3.6 (-39.9 to 32.7)
% females	Oxcarbazepine	Pindolol	-1.0 (-45.5 to 43.5)
% females	Oxcarbazepine	Propranolol	6.6 (-26.4 to 39.6)
% females	Oxcarbazepine	Rofecoxib	0.2 (-44.3 to 44.7)
% females	Oxcarbazepine	Telmisartan	0.2 (-44.3 to 44.7)
% females	Oxcarbazepine	Timolol	13.0 (-25.5 to 51.5)
% females	Oxcarbazepine	Tizanidine	5.7 (-38.8 to 50.2)
% females	Oxcarbazepine	Tolfenamic Acid	-2.3 (-46.8 to 42.2)
% females	Oxcarbazepine	Tonabersat	-7.6 (-52.1 to 36.9)
% females	Oxcarbazepine	Topiramate	14.7 (-18.5 to 47.8)
% females	Oxcarbazepine	Valproate	2.1 (-36.5 to 40.6)
% females	Oxcarbazepine	Verapamil	4.2 (-34.3 to 42.7)
% females	Oxcarbazepine	Vigabatrin	10.8 (-33.7 to 55.3)
% females	Pindolol	Propranolol	7.6 (-25.4 to 40.6)
% females	Pindolol	Rofecoxib	1.2 (-43.3 to 45.7)
% females	Pindolol	Telmisartan	1.2 (-43.3 to 45.7)
% females	Pindolol	Timolol	14.0 (-24.5 to 52.5)
% females	Pindolol	Tizanidine	6.7 (-37.8 to 51.2)
% females	Pindolol	Tolfenamic Acid	-1.3 (-45.8 to 43.2)
% females	Pindolol	Tonabersat	-6.6 (-51.1 to 37.9)
% females	Pindolol	Topiramate	15.7 (-17.5 to 48.8)
% females	Pindolol	Valproate	3.1 (-35.5 to 41.6)
% females	Pindolol	Verapamil	5.2 (-33.3 to 43.7)
% females	Pindolol	Vigabatrin	11.8 (-32.7 to 56.3)
% females	Propranolol	Rofecoxib	-6.4 (-39.4 to 26.6)
% females	Propranolol	Telmisartan	-6.4 (-39.4 to 26.6)
% females	Propranolol	Timolol	6.4 (-18.0 to 30.8)
% females	Propranolol	Tizanidine	-0.9 (-33.9 to 32.1)
% females	Propranolol	Tolfenamic Acid	-8.9 (-41.9 to 24.1)
% females	Propranolol	Tonabersat	-14.2 (-47.2 to 18.8)
% females	Propranolol	Topiramate	8.1 (-6.4 to 22.5)
% females	Propranolol	Valproate	-4.5 (-28.9 to 19.8)
% females	Propranolol	Verapamil	-2.4 (-26.8 to 22.0)
% females	Propranolol	Vigabatrin	4.2 (-28.8 to 37.2)
% females	Rofecoxib	Telmisartan	0.0 (-44.5 to 44.5)
% females	Rofecoxib	Timolol	12.8 (-25.7 to 51.3)
% females	Rofecoxib	Tizanidine	5.5 (-39.0 to 50.0)
% females	Rofecoxib	Tolfenamic Acid	-2.5 (-47.0 to 42.0)
% females	Rofecoxib	Tonabersat	-7.8 (-52.3 to 36.7)
% females	Rofecoxib	Topiramate	14.5 (-18.7 to 47.6)
% females	Rofecoxib	Valproate	1.9 (-36.7 to 40.4)
% females	Rofecoxib	Verapamil	4.0 (-34.5 to 42.5)
% females	Rofecoxib	Vigabatrin	10.6 (-33.9 to 55.1)
% females	Telmisartan	Timolol	12.8 (-25.7 to 51.3)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% females	Telmisartan	Tizanidine	5.5 (-39.0 to 50.0)
% females	Telmisartan	Tolfenamic Acid	-2.5 (-47.0 to 42.0)
% females	Telmisartan	Tonabersat	-7.8 (-52.3 to 36.7)
% females	Telmisartan	Topiramate	14.5 (-18.7 to 47.6)
% females	Telmisartan	Valproate	1.9 (-36.7 to 40.4)
% females	Telmisartan	Verapamil	4.0 (-34.5 to 42.5)
% females	Telmisartan	Vigabatrin	10.6 (-33.9 to 55.1)
% females	Timolol	Tizanidine	-7.3 (-45.8 to 31.2)
% females	Timolol	Tolfenamic Acid	-15.3 (-53.8 to 23.2)
% females	Timolol	Tonabersat	-20.6 (-59.1 to 17.9)
% females	Timolol	Topiramate	1.7 (-22.9 to 26.3)
% females	Timolol	Valproate	-11.0 (-42.4 to 20.5)
% females	Timolol	Verapamil	-8.8 (-40.2 to 22.6)
% females	Timolol	Vigabatrin	-2.2 (-40.7 to 36.3)
% females	Tizanidine	Tolfenamic Acid	-8.0 (-52.5 to 36.5)
% females	Tizanidine	Tonabersat	-13.3 (-57.8 to 31.2)
% females	Tizanidine	Topiramate	9.0 (-24.2 to 42.1)
% females	Tizanidine	Valproate	-3.7 (-42.2 to 34.9)
% females	Tizanidine	Verapamil	-1.5 (-40.0 to 37.0)
% females	Tizanidine	Vigabatrin	5.1 (-39.4 to 49.6)
% females	Tolfenamic Acid	Tonabersat	-5.3 (-49.8 to 39.2)
% females	Tolfenamic Acid	Topiramate	17.0 (-16.2 to 50.1)
% females	Tolfenamic Acid	Valproate	4.4 (-34.2 to 42.9)
% females	Tolfenamic Acid	Verapamil	6.5 (-32.0 to 45.0)
% females	Tolfenamic Acid	Vigabatrin	13.1 (-31.4 to 57.6)
% females	Tonabersat	Topiramate	22.3 (-10.9 to 55.4)
% females	Tonabersat	Valproate	9.7 (-28.9 to 48.2)
% females	Tonabersat	Verapamil	11.8 (-26.7 to 50.3)
% females	Tonabersat	Vigabatrin	18.4 (-26.1 to 62.9)
% females	Topiramate	Valproate	-12.6 (-37.2 to 11.9)
% females	Topiramate	Verapamil	-10.5 (-35.1 to 14.1)
% females	Topiramate	Vigabatrin	-3.9 (-37.0 to 29.3)
% females	Valproate	Verapamil	2.2 (-29.3 to 33.6)
% females	Valproate	Vigabatrin	8.8 (-29.8 to 47.3)
% females	Verapamil	Vigabatrin	6.6 (-31.9 to 45.1)
Obesity, BMI	Acetazolamide	Aspirin	-2.5 (-5.6 to 0.5)
Obesity, BMI	Acetazolamide	Dihydroergotamine	-0.7 (-4.3 to 3.0)
Obesity, BMI	Acetazolamide	Divalproex	-3.7 (-7.9 to 0.5)
Obesity, BMI	Acetazolamide	Gabapentin	-2.6 (-6.8 to 1.6)
Obesity, BMI	Acetazolamide	Nimodipine	0.0 (-4.2 to 4.2)
Obesity, BMI	Acetazolamide	Telmisartan	-1.0 (-5.2 to 3.2)
Obesity, BMI	Acetazolamide	Topiramate	-6.1 (-9.6 to -2.7)
Obesity, BMI	Aspirin	Dihydroergotamine	1.9 (-0.6 to 4.4)
Obesity, BMI	Aspirin	Divalproex	-1.2 (-4.2 to 1.9)
Obesity, BMI	Aspirin	Gabapentin	0.0 (-3.1 to 3.0)
Obesity, BMI	Aspirin	Nimodipine	2.6 (-0.5 to 5.6)
Obesity, BMI	Aspirin	Telmisartan	1.6 (-1.5 to 4.6)
Obesity, BMI	Aspirin	Topiramate	-3.6 (-5.9 to -1.3)
Obesity, BMI	Dihydroergotamine	Divalproex	-3.0 (-6.7 to 0.6)
Obesity, BMI	Dihydroergotamine	Gabapentin	-1.9 (-5.6 to 1.7)
Obesity, BMI	Dihydroergotamine	Nimodipine	0.7 (-3.0 to 4.3)
Obesity, BMI	Dihydroergotamine	Telmisartan	-0.3 (-4.0 to 3.3)
Obesity, BMI	Dihydroergotamine	Topiramate	-5.5 (-8.2 to -2.8)
Obesity, BMI	Divalproex	Gabapentin	1.1 (-3.1 to 5.3)
Obesity, BMI	Divalproex	Nimodipine	3.7 (-0.5 to 7.9)
Obesity, BMI	Divalproex	Telmisartan	2.7 (-1.5 to 6.9)
Obesity, BMI	Divalproex	Topiramate	-2.5 (-5.9 to 1.0)
Obesity, BMI	Gabapentin	Nimodipine	2.6 (-1.6 to 6.8)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Obesity, BMI	Gabapentin	Telmisartan	1.6 (-2.6 to 5.8)
Obesity, BMI	Gabapentin	Topiramate	-3.6 (-7.0 to -0.1)
Obesity, BMI	Nimodipine	Telmisartan	-1.0 (-5.2 to 3.2)
Obesity, BMI	Nimodipine	Topiramate	-6.2 (-9.6 to -2.7)
Obesity, BMI	Telmisartan	Topiramate	-5.2 (-8.6 to -1.7)
Duration of migraine, years	Atenolol	Clonidine	10.0 (-2.0 to 22.0)
Duration of migraine, years	Atenolol	Dihydroergotamine	10.1 (-2.7 to 22.9)
Duration of migraine, years	Atenolol	Divalproex	3.4 (-9.4 to 16.2)
Duration of migraine, years	Atenolol	Gabapentin	5.2 (-9.5 to 19.9)
Duration of migraine, years	Atenolol	Indomethacin	6.0 (-8.7 to 20.7)
Duration of migraine, years	Atenolol	Induprofen	11.0 (-3.7 to 25.7)
Duration of migraine, years	Atenolol	Magnesium	21.8 (7.1 to 36.6)
Duration of migraine, years	Atenolol	Methysergide	6.0 (-8.7 to 20.7)
Duration of migraine, years	Atenolol	Metoprolol	6.7 (-5.3 to 18.7)
Duration of migraine, years	Atenolol	Naproxen sodium	9.4 (-5.3 to 24.1)
Duration of migraine, years	Atenolol	Nicardipine	18.0 (3.3 to 32.7)
Duration of migraine, years	Atenolol	Nifedipine	17.2 (2.5 to 31.9)
Duration of migraine, years	Atenolol	Nimodipine	7.8 (-5.0 to 20.5)
Duration of migraine, years	Atenolol	Propranolol	9.1 (-2.9 to 21.2)
Duration of migraine, years	Atenolol	Topiramate	16.7 (5.1 to 28.4)
Duration of migraine, years	Atenolol	Valproate	12.0 (-2.7 to 26.7)
Duration of migraine, years	Atenolol	Verapamil	12.6 (-2.1 to 27.3)
Duration of migraine, years	Clonidine	Dihydroergotamine	0.1 (-9.4 to 9.6)
Duration of migraine, years	Clonidine	Divalproex	-6.6 (-16.1 to 2.9)
Duration of migraine, years	Clonidine	Gabapentin	-4.8 (-16.8 to 7.2)
Duration of migraine, years	Clonidine	Indomethacin	-4.0 (-16.0 to 8.0)
Duration of migraine, years	Clonidine	Induprofen	1.0 (-11.0 to 13.0)
Duration of migraine, years	Clonidine	Magnesium	11.8 (-0.2 to 23.9)
Duration of migraine, years	Clonidine	Methysergide	-4.0 (-16.0 to 8.0)
Duration of migraine, years	Clonidine	Metoprolol	-3.3 (-11.8 to 5.2)
Duration of migraine, years	Clonidine	Naproxen sodium	-0.6 (-12.6 to 11.4)
Duration of migraine, years	Clonidine	Nicardipine	8.0 (-4.0 to 20.0)
Duration of migraine, years	Clonidine	Nifedipine	7.2 (-4.8 to 19.2)
Duration of migraine, years	Clonidine	Nimodipine	-2.3 (-11.8 to 7.3)
Duration of migraine, years	Clonidine	Propranolol	-0.9 (-9.4 to 7.6)
Duration of migraine, years	Clonidine	Topiramate	6.7 (-1.3 to 14.7)
Duration of migraine, years	Clonidine	Valproate	2.0 (-10.0 to 14.0)
Duration of migraine, years	Clonidine	Verapamil	2.6 (-9.4 to 14.6)
Duration of migraine, years	Dihydroergotamine	Divalproex	-6.7 (-17.1 to 3.7)
Duration of migraine, years	Dihydroergotamine	Gabapentin	-4.9 (-17.7 to 7.9)
Duration of migraine, years	Dihydroergotamine	Indomethacin	-4.1 (-16.9 to 8.7)
Duration of migraine, years	Dihydroergotamine	Induprofen	0.9 (-11.9 to 13.7)
Duration of migraine, years	Dihydroergotamine	Magnesium	11.7 (-1.0 to 24.5)
Duration of migraine, years	Dihydroergotamine	Methysergide	-4.1 (-16.9 to 8.7)
Duration of migraine, years	Dihydroergotamine	Metoprolol	-3.4 (-12.9 to 6.1)
Duration of migraine, years	Dihydroergotamine	Naproxen sodium	-0.7 (-13.5 to 12.1)
Duration of migraine, years	Dihydroergotamine	Nicardipine	7.9 (-4.9 to 20.7)
Duration of migraine, years	Dihydroergotamine	Nifedipine	7.1 (-5.7 to 19.9)
Duration of migraine, years	Dihydroergotamine	Nimodipine	-2.4 (-12.8 to 8.1)
Duration of migraine, years	Dihydroergotamine	Propranolol	-1.0 (-10.5 to 8.5)
Duration of migraine, years	Dihydroergotamine	Topiramate	6.6 (-2.4 to 15.6)
Duration of migraine, years	Dihydroergotamine	Valproate	1.9 (-10.9 to 14.7)
Duration of migraine, years	Dihydroergotamine	Verapamil	2.5 (-10.3 to 15.3)
Duration of migraine, years	Divalproex	Gabapentin	1.8 (-11.0 to 14.6)
Duration of migraine, years	Divalproex	Indomethacin	2.6 (-10.2 to 15.4)
Duration of migraine, years	Divalproex	Induprofen	7.6 (-5.2 to 20.4)
Duration of migraine, years	Divalproex	Magnesium	18.4 (5.7 to 31.2)
Duration of migraine, years	Divalproex	Methysergide	2.6 (-10.2 to 15.4)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Duration of migraine, years	Divalproex	Metoprolol	3.3 (-6.2 to 12.8)
Duration of migraine, years	Divalproex	Naproxen sodium	6.0 (-6.8 to 18.8)
Duration of migraine, years	Divalproex	Nicardipine	14.6 (1.8 to 27.4)
Duration of migraine, years	Divalproex	Nifedipine	13.8 (1.0 to 26.6)
Duration of migraine, years	Divalproex	Nimodipine	4.4 (-6.1 to 14.8)
Duration of migraine, years	Divalproex	Propranolol	5.7 (-3.8 to 15.2)
Duration of migraine, years	Divalproex	Topiramate	13.3 (4.3 to 22.3)
Duration of migraine, years	Divalproex	Valproate	8.6 (-4.2 to 21.4)
Duration of migraine, years	Divalproex	Verapamil	9.2 (-3.6 to 22.0)
Duration of migraine, years	Gabapentin	Indomethacin	0.8 (-13.9 to 15.5)
Duration of migraine, years	Gabapentin	Induprofen	5.8 (-8.9 to 20.5)
Duration of migraine, years	Gabapentin	Magnesium	16.6 (1.9 to 31.4)
Duration of migraine, years	Gabapentin	Methysergide	0.8 (-13.9 to 15.5)
Duration of migraine, years	Gabapentin	Metoprolol	1.5 (-10.5 to 13.5)
Duration of migraine, years	Gabapentin	Naproxen sodium	4.2 (-10.5 to 18.9)
Duration of migraine, years	Gabapentin	Nicardipine	12.8 (-1.9 to 27.5)
Duration of migraine, years	Gabapentin	Nifedipine	12.0 (-2.7 to 26.7)
Duration of migraine, years	Gabapentin	Nimodipine	2.6 (-10.2 to 15.3)
Duration of migraine, years	Gabapentin	Propranolol	3.9 (-8.1 to 16.0)
Duration of migraine, years	Gabapentin	Topiramate	11.5 (-0.1 to 23.2)
Duration of migraine, years	Gabapentin	Valproate	6.8 (-7.9 to 21.5)
Duration of migraine, years	Gabapentin	Verapamil	7.4 (-7.3 to 22.1)
Duration of migraine, years	Indomethacin	Induprofen	5.0 (-9.7 to 19.7)
Duration of migraine, years	Indomethacin	Magnesium	15.8 (1.1 to 30.6)
Duration of migraine, years	Indomethacin	Methysergide	0.0 (-14.7 to 14.7)
Duration of migraine, years	Indomethacin	Metoprolol	0.7 (-11.3 to 12.7)
Duration of migraine, years	Indomethacin	Naproxen sodium	3.4 (-11.3 to 18.1)
Duration of migraine, years	Indomethacin	Nicardipine	12.0 (-2.7 to 26.7)
Duration of migraine, years	Indomethacin	Nifedipine	11.2 (-3.5 to 25.9)
Duration of migraine, years	Indomethacin	Nimodipine	1.8 (-11.0 to 14.5)
Duration of migraine, years	Indomethacin	Propranolol	3.1 (-8.9 to 15.2)
Duration of migraine, years	Indomethacin	Topiramate	10.7 (-0.9 to 22.4)
Duration of migraine, years	Indomethacin	Valproate	6.0 (-8.7 to 20.7)
Duration of migraine, years	Indomethacin	Verapamil	6.6 (-8.1 to 21.3)
Duration of migraine, years	Induprofen	Magnesium	10.8 (-3.9 to 25.6)
Duration of migraine, years	Induprofen	Methysergide	-5.0 (-19.7 to 9.7)
Duration of migraine, years	Induprofen	Metoprolol	-4.3 (-16.3 to 7.7)
Duration of migraine, years	Induprofen	Naproxen sodium	-1.6 (-16.3 to 13.1)
Duration of migraine, years	Induprofen	Nicardipine	7.0 (-7.7 to 21.7)
Duration of migraine, years	Induprofen	Nifedipine	6.2 (-8.5 to 20.9)
Duration of migraine, years	Induprofen	Nimodipine	-3.3 (-16.0 to 9.5)
Duration of migraine, years	Induprofen	Propranolol	-1.9 (-13.9 to 10.2)
Duration of migraine, years	Induprofen	Topiramate	5.7 (-5.9 to 17.4)
Duration of migraine, years	Induprofen	Valproate	1.0 (-13.7 to 15.7)
Duration of migraine, years	Induprofen	Verapamil	1.6 (-13.1 to 16.3)
Duration of migraine, years	Magnesium	Naproxen sodium	-12.4 (-27.2 to 2.3)
Duration of migraine, years	Magnesium	Nicardipine	-3.8 (-18.6 to 10.9)
Duration of migraine, years	Magnesium	Nifedipine	-4.6 (-19.4 to 10.1)
Duration of migraine, years	Magnesium	Nimodipine	-14.1 (-26.8 to -1.3)
Duration of migraine, years	Magnesium	Propranolol	-12.7 (-24.7 to -0.7)
Duration of migraine, years	Magnesium	Topiramate	-5.1 (-16.8 to 6.5)
Duration of migraine, years	Magnesium	Valproate	-9.8 (-24.6 to 4.9)
Duration of migraine, years	Magnesium	Verapamil	-9.2 (-24.0 to 5.5)
Duration of migraine, years	Methysergide	Magnesium	15.8 (1.1 to 30.6)
Duration of migraine, years	Methysergide	Metoprolol	0.7 (-11.3 to 12.7)
Duration of migraine, years	Methysergide	Naproxen sodium	3.4 (-11.3 to 18.1)
Duration of migraine, years	Methysergide	Nicardipine	12.0 (-2.7 to 26.7)
Duration of migraine, years	Methysergide	Nifedipine	11.2 (-3.5 to 25.9)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Duration of migraine, years	Methysergide	Nimodipine	1.8 (-11.0 to 14.5)
Duration of migraine, years	Methysergide	Propranolol	3.1 (-8.9 to 15.2)
Duration of migraine, years	Methysergide	Topiramate	10.7 (-0.9 to 22.4)
Duration of migraine, years	Methysergide	Valproate	6.0 (-8.7 to 20.7)
Duration of migraine, years	Methysergide	Verapamil	6.6 (-8.1 to 21.3)
Duration of migraine, years	Metoprolol	Magnesium	15.1 (3.1 to 27.2)
Duration of migraine, years	Metoprolol	Naproxen sodium	2.7 (-9.3 to 14.7)
Duration of migraine, years	Metoprolol	Nicardipine	11.3 (-0.7 to 23.3)
Duration of migraine, years	Metoprolol	Nifedipine	10.5 (-1.5 to 22.5)
Duration of migraine, years	Metoprolol	Nimodipine	1.1 (-8.5 to 10.6)
Duration of migraine, years	Metoprolol	Propranolol	2.4 (-6.1 to 10.9)
Duration of migraine, years	Metoprolol	Topiramate	10.0 (2.0 to 18.0)
Duration of migraine, years	Metoprolol	Valproate	5.3 (-6.7 to 17.3)
Duration of migraine, years	Metoprolol	Verapamil	5.9 (-6.1 to 17.9)
Duration of migraine, years	Naproxen sodium	Nicardipine	8.6 (-6.1 to 23.3)
Duration of migraine, years	Naproxen sodium	Nifedipine	7.8 (-6.9 to 22.5)
Duration of migraine, years	Naproxen sodium	Nimodipine	-1.7 (-14.4 to 11.1)
Duration of migraine, years	Naproxen sodium	Propranolol	-0.3 (-12.3 to 11.8)
Duration of migraine, years	Naproxen sodium	Topiramate	7.3 (-4.3 to 19.0)
Duration of migraine, years	Naproxen sodium	Valproate	2.6 (-12.1 to 17.3)
Duration of migraine, years	Naproxen sodium	Verapamil	3.2 (-11.5 to 17.9)
Duration of migraine, years	Nicardipine	Nifedipine	-0.8 (-15.5 to 13.9)
Duration of migraine, years	Nicardipine	Nimodipine	-10.3 (-23.0 to 2.5)
Duration of migraine, years	Nicardipine	Propranolol	-8.9 (-20.9 to 3.2)
Duration of migraine, years	Nicardipine	Topiramate	-1.3 (-12.9 to 10.4)
Duration of migraine, years	Nicardipine	Valproate	-6.0 (-20.7 to 8.7)
Duration of migraine, years	Nicardipine	Verapamil	-5.4 (-20.1 to 9.3)
Duration of migraine, years	Nifedipine	Nimodipine	-9.5 (-22.2 to 3.3)
Duration of migraine, years	Nifedipine	Propranolol	-8.1 (-20.1 to 4.0)
Duration of migraine, years	Nifedipine	Topiramate	-0.5 (-12.1 to 11.2)
Duration of migraine, years	Nifedipine	Valproate	-5.2 (-19.9 to 9.5)
Duration of migraine, years	Nifedipine	Verapamil	-4.6 (-19.3 to 10.1)
Duration of migraine, years	Nimodipine	Propranolol	1.4 (-8.1 to 10.9)
Duration of migraine, years	Nimodipine	Topiramate	9.0 (-0.1 to 18.0)
Duration of migraine, years	Nimodipine	Valproate	4.3 (-8.5 to 17.0)
Duration of migraine, years	Nimodipine	Verapamil	4.9 (-7.9 to 17.6)
Duration of migraine, years	Propranolol	Topiramate	7.6 (-0.4 to 15.5)
Duration of migraine, years	Propranolol	Valproate	2.9 (-9.2 to 14.9)
Duration of migraine, years	Propranolol	Verapamil	3.5 (-8.6 to 15.5)
Duration of migraine, years	Topiramate	Valproate	-4.7 (-16.4 to 6.9)
Duration of migraine, years	Topiramate	Verapamil	-4.1 (-15.8 to 7.5)
Duration of migraine, years	Valproate	Verapamil	0.6 (-14.1 to 15.3)
Baseline migraine frequency/month	Acebutolol	Acetazolamide	-0.2 (-8.6 to 8.2)
Baseline migraine frequency/month	Acebutolol	Alprenolol	1.8 (-6.6 to 10.2)
Baseline migraine frequency/month	Acebutolol	Atenolol	2.8 (-5.6 to 11.2)
Baseline migraine frequency/month	Acebutolol	Carbamazepine	1.8 (-6.5 to 10.2)
Baseline migraine frequency/month	Acebutolol	Clonidine	0.1 (-6.6 to 6.7)
Baseline migraine frequency/month	Acebutolol	Dihydroergocryptine	-1.2 (-9.6 to 7.2)
Baseline migraine frequency/month	Acebutolol	Dihydroergotamine	0.4 (-6.9 to 7.7)
Baseline migraine frequency/month	Acebutolol	Divalproex	3.3 (-4.0 to 10.6)
Baseline migraine frequency/month	Acebutolol	Femoxetine	-0.2 (-8.6 to 8.2)
Baseline migraine frequency/month	Acebutolol	Fluoxetine	-2.2 (-10.6 to 6.2)
Baseline migraine frequency/month	Acebutolol	Gabapentin	-0.2 (-7.0 to 6.7)
Baseline migraine frequency/month	Acebutolol	Induprofen	0.0 (-8.4 to 8.4)
Baseline migraine frequency/month	Acebutolol	Ketoprofen	2.0 (-6.4 to 10.4)
Baseline migraine frequency/month	Acebutolol	Lamotrigine	0.8 (-7.6 to 9.2)
Baseline migraine frequency/month	Acebutolol	Lisinopril	2.5 (-5.9 to 10.9)
Baseline migraine frequency/month	Acebutolol	Lisuride	1.3 (-7.1 to 9.7)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Baseline migraine frequency/month	Acebutolol	Magnesium	-0.2 (-7.5 to 7.1)
Baseline migraine frequency/month	Acebutolol	Methysergide	1.8 (-6.6 to 10.2)
Baseline migraine frequency/month	Acebutolol	Metoprolol	-0.8 (-7.6 to 6.0)
Baseline migraine frequency/month	Acebutolol	Montelukast	-0.3 (-8.7 to 8.1)
Baseline migraine frequency/month	Acebutolol	Naproxen sodium	3.5 (-4.9 to 11.9)
Baseline migraine frequency/month	Acebutolol	Nicardipine	0.5 (-7.8 to 8.9)
Baseline migraine frequency/month	Acebutolol	Nifedipine	-5.2 (-13.6 to 3.2)
Baseline migraine frequency/month	Acebutolol	Nimodipine	-0.5 (-7.7 to 6.8)
Baseline migraine frequency/month	Acebutolol	Oxcarbazepine	-1.2 (-9.6 to 7.2)
Baseline migraine frequency/month	Acebutolol	Pindolol	2.8 (-5.6 to 11.2)
Baseline migraine frequency/month	Acebutolol	Propranolol	1.6 (-5.1 to 8.2)
Baseline migraine frequency/month	Acebutolol	Rofecoxib	-0.4 (-8.8 to 8.0)
Baseline migraine frequency/month	Acebutolol	Telmisartan	-1.4 (-9.8 to 7.0)
Baseline migraine frequency/month	Acebutolol	Timolol	1.0 (-6.3 to 8.2)
Baseline migraine frequency/month	Acebutolol	Topiramate	-2.3 (-8.5 to 3.9)
Baseline migraine frequency/month	Acebutolol	Valproate	-0.5 (-7.8 to 6.8)
Baseline migraine frequency/month	Acebutolol	Verapamil	-0.5 (-8.9 to 7.9)
Baseline migraine frequency/month	Acebutolol	Vigabatrin	2.8 (-5.6 to 11.2)
Baseline migraine frequency/month	Acetazolamide	Alprenolol	2.0 (-6.4 to 10.4)
Baseline migraine frequency/month	Acetazolamide	Atenolol	3.0 (-5.4 to 11.4)
Baseline migraine frequency/month	Acetazolamide	Carbamazepine	2.0 (-6.3 to 10.4)
Baseline migraine frequency/month	Acetazolamide	Clonidine	0.3 (-6.4 to 6.9)
Baseline migraine frequency/month	Acetazolamide	Dihydroergocryptine	-1.0 (-9.4 to 7.4)
Baseline migraine frequency/month	Acetazolamide	Dihydroergotamine	0.6 (-6.7 to 7.9)
Baseline migraine frequency/month	Acetazolamide	Divalproex	3.5 (-3.8 to 10.8)
Baseline migraine frequency/month	Acetazolamide	Femoxetine	0.0 (-8.4 to 8.4)
Baseline migraine frequency/month	Acetazolamide	Fluoxetine	-2.0 (-10.4 to 6.4)
Baseline migraine frequency/month	Acetazolamide	Gabapentin	0.0 (-6.8 to 6.9)
Baseline migraine frequency/month	Acetazolamide	Induprofen	0.2 (-8.2 to 8.6)
Baseline migraine frequency/month	Acetazolamide	Ketoprofen	2.2 (-6.2 to 10.6)
Baseline migraine frequency/month	Acetazolamide	Lamotrigine	1.0 (-7.4 to 9.4)
Baseline migraine frequency/month	Acetazolamide	Lisinopril	2.7 (-5.7 to 11.1)
Baseline migraine frequency/month	Acetazolamide	Lisuride	1.5 (-6.9 to 9.9)
Baseline migraine frequency/month	Acetazolamide	Magnesium	0.0 (-7.3 to 7.3)
Baseline migraine frequency/month	Acetazolamide	Methysergide	2.0 (-6.4 to 10.4)
Baseline migraine frequency/month	Acetazolamide	Metoprolol	-0.6 (-7.4 to 6.2)
Baseline migraine frequency/month	Acetazolamide	Montelukast	-0.1 (-8.5 to 8.3)
Baseline migraine frequency/month	Acetazolamide	Naproxen sodium	3.7 (-4.7 to 12.1)
Baseline migraine frequency/month	Acetazolamide	Nicardipine	0.7 (-7.6 to 9.1)
Baseline migraine frequency/month	Acetazolamide	Nifedipine	-5.0 (-13.4 to 3.4)
Baseline migraine frequency/month	Acetazolamide	Nimodipine	-0.3 (-7.5 to 7.0)
Baseline migraine frequency/month	Acetazolamide	Oxcarbazepine	-1.0 (-9.4 to 7.4)
Baseline migraine frequency/month	Acetazolamide	Pindolol	3.0 (-5.4 to 11.4)
Baseline migraine frequency/month	Acetazolamide	Propranolol	1.8 (-4.9 to 8.4)
Baseline migraine frequency/month	Acetazolamide	Rofecoxib	-0.2 (-8.6 to 8.2)
Baseline migraine frequency/month	Acetazolamide	Telmisartan	-1.2 (-9.6 to 7.2)
Baseline migraine frequency/month	Acetazolamide	Timolol	1.2 (-6.1 to 8.4)
Baseline migraine frequency/month	Acetazolamide	Topiramate	-2.1 (-8.3 to 4.1)
Baseline migraine frequency/month	Acetazolamide	Valproate	-0.3 (-7.6 to 7.0)
Baseline migraine frequency/month	Acetazolamide	Verapamil	-0.3 (-8.7 to 8.1)
Baseline migraine frequency/month	Acetazolamide	Vigabatrin	3.0 (-5.4 to 11.4)
Baseline migraine frequency/month	Alprenolol	Atenolol	1.0 (-7.4 to 9.4)
Baseline migraine frequency/month	Alprenolol	Carbamazepine	0.0 (-8.3 to 8.4)
Baseline migraine frequency/month	Alprenolol	Clonidine	-1.7 (-8.4 to 4.9)
Baseline migraine frequency/month	Alprenolol	Dihydroergocryptine	-3.0 (-11.4 to 5.4)
Baseline migraine frequency/month	Alprenolol	Dihydroergotamine	-1.4 (-8.7 to 5.9)
Baseline migraine frequency/month	Alprenolol	Divalproex	1.5 (-5.8 to 8.8)
Baseline migraine frequency/month	Alprenolol	Femoxetine	-2.0 (-10.4 to 6.4)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Baseline migraine frequency/month	Alprenolol	Fluoxetine	-4.0 (-12.4 to 4.4)
Baseline migraine frequency/month	Alprenolol	Gabapentin	-2.0 (-8.8 to 4.9)
Baseline migraine frequency/month	Alprenolol	Induprofen	-1.8 (-10.2 to 6.6)
Baseline migraine frequency/month	Alprenolol	Ketoprofen	0.2 (-8.2 to 8.6)
Baseline migraine frequency/month	Alprenolol	Lamotrigine	-1.0 (-9.4 to 7.4)
Baseline migraine frequency/month	Alprenolol	Lisinopril	0.7 (-7.7 to 9.1)
Baseline migraine frequency/month	Alprenolol	Lisuride	-0.5 (-8.9 to 7.9)
Baseline migraine frequency/month	Alprenolol	Magnesium	-2.0 (-9.3 to 5.3)
Baseline migraine frequency/month	Alprenolol	Methysergide	0.0 (-8.4 to 8.4)
Baseline migraine frequency/month	Alprenolol	Metoprolol	-2.6 (-9.4 to 4.2)
Baseline migraine frequency/month	Alprenolol	Montelukast	-2.1 (-10.5 to 6.3)
Baseline migraine frequency/month	Alprenolol	Naproxen sodium	1.7 (-6.7 to 10.1)
Baseline migraine frequency/month	Alprenolol	Nicardipine	-1.3 (-9.6 to 7.1)
Baseline migraine frequency/month	Alprenolol	Nifedipine	-7.0 (-15.4 to 1.4)
Baseline migraine frequency/month	Alprenolol	Nimodipine	-2.3 (-9.5 to 5.0)
Baseline migraine frequency/month	Alprenolol	Oxcarbazepine	-3.0 (-11.4 to 5.4)
Baseline migraine frequency/month	Alprenolol	Pindolol	1.0 (-7.4 to 9.4)
Baseline migraine frequency/month	Alprenolol	Propranolol	-0.3 (-6.9 to 6.4)
Baseline migraine frequency/month	Alprenolol	Rofecoxib	-2.2 (-10.6 to 6.2)
Baseline migraine frequency/month	Alprenolol	Telmisartan	-3.2 (-11.6 to 5.2)
Baseline migraine frequency/month	Alprenolol	Timolol	-0.9 (-8.1 to 6.4)
Baseline migraine frequency/month	Alprenolol	Topiramate	-4.1 (-10.3 to 2.1)
Baseline migraine frequency/month	Alprenolol	Valproate	-2.3 (-9.6 to 5.0)
Baseline migraine frequency/month	Alprenolol	Verapamil	-2.3 (-10.7 to 6.1)
Baseline migraine frequency/month	Alprenolol	Vigabatrin	1.0 (-7.4 to 9.4)
Baseline migraine frequency/month	Atenolol	Carbamazepine	-1.0 (-9.3 to 7.4)
Baseline migraine frequency/month	Atenolol	Clonidine	-2.7 (-9.4 to 3.9)
Baseline migraine frequency/month	Atenolol	Dihydroergocryptine	-4.0 (-12.4 to 4.4)
Baseline migraine frequency/month	Atenolol	Dihydroergotamine	-2.4 (-9.7 to 4.9)
Baseline migraine frequency/month	Atenolol	Divalproex	0.5 (-6.8 to 7.8)
Baseline migraine frequency/month	Atenolol	Femoxetine	-3.0 (-11.4 to 5.4)
Baseline migraine frequency/month	Atenolol	Fluoxetine	-5.0 (-13.4 to 3.4)
Baseline migraine frequency/month	Atenolol	Gabapentin	-3.0 (-9.8 to 3.9)
Baseline migraine frequency/month	Atenolol	Induprofen	-2.8 (-11.2 to 5.6)
Baseline migraine frequency/month	Atenolol	Ketoprofen	-0.8 (-9.2 to 7.6)
Baseline migraine frequency/month	Atenolol	Lamotrigine	-2.0 (-10.4 to 6.4)
Baseline migraine frequency/month	Atenolol	Lisinopril	-0.3 (-8.7 to 8.1)
Baseline migraine frequency/month	Atenolol	Lisuride	-1.5 (-9.9 to 6.9)
Baseline migraine frequency/month	Atenolol	Magnesium	-3.0 (-10.3 to 4.3)
Baseline migraine frequency/month	Atenolol	Methysergide	-1.0 (-9.4 to 7.4)
Baseline migraine frequency/month	Atenolol	Metoprolol	-3.6 (-10.4 to 3.2)
Baseline migraine frequency/month	Atenolol	Montelukast	-3.1 (-11.5 to 5.3)
Baseline migraine frequency/month	Atenolol	Naproxen sodium	0.7 (-7.7 to 9.1)
Baseline migraine frequency/month	Atenolol	Nicardipine	-2.3 (-10.6 to 6.1)
Baseline migraine frequency/month	Atenolol	Nifedipine	-8.0 (-16.4 to 0.4)
Baseline migraine frequency/month	Atenolol	Nimodipine	-3.3 (-10.5 to 4.0)
Baseline migraine frequency/month	Atenolol	Oxcarbazepine	-4.0 (-12.4 to 4.4)
Baseline migraine frequency/month	Atenolol	Pindolol	0.0 (-8.4 to 8.4)
Baseline migraine frequency/month	Atenolol	Propranolol	-1.3 (-7.9 to 5.4)
Baseline migraine frequency/month	Atenolol	Rofecoxib	-3.2 (-11.6 to 5.2)
Baseline migraine frequency/month	Atenolol	Telmisartan	-4.2 (-12.6 to 4.2)
Baseline migraine frequency/month	Atenolol	Timolol	-1.9 (-9.1 to 5.4)
Baseline migraine frequency/month	Atenolol	Topiramate	-5.1 (-11.3 to 1.1)
Baseline migraine frequency/month	Atenolol	Valproate	-3.3 (-10.6 to 4.0)
Baseline migraine frequency/month	Atenolol	Verapamil	-3.3 (-11.7 to 5.1)
Baseline migraine frequency/month	Atenolol	Vigabatrin	0.0 (-8.4 to 8.4)
Baseline migraine frequency/month	Carbamazepine	Clonidine	-1.8 (-8.4 to 4.8)
Baseline migraine frequency/month	Carbamazepine	Dihydroergocryptine	-3.0 (-11.4 to 5.3)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Baseline migraine frequency/month	Carbamazepine	Dihydroergotamine	-1.4 (-8.7 to 5.8)
Baseline migraine frequency/month	Carbamazepine	Divalproex	1.5 (-5.8 to 8.7)
Baseline migraine frequency/month	Carbamazepine	Femoxetine	-2.0 (-10.4 to 6.3)
Baseline migraine frequency/month	Carbamazepine	Fluoxetine	-4.0 (-12.4 to 4.3)
Baseline migraine frequency/month	Carbamazepine	Gabapentin	-2.0 (-8.8 to 4.8)
Baseline migraine frequency/month	Carbamazepine	Induprofen	-1.8 (-10.2 to 6.5)
Baseline migraine frequency/month	Carbamazepine	Ketoprofen	0.2 (-8.2 to 8.5)
Baseline migraine frequency/month	Carbamazepine	Lamotrigine	-1.1 (-9.4 to 7.3)
Baseline migraine frequency/month	Carbamazepine	Lisinopril	0.7 (-7.7 to 9.0)
Baseline migraine frequency/month	Carbamazepine	Lisuride	-0.5 (-8.9 to 7.8)
Baseline migraine frequency/month	Carbamazepine	Magnesium	-2.0 (-9.3 to 5.2)
Baseline migraine frequency/month	Carbamazepine	Methysergide	0.0 (-8.4 to 8.3)
Baseline migraine frequency/month	Carbamazepine	Metoprolol	-2.6 (-9.5 to 4.2)
Baseline migraine frequency/month	Carbamazepine	Montelukast	-2.1 (-10.5 to 6.2)
Baseline migraine frequency/month	Carbamazepine	Naproxen sodium	1.7 (-6.7 to 10.0)
Baseline migraine frequency/month	Carbamazepine	Nicardipine	-1.3 (-9.7 to 7.1)
Baseline migraine frequency/month	Carbamazepine	Nifedipine	-7.0 (-15.4 to 1.3)
Baseline migraine frequency/month	Carbamazepine	Nimodipine	-2.3 (-9.5 to 5.0)
Baseline migraine frequency/month	Carbamazepine	Oxcarbazepine	-3.0 (-11.4 to 5.3)
Baseline migraine frequency/month	Carbamazepine	Pindolol	1.0 (-7.4 to 9.3)
Baseline migraine frequency/month	Carbamazepine	Propranolol	-0.3 (-6.9 to 6.3)
Baseline migraine frequency/month	Carbamazepine	Rofecoxib	-2.3 (-10.6 to 6.1)
Baseline migraine frequency/month	Carbamazepine	Telmisartan	-3.2 (-11.6 to 5.1)
Baseline migraine frequency/month	Carbamazepine	Timolol	-0.9 (-8.1 to 6.4)
Baseline migraine frequency/month	Carbamazepine	Topiramate	-4.2 (-10.4 to 2.1)
Baseline migraine frequency/month	Carbamazepine	Valproate	-2.3 (-9.6 to 4.9)
Baseline migraine frequency/month	Carbamazepine	Verapamil	-2.3 (-10.7 to 6.0)
Baseline migraine frequency/month	Carbamazepine	Vigabatrin	1.0 (-7.4 to 9.3)
Baseline migraine frequency/month	Clonidine	Dihydroergocryptine	-1.3 (-7.9 to 5.4)
Baseline migraine frequency/month	Clonidine	Dihydroergotamine	0.3 (-4.8 to 5.5)
Baseline migraine frequency/month	Clonidine	Divalproex	3.2 (-1.9 to 8.4)
Baseline migraine frequency/month	Clonidine	Femoxetine	-0.3 (-6.9 to 6.4)
Baseline migraine frequency/month	Clonidine	Fluoxetine	-2.3 (-8.9 to 4.4)
Baseline migraine frequency/month	Clonidine	Gabapentin	-0.2 (-4.7 to 4.3)
Baseline migraine frequency/month	Clonidine	Induprofen	-0.1 (-6.7 to 6.6)
Baseline migraine frequency/month	Clonidine	Ketoprofen	1.9 (-4.7 to 8.6)
Baseline migraine frequency/month	Clonidine	Lamotrigine	0.7 (-5.9 to 7.3)
Baseline migraine frequency/month	Clonidine	Lisinopril	2.4 (-4.2 to 9.1)
Baseline migraine frequency/month	Clonidine	Lisuride	1.2 (-5.4 to 7.9)
Baseline migraine frequency/month	Clonidine	Magnesium	-0.3 (-5.4 to 4.9)
Baseline migraine frequency/month	Clonidine	Methysergide	1.7 (-4.9 to 8.4)
Baseline migraine frequency/month	Clonidine	Metoprolol	-0.8 (-5.4 to 3.7)
Baseline migraine frequency/month	Clonidine	Montelukast	-0.4 (-7.0 to 6.3)
Baseline migraine frequency/month	Clonidine	Naproxen sodium	3.4 (-3.2 to 10.1)
Baseline migraine frequency/month	Clonidine	Nicardipine	0.5 (-6.1 to 7.1)
Baseline migraine frequency/month	Clonidine	Nifedipine	-5.3 (-11.9 to 1.4)
Baseline migraine frequency/month	Clonidine	Nimodipine	-0.5 (-5.6 to 4.6)
Baseline migraine frequency/month	Clonidine	Oxcarbazepine	-1.3 (-7.9 to 5.4)
Baseline migraine frequency/month	Clonidine	Pindolol	2.7 (-3.9 to 9.4)
Baseline migraine frequency/month	Clonidine	Propranolol	1.5 (-2.7 to 5.7)
Baseline migraine frequency/month	Clonidine	Rofecoxib	-0.5 (-7.1 to 6.1)
Baseline migraine frequency/month	Clonidine	Telmisartan	-1.5 (-8.1 to 5.2)
Baseline migraine frequency/month	Clonidine	Timolol	0.9 (-4.2 to 6.0)
Baseline migraine frequency/month	Clonidine	Topiramate	-2.4 (-5.9 to 1.1)
Baseline migraine frequency/month	Clonidine	Valproate	-0.6 (-5.7 to 4.6)
Baseline migraine frequency/month	Clonidine	Verapamil	-0.6 (-7.2 to 6.1)
Baseline migraine frequency/month	Clonidine	Vigabatrin	2.7 (-3.9 to 9.4)
Baseline migraine frequency/month	Dihydroergocryptine	Dihydroergotamine	1.6 (-5.7 to 8.9)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Baseline migraine frequency/month	Dihydroergocryptine	Divalproex	4.5 (-2.8 to 11.8)
Baseline migraine frequency/month	Dihydroergocryptine	Femoxetine	1.0 (-7.4 to 9.4)
Baseline migraine frequency/month	Dihydroergocryptine	Fluoxetine	-1.0 (-9.4 to 7.4)
Baseline migraine frequency/month	Dihydroergocryptine	Gabapentin	1.0 (-5.8 to 7.9)
Baseline migraine frequency/month	Dihydroergocryptine	Induprofen	1.2 (-7.2 to 9.6)
Baseline migraine frequency/month	Dihydroergocryptine	Ketoprofen	3.2 (-5.2 to 11.6)
Baseline migraine frequency/month	Dihydroergocryptine	Lamotrigine	2.0 (-6.4 to 10.4)
Baseline migraine frequency/month	Dihydroergocryptine	Lisinopril	3.7 (-4.7 to 12.1)
Baseline migraine frequency/month	Dihydroergocryptine	Lisuride	2.5 (-5.9 to 10.9)
Baseline migraine frequency/month	Dihydroergocryptine	Magnesium	1.0 (-6.3 to 8.3)
Baseline migraine frequency/month	Dihydroergocryptine	Methysergide	3.0 (-5.4 to 11.4)
Baseline migraine frequency/month	Dihydroergocryptine	Metoprolol	0.4 (-6.4 to 7.2)
Baseline migraine frequency/month	Dihydroergocryptine	Montelukast	0.9 (-7.5 to 9.3)
Baseline migraine frequency/month	Dihydroergocryptine	Naproxen sodium	4.7 (-3.7 to 13.1)
Baseline migraine frequency/month	Dihydroergocryptine	Nicardipine	1.7 (-6.6 to 10.1)
Baseline migraine frequency/month	Dihydroergocryptine	Nifedipine	-4.0 (-12.4 to 4.4)
Baseline migraine frequency/month	Dihydroergocryptine	Nimodipine	0.8 (-6.5 to 8.0)
Baseline migraine frequency/month	Dihydroergocryptine	Oxcarbazepine	0.0 (-8.4 to 8.4)
Baseline migraine frequency/month	Dihydroergocryptine	Pindolol	4.0 (-4.4 to 12.4)
Baseline migraine frequency/month	Dihydroergocryptine	Propranolol	2.8 (-3.9 to 9.4)
Baseline migraine frequency/month	Dihydroergocryptine	Rofecoxib	0.8 (-7.6 to 9.2)
Baseline migraine frequency/month	Dihydroergocryptine	Telmisartan	-0.2 (-8.6 to 8.2)
Baseline migraine frequency/month	Dihydroergocryptine	Timolol	2.2 (-5.1 to 9.4)
Baseline migraine frequency/month	Dihydroergocryptine	Topiramate	-1.1 (-7.3 to 5.1)
Baseline migraine frequency/month	Dihydroergocryptine	Valproate	0.7 (-6.6 to 8.0)
Baseline migraine frequency/month	Dihydroergocryptine	Verapamil	0.7 (-7.7 to 9.1)
Baseline migraine frequency/month	Dihydroergocryptine	Vigabatrin	4.0 (-4.4 to 12.4)
Baseline migraine frequency/month	Dihydroergotamine	Divalproex	2.9 (-3.0 to 8.8)
Baseline migraine frequency/month	Dihydroergotamine	Femoxetine	-0.6 (-7.9 to 6.7)
Baseline migraine frequency/month	Dihydroergotamine	Fluoxetine	-2.6 (-9.9 to 4.7)
Baseline migraine frequency/month	Dihydroergotamine	Gabapentin	-0.6 (-6.0 to 4.8)
Baseline migraine frequency/month	Dihydroergotamine	Induprofen	-0.4 (-7.7 to 6.9)
Baseline migraine frequency/month	Dihydroergotamine	Ketoprofen	1.6 (-5.7 to 8.9)
Baseline migraine frequency/month	Dihydroergotamine	Lamotrigine	0.4 (-6.9 to 7.6)
Baseline migraine frequency/month	Dihydroergotamine	Lisinopril	2.1 (-5.2 to 9.4)
Baseline migraine frequency/month	Dihydroergotamine	Lisuride	0.9 (-6.4 to 8.2)
Baseline migraine frequency/month	Dihydroergotamine	Magnesium	-0.6 (-6.5 to 5.3)
Baseline migraine frequency/month	Dihydroergotamine	Methysergide	1.4 (-5.9 to 8.7)
Baseline migraine frequency/month	Dihydroergotamine	Metoprolol	-1.2 (-6.6 to 4.2)
Baseline migraine frequency/month	Dihydroergotamine	Montelukast	-0.7 (-8.0 to 6.6)
Baseline migraine frequency/month	Dihydroergotamine	Naproxen sodium	3.1 (-4.2 to 10.4)
Baseline migraine frequency/month	Dihydroergotamine	Nicardipine	0.1 (-7.1 to 7.4)
Baseline migraine frequency/month	Dihydroergotamine	Nifedipine	-5.6 (-12.9 to 1.7)
Baseline migraine frequency/month	Dihydroergotamine	Nimodipine	-0.9 (-6.8 to 5.1)
Baseline migraine frequency/month	Dihydroergotamine	Oxcarbazepine	-1.6 (-8.9 to 5.7)
Baseline migraine frequency/month	Dihydroergotamine	Pindolol	2.4 (-4.9 to 9.7)
Baseline migraine frequency/month	Dihydroergotamine	Propranolol	1.2 (-4.0 to 6.3)
Baseline migraine frequency/month	Dihydroergotamine	Rofecoxib	-0.8 (-8.1 to 6.4)
Baseline migraine frequency/month	Dihydroergotamine	Telmisartan	-1.8 (-9.1 to 5.5)
Baseline migraine frequency/month	Dihydroergotamine	Timolol	0.6 (-5.4 to 6.5)
Baseline migraine frequency/month	Dihydroergotamine	Topiramate	-2.7 (-7.3 to 1.9)
Baseline migraine frequency/month	Dihydroergotamine	Valproate	-0.9 (-6.8 to 5.0)
Baseline migraine frequency/month	Dihydroergotamine	Verapamil	-0.9 (-8.2 to 6.4)
Baseline migraine frequency/month	Dihydroergotamine	Vigabatrin	2.4 (-4.9 to 9.7)
Baseline migraine frequency/month	Divalproex	Femoxetine	-3.5 (-10.8 to 3.8)
Baseline migraine frequency/month	Divalproex	Fluoxetine	-5.5 (-12.8 to 1.8)
Baseline migraine frequency/month	Divalproex	Gabapentin	-3.5 (-8.9 to 1.9)
Baseline migraine frequency/month	Divalproex	Induprofen	-3.3 (-10.6 to 4.0)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Baseline migraine frequency/month	Divalproex	Ketoprofen	-1.3 (-8.6 to 6.0)
Baseline migraine frequency/month	Divalproex	Lamotrigine	-2.5 (-9.8 to 4.7)
Baseline migraine frequency/month	Divalproex	Lisinopril	-0.8 (-8.1 to 6.5)
Baseline migraine frequency/month	Divalproex	Lisuride	-2.0 (-9.3 to 5.3)
Baseline migraine frequency/month	Divalproex	Magnesium	-3.5 (-9.4 to 2.4)
Baseline migraine frequency/month	Divalproex	Methysergide	-1.5 (-8.8 to 5.8)
Baseline migraine frequency/month	Divalproex	Metoprolol	-4.1 (-9.5 to 1.3)
Baseline migraine frequency/month	Divalproex	Montelukast	-3.6 (-10.9 to 3.7)
Baseline migraine frequency/month	Divalproex	Naproxen sodium	0.2 (-7.1 to 7.5)
Baseline migraine frequency/month	Divalproex	Nicardipine	-2.8 (-10.0 to 4.5)
Baseline migraine frequency/month	Divalproex	Nifedipine	-8.5 (-15.8 to -1.2)
Baseline migraine frequency/month	Divalproex	Nimodipine	-3.8 (-9.7 to 2.2)
Baseline migraine frequency/month	Divalproex	Oxcarbazepine	-4.5 (-11.8 to 2.8)
Baseline migraine frequency/month	Divalproex	Pindolol	-0.5 (-7.8 to 6.8)
Baseline migraine frequency/month	Divalproex	Propranolol	-1.8 (-6.9 to 3.4)
Baseline migraine frequency/month	Divalproex	Rofecoxib	-3.7 (-11.0 to 3.5)
Baseline migraine frequency/month	Divalproex	Telmisartan	-4.7 (-12.0 to 2.6)
Baseline migraine frequency/month	Divalproex	Timolol	-2.4 (-8.3 to 3.6)
Baseline migraine frequency/month	Divalproex	Topiramate	-5.6 (-10.2 to -1.0)
Baseline migraine frequency/month	Divalproex	Valproate	-3.8 (-9.7 to 2.1)
Baseline migraine frequency/month	Divalproex	Verapamil	-3.8 (-11.1 to 3.5)
Baseline migraine frequency/month	Divalproex	Vigabatrin	-0.5 (-7.8 to 6.8)
Baseline migraine frequency/month	Femoxetine	Fluoxetine	-2.0 (-10.4 to 6.4)
Baseline migraine frequency/month	Femoxetine	Gabapentin	0.0 (-6.8 to 6.9)
Baseline migraine frequency/month	Femoxetine	Induprofen	0.2 (-8.2 to 8.6)
Baseline migraine frequency/month	Femoxetine	Ketoprofen	2.2 (-6.2 to 10.6)
Baseline migraine frequency/month	Femoxetine	Lamotrigine	1.0 (-7.4 to 9.4)
Baseline migraine frequency/month	Femoxetine	Lisinopril	2.7 (-5.7 to 11.1)
Baseline migraine frequency/month	Femoxetine	Lisuride	1.5 (-6.9 to 9.9)
Baseline migraine frequency/month	Femoxetine	Magnesium	0.0 (-7.3 to 7.3)
Baseline migraine frequency/month	Femoxetine	Methysergide	2.0 (-6.4 to 10.4)
Baseline migraine frequency/month	Femoxetine	Metoprolol	-0.6 (-7.4 to 6.2)
Baseline migraine frequency/month	Femoxetine	Montelukast	-0.1 (-8.5 to 8.3)
Baseline migraine frequency/month	Femoxetine	Naproxen sodium	3.7 (-4.7 to 12.1)
Baseline migraine frequency/month	Femoxetine	Nicardipine	0.7 (-7.6 to 9.1)
Baseline migraine frequency/month	Femoxetine	Nifedipine	-5.0 (-13.4 to 3.4)
Baseline migraine frequency/month	Femoxetine	Nimodipine	-0.3 (-7.5 to 7.0)
Baseline migraine frequency/month	Femoxetine	Oxcarbazepine	-1.0 (-9.4 to 7.4)
Baseline migraine frequency/month	Femoxetine	Pindolol	3.0 (-5.4 to 11.4)
Baseline migraine frequency/month	Femoxetine	Propranolol	1.8 (-4.9 to 8.4)
Baseline migraine frequency/month	Femoxetine	Rofecoxib	-0.2 (-8.6 to 8.2)
Baseline migraine frequency/month	Femoxetine	Telmisartan	-1.2 (-9.6 to 7.2)
Baseline migraine frequency/month	Femoxetine	Timolol	1.2 (-6.1 to 8.4)
Baseline migraine frequency/month	Femoxetine	Topiramate	-2.1 (-8.3 to 4.1)
Baseline migraine frequency/month	Femoxetine	Valproate	-0.3 (-7.6 to 7.0)
Baseline migraine frequency/month	Femoxetine	Verapamil	-0.3 (-8.7 to 8.1)
Baseline migraine frequency/month	Femoxetine	Vigabatrin	3.0 (-5.4 to 11.4)
Baseline migraine frequency/month	Fluoxetine	Gabapentin	2.0 (-4.8 to 8.9)
Baseline migraine frequency/month	Fluoxetine	Induprofen	2.2 (-6.2 to 10.6)
Baseline migraine frequency/month	Fluoxetine	Ketoprofen	4.2 (-4.2 to 12.6)
Baseline migraine frequency/month	Fluoxetine	Lamotrigine	3.0 (-5.4 to 11.4)
Baseline migraine frequency/month	Fluoxetine	Lisinopril	4.7 (-3.7 to 13.1)
Baseline migraine frequency/month	Fluoxetine	Lisuride	3.5 (-4.9 to 11.9)
Baseline migraine frequency/month	Fluoxetine	Magnesium	2.0 (-5.3 to 9.3)
Baseline migraine frequency/month	Fluoxetine	Methysergide	4.0 (-4.4 to 12.4)
Baseline migraine frequency/month	Fluoxetine	Metoprolol	1.4 (-5.4 to 8.2)
Baseline migraine frequency/month	Fluoxetine	Montelukast	1.9 (-6.5 to 10.3)
Baseline migraine frequency/month	Fluoxetine	Naproxen sodium	5.7 (-2.7 to 14.1)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Baseline migraine frequency/month	Fluoxetine	Nicardipine	2.7 (-5.6 to 11.1)
Baseline migraine frequency/month	Fluoxetine	Nifedipine	-3.0 (-11.4 to 5.4)
Baseline migraine frequency/month	Fluoxetine	Nimodipine	1.8 (-5.5 to 9.0)
Baseline migraine frequency/month	Fluoxetine	Oxcarbazepine	1.0 (-7.4 to 9.4)
Baseline migraine frequency/month	Fluoxetine	Pindolol	5.0 (-3.4 to 13.4)
Baseline migraine frequency/month	Fluoxetine	Propranolol	3.8 (-2.9 to 10.4)
Baseline migraine frequency/month	Fluoxetine	Rofecoxib	1.8 (-6.6 to 10.2)
Baseline migraine frequency/month	Fluoxetine	Telmisartan	0.8 (-7.6 to 9.2)
Baseline migraine frequency/month	Fluoxetine	Timolol	3.2 (-4.1 to 10.4)
Baseline migraine frequency/month	Fluoxetine	Topiramate	-0.1 (-6.3 to 6.1)
Baseline migraine frequency/month	Fluoxetine	Valproate	1.7 (-5.6 to 9.0)
Baseline migraine frequency/month	Fluoxetine	Verapamil	1.7 (-6.7 to 10.1)
Baseline migraine frequency/month	Fluoxetine	Vigabatrin	5.0 (-3.4 to 13.4)
Baseline migraine frequency/month	Gabapentin	Induprofen	0.2 (-6.7 to 7.0)
Baseline migraine frequency/month	Gabapentin	Ketoprofen	2.2 (-4.7 to 9.0)
Baseline migraine frequency/month	Gabapentin	Lamotrigine	0.9 (-5.9 to 7.8)
Baseline migraine frequency/month	Gabapentin	Lisinopril	2.7 (-4.2 to 9.5)
Baseline migraine frequency/month	Gabapentin	Lisuride	1.5 (-5.4 to 8.3)
Baseline migraine frequency/month	Gabapentin	Magnesium	0.0 (-5.4 to 5.4)
Baseline migraine frequency/month	Gabapentin	Methysergide	2.0 (-4.9 to 8.8)
Baseline migraine frequency/month	Gabapentin	Metoprolol	-0.6 (-5.5 to 4.2)
Baseline migraine frequency/month	Gabapentin	Montelukast	-0.1 (-7.0 to 6.7)
Baseline migraine frequency/month	Gabapentin	Naproxen sodium	3.7 (-3.2 to 10.5)
Baseline migraine frequency/month	Gabapentin	Nicardipine	0.7 (-6.1 to 7.5)
Baseline migraine frequency/month	Gabapentin	Nifedipine	-5.0 (-11.9 to 1.8)
Baseline migraine frequency/month	Gabapentin	Nimodipine	-0.3 (-5.7 to 5.1)
Baseline migraine frequency/month	Gabapentin	Oxcarbazepine	-1.0 (-7.9 to 5.8)
Baseline migraine frequency/month	Gabapentin	Pindolol	3.0 (-3.9 to 9.8)
Baseline migraine frequency/month	Gabapentin	Propranolol	1.7 (-2.8 to 6.2)
Baseline migraine frequency/month	Gabapentin	Rofecoxib	-0.3 (-7.1 to 6.6)
Baseline migraine frequency/month	Gabapentin	Telmisartan	-1.2 (-8.1 to 5.6)
Baseline migraine frequency/month	Gabapentin	Timolol	1.1 (-4.3 to 6.5)
Baseline migraine frequency/month	Gabapentin	Topiramate	-2.2 (-6.1 to 1.7)
Baseline migraine frequency/month	Gabapentin	Valproate	-0.3 (-5.7 to 5.1)
Baseline migraine frequency/month	Gabapentin	Verapamil	-0.3 (-7.2 to 6.5)
Baseline migraine frequency/month	Gabapentin	Vigabatrin	3.0 (-3.9 to 9.8)
Baseline migraine frequency/month	Induprofen	Ketoprofen	2.0 (-6.4 to 10.4)
Baseline migraine frequency/month	Induprofen	Lamotrigine	0.8 (-7.6 to 9.2)
Baseline migraine frequency/month	Induprofen	Lisinopril	2.5 (-5.9 to 10.9)
Baseline migraine frequency/month	Induprofen	Lisuride	1.3 (-7.1 to 9.7)
Baseline migraine frequency/month	Induprofen	Magnesium	-0.2 (-7.5 to 7.1)
Baseline migraine frequency/month	Induprofen	Methysergide	1.8 (-6.6 to 10.2)
Baseline migraine frequency/month	Induprofen	Metoprolol	-0.8 (-7.6 to 6.0)
Baseline migraine frequency/month	Induprofen	Montelukast	-0.3 (-8.7 to 8.1)
Baseline migraine frequency/month	Induprofen	Naproxen sodium	3.5 (-4.9 to 11.9)
Baseline migraine frequency/month	Induprofen	Nicardipine	0.5 (-7.8 to 8.9)
Baseline migraine frequency/month	Induprofen	Nifedipine	-5.2 (-13.6 to 3.2)
Baseline migraine frequency/month	Induprofen	Nimodipine	-0.5 (-7.7 to 6.8)
Baseline migraine frequency/month	Induprofen	Oxcarbazepine	-1.2 (-9.6 to 7.2)
Baseline migraine frequency/month	Induprofen	Pindolol	2.8 (-5.6 to 11.2)
Baseline migraine frequency/month	Induprofen	Propranolol	1.6 (-5.1 to 8.2)
Baseline migraine frequency/month	Induprofen	Rofecoxib	-0.4 (-8.8 to 8.0)
Baseline migraine frequency/month	Induprofen	Telmisartan	-1.4 (-9.8 to 7.0)
Baseline migraine frequency/month	Induprofen	Timolol	1.0 (-6.3 to 8.2)
Baseline migraine frequency/month	Induprofen	Topiramate	-2.3 (-8.5 to 3.9)
Baseline migraine frequency/month	Induprofen	Valproate	-0.5 (-7.8 to 6.8)
Baseline migraine frequency/month	Induprofen	Verapamil	-0.5 (-8.9 to 7.9)
Baseline migraine frequency/month	Induprofen	Vigabatrin	2.8 (-5.6 to 11.2)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Baseline migraine frequency/month	Ketoprofen	Lamotrigine	-1.2 (-9.6 to 7.2)
Baseline migraine frequency/month	Ketoprofen	Lisinopril	0.5 (-7.9 to 8.9)
Baseline migraine frequency/month	Ketoprofen	Lisuride	-0.7 (-9.1 to 7.7)
Baseline migraine frequency/month	Ketoprofen	Magnesium	-2.2 (-9.5 to 5.1)
Baseline migraine frequency/month	Ketoprofen	Methysergide	-0.2 (-8.6 to 8.2)
Baseline migraine frequency/month	Ketoprofen	Metoprolol	-2.8 (-9.6 to 4.0)
Baseline migraine frequency/month	Ketoprofen	Montelukast	-2.3 (-10.7 to 6.1)
Baseline migraine frequency/month	Ketoprofen	Naproxen sodium	1.5 (-6.9 to 9.9)
Baseline migraine frequency/month	Ketoprofen	Nicardipine	-1.5 (-9.8 to 6.9)
Baseline migraine frequency/month	Ketoprofen	Nifedipine	-7.2 (-15.6 to 1.2)
Baseline migraine frequency/month	Ketoprofen	Nimodipine	-2.5 (-9.7 to 4.8)
Baseline migraine frequency/month	Ketoprofen	Oxcarbazepine	-3.2 (-11.6 to 5.2)
Baseline migraine frequency/month	Ketoprofen	Pindolol	0.8 (-7.6 to 9.2)
Baseline migraine frequency/month	Ketoprofen	Propranolol	-0.5 (-7.1 to 6.2)
Baseline migraine frequency/month	Ketoprofen	Rofecoxib	-2.4 (-10.8 to 6.0)
Baseline migraine frequency/month	Ketoprofen	Telmisartan	-3.4 (-11.8 to 5.0)
Baseline migraine frequency/month	Ketoprofen	Timolol	-1.1 (-8.3 to 6.2)
Baseline migraine frequency/month	Ketoprofen	Topiramate	-4.3 (-10.5 to 1.9)
Baseline migraine frequency/month	Ketoprofen	Valproate	-2.5 (-9.8 to 4.8)
Baseline migraine frequency/month	Ketoprofen	Verapamil	-2.5 (-10.9 to 5.9)
Baseline migraine frequency/month	Ketoprofen	Vigabatrin	0.8 (-7.6 to 9.2)
Baseline migraine frequency/month	Lamotrigine	Lisinopril	1.7 (-6.7 to 10.1)
Baseline migraine frequency/month	Lamotrigine	Lisuride	0.5 (-7.9 to 8.9)
Baseline migraine frequency/month	Lamotrigine	Magnesium	-1.0 (-8.2 to 6.3)
Baseline migraine frequency/month	Lamotrigine	Methysergide	1.0 (-7.4 to 9.4)
Baseline migraine frequency/month	Lamotrigine	Metoprolol	-1.6 (-8.4 to 5.3)
Baseline migraine frequency/month	Lamotrigine	Montelukast	-1.1 (-9.5 to 7.3)
Baseline migraine frequency/month	Lamotrigine	Naproxen sodium	2.7 (-5.7 to 11.1)
Baseline migraine frequency/month	Lamotrigine	Nicardipine	-0.2 (-8.6 to 8.1)
Baseline migraine frequency/month	Lamotrigine	Nifedipine	-6.0 (-14.4 to 2.4)
Baseline migraine frequency/month	Lamotrigine	Nimodipine	-1.2 (-8.5 to 6.0)
Baseline migraine frequency/month	Lamotrigine	Oxcarbazepine	-2.0 (-10.4 to 6.4)
Baseline migraine frequency/month	Lamotrigine	Pindolol	2.0 (-6.4 to 10.4)
Baseline migraine frequency/month	Lamotrigine	Propranolol	0.8 (-5.9 to 7.4)
Baseline migraine frequency/month	Lamotrigine	Rofecoxib	-1.2 (-9.6 to 7.2)
Baseline migraine frequency/month	Lamotrigine	Telmisartan	-2.2 (-10.6 to 6.2)
Baseline migraine frequency/month	Lamotrigine	Timolol	0.2 (-7.1 to 7.4)
Baseline migraine frequency/month	Lamotrigine	Topiramate	-3.1 (-9.3 to 3.1)
Baseline migraine frequency/month	Lamotrigine	Valproate	-1.3 (-8.5 to 6.0)
Baseline migraine frequency/month	Lamotrigine	Verapamil	-1.3 (-9.7 to 7.1)
Baseline migraine frequency/month	Lamotrigine	Vigabatrin	2.0 (-6.4 to 10.4)
Baseline migraine frequency/month	Lisinopril	Lisuride	-1.2 (-9.6 to 7.2)
Baseline migraine frequency/month	Lisinopril	Magnesium	-2.7 (-10.0 to 4.6)
Baseline migraine frequency/month	Lisinopril	Methysergide	-0.7 (-9.1 to 7.7)
Baseline migraine frequency/month	Lisinopril	Metoprolol	-3.3 (-10.1 to 3.5)
Baseline migraine frequency/month	Lisinopril	Montelukast	-2.8 (-11.2 to 5.6)
Baseline migraine frequency/month	Lisinopril	Naproxen sodium	1.0 (-7.4 to 9.4)
Baseline migraine frequency/month	Lisinopril	Nicardipine	-2.0 (-10.3 to 6.4)
Baseline migraine frequency/month	Lisinopril	Nifedipine	-7.7 (-16.1 to 0.7)
Baseline migraine frequency/month	Lisinopril	Nimodipine	-3.0 (-10.2 to 4.3)
Baseline migraine frequency/month	Lisinopril	Oxcarbazepine	-3.7 (-12.1 to 4.7)
Baseline migraine frequency/month	Lisinopril	Pindolol	0.3 (-8.1 to 8.7)
Baseline migraine frequency/month	Lisinopril	Propranolol	-1.0 (-7.6 to 5.7)
Baseline migraine frequency/month	Lisinopril	Rofecoxib	-2.9 (-11.3 to 5.5)
Baseline migraine frequency/month	Lisinopril	Telmisartan	-3.9 (-12.3 to 4.5)
Baseline migraine frequency/month	Lisinopril	Timolol	-1.6 (-8.8 to 5.7)
Baseline migraine frequency/month	Lisinopril	Topiramate	-4.8 (-11.0 to 1.4)
Baseline migraine frequency/month	Lisinopril	Valproate	-3.0 (-10.3 to 4.3)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Baseline migraine frequency/month	Lisinopril	Verapamil	-3.0 (-11.4 to 5.4)
Baseline migraine frequency/month	Lisinopril	Vigabatrin	0.3 (-8.1 to 8.7)
Baseline migraine frequency/month	Lisuride	Magnesium	-1.5 (-8.8 to 5.8)
Baseline migraine frequency/month	Lisuride	Methysergide	0.5 (-7.9 to 8.9)
Baseline migraine frequency/month	Lisuride	Metoprolol	-2.1 (-8.9 to 4.7)
Baseline migraine frequency/month	Lisuride	Montelukast	-1.6 (-10.0 to 6.8)
Baseline migraine frequency/month	Lisuride	Naproxen sodium	2.2 (-6.2 to 10.6)
Baseline migraine frequency/month	Lisuride	Nicardipine	-0.8 (-9.1 to 7.6)
Baseline migraine frequency/month	Lisuride	Nifedipine	-6.5 (-14.9 to 1.9)
Baseline migraine frequency/month	Lisuride	Nimodipine	-1.8 (-9.0 to 5.5)
Baseline migraine frequency/month	Lisuride	Oxcarbazepine	-2.5 (-10.9 to 5.9)
Baseline migraine frequency/month	Lisuride	Pindolol	1.5 (-6.9 to 9.9)
Baseline migraine frequency/month	Lisuride	Propranolol	0.3 (-6.4 to 6.9)
Baseline migraine frequency/month	Lisuride	Rofecoxib	-1.7 (-10.1 to 6.7)
Baseline migraine frequency/month	Lisuride	Telmisartan	-2.7 (-11.1 to 5.7)
Baseline migraine frequency/month	Lisuride	Timolol	-0.4 (-7.6 to 6.9)
Baseline migraine frequency/month	Lisuride	Topiramate	-3.6 (-9.8 to 2.6)
Baseline migraine frequency/month	Lisuride	Valproate	-1.8 (-9.1 to 5.5)
Baseline migraine frequency/month	Lisuride	Verapamil	-1.8 (-10.2 to 6.6)
Baseline migraine frequency/month	Lisuride	Vigabatrin	1.5 (-6.9 to 9.9)
Baseline migraine frequency/month	Magnesium	Montelukast	-0.1 (-7.4 to 7.2)
Baseline migraine frequency/month	Magnesium	Naproxen sodium	3.7 (-3.6 to 11.0)
Baseline migraine frequency/month	Magnesium	Nicardipine	0.7 (-6.5 to 8.0)
Baseline migraine frequency/month	Magnesium	Nifedipine	-5.0 (-12.3 to 2.3)
Baseline migraine frequency/month	Magnesium	Nimodipine	-0.3 (-6.2 to 5.7)
Baseline migraine frequency/month	Magnesium	Oxcarbazepine	-1.0 (-8.3 to 6.3)
Baseline migraine frequency/month	Magnesium	Pindolol	3.0 (-4.3 to 10.3)
Baseline migraine frequency/month	Magnesium	Propranolol	1.8 (-3.4 to 6.9)
Baseline migraine frequency/month	Magnesium	Rofecoxib	-0.2 (-7.5 to 7.0)
Baseline migraine frequency/month	Magnesium	Telmisartan	-1.2 (-8.5 to 6.1)
Baseline migraine frequency/month	Magnesium	Timolol	1.2 (-4.8 to 7.1)
Baseline migraine frequency/month	Magnesium	Topiramate	-2.1 (-6.7 to 2.5)
Baseline migraine frequency/month	Magnesium	Valproate	-0.3 (-6.2 to 5.6)
Baseline migraine frequency/month	Magnesium	Verapamil	-0.3 (-7.6 to 7.0)
Baseline migraine frequency/month	Magnesium	Vigabatrin	3.0 (-4.3 to 10.3)
Baseline migraine frequency/month	Methysergide	Magnesium	-2.0 (-9.3 to 5.3)
Baseline migraine frequency/month	Methysergide	Metoprolol	-2.6 (-9.4 to 4.2)
Baseline migraine frequency/month	Methysergide	Montelukast	-2.1 (-10.5 to 6.3)
Baseline migraine frequency/month	Methysergide	Naproxen sodium	1.7 (-6.7 to 10.1)
Baseline migraine frequency/month	Methysergide	Nicardipine	-1.3 (-9.6 to 7.1)
Baseline migraine frequency/month	Methysergide	Nifedipine	-7.0 (-15.4 to 1.4)
Baseline migraine frequency/month	Methysergide	Nimodipine	-2.3 (-9.5 to 5.0)
Baseline migraine frequency/month	Methysergide	Oxcarbazepine	-3.0 (-11.4 to 5.4)
Baseline migraine frequency/month	Methysergide	Pindolol	1.0 (-7.4 to 9.4)
Baseline migraine frequency/month	Methysergide	Propranolol	-0.3 (-6.9 to 6.4)
Baseline migraine frequency/month	Methysergide	Rofecoxib	-2.2 (-10.6 to 6.2)
Baseline migraine frequency/month	Methysergide	Telmisartan	-3.2 (-11.6 to 5.2)
Baseline migraine frequency/month	Methysergide	Timolol	-0.9 (-8.1 to 6.4)
Baseline migraine frequency/month	Methysergide	Topiramate	-4.1 (-10.3 to 2.1)
Baseline migraine frequency/month	Methysergide	Valproate	-2.3 (-9.6 to 5.0)
Baseline migraine frequency/month	Methysergide	Verapamil	-2.3 (-10.7 to 6.1)
Baseline migraine frequency/month	Methysergide	Vigabatrin	1.0 (-7.4 to 9.4)
Baseline migraine frequency/month	Metoprolol	Magnesium	0.6 (-4.8 to 6.0)
Baseline migraine frequency/month	Metoprolol	Montelukast	0.5 (-6.3 to 7.3)
Baseline migraine frequency/month	Metoprolol	Naproxen sodium	4.3 (-2.5 to 11.1)
Baseline migraine frequency/month	Metoprolol	Nicardipine	1.3 (-5.5 to 8.2)
Baseline migraine frequency/month	Metoprolol	Nifedipine	-4.4 (-11.2 to 2.4)
Baseline migraine frequency/month	Metoprolol	Nimodipine	0.3 (-5.1 to 5.8)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Baseline migraine frequency/month	Metoprolol	Oxcarbazepine	-0.4 (-7.2 to 6.4)
Baseline migraine frequency/month	Metoprolol	Pindolol	3.6 (-3.2 to 10.4)
Baseline migraine frequency/month	Metoprolol	Propranolol	2.3 (-2.2 to 6.9)
Baseline migraine frequency/month	Metoprolol	Rofecoxib	0.4 (-6.5 to 7.2)
Baseline migraine frequency/month	Metoprolol	Telmisartan	-0.6 (-7.4 to 6.2)
Baseline migraine frequency/month	Metoprolol	Timolol	1.7 (-3.7 to 7.2)
Baseline migraine frequency/month	Metoprolol	Topiramate	-1.5 (-5.4 to 2.4)
Baseline migraine frequency/month	Metoprolol	Valproate	0.3 (-5.1 to 5.7)
Baseline migraine frequency/month	Metoprolol	Verapamil	0.3 (-6.5 to 7.1)
Baseline migraine frequency/month	Metoprolol	Vigabatrin	3.6 (-3.2 to 10.4)
Baseline migraine frequency/month	Montelukast	Naproxen sodium	3.8 (-4.6 to 12.2)
Baseline migraine frequency/month	Montelukast	Nicardipine	0.8 (-7.5 to 9.2)
Baseline migraine frequency/month	Montelukast	Nifedipine	-4.9 (-13.3 to 3.5)
Baseline migraine frequency/month	Montelukast	Nimodipine	-0.2 (-7.4 to 7.1)
Baseline migraine frequency/month	Montelukast	Oxcarbazepine	-0.9 (-9.3 to 7.5)
Baseline migraine frequency/month	Montelukast	Pindolol	3.1 (-5.3 to 11.5)
Baseline migraine frequency/month	Montelukast	Propranolol	1.9 (-4.8 to 8.5)
Baseline migraine frequency/month	Montelukast	Rofecoxib	-0.1 (-8.5 to 8.3)
Baseline migraine frequency/month	Montelukast	Telmisartan	-1.1 (-9.5 to 7.3)
Baseline migraine frequency/month	Montelukast	Timolol	1.3 (-6.0 to 8.5)
Baseline migraine frequency/month	Montelukast	Topiramate	-2.0 (-8.2 to 4.2)
Baseline migraine frequency/month	Montelukast	Valproate	-0.2 (-7.5 to 7.1)
Baseline migraine frequency/month	Montelukast	Verapamil	-0.2 (-8.6 to 8.2)
Baseline migraine frequency/month	Montelukast	Vigabatrin	3.1 (-5.3 to 11.5)
Baseline migraine frequency/month	Naproxen sodium	Nicardipine	-3.0 (-11.3 to 5.4)
Baseline migraine frequency/month	Naproxen sodium	Nifedipine	-8.7 (-17.1 to -0.3)
Baseline migraine frequency/month	Naproxen sodium	Nimodipine	-4.0 (-11.2 to 3.3)
Baseline migraine frequency/month	Naproxen sodium	Oxcarbazepine	-4.7 (-13.1 to 3.7)
Baseline migraine frequency/month	Naproxen sodium	Pindolol	-0.7 (-9.1 to 7.7)
Baseline migraine frequency/month	Naproxen sodium	Propranolol	-2.0 (-8.6 to 4.7)
Baseline migraine frequency/month	Naproxen sodium	Rofecoxib	-3.9 (-12.3 to 4.5)
Baseline migraine frequency/month	Naproxen sodium	Telmisartan	-4.9 (-13.3 to 3.5)
Baseline migraine frequency/month	Naproxen sodium	Timolol	-2.6 (-9.8 to 4.7)
Baseline migraine frequency/month	Naproxen sodium	Topiramate	-5.8 (-12.0 to 0.4)
Baseline migraine frequency/month	Naproxen sodium	Valproate	-4.0 (-11.3 to 3.3)
Baseline migraine frequency/month	Naproxen sodium	Verapamil	-4.0 (-12.4 to 4.4)
Baseline migraine frequency/month	Naproxen sodium	Vigabatrin	-0.7 (-9.1 to 7.7)
Baseline migraine frequency/month	Nicardipine	Nifedipine	-5.7 (-14.1 to 2.6)
Baseline migraine frequency/month	Nicardipine	Nimodipine	-1.0 (-8.2 to 6.3)
Baseline migraine frequency/month	Nicardipine	Oxcarbazepine	-1.7 (-10.1 to 6.6)
Baseline migraine frequency/month	Nicardipine	Pindolol	2.3 (-6.1 to 10.6)
Baseline migraine frequency/month	Nicardipine	Propranolol	1.0 (-5.6 to 7.6)
Baseline migraine frequency/month	Nicardipine	Rofecoxib	-1.0 (-9.3 to 7.4)
Baseline migraine frequency/month	Nicardipine	Telmisartan	-1.9 (-10.3 to 6.4)
Baseline migraine frequency/month	Nicardipine	Timolol	0.4 (-6.8 to 7.7)
Baseline migraine frequency/month	Nicardipine	Topiramate	-2.9 (-9.1 to 3.4)
Baseline migraine frequency/month	Nicardipine	Valproate	-1.0 (-8.3 to 6.2)
Baseline migraine frequency/month	Nicardipine	Verapamil	-1.0 (-9.4 to 7.3)
Baseline migraine frequency/month	Nicardipine	Vigabatrin	2.3 (-6.1 to 10.6)
Baseline migraine frequency/month	Nifedipine	Nimodipine	4.8 (-2.5 to 12.0)
Baseline migraine frequency/month	Nifedipine	Oxcarbazepine	4.0 (-4.4 to 12.4)
Baseline migraine frequency/month	Nifedipine	Pindolol	8.0 (-0.4 to 16.4)
Baseline migraine frequency/month	Nifedipine	Propranolol	6.8 (0.1 to 13.4)
Baseline migraine frequency/month	Nifedipine	Rofecoxib	4.8 (-3.6 to 13.2)
Baseline migraine frequency/month	Nifedipine	Telmisartan	3.8 (-4.6 to 12.2)
Baseline migraine frequency/month	Nifedipine	Timolol	6.2 (-1.1 to 13.4)
Baseline migraine frequency/month	Nifedipine	Topiramate	2.9 (-3.3 to 9.1)
Baseline migraine frequency/month	Nifedipine	Valproate	4.7 (-2.6 to 12.0)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

Baseline migraine frequency/month	Nifedipine	Verapamil	4.7 (-3.7 to 13.1)
Baseline migraine frequency/month	Nifedipine	Vigabatrin	8.0 (-0.4 to 16.4)
Baseline migraine frequency/month	Nimodipine	Oxcarbazepine	-0.8 (-8.0 to 6.5)
Baseline migraine frequency/month	Nimodipine	Pindolol	3.3 (-4.0 to 10.5)
Baseline migraine frequency/month	Nimodipine	Propranolol	2.0 (-3.1 to 7.1)
Baseline migraine frequency/month	Nimodipine	Rofecoxib	0.0 (-7.2 to 7.3)
Baseline migraine frequency/month	Nimodipine	Telmisartan	-1.0 (-8.2 to 6.3)
Baseline migraine frequency/month	Nimodipine	Timolol	1.4 (-4.5 to 7.3)
Baseline migraine frequency/month	Nimodipine	Topiramate	-1.9 (-6.5 to 2.7)
Baseline migraine frequency/month	Nimodipine	Valproate	-0.1 (-6.0 to 5.9)
Baseline migraine frequency/month	Nimodipine	Verapamil	-0.1 (-7.3 to 7.2)
Baseline migraine frequency/month	Nimodipine	Vigabatrin	3.3 (-4.0 to 10.5)
Baseline migraine frequency/month	Oxcarbazepine	Pindolol	4.0 (-4.4 to 12.4)
Baseline migraine frequency/month	Oxcarbazepine	Propranolol	2.8 (-3.9 to 9.4)
Baseline migraine frequency/month	Oxcarbazepine	Rofecoxib	0.8 (-7.6 to 9.2)
Baseline migraine frequency/month	Oxcarbazepine	Telmisartan	-0.2 (-8.6 to 8.2)
Baseline migraine frequency/month	Oxcarbazepine	Timolol	2.2 (-5.1 to 9.4)
Baseline migraine frequency/month	Oxcarbazepine	Topiramate	-1.1 (-7.3 to 5.1)
Baseline migraine frequency/month	Oxcarbazepine	Valproate	0.7 (-6.6 to 8.0)
Baseline migraine frequency/month	Oxcarbazepine	Verapamil	0.7 (-7.7 to 9.1)
Baseline migraine frequency/month	Oxcarbazepine	Vigabatrin	4.0 (-4.4 to 12.4)
Baseline migraine frequency/month	Pindolol	Propranolol	-1.3 (-7.9 to 5.4)
Baseline migraine frequency/month	Pindolol	Rofecoxib	-3.2 (-11.6 to 5.2)
Baseline migraine frequency/month	Pindolol	Telmisartan	-4.2 (-12.6 to 4.2)
Baseline migraine frequency/month	Pindolol	Timolol	-1.9 (-9.1 to 5.4)
Baseline migraine frequency/month	Pindolol	Topiramate	-5.1 (-11.3 to 1.1)
Baseline migraine frequency/month	Pindolol	Valproate	-3.3 (-10.6 to 4.0)
Baseline migraine frequency/month	Pindolol	Verapamil	-3.3 (-11.7 to 5.1)
Baseline migraine frequency/month	Pindolol	Vigabatrin	0.0 (-8.4 to 8.4)
Baseline migraine frequency/month	Propranolol	Rofecoxib	-2.0 (-8.6 to 4.7)
Baseline migraine frequency/month	Propranolol	Telmisartan	-3.0 (-9.6 to 3.7)
Baseline migraine frequency/month	Propranolol	Timolol	-0.6 (-5.7 to 4.5)
Baseline migraine frequency/month	Propranolol	Topiramate	-3.9 (-7.4 to -0.4)
Baseline migraine frequency/month	Propranolol	Valproate	-2.1 (-7.2 to 3.1)
Baseline migraine frequency/month	Propranolol	Verapamil	-2.1 (-8.7 to 4.6)
Baseline migraine frequency/month	Propranolol	Vigabatrin	1.3 (-5.4 to 7.9)
Baseline migraine frequency/month	Rofecoxib	Telmisartan	-1.0 (-9.4 to 7.4)
Baseline migraine frequency/month	Rofecoxib	Timolol	1.4 (-5.9 to 8.6)
Baseline migraine frequency/month	Rofecoxib	Topiramate	-1.9 (-8.1 to 4.3)
Baseline migraine frequency/month	Rofecoxib	Valproate	-0.1 (-7.3 to 7.2)
Baseline migraine frequency/month	Rofecoxib	Verapamil	-0.1 (-8.5 to 8.3)
Baseline migraine frequency/month	Rofecoxib	Vigabatrin	3.2 (-5.2 to 11.6)
Baseline migraine frequency/month	Telmisartan	Timolol	2.4 (-4.9 to 9.6)
Baseline migraine frequency/month	Telmisartan	Topiramate	-0.9 (-7.1 to 5.3)
Baseline migraine frequency/month	Telmisartan	Valproate	0.9 (-6.4 to 8.2)
Baseline migraine frequency/month	Telmisartan	Verapamil	0.9 (-7.5 to 9.3)
Baseline migraine frequency/month	Telmisartan	Vigabatrin	4.2 (-4.2 to 12.6)
Baseline migraine frequency/month	Timolol	Topiramate	-3.3 (-7.9 to 1.3)
Baseline migraine frequency/month	Timolol	Valproate	-1.5 (-7.4 to 4.5)
Baseline migraine frequency/month	Timolol	Verapamil	-1.5 (-8.7 to 5.8)
Baseline migraine frequency/month	Timolol	Vigabatrin	1.9 (-5.4 to 9.1)
Baseline migraine frequency/month	Topiramate	Valproate	1.8 (-2.8 to 6.4)
Baseline migraine frequency/month	Topiramate	Verapamil	1.8 (-4.4 to 8.0)
Baseline migraine frequency/month	Topiramate	Vigabatrin	5.1 (-1.1 to 11.3)
Baseline migraine frequency/month	Valproate	Verapamil	0.0 (-7.3 to 7.3)
Baseline migraine frequency/month	Valproate	Vigabatrin	3.3 (-4.0 to 10.6)
Baseline migraine frequency/month	Verapamil	Vigabatrin	3.3 (-5.1 to 11.7)
% naïve	Dihydroergotamine	Femoxetine	-36.7 (-83.9 to 10.6)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% naïve	Dihydroergotamine	Metoprolol	-17.7 (-53.0 to 17.5)
% naïve	Dihydroergotamine	Pindolol	63.3 (16.1 to 110.6)
% naïve	Dihydroergotamine	Propranolol	37.6 (-9.6 to 84.9)
% naïve	Dihydroergotamine	Timolol	27.6 (-19.6 to 74.9)
% naïve	Dihydroergotamine	Tonabersat	-36.7 (-83.9 to 10.6)
% naïve	Dihydroergotamine	Topiramate	63.3 (16.1 to 110.6)
% naïve	Femoxetine	Metoprolol	18.9 (-25.6 to 63.5)
% naïve	Femoxetine	Pindolol	100.0 (45.4 to 154.6)
% naïve	Femoxetine	Propranolol	74.3 (19.7 to 128.9)
% naïve	Femoxetine	Timolol	64.3 (9.7 to 118.9)
% naïve	Femoxetine	Tonabersat	0.0 (-54.6 to 54.6)
% naïve	Femoxetine	Topiramate	100.0 (45.4 to 154.6)
% naïve	Metoprolol	Pindolol	81.1 (36.5 to 125.6)
% naïve	Metoprolol	Propranolol	55.4 (10.8 to 99.9)
% naïve	Metoprolol	Timolol	45.4 (0.8 to 89.9)
% naïve	Metoprolol	Tonabersat	-18.9 (-63.5 to 25.6)
% naïve	Metoprolol	Topiramate	81.1 (36.5 to 125.6)
% naïve	Pindolol	Propranolol	-25.7 (-80.3 to 28.9)
% naïve	Pindolol	Timolol	-35.7 (-90.3 to 18.9)
% naïve	Pindolol	Tonabersat	-100.0 (-154.6 to -45.4)
% naïve	Pindolol	Topiramate	0.0 (-54.6 to 54.6)
% naïve	Propranolol	Timolol	-10.0 (-64.6 to 44.6)
% naïve	Propranolol	Tonabersat	-74.3 (-128.9 to -19.7)
% naïve	Propranolol	Topiramate	25.7 (-28.9 to 80.3)
% naïve	Timolol	Tonabersat	-64.3 (-118.9 to -9.7)
% naïve	Timolol	Topiramate	35.7 (-18.9 to 90.3)
% naïve	Tonabersat	Topiramate	100.0 (45.4 to 154.6)
% with aura	Acetazolamide	Alprenolol	-8.8 (-112.2 to 94.6)
% with aura	Acetazolamide	Atenolol	9.4 (-80.1 to 98.9)
% with aura	Acetazolamide	Dihydroergocryptine	9.4 (-94.0 to 112.8)
% with aura	Acetazolamide	Dihydroergotamine	-11.6 (-96.1 to 72.8)
% with aura	Acetazolamide	Divalproex	5.4 (-84.1 to 94.9)
% with aura	Acetazolamide	Fluoxetine	-13.2 (-102.7 to 76.3)
% with aura	Acetazolamide	Gabapentin	-37.1 (-126.6 to 52.5)
% with aura	Acetazolamide	Indobufen	9.4 (-94.0 to 112.8)
% with aura	Acetazolamide	Lamotrigine	-30.9 (-134.3 to 72.5)
% with aura	Acetazolamide	Magnesium	-40.6 (-130.1 to 48.9)
% with aura	Acetazolamide	Metoprolol	-40.6 (-130.1 to 48.9)
% with aura	Acetazolamide	Nadolol	-75.0 (-178.4 to 28.4)
% with aura	Acetazolamide	Nicardipine	-90.6 (-194.0 to 12.8)
% with aura	Acetazolamide	Nimodipine	-17.8 (-107.3 to 71.7)
% with aura	Acetazolamide	Pindolol	-40.6 (-144.0 to 62.8)
% with aura	Acetazolamide	Propranolol	-45.9 (-123.4 to 31.7)
% with aura	Acetazolamide	Timolol	-0.1 (-89.6 to 89.4)
% with aura	Acetazolamide	Topiramate	-13.1 (-94.9 to 68.6)
% with aura	Acetazolamide	Valproate	-33.8 (-123.3 to 55.8)
% with aura	Acetazolamide	Verapamil	-32.3 (-135.7 to 71.1)
% with aura	Acetazolamide	Vigabatrin	-34.1 (-137.5 to 69.3)
% with aura	Alprenolol	Atenolol	18.2 (-71.4 to 107.7)
% with aura	Alprenolol	Dihydroergocryptine	18.2 (-85.2 to 121.6)
% with aura	Alprenolol	Dihydroergotamine	-2.9 (-87.3 to 81.6)
% with aura	Alprenolol	Divalproex	14.2 (-75.4 to 103.7)
% with aura	Alprenolol	Fluoxetine	-4.4 (-94.0 to 85.1)
% with aura	Alprenolol	Gabapentin	-28.3 (-117.8 to 61.3)
% with aura	Alprenolol	Indobufen	18.2 (-85.2 to 121.6)
% with aura	Alprenolol	Lamotrigine	-22.1 (-125.5 to 81.3)
% with aura	Alprenolol	Magnesium	-31.8 (-121.4 to 57.7)
% with aura	Alprenolol	Metoprolol	-31.8 (-121.4 to 57.7)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% with aura	Alprenolol	Nadolol	-66.2 (-169.6 to 37.2)
% with aura	Alprenolol	Nicardipine	-81.8 (-185.2 to 21.6)
% with aura	Alprenolol	Nimodipine	-9.0 (-98.6 to 80.5)
% with aura	Alprenolol	Pindolol	-31.8 (-135.2 to 71.6)
% with aura	Alprenolol	Propranolol	-37.1 (-114.6 to 40.5)
% with aura	Alprenolol	Timolol	8.7 (-80.9 to 98.2)
% with aura	Alprenolol	Topiramate	-4.3 (-86.1 to 77.4)
% with aura	Alprenolol	Valproate	-25.0 (-114.5 to 64.6)
% with aura	Alprenolol	Verapamil	-23.5 (-126.9 to 79.9)
% with aura	Alprenolol	Vigabatrin	-25.3 (-128.7 to 78.1)
% with aura	Atenolol	Dihydroergocryptine	0.0 (-89.5 to 89.5)
% with aura	Atenolol	Dihydroergotamine	-21.0 (-87.8 to 45.7)
% with aura	Atenolol	Divalproex	-4.0 (-77.1 to 69.1)
% with aura	Atenolol	Fluoxetine	-22.6 (-95.7 to 50.5)
% with aura	Atenolol	Gabapentin	-46.5 (-119.6 to 26.7)
% with aura	Atenolol	Indobufen	0.0 (-89.5 to 89.5)
% with aura	Atenolol	Lamotrigine	-40.3 (-129.8 to 49.2)
% with aura	Atenolol	Magnesium	-50.0 (-123.1 to 23.1)
% with aura	Atenolol	Metoprolol	-50.0 (-123.1 to 23.1)
% with aura	Atenolol	Nadolol	-84.4 (-173.9 to 5.1)
% with aura	Atenolol	Nicardipine	-100.0 (-189.5 to -10.5)
% with aura	Atenolol	Nimodipine	-27.2 (-100.3 to 45.9)
% with aura	Atenolol	Pindolol	-50.0 (-139.5 to 39.5)
% with aura	Atenolol	Propranolol	-55.3 (-113.1 to 2.5)
% with aura	Atenolol	Timolol	-9.5 (-82.6 to 63.6)
% with aura	Atenolol	Topiramate	-22.5 (-85.8 to 40.8)
% with aura	Atenolol	Valproate	-43.2 (-116.3 to 30.0)
% with aura	Atenolol	Verapamil	-41.7 (-131.2 to 47.8)
% with aura	Atenolol	Vigabatrin	-43.5 (-133.0 to 46.0)
% with aura	Dihydroergocryptine	Dihydroergotamine	-21.0 (-105.5 to 63.4)
% with aura	Dihydroergocryptine	Divalproex	-4.0 (-93.5 to 85.5)
% with aura	Dihydroergocryptine	Fluoxetine	-22.6 (-112.1 to 66.9)
% with aura	Dihydroergocryptine	Gabapentin	-46.5 (-136.0 to 43.1)
% with aura	Dihydroergocryptine	Indobufen	0.0 (-103.4 to 103.4)
% with aura	Dihydroergocryptine	Lamotrigine	-40.3 (-143.7 to 63.1)
% with aura	Dihydroergocryptine	Magnesium	-50.0 (-139.5 to 39.5)
% with aura	Dihydroergocryptine	Metoprolol	-50.0 (-139.5 to 39.5)
% with aura	Dihydroergocryptine	Nadolol	-84.4 (-187.8 to 19.0)
% with aura	Dihydroergocryptine	Nicardipine	-100.0 (-203.4 to 3.4)
% with aura	Dihydroergocryptine	Nimodipine	-27.2 (-116.7 to 62.3)
% with aura	Dihydroergocryptine	Pindolol	-50.0 (-153.4 to 53.4)
% with aura	Dihydroergocryptine	Propranolol	-55.3 (-132.8 to 22.3)
% with aura	Dihydroergocryptine	Timolol	-9.5 (-99.0 to 80.0)
% with aura	Dihydroergocryptine	Topiramate	-22.5 (-104.3 to 59.2)
% with aura	Dihydroergocryptine	Valproate	-43.2 (-132.7 to 46.4)
% with aura	Dihydroergocryptine	Verapamil	-41.7 (-145.1 to 61.7)
% with aura	Dihydroergocryptine	Vigabatrin	-43.5 (-146.9 to 59.9)
% with aura	Dihydroergotamine	Divalproex	17.0 (-49.7 to 83.8)
% with aura	Dihydroergotamine	Fluoxetine	-1.6 (-68.3 to 65.2)
% with aura	Dihydroergotamine	Gabapentin	-25.4 (-92.2 to 41.3)
% with aura	Dihydroergotamine	Indobufen	21.0 (-63.4 to 105.5)
% with aura	Dihydroergotamine	Lamotrigine	-19.3 (-103.7 to 65.2)
% with aura	Dihydroergotamine	Magnesium	-29.0 (-95.7 to 37.8)
% with aura	Dihydroergotamine	Metoprolol	-29.0 (-95.7 to 37.8)
% with aura	Dihydroergotamine	Nadolol	-63.4 (-147.8 to 21.1)
% with aura	Dihydroergotamine	Nicardipine	-79.0 (-163.4 to 5.5)
% with aura	Dihydroergotamine	Nimodipine	-6.2 (-72.9 to 60.6)
% with aura	Dihydroergotamine	Pindolol	-29.0 (-113.4 to 55.5)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% with aura	Dihydroergotamine	Propranolol	-34.2 (-83.7 to 15.3)
% with aura	Dihydroergotamine	Timolol	11.5 (-55.2 to 78.3)
% with aura	Dihydroergotamine	Topiramate	-1.5 (-57.3 to 54.3)
% with aura	Dihydroergotamine	Valproate	-22.1 (-88.9 to 44.6)
% with aura	Dihydroergotamine	Verapamil	-20.7 (-105.1 to 63.8)
% with aura	Dihydroergotamine	Vigabatrin	-22.5 (-106.9 to 62.0)
% with aura	Divalproex	Fluoxetine	-18.6 (-91.7 to 54.5)
% with aura	Divalproex	Gabapentin	-42.5 (-115.6 to 30.7)
% with aura	Divalproex	Indobufen	4.0 (-85.5 to 93.5)
% with aura	Divalproex	Lamotrigine	-36.3 (-125.8 to 53.2)
% with aura	Divalproex	Magnesium	-46.0 (-119.1 to 27.1)
% with aura	Divalproex	Metoprolol	-46.0 (-119.1 to 27.1)
% with aura	Divalproex	Nadolol	-80.4 (-169.9 to 9.1)
% with aura	Divalproex	Nicardipine	-96.0 (-185.5 to -6.5)
% with aura	Divalproex	Nimodipine	-23.2 (-96.3 to 49.9)
% with aura	Divalproex	Pindolol	-46.0 (-135.5 to 43.5)
% with aura	Divalproex	Propranolol	-51.3 (-109.1 to 6.5)
% with aura	Divalproex	Timolol	-5.5 (-78.6 to 67.6)
% with aura	Divalproex	Topiramate	-18.5 (-81.8 to 44.8)
% with aura	Divalproex	Valproate	-39.2 (-112.3 to 34.0)
% with aura	Divalproex	Verapamil	-37.7 (-127.2 to 51.8)
% with aura	Divalproex	Vigabatrin	-39.5 (-129.0 to 50.0)
% with aura	Fluoxetine	Gabapentin	-23.9 (-97.0 to 49.3)
% with aura	Fluoxetine	Indobufen	22.6 (-66.9 to 112.1)
% with aura	Fluoxetine	Lamotrigine	-17.7 (-107.2 to 71.8)
% with aura	Fluoxetine	Magnesium	-27.4 (-100.5 to 45.7)
% with aura	Fluoxetine	Metoprolol	-27.4 (-100.5 to 45.7)
% with aura	Fluoxetine	Nadolol	-61.8 (-151.3 to 27.7)
% with aura	Fluoxetine	Nicardipine	-77.4 (-166.9 to 12.1)
% with aura	Fluoxetine	Nimodipine	-4.6 (-77.7 to 68.5)
% with aura	Fluoxetine	Pindolol	-27.4 (-116.9 to 62.1)
% with aura	Fluoxetine	Propranolol	-32.7 (-90.5 to 25.1)
% with aura	Fluoxetine	Timolol	13.1 (-60.0 to 86.2)
% with aura	Fluoxetine	Topiramate	0.1 (-63.2 to 63.4)
% with aura	Fluoxetine	Valproate	-20.6 (-93.7 to 52.6)
% with aura	Fluoxetine	Verapamil	-19.1 (-108.6 to 70.4)
% with aura	Fluoxetine	Vigabatrin	-20.9 (-110.4 to 68.6)
% with aura	Gabapentin	Indobufen	46.5 (-43.1 to 136.0)
% with aura	Gabapentin	Lamotrigine	6.2 (-83.4 to 95.7)
% with aura	Gabapentin	Magnesium	-3.6 (-76.7 to 69.6)
% with aura	Gabapentin	Metoprolol	-3.6 (-76.7 to 69.6)
% with aura	Gabapentin	Nadolol	-38.0 (-127.5 to 51.6)
% with aura	Gabapentin	Nicardipine	-53.6 (-143.1 to 36.0)
% with aura	Gabapentin	Nimodipine	19.3 (-53.9 to 92.4)
% with aura	Gabapentin	Pindolol	-3.6 (-93.1 to 86.0)
% with aura	Gabapentin	Propranolol	-8.8 (-66.6 to 49.0)
% with aura	Gabapentin	Timolol	37.0 (-36.2 to 110.1)
% with aura	Gabapentin	Topiramate	23.9 (-39.4 to 87.2)
% with aura	Gabapentin	Valproate	3.3 (-69.8 to 76.4)
% with aura	Gabapentin	Verapamil	4.8 (-84.8 to 94.3)
% with aura	Gabapentin	Vigabatrin	3.0 (-86.6 to 92.5)
% with aura	Indobufen	Lamotrigine	-40.3 (-143.7 to 63.1)
% with aura	Indobufen	Magnesium	-50.0 (-139.5 to 39.5)
% with aura	Indobufen	Metoprolol	-50.0 (-139.5 to 39.5)
% with aura	Indobufen	Nadolol	-84.4 (-187.8 to 19.0)
% with aura	Indobufen	Nicardipine	-100.0 (-203.4 to 3.4)
% with aura	Indobufen	Nimodipine	-27.2 (-116.7 to 62.3)
% with aura	Indobufen	Pindolol	-50.0 (-153.4 to 53.4)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% with aura	Indobufen	Propranolol	-55.3 (-132.8 to 22.3)
% with aura	Indobufen	Timolol	-9.5 (-99.0 to 80.0)
% with aura	Indobufen	Topiramate	-22.5 (-104.3 to 59.2)
% with aura	Indobufen	Valproate	-43.2 (-132.7 to 46.4)
% with aura	Indobufen	Verapamil	-41.7 (-145.1 to 61.7)
% with aura	Indobufen	Vigabatrin	-43.5 (-146.9 to 59.9)
% with aura	Lamotrigine	Magnesium	-9.7 (-99.2 to 79.8)
% with aura	Lamotrigine	Metoprolol	-9.7 (-99.2 to 79.8)
% with aura	Lamotrigine	Nadolol	-44.1 (-147.5 to 59.3)
% with aura	Lamotrigine	Nicardipine	-59.7 (-163.1 to 43.7)
% with aura	Lamotrigine	Nimodipine	13.1 (-76.4 to 102.6)
% with aura	Lamotrigine	Pindolol	-9.7 (-113.1 to 93.7)
% with aura	Lamotrigine	Propranolol	-15.0 (-92.5 to 62.6)
% with aura	Lamotrigine	Timolol	30.8 (-58.7 to 120.3)
% with aura	Lamotrigine	Topiramate	17.8 (-64.0 to 99.5)
% with aura	Lamotrigine	Valproate	-2.9 (-92.4 to 86.7)
% with aura	Lamotrigine	Verapamil	-1.4 (-104.8 to 102.0)
% with aura	Lamotrigine	Vigabatrin	-3.2 (-106.6 to 100.2)
% with aura	Magnesium	Nadolol	-34.4 (-123.9 to 55.1)
% with aura	Magnesium	Nicardipine	-50.0 (-139.5 to 39.5)
% with aura	Magnesium	Nimodipine	22.8 (-50.3 to 95.9)
% with aura	Magnesium	Pindolol	0.0 (-89.5 to 89.5)
% with aura	Magnesium	Propranolol	-5.3 (-63.1 to 52.5)
% with aura	Magnesium	Timolol	40.5 (-32.6 to 113.6)
% with aura	Magnesium	Topiramate	27.5 (-35.8 to 90.8)
% with aura	Magnesium	Valproate	6.9 (-66.3 to 80.0)
% with aura	Magnesium	Verapamil	8.3 (-81.2 to 97.8)
% with aura	Magnesium	Vigabatrin	6.5 (-83.0 to 96.0)
% with aura	Metoprolol	Magnesium	0.0 (-73.1 to 73.1)
% with aura	Metoprolol	Nadolol	-34.4 (-123.9 to 55.1)
% with aura	Metoprolol	Nicardipine	-50.0 (-139.5 to 39.5)
% with aura	Metoprolol	Nimodipine	22.8 (-50.3 to 95.9)
% with aura	Metoprolol	Pindolol	0.0 (-89.5 to 89.5)
% with aura	Metoprolol	Propranolol	-5.3 (-63.1 to 52.5)
% with aura	Metoprolol	Timolol	40.5 (-32.6 to 113.6)
% with aura	Metoprolol	Topiramate	27.5 (-35.8 to 90.8)
% with aura	Metoprolol	Valproate	6.9 (-66.3 to 80.0)
% with aura	Metoprolol	Verapamil	8.3 (-81.2 to 97.8)
% with aura	Metoprolol	Vigabatrin	6.5 (-83.0 to 96.0)
% with aura	Nadolol	Nicardipine	-15.6 (-119.0 to 87.8)
% with aura	Nadolol	Nimodipine	57.2 (-32.3 to 146.7)
% with aura	Nadolol	Pindolol	34.4 (-69.0 to 137.8)
% with aura	Nadolol	Propranolol	29.1 (-48.4 to 106.7)
% with aura	Nadolol	Timolol	74.9 (-14.6 to 164.4)
% with aura	Nadolol	Topiramate	61.9 (-19.9 to 143.6)
% with aura	Nadolol	Valproate	41.3 (-48.3 to 130.8)
% with aura	Nadolol	Verapamil	42.7 (-60.7 to 146.1)
% with aura	Nadolol	Vigabatrin	40.9 (-62.5 to 144.3)
% with aura	Nicardipine	Nimodipine	72.8 (-16.7 to 162.3)
% with aura	Nicardipine	Pindolol	50.0 (-53.4 to 153.4)
% with aura	Nicardipine	Propranolol	44.7 (-32.8 to 122.3)
% with aura	Nicardipine	Timolol	90.5 (1.0 to 180.0)
% with aura	Nicardipine	Topiramate	77.5 (-4.3 to 159.2)
% with aura	Nicardipine	Valproate	56.9 (-32.7 to 146.4)
% with aura	Nicardipine	Verapamil	58.3 (-45.1 to 161.7)
% with aura	Nicardipine	Vigabatrin	56.5 (-46.9 to 159.9)
% with aura	Nimodipine	Pindolol	-22.8 (-112.3 to 66.7)
% with aura	Nimodipine	Propranolol	-28.1 (-85.9 to 29.7)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% with aura	Nimodipine	Timolol	17.7 (-55.4 to 90.8)
% with aura	Nimodipine	Topiramate	4.7 (-58.6 to 68.0)
% with aura	Nimodipine	Valproate	-16.0 (-89.1 to 57.2)
% with aura	Nimodipine	Verapamil	-14.5 (-104.0 to 75.0)
% with aura	Nimodipine	Vigabatrin	-16.3 (-105.8 to 73.2)
% with aura	Pindolol	Propranolol	-5.3 (-82.8 to 72.3)
% with aura	Pindolol	Timolol	40.5 (-49.0 to 130.0)
% with aura	Pindolol	Topiramate	27.5 (-54.3 to 109.2)
% with aura	Pindolol	Valproate	6.9 (-82.7 to 96.4)
% with aura	Pindolol	Verapamil	8.3 (-95.1 to 111.7)
% with aura	Pindolol	Vigabatrin	6.5 (-96.9 to 109.9)
% with aura	Propranolol	Timolol	45.8 (-12.0 to 103.6)
% with aura	Propranolol	Topiramate	32.7 (-12.0 to 77.5)
% with aura	Propranolol	Valproate	12.1 (-45.7 to 69.9)
% with aura	Propranolol	Verapamil	13.6 (-64.0 to 91.1)
% with aura	Propranolol	Vigabatrin	11.8 (-65.8 to 89.3)
% with aura	Timolol	Topiramate	-13.0 (-76.3 to 50.3)
% with aura	Timolol	Valproate	-33.7 (-106.8 to 39.5)
% with aura	Timolol	Verapamil	-32.2 (-121.7 to 57.3)
% with aura	Timolol	Vigabatrin	-34.0 (-123.5 to 55.5)
% with aura	Topiramate	Valproate	-20.6 (-83.9 to 42.7)
% with aura	Topiramate	Verapamil	-19.2 (-100.9 to 62.6)
% with aura	Topiramate	Vigabatrin	-21.0 (-102.7 to 60.8)
% with aura	Valproate	Verapamil	1.5 (-88.1 to 91.0)
% with aura	Valproate	Vigabatrin	-0.4 (-89.9 to 89.2)
% with aura	Verapamil	Vigabatrin	-1.8 (-105.2 to 101.6)
% loss to followup	Acetazolamide	Amitriptyline	-31.3 (-63.9 to 1.4)
% loss to followup	Acetazolamide	Candesartan	-5.0 (-42.7 to 32.7)
% loss to followup	Acetazolamide	Carbamazepine	-6.3 (-44.0 to 31.4)
% loss to followup	Acetazolamide	Clonidine	-22.5 (-50.5 to 5.4)
% loss to followup	Acetazolamide	Dihydroergotamine	-0.4 (-31.1 to 30.4)
% loss to followup	Acetazolamide	Divalproex	-1.8 (-34.5 to 30.8)
% loss to followup	Acetazolamide	Femoxetine	-24.1 (-53.9 to 5.7)
% loss to followup	Acetazolamide	Fluoxetine	-22.2 (-51.9 to 7.6)
% loss to followup	Acetazolamide	Gabapentin	-2.0 (-32.8 to 28.7)
% loss to followup	Acetazolamide	Guanfacine	-8.0 (-45.7 to 29.7)
% loss to followup	Acetazolamide	Lamotrigine	0.0 (-37.7 to 37.7)
% loss to followup	Acetazolamide	Lisinopril	-22.0 (-59.7 to 15.7)
% loss to followup	Acetazolamide	Lisuride	0.0 (-37.7 to 37.7)
% loss to followup	Acetazolamide	Magnesium	-23.0 (-53.8 to 7.8)
% loss to followup	Acetazolamide	Methysergide	-32.4 (-70.1 to 5.3)
% loss to followup	Acetazolamide	Mianserin	-10.5 (-48.2 to 27.2)
% loss to followup	Acetazolamide	Montelukast	-2.2 (-39.9 to 35.5)
% loss to followup	Acetazolamide	Naproxen sodium	-15.0 (-52.7 to 22.7)
% loss to followup	Acetazolamide	Nicardipine	-14.0 (-51.7 to 23.7)
% loss to followup	Acetazolamide	Nifedipine	-22.0 (-59.7 to 15.7)
% loss to followup	Acetazolamide	Nimodipine	-17.7 (-47.5 to 12.1)
% loss to followup	Acetazolamide	Oxcarbazepine	-3.5 (-41.2 to 34.2)
% loss to followup	Acetazolamide	Propranolol	-14.4 (-42.5 to 13.6)
% loss to followup	Acetazolamide	Telmisartan	-17.0 (-54.7 to 20.7)
% loss to followup	Acetazolamide	Tonabersat	-5.1 (-42.8 to 32.6)
% loss to followup	Acetazolamide	Valproate	-3.5 (-36.1 to 29.1)
% loss to followup	Acetazolamide	Verapamil	-34.0 (-66.6 to -1.4)
% loss to followup	Acetazolamide	Vigabatrin	0.0 (-37.7 to 37.7)
% loss to followup	Amitriptyline	Candesartan	26.3 (-6.4 to 58.9)
% loss to followup	Amitriptyline	Carbamazepine	25.0 (-7.7 to 57.6)
% loss to followup	Amitriptyline	Clonidine	8.7 (-11.9 to 29.4)
% loss to followup	Amitriptyline	Dihydroergotamine	30.9 (6.6 to 55.2)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% loss to followup	Amitriptyline	Divalproex	29.4 (2.8 to 56.1)
% loss to followup	Amitriptyline	Femoxetine	7.1 (-15.9 to 30.2)
% loss to followup	Amitriptyline	Fluoxetine	9.1 (-14.0 to 32.2)
% loss to followup	Amitriptyline	Gabapentin	29.2 (4.9 to 53.5)
% loss to followup	Amitriptyline	Guanfacine	23.3 (-9.4 to 55.9)
% loss to followup	Amitriptyline	Lamotrigine	31.3 (-1.4 to 63.9)
% loss to followup	Amitriptyline	Lisinopril	9.3 (-23.4 to 41.9)
% loss to followup	Amitriptyline	Lisuride	31.3 (-1.4 to 63.9)
% loss to followup	Amitriptyline	Magnesium	8.3 (-16.1 to 32.6)
% loss to followup	Amitriptyline	Methysergide	-1.2 (-33.8 to 31.5)
% loss to followup	Amitriptyline	Mianserin	20.8 (-11.9 to 53.4)
% loss to followup	Amitriptyline	Montelukast	29.1 (-3.6 to 61.7)
% loss to followup	Amitriptyline	Naproxen sodium	16.3 (-16.4 to 48.9)
% loss to followup	Amitriptyline	Nicardipine	17.3 (-15.4 to 49.9)
% loss to followup	Amitriptyline	Nifedipine	9.3 (-23.4 to 41.9)
% loss to followup	Amitriptyline	Nimodipine	13.6 (-9.5 to 36.6)
% loss to followup	Amitriptyline	Oxcarbazepine	27.8 (-4.9 to 60.4)
% loss to followup	Amitriptyline	Propranolol	16.8 (-4.0 to 37.6)
% loss to followup	Amitriptyline	Telmisartan	14.3 (-18.4 to 46.9)
% loss to followup	Amitriptyline	Tonabersat	26.2 (-6.5 to 58.8)
% loss to followup	Amitriptyline	Valproate	27.8 (1.1 to 54.4)
% loss to followup	Amitriptyline	Verapamil	-2.8 (-29.4 to 23.9)
% loss to followup	Amitriptyline	Vigabatrin	31.3 (-1.4 to 63.9)
% loss to followup	Candesartan	Carbamazepine	-1.3 (-39.0 to 36.4)
% loss to followup	Candesartan	Clonidine	-17.5 (-45.5 to 10.4)
% loss to followup	Candesartan	Dihydroergotamine	4.6 (-26.1 to 35.4)
% loss to followup	Candesartan	Divalproex	3.2 (-29.5 to 35.8)
% loss to followup	Candesartan	Femoxetine	-19.1 (-48.9 to 10.7)
% loss to followup	Candesartan	Fluoxetine	-17.2 (-46.9 to 12.6)
% loss to followup	Candesartan	Gabapentin	3.0 (-27.8 to 33.7)
% loss to followup	Candesartan	Guanfacine	-3.0 (-40.7 to 34.7)
% loss to followup	Candesartan	Lamotrigine	5.0 (-32.7 to 42.7)
% loss to followup	Candesartan	Lisinopril	-17.0 (-54.7 to 20.7)
% loss to followup	Candesartan	Lisuride	5.0 (-32.7 to 42.7)
% loss to followup	Candesartan	Magnesium	-18.0 (-48.8 to 12.8)
% loss to followup	Candesartan	Methysergide	-27.4 (-65.1 to 10.3)
% loss to followup	Candesartan	Mianserin	-5.5 (-43.2 to 32.2)
% loss to followup	Candesartan	Montelukast	2.8 (-34.9 to 40.5)
% loss to followup	Candesartan	Naproxen sodium	-10.0 (-47.7 to 27.7)
% loss to followup	Candesartan	Nicardipine	-9.0 (-46.7 to 28.7)
% loss to followup	Candesartan	Nifedipine	-17.0 (-54.7 to 20.7)
% loss to followup	Candesartan	Nimodipine	-12.7 (-42.5 to 17.1)
% loss to followup	Candesartan	Oxcarbazepine	1.5 (-36.2 to 39.2)
% loss to followup	Candesartan	Propranolol	-9.4 (-37.5 to 18.6)
% loss to followup	Candesartan	Telmisartan	-12.0 (-49.7 to 25.7)
% loss to followup	Candesartan	Tonabersat	-0.1 (-37.8 to 37.6)
% loss to followup	Candesartan	Valproate	1.5 (-31.1 to 34.1)
% loss to followup	Candesartan	Verapamil	-29.0 (-61.6 to 3.6)
% loss to followup	Candesartan	Vigabatrin	5.0 (-32.7 to 42.7)
% loss to followup	Carbamazepine	Clonidine	-16.2 (-44.2 to 11.7)
% loss to followup	Carbamazepine	Dihydroergotamine	5.9 (-24.8 to 36.7)
% loss to followup	Carbamazepine	Divalproex	4.5 (-28.2 to 37.1)
% loss to followup	Carbamazepine	Femoxetine	-17.8 (-47.6 to 12.0)
% loss to followup	Carbamazepine	Fluoxetine	-15.9 (-45.6 to 13.9)
% loss to followup	Carbamazepine	Gabapentin	4.3 (-26.5 to 35.0)
% loss to followup	Carbamazepine	Guanfacine	-1.7 (-39.4 to 36.0)
% loss to followup	Carbamazepine	Lamotrigine	6.3 (-31.4 to 44.0)
% loss to followup	Carbamazepine	Lisinopril	-15.7 (-53.4 to 22.0)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% loss to followup	Carbamazepine	Lisuride	6.3 (-31.4 to 44.0)
% loss to followup	Carbamazepine	Magnesium	-16.7 (-47.5 to 14.1)
% loss to followup	Carbamazepine	Methysergide	-26.1 (-63.8 to 11.6)
% loss to followup	Carbamazepine	Mianserin	-4.2 (-41.9 to 33.5)
% loss to followup	Carbamazepine	Montelukast	4.1 (-33.6 to 41.8)
% loss to followup	Carbamazepine	Naproxen sodium	-8.7 (-46.4 to 29.0)
% loss to followup	Carbamazepine	Nicardipine	-7.7 (-45.4 to 30.0)
% loss to followup	Carbamazepine	Nifedipine	-15.7 (-53.4 to 22.0)
% loss to followup	Carbamazepine	Nimodipine	-11.4 (-41.2 to 18.4)
% loss to followup	Carbamazepine	Oxcarbazepine	2.8 (-34.9 to 40.5)
% loss to followup	Carbamazepine	Propranolol	-8.1 (-36.2 to 19.9)
% loss to followup	Carbamazepine	Telmisartan	-10.7 (-48.4 to 27.0)
% loss to followup	Carbamazepine	Tonabersat	1.2 (-36.5 to 38.9)
% loss to followup	Carbamazepine	Valproate	2.8 (-29.8 to 35.4)
% loss to followup	Carbamazepine	Verapamil	-27.7 (-60.3 to 4.9)
% loss to followup	Carbamazepine	Vigabatrin	6.3 (-31.4 to 44.0)
% loss to followup	Clonidine	Dihydroergotamine	22.2 (4.6 to 39.7)
% loss to followup	Clonidine	Divalproex	20.7 (0.1 to 41.3)
% loss to followup	Clonidine	Femoxetine	-1.6 (-17.4 to 14.2)
% loss to followup	Clonidine	Fluoxetine	0.4 (-15.4 to 16.1)
% loss to followup	Clonidine	Gabapentin	20.5 (3.0 to 38.0)
% loss to followup	Clonidine	Guanfacine	14.5 (-13.4 to 42.5)
% loss to followup	Clonidine	Lamotrigine	22.5 (-5.4 to 50.5)
% loss to followup	Clonidine	Lisinopril	0.5 (-27.4 to 28.5)
% loss to followup	Clonidine	Lisuride	22.5 (-5.4 to 50.5)
% loss to followup	Clonidine	Magnesium	-0.5 (-18.0 to 17.1)
% loss to followup	Clonidine	Methysergide	-9.9 (-37.8 to 18.1)
% loss to followup	Clonidine	Mianserin	12.0 (-15.9 to 40.0)
% loss to followup	Clonidine	Montelukast	20.3 (-7.6 to 48.3)
% loss to followup	Clonidine	Naproxen sodium	7.5 (-20.4 to 35.5)
% loss to followup	Clonidine	Nicardipine	8.5 (-19.4 to 36.5)
% loss to followup	Clonidine	Nifedipine	0.5 (-27.4 to 28.5)
% loss to followup	Clonidine	Nimodipine	4.9 (-10.9 to 20.6)
% loss to followup	Clonidine	Oxcarbazepine	19.0 (-8.9 to 47.0)
% loss to followup	Clonidine	Propranolol	8.1 (-4.2 to 20.3)
% loss to followup	Clonidine	Telmisartan	5.5 (-22.4 to 33.5)
% loss to followup	Clonidine	Tonabersat	17.4 (-10.5 to 45.4)
% loss to followup	Clonidine	Valproate	19.0 (-1.6 to 39.7)
% loss to followup	Clonidine	Verapamil	-11.5 (-32.1 to 9.2)
% loss to followup	Clonidine	Vigabatrin	22.5 (-5.4 to 50.5)
% loss to followup	Dihydroergotamine	Divalproex	-1.5 (-25.8 to 22.9)
% loss to followup	Dihydroergotamine	Femoxetine	-23.8 (-44.1 to -3.4)
% loss to followup	Dihydroergotamine	Fluoxetine	-21.8 (-42.1 to -1.4)
% loss to followup	Dihydroergotamine	Gabapentin	-1.7 (-23.4 to 20.1)
% loss to followup	Dihydroergotamine	Guanfacine	-7.6 (-38.4 to 23.1)
% loss to followup	Dihydroergotamine	Lamotrigine	0.4 (-30.4 to 31.1)
% loss to followup	Dihydroergotamine	Lisinopril	-21.6 (-52.4 to 9.1)
% loss to followup	Dihydroergotamine	Lisuride	0.4 (-30.4 to 31.1)
% loss to followup	Dihydroergotamine	Magnesium	-22.6 (-44.4 to -0.9)
% loss to followup	Dihydroergotamine	Methysergide	-32.0 (-62.8 to -1.3)
% loss to followup	Dihydroergotamine	Mianserin	-10.1 (-40.9 to 20.6)
% loss to followup	Dihydroergotamine	Montelukast	-1.8 (-32.6 to 28.9)
% loss to followup	Dihydroergotamine	Naproxen sodium	-14.6 (-45.4 to 16.1)
% loss to followup	Dihydroergotamine	Nicardipine	-13.6 (-44.4 to 17.1)
% loss to followup	Dihydroergotamine	Nifedipine	-21.6 (-52.4 to 9.1)
% loss to followup	Dihydroergotamine	Nimodipine	-17.3 (-37.7 to 3.0)
% loss to followup	Dihydroergotamine	Oxcarbazepine	-3.1 (-33.9 to 27.6)
% loss to followup	Dihydroergotamine	Propranolol	-14.1 (-31.8 to 3.7)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% loss to followup	Dihydroergotamine	Telmisartan	-16.6 (-47.4 to 14.1)
% loss to followup	Dihydroergotamine	Tonabersat	-4.7 (-35.5 to 26.0)
% loss to followup	Dihydroergotamine	Valproate	-3.1 (-27.5 to 21.2)
% loss to followup	Dihydroergotamine	Verapamil	-33.6 (-58.0 to -9.3)
% loss to followup	Dihydroergotamine	Vigabatrin	0.4 (-30.4 to 31.1)
% loss to followup	Divalproex	Femoxetine	-22.3 (-45.4 to 0.8)
% loss to followup	Divalproex	Fluoxetine	-20.3 (-43.4 to 2.7)
% loss to followup	Divalproex	Gabapentin	-0.2 (-24.5 to 24.1)
% loss to followup	Divalproex	Guanfacine	-6.2 (-38.8 to 26.5)
% loss to followup	Divalproex	Lamotrigine	1.8 (-30.8 to 34.5)
% loss to followup	Divalproex	Lisinopril	-20.2 (-52.8 to 12.5)
% loss to followup	Divalproex	Lisuride	1.8 (-30.8 to 34.5)
% loss to followup	Divalproex	Magnesium	-21.2 (-45.5 to 3.1)
% loss to followup	Divalproex	Methysergide	-30.6 (-63.2 to 2.1)
% loss to followup	Divalproex	Mianserin	-8.7 (-41.3 to 24.0)
% loss to followup	Divalproex	Montelukast	-0.4 (-33.0 to 32.3)
% loss to followup	Divalproex	Naproxen sodium	-13.2 (-45.8 to 19.5)
% loss to followup	Divalproex	Nicardipine	-12.2 (-44.8 to 20.5)
% loss to followup	Divalproex	Nifedipine	-20.2 (-52.8 to 12.5)
% loss to followup	Divalproex	Nimodipine	-15.9 (-38.9 to 7.2)
% loss to followup	Divalproex	Oxcarbazepine	-1.7 (-34.3 to 31.0)
% loss to followup	Divalproex	Propranolol	-12.6 (-33.4 to 8.2)
% loss to followup	Divalproex	Telmisartan	-15.2 (-47.8 to 17.5)
% loss to followup	Divalproex	Tonabersat	-3.3 (-35.9 to 29.4)
% loss to followup	Divalproex	Valproate	-1.7 (-28.3 to 25.0)
% loss to followup	Divalproex	Verapamil	-32.2 (-58.8 to -5.5)
% loss to followup	Divalproex	Vigabatrin	1.8 (-30.8 to 34.5)
% loss to followup	Femoxetine	Fluoxetine	2.0 (-16.9 to 20.8)
% loss to followup	Femoxetine	Gabapentin	22.1 (1.7 to 42.4)
% loss to followup	Femoxetine	Guanfacine	16.1 (-13.7 to 45.9)
% loss to followup	Femoxetine	Lamotrigine	24.1 (-5.7 to 53.9)
% loss to followup	Femoxetine	Lisinopril	2.1 (-27.7 to 31.9)
% loss to followup	Femoxetine	Lisuride	24.1 (-5.7 to 53.9)
% loss to followup	Femoxetine	Magnesium	1.1 (-19.2 to 21.5)
% loss to followup	Femoxetine	Methysergide	-8.3 (-38.1 to 21.5)
% loss to followup	Femoxetine	Mianserin	13.6 (-16.2 to 43.4)
% loss to followup	Femoxetine	Montelukast	21.9 (-7.9 to 51.7)
% loss to followup	Femoxetine	Naproxen sodium	9.1 (-20.7 to 38.9)
% loss to followup	Femoxetine	Nicardipine	10.1 (-19.7 to 39.9)
% loss to followup	Femoxetine	Nifedipine	2.1 (-27.7 to 31.9)
% loss to followup	Femoxetine	Nimodipine	6.5 (-12.4 to 25.3)
% loss to followup	Femoxetine	Oxcarbazepine	20.6 (-9.2 to 50.4)
% loss to followup	Femoxetine	Propranolol	9.7 (-6.3 to 25.7)
% loss to followup	Femoxetine	Telmisartan	7.1 (-22.7 to 36.9)
% loss to followup	Femoxetine	Tonabersat	19.0 (-10.8 to 48.8)
% loss to followup	Femoxetine	Valproate	20.6 (-2.4 to 43.7)
% loss to followup	Femoxetine	Verapamil	-9.9 (-32.9 to 13.2)
% loss to followup	Femoxetine	Vigabatrin	24.1 (-5.7 to 53.9)
% loss to followup	Fluoxetine	Gabapentin	20.1 (-0.2 to 40.5)
% loss to followup	Fluoxetine	Guanfacine	14.2 (-15.6 to 43.9)
% loss to followup	Fluoxetine	Lamotrigine	22.2 (-7.6 to 51.9)
% loss to followup	Fluoxetine	Lisinopril	0.2 (-29.6 to 29.9)
% loss to followup	Fluoxetine	Lisuride	22.2 (-7.6 to 51.9)
% loss to followup	Fluoxetine	Magnesium	-0.9 (-21.2 to 19.5)
% loss to followup	Fluoxetine	Methysergide	-10.3 (-40.0 to 19.5)
% loss to followup	Fluoxetine	Mianserin	11.7 (-18.1 to 41.4)
% loss to followup	Fluoxetine	Montelukast	20.0 (-9.8 to 49.7)
% loss to followup	Fluoxetine	Naproxen sodium	7.2 (-22.6 to 36.9)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% loss to followup	Fluoxetine	Nicardipine	8.2 (-21.6 to 37.9)
% loss to followup	Fluoxetine	Nifedipine	0.2 (-29.6 to 29.9)
% loss to followup	Fluoxetine	Nimodipine	4.5 (-14.4 to 23.3)
% loss to followup	Fluoxetine	Oxcarbazepine	18.7 (-11.1 to 48.4)
% loss to followup	Fluoxetine	Propranolol	7.7 (-8.3 to 23.7)
% loss to followup	Fluoxetine	Telmisartan	5.2 (-24.6 to 34.9)
% loss to followup	Fluoxetine	Tonabersat	17.1 (-12.7 to 46.8)
% loss to followup	Fluoxetine	Valproate	18.7 (-4.4 to 41.7)
% loss to followup	Fluoxetine	Verapamil	-11.9 (-34.9 to 11.2)
% loss to followup	Fluoxetine	Vigabatrin	22.2 (-7.6 to 51.9)
% loss to followup	Gabapentin	Guanfacine	-6.0 (-36.7 to 24.8)
% loss to followup	Gabapentin	Lamotrigine	2.0 (-28.7 to 32.8)
% loss to followup	Gabapentin	Lisinopril	-20.0 (-50.7 to 10.8)
% loss to followup	Gabapentin	Lisuride	2.0 (-28.7 to 32.8)
% loss to followup	Gabapentin	Magnesium	-21.0 (-42.7 to 0.8)
% loss to followup	Gabapentin	Methysergide	-30.4 (-61.1 to 0.4)
% loss to followup	Gabapentin	Mianserin	-8.5 (-39.2 to 22.3)
% loss to followup	Gabapentin	Montelukast	-0.2 (-30.9 to 30.6)
% loss to followup	Gabapentin	Naproxen sodium	-13.0 (-43.7 to 17.8)
% loss to followup	Gabapentin	Nicardipine	-12.0 (-42.7 to 18.8)
% loss to followup	Gabapentin	Nifedipine	-20.0 (-50.7 to 10.8)
% loss to followup	Gabapentin	Nimodipine	-15.6 (-36.0 to 4.7)
% loss to followup	Gabapentin	Oxcarbazepine	-1.5 (-32.2 to 29.3)
% loss to followup	Gabapentin	Propranolol	-12.4 (-30.2 to 5.4)
% loss to followup	Gabapentin	Telmisartan	-15.0 (-45.7 to 15.8)
% loss to followup	Gabapentin	Tonabersat	-3.1 (-33.8 to 27.7)
% loss to followup	Gabapentin	Valproate	-1.5 (-25.8 to 22.9)
% loss to followup	Gabapentin	Verapamil	-32.0 (-56.3 to -7.6)
% loss to followup	Gabapentin	Vigabatrin	2.0 (-28.7 to 32.8)
% loss to followup	Guanfacine	Lamotrigine	8.0 (-29.7 to 45.7)
% loss to followup	Guanfacine	Lisinopril	-14.0 (-51.7 to 23.7)
% loss to followup	Guanfacine	Lisuride	8.0 (-29.7 to 45.7)
% loss to followup	Guanfacine	Magnesium	-15.0 (-45.8 to 15.8)
% loss to followup	Guanfacine	Methysergide	-24.4 (-62.1 to 13.3)
% loss to followup	Guanfacine	Mianserin	-2.5 (-40.2 to 35.2)
% loss to followup	Guanfacine	Montelukast	5.8 (-31.9 to 43.5)
% loss to followup	Guanfacine	Naproxen sodium	-7.0 (-44.7 to 30.7)
% loss to followup	Guanfacine	Nicardipine	-6.0 (-43.7 to 31.7)
% loss to followup	Guanfacine	Nifedipine	-14.0 (-51.7 to 23.7)
% loss to followup	Guanfacine	Nimodipine	-9.7 (-39.5 to 20.1)
% loss to followup	Guanfacine	Oxcarbazepine	4.5 (-33.2 to 42.2)
% loss to followup	Guanfacine	Propranolol	-6.4 (-34.5 to 21.6)
% loss to followup	Guanfacine	Telmisartan	-9.0 (-46.7 to 28.7)
% loss to followup	Guanfacine	Tonabersat	2.9 (-34.8 to 40.6)
% loss to followup	Guanfacine	Valproate	4.5 (-28.1 to 37.1)
% loss to followup	Guanfacine	Verapamil	-26.0 (-58.6 to 6.6)
% loss to followup	Guanfacine	Vigabatrin	8.0 (-29.7 to 45.7)
% loss to followup	Lamotrigine	Lisinopril	-22.0 (-59.7 to 15.7)
% loss to followup	Lamotrigine	Lisuride	0.0 (-37.7 to 37.7)
% loss to followup	Lamotrigine	Magnesium	-23.0 (-53.8 to 7.8)
% loss to followup	Lamotrigine	Methysergide	-32.4 (-70.1 to 5.3)
% loss to followup	Lamotrigine	Mianserin	-10.5 (-48.2 to 27.2)
% loss to followup	Lamotrigine	Montelukast	-2.2 (-39.9 to 35.5)
% loss to followup	Lamotrigine	Naproxen sodium	-15.0 (-52.7 to 22.7)
% loss to followup	Lamotrigine	Nicardipine	-14.0 (-51.7 to 23.7)
% loss to followup	Lamotrigine	Nifedipine	-22.0 (-59.7 to 15.7)
% loss to followup	Lamotrigine	Nimodipine	-17.7 (-47.5 to 12.1)
% loss to followup	Lamotrigine	Oxcarbazepine	-3.5 (-41.2 to 34.2)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% loss to followup	Lamotrigine	Propranolol	-14.4 (-42.5 to 13.6)
% loss to followup	Lamotrigine	Telmisartan	-17.0 (-54.7 to 20.7)
% loss to followup	Lamotrigine	Tonabersat	-5.1 (-42.8 to 32.6)
% loss to followup	Lamotrigine	Valproate	-3.5 (-36.1 to 29.1)
% loss to followup	Lamotrigine	Verapamil	-34.0 (-66.6 to -1.4)
% loss to followup	Lamotrigine	Vigabatrin	0.0 (-37.7 to 37.7)
% loss to followup	Lisinopril	Lisuride	22.0 (-15.7 to 59.7)
% loss to followup	Lisinopril	Magnesium	-1.0 (-31.8 to 29.8)
% loss to followup	Lisinopril	Methysergide	-10.4 (-48.1 to 27.3)
% loss to followup	Lisinopril	Mianserin	11.5 (-26.2 to 49.2)
% loss to followup	Lisinopril	Montelukast	19.8 (-17.9 to 57.5)
% loss to followup	Lisinopril	Naproxen sodium	7.0 (-30.7 to 44.7)
% loss to followup	Lisinopril	Nicardipine	8.0 (-29.7 to 45.7)
% loss to followup	Lisinopril	Nifedipine	0.0 (-37.7 to 37.7)
% loss to followup	Lisinopril	Nimodipine	4.3 (-25.5 to 34.1)
% loss to followup	Lisinopril	Oxcarbazepine	18.5 (-19.2 to 56.2)
% loss to followup	Lisinopril	Propranolol	7.6 (-20.5 to 35.6)
% loss to followup	Lisinopril	Telmisartan	5.0 (-32.7 to 42.7)
% loss to followup	Lisinopril	Tonabersat	16.9 (-20.8 to 54.6)
% loss to followup	Lisinopril	Valproate	18.5 (-14.1 to 51.1)
% loss to followup	Lisinopril	Verapamil	-12.0 (-44.6 to 20.6)
% loss to followup	Lisinopril	Vigabatrin	22.0 (-15.7 to 59.7)
% loss to followup	Lisuride	Magnesium	-23.0 (-53.8 to 7.8)
% loss to followup	Lisuride	Methysergide	-32.4 (-70.1 to 5.3)
% loss to followup	Lisuride	Mianserin	-10.5 (-48.2 to 27.2)
% loss to followup	Lisuride	Montelukast	-2.2 (-39.9 to 35.5)
% loss to followup	Lisuride	Naproxen sodium	-15.0 (-52.7 to 22.7)
% loss to followup	Lisuride	Nicardipine	-14.0 (-51.7 to 23.7)
% loss to followup	Lisuride	Nifedipine	-22.0 (-59.7 to 15.7)
% loss to followup	Lisuride	Nimodipine	-17.7 (-47.5 to 12.1)
% loss to followup	Lisuride	Oxcarbazepine	-3.5 (-41.2 to 34.2)
% loss to followup	Lisuride	Propranolol	-14.4 (-42.5 to 13.6)
% loss to followup	Lisuride	Telmisartan	-17.0 (-54.7 to 20.7)
% loss to followup	Lisuride	Tonabersat	-5.1 (-42.8 to 32.6)
% loss to followup	Lisuride	Valproate	-3.5 (-36.1 to 29.1)
% loss to followup	Lisuride	Verapamil	-34.0 (-66.6 to -1.4)
% loss to followup	Lisuride	Vigabatrin	0.0 (-37.7 to 37.7)
% loss to followup	Magnesium	Mianserin	12.5 (-18.3 to 43.3)
% loss to followup	Magnesium	Montelukast	20.8 (-10.0 to 51.6)
% loss to followup	Magnesium	Naproxen sodium	8.0 (-22.8 to 38.8)
% loss to followup	Magnesium	Nicardipine	9.0 (-21.8 to 39.8)
% loss to followup	Magnesium	Nifedipine	1.0 (-29.8 to 31.8)
% loss to followup	Magnesium	Nimodipine	5.3 (-15.0 to 25.7)
% loss to followup	Magnesium	Oxcarbazepine	19.5 (-11.3 to 50.3)
% loss to followup	Magnesium	Propranolol	8.6 (-9.2 to 26.3)
% loss to followup	Magnesium	Telmisartan	6.0 (-24.8 to 36.8)
% loss to followup	Magnesium	Tonabersat	17.9 (-12.9 to 48.7)
% loss to followup	Magnesium	Valproate	19.5 (-4.8 to 43.8)
% loss to followup	Magnesium	Verapamil	-11.0 (-35.3 to 13.3)
% loss to followup	Magnesium	Vigabatrin	23.0 (-7.8 to 53.8)
% loss to followup	Methysergide	Magnesium	9.4 (-21.4 to 40.2)
% loss to followup	Methysergide	Mianserin	21.9 (-15.8 to 59.6)
% loss to followup	Methysergide	Montelukast	30.2 (-7.5 to 67.9)
% loss to followup	Methysergide	Naproxen sodium	17.4 (-20.3 to 55.1)
% loss to followup	Methysergide	Nicardipine	18.4 (-19.3 to 56.1)
% loss to followup	Methysergide	Nifedipine	10.4 (-27.3 to 48.1)
% loss to followup	Methysergide	Nimodipine	14.7 (-15.1 to 44.5)
% loss to followup	Methysergide	Oxcarbazepine	28.9 (-8.8 to 66.6)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% loss to followup	Methysergide	Propranolol	18.0 (-10.1 to 46.0)
% loss to followup	Methysergide	Telmisartan	15.4 (-22.3 to 53.1)
% loss to followup	Methysergide	Tonabersat	27.3 (-10.4 to 65.0)
% loss to followup	Methysergide	Valproate	28.9 (-3.7 to 61.5)
% loss to followup	Methysergide	Verapamil	-1.6 (-34.2 to 31.0)
% loss to followup	Methysergide	Vigabatrin	32.4 (-5.3 to 70.1)
% loss to followup	Mianserin	Montelukast	8.3 (-29.4 to 46.0)
% loss to followup	Mianserin	Naproxen sodium	-4.5 (-42.2 to 33.2)
% loss to followup	Mianserin	Nicardipine	-3.5 (-41.2 to 34.2)
% loss to followup	Mianserin	Nifedipine	-11.5 (-49.2 to 26.2)
% loss to followup	Mianserin	Nimodipine	-7.2 (-37.0 to 22.6)
% loss to followup	Mianserin	Oxcarbazepine	7.0 (-30.7 to 44.7)
% loss to followup	Mianserin	Propranolol	-3.9 (-32.0 to 24.1)
% loss to followup	Mianserin	Telmisartan	-6.5 (-44.2 to 31.2)
% loss to followup	Mianserin	Tonabersat	5.4 (-32.3 to 43.1)
% loss to followup	Mianserin	Valproate	7.0 (-25.6 to 39.6)
% loss to followup	Mianserin	Verapamil	-23.5 (-56.1 to 9.1)
% loss to followup	Mianserin	Vigabatrin	10.5 (-27.2 to 48.2)
% loss to followup	Montelukast	Naproxen sodium	-12.8 (-50.5 to 24.9)
% loss to followup	Montelukast	Nicardipine	-11.8 (-49.5 to 25.9)
% loss to followup	Montelukast	Nifedipine	-19.8 (-57.5 to 17.9)
% loss to followup	Montelukast	Nimodipine	-15.5 (-45.3 to 14.3)
% loss to followup	Montelukast	Oxcarbazepine	-1.3 (-39.0 to 36.4)
% loss to followup	Montelukast	Propranolol	-12.2 (-40.3 to 15.8)
% loss to followup	Montelukast	Telmisartan	-14.8 (-52.5 to 22.9)
% loss to followup	Montelukast	Tonabersat	-2.9 (-40.6 to 34.8)
% loss to followup	Montelukast	Valproate	-1.3 (-33.9 to 31.3)
% loss to followup	Montelukast	Verapamil	-31.8 (-64.4 to 0.8)
% loss to followup	Montelukast	Vigabatrin	2.2 (-35.5 to 39.9)
% loss to followup	Naproxen sodium	Nicardipine	1.0 (-36.7 to 38.7)
% loss to followup	Naproxen sodium	Nifedipine	-7.0 (-44.7 to 30.7)
% loss to followup	Naproxen sodium	Nimodipine	-2.7 (-32.5 to 27.1)
% loss to followup	Naproxen sodium	Oxcarbazepine	11.5 (-26.2 to 49.2)
% loss to followup	Naproxen sodium	Propranolol	0.6 (-27.5 to 28.6)
% loss to followup	Naproxen sodium	Telmisartan	-2.0 (-39.7 to 35.7)
% loss to followup	Naproxen sodium	Tonabersat	9.9 (-27.8 to 47.6)
% loss to followup	Naproxen sodium	Valproate	11.5 (-21.1 to 44.1)
% loss to followup	Naproxen sodium	Verapamil	-19.0 (-51.6 to 13.6)
% loss to followup	Naproxen sodium	Vigabatrin	15.0 (-22.7 to 52.7)
% loss to followup	Nicardipine	Nifedipine	-8.0 (-45.7 to 29.7)
% loss to followup	Nicardipine	Nimodipine	-3.7 (-33.5 to 26.1)
% loss to followup	Nicardipine	Oxcarbazepine	10.5 (-27.2 to 48.2)
% loss to followup	Nicardipine	Propranolol	-0.4 (-28.5 to 27.6)
% loss to followup	Nicardipine	Telmisartan	-3.0 (-40.7 to 34.7)
% loss to followup	Nicardipine	Tonabersat	8.9 (-28.8 to 46.6)
% loss to followup	Nicardipine	Valproate	10.5 (-22.1 to 43.1)
% loss to followup	Nicardipine	Verapamil	-20.0 (-52.6 to 12.6)
% loss to followup	Nicardipine	Vigabatrin	14.0 (-23.7 to 51.7)
% loss to followup	Nifedipine	Nimodipine	4.3 (-25.5 to 34.1)
% loss to followup	Nifedipine	Oxcarbazepine	18.5 (-19.2 to 56.2)
% loss to followup	Nifedipine	Propranolol	7.6 (-20.5 to 35.6)
% loss to followup	Nifedipine	Telmisartan	5.0 (-32.7 to 42.7)
% loss to followup	Nifedipine	Tonabersat	16.9 (-20.8 to 54.6)
% loss to followup	Nifedipine	Valproate	18.5 (-14.1 to 51.1)
% loss to followup	Nifedipine	Verapamil	-12.0 (-44.6 to 20.6)
% loss to followup	Nifedipine	Vigabatrin	22.0 (-15.7 to 59.7)
% loss to followup	Nimodipine	Oxcarbazepine	14.2 (-15.6 to 44.0)
% loss to followup	Nimodipine	Propranolol	3.2 (-12.8 to 19.2)

Appendix Table D6. Differences in subject characteristics in randomized controlled clinical trials that examined efficacy of the drugs for migraine prevention in adults (differences are statistically significant when 95% CI do not include 0) (continued)

% loss to followup	Nimodipine	Telmisartan	0.7 (-29.1 to 30.5)
% loss to followup	Nimodipine	Tonabersat	12.6 (-17.2 to 42.4)
% loss to followup	Nimodipine	Valproate	14.2 (-8.9 to 37.2)
% loss to followup	Nimodipine	Verapamil	-16.3 (-39.4 to 6.7)
% loss to followup	Nimodipine	Vigabatrin	17.7 (-12.1 to 47.5)
% loss to followup	Oxcarbazepine	Propranolol	-10.9 (-39.0 to 17.1)
% loss to followup	Oxcarbazepine	Telmisartan	-13.5 (-51.2 to 24.2)
% loss to followup	Oxcarbazepine	Tonabersat	-1.6 (-39.3 to 36.1)
% loss to followup	Oxcarbazepine	Valproate	0.0 (-32.6 to 32.6)
% loss to followup	Oxcarbazepine	Verapamil	-30.5 (-63.1 to 2.1)
% loss to followup	Oxcarbazepine	Vigabatrin	3.5 (-34.2 to 41.2)
% loss to followup	Propranolol	Telmisartan	-2.6 (-30.6 to 25.5)
% loss to followup	Propranolol	Tonabersat	9.3 (-18.7 to 37.4)
% loss to followup	Propranolol	Valproate	10.9 (-9.9 to 31.8)
% loss to followup	Propranolol	Verapamil	-19.6 (-40.4 to 1.3)
% loss to followup	Propranolol	Vigabatrin	14.4 (-13.6 to 42.5)
% loss to followup	Telmisartan	Tonabersat	11.9 (-25.8 to 49.6)
% loss to followup	Telmisartan	Valproate	13.5 (-19.1 to 46.1)
% loss to followup	Telmisartan	Verapamil	-17.0 (-49.6 to 15.6)
% loss to followup	Telmisartan	Vigabatrin	17.0 (-20.7 to 54.7)
% loss to followup	Tonabersat	Valproate	1.6 (-31.0 to 34.2)
% loss to followup	Tonabersat	Verapamil	-28.9 (-61.5 to 3.7)
% loss to followup	Tonabersat	Vigabatrin	5.1 (-32.6 to 42.8)
% loss to followup	Valproate	Verapamil	-30.5 (-57.1 to -3.9)
% loss to followup	Valproate	Vigabatrin	3.5 (-29.1 to 36.1)
% loss to followup	Verapamil	Vigabatrin	34.0 (1.4 to 66.6)

Appendix Table D7. Risk of bias in randomized controlled clinical trials of drugs for migraine prevention in adults

	Adequate Allocation Concealment	Unclear Allocation Concealment	Randomization Adequate	Unclear Adequacy of Randomization	Randomized Inadequate	Planned Intention to treat	No Planned Intention to treat	Double Blind	Single Blind	Open Label	Low ROB	Medium ROB	High ROB	Unclear ROB	Total
Topiramate*	6	21	15	7	5	15	12	25	0	2	12	14	1	0	27
Divalproex*	0	3	3	0	0	2	1	3	0	0	2	1	0	0	3
Propranolol*	1	44	13	32	0	6	39	39	2	4	6	34	5	0	45
Timolol*	0	2	0	1	1	1	1	2	0	0	0	2	0	0	2
Acetazolamide	1	0	1	0	0	1	0	1	0	0	1	0	0	0	1
Gabapentin	1	3	1	2	1	2	2	4	0	0	1	3	0	0	4
Lamotrigine	0	1	0	1	0	1	0	1	0	0	1	0	0	0	1
Oxcarbazepine	1	0	1	0	0	1	0	1	0	0	1	0	0	0	1
Valproate	0	4	2	2	0	1	3	3	0	1	1	2	1	0	4
Vigabatrin	0	1	0	1	0	0	1	1	0	0	0	1	0	0	1
Carbamazepine	0	1	0	1	0	0	1	1	0	0	0	1	0	0	1
Alprenolol	0	1	0	1	0	0	1	1	0	0	0	1	0	0	1
Atenolol	0	2	0	2	0	0	2	2	0	0	0	2	0	0	2
Bisoprolol	0	1	1	0	0	1	0	1	0	0	0	1	0	0	1
Metoprolol	0	9	3	5	1	2	7	9	0	0	1	8	0	0	9
Nadolol	0	2	0	2	0	1	1	2	0	0	1	1	0	0	2
Pindolol	0	2	1	1	0	0	2	2	0	0	0	2	0	0	2
Acebutolol	0	1	0	1	0	0	1	1	0	0	0	1	0	0	1
Amitriptyline	0	4	3	1	0	1	3	3	0	1	0	4	0	0	4
Femoxetine	0	6	3	3	0	0	6	6	0	0	0	6	0	0	6
Fluoxetine	0	6	4	1	1	0	6	5	0	1	0	5	1	0	6
Fluvoxamine	0	1	1	0	0	0	1	1	0	0	0	1	0	0	1
Venlafaxine	0	3	2	0	1	1	2	2	0	1	0	2	1	0	3
Mianserin	0	1	0	0	1	0	1	1	0	0	0	0	1	0	1
Captopril	0	1	0	1	0	0	1	1	0	0	1	0	0	0	1
Lisinopril	1	0	0	1	0	1	0	1	0	0	1	0	0	0	1
Candesartan	1	0	0	1	0	1	0	1	0	0	1	0	0	0	1
Telmisartan	0	1	0	0	1	0	1	1	0	0	0	0	1	0	1
Nifedipine	0	1	0	1	0	0	1	1	0	0	0	1	0	0	1
Nimodipine	0	6	1	4	1	1	5	5	1	0	0	5	1	0	6
Verapamil	0	2	0	2	0	0	2	2	0	0	0	2	0	0	2
Nicardipine	0	1	1	0	0	0	1	1	0	0	0	1	0	0	1
Clonidine	0	14	1	13	0	0	14	13	0	1	3	9	1	1	14
Guanfacine	0	1	0	1	0	1	0	1	0	0	1	0	0	0	1
Dihydroergocryptine	0	3	0	2	1	0	3	3	0	0	0	2	1	0	3

Appendix Table D7. Risk of bias in randomized controlled clinical trials of drugs for migraine prevention in adults (continued)

	Adequate Allocation Concealment	Unclear Allocation Concealment	Randomization Adequate	Unclear Adequacy of Randomization	Randomized Inadequate	Planned Intention to-treat	No Planned Intention to-treat	Double Blind	Single Blind	Open Label	Low ROB	Medium ROB	High ROB	Unclear ROB	Total
Dihydro-ergotamine	0	4	2	2	0	1	3	3	0	1	1	3	0	0	4
Lisuride	0	3	2	1	0	0	3	3	0	0	0	3	0	0	3
Methysergide	0	2	0	2	0	0	2	2	0	0	0	2	0	0	2
Non -drug	2	2	3	0	1	3	1	0	1	3	1	2	1	0	4
Aspirin	0	5	1	3	1	1	4	5	0	0	2	3	0	0	5
Fenoprofen	0	1	0	0	1	0	1	0	0	1	0	1	0	0	1
Flurbiprofen	0	1	0	1	0	0	1	0	0	1	0	1	0	0	1
Indobufen	0	1	1	0	0	0	1	1	0	0	1	0	0	0	1
Indomethacin	0	1	0	1	0	1	0	0	0	1	0	1	0	0	1
Induprofen	0	1	1	0	0	0	1	0	0	1	0	1	0	0	1
Ketoprofen	0	1	0	1	0	0	1	0	0	1	0	1	0	0	1
Naproxen	0	3	1	1	1	0	3	0	0	3	0	0	2	1	3
Rofecoxib	0	1	1	0	0	1	0	1	0	0	0	1	0	0	1
Tolfenamic Acid	0	1	0	1	0	0	1	0	0	1	0	1	0	0	1
Magnesium	0	3	2	0	1	2	1	3	0	0	2	0	1	0	3
Montelukast	0	1	1	0	0	1	0	1	0	0	1	0	0	0	1
Tizanidine	0	1	1	0	0	0	1	1	0	0	0	1	0	0	1
Tonabersat	0	1	1	0	0	1	0	1	0	0	1	0	0	0	1

Total	14	206	87	111	22	53	167	188	5	27	45	148	25	2	220**
%	6.36	93.64	39.55	50.45	10	24.09	75.91	85.45	2.27	12.27	20.45	67.27	11.36	0.91	100

* approved drugs;**- 24 RCTs of flunarizine contributed to counts; ROB = risk of bias

Appendix Table D8. Randomized controlled clinical trials that examined efficacy of botulinum toxin for migraine prevention in adults

Reference	Trial	Country	Sample [Number Analyzed] % Women	Mean Age	Definition of Migraine	% Without Aura	Duration of Migraine, Months	Baseline Severity	Treatment History
Aurora, 2010 ¹	PREEMPT NCT00156910	North American	679 [679] 87.5% women	41.7	ICHD-II (2004) section 1, migraine, with the exception of “complicated migraine” (i.e., hemiplegic migraine, basilar- type migraine, ophthalmoplegic migraine, migrainous infarction)	NR % without aura NR	20.4	Migraine episodes: 12.1	% with prior preventive treatments 61.8
Diener, 2010 ² Lipton, 2011 ³	PREEMPT NCT00168428	North America & 16 European	705 [705] 85.4% women	41	ICHD-II (2004) section 1, migraine, with the exception of “complicated migraine”	NR % without aura NR	18	Migraine episodes: 12.1	% with prior preventive treatments 65.1
Saper, 2007 ⁴	BoNTA-009 Study Group	USA	232 [232] 85.8% women	43.6	Migraine headaches as defined by the International Headache Society criteria	Included % without aura NR	23.8	Migraines per month (historical): 5.7	% with prior preventive treatments NR
Freitag, 2008 ⁵		USA	60 [41] 73% women	42.3	Migraine episodes meeting the criteria 1.1 or 1.2 of the ICHD-I	NR % without aura NR	NR	Number of migraine episodes: 14.2	% with prior preventive treatments NR
Silberstein, 2000 ⁶	BOTOX Migraine Clinical Research Group	USA	123 [123] 85.4% women	44	Migraine, International Headache Society guideline	Included % without aura NR	NR	Mean migraine frequency: 4.4	% with prior preventive treatments NR
Elkind, 2006 ⁷	BoNTA-024- 026-036 Study Group	USA	418 [418] 84.7% women	44.1	Migraine, International Headache Society guideline	Included % without aura 50	21	Mean Migraine Headache Frequency: 5.5	% with prior preventive treatments NR
Chankrachang*, 2011 ⁸	NCT00258609*	Thailand	128 [Vary] 94.4% women	38.6	International Headache Society	% without aura 100	8.2	Migraine attacks per month: 5.1	% with prior preventive

Appendix Table D8. Randomized controlled clinical trials that examined efficacy of botulinum toxin for migraine prevention in adults (continued)

Reference	Trial	Country	Sample [Number Analyzed] % Women	Mean Age	Definition of Migraine	% Without Aura	Duration of Migraine, Months	Baseline Severity	Treatment History
									treatments 98.5
Petri*, 2009 ⁹	Dysport *Migraine Study Group	Germany	127 [122] 83.6% women	46.2	International Headache Society	Included % without aura NR	26.5	Mean attack frequency per month: 4.8	% with prior preventive treatments NR
Mathew, 2005 ¹⁰	BOTOX CDH Study Group	USA	355 [355] 84.5% women	43.5	International Headache Society	Included % without aura NR	Years since onset of chronic daily headache : 14.5	Frequency of migraines/probabl e migraines (month): 11	% with prior preventive treatments 35.8
Silberstein, 2005 ¹¹		North American	702 [702] 82.9% women	43.4	International Headache Society	Included % without aura NR	Years since onset of CDH: 13.7	Frequency of migraines/probabl e migraines (month): 10.5	% with prior preventive treatments 49.6
Anand, 2006 ¹²		India	32 [32] 75% women	NR	International Headache Society	Included % without aura NR	NR	Mean number of headache days per month: 8.3	% with prior preventive treatments NR
Cady, 2008 ¹³		USA	59 [54] 85.2% women	42.1	International Headache Society	Included % without aura 40.6	NR	Mean headache frequency=5.1; headache days=8.4	% with prior preventive treatments 100
Vo, 2007 ¹⁴	Walter Reed Army Medical Center Neurology trial	USA	32 [32] 84.4% women	42.4	International Headache Society	Included % without aura NR	19.5	Mean migraine frequency (days): 19.4	% with prior preventive treatments NR
Aurora, 2007 ¹⁵	BOTOX North American Episodic Migraine Study Group	North American	369 [369] 89.2% women	45	International Headache Society	Included % without aura NR	22.7	Migraine headache episodes per month: 6.5	% with prior preventive treatments 38.2
Barrientos, 2003 ¹⁶		Chile (Unclear)	30 [30] 80% women	41.1	International Headache Society	Included % without aura NR	15.1	Frequency of migraine attacks (month): 5.1	% with prior preventive treatments NR

Appendix Table D8. Randomized controlled clinical trials that examined efficacy of botulinum toxin for migraine prevention in adults (continued)

Reference	Trial	Country	Sample [Number Analyzed] % Women	Mean Age	Definition of Migraine	% Without Aura	Duration of Migraine, Months	Baseline Severity	Treatment History
Relja, 2007 ¹⁷	European BoNTA Headache Study Group	European countries (Belgium, Croatia, Denmark, Finland, France, Germany, Norway, Switzerland, UK)	515 [515] 87.9% women	43.2	International Headache Society	Included % without aura NR	Mean time since first migraine onset (years): 23.1	Mean number of days of acute medication use: 6.2	% with prior preventive treatments 57.6

NR = not reported; * trials of abobotulinumtoxin A

Appendix Table D9. Funding and conflict of interest in randomized controlled clinical trials that examined efficacy of botulinum toxin for migraine prevention in adults

Reference	Finance	Ethical Approval	Consent	Conflict of Interest	Conflict of Interest Disclosure
Aurora, 2010 ¹	Industry	Yes	Yes	Yes	SKA has received grants and research support from Advanced Bionics, Alexza, Allergan, Capnia, GlaxoSmithKline, MAP pharmaceuticals, Merck, Ortho-McNeil, Neuralieve, NuPathe and Takeda. She is a consultant for Ortho-McNeil, Merck, GlaxoSmithKline, Allergan, Neuralieve, NuPathe and MAP Pharmaceuticals. She has also received honoraria from Merck, GlaxoSmithKline, Kowa, NuPathe and Ortho-McNeil. DWD has received honoraria from Allergan, Merck, Neuralieve, Coherex, Kowa, Minster, NeurAxon, H Lundbeck, Endo, Pfizer, Nupathe and MAP Pharmaceuticals, in addition to being a consultant to and on the advisory board of these pharmaceutical companies. He has also received funding from Advanced Neurostimulation Systems, St. Jude Medical Center and Medtronic. CCT, RED and MFB are employees of Allergan, and own stock in the company. SDS and RBL have received honoraria and research funding from Allergan, in addition to being consultants to and on the advisory board of Allergan. HCD has received honoraria for participation in clinical trials, contribution to advisory boards, or oral presentations from Addex Pharma, Allergan, Almirall, AstraZeneca, Bayer Vital, Berlin Chemie, CoLucid, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Grunenthal, Janssen-Cilag, Lilly, La Roche, 3M Medica, Minster, MSD, Novartis, Johnson & Johnson, Pierre Fabre, Pfizer, Schaper and Brummer, Sanofi-Aventis and Weber & Weber. He has also received financial support for research projects from Allergan, Almirall, AstraZeneca, Bayer, GlaxoSmithKline, Janssen-Cilag, and Pfizer. Headache research at the Department of Neurology in Essen, where HCD is Professor, is supported by the German Research Council (DFG), the German Ministry of Education and Research (BMBF), and the European Union.
Diener, 2010 ²	Industry	Yes	Yes	Yes	HCD has received honoraria for participation in clinical trials, contribution to advisory boards and/or oral presentations from Addex Pharma, Allergan, Almirall, AstraZeneca, Bayer Vital, Berlin Chemie, CoLucid, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Grunenthal, Janssen-Cilag, Lilly, La Roche, 3M Medica, Minster, MSD, Novartis, Johnson & Johnson, Pierre Fabre, Pfizer, Schaper and Brummer, Sanofi-Aventis and Weber & Weber. He has also received financial support for research projects from Allergan, Almirall, AstraZeneca, Bayer, GlaxoSmithKline, Janssen-Cilag and Pfizer. Headache research at the Department of Neurology in Essen, where HCD is professor, is supported by the German Research Council (DFG), the German Ministry of Education and Research (BMBF) and the European Union. DWD has received honoraria from Allergan, Merck, Neuralieve, Coherex, Kowa, Minster, NeurAxon, H Lundbeck, Endo, Pfizer, Nupathe and MAP Pharmaceuticals, in addition to being a consultant to and on the advisory board of these pharmaceutical companies. He has also received funding from Advanced Neurostimulation Systems, St. Jude Medical Center and Medtronic. SKA received grants and research support from Advanced Bionics, Alexza, Allergan, Capnia, GlaxoSmithKline, MAP Pharmaceuticals, Merck, Ortho-McNeil, Neuralieve, NuPathe and Takeda. She is a consultant for Ortho-McNeil, Merck, GlaxoSmithKline, Allergan,

Appendix Table D9. Funding and conflict of interest in randomized controlled clinical trials that examined efficacy of botulinum toxin for migraine prevention in adults (continued)

Reference	Finance	Ethical Approval	Consent	Conflict of Interest	Conflict of Interest Disclosure
					Neuralie, NuPathe and MAP Pharmaceuticals. She has also received honoraria from Merck, GlaxoSmithKline, Kowa, NuPathe and Ortho-McNeil. CCT, RED and MFB are employees of Allergan, and own stock in the company. SDS and RBL have received honoraria and research funding from Allergan, in addition to being consultants to and on the advisory board of Allergan.
Saper, 2007 ⁴	Industry	No	Yes	Yes	Two authors are employed by Allergan, Inc.
Freitag, 2008 ⁵	Industry	Yes	Yes	Yes	Dr. Freitag has received grant support and consulting fees from Allergan.
Silberstein, 2000 ⁶	Industry	Yes	Yes	Yes	One author is employed by Allergan Inc, study funder.
Elkind, 2006 ⁷	Industry	Yes	Yes	Yes	Two authors are employed by Allergan Inc, study funder.
Chankrachang*, 2011 ^{8*}	Industry	Yes	Yes	No	Not applicable
Petri*, 2009 ^{9*}	Industry	Yes	Yes	Yes	One of the authors (Ceballos-Baumann) has received honoraria for speeches from Ipsen Pharma and from other companies that manufacture botulinum toxin,
Mathew, 2005 ¹⁰	Industry	Yes	Yes	Yes	R.Dimitrova, J.Gibson, and C.Turkel are employed by Allergan, Inc., and own stock in the company
Silberstein, 2005 ¹¹	Industry	Yes	Yes	Yes	Dr. Silberstein is on the advisory panel and speakers' bureau and receives research support from Allergan, Inc; Dr Stark has served as a principal investigator and sub investigator for Allergan, Inc, for the past 4 years. Dr Lucas is a consultant for Allergan, Inc. Dr Christie has received a research grant, consultancy fees, and honoraria from Allergan, Inc. Dr Turkel and Mr DeGryse are employed by and own stock in Allergan, Inc.
Anand, 2006 ¹²	Not reported	Yes	Yes	Not reported	Not applicable
Cady, 2008 ¹³	Industry	Yes	Yes	Not reported	Not applicable
Vo, 2007 ¹⁴	Grant	Yes	Yes	Not reported	Alexander Vo is an employee of Uniformed Services University of the Health Sciences (sponsor of the study)
Aurora, 2007 ¹⁵	Industry	Yes	Yes	Yes	Two authors are employed by Allergan, Inc, and own stock in the company.
Barrientos, 2003 ¹⁶	Industry	Yes	Yes	Not reported	Not applicable
Relja, 2007 ¹⁷	Industry	Yes	Yes	Yes	Two authors are employed by Allergan, Inc. and own stock in the company.

* Trials of abobotulinumtoxin A

Appendix Table D10. Risk of bias in randomized controlled clinical trials that examined efficacy of botulinum toxin for migraine prevention in adults

Reference	Masking	Intention to Treat Planned	Allocation Concealment	Adequacy of Randomization	Selective Outcome Reporting	Risk of Bias	Other Biases
Aurora, 2010 ¹	Double blind	Yes	Adequate	No	Unclear	Medium	Mean headache episodes during baseline & Mean migraine episodes during baseline are statistically different between group
Diener, 2010 ²	Double blind	Yes	Adequate	Yes	Unclear	Low	
Saper, 2007 ⁴	Double blind	Yes	Unclear	Yes	Unclear	Low	
Freitag, 2008 ⁵	Double blind	Yes	Unclear	Unclear (no tests conducted)	Unclear	Low	Poor reporting quality
Silberstein, 2000 ⁶	Double blind	Yes	Unclear	No	Unclear	Medium	Mean age differs by group: patients in vehicle group had higher mean age; Baseline frequencies of migraines of any severity were significantly lower in the 75-U BTX-A treatment group (4.40) than in the 25-U BTX-A (5.48) or vehicle (5.20) groups ($P<.046$). There was a statistically significant difference among groups in time since onset of migraines ($P=0.001$), with a greater mean time since onset in the vehicle (27.4 years) and 25-U BTX-A (23.4 years) groups than in the 75-U BTX-A group (16.9 years).
Elkind, 2006 ⁷	Double blind	Yes	Unclear	Yes (See note)	Unclear	Low	
Chankrachang*, 2011 ^{8*}	Double blind	Yes	Unclear	Yes	Unclear	Low	ITT planned only for efficacy measures
Petri*, 2009 ^{9*}	Double blind	Yes	Unclear	No	Yes	High	Mean age differs by groups
Mathew, 2005 ¹⁰	Double blind	Yes	Unclear	Yes	Unclear	Low	
Silberstein, 2005 ¹¹	Double blind	Yes	Unclear	Yes	Unclear	Low	does not provide loss at follow-up
Anand, 2006 ¹²	Double blind	No	Unclear	Unclear (Table not provided, but	Unclear	Medium	Concern regarding baseline severity: in text, authors

Appendix Table D10. Risk of bias in randomized controlled clinical trials that examined efficacy of botulinum toxin for migraine prevention in adults (continued)

Reference	Masking	Intention to Treat Planned	Allocation Concealment	Adequacy of Randomization	Selective Outcome Reporting	Risk of Bias	Other Biases
				authors mentioned "Demographic characteristics of patients in both the groups were comparable".			report mean number of headache days at baseline (4 moderate to severe headache in trt group vs. 12.6 in placebo group)
Cady, 2008 ¹³	Double blind	No	Unclear	Yes	Unclear	Low	
Vo, 2007 ¹⁴	Double blind	No	Unclear	Yes	Unclear	Low	Primary reason for attrition is attributable due the fluidality of personnel in a major military medical setting during a time of conflict
Aurora, 2007 ¹⁵	Double blind	Yes	Unclear	No	Unclear	Medium	
Barrientos, 2003 ¹⁶	Double blind	Yes	Unclear	Yes	Unclear	Low	
Relja, 2007 ¹⁷	Double blind	Yes	Unclear	Yes	Unclear	Low	

* Trials of abobotulinumtoxin A

Appendix Table D11. Strength of evidence of decrease in migraine frequency by $\geq 50\%$ with onabotulinumtoxin A

Reference	Risk of Bias	Directness	Consistency	Precision	Strength of Evidence
Silberstein, 2000 ⁶	Medium	Yes			
Freitag, 2008 ⁵	Low	Yes			
Mathew, 2005 ¹⁰	Low	Yes			
Overall	Medium	Yes	Yes	No	Low

Appendix Table D12. Decrease in migraine frequency by $\geq 50\%$ with onabotulinumtoxin A, pooled results from randomized controlled clinical trials, random effects models with inverse variance weights

Duration of Active Treatment in Weeks	Reference Risk of Bias	Events/ Randomized with Drug	Events/ Randomized with Placebo	Relative Risk (95% CI)	Weight, Inverse Variance	Absolute Risk Difference (95% CI)	Weight, Inverse Variance
12 weeks	Silberstein, 2000 ⁶ Medium	19/42	5/21	1.9 (0.8 to 4.4)	6.88	0.21 (-0.02 to 0.45)	13.85
16 weeks	Freitag, 2008 ⁵ Low	6/20	3/21	2.1 (0.6 to 7.3)	3.1	0.16 (-0.09 to 0.41)	12.33
24 weeks	Mathew, 2005 ¹⁰ Low	94/173	69/182	1.4 (1.1 to 1.8)	90.02	0.16 (0.06 to 0.27)	73.82
12-24 weeks	Pooled	119/235	77/224	1.5 (1.2 to 1.8)	100	0.17 (0.08 to 0.26)	100
Heterogeneity test				P value=0.7 I squared=0%		P value=0.9 I squared=0%	

Bold = differences are statistically significant when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

Appendix Table D13. Migraine headache frequency (change from baseline) with onabotulinumtoxin A, pooled results from randomized controlled clinical trials, random effects models

Reference	Dose, Weeks of Treatment	Sample in Active [Control]	Mean [Standard Deviation] with Drug	Mean [Standard Deviation] with Placebo	Cohen Mean Difference	Mean Difference (95% CI)	Mean Ratio (95% CI)
Elkind, 2006 ⁷	7.5U 4 weeks	105 [106]	-1.5 [2.6]	-1.3 [2.4]	-0.1 (-0.3 to 0.2)	-0.2 (-0.9 to 0.5)	1.1 (0.7 to 1.8)
	7.5U 8 weeks	105 [106]	-1.6 [2.2]	-1.4 [2.3]	-0.1 (-0.3 to 0.2)	-0.2 (-0.8 to 0.4)	1.1 (0.7 to 1.7)
	7.5U 12 weeks	105 [106]	-1.4 [2.6]	-1.2 [2.6]	-0.1 (-0.3 to 0.2)	-0.1 (-0.8 to 0.6)	1.1 (0.6 to 1.9)
	7.5U 16 weeks	105 [106]	-1.5 [2.6]	-1.5 [2.4]	0.0 (-0.3 to 0.3)	0.0 (-0.7 to 0.7)	1.0 (0.6 to 1.6)
	25U 4 weeks	101 [106]	-1.4 [2.2]	-1.3 [2.4]	0.0 (-0.3 to 0.3)	0.0 (-0.7 to 0.6)	1.0 (0.6 to 1.6)
	25U 8 weeks	101 [106]	-1.4 [2.7]	-1.4 [2.3]	0.0 (-0.2 to 0.3)	0.1 (-0.6 to 0.7)	1.0 (0.6 to 1.6)
	25U 12 weeks	101 [106]	-1.3 [2.6]	-1.2 [2.6]	0.0 (-0.3 to 0.2)	-0.1 (-0.8 to 0.6)	1.1 (0.6 to 1.9)
	25U 16 weeks	101 [106]	-1.0 [2.7]	-1.5 [2.4]	0.2 (-0.1 to 0.5)	0.5 (-0.2 to 1.2)	0.7 (0.4 to 1.2)
	50U 4 weeks	106.0 [106]	-1.1 [2.2]	-1.3 [2.4]	0.1 (-0.2 to 0.4)	0.2 (-0.4 to 0.8)	0.8 (0.5 to 1.4)
	50U 8 weeks	106.0 [106]	-1.2 [2.4]	-1.4 [2.3]	0.1 (-0.1 to 0.4)	0.3 (-0.3 to 0.9)	0.8 (0.5 to 1.3)
	50U 12 weeks	106.0 [106]	-1.4 [2.3]	-1.2 [2.6]	-0.1 (-0.3 to 0.2)	-0.1 (-0.8 to 0.5)	1.1 (0.7 to 1.9)
	50U 16 weeks	106.0 [106]	-1.6 [2.5]	-1.5 [2.4]	0.0 (-0.3 to 0.2)	-0.1 (-0.7 to 0.6)	1.0 (0.7 to 1.6)
Chankrachang*, 2011 ^{8*}	240U 12 (one time injection) weeks	43.0 [21]	1.8 [3.2]	2.2 [2.6]	-0.1 (-0.7 to 0.4)	-0.4 (-1.9 to 1.1)	0.8 (0.4 to 1.7)
	120U 12 (one time injection) weeks	43.0 [21]	2.0 [2.4]	2.2 [2.6]	-0.1 (-0.6 to 0.4)	-0.3 (-1.6 to 1.0)	0.9 (0.5 to 1.6)
Pooled					0.0 (-0.1 to 0.1)	0.0 (-0.2 to 0.2)	-0.02 (-0.15 to 0.12)

* trials of abobotulinumtoxin A

Appendix Table D14. Severity, disability, and quality of life with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials)

Definition	Reference	Dose, Weeks of Treatment	Sample Active [Control]	Mean [Standard Deviation] with Drug	Mean [Standard Deviation] with Placebo	Cohen Mean Difference (95% CI)	P value	Mean Difference (95% CI)
Migraine Disability Assessment Scores (MIDAS)	Freitag, 2008 ⁵	100U 16weeks	20.0 [21]	51.0 [0.0]	63.0 [0.0]		0.445	
Headache Pain Specific QoL (no information on scale)	Freitag, 2008 ⁵	100U 16weeks	20.0 [21]	178.0 [0.0]	191.0 [0.0]		0.078	
Change in Migraine Disability Assessment (MIDAS) from baseline	Cady, 2008¹³	139 U 12 (one time injection) weeks	40.0 [19]	-21.6 [38.7]	4.8 [18.9]	-0.8 (-1.3 to -0.2)		-26.4 (-41.1 to -11.7)
Change in Migraine Impact Questionnaire (MIQ): Global assessment	Cady, 2008¹³	139 U 12 (one time injection) weeks	40.0 [19]	2.0 [1.4]	0.9 [1.5]	0.8 (0.2 to 1.3)		1.1 (0.3 to 1.9)
Change in Migraine Impact Questionnaire (MIQ): Effectiveness of non-Rx treatment	Cady, 2008¹³	139 U 12 (one time injection) weeks	40.0 [19]	1.1 [1.2]	-0.3 [1.5]	1.1 (0.5 to 1.7)		1.5 (0.7 to 2.2)
Change in Migraine Impact Questionnaire (MIQ): Effectiveness of Rx treatment	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	0.5 [1.6]	0.4 [1.4]	0.0 (-0.5 to 0.6)		0.1 (-0.7 to 0.9)
Change in Migraine Impact Questionnaire (MIQ): Effectiveness of current Treatment on frequency of migraine symptoms	Cady, 2008¹³	139 U 12 (one time injection) weeks	40.0 [19]	1.4 [1.7]	0.0 [1.3]	0.9 (0.3 to 1.4)		1.4 (0.6 to 2.2)
Change in Migraine Impact Questionnaire (MIQ): Effectiveness of current Treatment on severity of migraine symptoms	Cady, 2008¹³	139 U 12 (one time injection) weeks	40.0 [19]	1.5 [1.8]	0.1 [1.4]	0.9 (0.3 to 1.4)		1.4 (0.6 to 2.2)
Change in Migraine Impact Questionnaire (MIQ): Feelings with current preventive migraine treatment	Cady, 2008¹³	139 U 12 (one time injection) weeks	40.0 [19]	1.7 [1.9]	0.4 [1.9]	0.7 (0.1 to 1.3)		1.3 (0.3 to 2.3)

Appendix Table D14. Severity, disability, and quality of life with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials) (continued)

Definition	Reference	Dose, Weeks of Treatment	Sample Active [Control]	Mean [Standard Deviation] with Drug	Mean [Standard Deviation] with Placebo	Cohen Mean Difference (95% CI)	P value	Mean Difference (95% CI)
Change in Migraine Impact Questionnaire (MIQ): Side effects of current preventive migraine treatment	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	1.7 [1.8]	0.5 [1.6]	0.7 (0.1 to 1.3)		1.2 (0.3 to 2.1)
Change in Migraine Impact Questionnaire (MIQ): Number of doses required for migraine preventive treatment	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	1.3 [2.0]	-0.2 [1.7]	0.8 (0.2 to 1.3)		1.4 (0.5 to 2.4)
Change in Migraine Impact Questionnaire (MIQ): Overall effectiveness of current migraine preventive treatment	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	1.4 [2.1]	0.1 [0.9]	0.7 (0.2 to 1.3)		1.3 (0.5 to 2.1)
Change in Migraine Impact Questionnaire (MIQ): Ability to self-manage migraine symptoms	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	1.0 [1.3]	-0.1 [1.3]	0.8 (0.3 to 1.4)		1.1 (0.4 to 1.8)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Mood	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	-0.5 [1.2]	-0.2 [1.1]	-0.3 (-0.8 to 0.3)		-0.3 (-1.0 to 0.3)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Mood	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	-0.8 [1.2]	-0.3 [1.1]	-0.4 (-1.0 to 0.1)		-0.5 (-1.1 to 0.1)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Mood	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	-1.1 [1.2]	-0.4 [0.9]	-0.7 (-1.2 to -0.1)		-0.7 (-1.3 to -0.2)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Ability to walk or move about	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	-0.5 [1.1]	-0.1 [1.1]	-0.3 (-0.9 to 0.2)		-0.4 (-0.9 to 0.2)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Ability to walk or move about	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	-0.7 [1.1]	0.1 [0.9]	-0.8 (-1.3 to -0.2)		-0.8 (-1.3 to -0.2)

Appendix Table D14. Severity, disability, and quality of life with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials) (continued)

Definition	Reference	Dose, Weeks of Treatment	Sample Active [Control]	Mean [Standard Deviation] with Drug	Mean [Standard Deviation] with Placebo	Cohen Mean Difference (95% CI)	P value	Mean Difference (95% CI)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Ability to walk or move about	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	-0.6 [1.1]	0.2 [0.8]	-0.8 (-1.3 to -0.2)		-0.8 (-1.3 to -0.3)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Sleep	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	-0.7 [1.3]	-0.4 [0.8]	-0.3 (-0.9 to 0.2)		-0.4 (-0.9 to 0.2)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Sleep	Cady, 2008¹³	139 U 12 (one time injection) weeks	40.0 [19]	-0.8 [1.1]	-0.1 [1.2]	-0.6 (-1.2 to -0.1)		-0.7 (-1.3 to -0.1)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Sleep	Cady, 2008¹³	139 U 12 (one time injection) weeks	40.0 [19]	-0.8 [1.0]	-0.2 [0.8]	-0.6 (-1.2 to -0.1)		-0.6 (-1.1 to -0.1)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Normal work	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	-0.7 [1.1]	-0.4 [0.9]	-0.4 (-0.9 to 0.2)		-0.4 (-0.9 to 0.2)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Normal work	Cady, 2008¹³	139 U 12 (one time injection) weeks	40.0 [19]	-0.9 [1.1]	-0.1 [0.9]	-0.7 (-1.3 to -0.1)		-0.8 (-1.3 to -0.2)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Normal work	Cady, 2008¹³	139 U 12 (one time injection) weeks	40.0 [19]	-1.1 [1.0]	-0.3 [0.8]	-0.8 (-1.4 to -0.2)		-0.8 (-1.3 to -0.3)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Recreational activity	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	-0.5 [1.1]	0.1 [0.9]	-0.6 (-1.1 to 0.0)		-0.6 (-1.1 to -0.1)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Recreational activity	Cady, 2008¹³	139 U 12 (one time injection) weeks	40.0 [19]	-0.6 [1.0]	0.3 [1.0]	-0.9 (-1.5 to -0.3)		-0.9 (-1.5 to -0.4)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Recreational activity	Cady, 2008¹³	139 U 12 (one time injection) weeks	40.0 [19]	-0.9 [1.0]	0.2 [1.2]	-1.0 (-1.6 to -0.4)		-1.1 (-1.7 to -0.5)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Enjoyment of life	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	-0.6 [1.2]	-0.2 [1.0]	-0.3 (-0.9 to 0.2)		-0.4 (-0.9 to 0.2)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Enjoyment of life	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	-0.7 [1.3]	0.0 [1.1]	-0.6 (-1.1 to 0.0)		-0.7 (-1.3 to 0.0)

Appendix Table D14. Severity, disability, and quality of life with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials) (continued)

Definition	Reference	Dose, Weeks of Treatment	Sample Active [Control]	Mean [Standard Deviation] with Drug	Mean [Standard Deviation] with Placebo	Cohen Mean Difference (95% CI)	P value	Mean Difference (95% CI)
Change in Migraine Impact Questionnaire (MIQ)-QOL: Enjoyment of life	Cady, 2008 ¹³	139 U 12 (one time injection) weeks	40.0 [19]	-1.0 [1.1]	-0.2 [1.1]	-0.7 (-1.3 to -0.1)		-0.8 (-1.3 to -0.2)
Beck's Depression Inventory (BDI)	Petri*, 2009 ⁹	210U 12 (one time injection) weeks	32.0 [32]				No differences	
Beck's Depression Inventory (BDI)	Petri*, 2009 ⁹	80U 12 (one time injection) weeks	32.0 [32]				No differences	
Change from baseline in total Headache Impact Test-6 (HIT-6) score	Aurora, 2010 ¹	155U-195U [Follow-the-Pain strategy] 24 (two injections over the course: week 1, week 12; open label three injections: week 24, 36, 48) weeks	341.0 [338]	-4.7 [0.0]	-2.4 [0.0]		<.001	
Change from baseline in total Headache Impact Test-6 (HIT-6) score	Diener, 2010 ²	155U-195U [Follow-the-Pain strategy] 24 (three injections over the course: week 1, week 12, week 24) weeks	347.0 [358]	-4.9 [-2.4]			<.001	
Severity of headache (VAS 10-point, 10 indicate no pain)	Anand, 2006 ¹²	50U 12 (one treatment) weeks	16.0 [16]	7.3 [3.0]	2.6 [1.0]	2.1 (1.2 to 3.0)		4.7 (3.1 to 6.2)
Severity of headache (VAS 10-point, 10 indicate no pain)	Anand, 2006 ¹²	50U 12 (one treatment) weeks	16.0 [16]	7.6 [3.2]	2.7 [1.1]	2.1 (1.2 to 2.9)		4.9 (3.2 to 6.5)
Severity of pain	Vo, 2007 ¹⁴	Differs by weight: 1) < 65 kg: 135 U; 2) ≥ 65 kg: 205 U GLM Repeated measure analysis of variance during 12 weeks	15.0 [17]				Not significant	

Appendix Table D14. Severity, disability, and quality of life with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials) (continued)

Definition	Reference	Dose, Weeks of Treatment	Sample Active [Control]	Mean [Standard Deviation] with Drug	Mean [Standard Deviation] with Placebo	Cohen Mean Difference (95% CI)	P value	Mean Difference (95% CI)
Mean severity of migraines (change from baseline)	Silberstein, 2000⁶	25U	42.0 [21]				Significantly greater reduction in the 25U group than in the vehicle group at week 4 & week 8 (≤ 0.029).	
Change in the mean total intensity score (no details) from baseline	Chankrachang*, 2011 ^{8*}	240U 12 (one time injection) weeks	43.0 [21]	-14.6 [74.3]	-10.5 [22.8]	-0.1 (-0.6 to 0.5)		-4.1 (-28.3 to 20.2)
Change in the mean total intensity score (no details) from baseline	Chankrachang*, 2011 ^{8*}	240U 12 (one time injection) weeks	43.0 [21]	-11.3 [85.5]	-5.2 [39.3]	-0.1 (-0.6 to 0.4)		-6.1 (-36.7 to 24.5)
Change in the mean total intensity score (no details) from baseline	Chankrachang*, 2011 ^{8*}	240U 12 (one time injection) weeks	43.0 [21]	-22.3 [83.4]	-9.7 [53.0]	-0.2 (-0.7 to 0.4)		-12.5 (-46.2 to 21.2)
Change in the mean total intensity score (no details) from baseline	Chankrachang*, 2011 ^{8*}	120U 12 (one time injection) weeks	43.0 [21]	-14.9 [35.9]	-10.5 [22.8]	-0.1 (-0.7 to 0.4)		-4.4 (-18.9 to 10.1)
Change in the mean total intensity score (no details) from baseline	Chankrachang*, 2011 ^{8*}	120U 12 (one time injection) weeks	43.0 [21]	-10.7 [49.9]	-5.2 [39.3]	-0.1 (-0.6 to 0.4)		-5.5 (-27.9 to 17.0)
Change in the mean total intensity score (no details) from baseline	Chankrachang*, 2011 ^{8*}	120U 12 (one time injection) weeks	43.0 [21]	-16.1 [32.5]	-9.7 [53.0]	-0.2 (-0.7 to 0.4)		-6.4 (-31.0 to 18.2)

Bold = differences are statistically significant when 95% CI of mean difference estimates do not include 0

CI = confidence interval

* trials of abobotulinumtoxin A

Appendix Table D15. Randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication)

Reference	Country	Design	Total Sample [Number Analyzed] % Women	Age of Subjects (Mean or Median)	Definition of Migraine	Presence of Aura	Duration of Migraine	Headache Frequency at Baseline/ Month	Concomitant Treatments
Storey, 2001 ¹⁸	Not reported	Randomized controlled clinical trial	40 [Not reported] 97.5% female	Mean 38.2 years	International Headache Society (IHS) criteria	Not reported	Not reported	4.7	Not reported
Edwards, 2003 ¹⁹	Previously reported	Randomized controlled clinical trial	70 [70] 97.1% female	Mean 41.1 years	International Headache Society criteria	Not reported	Not reported	4.5	Not reported
Silvestrini, 2003 ²⁰	Italy	Randomized controlled clinical trial	28 [28] 64.3% female	Mean 43.5 years	International Headache Society criteria	All patients had a history of migraine without aura attacks as inclusion criterion	3 years	20	Not reported
Silberstein, 2003 ²¹	Not reported	Randomized controlled clinical trial	469 [Not reported] % females not reported	Not reported	International Headache Society criteria	Not reported	At least 6 months	2 to 12	Not reported
Brandes, 2004 ²²	North America	Randomized controlled clinical trial	483 [468] 86.8% female	Mean 38.9 years	International Headache Society (IHS) criteria	Not reported	At least 6 months	5.5	Not reported
Silberstein, 2004 ²³	USA	Randomized controlled clinical trial	487 [469] 89.1% female	Mean 40.4 years	International Headache Society criteria	Not reported	Not reported	5.5	Not reported
Mei, 2004 ²⁴	Italy	Randomized controlled clinical trial	115 [72] 54.2% female	Mean 39.2 years	International Headache Society (1988) criteria	Patients with migraine without aura, n (%): Topiramate: 27 (77), Placebo: 31 (84)	Not reported	5.5	Subjects on continuing medication for other pathologies were included and did not modify the dosages during the study

Appendix Table 15 Randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication) (continued)

Reference	Country	Design	Total Sample [Number Analyzed] % Women	Age of Subjects (Mean or Median)	Definition of Migraine	Presence of Aura	Duration of Migraine	Headache Frequency at Baseline/ Month	Concomitant Treatments
Bussone, 2005 ²⁵	Not reported	Randomized controlled clinical trial (Pooled analysis)	758 [756] 84.3% female	Mean 39.8 years	International Headache Society criteria	Not reported	Not reported	5.4	Not reported
Diamond, 2005 ²⁶	Not reported	Randomized controlled clinical trial	756 [756] 84.7% female	Mean 40.4 years	International Headache Society criteria	Not reported	Not reported	3 to 12	Not reported
Silberstein, 2006 ²⁷	USA	Randomized controlled clinical trial	469 [469] 88.7% female	Mean 40.4 years	International Headache Society criteria	Not reported	Not reported	5.5	Not reported
Mei, 2006 ²⁸	Italy	Randomized controlled clinical trial	50 [35] 68.6% female	Mean 45.9 years	International Classification of Headache Disorders 2nd Edition	Not reported	4.97 years	Not reported	Not reported
Silberstein, 2006 ²⁹	USA	Randomized controlled clinical trial	213 [Variable] 85.8% female	Mean 40.5 years	International Headache Society criteria	75 subjects had migraine with aura	Not reported	4.9	Not reported
Brandes, 2006 ³⁰	USA	Randomized controlled clinical trial	483 [468] 86.8% female	Mean 38.9 years	International Headache Society criteria for migraine with or without aura	Not reported	At least 6 months	5.5	Not reported
Silberstein, 2007 ³¹	USA	Randomized controlled clinical trial	328 [Variable] 85.3% female	Mean 38.2 years	International Headache Society 1.1 or 1.2	Not reported	Duration: 9.2 years; Age at onset: 19.7 years	Not reported	Not reported
Lofland, 2007 ³²	North America	Randomized controlled clinical trial	325 [325] 89.0% female	Mean 40 years	International Headache Society criteria	Not reported	Not reported	3 to 12	Not reported
Limmroth, 2007 ³³	Not reported	Randomized controlled clinical trial	756 [756] 84.0% female	Mean 40 years	International Headache Society criteria	Not reported	Not reported	7.3	Not reported
Diener, 2007 ³⁴	Not reported	Randomized controlled clinical trial	59 [59] 74.5% female	Mean 46 years	Second edition of The International	Not reported	At least 1 year	Not reported	Not reported

Appendix Table 15 Randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication) (continued)

Reference	Country	Design	Total Sample [Number Analyzed] % Women	Age of Subjects (Mean or Median)	Definition of Migraine	Presence of Aura	Duration of Migraine	Headache Frequency at Baseline/ Month	Concomitant Treatments
					Classification of Headache Disorders criteria				
Lainez, 2007 ³⁵	Not reported	Randomized controlled clinical trial	774 [758] 84.4% female	Mean 39.9 years	International Headache Society criteria	Not reported	Not reported	Not reported	Not reported
Freitag, 2007 ³⁶	USA	Randomized controlled clinical trial (Pooled analysis)	937 [937] 87.7% female	Mean 39.7 years	International Headache Society criteria	Not reported	Not reported	5.5	Not reported
Dahlof, 2007 ³⁷	Not reported	Randomized controlled clinical trial	756 [756] 84.3% female	Mean 39.8 years	Not reported	Not reported	Not reported	3 to 12	Not reported
Diener, 2007 ³⁸	21 countries in Europe	Randomized controlled clinical trial	818 [Not reported] 89.0% female	Mean 40.1 years	International Headache Society criteria	Not reported	Not reported	8.7	Not reported
Dodick, 2007 ³⁹	USA	Randomized controlled clinical trial	328 [306] 85.3% female	Mean 38.2 years	International Classification of Headache Disorders, 2nd edition. However, for the inclusion criterion chronic migraine was defined by Silberstein–Lipton criteria	Not reported	Age at onset: 19.7 years	Not reported	Not reported
Adelman, 2008 ⁴⁰	USA, Australia, Canada, Denmark, Finland, France, Germany, Italy, Korea,	Randomized controlled clinical trial	1580 [1580] 85.0% female	Mean 40.1 years	International Headache Society criteria	Not reported	Not reported	Not reported	Not reported

Appendix Table 15 Randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication) (continued)

Reference	Country	Design	Total Sample [Number Analyzed] % Women	Age of Subjects (Mean or Median)	Definition of Migraine	Presence of Aura	Duration of Migraine	Headache Frequency at Baseline/ Month	Concomitant Treatments
	the Netherlands, South Africa, Spain, Sweden, Taiwan, and the United Kingdom								
Silberstein, 2009 ⁴¹	USA	Randomized controlled clinical trial	328 [321] 85.3% female	Mean 38.2 years	International Headache Society 1.1 or 1.2	Not reported	Duration: 9.2 years; Age at onset: 19.7 years	Not reported	Not reported
Lipton, 2011 ⁴²	Not reported	Randomized controlled clinical trial	385 [Variable] 10.9% female	Mean 40.3 years	International Headache Society criteria 1.1,1.2	Not reported	Age at migraine onset: 20.3 years	Not reported	Not reported

Appendix Table D16. Funding, ethical approval, and conflict of interest in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication)

Reference	How Project was Funded	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests - Relationship
Storey, 2001 ¹⁸	Industry	Yes	Yes	Not reported	Not applicable
Edwards, 2003 ¹⁹	Industry	Yes	Yes	Yes	Ms. Potter is on the Speakers' Bureau for biogen, GlaxoSmithKline and Ortho-McNeil Pharmaceutical, Inc, and has received funding from Biogen, Ortho-McNeil Pharmaceutical, Inc, Pfizer Inc, Wyeth Pharmaceuticals for previous research
Silvestrini, 2003 ²⁰	Not reported	Yes	Yes	Not reported	Not applicable
Silberstein, 2003 ²¹	Not reported	Not reported	Not reported	Not reported	Not applicable
Brandes, 2004 ²²	Industry	Yes	Yes	Yes	Dr. Brandes has received grants or research support from Merck, GlaxoSmithKline, Allergan, UCB Pharma, Johnson & Johnson, AstraZeneca, Pfizer, Bristol Myers-Squibb, Winston Laboratories, Forest Laboratories, Sanofi-Synthelabo, and Elan Pharmaceuticals; has served on the speakers bureau for GlaxoSmithKline, AstraZeneca, Merck, Allergan, Pfizer, Pharmacia, Ortho-McNeil, and UCB Pharma; has served as a consultant to Merck, GlaxoSmithKline, Pfizer, AstraZeneca, Allergan, and Ortho-McNeil; and has received educational funding from GlaxoSmithKline. Dr Saper has received research grants from GlaxoSmithKline, AstraZeneca, Merck, Abbott, Allergan, Elan, Pfizer, Ortho-McNeil, and Novartis; has served on advisory boards or as a consultant for AstraZeneca, GlaxoSmithKline, Allergan, Ortho-McNeil, and Medtronic; and has served on the speakers bureau for GlaxoSmithKline, Merck, AstraZeneca, Ortho-McNeil, Pfizer, and Xcel. Dr Diamond has served as a speaker, consultant, or both or has conducted research for AstraZeneca, Bristol-Myers Squibb, Ortho- McNeil, Elan, GlaxoSmithKline, Merck, and Pfizer. Dr Couch has participated in research for, been an advisory board member of, and served as a speaker for Ortho-McNeil.
Silberstein, 2004 ²³	Industry	Yes	Yes	Yes	Dr. Silberstein is on the advisory panel of, speakers bureau of, or serves as a consultant for Abbott Laboratories, Allergan, Inc, AstraZeneca, Elan Pharmaceutical Research Corp, Eli Lilly, Ortho-

Appendix Table 16. Funding, ethical approval, and conflict of interest in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication) (continued)

Reference	How Project was Funded	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests - Relationship
					McNeil Pharmaceutical, Merck & Co, and GlaxoSmithKline; receives research support from Allergan, Inc, AstraZeneca, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, Merck & Co, Ortho-McNeil Pharmaceutical, Pfizer, Inc, UCB Pharma, and Vernalis; and has received educational grants from Abbott Laboratories, Allergan, Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck & Co, Ortho-McNeil Pharmaceutical, and Parke-Davis. Drs Neto and Jacobs and Ms Schmitt hold shares in Johnson & Johnson Pharmaceutical Research and Development, LLC, a subsidiary of Johnson & Johnson Corporation.
Mei, 2004 ²⁴	Not reported	Yes	Yes	Not reported	Not applicable
Bussone, 2005 ²⁵	Not reported	Yes	Yes	Not reported	Not applicable
Diamond, 2005 ²⁶	Industry	Yes	Yes	Not reported, however, George Papadopoulos is from Jonhson & Johnson Pharmaceutical Services, LLC, Raritan, NJ; Dr. Neto is from Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ; and Dr. Wu is from Ortho-McNeil Neurologies, Inc., Raritan, NJ	
Silberstein, 2006 ²⁷	Industry	Yes	Yes	Yes	George Papadopoulos is from Johnson and Johnson Pharmaceutical Services, LLC, Raritan, NJ, USA and Steven Greenberg from Ortho-McNeil Neurologies, Titusville, NJ, USA. Personnel of Pharmaceutical Research and Development , Ortho-McNeil Neurologics, Inc, Titusville, New Jersey, and Phase Five Communications, New York, New York, contributed to the preparation of the manuscript
Mei, 2006 ²⁸	Not reported	Yes	Yes	Not reported	Not applicable
Silberstein, 2006 ²⁹	Industry	Yes	Yes	Not reported	Not applicable

Appendix Table 16. Funding, ethical approval, and conflict of interest in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication) (continued)

Reference	How Project was Funded	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests - Relationship
Brandes, 2006 ³⁰	Industry	Yes	Yes	Yes	Dr. Brandes has received grants or research support from Merck & Co, Inc, GlaxoSmithKline, UCB Pharma, Allergan Inc, Johnson & Johnson, AstraZeneca Pharmaceuticals LP, Pfizer Inc, Bristol-Meyers Squibb, Winston Laboratories, Sanofi-Aventis, Elan Pharmaceuticals, Inc, Novartis, Endo Pharmaceuticals, Pozen, Vernalis, Ortho-McNeil, and Advanced Bionics; has served on the speaker's bureau for GlaxoSmith-Kline, AstraZeneca Pharmaceuticals LP, Pfizer Inc, Merck & Co, Inc, Ortho-McNeil, Allergan Inc, MedPointe Pharmaceuticals, Endo Pharmaceuticals, UCB Pharma; has served as a consultant to Merck & Co, Inc, GlaxoSmithKline, Pfizer Inc, AstraZeneca Pharmaceuticals LP, Allergan Inc, Ortho-McNeil, and Aradigm Corp; and has received an educational grant from GlaxoSmithKline. Dr Kudrow has been on a speaker's bureau of GlaxoSmithKline and Ortho-McNeil and has received grant and research support from Ortho-McNeil, GlaxoSmithKline, Pozen, Merck & Co, Inc, and Eisai Inc. Dr Fairclough received financial support as a consultant to perform analyses of the data in this study. Drs Rupnow and Greenberg are fulltime employees of Johnson & Johnson. Dr Rothrock has served as a paid consultant to Ortho-McNeil, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, Pozen, and Allergan Inc; has received research support from those companies and from Abbott Laboratories, Elan Corporation, Esai Inc, and AstraZeneca Pharmaceuticals LP; and has received honoraria for lecturing from Ortho-McNeil, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, Elan Corporation, and Endo Pharmaceuticals.
Silberstein, 2007 ³¹	Industry	Yes	Yes	Yes	Dr. Silberstein has received personal compensation for activities with: GlaxoSmith-Kline, Inc., Johnson & Johnson, Merck & Co., Inc., UCB Pharma, AstraZeneca Pharmaceuticals, Inc., Pfizer, Inc., Allergan, Inc., Pozen, Inc., Abbott Laboratories, Inc., Eli Lilly & Company, NPS, and Xcel Pharmaceuticals; has received personal compensation in an editorial

Appendix Table 16. Funding, ethical approval, and conflict of interest in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication) (continued)

Reference	How Project was Funded	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests - Relationship
					capacity for CurrentPain and Headache; and has received financial support for scholarly activities from GlaxoSmithKline, Inc., Johnson & Johnson, Merck&Co., Inc., Pfizer, Inc., Allergan, Inc., and Abbott Laboratories, Inc. Dr. Lipton has consulted for, conducted studies funded by, or received lecture honoraria from Allergan, Inc., Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, Ortho-McNeil, Pfizer, Pozen, among other companies. Dr. Dodick has received personal compensation for activities with Allergan, Inc., GlaxoSmith-Kline, Inc., Pfizer, Inc., Endo Pharmaceuticals, Ortho-McNeil Pharmaceutical, Inc., Merck & Co., Inc., Medtronic, Neuralie; has received personal compensation in an editorial capacity for Headache Currents; and has received research support from St. Jude, Allergan, Inc., Medtronic, Inc., National Institutes of Health, Mayo Clinic College of Medicine, and Advanced Bionics. Dr. Freitag has received personal compensation for activities with Allergan, Inc., AstraZeneca Pharmaceuticals, Inc., Merck & Co., Inc., Ortho-McNeil Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Pfizer, Inc., and GlaxoSmithKline, Inc., and has received research support from Alzyer, AstraZeneca Pharmaceuticals, Inc., GlaxoSmithKline, Inc., Merck & Co., Inc., Ortho-McNeil Pharmaceuticals, Inc., Precision, Division of Boston Scientific, Solvay S.A., and Vernalis. Dr. Ramadan has received personal compensation for activities with GlaxoSmithKline, Inc., Ortho-McNeil Neurologics, Inc., Eli Lilly & Company, Eisai, Inc., AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company, Pfizer, Inc., Merck & Co., Inc., Aradign Corp., Boehringer Ingelheim Pharmaceuticals and Map Pharmaceuticals; has received personal compensation in an editorial capacity for Web Alert; and has received research support from Ortho-McNeil Neurologics, Eli Lilly&Company, Pfizer, Inc., and the National Headache Ambassador Program. Dr. Mathew has received personal compensation for

Appendix Table 16. Funding, ethical approval, and conflict of interest in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication) (continued)

Reference	How Project was Funded	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests - Relationship
					activities with Eisai. Dr. Brandes has received grants or research support from Merck, GlaxoSmithKline, UCB Pharma, Allergan, Johnson & Johnson, AstraZeneca, Pfizer, Bristol-Myers Squibb, Winston Laboratories, Sanofi-Aventis, Elan Pharmaceuticals, Novartis, Endo, Pozen, Inc., Vernalis, Ortho-McNeil, Advanced Bionics; has served on the speakers bureau for GlaxoSmithKline, AstraZeneca, Pfizer, Merck, Ortho-McNeil, Allergan, MedPointe Pharmaceuticals, Endo, UCB Pharma; has served as a consultant to Merck, GlaxoSmith-Kline, Pfizer, AstraZeneca, Allergan, Ortho-McNeil, Aradigm Corporation; and has received educational funding from GlaxoSmithKline. Dr. Bigal has received personal compensation for activities from Allergan, Boehringer Ingelheim, GlaxoSmithKline, Merck, Ortho-McNeil, UCB, AstraZeneca, Pfizer, Inc., and Advance PCS and has received research support from Allergan, Boehringer Ingelheim, GlaxoSmithKline, Merck, Ortho-McNeil, Pfizer, UCB, AstraZeneca, and Advance PCS. Dr. Saper has received honoraria for speaking from GlaxoSmithKline, Merck & Co., Inc., Abbott Laboratories, Inc., Elan Corporation, AstraZeneca Pharmaceuticals, Pfizer, Inc., Ortho-McNeil Pharmaceuticals, Bristol-Myers Squibb, Medtronic, Inc., Endo Pharmaceuticals, Advanced Bionics, Pozen, Inc., and Penwest Pharmaceuticals Co; has received personal compensation in an editorial capacity for Pain Watch and Migraine Monitor; holds stock in Pozen, Inc.; and has received research support from Novartis, Ortho-McNeil Pharmaceuticals, Merck & Co., Inc., GlaxoSmithKline, Allergan, Inc., Eisai, Inc., AstraZeneca Pharmaceuticals, Abbott, Advanced Bionics, Medtronic, Renovis, and Pozen, Inc. Dr. Ascher is an employee of Ortho-McNeil Janssen Scientific Affairs, LLC. Dr. Jordan is an employee of PriCara, a Unit of Ortho-McNeil, Inc. Drs. Greenberg and Joseph Hulihan are employees of Ortho-McNeil Neurologics.

Appendix Table 16. Funding, ethical approval, and conflict of interest in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication) (continued)

Reference	How Project was Funded	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests - Relationship
Lofland, 2007 ³²	Industry	Yes	Yes	Yes	Jennifer H. Lofland received grant from Ortho-McNeil Janssen, Inc
Limmroth, 2007 ³³	Industry	Yes	Yes	Yes	Volker Limmroth received honoraria as speaker from Janssen-Cilag, Germany. Susanne Schwalen is an employee of Janssen-Cilag, Germany
Diener, 2007 ³⁴	Industry	Not reported	Not reported	Yes	JC Van Oene, M Lahaye and S Schwalen are employees of Janssen-Cilag
Lainez, 2007 ³⁵	Not reported	Yes	Yes	Yes	Miguel JA La´inez has received personal compensation or research support from activities with Allergan, Inc., Almirall SA, GlaxoSmithKline, Inc Jansen Cilag, Inc., Menarini, Merck & Co., Inc, Medtronic and Pfizer Inc. Frederick Freitag has received personal compensation for activities with Allergan, Inc., AstraZeneca Pharmaceuticals,, Ortho-McNeil Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Pfizer Inc, and GlaxoSmithKline, Inc. Dr. Freitag has received research support from Alzyer, AstraZeneca Pharmaceuticals, GlaxoSmithKline, Inc., Merck & Co., Inc., Ortho-McNeil Pharmaceuticals, Inc., Advanced Bionics, Solvay S.A., and Vernalis. Joop Pfeil is a paid consultant for Janssen Pharmaceutical/J & J, Novartis, Sanofi-Aventis, Pfizer, Schering-Plough, Numico, Vitatron, Actelion Pharmaceuticals and Sankyo. S. Ascher is a full-time employee of Ortho-McNeil Janssen Pharmaceutical. W.H. Olson is a full-time employee of Ortho-McNeil Janssen Pharmaceutical. S. Schwalen is a full-time employee of Janssen-Cilag GmbH.
Freitag, 2007 ³⁶	Industry	Yes	Yes	Yes	Dr. Freitag has received honoraria, consulting fees, and research grant funds in excess of \$10,000 per year from Johnson & Johnson and Ortho-McNeil Neurologics. Dr. Forde has received honoraria in excess of \$10,000 per year from Johnson & Johnson and Ortho-McNeil Neurologics. Drs. Neto and Wang and Ms Schmitt are paid employees of Johnson & Johnson. Drs. Wu and Hulihan are paid employees of Ortho-McNeil Neurologics.
Dahlof, 2007 ³⁷	Industry	Yes	Yes	Yes	Professor Carl Dahlöf has been a consultant/scientific advisor on advisory boards, clinical trials, and

Appendix Table 16. Funding, ethical approval, and conflict of interest in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication) (continued)

Reference	How Project was Funded	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests - Relationship
					investigator-initiated trials and a speaker for: Allergan, Almirall Prodesfarma, AstraZeneca, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Janssen Cilag, Merck, Lilly, NMT Medical Inc., Novartis, Ortho-McNeil Pharmaceutical, Pharmacia, Pfizer, Pierre Fabre, and St Jude Medical EMEAC. Elizabeth Loder has had no financial relationship with any pharmaceutical company since July 2006, except grant support from NMT for a clinical trial. She has been a speaker, received grant support, or been a consultant for: OrthoMcNeil, Endo, AstraZeneca, GlaxoSmithKline, Pfizer, and Allergan. She serves on the Board of Directors of the American Headache Society, the Executive Council of the International Headache Society, and the Board of the Headache Cooperative of New England. Merle Diamond has served as a consultant and/or conducted research with AstraZeneca, Ortho-McNeil Neurologies, GlaxoSmithKline, Merck and Co., Pfizer, and Primary Care Network. Marcia Rupnow is a full-time salary employee of Ortho-McNeil Janssen Scientific Affairs, LLC. George Papadopoulos was an employee of J&J Pharmaceutical Services at the time of study completion. Lian Mao is a full-time salary employee of Ortho-McNeil Janssen Scientific Affairs, LLC.
Diener, 2007 ³⁸	Industry	Yes	Yes	Yes	Hans-Christoph Diener, Reto Agosti, Gianni Allais, Gennaro Bussone, Brendan Davies, Michel Lanteri-Minet, Mustafa Ertas, Uwe Reuter, Margarita Sanchez Del Rio, and Jean Schoenen have participated in clinical trials and advisory boards for Janssen-Cilag. Paul Bergmans, Susanne Schwalen, Joop van Oene are employees of Janssen-Cilag EMEA (Europe, Middle East, and Africa). Hans -Christoph Diener has received honoraria from Addex Pharmaceuticals, Allergan, Almirall, AstraZeneca, Bayer Vital, Berlin Chemie, CoLucid Pharmaceuticals, Böhringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Grünenthal, Janssen-Cilag, Eli Lilly, F Hoffmann-La Roche, 3M Medica, Merck Sharp and Dohme, Novartis Pharmaceuticals, Johnson and Johnson,

Appendix Table 16. Funding, ethical approval, and conflict of interest in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication) (continued)

Reference	How Project was Funded	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests - Relationship
					Pierre Fabre, Pfizer, Schaper and Brümmer, Sanofi - Aventis, and Weber and Weber, and financial support for research projects from Allergan, Almirall, AstraZeneca, Bayer, GlaxoSmithKline, Janssen-Cilag, and Pfizer.
Dodick, 2007 ³⁹	Industry	Yes	Yes	Yes	David W. Dodick is a consultant/advisor for Eli Lilly, Glaxo-SmithKline, Merck, Neuralie, Ortho-McNeil. He is involved in research studies with Advanced Bionics, AstraZeneca, Medtronic, and Alexza, for which his academic institution has received research grants. He is also the principal investigator of a multicenter clinical trial with St. Jude. He has no stock or equity in any pharmaceutical company. Stephen Silberstein has received personal compensation for activities with GlaxoSmithKline, Inc.; Johnson & Johnson; Merck & Co., Inc.; UCB Pharma; AstraZeneca Pharmaceuticals; Pfizer Inc.; Allergan, Inc.; Pozen, Inc.; Abbott Laboratories, Inc.; Eli Lilly & Company; NPS; and Xcel Pharmaceuticals. Dr. Silberstein has received personal compensation in an editorial capacity for Current Pain and Headache. Dr. Silberstein has received financial support for scholarly activities from GlaxoSmithKline, Inc.; Johnson & Johnson; Merck & Co., Inc.; Pfizer Inc.; Allergan, Inc.; and Abbott Laboratories, Inc. Joel Saper has received honoraria for speaking from Glaxo-SmithKline; Merck & Co., Inc.; Abbott Laboratories, Inc.; Elan Corporation; AstraZeneca Pharmaceuticals; Pfizer Inc.; Ortho-McNeil Pharmaceuticals, Inc.; Bristol-Myers Squibb; Medtronic Inc.; Endo Pharmaceuticals; Advanced Bionics; Pozen, Inc.; and Penwest Pharmaceuticals Co. Dr. Saper has received personal compensation in an editorial capacity for PainWatch and Migraine Monitor. He holds stock in Pozen, Inc. and has received research support from Novartis; Ortho-McNeil Pharmaceuticals, Inc; Merck & Co., Inc.; GlaxoSmith-Kline; Allergan, Inc.; Eisai Inc.; AstraZeneca Pharmaceuticals; Abbott; Advanced Bionics; Medtronic; Renovis; and Pozen, Inc. Fred G. Freitag has received personal compensation for

Appendix Table 16. Funding, ethical approval, and conflict of interest in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication) (continued)

Reference	How Project was Funded	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests - Relationship
					activities with Allergan, Inc.; AstraZeneca Pharmaceuticals; Merck & Co., Inc.; Ortho-McNeil Pharmaceuticals, Inc.; Valeant Pharmaceuticals International; Pfizer Inc.; and GlaxoSmithKline, Inc. Dr. Freitag has received research support from Alzyer; AstraZeneca Pharmaceuticals; GlaxoSmithKline, Inc.; Merck & Co., Inc.; Ortho-McNeil Pharmaceuticals, Inc.; Advanced Bionics; Solvay S.A.; and Vernalis. Roger K. Cady has received personal compensation for activities with Allergan; Atrix Labs; Capnia; Endo; GlaxoSmithKline; Johnson & Johnson; Med Point; Merck; Ortho-McNeil Pharmaceuticals, Inc.; and Winston Labs. Dr. Cady received compensation from NIPC for serving as a co-editor of their migraine newsletter. Dr. Cady has received research support from Abbott; Allergan; Alexa; Aradigm Corp; Capnia; Cipher; Eisai Pharmaceuticals; Endo Pharmaceuticals; GelStat; Glaxo-SmithKline; Johnson & Johnson; Matrixx; Merck; Ortho-McNeil Pharmaceuticals, Inc.; Pfizer Inc.; and Vernalis. Alan M. Rapoport has received personal compensation from the following pharmaceutical companies, advisory boards, speaker's bureau, research or educational grants: Abbott Laboratories; Allergan, Inc.; AstraZeneca; Eisai Pharmaceuticals; Endo Pharmaceuticals; Forest Laboratories; GlaxoSmithKline; Endo Pharmaceuticals; Forest Laboratories; GlaxoSmithKline; Merck; Ortho-McNeil Pharmaceuticals, Inc.; Pfizer Inc.; UCB Pharma; Valeant; Vernalis ; and Winston. Ninan T. Mathew has received personal compensation for activities with Eisai Pharmaceuticals. Joseph Hulihan, Concetta Crivera, Marcia F.T. Rupnow, Lian Mao, Gary Finlayson, and Steven J. Greenberg are employees of Ortho-McNeil Janssen Scientific Affairs, LLC.
Adelman, 2008 ⁴⁰	Industry	Yes	Yes	Yes	James Adelman: Clinical Trials 1998–2006 (Ortho-McNeil Pharmaceuticals), Advisory Boards (Ortho-McNeil Pharmaceuticals), Speaker (Ortho-McNeil Pharmaceuticals); Frederick Freitag: Consultant,

Appendix Table 16. Funding, ethical approval, and conflict of interest in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication) (continued)

Reference	How Project was Funded	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests - Relationship
					honoraria recipient (OrthoMcNeil Pharmaceuticals and Ortho-McNeil Neurologics), research grant recipient (Johnson and Johnson Pharmaceuticals, Ortho-McNeil Pharmaceuticals, and Ortho-McNeil Neurologics); Miguel Lainez: grant/research recipient, consultant/scientific advisor, honoraria recipient (Allergan, Almirall Prodesfarma, Boehringer Ingelheim, Bristol-Myers Squibb, Elan Pharmaceuticals, GlaxoSmithKline, Janssen Cilag, Johnson and Johnson, MSD, Novartis, Pierre Fabre, and Sanofi-Synthelabo).
Silberstein, 2009 ⁴¹	Industry	Yes	Yes	Yes	Stephen Silberstein has received personal compensation for activities with: Johnson & Johnson, GlaxoSmith-Kline, Merck, UCB Pharma, AstraZeneca, Pfizer, Allergan, Pozen, Abbott Laboratories., Eli Lilly & Company, NPS, and Xcel Pharmaceuticals; has received personal compensation in an editorial capacity for Current Pain and Headache; and has received financial support for scholarly activities from GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, Allergan, and Abbott Laboratories. Richard B. Lipton has consulted for, conducted studies funded by, or received lecture honoraria from Allergan, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, Ortho-McNeill, Pfizer, and Pozen, among other companies. David W. Dodick has served as a consultant for GlaxoSmithKline, Merck, Allergan, Endo, Pfizer, Eli Lilly, Addex, Solvay, and Neuralieve and has received research support from Advanced Neurostimulation Systems, Medtronic, and St. Jude. Fred Freitag has received grants and research support from Advanced Bionics Corporation, Alzyer, AstraZeneca, CAPNIA, GlaxoSmithKline, Johnson & Johnson, Merck, Ortho-McNeil Pharmaceutical, Ortho-McNeil Neurologics, Solvay, and Vernalis Pharmaceuticals. He has served as a consultant for Allergan, AstraZeneca, CAPNIA, Endo Pharmaceuticals, Merck, Ortho-McNeil Pharmaceutical, Ortho-McNeil Neurologics, and Valeant Pharmaceuticals International. He has served

Appendix Table 16. Funding, ethical approval, and conflict of interest in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication) (continued)

Reference	How Project was Funded	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests - Relationship
					on the speaker's bureaus of AstraZeneca, GlaxoSmithKline, Merck, Ortho-McNeil Pharmaceutical, Ortho-McNeil Neurologics, Pfizer, and Valeant Pharmaceuticals International. Ninan Mathew has received personal compensation for activities involving continuing medical education and for advisory board participation from Ortho McNeil, Merck, Allergan, GlaxoSmithKline, Endo, and Valiant. Jan Brandes has received grants, research support, or served as a consultant to Merck, GlaxoSmithKline, UCB Pharma, Pfizer, Allergan, Johnson & Johnson, AstraZeneca, Bristol-Myers Squibb, Winston Laboratories, Sanofi-Aventis, Elan, Novartis, Endo, Pozen, Vernalis, Ortho-McNeil, Advanced Bionics, MedPointe, and Aradigm. Marcelo E. Bigal is a full-time employee of Merck Research Laboratories. This manuscript was written during his tenure at the Albert Einstein College of Medicine. He has received, in the past, compensation from Ortho-McNeil Pharmaceutical, AstraZeneca, GlaxoSmithKline, Merck, Allergan, MAP, NMT, and Endo, among other pharmaceutical companies. Steve Ascher, Jacqueline D. Morein, and Pamela Wright are employees of Ortho-McNeil Janssen Scientific Affairs, LLC. Steven J. Greenberg is an employee of EMD Serono Inc.
Lipton, 2011 ⁴²	Industry	Yes	Yes	Yes	Not reported, however, David Biondi, Steven Ascher, William Olson and Joseph Hulihan were from Ortho-McNeil Janssen Scientific Affairs, USA

Appendix Table D17. Risk of bias in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication)

Reference	Masking of Treatment Status	Intention to Treat Analysis Preplanned	Allocation Concealment	Adequacy of Randomization	Selective Outcome Reporting	Risk of Bias
Storey, 2001 ¹⁸	Double-blind	No	Unclear	Yes (Topiramate group had no men and higher number of patients with concurrent preventative treatment, but the differences were not significant)	Unclear	Low
Edwards, 2003 ¹⁹	Double-blind	Yes	Unclear	Unclear	Unclear	Low
Silvestrini, 2003 ²⁰	Double-blind	No	Unclear	Yes	Unclear	Low
Silberstein, 2003 ²¹	Double-blind	No	Unclear	Yes	Unclear	Medium
Brandes, 2004 ²²	Double-blind	Yes	Clearly adequate	Yes	Unclear	Low
Silberstein, 2004 ²³	Double-blind	Yes	Unclear	Yes	Unclear	Low
Mei, 2004 ²⁴	Double-blind	No	Unclear	Unclear	Unclear	Medium
Bussone, 2005 ²⁵	Double-blind	Yes	Unclear	Yes	Unclear	Low
Diamond, 2005 ²⁶	Double-blind	Yes	Unclear	Previously reported ^{22, 23, 43}	Unclear	Low
Silberstein, 2006 ²⁷	Double-blind	Yes	Unclear	Not adequate. Topiramate 200mg/day group has lower % of women and higher % of men as compared to other groups, but the differences were not significant (previously reported)	Unclear	Medium
Mei, 2006 ²⁸	Double-blind	Yes	Unclear	Yes	Unclear	Low
Silberstein, 2006 ²⁹	Double-blind	Yes	Unclear	Not reported	Unclear	Medium
Brandes, 2006 ³⁰	Double-blind	Yes	Clearly adequate	Not adequate; the % of male patients were much lower in the topiramate 100mg and 200mg groups, but the difference were not significant	Unclear	Medium
Silberstein, 2007 ³¹	Double-blind	Yes	Unclear	Yes	Unclear	Low
Lofland, 2007 ³²	Double-blind	Yes	Unclear	Yes	Unclear	Low
Limmroth, 2007 ³³	Double-blind	Yes	Unclear	Yes	Unclear	Low
Diener, 2007 ³⁴	Double-blind	Yes	Unclear	Not adequate (Mean Beck Depression Inventory scores were higher in	Unclear	Medium

Appendix Table 17. Risk of bias in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication) (continued)

Reference	Masking of Treatment Status	Intention to Treat Analysis Preplanned	Allocation Concealment	Adequacy of Randomization	Selective Outcome Reporting	Risk of Bias
				placebo as compared to topiramate, but the differences were not significant)		
Lainez, 2007 ³⁵	Double-blind	No	Unclear	Yes	Unclear	Low
Freitag, 2007 ³⁶	Double-blind	Yes	Unclear	Yes	Unclear	Low
Dahlof, 2007 ³⁷	Double-blind	Yes	Unclear	Yes	Unclear	Low
Diener, 2007 ³⁸	Double-blind	Yes	Unclear	Yes	Unclear	Medium
Dodick, 2007 ³⁹	Double-blind	Yes	Unclear	Yes	Unclear	Low
Adelman, 2008 ⁴⁰	Double-blind	No	Unclear	Yes	Unclear	Low
Silberstein, 2009 ⁴¹	Double-blind	Yes	Clearly adequate	Yes	Unclear	Low
Lipton, 2011 ⁴²	Double-blind	Yes	Unclear	Yes	The study mentions the significance of the outcome: $\geq 50\%$ and 75% reduction in headache days and migraine headache days, however, the results are not given	Low

Appendix Table D18. Strength of evidence of migraine prevention with topiramate in adults

Outcome, Reference	Risk of Bias	Directness	Consistency	Precision	Strength of Evidence
≥50% Reduction in monthly migraine frequency ^{18, 20, 24, 25, 29, 31, 44}	Medium	Direct	Consistent	Precise	Moderate
≥50% Reduction in monthly migraine days ^{25, 34, 41}	Low	Direct	Consistent	Imprecise	Moderate
≥75% Reduction in monthly migraine days ^{25, 41}	Low	Direct	Consistent	Imprecise	Moderate
Complete migraine cessation ^{25, 29, 41}	Medium	Direct	Inconsistent	Imprecise	Low

Appendix Table D19. Migraine prevention with topiramate vs. placebo in adults (pooled results from randomized controlled clinical trials)

Outcome	Author, Year	Events/ Randomized	Events/ Randomized	Relative Risk (95% CI)	Weight Random Effects Inverse Variance	Absolute Risk Difference, (95% CI)	Weight, Random Effects Inverse Variance
Frequency:≥50% reduction	Storey, 2001 ¹⁸	5/19	2/21	2.8 (0.6 to 12.6)	3.34	0.17 (-0.07 to 0.40)	11
Frequency:≥50% reduction	Mei, 2004 ²⁴	37/58	12/57	3.0 (1.8 to 5.2)	15.25	0.43 (0.27 to 0.59)	14.67
Frequency:≥50% reduction	Bussone, 2005 ²⁵	188/386	93/372	1.9 (1.6 to 2.4)	27.28	0.24 (0.17 to 0.30)	19.77
Frequency:≥50% reduction	Silberstein, 2006 ²⁹	55/140	25/73	1.1 (0.8 to 1.7)	20.61	0.05 (-0.09 to 0.19)	16.2
Frequency:≥50% reduction	Silberstein, 2007 ³¹	58/112	8/36	2.3 (1.2 to 4.4)	12.66	0.30 (0.13 to 0.46)	14.58
Frequency:≥50% reduction	Silvestrini, 2003 ²⁰	10/14	1/14	10.0 (1.5 to 68.0)	2.18	0.64 (0.37 to 0.92)	9.41
Frequency:≥50% reduction	Gupta, 2007 ⁴⁴	38/60	18/60	2.1 (1.4 to 3.3)	18.69	0.33 (0.17 to 0.50)	14.36
Frequency:≥50% reduction	Pooled	391/789	159/633	2.0 (1.5 to 2.7)	100	0.29 (0.18 to 0.40)	100
Reduction in headache days by ≥50%	Bussone, 2005 ²⁵	175/386	81/372	2.1 (1.7 to 2.6)	50.32	0.24 (0.17 to 0.30)	41.85
Reduction in headache days by ≥50%	Diener, 2007 ³⁴	7/32	0/27	12.7 (0.8 to 213.1)	3.07	0.22 (0.07 to 0.37)	24.44
Reduction in headache days by ≥50%	Silberstein, 2009 ⁴¹	64/165	50/163	1.3 (0.9 to 1.7)	46.61	0.08 (-0.02 to 0.18)	33.71
Reduction in headache days by ≥50%	Pooled	246/583	131/562	1.7 (1.0 to 2.9)	100	0.18 (0.08 to 0.28)	100
Reduction in headache days by ≥75%	Bussone, 2005 ²⁵	98/386	41/372	2.3 (1.6 to 3.2)	60.07	0.14 (0.09 to 0.20)	52.98
Reduction in headache days by ≥75%	Silberstein, 2009 ⁴¹	25/165	18/163	1.4 (0.8 to 2.4)	39.93	0.04 (-0.03 to 0.11)	47.02

Appendix Table D19. Migraine prevention with topiramate vs. placebo in adults (pooled results from randomized controlled clinical trials) (continued)

Outcome	Author, Year	Events/ Randomized	Events/ Randomized	Relative Risk (95% CI)	Weight Random Effects Inverse Variance	Absolute Risk Difference, (95% CI)	Weight, Random Effects Inverse Variance
Reduction in headache days by ≥75%	Pooled	123/551	59/535	1.9 (1.1 to 3.1)	100	0.10 (-0.01 to 0.20)	100
Outcome	Heterogeneity statistics	Degree of freedom	P value Relative risk	I squared Relative risk		P value Absolute risk difference	I squared Absolute risk difference
Frequency: ≥50% reduction		6	0.036	55.50%		0.001	73.60%
Reduction in headache days by ≥50%		2	0.012	77.20%		0.042	68.40%
Reduction in headache days by ≥75%		1	0.123	58.00%		0.026	79.70%

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D20. Reduction in migraine frequency and duration in randomized controlled clinical trials that examined efficacy of topiramate in adults

Definition of the Outcome	Reference Risk of Bias	Mean [Standard Deviation] with Drug	Daily Dose	Mean [Standard Deviation] with Placebo	Cohen Mean Difference (95% CI)	Mean Difference (95% CI)
Mean monthly migraine days	Silberstein, 2004 ²³ Risk of bias Low	3.7 [3.3]	100 mg/day	5.3 [3.6]	-0.46 (-0.72 to -0.21)	-1.60 (-2.47 to -0.73)
Mean monthly migraine days	Mei, 2006 ²⁸ Risk of bias Low	3.1 [0.91]	100 mg/day	15.4 [4.38]	-4.30 (-5.32 to -3.27)	-12.22 (-14.17 to -10.27)
Mean monthly migraine days	Brandes, 2006 ³⁰ Risk of bias Medium	3.5 [3.5]	100 mg/day	4.5 [2.9]	-0.31 (-0.57 to -0.05)	-1.00 (-1.82 to -0.18)
Pooled with random effects	Risk of bias Low	Low	100 mg/day	Heterogeneity test: P value=0 I squared= 96.3%	-1.47 (-2.55 to -0.39)	-4.83 (-9.44 to -0.21)
Mean monthly migraine days	Silvestrini, 2003 ²⁰ Risk of bias Low	8.1 [8.3]	50mg/day	20.6 [4.4]	-1.9 (-2.8 to -1.0)	-12.5 (-17.4 to -7.6)
Mean monthly migraine days	Silberstein, 2004 ²³ Risk of bias Low	4.8 [4]	50mg/day	5.3 [3.6]	-0.1 (-0.4 to 0.1)	-0.5 (-1.5 to 0.5)
Pooled with random effects	Risk of bias Low	Low	50mg/day	Heterogeneity test: P value=0 I squared= 92.6%	-1.0 (-2.7 to 0.8)	-6.2 (-18.5 to 5.5)
Mean reduction in the monthly number of migraine days	Brandes, 2004 ²² Risk of bias Low	-2.6 [3.4]	100 mg/day	-1.3 [3.5]	-0.4 (-0.6 to -0.1)	-1.3 (-2.2 to -0.4)
Mean reduction in the monthly number of migraine days	Silberstein, 2007 ³¹ Risk of bias Low	-6.4 [5.8]	100 mg/day	-4.7 [6.1]	-0.3 (-0.5 to -0.1)	-1.7 (-3.0 to -0.4)
Mean reduction in the monthly number of migraine days	Lipton, 2011 ⁴² Risk of bias Low	-6.6 [3.5]	100 mg/day	-5.3 [3.6]	-0.4 (-0.6 to -0.2)	-1.3 (-2.0 to -0.6)
Mean reduction in the monthly number of migraine days	Brandes, 2004 ²² Risk of bias Low	-2.9 [3.41]	200mg/day	-1.3 [3.51]	-0.5 (-0.7 to -0.2)	-1.6 (-2.5 to -0.7)
Pooled with random effects	Risk of bias Low	Low	50 to 200mg/day	Heterogeneity test: P value=0.7 I squared= 0%	-0.4 (-0.5 to -0.3)	-1.4 (-1.9 to -1.8)
Monthly migraine frequency	Silberstein, 2004 ²³ Risk of bias Low	4.1 [3.6]	50mg/day	4.6 [3]	-0.2 (-0.4 to 0.1)	-0.5 (-1.3 to 0.3)

Appendix Table D20. Reduction in migraine frequency and duration in randomized controlled clinical trials that examined efficacy of topiramate in adults (continued)

Definition of the Outcome	Reference Risk of Bias	Mean [Standard Deviation] with Drug	Daily Dose	Mean [Standard Deviation] with Placebo	Cohen Mean Difference (95% CI)	Mean Difference (95% CI)
Monthly migraine frequency	Brandes, 2006 ³⁰ Risk of bias Medium	4.1 [3.6]	50mg/day	4.5 [2.9]	-0.1 (-0.4 to 0.1)	-0.4 (-1.2 to 0.4)
Pooled with random effects	Risk of bias: Medium	Medium	50mg/day	Heterogeneity test: P value=0.9 I squared= 0%	-0.1 (-0.3 to 0.0)	-0.4 (-1.5 to 1.1)

Bold = significant at 95% confidence limit when 95% CI of mean difference estimates do not include 0
CI = confidence interval

Appendix Table D21. Reduction in migraine severity and symptoms in randomized controlled clinical trials that examined efficacy of topiramate in adults

Reference Risk of Bias	Definition of the Outcome	Daily Dose	Subjects in Active [Control] Groups	Mean [Standard Deviation] with Drug	Mean [Standard Deviation] with Placebo	Cohen Mean Difference (95% CI)	Mean Difference (95% CI)
Storey, 2001 ¹⁸ Risk of bias Low	Mean migraine severity during treatment	200mg/day	19 [21]	2.0 [0.4]	2.0 [0.4]	-0.1 (-0.7 to 0.5)	0.0 (-0.3 to 0.2)
Silberstein, 2009 ⁴¹ Risk of bias Low	Mean change in the rating of average daily headache severity	100 mg/day	165 [163]	-0.3 [0.6]	-0.2 [0.4]	-0.2 (-0.4 to 0.0)	-0.1 (-0.2 to 0.0)
	Change in worst daily headache severity	100 mg/day	165 [163]	-0.4 [0.7]	-0.2 [0.5]	-0.3 (-0.5 to -0.1)	-0.2 (-0.3 to -0.1)
	Mean decrease from baseline in the severity of nausea, photophobia, and phonophobia	100 mg/day	165 [163]	-0.2 [0.5]	-0.1 [0.4]	-0.2 (-0.4 to 0.0)	-0.1 (-0.2 to 0.0)
	Mean change from baseline in the monthly frequency of nausea	100 mg/day	165 [163]	-3.4 [5.8]	-2.3 [5.7]	-0.2 (-0.4 to 0.0)	-1.1 (-2.3 to 0.1)
	Mean change from baseline in the monthly rate of vomiting	100 mg/day	165 [163]	-1.0 [2.1]	-0.7 [2.6]	-0.1 (-0.3 to 0.1)	-0.3 (-0.8 to 0.2)
	Mean change from baseline in the monthly frequency of photophobia	100 mg/day	165 [163]	-5.0 [6.4]	-3.8 [5.6]	-0.2 (-0.4 to 0.0)	-1.2 (-2.5 to 0.1)
	Mean change from baseline in the monthly frequency of phonophobia	100 mg/day	165 [163]	-5.2 [6.0]	-3.6 [6.2]	-0.3 (-0.5 to 0.0)	-1.6 (-2.9 to -0.3)

Bold = significant at 95% confidence limit when 95% CI of mean difference estimates do not include 0

CI = confidence interval

Appendix Table D22. Quality of life in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults

Reference Risk of Bias	Definition of the Outcome	Daily Dose	Subjects in Active [Control] Groups	Mean [Standard Deviation] with Drug	Mean [Standard Deviation] with Placebo	Cohen Mean Difference (95% CI)	Mean Difference (95% CI)
Silberstein, 2009⁴¹ Risk of bias Low	Mean change from baseline in the headache index (The headache index was calculated as the sum of the product of daily average headache severity multiplied by headache duration for the day, divided by the number of days in the specified period)	100 mg/day	165 [163]	-0.3 [0.3]	-0.2 [0.4]	-0.3 (-0.5 to -0.1)	-0.1 (-0.2 to 0.0)
	Mean change from baseline in the in the MSQ (Migraine Specific Questionnaire)scores: Emotional function domain	100 mg/day	165 [163]	-26.3 [27.8]	-21.0 [30.2]	-0.2 (-0.4 to 0.0)	-5.3 (-11.6 to 1.0)
	Mean change from baseline in the in the MSQ (Migraine Specific Questionnaire) scores: Role Function Preventive domain	100 mg/day	165 [163]	-16.1 [21.5]	-12.6 [21.0]	-0.2 (-0.4 to 0.1)	-3.5 (-8.1 to 1.1)
	Mean change from baseline in the in the MSQ (Migraine Specific Questionnaire) scores: Role Function Restrictive domain	100 mg/day	165 [163]	-23.7 [23.1]	-18.8 [22.6]	-0.2 (-0.4 to 0.0)	-4.9 (-9.8 to 0.0)
	Mean change from baseline in the MIDAS (Migraine Disability Assessment) score	100 mg/day	165 [163]	-31.4 [53.8]	-21.0 [52.2]	-0.2 (-0.4 to 0.0)	-10.4 (-21.9 to 1.1)
Diener, 2007³⁸ Risk of bias Medium	Mean change in HIT-6 (Headache Impact Test) questionnaire in the last 4 weeks of double-blind phase compared to open-label baseline	100mg/day	255 [259]				-1.9 (-3.4 to -0.4)
	Mean change in SF-12 mental component score in the last 4 weeks of double-blind phase compared to open-label baseline	100mg/day	255 [259]				-1.2 (-3.4 to 1.0)
	Mean change in SF-12 physical health	100mg/day	255 [259]	-1.7	-3.1	NS	
	MIDAS score change at end-point	50 to 200mg/day	32 [27]	-26.0 [61.0]	3.0 [21.0]	-0.6 (-1.1 to -0.1)	-29.0 (-51.6 to -6.4)

Appendix Table D22. Quality of life in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (continued)

Reference Risk of Bias	Definition of the Outcome	Daily Dose	Subjects in Active [Control] Groups	Mean [Standard Deviation] with Drug	Mean [Standard Deviation] with Placebo	Cohen Mean Difference (95% CI)	Mean Difference (95% CI)
Brandes, 2006 ³⁰ Risk of bias Medium	MSQ (Migraine Specific Questionnaire: scored from 0 to 100 with higher scores indicating better functioning)-emotional function: at end of study	50mg/day	117 [114]	77.6 [22.71]	74.1 [21.35]	0.2 (-0.1 to 0.4)	3.5 (-2.2 to 9.2)
	MSQ (Migraine Specific Questionnaire: scored from 0 to 100 with higher scores indicating better functioning)-emotional function: at end of study	100 mg/day	120 [114]	82.9 [23.00]	74.1 [21.35]	0.4 (0.1 to 0.7)	8.8 (3.1 to 14.5)
	MSQ (Migraine Specific Questionnaire: scored from 0 to 100 with higher scores indicating better functioning)-emotional function: at end of study	200mg/day	117 [114]	82.7 [22.71]	74.1 [21.35]	0.4 (0.1 to 0.7)	8.6 (2.9 to 14.3)
	MSQ (Migraine Specific Questionnaire: scored from 0 to 100 with higher scores indicating better functioning)-role function: prevention: at end of study	50mg/day	117 [114]	82.6 [18.39]	80.8 [17.08]	0.1 (-0.2 to 0.4)	1.8 (-2.8 to 6.4)
	MSQ (Migraine Specific Questionnaire: scored from 0 to 100 with higher scores indicating better functioning)-role function: prevention: at end of study	100 mg/day	120 [114]	85.5 [18.62]	80.8 [17.08]	0.3 (0.0 to 0.5)	4.7 (0.1 to 9.3)
	MSQ (Migraine Specific Questionnaire: scored from 0 to 100 with higher scores indicating better functioning)-role function: prevention: at end of study	200mg/day	117 [114]	87.2 [18.39]	80.8 [17.08]	0.4 (0.1 to 0.6)	6.4 (1.8 to 11.0)
	MSQ (Migraine Specific Questionnaire: scored from 0 to 100 with higher scores indicating better functioning)-role function: restrictive: at end of study	50mg/day	117 [114]	71.9 [20.55]	67.2 [19.22]	0.2 (0.0 to 0.5)	4.7 (-0.4 to 9.8)
	MSQ (Migraine Specific Questionnaire: scored from 0 to 100 with higher scores indicating	100 mg/day	120 [114]	75.8 [20.81]	67.2 [19.22]	0.4 (0.2 to 0.7)	8.6 (3.5 to 13.7)

Appendix Table D22. Quality of life in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (continued)

Reference Risk of Bias	Definition of the Outcome	Daily Dose	Subjects in Active [Control] Groups	Mean [Standard Deviation] with Drug	Mean [Standard Deviation] with Placebo	Cohen Mean Difference (95% CI)	Mean Difference (95% CI)
	better functioning)-role function: restrictive: at end of study						
	MSQ (Migraine Specific Questionnaire: scored from 0 to 100 with higher scores indicating better functioning)-role function: restrictive: at end of study	200mg/day	117 [114]	77.9 [18.39]	67.2 [17.08]	0.6 (0.3 to 0.9)	10.7 (6.1 to 15.3)
Silberstein, 2006²⁷ Risk of bias Medium	MSQ role function: prevention domain score at end point	100 mg/day	125 [115]	88.3 [15.7]	80.6 [16.1]	0.5 (0.2 to 0.7)	7.7 (3.7 to 11.7)
	MSQ role function: prevention domain score at end point	200mg/day	112 [115]	84.4 [18.0]	80.6 [16.1]	0.2 (0.0 to 0.5)	3.8 (-0.6 to 8.2)
	MSQ role function: prevention domain score at end point	50mg/day	117 [115]	84.3 [16.2]	80.6 [16.1]	0.2 (0.0 to 0.5)	3.7 (-0.5 to 7.9)
	MSQ role function: restrictive domain score at end point	100 mg/day	125 [115]	77.2 [19.0]	65.8 [19.3]	0.6 (0.3 to 0.9)	11.4 (6.5 to 16.3)
	MSQ role function: restrictive domain score at end point	200mg/day	112 [115]	75.8 [21.2]	65.8 [19.3]	0.5 (0.2 to 0.8)	10.0 (4.7 to 15.3)
	MSQ role function: restrictive domain score at end point	50mg/day	117 [115]	72.2 [19.5]	65.8 [19.3]	0.3 (0.1 to 0.6)	6.4 (1.4 to 11.4)
	MSQ role function: emotional function score at end point	100 mg/day	125 [115]	84.4 [21.2]	72.9 [21.4]	0.5 (0.3 to 0.8)	11.5 (6.1 to 16.9)
	MSQ role function: emotional function score at end point	200mg/day	112 [115]	81.2 [23.3]	72.9 [21.4]	0.4 (0.1 to 0.6)	8.3 (2.5 to 14.1)
	MSQ role function: emotional function score at end point	50mg/day	117 [115]	78.5 [21.6]	72.9 [21.4]	0.3 (0.0 to 0.5)	5.6 (0.1 to 11.1)
	MSQ: Emotional domain: endpoint score	100 mg/day	384 [372]	82.5 [21.6]	73.5 [21.2]	0.4 (0.3 to 0.6)	9.0 (6.0 to 12.0)
Diamond, 2005²⁶ Risk of bias Low	MSQ: Prevention domain: endpoint score	100 mg/day	384 [372]	85.5 [17.6]	79.9 [17.4]	0.3 (0.2 to 0.5)	5.6 (3.1 to 8.1)
	MSQ: Restriction domain: endpoint score	100 mg/day	384 [372]	75.4 [21.6]	66.5 [19.3]	0.4 (0.3 to 0.6)	8.9 (6.0 to 11.8)

Bold = significant at 95% confidence limit when 95% CI of mean difference estimates do not include 0; SF-12 = Short Form 12-Item Health Survey; CI = confidence interval

Appendix Table D23. General health status in pooled analysis of individual patient data from randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (Medical Outcome Study Short Form 36 (SF-36) scores for each domain range from 0 to 100 with a higher score representing better function, a change of five points on the SF-36 is generally considered clinically meaningful)³⁷

Definition of the Outcome	Daily Dose	Subjects in Active [Control] Groups	Mean [Standard Deviation] with Drug	Mean [Standard Deviation] with Placebo	Cohen Mean Difference (95% CI)	Mean Difference (95% CI)
SF-36: Bodily pain: change from baseline	100 mg/day	384 [372]	11.5 [1.2]	4.6 [1.2]	5.8 (5.4 to 6.1)	6.9 (6.7 to 7.1)
SF-36: General health: Change from baseline	100 mg/day	384 [372]	2.2 [0.8]	0.8 [0.8]	1.8 (1.6 to 1.9)	1.4 (1.3 to 1.5)
SF-36: Mental component summary: change from baseline	100 mg/day	384 [372]	-0.2 [0.5]	0.1 [0.5]	-0.6 (-0.7 to -0.5)	-0.3 (-0.4 to -0.2)
SF-36: Mental health: change from baseline	100 mg/day	384 [372]	-0.5 [0.9]	-0.2 [0.9]	-0.3 (-0.5 to -0.2)	-0.3 (-0.4 to -0.2)
SF-36: Physical component summary: change from baseline	100 mg/day	384 [372]	4.7 [0.4]	2.5 [0.4]	5.5 (5.2 to 5.8)	2.2 (2.1 to 2.3)
SF-36: Physical functioning: change from baseline	100 mg/day	384 [372]	5.3 [0.8]	3.6 [0.9]	2.0 (1.8 to 2.2)	1.7 (1.6 to 1.8)
SF-36: Role-emotional: change from baseline	100 mg/day	384 [372]	2.3 [2.0]	3.0 [2.0]	-0.4 (-0.5 to -0.2)	-0.7 (-1.0 to -0.4)
SF-36: Role-physical: change from baseline	100 mg/day	384 [372]	17.9 [2.1]	12.0 [2.1]	2.8 (2.6 to 3.0)	5.9 (5.6 to 6.2)
SF-36: Social functional: change from baseline	100 mg/day	384 [372]	4.8 [1.2]	4.8 [1.2]	0.0 (-0.1 to 0.1)	0.0 (-0.2 to 0.2)
SF-36: Vitality: change from baseline	100 mg/day	384 [372]	5.2 [1.0]	1.8 [1.0]	3.4 (3.2 to 3.6)	3.4 (3.3 to 3.5)

Bold = significant differences at 95% confidence limit when 95% CI of mean difference estimates do not include 0

CI = confidence interval

Appendix Table D24. Drug utilization for acute migraine attacks in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults

Reference Risk of Bias	Definition of the Outcome	Daily Dose	Subjects in Active [Control] Groups	Mean [Standard Deviation] with Drug	Mean [Standard Deviation] with Placebo	Cohen Mean Difference (95% CI)	Mean Difference (95% CI)
Mei, 2006²⁸ Risk of bias Low	Amount of acute medication taken monthly	100 mg/day	30 [20]	3.2 [1.0]	15.4 [4.4]	-4.2 (-5.2 to -3.2)	-12.2 (-14.2 to -10.3)
Diener, 2007 ³⁴ Risk of bias Medium	Change in number of days per month of acute medications intake	50 to 200mg/day	32 [27]	-3.0 [5.9]	-0.7 [6.2]	-0.4 (-0.9 to 0.1)	-2.3 (-5.4 to 0.8)
Silberstein, 2009 ⁴¹ Risk of bias Low	Mean change from baseline in the number of days per month that subjects used acute headache medications	100 mg/day	165 [163]	-4.4 [5.8]	-3.4 [5.3]	-0.2 (-0.4 to 0.0)	-1.0 (-2.2 to 0.2)
Diener, 2007 ³⁸ Risk of bias Medium	Mean change in intake of acute medication in the last 4 weeks of double-blind phase compared to open-label baseline	100mg/day	255 [259]				-1.0 (-1.5 to -0.4)
Silberstein, 2004²³ Risk of bias Low	Mean monthly Acute rescue medications days during the double-blind phase	100 mg/day	128 [117]	4.0 [3.4]	5.2 [3.3]	-0.4 (-0.6 to -0.1)	-1.2 (-2.0 to -0.4)
	Mean monthly Acute rescue medications days during the double-blind phase	50mg/day	125 [117]	4.5 [3.1]	5.2 [3.3]	-0.2 (-0.5 to 0.0)	-0.7 (-1.5 to 0.1)
Brandes, 2004²² Risk of bias Low	Mean reduction in the monthly number of days when acute rescue medications were used	100 mg/day	122 [120]	-2.1 [3.20]	-1.0 [3.18]	-0.3 (-0.6 to -0.1)	-1.1 (-1.9 to -0.3)
	Mean reduction in the monthly number of days when acute rescue medications were used	200mg/day	121 [120]	-2.2 [3.19]	-1.0 [3.18]	-0.4 (-0.6 to -0.1)	-1.2 (-2.0 to -0.4)

Appendix Table D24. Drug utilization for acute migraine attacks in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (continued)

Reference Risk of Bias	Definition of the Outcome	Daily Dose	Subjects in Active [Control] Groups	Mean [Standard Deviation] with Drug	Mean [Standard Deviation] with Placebo	Cohen Mean Difference (95% CI)	Mean Difference (95% CI)
Lipton, 2011⁴² Risk of bias Low	Number of days of acute medications use	100 mg/day	188 [197]	-4.8 [3.5]	-3.8 [3.7]	-0.3 (-0.5 to -0.1)	-1.0 (-1.7 to -0.3)
Bussone, 2005²⁵ Risk of bias Low	Percentage of migraine days with intake of medication to treat acute migraine attacks: from baseline to endpoint	100 mg/day	386 [372]	12.7 [0.6]	16.4 [0.6]	-6.7 (-7.1 to -6.4)	-3.7 (-3.8 to -3.6)

Bold = significant differences at 95% confidence limit when 95% CI of mean difference estimates do not include 0

CI = confidence interval

Appendix Table D25. Randomized controlled clinical trials that examined efficacy of divalproex or valproate for migraine prevention in adults

Active Drug	Reference Sample Number Analyzed % Women	Definition of Migraine % without Aura	Baseline Severity	Age of Subjects (Eligible and Mean)	Years of Migraine % with prior Preventative Treatment
Divalproex	Mathew, 1995 ⁴⁵ Sample 107 Analyzed 105 % of women 77.6	Migraine (International Headache Society) % without aura: 95	Days per 4 week with migraine headaches during baseline phase: 7	16-75 Mean: 45.6	Years of migraine: 25 % with prior treatment: NR
Divalproex	Freitag, 2002 ⁴⁶ Sample 239 Analyzed 237 % of women 79	Migraine (International Headache Society) % without aura: 97	Days per 4 week with migraine headaches during baseline phase: 6.1	≥12 Mean: 40.5	Years of migraine: 20.2 % with prior treatment: NR
Divalproex	Klapper, 1997 ⁴⁷ Sample 176 Analyzed 171 % of women 89	Migraine (International Headache Society) % without aura: NR	Migraine attacks impairing usual activities during baseline (4 weeks): 5.8	≥16 Mean: 40.8	Years of migraine: 21.6 % with prior treatment: 53
Valproate	Hering, 1992 ⁴⁸ Sample 32 Analyzed 29 % of women 79.3	Migraine with aura (classical); patients suffering from migraine without aura (common); Ad Hoc Committee on Classification of Headache. % without aura: 13.7 (assumed)	From inclusion criteria: at least four attacks per months	NR (range: 18-54) Mean: 34	Years of migraine: 14 % with prior treatment: NR
Valproate	Jensen, 1994 ⁴⁹ Sample 43 Analyzed 34 % of women 86	Diagnosis of migraine without aura (International Headache Society) % without aura: 100	Mean frequency of migraines (4 weeks): 6.6	18-70 Mean: 46	Years of migraine: NR % with prior treatment: NR

NR = Not reported

Appendix Table D26. Funding and conflict of interest in randomized controlled clinical trials that examined efficacy of divalproex or valproate for migraine prevention in adults

Active drug	Reference	Funding	Ethical Approval	Consent	Conflict of Interest	Disclosed Relationships
Divalproex	Mathew, 1995 ⁴⁵	Industry	Yes	Yes	Yes	One author is employed by Abbott Laboratory, study funder.
Divalproex	Freitag, 2002 ⁴⁶	Industry	Yes	Yes	Yes	Three authors are employed by Abbott Laboratory, study funder.
Divalproex	Klapper, 1997 ⁴⁷	Industry	Not reported	Not reported	Yes	Five study participants are employed by Abbott Laboratory, study funder.
Valproate	Hering, 1992 ⁴⁸	Not reported	Yes	Yes	Not reported	Not reported
Valproate	Jensen, 1994 ⁴⁹	Industry	Yes	Yes	Not reported	Not reported

Appendix Table D27. Risk of bias in randomized controlled clinical trials that examined efficacy of divalproex or valproate for migraine prevention in adults

Reference	Masking of Treatment Status	Planned Intention to Treat	Allocation Concealment	Adequacy of Randomization	Baseline Migraine Similarity	Selective Outcome Reporting	Risk of Bias
Mathew, 1995 ⁴⁵	DB	No	Unclear	Yes	D	No	Medium
Freitag, 2002 ⁴⁶	DB	Yes	Unclear	Yes	F, S & D	No	Low
Klapper, 1997 ⁴⁷	DB	Yes	Unclear	Yes	D	No	Low
Hering, 1992 ⁴⁸	DB	No	Unclear	Not reported	Not reported	No	Medium
Jensen, 1994 ⁴⁹	TB	No	Unclear	Yes	F, S & D	No	Medium

DB = double blind

TB = triple blind

D = duration

F = frequency

S = severity

Appendix Table D28. Strength of evidence of migraine prevention in adults with divalproex vs. placebo, results from randomized controlled clinical trials

Outcome	Daily Dose	Reference	Sample	Risk of Bias	Directness	Consistency	Precision	Strength of Evidence
≥ 50% reduction in migraine headache rate		Mathew, 1995 ⁴⁵ Freitag, 2002 ⁴⁶ Klapper, 1997 ⁴⁷						
≥ 50% reduction in migraine headache rate		Pooled	405	Medium	Yes	No	No	Low
50% improvement in migraine attacks impairing usual activities	500 mg	Klapper, 1997 ⁴⁷	60	Low	Yes	NA	No	Low
50% improvement in migraine attacks impairing usual activities	1000 mg	Klapper, 1997 ⁴⁷	58	Low	Yes	NA	No	Low
50% improvement in migraine attacks impairing usual activities	1500 mg	Klapper, 1997 ⁴⁷	59	Low	Yes	NA	No	Low
50% improvement in migraine attacks necessitating symptomatic medication	500 mg	Klapper, 1997 ⁴⁷	60	Low	Yes	NA	No	Low
50% improvement in migraine attacks necessitating symptomatic medication	1000 mg	Klapper, 1997 ⁴⁷	57	Low	Yes	NA	No	Low
50% improvement in migraine attacks necessitating symptomatic medication	1500 mg	Klapper, 1997 ⁴⁷	59	Low	Yes	NA	No	Low
50% improvement in migraine attacks with nausea, vomiting, phonophobia or photophobia	500 mg	Klapper, 1997 ⁴⁷	60	Low	Yes	NA	No	Low
50% improvement in migraine attacks with nausea, vomiting, phonophobia or photophobia	1000 mg	Klapper, 1997 ⁴⁷	58	Low	Yes	NA	No	Low
50% improvement in migraine attacks with nausea, vomiting, phonophobia or photophobia	1500 mg	Klapper, 1997 ⁴⁷	59	Low	Yes	NA	No	Low

NA = not applicable

Appendix Table D29. Migraine prevention in adults with divalproex vs. placebo, results from randomized controlled clinical trials

Outcome	Daily Dose	Reference Risk of Bias	Events/Randomized with Divalproex	Events/Randomized with Placebo	Rate,% with Divalproex [Placebo]	Relative Risk (95%CI)	Absolute Risk Difference (95%CI)
≥50% reduction in migraine headache rate		Mathew, 1995 ⁴⁵ Medium	33/70	5/37	47.1 [13.5]	3.5 (1.5 to 8.2)	0.34 (0.18 to 0.50)
≥50% reduction in migraine headache rate		Freitag, 2002 ⁴⁶ Low	50/123	32/116	40.7 [27.6]	1.5 (1.0 to 2.1)	0.13 (0.01 to 0.25)
≥50% reduction in migraine headache rate		Klapper, 1997 ⁴⁷ Low	19/44	2/15	43.2 [13.6]	3.2 (0.9 to 12.3)	0.30 (0.07 to 0.52)
≥50% reduction in migraine headache rate	1,000-1,500mg	Medium	102/237	39/168	43.0 [23.3]	2.2 (1.1 to 4.2)	0.24 (0.10 to 0.38)
≥50% reduction in migraine headache rate	Heterogeneity P value					0.098	0.108
≥50% reduction in migraine headache rate	Heterogeneity P value I squared					56.90%	55.10%
50% improvement in migraine attacks impairing usual activities	500 mg	Klapper, 1997 ⁴⁷ Risk of bias Low	26/45	4/15	57.8 [25.0]	2.2 (0.9 to 5.2)	0.31 (0.04 to 0.58)
50% improvement in migraine attacks impairing usual activities	1000 mg	Klapper, 1997 ⁴⁷ Risk of bias Low	16/43	4/14	37.2 [25.0]	1.4 (0.6 to 3.5)	0.11 (-0.16 to 0.37)
50% improvement in migraine attacks impairing usual activities	1500 mg	Klapper, 1997 ⁴⁷ Risk of bias Low	24/44	4/15	54.5 [25.0]	2.0 (0.8 to 4.9)	0.28 (0.01 to 0.55)
50% improvement in migraine attacks necessitating symptomatic medication	500 mg	Klapper, 1997 ⁴⁷ Risk of bias Low	19/45	2/15	42.2 [13.6]	3.2 (0.8 to 12.0)	0.29 (0.06 to 0.51)

Appendix Table D29. Migraine prevention in adults with divalproex vs. placebo, the results from randomized controlled clinical trials (continued)

Outcome	Daily Dose	Reference Risk of Bias	Events/Randomized with Divalproex	Events/Randomized with Placebo	Rate,% with Divalproex [Placebo]	Relative Risk (95%CI)	Absolute Risk Difference (95%CI)
50% improvement in migraine attacks necessitating symptomatic medication	1000 mg	Klapper, 1997 ⁴⁷ Risk of bias Low	16/43	2/14	37.2 [13.6]	2.6 (0.7 to 10.0)	0.23 (0.00 to 0.46)
50% improvement in migraine attacks necessitating symptomatic medication	1500 mg	Klapper, 1997 ⁴⁷ Risk of bias Low	19/44	2/15	43.2 [13.6]	3.2 (0.9 to 12.3)	0.30 (0.07 to 0.52)
50% improvement in migraine attacks with nausea, vomiting, phonophobia or photophobia	500 mg	Klapper, 1997 ⁴⁷ Risk of bias Low	21/45	3/15	46.7 [18.2]	2.3 (0.8 to 6.7)	0.27 (0.02 to 0.52)
50% improvement in migraine attacks with nausea, vomiting, phonophobia or photophobia	1000 mg	Klapper, 1997 ⁴⁷ Risk of bias Low	18/43	3/14	41.9 [18.2]	2.1 (0.7 to 6.1)	0.22 (-0.03 to 0.47)
50% improvement in migraine attacks with nausea, vomiting, phonophobia or photophobia	1500 mg	Klapper, 1997 ⁴⁷ Risk of bias Low	22/44	3/15	50.0 [18.2]	2.5 (0.9 to 7.2)	0.30 (0.05 to 0.55)

Bold = significant at 95% confidence limit 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

CI = confidence level

Appendix Table D30. Migraine frequency, severity, and drug utilization with valproate vs. placebo for migraine prevention in adults, results from medium risk of bias randomized controlled clinical trials

Outcome	Daily Dose	Reference	Mean [Standard deviation] with Valproate	Mean [Standard deviation] with Placebo	Randomized to Valproate vs. Placebo	Mean Difference (95% CI)	Cohen Standardized Mean Difference (95% CI)
Mean number of days with migraine	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	3.5 [4.8]	6.1 [7.7]	43 [43]	-2.6 (-5.3 to 0.1)	-0.4 (-0.8 to 0.0)
Total drug consumption	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	NR [NR]	NR [NR]	43 [43]	p value <0.001	
Consumption of symptomatic medication per attack	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	NR [NR]	NR [NR]	43 [43]	p value 0.61	
Mean number of attacks (4 weeks)	400 mg twice a day	Hering, 1992 ⁴⁸	8.8 [6.1]	15.6 [8.3]	32 [32]	-6.8 (-10.3 to -3.2)	-0.9 (-1.4 to -0.4)
Duration of the remaining attack (hours)	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	11.1 [NR]	11.5 [NR]	43 [43]	p value 0.9	
Duration of the attack (total hours)	400 mg twice a day	Hering, 1992 ⁴⁸	1731.0 [NR]	2789.0 [NR]	32 [32]	p value = 0.002	
Intensity of the remaining attacks (no details provided)	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	2.3 [NR]	2.3 [NR]	43 [43]	p value 0.45	
Mean number of severe migraine attacks (4 weeks)	400 mg twice a day	Hering, 1992 ⁴⁸	14.6 [9.8]	24.0 [15.4]	32 [32]	-9.4 (-15.7 to -3.1)	-0.7 (-1.2 to -0.2)

Bold = significant at 95% confidence limit when 95% CI of mean difference estimates do not include 0

CI = confidence level

NR = not reported

Appendix Table D31. Randomized controlled clinical trials that examined efficacy of propranolol for migraine prevention in adults

Reference Total Sample Size as Randomized % Women	Aim	Definition of Migraine	Duration of Migraine, Years	Age of Subjects	Baseline Severity
Diamond, 1976 ⁵⁰ Sample 83 80.7% women	To evaluate propranolol in the prophylaxis of migraine	Classic or common migraine (Ad Hoc Committee)	Not reported	Mean: 38.1	Not reported
Stensrud, 1976 ⁵¹ Stensrud, 1976 ⁵¹ Sample 20 70% women	To investigate the effects of propranolol in the racemic form (Inderal) and d-propranolol.	Common and classic migraine (as defined by the Ad Hoc Committee)	Not reported	43.5	Not reported
Forssman, 1976 ⁵² Sample 40 87.5% women	To compare the preventive effect of propranolol on migraine attacks with placebo in a double-blind crossover trial	Not reported	18.9	Mean: 37.4	Not reported
Pradalier, 1989 ⁵³ Sample 55 76% women	To evaluate the efficacy and tolerability of long-acting propranolol in migraine	International Headache Society	Not reported	Mean: 37.4	Mean frequency of migraine (month): 4
Nadelman, 1986 ⁵⁴ Sample 57 85.5% women	To compare the relative efficacy and safety of propranolol with that of placebo in the prophylaxis of migraine headache	Classic and/or common migraine headaches as set forth by the Ad Hoc Committee on the Classification of Headache	1-5: 22.6%; 6-10: 27.4%; 11-15: 14.5%; 16-20: 9.7%; 21-25: 8.1%; 26+: 17.7%	Not reported	Headache Unit Index: 1.09
Sargent, 1985 ⁵⁵ Sample 149 79% women	To evaluate the prophylactic effect and tolerance of naproxen sodium compared to propranolol hydrochloride and placebo in migraine	Common or classical migraine, or a combination migraine and muscle contraction headache (no definition provided)	20	Mean: 30	Not reported
Ahuja, 1985 ⁵⁶ Sample 26 46.2% women	To compare the effectiveness of a selective and a non-selective beta1-receptor antagonist i.e. atenolol (Tenormin) and propranolol (Inderal), in the prophylaxis of migraine	Ad Hoc Committee on Classification of Headache (1962)	Not reported	Not reported	Not reported
Malvea, 1973 ⁵⁷ Sample 31 87% women	To determine the relative effectiveness of propranolol in the prevention of migraine as compared to a placebo in a double-blind trial	Not reported	Not reported	Not reported (ranges: 25-57)	Average headache units: 25.4 (no definition provided)

Appendix Table D31. Randomized controlled clinical trials that examined efficacy of propranolol for migraine prevention in adults (continued)

Reference Total Sample Size as Randomized % Women	Aim	Definition of Migraine	Duration of Migraine, Years	Age of Subjects	Baseline Severity
Wideroe, 1974 ⁵⁸ Sample 30 86.7% women	To investigate the value of propranolol in preventing attacks of migraine	Classic or common migraine (Ad Hoc Committee, 1962)	Not reported	Mean: 40	All except four patients had two or more attacks a month
Palferman, 1983 ⁵⁹ Sample 36 80% women	To assess the efficacy of prophylactic propranolol on the severity and frequency of their symptoms	Episodic headache with other accepted disorders of cerebral function including visual disturbances and vomiting	17.5 (all patients: 11.3)	Mean: 41.4 (all patients: 37.8)	Not reported
Tfelt-Hansen, 1984 ⁶⁰ Sample 96 74% women	To compare the beta-adrenergic blocker timolol to an established drug, propranolol, and to placebo for prophylactic effect in common migraine	Between 2 and 6 common migraine attacks per month as defined by the ad hoc committee and by Olsen	20.9	Mean: 39.5	Number of migraine attacks per 4 weeks: 5.7
Standnes, 1982 ⁶¹ Sample 25 80% women	To evaluate the prophylactic effect of timolol in migraine	Common migraine attacks (as defined by the Ad Hoc Committee)	Not reported	Mean: 41.4	Mean number of attacks (4 weeks): 6.65
Stensrud, 1980 ⁶² Sample 35 68.6% women	To compare the effectiveness of a selective and a non-selective beta1-receptor antagonist i.e. atenolol (Tenormin) and propranolol (Inderal), in the prophylaxis of migraine	Ad Hoc Committee on Classification of Headache (1962)	Not reported	Not reported	Not reported
al-Qassab, 1993 ⁶³ Sample 45 80% women	To assess the effectiveness of two different doses of a long-acting formulation of propranolol (propranolol LA) in patients with severe migraine	Diagnosis of migraine was made on clinical assessment.	Median: 9	Median: 36	Median attacks (month): 4
Diener, 2004 ⁴³ Sample 575 79.8% women	To evaluate the efficacy and safety of two doses of topiramate and safety of two doses of topiramate vs. placebo for migraine prophylaxis, with propranolol (PROP) as an active control	International Headache Society	Not reported	Median: 41	Mean monthly migraine frequency: 5.1

Appendix Table D31. Randomized controlled clinical trials that examined efficacy of propranolol for migraine prevention in adults (continued)

Reference Total Sample Size as Randomized % Women	Aim	Definition of Migraine	Duration of Migraine, Years	Age of Subjects	Baseline Severity
Rafieian-Kopaei, 2005 ⁶⁴ Sample 105 % women Not reported	To compare the prophylactic activity of propranolol and amitriptyline on frequency, duration and severity of migraine attacks	Migraine (International Headache Society)	>1 (from inclusion criteria)	Not reported	Mean attack frequency: 4.02 (per month)
Weber, 1972 ⁶⁵ Sample 25 52% women	To compare the prophylactic effect of the propranolol to placebo	Migraine (Classification of headache, JAMA (1962) 179, 717)	Not reported	Mean: 40.6	Not reported
Pradalier, 1989 ⁶⁶ Sample 55 75.7% women	To assess the efficacy and safety of long-acting propranolol (LA. P) 160 mg once-daily in the prophylactic treatment of migraine	Migraine (International Headache Society)	Not reported	Not reported	Not reported
Kuritzky, 1987 ⁶⁷ Sample 38 % women Not reported	1) To evaluate the efficacy of long acting propranolol (Deralin SR) in reducing the frequency, duration and severity of migraine when compared with placebo, 2) To register possible side effects, and 3) to study correlation between plasma propranolol levels and clinical effectiveness in migraine.	Not reported (While eligibility criteria are not reported, author described "classic or common migraine" patients were included.)	14.2	Not reported	Mean number of migraine attacks: 3 ("All patients averaged at least 3 attacks per month when untreated.")

Appendix Table D32. Funding and conflict of interest in randomized controlled clinical trials that examined efficacy of propranolol for migraine prevention in adults

Reference	Funding	Ethical Approval	Consent	Conflict of Interest	Disclosed - Relationships
Diamond, 1976 ⁵⁰	Not reported	Not reported	Yes	Not reported	Not reported
Stensrud, 1976 ⁵¹	Not reported	Not reported	Not reported	Not reported	Not reported
Forssman, 1976 ⁵²	Not reported	Not reported	Not reported	Not reported	Not reported
Pradalier, 1989 ⁵³	Not reported	Not reported	Yes	Not reported	Not reported
Nadelmann, 1986 ⁵⁴	Not reported	Not reported	Yes	Unclear	Two authors are employed by pharmaceutical industry (Ayerst Laboratories), but unclear their relationship (no funding source reported.)
Sargent, 1985 ⁵⁵	Not reported	Not reported	Not reported	Not reported	Not reported
Ahuja, 1985 ⁵⁶	Industry (Inderal brand of propranolol and identical looking placebo tablets were supplied by Alkali and Chemical Corp. India Ltd.	Not reported	Not reported	Not reported	Not reported
Malvea, 1973 ⁵⁷	Industry	Not reported	Not reported	Not reported	Not reported
Wideroe, 1974 ⁵⁸	Not reported	Not reported	Not reported	Not reported	Not reported
Palferman, 1983 ⁵⁹	Industry (all tablets were supplied by ICI Pharmaceuticals)	Not reported	Not reported	Not reported	Not reported
Tfelt-Hansen, 1984 ⁶⁰	Not reported	Not reported	Yes	Not reported	Not reported
Standnes, 1982 ⁶¹	Industry	Not reported	Yes	Not reported	Not reported
Stensrud, 1980 ⁶²	Not reported	Not reported	Not reported	Not reported	Not reported
al-Qassab, 1993 ⁶³	Industry	Yes	Yes	Not reported	Not reported
Diener, 2004 ⁴³	Industry	Yes	Yes	Yes	Hans-Christoph Diener has received grant/research support from, has been a consultant/scientific advisor for, and/or has received honoraria for oral presentations from 3M Medica, Allergan, Almirall Prodesfarma, AstraZeneca, Bayer Vital, Böhringer Ingelheim, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Grünenthal, Janssen-Cilag, Johnson & Johnson, La Roche, Lilly, Novartis, MSD, Parke-Davis, Pfizer, Pharmacia, Pierre Fabre, Schaper and Brümmer, and Weber & Weber. Peer Tfelt-Hansen has been a consultant/scientific advisor for, and/or has received honoraria for oral presentation from Almirall Prodesfarma, AstraZeneca, GlaxoSmithKline, Johnson & Johnson, MSD, Pfizer, and Quintiles. Carl Dahlöf has been a

Appendix Table D32. Funding and conflict of interest in randomized controlled clinical trials that examined efficacy of propranolol for migraine prevention in adults (continued)

Reference	Funding	Ethical Approval	Consent	Conflict of Interest	Disclosed - Relationships
					consultant/scientific advisor for, and has received honoraria for oral presentations from Allergan, Almirall Prodesfarma, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen-Cilag, Johnson & Johnson, Lilly, MSD, Novartis, Pfizer, Pharmacia, and Pierre Fabre. Miguel JA Láinez has received grant/research support from, has been a consultant/scientific advisor for, and/or has received honoraria for oral presentations from Almirall Prodesfarma, AstraZeneca, Böhringer Ingelheim, Bristol-Myers Squibb, Elan Pharmaceuticals, GlaxoSmithKline, Janssen-Cilag, Johnson & Johnson, MSD, Novartis, Pfizer, Pierre Fabre, and Sanofi-Synthelabo. Giorgio Sandrini has received grant/research support from, has been a consultant/scientific advisor for, and/or has received honoraria for oral presentations from Allergan, AstraZeneca, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Grünenthal, Janssen-Cilag, Johnson & Johnson, Lilly, MSD, Pfizer, Pharmacia, and Solvay Pharma. Shuu-Jiun Wang has received grant/research support from and/or received honoraria for oral presentations from AstraZeneca, Glaxo-SmithKline, Johnson & Johnson, Lilly, MSD, and Pfizer. Walter Neto, Ujjwalla Vijapurkar, Aiden Doyle, and David Jacobs are employed by Johnson & Johnson Pharmaceutical Research and Development, LLC.
Rafieian-Kopaei, 2005 ⁶⁴	Other	Not reported	Yes	Not reported	All authors are from the University that sponsored the study
Weber, 1972 ⁶⁵	Industry (drugs were provided by Ayerst laboratories)	Not reported	Not reported	Unclear	Dr. Trent and Kyle of Ayerst laboratories assisted in the study. Their contribution not known.
Pradalier, 1989 ⁶⁶	Not reported	Not reported	Not reported	Not reported	Not reported
Kuritzky, 1987 ⁶⁷	Not reported	Yes	Yes	Not reported	Not reported

Appendix Table D33. Risk of bias in randomized controlled clinical trials that examined efficacy of propranolol for migraine prevention in adults

Reference	Masking Treatment Status	Planned Intention to Treat	Allocation Concealment	Adequacy of Randomization	Baseline Similarity by Migraine Status	Selective Outcome Reporting	Risk of Bias
Diamond, 1976 ⁵⁰	Double blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Stensrud, 1976 ⁵¹	Double blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Forssman, 1976 ⁵²	Double blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Pradalier, 1989 ⁵³	Double blind	Yes	Unclear	Yes	F & S	Unclear	Low
Nadelmann, 1986 ⁵⁴	Double blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Sargent, 1985 ⁵⁵	Double blind	No	Unclear	Yes	Not reported	Unclear	Medium
Ahuja, 1985 ⁵⁶	Double blind	No	Unclear	Not reported	Not reported	Unclear	Low
Malvea, 1973 ⁵⁷	Double blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Wideroe, 1974 ⁵⁸	Double blind	No	Unclear	Not reported	S	Unclear	Medium
Palferman, 1983 ⁵⁹	Double blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Tfelt-Hansen, 1984 ⁶⁰	Double blind	No	Unclear	Yes	F, S & D	Unclear	Medium
Standnes, 1982 ⁶¹	Double blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Stensrud, 1980 ⁶²	Double blind	No	Unclear	Not reported	Not reported	Unclear	Medium
al-Qassab, 1993 ⁶³	Double blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Diener, 2004 ⁴³	Double blind	Yes	Unclear	Yes	F	Unclear	Low
Rafieian-Kopaei, 2005 ⁶⁴	Double blind	No	Unclear	Not reported	F	Unclear	Medium
Weber, 1972 ⁶⁵	Double blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Pradalier, 1989 ⁶⁶	Double blind	Yes	Unclear	Not reported	Not reported	Unclear	Low
Kuritzky, 1987 ⁶⁷	Open-label	No	Unclear	Not reported	Not reported	Unclear	High

F = monthly migraine frequency; S = migraine severity; D = migraine duration

Appendix Table D34. Strength of evidence of migraine prevention with propranolol (randomized controlled clinical trials)

Reference	Active Drug	Control Drug	Sample Size	Risk of Bias	Directness	Consistency	Precision	Strength of Evidence
Tfelt-Hansen, 1984 ⁶⁰				Medium				
Diener, 2004 ⁴³				Low				
Diamond, 1976 ⁵⁰				Medium				
Standnes, 1982 ⁶¹				Medium				
Pooled	Propranolol	Placebo	541	Medium	Yes	Consistent	No	Low
Diener, 2004 ⁴³	Topiramate	Propranolol	288	Low	Yes	Not applicable	No	Low
Kaniecki, 1997 ⁶⁸	Divalproex	Propranolol	74	High	Yes	Not applicable	No	Insufficient
Kass, 1980 ⁶⁹	Propranolol	Clonidine	46	Medium	Yes	Not applicable	No	Low
Kangasniemi, 1984 ⁷⁰				Medium				
Gerber, 1991 ⁷¹				Medium				
Pooled	Propranolol	Metoprolol.	113	Medium	Yes	Yes	No	Low
Sudilovsky, 1987 ⁷²	Propranolol	Nadolol	93	Medium	Yes	Not applicable	No	Low
Olerud, 1986 ⁷³	Nadolol	Propranolol	28	Medium	Yes	Not applicable	No	Low
Tfelt-Hansen, 1984 ⁶⁰				Medium				
Standnes, 1982 ⁶¹				Medium				
Pooled	Timolol	Propranolol	242	Medium	Yes	Yes	No	Low
Gerber, 1991 ⁷¹	Propranolol	Nifedipine	36	Medium				Low
Albers, 1989 ⁷⁴	Propranolol	Nifedipine	40	High				Low
Pooled	Propranolol	Nifedipine	76	High	Yes	Yes	No	Low
Domingues, 2009 ⁷⁵	Propranolol	Nortriptyline	49	Medium	Yes	Not applicable	No	Low
Ziegler, 1987 ⁷⁶	Propranolol	Amitriptyline	108	Medium	Yes	Not applicable	Yes	Low
Kangasniemi, 1983 ⁷⁷	Propranolol	Femoxetine	29	Medium	Yes	Not applicable	No	Low
Domingues, 2009 ⁷⁵	Nortriptyline	Propranolol + Nortriptyline	51	Medium	Yes	Not applicable	No	Low
Domingues, 2009 ⁷⁵	Propranolol	Propranolol + Nortriptyline	52	Medium	Yes	Not applicable	No	Low
Silberstein, 2012 ⁷⁸	Propranolol	Propranolol+ Topiramate	191	Medium	Yes	Not applicable	No	Low

Appendix Table D35. Migraine prevention with propranolol, results from randomized controlled clinical trials

Definition Outcomes	Reference Risk of Bias	Active Drug, Daily Dose	Control, Daily Dose	Events/ Randomized with Active Drug	Events/ Randomized with Control	Rate,% with Active [Control] Treatments	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
≥50% reduction of average monthly migraine frequency	Tfelt-Hansen, 1984 ⁶⁰ Medium	80 mg b.i.d. (plus timolol placebo)	Placebo	48/96	12/48	50.0 [25.0]	2.0 (1.2 to 3.4)	0.25 (0.09 to 0.41)
≥50% reduction of average monthly migraine frequency	Diener, 2004 ⁴³ Low	160 mg/d	Placebo	62/144	11/49	43.1 [21.9]	1.9 (1.1 to 3.3)	0.21 (0.06 to 0.35)
≥50% reduction of average monthly migraine frequency	Diamond, 1976 ⁵⁰ Medium	80 or 160 mg	Placebo	34/83	17/83	41.0 [20.5]	2.0 (1.2 to 3.3)	0.21 (0.07 to 0.34)
≥50% reduction of average monthly migraine frequency	Standnes, 1982 ⁶¹ Medium	80 mg + (timolol placebo)	Placebo	13/25	3/13	52.0 [24.0]	2.3 (0.8 to 6.5)	0.29 (-0.01 to 0.59)
≥50% reduction of average monthly migraine frequency	Pooled Medium	80-160mg	Placebo	157/348	43/193	45.1 [22.3]	2.0 (1.5 to 2.7)	0.22 (0.14 to 0.30)
Heterogeneity							P value = 0.9 I squared = 0%	P value = 0.9 I squared = 0%
≥50% reduction of average monthly migraine frequency	Diener, 2004 ⁴³ Risk of bias Low	Topiramate 100 mg/d	Propranolol 160 mg/d	52/141	62/144	36.9 [43.1]	0.9 (0.6 to 1.1)	-0.06 (-0.18 to 0.05)

Appendix Table D35. Migraine prevention with propranolol, results from randomized controlled clinical trials (continued)

Definition Outcomes	Reference Risk of Bias	Active Drug, Daily Dose	Control, Daily Dose	Events/ Randomized with Active Drug	Events/ Randomized with Control	Rate,% with Active [Control] Treatments	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
≥ 50% reduction of average monthly migraine frequency	Diener, 2004 ⁴³ Risk of bias Low	Topiramate 200 mg/d	Propranolol 160 mg/d	50/144	62/144	34.7 [43.1]	0.8 (0.6 to 1.1)	-0.08 (-0.20 to 0.03)
Greater than 50% reduction in 28 day rate of moderate to severe headaches	Silberstein, 2012 ⁷⁸ Risk of bias medium	Propranolol, 240 mg/day + topiramate 88 mg/day	Topiramate 88 mg/day	26/96	23/95	27 [24]	1.1 (0.7 to 1.8)	0.03 (-0.10 to 0.15)
Patients responding with a 50% or greater reduction in mean migraine frequency (month)	Kaniecki, 1997 ⁶⁸ Risk of bias High	Divalproex Mean dose: 1414mg/d	Propranolol Mean dose: 174mg/d	21/37	20/37	56.8 [54.1]	1.1 (0.7 to 1.6)	0.03 (-0.20 to 0.25)
Patients responding with a 50% or greater reduction in mean migraine days (month)	Kaniecki, 1997 ⁶⁸ Risk of bias High	Divalproex Mean dose: 1414mg/d	Propranolol Mean dose: 174mg/d	21/37	22/37	56.8 [59.5]	1.0 (0.6 to 1.4)	-0.03 (-0.25 to 0.20)
>50% reduction of headache days, 4 weeks (comparing pretreatment period with the last 4 wks of treatment)	Kass, 1980 ⁶⁹ Risk of bias Medium	Propranolol 160 mg (two 40 mg tablets twice daily)	Clonidine 100 µg (two 25 µg tablets twice daily)	13/23	8/23	56.5 [34.8]	1.6 (0.8 to 3.2)	0.22 (-0.06 to 0.50)

Appendix Table D35. Migraine prevention with propranolol, results from randomized controlled clinical trials (continued)

Definition Outcomes	Reference Risk of Bias	Active Drug, Daily Dose	Control, Daily Dose	Events/ Randomized with Active Drug	Events/ Randomized with Control	Rate,% with Active [Control] Treatments	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
≥50% reduction of the sum of severity scores	Kangasniemi, 1984 ⁷⁰ Risk of bias Medium	Propranolol 80 mg b.i.d.	Metoprolol 200 mg o.m.	15/36	17/36	41.7 [47.2]	0.9 (0.5 to 1.5)	-0.06 (-0.29 to 0.17)
Responder of Migraine days	Gerber, 1991 ⁷¹ Risk of bias Medium	Propranolol Hydrochloride 160 m/day (HD)	Metoprolol 200 mg / day (HD)	6/19	12/22	31.6 [54.5]	0.6 (0.3 to 1.2)	-0.23 (-0.53 to 0.07)
	Pooled with random effects model	Propranolol	Metoprolol	21/55	29/58	38.2 [50.0]	0.8 (0.5 to 1.2)	-0.12 (-0.30 to 0.06)
	Heterogeneity						p=0.371 (I-squared (variation in RR Attributable Due heterogeneity)=0.0%)	p=0.361 (I-squared (variation in RD Attributable Due heterogeneity)=0.0%)
≥50% reduction of frequency of distinct headache	Sudilovsky, 1987 ⁷² Risk of bias Medium	Propranolol Hydrochloride 80 mg b.i.d.	Nadolol 80 mg o.d.	4/44	13/49	9.1 [26.5]	0.3 (0.1 to 1.0)	-0.17 (-0.32 to -0.02)
≥50% reduction of frequency of distinct headache	Sudilovsky, 1987⁷² Risk of bias Medium	Propranolol Hydrochloride 80 mg b.i.d.	Nadolol 160 mg o.d.	4/44	17/47	9.1 [36.2]	0.3 (0.1 to 0.7)	-0.27 (-0.43 to -0.11)
≥50% reduction of frequency of distinct headache	Sudilovsky, 1987 ⁷² Risk of bias Medium	Propranolol Hydrochloride 80 mg b.i.d.	Nadolol 80 mg o.d.	5/44	11/49	11.4 [22.4]	0.5 (0.2 to 1.3)	-0.11 (-0.26 to 0.04)
≥50% reduction of frequency of distinct headache	Sudilovsky, 1987⁷² Risk of bias Medium	Propranolol Hydrochloride 80 mg b.i.d.	Nadolol 160 mg o.d.	5/44	18/47	11.4 [38.3]	0.3 (0.1 to 0.7)	-0.27 (-0.44 to -0.10)
≥50% reduction of headache intensity	Sudilovsky, 1987 ⁷² Risk of bias Medium	Propranolol Hydrochloride 80 mg b.i.d.	Nadolol 80 mg o.d.	8/44	14/49	18.2 [28.6]	0.6 (0.3 to 1.4)	-0.10 (-0.27 to 0.07)

Appendix Table D35. Migraine prevention with propranolol, results from randomized controlled clinical trials (continued)

Definition Outcomes	Reference Risk of Bias	Active Drug, Daily Dose	Control, Daily Dose	Events/ Randomized with Active Drug	Events/ Randomized with Control	Rate,% with Active [Control] Treatments	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
≥50% reduction of headache intensity	Sudilovsky, 1987 ⁷² Risk of bias Medium	Propranolol Hydrochloride 80 mg b.i.d.	Nadolol 160 mg o.d.	8/44	19/47	18.2 [40.4]	0.4 (0.2 to 0.9)	-0.22 (-0.40 to -0.04)
≥50% reduction of headache intensity	Sudilovsky, 1987 ⁷² Risk of bias Medium	Propranolol Hydrochloride 80 mg b.i.d.	Nadolol 80 mg o.d.	10/44	11/49	22.7 [22.4]	1.0 (0.5 to 2.2)	0.00 (-0.17 to 0.17)
≥50% reduction of headache intensity	Sudilovsky, 1987 ⁷² Risk of bias Medium	Propranolol Hydrochloride 80 mg b.i.d.	Nadolol 160 mg o.d.	10/44	21/47	22.7 [44.7]	0.5 (0.3 to 1.0)	-0.22 (-0.41 to -0.03)
≥50% reduction of pain days	Sudilovsky, 1987 ⁷² Risk of bias Medium	Propranolol Hydrochloride 80 mg b.i.d.	Nadolol 80 mg o.d.	8/44	9/49	18.2 [18.4]	1.0 (0.4 to 2.3)	0.00 (-0.16 to 0.16)
≥50% reduction of pain days	Sudilovsky, 1987 ⁷² Risk of bias Medium	Propranolol Hydrochloride 80 mg b.i.d.	Nadolol 160 mg o.d.	8/44	19/47	18.2 [40.4]	0.4 (0.2 to 0.9)	-0.22 (-0.40 to -0.04)
≥50% reduction of pain days	Sudilovsky, 1987 ⁷² Risk of bias Medium	Propranolol Hydrochloride 80 mg b.i.d.	Nadolol 80 mg o.d.	9/44	11/49	20.5 [22.4]	0.9 (0.4 to 2.0)	-0.02 (-0.19 to 0.15)
≥50% reduction of pain days	Sudilovsky, 1987 ⁷² Risk of bias Medium	Propranolol Hydrochloride 80 mg b.i.d.	Nadolol 160 mg o.d.	9/44	18/47	20.5[38.3]	0.5 (0.3 to 1.1)	-0.18 (-0.36 to 0.00)
>50% reduction of number of migraine attacks compared to placebo period	Sudilovsky, 1987 ⁷² Risk of bias Medium	Nadolol 80 mg/daily (every morning + matching placebo tablet every night)	Propranolol 80 mg (40 mg twice daily)	5/13	9/15	38.5 [60.0]	0.6 (0.3 to 1.4)	-0.22 (-0.58 to 0.15)
Responder of Migraine days	Gerber, 1991 ⁷¹ Risk of bias Medium	Propranolol Hydrochloride 80 mg/day	Nifedipine 20 mg/day	0/19	0/17	0.0 [0.0]	0.0 (0.0 to 0.0)	0.00 (-0.10 to 0.10)

Appendix Table D35. Migraine prevention with propranolol, results from randomized controlled clinical trials (continued)

Definition Outcomes	Reference Risk of Bias	Active Drug, Daily Dose	Control, Daily Dose	Events/ Randomized with Active Drug	Events/ Randomized with Control	Rate,% with Active [Control] Treatments	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Responder of Migraine days	Gerber, 1991 ⁷¹ Risk of bias Medium	Propranolol Hydrochloride 40 mg/day	Nifedipine 10 mg/day	3/19	0/17	15.8 [0.0]	6.3 (0.3 to 113.8)	0.16 (-0.03 to 0.34)
Responder of Migraine days	Gerber, 1991 ⁷¹ Risk of bias Medium	Propranolol Hydrochloride 120 mg/day	Nifedipine 30 mg/day	4/19	2/17	21.1 [11.8]	1.8 (0.4 to 8.6)	0.09 (-0.15 to 0.33)
Responder of Migraine days	Gerber, 1991 ⁷¹ Risk of bias Medium	Propranolol Hydrochloride 160 mg/day	Nifedipine 40 mg/day	6/19	1/17	31.6 [5.9]	5.4 (0.7 to 40.2)	0.26 (0.02 to 0.49)
Drug efficacy: >50% improvement	Albers, 1989 ⁷⁴ Risk of bias High	Propranolol 60 mg TID	Nifedipine 30 mg TID	12/20	6/20	60.0 [30.0]	2.0 (0.9 to 4.3)	0.30 (0.01 to 0.59)
Reduction by 50% or more in migraine days	Pooled with random effects models^{71, 74}	Propranolol 160-180mg	Nifedipine	18/39	7/37	46.2 [18.9]	2.3 (1.1 to 4.6)	0.27 (0.09 to 0.46)
	Heterogeneity						p=0.368 (I-squared (variation in RR Attributable Due heterogeneity)=0.0%	p=0.823 (I-squared (variation in RD Attributable Due heterogeneity)=0.0%
≥50% reduction of the number of days with headache	Domingues, 2009 ⁷⁵ Risk of bias Medium	Propranolol 40 mg/d	Nortriptyline 20 mg/d	11/25	7/24	33.3 [39.3]	1.5 (0.7 to 3.2)	0.15 (-0.12 to 0.41)
Good response: fall in headache score (compared with placebo treatment) of 50% or more	Ziegler, 1987 ⁷⁶ Risk of bias Medium	Propranolol 80-240 mg/d	Amitriptyline 50-150 mg/d	12/54	10/54	19.2 [21.4]	1.2 (0.6 to 2.5)	0.04 (-0.11 to 0.19)
>50% reduction of frequency of attack	Kangasniemi, 1983 ⁷⁷ Risk of bias Medium	Propranolol 80 mg twice a day	Femoxetine 200 mg twice a day	3/15	1/14	20.0 [7.1]	2.8 (0.3 to 23.9)	0.13 (-0.11 to 0.37)

Appendix Table D35. Migraine prevention with propranolol, results from randomized controlled clinical trials (continued)

Definition Outcomes	Reference Risk of Bias	Active Drug, Daily Dose	Control, Daily Dose	Events/ Randomized with Active Drug	Events/ Randomized with Control	Rate,% with Active [Control] Treatments	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
≥50% reduction of the number of days with headache	Domingues, 2009 ⁷⁵ Risk of bias Medium	Nortriptyline 20 mg/d	Propranolol + Nortriptyline	7/24	10/27	29.2 [37.0]	0.8 (0.4 to 1.7)	-0.08 (-0.34 to 0.18)
≥ 50% reduction of the number of days with headache	Domingues, 2009 ⁷⁵ Risk of bias Medium	Propranolol 40 mg/d	Propranolol + Nortriptyline	11/25	10/27	44.0 [37.0]	1.2 (0.6 to 2.3)	0.07 (-0.20 to 0.34)

Bold = significant at 95% confidence limit. Bold differences are statistically significant when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

CI = confidence interval

Appendix Table D36. Reduction in frequency of migraine attack by $\geq 50\%$ from baseline with timolol 10mg twice a day (pooled with random effects model results from randomized controlled clinical trials)

Reference Risk of Bias	Events/ Randomized with Active Drug	Events/ Randomized with Placebo	Rate,% with Active Drug [Placebo]	Relative Risk (95% CI)	Weight, Random Effects Inverse Variance	Absolute Risk Difference (95% CI)	Weight, Random Effects Inverse Variance
Tfelt-Hansen, 1984 ⁶⁰ Medium	44/96	12/48	45.8[25.0]	1.8 (1.1 to 3.1)	49.32	0.21 (0.05 to 0.37)	49.78
Standnes, 1982 ⁶¹ Medium	14/25	3/13	56.0[24.0]	2.4 (0.8 to 6.9)	12.82	0.33 (0.03 to 0.63)	13.75
Stellar, 1984 ⁷⁹ Medium	25/47	10/47	53.2[21.3]	2.5 (1.4 to 4.6)	37.86	0.32 (0.14 to 0.50)	36.47
Pooled	83/168	25/108	49.4[23.3]	2.1 (1.5 to 3.1)	100	0.27 (0.15 to 0.38)	100
Heterogeneity test				p = 0.732	I-squared=0.0%	p = 0.606	I-squared = 0.0%

CI = confidence interval. Bold- differences are statistically significant when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

Appendix Table D37. Strength of evidence of migraine prevention with timolol

Sample Size, References	Risk of Bias	Directness	Consistency	Precision	Strength of Evidence
Tfelt-Hansen, 1984 ⁶⁰ Standnes, 1982 ⁶¹ Stellar, 1984 ⁷⁹ 276 ^{60, 61, 79}	Medium	Yes	Yes	No	Low

Appendix Table D38. Reduction in migraine attack frequency and severity with timolol 10mg twice a day (results from randomized controlled clinical trial⁶⁰)

Outcomes	Mean [Standard Deviation] with Drug	Mean [Standard Deviation] with Placebo	Mean Difference (95% CI)	Cohen Standardized Mean Difference (95% CI)	Mean Ratio (95% CI)
Frequency of attacks	3.4 [3.1]	4.8 [3.9]	-1.5 (-2.5 to -0.5)	-0.4 (-0.7 to -0.1)	0.7 (0.5 to 1.0)
Number of attacks (4 weeks)	2.8 [NR]	4.7 [NR]	P<0.01		
Duration of attacks (hours)	7.4 [7.3]	8.0 [6.7]	-0.5 (-2.5 to 1.4)	-0.1 (-0.4 to 0.2)	0.9 (0.7 to 1.3)
Frequency of attacks with any therapy	2.8 [3.0]	4.2 [3.7]	-1.4 (-2.4 to -0.4)	-0.4 (-0.7 to -0.1)	0.7 (0.5 to 0.9)
Frequency of attacks with nausea	1.4 [1.9]	1.9 [2.1]	-0.5 (-1.0 to 0.1)	-0.2 (-0.5 to 0.0)	0.7 (0.6 to 0.9)
Headache index (2) (frequency x average severity)	41.7 [50.2]	69.3 [69.4]	-27.6 (-44.7 to -10.5)	-0.5 (-0.7 to -0.2)	0.6 (0.5 to 0.8)
Headache index (1) (frequency x average severity)	5.7 [5.1]	9.0 [7.3]	-3.3 (-5.1 to -1.5)	-0.5 (-0.8 to -0.2)	0.6 (0.5 to 0.9)
Severity of attacks	1.8 [0.6]	1.9 [0.5]	-0.2 (-0.3 to 0.0)	-0.4 (-0.6 to -0.1)	0.9 (0.3 to 2.6)

Bold = significant at 95% confidence limit when 95% CI of mean difference estimates do not include 0

CI = confidence interval

Appendix Table D39. Randomized controlled clinical trials that examined off label anti-epileptic drugs for migraine prevention in adults

Active Drug	Reference Sample Number Analyzed % Women	Definition of Migraine % Without Aura	Baseline Severity	Eligible Age of Subjects	Years of Migraine % with prior Preventative Treatment
Acetazolamide	Vahedi, 2002 ⁸⁰ Sample 53 Analyzed 53 % of women 75.5	Migraine (International Headache Society) % without aura 90.6	Attack frequency (4wks): 5	18-65 Mean: 39.2	Years of migraine NR % with prior treatment NR
Gabapentin	Mathew, 2001 ⁸¹ Sample 145 Analyzed 87 % of women 82.8	Migraine (International Headache Society) % without aura 56.3	Migraine headache frequency during last 6 months: 4.9	16-75 Mean: 39.6	Years of migraine 20.8 % with prior treatment NR
Vigabatrin	Ghose, 2002 ⁸² Sample 23 Analyzed 15 % of women 73.9	Migraine (International Headache Society) % without aura 56.5	Headache frequency (1 week): 2.14	NR (range: 18-66) Mean: 43.6	Years of migraine NR % with prior treatment Sodium Valproate: 65.2%
Oxcarbazepine	Silberstein, 2008 ⁸³ Sample 170 Analyzed 170 % of women 84.7	Migraine (International Headache Society) % without aura NR	Frequency of migraine headache per month (range, inclusion criteria): 3 to 9	16-65 Mean: 40.5	Years of migraine NR % with prior treatment NR
Gabapentin	Wessely, 1987 ⁸⁴ Sample 45 Analyzed 33 % of women 88.9	Common or classic migraine % without aura NR	Frequency of migraine headache per month: 5.23	NR Mean: 43	Years of migraine NR % with prior treatment NR
Gabapentin	Di Trapani, 2000 ⁸⁵ Sample 63 Analyzed 63 % of women 52.4	Migraine with or without aura according to the international Headache Society Classification of Headache % without aura 50.8	Frequency of migraine attack: 5.24	18-65 NR	Years of migraine NR % with prior treatment NR
Carbamazepine	Rompel, 1970 ⁸⁶ Sample NR Analyzed 48 % of women 68.8	"Typical Migraine" % without aura NR	Frequency of migraine attack: 2.97	NR (range: 14-60) NR	Years of migraine NR % with prior treatment NR
Lamotrigine	Steiner, 1997 ⁸⁷ Sample 77 Analyzed 77 % of women 81.8	Migraine (International Headache Society) % without aura 59.7	Frequency of migraine attack: 4.02	18-60 Mean: 37.2	Years of migraine NR (At least 2 years of recognizable attacks was required at entry) % with prior treatment NR

NR = not reported

Appendix Table D40. Funding and conflict of interest in randomized controlled clinical trials that examined off label anti-epileptic drugs for migraine prevention in adults

Active drug	Reference	Funding	Ethical Approval	Consent	Conflict of Interest	Disclosed Relationships
Acetazolamide	Vahedi, 2002 ⁸⁰	Unclear (Funded from Association pour le Developpement des Neurosciences a Lariboisiere)	Yes	Yes	Not reported	All authors are employed in a hospital.
Gabapentin	Mathew, 2001 ⁸¹	Not reported	Yes	Yes	Not reported	Not reported
Vigabatrin	Ghose, 2002 ⁸²	Industry	Yes	Yes	Not reported	Not reported
Oxcarbazepine	Silberstein, 2008 ⁸³	Industry	Yes	Yes	Yes	S. Silberstein has received grants for other research or activities not reported in this article and has received honoraria during the course of this study from Novartis Pharmaceuticals Corporation, not in excess of US \$10,000 per year. J. Saper has received honoraria from Novartis Pharmaceuticals Corporation, not in excess of US \$10,000 per year, during the course of this study for other activities not reported in this article. F. Berenson has received honoraria from Novartis Pharmaceuticals Corporation, not in excess of US \$10,000 per year, during the course of this study for other activities not reported in this article. M. Somogyi, K. McCague and J. D'Souza are employees of Novartis Pharmaceuticals Corporation.
Gabapentin	Wessely, 1987 ⁸⁴	Not reported	Not reported	Not reported	Not reported	Not reported
Gabapentin	Di Trapani, 2000 ⁸⁵	Not reported	Not reported	Yes	Not reported	Not reported
Carbamazepine	Rompel, 1970 ⁸⁶	Industry supplied the drugs.	Not reported	Not reported	Not reported	Not reported
Lamotrigine	Steiner, 1997 ⁸⁷	Not reported	Yes	Yes	Not reported	Not reported

Appendix Table D41. Risk of bias in randomized controlled clinical trials that examined off label anti-epileptic drugs for migraine prevention in adults

Reference	Masking of Treatment Status	Planned Intention to Treat	Allocation Concealment	Adequacy of Randomization	Baseline Migraine Similarity	Selective Outcome Reporting	Risk of Bias
Vahedi, 2002 ⁸⁰	DB	Yes	Yes	Yes	D	Unclear	Low
Mathew, 2001 ⁸¹	DB	Yes	Yes	No	F, S & D	Unclear	Medium
Ghose, 2002 ⁸²	DB	No	Unclear	Not reported	F	Unclear	Medium
Silberstein, 2008 ⁸³	DB	Yes	Yes	Yes	F, S & D (D: age at onset provided)	Unclear	Low
Wessely, 1987 ⁸⁴	DB	No	Unclear	Not reported	Not reported	Unclear	Medium
Di Trapani, 2000 ⁸⁵	DB	No	Unclear	Yes	F & S	Unclear	Medium
Rompel, 1970 ⁸⁶	DB	No	Unclear	Not reported	Not reported	Unclear	Medium
Steiner, 1997 ⁸⁷	DB	Yes	Unclear	Not reported (No formal testing conducted, and no mention about the random adequacy)	Not reported (No formal testing conducted, and no mention about the random adequacy)	Unclear	Low

DB = double-blind

F = frequency

D = duration

S = severity

Appendix Table D42. Randomized controlled clinical trials that examined efficacy of beta-blockers for migraine prevention in adults

Reference Aim	Total Sample [Number Analyzed] % Females in Sample	Definition of Migraine	Duration of Migraine	Presence of Aura	Migraine Frequency at Baseline/Month	Age of Subjects (Mean or Median)
Ekbom, 1972 ⁸⁸ To investigate the effect of beta-receptor blocking agents on migraine by using a new compound, LB-46 (d,1-4-indol)	30 [26] 86.7	Ad Hoc Committee, 1962	Not reported	Since 4 had classic migraine it was assumed that these patients had migraine with aura	4	Mean 33.7 years
Sjaastad, 1972 ⁸⁹ To test the efficacy of Visken (LB-46) in migraine prophylaxis with a double-blind technique	28 [24] 85.7	Ad Hoc Committee on classification of headache (1962)	Not reported	Since 14 patients had classical migraine it was assumed that they had migraine with aura	2	Mean 35.8 years
Ekbom, 1975 ⁹⁰ Not reported	33 [28] 81.8	Ad Hoc Committee on classification of headache and World Federation of Neurology's Research Group on Migraine and Headache	Not reported	Since 6 patients had classic migraine it was assumed that these patients had migraine with aura	3	Mean 41.3 years
Nanda, 1978 ⁹¹ Not reported	43 [33] 74.4	Migraine with the following characteristics: 1) Onset of first attack before age 25 years; 2) No evidence of a progressive neurological deficit over three years; 3) Hemicrania in association with any two of the following: a) family history, b) nausea and vomiting, and c) psychic, visual, or sensory prodroma	Not reported	Not reported	4.8	Not reported
Briggs, 1979 ⁹² To assess the value of timolol in migraine prophylaxis and to elucidate further the reason for the varied response to different beta-blockers.	14 [Variable] 71.4	Ad Hoc Committee on classification of headache	Not reported	Since 2 patients had classical it was assumed that these patients had migraine with aura	2	Not reported

Appendix Table D42. Randomized controlled clinical trials that examined efficacy of beta-blockers for migraine prevention in adults (continued)

Reference Aim	Total Sample [Number Analyzed] % Females in Sample	Definition of Migraine	Duration of Migraine	Presence of Aura	Migraine Frequency at Baseline/Month	Age of Subjects (Mean or Median)
Ryan, 1982 ⁹³ Ryan, 1983 ⁹⁴ To determine the relative efficacy and safety of nadolol in reducing the frequency and/or the severity of migraine attacks as compared to placebo	80 [80] 77.5	Not reported	Not reported	Not reported	3	Not reported
Forssman, 1982 ⁹⁵ Forssman, 1983 ⁹⁶ To confirm the use of atenolol in migraine prophylaxis in a double-blind cross-over study with placebo	24 [20] 80.0	Ad Hoc Committee on classification of headache	Not reported	Since the definition of migraine was according to the Ad Hoc Committee classification it was assumed that none of the patients had aura	Not reported	Mean 40 years
Andersson, 1983 ⁹⁷ To evaluate whether metoprolol decreases 1) the frequency, 2) the severity of the migraine attacks, 3) days with migraine, 4) consumption of acute migraine medication, compared with placebo in patients with classical and non-classical migraine	71 [65] 84.5	Vahlquist's criteria and World Federation of Neurology Research Group on Migraine and Headache	18.4 years	Not reported	4.8	Mean 39.7 years
Stellar, 1984 ⁷⁹ To compare timolol with placebo	107 [94] 72.0	Ad Hoc Committee on Classification of Headache.	Not reported	Since 5 patients had classic migraine it was assumed that they had migraine with aura.	3	Mean 43 years
Freitag, 1984 ⁹⁸ To evaluate the efficacy of nadolol in reducing the frequency and severity of migraine headaches	32 [32] 81.3	Ad Hoc Committee on classification of headache	Not reported	Not reported	Not reported	Mean 36.3 years

Appendix Table D42. Randomized controlled clinical trials that examined efficacy of beta-blockers for migraine prevention in adults (continued)

Reference Aim	Total Sample [Number Analyzed] % Females in Sample	Definition of Migraine	Duration of Migraine	Presence of Aura	Migraine Frequency at Baseline/Month	Age of Subjects (Mean or Median)
Johannsson, 1987 ⁹⁹ To investigate the prophylactic anti-migraine effect of atenolol, a cardiovascular, water-soluble beta-antagonist	72 [63] 69.8	Ad Hoc Committee on classification of headache	26 years	Since the definition of migraine was according to the Ad Hoc Committee classification it was assumed that none of the patients had aura	2	Mean 43 years
Kangasneimi, 1987 ¹⁰⁰ To compare metoprolol with placebo in patients with frequent classic migraine attacks	77 [74] 79.7	NIH Ad Hoc Committee	17.2 years	Since all had classic migraine it was assumed all had migraine with aura	4.3	Mean 37.5 years
van de Ven, 1997 ¹⁰¹ To assess the efficacy of bisoprolol in migraine prophylaxis	226 [Not reported] 82.0	Not reported	Age at onset (years): 20.3	23% of patients had migraine with aura and 77% migraine without aura	5.5	Mean 38.7 years
Siniatchkin, 2007 ¹⁰² To investigate the influence of a controlled-release (CR) form of metoprolol on the amplitude and habituation of the early and late control negative variation (CNV) components using a double-blind, placebo-controlled, parallel-group design with systematic multiple CNV recordings during the treatment phase in order to provide more complete analysis of the treatment process.	20 [20] 85.0	International Headache Society criteria	22.3 years	One of the inclusion criteria was patients having migraine without aura	4.6	Mean 37 years

Appendix Table D43. Funding and conflict of interest in randomized controlled clinical trials that examined efficacy of beta-blockers for migraine prevention in adults

Reference	Funding	Ethical Approval	Consensus	Conflict of Interest
Ekbom, 1972 ⁸⁸	Not reported	Not reported	Not reported	Not reported
Sjaastad, 1972 ⁸⁹	Not reported	Not reported	Not reported	Not reported
Ekbom, 1975 ⁹⁰	Not reported (however, alprenolol was donated by AB Hassle, Gothenburg, Sweden)	Not reported	Not reported	Not reported
Nanda, 1978 ⁹¹	Grant	Not reported	Yes	Not reported
Briggs, 1979 ⁹²	Not reported	Yes	Yes	Not reported
Ryan, 1982 ⁹³ Ryan, 1983 ⁹⁴	Not reported	Not reported	Yes	Not reported
Forssman, 1982 ⁹⁵ Forssman, 1983 ⁹⁶	Not reported	Not reported	Not reported	Not reported
Andersson, 1983 ⁹⁷	Not reported	Yes	Yes	Not reported
Stellar, 1984 ⁷⁹	Not reported	Not reported	Yes	Not reported
Freitag, 1984 ⁹⁸	Not reported	Not reported	Yes	Not reported
Johannsson, 1987 ⁹⁹	Not reported	Not reported	Not reported	Not reported
Kangasneimi, 1987 ¹⁰⁰	Not reported	Yes	Yes	Not reported
van de Ven, 1997 ¹⁰¹	Industry	Yes	Yes	Not reported
Siniatchkin, 2007 ¹⁰²	Not reported	Yes	Yes	Not reported

Appendix Table D44. Risk of bias in randomized controlled clinical trials that examined efficacy of beta-blockers for migraine prevention in adults

Reference	Masking of the Treatment Status	Intention to Treat Analysis Preplanned	Allocation Concealment	Adequacy of Randomization	Baseline Similarity	Selective Outcome Reporting	Risk of Bias
Ekbom, 1972 ⁸⁸	Double-blind	No	Unclear	Yes	Frequency: similar; Severity: similar; Duration: similar	Unclear	Medium
Sjaastad, 1972 ⁸⁹	Double-blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Ekbom, 1975 ⁹⁰	Double-blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Nanda, 1978 ⁹¹	Double-blind	No	Unclear	Not reported	Frequency: similar; Severity: not reported; Duration: not reported	Unclear	Medium
Briggs, 1979 ⁹²	Double-blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Ryan, 1982 ⁹³	Double-blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Ryan, 1983 ⁹⁴							
Forssman, 1982 ⁹⁵	Double-blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Forssman, 1983 ⁹⁶							
Andersson, 1983 ⁹⁷	Double-blind	No	Unclear	Not reported. However, there were more males in metoprolol group (9/34 as compared to placebo group (2/37); the metoprolol group patients had more years of migraine (22.6 years) as compared to the placebo group (14.6 years)	The metoprolol group patients had more years of migraine (22.6 years) as compared to the placebo group (14.6 years). Frequency and severity of migraine were similar across the groups	Unclear	Medium
Stellar, 1984 ⁷⁹	Double-blind	Yes	Unclear	Not adequate (The frequency of headaches with unilateral pain was significantly greater ($p<0.05$) in the timolol-placebo sequence group than in the placebo-timolol group)	Frequency: similar; Severity: similar; Duration: similar	Unclear	Medium

Appendix Table D44. Risk of bias in randomized controlled clinical trials that examined efficacy of beta-blockers for migraine prevention in adults (continued)

Reference	Masking of the Treatment Status	Intention to Treat Analysis Preplanned	Allocation Concealment	Adequacy of Randomization	Baseline Similarity	Selective Outcome Reporting	Risk of Bias
Freitag, 1984 ⁹⁸	Double-blind	Yes	Unclear	Not reported	Not reported	Unclear	Low
Johannsson, 1987 ⁹⁹	Double-blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Kangasneimi, 1987 ¹⁰⁰	Double-blind	No	Unclear	Not reported	Not reported	Unclear	Medium
van de Ven, 1997 ¹⁰¹	Double-blind	Yes	Unclear	Yes	Frequency: similar; Severity: similar; Duration: similar	Unclear	Medium
Siniatchkin, 2007 ¹⁰²	Double-blind	No	Unclear	Yes	Frequency: similar; Severity: similar; Duration: similar	Unclear	Medium

Appendix Table D45. Strength of evidence of migraine prevention with beta-blockers in adults (sorted by drug name)

Definition of the Outcome	Drug Name	Reference	Risk of Bias	Directness	Consistency	Precision	Strength of Evidence
Better during the period of the trial	Acebutolol	Nanda, 1978 ⁹¹	Medium	Yes	Not applicable	Yes	Low
Better during the period of the trial	Alprenolol	Ekbom, 1975 ⁹⁰	Medium	Yes	Not applicable	No	Low
Reduction of integrated headache more than 50%	Atenolol	Forssman, 1982 ⁹⁵ Forssman, 1983 ⁹⁶	Medium	Yes	Not applicable	Yes	Low
Reduction of number of attacks more than 50%	Atenolol	Forssman, 1982 ⁹⁵ Forssman, 1983 ⁹⁶	Medium	Yes	Not applicable	Yes	Low
Consumption of ergotamine drugs	Atenolol	Forssman, 1982 ⁹⁵ Forssman, 1983 ⁹⁶	Medium	Yes	Not applicable	Yes	Low
Patients' subjective judgment of their migraine: complete remission/marked improvement	Metoprolol	Kangasneimi, 1987 ¹⁰⁰	Medium				
Effect: marked or moderate	Metoprolol	Andersson, 1983 ⁹⁷	Medium				
Pooled	Metoprolol		Medium	Yes	Yes	No	Low
Patients' subjective judgment of their migraine: Medium improvement	Metoprolol	Kangasneimi, 1987 ¹⁰⁰	Medium	Yes	Not applicable	No	Low
Effect: slight	Metoprolol	Andersson, 1983 ⁹⁷	Medium	Yes	Not applicable	No	Low
Treatment successful: Frequency	Nadolol	Freitag, 1984 ⁹⁸	Low	Yes	Not applicable	No	Low
Treatment successful: Intensity	Nadolol	Freitag, 1984 ⁹⁸	Low	Yes	Not applicable	No	Low
Treatment successful: Pain	Nadolol	Freitag, 1984 ⁹⁸	Low	Yes	Not applicable	No	Low
Treatment successful: Relief	Nadolol	Freitag, 1984 ⁹⁸	Low	Yes	Not applicable	No	Low
Completely relieved of migraine	Timolol	Briggs, 1979 ⁹²	Medium	Yes	Not applicable		Low
Responders (Patients with 50% or greater reduction in headache frequency)	Timolol	Stellar, 1984 ⁷⁹	Medium	Yes	Not applicable	No	Low
Global response of great or moderate improvement: to only one therapy	Timolol	Stellar, 1984 ⁷⁹	Medium	Yes	Not applicable	No	Low
Patient rating of medication as extremely or moderately helpful: to only one therapy	Timolol	Stellar, 1984 ⁷⁹	Medium	Yes	Not applicable	No	Low
Headaches with nausea: frequency per 28 days	Timolol	Stellar, 1984 ⁷⁹	Medium	Yes	Not applicable	No	Low

Appendix Table D46. Efficacy of beta-blockers in prevention of migraine in adults; results from randomized controlled clinical trials (sorted by drug name)

Reference Risk of Bias	Drug and Dose	Outcome	Events/ Randomized [Rate of Outcome with Drug, %]	Events/ Randomized [Rate of Outcome with Placebo, %]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events per 1000 Treated (95% CI)
Ekbom, 1975 ⁹⁰ Medium	Alprenolol 200mg/day ("Durules")	Better during the period of the trial	11/33 [33.3%]	12/33 [36.4%]	0.9 (0.5 to 1.8)	-0.03 (-0.26 to 0.2)		
Forssman, 1982 ⁹⁵ Forssman, 1983 ⁹⁶ Medium	Atenolol 100mg/day	Reduction of integrated headache more than 50%	11/24 [45.8%]	0/24 [0.0%]	23.0 (1.4 to 369.5)	0.46 (0.26 to 0.7)	2 (2 to 4)	458 (255 to 661)
Forssman, 1982 ⁹⁵ Forssman, 1983 ⁹⁶ Medium	Atenolol 100mg/day	Reduction of number of attacks more than 50%	8/24 [33.3%]	0/24 [0.0%]	17.0 (1.0 to 278.9)	0.33 (0.14 to 0.5)	3 (2 to 7)	333 (140 to 527)
Forssman, 1982 ⁹⁵ Forssman, 1983 ⁹⁶ Medium	Atenolol 100mg/day	Consumption of ergotamine drugs	14/24 [58.3%]	0/24 [0.0%]	29.0 (1.8 to 460.1)	0.58 (0.38 to 0.8)	2 (1 to 3)	583 (382 to 784)
Kangasneimi, 1987 ¹⁰⁰ Medium	Metoprolol 200mg once daily ("Durules")	Patients' evaluation: complete remission/marked improvement	29/77 [38.0%]	16/77 [21.0%]	1.8 (1.1 to 3.1)	0.17 (0.03 to 0.3)	6 (3 to 36)	169 (28 to 310)
Andersson, 1983 ⁹⁷ Medium	Metoprolol 200mg once daily ("Durules")	Patients' evaluation: complete remission/marked improvement	15/34 [44.1%]	6/37 [16.2%]	2.7 (1.2 to 6.2)	0.28 (0.07 to 0.5)	4 (2 to 13)	279 (74 to 484)
		Pooled ⁹⁷⁻¹⁰⁰	44/111 [39.9%]	22/114 [19.4%]	2.0 (1.3 to 3.2)	0.20 (0.09 to 0.3)	5 (3 to 11)	204 (88 to 321)
		Heterogeneity			P value = 0.42 I squared = 0%	P value = 0.39 I squared = 0%		
Kangasneimi, 1987 ¹⁰⁰ Medium	Metoprolol 200mg once daily ("Durules")	Patients' subjective judgment of their migraine: moderate improvement	14/77 [18.0%]	15/77 [19.0%]	0.9 (0.5 to 1.8)	-0.01 (-0.14 to 0.1)		
Andersson, 1983 ⁹⁷ Medium	Metoprolol 200mg once daily ("Durules")	Patients' subjective judgment of their migraine: slight	7/34 [20.6%]	10/37 [27.0%]	0.8 (0.3 to 1.8)	-0.06 (-0.26 to 0.1)		

Appendix Table D46. Efficacy of beta-blockers in prevention of migraine in adults; results from randomized controlled clinical trials (sorted by drug name) (continued)

Reference Risk of Bias	Drug and Dose	Outcome	Events/ Randomized [Rate of Outcome with Drug, %]	Events/ Randomized [Rate of Outcome with Placebo, %]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events per 1000 Treated (95% CI)
Freitag, 1984⁹⁸ Low	Nadolol 80mg to 240mg/day	Treatment successful: Frequency	6/24 [25.0%]	0/8 [0.0%]	4.7 (0.3 to 75.0)	0.25 (0.02 to 0.5)	4 (2 to 45)	250 (22 to 478)
	Nadolol 80mg to 240mg/day	Treatment successful: Intensity	7/24 [29.2%]	0/8 [0.0%]	5.4 (0.3 to 85.3)	0.29 (0.06 to 0.5)	3 (2 to 17)	292 (58 to 525)
	Nadolol 80mg to 240mg/day	Treatment successful: Pain	7/24 [29.2%]	0/8 [0.0%]	5.4 (0.3 to 85.3)	0.29 (0.06 to 0.5)	3 (2 to 17)	292 (58 to 525)
	Nadolol 80mg to 240mg/day	Treatment successful: Relief	10/24 [41.7%]	0/8 [0.0%]	7.6 (0.5 to 116.2)	0.42 (0.17 to 0.7)	2 (2 to 6)	417 (172 to 661)
Briggs, 1979⁹² Medium	Timolol 10mg twice a day	Completely relieved of migraine	2/14 [14.3%]	0/14 [0.0%]	5.0 (0.3 to 95.6)	0.14 (-0.07 to 0.4)		
Stellar, 1984⁷⁹ Medium	Timolol 10mg twice a day	Responders (Patients with 50% or greater reduction in headache frequency)	25/47 [53.2%]	10/47 [21.3%]	2.5 (1.4 to 4.6)	0.32 (0.13 to 0.5)	3 (2 to 7)	319 (135 to 504)
	Timolol 10mg twice a day	Global response of great or moderate improvement	35/47 [74.5%]	12/47 [25.5%]	2.9 (1.7 to 4.9)	0.49 (0.31 to 0.7)	2 (2 to 3)	489 (313 to 666)
	Timolol 10mg twice a day	Patient rating of medication as extremely or moderately helpful	32/47 [68.1%]	12/47 [25.5%]	2.7 (1.6 to 4.5)	0.43 (0.24 to 0.6)	2 (2 to 4)	426 (243 to 608)

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D47. Efficacy of beta-blockers for migraine prevention in adults on intermediate outcomes of migraine frequency, duration, and severity (results from randomized controlled clinical trials) (sorted by drug name)

Reference Risk of Bias	Drug, Dose	Outcome	Randomized into Drug/Placebo Groups	Mean Difference (95% CI)
Ekbom, 1975 ⁹⁰ Medium	Alprenolol 200mg/day ("Durules")	Migraine attacks per week	33/33	0.2 (-0.9 to 1.3)
	Alprenolol 200mg/day ("Durules")	Headache index per week	33/33	0.2 (-1.7 to 2.1)
Kangasneimi, 1987 ¹⁰⁰ Medium	Metoprolol 200mg once daily ("Durules")	Day with migraine per 4 weeks	77/77	0.7 (0.1 to 1.1)
Andersson, 1983⁹⁷ Medium	Metoprolol 200mg once daily ("Durules")	Mean number of migraine days	34/37	-2.1 (-3.8 to -0.5)
Kangasneimi, 1987 ¹⁰⁰ Medium	Metoprolol 200mg once daily ("Durules")	Day with migraine per 4 weeks: aura attacks	77/77	0.8 (0.0 to 0.7)
	Metoprolol 200mg once daily ("Durules")	Mean duration (h) per attack: total	77/77	2.0 (0.2 to 2.9)
	Metoprolol 200mg once daily ("Durules")	Mean duration (h) per attack: aura attacks	77/77	1.3 (-0.3 to 2.5)
	Metoprolol 200mg once daily ("Durules")	Attack frequency per 4 weeks: total	77/77	0.7 (0.2 to 1.0)
Andersson, 1983 ⁹⁷ Medium	Metoprolol 200mg once daily ("Durules")	Mean attack frequency	34/37	-1.5 (-2.4 to -0.6)
Siniatchkin, 2007 ¹⁰² Medium	Metoprolol 200mg once daily ("Durules")	Frequency of migraine attacks	10/10	-0.9 (-2.2 to 0.4)
			Pooled ^{97, 102}	-0.5 (-2.1 to 1.1)
Kangasneimi, 1987¹⁰⁰ Medium	Metoprolol 200mg once daily ("Durules")	Attack frequency per 4 weeks: aura attacks	77/77	0.6 (0.1 to 0.6)
	Metoprolol 200mg once daily ("Durules")	Sum of intensity score per 4 weeks: total	77/77	0.9 (0.7 to 2.4)
	Metoprolol 200mg once daily ("Durules")	Sum of intensity score per 4 weeks: aura attacks	77/77	1.2 (0.3 to 1.8)
	Metoprolol 200mg once daily ("Durules")	Mean intensity score per attack: total	77/77	0.1 (0.1 to 0.4)
	Metoprolol 200mg once daily ("Durules")	Mean intensity score per attack: aura attacks	77/77	0.0 (-0.1 to 0.4)
Andersson, 1983⁹⁷ Medium	Metoprolol 200mg once daily ("Durules")	Sum of severity score (migraine days' intensity) 1=Annoying, but patient not disabled; 2=Patient partly disabled (affecting his/her ability to work); and 3=Patient disabled -unable to work or in bed)	34/37	-4.6 (-8.2 to -0.9)

Appendix Table D47. Efficacy of beta-blockers for migraine prevention in adults on intermediate outcomes of migraine frequency, duration, and severity (results from randomized controlled clinical trials) (sorted by drug name) (continued)

Reference Risk of Bias	Drug, Dose	Outcome	Randomized into Drug/Placebo Groups	Mean Difference (95% CI)
Kangasneimi, 1987 ¹⁰⁰ Medium	Metoprolol 200mg once daily ("Durules")	Sum of global ratings per 4 weeks: total	77/77	4.1 (1.3 to 6.4)
	Metoprolol 200mg once daily ("Durules")	Sum of global ratings per 4 weeks: aura attacks	77/77	3.6 (0.7 to 5.5)
	Metoprolol 200mg once daily ("Durules")	Mean global rating (1-10) per attack: total	77/77	1.0 (0.2 to 1.3)
	Metoprolol 200mg once daily ("Durules")	Mean global rating (1-10) per attack: aura attacks	77/77	0.6 (0.2 to 1.5)
	Metoprolol 200mg once daily ("Durules")	Consumption of analgesic tablets per 4 weeks: aura attacks	77/77	0.8 (0.2 to 2.9)
	Metoprolol 200mg once daily ("Durules")	Consumption of analgesic tablets per attack: total	77/77	1.0 (0.2 to 1.0)
	Metoprolol 200mg once daily ("Durules")	Consumption of analgesic tablets per attack: aura attack	77/77	0.5 (0.1 to 0.8)
	Metoprolol 200mg once daily ("Durules")	Consumption of ergotamine tablets per 4 weeks: total	77/77	1.5 (0.0 to 2.1)
	Metoprolol 200mg once daily ("Durules")	Consumption of ergotamine tablets per 4 weeks: aura attacks	77/77	1.5 (-0.4 to 1.4)
Andersson, 1983 ⁹⁷ Medium	Metoprolol 200mg once daily ("Durules")	Acute tablet consumption	34/37	-9.3 (-16.4 to -2.2)
Kangasneimi, 1987 ¹⁰⁰ Medium	Metoprolol 200mg once daily ("Durules")	Consumption of analgesic tablets per 4 weeks	77/77	2.5 (0.5 to 4.8)
			Pooled ^{97,100}	-2.9 (-14.5 to 8.6)
Sjaastad, 1972 ⁸⁹ Medium	Pindolol (LB-46) 7.5 to 15mg	Headache days	28/28	0.5 (-2.3 to 3.4)
	Pindolol (LB-46) 7.5 to 15mg	Headache indices	28/28	-0.1 (-4.5 to 4.3)
Briggs, 1979 ⁹² Medium	Timolol 10mg twice a day	Headache frequency	14/14	1.6 (-1.2 to 4.4)
	Timolol 10mg twice a day	Headache frequency	14/14	3.1 (0.2 to 5.9)

Bold = significant differences at 95% confidence limit when 95%CI of mean difference estimates do not include 0
CI = confidence interval

Appendix Table D48. Efficacy of beta-blockers on migraine severity in adults; results from randomized controlled clinical trials (sorted by drug name)

Reference Risk of Bias	Drug and Dose	Outcome	Events/ Randomized [Rate of Outcome with Drug, %]	Events/ Randomized [Rate of Outcome with Placebo, %]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events per 1000 Treated (95% CI)
Andersson, 1983⁹⁷ Medium	Metoprolol 200mg/day	50% reduction in sum of severity score	10/34 [29.4%]	4/37 [10.8%]	2.7 (0.9 to 7.9)	0.19 (0.00 to 0.4)	5 (3 to 326)	186 (3 to 369)
	Metoprolol 200mg/day	1-50% reduction in the sum of severity score	15/34 [44.1%]	8/37 [21.6%]	2.0 (1.0 to 4.2)	0.22 (0.01 to 0.4)	4 (2 to 85)	225 (12 to 438)
Sjaastad, 1972 ⁸⁹ Medium	Pindolol 7.5 to 15mg	50% reduction in headache indices	3/28 [10.7%]	0/28 [0.0%]	7.0 (0.4 to 129.5)	0.11 (-0.02 to 0.2)		

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D49. Randomized controlled clinical trials that examined off label antidepressants for migraine prevention in adults

Examined Drug	Reference, Total Sample Size Number of Analyzed % Women	Definition of Migraine % of Patients without Aura	Baseline Monthly Migraine Frequency	Eligible Age Mean Age of Subjects	Duration of Migraine Prior Treatment
Amitriptyline	Couch, 1979 ¹⁰³ Sample 116 Analyzed 100 % women 84	Modified 1962 Ad Hoc National Institutes of Health Committee NR	NR	15-60 NR	NR NR
Amitriptyline	Gomersall, 1973 ¹⁰⁴ Sample 26 Analyzed 20 % women 75	Ad hoc committee NR	NR	NR 21-30 years old:1 31-40 years old:4 41-50 years old:11 51-60 years old:2 61-70 years old:2	1-10 yr:5 11-20 yr:5 21-30 yr:6 31-40:2 41-50:2 NR
Amitriptyline	Mathew, 1981 ¹⁰⁵ Sample 715 Analyzed 554 % women 94.5	NR NR	NR	NR (age ranged from 19-57) Mean: 38	NR NR
Amitriptyline	Bank, 1994 ¹⁰⁶ Sample 64 Analyzed 51 % women 73.4	International Headache Society 81.25	Headache Unit Index active group = 0.16, Headache Unit Index control group = 0.24	NR 34	At least 12 months NR
Amitriptyline	Oguzhanoglu, 1999 ¹⁰⁷ Sample 17 Analyzed 15 % women 80	International Headache Society NR	NR	NR 31	NR NR
Amitriptyline	Krymchantowski, 2002 ¹⁰⁸ Sample 39 Analyzed 27 % women 66.7	NR NR	NR	NR 36.4	NR 100% overusing symptomatic medications
Amitriptyline	Bulut, 2004 ¹⁰⁹ Sample 76 Analyzed 52 % women 84.6	International Headache Society 77	Yes	16-50 31.9	NR NR
Amitriptyline	Lampl, 2009 ¹¹⁰ Sample 132 Analyzed 132 % women 73	International Headache Society 76	Yes	18-60 32	16 years NR

Appendix Table D49. Randomized controlled clinical trials that examined off label antidepressants for migraine prevention in adults (continued)

Examined Drug	Reference, Total Sample Size Number of Analyzed % Women	Definition of Migraine % of Patients without Aura	Baseline Monthly Migraine Frequency	Eligible Age Mean Age of Subjects	Duration of Migraine Prior Treatment
Amitriptyline	Couch, 2011 ¹¹¹ Sample 391 Analyzed 317 % women 81	Modified 1962 Ad Hoc National Institutes of Health Committee NR	NR	18-70 34.9	NR NR
Amitriptyline	Couch, 1976 ¹¹² Sample 114 Analyzed 73 % women 84.9	Not specified NR	NR	NR NR	NR NR
Amitriptyline	Rafieian-Kopaei, 2005 ⁶⁴ Sample 105 Analyzed 95 % women NR	International Headache Society NR	Mean attack frequency: 4.02 (per month)	Adolescent & Adults NR	>1 (from inclusion criteria) NR
Amitriptyline	Rafieian-Kopaei, 2005 ⁶⁴ Sample 105 Analyzed 95 % women NR	International Headache Society NR	4.02 migraine attacks per month, 25.12 h average duration	15-45 NR	At least 12 months NR
Femoxetine	Orholm, 1986 ¹¹³ Sample 65 Analyzed 53 % women 84.9	Paroxysmal headache associated with discomfort, possibly with inability to work, and at least one of the following symptoms: nausea, vomiting, visual disturbances and paresthesia NR	Yes	NR ≥50 years old = 12 30-50 years old = 38 <30 years old = 3	NR NR
Femoxetine	Zeeberg, 1981 ¹¹⁴ Sample 59 Analyzed 45 % women 86.7	Paroxysmal headache associated with discomfort, possibly with inability to work, and at least one of the following symptoms: nausea, vomiting, visual disturbances and paresthesia NR	Yes	NR ≥50 years old = 9 30-50 years old = 29 <30 years old = 7	NR NR
Femoxetine	Kangasniemi, 1983 ⁷⁷ Sample 29 Analyzed 24 % women 86.2	NR NR	Yes	NR 37	NR NR

Appendix Table D49. Randomized controlled clinical trials that examined off label antidepressants for migraine prevention in adults (continued)

Examined Drug	Reference, Total Sample Size Number of Analyzed % Women	Definition of Migraine % of Patients without Aura	Baseline Monthly Migraine Frequency	Eligible Age Mean Age of Subjects	Duration of Migraine Prior Treatment
Femoxetine	Orholm, 1985 ¹¹⁵ Sample 59 Analyzed 47 % women NR	NR NR	NR	NR NR	NR NR
Fluoxetine	Adly, 1992 ¹¹⁶ Sample 32 Analyzed 18 % women 83.3	the Ad hoc Committee on Classification of headache NR	Headache score 33.5	NR 37.5	NR 2 amitriptyline or nadolol, 1 imipramine
Fluoxetine	Saper, 1994 ¹¹⁷ Sample 111 Analyzed 111 % women 87.4	International Headache Society NR	NR	18-60 36.6	At least 24 months NR
Fluoxetine	Steiner, 1998 ¹¹⁸ Sample 53 Analyzed 49 % women 75.5	NR 54.8	Yes	18-45 40.6	NR NR
Fluoxetine	d'Amato, 1999 ¹¹⁹ Sample 52 Analyzed 52 % women 63.5	International Headache Society 1988 criteria 100	NR	18-65 37.6	At least 6 months NR
Mianserin	Monro, 1985 ¹²⁰ Sample 38 Analyzed 34 % women NR	NR NR	NR	18-65 NR	NR NR
Tonabersat*	Goadsby, 2009 ¹²¹ Sample 124 Analyzed 124 % women 92.3	International Headache Society NR	Yes	18-55 36	NR NR
Venlafaxine	Ozyalcin, 2005 ¹²² Sample 60 Analyzed 49 % women 90	International Headache Society 100	Yes	18-70 placebo 38.16; V75 34.25; V150 37.19	NR NR
Venlafaxine	Tarlaci, 2009 ¹²³ Sample 105 Analyzed 93 % women 81.7	International Headache Society 93.5	Yes	NR 31.4	NR NR

NR = not reported; *Cortical spreading depression inhibitor

Appendix Table D50. Funding and conflict of interest in randomized controlled clinical trials that examined off label antidepressants for migraine prevention in adults

Reference	Funding	Ethical Approval	Consent	Conflict of Interest	Disclosed Relationships
Couch, 1979 ¹⁰³	Industry	No	Yes	NR	NA
Gomersall, 1973 ¹⁰⁴	Industry	No	Yes	NR	NA
Mathew, 1981 ¹⁰⁵	NR	NR	NR	NR	NR
Bank, 1994 ¹⁰⁶	NR	No	Yes	NR	NA
Oguzhanoglu, 1999 ¹⁰⁷	NR	No	NR	NR	NA
Krymchantowski, 2002 ¹⁰⁸	No	No	Yes	NR	NA
Bulut, 2004 ¹⁰⁹	Industry	Yes	Yes	NR	NA
Lampl, 2009 ¹¹⁰	No	Yes	Yes	Yes	Dr. Lampl received personal compensation from Glaxo, Pfizer Austria, Mundipharma, Grunenthal, Bayer-Shering, Biogen Idec and Astra Zeneca
Couch, 2011 ¹¹¹	Industry	Yes	Yes	NR	NA
Couch, 1976 ¹¹²	No	No	NR	NR	NA
Rafieian-Kopaei, 2005 ⁶⁴	Other	NR	Yes	NR	All authors are from the University that sponsored the study
Rafien-Kopaei, 2005 ⁶⁴	University	No	Yes	NR	NA
Orholm, 1986 ¹¹³	No	Yes	Yes	NR	NA
Zeeberg, 1981 ¹¹⁴	No	Yes	Yes	NR	NA
Kangasniemi, 1983 ⁷⁷	No	No	NR	NR	NA
Orholm, 1985 ¹¹⁵	NR	NR	NR	NR	NA
Adly, 1992 ¹¹⁶	NR	No	Yes	NR	NA
Saper, 1994 ¹¹⁷	Industry	Yes	Yes	NR	NA
Steiner, 1998 ¹¹⁸	Industry	Yes	Yes	NR	NA
d'Amato, 1999 ¹¹⁹	NR	Yes	Yes	NR	NA
Monro, 1985 ¹²⁰	Industry	No	Yes	NR	NA
Goadsby, 2009 ^{121*}	Industry	No	Yes	NR	JGM is an employee of Minster Research Ltd
Ozyalcin, 2005 ¹²²	Industry	Yes	Yes	NR	NA
Tarlaci, 2009 ¹²³	No	No	NR	NR	NA

NA = Not applicable; NR = Not reported; * RCT of Cortical spreading depression inhibitor

Appendix Table D51. Risk of bias in randomized controlled clinical trials that examined off label antidepressants and tonabersat for migraine prevention in adults

Reference	Masking of Treatment Status	Planned Intention to Treat Analysis	Allocation Concealment	Adequacy of Randomization	Adequacy of Randomization (Migraine Characteristics)	Selective Outcome Reporting	Risk of Bias
Couch, 1979 ¹⁰³	DB	No	NR	Yes	Unclear	Unclear	Medium
Gomersall, 1973 ¹⁰⁴	DB	No	Unclear	Unclear (crossover trial)	Unclear (crossover trial)	Unclear	Medium
Mathew, 1981 ¹⁰⁵	Open-label	No	Unclear	Yes	NR	Unclear	High
Bank, 1994 ¹⁰⁶	DB	No	Unclear	Yes	F & S	Unclear	Medium
Oguzhanoglu, 1999 ¹⁰⁷	Open-label	No	Unclear	Unclear	F & S	Unclear	Medium
Krymchantowski, 2002 ¹⁰⁸	DB	No	Unclear	Yes	F & S	Unclear	Medium
Bulutm 2004 ¹⁰⁹	DB	No	Unclear	Yes	F & S	Unclear	Medium
Lampl, 2009 ¹¹⁰	Open-label	Yes	NR	Yes	F & S	Unclear	Medium
Couch, 2011 ¹¹¹	DB	No	NR	Yes	F & S	Unclear	Medium
Couch, 1976 ¹¹²	DB	No	Unclear	NR	NR	Unclear	Medium
Rafieian-Kopaei, 2005 ⁶⁴	DB	No	Unclear	NR	F	Unclear	Medium
Rafieian-Kopaei, 2005 ⁶⁴	DB	No	NR	Unclear	S	Unclear	Medium
Orholm, 1986 ¹¹³	DB	No	Unclear	Yes	F & S	Unclear	Medium
Zeeberg, 1981 ¹¹⁴	DB	No	Unclear	Yes	F & S	Unclear	Medium
Kangasniemi, 1983 ⁷⁷	DB	No	Unclear	NR	NR	Unclear	Medium
Orholm, 1985 ¹¹⁵	DB	No	NR	Yes	F & S	Unclear	Medium
Adly, 1992 ¹¹⁶	DB	No	Unclear	Yes	S	Unclear	Medium
Saper, 1994 ¹¹⁷	DB	No	NR	Yes	S	Unclear	Medium
Steiner, 1998 ¹¹⁸	DB	No	NR	No	No for F, but S is OK	Unclear	High
d'Amato, 1999 ¹¹⁹	DB	No	NR	Yes	S	Unclear	Medium
Monro, 1985 ¹²⁰	DB	No	Unclear	No	Unclear	Unclear	High
Goadsby, 2009 ^{121*}	DB	Yes	NR	Yes	F & S	Unclear	Low
Ozyalcin, 2005 ¹²²	DB	No	Unclear	Yes	Unclear	Unclear	Medium
Tarlaci, 2009 ¹²³	NR (seems open-label)	Yes	NR	No	F	Unclear	High

DB = double-blind

NR = not reported

F = migraine frequency

S = migraine severity

D = migraine duration

* RCT of Cortical spreading depression inhibitor

Appendix Table D52. Randomized controlled clinical trials that examined calcium channel antagonists for migraine prevention in adults

Reference Sample Analyzed % Women	Definition of Migraine Years of Migraine	Age of Subjects	Baseline Migraine Status
Markley, 1984 ¹²⁴ Sample 20 Analyzed 14 % women 86	"Standard criteria" confirmed by self assessment questionnaire Years of migraine- Chronic headaches for an average of 13.4 years	20 to 50 year Mean age 33 years	57% had no significant relief when treated in the past with drugs used for migraine prophylaxis
Stewart, 1988 ¹²⁵ Sample 49 Analyzed 26 % women not reported	Not reported Years of migraine not reported	18-65	Headache index at baseline: active=126.7 (SD=112.5), placebo=141.1 (SD=142.3); number of headaches at baseline: active=6.15 (SD+3.62), placebo=6.46 (SD=4.21)
Leandri, 1990 ¹²⁶ Sample 30 Analyzed 30 % women 73	International Headache Society criteria Years of migraine, mean: 7.9 +/- 6.2 years	Not reported Not reported	Mean frequency \pm SD: 4.26 \pm 3.03, mean intensity: 2.60 \pm 0.49, mean duration: 35.76 \pm 21.69, index a (monthly number x mean intensity of attacks): 12.61 \pm 10.96, index b (monthly number x mean intensity x mean duration of attacks): 351.88 \pm 214.84
Gelmers, 1983 ¹²⁷ Sample 60 Analyzed 50 % women 62	Ad Hoc Committee definition Years of migraine- 20 years	Not reported Mean (SD): 30 (9)	Classic migraine active: 8, class migraine placebo: 4, common migraine active: 20, common migraine placebo: 18, age at migraine onset active: 11 (SD=9), age at migraine onset placebo: 10 (SD=8), migraine index active: 56 (SD=25), migraine index placebo: 72 (SD=39)
Migraine-Nimodipine European Study Group, 1989 ¹²⁸ Sample 192 Analyzed 192 % women 78	Ad hoc committee definition Years of migraine, active: 16, placebo 17	Age 18-60 Mean: active 38, placebo 38.3 years	Median duration of migraine in years, active: 16, placebo: 17; migraine days per 4 weeks, active: 4.5, placebo: 4.2; migraine index of days per 4 weeks times severity, active: 9.27, placebo 8.79
McArthur, 1989 ¹²⁹ Sample 24 Analyzed 14 % women Not reported	Ad hoc committee on the classification of headache Years of migraine Not reported	Not reported Not reported	Not reported
Solomon, 1983 ¹³⁰ Sample 23 Analyzed 12 % women 75	Classic or common migraine by ad hoc committee on classification of headache Years of migraine Not reported	Age 19-60 Mean 38.9 years	7/12 (58%) had common migraine and 5/12 (42%) had classic migraine

Appendix Table D52. Randomized controlled clinical trials that examined calcium channel antagonists for migraine prevention in adults (continued)

Reference Sample Analyzed % Women	Definition of Migraine Years of Migraine	Age of Subjects	Baseline Migraine Status
Meyer, 1983 ¹³¹ Sample 35 Analyzed 35 % women 66	Ad hoc committee Years of migraine Not reported	Age 20 years and older Mean 39.6 (SD=12.1) years	27/35 (77%) patients with migraine, common migraine: 14/35 (40%), classic migraine: 13/35 (37%), cluster headaches: 8/35 (23%)
Havanka-Kanniainen, 1985 ¹³² Sample 33 Analyzed 29 % women 85	Ad hoc committee Years of migraine- Mean duration of 14 years (1.6)	Not reported Mean age 32 (SD=1.3)	20/30 (67%) with classical migraine, 33% with common,
Migraine-Nimodipine European Study Group, 1989 ¹³³ Sample 89 Analyzed 72 % women 79	National Institute of Health for classic migraine Years of migraine- Active: 15 years, control: 10 years	18-60 Mean age active: 33.2 yrs., control: 34.8 yrs.	Migraine days/4 weeks active: 3.4, control: 3.4; migraine index active: 7.7, control: 8.1
Ansell, 1988 ¹³⁴ Sample 68 Analyzed 57 % women 71	Defined in accordance with the definition of the research group on migraine and headache of the world federation of neurology, 1969 Years of migraine- Not reported	18-60 Not reported	Placebo group: 16 common migraine, 11 classical migraine; active group: 14 with common migraine and 14 with classical migraine
Shukla, 1995 ¹³⁵ Sample 36 Analyzed 28 % women 79	International Headache Society Years of migraine- 8.8 (1.18) years	15-45 Mean years: 29.8 (SD=1.89)	Frequency: 10.4 (1.76), mild severity 0/28, moderate severity 12/28, severe severity 16/28, 100% with nausea/vomiting

Appendix Table D53. Funding and conflict of interest in randomized controlled clinical trials that examined calcium channel antagonists for migraine prevention in adults

Reference	Sponsorship	Ethical Approval of Study	Consent of Participants	Conflict of Interest
Markley, 1984 ¹²⁴	Industry (Knoll Pharmaceutical) provided medication	Not reported	Yes	Not reported
Leandri, 1990 ¹²⁶	Industry (Sandoz Prodotti Farmaceutici supplied medications)	Not reported	Yes	Not reported
Stewart, 1988 ¹²⁵	Not reported	Not reported	Yes	Not reported
Gelmers, 1983 ¹²⁷	Not reported	Not reported	Yes	Not reported
Migraine-Nimodipine European Study Group, 1989 ¹²⁸	Not reported	Not reported	Not reported	Not reported
McArthur, 1989 ¹²⁹	Industry (Pfizer) and not for profit (national migraine foundations)	Not reported	Yes	Not reported
Solomon, 1983 ¹³⁰	Industry (Knoll Pharmaceutical) provided medication	Not reported	Yes	Not reported
Meyer, 1983 ¹³¹	Grant from government	Yes	Yes	Not reported
Havanka-Kanniainen, 1985 ¹³²	Industry (Bayer Ltd supplied medications)	Yes	Yes	Not reported
Migraine-Nimodipine European Study Group, 1989 ¹³³	Not reported	Not reported	Not reported	Not reported
Ansell, 1988 ¹³⁴	Not reported	Not reported	Yes	Not reported
Shukla, 1995 ¹³⁵	Not reported	Not reported	Yes	Not reported

Appendix Table D54. Risk of bias in randomized controlled clinical trials that examined calcium channel antagonists for migraine prevention in adults

Reference	Masking of the Treatment Status	Intention to Treat Analysis Preplanned	Allocation Concealment	Adequacy of Randomization	Selective Outcome Reporting	Risk of Bias
Markley, 1984 ¹²⁴	Double blind	No	Unclear	Not reported	No	Medium
Stewart, 1988 ¹²⁵	Double blind	No	Unclear	Unclear	Unclear	Medium
Leandri, 1990 ¹²⁶	Double blind	No	Unclear	Yes	No	Medium
Gelmers, 1983 ¹²⁷	Double blind	No	Unclear	Yes	No	Medium
Migraine-Nimodipine European Study Group, 1989 ¹²⁸	Double blind	Yes	Unclear	No, migraine index different between nimodipine and placebo groups	No	Medium
McArthur, 1989 ¹²⁹	Double blind	No	Unclear	No, migraine index different between nimodipine and placebo groups	No	High
Solomon, 1983 ¹³⁰	Double blind	No	Unclear	Unclear	No	Medium
Meyer, 1983 ¹³¹	Double blind	No	Unclear	Unclear	No	Medium
Havanka-Kanninen, 1985 ¹³²	Double blind	No	Unclear	Unclear	No	Medium
Migraine-Nimodipine European Study Group, 1989 ¹³³	Double blind	Yes	Unclear	Yes	No	Low
Ansell, 1988 ¹³⁴	Double blind	No	Unclear	Unclear, more classical migraine in active group	No	Medium
Shukla, 1995 ¹³⁵	Double blind	No	Unclear	Unclear	No	Medium

Appendix Table D55. Randomized controlled clinical trials that examined ACE inhibitors of Angiotensin II receptor blockers for migraine prevention in adults

Active Drug	Reference Sample Analyzed % Women	Definition of Migraine Years of Migraine	Eligible Age of Subjects	Baseline Migraine Status
Lisinopril	Schrader, 2001 ¹³⁶ Sample 60 Analyzed 55 % women 81	International Headache Society criteria Years of migraine Not reported	Age 18 to 60 years gender, mean (SD): women, 41 (9), men, 43 (5) years	Mean (SD); hours with headache: 65(74), days with headache 9.4(4.0), days with migraine 6.8(3.0)
Captopril	Minervini, 1987 ¹³⁷ Sample 12 Analyzed 12 % women 58	Ad Hoc committee on the classification of headache Years of migraine 7-36 years	Not reported 35-64	Not reported
Candesartan	Tonvik, 2003 ¹³⁸ Sample 60 Analyzed 57 % women 79	International Headache Society criteria Years of migraine Not reported	Age 18 to 65 years mean (SD) women: 42(11), men: 48(12)	Mean (SD) of Migraine days 5.7 (2.9) Disability level 9.7 (6.4) Sick leave days 1.00 (2.00)
Telmisartan	Diener, 2009 ¹³⁹ Sample 84 Analyzed 84 % women 84.5	International Headache Society criteria Years of migraine Not reported	18-65 Active group: 39.8 (11.7), placebo: 41.6 (12.9) years	Migraine days active: 6.2 (SD=2.9), placebo: 7.6 (SD=3.7); headache hours active: 58.2 (SD=50.4), placebo: 74.4 (SD=64.2)

Appendix Table D56. Funding and conflict of interest in randomized controlled clinical trials that examined ACE inhibitors of Angiotensin II receptor blockers for migraine prevention in adults

Reference	Sponsorship	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Disclosed Relationships
Schrader, 2001 ¹³⁶	Industry by AstraZeneca	Yes	Yes	Yes	HS and GB have been reimbursed by AstraZeneca, one of the manufacturers of lisinopril, for attending conferences. These conferences were unrelated to the present study.
Minervini, 1987 ¹³⁷	Not reported	Not reported	Not reported	Not reported	Not applicable
Tronvik, 2003 ¹³⁸	Industry by AstraZeneca	Yes	Yes	Yes	Dr. Tronvik has been reimbursed by AstraZeneca for attending a conference unrelated to the present study.
Diener, 2009 ¹³⁹	By industry (Boehringer Ingelheim)	Yes	Yes	Yes	Multiple authors with honoraria or past research funding with pharmaceutical industry

Appendix Table D57. Risk of bias in randomized controlled clinical trials that examined ACE inhibitors of Angiotensin II receptor blockers for migraine prevention in adults

Reference	Masking of the Treatment Status	Intention to Treat Analysis Preplanned	Allocation Concealment	Adequacy of Randomization	Selective Outcome Reporting	Risk of Bias
Schrader, 2001 ¹³⁶	Double blind	Yes	Adequate	Not reported	No	Low
Minervini, 1987 ¹³⁷	Double blind	Unclear	Unclear	Unclear	No	Low
Tronvik, 2003 ¹³⁸	Double blind	Yes	Adequate	Not reported	No	Low
Diener, 2009 ¹³⁹	Double blind	No	Unclear	Headache hours greater in placebo group at baseline	No	High

Appendix Table D58. Randomized controlled clinical trials that examined clonidine for migraine prevention in adults

Reference Sample Analyzed % Women	Definition of Migraine Years of Migraine	Eligible Age of Subjects	Baseline Migraine Status
Ryan, 1975 ¹⁴⁰ Sample 75 Analyzed 75 % women 80	Common or classical migraine Years of migraine Not reported	21-60 Not reported	17 tyramine positive, 58 tyramine negative
Ryan, 1975 ¹⁴¹ Sample 133 Analyzed 133 % women 78	Not reported Years of migraine: Median duration 22 years	Not reported Median age 41 years	4/133 (3%) had migraine related to menses, 32/133 (24%) had migraine related to emotional stress
Shafar, 1972 ¹⁴² Sample 65 Analyzed 50 % women 84	Not reported Years of migraine: Not reported	Not reported Median age females=48 years, median age males=45 years	Not reported
Stensrud, 1976 ¹⁴³ Sample 29 Analyzed 27 % women 83	Not reported Years of migraine: Not reported	Not reported Mean 45.4 years	Mean number of headache days at baseline: 5.78, mean headache index at baseline: 10.67
Martucci, 1985 ¹⁴⁴ Sample 20 Analyzed 20 % women 70	Ad hoc committee classification system Years of migraine: All participants had a clinical history longer than 5 years	Not reported Mean age 32.5 years	Not reported
Denaro, 1985 ¹⁴⁵ Sample 20 Analyzed 20 % women 70	Ad hoc committee classification system Years of migraine All participants had a clinical history longer than 5 years	Not reported Mean age 32.5 years	Not reported
Boisen, 1978 ¹⁴⁶ Sample 71 Analyzed 49 % women Not reported	Migraine was defined as paroxysmal headache associated with discomfort, possibly with inability to work, and one or more of the following symptoms: nausea, vomiting, visual disturbances and paresthesia Years of migraine: Not reported	16 to 60 years Not reported	7/49 had 4 migraine days monthly, 20/49 had 4-8 days with migraine, 21/49 had more than 8 days with migraine in past two months
Wilkinson, 1970 ¹⁴⁷ Sample 27 Analyzed 24 % women 89	Not reported Years of migraine: Not reported	Over 16 years of age Average age of men: 38, of women: 37.5	Not reported
Adam, 1978 ¹⁴⁸ Sample 96 Analyzed 70 % women 84.3	Not reported Years of migraine: Not reported	Not reported Mean age group one (clonidine to placebo) 40 years; mean age group two (placebo to clonidine) 35 years	Less than 3 headaches per 3 months 24/70 (34%), more than 3 headaches per 3 months 46/70 (66%)

Appendix Table D58. Randomized controlled clinical trials that examined clonidine for migraine prevention in adults (continued)

Reference Sample Analyzed % Women	Definition of Migraine Years of Migraine	Eligible Age of Subjects	Baseline Migraine Status
Bredfeldt, 1989 ¹⁴⁹ Sample 43 Analyzed 30 % women 80	Ad hoc committee on the classification of headache Years of migraine: Not reported	18 years or more Range 20-57 years	Not reported
Kallanranta, 1977 ¹⁵⁰ Sample 50 Analyzed 50 % women 72	Not reported Years of migraine: Not reported	Not reported mean age 31.6 years	24/50 (48%) with classic migraine, 26 (52%) with common migraine, 6/50 (12%) with dietary migraine, mean frequency of attacks was 3.94 (sd 2.19)
Kallanranta, 1977 ¹⁵⁰ Sample 50 Analyzed 50 % women 64	Not reported Years of migraine Not reported	Not reported Mean age 36.3 years	14/50 (28%) with classic migraine, 36/50 (72%) with common migraine, 3/50 (6%) with dietary migraine, mean frequency of attacks was 4 (sd 2.20)
Das, 1979 ¹⁵¹ Sample 20 Analyzed 20 % women 70	Ad hoc committee on classification of headache Years of migraine: Not reported	Not reported 20-48 years	Not reported

Appendix Table D59. Sponsorship and conflict of interest in randomized controlled clinical trials that examined clonidine for migraine prevention in adults

Reference	Sponsorship	Ethical Approval of Study	Consent of Participants	Conflict of Interest
Ryan, 1975 ¹⁴⁰	Not reported	Not reported	Not reported	Not reported
Ryan, 1975 ¹⁴¹	Not reported	Not reported	Not reported	Not reported
Shafar, 1972 ¹⁴²	Not reported	Not reported	Yes	Not reported
Stensrud, 1976 ¹⁴³	Not reported	Not reported	Not reported	Not reported
Martucci, 1985 ¹⁴⁴	Not reported	Not reported	Yes	Not reported
Denaro, 1985 ¹⁴⁵	Not reported	Not reported	Yes	Not reported
Boisen, 1978 ¹⁴⁶	Not reported	Not reported	Yes	Not reported
Wilkinson, 1970 ¹⁴⁷	Not reported	Not reported	Yes	Not reported
Adam, 1978 ¹⁴⁸	Industry (Boehringer Ingelheim Limited)	Not reported	Yes	Not reported
Bredfeldt, 1989 ¹⁴⁹	Industry (Boehringer Ingelheim Pharmaceuticals)	Not reported	Yes	Not reported
Kallanranta, 1977 ¹⁵⁰	Not reported	Not reported	Not reported	Not reported
Kallanranta, 1977 ¹⁵⁰	Not reported	Not reported	Not reported	Not reported
Das, 1979 ¹⁵¹	Industry (Unichem Labs supplied medication)	Not reported	Not reported	Not reported

Appendix Table D60. Risk of bias in randomized controlled clinical trials that examined clonidine for migraine prevention in adults

Reference	Masking of the Treatment Status	Intention to Treat Analysis Preplanned	Allocation Concealment	Adequacy of Randomization	Selective Outcome Reporting	Risk of Bias
Ryan, 1975 ¹⁴⁰	Double blind	Unclear	Unclear	Unclear	No	Low
Ryan, 1975 ¹⁴¹	Double blind	Unclear	Unclear	Unclear	No	Low
Shafar, 1972 ¹⁴²	Double blind	No	Unclear	Unclear	No	Medium
Stensrud, 1976 ¹⁴³	Double blind	No	Unclear	Unclear	No	Medium
Martucci, 1985 ¹⁴⁴	Double blind	Unclear	Unclear	Unclear	No	Low
Denaro, 1985 ¹⁴⁵	Double blind	Unclear	Unclear	Unclear	No	Low
Boisen, 1978 ¹⁴⁶	Double blind	No	Unclear	Unclear	No	Medium
Wilkinson, 1970 ¹⁴⁷	Double blind	No	Unclear	Unclear	Unclear, different dosages of clonidine not reported separately	Medium
Adam, 1978 ¹⁴⁸	Double blind	No	Unclear	Yes	No	Medium
Bredfeldt, 1989 ¹⁴⁹	Double blind	No	Unclear	Unclear	No	High
Kallanranta, 1977 ¹⁵⁰	Not reported	Unclear	Unclear	Unclear	No	Unclear
Kallanranta, 1977 ¹⁵⁰	Not reported	Unclear	Unclear	Unclear	No	Unclear
Das, 1979 ¹⁵¹	Double blind	Unclear	Unclear	Unclear	No	Low

Appendix Table D61. Randomized controlled clinical trials that examined ergot alkaloids for migraine prevention in adults

Reference Sample Analyzed % Women	Definition of Migraine % Without Aura	Baseline Severity	Eligible Age Age of Subjects	Duration of Migraine Prior Treatment History
Martucci, 1983 ¹⁵² Sample 90 Analyzed 79 % women 60	Common migraine (Ad Hoc Committee on Classification of Headache) 100 (assumed)	NR	Adults & Middle aged Mean: 36.6	NR NR
Herrmann, 1977 ¹⁵³ Sample 153 Analyzed unclear % women 73.2	NR 32.5 (assumed)	NR (Median frequency lies around 7-10 attacks per month)	NR NR (median lies around 20-40)	<1y: 6.8%, 1-5y: 35.8%, 5-10y: 15.9%, 10y: 37% NR
Whewell, 1966 ¹⁵⁴ Sample 74 Analyzed 50 % women 80	Migraine defined as a periodic throbbing headache, unilateral initially, with at least three of the following features: a) sensory prodromata, b) photophobia, c) nausea or vomiting, d) family history of migraine, and e) fluid retention before or diuresis during attack. NR	≥1 for 4 wks (from exclusion criterion)	Adolescent, Adults & Middle aged Mean: 42	20 NR
Pradalier, 2004 ¹⁵⁵ Sample 384 Analyzed 363 % women 80.7	Migraine (with or without aura) was based on criteria defined by the International Headache Society 36.9	Mean migraine attacks: 3.3	Adults & Middle aged Mean: 39.1	15.8 NR
Neuman, 1986 ¹⁵⁶ Sample 40 Analyzed 40 % women 45	Migraine NR	Mean migraine attacks: 3.3	Adults, Middle aged, & Aged Mean: 47	NR NR
Buscaino, 1991 ¹⁵⁷ Sample 90 Analyzed 90 % women 70	Migraine (Ad Hoc Committee) 100	NR (median lies around 5 to 6 attacks per month")	Adults & Middle aged Mean: 36.8	16 Flunarizine, ergot derivatives, and anti-depressants
Buscaino, 1991 ¹⁵⁷ Sample 18 Analyzed 13 % women 83.3	Common (n=16), Classic (n=1), Cluster (n=1) 88.9	NR	Adults & Middle aged Mean: 33.2	NR NR
Somerville, 1976 ¹⁵⁸ Sample 150 Analyzed 132 % women NR	Migraine defined as recurrent paroxysmal headache lasting a minimum of one hour and associated with at least one of the following symptoms: nausea, vomiting, photophobia, visual, motor or sensory symptoms or dysphasia NR	NR (Median frequency lies around 3-4 attacks per month)	NR NR	NR NR

Appendix Table D61. Randomized controlled clinical trials that examined ergot alkaloids for migraine prevention in adults (continued)

Reference Sample Analyzed % Women	Definition of Migraine % Without Aura	Baseline Severity	Eligible Age Age of Subjects	Duration of Migraine Prior Treatment History
Bonuso, 1983 ¹⁵⁹ Sample 41 Analyzed unclear % women 68.3	Mixed headache diagnosed in accordance with the definitions of the "ad hoc Committee" 100 (assumed)	NR	Adults & Middle aged NR	NR NR

NR = Not reported

Appendix Table D62. Funding and conflict of interest in randomized controlled clinical trials that examined ergot alkaloids for migraine prevention in adults

Reference	Funding	Ethical Approval	Consent	Conflict of Interest	Disclosed Relationships
Martucci, 1983 ¹⁵²	NR	NR	NR	NR	NR
Herrmann, 1977 ¹⁵³	NR	NR	Yes	NR	NR
Whewell, 1966 ¹⁵⁴	NR	NR	NR	NR	NR
Pradalier, 2004 ¹⁵⁵	Industry	Yes	Yes	No	NA
Neuman, 1986 ¹⁵⁶	NR	NR	NR	NR	NR
Buscaino, 1991 ¹⁵⁷	NR	NR	Yes	NR	NR
Buscaino, 1991 ¹⁵⁷	NR	NR	Yes (unclear if it is fully informed, but patients agreed to participate in the study)	NR	NR
Somerville, 1976 ¹⁵⁸	NR	NR	NR	NR	NR
Bonuso, 1983 ¹⁵⁹	NR	NR	NR	NR	NR

NR = not reported

Appendix Table D63. Risk of bias in randomized controlled clinical trials that examined ergot alkaloids for migraine prevention in adults

Reference	Masking of Treatment Status	ITT Planned	Allocation Concealment	Adequacy of Randomization	Adequacy of Randomization (Migraine Characteristics)	Selective Outcome Reporting	Risk of Bias
Martucci, 1983 ¹⁵²	DB	No	Unclear	NR	NR	No	Medium
Herrmann, 1977 ¹⁵³	DB	No	Unclear	Yes	F, S & D	Unclear	Medium
Whewell, 1966 ¹⁵⁴	DB	No	Unclear	NR	NR	Unclear	Medium
Pradalier, 2004 ¹⁵⁵	DB	Yes	Unclear	Yes	F & D	No	Low
Neuman, 1986 ¹⁵⁶	DB	No	Unclear	Yes	F	Unclear	Medium
Buscaino, 1991 ¹⁵⁷	DB	No	Unclear	Yes	F, S & D	Unclear	Medium
Buscaino, 1991 ¹⁵⁷	DB	No	Unclear	NR	F	Unclear	Medium
Somerville, 1976 ¹⁵⁸	DB	No	Unclear	NR	F	Unclear	Medium
Bonuso, 1983 ¹⁵⁹	NR	No	Unclear	NR	S & D	Unclear	Medium

ITT = Intention to treat

F= frequency

S = severity

D = duration

DB = double blind

NR = not reported

Appendix Table D64. Randomized controlled clinical trials that examined comparative effectiveness of onabotulinumtoxin A for migraine prevention in adults

Reference	Country	Objective	Sample [Number Analyzed] % Women	Age	Definition of Migraine	Presence of Aura % Without Aura	Duration of Migraine, Years	Baseline Severity	Comorbidity
Millan-Guerrero, 2009 ¹⁶⁰	Mexico	Histamine vs. botulinum toxin type A (BoNTA)	100 [100] 92% women	Mean: 33	International Headache Society	Included % without aura 81	15	Mean migraine frequency (days): 4.12	NR
Mathew, 2009 ¹⁶¹	USA	Onabotulinumtoxin A (BOTOX, Allergan, Inc) vs. topiramate (TOPAMAX, Ortho-McNeil)	60 [33] 90% women	Mean: 36.8	Migraine headache with or without aura occurring on >14 days/month for >3 months in the absence of medication overuse	Included % without aura NR	NR	Headache days: 15.6	NR
Magalhaes, 2010 ¹⁶²	Brazil	Botulinum toxin type A vs. amitriptyline	72 [unclear] 97.2% women	Mean: 34.1	Chronic daily migraines, according to the International Classification of Headache Disorders-II	NR % without aura NR	NR	NR (Number of pain days at baseline: 24)	NR
Cady, 2011 ¹⁶³	USA	Onabotulinumtoxin A vs. topiramate (CM)	59 [44] 91.5% women	Mean: 39.6	Chronic migraine (CM) fulfilling criteria of the Second Edition of the ICHD	NR % without aura NR	16 (median)	NR (Headache days/month: 21.1)	Every subject reported at least one problem with a body system (58/59, neurological; 39/59, psychological). A physical/neurological abnormality was found in 13.6% (8/59)
Blumenfeld, 2008 ¹⁶⁴	USA	Botulinum toxin type A (BoNTA; BOTOX®: Allergan, Inc.) vs. divalproex sodium (DVPX; DEPAKOTE®: Abbott Laboratories)	59 [59] 84.7% women	Mean: 42.4	Episodic migraine (defined for this study as ≥3 migrainous headaches but <15 days	NR % without aura NR	NR	Number of headache days per month: 11.7	NR

Appendix Table D64. Randomized controlled clinical trials that examined comparative effectiveness of botulinum toxin for migraine prevention in adults (continued)

Reference	Country	Objective	Sample [Number Analyzed] % Women	Age	Definition of Migraine	Presence of Aura % Without Aura	Duration of Migraine, Years	Baseline Severity	Comorbidity
					/month) or chronic migraine (defined for this study as migrainous headaches on 15 days/month)				

NR = not reported

Appendix Table D65. Funding and conflict of interest in randomized controlled clinical trials that examined comparative effectiveness of botulinum toxin for migraine prevention in adults

Reference	Finance	Ethical Approval	Consent	Conflict of Interest	Conflict of Interest Disclosure
Millan-Guerrero, 2009 ¹⁶⁰	Not reported	Yes	Yes	Not reported	Not applicable
Mathew, 2009 ¹⁶¹	Industry	Yes	Yes	Yes	Dr. Matthew is on the scientific advisory board of Merck, Allergan, and Ortho-McNeil. Hi is also on the speaker's bureau for Merck, GSK, Endo Pharmaceuticals, and Allergan.
Magalhaes, 2010 ¹⁶²	Government	Yes	Yes	Not reported	Not applicable
Cady, 2011 ¹⁶³	Not reported	Yes	Yes	Yes	Dr. Roger Cady: Consultant for GlaxoSmithKline, Merck, Ortho-McNeil. Research grants from Allergan, Endo Pharmaceuticals, GlaxoSmithKline, Merck, and Wyeth. Dr. John Porter: Consulting Speakers panel with Novartis, Forest, Biogen, UCB Pharma, Pfizer, TEVA. Dr. Andrew Blumenfeld: Consultant, speaker's bureau, and research grants from Allergan. Dr. Curtis Schreiber and Dr. Kathleen Farmer: None to disclose.
Blumenfeld, 2008 ¹⁶⁴	Industry	Yes	Yes	Yes	Dr. Blumenfeld has received honoraria for speaking activities and a research grant from Allergan, Inc. Dr. Schim has received research grants from Allergan, Inc., has been a consultant for Allergan, Inc., and serves on the speaker's bureau for Allergan. He has received research grants from Boehringer, Pfizer, GlaxoSmithKline, Merck, Astra-Zeneca, and Ortho-McNeil. He serves on the speaker's bureau for Boehringer, Pfizer, GlaxoSmithKline, Merck, and Ortho-McNeil. Dr. Chippendale has received personal compensation from Allergan, Inc., and Photothera for consulting services. He received personal compensation from Boehringer Ingelheim, Pfizer, and Teva for speaking.

Appendix Table D66. Risk of bias in randomized controlled clinical trials that examined comparative effectiveness of botulinum toxin for migraine prevention in adults

Reference	Masking of Treatment	Planned Intention to Treat Analysis	Allocation Concealment	Adequacy of Randomization	Selective Outcome Reporting	Risk of Bias	Other Concerns
Millan-Guerrero, 2009 ¹⁶⁰	Double blind	No	Unclear	Yes	Unclear	Low	Poor reporting quality
Mathew, 2009 ¹⁶¹	Double blind	No	Unclear	No	Unclear	Medium	
Magalhaes, 2010 ¹⁶²	Open label	No	Unclear	Unclear (age seems to differ by groups; no tests conducted)	Unclear	High	
Cady, 2011 ¹⁶³	Double blind	No	Unclear	Unclear (unclear in demographic characters, but adequate in migraine characteristics)	Unclear	Medium	
Blumenfeld, 2008 ¹⁶⁴	Double blind	Yes	Unclear	No	Unclear	Medium	Baseline Headache severity differs by groups

Appendix Table D67. Comparative effectiveness of onabotulinumtoxin A vs. topiramate in migraine prevention (results from individual randomized controlled clinical trials)

Outcome	Reference Risk of Bias	Active vs. Control Drug	Events/ Randomized with Active Drug	Events/ Randomized with Control Drug	Relative Risk 95% CI)	Absolute Risk Difference (95% CI)
At least a 50% reduction in headache days per month	Cady, 2011 ¹⁶³ Medium	Topiramate vs. Onabotulinumtoxin A	12/30	9/29	1.3 (0.6 to 2.6)	0.09 (-0.15 to 0.33)
≥ 50% reduction in HA/migraine days	Mathew, 2009 ¹⁶¹ High	Topiramate plus placebo injection vs. Onabotulinumtoxin A (Botox) + Oral placebo	9/30	9/30	1.0 (0.5 to 2.2)	0.00 (-0.23 to 0.23)
Migraine Disability Assessment (MIDAS) total score >21 (severe disability)	Mathew, 2009 ¹⁶¹ High	Topiramate plus placebo injection vs. Onabotulinumtoxin A (Botox) + Oral placebo	7/30	6/30	1.2 (0.4 to 3.1)	0.03 (-0.17 to 0.24)
≥ 50% improvement in the Migraine Disability Assessment (MIDAS) total score	Mathew, 2009 ¹⁶¹ High	Topiramate plus placebo injection vs. Onabotulinumtoxin A (Botox) + Oral placebo	12/30	11/30	1.1 (0.6 to 2.1)	0.03 (-0.21 to 0.28)
Physician global assessment: marked improvement	Cady, 2011 ¹⁶³ Medium	Topiramate vs. Onabotulinumtoxin A	10/30	10/29	1.0 (0.5 to 2.0)	-0.01 (-0.25 to 0.23)
Physician global assessment: moderate improvement	Cady, 2011 ¹⁶³ Medium	Topiramate vs. Onabotulinumtoxin A	6/30	4/29	1.5 (0.5 to 4.6)	0.06 (-0.13 to 0.25)
Physician global assessment: slight improvement	Cady, 2011 ¹⁶³ Medium	Topiramate vs. Onabotulinumtoxin A	1/30	5/29	0.2 (0.0 to 1.6)	-0.14 (-0.29 to 0.01)
Physician Global Assessment - response to treatment: Marked improvement (defined as at least 75% improvement)	Mathew, 2009¹⁶¹ Medium	Topiramate plus placebo injection vs. Onabotulinumtoxin A (Botox) + Oral placebo	18/30	8/30	2.3 (1.2 to 4.4)	0.33 (0.10 to 0.57)

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D68. Comparative effectiveness of onabotulinumtoxin A vs. divalproex sodium in migraine prevention (results from a single medium risk of bias randomized controlled clinical trial)¹⁶⁵

Outcome	Active vs. Control Drug	Events/ Randomized with Active Drug	Events/ Randomized with Control Drug	Relative Risk 95% CI)	Absolute Risk Difference (95% CI)
≥50% reduction in attack frequency per month	Divalproex sodium (plus placebo BoNTA) vs. Botulinum toxin type A (plus placebo-tablets)	2/7	0/7	5.0 (0.3 to 88.5)	0.29 (-0.08 to 0.65)
≥50% reduction in attack frequency per month	Divalproex sodium (plus placebo BoNTA) vs. Botulinum toxin type A (plus placebo-tablets)	4/7	2/7	2.0 (0.5 to 7.6)	0.29 (-0.21 to 0.78)
≥50% reduction in attack frequency per month	Divalproex sodium (plus placebo BoNTA) vs. Botulinum toxin type A (plus placebo-tablets)	4/7	4/7	1.0 (0.4 to 2.5)	0.00 (-0.52 to 0.52)
≥50% reduction in attack frequency per month	Divalproex sodium (plus placebo BoNTA) vs. Botulinum toxin type A (plus placebo-tablets)	4/7	3/7	1.3 (0.5 to 3.9)	0.14 (-0.38 to 0.66)
≥50% reduction in attack frequency per month	Divalproex sodium (plus placebo BoNTA) vs. Botulinum toxin type A (plus placebo-tablets)	5/22	4/23	1.3 (0.4 to 4.2)	0.05 (-0.18 to 0.29)
≥50% reduction in attack frequency per month	Divalproex sodium (plus placebo BoNTA) vs. Botulinum toxin type A (plus placebo-tablets)	10/22	17/23	0.6 (0.4 to 1.0)	-0.28 (-0.56 to -0.01)
≥50% reduction in attack frequency per month	Divalproex sodium (plus placebo BoNTA) vs. Botulinum toxin type A (plus placebo-tablets)	12/22	12/23	1.0 (0.6 to 1.8)	0.02 (-0.27 to 0.32)
≥50% reduction in attack frequency per month	Divalproex sodium (plus placebo BoNTA) vs. Botulinum toxin type A (plus placebo-tablets)	12/22	16/23	0.8 (0.5 to 1.3)	-0.15 (-0.43 to 0.13)
≥75% reduction in Migraine Disability Assessment Scores (MIDAS)	Divalproex sodium (plus placebo BoNTA) vs. Botulinum toxin type A (plus placebo-tablets)	5/29	16/30	0.3 (0.1 to 0.8)	-0.36 (-0.59 to -0.14)

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D69. Comparative effectiveness of onabotulinumtoxin A vs. amitriptyline in migraine prevention (results from a single high risk of bias randomized controlled clinical trial)¹⁶²

Outcome	Active vs. Control Drug	Events/ Randomized with Active Drug	Events/ Randomized with Control Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Physician assessment: improvement	Amitriptyline vs. Botulinum toxin type A	32/37	31/35	1.0 (0.8 to 1.2)	-0.02 (-0.17 to 0.13)
Patient self assessment: improvement	Amitriptyline vs. Botulinum toxin type A	33/37	29/35	1.1 (0.9 to 1.3)	0.06 (-0.10 to 0.22)
Improvement a) any single criterion met among objective criteria: a) a reduction by at least 50% in the number of pain episodes, b) a reduction in the intensity of pain of at least 3 point, and c) a reduction by at least 50% in the number of pain drug doses used for migraine	Amitriptyline vs. Botulinum toxin type A	35/37	31/35	1.1 (0.9 to 1.2)	0.06 (-0.07 to 0.19)
A reduction by at least 50% in the number of pain drug doses used for migraines	Amitriptyline vs. Botulinum toxin type A	26/37	27/35	0.9 (0.7 to 1.2)	-0.07 (-0.27 to 0.13)
A reduction by at least 50% in the number of days of pain	Amitriptyline vs. Botulinum toxin type A	27/37	24/35	1.1 (0.8 to 1.4)	0.04 (-0.17 to 0.25)

CI = confidence interval

Appendix Table D70. Randomized controlled clinical trials of comparative effectiveness of topiramate for migraine prevention in adults (all trials did not report prior migraine preventive treatments)

Reference	Country	Total Sample [Number Analyzed] % Females	Age	Definition of Migraine	Presence of Aura	Duration of Migraine	Migraine Frequency/ Month	Baseline Comorbidity
Bartolini, 2005 ¹⁶⁶	Italy	49 [44] 70.5% females	Mean 41.8 years	International Headache Society Classification of Head and Facial Pain	Patients having migraine without aura were included in the study	5.45 years	26.6	Not reported
Shaygannejad, 2006 ¹⁶⁷	Iran	64 [64] 56.3% females	Mean 34.1 years	International Headache Society criteria	Not reported	11.2 years	5.4	Not reported
Gupta, 2007 ⁴⁴	India	60 [Variable] 78.3% females	Mean 29.41 years	International Headache Society criteria	31.67% had aura	5.08 years	6.98	30% of patients had preigrainous depression
de Tommaso, 2007 ¹⁶⁸	Italy	45 [39] 86.0% females	Mean 37.86 years	Headache Classification Committee, 2004	None of the patients had aura	Not reported	Not reported	Not reported
Millan-Guerrero, 2008 ¹⁶⁹	Not reported	90 [90] 86.0% females	Mean 32 years	International Headache Society criteria	With aura (n): Histamine:3, Topiramate: 5, Without aura (n); Histamine: 42, Topiramate: 40	14.8 years	4.1	Not reported
Keskinbora, 2008 ¹⁷⁰	Turkey	75 [63] 66.7% females	Mean 37.5 years	International Headache Society criteria	Not reported	Not reported	6.1	Beck Depression Inventory BDI-II score: Topiramate: 17.95±5.64, Amitriptyline: 17.05±8.90, Combined: 16.95±6.05
Ashtan, 2008 ¹⁷¹	Iran	62 [60] 81.7% females	Mean 30.5 years	International Headache Society	Not reported	At least 1 year	5.9	Not reported

Appendix Table D70. Randomized controlled clinical trials of comparative effectiveness of topiramate for migraine prevention in adults (all trials did not report prior migraine preventive treatments) (continued)

Reference	Country	Total Sample [Number Analyzed] % Females	Age	Definition of Migraine	Presence of Aura	Duration of Migraine	Migraine Frequency/ Month	Baseline Comorbidity
Dodick, 2009 ¹⁷²	USA	347 [Variable] 84.9% females	Mean 38.8 years	International Headache Society 1.1 or 1.2	Not reported	Age at migraine onset: 20.25 years	6.15	Not reported
Mohammadianinejad, 2011 ¹⁷³	Iran	80 [75] 78.8% females	Mean 34.2 years	International Headache Society criteria	Not reported	9.9 years	7.4	Not reported

Appendix Table D71. Funding and conflict of interest in randomized controlled clinical trials that examined comparative effectiveness of topiramate for migraine prevention in adults

Reference	How Project was Funded	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests - Relationship
Bartolini, 2005 ¹⁶⁶	Not reported	Yes	Yes	Not reported	Not applicable
Shaygannejad, 2006 ¹⁶⁷	Not reported	Yes	Yes	Not reported	Not applicable
Gupta, 2007 ⁴⁴	Not reported	Yes	Yes	None	Not applicable
de Tommaso, 2007 ¹⁶⁸	Not reported	Yes	Yes	Not reported	Not applicable
Millan-Guerrero, 2008 ¹⁶⁹	Not reported	Yes	Yes	Not reported	Not applicable
Keskinbora, 2008 ¹⁷⁰	Not reported	Yes	Yes	Not reported	Not applicable
Ashtan, 2008 ¹⁷¹	Not reported	Yes	Yes	Not reported	Not applicable
Dodick, 2009 ¹⁷²	Industry	Yes	Yes	Not reported	Not reported, however, Jim Xiang, Marcia Rupnow, and David Biondi are employees of Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey
Mohammadianinejad, 2011 ¹⁷³	Other	Yes	Yes	None	Not applicable

Appendix Table D72. Risk of bias in randomized controlled clinical trials that examined comparative effectiveness of topiramate for migraine prevention in adults

Reference	Masking of the Treatment Status	Intention to Treat Analysis Preplanned	Allocation Concealment	Adequacy of Randomization	Selective Outcome Reporting	Risk of Bias
Bartolini, 2005 ¹⁶⁶	Open-label	Not reported	Unclear	No (Females were more in the valproate group and males in the topiramate group)	Unclear	High
Shaygannejad, 2006 ¹⁶⁷	Double-blind	Yes	Unclear	No (sodium valproate group had slightly more severe headache and lower duration of migraine than topiramate group)	Unclear	Medium
Gupta, 2007 ⁴⁴	Double-blind	Yes	Unclear	Unclear	Unclear	Low
de Tommaso, 2007 ¹⁶⁸	Double-blind	No	Unclear	Not reported	Unclear	Medium
Milan-Guerrero, 2008 ¹⁶⁹	Double-blind	No	Unclear	Yes	Unclear	Low
Keskinbora, 2008 ¹⁷⁰	Double-blind	No	Unclear	Yes	Unclear	Medium
Ashtari, 2008 ¹⁷¹	Double-blind	No	Unclear	Yes	Unclear	Medium
Dodick, 2009 ¹⁷²	Double-blind	Yes	Unclear	Yes	Unclear	Low
Mohammadianinejad, 2011 ¹⁷³	Double-blind	No	Clearly adequate	Yes	Unclear	Medium

Appendix Table D73. Comparative effectiveness of topiramate for migraine prevention in adults (individual randomized controlled clinical trials)

Definition of the Outcome	Active Drug Daily Dose	Control Drug Daily Dose	Reference Risk of Bias	Events/ Randomized [Rate, %] with Topiramate	Events/ Randomized [Rate, %] with Control Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Decrease in headache days by more than 50%	Topiramate 100mg	Amitriptyline 100mg	Dodick, 2009¹⁷² Low	97/178 [54.4]	74/169 [43.9]	1.2 (1.0 to 1.5)	0.11 (0.00 to 0.21)
Decrease in migraine by more than 50%	Topiramate 100mg	Amitriptyline 100mg	Dodick, 2009 ¹⁷² Low	99/178 [55.6]	78/169 [45.9]	1.2 (1.0 to 1.5)	0.09 (-0.01 to 0.20)
Decrease in headache frequency by more than 50%	Topiramate 25mg BD	Lamotrigine 25mg BD	Gupta, 2007 ⁴⁴ Low	38/60 [63.0]	28/60 [46.0]	1.4 (1.0 to 1.9)	0.17 (-0.01 to 0.34)
Headache intensity (≥50% reduction in mean migraine intensity)	Topiramate 25mg BD	Lamotrigine 25mg BD	Gupta, 2007⁴⁴ Low	30/60 [50.0]	13/60 [21.0]	2.3 (1.3 to 4.0)	0.28 (0.12 to 0.45)
Migraine frequency of less than 50% of the basal frequency	Topiramate 100mg BD	Levetiracetam 1000mg BD	de Tommaso, 2007 ¹⁶⁸ Medium	8/13 [61.5]	8/15 [53.3]	1.2 (0.6 to 2.2)	0.08 (-0.28 to 0.45)
Reduction of at least 50% in days with headache	Topiramate 75mg/day (25mg in the morning and 50mg in the evening)	Valproate(Slow-release) 750mg/day (250mg in the morning and 500mg in the evening)	Bartolini, 2005 ¹⁶⁶ High	20/22 [90.9]	21/22 [95.5]	1.0 (0.8 to 1.1)	-0.05 (-0.19 to 0.10)
Decrease in headache frequency by more than 50%	Topiramate 25mg/day, gradually titrated up to 100mg/day	Zonisamide 50mg/day, gradually titrated up to 200mg/day	Mohammadianinejad, 2011 ¹⁷³ Medium	16/40 [40.0]	15/40 [37.5]	1.1 (0.6 to 1.9)	0.03 (-0.19 to 0.24)
Presence of concomitant symptoms	Topiramate 200mg	Amitriptyline 150mg of 150mg/day)	Keskinbora, 2008 ¹⁷⁰ Medium	3/24 [12.5]	8/28 [28.6]	0.4 (0.1 to 1.5)	-0.16 (-0.37 to 0.05)
Presence of concomitant symptoms	Topiramate + Amitriptyline Initial doses of topiramate 25mg/day and amitriptyline	Amitriptyline 150mg	Keskinbora, 2008 ¹⁷⁰ Medium	5/23 [21.7]	8/28 [28.6]	0.8 (0.3 to 2.0)	-0.07 (-0.31 to 0.17)

Appendix Table 73. Comparative effectiveness of topiramate for migraine prevention in adults (individual randomized controlled clinical trials (continued))

Definition of the Outcome	Active Drug Daily Dose	Control Drug Daily Dose	Reference Risk of Bias	Events/ Randomized [Rate, %] with Topiramate	Events/ Randomized [Rate, %] with Control Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
	10mg/day and this was followed by weekly increases of 25mg/day topiramate and 10mg/day amitriptyline						
Presence of concomitant symptoms	Topiramate 200mg	Topiramate + Amitriptyline Initial doses of topiramate 25mg/day and amitriptyline 10mg/day and this was followed by weekly increases of 25mg/day topiramate and 10mg/day amitriptyline	Keskinbora, 2008 ¹⁷⁰ Medium	3/24 [12.5]	5/23 [21.7]	0.6 (0.2 to 2.1)	-0.09 (-0.31 to 0.12)

Bold = differences are statistically significant when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

Appendix Table D74. Randomized controlled clinical trials that examined comparative effectiveness of propranolol of migraine prevention in adults

Reference Total Sample Size as Randomized % Women	Aim	Definition of Migraine	Duration of Migraine, Years	Age of Subjects	Baseline Severity
Ashtari, 2008 ¹⁷¹ Sample Not reported 81.7% women	To assess the efficacy and safety of low-dose topiramate in migraine prophylaxis vs. propranolol	International Headache Society	Not reported	Mean: 30.8	Mean monthly headache frequency: 5.95
Behan, 1980 ¹⁷⁴ Sample 56 66.1% women	To compare propranolol with methysergide in a large group of patients with chronic, incapacitating migraine	Chronic, incapacitating migraine	0.5 to 33	Not reported	Not reported; inclusion criterion: at least two attacks of severe migraine per month
Rafieian-Kopaei, 2005 ⁶⁴ Sample 105 % women Not reported	To compare the prophylactic activity of propranolol and amitriptyline on frequency, duration and severity of migraine attacks	Migraine (International Headache Society)	>1 (from inclusion criteria)	Not reported	Mean attack frequency: 4.02 (per month)
Kangasniemi, 1983 ⁷⁷ Sample 29 86.2% women	1) To compare the relative efficacy of propranolol and fexofenadine in migraine prophylaxis, and 2) to assess the usefulness of steady state VEP (visual evoked potential) recording in the evaluation of drug effects on migraine.	Common and classic migraine	17	37	Mean frequency of migraine attacks: 7.18
Domingues, 2009 ⁷⁵ Sample 76 % women Not reported	To evaluate the short term efficacy and safety of the combination of low doses of propranolol and nortriptyline compared to these drugs alone	International Headache Society	Not reported	Not reported	Not reported
Carroll, 1990 ¹⁷⁵ Sample 55 69% women	To compare the efficacy and tolerability of two long-acting formulations of propranolol	Classical or common migraine (Ad hoc committee classification of headache)	Median: 14	Mean: 39	Mean frequency of migraine (month): 6.1
Kaniecki, 1997 ⁶⁸ Sample 37 81% women	To compare the efficacy of divalproex sodium (Depakote) with that of	Migraine without aura as defined by the International Headache	Not reported	Not reported	Mean attacks (month): 4.38

Appendix Table 74. Randomized controlled clinical trials that examined comparative effectiveness of propranolol of migraine prevention in adults (continued)

Reference Total Sample Size as Randomized % Women	Aim	Definition of Migraine	Duration of Migraine, Years	Age of Subjects	Baseline Severity
	propranolol hydrochloride (and placebo) for the prophylaxis of migraine without aura	Society			
Ziegler, 1987 ⁷⁶ Sample 54 73% women	To compare efficacy of propranolol and amitriptyline in the prophylaxis of migraine headache	Patients were admitted to the study when two senior neurologists agreed on the diagnosis of migraine based on the frequent occurrence of the following factors: 1) unilateral nature of the headache; 2) nausea and/or vomiting, 3) premonitory visual phenomena, and 4) headache with no consistent association with transient stress or anxiety	Not reported	Mean: 38	More than half of the headache episodes were classified as either "severe" (defined as "able to carry on some activities with discomfort but not with normal efficiency") or "disabling" (defined as "cannot carry on any normal activity, must go to bed")
Kaushik, 2005 ¹⁷⁶ Sample 192 69% women	To evaluate utility of biofeedback assisted diaphragmatic breathing and systematic relaxation in migraine and to compare their efficacy with propranolol in long term prophylaxis of migraine	International Headache Society	Not reported	Not applicable	Frequency of migraine episodes (per month): 4-5 (propranolol vs. biofeedback, 71.9% and 76%, respectively)
Kangasniemi, 1984 ⁷⁰ Sample 36 89% women	To compare the well- established migraine prophylactic effect of the non-selective beta-blocker propranolol with that of the beta1-selective beta- blocker metoprolol	World Federation of Neurology Research Group on Migraine and Headache, 1969	15.6	Mean: 33.8	Number of migraine attacks per 4 weeks: 5.3
Tfelt-Hansen, 1984 ⁶⁰ Sample 96 74% women	To compare the beta- adrenergic blocker timolol to an established drug,	Between 2 and 6 common migraine attacks per month as defined by the	20.9	Mean: 39.5	Number of migraine attacks per 4 weeks: 5.7

Appendix Table 74. Randomized controlled clinical trials that examined comparative effectiveness of propranolol of migraine prevention in adults (continued)

Reference Total Sample Size as Randomized % Women	Aim	Definition of Migraine	Duration of Migraine, Years	Age of Subjects	Baseline Severity
	propranolol, and to placebo for prophylactic effect in common migraine	ad hoc committee and by Olsen			
Olerud, 1986 ⁷³ Sample 28 % women 79	To compare the prophylactic efficacy of nadolol with that of propranolol in patients with classic or common migraine	Classic and/or common migraine headaches as set forth by the Ad Hoc Committee on the Classification of Headache	Range: 2-45	Not reported (range: 17-61)	Median number of migraine attack per month during single blind placebo period: 5.6 (Nadolol), 3.6 (Propranolol)
Mathew, 1981 ¹⁰⁵ Sample 715 94.5% women	To determine propranolol long-term effectiveness and tolerance, and to the patient's migraine status after termination of therapy	Not reported	Not reported	Mean: 38	Not reported
Albers, 1989 ⁷⁴ Sample 40 89.5% women	To compare the effectiveness of nifedipine to that of propranolol in the initial prophylaxis of migraine headache	Ad Hoc Committee on the Classification of Headache	Not reported	Mean: 35.2	5.2
Andersson, 1981 ¹⁷⁷ Sample 49 69.4% women	To compare the prophylactic effect of femoxetine with the effect of propranolol (Frekven) in a double-blind crossover study	Migraine was defined as paroxysmal headache associated with discomfort, possibly with inability to work, and one or more of the following symptoms: nausea, vomiting, visual disturbances and paresthesia.	Not reported	Mean: 38	Migraine attacks per 4 weeks: 5.7
Kass, 1980 ⁶⁹ Sample 23 69.6% women	To compare the prophylactic effect on migraine of propranolol and clonidine	World Federation of Neurology, 1969	Not reported	Mean: 39.7	Not reported
Havanka-Kanniainen, 1988 ¹⁷⁸ Sample Not reported 81% women	To compare the efficacy and side-effects of LA propranolol 80 mg once a day with that of LA propranolol 160 mg once daily in the prophylactic	Ad Hoc Committee on the Classification of Headache	17.5	Mean: 37.7	Migraine attack: 5.1

Appendix Table 74. Randomized controlled clinical trials that examined comparative effectiveness of propranolol of migraine prevention in adults (continued)

Reference Total Sample Size as Randomized % Women	Aim	Definition of Migraine	Duration of Migraine, Years	Age of Subjects	Baseline Severity
	treatment of classic and common migraine				
Olerud, 1986 ⁷³ Sample 42 % women Not reported	To evaluate the effectiveness of a Beta- blocker (propranolol) alone, a calcium antagonist (cinnarizine) alone, and both in combination	Not reported	Not reported	Not reported	Not reported
Solomon, 1986 ¹⁷⁹ Sample Not reported % women Not reported	To compare the prophylactic antimigraine effect of the calcium entry blocker verapamil with beta-blocker propranolol	Not reported	Not reported	Not reported	Not reported
Ryan, 1984 ¹⁸⁰ Sample 48 73% women	To compare the relative efficacy and safety of propranolol and nadolol in the prophylactic phase of the treatment of migraine	Common or classical migraine (no definition provided)	Not reported	Not reported	Headache frequency/4 weeks: 6.3
Gerber, 1991 ⁷¹ Sample 58 81% women	To ascertain, on the basis of single case statistics and time-series analysis, responder and non- responder rates for metoprolol, propranolol and nifedipine in migraine prophylaxis. In addition, an attempt was made to identify the dose relationship for the various drugs on headache parameters.	Common or classical migraine (no definition provided)	21	Mean: 42.4	Headache frequency/4 weeks: 3.55
Sudilovsky, 1987 ⁷² Sample 140 76% women	To compare the effects of nadolol with those of propranolol in the prophylactic treatment of migraine	Classic or common migraine as defined by Ad Hoc Committee on Classification of Headache	20.7	Mean: 39.3	Headache frequency/4 weeks (during last year): 5.29
Stensrud, 1980 ⁶² Sample 35	To compare the effectiveness of a selective	Ad Hoc Committee on Classification of	Not reported	Not reported	Not reported

Appendix Table 74. Randomized controlled clinical trials that examined comparative effectiveness of propranolol of migraine prevention in adults (continued)

Reference Total Sample Size as Randomized % Women	Aim	Definition of Migraine	Duration of Migraine, Years	Age of Subjects	Baseline Severity
68.6% women	and a non-selective beta1-receptor antagonist i.e. atenolol (Tenormin) and propranolol (Inderal), in the prophylaxis of migraine	Headache (1962)			
Olsson, 1984 ¹⁸¹ Sample 56 73.2% women	To investigate the prophylactic effect of metoprolol under double-blind controlled conditions and to compare the effect with that of propranolol in dosages that could be regarded as starting dosage	Classical or common migraine (defined by the World Federation of Neurology Research Group on Migraine and Headache, 1969/18/)	20.7	Mean: 39.6	Migraine attack (median) / 4 weeks (during placebo run in): 5.4
Ahuja, 1985 ⁵⁶ Sample 26 46.2% women	To compare the effectiveness of a selective and a non-selective beta1-receptor antagonist i.e. atenolol (Tenormin) and propranolol (Inderal), in the prophylaxis of migraine	Ad Hoc Committee on Classification of Headache (1962)	Not reported	Not reported	Not reported
Sargent, 1985 ⁵⁵ Sample 149 79% women	To evaluate the prophylactic effect and tolerance of naproxen sodium compared to propranolol hydrochloride and placebo in migraine	Common or classical migraine, or a combination migraine and muscle contraction headache (no definition provided)	20	Mean: 30	Not reported
Standnes, 1982 ⁶¹ Sample 25 80% women	To evaluate the prophylactic effect of timolol in migraine	Common migraine attacks (as defined by the Ad Hoc Committee)	Not reported	Mean: 41.4	Mean number of attacks (4 weeks): 6.65
Diener, 2004 ⁴³ Sample 575 79.8% women	To evaluate the efficacy and safety of two doses of topiramate and safety of two doses of topiramate vs. placebo for migraine prophylaxis, with propranolol (PROP) as an active control	International Headache Society	Not reported	Median: 41	Mean monthly migraine frequency: 5.1

Appendix Table D75. Funding and conflict of interest in randomized controlled clinical trials that examined comparative effectiveness of propranolol for migraine prevention in adults

Reference	Funding	Ethical Approval	Consent	Conflict of Interest	Disclosed Relationships
Ashtari, 2008 ¹⁷¹	Not reported	Yes	Yes	Not reported	Not reported
Behan, 1980 ¹⁷⁴	Other	Not reported	Not reported	Not reported	Not reported
Rafieian-Kopaei, 2005 ⁶⁴	Other	Not reported	Yes	Not reported	All authors are from the University that sponsored the study
Kangasniemi, 1983 ⁷⁷	Not reported	Not reported	Not reported	Not reported	Not reported
Domingues, 2009 ⁷⁵	Not reported	Yes	Yes	Not reported	Not reported
Diener, 2002 ¹⁸²	Industry	Yes	Yes	Not reported	Not reported
Carroll, 1990 ¹⁷⁵	Not reported	Yes	Yes	Unclear	One of author is employed by industry (ICI pharmaceuticals), but unclear their relationship (no funding source reported.)
Kaniecki, 1997 ⁶⁸	Industry	Not reported	Yes	Not reported	Not reported
Ziegler, 1987 ⁷⁶	Grant	Not reported	Not reported	Not reported	Not reported
Kaushik, 2005 ¹⁷⁶	Other	Yes	Yes	Not reported	Not reported
Kangasniemi, 1984 ⁷⁰	Not reported	Not reported	Yes	Not reported	Not reported
Tfelt-Hansen, 1984 ⁶⁰	Not reported	Not reported	Yes	Not reported	Not reported
Olerud, 1986 ⁷³	Not reported	Not reported	Yes	Not reported	Not reported
Mathew, 1981 ¹⁰⁵	Not reported	Not reported	Not reported	Not reported	Not reported
Albers, 1989 ⁷⁴	Industry + Grant	Not reported	Yes	No	Not reported
Andersson, 1981 ¹⁷⁷	Not reported	Not reported	Not reported	Not reported	Not reported
Kass, 1980 ⁶⁹	Industry	Not reported	Not reported	Not reported	Not reported
Havanka-Kanninen, 1988 ¹⁷⁸	Industry	Yes	Not reported	Not reported	Not reported
Olerud, 1986 ⁷³	Not reported	Not reported	Not reported	Not reported	Not reported
Solomon, 1986 ¹⁷⁹	Not reported	Not reported	Not reported	Not reported	Not reported
Ryan, 1984 ¹⁸⁰	Not reported	Not reported	Yes	Not reported	Not reported
Gerber, 1991 ⁷¹	Not reported	Not reported	Not reported	Not reported	Not reported
Sudilovsky, 1987 ⁷²	Not reported	Yes	Yes	Not reported	Not reported
Stensrud, 1980 ⁶²	Not reported	Not reported	Not reported	Not reported	Not reported
Olsson, 1984 ¹⁸¹	Not reported	Yes	Yes	Not reported	Not reported
Ahuja, 1985 ⁵⁶	Industry (Inderal brand of propranolol and identical looking placebo tablets were supplied by Alkali and Chemical Corp. India Ltd.	Not reported	Not reported	Not reported	Not reported
Sargent, 1985 ⁵⁵	Not reported	Not reported	Not reported	Not reported	Not reported
Standnes, 1982 ⁶¹	Industry	Not reported	Yes	Not reported	Not reported

Appendix Table D75. Funding and conflict of interest in randomized controlled clinical trials that examined comparative effectiveness of propranolol for migraine prevention in adults (continued)

Reference	Funding	Ethical Approval	Consent	Conflict of Interest	Disclosed Relationships
Diener, 2004 ⁴³	Industry	Yes	Yes	Yes	Hans-Christoph Diener has received grant/research support from, has been a consultant/scientific advisor for, and/or has received honoraria for oral presentations from 3M Medica, Allergan, Almirall Prodesfarma, AstraZeneca, Bayer Vital, Böhringer Ingelheim, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Grünenthal, Janssen-Cilag, Johnson & Johnson, La Roche, Lilly, Novartis, MSD, Parke-Davis, Pfizer, Pharmacia, Pierre Fabre, Schaper and Brümmer, and Weber & Weber. Peer Tfelt-Hansen has been a consultant/scientific advisor for, and/or has received honoraria for oral presentation from Almirall Prodesfarma, AstraZeneca, GlaxoSmithKline, Johnson & Johnson, MSD, Pfizer, and Quintiles. Carl Dahlöf has been a consultant/scientific advisor for, and has received honoraria for oral presentations from Allergan, Almirall Prodesfarma, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Jansen-Cilag, Johnson & Johnson, Lilly, MSD, Novartis, Pfizer, Pharmacia, and Pierre Fabre. Miguel JA Láinez has received grant/research support from, has been a consultant/scientific advisor for, and/or has received honoraria for oral presentations from Almirall Prodesfarma, AstraZeneca, Böhringer Ingelheim, Bristol-Myers Squibb, Elan Pharmaceuticals, GlaxoSmithKline, Janssen-Cilag, Johnson & Johnson, MSD, Novartis, Pfizer, Pierre Fabre, and Sanofi-Synthelabo. Giorgio Sandrini has received grant/research support from, has been a consultant/scientific advisor for, and/or has received honoraria for oral presentations from Allergan, AstraZeneca, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Grünenthal, Janssen-Cilag, Johnson & Johnson, Lilly, MSD, Pfizer, Pharmacia, and Solvay Pharma. Shuu-Jiun Wang has received grant/research support from and/or received honoraria for oral presentations from AstraZeneca, Glaxo-SmithKline, Johnson & Johnson, Lilly, MSD, and Pfizer. Walter Neto, Ujjwala Vijapurkar, Aiden Doyle, and David Jacobs are employed by Johnson & Johnson Pharmaceutical Research and Development, LLC.

Appendix Table D76. Risk of bias in randomized controlled clinical trials that examined comparative effectiveness of propranolol for migraine prevention in adults

Reference	Masking Treatment Status	Planned Intention to Treat	Allocation Concealment	Baseline Similarity in Migraine	Selective Outcome Reporting	Risk of Bias
Ashtari, 2008 ¹⁷¹	Double blind	No	Unclear	F & S	Unclear	Medium
Behan, 1980 ¹⁷⁴	Double blind	No	Unclear	D	Unclear	Medium
Rafieian-Kopaei, 2005 ⁶⁴	Double blind	No	Unclear	F	Unclear	Medium
Kangasniemi, 1983 ⁷⁷	Double blind	No	Unclear	Not reported	Unclear	Medium
Domingues, 2009 ⁷⁵	Double blind	No	Unclear	Not reported	Unclear	Medium
Diener, 2002 ¹⁸²	Double blind	Yes	Unclear	F	Unclear	Low
Carroll, 1990 ¹⁷⁵	Double blind	No	Unclear	F & S	Unclear	Medium
Kaniecki, 1997 ⁶⁸	Single blind	No	Unclear	Not reported	Unclear	High
Ziegler, 1987 ⁷⁶	Double blind	No	Unclear	S	Unclear	Medium
Kaushik, 2005 ¹⁷⁶	Single blind	Yes	Adequate	F & S	Unclear	Medium
Kangasniemi, 1984 ⁷⁰	Double blind	No	Unclear	Not reported	Unclear	Medium
Tfelt-Hansen, 1984 ⁶⁰	Double blind	No	Unclear	F, S & D	Unclear	Medium
Olerud, 1986 ⁷³	Double blind	No	Unclear	F	Unclear	Medium
Mathew, 1981 ¹⁰⁵	Open-label	No	Unclear	Not reported	Unclear	High
Albers, 1989 ⁷⁴	Open-label	No	Unclear	F	Unclear	High
Andersson, 1981 ¹⁷⁷	Double blind	No	Unclear	Not reported	Unclear	Medium
Kass, 1980 ⁶⁹	Double blind	No	Unclear	Not reported	Unclear	Medium
Havanka-Kanniainen, 1988 ¹⁷⁸	Double blind	No	Unclear	Not reported	Unclear	Medium
Olerud, 1986 ⁷³	Double blind	No	Unclear	Not reported	Unclear	Low
Solomon, 1986 ¹⁷⁹	Double blind	No	Unclear	Not reported	Unclear	Medium
Ryan, 1984 ¹⁸⁰	Double blind	No	Unclear	Not reported	Unclear	Medium
Gerber, 1991 ⁷¹	Double blind	No	Unclear	F & D	Unclear	Medium
Sudilovsky, 1987 ⁷²	Double blind	No	Unclear	F & D	Unclear	Medium
Stensrud, 1980 ⁶²	Double blind	No	Unclear	Not reported	Unclear	Medium
Olsson, 1984 ¹⁸¹	Double blind	No	Unclear	Not reported	Unclear	Medium
Ahuja, 1985 ⁵⁶	Double blind	No	Unclear	Not reported	Unclear	Low
Sargent, 1985 ⁵⁵	Double blind	No	Unclear	Not reported	Unclear	Medium
Standnes, 1982 ⁶¹	Double blind	No	Unclear	Not reported	Unclear	Medium
Diener, 2004 ⁴³	Double blind	Yes	Unclear	F	Unclear	Low

F = migraine frequency; S = migraine severity; D = migraine duration

Appendix Table D77. Randomized controlled clinical trials that examined comparative effectiveness of beta-blockers for migraine prevention in adults

Reference Aim	Total Sample [Number Analyzed] % Females in Sample	Definition of Migraine	Duration of Migraine	Presence of Aura	Migraine Frequency at Baseline/Month	Age of Subjects (Mean or Median)
Louis, 1985 ¹⁸³ To compare the effect of clonidine with that of the β 1-selective β -adreno-receptor antagonist metoprolol in patients with classical and common migraine.	33 [31] 80.6	World Federation of Neurology Research Group on Migraine and Headache, 1969	18.7 years	Not reported	3 to 10 (inclusion criterion)	Mean 35.5 years
Langohr, 1985 ¹⁸⁴ To compare the efficacy of clomipramine, a serotonin-reuptake inhibitor, as anti-migraine drug, with that of metoprolol, a beta-blocking agent	63 [34] 66.7	Ad Hoc Committee on classification of headache	20.8 years	Since 13 patients had classical migraine it was assumed that these patients had migraine with aura	Not reported	Mean 44.4 years
Grotemeyer, 1990 ¹⁸⁵ To compare in a double-blind cross-over study with a well-demarcated run-in period the effectiveness of ASA with that of a well-established beta-blocker	28 [Not reported] 82.1	Ad hoc Committee	10 years	None of the patients had aura	4 to 8	Mean 31 years
Worz, 1991 ¹⁸⁶ To compare the efficacy and safety of bisoprolol (5-10mg once daily) in migraine prophylaxis with that of the beta1-selective blocker metoprolol (50-100mg twice daily), a well established migraine prophylactic drug	78 [Variable] 80.8	International Headache Society criteria	At least 2 years	55 had migraine without aura and 23 had migraine with aura	4	Not reported
Worz, 1992 ¹⁸⁷ To compare bisoprolol	125 [78] 77.6	International Headache Society	19.5 years	Migraine with aura: 27.2% and migraine	4.01	Mean 38.5 years

Appendix Table D77. Randomized controlled clinical trials that examined comparative effectiveness of beta-blockers for migraine prevention in adults (continued)

Reference Aim	Total Sample [Number Analyzed] % Females in Sample	Definition of Migraine	Duration of Migraine	Presence of Aura	Migraine Frequency at Baseline/Month	Age of Subjects (Mean or Median)
5mg once daily with metoprolol 50mg twice daily in migraine prophylaxis		criteria (Olesen, 1988)		without aura:72.8%		
Diener, 2001 ¹⁸⁸ To show equivalence of Aspirin with metoprolol with respect to efficacy, defined as a 50% reduction in the rate of migraine attacks.	270 [270] 81.1	International Headache Society criteria	13.8 years	50 Patients had migraine with aura	3.5	Mean 41.25 years
Schellenberg, 2008 ¹⁸⁹ To evaluate the efficacy of oral treatment with nebivolol and metoprolol in the prophylaxis of migraine attacks.	30 [30] 86.7	International Headache Society criteria -II: 1.1 and 1.2	17 years	Headache with aura/other symptoms: n (%): Metoprolol: 14 (100), Nebivolol: 15 (94)	3.4	Mean 39 years

Appendix Table D78. Funding and conflict of interest in randomized controlled clinical trials that examined comparative effectiveness of beta-blockers for migraine prevention in adults

Reference	Funding	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Disclosed Relationships
Louis, 1985 ¹⁸³	Not reported	Yes	Yes	Not reported	Not applicable
Langohr, 1985 ¹⁸⁴	Industry	Not reported	Not reported	Not reported	Not applicable
Grotemeyer, 1990 ¹⁸⁵	Not reported	Not reported	Not reported	Not reported	Not applicable
Worz, 1991 ¹⁸⁶	Not reported	Not reported	Not reported	Not reported	Not applicable
Worz, 1992 ¹⁸⁷	Not reported	Yes	Yes	Not reported	Not applicable
Diener, 2001 ¹⁸⁸	Industry	Yes	Yes	Yes	G.Latta is from Bayer, Leverkusen, Germany
Schellenberg, 2008 ¹⁸⁹	Industry	Yes	Yes	None	Not applicable

Appendix Table D79. Risk of bias in randomized controlled clinical trials that examined comparative effectiveness of beta-blockers for migraine prevention in adults

Reference	Masking of the Treatment Status	Intention to Treat Analysis Preplanned	Allocation Concealment	Adequacy of Randomization	Baseline Similarity	Selective Outcome Reporting	Risk of Bias
Louis, 1985 ¹⁸³	Double-blind	No	Unclear	Not reported	Frequency: not reported; Severity: not reported; Duration: not reported	Unclear	Medium
Langohr, 1985 ¹⁸⁴	Double-blind	No	Unclear	Not reported	Not reported	Unclear	Medium
Grotemeyer, 1990 ¹⁸⁵	Double-blind	No	Unclear	Not reported	Frequency: not reported; Severity: not reported; Duration: not reported	Unclear	Medium
Worz, 1991 ¹⁸⁶	Double-blind	No	Unclear	Not reported	Frequency: similar; Severity: not reported; Duration: not reported	Unclear	Medium
Worz, 1992 ¹⁸⁷	Double-blind	No	Unclear	Not reported	Frequency: similar; Severity: not reported; Duration: not reported	Unclear	Medium
Diener, 2001 ¹⁸⁸	Double-blind	Yes	Unclear	Yes	Frequency: similar; Severity: similar; Duration: similar	Unclear	Low
Schellenberg, 2008 ¹⁸⁹	Double-blind	Yes	Unclear	No, there were no males in the metoprolol group	Frequency: similar; Severity: similar; Duration: similar	Unclear	Medium

Appendix Table D80. Strength of evidence of comparative effectiveness of beta-blockers for migraine prevention in adults

Definition of the Outcome	Reference	Active Drug	Control Drug	Risk of Bias	Directness	Consistency	Precision	Strength of Evidence
Reduction of frequency of attacks by more than 50%	Worz, 1992 ¹⁸⁷	Metoprolol	Bisoprolol	Medium	Yes	Not applicable	No	Low
Responder rate(at least 50% in number of attacks from baseline to endpoint)	Schellenberg, 2008 ¹⁸⁹	Metoprolol	Nebivolol	Medium	Yes	Not applicable	No	Low
Reduction of attacks more than 50%	Grotemeyer, 1990 ¹⁸⁵	Metoprolol	Aspirin	Medium	Yes	Not applicable	No	Low
Responder rate (Reduction in the number of migraine attacks greater than 50%)	Diener, 2001 ¹⁸⁸	Metoprolol	Aspirin, 1500mg/day	Low	Yes	Not applicable	No	Low
Reduction of more than 50% in the number of migraine days	Louis, 1985 ¹⁸³	Metoprolol	Clonidine	Medium	Yes	Not applicable	No	Low

Appendix Table D81. Comparative effectiveness of beta-blockers on migraine frequency, severity, and impact (results from randomized controlled clinical trials)

Definition of the Outcome	Reference Risk of Bias	Active Drug Dose	Control Drug, Dose	Randomized to Active/Control Drug	Mean [Standard Deviation] with Active Drug	Mean [Standard Deviation] with Control Drug	Mean Difference (95% CI)
Number of attacks per 4 weeks	Worz, 1991 ¹⁸⁶ Medium	Bisoprolol 5 to 10mg once daily	Metoprolol 50 to 100mg twice daily	78/78	Not reported	Not reported	0.1 (-0.2 to 0.4)
Mean frequency per 28 days in phase I	Worz, 1992 ¹⁸⁷ Medium	Metoprolol 50mg BID (max. 200mg daily after 4 weeks)	Bisoprolol 5mg/day (max. 10mg daily after 4 weeks)	65/60	2.0 [1.7]	2.4 [2.0]	-0.4 (-1.0 to 0.3)
Mean frequency per 28 days in phase II	Worz, 1992 ¹⁸⁷ Medium	Metoprolol 50mg BID (max. 200mg daily after 4 weeks)	Bisoprolol 5mg/day (max. 10mg daily after 4 weeks)	60/65	2.0 [1.7]	1.8 [1.7]	0.2 (-0.4 to 0.8)
Mean frequency per 28 days (overall)	Worz, 1992 ¹⁸⁷ Medium	Metoprolol 50mg BID (max. 200mg daily after 4 weeks)	Bisoprolol 5mg/day (max. 10mg daily after 4 weeks)	125/125	2.0 [1.5]	2.1 [1.8]	-0.1 (-0.5 to 0.4)
Frequency of migraine attacks	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 - 16:142.5mg	Nebivolol 5mg daily	14/16	1.3 [1.0]	1.6 [1.5]	-0.3 (-1.2 to 0.6)
Duration of migraine attacks at endpoint (hours)	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 - 16:142.5mg	Nebivolol 5mg daily	14/16	26.0 [55.0]	15.0 [14.0]	11.0 (-18.6 to 40.6)
Severity at endpoint (measured on 100 mm visual analog scale)	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 - 16:142.5mg	Nebivolol 5mg daily	14/16	54.0 [16.0]	50.0 [24.0]	4.0 (-10.4 to 18.4)
MIDAS: days with headache	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 - 16:142.5mg	Nebivolol 5mg daily	14/16	13.0 [18.0]	14.0 [14.0]	-1.0 (-12.7 to 10.7)
MIDAS: pain intensity	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg,	Nebivolol 5mg daily	14/16	6.0 [2.0]	6.0 [3.0]	0.0 (-1.8 to 1.8)

Appendix Table D81. Comparative effectiveness of beta-blockers on migraine frequency, severity, and impact (results from randomized controlled clinical trials)

Definition of the Outcome	Reference Risk of Bias	Active Drug Dose	Control Drug, Dose	Randomized to Active/Control Drug	Mean [Standard Deviation] with Active Drug	Mean [Standard Deviation] with Control Drug	Mean Difference (95% CI)
	Medium	week 2: 95mg, week 3 - 16:142.5mg					
Quality of life(SF-36): Physical	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 - 16:142.5mg	Nebivolol 5mg daily	14/16	46.0 [7.0]	50.0 [10.0]	-4.0 (-10.1 to 2.1)
Quality of life(SF-36): Mental	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 - 16:142.5mg	Nebivolol 5mg daily	14/16	48.0 [8.0]	45.0 [13.0]	3.0 (-4.6 to 10.6)
% change in frequency of migraine attacks	Grotemeyer, 1990 ¹⁸⁵ Medium	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 1500mg/day	28/28	-50.0 [18.0]	-26.0 [22.0]	-24.0 (-34.5 to -13.5)
Intensity of attacks	Grotemeyer, 1990 ¹⁸⁵ Medium	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 1500mg/day	28/28	1.6 [0.7]	1.4 [0.5]	0.2 (-0.1 to 0.5)
Frequency of migraine attacks	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	135/135	1.8 [1.6]	2.4 [1.9]	-0.5 (-1.0 to -0.1)

Bold = significant differences at 95% confidence limit when 95% CI of mean difference estimates do not include 0
CI = confidence interval

Appendix Table D82. Comparative effectiveness of beta-blockers for migraine prevention in adults (results from randomized controlled clinical trials)

Definition of the Outcome	Reference Risk of Bias	Active Drug Dose	Control Drug Dose	Events/ Randomized [Rate of Outcome in Active Group]	Events/ Randomized [Rate of Outcome in Control Group]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Reduction of frequency of attacks by more than 50%	Worz, 1992 ¹⁸⁷ Medium	Metoprolol 50mg BID (max. 200mg daily after 4 weeks)	Bisoprolol 5mg/day (max. 10mg daily after 4 weeks)	11/125 [8.8]	12/125 [9.6]	0.9 (0.4 to 2.0)	-0.01 (-0.08 to 0.06)
Patients rated treatment as more effective	Worz, 1992 ¹⁸⁷ Medium	Metoprolol 50mg BID (max. 200mg daily after 4 weeks)	Bisoprolol 5mg/day (max. 10mg daily after 4 weeks)	28/125 [22.4]	37/125 [29.6]	0.8 (0.5 to 1.2)	-0.07 (-0.18 to 0.04)
MIDAS :No impairment	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 -16:142.5mg	Nebivolol 5mg daily	2/14 [14.3]	2/16 [12.5]	1.1 (0.2 to 7.1)	0.02 (-0.23 to 0.26)
MIDAS :Severe impairment	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 -16:142.5mg	Nebivolol 5mg daily	2/14 [14.3]	5/16 [31.3]	0.5 (0.1 to 2.0)	-0.17 (-0.46 to 0.12)
MIDAS :Moderate impairment	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 -16:142.5mg	Nebivolol 5mg daily	4/14 [28.6]	6/16 [37.5]	0.8 (0.3 to 2.2)	-0.09 (-0.42 to 0.25)
MIDAS :Mild impairment	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 -16:142.5mg	Nebivolol 5mg daily	5/14 [35.7]	2/16 [12.5]	2.9 (0.7 to 12.5)	0.23 (-0.07 to 0.53)
Responder rate(at least 50% in number of attacks from baseline to endpoint)	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 -16:142.5mg	Nebivolol 5mg daily	8/14 [57.0]	8/16 [50.0]	1.1 (0.6 to 2.2)	0.07 (-0.29 to 0.43)

Appendix Table D82. Comparative effectiveness of beta-blockers for migraine prevention in adults (results from randomized controlled clinical trials) (continued)

Definition of the Outcome	Reference Risk of Bias	Active Drug Dose	Control Drug Dose	Events/ Randomized [Rate of Outcome in Active Group]	Events/ Randomized [Rate of Outcome in Control Group]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Patients using pain medications at endpoint	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 -16:142.5mg	Nebivolol 5mg daily	10/14 [71.4]	10/16 [62.5]	1.1 (0.7 to 1.9)	0.09 (-0.25 to 0.42)
Pain intensity: mild	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	6/135 [4.4]	9/135 [6.7]	0.7 (0.2 to 1.8)	-0.02 (-0.08 to 0.03)
Reduction of attacks more than 50%	Grotemeyer, 1990¹⁸⁵ Medium	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 1500mg/day (14/28 [50.0]	3/28 [10.7]	4.7 (1.5 to 14.5)	0.39 (0.18 to 0.61)
Photophobia: mild	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	17/135 [12.6]	23/135 [17.0]	0.7 (0.4 to 1.3)	-0.04 (-0.13 to 0.04)
Phonophobia: mild	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	25/135 [18.5]	17/135 [12.6]	1.5 (0.8 to 2.6)	0.06 (-0.03 to 0.15)
Nausea: mild	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	33/135 [24.4]	22/135 [16.3]	1.5 (0.9 to 2.4)	0.08 (-0.01 to 0.18)

Appendix Table D82. Comparative effectiveness of beta-blockers for migraine prevention in adults (results from randomized controlled clinical trials) (continued)

Definition of the Outcome	Reference Risk of Bias	Active Drug Dose	Control Drug Dose	Events/ Randomized [Rate of Outcome in Active Group]	Events/ Randomized [Rate of Outcome in Control Group]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Vomiting: mild	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	38/135 [28.1]	32/135 [23.7]	1.2 (0.8 to 1.8)	0.04 (-0.06 to 0.15)
Responder rate (Reduction in the number of migraine attacks greater than 50%)	Diener, 2001¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	40/135 [29.6]	61/135 [45.2]	0.7 (0.5 to 0.9)	-0.16 (-0.27 to -0.04)
Reduction of more than 50% in the number of migraine days	Louis, 1985 ¹⁸³ Medium	Metoprolol 50mg BID	Clonidine 50µg BID	10/31 [32.3]	8/31 [25.8]	1.3 (0.6 to 2.7)	0.06 (-0.16 to 0.29)
Migraine days with nausea symptoms	Louis, 1985 ¹⁸³ Medium	Metoprolol 50mg BID	Clonidine 50µg BID	11/31 [35.0]	12/31 [39.0]	0.9 (0.5 to 1.8)	-0.03 (-0.27 to 0.21)
Migraine attacks accompanied by visual disturbances	Louis, 1985 ¹⁸³ Medium	Metoprolol 50mg BID	Clonidine 50µg BID	12/31 [38.7]	17/31 [54.8]	0.7 (0.4 to 1.2)	-0.16 (-0.41 to 0.08)
Subjective therapeutic evaluation: Marked or moderate	Louis, 1985 ¹⁸³ Medium	Metoprolol 50mg BID	Clonidine 50µg BID	22/31 [71.0]	15/31 [48.4]	1.5 (1.0 to 2.2)	0.23 (-0.01 to 0.46)
Number of migraine days reduced	Louis, 1985¹⁸³ Medium	Metoprolol 50mg BID	Clonidine 50µg BID	24/31 [77.4]	14/31 [45.2]	1.7 (1.1 to 2.6)	0.32 (0.09 to 0.55)

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D83. Exploratory Network Bayesian Meta-analysis of clinical response (defined as $\geq 50\%$ reduction in migraine or self reported substantial reduction in monthly migraine frequency) with preventive approved drugs and off label drug classes in adults, results from randomized controlled clinical trials

Active Class	Control Class	Active Drug	Control Drugs	Risk of Bias, Reference	Events/ Randomized In Active Group	Events/Randomized in Control Group	Events/Randomized in the Second control Group
Placebo	Beta-blocker	Placebo	Propranolol	Medium ⁵⁰	17/83	34/83	NA/1
Anti-epileptic	Antidepressant	Topiramate	Amitriptyline	Low ¹⁷²	99/178	78/169	NA/1
Anti-epileptic	Anti-epileptic	Topiramate	Levetiracetam	Medium ¹⁶⁸	8/13	8/15	NA/1
Anti-epileptic	Anti-epileptic	Topiramate	Valproate	High ¹⁶⁶	20/22	21/22	NA/1
Anti-epileptic	Beta-blocker	Divalproex	Propranolol	High ⁶⁸	24/37	25/37	NA/1
Anti-epileptic	Other	Valproate	Cinnarizine	Low ¹⁹⁰	37/58	41/67	NA/1
Anti-epileptic	Other	Topiramate	Histamine	Low ¹⁶⁹	27/45	30/45	NA/1
Anti-epileptic	Other	Topiramate	Zonisamide	Medium ¹⁷³	16/40	15/40	NA/1
Beta-blocker	Anti-adrenergic	Metoprolol	Clonidine	Medium ¹⁸³	10/31	8/31	NA/1
Beta-blocker	Anti-adrenergic	Propranolol	Clonidine	Medium ⁶⁹	13/23	8/23	NA/1
Beta-blocker	Antidepressant	Propranolol	Amitriptyline	Medium ⁷⁶	12/54	10/54	NA/1
Beta-blocker	Antidepressant	Propranolol	Femoxetine	Medium ⁷⁷	3/15	1/14	NA/1
Beta-blocker	Antidepressant	Propranolol	Femoxetine	Medium ⁷⁷	1/13	3/11	NA/1
Beta-blocker	Antidepressant	Propranolol	Nortriptyline	Medium ⁷⁵	11/25	7/24	NA/1
Beta-blocker	Beta-blocker	Propranolol	Metoprolol	Medium ⁷⁰	15/36	17/36	NA/1
Beta-blocker	Beta-blocker Ca++ blocker	Propranolol	Metoprolol, Nifedipine	Medium ⁷¹	0/19	6/22	0/17
Beta-blocker	Beta-blocker	Propranolol	Nadolol	Medium ^{73, 191}	9/15	5/13	NA/1
Beta-blocker	Beta-blocker	Propranolol	Nadolol	Medium ¹⁹¹	5/44	18/47	NA/1
Beta-blocker	Calcium Channel Blockers	Propranolol	Nifedipine	High ⁷⁴	12/20	6/20	NA/1
Beta-blocker	Other	Propranolol	Cinnarizine	Low ⁷³	1/14	2/14	NA/1
NSAID	Beta-blocker	Aspirin	Metoprolol	Medium ¹⁸⁵	3/28	14/28	NA/1
NSAID	Beta-blocker	Aspirin	Metoprolol	Low ¹⁸⁸	61/135	40/135	NA/1
Placebo	ACE Inhibitors	Placebo	Captopril	Low ¹³⁷	0/12	8/12	NA/1
Placebo	ACE Inhibitors	Placebo	Lisinopril	Low ¹³⁶	0/60	14/60	NA/1
Placebo	Anti-adrenergic	Placebo	Clonidine	Medium ¹⁴³	0/30	10/30	NA/1
Placebo	Antidepressant	Placebo	Amitriptyline	Medium ¹⁰³	18/61	26/55	NA/1
Placebo	Antidepressant	Placebo	Amitriptyline	Medium ¹¹¹	48/197	47/194	NA/1
Placebo	Antidepressant	Placebo	Amitriptyline	Medium ¹¹²	7/36	16/37	NA/1
Placebo	Antidepressant	Placebo	Fluoxetine	Medium ¹¹⁶	1/16	6/16	NA/1
Placebo	Antidepressant	Placebo	Venlafaxine	Medium ¹²²	0/19	9/21	NA/1
Placebo	Anti-epileptic	Placebo	Acetazolamide	Low ⁸⁰	9/27	8/26	NA/1

Appendix Table D83. Exploratory Network Bayesian Meta-analysis of clinical response (defined as $\geq 50\%$ reduction in migraine or self reported substantial reduction in monthly migraine frequency) with preventive approved drugs and off label drug classes in adults, results from randomized controlled clinical trials (continued)

Active Class	Control Class	Active Drug	Control Drugs	Risk of Bias, Reference	Events/ Randomized In Active Group	Events/Randomized in Control Group	Events/Randomized in the Second control Group
Placebo	Anti-epileptic	Placebo	Carbamazepin	Medium ⁸⁶	5/48	26/48	NA/1
Placebo	Anti-epileptic	Placebo	Divalproex	Medium ⁴⁵	5/37	33/70	NA/1
Placebo	Anti-epileptic	Placebo	Divalproex	Low ⁴⁷	2/15	19/44	NA/1
Placebo	Anti-epileptic	Placebo	Divalproex	Low ⁴⁶	32/116	50/123	NA/1
Placebo	Anti-epileptic	Placebo	Gabapentin	Medium ⁸⁴	12/22	18/23	NA/1
Placebo	Anti-epileptic	Placebo	Gabapentin	Medium ⁸¹	5/45	26/98	NA/1
Placebo	Anti-epileptic	Placebo	Gabapentin	Low ¹⁹²	10/20	40/62	NA/1
Placebo	Anti-epileptic	Placebo	Oxcarbazepine	Low ⁸³	31/85	28/85	NA/1
Placebo	Anti-epileptic	Placebo	Valproate	Medium ⁴⁹	6/43	17/43	NA/1
Placebo	Anti-epileptic	Placebo	Topiramate	Medium ³¹	8/36	58/112	NA/1
Placebo	Anti-epileptic	Placebo	Topiramate	Low ³³	16/372	8/384	NA/1
Placebo	Anti-epileptic	Placebo	Topiramate	Low ⁴¹	50/163	64/165	NA/1
Placebo	Anti-epileptic	Placebo	Topiramate	Low ¹⁸	2/21	5/19	NA/1
Placebo	Anti-epileptic	Placebo	Topiramate	Low ²⁰	1/14	10/14	NA/1
Placebo	Anti-epileptic	Placebo	Topiramate	Medium ²⁴	12/57	37/58	NA/1
Placebo	Anti-epileptic	Placebo	Topiramate	Low ²⁵	93/372	188/386	NA/1
Placebo	Anti-epileptic	Placebo	Topiramate	Medium ²⁹	25/73	55/140	NA/1
Placebo	Anti-epileptic	Placebo	Topiramate	Medium ³⁴	0/27	7/32	NA/1
Placebo	Anti-epileptic Beta-blocker	Placebo	Topiramate, propranolol	Low ⁴³	11/49	50/144	62/144
Placebo	Anti-epileptic	Placebo	Topiramate, lamotrigine	Low ⁴⁴	18/60	38/60	28/60
Placebo	Angiotensin II Antagonists	Placebo	Candesartan	Low ¹³⁸	2/60	23/60	NA/1
Placebo	Angiotensin II Antagonists	Placebo	Telmisartan	High ¹³⁹	11/47	16/48	NA/1
Placebo	Beta-blocker	Placebo	Acebutolol	Medium ⁹¹	2/43	13/43	NA/1
Placebo	Beta-blocker	Placebo	Alprenolol	Medium ⁹⁰	12/33	11/33	NA/1
Placebo	Beta-blocker	Placebo	Atenolol	Medium ⁹⁵	0/24	8/24	NA/1
Placebo	Beta-blocker	Placebo	Metoprolol	Medium ¹⁰⁰	16/77	29/77	NA/1
Placebo	Beta-blocker	Placebo	Metoprolol	Medium ⁹⁷	4/37	10/34	NA/1
Placebo	Beta-blocker	Placebo	Nadolol	Low ⁹⁸	0/8	6/24	NA/1
Placebo	Beta-blocker	Placebo	Pindolol	Medium ⁸⁹	0/28	3/28	NA/1
Placebo	Beta-blocker Antiadrenergic	Placebo	Practolol, clonidine	Unclear ¹⁵⁰	13/50	21/50	22/50

Appendix Table D83. Exploratory Network Bayesian Meta-analysis of clinical response (defined as $\geq 50\%$ reduction in migraine or self reported substantial reduction in monthly migraine frequency) with preventive approved drugs and off label drug classes in adults, results from randomized controlled clinical trials (continued)

Active Class	Control Class	Active Drug	Control Drugs	Risk of Bias, Reference	Events/ Randomized In Active Group	Events/Randomized in Control Group	Events/Randomized in the Second control Group
Placebo	Beta-blocker	Placebo	Propranolol, Timolol	Medium ⁶⁰	12/48	48/96	44/96
Placebo	Beta-blocker	Placebo	Propranolol	Medium ⁶⁵	0/11	5/8	NA/1
Placebo	Beta-blocker	Placebo	Propranolol, Timolol	Medium ⁶¹	3/13	13/25	14/25
Placebo	Beta-blocker	Placebo	Propranolol	Low ¹⁹³	6/16	18/53	NA/1
Placebo	Beta-blocker	Placebo	Timolol	Medium ⁹²	0/14	2/14	NA/1
Placebo	Beta-blocker	Placebo	Timolol	Medium ⁷⁹	10/47	25/47	NA/1
Placebo	Calcium Channel Blockers	Placebo	Nifedipine	Medium ¹³⁵	4/36	20/36	NA/1
Placebo	Calcium Channel Blockers	Placebo	Nimodipine	Medium ¹³²	0/33	10/33	NA/1
Placebo	Calcium Channel Blockers	Placebo	Nimodipine	Medium ¹²⁷	4/30	8/30	NA/1
Placebo	Ergot alkaloid	Placebo	Dihydroergotamine	Low ¹⁵⁵	112/200	112/184	NA/1
Placebo	Ergot alkaloid	Placebo	Lisuride	Medium ¹⁵⁸	19/75	28/75	NA/1
Placebo	Magnesium	Placebo	Magnesium	Low ¹⁹⁴	10/34	10/35	NA/1
Placebo	Magnesium	Placebo	Magnesium	Low ¹⁹⁵	7/32	14/36	NA/1
Placebo	NSAID	Placebo	Aspirin	Low ¹⁹⁶	818/11034	661/11037	NA/1
Placebo	NSAID	Placebo	Aspirin	Medium ¹⁹⁷	1/40	17/40	NA/1
Placebo	NSAID	Placebo	Fenoprofen	Low ¹⁹⁸	11/35	10/38	NA/1
Placebo	NSAID	Placebo	Flurbiprofen	Medium ¹⁹⁹	7/23	16/23	NA/1
Placebo	NSAID	Placebo	Indomethacin	Medium ²⁰⁰	5/19	6/19	NA/1
Placebo	NSAID	Placebo	Rofecoxib	Medium ²⁰¹	8/84	20/91	NA/1
Placebo	NSAID	Placebo	Tolfenamic Acid	Medium ²⁰²	2/31	14/31	NA/1
Placebo	Other	Placebo	Montelukast	Low ²⁰³	18/84	23/93	NA/1
Placebo	Other	Placebo	Tonabersat	Low ¹²¹	24/65	24/59	NA/1

NA = Not available from 2 arms trials

Appendix Table D84. Clinical response defined as ≥50 percent reduction in monthly migraine frequency or self reported substantial reduction in monthly migraine frequency; indirect adjusted frequentist comparisons of migraine preventive drugs in adults from RCTs (analyzed for drugs that were more effective than placebo) (Strength of indirect evidence is low due to risk of bias and imprecision)

Active Drug, Reference	Control Drug, Reference	Odds Ratio (95% CI) with Active Drug vs. Placebo	Odds Ratio (95% CI) with Control Drug vs. Placebo	Odds Ratio (95% CI) with Active vs. Control Drug	Risk of Bias
Divalproex ⁴⁵⁻⁴⁷	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	3.2 (1.3 to 7.5)	3.4 (2.1 to 5.6)	0.9 (0.3 to 2.5)	Medium
Propranolol ^{43, 50, 60, 61}	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	2.8 (1.9 to 4.2)	3.4 (2.1 to 5.6)	0.8 (0.4 to 1.6)	Medium
Timolol ^{60, 61, 79}	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	3.3 (1.9 to 5.6)	3.4 (2.1 to 5.6)	1.0 (0.5 to 2.0)	Medium
Valproate ⁴⁹	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	4.0 (1.4 to 11.6)	3.4 (2.1 to 5.6)	1.2 (0.4 to 3.8)	Medium
Valproate ⁴⁹	Divalproex ⁴⁵⁻⁴⁷	4.0 (1.4 to 11.6)	3.2 (1.3 to 7.5)	1.3 (0.3 to 5.0)	Medium
Divalproex ⁴⁵⁻⁴⁷	Propranolol ^{43, 50, 60, 61}	3.2 (1.3 to 7.5)	2.8 (1.9 to 4.2)	1.1 (0.4 to 2.9)	Medium
Valproate ⁴⁹	Propranolol ^{43, 50, 60, 61}	4.0 (1.4 to 11.6)	2.8 (1.9 to 4.2)	1.4 (0.5 to 4.5)	Medium
Divalproex ⁴⁵⁻⁴⁷	Timolol ^{60, 61, 79}	3.2 (1.3 to 7.5)	3.3 (1.9 to 5.6)	1.0 (0.4 to 2.7)	Medium
Propranolol ^{43, 50, 60, 61}	Timolol ^{60, 61, 79}	2.8 (1.9 to 4.2)	3.3 (1.9 to 5.6)	0.9 (0.4 to 1.7)	Medium
Valproate ⁴⁹	Timolol ^{60, 61, 79}	4.0 (1.4 to 11.6)	3.3 (1.9 to 5.6)	1.2 (0.4 to 4.1)	Medium
Divalproex ⁴⁵⁻⁴⁷	Magnesium ^{194, 195}	3.2 (1.3 to 7.5)	1.5 (0.6 to 3.4)	2.2 (0.6 to 7.2)	Medium
Valproate ⁴⁹	Magnesium ^{194, 195}	4.0 (1.4 to 11.6)	1.5 (0.6 to 3.4)	2.8 (0.7 to 10.7)	Medium
Divalproex ⁴⁵⁻⁴⁷	Gabapentin ^{81, 84, 192}	3.2 (1.3 to 7.5)	2.4 (1.3 to 4.6)	1.3 (0.4 to 3.8)	Medium
Valproate ⁴⁹	Gabapentin ^{81, 84, 192}	4.0 (1.4 to 11.6)	2.4 (1.3 to 4.6)	1.7 (0.5 to 5.7)	Medium
Divalproex ⁴⁵⁻⁴⁷	Nimodipine ^{127, 132}	3.2 (1.3 to 7.5)	6.0 (0.5 to 66.2)	0.5 (0.0 to 6.7)	Medium
Valproate ⁴⁹	Nimodipine ^{127, 132}	4.0 (1.4 to 11.6)	6.0 (0.5 to 66.2)	0.7 (0.0 to 9.2)	Medium
Telmisartan ¹³⁹	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	1.6 (0.7 to 4.0)	3.4 (2.1 to 5.6)	0.5 (0.2 to 1.4)	High
Telmisartan ¹³⁹	Divalproex ^{45, 46}	1.6 (0.7 to 4.0)	3.2 (1.3 to 7.5)	0.5 (0.1 to 1.8)	High
Telmisartan ¹³⁹	Propranolol ^{43, 50, 60, 61}	1.6 (0.7 to 4.0)	2.8 (1.9 to 4.2)	0.6 (0.2 to 1.6)	High
Telmisartan ¹³⁹	Timolol ^{60, 61, 79}	1.6 (0.7 to 4.0)	3.3 (1.9 to 5.6)	0.5 (0.2 to 1.4)	High
Telmisartan ¹³⁹	Valproate ⁴⁹	1.6 (0.7 to 4.0)	4.0 (1.4 to 11.6)	0.4 (0.1 to 1.6)	High
Candesartan ¹³⁸	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	18.0 (4.0 to 81.0)	3.4 (2.1 to 5.6)	5.3 (1.1 to 26.0)	Low
Dihydroergotamine ¹⁵⁵	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	1.2 (0.8 to 1.8)	3.4 (2.1 to 5.6)	0.4 (0.2 to 0.7)	Low
Lamotrigine ⁴⁴	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	1.8 (0.8 to 3.7)	3.4 (2.1 to 5.6)	0.5 (0.2 to 1.3)	Low
Lisinopril ¹³⁶	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	37.7 (2.2 to 649.0)	3.4 (2.1 to 5.6)	11.2 (0.6 to 200.5)	Low
Magnesium ^{194, 195}	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	1.5 (0.6 to 3.4)	3.4 (2.1 to 5.6)	0.4 (0.2 to 1.2)	Low
Montelukast ²⁰³	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	1.2 (0.6 to 2.4)	3.4 (2.1 to 5.6)	0.4 (0.2 to 0.8)	Low
Nadolol ⁹⁸	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	6.0 (0.3 to 118.6)	3.4 (2.1 to 5.6)	1.8 (0.1 to 36.6)	Low
Tonabersat ¹²¹	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	1.2 (0.6 to 2.4)	3.4 (2.1 to 5.6)	0.3 (0.1 to 0.8)	Low
Candesartan ¹³⁸	Divalproex ⁴⁵⁻⁴⁷	18.0 (4.0 to 81.0)	3.2 (1.3 to 7.5)	5.7 (1.0 to 32.2)	Medium
Dihydroergotamine ¹⁵⁵	Divalproex ⁴⁵⁻⁴⁷	1.2 (0.8 to 1.8)	3.2 (1.3 to 7.5)	0.4 (0.1 to 1.0)	Medium
Lamotrigine ⁴⁴	Divalproex ⁴⁵⁻⁴⁷	1.8 (0.8 to 3.7)	3.2 (1.3 to 7.5)	0.6 (0.2 to 1.7)	Medium
Lisinopril ¹³⁶	Divalproex ⁴⁵⁻⁴⁷	37.7 (2.2 to 649.0)	3.2 (1.3 to 7.5)	11.9 (0.6 to 233.2)	Medium
Montelukast ²⁰³	Divalproex ⁴⁵⁻⁴⁷	1.2 (0.6 to 2.4)	3.2 (1.3 to 7.5)	0.4 (0.1 to 1.2)	Medium
Nadolol ⁹⁸	Divalproex ⁴⁵⁻⁴⁷	6.0 (0.3 to 118.6)	3.2 (1.3 to 7.5)	1.9 (0.1 to 42.4)	Medium

Appendix Table D84. Clinical response defined as ≥ 50 percent reduction in monthly migraine frequency or self reported substantial reduction in monthly migraine frequency; indirect adjusted frequentist comparisons of migraine preventive drugs in adults from RCTs (analyzed for drugs that were more effective than placebo) (Strength of indirect evidence is low due to risk of bias and imprecision) (continued)

Active Drug, Reference	Control Drug, Reference	Odds Ratio (95% CI) with Active Drug vs. Placebo	Odds Ratio (95% CI) with Control Drug vs. Placebo	Odds Ratio (95% CI) with Active vs. Control Drug	Risk of Bias
Tonabersat ¹²¹	Divalproex ⁴⁵⁻⁴⁷	1.2 (0.6 to 2.4)	3.2 (1.3 to 7.5)	0.4 (0.1 to 1.1)	Medium
Candesartan ¹³⁸	Propranolol ^{43, 50, 60, 61}	18.0 (4.0 to 81.0)	2.8 (1.9 to 4.2)	6.4 (1.4 to 30.4)	Medium
Dihydroergotamine ¹⁵⁵	Propranolol ^{43, 50, 60, 61}	1.2 (0.8 to 1.8)	2.8 (1.9 to 4.2)	0.4 (0.2 to 0.8)	Medium
Lamotrigine ⁴⁴	Propranolol ^{43, 50, 60, 61}	1.8 (0.8 to 3.7)	2.8 (1.9 to 4.2)	0.6 (0.3 to 1.4)	Medium
Lisinopril ¹³⁶	Propranolol ^{43, 50, 60, 61}	37.7 (2.2 to 649.0)	2.8 (1.9 to 4.2)	13.4 (0.8 to 237.7)	Medium
Magnesium ^{194, 195}	Propranolol ^{43, 50, 60, 61}	1.5 (0.6 to 3.4)	2.8 (1.9 to 4.2)	0.5 (0.2 to 1.3)	Medium
Montelukast ²⁰³	Propranolol ^{43, 50, 60, 61}	1.2 (0.6 to 2.4)	2.8 (1.9 to 4.2)	0.4 (0.2 to 1.0)	Medium
Nadolol ⁹⁸	Propranolol ^{43, 50, 60, 61}	6.0 (0.3 to 118.6)	2.8 (1.9 to 4.2)	2.1 (0.1 to 43.4)	Medium
Tonabersat ¹²¹	Propranolol ^{43, 50, 60, 61}	1.2 (0.6 to 2.4)	2.8 (1.9 to 4.2)	0.4 (0.2 to 1.0)	Medium
Candesartan ¹³⁸	Timolol ^{60, 61, 79}	18.0 (4.0 to 81.0)	3.3 (1.9 to 5.6)	5.5 (1.1 to 27.3)	Medium
Dihydroergotamine ¹⁵⁵	Timolol ^{60, 61, 79}	1.2 (0.8 to 1.8)	3.3 (1.9 to 5.6)	0.4 (0.2 to 0.7)	Medium
Lamotrigine ⁴⁴	Timolol ^{60, 61, 79}	1.8 (0.8 to 3.7)	3.3 (1.9 to 5.6)	0.5 (0.2 to 1.3)	Medium
Lisinopril ¹³⁶	Timolol ^{60, 61, 79}	37.7 (2.2 to 649.0)	3.3 (1.9 to 5.6)	11.6 (0.6 to 209.6)	Medium
Magnesium ^{194, 195}	Timolol ^{60, 61, 79}	1.5 (0.6 to 3.4)	3.3 (1.9 to 5.6)	0.4 (0.2 to 1.2)	Medium
Montelukast ²⁰³	Timolol ^{60, 61, 79}	1.2 (0.6 to 2.4)	3.3 (1.9 to 5.6)	0.4 (0.2 to 0.9)	Medium
Nadolol ⁹⁸	Timolol ^{60, 61, 79}	6.0 (0.3 to 118.6)	3.3 (1.9 to 5.6)	1.8 (0.1 to 38.2)	Medium
Tonabersat ¹²¹	Timolol ^{60, 61, 79}	1.2 (0.6 to 2.4)	3.3 (1.9 to 5.6)	0.4 (0.1 to 0.9)	Medium
Candesartan ¹³⁸	Valproate ⁴⁹	18.0 (4.0 to 81.0)	4.0 (1.4 to 11.6)	4.5 (0.7 to 28.1)	Medium
Dihydroergotamine ¹⁵⁵	Valproate ⁴⁹	1.2 (0.8 to 1.8)	4.0 (1.4 to 11.6)	0.3 (0.1 to 0.9)	Medium
Lamotrigine ⁴⁴	Valproate ⁴⁹	1.8 (0.8 to 3.7)	4.0 (1.4 to 11.6)	0.4 (0.1 to 1.6)	Medium
Lisinopril ¹³⁶	Valproate ⁴⁹	37.7 (2.2 to 649.0)	4.0 (1.4 to 11.6)	9.4 (0.4 to 194.7)	Medium
Montelukast ²⁰³	Valproate ⁴⁹	1.2 (0.6 to 2.4)	4.0 (1.4 to 11.6)	0.3 (0.1 to 1.1)	Medium
Nadolol ⁹⁸	Valproate ⁴⁹	6.0 (0.3 to 118.6)	4.0 (1.4 to 11.6)	1.5 (0.1 to 35.3)	Medium
Tonabersat ¹²¹	Valproate ⁴⁹	1.2 (0.6 to 2.4)	4.0 (1.4 to 11.6)	0.3 (0.1 to 1.0)	Medium
Acebutolol ⁹¹	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	8.9 (1.9 to 42.3)	3.4 (2.1 to 5.6)	2.6 (0.5 to 13.5)	Medium
Amitriptyline ¹¹²	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	3.2 (1.1 to 9.0)	3.4 (2.1 to 5.6)	0.9 (0.3 to 3.0)	Medium
Atenolol ⁹⁵	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	25.2 (1.4 to 467.9)	3.4 (2.1 to 5.6)	7.5 (0.4 to 144.4)	Medium
Flurbiprofen ¹⁹⁹	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	5.2 (1.5 to 18.3)	3.4 (2.1 to 5.6)	1.5 (0.4 to 6.0)	Medium
Gabapentin ^{81, 84, 192}	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	2.4 (1.3 to 4.6)	3.4 (2.1 to 5.6)	0.7 (0.3 to 1.6)	Medium
Indomethacin ²⁰⁰	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	1.3 (0.3 to 5.3)	3.4 (2.1 to 5.6)	0.4 (0.1 to 1.7)	Medium
Lisuride ¹⁵⁸	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	1.8 (0.9 to 3.5)	3.4 (2.1 to 5.6)	0.5 (0.2 to 1.2)	Medium
Nifedipine ¹³⁵	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	10.0 (2.9 to 34.2)	3.4 (2.1 to 5.6)	3.0 (0.8 to 11.2)	Medium
Nimodipine ^{127, 132}	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	6.0 (0.5 to 66.2)	3.4 (2.1 to 5.6)	1.8 (0.2 to 20.6)	Medium
Rofecoxib ²⁰¹	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	2.7 (1.1 to 6.5)	3.4 (2.1 to 5.6)	0.8 (0.3 to 2.2)	Medium
Tofenamic Acid ²⁰²	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	11.9 (2.4 to 59.0)	3.4 (2.1 to 5.6)	3.5 (0.7 to 18.8)	Medium

Appendix Table D84. Clinical response defined as ≥ 50 percent reduction in monthly migraine frequency or self reported substantial reduction in monthly migraine frequency; indirect adjusted frequentist comparisons of migraine preventive drugs in adults from RCTs (analyzed for drugs that were more effective than placebo) (Strength of indirect evidence is low due to risk of bias and imprecision) (continued)

Active Drug, Reference	Control Drug, Reference	Odds Ratio (95% CI) with Active Drug vs. Placebo	Odds Ratio (95% CI) with Control Drug vs. Placebo	Odds Ratio (95% CI) with Active vs. Control Drug	Risk of Bias
Amitriptyline ¹¹²	Divalproex ⁴⁵⁻⁴⁷	3.2 (1.1 to 9.0)	3.2 (1.3 to 7.5)	1.0 (0.3 to 3.9)	Medium
Atenolol ⁹⁵	Divalproex ⁴⁵⁻⁴⁷	25.2 (1.4 to 467.9)	3.2 (1.3 to 7.5)	8.0 (0.4 to 167.6)	Medium
Flurbiprofen ¹⁹⁹	Divalproex ⁴⁵⁻⁴⁷	5.2 (1.5 to 18.3)	3.2 (1.3 to 7.5)	1.7 (0.4 to 7.6)	Medium
Indomethacin ²⁰⁰	Divalproex ⁴⁵⁻⁴⁷	1.3 (0.3 to 5.3)	3.2 (1.3 to 7.5)	0.4 (0.1 to 2.1)	Medium
Lisuride ¹⁵⁸	Divalproex ⁴⁵⁻⁴⁷	1.8 (0.9 to 3.5)	3.2 (1.3 to 7.5)	0.6 (0.2 to 1.7)	Medium
Nifedipine ¹³⁵	Divalproex ⁴⁵⁻⁴⁷	10.0 (2.9 to 34.2)	3.2 (1.3 to 7.5)	3.2 (0.7 to 14.2)	Medium
Rofecoxib ²⁰¹	Divalproex ⁴⁵⁻⁴⁷	2.7 (1.1 to 6.5)	3.2 (1.3 to 7.5)	0.8 (0.2 to 2.9)	Medium
Tolfenamic Acid ²⁰²	Divalproex ⁴⁵⁻⁴⁷	11.9 (2.4 to 59.0)	3.2 (1.3 to 7.5)	3.8 (0.6 to 23.2)	Medium
Acebutolol ⁹¹	Propranolol ^{43, 50, 60, 61}	8.9 (1.9 to 42.3)	2.8 (1.9 to 4.2)	3.2 (0.6 to 15.9)	Medium
Amitriptyline ¹¹²	Propranolol ^{43, 50, 60, 61}	3.2 (1.1 to 9.0)	2.8 (1.9 to 4.2)	1.1 (0.4 to 3.5)	Medium
Atenolol ⁹⁵	Propranolol ^{43, 50, 60, 61}	25.2 (1.4 to 467.9)	2.8 (1.9 to 4.2)	9.0 (0.5 to 171.2)	Medium
Flurbiprofen ¹⁹⁹	Propranolol ^{43, 50, 60, 61}	5.2 (1.5 to 18.3)	2.8 (1.9 to 4.2)	1.9 (0.5 to 7.0)	Medium
Gabapentin ^{81, 84, 192}	Propranolol ^{43, 50, 60, 61}	2.4 (1.3 to 4.6)	2.8 (1.9 to 4.2)	0.9 (0.4 to 1.8)	Medium
Indomethacin ²⁰⁰	Propranolol ^{43, 50, 60, 61}	1.3 (0.3 to 5.3)	2.8 (1.9 to 4.2)	0.5 (0.1 to 2.0)	Medium
Lisuride ¹⁵⁸	Propranolol ^{43, 50, 60, 61}	1.8 (0.9 to 3.5)	2.8 (1.9 to 4.2)	0.6 (0.3 to 1.4)	Medium
Nifedipine ¹³⁵	Propranolol ^{43, 50, 60, 61}	10.0 (2.9 to 34.2)	2.8 (1.9 to 4.2)	3.6 (1.0 to 13.0)	Medium
Nimodipine ^{127, 132}	Propranolol ^{43, 50, 60, 61}	6.0 (0.5 to 66.2)	2.8 (1.9 to 4.2)	2.1 (0.2 to 24.3)	Medium
Rofecoxib ²⁰¹	Propranolol ^{43, 50, 60, 61}	2.7 (1.1 to 6.5)	2.8 (1.9 to 4.2)	1.0 (0.4 to 2.5)	Medium
Tolfenamic Acid ²⁰²	Propranolol ^{43, 50, 60, 61}	11.9 (2.4 to 59.0)	2.8 (1.9 to 4.2)	4.2 (0.8 to 22.1)	Medium
Acebutolol ⁹¹	Timolol ^{60, 61, 79}	8.9 (1.9 to 42.3)	3.3 (1.9 to 5.6)	2.7 (0.5 to 14.2)	Medium
Amitriptyline ¹¹²	Timolol ^{60, 61, 79}	3.2 (1.1 to 9.0)	3.3 (1.9 to 5.6)	1.0 (0.3 to 3.2)	Medium
Atenolol ⁹⁵	Timolol ^{60, 61, 79}	25.2 (1.4 to 467.9)	3.3 (1.9 to 5.6)	7.7 (0.4 to 150.9)	Medium
Flurbiprofen ¹⁹⁹	Timolol ^{60, 61, 79}	5.2 (1.5 to 18.3)	3.3 (1.9 to 5.6)	1.6 (0.4 to 6.3)	Medium
Gabapentin ^{81, 84, 192}	Timolol ^{60, 61, 79}	2.4 (1.3 to 4.6)	3.3 (1.9 to 5.6)	0.7 (0.3 to 1.7)	Medium
Indomethacin ²⁰⁰	Timolol ^{60, 61, 79}	1.3 (0.3 to 5.3)	3.3 (1.9 to 5.6)	0.4 (0.1 to 1.8)	Medium
Lisuride ¹⁵⁸	Timolol ^{60, 61, 79}	1.8 (0.9 to 3.5)	3.3 (1.9 to 5.6)	0.5 (0.2 to 1.3)	Medium
Nifedipine ¹³⁵	Timolol ^{60, 61, 79}	10.0 (2.9 to 34.2)	3.3 (1.9 to 5.6)	3.1 (0.8 to 11.8)	Medium
Nimodipine ^{127, 132}	Timolol ^{60, 61, 79}	6.0 (0.5 to 66.2)	3.3 (1.9 to 5.6)	1.8 (0.2 to 21.6)	Medium
Rofecoxib ²⁰¹	Timolol ^{60, 61, 79}	2.7 (1.1 to 6.5)	3.3 (1.9 to 5.6)	0.8 (0.3 to 2.3)	Medium
Tolfenamic Acid ²⁰²	Timolol ^{60, 61, 79}	11.9 (2.4 to 59.0)	3.3 (1.9 to 5.6)	3.7 (0.7 to 19.8)	Medium
Acebutolol ⁹¹	Valproate ⁴⁹	8.9 (1.9 to 42.3)	4.0 (1.4 to 11.6)	2.2 (0.3 to 14.5)	Medium
Amitriptyline ¹¹²	Valproate ⁴⁹	3.2 (1.1 to 9.0)	4.0 (1.4 to 11.6)	0.8 (0.2 to 3.5)	Medium
Atenolol ⁹⁵	Valproate ⁴⁹	25.2 (1.4 to 467.9)	4.0 (1.4 to 11.6)	6.3 (0.3 to 139.7)	Medium
Flurbiprofen ¹⁹⁹	Valproate ⁴⁹	5.2 (1.5 to 18.3)	4.0 (1.4 to 11.6)	1.3 (0.3 to 6.7)	Medium
Indomethacin ²⁰⁰	Valproate ⁴⁹	1.3 (0.3 to 5.3)	4.0 (1.4 to 11.6)	0.3 (0.1 to 1.9)	Medium

Appendix Table D84. Clinical response defined as ≥ 50 percent reduction in monthly migraine frequency or self reported substantial reduction in monthly migraine frequency; indirect adjusted frequentist comparisons of migraine preventive drugs in adults from RCTs (analyzed for drugs that were more effective than placebo) (Strength of indirect evidence is low due to risk of bias and imprecision) (continued)

Active Drug, Reference	Control Drug, Reference	Odds Ratio (95% CI) with Active Drug vs. Placebo	Odds Ratio (95% CI) with Control Drug vs. Placebo	Odds Ratio (95% CI) with Active vs. Control Drug	Risk of Bias
Lisuride ¹⁵⁸	Valproate ⁴⁹	1.8 (0.9 to 3.5)	4.0 (1.4 to 11.6)	0.4 (0.1 to 1.5)	Medium
Nifedipine ¹³⁵	Valproate ⁴⁹	10.0 (2.9 to 34.2)	4.0 (1.4 to 11.6)	2.5 (0.5 to 12.6)	Medium
Rofecoxib ²⁰¹	Valproate ⁴⁹	2.7 (1.1 to 6.5)	4.0 (1.4 to 11.6)	0.7 (0.2 to 2.6)	Medium
Tolfenamic Acid ²⁰²	Valproate ⁴⁹	11.9 (2.4 to 59.0)	4.0 (1.4 to 11.6)	3.0 (0.4 to 20.1)	Medium
Clonidine ¹⁵⁰	Topiramate ^{18, 20, 24, 25, 29, 31, 44}	2.2 (1.0 to 5.2)	3.4 (2.1 to 5.6)	0.7 (0.2 to 1.8)	Medium
Clonidine ¹⁵⁰	Divalproex ⁴⁵⁻⁴⁷	2.2 (1.0 to 5.2)	3.2 (1.3 to 7.5)	0.7 (0.2 to 2.4)	Medium
Clonidine ¹⁵⁰	Propranolol ^{43, 50, 60, 61}	2.2 (1.0 to 5.2)	2.8 (1.9 to 4.2)	0.8 (0.3 to 2.0)	Medium
Clonidine ¹⁵⁰	Timolo ^{60, 61, 79}	2.2 (1.0 to 5.2)	3.3 (1.9 to 5.6)	0.7 (0.3 to 1.9)	Medium
Clonidine ¹⁵⁰	Valproate ⁴⁹	2.2 (1.0 to 5.2)	4.0 (1.4 to 11.6)	0.6 (0.1 to 2.1)	Medium
Telmisartan ¹³⁹	Magnesium ^{194, 195}	1.6 (0.7 to 4.0)	1.5 (0.6 to 3.4)	1.1 (0.3 to 3.9)	High
Telmisartan ¹³⁹	Tonabersat ¹²¹	1.6 (0.7 to 4.0)	1.2 (0.6 to 2.4)	1.4 (0.4 to 4.4)	High
Telmisartan ¹³⁹	Gabapentin ^{81, 84, 192}	1.6 (0.7 to 4.0)	2.4 (1.3 to 4.6)	0.7 (0.2 to 2.0)	High
Telmisartan ¹³⁹	Nimodipine ^{127, 132}	1.6 (0.7 to 4.0)	6.0 (0.5 to 66.2)	0.3 (0.0 to 3.5)	High
Telmisartan ¹³⁹	Tolfenamic Acid ²⁰²	1.6 (0.7 to 4.0)	11.9 (2.4 to 59.0)	0.1 (0.0 to 0.9)	High
Candesartan ¹³⁸	Telmisartan ¹³⁹	18.0 (4.0 to 81.0)	1.6 (0.7 to 4.0)	11.0 (1.9 to 63.6)	High
Dihydroergotamine ¹⁵⁵	Telmisartan ¹³⁹	1.2 (0.8 to 1.8)	1.6 (0.7 to 4.0)	0.7 (0.3 to 2.0)	High
Lamotrigine ⁴⁴	Telmisartan ¹³⁹	1.8 (0.8 to 3.7)	1.6 (0.7 to 4.0)	1.1 (0.3 to 3.4)	High
Lisinopril ¹³⁶	Telmisartan ¹³⁹	37.7 (2.2 to 649.0)	1.6 (0.7 to 4.0)	23.1 (1.2 to 456.2)	High
Montelukast ²⁰³	Telmisartan ¹³⁹	1.2 (0.6 to 2.4)	1.6 (0.7 to 4.0)	0.7 (0.2 to 2.3)	High
Nadolol ⁹⁸	Telmisartan ¹³⁹	6.0 (0.3 to 118.6)	1.6 (0.7 to 4.0)	3.7 (0.2 to 82.9)	High
Candesartan ¹³⁸	Dihydroergotamine ¹⁵⁵	18.0 (4.0 to 81.0)	1.2 (0.8 to 1.8)	14.7 (3.1 to 70.0)	Low
Candesartan ¹³⁸	Fenoprofen ¹⁹⁸	18.0 (4.0 to 81.0)	0.8 (0.3 to 2.2)	23.1 (3.8 to 141.8)	Low
Dihydroergotamine ¹⁵⁵	Fenoprofen ¹⁹⁸	1.2 (0.8 to 1.8)	0.8 (0.3 to 2.2)	1.6 (0.5 to 4.7)	Low
Candesartan ¹³⁸	Lamotrigine ⁴⁴	18.0 (4.0 to 81.0)	1.8 (0.8 to 3.7)	10.3 (1.9 to 55.0)	Low
Dihydroergotamine ¹⁵⁵	Lamotrigine ⁴⁴	1.2 (0.8 to 1.8)	1.8 (0.8 to 3.7)	0.7 (0.3 to 1.6)	Low
Candesartan ¹³⁸	Lisinopril ¹³⁶	18.0 (4.0 to 81.0)	37.7 (2.2 to 649.0)	0.5 (0.0 to 11.9)	Low
Dihydroergotamine ¹⁵⁵	Lisinopril ¹³⁶	1.2 (0.8 to 1.8)	37.7 (2.2 to 649.0)	0.0 (0.0 to 0.6)	Low
Lamotrigine ⁴⁴	Lisinopril ¹³⁶	1.8 (0.8 to 3.7)	37.7 (2.2 to 649.0)	0.0 (0.0 to 0.9)	Low
Candesartan ¹³⁸	Magnesium ^{194, 195}	18.0 (4.0 to 81.0)	1.5 (0.6 to 3.4)	12.3 (2.2 to 69.1)	Low
Dihydroergotamine ¹⁵⁵	Magnesium ^{194, 195}	1.2 (0.8 to 1.8)	1.5 (0.6 to 3.4)	0.8 (0.3 to 2.1)	Low
Lamotrigine ⁴⁴	Magnesium ^{194, 195}	1.8 (0.8 to 3.7)	1.5 (0.6 to 3.4)	1.2 (0.4 to 3.7)	Low
Lisinopril ¹³⁶	Magnesium ^{194, 195}	37.7 (2.2 to 649.0)	1.5 (0.6 to 3.4)	25.8 (1.3 to 501.9)	Low
Montelukast ²⁰³	Magnesium ^{194, 195}	1.2 (0.6 to 2.4)	1.5 (0.6 to 3.4)	0.8 (0.3 to 2.5)	Low
Nadolol ⁹⁸	Magnesium ^{194, 195}	6.0 (0.3 to 118.6)	1.5 (0.6 to 3.4)	4.1 (0.2 to 91.2)	Low
Tonabersat ¹²¹	Magnesium ^{194, 195}	1.2 (0.6 to 2.4)	1.5 (0.6 to 3.4)	0.8 (0.3 to 2.4)	Low

Appendix Table D84. Clinical response defined as ≥ 50 percent reduction in monthly migraine frequency or self reported substantial reduction in monthly migraine frequency; indirect adjusted frequentist comparisons of migraine preventive drugs in adults from RCTs (analyzed for drugs that were more effective than placebo) (Strength of indirect evidence is low due to risk of bias and imprecision) (continued)

Active Drug, Reference	Control Drug, Reference	Odds Ratio (95% CI) with Active Drug vs. Placebo	Odds Ratio (95% CI) with Control Drug vs. Placebo	Odds Ratio (95% CI) with Active vs. Control Drug	Risk of Bias
Candesartan ¹³⁸	Montelukast ²⁰³	18.0 (4.0 to 81.0)	1.2 (0.6 to 2.4)	15.0 (2.8 to 78.6)	Low
Dihydroergotamine ¹⁵⁵	Montelukast ²⁰³	1.2 (0.8 to 1.8)	1.2 (0.6 to 2.4)	1.0 (0.5 to 2.3)	Low
Lamotrigine ⁴⁴	Montelukast ²⁰³	1.8 (0.8 to 3.7)	1.2 (0.6 to 2.4)	1.5 (0.5 to 4.0)	Low
Lisinopril ¹³⁶	Montelukast ²⁰³	37.7 (2.2 to 649.0)	1.2 (0.6 to 2.4)	31.3 (1.7 to 586.8)	Low
Candesartan ¹³⁸	Nadolol ⁹⁸	18.0 (4.0 to 81.0)	6.0 (0.3 to 118.6)	3.0 (0.1 to 85.6)	Low
Dihydroergotamine ¹⁵⁵	Nadolol ⁹⁸	1.2 (0.8 to 1.8)	6.0 (0.3 to 118.6)	0.2 (0.0 to 4.2)	Low
Lamotrigine ⁴⁴	Nadolol ⁹⁸	1.8 (0.8 to 3.7)	6.0 (0.3 to 118.6)	0.3 (0.0 to 6.4)	Low
Lisinopril ¹³⁶	Nadolol ⁹⁸	37.7 (2.2 to 649.0)	6.0 (0.3 to 118.6)	6.3 (0.1 to 391.4)	Low
Montelukast ²⁰³	Nadolol ⁹⁸	1.2 (0.6 to 2.4)	6.0 (0.3 to 118.6)	0.2 (0.0 to 4.3)	Low
Candesartan ¹³⁸	Oxcarbazepine ⁸³	18.0 (4.0 to 81.0)	0.9 (0.5 to 1.6)	21.1 (4.1 to 107.5)	Low
Dihydroergotamine ¹⁵⁵	Oxcarbazepine ⁸³	1.2 (0.8 to 1.8)	0.9 (0.5 to 1.6)	1.4 (0.7 to 3.0)	Low
Lamotrigine ⁴⁴	Oxcarbazepine ⁸³	1.8 (0.8 to 3.7)	0.9 (0.5 to 1.6)	2.0 (0.8 to 5.4)	Low
Lisinopril ¹³⁶	Oxcarbazepine ⁸³	37.7 (2.2 to 649.0)	0.9 (0.5 to 1.6)	44.1 (2.4 to 813.0)	Low
Montelukast ²⁰³	Oxcarbazepine ⁸³	1.2 (0.6 to 2.4)	0.9 (0.5 to 1.6)	1.4 (0.5 to 3.6)	Low
Nadolol ⁹⁸	Oxcarbazepine ⁸³	6.0 (0.3 to 118.6)	0.9 (0.5 to 1.6)	7.0 (0.3 to 148.1)	Low
Candesartan ¹³⁸	Tonabersat ¹²¹	18.0 (4.0 to 81.0)	1.2 (0.6 to 2.4)	15.4 (2.9 to 81.6)	Low
Dihydroergotamine ¹⁵⁵	Tonabersat ¹²¹	1.2 (0.8 to 1.8)	1.2 (0.6 to 2.4)	1.0 (0.5 to 2.4)	Low
Lamotrigine ⁴⁴	Tonabersat ¹²¹	1.8 (0.8 to 3.7)	1.2 (0.6 to 2.4)	1.5 (0.5 to 4.2)	Low
Lisinopril ¹³⁶	Tonabersat ¹²¹	37.7 (2.2 to 649.0)	1.2 (0.6 to 2.4)	32.2 (1.7 to 606.6)	Low
Montelukast ²⁰³	Tonabersat ¹²¹	1.2 (0.6 to 2.4)	1.2 (0.6 to 2.4)	1.0 (0.4 to 2.8)	Low
Nadolol ⁹⁸	Tonabersat ¹²¹	6.0 (0.3 to 118.6)	1.2 (0.6 to 2.4)	5.1 (0.2 to 110.4)	Low
Candesartan ¹³⁸	Carbamazepine ⁸⁶	18.0 (4.0 to 81.0)	10.2 (3.4 to 30.1)	1.8 (0.3 to 11.3)	Medium
Candesartan ¹³⁸	Flurbiprofen ¹⁹⁹	18.0 (4.0 to 81.0)	5.2 (1.5 to 18.3)	3.5 (0.5 to 24.5)	Medium
Dihydroergotamine ¹⁵⁵	Flurbiprofen ¹⁹⁹	1.2 (0.8 to 1.8)	5.2 (1.5 to 18.3)	0.2 (0.1 to 0.9)	Medium
Candesartan ¹³⁸	Gabapentin ^{81, 84, 192}	18.0 (4.0 to 81.0)	2.4 (1.3 to 4.6)	7.4 (1.4 to 37.8)	Medium
Dihydroergotamine ¹⁵⁵	Gabapentin ^{81, 84, 192}	1.2 (0.8 to 1.8)	2.4 (1.3 to 4.6)	0.5 (0.2 to 1.1)	Medium
Lamotrigine ⁴⁴	Gabapentin ^{81, 84, 192}	1.8 (0.8 to 3.7)	2.4 (1.3 to 4.6)	0.7 (0.3 to 1.9)	Medium
Lisinopril ¹³⁶	Gabapentin ^{81, 84, 192}	37.7 (2.2 to 649.0)	2.4 (1.3 to 4.6)	15.5 (0.8 to 285.4)	Medium
Montelukast ²⁰³	Gabapentin ^{81, 84, 192}	1.2 (0.6 to 2.4)	2.4 (1.3 to 4.6)	0.5 (0.2 to 1.3)	Medium
Nadolol ⁹⁸	Gabapentin ^{81, 84, 192}	6.0 (0.3 to 118.6)	2.4 (1.3 to 4.6)	2.4 (0.1 to 52.0)	Medium
Tonabersat ¹²¹	Gabapentin ^{81, 84, 192}	1.2 (0.6 to 2.4)	2.4 (1.3 to 4.6)	0.5 (0.2 to 1.3)	Medium
Candesartan ¹³⁸	Indomethacin ²⁰⁰	18.0 (4.0 to 81.0)	1.3 (0.3 to 5.3)	13.9 (1.8 to 109.3)	Medium
Dihydroergotamine ¹⁵⁵	Indomethacin ²⁰⁰	1.2 (0.8 to 1.8)	1.3 (0.3 to 5.3)	0.9 (0.2 to 4.1)	Medium
Candesartan ¹³⁸	Lisuride ¹⁵⁸	18.0 (4.0 to 81.0)	1.8 (0.9 to 3.5)	10.3 (2.0 to 53.9)	Medium
Dihydroergotamine ¹⁵⁵	Lisuride ¹⁵⁸	1.2 (0.8 to 1.8)	1.8 (0.9 to 3.5)	0.7 (0.3 to 1.6)	Medium

Appendix Table D84. Clinical response defined as ≥ 50 percent reduction in monthly migraine frequency or self reported substantial reduction in monthly migraine frequency; indirect adjusted frequentist comparisons of migraine preventive drugs in adults from RCTs (analyzed for drugs that were more effective than placebo) (Strength of indirect evidence is low due to risk of bias and imprecision) (continued)

Active Drug, Reference	Control Drug, Reference	Odds Ratio (95% CI) with Active Drug vs. Placebo	Odds Ratio (95% CI) with Control Drug vs. Placebo	Odds Ratio (95% CI) with Active vs. Control Drug	Risk of Bias
Lamotrigine ⁴⁴	Lisuride ¹⁵⁸	1.8 (0.8 to 3.7)	1.8 (0.9 to 3.5)	1.0 (0.4 to 2.8)	Medium
Lisinopril ¹³⁶	Lisuride ¹⁵⁸	37.7 (2.2 to 649.0)	1.8 (0.9 to 3.5)	21.5 (1.1 to 402.3)	Medium
Candesartan ¹³⁸	Nifedipine ¹³⁵	18.0 (4.0 to 81.0)	10.0 (2.9 to 34.2)	1.8 (0.3 to 12.6)	Medium
Dihydroergotamine ¹⁵⁵	Nifedipine ¹³⁵	1.2 (0.8 to 1.8)	10.0 (2.9 to 34.2)	0.1 (0.0 to 0.4)	Medium
Lamotrigine ⁴⁴	Nifedipine ¹³⁵	1.8 (0.8 to 3.7)	10.0 (2.9 to 34.2)	0.2 (0.0 to 0.7)	Medium
Lisinopril ¹³⁶	Nifedipine ¹³⁵	37.7 (2.2 to 649.0)	10.0 (2.9 to 34.2)	3.8 (0.2 to 83.7)	Medium
Montelukast ²⁰³	Nifedipine ¹³⁵	1.2 (0.6 to 2.4)	10.0 (2.9 to 34.2)	0.1 (0.0 to 0.5)	Medium
Nadolol ⁹⁸	Nifedipine ¹³⁵	6.0 (0.3 to 118.6)	10.0 (2.9 to 34.2)	0.6 (0.0 to 15.1)	Medium
Candesartan ¹³⁸	Nimodipine ^{127, 132}	18.0 (4.0 to 81.0)	6.0 (0.5 to 66.2)	3.0 (0.2 to 50.9)	Medium
Dihydroergotamine ¹⁵⁵	Nimodipine ^{127, 132}	1.2 (0.8 to 1.8)	6.0 (0.5 to 66.2)	0.2 (0.0 to 2.3)	Medium
Lamotrigine ⁴⁴	Nimodipine ^{127, 132}	1.8 (0.8 to 3.7)	6.0 (0.5 to 66.2)	0.3 (0.0 to 3.6)	Medium
Lisinopril ¹³⁶	Nimodipine ^{127, 132}	37.7 (2.2 to 649.0)	6.0 (0.5 to 66.2)	6.3 (0.2 to 259.5)	Medium
Magnesium ^{194, 195}	Nimodipine ^{127, 132}	1.5 (0.6 to 3.4)	6.0 (0.5 to 66.2)	0.2 (0.0 to 3.1)	Medium
Montelukast ²⁰³	Nimodipine ^{127, 132}	1.2 (0.6 to 2.4)	6.0 (0.5 to 66.2)	0.2 (0.0 to 2.4)	Medium
Nadolol ⁹⁸	Nimodipine ^{127, 132}	6.0 (0.3 to 118.6)	6.0 (0.5 to 66.2)	1.0 (0.0 to 45.9)	Medium
Tonabersat ¹²¹	Nimodipine ^{127, 132}	1.2 (0.6 to 2.4)	6.0 (0.5 to 66.2)	0.2 (0.0 to 2.4)	Medium
Candesartan ¹³⁸	Rofecoxib ²⁰¹	18.0 (4.0 to 81.0)	2.7 (1.1 to 6.5)	6.7 (1.2 to 38.5)	Medium
Dihydroergotamine ¹⁵⁵	Rofecoxib ²⁰¹	1.2 (0.8 to 1.8)	2.7 (1.1 to 6.5)	0.5 (0.2 to 1.2)	Medium
Lamotrigine ⁴⁴	Rofecoxib ²⁰¹	1.8 (0.8 to 3.7)	2.7 (1.1 to 6.5)	0.7 (0.2 to 2.1)	Medium
Lisinopril ¹³⁶	Rofecoxib ²⁰¹	37.7 (2.2 to 649.0)	2.7 (1.1 to 6.5)	14.1 (0.7 to 277.1)	Medium
Montelukast ²⁰³	Rofecoxib ²⁰¹	1.2 (0.6 to 2.4)	2.7 (1.1 to 6.5)	0.5 (0.1 to 1.4)	Medium
Nadolol ⁹⁸	Rofecoxib ²⁰¹	6.0 (0.3 to 118.6)	2.7 (1.1 to 6.5)	2.2 (0.1 to 50.4)	Medium
Candesartan ¹³⁸	Tolfenamic Acid ²⁰²	18.0 (4.0 to 81.0)	11.9 (2.4 to 59.0)	1.5 (0.2 to 13.5)	Medium
Dihydroergotamine ¹⁵⁵	Tolfenamic Acid ²⁰²	1.2 (0.8 to 1.8)	11.9 (2.4 to 59.0)	0.1 (0.0 to 0.5)	Medium
Lamotrigine ⁴⁴	Tolfenamic Acid ²⁰²	1.8 (0.8 to 3.7)	11.9 (2.4 to 59.0)	0.1 (0.0 to 0.9)	Medium
Lisinopril ¹³⁶	Tolfenamic Acid ²⁰²	37.7 (2.2 to 649.0)	11.9 (2.4 to 59.0)	3.2 (0.1 to 82.6)	Medium
Montelukast ²⁰³	Tolfenamic Acid ²⁰²	1.2 (0.6 to 2.4)	11.9 (2.4 to 59.0)	0.1 (0.0 to 0.6)	Medium
Nadolol ⁹⁸	Tolfenamic Acid ²⁰²	6.0 (0.3 to 118.6)	11.9 (2.4 to 59.0)	0.5 (0.0 to 14.8)	Medium
Candesartan ¹³⁸	Clonidine ¹⁵⁰	18.0 (4.0 to 81.0)	2.2 (1.0 to 5.2)	8.1 (1.4 to 45.2)	Medium
Acebutolol ⁹¹	Telmisartan ¹³⁹	8.9 (1.9 to 42.3)	1.6 (0.7 to 4.0)	5.4 (0.9 to 33.0)	High
Amitriptyline ¹¹²	Telmisartan ¹³⁹	3.2 (1.1 to 9.0)	1.6 (0.7 to 4.0)	1.9 (0.5 to 7.7)	High
Atenolol ⁹⁵	Telmisartan ¹³⁹	25.2 (1.4 to 467.9)	1.6 (0.7 to 4.0)	15.4 (0.7 to 327.8)	High
Flurbiprofen ¹⁹⁹	Telmisartan ¹³⁹	5.2 (1.5 to 18.3)	1.6 (0.7 to 4.0)	3.2 (0.7 to 15.0)	High
Indomethacin ²⁰⁰	Telmisartan ¹³⁹	1.3 (0.3 to 5.3)	1.6 (0.7 to 4.0)	0.8 (0.1 to 4.2)	High
Lisuride ¹⁵⁸	Telmisartan ¹³⁹	1.8 (0.9 to 3.5)	1.6 (0.7 to 4.0)	1.1 (0.3 to 3.4)	High

Appendix Table D84. Clinical response defined as ≥50 percent reduction in monthly migraine frequency or self reported substantial reduction in monthly migraine frequency; indirect adjusted frequentist comparisons of migraine preventive drugs in adults from RCTs (analyzed for drugs that were more effective than placebo) (Strength of indirect evidence is low due to risk of bias and imprecision) (continued)

Active Drug, Reference	Control Drug, Reference	Odds Ratio (95% CI) with Active Drug vs. Placebo	Odds Ratio (95% CI) with Control Drug vs. Placebo	Odds Ratio (95% CI) with Active vs. Control Drug	Risk of Bias
Nifedipine ¹³⁵	Telmisartan ¹³⁹	10.0 (2.9 to 34.2)	1.6 (0.7 to 4.0)	6.1 (1.3 to 28.1)	High
Rofecoxib ²⁰¹	Telmisartan ¹³⁹	2.7 (1.1 to 6.5)	1.6 (0.7 to 4.0)	1.6 (0.5 to 5.8)	High
Acebutolol ⁹¹	Acetazolamide ⁸⁰	8.9 (1.9 to 42.3)	0.9 (0.3 to 2.8)	10.0 (1.4 to 69.7)	Medium
Acebutolol ⁹¹	Aspirin ¹⁹⁶	8.9 (1.9 to 42.3)	0.8 (0.7 to 0.9)	11.2 (2.3 to 53.4)	Medium
Amitriptyline ¹¹²	Aspirin ¹⁹⁶	3.2 (1.1 to 9.0)	0.8 (0.7 to 0.9)	4.0 (1.4 to 11.4)	Medium
Acebutolol ⁹¹	Candesartan ¹³⁸	8.9 (1.9 to 42.3)	18.0 (4.0 to 81.0)	0.5 (0.1 to 4.3)	Medium
Amitriptyline ¹¹²	Candesartan ¹³⁸	3.2 (1.1 to 9.0)	18.0 (4.0 to 81.0)	0.2 (0.0 to 1.1)	Medium
Atenolol ⁹⁵	Candesartan ¹³⁸	25.2 (1.4 to 467.9)	18.0 (4.0 to 81.0)	1.4 (0.1 to 37.3)	Medium
Acebutolol ⁹¹	Dihydroergotamine ¹⁵⁵	8.9 (1.9 to 42.3)	1.2 (0.8 to 1.8)	7.3 (1.4 to 36.5)	Medium
Amitriptyline ¹¹²	Dihydroergotamine ¹⁵⁵	3.2 (1.1 to 9.0)	1.2 (0.8 to 1.8)	2.6 (0.8 to 8.0)	Medium
Atenolol ⁹⁵	Dihydroergotamine ¹⁵⁵	25.2 (1.4 to 467.9)	1.2 (0.8 to 1.8)	20.7 (1.1 to 393.8)	Medium
Acebutolol ⁹¹	Fenoprofen ¹⁹⁸	8.9 (1.9 to 42.3)	0.8 (0.3 to 2.2)	11.4 (1.8 to 73.4)	Medium
Amitriptyline ¹¹²	Fenoprofen ¹⁹⁸	3.2 (1.1 to 9.0)	0.8 (0.3 to 2.2)	4.1 (0.9 to 17.5)	Medium
Atenolol ⁹⁵	Fenoprofen ¹⁹⁸	25.2 (1.4 to 467.9)	0.8 (0.3 to 2.2)	32.4 (1.5 to 712.7)	Medium
Acebutolol ⁹¹	Lamotrigine ⁴⁴	8.9 (1.9 to 42.3)	1.8 (0.8 to 3.7)	5.1 (0.9 to 28.6)	Medium
Amitriptyline ¹¹²	Lamotrigine ⁴⁴	3.2 (1.1 to 9.0)	1.8 (0.8 to 3.7)	1.8 (0.5 to 6.5)	Medium
Atenolol ⁹⁵	Lamotrigine ⁴⁴	25.2 (1.4 to 467.9)	1.8 (0.8 to 3.7)	14.4 (0.7 to 293.1)	Medium
Flurbiprofen ¹⁹⁹	Lamotrigine ⁴⁴	5.2 (1.5 to 18.3)	1.8 (0.8 to 3.7)	3.0 (0.7 to 12.8)	Medium
Indomethacin ²⁰⁰	Lamotrigine ⁴⁴	1.3 (0.3 to 5.3)	1.8 (0.8 to 3.7)	0.7 (0.2 to 3.6)	Medium
Acebutolol ⁹¹	Lisinopril ¹³⁶	8.9 (1.9 to 42.3)	37.7 (2.2 to 649.0)	0.2 (0.0 to 6.0)	Medium
Amitriptyline ¹¹²	Lisinopril ¹³⁶	3.2 (1.1 to 9.0)	37.7 (2.2 to 649.0)	0.1 (0.0 to 1.7)	Medium
Atenolol ⁹⁵	Lisinopril ¹³⁶	25.2 (1.4 to 467.9)	37.7 (2.2 to 649.0)	0.7 (0.0 to 39.4)	Medium
Flurbiprofen ¹⁹⁹	Lisinopril ¹³⁶	5.2 (1.5 to 18.3)	37.7 (2.2 to 649.0)	0.1 (0.0 to 3.1)	Medium
Indomethacin ²⁰⁰	Lisinopril ¹³⁶	1.3 (0.3 to 5.3)	37.7 (2.2 to 649.0)	0.0 (0.0 to 0.8)	Medium
Acebutolol ⁹¹	Magnesium ^{194, 195}	8.9 (1.9 to 42.3)	1.5 (0.6 to 3.4)	6.1 (1.0 to 35.9)	Medium
Amitriptyline ¹¹²	Magnesium ^{194, 195}	3.2 (1.1 to 9.0)	1.5 (0.6 to 3.4)	2.2 (0.6 to 8.3)	Medium
Atenolol ⁹⁵	Magnesium ^{194, 195}	25.2 (1.4 to 467.9)	1.5 (0.6 to 3.4)	17.3 (0.8 to 360.7)	Medium
Flurbiprofen ¹⁹⁹	Magnesium ^{194, 195}	5.2 (1.5 to 18.3)	1.5 (0.6 to 3.4)	3.6 (0.8 to 16.2)	Medium
Gabapentin ^{81, 84, 192}	Magnesium ^{194, 195}	2.4 (1.3 to 4.6)	1.5 (0.6 to 3.4)	1.7 (0.6 to 4.8)	Medium
Indomethacin ²⁰⁰	Magnesium ^{194, 195}	1.3 (0.3 to 5.3)	1.5 (0.6 to 3.4)	0.9 (0.2 to 4.6)	Medium
Lisuride ¹⁵⁸	Magnesium ^{194, 195}	1.8 (0.9 to 3.5)	1.5 (0.6 to 3.4)	1.2 (0.4 to 3.6)	Medium
Nifedipine ¹³⁵	Magnesium ^{194, 195}	10.0 (2.9 to 34.2)	1.5 (0.6 to 3.4)	6.8 (1.5 to 30.4)	Medium
Rofecoxib ²⁰¹	Magnesium ^{194, 195}	2.7 (1.1 to 6.5)	1.5 (0.6 to 3.4)	1.8 (0.5 to 6.2)	Medium
Tolfenamic Acid ²⁰²	Magnesium ^{194, 195}	11.9 (2.4 to 59.0)	1.5 (0.6 to 3.4)	8.2 (1.3 to 49.8)	Medium
Acebutolol ⁹¹	Montelukast ²⁰³	8.9 (1.9 to 42.3)	1.2 (0.6 to 2.4)	7.4 (1.3 to 40.9)	Medium

Appendix Table D84. Clinical response defined as ≥ 50 percent reduction in monthly migraine frequency or self reported substantial reduction in monthly migraine frequency; indirect adjusted frequentist comparisons of migraine preventive drugs in adults from RCTs (analyzed for drugs that were more effective than placebo) (Strength of indirect evidence is low due to risk of bias and imprecision) (continued)

Active Drug, Reference	Control Drug, Reference	Odds Ratio (95% CI) with Active Drug vs. Placebo	Odds Ratio (95% CI) with Control Drug vs. Placebo	Odds Ratio (95% CI) with Active vs. Control Drug	Risk of Bias
Amitriptyline ¹¹²	Montelukast ²⁰³	3.2 (1.1 to 9.0)	1.2 (0.6 to 2.4)	2.6 (0.7 to 9.3)	Medium
Atenolol ⁹⁵	Montelukast ²⁰³	25.2 (1.4 to 467.9)	1.2 (0.6 to 2.4)	21.0 (1.0 to 422.1)	Medium
Flurbiprofen ¹⁹⁹	Montelukast ²⁰³	5.2 (1.5 to 18.3)	1.2 (0.6 to 2.4)	4.3 (1.0 to 18.3)	Medium
Indomethacin ²⁰⁰	Montelukast ²⁰³	1.3 (0.3 to 5.3)	1.2 (0.6 to 2.4)	1.1 (0.2 to 5.2)	Medium
Lisuride ¹⁵⁸	Montelukast ²⁰³	1.8 (0.9 to 3.5)	1.2 (0.6 to 2.4)	1.5 (0.5 to 3.9)	Medium
Acebutolol ⁹¹	Nadolol ⁹⁸	8.9 (1.9 to 42.3)	6.0 (0.3 to 118.6)	1.5 (0.1 to 43.3)	Medium
Amitriptyline ¹¹²	Nadolol ⁹⁸	3.2 (1.1 to 9.0)	6.0 (0.3 to 118.6)	0.5 (0.0 to 12.6)	Medium
Atenolol ⁹⁵	Nadolol ⁹⁸	25.2 (1.4 to 467.9)	6.0 (0.3 to 118.6)	4.2 (0.1 to 275.8)	Medium
Flurbiprofen ¹⁹⁹	Nadolol ⁹⁸	5.2 (1.5 to 18.3)	6.0 (0.3 to 118.6)	0.9 (0.0 to 22.4)	Medium
Indomethacin ²⁰⁰	Nadolol ⁹⁸	1.3 (0.3 to 5.3)	6.0 (0.3 to 118.6)	0.2 (0.0 to 5.9)	Medium
Lisuride ¹⁵⁸	Nadolol ⁹⁸	1.8 (0.9 to 3.5)	6.0 (0.3 to 118.6)	0.3 (0.0 to 6.3)	Medium
Acebutolol ⁹¹	Oxcarbazepine ⁸³	8.9 (1.9 to 42.3)	0.9 (0.5 to 1.6)	10.4 (1.9 to 56.0)	Medium
Amitriptyline ¹¹²	Oxcarbazepine ⁸³	3.2 (1.1 to 9.0)	0.9 (0.5 to 1.6)	3.7 (1.1 to 12.6)	Medium
Atenolol ⁹⁵	Oxcarbazepine ⁸³	25.2 (1.4 to 467.9)	0.9 (0.5 to 1.6)	29.5 (1.5 to 585.1)	Medium
Flurbiprofen ¹⁹⁹	Oxcarbazepine ⁸³	5.2 (1.5 to 18.3)	0.9 (0.5 to 1.6)	6.1 (1.5 to 24.9)	Medium
Indomethacin ²⁰⁰	Oxcarbazepine ⁸³	1.3 (0.3 to 5.3)	0.9 (0.5 to 1.6)	1.5 (0.3 to 7.1)	Medium
Lisuride ¹⁵⁸	Oxcarbazepine ⁸³	1.8 (0.9 to 3.5)	0.9 (0.5 to 1.6)	2.1 (0.8 to 5.3)	Medium
Nifedipine ¹³⁵	Oxcarbazepine ⁸³	10.0 (2.9 to 34.2)	0.9 (0.5 to 1.6)	11.7 (2.9 to 46.6)	Medium
Acebutolol ⁹¹	Tonabersat ¹²¹	8.9 (1.9 to 42.3)	1.2 (0.6 to 2.4)	7.6 (1.4 to 42.4)	Medium
Amitriptyline ¹¹²	Tonabersat ¹²¹	3.2 (1.1 to 9.0)	1.2 (0.6 to 2.4)	2.7 (0.8 to 9.7)	Medium
Atenolol ⁹⁵	Tonabersat ¹²¹	25.2 (1.4 to 467.9)	1.2 (0.6 to 2.4)	21.5 (1.1 to 436.3)	Medium
Flurbiprofen ¹⁹⁹	Tonabersat ¹²¹	5.2 (1.5 to 18.3)	1.2 (0.6 to 2.4)	4.5 (1.0 to 19.0)	Medium
Indomethacin ²⁰⁰	Tonabersat ¹²¹	1.3 (0.3 to 5.3)	1.2 (0.6 to 2.4)	1.1 (0.2 to 5.4)	Medium
Lisuride ¹⁵⁸	Tonabersat ¹²¹	1.8 (0.9 to 3.5)	1.2 (0.6 to 2.4)	1.5 (0.5 to 4.1)	Medium
Nifedipine ¹³⁵	Tonabersat ¹²¹	10.0 (2.9 to 34.2)	1.2 (0.6 to 2.4)	8.5 (2.0 to 35.6)	Medium
Rofecoxib ²⁰¹	Tonabersat ¹²¹	2.7 (1.1 to 6.5)	1.2 (0.6 to 2.4)	2.3 (0.7 to 7.1)	Medium
Tolfenamic Acid ²⁰²	Tonabersat ¹²¹	11.9 (2.4 to 59.0)	1.2 (0.6 to 2.4)	10.2 (1.8 to 58.9)	Medium
Acebutolol ⁹¹	Amitriptyline ¹¹²	8.9 (1.9 to 42.3)	3.2 (1.1 to 9.0)	2.8 (0.4 to 18.5)	Medium
Acebutolol ⁹¹	Atenolol ⁹⁵	8.9 (1.9 to 42.3)	0.9 (0.3 to 2.4)	10.2 (1.6 to 65.3)	Medium
Acebutolol ⁹¹	Atenolol ⁹⁵	8.9 (1.9 to 42.3)	25.2 (1.4 to 467.9)	0.4 (0.0 to 9.6)	Medium
Amitriptyline ¹¹²	Atenolol ⁹⁵	3.2 (1.1 to 9.0)	25.2 (1.4 to 467.9)	0.1 (0.0 to 2.8)	Medium
Acebutolol ⁹¹	Carbamazepine ⁸⁶	8.9 (1.9 to 42.3)	10.2 (3.4 to 30.1)	0.9 (0.1 to 5.9)	Medium
Amitriptyline ¹¹²	Carbamazepine ⁸⁶	3.2 (1.1 to 9.0)	10.2 (3.4 to 30.1)	0.3 (0.1 to 1.4)	Medium
Atenolol ⁹⁵	Carbamazepine ⁸⁶	25.2 (1.4 to 467.9)	10.2 (3.4 to 30.1)	2.5 (0.1 to 56.0)	Medium
Acebutolol ⁹¹	Divalproex ⁴⁵⁻⁴⁷	8.9 (1.9 to 42.3)	3.2 (1.3 to 7.5)	2.8 (0.5 to 16.7)	Medium

Appendix Table D84. Clinical response defined as ≥ 50 percent reduction in monthly migraine frequency or self reported substantial reduction in monthly migraine frequency; indirect adjusted frequentist comparisons of migraine preventive drugs in adults from RCTs (analyzed for drugs that were more effective than placebo) (Strength of indirect evidence is low due to risk of bias and imprecision) (continued)

Active Drug, Reference	Control Drug, Reference	Odds Ratio (95% CI) with Active Drug vs. Placebo	Odds Ratio (95% CI) with Control Drug vs. Placebo	Odds Ratio (95% CI) with Active vs. Control Drug	Risk of Bias
Acebutolol ⁹¹	Flurbiprofen ¹⁹⁹	8.9 (1.9 to 42.3)	5.2 (1.5 to 18.3)	1.7 (0.2 to 12.6)	Medium
Amitriptyline ¹¹²	Flurbiprofen ¹⁹⁹	3.2 (1.1 to 9.0)	5.2 (1.5 to 18.3)	0.6 (0.1 to 3.1)	Medium
Atenolol ⁹⁵	Flurbiprofen ¹⁹⁹	25.2 (1.4 to 467.9)	5.2 (1.5 to 18.3)	4.8 (0.2 to 116.0)	Medium
Acebutolol ⁹¹	Gabapentin ^{81, 84, 192}	8.9 (1.9 to 42.3)	2.4 (1.3 to 4.6)	3.6 (0.7 to 19.6)	Medium
Amitriptyline ¹¹²	Gabapentin ^{81, 84, 192}	3.2 (1.1 to 9.0)	2.4 (1.3 to 4.6)	1.3 (0.4 to 4.4)	Medium
Atenolol ⁹⁵	Gabapentin ^{81, 84, 192}	25.2 (1.4 to 467.9)	2.4 (1.3 to 4.6)	10.4 (0.5 to 205.4)	Medium
Flurbiprofen ¹⁹⁹	Gabapentin ^{81, 84, 192}	5.2 (1.5 to 18.3)	2.4 (1.3 to 4.6)	2.1 (0.5 to 8.7)	Medium
Indomethacin ²⁰⁰	Gabapentin ^{81, 84, 192}	1.3 (0.3 to 5.3)	2.4 (1.3 to 4.6)	0.5 (0.1 to 2.5)	Medium
Lisuride ¹⁵⁸	Gabapentin ^{81, 84, 192}	1.8 (0.9 to 3.5)	2.4 (1.3 to 4.6)	0.7 (0.3 to 1.9)	Medium
Nifedipine ¹³⁵	Gabapentin ^{81, 84, 192}	10.0 (2.9 to 34.2)	2.4 (1.3 to 4.6)	4.1 (1.0 to 16.4)	Medium
Rofecoxib ²⁰¹	Gabapentin ^{81, 84, 192}	2.7 (1.1 to 6.5)	2.4 (1.3 to 4.6)	1.1 (0.4 to 3.2)	Medium
Tolfenamic Acid ²⁰²	Gabapentin ^{81, 84, 192}	11.9 (2.4 to 59.0)	2.4 (1.3 to 4.6)	4.9 (0.9 to 27.3)	Medium
Acebutolol ⁹¹	Indomethacin ²⁰⁰	8.9 (1.9 to 42.3)	1.3 (0.3 to 5.3)	6.9 (0.8 to 56.2)	Medium
Amitriptyline ¹¹²	Indomethacin ²⁰⁰	3.2 (1.1 to 9.0)	1.3 (0.3 to 5.3)	2.4 (0.4 to 14.1)	Medium
Atenolol ⁹⁵	Indomethacin ²⁰⁰	25.2 (1.4 to 467.9)	1.3 (0.3 to 5.3)	19.5 (0.8 to 499.2)	Medium
Flurbiprofen ¹⁹⁹	Indomethacin ²⁰⁰	5.2 (1.5 to 18.3)	1.3 (0.3 to 5.3)	4.0 (0.6 to 26.6)	Medium
Acebutolol ⁹¹	Lisuride ¹⁵⁸	8.9 (1.9 to 42.3)	1.8 (0.9 to 3.5)	5.1 (0.9 to 28.0)	Medium
Amitriptyline ¹¹²	Lisuride ¹⁵⁸	3.2 (1.1 to 9.0)	1.8 (0.9 to 3.5)	1.8 (0.5 to 6.4)	Medium
Atenolol ⁹⁵	Lisuride ¹⁵⁸	25.2 (1.4 to 467.9)	1.8 (0.9 to 3.5)	14.4 (0.7 to 289.4)	Medium
Flurbiprofen ¹⁹⁹	Lisuride ¹⁵⁸	5.2 (1.5 to 18.3)	1.8 (0.9 to 3.5)	3.0 (0.7 to 12.5)	Medium
Indomethacin ²⁰⁰	Lisuride ¹⁵⁸	1.3 (0.3 to 5.3)	1.8 (0.9 to 3.5)	0.7 (0.2 to 3.5)	Medium
Acebutolol ⁹¹	Nifedipine ¹³⁵	8.9 (1.9 to 42.3)	10.0 (2.9 to 34.2)	0.9 (0.1 to 6.5)	Medium
Amitriptyline ¹¹²	Nifedipine ¹³⁵	3.2 (1.1 to 9.0)	10.0 (2.9 to 34.2)	0.3 (0.1 to 1.6)	Medium
Atenolol ⁹⁵	Nifedipine ¹³⁵	25.2 (1.4 to 467.9)	10.0 (2.9 to 34.2)	2.5 (0.1 to 60.0)	Medium
Flurbiprofen ¹⁹⁹	Nifedipine ¹³⁵	5.2 (1.5 to 18.3)	10.0 (2.9 to 34.2)	0.5 (0.1 to 3.0)	Medium
Indomethacin ²⁰⁰	Nifedipine ¹³⁵	1.3 (0.3 to 5.3)	10.0 (2.9 to 34.2)	0.1 (0.0 to 0.8)	Medium
Lisuride ¹⁵⁸	Nifedipine ¹³⁵	1.8 (0.9 to 3.5)	10.0 (2.9 to 34.2)	0.2 (0.0 to 0.7)	Medium
Acebutolol ⁹¹	Nimodipine ^{127, 132}	8.9 (1.9 to 42.3)	6.0 (0.5 to 66.2)	1.5 (0.1 to 25.9)	Medium
Amitriptyline ¹¹²	Nimodipine ^{127, 132}	3.2 (1.1 to 9.0)	6.0 (0.5 to 66.2)	0.5 (0.0 to 7.2)	Medium
Atenolol ⁹⁵	Nimodipine ^{127, 132}	25.2 (1.4 to 467.9)	6.0 (0.5 to 66.2)	4.2 (0.1 to 183.8)	Medium
Flurbiprofen ¹⁹⁹	Nimodipine ^{127, 132}	5.2 (1.5 to 18.3)	6.0 (0.5 to 66.2)	0.9 (0.1 to 13.0)	Medium
Gabapentin ^{81, 84, 192}	Nimodipine ^{127, 132}	2.4 (1.3 to 4.6)	6.0 (0.5 to 66.2)	0.4 (0.0 to 4.8)	Medium
Indomethacin ²⁰⁰	Nimodipine ^{127, 132}	1.3 (0.3 to 5.3)	6.0 (0.5 to 66.2)	0.2 (0.0 to 3.5)	Medium
Lisuride ¹⁵⁸	Nimodipine ^{127, 132}	1.8 (0.9 to 3.5)	6.0 (0.5 to 66.2)	0.3 (0.0 to 3.6)	Medium
Nifedipine ¹³⁵	Nimodipine ^{127, 132}	10.0 (2.9 to 34.2)	6.0 (0.5 to 66.2)	1.7 (0.1 to 24.7)	Medium

Appendix Table D84. Clinical response defined as ≥ 50 percent reduction in monthly migraine frequency or self reported substantial reduction in monthly migraine frequency; indirect adjusted frequentist comparisons of migraine preventive drugs in adults from RCTs (analyzed for drugs that were more effective than placebo) (Strength of indirect evidence is low due to risk of bias and imprecision) (continued)

Active Drug, Reference	Control Drug, Reference	Odds Ratio (95% CI) with Active Drug vs. Placebo	Odds Ratio (95% CI) with Control Drug vs. Placebo	Odds Ratio (95% CI) with Active vs. Control Drug	Risk of Bias
Rofecoxib ²⁰¹	Nimodipine ^{127, 132}	2.7 (1.1 to 6.5)	6.0 (0.5 to 66.2)	0.4 (0.0 to 5.7)	Medium
Tolfenamic Acid ²⁰²	Nimodipine ^{127, 132}	11.9 (2.4 to 59.0)	6.0 (0.5 to 66.2)	2.0 (0.1 to 35.5)	Medium
Acebutolol ⁹¹	Rofecoxib ²⁰¹	8.9 (1.9 to 42.3)	2.7 (1.1 to 6.5)	3.3 (0.6 to 19.9)	Medium
Amitriptyline ¹¹²	Rofecoxib ²⁰¹	3.2 (1.1 to 9.0)	2.7 (1.1 to 6.5)	1.2 (0.3 to 4.6)	Medium
Atenolol ⁹⁵	Rofecoxib ²⁰¹	25.2 (1.4 to 467.9)	2.7 (1.1 to 6.5)	9.4 (0.4 to 199.1)	Medium
Flurbiprofen ¹⁹⁹	Rofecoxib ²⁰¹	5.2 (1.5 to 18.3)	2.7 (1.1 to 6.5)	2.0 (0.4 to 9.1)	Medium
Indomethacin ²⁰⁰	Rofecoxib ²⁰¹	1.3 (0.3 to 5.3)	2.7 (1.1 to 6.5)	0.5 (0.1 to 2.5)	Medium
Lisuride ¹⁵⁸	Rofecoxib ²⁰¹	1.8 (0.9 to 3.5)	2.7 (1.1 to 6.5)	0.7 (0.2 to 2.0)	Medium
Nifedipine ¹³⁵	Rofecoxib ²⁰¹	10.0 (2.9 to 34.2)	2.7 (1.1 to 6.5)	3.7 (0.8 to 17.0)	Medium
Acebutolol ⁹¹	Tolfenamic Acid ²⁰²	8.9 (1.9 to 42.3)	11.9 (2.4 to 59.0)	0.7 (0.1 to 6.9)	Medium
Amitriptyline ¹¹²	Tolfenamic Acid ²⁰²	3.2 (1.1 to 9.0)	11.9 (2.4 to 59.0)	0.3 (0.0 to 1.8)	Medium
Atenolol ⁹⁵	Tolfenamic Acid ²⁰²	25.2 (1.4 to 467.9)	11.9 (2.4 to 59.0)	2.1 (0.1 to 59.0)	Medium
Flurbiprofen ¹⁹⁹	Tolfenamic Acid ²⁰²	5.2 (1.5 to 18.3)	11.9 (2.4 to 59.0)	0.4 (0.1 to 3.3)	Medium
Indomethacin ²⁰⁰	Tolfenamic Acid ²⁰²	1.3 (0.3 to 5.3)	11.9 (2.4 to 59.0)	0.1 (0.0 to 0.9)	Medium
Lisuride ¹⁵⁸	Tolfenamic Acid ²⁰²	1.8 (0.9 to 3.5)	11.9 (2.4 to 59.0)	0.1 (0.0 to 0.8)	Medium
Nifedipine ¹³⁵	Tolfenamic Acid ²⁰²	10.0 (2.9 to 34.2)	11.9 (2.4 to 59.0)	0.8 (0.1 to 6.3)	Medium
Rofecoxib ²⁰¹	Tolfenamic Acid ²⁰²	2.7 (1.1 to 6.5)	11.9 (2.4 to 59.0)	0.2 (0.0 to 1.4)	Medium
Acebutolol ⁹¹	Clonidine ¹⁵⁰	8.9 (1.9 to 42.3)	2.2 (1.0 to 5.2)	4.0 (0.7 to 23.4)	Medium
Amitriptyline ¹¹²	Clonidine ¹⁵⁰	3.2 (1.1 to 9.0)	2.2 (1.0 to 5.2)	1.4 (0.4 to 5.4)	Medium
Atenolol ⁹⁵	Clonidine ¹⁵⁰	25.2 (1.4 to 467.9)	2.2 (1.0 to 5.2)	11.3 (0.5 to 235.7)	Medium
Clonidine ¹⁵⁰	Telmisartan ¹³⁹	2.2 (1.0 to 5.2)	1.6 (0.7 to 4.0)	1.4 (0.4 to 4.7)	High
Clonidine ¹⁵⁰	Dihydroergotamine ¹⁵⁵	2.2 (1.0 to 5.2)	1.2 (0.8 to 1.8)	1.8 (0.7 to 4.7)	Medium
Clonidine ¹⁵⁰	Fenoprofen ¹⁹⁸	2.2 (1.0 to 5.2)	0.8 (0.3 to 2.2)	2.9 (0.8 to 10.7)	Medium
Clonidine ¹⁵⁰	Lamotrigine ⁴⁴	2.2 (1.0 to 5.2)	1.8 (0.8 to 3.7)	1.3 (0.4 to 3.9)	Medium
Clonidine ¹⁵⁰	Lisinopril ¹³⁶	2.2 (1.0 to 5.2)	37.7 (2.2 to 649.0)	0.1 (0.0 to 1.2)	Medium
Clonidine ¹⁵⁰	Magnesium ^{194, 195}	2.2 (1.0 to 5.2)	1.5 (0.6 to 3.4)	1.5 (0.5 to 5.0)	Medium
Clonidine ¹⁵⁰	Montelukast ²⁰³	2.2 (1.0 to 5.2)	1.2 (0.6 to 2.4)	1.9 (0.6 to 5.6)	Medium
Clonidine ¹⁵⁰	Nadolol ¹⁹⁸	2.2 (1.0 to 5.2)	6.0 (0.3 to 118.6)	0.4 (0.0 to 8.4)	Medium
Clonidine ¹⁵⁰	Oxcarbazepine ⁸³	2.2 (1.0 to 5.2)	0.9 (0.5 to 1.6)	2.6 (0.9 to 7.5)	Medium
Clonidine ¹⁵⁰	Tonabersat ¹²¹	2.2 (1.0 to 5.2)	1.2 (0.6 to 2.4)	1.9 (0.6 to 5.8)	Medium
Clonidine ¹⁵⁰	Flurbiprofen ¹⁹⁹	2.2 (1.0 to 5.2)	5.2 (1.5 to 18.3)	0.4 (0.1 to 1.9)	Medium
Clonidine ¹⁵⁰	Gabapentin ^{81, 84, 192}	2.2 (1.0 to 5.2)	2.4 (1.3 to 4.6)	0.9 (0.3 to 2.6)	Medium
Clonidine ¹⁵⁰	Indomethacin 4867513	2.2 (1.0 to 5.2)	1.3 (0.3 to 5.3)	1.7 (0.3 to 8.9)	Medium
Clonidine ¹⁵⁰	Lisuride ¹⁵⁸	2.2 (1.0 to 5.2)	1.8 (0.9 to 3.5)	1.3 (0.4 to 3.8)	Medium
Clonidine ¹⁵⁰	Nifedipine ¹³⁵	2.2 (1.0 to 5.2)	10.0 (2.9 to 34.2)	0.2 (0.1 to 1.0)	Medium

Appendix Table D84. Clinical response defined as ≥ 50 percent reduction in monthly migraine frequency or self reported substantial reduction in monthly migraine frequency; indirect adjusted frequentist comparisons of migraine preventive drugs in adults from RCTs (analyzed for drugs that were more effective than placebo) (Strength of indirect evidence is low due to risk of bias and imprecision) (continued)

Active Drug, Reference	Control Drug, Reference	Odds Ratio (95% CI) with Active Drug vs. Placebo	Odds Ratio (95% CI) with Control Drug vs. Placebo	Odds Ratio (95% CI) with Active vs. Control Drug	Risk of Bias
Clonidine ¹⁵⁰	Nimodipine ^{127, 132}	2.2 (1.0 to 5.2)	6.0 (0.5 to 66.2)	0.4 (0.0 to 4.7)	Medium
Clonidine ¹⁵⁰	Rofecoxib ²⁰¹	2.2 (1.0 to 5.2)	2.7 (1.1 to 6.5)	0.8 (0.2 to 2.8)	Medium
Clonidine ¹⁵⁰	Tolfenamic Acid ²⁰²	2.2 (1.0 to 5.2)	11.9 (2.4 to 59.0)	0.2 (0.0 to 1.1)	Medium

Appendix Table D85. Comparative effectiveness of antidepressant amitriptyline and spinal manipulation for migraine prevention in adults, individual medium risk of bias randomized controlled clinical trial²⁰⁴

Definition of the Outcome	Active Treatment	Control Treatment	Events/ Randomized Rate,% with Active	Events/ Randomized Rate,% with Control	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
>60% reduction in HI in last 4 weeks of treatment phase	Spinal Manipulation (high-velocity, low-amplitude, short-lever arm)	Amitriptyline 100mg/day	17/34 22.15	34/77 48.65	0.5 (0.3 to 0.7)	-0.26 (-0.41 to -0.12)
>60% reduction in HI during the 4-week post-treatment followup phase	Spinal Manipulation (high-velocity, low-amplitude, short-lever arm)	Amitriptyline 100mg/day	17/11 22.15	11/77 15.75	1.4 (0.7 to 2.8)	0.06 (-0.06 to 0.19)
Reduction in HI from baseline during the post-treatment followup period	Spinal Manipulation + Amitriptyline 100mg/day	Amitriptyline 100mg/day	18/17 25.45	17/71 24.35	1.0 (0.6 to 1.9)	0.01 (-0.13 to 0.15)
Reduction in HI (headache index) scores during treatment compared with baseline	Spinal Manipulation + Amitriptyline 100mg/day	Amitriptyline 100mg/day	29/34 40.85	34/71 48.65	0.8 (0.6 to 1.2)	-0.08 (-0.24 to 0.09)
Reduction in HI (headache index) scores during treatment compared with baseline	Spinal Manipulation (high-velocity, low-amplitude, short-lever arm)	Amitriptyline 100mg/day	31/34 40.35	34/77 48.65	0.8 (0.6 to 1.2)	-0.08 (-0.24 to 0.08)
Reduction in HI from baseline during the post-treatment followup period	Spinal Manipulation (high-velocity, low-amplitude, short-lever arm)	Amitriptyline 100mg/day	32/17 41.65	17/77 24.35	1.7 (1.0 to 2.8)	0.17 (0.02 to 0.32)
Reduction in HI (headache index) scores during treatment compared with baseline	Spinal Manipulation	Spinal Manipulation + Amitriptyline 100mg/day	31/29 40.35	29/77 40.85	1.0 (0.7 to 1.5)	-0.01 (-0.16 to 0.15)
Reduction in HI from baseline during the post-treatment followup period	Spinal Manipulation	Spinal Manipulation + Amitriptyline 100mg/day	32/18 41.65	18/77 25.45	1.6 (1.0 to 2.6)	0.16 (0.01 to 0.31)

HI = headache index ; Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0; CI = confidence interval

Appendix Table D86. Comparative effectiveness of drugs with nonpharmacological treatments for migraine prevention in adults, randomized controlled clinical trials

Reference Country Sample	Drug	Aim	Definition of Migraine	Concurrent Medication	Age % Women Baseline Status of Subjects
Nelson, 1998 ²⁰⁴ Country: USA Sample: 218	Amitriptyline	To measure the relative efficacy of amitriptyline, spinal manipulation and the combination of both therapies for the prophylaxis of migraine headache.	International Headache Society criteria	None	Age Mean 37.9 years; % women 78.9 Migraine interfered substantially with work (% of patients): Amitriptyline group: 47.2; SMT group: 41.6; Combined treatment: 46.5 Days with headache (% of possible days during past month): Amitriptyline group: 54.5; SMT group: 53.3; Combined treatment: 50.8 Headache Index (mean diary score (0-70) during the 1-month baseline period): Amitriptyline group: 18.2(9.8); SMT group: 18.2 (9.1); Combined treatment: 10.1 (7.0)
Holroyd, 1995 ²⁰⁵ Country: Not reported Sample: 33	Beta-blocker	To evaluate the ability of propranolol to enhance results achieved with relaxation-biofeedback training	International Headache Society diagnostic criteria (Headache Classification Committee of the IHS, 1988)	None	Age Mean 31.7 years; % women 79 Mean years of problem headache: 15.2 years (range, 1-47)
Streng, 2006 ²⁰⁶ Country: Germany Sample: 114	Beta-blocker	To investigate whether acupuncture is as effective and safe as metoprolol in the prophylactic treatment migraine under conditions similar to routine care.	International Headache Society criteria	None	Age Mean 40.1 years; % women 87.72 Days with migraine, Mean (SD): Acupuncture: 5.8 (2.5); Metoprolol: 5.8 (2.9) Number of migraine attacks, Mean (SD): Acupuncture: 3.0 (1.4); Metoprolol: 2.9 (1.3)
Seng, 2010 ²⁰⁷ Country: USA Sample: 232	Beta-blocker	To examine expectancy changes with various combinations of Behavioral Migraine Management and migraine drug therapy	International Classification of Headache Disorders	Rescue drugs such as steroids were allowed	Age Mean 39.1 years; % women 79 Migraine days/30 days, mean (SD): 8.8 (11.5)
Holroyd, 2010 ¹⁹³ Country: USA Sample: 232	Beta-blocker	To determine if the addition of preventive drug treatment (β blocker), brief behavioral migraine management, or their combination improves the outcome of optimized acute treatment in the management of frequent migraine.	International Classification of Headache Disorders	Rescue drugs such as steroids were allowed	Age Mean 38.3 years; % women 79 Mean (SD) migraine days/30 days: Optimized acute treatment + placebo: 8.4 (3.5); Optimized acute treatment + β blocker: 8.6 (3.3); Optimized acute treatment plus behavioral migraine management + placebo: 8.1 (3.4); Optimized acute treatment plus behavioral migraine management + β blocker: 8.7 (4.0)

Appendix Table D87. Funding and conflict of interest in randomized controlled clinical trials that examined comparative effectiveness of drugs and nonpharmacological migraine preventive treatments in adults

Reference	Funding	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Disclosed Relationships
Nelson, 1998 ²⁰⁴	Grant	Yes	Yes	Not reported	Not applicable
Holroyd, 1994 ²⁰⁵	Grant	Not reported	Yes	Not reported	Not applicable
Streng, 2006 ²⁰⁶	Other	Yes	Yes	None	Not applicable
Seng, 2010 ²⁰⁷	Grant	Yes	Yes	Yes	Ms. Seng reports no conflicts of interest. Dr. Holroyd has received support from the National Institutes of Health (NINDS; NS32375), has consulted for ENDO Pharmaceuticals and Takeda Pharmaceuticals North America, and received an investigator initiated grant from ENDO Pharmaceuticals.
Holroyd, 2010 ¹⁹³	Grant	Yes	Yes	Yes	KA Holroyd has consulted for ENDO Pharmaceuticals and for Takeda Pharmaceuticals North America and received an investigator initiated grant from ENDO Pharmaceuticals. He has also received support from the National Institutes of Health (NINDS; NS32375). CK Cottrell has received research funding and materials from GlaxoSmithKline Pharmaceuticals (GSK) and Merck and participates in industry sponsored research involving GSK, Merck, UCB Pharma, and Allergan. FJ O'Donnell has received research funding and materials from GSK and Merck; receives educational funding from GSK, Merck, and Allergan; participates in industry sponsored research involving GSK, Merck, UCB Pharma, and Allergan; and has consulted for and received honorariums from GSK. GE Corfingley owns stock in Johnson and Johnson, Novartis, and Wyeth Pharmaceuticals.
Wang, 2011 ²⁰⁸	Other	Yes	Yes	None	Not applicable
Dahlof, 1987 ²⁰⁹	Not reported	Not reported	Yes	Not reported	Not applicable

Appendix Table D88. Risk of bias in randomized controlled clinical trials that examined comparative effectiveness of drugs and nonpharmacological migraine preventive treatments in adults

Reference	Masking of the Treatment Status	Masking - Outcome Assessment	Intention to Treat Analysis Preplanned	Allocation Concealment	Adequacy of Randomization	Baseline Similarity	Selective Outcome Reporting	Risk of Bias
Nelson, 1998 ²⁰⁴	Open-label	Not reported	Yes	Unclear	Yes	Frequency: not reported; Severity: not reported; Duration: not reported	Unclear	Medium
Holroyd, 1995 ²⁰⁵	Open-label	Not reported	No	Unclear	Not reported	Not reported	Unclear	High
Streng, 2006 ²⁰⁶	Open-label	Outcome evaluators were blinded	Yes	Clearly Adequate	No (there was a significant difference between the groups for the scale for sensoric pain of the SES)	Frequency: similar; Severity: not reported; Duration: not reported	Unclear	High
Seng, 2010 ²⁰⁷	Double-blind	Not reported	No	Unclear	Yes	Not reported	Unclear	Medium
Holroyd, 2010 ¹⁹³	Double-blind for the drug and not for behavioral migraine management	Not reported	Yes	Unclear	Not reported The optimized treatment + beta-blocker group had migraine with current frequency for fewer number of years as compared to other groups	Not reported	Unclear	Low
Wang, 2011 ²⁰⁸	Single-blind	The outcome measurements were evaluated by blinded assessors who were unaware of patient allocation	Yes	Clearly adequate	Yes	Not reported	Unclear	Low
Dahlof, 1987 ²⁰⁹	Open-label	The analysis of the diary data was conducted by blind operators who did not know the group of each patient.	No	Unclear	Yes	Frequency: similar Severity: similar; Duration: not reported	Unclear	Medium

Appendix Table D89. Migraine prevention with beta-blockers combined with behavior therapy vs. placebo in adults, results from individual low risk of bias randomized controlled clinical trial¹⁹³

Definition of the Outcome	Active Treatment	Events/ Randomized with Active Treatment	Events/ Randomized with Placebo	Rate of Outcome, % in Active Group [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Clinically improved (≥50% reduction in migraines) at month 10	Behavioral migraine management and relaxation + propranolol (max dose 240mg/day) or nadolol (max dose 120mg/day)	53/69	8/21	76.8[40.0]	2.0 (1.2 to 3.5)	0.39 (0.16 to 0.62)
Dropped due to lack of efficacy	Behavioral migraine management and relaxation + propranolol (max dose 240mg/day) or nadolol (max dose 120mg/day)	1/69	2/21	1.4 [7.3]	0.2 (0.0 to 1.6)	-0.08 (-0.21 to 0.05)
Dropped due to side effects	Behavioral migraine management and relaxation + propranolol (max dose 240mg/day) or nadolol (max dose 120mg/day)	6/69	2/21	8.7 [9.1]	0.9 (0.2 to 4.2)	-0.01 (-0.15 to 0.13)
Dropped out	Behavioral migraine management and relaxation + propranolol (max dose 240mg/day) or nadolol (max dose 120mg/day)	24/69	9/21	34.8 [41.8]	0.8 (0.4 to 1.5)	-0.08 (-0.32 to 0.16)

Bold = significant differences at 95% confidence limit when 95%CI of absolute risk difference do not include 0
CI = confidence interval

Appendix Table D90. Strength of evidence - efficacy and safety of beta-blockers combined with behavioral therapy (orientation + relaxation training; migraine warning signs and triggers; effectively using migraine medication and reducing impact of migraines; stress management or biofeedback training; migraine management plan) vs. placebo for migraine prevention in adults, results from individual low risk of bias randomized controlled clinical trial¹⁹³

Definition of the Outcome	Active Treatment	Control Treatment	Risk of Bias	Directness	Consistency	Precision	Strength of Evidence
Clinically improved (≥50% reduction in migraines) at month 10	Behavioral migraine management + Placebo	Propranolol/nadolol	Low	Yes	NA	No	Low
Clinically improved (≥50% reduction in migraines) at month 10	Behavioral migraine management + Propranolol/nadolol	Propranolol/nadolol	Low	Yes	NA	No	Low
Clinically improved (≥50% reduction in migraines) at month 10	Behavioral migraine management + placebo	Behavioral migraine management + Propranolol/nadolol	Low	Yes	NA	No	Low

Appendix Table D91. Efficacy of beta-blockers combined with behavioral therapy (orientation + relaxation training; migraine warning signs and triggers; effectively using migraine medication and reducing impact of migraines; stress management or biofeedback training; migraine management plan) vs. placebo for migraine prevention in adults, results from individual medium risk of bias randomized controlled clinical trial²⁰⁷

Definition of the Outcome	Active Treatment	Randomized for Active Treatment [Placebo]	Mean [Standard Deviation] with Active Treatment	Mean [Standard Deviation] with Placebo	Mean Difference (95% CI)	Cohen Standardized Mean Difference (95% CI)
Mean HSE (Headache Management Self-Efficacy Scale) at month 16	Propranolol(240mg/day) or nadolol (120mg/day) plus behavioral Migraine Management	69 [55]	144.8 [23.6]	117.2 [18.6]	27.6 (20.2 to 35.0)	1.3 (0.9 to 1.7)
Mean Internal HSLC (Headache Specific Locus of Control) at month 16	Propranolol(240mg/day) or nadolol (120mg/day) plus behavioral Migraine Management	69 [55]	63.9 [7.7]	55.5 [9.5]	8.4 (5.3 to 11.5)	1.0 (0.6 to 1.4)
Mean Chance HSLC (Headache Specific Locus of Control) at month 16	Propranolol(240mg/day) or nadolol (120mg/day) plus behavioral Migraine Management	69 [55]	21.1 [8.4]	30.7 [8.5]	-9.6 (-12.6 to -6.6)	-1.1 (-1.5 to -0.8)
Mean Medical Professionals HSLC (Headache Specific Locus of Control) at month 16	Propranolol(240mg/day) or nadolol (120mg/day) plus behavioral Migraine Management	69 [55]	31.6 [6.9]	35.4 [6.5]	-3.8 (-6.2 to -1.4)	-0.6 (-0.9 to -0.2)

Bold = significant differences at 95% confidence limit when 95% CI of mean difference estimates do not include 0

CI = confidence interval

Appendix Table D92. Comparative effectiveness of antidepressant amitriptyline, 100mg/day and spinal manipulation on intermediate outcomes in adults with migraine, individual medium risk of bias randomized controlled clinical trial²⁰⁴

Definition of the Outcome	Active Treatment	Control Treatment	Mean [Standard Deviation] with Active Treatment	Mean [Standard Deviation] with Drug	Mean Difference (95% CI)	Standardized Cohen Mean Difference (95% CI)
HI (Headache Index): mean of last 4 week of the treatment period	Spinal Manipulation The spinal manipulation administered was a type described as high-velocity, low-amplitude, and short-lever arm.	Amitriptyline 100mg/days	9.8 [6.3]	9.1 [6.3]	0.7 (-1.3 to 2.7)	0.1 (-0.2 to 0.4)
HI (Headache Index): mean of last 4 week of the treatment period	Spinal Manipulation + Amitriptyline 100mg/day	Amitriptyline 100mg/days	9.8 [6.3]	9.1 [6.3]	0.7 (-1.4 to 2.8)	0.1 (-0.2 to 0.4)
HI (Headache Index): mean during post-treatment follow-up period	Spinal Manipulation + Amitriptyline 100mg/day	Amitriptyline 100mg/days	12.6 [7.0]	12.6 [7.0]	0.0 (-2.3 to 2.3)	0.0 (-0.3 to 0.3)
HI (Headache Index): mean during post-treatment follow-up period	Spinal Manipulation	Amitriptyline 100mg/days	12.6 [7.0]	12.6 [7.0]	0.0 (-2.3 to 2.3)	0.0 (-0.3 to 0.3)
OTC pills/day: mean of last 4 weeks of the treatment period	Spinal Manipulation	Amitriptyline 100mg/days	1.1 [1.1]	0.9 [1.0]	0.2 (-0.1 to 0.5)	0.2 (-0.1 to 0.5)
OTC pills/day: mean of last 4 weeks of the treatment period	Spinal Manipulation + Amitriptyline 100mg/day	Amitriptyline 100mg/days	1.1 [1.1]	0.9 [1.0]	0.2 (-0.1 to 0.5)	0.2 (-0.1 to 0.5)
OTC pills/day: mean during post-treatment follow-up period	Spinal Manipulation	Amitriptyline 100mg/days	1.1 [1.3]	1.4 [1.3]	-0.3 (-0.7 to 0.1)	-0.2 (-0.6 to 0.1)
OTC pills/day: mean during post-treatment follow-up period	Spinal Manipulation + Amitriptyline 100mg/day		1.2 [1.5]	1.4 [1.3]	-0.2 (-0.7 to 0.3)	-0.1 (-0.5 to 0.2)
General health status (S-36): % points during post-treatment follow-up period	Spinal Manipulation	Amitriptyline 100mg/days	73.6 [10.7]	71.2 [10.5]	2.4 (-1.0 to 5.8)	0.2 (-0.1 to 0.6)
General health status (S-36): % points during post-treatment follow-up period	Spinal Manipulation + Amitriptyline 100mg/day	Amitriptyline 100mg/days	72.9 [10.5]	71.2 [10.5]	1.7 (-1.8 to 5.2)	0.2 (-0.2 to 0.5)

Appendix Table 92. Comparative effectiveness of antidepressant amitriptyline, 100mg/day and spinal manipulation on intermediate outcomes in adults with migraine, individual medium risk of bias randomized controlled clinical trial (continued)

Definition of the Outcome	Active Treatment	Control Treatment	Mean [Standard Deviation] with Active Treatment	Mean [Standard Deviation] with Drug	Mean Difference (95% CI)	Standardized Cohen Mean Difference (95% CI)
HI (Headache Index) : mean of last 4 week of the treatment period	Spinal Manipulation	Spinal Manipulation + Amitriptyline 100mg/day	9.8 [6.3]	9.8 [6.3]	0.0 (-2.0 to 2.0)	0.0 (-0.3 to 0.3)
HI (Headache Index) : mean during post-treatment follow-up period	Spinal Manipulation	Spinal Manipulation + Amitriptyline 100mg/day	9.8 [7.0]	12.6 [7.0]	-2.8 (-5.1 to -0.5)	-0.4 (-0.7 to -0.1)
OTC pills/day: mean of last 4 weeks of the treatment period	Spinal Manipulation	Spinal Manipulation + Amitriptyline 100mg/day	1.1 [1.1]	1.1 [1.1]	0.0 (-0.4 to 0.4)	0.0 (-0.3 to 0.3)
OTC pills/day: mean during post-treatment follow-up period	Spinal Manipulation	Spinal Manipulation + Amitriptyline 100mg/day	1.1 [1.3]	1.2 [1.5]	-0.1 (-0.6 to 0.4)	-0.1 (-0.4 to 0.3)
General health status (S-36): % points during post-treatment follow-up period	Spinal Manipulation	Spinal Manipulation + Amitriptyline 100mg/day	73.6 [10.7]	72.9 [10.5]	0.7 (-2.7 to 4.1)	0.1 (-0.3 to 0.4)

OTC = over-the-counter medications

Appendix Table D93. Dose response in acute treatment utilization with onabotulinumtoxin A for migraine prevention in adults (individual low risk of bias RCT)¹¹

Outcome	Dose of Onabotulinumtoxin A in Active vs. Control, units	Events/Randomized with Larger Dose	Events/Randomized with Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Patients using and overusing acute headache pain medications	225 vs. 150	144/182	152/168	0.9 (0.8 to 1.0)	-0.11 (-0.19 to -0.04)
Patients using and overusing acute headache pain medications	225 vs. 150	151/182	157/168	0.9 (0.8 to 1.0)	-0.10 (-0.17 to -0.04)

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D94. Dose response in global assessment of treatment success with onabotulinumtoxin A for migraine prevention in adults (individual low risk of bias RCT)⁸

Outcome	Dose of Onabotulinumtoxin A in Active vs. Control, Units	Events/Randomized with Larger Dose	Events/Randomized with Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Improvement in global assessment (patient score) week 4-8	240 vs. 120	11/43	14/43	0.8 (0.4 to 1.5)	-0.07 (-0.26 to 0.12)
Improvement in global assessment (investigator score) week 4-8	240 vs. 120	12/43	11/43	1.1 (0.5 to 2.2)	0.02 (-0.16 to 0.21)
Improvement in global assessment (patient score) week 4-12	240 vs. 120	16/43	16/43	1.0 (0.6 to 1.7)	0.00 (-0.20 to 0.20)
Improvement in global assessment (investigator score) week 4-12	240 vs. 120	17/43	18/43	0.9 (0.6 to 1.6)	-0.02 (-0.23 to 0.18)

CI = confidence interval

Appendix Table D95. Dose response reduction in migraine attacks by $\geq 50\%$ from baseline with topiramate in adults

Reference	Active Dose	Control Dose	Relative Risk (95% CI)	Weight	Absolute Risk Difference (95% CI)	Weight
Brandes, 2004 ²²	100mg/day	50mg/day	1.3 (0.9 to 1.7)	33.7	0.10 (-0.02 to 0.23)	32.30
Silberstein, 2003 ²¹	100mg/day	50mg/day	1.5 (1.1 to 2.1)	31.9	0.19 (0.07 to 0.31)	33.27
Silberstein, 2004 ²³	100mg/day	50mg/day	1.5 (1.1 to 2.0)	34.5	0.18 (0.06 to 0.30)	34.43
Pooled, random effects model, inverse variance	100mg/day	50mg/day	1.4 (1.2 to 1.7)	100.0	0.16 (0.09 to 0.23)	100
Heterogeneity			P value = 0.6 I squared = 0%		P value = 0.6 I squared = 0%	
Brandes, 2004 ²²	200mg/day	100mg/day	1.0 (0.7 to 1.2)	29.42	-0.02 (-0.15 to 0.11)	33.49
Silberstein, 2003 ²¹	200mg/day	100mg/day	1.0 (0.8 to 1.2)	34.63	-0.02 (-0.15 to 0.11)	32.75
Silberstein, 2004 ²³	200mg/day	100mg/day	1.0 (0.8 to 1.2)	35.95	-0.02 (-0.14 to 0.11)	33.77
Pooled, random effects model, inverse variance	200mg/day	100mg/day	1.0 (0.8 to 1.1)	100	-0.02 (-0.09 to 0.05)	100
Heterogeneity			P value = 0.0 I squared = 0%		P value = 0.0 I squared = 0%	
Brandes, 2004 ²²	200mg/day	50mg/day	1.2 (0.9 to 1.6)	34.17	0.08 (-0.05 to 0.20)	33.49
Silberstein, 2003 ²¹	200mg/day	50mg/day	1.5 (1.1 to 2.0)	31.43	0.17 (0.04 to 0.29)	32.44
Silberstein, 2004 ²³	200mg/day	50mg/day	1.4 (1.1 to 1.9)	34.4	0.16 (0.04 to 0.29)	34.07
Pooled, random effects model, inverse variance	200mg/day	50mg/day	1.4 (1.2 to 1.6)	100	0.14 (0.06 to 0.21)	100
Heterogeneity			P value = 0.6 I squared = 0%		P value = 0.6 I squared = 0%	

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D96. Dose response migraine prevention with divalproex in adults, results from low risk of bias randomized controlled clinical trial⁴⁷

Outcome	Daily Doses of Divalproex	Events/ Randomized with Larger Dose	Events/ Randomized with Smaller Dose	Relative Risk	Absolute Risk Difference (95% CI)	Attributable Events per 1000 Treated (95% CI)
50% improvement in migraine attacks impairing usual activities	1000 mg vs. 500 mg	16/43	26/45	0.6 (0.4 to 1.0)	-0.21 (-0.41 to 0.00)	-206 (-410 to -1)
50% improvement in migraine attacks impairing usual activities	1500 mg vs. 500 mg	24/44	26/45	0.9 (0.7 to 1.4)	-0.03 (-0.24 to 0.17)	NS
50% improvement in migraine attacks impairing usual activities	1500 mg vs. 1000 mg	24/44	16/43	1.5 (0.9 to 2.4)	0.17 (-0.03 to 0.38)	NS
50% improvement in migraine attacks necessitating symptomatic medication	1000 mg vs. 500 mg	16/43	19/45	0.9 (0.5 to 1.5)	-0.05 (-0.25 to 0.15)	NS
50% improvement in migraine attacks necessitating symptomatic medication	1500 mg vs. 500 mg	19/44	19/45	1.0 (0.6 to 1.7)	0.01 (-0.20 to 0.22)	NS
50% improvement in migraine attacks necessitating symptomatic medication	1500 mg vs. 1000 mg	19/44	16/43	1.2 (0.7 to 1.9)	0.06 (-0.15 to 0.27)	NS
50% improvement in migraine attacks with nausea, vomiting, phonophobia or photophobia	1000 mg vs. 500 mg	18/43	21/45	0.9 (0.6 to 1.4)	-0.05 (-0.26 to 0.16)	NS
50% improvement in migraine attacks with nausea, vomiting, phonophobia or photophobia	1500 mg vs. 500 mg	22/44	21/45	1.1 (0.7 to 1.6)	0.03 (-0.17 to 0.24)	NS
50% improvement in migraine attacks with nausea, vomiting, phonophobia or photophobia	1500 mg vs. 1000 mg	22/44	18/43	1.2 (0.8 to 1.9)	0.08 (-0.13 to 0.29)	NS

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence level; NS = not significant

Appendix Table D97. Migraine management programs examined in randomized controlled clinical trials

Reference Country Sample	Aim	Definition of Migraine	Concurrent Medication	Age of Subjects (Mean or Median) % Women Baseline Migraine Severity
Lemstra, 2002 ²¹⁰ Country: Not reported Sample: 80	To test the effectiveness of a multidisciplinary management program for migraine treatment in a group, low-cost, nonclinical setting	International Headache Society criteria	Not reported	Mean 34.5 years 66.3% women Average pain in last month (1-10): Intervention: 7.34±1.87, Control: 7.14±2.02 Pain Disability Index: Intervention: 32.95±12.92, Control: 34.19±16.06
Matchar, 2008 ²¹¹ Country: USA Sample: 614	To determine if patients cared for in a coordinated headache management program would achieve reduced headache disability compared with patients in usual care	Not reported	Not reported	Mean 43.5 years 87% women Migraine Disability Assessment (MIDAS), mean (SD): 48.8 (64.0)
Rothrock, 2006 ²¹² Country: USA Sample: 100	To determine whether the addition of patient education to routine medical management improves the clinical status of migraine patients and reduces their utilization of healthcare resources.	International Headache Society criteria	Prophylactic medication was prescribed to all "school" patients and to 41 (82%) of the "no school" patients: antiepileptic drug or gabapentin.	Mean 42.5 years 92% women Mean headache days: intervention=14, control=23
Fritsche, 2010 ²¹³ Country: Germany Sample: 158	To compare the therapeutic effect of a cognitive-behavioral minimal contact program (MCT) to the effect of a brochure (bibliotherapy) for the prevention of medication overuse headache (MOH) in migraine patients.	International Headache Society criteria -II criteria	Not reported	Mean 48 years 91% women Migraine days, mean (SD): MCT=7.23 (3.70), bibliography=7.27 (3.82); Headache disability, mean (SD): MCT=4.46 (1.80), bibliography=4.16 (1.56)
Sondergaard, 2006 ²¹⁴ Country: Denmark Sample: 2463	To evaluate the impact of an intensive pharmaceutical care campaign targeting inappropriate use of triptans	Not reported	Triptans	Median: Intervention: 47 years, Control: 46 years 83% women Baseline severity not reported
Hoffmann, 2008 ²¹⁵ Country: Germany Sample: 410	To evaluate the effects of pharmaceutical care (defined as intensified structured counseling between patient and pharmacist, including the use of drug databases), for patients with headache or migraine, on both clinical and psychological endpoints.	Criteria of the International Headache Society and the Kiel Headache Questionnaire	Not reported	Mean 43.3 years 83% women Headache attacks/month, n: Intervention group: 5.12±7.29, Control group: 4.81±5.65 Treated: Intervention group: 27.43±70.27, Control group: 22.37±56.87 Intensity of headache pain: Untreated: Intervention group: 8.38±1.52, Control group: 8.45±1.61

Appendix Table D98. Funding and conflict of interest in randomized controlled clinical trials that examined migraine management programs in adults

Reference	Funding	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Disclosed Relationships
Lemstra, 2002 ²¹⁰	Not reported	Yes	Yes	Not reported	Not applicable
Matchar, 2008 ²¹¹	Grant	Yes	Yes	Yes	Richard Lipton has consulted for, conducted studies funded by, and/or received lecture honoraria from Advanced Bionics, Allergan, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Cierra, Endo, GlaxoSmithKline, Merck, Neulieve, Ortho-McNeil, Pfizer, Pozen, ProEthics and St Judes. The following authors have no conflict of interest. Including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript: David B. Matchar, Gregory Samsa, Annette Jurgelski. Dr. Harpole and Kori are presently employees of GlaxoSmithKline.
Rothrock, 2006 ²¹²	Not reported	Yes	Yes	Not reported	Not applicable
Fritsche, 2010 ²¹³	Grant	Yes	Yes	None	Not applicable
Sondergaard, 2006 ²¹⁴	Grant	Yes	Not reported	Not reported	Not applicable
Hoffmann, 2008 ²¹⁵	Industry + Other	Yes	Yes	Not reported	Not reported, however, Michael Cramer is the Head of Division for Pharmacies and Health Provision, Ministry for Work, Social, Health, Family and Gender Issues, Mainz, Germany. Doris Gresselmeyer is a pharmacist from Linden - Apotheke, Bremen, Germany

Appendix Table D99. Risk of bias in randomized controlled clinical trials that examined migraine management programs in adults

Reference	Masking of the Treatment Status	Masking - Outcome Assessment	Intention to Treat Analysis Preplanned	Allocation Concealment	Adequacy of Randomization	Groups Similarity	Risk of Bias
Lemstra, 2002 ²¹⁰	Open-label (Therapists were blind as to which specific outcome variables were primarily under evaluation).	The outcome assessor was blind to the intervention status.	Yes	Unclear	Yes	Frequency: similar; Severity: similar; Duration: not reported	Medium
Matchar, 2008 ²¹¹	Not reported	Yes	No	Unclear	Not adequate	Frequency: not reported; Severity: similar (MIDAS score include headache days and severity of pain and they were similar across the groups); Duration: not reported	Medium
Rothrock, 2006 ²¹²	Not reported	Yes	No	Unclear	Not adequate : difference in episodic migraine in control group (36% vs. 2%); frequent episodic migraine (72% vs. 28%); and mean Migraine Disability Assessment (MIDAS) score was lower in the intervention group	Not reported	Medium
Fritsche, 2010 ²¹³	Not reported	Not reported	No	Clearly adequate (central randomization)	Not reported (There were no patients with aura in the control group)	Frequency: similar; Severity: similar; Duration: not reported	Low
Sondergaard, 2006 ²¹⁴	Not reported	Not reported	Not reported	Unclear	Yes	Not reported	Low
Hoffman, 2008 ²¹⁵	Not reported	Not reported	Yes	Unclear	Yes	Frequency: similar; Severity: similar; Duration: similar	Low

Appendix Table D100. Description of disease management programs for migraine prevention in adults

Reference	Program	Description	Control	Description
Lemstra, 2002 ²¹⁰	Multidisciplinary intervention: It consisted of a neurologist intake, physical therapist intake, 18 group-supervised exercise therapy sessions with an exercise therapist, 2 group lectures with a registered psychologist 1 group lecture with a dietitian, 2 massage therapy sessions, and a neurologist and physical therapist discharge. The initial neurologist evaluation was intended to confirm the diagnosis, obtain a detailed history, and confirm appropriateness to participate. The physical therapist provided a detailed biomechanical evaluation, provided education on hurt versus harm, identified barriers to participation, and initiated an action plan to prevent dropout. The exercise therapist supervised the exercise therapy sessions, which included submaximal aerobic exercise, stretching, and light weight training, and monitored attendance and created a social no intimidating environment for the patients. The psychologist provided 1 group lecture on relaxation training and another on behavioral modification and stress management. The dietitian provided 1 group lecture on general dietary goals and explained how to substitute alternatives to potential dietary triggers. The massage therapist provided 2 individual sessions with the goal of relaxation and a means of reward after initial exercise sessions rather than any type of therapeutic benefit.	Multidisciplinary intervention: It consisted of a neurologist intake, physical therapist intake, 18 group-supervised exercise therapy sessions with an exercise therapist, 2 group lectures with a registered psychologist 1 group lecture with a dietitian, 2 massage therapy sessions, and a neurologist and physical therapist discharge. The initial neurologist evaluation was intended to confirm the diagnosis, obtain a detailed history, and confirm appropriateness to participate. The physical therapist provided a detailed biomechanical evaluation, provided education on hurt versus harm, identified barriers to participation, and initiated an action plan to prevent dropout. The exercise therapist supervised the exercise therapy sessions, which included submaximal aerobic exercise, stretching, and light weight training, and monitored attendance and created a social no intimidating environment for the patients. The psychologist provided 1 group lecture on relaxation training and another on behavioral modification and stress management. The dietitian provided 1 group lecture on general dietary goals and explained how to substitute alternatives to potential dietary triggers. The massage therapist provided 2 individual sessions with the goal of relaxation and a means of reward after initial exercise sessions rather than any type of therapeutic benefit.	Standard medical care with the patient's family physician	Standard medical care with the patient's family physician

Appendix Table 100. Description of disease management programs for migraine prevention in adults (continued)

Reference	Program	Description	Control	Description
Matchar, 2008 ²¹¹	Headache management program: This involved developing a set of general functional specifications for a headache program, identifying local site-specific barriers to implementing the functional specifications, and working with investigators to develop a set of mutually acceptable tools that assured comparability and standardization across sites. The intervention was administered by a mid-level provider (e.g. nurse practitioner or PA) with expertise in headache evaluation and management. The program included an educational session attended by all intervention patients either individually or as a group (the headache class). Patients were given educational materials that included information on headache types and etiologies, pharmacologic treatment, triggers, sleep hygiene, and relaxation techniques.	Headache management program consisting of :1) a class specifically designed to inform patients about headache types, triggers, and treatment options; 2) diagnosis and treatment by a professional especially trained in headache care (based on US Headache Consortium guidelines); and 3) proactive follow-up by a case-manager. It also included an educational session attended by all intervention patients either individually or as a group; an initial visit to the clinic for evaluation; and follow-up visits (in-person or by telephone) at 1, 3, and 6 months.	Usual care	Continue with current clinician and no access to the headache management program
Fritsche, 2010 ²¹³	Cognitive-behavioral minimal contact program (MCT)	It consisted of 5 sessions with sic participants and lasting 2 hours (2*50min plus 20-min plus a 20-min break) each. The first unit (session) was called "Introduction and syndrome education". It main components included information about symptoms, pathophysiology and pathopsychology of migraine as well as instructions for progressive muscle relaxation (PMR). The 2nd unit was called "Medication rules and the risk of Medication Overuse Headache" including information about acute and prophylactic migraine medication and medication overuse headache-symptoms and patho-mechanisms. The 3rd unit was called "Medication intake behavior" aimed at raising awareness for "external" (e.g. availability of drugs, stock-keeping, iatrogenic risk factors like doctor shopping) and "internal" (e.g. fear of attack and losing social functioning, stress level in private and professional life) influences on patient's medication intake behavior. The 4th	Brochure (bibliography)	The participants received two brochures: a detailed brochure as a patient guide with information about physiological and psychological aspects of migraine, medication-overuse headache and migraine medication. It summarized the topics which were covered by the MCT, written in the style of a self-help manual containing instructions for exercises to minimize drug consumption and instructions for PMR. Each chapter of the brochure ended with questions about the

Appendix Table 100. Description of disease management programs for migraine prevention in adults (continued)

Reference	Program	Description	Control	Description
		unit was called "general and personal risk factors for drug intake" and established a general risk profile of medication overuse for each patient. The 5th unit was called "everyday transfer" with the aim of establishing individual goals for future drug intake and learning how to make use of social support to control intake behavior. At the end of the 5th session, participants received the brochures given to the biblio-group.		content of the chapter which the patients were to answer. The brochure was called "Migraine and medication – Which problems can arise and what to do". The second brochure (extended information about migraine medication) contained information material without any exercise instructions. Part one of the brochure described the indication, the pharmacological mechanisms of action and the side-effects of different acute migraine medications, and part two discussed prophylactic medication. There was no face-to-face contact and the participants had the opportunity to obtain advice by telephone if they had any questions regarding the brochures.
Rothrock, 2006 ²¹²	Standardized course of didactic instructions regarding migraine biogenesis and management ("headache school")	The curriculum consisted of 3 90-minute classes held on evenings and weekends and taught by lay migraineurs who previously had undergone intensive classroom and in-clinic training by 1 of the neurology investigators (Johns Rothrock). The 3 "headache school" classes primarily involved the topics of migraine biogenesis, acute treatment of migraine, and prevention of migraine. Working together, in each class 2 instructors provided 30 to 45 minutes of didactic instruction, followed by a review of hard copy materials related to the primary topic and permanently provided to the participants, demonstration of therapeutic devices (e.g., the autoinjector used to administer sumatriptan; subcutaneous administration of Dihydroergotamine via a 1 cc syringe and 27 g needle), and, to close, an interactive question and answer session cum open forum. All individuals serving as patient instructors underwent 12 hours of classroom instruction in headache theory and treatment, received and reviewed a	Routine medical management	

Appendix Table 100. Description of disease management programs for migraine prevention in adults (continued)

Reference	Program	Description	Control	Description
		related course syllabus, were required to pass successfully a written examination based on that didactic instruction, and then served a minimum of 12 hours as observers in the headache clinics.		
Hoffmann, 2008 ²¹⁵	Pharmaceutical care for migraine	Pharmacists from the intervention pharmacies participated in a 2-day central training program conducted by a physician and a pharmacist who were employees of the university. Together with the patient, the intervention pharmacist prioritized problems, defined goals, and devised a plan to work toward them. The training was based on a comprehensive standard operation manual that was distributed to the intervention pharmacists upon completion of the program. The manual was developed by the Federal Union of German Associations of Pharmacists, in cooperation with the principal investigators, and contains central definitions of pharmaceutical care (PC), with a focus on PC in patients with different types of pain (e.g., headache, muscle).	Standard counseling	Patients received the regular pharmaceutical consultation; their pharmacists were not specially trained, did not receive the standard manual, and were not included in the documentation scheme for counseling. This regular counseling includes general information about application and possible adverse drug effects.
Sondergaard, 2006 ²¹⁴	Intensive pharmaceutical care campaign	Pharmacists from the intervention pharmacies provided the intervention. They were encouraged to involve the pharmacy assistants. A manual given to pharmacy staff described how to identify inappropriate triptan use, how to establish a dialogue and how to ask questions. Moreover, it offered suggestions for relevant questions, advice, literature on headache, migraine and pharmaceutical care, and included a checklist. The training package was developed in cooperation with the Danish College of Pharmacy Practice (Pharmakon). When presenting a triptan prescription at the pharmacy, the user received a folder designed to support the dialogue and assist the pharmacist in detecting triptan overuse. It included information on the campaign and questions on the patient's drug use, e.g. the type of headache for which the patient used triptans, monthly consumption of triptans, repeated use of triptans even if the first dose had no effect on the attack, and the frequency of use of other types of painkillers. The dialogue between the pharmacist and the patient took place immediately after the folder had been read and its questions answered. To ensure an undisturbed, confidential conversation, the pharmacies were encouraged to let the dialogue with triptan users take place in a separate room. Each dialogue was estimated to last on average 15 minutes and each triptan user participated only once.	Control pharmacy	

Appendix Table D101. Adherence to multidisciplinary intervention for migraine prevention in adults compared to standard care, results from medium risk of bias randomized controlled clinical trial²¹⁰

Definition of the Outcome	Events/Randomized with Multidisciplinary Intervention	Events/Randomized with Usual Care	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Quit intervention due to inefficiency	1/44	0/36	2.5 (0.1 to 58.8)	0.02 (-0.04 to 0.09)
Quit intervention	3/44	0/36	5.8 (0.3 to 107.9)	0.07 (-0.02 to 0.15)

CI = confidence interval

Appendix Table D102. Effectiveness of multidisciplinary intervention for migraine prevention in adults compared to standard care (results from medium risk of bias randomized controlled clinical trial)²¹⁰

Definition of the Outcome at 3 Months of followup After the Intervention	Mean [Standard Deviation] with Multidisciplinary Intervention	Mean [Standard Deviation] with Usual Care	Mean Difference (95% CI)	Cohen Standardized Mean Difference (95% CI)
% change in self-perceived pain frequency (Visual Analogue Scale that included values from 100% worse to 100% improvement)	56.9 [9.1]	-2.2 [2.2]	59.15 (56.36 to 61.94)	8.5 (7.1 to 9.9)
% change in pain intensity (Visual Analogue Scale that included values from 100% worse to 100% improvement)	38.2 [8.5]	-2.8 [2.0]	40.96 (38.36 to 43.56)	6.3 (5.2 to 7.4)
% change in pain duration (Visual Analogue Scale that included values from 100% worse to 100% improvement)	47.2 [8.3]	-5.0 [2.9]	52.16 (49.52 to 54.80)	8.0 (6.7 to 9.4)
% change in functional status (Visual Analogue Scale that included values from 100% worse to 100% improvement)	51.6 [7.7]	-0.6 [2.0]	52.15 (49.78 to 54.52)	8.9 (7.4 to 10.3)
% change in quality of life (Visual Analogue Scale that included values from 100% worse to 100% improvement)	57.1 [8.2]	-1.9 [1.9]	58.99 (56.49 to 61.49)	9.5 (8.0 to 11.1)
% change in Pain Disability Index (Visual Analogue Scale that included values from 100% worse to 100% improvement)	18.8 [2.2]	1.7 [1.0]	17.08 (16.35 to 17.81)	9.6 (8.0 to 11.2)
% change in Beck Depression Inventory (Visual Analogue Scale that included values from 100% worse to 100% improvement)	10.6 [1.3]	1.2 [0.5]	9.44 (9.04 to 9.84)	9.7 (8.1 to 11.2)

Bold = significant differences at 95% CI when 95% CI of mean difference estimates do not include 0

CI = confidence interval

Appendix Table D103. Reduction in disability with headache management program for migraine prevention in adults compared to standard care (results from medium risk of bias randomized controlled clinical trial)²¹¹

Definition of the Outcome	Events/Randomized with Headache Management Program	Events/Randomized with Usual Care	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events per 1000 Treated (95% CI)
6 months: Achieved a Migraine Disability Assessment (MIDAS) score of 0 reflecting no headache-related disability	124/305	65/309	1.9 (1.5 to 2.5)	0.20 (0.12 to 0.27)	5 (4 to 8)	196 (125 to 258)

CI = confidence interval

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

Appendix Table D104. Effectiveness of headache management program for migraine prevention in adults compared to standard care (results from medium risk of bias randomized controlled clinical trial)²¹¹

Definition of the Outcome	Mean [Standard Deviation] with Headache Management Program	Mean [Standard Deviation] with Usual Care	Mean Difference (95% CI)	Cohen Standardized Mean Difference (95% CI)
MIDAS score at 6 months	15.9 [24.4]	23.6 [37.6]	-7.70 (-12.71 to -2.69)	-0.2 (-0.4 to -0.1)
Quality of life (SF-36): Physical function domain	84.0 [20.6]	79.0 [22.3]	5.00 (1.60 to 8.40)	0.2 (0.1 to 0.4)
Quality of life (SF-36): Role physical domain	75.7 [24.8]	67.5 [25.1]	8.20 (4.25 to 12.15)	0.3 (0.2 to 0.5)
Quality of life (SF-36): Pain domain	63.8 [23.0]	55.5 [22.5]	8.30 (4.70 to 11.90)	0.4 (0.2 to 0.5)
Quality of life (SF-36): General health domain	53.3 [9.9]	52.3 [9.8]	1.00 (-0.56 to 2.56)	0.1 (-0.1 to 0.3)
Quality of life (SF-36): Vitality domain	52.8 [21.4]	48.8 [19.3]	4.00 (0.78 to 7.22)	0.2 (0.0 to 0.4)
Quality of life (SF-36): Social function domain	73.4 [24.9]	68.7 [24.8]	4.70 (0.77 to 8.63)	0.2 (0.0 to 0.3)
Quality of life (SF-36): Role emotional domain	77.9 [24.1]	73.8 [25.6]	4.10 (0.17 to 8.03)	0.2 (0.0 to 0.3)
Quality of life (SF-36): Mental health domain	69.7 [19.2]	66.8 [19.9]	2.90 (-0.19 to 5.99)	0.1 (0.0 to 0.3)
Quality of life (SF-36): Physical summary domain	47.6 [7.7]	45.0 [8.4]	2.60 (1.33 to 3.87)	0.3 (0.2 to 0.5)
Quality of life (SF-36): Mental summary domain	45.4 [11.6]	43.9 [11.6]	1.50 (-0.34 to 3.34)	0.1 (0.0 to 0.3)
General health (from 1 [excellent] to 5 [poor])	2.4 [0.9]	2.7 [0.9]	-0.30 (-0.44 to -0.16)	-0.3 (-0.5 to -0.2)
Change since last year (from 1 [much better] to 5 [much worse])	2.5 [0.9]	2.8 [0.9]	-0.30 (-0.44 to -0.16)	-0.3 (-0.5 to -0.2)
Depression (PHQ-9) (Patient Health Questionnaire-Short Form)	5.6 [5.2]	6.6 [5.3]	-1.00 (-1.83 to -0.17)	-0.2 (-0.3 to 0.0)
MIDAS: Missed work days	1.2 [2.7]	1.6 [6.5]	-0.40 (-1.19 to 0.39)	-0.1 (-0.2 to 0.1)
MIDAS: Missed half work days	3.9 [7.9]	5.2 [8.8]	-1.30 (-2.62 to 0.02)	-0.2 (-0.3 to 0.0)
MIDAS: Missed house days	5.0 [10.2]	7.1 [11.2]	-2.10 (-3.79 to -0.41)	-0.2 (-0.4 to 0.0)
MIDAS: Missed half house days	3.9 [6.0]	6.8 [10.5]	-2.90 (-4.25 to -1.55)	-0.3 (-0.5 to -0.2)
MIDAS: Missed family days	2.4 [4.9]	3.6 [8.1]	-1.20 (-2.26 to -0.14)	-0.2 (-0.3 to 0.0)
MIDAS: Headache days	13.8 [17.6]	17.7 [20.9]	-3.90 (-6.95 to -0.85)	-0.2 (-0.4 to 0.0)
MIDAS: Headache pain (from 0 [no pain at all] to 10 [pain as bad as it can be])	5.6 [2.3]	6.1 [2.2]	-0.50 (-0.86 to -0.14)	-0.2 (-0.4 to -0.1)
Worried about headache (from 0 [not worried at all] to 10 [extremely worried])	4.4 [2.7]	5.1 [2.7]	-0.70 (-1.13 to -0.27)	-0.3 (-0.4 to -0.1)
Problems with headache management (from 1 [no problems] to 4 [severe amount of problems])	2.1 [0.8]	2.4 [0.7]	-0.30 (-0.42 to -0.18)	-0.4 (-0.6 to -0.2)
Satisfaction with care (from 1 [very satisfied] to 5 [very dissatisfied]): Headache care	1.8 [1.0]	2.4 [1.2]	-0.60 (-0.77 to -0.43)	-0.5 (-0.7 to -0.4)
Satisfaction with care (from 1 [very satisfied] to 5 [very dissatisfied]): Understanding	1.7 [1.0]	2.4 [1.2]	-0.70 (-0.87 to -0.53)	-0.6 (-0.8 to -0.5)
Satisfaction with care (from 1 [very satisfied] to 5 [very dissatisfied]): Medications	2.0 [1.1]	2.5 [1.2]	-0.50 (-0.68 to -0.32)	-0.4 (-0.6 to -0.3)
Satisfaction with care (from 1 [very satisfied] to 5 [very dissatisfied]): Medical care in general	1.7 [0.9]	2.0 [1.0]	-0.30 (-0.45 to -0.15)	-0.3 (-0.5 to -0.2)

Bold = significant differences at 95% confidence limit when 95% CI of mean difference estimates do not include 0

CI = confidence interval

Appendix Table D105. Effectiveness of cognitive-behavioral minimal contact program for migraine prevention in adults compared to educational brochure (results from medium risk of bias randomized controlled clinical trial)²¹⁶

Definition of the Outcome	Mean [Standard Deviation] with Cognitive-behavioral Minimal Contact Program	Mean [Standard Deviation] with Educational Brochure	Mean Difference (95% CI)	Cohen Standardized Mean Difference (95% CI)
Headache days: 3 months after treatment	8.6 [5.5]	8.1 [4.8]	0.44 (-1.21 to 2.09)	0.1 (-0.2 to 0.4)
Headache days: 1-2 years after treatment	8.7 [5.3]	8.3 [5.2]	0.35 (-1.32 to 2.02)	0.1 (-0.3 to 0.4)
Migraine days: 3 months after treatment	6.2 [4.0]	5.5 [3.2]	0.70 (-0.44 to 1.84)	0.2 (-0.1 to 0.5)
Migraine days: 1-2 years after treatment	6.2 [4.0]	5.8 [3.8]	0.31 (-0.94 to 1.56)	0.1 (-0.2 to 0.4)
Headache disability: 3 months after treatment	4.6 [2.0]	4.3 [1.9]	0.36 (-0.26 to 0.98)	0.2 (-0.1 to 0.5)
Headache disability: 1-2 years after treatment	4.4 [2.2]	4.4 [1.7]	-0.01 (-0.63 to 0.61)	0.0 (-0.3 to 0.3)
Intake at headache days: 3 months after treatment	5.9 [3.2]	6.5 [3.2]	-0.54 (-1.57 to 0.49)	-0.2 (-0.5 to 0.2)
Intake at headache days: 1-2 years after treatment	6.2 [3.7]	6.0 [2.8]	0.18 (-0.86 to 1.22)	0.1 (-0.3 to 0.4)
Intake at migraine days: 3 months after treatment	4.8 [3.0]	4.8 [2.8]	0.08 (-0.85 to 1.01)	0.0 (-0.3 to 0.3)
Intake at migraine days: 1-2 years after treatment	5.0 [3.5]	5.0 [2.8]	0.01 (-1.00 to 1.02)	0.0 (-0.3 to 0.3)
CPAQ-AE ('Activity engagement' subscale of the "Chronic Pain Acceptance Questionnaire"): 3 months after intervention; lower score indicates worse and higher score indicates better ability to maintain functioning in the presence of chronic pain	34.6 [10.9]	34.9 [9.4]	-0.32 (-3.56 to 2.92)	0.0 (-0.4 to 0.3)
CPAQ-AE ('Activity engagement' subscale of the "Chronic Pain Acceptance Questionnaire"): 1-2 years after intervention; lower score indicates worse and higher score indicates better ability to maintain functioning in the presence of chronic pain	35.5 [10.8]	34.4 [9.4]	1.12 (-2.11 to 4.35)	0.1 (-0.2 to 0.4)
CPAQ-PW ('Pain willingness' subscale of the "Chronic Pain Acceptance Questionnaire"): 3 months after intervention; lower score indicates worse and higher score indicates better ability to maintain functioning in the presence of chronic pain	22.5 [8.9]	23.4 [8.0]	-0.89 (-3.58 to 1.80)	-0.1 (-0.4 to 0.2)
CPAQ-PW ('Pain Willingness' subscale of the "Chronic Pain Acceptance Questionnaire"): 1-2 years after intervention; lower score indicates worse and higher score indicates better ability to maintain functioning in the presence of chronic pain	26.8 [9.6]	25.2 [7.6]	1.55 (-1.21 to 4.31)	0.2 (-0.1 to 0.5)
FSS-CATA ('Catastrophising cognitions' subscale of the "Pain-related self instructions" questionnaire): 3 months after intervention. It consists of 9 items on a 6-point scale (0=almost never, 5=almost always)	24.2 [7.3]	25.5 [7.3]	-1.33 (-3.67 to 1.01)	-0.2 (-0.5 to 0.1)
FSS-CATA ('Catastrophising cognitions' subscale of the "Pain-related self instructions" questionnaire): 1-2 years after intervention. It consists of 9 items on a 6-point scale (0=almost never, 5=almost always)	21.4 [10.3]	22.1 [8.5]	-0.68 (-3.70 to 2.34)	-0.1 (-0.4 to 0.2)

Appendix Table 105. Effectiveness of cognitive-behavioral minimal contact program for migraine prevention in adults compared to educational brochure (results from medium risk of bias randomized controlled clinical trial) (continued)

Definition of the Outcome	Mean [Standard Deviation] with Cognitive-behavioral Minimal Contact Program	Mean [Standard Deviation] with Educational Brochure	Mean Difference (95% CI)	Cohen Standardized Mean Difference (95% CI)
FSS-FUNC ('Functional cognitions' subscale of the "Pain-related self instructions" questionnaire): 3 months after intervention. It consists of 9 items on a 6-point scale (0=almost never, 5=almost always)	34.2 [14.7]	29.8 [6.1]	4.32 (0.79 to 7.85)	0.4 (0.1 to 0.7)
FSS-FUNC ('Functional cognitions' subscale of the "Pain-related self instructions" questionnaire): 1-2 years after intervention. It consists of 9 items on a 6-point scale (0=almost never, 5=almost always)	29.5 [7.3]	29.2 [6.3]	0.33 (-1.84 to 2.50)	0.0 (-0.3 to 0.4)
HADS -A ('Anxiety 'subscale of the "Hospital Anxiety and Depression Scale"; 7 items on a 4-point Likert scale (0-3), with higher scores being worse condition): 3 months after intervention.	6.2 [2.3]	6.4 [2.2]	-0.17 (-0.90 to 0.56)	-0.1 (-0.4 to 0.2)
HADS -A ('Anxiety 'subscale of the "Hospital Anxiety and Depression Scale"; 7 items on a 4-point Likert scale (0-3), with higher scores being worse condition): 1-2 years after intervention.	5.9 [3.8]	6.2 [4.1]	-0.32 (-1.58 to 0.94)	-0.1 (-0.4 to 0.2)
HADS -D ('Depression 'subscale of the "Hospital Anxiety and Depression Scale"; 7 items on a 4-point Likert scale (0-3), with higher scores being worse condition): 3 months after intervention.	4.8 [1.2]	4.8 [1.3]	0.03 (-0.37 to 0.43)	0.0 (-0.3 to 0.3)
HADS -D ('Depression 'subscale of the "Hospital Anxiety and Depression Scale"; 7 items on a 4-point Likert scale (0-3), with higher scores being worse condition): 1-2 years after intervention.	4.8 [4.2]	4.9 [4.0]	-0.14 (-1.45 to 1.17)	0.0 (-0.4 to 0.3)
KKG-INT ('Internal control 'subscale of the "Illness -specific locus of control"; 7 items on a 6-point Likert scale (range1=totally not correct to 6=totally correct): 3 months after intervention	26.2 [5.3]	25.1 [4.4]	1.07 (-0.48 to 2.62)	0.2 (-0.1 to 0.5)
KKG-INT ('Internal control 'subscale of the "Illness -specific locus of control"; 7 items on a 6-point Likert scale (range1=totally not correct to 6=totally correct): 1-2 years after intervention	26.3 [4.3]	25.2 [4.9]	1.10 (-0.38 to 2.58)	0.2 (-0.1 to 0.6)
KKG-EXT ('External control 'subscale of the "Illness -specific locus of control"; 7 items on a 6-point Likert scale (range1=totally not correct to 6=totally correct): 3 months after intervention	21.0 [5.7]	21.2 [5.1]	-0.17 (-1.90 to 1.56)	0.0 (-0.4 to 0.3)
KKG-EXT ('External control 'subscale of the "Illness -specific locus of control"; 7 items on a 6-point Likert scale (range1=totally not correct to 6=totally correct): 1-2 years after intervention	21.0 [5.5]	20.7 [6.8]	0.26 (-1.73 to 2.25)	0.0 (-0.3 to 0.4)
KKG-FATA ('Fatalistic' subscale of the "Illness -specific locus of control"; 7 items on a 6-point Likert scale (range1=totally not correct to 6=totally correct): 3 months after intervention	16.8 [6.3]	19.5 [6.1]	-2.72 (-4.71 to -0.73)	-0.4 (-0.8 to -0.1)
KKG-FATA ('Fatalistic' subscale of the "Illness -specific locus of control"; 7 items on a 6-point Likert scale (range1=totally not correct to 6=totally correct): 1-2 years after intervention	18.5 [6.7]	18.4 [6.5]	0.10 (-2.03 to 2.23)	0.0 (-0.3 to 0.3)

Appendix Table 105. Effectiveness of cognitive-behavioral minimal contact program for migraine prevention in adults compared to educational brochure (results from medium risk of bias randomized controlled clinical trial) (continued)

Definition of the Outcome	Mean [Standard Deviation] with Cognitive-behavioral Minimal Contact Program	Mean [Standard Deviation] with Educational Brochure	Mean Difference (95% CI)	Cohen Standardized Mean Difference (95% CI)
Satisfied with treatment (assessed in a telephone interview three months after the intervention. Patients rated the extent of helpfulness of the treatment in reducing medication intake and whether and to what extent they would recommend the treatment to a friend on a range of 1-6 (1=very good to 6=very bad))	1.7 [0.6]	2.8 [1.0]	-1.10 (-1.37 to -0.83)	-1.3 (-1.7 to -1.0)
Satisfied that treatment is helpful for reducing medication intake (assessed in a telephone interview three months after the intervention. Patients rated the extent of helpfulness of the treatment in reducing medication intake and whether and to what extent they would recommend the treatment to a friend on a range of 1-6 (1=very good to 6=very bad))	1.9 [0.6]	2.6 [0.8]	-0.68 (-0.91 to -0.45)	-1.0 (-1.3 to -0.6)

Bold = significant differences at 95% CI when 95% CI of mean difference estimates do not include 0

CI = confidence interval

Appendix Table D106. Reduction in acute drug overuse with headache school for migraine prevention in adults on acute drug utilization (results from medium risk of bias randomized controlled clinical trial)²¹²

Definition of the Outcome	Events/Randomized with Headache School	Events/Randomized with Usual Care	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events per 1000 Treated (95% CI)
Analgesic overuse: at 6 months (number of patients using a given abortive agent or class of abortive agents >3 days/week for >4 weeks)	0/50	18/50	0.0 (0.0 to 0.4)	-0.36 (-0.49 to -0.23)	-3 (-4- to -2)	360 (225 to 495)

Bold = significant differences at 95% CI when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D107. Effectiveness of headache school for migraine prevention in adults (results from medium risk of bias randomized controlled clinical trial)²¹²

Definition of the Outcome	Mean [Standard Deviation] with Headache School	Mean [Standard Deviation] with Usual Care	Mean Difference (95% CI)	Cohen Standardized Mean Difference (95% CI)
Mean Migraine Disability Assessment (MIDAS): change relative to baseline	15.0 [24.0]	54.0 [14.0]	-39.00 (-46.70 to -31.30)	-2.0 (-2.5 to -1.5)
Mean functionally incapacitating headache days per month	3.0 [2.6]	4.6 [1.7]	-1.60 (-2.46 to -0.74)	-0.7 (-1.1 to -0.3)

Bold = significant differences at 95% CI when 95% CI of mean difference estimates do not include 0

CI = confidence interval

**Appendix Table D108. Migraine cessation with specialized pharmaceutical care for migraine compared to standard counseling in adults
(results from low risk of bias randomized controlled clinical trial)²¹⁵**

Definition of the Outcome	Events/Randomized with Active Intervention	Events/Randomized with Control Intervention	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
No headache during the preceding 4 weeks	21/201	16/209	1.4 (0.7to 2.5)	0.03 (-0.03 to 0.08)

CI = confidence interval

Appendix Table D109. Effectiveness of specialized pharmaceutical care for migraine compared to standard counseling for migraine prevention in adults (results from low risk of bias randomized controlled clinical trial)²¹⁵

Definition of the Outcome	Mean [Standard Deviation] with Active Intervention	Mean [Standard Deviation] with Control Intervention	Mean Difference (95% CI)	Cohen Standardized Mean Difference (95% CI)
Days/month with headache	6.1 [6.7]	6.4 [6.9]	-0.30 (-1.61 to 1.01)	0.0 (-0.2 to 0.1)
Headache attacks/month	4.6 [6.1]	5.1 [7.3]	-0.43 (-1.74 to 0.88)	-0.1 (-0.3 to 0.1)
Intensity of pain: Untreated (on an analog scale of 1 (no headache) to 10 (extremely intense headache))	6.8 [3.4]	7.3 [2.9]	-0.46 (-1.07 to 0.15)	-0.1 (-0.3 to 0.0)
Intensity of pain: Treated (on an analog scale of 1 (no headache) to 10 (extremely intense headache))	3.3 [2.7]	3.5 [2.8]	-0.19 (-0.73 to 0.35)	-0.1 (-0.3 to 0.1)
Self-efficacy (Definitions of Schwarzer et al. Higher the score better the self-efficacy)	83.8 [7.5]	84.5 [8.2]	-0.78 (-2.30 to 0.74)	-0.1 (-0.3 to 0.1)
Quality of life: physical health (SF-36)	43.0 [10.3]	44.4 [9.1]	-1.37 (-3.25 to 0.51)	-0.1 (-0.3 to 0.1)
Quality of life: mental health (SF-36)	49.4 [9.1]	49.5 [10.4]	-0.09 (-1.98 to 1.80)	0.0 (-0.2 to 0.2)

Appendix Table D110. Effectiveness of intensive pharmaceutical care campaign for migraine prevention in adults (results from low risk of bias randomized controlled clinical trial)²¹⁴

Definition of the Outcome	Mean [Standard Deviation] with Intensive Pharmaceutical Care Campaign	Mean [Standard Deviation] with Usual Pharmacy Service	Reported Results
3 months: Incident users (No prescription 9 months before index date): Patients' triptan consumption (doses per month)	2.5 [Not reported]	2.5 [Not reported]	Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(2.45, 2.61), control=(2.29, 2.64)
3 months: Prevalent users (One or more prescriptions 9 months before index date): Patients' triptan consumption (doses per month)	7.1 [Not reported]	7.1 [Not reported]	Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(6.66, 7.51), control=(6.49, 7.65)
6 months: Incident users (No prescription 9 months before index date): Patients' triptan consumption (doses per month)	1.3 [Not reported]	1.3 [Not reported]	Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(1.21, 1.39), control=(1.19, 1.46)
6 months: Prevalent users (One or more prescriptions 9 months before index date): Patients' triptan consumption (doses per month)	5.3 [Not reported]	5.3 [Not reported]	Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(5.04, 5.61), control=(4.75, 5.89)
9 months: Incident users (No prescription 9 months before index date): Patients' triptan consumption (doses per month)	0.8 [Not reported]	0.8 [Not reported]	Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(0.73, 0.97), control=(0.78, 0.90)
9 months: Prevalent users (One or more prescriptions 9 months before index date): Patients' triptan consumption (doses per month)	4.2 [Not reported]	4.3 [Not reported]	Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(3.89, 4.51), control=(3.87, 4.72)
9 months: Prevalent users (One or more prescriptions 9 months before index date): <6 doses per month: Patients' triptan consumption (doses per month)	3.0 [Not reported]	3.0 [Not reported]	Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(2.78, 3.17), control=(2.71, 3.20)
9 months: Prevalent users (One or more prescriptions 9 months before index date): ≥6 and <15 doses per month: Patients' triptan consumption (doses per month)	9.9 [Not reported]	9.3 [Not reported]	Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(9.3, 10.5), control=(10.4, 11.2)
9 months: Prevalent users (One or more prescriptions 9 months before index date): ≥15 doses per month: Patients' triptan consumption (doses per month)	25.4 [Not reported]	26.0 [Not reported]	Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(20.9, 31.0), control=(22.4, 30.1)

Appendix Table D111. Funding, ethical approval, and disclosure of conflict of interest in placebo controlled randomized controlled clinical trials of drugs for migraine prevention that included adverse effects

Drugs	Funded by Grant	Funded by Industry	Funding not Reported	Clear Reporting of Consent	COI not Disclosed	No COI	Disclosed COI	Total
Topiramate	0	6	5	9	6	0	5	11
Divalproex	0	2	0	2	0	0	2	2
Valproate	0	0	1	1	1	0	0	1
Propranolol	0	0	4	3	4	0	0	4
Timolol	0	0	1	1	1	0	0	1
Lamotrigine	0	0	1	1	1	0	0	1
Carbamazepine	0	1	0	0	1	0	0	1
Gabapentin	0	0	2	1	2	0	0	2
Acetazolamide	1	0	0	1	1	0	0	1
Amitriptyline	0	3	0	3	3	0	0	3
Nadolol	0	0	1	1	1	0	0	1
Metoprolol	0	0	3	3	3	0	0	3
Atenolol	0	0	2	0	2	0	0	2
Alprenolol	0	1	0	0	1	0	0	1
Pindolol	0	0	1	0	1	0	0	1
Captopril	0	0	1	0	1	0	0	1
Lisinopril	0	1	0	1	0	0	1	1
Telmisartan	0	1	0	1	0	0	1	1
Candesartan	0	1	0	1	0	0	1	1
Nimodipine	0	1	3	2	4	0	0	4
Verapamil	0	1	0	1	1	0	0	1
Nicardipine	0	1	0	1	1	0	0	1
Nifedipine	0	1	1	2	2	0	0	2
Clonidine	0	3	3	5	6	0	0	6
Dihydroergocryptine	0	0	1	0	1	0	0	1
Dihydroergotamine	0	1	2	3	2	1	0	3
Lisuride	0	0	1	0	1	0	0	1
Methysergide	0	0	1	0	1	0	0	1
Tizanidine	0	1	0	1	1	0	0	1
Montelukast	0	1	0	1	0	0	1	1
Femoxetine	2	0	1	2	3	0	0	3
Fluoxetine	0	2	2	4	4	0	0	4
Indomethacin	0	1	0	0	1	0	0	1
Induprofen	0	0	1	1	1	0	0	1
Ketoprofen	0	1	0	0	1	0	0	1
Naproxen sodium	1	0	1	1	2	0	0	2
Oxcarbazepine	0	1	0	1	0	0	1	1
Tolfenamic Acid	0	1	0	0	1	0	0	1
Tonabersat	0	1	0	1	1	0	0	1
Mg	0	0	2	2	2	0	0	2
Total*	4	34	45	59	70	1	12	83

*-Total includes flunarizine trials

Appendix Table D112. Patient characteristics in placebo controlled randomized controlled clinical trials of adverse effects with drugs for migraine prevention in adults

Drug	# RCTs	Mean Age in Years	# RCTs	% Women	# RCTs	% with Aura	# RCTs	Migraine Frequency/Month	Total RCTs
Topiramate	10	40.7	10	71.6	5	19.8	10	7.01	11
Divalproex	2	43.1	2	78.3	2	4	2	1.5	2
Valproate	1	34	1	79.3	1	86.3	1	4	1
Propranolol	3	37.6	4	82.4	4	22.4	2	3.5	4
Timolol	1	43	1	72	1	4.7	1	5.7	1
Lamotrigine	1	37.2	1	81.8	1	0	1	4.02	1
Gabapentin	2	41.3	2	85.9	1	43.7	2	4.95	2
Acetazolamide	1	39.2	1	75.5	1	9.4	1	5	1
Amitriptyline	2	37.5	3	80	1	0	1	5	3
Nadolol	1	36.3	1	81.3	1	15.6	0		1
Metoprolol	3	38.1	3	83.1	2	0	3	5.59	3
Atenolol	2	41.5	2	74.9	2	0	1	2	2
Alprenolol	1	41.3	1	81.8	1	18.2	1	3	1
Pindolol	1	35.8	1	85.7	1	50	1	2	1
Captopril	1	49	1	58	2	0	2	4.6	1
Lisinopril	1	41	1	81	0		1	2.3	1
Telmisartan	1	39.8	1	84.5	0		1	6.2	1
Candesartan	1	42	1	79	1	0	1	2.97	1
Nimodipine	4	33.5	4	76	4	25	1	4	4
Verapamil	1	33	1	86	0		1	5.3	1
Nicardipine	0		1	73	1	0	1	4.26	1
Nifedipine	1	29.8	1	79	1	0	1	10	2
Clonidine	4	40.1	5	80.8	1	0	1	6	6
Dihydroergotamine	3	38.5	3	72.9	3	21.0	2	4.4	3
Lisuride	0		0		0		1	3.5	1
Methysergide	1	42	1	80	0		1	3	1
Montelukast	1	40	1	88	0		1	5.1	1
Femoxetine	2	40	2	85.8	0		0		3
Fluoxetine	4	38.1	4	77.4	2	22.6	1	7	4
Indomethacin	1	40	1	76	0		0		1
Induprofen	1	35.8	1	60	1	40.3	1	4.8	1
Ketoprofen	1	36	1	88	1	0	1	2.8	1
Magnesium	2	42.4	2	89.5	1	0	2	5	2
Naproxen sodium	2	39.2	2	85	1	0	0		2
Oxcarbazepine	1	40.5	1	84.7	0		1	6	1
Tizanidine	1	40.3	1	79	0		0		1
Tolfenamic Acid	1	35	1	87	1	0	0		1
Tonabersat	1	36	1	92.3	0		0		1

RCTs = number of randomized controlled clinical trials that reported baseline variables

Appendix Table D113. Followup characteristics in placebo controlled randomized controlled clinical trials of adverse effects with drugs for migraine prevention in adults

Drug	Mean Length of followup in Weeks	# RCTs	Mean % Lost to followup	# RCTs
Topiramate	17.9	10	8.4	4
Divalproex	12	2	1.8	2
Valproate	16	1	0	1
Propranolol	12	3	17.3	4
Timolol	16	1	Not reported	Not reported
Lamotrigine	12	1	0	1
Carbamazepine	12	1	6.3	1
Gabapentin	12	2	3.1	2
Acetazolamide	12	1	0	1
Amitriptyline	17	3	28.5	3
Nadolol	12	1	Not reported	Not reported
Metoprolol	13.3	3	Not reported	Not reported
Atenolol	27	2	Not reported	Not reported
Alprenolol	13	1	Not reported	Not reported
Pindolol	11	1	Not reported	Not reported
Captopril	68	1	Not reported	Not reported
Lisinopril	7.5	1	22	1
Telmisartan	12	1	17	1
Candesartan	32	1	5	1
Nimodipine	13	4	8.6	3
Verapamil	20	1	20	1
Nicardipine	16	1	14	1
Nifedipine	16	2	32	2
Clonidine	26	6	29.3	5
Dihydroergocryptine	16	1	Not reported	Not reported
Dihydroergotamine	14.7	3	5.7	3
Lisuride	12	1	0	1
Methysergide	24	1	32.4	1
Montelukast	20	1	2.2	1
Femoxetine	14.7	3	24.5	3
Fluoxetine	15	4	22.2	4
Indomethacin	4	1	Not reported	Not reported
Induprofen	12	1	Not reported	Not reported
Ketoprofen	12	1	Not reported	Not reported
Magnesium	14	2	13.5	2
Naproxen sodium	19	2	15	1
Oxcarbazepine	15	1	3.5	1
Tizanidine	12	1	Not reported	Not reported
Tofenamic Acid	22	1	Not reported	Not reported
Tonabersat	13	1	5.1	1
Total	17.35	81		

RCTs = number of randomized controlled clinical trials that reported baseline variables

Appendix Table D114. Risk of bias in placebo controlled randomized controlled clinical trials of adverse effects with drugs for migraine prevention

Drugs	High	Low	Medium	Total	% Low
Topiramate	0	6	5	11	54.5
Divalproex	0	1	1	2	50
Valproate	0	0	1	1	0
Propranolol	0	1	3	4	25
Timolol	0	0	1	1	0
Lamotrigine	0	1	0	1	100
Carbamazepine	0	0	1	1	0
Acetazolamide	0	1	0	1	100
Amitriptyline	0	0	3	3	0
Nadolol	0	1	0	1	100
Metoprolol	0	0	3	3	0
Atenolol	0	0	2	2	0
Alprenolol	0	0	1	1	0
Pindolol	0	0	1	1	0
Captopril	0	1	0	1	100
Lisinopril	0	1	0	1	100
Telmisartan	1	0	0	1	0
Candesartan	0	1	0	1	100
Nimodipine	0	1	3	4	25
Verapamil	0	0	1	1	0
Nicardipine	0	0	1	1	0
Nifedipine	1	0	1	2	0
Clonidine	1	1	4	6	16.67
Dihydroergocryptine	0	0	1	1	0
Dihydroergotamine	0	1	2	3	33.33
Lisuride	0	0	1	1	0
Methysergide	0	0	1	1	0
Tizanidine	0	0	1	1	0
Montelukast	0	1	0	1	100
Femoxetine	0	0	3	3	0
Fluoxetine	1	0	3	4	0
Gabapentin	0	0	2	2	0
Indomethacin	0	0	1	1	0
Induprofen	0	0	1	1	0
Ketoprofen	0	0	1	1	0
Naproxen sodium	2	0	0	2	0
Magnesium	0	2	0	2	100
Oxcarbazepine	0	1	0	1	100
Tolfenamic Acid	0	0	1	1	0
Tonabersat	0	1	0	1	100
TOTAL*(includes flunarizine trials)	7	22	54	83	26.51

Appendix Table D115. Adverse effects with drugs for migraine prevention in adults, results from nonrandomized studies

Drugs, Daily Doses	Reference, Design	Total Length of followup, Weeks	Migraine Definition	Definition of the Adverse Effects	Rate ,%
Botulinum toxin type A 25 U	Guyron, 2004 ²¹⁷ Non-RCT: Case reports	Not reported	Not reported	Depression of temple area (Patient reported)	28.3
Botulinum toxin type A 25 U	Guyron, 2004 ²¹⁷ Non-RCT: Case reports	Not reported	Not reported	Deformity (Physician examined)	100.0
Botulinum toxin type A (and Lidocaine 2 mL) 50 U	Omoigui, 2005 ²¹⁸ Non-RCT: Case reports	Not reported	Not reported	Ptosis	100.0
Zonisamide Initiated with 25 mg/day and titrated up to 100 mg/day	Villani, 2011 ²¹⁹ Non-RCT: Uncontrolled prospective observational study	24	Migraine (International Headache Society)	Difficulty concentrating (transient)	5.9
Zonisamide Initiated with 25 mg/day and titrated up to 100 mg/day	Villani, 2011 ²¹⁹ Non-RCT: Uncontrolled prospective observational study	24	Migraine (International Headache Society)	Mood disorders (transient)	5.9
Zonisamide Initiated with 100 mg/day and titrated up to 300 mg/day	Ashkenazi, 2006 ²²⁰ Non-RCT: Retrospective uncontrolled study (chart review)	Unclear	Episodic migraine or Transformed migraine according to the Silberstein-Lipton criteria	All	42.4
Zonisamide Initiated with 100 mg/day and titrated up to 300 mg/day	Ashkenazi, 2006 ²²⁰ Non-RCT: Retrospective uncontrolled study (chart review)	Unclear	Episodic migraine or Transformed migraine according to the Silberstein-Lipton criteria	Fatigue	12.1
Lamotrigine 500 mg/die for 1 wk and 1000 mg/die for 24 wks	Pizza, 2011 ²²¹ Non-RCT: Uncontrolled study	25	Not reported	Somnolence, lack of concentration and a modest gastralgia	53.8
Gabapentin 900-1800 mg	Vukovic, 2009 ²²² Non-RCT: Prospective uncontrolled open-label	Mean: 28.8 (range: 12-48)	Migraine (International Headache Society - 2 criteria)	All	47.8
Gabapentin 900-1800 mg	Vukovic, 2009 ²²² Non-RCT: Prospective uncontrolled open-label	Mean: 28.8 (range: 12-48)	Migraine (International Headache Society - 2 criteria)	Drowsiness	22.4
Gabapentin 900-1800 mg	Vukovic, 2009 ²²² Non-RCT: Prospective uncontrolled open-label	Mean: 28.8 (range: 12-48)	Migraine (International Headache Society - 2 criteria)	Dizziness	5.9
Gabapentin 900-1800 mg	Vukovic, 2009 ²²² Non-RCT: Prospective uncontrolled open-label	Mean: 28.8 (range: 12-48)	Migraine (International Headache Society - 2 criteria)	Slowness	11.9

Appendix Table 115. Adverse effects with drugs for migraine prevention in adults, results from nonrandomized studies (continued)

Drugs, Daily Doses	Reference, Design	Total Length of followup, Weeks	Migraine Definition	Definition of the Adverse Effects	Rate ,%
Gabapentin 900-1800 mg	Vukovic, 2009 ²²² Non-RCT: Prospective uncontrolled open-label	Mean: 28.8 (range: 12-48)	Migraine (International Headache Society - 2 criteria)	Constipation	5.9
Gabapentin 900-1800 mg	Vukovic, 2009 ²²² Non-RCT: Prospective uncontrolled open-label	Mean: 28.8 (range: 12-48)	Migraine (International Headache Society - 2 criteria)	Ataxia	3.0
Gabapentin 900-1800 mg	Vukovic, 2009 ²²² Non-RCT: Prospective uncontrolled open-label	Mean: 28.8 (range: 12-48)	Migraine (International Headache Society - 2 criteria)	Swollen face/body	3.0
Gabapentin 900-1800 mg	Vukovic, 2009 ²²² Non-RCT: Prospective uncontrolled open-label	Mean: 28.8 (range: 12-48)	Migraine (International Headache Society - 2 criteria)	Weight gain	3.0
Gabapentin 900-1800 mg	Vukovic, 2009 ²²² Non-RCT: Prospective uncontrolled open-label	Mean: 28.8 (range: 12-48)	Migraine (International Headache Society - 2 criteria)	Discontinuation due to adverse effects	22.4
Divalproex Mean: 974 mg /day	Vukovic, 2009 ²²² Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Nausea	42.0
Divalproex Mean: 974 mg /day	Vukovic, 2009 ²²² Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Infection	39.0
Divalproex Mean: 974 mg /day	Vukovic, 2009 ²²² Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Alopecia	31.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Tremor	28.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Asthenia	25.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Dyspepsia	25.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Somnolence	25.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Pharyngitis	23.0

Appendix Table 115. Adverse effects with drugs for migraine prevention in adults, results from nonrandomized studies (continued)

Drugs, Daily Doses	Reference, Design	Total Length of followup, Weeks	Migraine Definition	Definition of the Adverse Effects	Rate ,%
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Flu-like syndrome	21.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Pain	19.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Weight gain	19.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Abdominal pain	18.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Back pain	17.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Dizziness	17.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Diarrhea	16.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Rhinitis	15.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Nervousness	11.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Vomiting	11.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Insomnia	10.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Myalgia	9.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Sinusitis	9.0

Appendix Table 115. Adverse effects with drugs for migraine prevention in adults, results from nonrandomized studies (continued)

Drugs, Daily Doses	Reference, Design	Total Length of followup, Weeks	Migraine Definition	Definition of the Adverse Effects	Rate ,%
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Depression	9.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Neck pain	9.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Bronchitis	8.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Increased appetite	8.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Accidental injury	7.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Allergic reaction	7.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Chest pain	7.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Increased cough	7.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Constipation	7.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Arthralgia	6.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Rash	6.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Ecchymosis	6.0
Divalproex Mean: 974 mg /day	Silberstein, 1999 ²²³ Non-RCT: Prospective uncontrolled open-label	Up to 144 (3y)	Migraine (International Headache Society)	Flatulence	6.0

Appendix Table 115. Adverse effects with drugs for migraine prevention in adults, results from nonrandomized studies (continued)

Drugs, Daily Doses	Reference, Design	Total Length of followup, Weeks	Migraine Definition	Definition of the Adverse Effects	Rate ,%
Valproic acid 300 to 1200 mg per day	Kinze, 2001 ²²⁴ Non-RCT: Prospective open-label	24	Migraine (International Headache Society)	Discontinuation due to hair loss	1.9
Valproic acid Adjusted to maintain blood levels between 50 and 100 µg/mL (mean 61 µg/m)	Vijayan, 1995 ²²⁵ Non-RCT: Prospective cohort	Variable (Up to 52)	Chronic daily headache	Sleepiness	12.5
Valproic acid Adjusted to maintain blood levels between 50 and 100 µg/mL (mean 61 µg/m)	Vijayan, 1995 ²²⁵ Non-RCT: Prospective cohort	Variable (Up to 52)	Chronic daily headache	Nausea	6.3
Valproic acid Adjusted to maintain blood levels between 50 and 100 µg/mL (mean 61 µg/m)	Vijayan, 1995 ²²⁵ Non-RCT: Prospective cohort	Variable (Up to 52)	Chronic daily headache	Blurry vision	6.3
Valproic acid Adjusted to maintain blood levels between 50 and 100 µg/mL (mean 61 µg/m)	Vijayan, 1995 ²²⁵ Non-RCT: Prospective cohort	Variable (Up to 52)	Chronic daily headache	Sluggish	6.3
Valproic acid Adjusted to maintain blood levels between 50 and 100 µg/mL (mean 61 µg/m)	Vijayan, 1995 ²²⁵ Non-RCT: Prospective cohort	Variable (Up to 52)	Chronic daily headache	Libido	6.3
Valproic acid Adjusted to maintain blood levels between 50 and 100 µg/mL (mean 61 µg/m)	Vijayan, 1995 ²²⁵ Non-RCT: Prospective cohort	Variable (Up to 52)	Chronic daily headache	Upset stomach	12.5
Valproic acid Adjusted to maintain blood levels between 50 and 100 µg/mL (mean 61 µg/m)	Vijayan, 1995 ²²⁵ Non-RCT: Prospective cohort	Variable (Up to 52)	Chronic daily headache	Confusion	6.3
Valproic acid Adjusted to maintain blood levels between 50	Vijayan, 1995 ²²⁵ Non-RCT: Prospective cohort	Variable (Up to 52)	Chronic daily headache	All adverse effects	50.0

Appendix Table 115. Adverse effects with drugs for migraine prevention in adults, results from nonrandomized studies (continued)

Drugs, Daily Doses	Reference, Design	Total Length of followup, Weeks	Migraine Definition	Definition of the Adverse Effects	Rate ,%
and 100 µg/mL (mean 61 µg/m)					
Valproic acid Adjusted to maintain blood levels between 50 and 100 µg/mL (mean 61 µg/m)	Vijayan, 1995 ²²⁵ Non-RCT: Prospective cohort	Variable (Up to 52)	Chronic daily headache	Discontinuation due to Nausea	6.3
Valproic acid Adjusted to maintain blood levels between 50 and 100 µg/mL (mean 61 µg/m)	Vijayan, 1995 ²²⁵ Non-RCT: Prospective cohort	Variable (Up to 52)	Chronic daily headache	Discontinuation due to GI Upset	12.5
Valproic acid Adjusted to maintain blood levels between 50 and 100 µg/mL (mean 61 µg/m)	Vijayan, 1995 ²²⁵ Non-RCT: Prospective cohort	Variable (Up to 52)	Chronic daily headache	Discontinuation due to Confusion	6.3
Valproic acid Adjusted to maintain blood levels between 50 and 100 µg/mL (mean 61 µg/m)	Vijayan, 1995 ²²⁵ Non-RCT: Prospective cohort	Variable (Up to 52)	Chronic daily headache	Discontinuation due to Sleepiness	6.3
Sodium valproate 600 to 1000 mg daily	Ghose, 1999 ²²⁶ Non-RCT: Prospective, open-label	240 (5y)	Migraine with or without aura	Discontinuation due to adverse effects	12.0
Sodium valproate 600 to 1000 mg daily	Ghose, 1999 ²²⁶ Non-RCT: Prospective, open-label	240 (5y)	Migraine with or without aura	Abnormal liver function test	3.3
Sodium valproate 600 to 1000 mg daily	Ghose, 1999 ²²⁶ Non-RCT: Prospective, open-label	240 (5y)	Migraine with or without aura	Weight gain	50.0
Sodium valproate 600 to 1000 mg daily	Ghose, 1999 ²²⁶ Non-RCT: Prospective, open-label	240 (5y)	Migraine with or without aura	Tremor	5.0
Sodium valproate 600 to 1000 mg daily	Ghose, 1999 ²²⁶ Non-RCT: Prospective, open-label	240 (5y)	Migraine with or without aura	Other	5.0
Sodium valproate 600 to 1000 mg daily	Ghose, 1999 ²²⁶ Non-RCT: Prospective, open-label	240 (5y)	Migraine with or without aura	Abnormal liver function test	2.8
Sodium valproate 600 to 1000 mg daily	Ghose, 1999 ²²⁶ Non-RCT: Prospective, open-label	240 (5y)	Migraine with or without aura	Weight gain	77.8
Sodium valproate 600 to 1000 mg daily	Ghose, 1999 ²²⁶ Non-RCT: Prospective, open-label	240 (5y)	Migraine with or without aura	Tremor	13.9
Sodium valproate 600 to 1000 mg daily	Ghose, 1999 ²²⁶ Non-RCT: Prospective, open-label	240 (5y)	Migraine with or without aura	Other adverse effects	8.3

Appendix Table 115. Adverse effects with drugs for migraine prevention in adults, results from nonrandomized studies (continued)

Drugs, Daily Doses	Reference, Design	Total Length of followup, Weeks	Migraine Definition	Definition of the Adverse Effects	Rate ,%
Sodium valproate 600 to 1000 mg daily	Ghose, 1999 ²²⁶ Non-RCT: Prospective, open-label	240 (5y)	Migraine with or without aura	Abnormal liver function test	3.3
Sodium valproate 600 to 1000 mg daily	Ghose, 1999 ²²⁶ Non-RCT: Prospective, open-label	240 (5y)	Migraine with or without aura	Weight gain	33.3
Sodium valproate 600 to 1000 mg daily	Ghose, 1999 ²²⁶ Non-RCT: Prospective, open-label	240 (5y)	Migraine with or without aura	Tremor	10.0
Sodium valproate 600 to 1000 mg daily	Ghose, 1999 ²²⁶ Non-RCT: Prospective, open-label	240 (5y)	Migraine with or without aura	Other adverse effects	6.7
Carbamazepine 200 mg three times daily vs. Clonidine 75 µg three times daily	Anthony, 1972 ²²⁷ Non-RCT: Controlled trial	Variable (up to 72 for Clonidine and to 16 for Carbamazepine)	Migraine (Friedman's Criteria, 1962)	Drowsiness, tiredness, weakness	13.7 vs. 20.5
Carbamazepine 200 mg three times daily vs. Clonidine 75 µg three times daily	Anthony, 1972 ²²⁷ Non-RCT: Controlled trial	Variable (up to 72 for Clonidine and to 16 for Carbamazepine)	Migraine (Friedman's Criteria, 1962)	Dryness of mouth, sore tongue, bad taste	0.0 vs. 13.7
Carbamazepine 200 mg three times daily vs. Clonidine 75 µg three times daily	Anthony, 1972 ²²⁷ Non-RCT: Controlled trial	Variable (up to 72 for Clonidine and to 16 for Carbamazepine)	Migraine (Friedman's Criteria, 1962)	Giddiness, ataxia	19.6 vs. 0.0
Carbamazepine 200 mg three times daily vs. Clonidine 75 µg three times daily	Anthony, 1972 ²²⁷ Non-RCT: Controlled trial	Variable (up to 72 for Clonidine and to 16 for Carbamazepine)	Migraine (Friedman's Criteria, 1962)	Faintness, dizziness	5.9 vs. 6.8
Carbamazepine 200 mg three times daily vs. Clonidine 75 µg three times daily	Anthony, 1972 ²²⁷ Non-RCT: Controlled trial	Variable (up to 72 for Clonidine and to 16 for Carbamazepine)	Migraine (Friedman's Criteria, 1962)	Nausea	11.8 vs. 6.8
Carbamazepine 200 mg three times daily vs. Clonidine 75 µg three times daily	Anthony, 1972 ²²⁷ Non-RCT: Controlled trial	Variable (up to 72 for Clonidine and to 16 for Carbamazepine)	Migraine (Friedman's Criteria, 1962)	Increased appetite	2.0 vs. 0.0
Carbamazepine 200 mg three times daily vs. Clonidine 75 µg three times daily	Anthony, 1972 ²²⁷ Non-RCT: Controlled trial	Variable (up to 72 for Clonidine and to 16 for Carbamazepine)	Migraine (Friedman's Criteria, 1962)	Epigastric discomfort	2.0 vs. 1.4
Carbamazepine 200 mg three times daily vs. Clonidine 75 µg three times daily	Anthony, 1972 ²²⁷ Non-RCT: Controlled trial	Variable (up to 72 for Clonidine and to 16 for Carbamazepine)	Migraine (Friedman's Criteria, 1962)	Cramps, limb pains	3.9 vs. 1.4

Appendix Table 115. Adverse effects with drugs for migraine prevention in adults, results from nonrandomized studies (continued)

Drugs, Daily Doses	Reference, Design	Total Length of followup, Weeks	Migraine Definition	Definition of the Adverse Effects	Rate ,%
Carbamazepine 200 mg three times daily vs. Clonidine 75 µg three times daily	Anthony, 1972 ²²⁷ Non-RCT: Controlled trial	Variable (up to 72 for Clonidine and to 16 for Carbamazepine)	Migraine (Friedman's Criteria, 1962)	Irritability, agitation	3.9 vs. 2.7
Carbamazepine 200 mg three times daily vs. Clonidine 75 µg three times daily	Anthony, 1972 ²²⁷ Non-RCT: Controlled trial	Variable (up to 72 for Clonidine and to 16 for Carbamazepine)	Migraine (Friedman's Criteria, 1962)	Insomnia, nightmare	2.0 vs. 1.4
Carbamazepine 200 mg three times daily vs. Clonidine 75 µg three times daily	Anthony, 1972 ²²⁷ Non-RCT: Controlled trial	Variable (up to 72 for Clonidine and to 16 for Carbamazepine)	Migraine (Friedman's Criteria, 1962)	Bruising, prominent veins	0.0 vs. 1.4
Carbamazepine 200 mg three times daily vs. Clonidine 75 µg three times daily	Anthony, 1972 ²²⁷ Non-RCT: Controlled trial	Variable (up to 72 for Clonidine and to 16 for Carbamazepine)	Migraine (Friedman's Criteria, 1962)	Skin itching, rash	3.9 vs. 0.0
Carbamazepine 200 mg three times daily vs. Clonidine 75 µg three times daily	Anthony, 1972 ²²⁷ Non-RCT: Controlled trial	Variable (up to 72 for Clonidine and to 16 for Carbamazepine)	Migraine (Friedman's Criteria, 1962)	Blurred vision	3.9 vs. 0.0
Carbamazepine 200 mg three times daily vs. Clonidine 75 µg three times daily	Anthony, 1972 ²²⁷ Non-RCT: Controlled trial	Variable (up to 72 for Clonidine and to 16 for Carbamazepine)	Migraine (Friedman's Criteria, 1962)	Lack of concentration	3.9 vs. 0.0
Carbamazepine 200 mg three times daily vs. Clonidine 75 µg three times daily	Anthony, 1972 ²²⁷ Non-RCT: Controlled trial	Variable (up to 72 for Clonidine and to 16 for Carbamazepine)	Migraine (Friedman's Criteria, 1962)	Swelling of throat	2.0 vs. 0.0
Propranolol 40 mg four times a day (three times a day below age 10)	Rosen, 1983 ²²⁸ Non-RCT: Prospective cohort	48	Not reported	Discontinuation due to adverse effects	4.7
Propranolol 40 mg four times a day (three times a day below age 10)	Rosen, 1983 ²²⁸ Non-RCT: Prospective cohort	48	Not reported	Discontinuation due to incident asthma (not previously experienced)	0.1
Propranolol 40 mg four times a day (three times a day below age 10)	Rosen, 1983 ²²⁸ Non-RCT: Prospective cohort	48	Not reported	Discontinuation due to hypotension with or without bradycardia	2.5

Appendix Table 115. Adverse effects with drugs for migraine prevention in adults, results from nonrandomized studies (continued)

Drugs, Daily Doses	Reference, Design	Total Length of followup, Weeks	Migraine Definition	Definition of the Adverse Effects	Rate ,%
Propranolol 40 mg four times a day (three times a day below age 10)	Rosen, 1983 ²²⁸ Non-RCT: Prospective cohort	48	Not reported	Discontinuation due to Excessive weight gain	0.8
Propranolol 40 mg four times a day (three times a day below age 10)	Rosen, 1983 ²²⁸ Non-RCT: Prospective cohort	48	Not reported	Discontinuation due to Congestive heart failure	0.2
Propranolol 40 mg four times a day (three times a day below age 10)	Rosen, 1983 ²²⁸ Non-RCT: Prospective cohort	48	Not reported	Discontinuation due to Insomnia	0.7
Propranolol 40 mg four times a day (three times a day below age 10)	Rosen, 1983 ²²⁸ Non-RCT: Prospective cohort	48	Not reported	Discontinuation due to Severe psychological depression	0.3
Propranolol 40mg vs. Methysergide 6 to 10 mg/day	Steardo, 1982 ²²⁹ Non-RCT: Controlled open-label	24	Migraine (ad hoc Committee)	Bradycardia	4.4
Propranolol 40mg vs. Methysergide 6 to 10 mg/day	Steardo, 1982 ²²⁹ Non-RCT: Controlled open-label	24	Migraine (ad hoc Committee)	Insomnia	1.5
Propranolol 40mg vs. Methysergide 6 to 10 mg/day	Steardo, 1982 ²²⁹ Non-RCT: Controlled open-label	24	Migraine (ad hoc Committee)	Depression	1.5
Propranolol 40mg vs. Methysergide 6 to 10 mg/day	Steardo, 1982 ²²⁹ Non-RCT: Controlled open-label	24	Migraine (ad hoc Committee)	Precordialgia	1.5 vs. 2.8
Propranolol 40mg vs. Methysergide 6 to 10 mg/day	Steardo, 1982 ²²⁹ Non-RCT: Controlled open-label	24	Migraine (ad hoc Committee)	Dizziness	2.9 vs. 0.0
Propranolol 40mg vs. Methysergide 6 to 10 mg/day	Steardo, 1982 ²²⁹ Non-RCT: Controlled open-label	24	Migraine (ad hoc Committee)	Paresthesia	0.0 vs. 8.3

Appendix Table 115. Adverse effects with drugs for migraine prevention in adults, results from nonrandomized studies (continued)

Drugs, Daily Doses	Reference, Design	Total Length of followup, Weeks	Migraine Definition	Definition of the Adverse Effects	Rate ,%
Propranolol 40mg vs. Methysergide 6 to 10 mg/day	Steardo, 1982 ²²⁹ Non-RCT: Controlled open-label	24	Migraine (ad hoc Committee)	Gastralgia	0.0 vs. 5.6
Propranolol 40mg vs. Metoprolol 40mg	Steardo, 1982 ²²⁹ Non-RCT: Controlled open-label	24	Migraine (ad hoc Committee)	Bradycardia	4.4 vs. 16.7
Propranolol 40mg vs. Metoprolol 40mg	Steardo, 1982 ²²⁹ Non-RCT: Controlled open-label	24	Migraine (ad hoc Committee)	Hypotension	0.0 vs. 10.0
Propranolol 40mg vs. Methysergide 6 to 10 mg/day	Steardo, 1982 ²²⁹ Non-RCT: Controlled open-label	24	Migraine (ad hoc Committee)	Discontinuation due to adverse effects	11.8 vs. 16.7
Propranolol 40mg vs. Metoprolol 40mg	Steardo, 1982 ²²⁹ Non-RCT: Controlled open-label	24	Migraine (ad hoc Committee)	Discontinuation due to adverse effects	11.8 vs. 26.7
Metoprolol 40mg vs. Methysergide 6 to 10 mg/day	Steardo, 1982 ²²⁹ Non-RCT: Controlled open-label	24	Migraine (ad hoc Committee)	Discontinuation due to adverse effects	26.7 vs. 16.7
Methysergide 6 mg daily	Curran, 1964 ²³⁰ Non-RCT: Prospective cohort	Variable ("3 or less to 13 or more (month)")	Not reported	All adverse effects	45.0
Methysergide 6 mg daily	Curran, 1964 ²³⁰ Non-RCT: Prospective cohort	Variable ("3 or less to 13 or more (month)")	Not reported	Discontinuation due to adverse effects	10.0
Methysergide 6 mg daily	Curran, 1964 ²³⁰ Non-RCT: Prospective cohort	Variable ("3 or less to 13 or more (month)")	Not reported	Adverse effects (Severe): Angina pectoris	0.7
Methysergide 6 mg daily	Curran, 1964 ²³⁰ Non-RCT: Prospective cohort	Variable ("3 or less to 13 or more (month)")	Not reported	Adverse effects (Severe): Intermittent claudication	1.3
Methysergide 6 mg daily	Curran, 1964 ²³⁰ Non-RCT: Prospective cohort	Variable ("3 or less to 13 or more (month)")	Not reported	Adverse effects (Severe): Lower limb pains	2.6

Appendix Table 115. Adverse effects with drugs for migraine prevention in adults, results from nonrandomized studies (continued)

Drugs, Daily Doses	Reference, Design	Total Length of followup, Weeks	Migraine Definition	Definition of the Adverse Effects	Rate ,%
Methysergide 6 mg daily	Curran, 1964 ²³⁰ Non-RCT: Prospective cohort	Variable ("3 or less to 13 or more (month)")	Not reported	Adverse effects (Severe): Upper limb pains	0.3
Methysergide 6 mg daily	Curran, 1964 ²³⁰ Non-RCT: Prospective cohort	Variable ("3 or less to 13 or more (month)")	Not reported	Adverse effects (Severe): Swelling of ankles	0.3
Methysergide 6 mg daily	Curran, 1964 ²³⁰ Non-RCT: Prospective cohort	Variable ("3 or less to 13 or more (month)")	Not reported	Adverse effects (Severe): venules over nose and cheeks	0.3
Methysergide 6 mg daily	Curran, 1964 ²³⁰ Non-RCT: Prospective cohort	Variable ("3 or less to 13 or more (month)")	Not reported	Adverse effects (Severe): Facial flushing	0.3
Methysergide 6 mg daily	Curran, 1964 ²³⁰ Non-RCT: Prospective cohort	Variable ("3 or less to 13 or more (month)")	Not reported	Adverse effects (Severe): Vomiting	2.3
Methysergide 6 mg daily	Curran, 1964 ²³⁰ Non-RCT: Prospective cohort	Variable ("3 or less to 13 or more (month)")	Not reported	Adverse effects (Severe): Abdominal cramps	0.7
Methysergide 6 mg daily	Curran, 1964 ²³⁰ Non-RCT: Prospective cohort	Variable ("3 or less to 13 or more (month)")	Not reported	Adverse effects (Severe): Rash	0.3
Methysergide 6 mg daily	Curran, 1964 ²³⁰ Non-RCT: Prospective cohort	Variable ("3 or less to 13 or more (month)")	Not reported	Adverse effects (Severe): Scalp hair falling out	0.3
Methysergide 6 mg daily	Curran, 1964 ²³⁰ Non-RCT: Prospective cohort	Variable ("3 or less to 13 or more (month)")	Not reported	Adverse effects (Severe): Vertigo and ataxia	1.0
Ergotamine NR	Kim, 2005 ²³¹ Non-RCT: Case report	Not applicable	Not reported	Upper extremity ischemia	100.0

Appendix Table D116. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with random effects model, inverse variance weights)

Adverse Effect	Dose Weeks of Treatment	Reference Risk of Bias	Events Randomized Onabotulinumtoxin A	Events Randomized Placebo	Relative Risk (95% CI)	Weight (Relative Risk)	Absolute Risk Difference (95% CI)	Weight (Risk Difference)
Any adverse effect	6U 12 weeks	Saper, 2007 ⁴ Low	8/45	3/11	0.7 (0.2 to 2.1)	2.35	-0.10 (-0.38 to 0.19)	3.06
Any adverse effect	7.5U 16 weeks	Elkind, 2006 ⁷ Low	52/105	17/36	1.0 (0.7 to 1.6)	6.71	0.02 (-0.17 to 0.21)	4.58
Any adverse effect	9U 12 weeks	Saper, 2007 ⁴ Low	11/49	3/12	0.9 (0.3 to 2.7)	2.48	-0.03 (-0.30 to 0.25)	3.25
Any adverse effect	10U 12 weeks	Saper, 2007 ⁴ Low	9/44	3/11	0.8 (0.2 to 2.3)	2.42	-0.07 (-0.36 to 0.22)	3.02
Any adverse effect	25U 16 weeks	Elkind, 2006 ⁷ Low	47/101	16/34	1.0 (0.7 to 1.5)	6.57	-0.01 (-0.20 to 0.19)	4.49
Any adverse effect	25U 12 weeks	Saper, 2007 ⁴ Low	17/49	3/12	1.4 (0.5 to 4.0)	2.67	0.10 (-0.18 to 0.38)	3.15
Any adverse effect	50U 16 weeks	Elkind, 2006 ⁷ Low	60/106	17/36	1.2 (0.8 to 1.8)	6.82	0.09 (-0.10 to 0.28)	4.59
Any adverse effect	75U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	97/174	13/59	2.5 (1.5 to 4.2)	5.86	0.34 (0.21 to 0.47)	5.77
Any adverse effect	80U 12 (one time injection) weeks	Petri*, 2009 ⁹ High	4/32	5/32	0.8 (0.2 to 2.7)	2.16	-0.03 (-0.20 to 0.14)	4.94
Any adverse effect	139U 12 (one time injection) weeks	Cady, 2008 ¹³ Low	0/40	0/19	2.6 (1.5 to 4.4)	5.68	0.00 (-0.08 to 0.08)	6.77
Any adverse effect	150U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	92/168	12/57	2.2 (1.6 to 3.0)	7.48	0.34 (0.21 to 0.47)	5.75
Any adverse effect	105U-260U ("Follow-the-pain" approach) 24 (three injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	88/173	42/182	2.2 (1.5 to 3.1)	7.12	0.28 (0.18 to 0.37)	6.41
Any adverse effect	155U-195U [Follow-the-Pain strategy] 24 (two injections over the	Aurora, 2010 ¹ Medium	86/341	39/338	2.4 (1.8 to 3.3)	7.51	0.14 (0.08 to 0.19)	7.06

Appendix Table 116. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with random effects model, inverse variance weights) (continued)

Adverse Effect	Dose Weeks of Treatment	Reference Risk of Bias	Events Randomized Onabotulinumtoxin A	Events Randomized Placebo	Relative Risk (95% CI)	Weight (Relative Risk)	Absolute Risk Difference (95% CI)	Weight (Risk Difference)
	course: week 1, week 12; open label three injections: week 24, 36, 48) weeks							
Any adverse effect	155U-195U [Follow-the-Pain strategy] 24 (three injections over the course: week 1, week 12, week 24) weeks	Diener, 2010 ² Low	116/347	49/358	1.3 (1.1 to 1.5)	8.56	0.20 (0.14 to 0.26)	7
Any adverse effect	155U-195U [Follow-the-Pain strategy] 24 (two injections over the course: wk 1, week 12; open label three injections: week 24, 36, 48) weeks	Aurora, 2010 ¹ Medium	203/341	156/338	2.8 (2.1 to 3.8)	7.5	0.13 (0.06 to 0.21)	6.8
Any adverse effect	110U to 260U per treatment weeks	Aurora, 2007 ¹⁵ Medium	113/187	39/182	1.2 (1.0 to 1.3)	8.67	0.39 (0.30 to 0.48)	6.5
Any adverse effect	155U-195U [Follow-the-Pain strategy] 24 (three injections over the course: week 1, week 12, week 24) weeks	Diener, 2010 ² Low	226/347	202/358	2.0 (0.9 to 4.7)	3.54	0.09 (0.02 to 0.16)	6.84
Any adverse effect	210U 12 (one time injection) weeks	Petri*, 2009 ⁹ High	12/32	6/32	3.1 (1.9 to 5.1)	5.89	0.19 (-0.03 to 0.40)	4.11
Any adverse effect	225U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	119/182	13/62	(Excluded) (0.0 to 0.0)		0.44 (0.32 to 0.57)	5.9
Any adverse effect	All doses	Pooled	1360/2863	637/2168	1.6 (1.3 to 2.0)	100	0.16 (0.09 to 0.22)	100

Appendix Table 116. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with random effects model, inverse variance weights) (continued)

Adverse Effect	Dose Weeks of Treatment	Reference Risk of Bias	Events Randomized Onabotulinumtoxin A	Events Randomized Placebo	Relative Risk (95% CI)	Weight (Relative Risk)	Absolute Risk Difference (95% CI)	Weight (Risk Difference)
Back pain	75U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	3/174	0/59	2.4 (0.1 to 45.8)	17.6	0.02 (-0.01 to 0.05)	20.51
Back pain	100U 16 weeks	Freitag, 2008 ⁵ Low	0/20	1/21	0.3 (0.0 to 8.1)	15.48	-0.05 (-0.17 to 0.08)	1.28
Back pain	150U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	4/168	0/57	3.1 (0.2 to 56.5)	18.12	0.02 (-0.01 to 0.06)	17.03
Back pain	11 U to 260U per treatment weeks	Aurora, 2007 ¹⁵ Medium	3/187	1/182	2.9 (0.3 to 27.8)	30.12	0.01 (-0.01 to 0.03)	44.76
Back pain	225U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	6/182	0/62	4.5 (0.3 to 78.3)	18.68	0.03 (0.00 to 0.07)	16.41
Back pain	All doses	Pooled	16/731	2/381	2.2 (0.6 to 7.7)	100	0.02 (0.00 to 0.03)	100
Discontinuations related to adverse effects	155U-195U [Follow-the-Pain strategy] 24 (three injections over the course: week 1, week 12, week 24) weeks	Diener, 2010 ² Low	12/347	5/358	2.5 (0.9 to 7.0)	58.96	0.02 (0.00 to 0.04)	51.23
Discontinuations related to adverse effects	155U-195U [Follow-the-Pain strategy] 24 (two injections over the course: week 1, week 12; open label three injections: week 24, 36, 48) weeks	Aurora, 2010 ¹ Medium	14/341	3/338	4.6 (1.3 to 16.0)	41.04	0.03 (0.01 to 0.06)	48.77
Discontinuations related to adverse effects	All doses	Pooled	26/688	8/696	3.2 (1.4 to 7.1)	100	0.03 (0.01 to 0.04)	100
Dizziness	100U 16 weeks	Freitag, 2008 ⁵ Low	0/20	1/21	0.3 (0.0 to 8.1)	16.12	-0.05 (-0.17 to 0.08)	3.06

Appendix Table 116. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with random effects model, inverse variance weights) (continued)

Adverse Effect	Dose Weeks of Treatment	Reference Risk of Bias	Events Randomized Onabotulinumtoxin A	Events Randomized Placebo	Relative Risk (95% CI)	Weight (Relative Risk)	Absolute Risk Difference (95% CI)	Weight (Risk Difference)
Dizziness	120U 12 (one time injection) weeks	Chankrachang*, 2011 ⁸ *Low	2/43	0/21	2.5 (0.1 to 49.9)	17.79	0.05 (-0.05 to 0.14)	5.31
Dizziness	105U-260U ("Follow-the-pain" approach) 24 (three injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	1/173	3/182	0.4 (0.0 to 3.3)	31.37	-0.01 (-0.03 to 0.01)	43.71
Dizziness	110 U to 260 U per treatment weeks	Aurora, 2007 ¹⁵ Medium	4/187	0/182	8.8 (0.5 to 161.6)	18.76	0.02 (0.00 to 0.05)	41.31
Dizziness	240U 12 (one time injection) weeks	Chankrachang*, *2011 ⁸ Low	1/43	0/21	1.5 (0.1 to 35.3)	15.96	0.02 (-0.06 to 0.11)	6.61
Dizziness	All doses	Pooled	8/466	4/427	1.1 (0.3 to 4.1)	100	0.01 (-0.02 to 0.03)	100
Dysphagia	75 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	3/174	0/59	2.4 (0.1 to 45.8)	23.99	0.02 (-0.01 to 0.05)	25.86
Dysphagia	150 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	5/168	0/57	3.8 (0.2 to 67.2)	25.16	0.03 (-0.01 to 0.07)	19.36
Dysphagia	105U-260U ("Follow-the-pain" approach) 24 (three injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	4/173	0/182	9.5 (0.5 to 174.5)	24.56	0.02 (0.00 to 0.05)	40.45
Dysphagia	225 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	11/182	0/62	7.8 (0.5 to 130.3)	26.29	0.06 (0.02 to 0.10)	14.33
Dysphagia	All doses	Pooled	23/697	1/360	5.1 (1.2 to 21.8)	100	0.03 (0.01 to 0.04)	100

Appendix Table 116. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with random effects model, inverse variance weights) (continued)

Adverse Effect	Dose Weeks of Treatment	Reference Risk of Bias	Events Randomized Onabotulinumtoxin A	Events Randomized Placebo	Relative Risk (95% CI)	Weight (Relative Risk)	Absolute Risk Difference (95% CI)	Weight (Risk Difference)
Eyelid edema	7.5U 16 weeks	Elkind, 2006 ⁷ Low	1/105	0/36	1.0 (0.0 to 25.1)	18.17	0.01 (-0.03 to 0.05)	21.56
Eyelid edema	25U 16 weeks	Elkind, 2006 ⁷ Low	0/101	0/34	5.2 (0.3 to 88.6)	20.8	0.00 (-0.04 to 0.04)	22.27
Eyelid edema	50U 16 weeks	Elkind, 2006 ⁷ Low	7/106	0/36	0.5 (0.0 to 7.8)	21.78	0.07 (0.01 to 0.13)	15.8
Eyelid edema	120U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	1/43	1/21	24.3 (1.5 to 408.0)	20.96	-0.02 (-0.12 to 0.08)	8.51
Eyelid edema	110 U to 260 U per treatment weeks	Aurora, 2007 ¹⁵ Medium	12/187	0/182	0.2 (0.0 to 4.1)	18.3	0.06 (0.03 to 0.10)	24.28
Eyelid edema	240U 12 (one time injection) weeks	Chankrachang*, *2011 ⁸ Low	0/43	1/21	(Excluded) (0.0 to 0.0)		-0.05 (-0.15 to 0.06)	7.59
Eyelid edema	All doses	Pooled	21/585	1/330	1.7 (0.3 to 9.7)	100	0.02 (-0.01 to 0.06)	100
Headache	6U 12 weeks	Saper, 2007 ⁴ Low	2/45	0/11	1.2 (0.1 to 23.2)	1.84	0.04 (-0.10 to 0.18)	1.94
Headache	7.5U 16 weeks	Elkind, 2006 ⁷ Low	1/105	1/36	0.3 (0.0 to 5.3)	2.15	-0.02 (-0.08 to 0.04)	11.71
Headache	9U 12 weeks	Saper, 2007 ⁴ Low	0/49	1/12	0.1 (0.0 to 2.0)	1.64	-0.08 (-0.26 to 0.09)	1.22
Headache	10U 12 weeks	Saper, 2007 ⁴ Low	1/44	0/11	0.8 (0.0 to 18.4)	1.64	0.02 (-0.10 to 0.15)	2.43
Headache	25U 12 weeks	Saper, 2007 ⁴ Low	3/49	1/12	0.7 (0.1 to 6.5)	3.42	-0.02 (-0.19 to 0.15)	1.31
Headache	25U 16 weeks	Elkind, 2006 ⁷ Low	2/101	1/34	0.7 (0.1 to 7.4)	2.88	-0.01 (-0.07 to 0.05)	9.99
Headache	50U 16 weeks	Elkind, 2006 ⁷ Low	8/106	1/36	2.7 (0.4 to 21.0)	3.87	0.05 (-0.03 to 0.12)	6.99
Headache	75 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	7/174	3/59	0.8 (0.2 to 3.0)	9.29	-0.01 (-0.07 to 0.05)	9.46
Headache	120U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	0/43	1/21	0.2 (0.0 to 4.1)	1.62	-0.05 (-0.15 to 0.06)	3.39
Headache	150 U 24 (three	Silberstein, 2005 ¹¹	14/168	3/57	1.6 (0.5 to 5.4)	11.04	0.03	7.57

Appendix Table 116. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with random effects model, inverse variance weights) (continued)

Adverse Effect	Dose Weeks of Treatment	Reference Risk of Bias	Events Randomized Onabotulinumtoxin A	Events Randomized Placebo	Relative Risk (95% CI)	Weight (Relative Risk)	Absolute Risk Difference (95% CI)	Weight (Risk Difference)
	injection at day 0, day 90, and day 180) weeks	Low					(-0.04 to 0.10)	
Headache	105U-260U ("Follow-the-pain" approach) 24 (three injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	12/173	11/182	1.1 (0.5 to 2.5)	25.84	0.01 (-0.04 to 0.06)	14.36
Headache	110 U to 260 U per treatment weeks	Aurora, 2007 ¹⁵ Medium	11/187	9/182	1.2 (0.5 to 2.8)	22.03	0.01 (-0.04 to 0.06)	17.75
Headache	225 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	15/182	3/62	1.7 (0.5 to 5.7)	11.13	0.03 (-0.03 to 0.10)	8.5
Headache	240U 12 (one time injection) weeks	Chankrachang*, 2011 ⁸ *Low	0/43	1/21	0.2 (0.0 to 4.1)	1.62	-0.05 (-0.15 to 0.06)	3.39
Headache	All doses	Pooled	76/1469	33/735	1.1 (0.7 to 1.6)	100	0.01 (-0.02 to 0.02)	100
Hypertonia	75 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	13/174	0/59	9.3 (0.6 to 153.4)	8	0.08 (0.03 to 0.12)	17.89
Hypertonia	150 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	15/168	0/57	10.6 (0.6 to 175.0)	8.04	0.09 (0.04 to 0.14)	15.31
Hypertonia	105U-260U ("Follow-the-pain" approach) 24 (three injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	9/173	4/182	2.4 (0.7 to 7.5)	46.94	0.03 (-0.01 to 0.07)	23.81
Hypertonia	110 U to 260 U per treatment	Aurora, 2007 ¹⁵ Medium	13/187	2/182	6.3 (1.4 to 27.6)	29.01	0.06 (0.02 to 0.10)	23.67

Appendix Table 116. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with random effects model, inverse variance weights) (continued)

Adverse Effect	Dose Weeks of Treatment	Reference Risk of Bias	Events Randomized Onabotulinumtoxin A	Events Randomized Placebo	Relative Risk (95% CI)	Weight (Relative Risk)	Absolute Risk Difference (95% CI)	Weight (Risk Difference)
	weeks							
Hypertonia	225 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Risk of bias Low	13/182	0/62	9.1 (0.6 to 151.6)	8	0.07 (0.03 to 0.12)	19.32
Hypertonia	All doses	Pooled	63/884	7/542	4.4 (2.0 to 9.8)	100	0.06 (0.04 to 0.08)	100
Neck pain	75 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	30/174	1/59	10.2 (1.4 to 73.0)	12.65	0.16 (0.09 to 0.22)	12.91
Neck pain	120U 12 (one time injection) weeks	Chankrachang*, 2011 ⁸ Low	2/43	1/21	1.0 (0.1 to 10.7)	10.24	0.00 (-0.11 to 0.11)	9.63
Neck pain	150 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	37/168	1/57	12.6 (1.8 to 89.4)	12.7	0.20 (0.13 to 0.27)	12.42
Neck pain	105U-260U ("Follow-the-pain" approach) 24 (three injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	23/173	1/182	24.2 (3.3 to 177.2)	12.5	0.13 (0.08 to 0.18)	13.93
Neck pain	155U-195U [Follow-the-Pain strategy] 24 (two injections over the course: week 1, week 12; open label three injections: week 24, 36, 48) weeks	Aurora, 2010 ¹ Medium	20/341	0/338	40.6 (2.5 to 669.2)	8.02	0.06 (0.03 to 0.08)	15.51
Neck pain	110 U to 260 U per treatment weeks	Aurora, 2007 ¹⁵ Medium	32/187	8/182	3.9 (1.8 to 8.2)	24.5	0.13 (0.07 to 0.19)	13.18
Neck pain	225 U 24 (three injection at day 0,	Silberstein, 2005 ¹¹ Low	41/182	1/62	14.0 (2.0 to 99.4)	12.7	0.21 (0.14 to 0.28)	12.66

Appendix Table 116. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with random effects model, inverse variance weights) (continued)

Adverse Effect	Dose Weeks of Treatment	Reference Risk of Bias	Events Randomized Onabotulinumtoxin A	Events Randomized Placebo	Relative Risk (95% CI)	Weight (Relative Risk)	Absolute Risk Difference (95% CI)	Weight (Risk Difference)
	day 90, and day 180) weeks							
Neck pain	240U 12 (one time injection)weeks	Chankrachang*, 2011 ^{8*} Risk of bias Low	0/43	1/21	0.2 (0.0 to 4.1)	6.7	-0.05 (-0.15 to 0.06)	9.76
Neck pain	All doses	Pooled	185/1311	13/922	6.4 (2.5 to 16.4)	100	0.11 (0.06 to 0.16)	100
Neck rigidity	75 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	14/174	0/59	9.9 (0.6 to 164.1)	5.8	0.08 (0.03 to 0.13)	18.99
Neck stiffness	100U 16 weeks	Freitag, 2008 ⁵ Low	1/20	1/21	1.1 (0.1 to 15.7)	6.24	0.00 (-0.13 to 0.13)	5.5
Neck rigidity	150 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	14/168	0/57	10.0 (0.6 to 164.2)	5.8	0.08 (0.04 to 0.13)	18.54
Neck rigidity	105U-260U ("Follow-the-pain" approach) 24 (three injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	8/173	2/182	4.2 (0.9 to 19.5)	19.34	0.04 (0.00 to 0.07)	22.59
Neck rigidity	110 U to 260 U per treatment weeks	Aurora, 2007 ¹⁵ Medium	19/187	6/182	3.1 (1.3 to 7.5)	56.93	0.07 (0.02 to 0.12)	17.98
Neck rigidity	225 U 24 (three injections at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	27/182	0/62	18.6 (1.2 to 301.0)	5.89	0.15 (0.09 to 0.21)	16.4
Neck rigidity	All doses	Pooled	83/904	10/563	3.9 (2.0 to 7.7)	100	0.08 (0.04 to 0.11)	100
Injection site pain	75U 24 (three injections at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	8/174	3/59	0.9 (0.2 to 3.3)	17.11	-0.01 (-0.07 to 0.06)	3.24
Injection site pain	120U 12 (one time injection)	Chankrachang*, 2011 ^{8*} Low	0/43	1/21	0.3 (0.0 to 8.1)	2.87	-0.05 (-0.17 to 0.08)	1.19

Appendix Table 116. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with random effects model, inverse variance weights) (continued)

Adverse Effect	Dose Weeks of Treatment	Reference Risk of Bias	Events Randomized Onabotulinumtoxin A	Events Randomized Placebo	Relative Risk (95% CI)	Weight (Relative Risk)	Absolute Risk Difference (95% CI)	Weight (Risk Difference)
	weeks							
Injection site pain	150U 24 (three injections at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	10/168	3/57	0.2 (0.0 to 4.1)	18.19	-0.05 (-0.15 to 0.06)	2.87
Injection site pain	105U-260U ("Follow-the-pain" approach) 24 (three injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	4/173	4/182	1.1 (0.3 to 4.0)	15.26	0.01 (-0.06 to 0.08)	13.95
Injection site pain	110 U to 260 U per treatment weeks	Aurora, 2007 ¹⁵ Medium	4/187	1/182	1.1 (0.3 to 4.1)	6.02	0.00 (-0.03 to 0.03)	24.43
Injection site pain	225 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	17/182	3/62	3.9 (0.4 to 34.5)	20.14	0.02 (-0.01 to 0.04)	2.82
Injection site pain	240U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	0/43	1/21	6.8 (0.4 to 131.0)	2.87	0.02 (-0.01 to 0.04)	1.19
Pain	110 U to 260 U per treatment weeks	Aurora, 2007 ¹⁵ Medium	3/187	0/182	1.1 (0.2 to 5.1)	3.28	0.00 (-0.03 to 0.03)	30.95
Pain	105U-260U ("Follow-the-pain" approach) 24 (three injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	3/173	3/182	1.9 (0.6 to 6.3)	11.38	0.04 (-0.03 to 0.11)	18.49
Pain	100U 16 weeks	Freitag, 2008 ⁵ Low	0/20	1/21	0.2 (0.0 to 4.1)	2.9	-0.05 (-0.15 to 0.06)	0.87
Pain	All doses	Pooled	49/1350	20/969	1.2 (0.7 to 2.0)	100	0.01 (0.00 to 0.02)	100
Blepharoptosis	6U 12 weeks	Saper, 2007 ⁴ Low	1/45	0/11	0.8 (0.0 to 18.0)	3.72	0.02 (-0.10 to 0.15)	2.32

Appendix Table 116. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with random effects model, inverse variance weights) (continued)

Adverse Effect	Dose Weeks of Treatment	Reference Risk of Bias	Events Randomized Onabotulinumtoxin A	Events Randomized Placebo	Relative Risk (95% CI)	Weight (Relative Risk)	Absolute Risk Difference (95% CI)	Weight (Risk Difference)
Blepharoptosis	7.5U 16 weeks	Elkind, 2006 ⁷ Low	2/105	0/36	1.7 (0.1 to 35.5)	4.03	0.02 (-0.03 to 0.07)	8.98
Blepharoptosis	9U 12 weeks	Saper, 2007 ⁴ Low	0/49	0/12	2.2 (0.1 to 37.5)	4.5	0.00 (-0.12 to 0.12)	2.59
Blepharoptosis	10U 12 weeks	Saper, 2007 ⁴ Low	0/44	0/11	3.8 (0.2 to 66.5)	4.45	0.00 (-0.12 to 0.12)	2.56
Blepharoptosis	25U 12 weeks	Saper, 2007 ⁴ Low	4/49	0/12	6.7 (0.4 to 112.7)	4.57	0.08 (-0.06 to 0.22)	1.92
Blepharoptosis	25U 16 weeks	Elkind, 2006 ⁷ Low	5/101	0/34	5.9 (0.3 to 99.4)	4.58	0.05 (-0.01 to 0.11)	7.06
Blepharoptosis	25U 12 weeks	Silberstein, 2000 ⁶ Medium	6/42	0/21	7.7 (0.5 to 128.1)	4.62	0.14 (0.02 to 0.27)	2.33
Blepharoptosis	50U 16 weeks	Elkind, 2006 ⁷ Low	8/106	0/36	2.0 (0.3 to 16.6)	8.33	0.08 (0.01 to 0.14)	6.46
Blepharoptosis	75U 12 weeks	Silberstein, 2000 ⁶ Risk of bias Medium	7/40	0/20	4.9 (0.2 to 100.5)	8.52	0.18 (0.04 to 0.31)	2
Blepharoptosis	75 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	6/174	1/59	2.4 (0.3 to 18.9)	8.89	0.02 (-0.03 to 0.06)	9.83
Blepharoptosis	120U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	0/43	0/21	12.6 (1.7 to 96.1)	26.7	0.00 (-0.07 to 0.07)	5.7
Blepharoptosis	150 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	7/168	1/57	9.4 (2.9 to 30.3)	8.98	0.03 (-0.02 to 0.08)	9.27
Blepharoptosis	105U-260U ("Follow-the-pain" approach) 24 (three injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	12/173	1/182	4.1 (0.5 to 30.8)	4.09	0.02 (-0.02 to 0.07)	10.51
Blepharoptosis	110 U to 260 U per treatment weeks	Aurora, 2007 ¹⁵ Medium	29/187	3/182	2.5 (0.1 to 49.9)	4.02	0.06 (0.03 to 0.10)	7.63

Appendix Table 116. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with random effects model, inverse variance weights) (continued)

Adverse Effect	Dose Weeks of Treatment	Reference Risk of Bias	Events Randomized Onabotulinumtoxin A	Events Randomized Placebo	Relative Risk (95% CI)	Weight (Relative Risk)	Absolute Risk Difference (95% CI)	Weight (Risk Difference)
Blepharoptosis	225 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	12/182	1/62	(Excluded) (0.0 to 0.0)		0.14 (0.08 to 0.19)	8.85
Blepharoptosis	240U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	2/43	0/21	(Excluded) (0.0 to 0.0)		0.05 (0.00 to 0.10)	3.77
Blepharoptosis	210U plus 80U 12 (one time injection) weeks	Petri*, 2009 ⁹ High	2/64	0/63	(Excluded) (0.0 to 0.0)		0.05 (-0.05 to 0.14)	8.21
Blepharoptosis	All doses	Pooled	103/1615	7/839	4.7 (2.6 to 8.7)	100	0.05 (0.03 to 0.07)	100
Muscle weakness	6U 12 weeks	Saper, 2007 ⁴ Low	0/45	0/11	3.4 (0.2 to 56.2)	16.37	0.00 (-0.12 to 0.12)	10.02
Muscle weakness	9U 12 weeks	Saper, 2007 ⁴ Low	0/49	0/12	20.2 (1.3 to 326.0)	16.74	0.00 (-0.11 to 0.11)	10.37
Muscle weakness	10U 12 weeks	Saper, 2007 ⁴ Low	0/44	0/11	30.5 (1.9 to 488.1)	16.84	0.00 (-0.12 to 0.12)	10.01
Muscle weakness	25U 12 weeks	Saper, 2007 ⁴ R Low	6/49	0/12	81.0 (5.0 to 1308.0)	16.71	0.12 (-0.02 to 0.26)	9.1
Muscle weakness	75U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	29/174	0/59	40.6 (2.5 to 669.2)	16.48	0.17 (0.11 to 0.23)	12.09
Muscle weakness	150 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	44/168	0/57	38.3 (2.4 to 610.4)	16.87	0.26 (0.19 to 0.33)	11.76
Muscle weakness	105U-260U ("Follow-the-pain" approach) 24 (three injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	38/173	0/182	(Excluded) (0.0 to 0.0)		0.22 (0.16 to 0.28)	12.03
Muscle weakness	155U-195U [Follow-the-Pain strategy] 24 (two injections over the	Aurora, 2010 ¹ Medium	20/341	0/338	(Excluded) (0.0 to 0.0)		0.06 (0.03 to 0.08)	12.87

Appendix Table 116. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with random effects model, inverse variance weights) (continued)

Adverse Effect	Dose Weeks of Treatment	Reference Risk of Bias	Events Randomized Onabotulinumtoxin A	Events Randomized Placebo	Relative Risk (95% CI)	Weight (Relative Risk)	Absolute Risk Difference (95% CI)	Weight (Risk Difference)
	course: week 1, week 12; open label three injections: week 24, 36, 48) weeks							
Muscle weakness	225 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	56/182	0/62	(Excluded) (0.0 to 0.0)		0.31 (0.24 to 0.38)	11.76
Muscle weakness	All doses	Pooled	193/1225	1/743	25.5 (8.2 to 79.5)	100	0.13 (0.06 to 0.21)	100
Fever	100U 16 weeks	Freitag, 2008 ⁵ Low	0/20	2/21	1.3 (0.4 to 4.3)	5.48	0.02 (-0.09 to 0.13)	9.11
Flu syndrome	25U 16 weeks	Elkind, 2006 ⁷ Low	4/101	3/34	0.4 (0.1 to 1.9)	23.26	-0.05 (-0.15 to 0.05)	18.89
Flu syndrome	50U 16 weeks	Elkind, 2006 ⁷ Low	7/106	3/36	0.8 (0.2 to 2.9)	28.82	-0.02 (-0.12 to 0.09)	19.16
Flu syndrome	7.5U 16 weeks	Elkind, 2006 ⁷ Low	11/105	3/36	0.2 (0.0 to 4.1)	32.7	-0.10 (-0.24 to 0.05)	17.18
Pyrexia	240U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	0/43	1/21	0.2 (0.0 to 4.1)	4.87	-0.05 (-0.15 to 0.06)	17.83
Pyrexia	120U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	0/43	1/21	0.2 (0.0 to 4.1)	4.87	-0.05 (-0.15 to 0.06)	17.83
Pyrexia	All doses	Pooled	22/418	12/169	0.6 (0.3 to 1.3)	100	-0.03 (-0.08 to 0.01)	100

Outcomes	P Value for Relative Risk	I Squared for Relative Risk	P Value for Absolute Risk Difference	I Squared for Absolute Risk Difference
Any adverse effect	0	81.20%	0	82.90%
Back pain	0.80	0.00%	0.67	0.00%
Discontinuations related to adverse effects	0.45	0.00%	0.49	0.00%
Dizziness	0.44	0.00%	0.23	28.60%
Dysphagia	0.90	0.00%	0.40	0.00%
Eyelid edema	0.15	41.50%	0.06	52.80%
Headache	0.84	0.00%	0.91	0.00%

Appendix Table 116. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with random effects model, inverse variance weights) (continued)

Outcomes	P Value for Relative Risk	I Squared for Relative Risk	P Value for Absolute Risk Difference	I Squared for Absolute Risk Difference
Hypertonia	0.69	0.00%	0.38	4.70%
Neck pain	0.06	47.70%	0	83.70%
Neck rigidity	0.66	0.00%	0.03	60.80%
Injection site pain	0.67	0.00%	0.80	0.00%
Blepharoptosis	0.96	0.00%	0.06	37.90%
Muscle weakness	0.72	0.00%	0	91.10%
Fever	0.65	0.00%	0.86	0.00%

CI = confidence interval; Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0; * trials of abobotulinumtoxin A

Appendix Table D117. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with Bayesian odds ratios and maximum likelihood absolute risk difference)

Adverse Effect	Dose and Weeks of Treatment	Reference Risk of Bias	Events/ Randomized with Drug	Events/ Randomized with Placebo	Bayesian Odds Ratio (Median, 2.5 and 97.5% CrI)	Weight	Absolute Risk Difference, Maximum Likelihood Method (95% CI)	Weight
Any adverse effect	6U 12 weeks	Saper, 2007 ⁴ Low	8/45	3/11	0.6 (0.1 to 2.7)	0.027	0.04 (-0.16 to 0.24)	0.03
Any adverse effect	7.5U 16 weeks	Elkind, 2006 ⁷ Low	52/105	17/36	1.1 (0.5 to 2.3)	0.058	0.07 (-0.09 to 0.22)	0.045
Any adverse effect	9U 12 weeks	Saper, 2007 ⁴ Low	11/49	3/12	0.9 (0.2 to 3.8)	0.029	0.07 (-0.13 to 0.26)	0.031
Any adverse effect	10U 12 weeks	Saper, 2007 ⁴ Low	9/44	3/11	6.2 (0.3 to 114.2)	0.009	0.19 (0.05 to 0.33)	0.049
Any adverse effect	25U 16 weeks	Elkind, 2006 ⁷ Low	47/101	16/34	1.0 (0.4 to 2.1)	0.056	0.05 (-0.11 to 0.21)	0.044
Any adverse effect	25U 12 weeks	Saper, 2007 ⁴ Low	17/49	3/12	1.6 (0.4 to 6.7)	0.03	0.13 (-0.07 to 0.32)	0.03
Any adverse effect	50U 16 weeks	Elkind, 2006 ⁷ Low	60/106	17/36	1.5 (0.7 to 3.1)	0.058	0.11 (-0.04 to 0.27)	0.045
Any adverse effect	75 U 24 weeks	Silberstein, 2005 ¹¹ Low	97/174	13/59	4.5 (2.2 to 8.8)	0.062	0.30 (0.19 to 0.42)	0.057
Any adverse effect	80U 12 weeks	Petri*, 2009 ⁹ High	4/32	5/32	0.8 (0.2 to 3.2)	0.03	0.02 (-0.12 to 0.17)	0.048
Any adverse effect	139U 12 weeks	Cady, 2008 ¹³ Low	0/40	0/19	0.5 (0.0 to 25.2)	0.005	0.01 (-0.06 to 0.09)	0.067
Any adverse effect	150 U 24 weeks	Silberstein, 2005 ¹¹ Low	92/168	12/57	4.5 (2.2 to 9.2)	0.061	0.30 (0.19 to 0.42)	0.056
Any adverse effect	105U-260U ("Follow-the-pain" approach) 24 (3 injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Risk of bias Low	88/173	42/182	3.5 (2.2 to 5.4)	0.075	0.26 (0.17 to 0.36)	0.063
Any adverse effect	155U-195U [Follow-the-pain strategy] 24 (two injections over the course: week 1, week 12; open label 3 injections: week 24, 36, 48) weeks	Aurora, 2010 ¹ Medium	86/341	39/338	2.6 (1.7 to 3.9)	0.078	0.14 (0.08 to 0.19)	0.07

Appendix Table 117. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with Bayesian odds ratios and maximum likelihood absolute risk difference) (continued)

Adverse Effect	Dose and Weeks of Treatment	Reference Risk of Bias	Events/ Randomized with Drug	Events/ Randomized with Placebo	Bayesian Odds Ratio (Median, 2.5 and 97.5% CrI)	Weight	Absolute Risk Difference, Maximum Likelihood Method (95% CI)	Weight
Any adverse effect	155U-195U [Follow-the-Pain strategy] 24 (three injections over the course: week 1, week 12, week 24) weeks	Diener, 2010 ² Low	116/347	49/358	3.2 (2.2 to 4.6)	0.08	0.20 (0.14 to 0.26)	0.069
Any adverse effect	155U-195U [Follow-the-Pain strategy] 24 (2 injections over the course: week 1, week 12; open label 3 injections: week 24, 36, 48) weeks	Aurora, 2010 ¹ Medium	203/341	156/338	1.7 (1.3 to 2.3)	0.083	0.14 (0.06 to 0.21)	0.067
Any adverse effect	110 U to 260 U per treatment weeks	Aurora, 2007 ¹⁵ Medium	113/187	39/182	5.6 (3.5 to 8.9)	0.075	0.37 (0.28 to 0.45)	0.064
Any adverse effect	155U-195U [Follow-the-Pain strategy] 24 (3 injections over the course: week 1, week 12, week 24) weeks	Diener, 2010 ² Low	226/347	202/358	1.4 (1.1 to 2.0)	0.083	0.09 (0.02 to 0.16)	0.068
Any adverse effect	210U 12 (one time injection) weeks	Petri*, 2009 ⁹ High	12/32	6/32	2.6 (0.8 to 8.1)	0.039	0.18 (0.01 to 0.35)	0.04
Any adverse effect	225 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	119/182	13/62	7.1 (3.6 to 14.1)	0.062	0.40 (0.28 to 0.51)	0.058
Any adverse effect	Pooled		1360/2863	637/2168	2.2 (1.5 to 3.0)	1	0.16 (0.09 to 0.23)	1
Back pain	75 U 24 (3 injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	3/174	0/59	2.4 (0.1 to 47.7)	0.177	0.02 (-0.01 to 0.04)	0.205

Appendix Table 117. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with Bayesian odds ratios and maximum likelihood absolute risk difference) (continued)

Adverse Effect	Dose and Weeks of Treatment	Reference Risk of Bias	Events/ Randomized with Drug	Events/ Randomized with Placebo	Bayesian Odds Ratio (Median, 2.5 and 97.5% CrI)	Weight	Absolute Risk Difference, Maximum Likelihood Method (95% CI)	Weight
Back pain	100U 16 weeks	Freitag, 2008 ⁵ Low	0/20	1/21	0.3 (0.0 to 8.7)	0.148	0.01 (-0.02 to 0.04)	0.013
Back pain	150 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	4/168	0/57	3.1 (0.2 to 59.3)	0.182	0.02 (0.00 to 0.04)	0.17
Back pain	110 U to 260 U per treatment weeks	Aurora, 2007 ¹⁵ Medium	3/187	1/182	3.0 (0.3 to 28.6)	0.304	0.01 (-0.01 to 0.03)	0.448
Back pain	225 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	6/182	0/62	4.6 (0.3 to 82.9)	0.188	0.02 (0.00 to 0.05)	0.164
Back pain	All doses	Pooled	16/731	2/381	4.9 (1.2 to 35.7)	1	0.02 (0.00 to 0.04)	1
Discontinuations related to AE	155U-195U [Follow-the-Pain strategy] 24 (three injections over the course: week 1, week 12, week 24) weeks	Diener, 2010 ² Low	12/347	5/358	2.5 (0.9 to 7.3)	0.587	0.03 (0.01 to 0.04)	0.512
Discontinuations related to AE	155U-195U [Follow-the-Pain strategy] 24 (2 injections over the course: week 1, week 12; open label 3 injections: week 24, 36, 48) weeks	Aurora, 2010 ¹ Medium	14/341	3/338	4.8 (1.4 to 16.8)	0.413	0.03 (0.02 to 0.04)	0.488
Discontinuations related to adverse effects	All doses	Pooled	26/688	8/696	3.5 (1.2 to 10.9)	1	0.03 (0.01 to 0.05)	1
Dizziness	100U 16 weeks	Freitag, 2008 ⁵ Low	0/20	1/21	0.3 (0.0 to 8.7)	0.156	0.00 (-0.05 to 0.05)	0.031
Dizziness	120U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	2/43	0/21	2.6 (0.1 to 56.4)	0.174	0.02 (-0.03 to 0.06)	0.053

Appendix Table 117. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with Bayesian odds ratios and maximum likelihood absolute risk difference) (continued)

Adverse Effect	Dose and Weeks of Treatment	Reference Risk of Bias	Events/ Randomized with Drug	Events/ Randomized with Placebo	Bayesian Odds Ratio (Median, 2.5 and 97.5% CrI)	Weight	Absolute Risk Difference, Maximum Likelihood Method (95% CI)	Weight
Dizziness	105U-260U ("Follow-the-pain" approach) 24 weeks	Mathew, 2005 ¹⁰ Low	1/173	3/182	0.3 (0.0 to 3.4)	0.32	-0.01 (-0.03 to 0.01)	0.437
Dizziness	110 U to 260 U per treatment weeks	Aurora, 2007 ¹⁵ Medium	4/187	0/182	9.0 (0.5 to 167.5)	0.193	0.02 (0.00 to 0.04)	0.413
Dizziness	240U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	1/43	0/21	1.5 (0.1 to 38.8)	0.157	0.01 (-0.03 to 0.06)	0.066
Dizziness	All doses	Pooled	8/466	4/427	1.8 (0.5 to 8.0)	1	0.01 (-0.02 to 0.04)	1
Dysphagia	75 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	3/174	0/59	2.4 (0.1 to 47.7)	0.24	0.03 (0.00 to 0.05)	0.258
Dysphagia	150 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	5/168	0/57	3.9 (0.2 to 71.1)	0.251	0.03 (0.01 to 0.05)	0.193
Dysphagia	105U-260U ("Follow-the-pain" approach) 24 (3 injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	4/173	0/182	9.7 (0.5 to 181.3)	0.248	0.03 (0.01 to 0.05)	0.404
Dysphagia	225 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	11/182	0/62	8.4 (0.5 to 144.4)	0.262	0.04 (0.02 to 0.07)	0.144
Dysphagia	All doses	Pooled	23/697	1/360			0.03 (0.01 to 0.05)	1
Eyelid edema	7.5U 16 weeks	Elkind, 2006 ⁷ Low	1/105	0/36	1.0 (0.0 to 26.3)	0.16	0.01 (-0.03 to 0.05)	0.217
Eyelid edema	25U 16 weeks	Elkind, 2006 ⁷ Low	0/101	0/34	0.3 (0.0 to 17.5)	0.121	0.00 (-0.03 to 0.04)	0.225
Eyelid edema	50U 16 weeks	Elkind, 2006 ⁷ Low	7/106	0/36	5.5 (0.3 to 98.8)	0.184	0.05 (0.00 to 0.09)	0.16
Eyelid edema	120U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	1/43	1/21	0.5 (0.0 to 8.0)	0.189	0.00 (-0.06 to 0.06)	0.081

Appendix Table 117. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with Bayesian odds ratios and maximum likelihood absolute risk difference) (continued)

Adverse Effect	Dose and Weeks of Treatment	Reference Risk of Bias	Events/ Randomized with Drug	Events/ Randomized with Placebo	Bayesian Odds Ratio (Median, 2.5 and 97.5% CrI)	Weight	Absolute Risk Difference, Maximum Likelihood Method (95% CI)	Weight
Eyelid edema	110 U to 260 U per treatment weeks	Aurora, 2007 ¹⁵ Medium	12/187	0/182	26.0 (1.5 to 442.4)	0.188	0.06 (0.02 to 0.09)	0.245
Eyelid edema	240U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	0/43	1/21	0.2 (0.0 to 4.0)	0.159	0.00 (-0.06 to 0.06)	0.072
Eyelid edema	All doses	Pooled	21/585	1/330	5.5 (0.8 to 62.0)	1	0.02 (-0.02 to 0.06)	1
Headache	6U 12 weeks	Saper, 2007 ⁴ Low	2/45	0/11	1.3 (0.1 to 29.5)	0.019	0.01 (-0.05 to 0.06)	0.022
Headache	7.5U 16 weeks	Elkind, 2006 ⁷ Low	1/105	1/36	0.3 (0.0 to 5.5)	0.023	-0.01 (-0.05 to 0.03)	0.118
Headache	9U 12 weeks	Saper, 2007 ⁴ Low	0/49	1/12	0.1 (0.0 to 2.0)	0.017	-0.01 (-0.07 to 0.05)	0.012
Headache	10U 12 weeks	Saper, 2007 ⁴ Low	1/44	0/11	0.8 (0.0 to 20.8)	0.017	0.00 (-0.05 to 0.06)	0.025
Headache	25U 12 weeks	Saper, 2007 ⁴ Low	3/49	1/12	0.7 (0.1 to 7.6)	0.032	0.00 (-0.06 to 0.06)	0.013
Headache	25U 16 weeks	Elkind, 2006 ⁷ Low	2/101	1/34	0.7 (0.1 to 7.6)	0.031	-0.01 (-0.05 to 0.04)	0.096
Headache	50U 16 weeks	Elkind, 2006 ⁷ Low	8/106	1/36	2.9 (0.3 to 23.7)	0.04	0.02 (-0.03 to 0.07)	0.07
Headache	75 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	7/174	3/59	0.8 (0.2 to 3.1)	0.094	-0.01 (-0.05 to 0.04)	0.095
Headache	120U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	0/43	1/21	0.2 (0.0 to 4.0)	0.017	-0.01 (-0.07 to 0.04)	0.032
Headache	150U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	14/168	3/57	1.6 (0.5 to 5.9)	0.109	0.01 (-0.03 to 0.06)	0.075
Headache	105U-260U ("Follow-the-pain" approach) 24 (three injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	12/173	11/182	1.2 (0.5 to 2.7)	0.252	0.01 (-0.03 to 0.05)	0.145

Appendix Table 117. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with Bayesian odds ratios and maximum likelihood absolute risk difference) (continued)

Adverse Effect	Dose and Weeks of Treatment	Reference Risk of Bias	Events/ Randomized with Drug	Events/ Randomized with Placebo	Bayesian Odds Ratio (Median, 2.5 and 97.5% CrI)	Weight	Absolute Risk Difference, Maximum Likelihood Method (95% CI)	Weight
Headache	110U to 260 U per treatment weeks	Aurora, 2007 ¹⁵ Medium	11/187	9/182	1.2 (0.5 to 3.0)	0.22	0.01 (-0.03 to 0.04)	0.179
Headache	225U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	15/182	3/62	1.8 (0.5 to 6.3)	0.111	0.02 (-0.03 to 0.06)	0.086
Headache	240U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	0/43	1/21	0.2 (0.0 to 4.0)	0.017	-0.01 (-0.07 to 0.04)	0.032
Headache	All doses	Pooled	76/1469	33/735	1.0 (0.5 to 1.6)	1	0.00 (-0.02 to 0.03)	1
Hypertonia	75U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	13/174	0/59	9.9 (0.6 to 170.0)	0.082	0.07 (0.04 to 0.10)	0.179
Hypertonia	150U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	15/168	0/57	11.6 (0.7 to 197.3)	0.082	0.07 (0.04 to 0.10)	0.153
Hypertonia	105U-260U ("Follow-the-pain" approach) 24 (3 injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	9/173	4/182	2.4 (0.7 to 8.1)	0.461	0.05 (0.02 to 0.08)	0.238
Hypertonia	110U to 260U per treatment weeks	Aurora, 2007 ¹⁵ Medium	13/187	2/182	6.7 (1.5 to 30.2)	0.292	0.06 (0.04 to 0.09)	0.236
Hypertonia	22U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	13/182	0/62	10.0 (0.6 to 170.0)	0.082	0.07 (0.04 to 0.10)	0.194
Hypertonia	All doses	Pooled	63/884	7/542	7.3 (3.1 to 20.9)	1	0.06 (0.04 to 0.09)	1
Neck pain	75U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	30/174	1/59	12.1 (1.6 to 90.7)	0.128	0.15 (0.09 to 0.21)	0.13
Neck pain	120U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	2/43	1/21	1.0 (0.1 to 11.4)	0.101	0.04 (-0.05 to 0.13)	0.094

Appendix Table 117. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with Bayesian odds ratios and maximum likelihood absolute risk difference) (continued)

Adverse Effect	Dose and Weeks of Treatment	Reference Risk of Bias	Events/ Randomized with Drug	Events/ Randomized with Placebo	Bayesian Odds Ratio (Median, 2.5 and 97.5% CrI)	Weight	Absolute Risk Difference, Maximum Likelihood Method (95% CI)	Weight
Neck pain	150 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	37/168	1/57	15.8 (2.1 to 118.1)	0.128	0.19 (0.12 to 0.25)	0.125
Neck pain	105U-260U ("Follow-the-pain" approach) 24 (3 injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	23/173	1/182	27.8 (3.7 to 207.9)	0.128	0.13 (0.08 to 0.17)	0.14
Neck pain	155U-195U [Follow-the-Pain strategy] 24 (two injections over the course: week 1, week 12; open label 3 injections: week 24, 36, 48) weeks	Aurora, 2010 ¹ Medium	20/341	0/338	43.2 (2.6 to 716.7)	0.085	0.06 (0.04 to 0.09)	0.156
Neck pain	110U to 260U per treatment weeks	Aurora, 2007 ¹⁵ Medium	32/187	8/182	4.5 (2.0 to 10.0)	0.233	0.13 (0.07 to 0.18)	0.133
Neck pain	225U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	41/182	1/62	17.7 (2.4 to 131.9)	0.128	0.19 (0.13 to 0.26)	0.127
Neck pain	240U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	0/43	1/21	0.2 (0.0 to 4.0)	0.069	0.01 (-0.08 to 0.10)	0.095
Neck pain	All doses	Pooled	185/1311	13/922	9.5 (4.7 to 19.2)	1	0.11 (0.05 to 0.17)	1
Neck rigidity	75U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	14/174	0/59	10.8 (0.6 to 183.1)	0.061	0.08 (0.04 to 0.12)	0.19
Neck stiffness	100U 16 weeks	Freitag, 2008 ⁵ Low	1/20	1/21	1.1 (0.1 to 18.1)	0.061	0.06 (-0.01 to 0.12)	0.055
Neck rigidity	150U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	14/168	0/57	10.8 (0.6 to 183.9)	0.061	0.08 (0.04 to 0.12)	0.185

Appendix Table 117. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with Bayesian odds ratios and maximum likelihood absolute risk difference) (continued)

Adverse Effect	Dose and Weeks of Treatment	Reference Risk of Bias	Events/ Randomized with Drug	Events/ Randomized with Placebo	Bayesian Odds Ratio (Median, 2.5 and 97.5% CrI)	Weight	Absolute Risk Difference, Maximum Likelihood Method (95% CI)	Weight
Neck rigidity	105U-260U ("Follow-the-pain" approach) 24 (3 injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	8/173	2/182	4.4 (0.9 to 20.8)	0.201	0.04 (0.01 to 0.07)	0.226
Neck rigidity	110U to 260U per treatment weeks	Aurora, 2007 ¹⁵ Medium	19/187	6/182	3.3 (1.3 to 8.5)	0.554	0.07 (0.03 to 0.11)	0.18
Neck rigidity	225U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	27/182	0/62	22.1 (1.3 to 368.0)	0.062	0.12 (0.08 to 0.17)	0.164
Neck rigidity	All doses	Pooled	83/904	10/563	6.2 (2.9 to 14.1)	1	0.08 (0.04 to 0.11)	1
Injection site pain	75U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	8/174	3/59	0.9 (0.2 to 3.5)	0.167	0.00 (-0.04 to 0.04)	0.032
Injection site pain	120U 12 (one time injection) weeks	Chankrachang*, 2011 ⁸ *Low	0/43	1/21	0.2 (0.0 to 4.0)	0.029	-0.01 (-0.05 to 0.04)	0.011
Injection site pain	150U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	10/168	3/57	1.1 (0.3 to 4.3)	0.176	0.00 (-0.04 to 0.04)	0.029
Injection site pain	105U-260U ("Follow-the-pain" approach) 24 (3 injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	4/173	4/182	1.1 (0.3 to 4.3)	0.157	0.00 (-0.03 to 0.03)	0.14
Injection site pain	110U to 260U per treatment weeks	Aurora, 2007 ¹⁵ Medium	4/187	1/182	4.0 (0.4 to 35.7)	0.064	0.01 (-0.01 to 0.03)	0.245
Injection site pain	225U 24 (three injections at day 0, day 90, and day 180) weeks	Silberstein, 205 ¹¹ Low	17/182	3/62	2.0 (0.6 to 7.2)	0.194	0.01 (-0.03 to 0.05)	0.029
Injection site pain	240U 12 (one time injection) weeks	Chankrachang*, 2011 ⁸ *Low	0/43	1/21	0.2 (0.0 to 4.0)	0.029	-0.01 (-0.05 to 0.04)	0.011

Appendix Table 117. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with Bayesian odds ratios and maximum likelihood absolute risk difference) (continued)

Adverse Effect	Dose and Weeks of Treatment	Reference Risk of Bias	Events/ Randomized with Drug	Events/ Randomized with Placebo	Bayesian Odds Ratio (Median, 2.5 and 97.5% CrI)	Weight	Absolute Risk Difference, Maximum Likelihood Method (95% CI)	Weight
Pain	110U to 260U per treatment weeks	Aurora, 2007 ¹⁵ Medium	3/187	0/182	6.9 (0.4 to 135.0)	0.035	0.01 (-0.01 to 0.03)	0.31
Pain	105U-260U ("Follow-the-pain" approach) 24 (3 injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	3/173	3/182	1.1 (0.2 to 5.3)	0.119	0.00 (-0.02 to 0.02)	0.185
Pain	100U 16 weeks	Freitag, 2008 ⁵ Low	0/20	1/21	0.3 (0.0 to 8.7)	0.029	-0.01 (-0.05 to 0.04)	0.009
Injection site pain	All doses	Pooled	49/1350	20/969	1.4 (0.7 to 2.5)	1	0.00 (-0.02 to 0.02)	1
Blepharoptosis	6U 12 weeks	Saper, 2007 ⁴ Low	1/45	0/11	0.8 (0.0 to 20.3)	0.034	0.04 (-0.03 to 0.11)	0.023
Blepharoptosis	7.5U 16 weeks	Elkind, 2006 ⁷ Low	2/105	0/36	1.8 (0.1 to 37.6)	0.038	0.03 (-0.01 to 0.07)	0.089
Blepharoptosis	9U 12 weeks	Saper, 2007 ⁴ Low	0/49	0/12	0.3 (0.0 to 13.4)	0.023	0.03 (-0.03 to 0.10)	0.029
Blepharoptosis	10U 12 weeks	Saper, 2007 ⁴ Low	0/44	0/11	0.3 (0.0 to 13.7)	0.023	0.04 (-0.03 to 0.10)	0.026
Blepharoptosis	25U 12 weeks	Saper, 2007 ⁴ Low	4/49	0/12	2.5 (0.1 to 49.1)	0.04	0.06 (-0.01 to 0.13)	0.021
Blepharoptosis	25U 16 weeks	Elkind, 2006 ⁷ Low	5/101	0/34	3.9 (0.2 to 73.0)	0.042	0.05 (0.00 to 0.10)	0.07
Blepharoptosis	25U 12 weeks	Silberstein, 2000 ⁶ Medium	6/42	0/21	7.7 (0.4 to 142.8)	0.042	0.08 (0.01 to 0.15)	0.023
Blepharoptosis	50U 16 weeks	Elkind, 2006 ⁷ Low	8/106	0/36	6.3 (0.4 to 111.9)	0.043	0.07 (0.02 to 0.12)	0.064
Blepharoptosis	75U 12 weeks	Silberstein, 2000 ⁶ Medium	7/40	0/20	9.2 (0.5 to 169.4)	0.042	0.09 (0.02 to 0.16)	0.02
Blepharoptosis	75U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	6/174	1/59	2.1 (0.2 to 17.6)	0.078	0.03 (-0.01 to 0.06)	0.098
Blepharoptosis	120U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	0/43	0/21	0.5 (0.0 to 25.8)	0.023	0.02 (-0.03 to 0.08)	0.057
Blepharoptosis	150U 24 (three injection at day 0,	Silberstein, 2005 ¹¹	7/168	1/57	2.4 (0.3 to 20.2)	0.08	0.03 (-0.01 to 0.07)	0.092

Appendix Table 117. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with Bayesian odds ratios and maximum likelihood absolute risk difference) (continued)

Adverse Effect	Dose and Weeks of Treatment	Reference Risk of Bias	Events/ Randomized with Drug	Events/ Randomized with Placebo	Bayesian Odds Ratio (Median, 2.5 and 97.5% CrI)	Weight	Absolute Risk Difference, Maximum Likelihood Method (95% CI)	Weight
	day 90, and day 180) weeks	Low						
Blepharoptosis	105U-260U ("Follow-the-pain" approach) 24 (three injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	12/173	1/182	13.5 (1.7 to 104.9)	0.085	0.06 (0.03 to 0.10)	0.104
Blepharoptosis	110U to 260U per treatment weeks	Aurora, 2007 ¹⁵ Medium	29/187	3/182	11.0 (3.3 to 36.6)	0.246	0.11 (0.07 to 0.16)	0.076
Blepharoptosis	225U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	12/182	1/62	4.3 (0.5 to 33.8)	0.084	0.05 (0.01 to 0.09)	0.088
Blepharoptosis	240U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	2/43	0/21	2.6 (0.1 to 56.4)	0.038	0.05 (-0.01 to 0.11)	0.038
Blepharoptosis	210U plus 80U 12 (one time injection) weeks	Petri*, 2009 ⁹ High	2/64	0/63	5.1 (0.2 to 108.0)	0.038	0.04 (-0.01 to 0.08)	0.082
Blepharoptosis	All doses	Pooled	103/1615	7/839	8.0 (3.5 to 21.6)	1	0.05 (0.03 to 0.08)	1
Muscle weakness	6U 12 weeks	Saper, 2007 ⁴ Low	0/45	0/11	0.3 (0.0 to 13.4)	0.087	0.03 (-0.07 to 0.13)	0.1
Muscle weakness	9U 12 weeks	Saper, 2007 ⁴ Low	0/49	0/12	0.3 (0.0 to 13.4)	0.087	0.03 (-0.07 to 0.12)	0.104
Muscle weakness	10U 12 weeks	Saper, 2007 ⁴ Low	0/44	0/11	0.3 (0.0 to 13.7)	0.087	0.03 (-0.07 to 0.13)	0.1
Muscle weakness	25U 12 weeks	Saper, 2007 ⁴ Low	6/49	0/12	3.7 (0.2 to 71.0)	0.119	0.13 (0.01 to 0.24)	0.091
Muscle weakness	75 U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	29/174	0/59	24.1 (1.5 to 401.3)	0.124	0.16 (0.11 to 0.22)	0.121
Muscle weakness	150 U 24 (three injections at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	44/168	0/57	41.1 (2.5 to 679.2)	0.124	0.25 (0.18 to 0.32)	0.118

Appendix Table 117. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with Bayesian odds ratios and maximum likelihood absolute risk difference) (continued)

Adverse Effect	Dose and Weeks of Treatment	Reference Risk of Bias	Events/ Randomized with Drug	Events/ Randomized with Placebo	Bayesian Odds Ratio (Median, 2.5 and 97.5% CrI)	Weight	Absolute Risk Difference, Maximum Likelihood Method (95% CI)	Weight
Muscle weakness	105U-260U ("Follow-the-pain" approach) 24 (three injections at day 0, day 90, and day 180) weeks	Mathew, 2005 ¹⁰ Low	38/173	0/182	103.7 (6.3 to 1703.1)	0.124	0.21 (0.15 to 0.27)	0.12
Muscle weakness	155U-195U [Follow-the-Pain strategy] 24 (two injections over the course: week 1, week 12; open label three injections: week 24, 36, 48) weeks	Aurora, 2010 ¹ Medium	20/341	0/338	43.2 (2.6 to 716.7)	0.124	0.06 (0.03 to 0.09)	0.129
Muscle weakness	225U 24 (three injection at day 0, day 90, and day 180) weeks	Silberstein, 2005 ¹¹ Low	56/182	0/62	55.8 (3.4 to 918.6)	0.124	0.29 (0.22 to 0.36)	0.118
Muscle weakness	All doses	Pooled	193/1225	1/743			0.13 (0.06 to 0.21)	1
Fever	100U 16 weeks	Freitag, 2008 ³ Low	0/20	2/21	0.2 (0.0 to 4.2)	0.059	-0.05 (-0.11 to 0.01)	0.094
Flu syndrome	25U 16 weeks	Elkind, 2006 ⁷ Low	4/101	3/34	0.4 (0.1 to 2.0)	0.234	-0.04 (-0.10 to 0.01)	0.194
Flu syndrome	50U 16 weeks	Elkind, 2006 ⁷ Low	7/106	3/36	0.8 (0.2 to 3.2)	0.284	-0.03 (-0.09 to 0.02)	0.197
Flu syndrome	7.5U 16 weeks	Elkind, 2006 ⁷ Low	11/105	3/36	1.3 (0.3 to 4.9)	0.316	-0.02 (-0.08 to 0.04)	0.177
Pyrexia	240U 12 (one time injection) weeks	Chankrachang*, 2011 ^{8*} Low	0/43	1/21	0.2 (0.0 to 4.0)	0.054	-0.04 (-0.10 to 0.02)	0.169
Pyrexia	120U 12 (one time injection) weeks	Chrankrachang, 2011 ⁸ Low	0/43	1/21	0.2 (0.0 to 4.0)	0.054	-0.04 (-0.10 to 0.02)	0.169
Pyrexia	All doses	Pooled	22/418	12/169	0.5 (0.1 to 1.3)	1	-0.04 (-0.09 to 0.01)	1

Bold = significant differences at 95% confidence limit when 95% CI of relative measure of the association estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0; CrI = credible intervals; * trials of abobotulinumtoxinA

Appendix Table D118. Dose response adverse effects with onabotulinumtoxin A for migraine prevention in adults (results from individual randomized controlled clinical trials)

Adverse Effect	Reference Risk of Bias	Dose of Drug, Units	Events/ Randomized Larger Dose	Events/ Randomized Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Edema	Chankrachang*, 2011 ^{8*} Low	240 vs. 120	1/43	0/43	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.09)
Eyelid edema	Elkind, 2006 ⁷ Low	25 vs. 7.5	0/101	1/105	0.3 (0.0 to 8.4)	-0.01 (-0.04 to 0.02)
Eyelid edema	Elkind, 2006 ⁷ Low	50 vs. 25	7/106	0/101	14.3 (0.8 to 247.2)	0.07 (0.02 to 0.12)
Eyelid edema	Elkind, 2006 ⁷ Low	50 vs. 7.5	7/106	1/105	6.9 (0.9 to 55.4)	0.06 (0.01 to 0.11)
Eyelid edema	Relja, 2007 ¹⁷ Low	150 vs. 75	0/125	2/123	0.2 (0.0 to 4.1)	-0.02 (-0.04 to 0.01)
Eyelid edema	Relja, 2007 ¹⁷ Low	225 vs. 150	3/129	0/125	6.8 (0.4 to 130.0)	0.02 (-0.01 to 0.05)
Eyelid edema	Relja, 2007 ¹⁷ Low	225 vs. 75	3/129	2/123	1.4 (0.2 to 8.4)	0.01 (-0.03 to 0.04)
Eyelid edema	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	1/43	0.3 (0.0 to 8.0)	-0.02 (-0.09 to 0.04)
Rash	Relja, 2007 ¹⁷ Low	150 vs. 75	0/125	3/123	0.1 (0.0 to 2.7)	-0.02 (-0.06 to 0.01)
Rash	Relja, 2007 ¹⁷ Low	225 vs. 150	1/129	0/125	2.9 (0.1 to 70.7)	0.01 (-0.01 to 0.03)
Rash	Relja, 2007 ¹⁷ Low	225 vs. 75	1/129	3/123	0.3 (0.0 to 3.0)	-0.02 (-0.05 to 0.01)
Adverse effects	Saper, 2007 ⁴ Low	9 vs. 6	11/49	8/45	1.3 (0.6 to 2.9)	0.05 (-0.11 to 0.21)
Adverse effects	Saper, 2007 ⁴ Low	10 vs. 6	9/44	8/45	1.2 (0.5 to 2.7)	0.03 (-0.14 to 0.19)
Adverse effects	Saper, 2007 ⁴ Low	10 vs. 9	9/44	11/49	0.9 (0.4 to 2.0)	-0.02 (-0.19 to 0.15)
Adverse effects	Saper, 2007 ⁴ Low	25 vs. 10	17/49	9/44	1.7 (0.8 to 3.4)	0.14 (-0.04 to 0.32)
Adverse effects	Saper, 2007 ⁴ Low	25 vs. 6	17/49	8/45	2.0 (0.9 to 4.1)	0.17 (0.00 to 0.34)
Adverse effects	Saper, 2007 ⁴ Low	25 vs. 9	17/49	11/49	1.5 (0.8 to 3.0)	0.12 (-0.05 to 0.30)
Adverse effects	Elkind, 2006 ⁷ Low	25 vs. 7.5	47/101	52/105	0.9 (0.7 to 1.2)	-0.03 (-0.17 to 0.11)
Adverse effects	Elkind, 2006 ⁷ Low	50 vs. 25	60/106	47/101	1.2 (0.9 to 1.6)	0.10 (-0.03 to 0.24)

Appendix Table 118. Dose response adverse effects with onabotulinumtoxin A for migraine prevention in adults (results from individual randomized controlled clinical trials) (continued)

Adverse Effect	Reference Risk of Bias	Dose of Drug, Units	Events/ Randomized Larger Dose	Events/ Randomized Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Adverse effects	Elkind, 2006 ⁷ Low	50 vs. 7.5	60/106	52/105	1.1 (0.9 to 1.5)	0.07 (-0.06 to 0.21)
Adverse effects	Relja, 2007 ¹⁷ Low	150 vs. 75	79/125	77/123	1.0 (0.8 to 1.2)	0.01 (-0.11 to 0.13)
Adverse effects	Silberstein, 2005 ¹¹ Low	150 vs. 75	92/168	97/174	1.0 (0.8 to 1.2)	-0.01 (-0.12 to 0.10)
Adverse effects	Petri*, 2009⁹ High	210 vs. 80	12/32	4/32	3.0 (1.1 to 8.3)	0.25 (0.05 to 0.45)
Adverse effects	Relja, 2007 ¹⁷ Low	225 vs. 150	87/129	79/125	1.1 (0.9 to 1.3)	0.04 (-0.07 to 0.16)
Adverse effects	Relja, 2007 ¹⁷ Low	225 vs. 75	87/129	77/123	1.1 (0.9 to 1.3)	0.05 (-0.07 to 0.17)
Adverse effects	Silberstein, 2005¹¹ Low	225 vs. 150	119/182	92/168	1.2 (1.0 to 1.4)	0.11 (0.00 to 0.21)
Adverse effects	Silberstein, 2005¹¹ Low	225 vs. 75	119/182	97/174	1.2 (1.0 to 1.4)	0.10 (0.00 to 0.20)
Adverse effects	Elkind, 2006 ⁷ Low	7.5 or 50 vs. 7.5 or 25	139/180	135/173	1.0 (0.9 to 1.1)	-0.01 (-0.10 to 0.08)
Mastication disorder	Chankrachang*, 2011 ⁸ Low	240 vs. 120	1/43	0/43	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.09)
Menorrhagia	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	0/43	0.0 (0.0 to 0.0)	0.00 (-0.04 to 0.04)
Bronchitis	Elkind, 2006 ⁷ Low	7.5 or 50 vs. 7.5 or 25	10/180	6/173	1.6 (0.6 to 4.3)	0.02 (-0.02 to 0.06)
Flu syndrome	Elkind, 2006 ⁷ Low	25 vs. 7.5	4/101	11/105	0.4 (0.1 to 1.1)	-0.07 (-0.13 to 0.00)
Flu syndrome	Elkind, 2006 ⁷ Low	50 vs. 25	7/106	4/101	1.7 (0.5 to 5.5)	0.03 (-0.03 to 0.09)
Flu syndrome	Elkind, 2006 ⁷ Low	50 vs. 7.5	7/106	11/105	0.6 (0.3 to 1.6)	-0.04 (-0.11 to 0.04)
Flu syndrome	Elkind, 2006 ⁷ Low	7.5 or 50 vs. 7.5 or 25	14/180	12/173	1.1 (0.5 to 2.4)	0.01 (-0.05 to 0.06)
Herpes zoster	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	0/43	0.0 (0.0 to 0.0)	0.00 (-0.04 to 0.04)
Infection	Elkind, 2006 ⁷ Low	7.5 or 50 vs. 7.5 or 25	15/180	20/173	0.7 (0.4 to 1.4)	-0.03 (-0.09 to 0.03)
Respiratory infection	Elkind, 2006 ⁷ Low	25 vs. 7.5	10/101	12/105	0.9 (0.4 to 1.9)	-0.02 (-0.10 to 0.07)

Appendix Table 118. Dose response adverse effects with onabotulinumtoxin A for migraine prevention in adults (results from individual randomized controlled clinical trials) (continued)

Adverse Effect	Reference Risk of Bias	Dose of Drug, Units	Events/ Randomized Larger Dose	Events/ Randomized Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Respiratory infection	Elkind, 2006 ⁷ Low	50 vs. 25	11/106	10/101	1.0 (0.5 to 2.4)	0.00 (-0.08 to 0.09)
Respiratory infection	Elkind, 2006 ⁷ Low	50 vs. 7.5	11/106	12/105	0.9 (0.4 to 2.0)	-0.01 (-0.09 to 0.07)
Respiratory infection	Elkind, 2006 ⁷ Low	7.5 or 50 vs. 7.5 or 25	12/180	14/173	0.8 (0.4 to 1.7)	-0.01 (-0.07 to 0.04)
Sinus infection	Elkind, 2006 ⁷ Low	25 vs. 7.5	7/101	4/105	1.8 (0.5 to 6.0)	0.03 (-0.03 to 0.09)
Sinus infection	Elkind, 2006 ⁷ Low	50 vs. 25	4/106	7/101	0.5 (0.2 to 1.8)	-0.03 (-0.09 to 0.03)
Sinus infection	Elkind, 2006 ⁷ Low	50 vs. 7.5	4/106	4/105	1.0 (0.3 to 3.9)	0.00 (-0.05 to 0.05)
Sinus infection	Elkind, 2006 ⁷ Low	7.5 or 50 vs. 7.5 or 25	15/180	16/173	0.9 (0.5 to 1.8)	-0.01 (-0.07 to 0.05)
Injection site hemorrhage	Relja, 2007 ¹⁷ Low	150 vs. 75	2/125	3/123	0.7 (0.1 to 3.9)	-0.01 (-0.04 to 0.03)
Injection site hemorrhage	Relja, 2007 ¹⁷ Low	225 vs. 150	0/129	2/125	0.2 (0.0 to 4.0)	-0.02 (-0.04 to 0.01)
Injection site hemorrhage	Relja, 2007 ¹⁷ Low	225 vs. 75	0/129	3/123	0.1 (0.0 to 2.6)	-0.02 (-0.06 to 0.01)
Injection site pain	Relja, 2007 ¹⁷ Low	150 vs. 75	9/125	4/123	2.2 (0.7 to 7.0)	0.04 (-0.02 to 0.09)
Injection site pain	Relja, 2007 ¹⁷ Low	225 vs. 150	3/129	9/125	0.3 (0.1 to 1.2)	-0.05 (-0.10 to 0.00)
Injection site pain	Relja, 2007 ¹⁷ Low	225 vs. 75	3/129	4/123	0.7 (0.2 to 3.1)	-0.01 (-0.05 to 0.03)
Injection site pain	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	0/43	0.0 (0.0 to 0.0)	0.00 (-0.04 to 0.04)
Injection site weakness	Silberstein, 2000 ⁶ Medium	75 vs. 25	5/40	4/42	1.3 (0.4 to 4.5)	0.03 (-0.11 to 0.17)
Injection-site pain	Silberstein, 2005 ¹¹ Low	150 vs. 75	10/168	8/174	1.3 (0.5 to 3.2)	0.01 (-0.03 to 0.06)
Injection-site pain	Silberstein, 2005 ¹¹ Low	225 vs. 150	17/182	10/168	1.6 (0.7 to 3.3)	0.03 (-0.02 to 0.09)
Injection-site pain	Silberstein, 2005 ¹¹ Low	225 vs. 75	17/182	8/174	2.0 (0.9 to 4.6)	0.05 (-0.01 to 0.10)
Injection-site stinging	Silberstein, 2005 ¹¹ Low	150 vs. 75	5/168	2/174	2.6 (0.5 to 13.2)	0.02 (-0.01 to 0.05)

Appendix Table 118. Dose response adverse effects with onabotulinumtoxin A for migraine prevention in adults (results from individual randomized controlled clinical trials) (continued)

Adverse Effect	Reference Risk of Bias	Dose of Drug, Units	Events/ Randomized Larger Dose	Events/ Randomized Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Injection-site stinging	Silberstein, 2005 ¹¹ Low	225 vs. 150	3/182	5/168	0.6 (0.1 to 2.3)	-0.01 (-0.04 to 0.02)
Injection-site stinging	Silberstein, 2005 ¹¹ Low	225 vs. 75	3/182	2/174	1.4 (0.2 to 8.5)	0.00 (-0.02 to 0.03)
Pyrexia	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	0/43	0.0 (0.0 to 0.0)	0.00 (-0.04 to 0.04)
Blepharoptosis	Saper, 2007 ⁴ Low	9 vs. 6	0/49	1/45	0.3 (0.0 to 7.3)	-0.02 (-0.08 to 0.04)
Blepharoptosis	Saper, 2007 ⁴ Low	10 vs. 6	0/44	1/45	0.3 (0.0 to 8.1)	-0.02 (-0.08 to 0.04)
Blepharoptosis	Saper, 2007 ⁴ Low	10 vs. 9	0/44	0/49	0.0 (0.0 to 0.0)	0.00 (-0.04 to 0.04)
Blepharoptosis	Saper, 2007 ⁴ Low	25 vs. 10	4/49	0/44	8.1 (0.4 to 146.3)	0.08 (0.00 to 0.17)
Blepharoptosis	Saper, 2007 ⁴ Low	25 vs. 6	4/49	1/45	3.7 (0.4 to 31.7)	0.06 (-0.03 to 0.15)
Blepharoptosis	Saper, 2007 ⁴ Low	25 vs. 9	4/49	0/49	9.0 (0.5 to 162.8)	0.08 (0.00 to 0.17)
Blepharoptosis	Elkind, 2006 ⁷ Low	25 vs. 7.5	5/101	2/105	2.6 (0.5 to 13.1)	0.03 (-0.02 to 0.08)
Blepharoptosis	Elkind, 2006 ⁷ Low	50 vs. 25	8/106	5/101	1.5 (0.5 to 4.5)	0.03 (-0.04 to 0.09)
Blepharoptosis	Elkind, 2006 ⁷ 18329 Low	50 vs. 7.5	8/106	2/105	4.0 (0.9 to 18.2)	0.06 (0.00 to 0.11)
Blepharoptosis	Silberstein, 2000 ⁶ Medium	75 vs. 25	7/40	6/42	1.2 (0.5 to 3.3)	0.03 (-0.13 to 0.19)
Blepharoptosis	Relja, 2007¹⁷ Low	150 vs. 75	12/125	3/123	3.9 (1.1 to 13.6)	0.07 (0.01 to 0.13)
Blepharoptosis	Silberstein, 2005 ¹¹ Low	150 vs. 75	7/168	6/174	1.2 (0.4 to 3.5)	0.01 (-0.03 to 0.05)
Blepharoptosis	Relja, 2007 ¹⁷ Low	225 vs. 150	18/129	12/125	1.5 (0.7 to 2.9)	0.04 (-0.04 to 0.12)
Blepharoptosis	Relja, 2007¹⁷ Low	225 vs. 75	18/129	3/123	5.7 (1.7 to 18.9)	0.12 (0.05 to 0.18)
Blepharoptosis	Silberstein, 2005 ¹¹ Low	225 vs. 150	12/182	7/168	1.6 (0.6 to 3.9)	0.02 (-0.02 to 0.07)
Blepharoptosis	Silberstein, 2005 ¹¹ Low	225 vs. 75	12/182	6/174	1.9 (0.7 to 5.0)	0.03 (-0.01 to 0.08)

Appendix Table 118. Dose response adverse effects with onabotulinumtoxin A for migraine prevention in adults (results from individual randomized controlled clinical trials) (continued)

Adverse Effect	Reference Risk of Bias	Dose of Drug, Units	Events/ Randomized Larger Dose	Events/ Randomized Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Blepharoptosis	Chankrachang*, 2011 ⁸ Risk of bias Low	240 vs. 120	2/43	0/43	5.0 (0.2 to 101.2)	0.05 (-0.03 to 0.12)
Blepharoptosis	Elkind, 2006 ⁷ Low	7.5 or 50 vs. 7.5 or 25	16/180	7/173	2.2 (0.9 to 5.2)	0.05 (0.00 to 0.10)
Muscle tightness	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	2/43	0.2 (0.0 to 4.0)	-0.05 (-0.12 to 0.03)
Muscle weakness	Saper, 2007 ⁴ Low	9 vs. 6	0/49	0/45	0.0 (0.0 to 0.0)	0.00 (-0.04 to 0.04)
Muscle weakness	Saper, 2007 ⁴ Low	10 vs. 6	0/44	0/45	0.0 (0.0 to 0.0)	0.00 (-0.04 to 0.04)
Muscle weakness	Saper, 2007 ⁴ Low	10 vs. 9	0/44	0/49	0.0 (0.0 to 0.0)	0.00 (-0.04 to 0.04)
Muscle weakness	Saper, 2007⁴ Low	25 vs. 10	6/49	0/44	11.7 (0.7 to 201.9)	0.12 (0.02 to 0.22)
Muscle weakness	Saper, 2007⁴ Low	25 vs. 6	6/49	0/45	12.0 (0.7 to 206.4)	0.12 (0.02 to 0.22)
Muscle weakness	Saper, 2007⁴ Low	25 vs. 9	6/49	0/49	13.0 (0.8 to 224.7)	0.12 (0.03 to 0.22)
Muscle weakness	Relja, 2007 ¹⁷ Low	150 vs. 75	35/125	30/123	1.1 (0.8 to 1.7)	0.04 (-0.07 to 0.15)
Muscle weakness	Silberstein, 2005¹¹ Low	150 vs. 75	44/168	29/174	1.6 (1.0 to 2.4)	0.10 (0.01 to 0.18)
Muscle weakness	Relja, 2007 ¹⁷ Low	225 vs. 150	35/129	35/125	1.0 (0.7 to 1.4)	-0.01 (-0.12 to 0.10)
Muscle weakness	Relja, 2007 ¹⁷ Low	225 vs. 75	35/129	30/123	1.1 (0.7 to 1.7)	0.03 (-0.08 to 0.14)
Muscle weakness	Silberstein, 2005 ¹¹ Low	225 vs. 150	56/182	44/168	1.2 (0.8 to 1.6)	0.05 (-0.05 to 0.14)
Muscle weakness	Silberstein, 2005¹¹ Low	225 vs. 75	56/182	29/174	1.8 (1.2 to 2.7)	0.14 (0.05 to 0.23)
Musculoskeletal stiffness	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	1/43	0.3 (0.0 to 8.0)	-0.02 (-0.09 to 0.04)
Neck rigidity	Relja, 2007 ¹⁷ Low	150 vs. 75	20/125	13/123	1.5 (0.8 to 2.9)	0.05 (-0.03 to 0.14)
Neck rigidity	Silberstein, 2005 ¹¹ Low	150 vs. 75	14/168	14/174	1.0 (0.5 to 2.1)	0.00 (-0.06 to 0.06)
Neck rigidity	Relja, 2007 ¹⁷ Low	225 vs. 150	22/129	20/125	1.1 (0.6 to 1.9)	0.01 (-0.08 to 0.10)

Appendix Table 118. Dose response adverse effects with onabotulinumtoxin A for migraine prevention in adults (results from individual randomized controlled clinical trials) (continued)

Adverse Effect	Reference Risk of Bias	Dose of Drug, Units	Events/ Randomized Larger Dose	Events/ Randomized Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Neck rigidity	Relja, 2007 ¹⁷ Low	225 vs. 75	22/129	13/123	1.6 (0.9 to 3.1)	0.06 (-0.02 to 0.15)
Neck rigidity	Silberstein, 2005¹¹ Low	225 vs. 150	27/182	14/168	1.8 (1.0 to 3.3)	0.07 (0.00 to 0.13)
Neck rigidity	Silberstein, 2005¹¹ Low	225 vs. 75	27/182	14/174	1.8 (1.0 to 3.4)	0.07 (0.00 to 0.13)
Skin tightness	Relja, 2007 ¹⁷ Low	150 vs. 75	9/125	7/123	1.3 (0.5 to 3.3)	0.02 (-0.05 to 0.08)
Skin tightness	Relja, 2007 ¹⁷ Low	225 vs. 150	6/129	9/125	0.6 (0.2 to 1.8)	-0.03 (-0.08 to 0.03)
Skin tightness	Relja, 2007 ¹⁷ Low	225 vs. 75	6/129	7/123	0.8 (0.3 to 2.4)	-0.01 (-0.07 to 0.04)
Tenderness	Chankrachang*, 2011 ⁸ Low	240 vs. 120	1/43	0/43	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.09)
Diplopia	Silberstein, 2000 ⁶ Medium	75 vs. 25	2/40	0/42	5.2 (0.3 to 106.0)	0.05 (-0.03 to 0.13)
Dizziness	Relja, 2007 ¹⁷ Low	150 vs. 75	3/125	3/123	1.0 (0.2 to 4.8)	0.00 (-0.04 to 0.04)
Dizziness	Relja, 2007 ¹⁷ Low	225 vs. 150	2/129	3/125	0.6 (0.1 to 3.8)	-0.01 (-0.04 to 0.03)
Dizziness	Relja, 2007 ¹⁷ Low	225 vs. 75	2/129	3/123	0.6 (0.1 to 3.7)	-0.01 (-0.04 to 0.03)
Dizziness	Chankrachang*, 2011 ⁸ Low	240 vs. 120	1/43	2/43	0.5 (0.0 to 5.3)	-0.02 (-0.10 to 0.05)
Dizziness	Elkind, 2006 ⁷ Low	7.5 or 50 vs. 7.5 or 25	9/180	2/173	4.3 (0.9 to 19.7)	0.04 (0.00 to 0.07)
Dyskinesia	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	1/43	0.3 (0.0 to 8.0)	-0.02 (-0.09 to 0.04)
Dysphagia	Relja, 2007 ¹⁷ Low	150 vs. 75	3/125	1/123	3.0 (0.3 to 28.0)	0.02 (-0.02 to 0.05)
Dysphagia	Silberstein, 2005 ¹¹ Low	150 vs. 75	5/168	3/174	1.7 (0.4 to 7.1)	0.01 (-0.02 to 0.04)
Dysphagia	Relja, 2007 ¹⁷ Low	225 vs. 150	4/129	3/125	1.3 (0.3 to 5.7)	0.01 (-0.03 to 0.05)
Dysphagia	Relja, 2007 ¹⁷ Low	225 vs. 75	4/129	1/123	3.8 (0.4 to 33.6)	0.02 (-0.01 to 0.06)
Dysphagia	Silberstein, 2005 ¹¹ Low	225 vs. 150	11/182	5/168	2.0 (0.7 to 5.7)	0.03 (-0.01 to 0.07)

Appendix Table 118. Dose response adverse effects with onabotulinumtoxin A for migraine prevention in adults (results from individual randomized controlled clinical trials) (continued)

Adverse Effect	Reference Risk of Bias	Dose of Drug, Units	Events/ Randomized Larger Dose	Events/ Randomized Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Dysphagia	Silberstein, 2005 ¹¹ Low	225 vs. 75	11/182	3/174	3.5 (1.0 to 12.4)	0.04 (0.00 to 0.08)
Hypertonia	Relja, 2007 ¹⁷ Low	150 vs. 75	3/125	3/123	1.0 (0.2 to 4.8)	0.00 (-0.04 to 0.04)
Hypertonia	Silberstein, 2005 ¹¹ Low	150 vs. 75	15/168	13/174	1.2 (0.6 to 2.4)	0.01 (-0.04 to 0.07)
Hypertonia	Relja, 2007 ¹⁷ Low	225 vs. 150	4/129	3/125	1.3 (0.3 to 5.7)	0.01 (-0.03 to 0.05)
Hypertonia	Relja, 2007 ¹⁷ Low	225 vs. 75	4/129	3/123	1.3 (0.3 to 5.6)	0.01 (-0.03 to 0.05)
Hypertonia	Silberstein, 2005 ¹¹ Low	225 vs. 150	13/182	15/168	0.8 (0.4 to 1.6)	-0.02 (-0.07 to 0.04)
Hypertonia	Silberstein, 2005 ¹¹ Low	225 vs. 75	13/182	13/174	1.0 (0.5 to 2.0)	0.00 (-0.06 to 0.05)
Hypesthesia	Silberstein, 2005 ¹¹ Low	150 vs. 75	11/168	11/174	1.0 (0.5 to 2.3)	0.00 (-0.05 to 0.05)
Hypesthesia	Silberstein, 2005 ¹¹ Low	225 vs. 150	12/182	11/168	1.0 (0.5 to 2.2)	0.00 (-0.05 to 0.05)
Hypesthesia	Silberstein, 2005 ¹¹ Low	225 vs. 75	12/182	11/174	1.0 (0.5 to 2.3)	0.00 (-0.05 to 0.05)
Hypoesthesia	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	1/43	0.3 (0.0 to 8.0)	-0.02 (-0.09 to 0.04)
Nausea	Relja, 2007 ¹⁷ Low	150 vs. 75	2/125	1/123	2.0 (0.2 to 21.4)	0.01 (-0.02 to 0.03)
Nausea	Relja, 2007 ¹⁷ Low	225 vs. 150	4/129	2/125	1.9 (0.4 to 10.4)	0.02 (-0.02 to 0.05)
Nausea	Relja, 2007 ¹⁷ Low	225 vs. 75	4/129	1/123	3.8 (0.4 to 33.6)	0.02 (-0.01 to 0.06)
Nausea	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	1/43	0.3 (0.0 to 8.0)	-0.02 (-0.09 to 0.04)
Paresthesia	Relja, 2007 ¹⁷ Low	150 vs. 75	4/125	4/123	1.0 (0.3 to 3.8)	0.00 (-0.04 to 0.04)
Paresthesia	Relja, 2007 ¹⁷ Low	225 vs. 150	6/129	4/125	1.5 (0.4 to 5.0)	0.01 (-0.03 to 0.06)
Paresthesia	Relja, 2007 ¹⁷ Low	225 vs. 75	6/129	4/123	1.4 (0.4 to 4.9)	0.01 (-0.03 to 0.06)
Sedation	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	1/43	0.3 (0.0 to 8.0)	-0.02 (-0.09 to 0.04)

Appendix Table 118. Dose response adverse effects with onabotulinumtoxin A for migraine prevention in adults (results from individual randomized controlled clinical trials) (continued)

Adverse Effect	Reference Risk of Bias	Dose of Drug, Units	Events/ Randomized Larger Dose	Events/ Randomized Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Somnolence	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	1/43	0.3 (0.0 to 8.0)	-0.02 (-0.09 to 0.04)
Trismus	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	0/43	0.0 (0.0 to 0.0)	0.00 (-0.04 to 0.04)
Vomiting	Chankrachang*, 2011 ⁸ Low	240 vs. 120	1/43	0/43	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.09)
Arm pain	Relja, 2007 ¹⁷ Low	150 vs. 75	6/125	7/123	0.8 (0.3 to 2.4)	-0.01 (-0.06 to 0.05)
Arm pain	Relja, 2007 ¹⁷ Low	225 vs. 150	6/129	6/125	1.0 (0.3 to 2.9)	0.00 (-0.05 to 0.05)
Arm pain	Relja, 2007 ¹⁷ Low	225 vs. 75	6/129	7/123	0.8 (0.3 to 2.4)	-0.01 (-0.07 to 0.04)
Asthenia	Relja, 2007 ¹⁷ Low	150 vs. 75	3/125	4/123	0.7 (0.2 to 3.2)	-0.01 (-0.05 to 0.03)
Asthenia	Silberstein, 2005 ¹¹ Low	150 vs. 75	6/168	1/174	6.2 (0.8 to 51.1)	0.03 (0.00 to 0.06)
Asthenia	Relja, 2007 ¹⁷ Low	225 vs. 150	5/129	3/125	1.6 (0.4 to 6.6)	0.01 (-0.03 to 0.06)
Asthenia	Relja, 2007 ¹⁷ Low	225 vs. 75	5/129	4/123	1.2 (0.3 to 4.3)	0.01 (-0.04 to 0.05)
Asthenia	Silberstein, 2005 ¹¹ Low	225 vs. 150	2/182	6/168	0.3 (0.1 to 1.5)	-0.02 (-0.06 to 0.01)
Asthenia	Silberstein, 2005 ¹¹ Low	225 vs. 75	2/182	1/174	1.9 (0.2 to 20.9)	0.01 (-0.01 to 0.02)
Back pain	Silberstein, 2005 ¹¹ Low	150 vs. 75	4/168	3/174	1.4 (0.3 to 6.1)	0.01 (-0.02 to 0.04)
Back pain	Silberstein, 2005 ¹¹ Low	225 vs. 150	6/182	4/168	1.4 (0.4 to 4.8)	0.01 (-0.03 to 0.04)
Back pain	Silberstein, 2005 ¹¹ Low	225 vs. 75	6/182	3/174	1.9 (0.5 to 7.5)	0.02 (-0.02 to 0.05)
Face pain	Relja, 2007 ¹⁷ Low	150 vs. 75	6/125	4/123	1.5 (0.4 to 5.1)	0.02 (-0.03 to 0.06)
Face pain	Relja, 2007 ¹⁷ Low	225 vs. 150	4/129	6/125	0.6 (0.2 to 2.2)	-0.02 (-0.06 to 0.03)
Face pain	Relja, 2007 ¹⁷ Low	225 vs. 75	4/129	4/123	1.0 (0.2 to 3.7)	0.00 (-0.04 to 0.04)
Headache	Saper, 2007 ⁴ Low	9 vs. 6	0/49	2/45	0.2 (0.0 to 3.7)	-0.04 (-0.12 to 0.03)

Appendix Table 118. Dose response adverse effects with onabotulinumtoxin A for migraine prevention in adults (results from individual randomized controlled clinical trials) (continued)

Adverse Effect	Reference Risk of Bias	Dose of Drug, Units	Events/ Randomized Larger Dose	Events/ Randomized Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Headache	Saper, 2007 ⁴ Low	10 vs. 6	1/44	2/45	0.5 (0.0 to 5.4)	-0.02 (-0.10 to 0.05)
Headache	Saper, 2007 ⁴ Low	10 vs. 9	1/44	0/49	3.3 (0.1 to 79.8)	0.02 (-0.04 to 0.08)
Headache	Saper, 2007 ⁴ Low	25 vs. 10	3/49	1/44	2.7 (0.3 to 25.0)	0.04 (-0.04 to 0.12)
Headache	Saper, 2007 ⁴ Low	25 vs. 6	3/49	2/45	1.4 (0.2 to 7.9)	0.02 (-0.07 to 0.11)
Headache	Saper, 2007 ⁴ Low	25 vs. 9	3/49	0/49	7.0 (0.4 to 132.0)	0.06 (-0.01 to 0.14)
Headache	Elkind, 2006 ⁷ Low	25 vs. 7.5	2/101	1/105	2.1 (0.2 to 22.6)	0.01 (-0.02 to 0.04)
Headache	Elkind, 2006 ⁷ Low	50 vs. 25	8/106	2/101	3.8 (0.8 to 17.5)	0.06 (0.00 to 0.11)
Headache	Elkind, 2006⁷ Low	50 vs. 7.5	8/106	1/105	7.9 (1.0 to 62.3)	0.07 (0.01 to 0.12)
Headache	Relja, 2007 ¹⁷ Low	150 vs. 75	5/125	4/123	1.2 (0.3 to 4.5)	0.01 (-0.04 to 0.05)
Headache	Silberstein, 2005 ¹¹ Low	150 vs. 75	14/168	7/174	2.1 (0.9 to 5.0)	0.04 (-0.01 to 0.09)
Headache	Relja, 2007 ¹⁷ Low	225 vs. 150	2/129	5/125	0.4 (0.1 to 2.0)	-0.02 (-0.06 to 0.02)
Headache	Relja, 2007 ¹⁷ Low	225 vs. 75	2/129	4/123	0.5 (0.1 to 2.6)	-0.02 (-0.05 to 0.02)
Headache	Silberstein, 2005 ¹¹ Low	225 vs. 150	15/182	14/168	1.0 (0.5 to 2.0)	0.00 (-0.06 to 0.06)
Headache	Silberstein, 2005 ¹¹ Low	225 vs. 75	15/182	7/174	2.0 (0.9 to 4.9)	0.04 (-0.01 to 0.09)
Headache	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	0/43	0.0 (0.0 to 0.0)	0.00 (-0.04 to 0.04)
Headache	Elkind, 2006 ⁷ Low	7.5 or 50 vs. 7.5 or 25	10/180	8/173	1.2 (0.5 to 3.0)	0.01 (-0.04 to 0.06)
Infection site pain	Elkind, 2006 ⁷ Low	7.5 or 50 vs. 7.5 or 25	4/180	9/173	0.4 (0.1 to 1.4)	-0.03 (-0.07 to 0.01)
Malaise	Relja, 2007 ¹⁷ Low	150 vs. 75	0/125	0/123	0.0 (0.0 to 0.0)	0.00 (-0.02 to 0.02)
Malaise	Relja, 2007 ¹⁷ Low	225 vs. 150	4/129	0/125	8.7 (0.5 to 160.4)	0.03 (0.00 to 0.06)

Appendix Table 118. Dose response adverse effects with onabotulinumtoxin A for migraine prevention in adults (results from individual randomized controlled clinical trials) (continued)

Adverse Effect	Reference Risk of Bias	Dose of Drug, Units	Events/ Randomized Larger Dose	Events/ Randomized Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Malaise	Relja, 2007 ¹⁷ Low	225 vs. 75	4/129	0/123	8.6 (0.5 to 157.8)	0.03 (0.00 to 0.06)
Migraine	Relja, 2007 ¹⁷ Low	150 vs. 75	3/125	2/123	1.5 (0.3 to 8.7)	0.01 (-0.03 to 0.04)
Migraine	Silberstein, 2005 ¹¹ Low	150 vs. 75	5/168	2/174	2.6 (0.5 to 13.2)	0.02 (-0.01 to 0.05)
Migraine	Relja, 2007 ¹⁷ Low	225 vs. 150	1/129	3/125	0.3 (0.0 to 3.1)	-0.02 (-0.05 to 0.01)
Migraine	Relja, 2007 ¹⁷ Low	225 vs. 75	1/129	2/123	0.5 (0.0 to 5.2)	-0.01 (-0.04 to 0.02)
Migraine	Silberstein, 2005 ¹¹ Low	225 vs. 150	0/182	5/168	0.1 (0.0 to 1.5)	-0.03 (-0.06 to 0.00)
Migraine	Silberstein, 2005 ¹¹ Low	225 vs. 75	0/182	2/174	0.2 (0.0 to 4.0)	-0.01 (-0.03 to 0.01)
Myalgia	Relja, 2007 ¹⁷ Low	150 vs. 75	5/125	7/123	0.7 (0.2 to 2.2)	-0.02 (-0.07 to 0.04)
Myalgia	Relja, 2007 ¹⁷ Low	225 vs. 150	10/129	5/125	1.9 (0.7 to 5.5)	0.04 (-0.02 to 0.10)
Myalgia	Relja, 2007 ¹⁷ Low	225 vs. 75	10/129	7/123	1.4 (0.5 to 3.5)	0.02 (-0.04 to 0.08)
Neck pain	Relja, 2007 ¹⁷ Low	150 vs. 75	24/125	22/123	1.1 (0.6 to 1.8)	0.01 (-0.08 to 0.11)
Neck pain	Silberstein, 2005 ¹¹ Low	150 vs. 75	37/168	30/174	1.3 (0.8 to 2.0)	0.05 (-0.04 to 0.13)
Neck pain	Relja, 2007 ¹⁷ Low	225 vs. 150	30/129	24/125	1.2 (0.8 to 2.0)	0.04 (-0.06 to 0.14)
Neck pain	Relja, 2007 ¹⁷ Low	225 vs. 75	30/129	22/123	1.3 (0.8 to 2.1)	0.05 (-0.05 to 0.15)
Neck pain	Silberstein, 2005 ¹¹ Low	225 vs. 150	41/182	37/168	1.0 (0.7 to 1.5)	0.01 (-0.08 to 0.09)
Neck pain	Silberstein, 2005 ¹¹ Low	225 vs. 75	41/182	30/174	1.3 (0.9 to 2.0)	0.05 (-0.03 to 0.14)
Neck pain	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	2/43	0.2 (0.0 to 4.0)	-0.05 (-0.12 to 0.03)
Pain	Relja, 2007 ¹⁷ Low	150 vs. 75	3/125	3/123	1.0 (0.2 to 4.8)	0.00 (-0.04 to 0.04)
Pain	Relja, 2007 ¹⁷ Low	225 vs. 150	5/129	3/125	1.6 (0.4 to 6.6)	0.01 (-0.03 to 0.06)

Appendix Table 118. Dose response adverse effects with onabotulinumtoxin A for migraine prevention in adults (results from individual randomized controlled clinical trials) (continued)

Adverse Effect	Reference Risk of Bias	Dose of Drug, Units	Events/ Randomized Larger Dose	Events/ Randomized Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Pain	Relja, 2007 ¹⁷ Low	225 vs. 75	5/129	3/123	1.6 (0.4 to 6.5)	0.01 (-0.03 to 0.06)
Pain	Elkind, 2006 ⁷ Low	7.5 or 50 vs. 7.5 or 25	14/180	13/173	1.0 (0.5 to 2.1)	0.00 (-0.05 to 0.06)
Radicular pain	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	1/43	0.3 (0.0 to 8.0)	-0.02 (-0.09 to 0.04)
Shoulder / arm pain	Silberstein, 2005 ¹¹ Low	150 vs. 75	11/168	8/174	1.4 (0.6 to 3.5)	0.02 (-0.03 to 0.07)
Shoulder / arm pain	Silberstein, 2005 ¹¹ Low	225 vs. 150	12/182	11/168	1.0 (0.5 to 2.2)	0.00 (-0.05 to 0.05)
Shoulder / arm pain	Silberstein, 2005 ¹¹ Low	225 vs. 75	12/182	8/174	1.4 (0.6 to 3.4)	0.02 (-0.03 to 0.07)
Tension headache	Chankrachang*, 2011 ⁸ Low	240 vs. 120	0/43	1/43	0.3 (0.0 to 8.0)	-0.02 (-0.09 to 0.04)

CI = confidence interval

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

* trials of abobotulinumtoxinA

Appendix Table D119. Randomized controlled clinical trials that examined adverse effects with topiramate vs. placebo

Reference	Country where Study was Conducted	Total Sample [Number Analyzed] % Females	Age	Definition of Migraine	Presence of Aura	Duration of Migraine	Migraine Frequency/ Month	Baseline Comorbidity
Storey, 2001 ¹⁸	Not reported	40 [Not reported] 97.5% female	Mean 38.2 years	International Headache Society (IHS) criteria	Not reported	Not reported	4.7	Not reported
Edwards, 2003 ¹⁹	Previously reported	70 [70] 97.1% female	Mean 41.1 years	International Headache Society criteria	Not reported	Not reported	4.5	Not reported
Silvestrini, 2003 ²⁰	Italy	28 [28] 64.3% female	Mean 43.5 years	International Headache Society criteria	All patients had a history of migraine without aura attacks as inclusion criterion	3 years	20	Not reported
Brandes, 2004 ²²	North America	483 [468] 86.8% female	Mean 38.9 years	International Headache Society criteria	Not reported	At least 6 months	5.5	Not reported
Silberstein, 2004 ²³	USA	487 [469] 89.1% female	Mean 40.4 years	International Headache Society criteria	Not reported	Not reported	5.5	Not reported
Mei, 2004 ²⁴	Italy	115 [72] 54.2% female	Mean 39.2 years	International Headache Society (1988) criteria	Patients with migraine without aura, n (%): Topiramate: 27 (77), Placebo: 31 (84)	Not reported	5.5	Not reported
Bussone, 2005 ²⁵	Not reported (Pooled analysis)	758 [756] 84.3% female	Mean 39.8 years	International Headache Society criteria	Not reported	Not reported	5.4	Not reported
Silberstein, 2006 ²⁷	USA	469 (ITT population). Number randomized not given [469] 88.7% female	Mean 40.4 years	International Headache Society criteria	Not reported	Not reported	5.5	Not reported

Appendix Table 119. Randomized controlled clinical trials that examined adverse effects with topiramate versus placebo (continued)

Reference	Country where Study was Conducted	Total Sample [Number Analyzed] % Females	Age	Definition of Migraine	Presence of Aura	Duration of Migraine	Migraine Frequency/ Month	Baseline Comorbidity
Mei, 2006 ²⁸	Italy	50 [35] 68.6% female	Mean 45.9 years	International Classification of Headache Disorders 2nd Edition	Not reported	4.97 years	Not reported	Not reported
Silberstein, 2006 ²⁹	USA	213 [Variable] 85.8% female	Mean 40.5 years	International Headache Society criteria	75 subjects had migraine with aura	Not reported	4.9	Not reported
Brandes, 2006 ³⁰	USA	483 [468] 86.8% female	Mean 38.9 years	International Headache Society criteria for migraine with or without aura	Not reported	At least 6 months	5.5	Not reported
Silberstein, 2007 ³¹	USA	328 [Variable] 85.3% female	Mean 38.2 years	International Headache Society 1.1 or 1.2	Not reported	Duration:9.2 years; Age at onset (years): 19.7	Not reported	Not reported
Diener, 2007 ³⁴	Not reported	59 [59] 74.5% female	Mean 46 years	Second edition of The International Classification of Headache Disorders criteria	Not reported	At least 1 year	Not reported	Beck Depression Inventory, mean (SD): Placebo: 13.4 (8.8), Topiramate: 9.0 (7.0)
Lainez, 2007 ³⁵	Not reported	774 [758] 84.4% female	Mean 39.9 years	International Headache Society criteria	Not reported	Not reported	Not reported	Not reported
Diener, 2007 ³⁸	21 countries in Europe	818 in open-label phase and 514 in the double-blind phase [Not reported] 89.0% female	Mean 40.1 years	International Headache Society criteria	Not reported	Not reported	8.7	Not reported
Adelman, 2008 ⁴⁰	USA, Australia, Canada, Denmark, Finland,	1580 [1580] 85.0% female	Mean 40.1 years	International Headache Society criteria	Not reported	Not reported	Not reported	Not reported

Appendix Table 119. Randomized controlled clinical trials that examined adverse effects with topiramate versus placebo (continued)

Reference	Country where Study was Conducted	Total Sample [Number Analyzed] % Females	Age	Definition of Migraine	Presence of Aura	Duration of Migraine	Migraine Frequency/ Month	Baseline Comorbidity
	France, Germany, Italy, Korea, the Netherlands, South Africa, Spain, Sweden, Taiwan, and the United Kingdom							
Silberstein, 2009 ⁴¹	USA	328 [321] 85.3% female	Mean 38.2 years	International Headache Society 1.1 or 1.2	Not reported	Duration:9.2 years; Age at onset (years): 19.7	Not reported	Not reported
Lipton, 2011 ⁴²	Not reported	385 [Variable] 10.9% female	Mean 40.3 years	International Headache Society criteria 1.1,1.2	Not reported	Age at migraine onset (years): 20.3	Not reported	Not reported

SD = Standard deviation

Appendix Table D120. Funding and conflict of interest in randomized controlled clinical trials that examined adverse effects with topiramate vs. placebo

Reference	Funding	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests-Relationship
Storey, 2001 ¹⁸	Industry	Yes	Yes	Not reported	Not applicable
Edwards, 2003 ¹⁹	Industry	Yes	Yes	Yes	Ms. Potter is on the Speakers' Bureau for biogen, GlaxoSmithKline and Ortho-McNeil Pharmaceutical, Inc, and has received funding from Biogen, Ortho-McNeil Pharmaceutical, Inc, Pfizer Inc, Wyeth Pharmaceuticals for previous research
Silvestrini, 2003 ²⁰	Not reported	Yes	Yes	Not reported	Not applicable
Brandes, 2004 ²²	Industry	Yes	Yes	Yes	Dr. Brandes has received grants or research support from Merck, GlaxoSmithKline, Allergan, UCB Pharma, Johnson & Johnson, AstraZeneca, Pfizer, Bristol Myers-Squibb, Winston Laboratories, Forest Laboratories, Sanofi-Synthelabo, and Elan Pharmaceuticals; has served on the speakers bureau for GlaxoSmithKline, AstraZeneca, Merck, Allergan, Pfizer, Pharmacia, Ortho-McNeil, and UCB Pharma; has served as a consultant to Merck, GlaxoSmithKline, Pfizer, AstraZeneca, Allergan, and Ortho-McNeil; and has received educational funding from GlaxoSmithKline. Dr Saper has received research grants from GlaxoSmithKline, AstraZeneca, Merck, Abbott, Allergan, Elan, Pfizer, Ortho-McNeil, and Novartis; has served on advisory boards or as a consultant for AstraZeneca, GlaxoSmithKline, Allergan, Ortho-McNeil, and Medtronic; and has served on the speakers bureau for GlaxoSmithKline, Merck, AstraZeneca, Ortho-McNeil, Pfizer, and Xcel. Dr Diamond has served as a speaker, consultant, or both or has conducted research for AstraZeneca, Bristol-Myers Squibb, Ortho-McNeil, Elan, GlaxoSmithKline, Merck, and Pfizer. Dr Couch has participated in research for, been an advisory board member of, and served as a speaker for Ortho-McNeil.
Silberstein, 2004 ²³	Industry	Yes	Yes	Yes	Silberstein is on the advisory panel of, speakers bureau of, or serves as a consultant for Abbott Laboratories, Allergan, Inc, AstraZeneca, Elan Pharmaceutical Research Corp, Eli Lilly, Ortho-McNeil Pharmaceutical, Merck & Co, and GlaxoSmithKline; receives research support from Allergan, Inc, AstraZeneca, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, Merck & Co, Ortho-McNeil Pharmaceutical, Pfizer, Inc, UCB Pharma, and Vernalis; and has received educational grants from Abbott Laboratories, Allergan, Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck & Co, Ortho-McNeil Pharmaceutical, and Parke-Davis. Drs Neto and Jacobs and Ms Schmitt hold shares in Johnson & Johnson Pharmaceutical Research and Development, LLC, a subsidiary of Johnson & Johnson Corporation.
Mei, 2004 ²⁴	Not reported	Yes	Yes	Not reported	Not applicable

Appendix Table 120. Funding and conflict of interest in randomized controlled clinical trials that examined adverse effects with topiramate versus placebo (continued)

Reference	Funding	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests-Relationship
Bussone, 2005 ²⁵	Not reported	Yes	Yes	Not reported	Not applicable
Silberstein, 2006 ²⁷	Industry	Yes	Yes	Yes	George Papadopoulos is from Johnson and Johnson Pharmaceutical Services, LLC, Raritan, NJ, USA and Steven Greenberg from Ortho-McNeil Neurologics, Titusville, NJ, USA. Personnel of Pharmaceutical Research and Development, Ortho-McNeil Neurologics, Inc, Titusville, New Jersey, and Phase Five Communications, New York, New York, contributed to the preparation of the manuscript
Mei, 2006 ²⁸	Not reported	Yes	Yes	Not reported	Not applicable
Silberstein, 2006 ²⁹	Industry	Yes	Yes	Not reported	Not applicable
Brandes, 2006 ³⁰	Industry	Yes	Yes	Yes	Dr. Brandes has received grants or research support from Merck & Co, Inc, GlaxoSmithKline, UCB Pharma, Allergan Inc, Johnson & Johnson, AstraZeneca Pharmaceuticals LP, Pfizer Inc, Bristol-Meyers Squibb, Winston Laboratories, Sanofi-Aventis, Elan Pharmaceuticals, Inc, Novartis, Endo Pharmaceuticals, Pozen, Vernalis, Ortho-McNeil, and Advanced Bionics; has served on the speaker's bureau for GlaxoSmith-Kline, AstraZeneca Pharmaceuticals LP, Pfizer Inc, Merck & Co, Inc, Ortho-McNeil, Allergan Inc, MedPointe Pharmaceuticals, Endo Pharmaceuticals, UCB Pharma; has served as a consultant to Merck & Co, Inc, GlaxoSmithKline, Pfizer Inc, AstraZeneca Pharmaceuticals LP, Allergan Inc, Ortho-McNeil, and Aradigm Corp; and has received an educational grant from GlaxoSmithKline. Dr Kudrow has been on a speaker's bureau of GlaxoSmithKline and Ortho-McNeil and has received grant and research support from Ortho-McNeil, GlaxoSmithKline, Pozen, Merck & Co, Inc, and Eisai Inc. Dr Fairclough received financial support as a consultant to perform analyses of the data in this study. Drs Rupnow and Greenberg are fulltime employees of Johnson & Johnson. Dr Rothrock has served as a paid consultant to Ortho-McNeil, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, Pozen, and Allergan Inc; has received research support from those companies and from Abbott Laboratories, Elan Corporation, Eisai Inc, and AstraZeneca Pharmaceuticals LP; and has received honoraria for lecturing from Ortho-McNeil, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, Elan Corporation, and Endo Pharmaceuticals.
Silberstein, 2007 ³¹	Industry	Yes	Yes	Yes	Dr. Silberstein has received personal compensation for activities with: GlaxoSmith-Kline, Inc., Johnson & Johnson, Merck & Co., Inc., UCB Pharma, AstraZeneca Pharmaceuticals, Inc., Pfizer, Inc., Allergan, Inc., Pozen, Inc., Abbott Laboratories, Inc., Eli Lilly & Company, NPS, and Xcel

Appendix Table 120. Funding and conflict of interest in randomized controlled clinical trials that examined adverse effects with topiramate versus placebo (continued)

Reference	Funding	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests-Relationship
					<p>Pharmaceuticals; has received personal compensation in an editorial capacity for CurrentPain and Headache; and has received financial support for scholarly activities from GlaxoSmithKline, Inc., Johnson & Johnson, Merck&Co., Inc., Pfizer, Inc., Allergan, Inc., and Abbott Laboratories, Inc. Dr. Lipton has consulted for, conducted studies funded by, or received lecture honoraria from Allergan, Inc., Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, Ortho-McNeil, Pfizer, Pozen, among other companies. Dr. Dodick has received personal compensation for activities with Allergan, Inc., GlaxoSmith-Kline, Inc., Pfizer, Inc., Endo Pharmaceuticals, Ortho-McNeil Pharmaceutical, Inc., Merck & Co., Inc., Medtronic, Neuralieve; has received personal compensation in an editorial capacity for Headache Currents; and has received research support from St. Jude, Allergan, Inc., Medtronic, Inc., National Institutes of Health, Mayo Clinic College of Medicine, and Advanced Bionics. Dr. Freitag has received personal compensation for activities with Allergan, Inc., AstraZeneca Pharmaceuticals, Inc., Merck & Co., Inc., Ortho-McNeil Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Pfizer, Inc., and GlaxoSmithKline, Inc., and has received research support from Alzyer, AstraZeneca Pharmaceuticals, Inc., GlaxoSmithKline, Inc., Merck & Co., Inc., Ortho-McNeil Pharmaceuticals, Inc., Precision, Division of Boston Scientific, Solvay S.A., and Vernalis. Dr. Ramadan has received personal compensation for activities with GlaxoSmithKline, Inc., Ortho-McNeil Neurologics, Inc., Eli Lilly & Company, Eisai, Inc., AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company, Pfizer, Inc., Merck & Co., Inc., Aradigm Corp., Boehringer Ingelheim Pharmaceuticals and Map Pharmaceuticals; has received personal compensation in an editorial capacity for Web Alert; and has received research support from Ortho-McNeil Neurologics, Eli Lilly&Company, Pfizer, Inc., and the National Headache Ambassador Program. Dr. Mathew has received personal compensation for activities with Eisai. Dr. Brandes has received grants or research support from Merck, GlaxoSmithKline, UCB Pharma, Allergan, Johnson & Johnson, AstraZeneca, Pfizer, Bristol-Myers Squibb, Winston Laboratories, Sanofi-Aventis, Elan Pharmaceuticals, Novartis, Endo, Pozen, Inc., Vernalis, Ortho-McNeil, Advanced Bionics; has served on the speakers bureau for GlaxoSmithKline, AstraZeneca, Pfizer, Merck, Ortho-McNeil, Allergan, MedPointe Pharmaceuticals, Endo, UCB Pharma; has served as a consultant to Merck, GlaxoSmith-Kline, Pfizer, AstraZeneca, Allergan, Ortho-McNeil, Aradigm Corporation; and has received educational funding from GlaxoSmithKline. Dr. Bigal has received personal compensation for activities from Allergan, Boehringer Ingelheim, GlaxoSmithKline, Merck, Ortho-McNeil,</p>

Appendix Table 120. Funding and conflict of interest in randomized controlled clinical trials that examined adverse effects with topiramate versus placebo (continued)

Reference	Funding	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests-Relationship
					UCB, AstraZeneca, Pfizer, Inc., and Advance PCS and has received research support from Allergan, Boehringer Ingelheim, GlaxoSmithKline, Merck, Ortho-McNeil, Pfizer, UCB, AstraZeneca, and Advance PCS. Dr. Saper has received honoraria for speaking from GlaxoSmithKline, Merck & Co., Inc., Abbott Laboratories, Inc., Elan Corporation, AstraZeneca Pharmaceuticals, Pfizer, Inc., Ortho-McNeil Pharmaceuticals, Bristol-Myers Squibb, Medtronic, Inc., Endo Pharmaceuticals, Advanced Bionics, Pozen, Inc., and Penwest Pharmaceuticals Co; has received personal compensation in an editorial capacity for Pain Watch and Migraine Monitor; holds stock in Pozen, Inc.; and has received research support from Novartis, Ortho-McNeil Pharmaceuticals, Merck & Co., Inc., GlaxoSmithKline, Allergan, Inc., Eisai, Inc., AstraZeneca Pharmaceuticals, Abbott, Advanced Bionics, Medtronic, Renovis, and Pozen, Inc. Dr. Ascher is an employee of Ortho-McNeil Janssen Scientific Affairs, LLC. Dr. Jordan is an employee of PriCara, a Unit of Ortho-McNeil, Inc. Drs. Greenberg and Joseph Hulihan are employees of Ortho-McNeil Neurologics.
Diener, 2007 ³⁴	Industry	Not reported	Not reported	Yes	JC Van Oene, M Lahaye and S Schwalen are employees of Janssen-Cilag
Lainez, 2007 ³⁵	Not reported	Yes	Yes	Yes	Miguel JA La´inez has received personal compensation or research support from activities with Allergan, Inc., Almirall SA, GlaxoSmithKline, Inc Jansen Cilag, Inc., Menarini, Merck & Co., Inc, Medtronic and Pfizer Inc. Frederick Freitag has received personal compensation for activities with Allergan, Inc., AstraZeneca Pharmaceuticals,., Ortho-McNeil Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Pfizer Inc, and GlaxoSmithKline, Inc. Dr. Freitag has received research support from Alzyer, AstraZeneca Pharmaceuticals, GlaxoSmithKline, Inc., Merck & Co., Inc., Ortho-McNeil Pharmaceuticals, Inc., Advanced Bionics, Solvay S.A., and Vernalis. Joop Pfeil is a paid consultant for Janssen Pharmaceutical/J & J, Novartis, Sanofi-Aventis, Pfizer, Schering-Plough, Numico, Vitatron, Actelion Pharmaceuticals and Sankyo. S. Ascher is a full-time employee of Ortho-McNeil Janssen Pharmaceutical. W.H. Olson is a full-time employee of Ortho-McNeil Janssen Pharmaceutical. S. Schwalen is a full-time employee of Janssen-Cilag GmbH.
Diener, 2007 ³⁸	Industry	Yes	Yes	Yes	Hans-Christoph Diener, Reto Agosti, Gianni Allais, Gennaro Bussone, Brendan Davies, Michel Lanteri-Minet, Mustafa Ertas, Uwe Reuter, Margarita Sanchez Del Rio, and Jean Schoenen have participated in clinical trials and advisory boards for Janssen-Cilag. Paul Bergmans, Susanne Schwalen, Joop van Oene are employees of Janssen-Cilag EMEA (Europe, Middle East, and Africa). Hans-Christoph Diener has received honoraria from Addex Pharmaceuticals, Allergan, Almirall, AstraZeneca, Bayer Vital, Berlin Chemie, CoLucid Pharmaceuticals, Böhringer Ingelheim, Bristol-Myers Squibb,

Appendix Table 120. Funding and conflict of interest in randomized controlled clinical trials that examined adverse effects with topiramate versus placebo (continued)

Reference	Funding	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests-Relationship
					GlaxoSmithKline, Grünenthal, Janssen-Cilag, Eli Lilly, F Hoffmann-La Roche, 3M Medica, Merck Sharp and Dohme, Novartis Pharmaceuticals, Johnson and Johnson, Pierre Fabre, Pfizer, Schaper and Brümmer, Sanofi-Aventis, and Weber and Weber, and financial support for research projects from Allergan, Almirall, AstraZeneca, Bayer, GlaxoSmithKline, Janssen-Cilag, and Pfizer.
Adelman, 2008 ⁴⁰	Industry	Yes	Yes	Yes	James Adelman: Clinical Trials 1998–2006 (Ortho-McNeil Pharmaceuticals), Advisory Boards (Ortho-McNeil Pharmaceuticals), Speaker (Ortho-McNeil Pharmaceuticals); Frederick Freitag: Consultant, honoraria recipient (OrthoMcNeil Pharmaceuticals and Ortho-McNeil Neurologics), research grant recipient (Johnson and Johnson Pharmaceuticals, Ortho-McNeil Pharmaceuticals, and Ortho-McNeil Neurologics); Miguel Lainez: grant/research recipient, consultant/scientific advisor, honoraria recipient (Allergan, Almirall Prodesfarma, Boehringer Ingelheim, Bristol-Myers Squibb, Elan Pharmaceuticals, GlaxoSmithKline, Janssen Cilag, Johnson and Johnson, MSD, Novartis, Pierre Fabre, and Sanofi-Synthelabo).
Silberstein, 2009 ⁴¹	Industry	Yes	Yes	Yes	Stephen Silberstein has received personal compensation for activities with: Johnson & Johnson, GlaxoSmith-Kline, Merck, UCB Pharma, AstraZeneca, Pfizer, Allergan, Pozen, Abbott Laboratories., Eli Lilly & Company, NPS, and Xcel Pharmaceuticals; has received personal compensation in an editorial capacity for Current Pain and Headache; and has received financial support for scholarly activities from GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, Allergan, and Abbott Laboratories. Richard B. Lipton has consulted for, conducted studies funded by, or received lecture honoraria from Allergan, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, Ortho-McNeill, Pfizer, and Pozen, among other companies. David W. Dodick has served as a consultant for GlaxoSmithKline, Merck, Allergan, Endo, Pfizer, Eli Lilly, Addex, Solvay, and Neuralieve and has received research support from Advanced Neurostimulation Systems, Medtronic, and St. Jude. Fred Freitag has received grants and research support from Advanced Bionics Corporation, Alzyer, AstraZeneca, CAPNIA, GlaxoSmithKline, Johnson & Johnson, Merck, Ortho-McNeil Pharmaceutical, Ortho-McNeil Neurologics, Solvay, and Vernalis Pharmaceuticals. He has served as a consultant for Allergan, AstraZeneca, CAPNIA, Endo Pharmaceuticals, Merck, Ortho-McNeil Pharmaceutical, Ortho-McNeil Neurologics, and Valeant Pharmaceuticals International. He has served on the speaker's bureaus of AstraZeneca, GlaxoSmithKline, Merck, Ortho-McNeil Pharmaceutical, Ortho-McNeil Neurologics, Pfizer, and Valeant Pharmaceuticals International. Ninan Mathew has received personal compensation for activities involving continuing medical education and for advisory board participation from Ortho McNeil, Merck, Allergan,

Appendix Table 120. Funding and conflict of interest in randomized controlled clinical trials that examined adverse effects with topiramate versus placebo (continued)

Reference	Funding	Ethical Approval of Study	Consent of Participants	Conflict of Interest	Conflict of Interests-Relationship
					GlaxoSmithKline, Endo, and Valiant. Jan Brandes has received grants, research support, or served as a consultant to Merck, GlaxoSmithKline, UCB Pharma, Pfizer, Allergan, Johnson & Johnson, AstraZeneca, Bristol-Myers Squibb, Winston Laboratories, Sanofi-Aventis, Elan, Novartis, Endo, Pozen, Vernalis, Ortho-McNeil, Advanced Bionics, MedPointe, and Aradigm. Marcelo E. Bigal is a full-time employee of Merck Research Laboratories. This manuscript was written during his tenure at the Albert Einstein College of Medicine. He has received, in the past, compensation from Ortho-McNeil Pharmaceutical, AstraZeneca, GlaxoSmithKline, Merck, Allergan, MAP, NMT, and Endo, among other pharmaceutical companies. Steve Ascher, Jacqueline D. Morein, and Pamela Wright are employees of Ortho-McNeil Janssen Scientific Affairs, LLC. Steven J. Greenberg is an employee of EMD Serono Inc.
Lipton, 2011 ⁴²	Industry	Yes	Yes	Yes	Not reported, however, David Biondi, Steven Ascher, William Olson and Joseph Hulihan were from Ortho-McNeil Janssen Scientific Affairs, USA

Appendix Table D121. Risk of bias in randomized controlled clinical trials that examined adverse effects with topiramate vs. placebo

Reference	Masking of the Treatment Status	Intention to Treat Analysis	Allocation Concealment	Adequacy of Randomization	Selective Outcome Reporting	Risk of Bias
Storey, 2001 ¹⁸	Double-blind	No	Unclear	Yes (Topiramate group had no men and higher number of patients with concurrent preventative treatment), but the differences were not significant	Unclear	Low
Edwards, 2003 ¹⁹	Double-blind	Yes	Unclear	Unclear	Unclear	Low
Silvestrini, 2003 ²⁰	Double-blind	No	Unclear	Yes	Unclear	Low
Brandes, 2004 ²²	Double-blind	Yes	Clearly adequate	Yes	Unclear	Low
Silberstein, 2004 ²³	Double-blind	Yes	Unclear	Yes	Unclear	Low
Mei, 2004 ²⁴	Double-blind	No	Unclear	Unclear	Unclear	Medium
Bussone, 2005 ²⁵	Double-blind	Yes	Unclear	Yes	Unclear	Low
Silberstein, 2006 ²⁷	Double-blind	Yes	Unclear	Not adequate. Topiramate 200mg/day group has lower % of women and higher % of men as compared to other groups, but the differences were not significant (previously reported)	Unclear	Medium
Mei, 2006 ²⁸	Double-blind	Yes	Unclear	Yes	Unclear	Low
Silberstein, 2006 ²⁹	Double-blind	Yes	Unclear	Not reported	Unclear	Medium
Brandes, 2006 ³⁰	Double-blind	Yes	Clearly adequate	Not adequate; the % of male patients was much lower in the topiramate 100mg and 200mg groups, but the difference was not significant	Unclear	Medium
Brandes, 2006 ³⁰	Double-blind	Yes	Unclear	Yes	Unclear	Low
Diener, 2007 ³⁴	Double-blind	Yes	Unclear	Not adequate (Mean Beck Depression Inventory scores were higher in placebo as compared to topiramate), but the differences were not significant	Unclear	Medium
Lainez, 2007 ³⁵	Double-blind	No	Unclear	Yes	Unclear	Low
Diener, 2007 ³⁸	Double-blind	Yes	Unclear	Yes	Unclear	Medium
Adelman, 2008 ⁴⁰	Double-blind	No	Unclear	Yes	Unclear	Low
Silberstein, 2009 ⁴¹	Double-blind	Yes	Clearly adequate	Yes	Unclear	Low
Lipton, 2011 ⁴²	Double-blind	Yes	Unclear	Yes	The study mentions the significance of the outcome: $\geq 50\%$ and 75% reduction in headache days and migraine headache days, however, the results are not given	Low

Appendix Table D122. Treatment discontinuation due to adverse effects with approved drugs vs. placebo (pooled with random effects models results from randomized controlled clinical trials)

Active Drug	Author, Year	Events/ Randomized with Drug	Events/ Randomized with Placebo	Relative Risk (95% CI)	Relative Risk Weight (Inverse Variance)	Absolute Risk Difference (95% CI)	Absolute Risk Difference Weight (Inverse Variance)	Arcsine Transformed Risk Difference (95% CI)	Arcsine Transformed Risk Difference Weight
Topiramate	Silberstein, 2006 ²⁹	21/140	4/73	2.7 (1.0 to 7.7)	8.11	0.10 (0.02 to 0.17)	13.26	0.16 (0.02 to 0.30)	13.19
Topiramate	Silberstein, 2007 ³¹	18/165	10/163	1.8 (0.8 to 3.7)	14.16	0.05 (-0.01 to 0.11)	16.09	0.09 (-0.02 to 0.20)	16.26
Topiramate	Gupta, 2007 ⁴⁴	3/60	3/60	1.0 (0.2 to 4.8)	3.78	0.00 (-0.08 to 0.08)	13.39	0.00 (-0.18 to 0.18)	10.36
Topiramate	Lainez, 2007 ³⁵	96/391	41/383	2.3 (1.6 to 3.2)	38.96	0.14 (0.09 to 0.19)	17.29	0.19 (0.12 to 0.26)	20.05
Topiramate	Lipton, 2011 ⁴²	21/188	18/197	1.2 (0.7 to 2.2)	19.75	0.02 (-0.04 to 0.08)	16.06	0.03 (-0.07 to 0.13)	17.09
Topiramate	Mei, 2004 ²⁴	3/58	2/57	1.5 (0.3 to 8.5)	3.03	0.02 (-0.06 to 0.09)	13.92	0.04 (-0.14 to 0.22)	10.11
Topiramate	Mei, 2006 ²⁸	9/30	6/20	1.0 (0.4 to 2.4)	11.01	0.00 (-0.26 to 0.26)	2.59	0.00 (-0.28 to 0.28)	5.58
Topiramate	Edwards, 2003 ¹⁹	6/34	0/36	13.7 (0.8 to 235.0)	1.19	0.18 (0.04 to 0.31)	7.4	0.43 (0.20 to 0.67)	7.36
Topiramate	Pooled	177/1066	84/989	1.8 (1.3 to 2.4)	100	0.06 (0.02 to 0.11)	100	0.11 (0.04 to 0.19)	100
Divalproex	Mathew, 1995 ⁴⁵	9/70	2/37	2.4 (0.5 to 10.4)	27.42	0.08 (-0.03 to 0.18)	36.56	0.13 (-0.07 to 0.33)	34.55
Divalproex	Freitag, 2002 ⁴⁶	10/237	10/204	0.9 (0.4 to 2.2)	72.58	-0.01 (-0.08 to 0.07)	63.44	-0.01 (-0.14 to 0.12)	65.45
Divalproex	Pooled	19/307	12/241	1.2 (0.5 to 2.7)	100	0.02 (-0.05 to 0.10)	100	0.04 (-0.09 to 0.17)	100
Valproate	Hering, 1992 ⁴⁸	1/32	2/32	0.5 (0.0 to 5.2)	32.86	-0.03 (-0.14 to 0.07)	51.79	-0.08 (-0.32 to 0.17)	42.88
Valproate	Jensen, 1994 ⁴⁹	4/43	2/43	2.0 (0.4 to 10.4)	67.14	0.05 (-0.06 to 0.15)	48.21	0.09 (-0.12 to 0.30)	57.12
Valproate	Pooled	5/75	4/75	1.3 (0.3 to 4.9)	100	0.01 (-0.07 to 0.08)	100	0.02 (-0.14 to 0.18)	100
Propranolol	Diamond, 1976 ⁵⁰	6/83	1/83	6.0 (0.7 to 48.8)	28.76	0.06 (0.00 to 0.12)	93.42	0.16 (0.01 to 0.31)	75.42
Propranolol	Pradalier, 1989 ⁵³	9/31	5/24	1.4 (0.5 to 3.6)	71.24	0.08 (-0.15 to 0.31)	6.58	0.10 (-0.17 to 0.36)	24.58

Appendix Table D122. Treatment discontinuation due to adverse effects with approved drugs vs. placebo (pooled with random effects models results from randomized controlled clinical trials) (continued)

Active Drug	Author, Year	Events/ Randomized with Drug	Events/ Randomized with Placebo	Relative Risk (95% CI)	Relative Risk Weight (Inverse Variance)	Absolute Risk Difference (95% CI)	Absolute Risk Difference Weight (Inverse Variance)	Arcsine Transformed Risk Difference (95% CI)	Arcsine Transformed Risk Difference Weight
Propranolol	Pooled	15/114	6/107	2.1 (0.6 to 7.7)	100	0.06 (0.00 to 0.12)	100	0.15 (0.01 to 0.28)	100
Active drug	Heterogeneity statistics		Degree of freedom	P value Relative risk	I squared Relative risk	P value Absolute risk different	I squared Absolute risk difference	P value, arcsine transformed risk difference	I squared, arcsine transformed risk difference
Topiramate			7	0.291	17.60%	0.014	60.30%	0.018	58.40%
Divalproex			1	0.286	12.00%	0.224	32.30%	0.242	26.90%
Valproate			1	0.343	0.00%	0.306	4.60%	0.31	2.90%
Propranolol			1	0.214	35.30%	0.857	0.00%	0.668	0.00%

CI = confidence interval

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

Appendix Table D123. Treatment discontinuation due to specific adverse effects with topiramate vs. placebo, pooled with random effects model results from individual randomized controlled clinical trials

Adverse Effect Leading to Treatment Discontinuation	Author, Year	Events/Randomized with Drug	Events/Randomized with Placebo	Relative Risk (95% CI)	Relative Risk Weight (Inverse Variance)	Absolute Risk Difference (95% CI)	Absolute Risk Difference Weight (Inverse Variance)	Arcsine Transformed Risk Difference (95% CI)	Arcsine Transformed Risk Difference Weight
Cognitive difficulties	Lainez, 2007 ³⁵	28/391	8/383	3.4 (1.6 to 7.4)	56.75	0.05 (0.02 to 0.08)	49.71	0.13 (0.06 to 0.20)	40.3
Cognitive difficulties	Mei, 2004 ²⁴	7/58	0/57	14.7 (0.9 to 252.3)	23.12	0.12 (0.03 to 0.21)	29.13	0.36 (0.17 to 0.54)	33.48
Cognitive difficulties	Mei, 2006 ²⁸	0/30	1/20	0.2 (0.0 to 5.3)	20.13	-0.05 (-0.17 to 0.07)	21.16	-0.23 (-0.51 to 0.06)	26.21
Cognitive difficulties	Pooled	35/479	9/460	2.8 (0.5 to 15.3)	100	0.05 (-0.02 to 0.12)	100	0.11 (-0.13 to 0.35)	100
Difficulty with memory	Adelman, 2008 ⁴⁰	9/514	1/202	3.5 (0.4 to 27.6)	59.83	0.01 (0.00 to 0.03)	96.19	0.05 (-0.03 to 0.13)	62.52
Difficulty with memory	Mei, 2006 ²⁸	0/30	1/20	0.2 (0.0 to 5.3)	40.17	-0.05 (-0.17 to 0.07)	3.81	-0.23 (-0.51 to 0.06)	37.48
Difficulty with memory	Pooled	9/544	2/222	1.2 (0.1 to 16.3)	100	0.01 (-0.01 to 0.03)	100	-0.05 (-0.32 to 0.21)	100
Dizziness	Lainez, 2007 ³⁵	8/391	6/383	1.3 (0.5 to 3.7)	69.8	0.01 (-0.01 to 0.02)	74.65	0.02 (-0.05 to 0.09)	58.46
Dizziness	Mei, 2006 ²⁸	0/30	2/20	0.1 (0.0 to 2.7)	30.2	-0.10 (-0.25 to 0.05)	25.35	-0.32 (-0.61 to -0.04)	41.54
Dizziness	Pooled	8/421	8/403	0.7 (0.1 to 5.1)	100	-0.02 (-0.11 to 0.07)	100	-0.12 (-0.45 to 0.21)	100
Fatigue	Lainez, 2007 ³⁵	18/391	3/383	5.9 (1.7 to 19.8)	66.18	0.04 (0.02 to 0.06)	96.3	0.13 (0.06 to 0.20)	84
Fatigue	Mei, 2006 ²⁸	1/30	1/20	0.7 (0.0 to 10.1)	33.82	-0.02 (-0.13 to 0.10)	3.7	-0.04 (-0.33 to 0.24)	16
Fatigue	Pooled	19/421	4/403	2.8 (0.4 to 21.2)	100	0.04 (0.01 to 0.06)	100	0.1 (0.1 to 0.22)	100
Insomnia	Lainez, 2007 ³⁵	13/391	4/383	3.2 (1.0 to 9.7)	66.18	0.02 (0.00 to 0.04)	83.59	0.08 (0.01 to 0.15)	60.4
Insomnia	Mei, 2006 ²⁸	0/30	1/20	0.2 (0.0 to 5.3)	33.82	-0.05 (-0.17 to 0.07)	16.41	-0.23 (-0.51 to 0.06)	39.6
Insomnia	Pooled	13/421	5/403	1.3 (0.1 to 15.1)	100	0.01 (-0.04 to 0.06)	100	-0.04 (-0.33 to 0.25)	100
Language problems	Adelman, 2008 ⁴⁰	10/514	1/202	3.9 (0.5 to 30.5)	67.97	0.02 (0.00 to 0.03)	98.27	0.07 (-0.01 to 0.15)	76.93
Language problems	Mei, 2006 ²⁸	2/30	0/20	3.4	32.03	0.07	1.73	0.26	23.07

Appendix Table D123. Treatment discontinuation due to specific adverse effects with topiramate vs. placebo, pooled with random effects model results from individual randomized controlled clinical trials (continued)

Adverse Effect Leading to Treatment Discontinuation	Author, Year	Events/Randomized with Drug	Events/Randomized with Placebo	Relative Risk (95% CI)	Relative Risk Weight (Inverse Variance)	Absolute Risk Difference (95% CI)	Absolute Risk Difference Weight (Inverse Variance)	Arcsine Transformed Risk Difference (95% CI)	Arcsine Transformed Risk Difference Weight
				(0.2 to 67.0)		(-0.05 to 0.18)		(-0.02 to 0.54)	
Language problems	Pooled	12/544	1/222	3.7 (0.7 to 20.3)	100	0.02 (0.00 to 0.03)	100	0.12 (-0.04 to 0.27)	100
Paresthesia	Lainez, 2007 ³⁵	31/391	3/383	10.1 (3.1 to 32.8)	74.85	0.07 (0.04 to 0.10)	85.36	0.20 (0.13 to 0.27)	75.34
Paresthesia	Mei, 2004 ²⁴	5/58	0/57	10.8 (0.6 to 191.2)	12.56	0.09 (0.01 to 0.16)	11.18	0.30 (0.12 to 0.48)	17.11
Paresthesia	Mei, 2006 ²⁸	4/30	0/20	6.1 (0.3 to 107.4)	12.59	0.13 (-0.01 to 0.27)	3.46	0.37 (0.09 to 0.66)	7.55
Paresthesia	Pooled	40/479	3/460	9.6 (3.5 to 26.5)	100	0.08 (0.05 to 0.10)	100	0.23 (0.15 to 0.31)	100
Somnolence	Adelman, 2008 ⁴⁰	10/514	4/202	1.0 (0.3 to 3.1)	81.03	0.00 (-0.02 to 0.02)	86.81	0.01 (-0.08 to 0.09)	83.43
Somnolence	Mei, 2004 ²⁴	2/58	1/57	2.0 (0.2 to 21.1)	18.97	0.02 (-0.04 to 0.08)	13.19	0.05 (-0.13 to 0.24)	16.57
Somnolence	Pooled	12/572	5/259	1.1 (0.4 to 3.2)	100	0.00 (-0.02 to 0.02)	100	0.01 (-0.06 to 0.09)	100
Taste perversion	Adelman, 2008 ⁴⁰	6/514	0/202	5.1 (0.3 to 90.5)	36.48	0.01 (0.00 to 0.02)	93.08	0.11 (0.03 to 0.19)	78.03
Taste perversion	Mei, 2004 ²⁴	1/58	0/57	2.9 (0.1 to 70.9)	29.76	0.02 (-0.03 to 0.06)	5.96	0.13 (-0.05 to 0.31)	15.5
Taste perversion	Mei, 2006 ²⁸	2/30	0/20	3.4 (0.2 to 67.0)	33.76	0.07 (-0.05 to 0.18)	0.97	0.26 (-0.02 to 0.54)	6.47
Taste perversion	Pooled	9/602	0/279	3.8 (0.7 to 21.4)	100	0.01 (0.00 to 0.02)	100	0.12 (0.05 to 0.19)	100

Heterogeneity Statistics	Degree of Freedom	P Value Relative Risk	I Squared Relative Risk	P Value Absolute Risk Difference	I Squared Absolute Risk Difference	P Value Arcsine Transformed Risk Difference	I Squared Arcsine Transformed Risk Difference
Any cognitive symptom	2	0.15	48.10%	0.08	61.30%	0.003	83.10%
Difficulty with memory	1	0.15	51.10%	0.31	4.70%	0.07	70.40%
Dizziness	1	0.16	49.20%	0.16	49.00%	0.02	80.80%

Appendix Table D123. Treatment discontinuation due to specific adverse effects with topiramate vs. placebo, pooled with random effects model results from individual randomized controlled clinical trials (continued)

Heterogeneity Statistics	Degree of Freedom	P Value Relative Risk	I Squared Relative Risk	P Value Absolute Risk Difference	I Squared Absolute Risk Difference	P Value Arcsine Transformed Risk Difference	I Squared Arcsine Transformed Risk Difference
Fatigue	1	0.12	51%	0.40	0.00%	0.30	23%
Insomnia	1	0.12	58.50%	0.24	28.70%	0.04	76.40%
Language problems	1	0.94	0.00%	0.38	0.00%	0.21	36.40%
Paresthesia	2	0.95	0.00%	0.67	0.00%	0.33	11.00%
Somnolence	1	0.61	0.00%	0.59	0.00%	0.63	0.00%
Taste perversion	2	0.97	0.00%	0.64	0.00%	0.59	0.00%

Appendix Table D124. Discontinuation due to adverse effects with topiramate in pooled analysis of individual patient data from three randomized controlled clinical trials of migraine prevention in adults⁴⁰

Outcome, Daily Dose	Events/Randomized with Drug [Placebo]	Rate % with Drug [Placebo]	Peto Odds Ratio (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm 1 Person (95% CI) Attributable Events per 1000 Treated (95% CI)
Abdominal pain leading to withdrawal 50mg/day	5/235 [1/92]	2.1 [0.9]	1.8 (0.3 to 10.7)	0.01 (-0.02 to 0.04)	NS
Abdominal pain leading to withdrawal 100mg/day	3/386 [1/151]	0.8 [0.9]	1.2 (0.1 to 10.4)	0.00 (-0.01 to 0.02)	NS
Abdominal pain leading to withdrawal 200mg/day	12/514 [2/202]	2.3 [0.9]	2.0 (0.6 to 6.5)	0.01 (-0.01 to 0.03)	NS
Abnormal vision leading to withdrawal 50mg/day	2/235 [0/92]	0.9 [0.0]	4.0 (0.2 to 88.5)	0.01 (-0.01 to 0.03)	NS
Abnormal vision leading to withdrawal 100 mg/day	3/386 [0/151]	0.8 [0.0]	4.0 (0.3 to 50.3)	0.01 (-0.01 to 0.02)	NS
Abnormal vision leading to withdrawal 200mg/day	5/514 [0/202]	1.0 [0.0]	4.1 (0.6 to 28.6)	0.01 (0.00 to 0.02)	NS
Anorexia leading to withdrawal 50mg/day	2/235 [0/92]	0.9 [0.5]	4.0 (0.2 to 88.5)	0.01 (-0.01 to 0.03)	NS
Anorexia leading to withdrawal 100 mg/day	8/386 [1/151]	2.1 [0.5]	2.4 (0.5 to 10.2)	0.01 (-0.01 to 0.03)	NS
Anorexia leading to withdrawal 200mg/day	14/514 [1/202]	2.7 [0.5]	3.0 (1.0 to 9.2)	0.02 (0.01 to 0.04)	NNT 45 (25 to 192) Attributable events 22 (5 to 39)
Anxiety leading to withdrawal 50mg/day	3/235 [0/92]	1.3 [0.0]	4.1 (0.3 to 50.6)	0.01 (-0.01 to 0.03)	NS
Anxiety leading to withdrawal 100 mg/day	8/386 [0/151]	2.1 [0.2]	4.1 (0.9 to 19.3)	0.02 (0.00 to 0.04)	NNT 48 (26 to 284) Attributable events 21 (4 to 38)
Anxiety leading to withdrawal 200mg/day	9/514 [0/202]	1.8 [0.2]	4.1 (0.9 to 17.6)	0.02 (0.00 to 0.03)	NNT 57 (32 to 249) Attributable events 18 (4 to 31)
Arthralgia leading to withdrawal 50mg/day	1/235 [0/92]	0.4 [0.0]	4.0 (0.1 to 314.3)	0.00 (-0.01 to 0.02)	NS
Arthralgia leading to withdrawal 100 mg/day	2/386 [0/151]	0.5 [0.0]	4.0 (0.2 to 88.2)	0.01 (-0.01 to 0.02)	NS
Arthralgia leading to withdrawal 200mg/day	1/514 [0/202]	0.2 [0.0]	4.0 (0.1 to 313.6)	0.00 (-0.01 to 0.01)	NS
Back pain leading to withdrawal 50mg/day	2/235 [0/92]	0.9 [0.0]	4.0 (0.2 to 88.5)	0.01 (-0.01 to 0.03)	NS
Back pain leading to withdrawal 200mg/day	1/514 [0/202]	0.2 [0.0]	4.0 (0.1 to 313.6)	0.00 (-0.01 to 0.01)	NS
Depression leading to withdrawal 50mg/day	1/235 [1/92]	0.4 [0.7]	0.3 (0.0 to 7.5)	-0.01 (-0.03 to 0.02)	NS

Appendix Table 124. Discontinuation due to adverse effects with topiramate in pooled analysis of individual patient data from three randomized controlled clinical trials of migraine prevention in adults (continued)

Outcome, Daily Dose	Events/Randomized with Drug [Placebo]	Rate % with Drug [Placebo]	Peto Odds Ratio (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm 1 Person (95% CI) Attributable Events per 1000 Treated (95% CI)
Depression leading to withdrawal 100 mg/day	3/386 [1/151]	0.8 [0.7]	1.2 (0.1 to 10.4)	0.00 (-0.01 to 0.02)	NS
Depression leading to withdrawal 200mg/day	14/514 [1/202]	2.7 [0.7]	3.0 (0.9 to 9.2)	0.02 (0.01 to 0.04)	NNT 45 (25 to 194) Attributable events 22 (5 to 40)
Diarrhea leading to withdrawal 50mg/day	2/235 [0/92]	0.9 [0.5]	4.0 (0.2 to 88.5)	0.01 (-0.01 to 0.03)	NS
Diarrhea leading to withdrawal 100 mg/day	6/386 [1/151]	1.6 [0.5]	2.0 (0.4 to 10.5)	0.01 (-0.01 to 0.03)	NS
Diarrhea leading to withdrawal 200mg/day	10/514 [1/202]	1.9 [0.5]	2.6 (0.7 to 9.8)	0.01 (0.00 to 0.03)	NS
Dry mouth leading to withdrawal 50mg/day	1/235 [0/92]	0.4 [0.5]	4.0 (0.1 to 314.3)	0.00 (-0.01 to 0.02)	NS
Dry mouth leading to withdrawal 100 mg/day	2/386 [1/151]	0.5 [0.5]	0.8 (0.1 to 9.6)	0.00 (-0.02 to 0.01)	NS
Dry mouth leading to withdrawal 200mg/day	5/514 [1/202]	1.0 [0.5]	1.8 (0.3 to 10.6)	0.00 (-0.01 to 0.02)	NS
Dyspepsia leading to withdrawal 50mg/day	1/235 [0/92]	0.4 [0.2]	4.0 (0.1 to 314.3)	0.00 (-0.01 to 0.02)	NS
Dyspepsia leading to withdrawal 100 mg/day	4/386 [0/151]	1.0 [0.0]	4.1 (0.5 to 36.1)	0.01 (0.00 to 0.02)	NS
Dyspepsia leading to withdrawal 200mg/day	1/514 [0/202]	0.2 [0.0]	4.0 (0.1 to 313.6)	0.00 (-0.01 to 0.01)	NS
Hypesthesia leading to withdrawal 50mg/day	1/235 [0/92]	0.4 [0.2]	4.0 (0.1 to 314.3)	0.00 (-0.01 to 0.02)	NS
Hypesthesia leading to withdrawal 100 mg/day	7/386 [0/151]	1.8 [0.2]	4.1 (0.8 to 21.4)	0.02 (0.00 to 0.03)	NNT 55 (29 to 603) Attributable events 18 (2 to 35)
Hypesthesia leading to withdrawal 200mg/day	12/514 [0/202]	2.3 [0.2]	4.1 (1.2 to 14.6)	0.02 (0.01 to 0.04)	NNT 43 (26 to 119) Attributable events 23 (8 to 38)
Injury leading to withdrawal 100 mg/day	1/386 [0/151]	0.3 [0.0]	4.0 (0.1 to 314.4)	0.00 (-0.01 to 0.01)	NS
Mood problems leading to withdrawal 50mg/day	2/235 [0/92]	0.9 [0.2]	4.0 (0.2 to 88.5)	0.01 (-0.01 to 0.03)	NS
Mood problems leading to withdrawal 100 mg/day	5/386 [0/151]	1.3 [0.2]	4.1 (0.6 to 28.7)	0.01 (0.00 to 0.03)	
Mood problems leading to withdrawal 200mg/day	10/514 [0/202]	1.9 [0.2]	4.1 (1.0 to 16.4)	0.02 (0.01 to 0.03)	NNT 51 (30 to 183) Attributable events 20 (6 to 34)

Appendix Table 124. Discontinuation due to adverse effects with topiramate in pooled analysis of individual patient data from three randomized controlled clinical trials of migraine prevention in adults (continued)

Outcome, Daily Dose	Events/Randomized with Drug [Placebo]	Rate % with Drug [Placebo]	Peto Odds Ratio (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm 1 Person (95% CI) Attributable Events per 1000 Treated (95% CI)
Nausea leading to withdrawal 50mg/day	7/235 [1/92]	3.0 [1.1]	2.2 (0.5 to 10.5)	0.02 (-0.01 to 0.05)	NS
Nausea leading to withdrawal 100 mg/day	9/386 [2/151]	2.3 [1.1]	1.7 (0.4 to 6.2)	0.01 (-0.01 to 0.03)	NS
Nausea leading to withdrawal 200mg/day	29/514 [2/202]	5.6 [1.1]	3.1 (1.4 to 6.8)	0.05 (0.02 to 0.07)	NNT 22 (14 to 45) Attributable events 47 (23 to 71)
Pharyngitis leading to withdrawal 50mg/day	1/235 [0/92]	0.4 [0.0]	4.0 (0.1 to 314.3)	0.00 (-0.01 to 0.02)	NS
Pharyngitis leading to withdrawal 100 mg/day	2/386 [0/151]	0.5 [0.0]	4.0 (0.2 to 88.2)	0.01 (-0.01 to 0.02)	NS
Sinusitis leading to withdrawal 200mg/day	1/514 [0/202]	0.2 [0.0]	4.0 (0.1 to 313.6)	0.00 (-0.01 to 0.01)	NS
Weight loss leading to withdrawal 50mg/day	1/235 [0/92]	0.4 [0.0]	4.0 (0.1 to 314.3)	0.00 (-0.01 to 0.02)	NS
Weight loss leading to withdrawal 100 mg/day	4/386 [0/151]	1.0 [0.0]	4.1 (0.5 to 36.1)	0.01 (0.00 to 0.02)	NS
Weight loss leading to withdrawal 200mg/day	6/514 [0/202]	1.2 [0.0]	4.1 (0.7 to 24.2)	0.01 (0.00 to 0.02)	NS

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval; NS= not significant; Number needed to treat and number of attributable events were calculated for statistically significant differences

Appendix Table D125. Treatment discontinuation due to adverse effects with approved and off label drugs vs. placebo, results from individual randomized controlled clinical trials

Active Drug, Daily Dose Reference	Adverse Effect that Resulted in Treatment Discontinuation	Sample Size Risk of Bias	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Approved drugs				
Topiramate 200mg Adelman, 2008	Hypesthesia	715 Risk of bias Low	9.8 (0.6 to 164.8)	0.02 (0.01 to 0.04)
Topiramate 200mg Adelman, 2008 ⁴⁰	Dry mouth	716 Risk of bias Low	2.0 (0.2 to 16.7)	0.00 (-0.01 to 0.02)
Topiramate 200mg Adelman, 2008 ⁴⁰	Mood problems	715 Risk of bias Low	8.2 (0.5 to 139.9)	0.02 (0.01 to 0.03)
Topiramate 200mg Adelman, 2008 ⁴⁰	Weight decrease	716 Risk of bias Low	5.1 (0.3 to 90.5)	0.01 (0.00 to 0.02)
Topiramate 200mg Adelman, 2008 ⁴⁰	Abdominal pain	716 Risk of bias Low	2.4 (0.5 to 10.4)	0.01 (-0.01 to 0.03)
Topiramate 200mg Adelman, 2008 ⁴⁰	Anorexia	716 Risk of bias Low	5.5 (0.7 to 41.6)	0.02 (0.01 to 0.04)
Topiramate 200mg Adelman, 2008 ⁴⁰	Diarrhea	716 Risk of bias Low	3.9 (0.5 to 30.5)	0.01 (0.00 to 0.03)
Topiramate 200mg Adelman, 2008 ⁴⁰	Dyspepsia	716 Risk of bias Low	1.2 (0.0 to 28.9)	0.00 (-0.01 to 0.01)
Topiramate 100mg Lainez, 2007 ³⁵	Nausea	774 Risk of bias Low	1.8 (0.6 to 5.2)	0.01 (-0.01 to 0.03)
Topiramate 100mg Adelman, 2008 ⁴⁰	Pharyngitis	537 Risk of bias Low	2.0 (0.1 to 40.7)	0.01 (-0.01 to 0.02)
Topiramate 200mg Adelman, 2008 ⁴⁰	Sinusitis	716 Risk of bias Low	1.2 (0.0 to 28.9)	0.00 (-0.01 to 0.01)
Topiramate 200mg Freitag, 2007 ³⁶	Upper respiratory tract infection	304 Risk of bias Low	0.0 (0.0 to 0.0)	0.00 (-0.02 to 0.02)
Topiramate 100mg Adelman, 2008 ⁴⁰	Injury	537 Risk of bias Low	1.2 (0.0 to 28.8)	0.00 (-0.01 to 0.01)
Topiramate 200mg Adelman, 2008 ⁴⁰	Arthralgia	716 Risk of bias Low	1.2 (0.0 to 28.9)	0.00 (-0.01 to 0.01)
Topiramate 200mg Adelman, 2008 ⁴⁰	Back pain	716 Risk of bias Low	1.2 (0.0 to 28.9)	0.00 (-0.01 to 0.01)
Topiramate 200mg Adelman, 2008 ⁴⁰	Abnormal vision	716 Risk of bias Low	4.3 (0.2 to 78.1)	0.01 (0.00 to 0.02)
Topiramate 75mg Bavrasad, 2010 ²³²	Paresthesia	70 Risk of bias Medium	3.0 (0.1 to 71.2)	0.03 (-0.05 to 0.10)
Topiramate 75mg Bavrasad, 2010 ²³²	Nausea	70 Risk of bias Medium	0.3 (0.0 to 7.9)	-0.03 (-0.10 to 0.05)
Topiramate 200mg Diener, 2004 ⁴³	Fatigue	288 Risk of bias Low	1.7 (0.8 to 3.7)	0.04 (-0.02 to 0.11)

Appendix Table D125. Treatment discontinuation due to adverse effects with approved and off label drugs vs. placebo, results from individual randomized controlled clinical trials (continued)

Active Drug, Daily Dose Reference	Adverse Effect that Resulted in Treatment Discontinuation	Sample Size Risk of Bias	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Topiramate 200mg Diener, 2004 ⁴³	Difficulty with memory	288 Risk of bias Low	3.0 (0.3 to 28.5)	0.01 (-0.01 to 0.04)
Topiramate 200mg Diener, 2004 ⁴³	Insomnia	288 Risk of bias Low	2.0 (0.7 to 5.7)	0.03 (-0.02 to 0.09)
Topiramate 200mg Diener, 2004 ⁴³	Somnolence	288 Risk of bias Low	0.7 (0.1 to 3.9)	-0.01 (-0.04 to 0.02)
Topiramate 100mg Diener, 2004 ⁴³	Taste perversion	285 Risk of bias Low	0.0 (0.0 to 0.0)	0.00 (-0.01 to 0.01)
Topiramate 200mg Diener, 2004 ⁴³	Weight decrease	288 Risk of bias Low	7.0 (0.4 to 134.3)	0.02 (-0.01 to 0.05)
Topiramate 200mg Diener, 2004 ⁴³	Nausea	288 Risk of bias Low	3.2 (1.2 to 8.5)	0.08 (0.02 to 0.14)
Divalproex sodium 1000 mg Klapper, 1997 ⁴⁷	Abdominal pain	87 Risk of bias Low	3.1 (0.1 to 73.3)	0.02 (-0.04 to 0.09)
Divalproex sodium 1500 mg Klapper, 1997 ⁴⁷	Alopecia	88 Risk of bias Low	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.08)
Divalproex sodium 1500 mg Klapper, 1997 ⁴⁷	Back pain	88 Risk of bias Low	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.08)
Divalproex sodium 500 mg Klapper, 1997 ⁴⁷	Constipation	89 Risk of bias Low	2.9 (0.1 to 70.2)	0.02 (-0.04 to 0.08)
Divalproex sodium 1500 mg Klapper, 1997 ⁴⁷	Emotional lability	88 Risk of bias Low	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.08)
Divalproex sodium 1500 mg Klapper, 1997 ⁴⁷	Gastrointestinal disorder	58 Risk of bias Low	0.0 (0.0 to 0.0)	0.00 (-0.10 to 0.10)
Divalproex sodium 1500 mg Klapper, 1997 ⁴⁷	Nausea	88 Risk of bias Low	9.0 (0.5 to 162.3)	0.09 (0.00 to 0.18)
Divalproex sodium 1000 mg Klapper, 1997 ⁴⁷	Pharyngitis	87 Risk of bias Low	3.1 (0.1 to 73.3)	0.02 (-0.04 to 0.09)
Divalproex sodium 500 mg Klapper, 1997 ⁴⁷	Pneumonia	89 Risk of bias Low	2.9 (0.1 to 70.2)	0.02 (-0.04 to 0.08)
Divalproex sodium 1500 mg Klapper, 1997 ⁴⁷	Somnolence	88 Risk of bias Low	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.08)
Divalproex sodium 1500 mg Klapper, 1997 ⁴⁷	Thinking abnormal	88 Risk of bias Low	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.08)
Divalproex sodium 1500 mg Klapper, 1997 ⁴⁷	Vomiting	88 Risk of bias Low	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.08)
Divalproex sodium 1500 mg Klapper, 1997 ⁴⁷	Weight increase (gain)	88 Risk of bias Low	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.08)
Divalproex sodium 1500 mg Klapper, 1997 ⁴⁷	Diarrhea	88 Risk of bias Low	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.08)

Appendix Table D125. Treatment discontinuation due to adverse effects with approved and off label drugs vs. placebo, results from individual randomized controlled clinical trials (continued)

Active Drug, Daily Dose Reference	Adverse Effect that Resulted in Treatment Discontinuation	Sample Size Risk of Bias	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Sodium valproate 1000mg to 1500 mg per day Jensen, 1994 ⁴⁹	Dry mouth	86 Risk of bias Medium	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.09)
Sodium valproate 1000mg to 1500 mg per day Jensen, 1994 ⁴⁹	Tremor	86 Risk of bias Medium	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.09)
Sodium valproate 1000mg to 1500 mg per day Jensen, 1994 ⁴⁹	Vertigo	86 Risk of bias Medium	5.0 (0.2 to 101.2)	0.05 (-0.03 to 0.12)
Sodium valproate 1000mg to 1500 mg per day Jensen, 1994 ⁴⁹	Weight increase (gain)	86 Risk of bias Medium	1.0 (0.1 to 15.5)	0.00 (-0.06 to 0.06)
Sodium valproate 1000mg to 1500 mg per day Jensen, 1994 ⁴⁹	Abdominal pain	86 Risk of bias Medium	0.3 (0.0 to 8.0)	-0.02 (-0.09 to 0.04)
Sodium valproate 1000mg to 1500 mg per day Jensen, 1994 ⁴⁹	Appetite increase	86 Risk of bias Medium	0.3 (0.0 to 8.0)	-0.02 (-0.09 to 0.04)
Sodium valproate 1000mg to 1500 mg per day Jensen, 1994 ⁴⁹	Nausea	86 Risk of bias Medium	7.0 (0.4 to 131.6)	0.07 (-0.02 to 0.16)
Timolol 10mg twice a day Stellar, 1984 ⁷⁹	Any adverse event	94 Risk of bias Medium	5.0 (0.2 to 101.4)	0.04 (-0.03 to 0.11)
Timolol 10mg twice a day Stellar, 1984 ⁷⁹	Chest pain(moderate) on day 28	94 Risk of bias Medium	3.0 (0.1 to 71.8)	0.02 (-0.04 to 0.08)
Timolol 10mg twice a day Stellar, 1984 ⁷⁹	Epigastric distress(severe) and fecal impaction	94 Risk of bias Medium	3.0 (0.1 to 71.8)	0.02 (-0.04 to 0.08)
Propranolol 160 mg/d Diener, 2004⁴³	Fatigue	290 Risk of bias Low	19.3 (1.1 to 327.9)	0.06 (0.02 to 0.10)
Propranolol 160 mg/d Diener, 2004 ⁴³	Difficulty with memory	290 Risk of bias Low	3.0 (0.1 to 74.0)	0.01 (-0.01 to 0.03)
Propranolol 160 mg/d Diener, 2004 ⁴³	Somnolence	193 Risk of bias Low	2.4 (0.1 to 45.9)	0.02 (-0.02 to 0.06)
Propranolol 160 mg/d Diener, 2004 ⁴³	Weight decrease	290 Risk of bias Low	0.0 (0.0 to 0.0)	0.00 (-0.01 to 0.01)
Propranolol 160 mg/d Diener, 2004 ⁴³	Nausea	193 Risk of bias Low	1.7 (0.2 to 14.2)	0.01 (-0.04 to 0.06)
Propranolol 160 mg Pradalier, 1989 ⁵³	Psoriasis	55 Risk of bias Low	0.3 (0.0 to 6.1)	-0.04 (-0.14 to 0.06)

Appendix Table D125. Treatment discontinuation due to adverse effects with approved and off label drugs vs. placebo, results from individual randomized controlled clinical trials (continued)

Active Drug, Daily Dose Reference	Adverse Effect that Resulted in Treatment Discontinuation	Sample Size Risk of Bias	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Off label drugs				
Acetazolamide 500 mg Vahedi, 2002 ⁸⁰	Discontinued due to adverse event	53 Risk of bias Low	4.7 (1.1 to 19.6)	0.27 (0.06 to 0.48)
Carbamazepine Rompel, 1970 ⁸⁶	Discontinued due to adverse event	96 Risk of bias Medium	3.0 (0.1 to 71.9)	0.02 (-0.04 to 0.08)
Lamotrigine 25 mg-200 mg Steiner, 1997 ⁸⁷	Dizziness	58 Risk of bias Low	6.5 (0.3 to 151.7)	0.06 (-0.07 to 0.18)
Lamotrigine 26 mg-200 mg Steiner, 1997 ⁸⁷	Dyspepsia	59 Risk of bias Low	0.7 (0.0 to 16.0)	-0.03 (-0.11 to 0.06)
Lamotrigine 27 mg-200 mg Steiner, 1997 ⁸⁷	Nausea	58 Risk of bias Low	0.7 (0.0 to 16.9)	-0.03 (-0.12 to 0.07)
Lamotrigine 28 mg-200 mg Steiner, 1997 ⁸⁷	Leucopenia	58 Risk of bias Low	0.7 (0.0 to 16.9)	-0.03 (-0.12 to 0.07)
Lamotrigine 29 mg-200 mg Steiner, 1997⁸⁷	Rash	58 Risk of bias Low	15.6 (2.1 to 117.3)	0.36 (0.13 to 0.59)
Oxcarbazepine up to 1,200 mg Silberstein, 2008 ⁸³	Discontinued due to adverse event	170 Risk of bias Low	2.0 (0.6 to 6.4)	0.05 (-0.03 to 0.12)
Femoxetine 200 mg-400mg Kangasniemi, 1983 ⁷⁷	Discontinued due to adverse event	58 Risk of bias Medium	7.0 (0.4 to 129.7)	0.10 (-0.02 to 0.23)
Tonabersat 20 mg-40 mg Goadsby, 2009 ¹²¹	Discontinued due to adverse event	124 Risk of bias Low	2.2 (0.2 to 23.7)	0.02 (-0.04 to 0.07)
Tonabersat 20 mg-40 mg Goadsby, 2009 ¹²¹	Dizziness	124 Risk of bias Low	1.8 (0.5 to 7.4)	0.04 (-0.05 to 0.13)
Atenolol 100mg Johannsson, 1987 ⁹⁹	Discontinued due to adverse event	144 Risk of bias Medium	0.1 (0.0 to 2.7)	-0.04 (-0.09 to 0.01)
Bisoprolol 100mg van de Ven, 1997 ¹⁰¹	Discontinued due to adverse event	115 Risk of bias Medium	1.7 (0.4 to 7.9)	0.04 (-0.06 to 0.13)
Metoprolol 200mg Andersson, 1983 ⁹⁷	Discontinued due to adverse event	71 Risk of bias Medium	1.1 (0.1 to 16.7)	0.00 (-0.07 to 0.08)
Nadolol 80mg -240mg Freitag, 1984 ⁹⁸	Bradycardia	32 Risk of bias Low	1.1 (0.0 to 24.2)	0.04 (-0.13 to 0.22)
Pindolol 7.5 -15mg Sjaastad, 1972 ⁸⁹	Discontinued due to adverse event	56 Risk of bias Medium	7.0 (0.4 to 129.5)	0.11 (-0.02 to 0.23)
Nicardipine 40mg Leandri, 1990 ¹²⁶	Dyspepsia	60 Risk of bias Medium	0.5 (0.0 to 5.2)	-0.03 (-0.14 to 0.08)
Verapamil 240mg Markley, 1984 ¹²⁴	Constipation	40 Risk of bias Medium	3.0 (0.1 to 69.5)	0.05 (-0.08 to 0.18)
Dihydroergotamine 10mg Boussier, 1988 ²³³	Intolerance(alleged)	90 Risk of bias Medium	0.1 (0.0 to 2.7)	-0.07 (-0.15 to 0.02)

Appendix Table D125. Treatment discontinuation due to adverse effects with approved and off label drugs vs. placebo, results from individual randomized controlled clinical trials (continued)

Active Drug, Daily Dose Reference	Adverse Effect that Resulted in Treatment Discontinuation	Sample Size Risk of Bias	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Lisuride 0.075 mg Somerville, 1976 ¹⁵⁸	Discontinued due to adverse event	150 Risk of bias Medium	2.4 (0.9 to 6.5)	0.09 (-0.01 to 0.19)
Lisuride 0.075 mg Somerville, 1976 ¹⁵⁸	Fatigue, weakness	150 Risk of bias Medium	7.0 (0.4 to 133.2)	0.04 (-0.01 to 0.09)
Lisuride 0.075 mg Somerville, 1976 ¹⁵⁸	Hallucinations	150 Risk of bias Medium	3.0 (0.1 to 72.5)	0.01 (-0.02 to 0.05)
Lisuride 0.075 mg Somerville, 1976 ¹⁵⁸	Numbness of tongue	150 Risk of bias Medium	0.3 (0.0 to 8.1)	-0.01 (-0.05 to 0.02)
Lisuride 0.075 mg Somerville, 1976 ¹⁵⁸	Somnolence (Drowsiness)	150 Risk of bias Medium	1.0 (0.1 to 15.7)	0.00 (-0.04 to 0.04)
Lisuride 0.075 mg Somerville, 1976 ¹⁵⁸	Vertigo	150 Risk of bias Medium	3.0 (0.1 to 72.5)	0.01 (-0.02 to 0.05)
Lisuride 0.075 mg Somerville, 1976 ¹⁵⁸	Chest pains	150 Risk of bias Medium	2.0 (0.2 to 21.6)	0.01 (-0.03 to 0.06)
Lisuride 0.075 mg Somerville, 1976 ¹⁵⁸	Subcutaneous hemorrhage	150 Risk of bias Medium	0.5 (0.0 to 5.4)	-0.01 (-0.06 to 0.03)
Lisuride 0.075 mg Somerville, 1976 ¹⁵⁸	Blurred vision	150 Risk of bias Medium	3.0 (0.1 to 72.5)	0.01 (-0.02 to 0.05)
Lisuride 0.075 mg Somerville, 1976 ¹⁵⁸	Eye irritation	150 Risk of bias Medium	3.0 (0.1 to 72.5)	0.01 (-0.02 to 0.05)
Lisuride 0.075 mg Somerville, 1976 ¹⁵⁸	Nausea	150 Risk of bias Medium	1.0 (0.1 to 6.9)	0.00 (-0.05 to 0.05)
Lisuride 0.075 mg Somerville, 1976 ¹⁵⁸	Back pains	150 Risk of bias Medium	3.0 (0.1 to 72.5)	0.01 (-0.02 to 0.05)
Lisuride 0.075 mg Somerville, 1976 ¹⁵⁸	Impotence	150 Risk of bias Medium	3.0 (0.1 to 72.5)	0.01 (-0.02 to 0.05)
Methysergide 1 mg q.d.s. Whewell, 1966 ¹⁵⁴	Discontinued due to adverse event	148 Risk of bias Medium	0.5 (0.0 to 5.4)	-0.01 (-0.06 to 0.03)
Methysergide 1 mg q.d.s. Whewell, 1966 ¹⁵⁴	Nausea(excessive)	148 Risk of bias Medium	3.0 (0.1 to 72.5)	0.01 (-0.02 to 0.05)
Tizanidine 4mg Saper, 2002 ²³⁴	Adverse event other than death	136 Risk of bias Medium	2.0 (0.6 to 6.2)	0.06 (-0.03 to 0.16)
Tizanidine 4mg Saper, 2002 ²³⁴	Headache	136 Risk of bias Medium	2.7 (0.1 to 64.4)	0.01 (-0.02 to 0.05)
Fenopropfen 600 mg TID CN-00048653	Fatigue	75 Risk of bias Medium	0.9 (0.1 to 14.2)	0.00 (-0.08 to 0.07)
Fenopropfen 600 mg TID Solomon, 1987 ¹⁹⁸	Adverse effects: fatigue and/or somnolence	Risk of bias Low	0.9 (0.1 to 14.2)	0.00 (-0.08 to 0.07)
Fenopropfen 600 mg TID Diamond, 1987 ²³⁵	Gastrointestinal symptoms	75 Risk of bias Medium	2.8 (0.3 to 25.4)	0.05 (-0.05 to 0.15)

Appendix Table D125. Treatment discontinuation due to adverse effects with approved and off label drugs vs. placebo, results from individual randomized controlled clinical trials (continued)

Active Drug, Daily Dose Reference	Adverse Effect that Resulted in Treatment Discontinuation	Sample Size Risk of Bias	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Tolfenamic Acid 300mg Mikkelsen, 1982 ²⁰²	Discontinued due to adverse event	76 Risk of bias Medium	2.0 (0.2 to 21.1)	0.03 (-0.06 to 0.11)
Montelukast 20 mg Brandes, 2004 ²⁰³	Discontinued due to adverse event	177 Risk of bias Low	0.9 (0.1 to 6.3)	0.00 (-0.05 to 0.04)

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

CI = confidence interval

Appendix Table D126. Adverse effects with topiramate in adults with migraine (pooled with random effects models—results from randomized controlled clinical trials)

Outcome, Reference	Sample	Rate with Topiramate [Placebo]	Odds Ratio (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm (95% CI)	Attributable Events per 1000 Treated (95% CI)
Adverse events ^{29, 31, 34, 40, 42, 44}	1700	59.9 [56.1]	2.0 (1.1 to 3.5)	0.12 (0.02 to 0.22)	8 (4 to 42)	124 (24 to 223)
Paresthesia ^{18, 20, 24, 28, 29, 31, 34, 40, 42, 44}	1876	24.0 [5.5]	6.8 (4.8 to 9.7)	0.24 (0.14 to 0.33)	4 (3 to 7)	235 (142 to 328)
Weight decrease ^{18, 24, 28, 29, 38, 40}	1648	12.3 [4.4]	4.7 (1.7 to 12.6)	0.10 (0.05 to 0.15)	10 (6 to 19)	104 (53 to 154)
Cognitive difficulties ^{24, 28, 31, 34, 38, 40, 43}	1782	8 [3]	2.3 (1.1 to 4.8)	0.045 (0.01 to 0.08)	22 (13 to 100)	45 (10 to 80)
Diarrhea ^{19, 40, 42}	1170	9.8 [3.6]	2.9 (1.6 to 5.2)	0.06 (0.01 to 0.10)	18 (10 to 71)	57 (14 to 100)
Dry mouth ⁴⁰⁻⁴²	1429	6.1 [2.7]	2.6 (1.4 to 4.6)	0.04 (0.01 to 0.06)	29 (18 to 71)	35 (14 to 57)
Fatigue ^{34, 40}	1857	9.6 [4.6]	1.8 (1.3 to 2.6)	0.05 (0.03 to 0.08)	20 (13 to 38)	50 (26 to 75)
Hyperesthesia ^{31, 40, 42}	1756	7.4 [1.6]	3.7 (1.9 to 7.1)	0.06 (0.03 to 0.08)	18 (13 to 30)	57 (33 to 80)
Insomnia ^{19, 25, 28, 43}	878	4 [2]	1.7 (0.5 to 5.1)	0.021 (0.001 to 0.042)		21 (1 to 42)
Memory impairment ^{19, 28, 29, 34, 40, 41, 43}	1436	10.4 [3.9]	2.5 (1.2 to 5.3)	0.058 (0.017 to 0.099)	17 (10 to 59)	58 (17 to 99)
Nausea ^{29, 31, 38, 40, 42, 43}	2156	11 [6]	1.6 (1.1 to 2.2)	0.034 (0.003 to 0.065)	29 (15 to 333)	34 (3 to 65)
Taste perversion ^{18, 24, 28, 40-43}	1634	5.9 [1.3]	5.5 (2.7 to 11.1)	0.083 (0.025 to 0.14)	12 (7 to 40)	83 (25 to 140)
Abdominal pain ^{38, 40}	1229	2.0 [2.3]	0.9 (0.4 to 2.0)	0.00 (-0.02 to 0.02)		
Anorexia ^{18, 28, 29, 31, 34, 38, 40, 42, 44}	2424	5.6 [3.3]	1.8 (1.2 to 2.9)	0.03 (0.00 to 0.05)		
Back pain ^{40, 42}	1100	4.6 [5.1]	0.9 (0.5 to 1.7)	0.00 (-0.03 to 0.02)		
Giddiness ^{28, 29, 31, 34, 40, 42, 44}	1871	10.1 [7.8]	1.2 (0.7 to 1.8)	0.01 (-0.02 to 0.04)		
Dyspepsia ^{34, 40}	1018	1.5 [1.1]	1.3 (0.4 to 3.8)	0.01 (-0.03 to 0.05)		
Infection, viral ^{34, 42}	444	8.2 [8.0]	1.0 (0.5 to 2.1)	0.00 (-0.05 to 0.05)		
Injury ^{31, 40, 42}	1672	5.0 [6.1]	0.8 (0.2 to 3.4)	-0.01 (-0.07 to 0.04)		
Adverse events: Serious ^{38, 41}	842	7.9 [6.6]	1.1 (0.5 to 2.3)	0.01 (-0.05 to 0.06)		
Sinusitis ^{31, 40, 42}	1429	7.4 [6.4]	1.1 (0.7 to 1.8)	0.01 (-0.02 to 0.03)		
Sleepiness ^{20, 24, 28, 29, 34, 40-42}	1893	4.4 [3.4]	1.6 (0.8 to 3.2)	0.02 (-0.01 to 0.04)		
Language problems: Treatment - emergent adverse events ^{19, 28, 40}	657	3.6 [0.5]	5.1 (1.2 to 22.8)	0.09 (-0.03 to 0.21)		
Upper respiratory tract infection ^{29, 40-42}	1641	8.7 [9.0]	1.0 (0.7 to 1.5)	0.00 (-0.03 to 0.03)		
Vision, abnormal ^{18, 40}	756	7.7 [2.2]	3.5 (1.4 to 8.5)	0.07 (-0.01 to 0.15)		

Bold = significant at 95% confidence limit when 95% CI of relative measure of the association estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

CI = confidence interval

Appendix Table D127. Significant increase in risk of adverse effects with migraine preventive drugs vs. placebo, results from individual RCTs

Drug	Adverse Effect	Risk of Bias Reference	Sample	% with Active Drugs [Placebo]	Relative Risk (95%CI)	Absolute Risk Difference (95%CI)	Number Needed to Treat (95%C)	Attributable Events (95%CI)
Topiramate	Mood problems	Low Adelman, 2008 ⁴⁰	716	5.4 [1.8]	2.8 (1.0 to 7.7)	0.03 (0.01 to 0.06)	29 (16 to 139)	35 (7 to 62)
Topiramate	Paresthesia: Moderate	Low Adelman, 2008 ⁴⁰	716	12.6 [1.4]	8.5 (2.7 to 26.8)	0.11 (0.08 to 0.14)	9 (7 to 13)	112 (78 to 145)
Topiramate	Nausea: Mild/moderate	Low Bussone, 2005 ²⁵	758	11.1 [6.5]	1.7 (1.1 to 2.8)	0.05 (0.01 to 0.09)	21 (11 to 148)	47 (7 to 87)
Topiramate	Anorexia: Severe	Low Bussone, 2005 ²⁵	758	1.3 [0.0]	10.6 (0.6 to 191.1)	0.01 (0.00 to 0.03)	77 (39 to 1695)	13 (1 to 25)
Topiramate	Low bicarbonate values that met the study-defined criteria for markedly abnormal laboratory values	Low Lipton, 2011 ⁴²	385	7.4 [0.0]	30.4 (1.8 to 505.7)	0.07 (0.04 to 0.11)	13 (9 to 28)	74 (36 to 113)
Divalproex	Hair loss(Alopecia)	Medium Mathew, 1995 ⁴⁵	107	12.9 [0.0]	10.2 (0.6 to 170.0)	0.13 (0.04 to 0.22)	8 (5 to 24)	129 (41 to 216)
Propranolol	Weight increase >2kg	Medium Forssman, 1976 ⁵²	80	12.5 [0.0]	11.0 (0.6 to 192.6)	0.1 (0.02 to 0.23)	8 (4 to 65)	125 (15 to 235)
Propranolol	Bradycardia	Medium Nadelmann, 1986 ²³⁶	114	8.8 [0.0]	11.0 (0.6 to 194.4)	0.09 (0.01 to 0.17)	11 (6 to 116)	88 (9 to 167)
Propranolol	Epigastric distress	Medium Nadelmann, 1986 ²³⁶	114	19.3 [3.5]	5.5 (1.3 to 23.7)	0.16 (0.04 to 0.27)	6 (4 to 22)	158 (45 to 271)
Propranolol	Malaise	Medium Nadelmann, 1986 ²³⁶	114	15.8 [3.5]	4.5 (1.0 to 19.9)	0.12 (0.02 to 0.23)	8 (4 to 60)	123 (17 to 229)
Acetazolamide	Fatigue, drowsiness, memory impairment	Low Vahedi, 2002 ⁸⁰	53	57.7 [14.8]	3.9 (1.5 to 10.2)	0.43 (0.20 to 0.66)	2 (2 to 5)	429 (196 to 661)
Acetazolamide	Paresthesia	Low Vahedi, 2002 ⁸⁰	53	80.8 [7.4]	10.9 (2.8 to 41.9)	0.73 (0.55 to 0.91)	1 (1 to 2)	734 (553 to 914)
Carbamazepine	Total adverse effects	Medium Rompel, 1970 ⁸⁶	96	62.5 [22.9]	2.7 (1.6 to 4.8)	0.40 (0.21 to 0.58)	3 (2 to 5)	396 (214 to 577)
Carbamazepine	Sleepiness	Medium Rompel, 1970 ⁸⁶	96	10.4 [0.0]	11.0 (0.6 to 193.6)	0.10 (0.01 to 0.20)	10 (5 to 88)	104 (11 to 197)
Carbamazepine	Vertigo or giddiness	Medium Rompel, 1970 ⁸⁶	96	47.9 [4.2]	11.5 (2.9 to 46.1)	0.44 (0.29 to 0.59)	2 (2 to 4)	438 (285 to 590)
Oxcarbazepine	Total adverse effects	Unclear Silberstein, 2008 ⁸³	170	80.0 [64.7]	1.2 (1.0 to 1.5)	0.15 (0.02 to 0.29)	7 (4 to 49)	153 (20 to 285)

Appendix Table D127. Significant increase in risk of adverse effects with migraine preventive drugs vs. placebo, results from individual RCTs (continued)

Drug	Adverse Effect	Risk of Bias Reference	Sample	% with Active Drugs [Placebo]	Relative Risk (95%CI)	Absolute Risk Difference (95%CI)	Number Needed to Treat (95%CI)	Attributable Events (95%CI)
Oxcarbazepine	Dizziness	Unclear Silberstein, 2008 ⁸³	170	17.6 [7.1]	2.5 (1.0 to 6.1)	0.11 (0.01 to 0.20)	9 (5 to 121)	106 (8 to 204)
Oxcarbazepine	Fatigue	Unclear Silberstein, 2008 ⁸³	170	20.0 [7.1]	2.8 (1.2 to 6.8)	0.13 (0.03 to 0.23)	8 (4 to 35)	129 (28 to 230)
Oxcarbazepine	Nausea	Unclear Silberstein, 2008 ⁸³	170	16.5 [4.7]	3.5 (1.2 to 10.2)	0.12 (0.03 to 0.21)	8 (5 to 37)	118 (27 to 208)
Atenolol	Dizziness (slight) of orthostatic type during first week	Medium Forssman, 1982 ⁹⁵	48	25.0 [4.2]	6.0 (0.8 to 46.1)	0.21 (0.02 to 0.40)	5 (3 to 57)	208 (18 to 399)
Pindolol	Dizziness/faintness (orthostatic)	Medium Sjaastad, 1972 ⁸⁹	56	21.4 [0.0]	13.0 (0.8 to 220.3)	0.21 (0.06 to 0.37)	5 (3 to 18)	214 (55 to 373)
Metoprolol	Adverse events	Medium Kangasniemi, 1987 ¹⁰⁰	154	55.8 [27.3]	2.0 (1.4 to 3.1)	0.29 (0.14 to 0.43)	3 (2 to 7)	286 (137 to 435)
Metoprolol	Fatigue/tiredness	Medium Kangasniemi, 1987 ¹⁰⁰	154	16.9 [5.2]	3.3 (1.1 to 9.5)	0.12 (0.02 to 0.21)	9 (5 to 51)	117 (20 to 214)
Metoprolol	Gastrointestinal adverse events	Medium Kangasniemi, 1987 ¹⁰⁰	154	20.8 [3.9]	5.3 (1.6 to 17.6)	0.17 (0.07 to 0.27)	6 (4 to 15)	169 (68 to 269)
Lisinopril	Total adverse effects	Low Schrader, 2001 ¹³⁶	120	40.0 [21.7]	1.8 (1.0 to 3.3)	0.18 (0.02 to 0.35)	5 (3 to 47)	183 (21 to 345)
Clonidine	Total adverse effects	Medium Shafar, 1972 ¹⁴²	130	55.4 [26.2]	2.1 (1.3 to 3.4)	0.29 (0.13 to 0.45)	3 (2 to 8)	292 (131 to 454)
Amitriptyline	Adverse events: Severe	Medium Couch, 2011 ¹¹¹	391	15.5 [5.1]	3.0 (1.5 to 6.1)	0.10 (0.04 to 0.16)	10 (6 to 22)	104 (44 to 163)
Amitriptyline	Body as a whole	Medium Couch, 2011 ¹¹¹	391	12.9 [6.6]	2.0 (1.0 to 3.7)	0.06 (0.00 to 0.12)	16 (8 to 230)	63 (4 to 121)
Amitriptyline	Integument	Medium Couch, 2011 ¹¹¹	391	35.1 [9.1]	3.8 (2.4 to 6.2)	0.26 (0.18 to 0.34)	4 (3 to 6)	259 (181 to 337)
Amitriptyline	Psychiatric	Medium Couch, 2011 ¹¹¹	391	31.4 [15.2]	2.1 (1.4 to 3.0)	0.16 (0.08 to 0.24)	6 (4 to 13)	162 (80 to 245)
Amitriptyline	Digestive	Medium Couch, 2011 ¹¹¹	391	14.4 [7.6]	1.9 (1.0 to 3.4)	0.07 (0.01 to 0.13)	15 (8 to 156)	68 (6 to 130)
Amitriptyline	Urogenital Urinary retention	Medium Couch, 2011 ¹¹¹	391	3.1 [0.0]	13.2 (0.7 to 232.7)	0.03 (0.00 to 0.06)	32 (18 to 209)	31 (5 to 57)
Fluoxetine	Tremor	Medium Saper, 1994 ¹¹⁷	111	19.7 [6.0]	3.3 (1.0 to 11.0)	0.14 (0.02 to 0.26)	7 (4 to 58)	137 (17 to 256)
Fluoxetine	Stomach pain	Medium Saper, 1994 ¹¹⁷	111	13.1 [0.0]	14.0 (0.8 to 236.5)	0.13 (0.04 to 0.22)	8 (5 to 24)	131 (41 to 221)

Appendix Table D127. Significant increase in risk of adverse effects with migraine preventive drugs vs. placebo, results from individual RCTs (continued)

Drug	Adverse Effect	Risk of Bias Reference	Sample	% with Active Drugs [Placebo]	Relative Risk (95%CI)	Absolute Risk Difference (95%CI)	Number Needed to Treat (95%CI)	Attributable Events (95%CI)
Fluoxetine	Pyrosis	Medium d'Amato, 1999 ¹¹⁹	52	21.9 [0.0]	9.5 (0.6 to 158.5)	0.22 (0.06 to 0.38)	5 (3 to 16)	219 (62 to 376)
Venlafaxine	Vomiting	Medium Ozyalcin, 2005 ¹²²	40	23.8 [0.0]	10.0 (0.6 to 169.6)	0.24 (0.04 to 0.43)	4 (2 to 22)	238 (45 to 432)
Dihydro-ergotamine	Nausea, sleepiness, mild gastralgias and abdominal discomfort	Medium Bousser, 1988 ²³³	90	13.3 [2.2]	6.0 (0.8 to 47.8)	0.11 (0.00 to 0.22)	9 (5 to 350)	111 (3 to 219)
Magnesium	Total adverse effects	Low Pfaffenrath, 1996	69	45.7 [23.5]	1.9 (1.0 to 3.9)	0.22 (0.00 to 0.44)	5 (2 to 267)	222 (4 to 440)
Tizanidine	Dizziness	Medium Saper, 2002 ²³⁴	136	23.6 [6.3]	3.8 (1.3 to 10.6)	0.17 (0.06 to 0.29)	6 (3 to 17)	174 (59 to 288)
Tizanidine	Dry mouth	Medium Saper, 2002 ²³⁴	136	22.2 [1.6]	14.2 (1.9 to 104.3)	0.21 (0.11 to 0.31)	5 (3 to 9)	207 (106 to 307)
Tizanidine	Asthenia	Medium Saper, 2002 ²³⁴	136	19.4 [3.1]	6.2 (1.5 to 26.3)	0.16 (0.06 to 0.26)	6 (4 to 16)	163 (62 to 264)
Tizanidine	Sleepiness	Medium Saper, 2002 ²³⁴	136	45.8 [4.7]	9.8 (3.1 to 30.4)	0.41 (0.29 to 0.54)	2 (2 to 4)	411 (285 to 538)
Indomethacin	Insomnia	Medium Anthony, 1968 ²⁰⁰	38	26.3 [0.0]	11.0 (0.7 to 186.0)	0.26 (0.06 to 0.47)	4 (2 to 18)	263 (56 to 470)
Indomethacin	Indigestion	Medium Anthony, 1968 ²⁰⁰	38	36.8 [5.3]	7.0 (1.0 to 51.5)	0.32 (0.08 to 0.55)	3 (2 to 13)	316 (77 to 555)
Nifedipine	Total adverse effects	High McArthur, 1989 ¹²⁹	48	54.2 [8.3]	6.5 (1.6 to 25.8)	0.46 (0.23 to 0.69)	2 (1 to 4)	458 (230 to 686)
Nifedipine	Dizziness	High McArthur, 1989 ¹²⁹	48	45.8 [0.0]	23.0 (1.4 to 369.5)	0.46 (0.26 to 0.66)	2 (2 to 4)	458 (255 to 661)
Nifedipine	Headache	High McArthur, 1989 ¹²⁹	48	16.7 [0.0]	9.0 (0.5 to 158.5)	0.17 (0.01 to 0.33)	6 (3 to 157)	167 (6 to 327)
Nimodipine	Abdominal cramps	Medium Gelmers, 1983 ¹²⁷	60	16.7 [0.0]	11.0 (0.6 to 190.5)	0.17 (0.03 to 0.31)	6 (3 to 40)	167 (25 to 308)
Verapamil	Constipation	Medium Markley, 1984 ¹²⁴	40	30.0 [0.0]	13.0 (0.8 to 216.4)	0.30 (0.09 to 0.51)	3 (2 to 11)	300 (92 to 508)
Nifedipine	Edema	High McArthur, 1989 ¹²⁹	48	45.8 [0.0]	23.0 (1.4 to 369.5)	0.46 (0.26 to 0.66)	2 (2 to 4)	458 (255 to 661)
Tonabersat	Total adverse effects	Low 19222510	124	39.0 [15.4]	2.5 (1.3 to 4.9)	0.24 (0.08 to 0.39)	4 (3 to 12)	236 (84 to 388)
Tonabersat	Vertigo	Low Goadsby, 2009 ¹²¹	124	8.5 [0.0]	12.1 (0.7 to 214.2)	0.08 (0.01 to 0.16)	12 (6 to 114)	85 (9 to 161)

Appendix Table D128. Dose response adverse effects with topiramate in adults

Adverse effect	Reference Risk of Bias	Active vs. Control Daily Dose	Events/Randomized (Rate of Outcome in Active Group) Events/Randomized (Rate of Outcome in Control Group)	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Abnormal vision	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	6/514 (1.2) 12/235 (5.1)	0.2 (0.1 to 0.6)	-0.04 (-0.07 to -0.01)
Abnormal vision	Adelman, 2008⁴⁰ Risk of bias Low	200 vs. 100	38/514 (7.4) 14/386 (3.6)	2.0 (1.1 to 3.7)	0.04 (0.01 to 0.07)
Anorexia	Adelman, 2008⁴⁰ Risk of bias Low	100 vs. 50	56/386 (14.5) 22/235 (9.4)	1.5 (1.0 to 2.5)	0.05 (0.00 to 0.10)
Anorexia leading to withdrawal	Adelman, 2008⁴⁰ Risk of bias Low	200 vs. 50	14/514 (2.7) 2/235 (0.9)	3.2 (0.7 to 14.0)	0.02 (0.00 to 0.04)
Any adverse event	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 100	187/514 (36.4) 227/386 (58.8)	0.6 (0.5 to 0.7)	-0.22 (-0.29 to -0.16)
Arthralgia	Adelman, 2008 ⁴⁰ Risk of bias Low	100 vs. 50	11/386 (2.8) 17/235 (7.2)	0.4 (0.2 to 0.8)	-0.04 (-0.08 to -0.01)
Arthralgia	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	7/514 (1.4) 17/235 (7.2)	0.2 (0.1 to 0.4)	-0.06 (-0.09 to -0.02)
Arthralgia	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	4/514 (0.8) 8/235 (3.4)	0.2 (0.1 to 0.8)	-0.03 (-0.05 to 0.00)
Depression leading to withdrawal	Adelman, 2008⁴⁰ Risk of bias Low	200 vs. 50	14/514 (2.7) 1/235 (0.4)	6.4 (0.8 to 48.4)	0.02 (0.01 to 0.04)
Depression leading to withdrawal	Adelman, 2008⁴⁰ Risk of bias Low	200 vs. 100	14/514 (2.7) 3/386 (0.8)	3.5 (1.0 to 12.1)	0.02 (0.00 to 0.04)
Difficulty in memory leading to withdrawal	Adelman, 2008⁴⁰ Risk of bias Low	100 vs. 50	8/386 (2.1) 1/235 (0.4)	4.9 (0.6 to 38.7)	0.02 (0.00 to 0.03)
Difficulty in memory leading to withdrawal	Adelman, 2008⁴⁰ Risk of bias Low	200 vs. 50	24/514 (4.7) 1/235 (0.4)	11.0 (1.5 to 80.6)	0.04 (0.02 to 0.06)
Difficulty in memory leading to withdrawal	Adelman, 2008⁴⁰ Risk of bias Low	200 vs. 100	24/514 (4.7) 8/386 (2.1)	2.3 (1.0 to 5.0)	0.03 (0.00 to 0.05)
Difficulty with concentration/attention	Adelman, 2008⁴⁰ Risk of bias Low	200 vs. 50	51/514 (9.9) 7/235 (3.0)	3.3 (1.5 to 7.2)	0.07 (0.04 to 0.10)
Difficulty with concentration/attention	Adelman, 2008⁴⁰ Risk of bias Low	200 vs. 100	51/514 (9.9) 23/386 (6.0)	1.7 (1.0 to 2.7)	0.04 (0.00 to 0.07)
Difficulty with memory	Adelman, 2008⁴⁰ Risk of bias Low	200 vs. 100	57/514 (11.1) 26/386 (6.7)	1.6 (1.1 to 2.6)	0.04 (0.01 to 0.08)
Dry mouth	Adelman, 2008⁴⁰ Risk of bias Low	200 vs. 50	26/514 (5.1) 4/235 (1.7)	3.0 (1.0 to 8.4)	0.03 (0.01 to 0.06)
Hypoesthesia leading to withdrawal	Adelman, 2008⁴⁰ Risk of bias Low	200 vs. 50	12/514 (2.3) 1/235 (0.4)	5.5 (0.7 to 41.9)	0.02 (0.00 to 0.03)

Appendix Table 128. Significant dose response adverse effects with topiramate in adults (continued)

Adverse effect	Reference Risk of Bias	Active vs. Control Daily Dose	Events/Randomized (Rate of Outcome in Active Group) Events/Randomized (Rate of Outcome in Control Group)	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Marked anorexia	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	6/514 (1.2) 0/235 (0.0)	6.0 (0.3 to 105.3)	0.01 (0.00 to 0.02)
Marked fatigue	Adelman, 2008 ⁴⁰ Risk of bias Low	100 vs. 50	6/386 (1.6) 0/235 (0.0)	7.9 (0.4 to 140.1)	0.02 (0.00 to 0.03)
Marked fatigue	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	15/514 (2.9) 0/235 (0.0)	14.2 (0.9 to 236.4)	0.03 (0.01 to 0.05)
Marked paresthesia	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	20/514 (3.9) 3/235 (1.3)	3.0 (0.9 to 10.2)	0.03 (0.00 to 0.05)
Markedly low serum bicarbonate levels (range >5mmol/L to <17mmo/L below baseline)	Adelman, 2008 ⁴⁰ Risk of bias Low	50 vs. 0	5/235 (2.0) 57/514 (11.0)	0.2 (0.1 to 0.5)	-0.09 (-0.12 to -0.06)
Markedly low serum bicarbonate levels (range >5mmol/L to <17mmo/L below baseline)	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	35/386 (9.0) 5/235 (2.0)	4.3 (1.7 to 10.7)	0.07 (0.04 to 0.10)
Mild paresthesia	Adelman, 2008 ⁴⁰ Risk of bias Low	100 vs. 50	130/386 (33.7) 54/235 (23.0)	1.5 (1.1 to 1.9)	0.11 (0.04 to 0.18)
Mild paresthesia	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	169/514 (32.9) 54/235 (23.0)	1.4 (1.1 to 1.9)	0.10 (0.03 to 0.17)
Moderate anorexia	Adelman, 2008 ⁴⁰ Risk of bias Low	100 vs. 50	23/386 (6.0) 4/235 (1.7)	3.5 (1.2 to 10.0)	0.04 (0.01 to 0.07)
Moderate anorexia	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	22/514 (4.3) 4/235 (1.7)	2.5 (0.9 to 7.2)	0.03 (0.00 to 0.05)
Moderate nausea	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	36/514 (7.0) 7/235 (3.0)	2.4 (1.1 to 5.2)	0.04 (0.01 to 0.07)
Mood problems	Adelman, 2008 ⁴⁰ Risk of bias Low	100 vs. 50	23/386 (6.0) 6/235 (2.6)	2.3 (1.0 to 5.6)	0.03 (0.00 to 0.07)
Mood problems	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	28/514 (5.4) 6/235 (2.6)	2.1 (0.9 to 5.1)	0.03 (0.00 to 0.06)
Nausea	Adelman, 2008 ⁴⁰ Risk of bias Low	100 vs. 50	16/386 (4.1) 2/235 (0.9)	4.9 (1.1 to 21.0)	0.03 (0.01 to 0.06)
Nausea	Adelman, 2008 ⁴⁰ Risk of bias Low	100 vs. 50	51/235 (21.7) 21/386 (5.4)	4.0 (2.5 to 6.5)	0.16 (0.11 to 0.22)
Nausea	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	73/235 (31.1) 21/514 (4.1)	7.6 (4.8 to 12.0)	0.27 (0.21 to 0.33)
Nausea	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 100	8/514 (1.6) 16/386 (4.1)	0.4 (0.2 to 0.9)	-0.03 (-0.05 to 0.00)
Nausea	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 100	73/386 (18.9) 51/514 (9.9)	1.9 (1.4 to 2.7)	0.09 (0.04 to 0.14)

Appendix Table 128. Significant dose response adverse effects with topiramate in adults (continued)

Adverse effect	Reference Risk of Bias	Active vs. Control Daily Dose	Events/Randomized (Rate of Outcome in Active Group) Events/Randomized (Rate of Outcome in Control Group)	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Nausea leading to withdrawal	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 100	29/514 (5.6) 9/386 (2.3)	2.4 (1.2 to 5.1)	0.03 (0.01 to 0.06)
Paresthesia	Adelman, 2008 ⁴⁰ Risk of bias Low	100 vs. 50	34/386 (8.8) 11/235 (4.7)	1.9 (1.0 to 3.6)	0.04 (0.00 to 0.08)
Paresthesia	Adelman, 2008 ⁴⁰ Risk of bias Low	100 vs. 50	195/386 (50.5) 83/235 (35.3)	1.4 (1.2 to 1.7)	0.15 (0.07 to 0.23)
Paresthesia	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	254/514 (49.4) 83/235 (35.3)	1.4 (1.2 to 1.7)	0.14 (0.07 to 0.22)
Paresthesia leading to withdrawal	Adelman, 2008 ⁴⁰ Risk of bias Low	100 vs. 50	31/386 (8.0) 8/235 (3.4)	2.4 (1.1 to 5.0)	0.05 (0.01 to 0.08)
Paresthesia leading to withdrawal	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	37/514 (7.2) 8/235 (3.4)	2.1 (1.0 to 4.5)	0.04 (0.01 to 0.07)
Pharyngitis	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	9/514 (1.8) 11/235 (4.7)	0.4 (0.2 to 0.9)	-0.03 (-0.06 to 0.00)
Pharyngitis	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 100	9/514 (1.8) 22/386 (5.7)	0.3 (0.1 to 0.7)	-0.04 (-0.07 to -0.01)
Pharyngitis	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 100	4/514 (0.8) 12/386 (3.1)	0.3 (0.1 to 0.8)	-0.02 (-0.04 to 0.00)
Taste perversion	Adelman, 2008 ⁴⁰ Risk of bias Low	100 vs. 50	30/386 (7.8) 36/235 (15.3)	0.5 (0.3 to 0.8)	-0.08 (-0.13 to -0.02)
Taste perversion	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 100	63/514 (12.3) 30/386 (7.8)	1.6 (1.0 to 2.4)	0.04 (0.01 to 0.08)
Treatment discontinuation	Adelman, 2008 ⁴⁰ Risk of bias Low	100 vs. 50	146/386 (37.8) 108/235 (46.0)	0.8 (0.7 to 1.0)	-0.08 (-0.16 to 0.00)
Treatment discontinuation	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	149/514 (29.0) 41/235 (17.4)	1.7 (1.2 to 2.3)	0.12 (0.05 to 0.18)
Treatment discontinuation	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 100	239/514 (46.5) 146/386 (37.8)	1.2 (1.0 to 1.4)	0.09 (0.02 to 0.15)
Upper respiratory tract infection	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 100	32/514 (6.2) 42/386 (10.9)	0.6 (0.4 to 0.9)	-0.05 (-0.08 to -0.01)
Weight loss	Adelman, 2008 ⁴⁰ Risk of bias Low	200 vs. 50	58/514 (11.3) 13/235 (5.5)	2.0 (1.1 to 3.6)	0.06 (0.02 to 0.10)

Bold = significant increase in risk of adverse effects with increasing the dose of topiramate when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

CI = confidence interval

Appendix Table D129. Dose response in treatment discontinuation due to bothersome adverse effects with divalproex for migraine prevention in adults, results from low risk of bias randomized controlled clinical trial⁴⁷

Adverse Effect that Lead to Discontinuation	Daily Doses of Divalproex	Events/Randomized with Larger Dose	Events/Randomized with Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Abdominal pain	1000 mg vs. 500 mg	1/43	0/45	3.1 (0.1 to 75.0)	0.02 (-0.04 to 0.08)
Abdominal pain	1500 mg vs. 1000 mg	0/44	1/43	0.3 (0.0 to 7.8)	-0.02 (-0.09 to 0.04)
Alopecia	1500 mg vs. 500 mg	1/44	0/45	3.1 (0.1 to 73.3)	0.02 (-0.04 to 0.08)
Alopecia	1500 mg vs. 1000 mg	1/44	0/43	2.9 (0.1 to 70.1)	0.02 (-0.04 to 0.08)
Asthenia	1000 mg vs. 500 mg	0/43	1/45	0.3 (0.0 to 8.3)	-0.02 (-0.08 to 0.04)
Asthenia	1500 mg vs. 500 mg	0/44	1/45	0.3 (0.0 to 8.1)	-0.02 (-0.08 to 0.04)
Back pain	1500 mg vs. 500 mg	1/44	0/45	3.1 (0.1 to 73.3)	0.02 (-0.04 to 0.08)
Back pain	1500 mg vs. 1000 mg	1/44	0/43	2.9 (0.1 to 70.1)	0.02 (-0.04 to 0.08)
Constipation	1000 mg vs. 500 mg	0/43	1/45	0.3 (0.0 to 8.3)	-0.02 (-0.08 to 0.04)
Constipation	1500 mg vs. 500 mg	0/44	1/45	0.3 (0.0 to 8.1)	-0.02 (-0.08 to 0.04)
Depression	1000 mg vs. 500 mg	3/43	0/45	7.3 (0.4 to 137.6)	0.07 (-0.02 to 0.16)
Depression	1500 mg vs. 1000 mg	0/44	3/43	0.1 (0.0 to 2.6)	-0.07 (-0.16 to 0.02)
Diarrhea	1500 mg vs. 500 mg	1/44	0/45	3.1 (0.1 to 73.3)	0.02 (-0.04 to 0.08)
Diarrhea	1500 mg vs. 1000 mg	1/44	0/43	2.9 (0.1 to 70.1)	0.02 (-0.04 to 0.08)
Emotional liability	1500 mg vs. 500 mg	1/44	0/45	3.1 (0.1 to 73.3)	0.02 (-0.04 to 0.08)
Emotional liability	1500 mg vs. 1000 mg	1/44	0/43	2.9 (0.1 to 70.1)	0.02 (-0.04 to 0.08)
Nausea	1000 mg vs. 500 mg	1/43	1/45	1.0 (0.1 to 16.2)	0.00 (-0.06 to 0.06)
Nausea	1500 mg vs. 500 mg	4/44	1/45	4.1 (0.5 to 35.2)	0.07 (-0.03 to 0.16)

Appendix Table D129. Dose response in treatment discontinuation due to bothersome adverse effects with divalproex for migraine prevention in adults, results from low risk of bias randomized controlled clinical trial (continued)

Adverse Effect that Lead to Discontinuation	Daily Doses of Divalproex	Events/Randomized with Larger Dose	Events/Randomized with Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Nausea	1500 mg vs. 1000 mg	4/44	1/43	3.9 (0.5 to 33.6)	0.07 (-0.03 to 0.16)
Pharyngitis	1000 mg vs. 500 mg	1/43	0/45	3.1 (0.1 to 75.0)	0.02 (-0.04 to 0.08)
Pharyngitis	1500 mg vs. 1000 mg	0/44	1/43	0.3 (0.0 to 7.8)	-0.02 (-0.09 to 0.04)
Pneumonia	1000 mg vs. 500 mg	0/43	1/45	0.3 (0.0 to 8.3)	-0.02 (-0.08 to 0.04)
Pneumonia	1500 mg vs. 500 mg	0/44	1/45	0.3 (0.0 to 8.1)	-0.02 (-0.08 to 0.04)
Somnolence	1500 mg vs. 500 mg	1/44	0/45	3.1 (0.1 to 73.3)	0.02 (-0.04 to 0.08)
Somnolence	1500 mg vs. 1000 mg	1/44	0/43	2.9 (0.1 to 70.1)	0.02 (-0.04 to 0.08)
Thinking abnormal	1500 mg vs. 500 mg	1/44	0/45	3.1 (0.1 to 73.3)	0.02 (-0.04 to 0.08)
Thinking abnormal	1500 mg vs. 1000 mg	1/44	0/43	2.9 (0.1 to 70.1)	0.02 (-0.04 to 0.08)
Vomiting	1000 mg vs. 500 mg	0/43	1/45	0.3 (0.0 to 8.3)	-0.02 (-0.08 to 0.04)
Vomiting	1500 mg vs. 500 mg	1/44	1/45	1.0 (0.1 to 15.8)	0.00 (-0.06 to 0.06)
Vomiting	1500 mg vs. 1000 mg	1/44	0/43	2.9 (0.1 to 70.1)	0.02 (-0.04 to 0.08)
Weight gain	1500 mg vs. 500 mg	1/44	0/45	3.1 (0.1 to 73.3)	0.02 (-0.04 to 0.08)
Weight gain	1500 mg vs. 1000 mg	1/44	0/43	2.9 (0.1 to 70.1)	0.02 (-0.04 to 0.08)

CI = confidence interval

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

Appendix Table D130. Dose response in adverse effects with divalproex for migraine prevention in adults, results from low risk of bias randomized controlled clinical trial⁴⁷

Adverse Effect	Daily Doses of Divalproex	Events/ Randomized with Larger Dose	Events/ Randomized with Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Attributable Events per 1000 Treated (95% CI)
Asthenia	1000 mg vs. 500 mg	4/43	4/45	1.0 (0.3 to 3.9)	0.00 (-0.12 to 0.12)	NS
Asthenia	1500 mg vs. 500 mg	10/44	4/45	2.6 (0.9 to 7.5)	0.14 (-0.01 to 0.29)	NS
Asthenia	1500 mg vs. 1000 mg	10/44	4/43	2.4 (0.8 to 7.2)	0.13 (-0.02 to 0.29)	NS
Back pain	1000 mg vs. 500 mg	2/43	3/45	0.7 (0.1 to 4.0)	-0.02 (-0.12 to 0.08)	NS
Back pain	1500 mg vs. 500 mg	6/44	3/45	2.0 (0.5 to 7.7)	0.07 (-0.06 to 0.19)	NS
Back pain	1500 mg vs. 1000 mg	6/44	2/43	2.9 (0.6 to 13.7)	0.09 (-0.03 to 0.21)	NS
Diarrhea	1000 mg vs. 500 mg	2/43	3/45	0.7 (0.1 to 4.0)	-0.02 (-0.12 to 0.08)	NS
Diarrhea	1500 mg vs. 500 mg	8/44	3/45	2.7 (0.8 to 9.6)	0.12 (-0.02 to 0.25)	NS
Diarrhea	1500 mg vs. 1000 mg	8/44	2/43	3.9 (0.9 to 17.4)	0.14 (0.01 to 0.27)	135 (5 to 265)
Dizziness	1000 mg vs. 500 mg	3/43	3/45	1.0 (0.2 to 4.9)	0.00 (-0.10 to 0.11)	NS
Dizziness	1500 mg vs. 500 mg	9/44	3/45	3.1 (0.9 to 10.6)	0.14 (0.00 to 0.28)	NS
Dizziness	1500 mg vs. 1000 mg	9/44	3/43	2.9 (0.9 to 10.1)	0.13 (-0.01 to 0.28)	NS
Dyspepsia	1000 mg vs. 500 mg	8/43	3/45	2.8 (0.8 to 9.8)	0.12 (-0.02 to 0.26)	NS
Dyspepsia	1500 mg vs. 500 mg	7/44	3/45	2.4 (0.7 to 8.6)	0.09 (-0.04 to 0.22)	NS
Dyspepsia	1500 mg vs. 1000 mg	7/44	8/43	0.9 (0.3 to 2.2)	-0.03 (-0.19 to 0.13)	NS
Infection	1000 mg vs. 500 mg	7/43	8/45	0.9 (0.4 to 2.3)	-0.01 (-0.17 to 0.14)	NS
Infection	1500 mg vs. 500 mg	9/44	8/45	1.2 (0.5 to 2.7)	0.03 (-0.14 to 0.19)	NS
Infection	1500 mg vs. 1000 mg	9/44	7/43	1.3 (0.5 to 3.1)	0.04 (-0.12 to 0.20)	NS

Appendix Table 130. Dose response in adverse effects with divalproex for migraine prevention in adults, results from low risk of bias randomized controlled clinical trial (continued)

Adverse Effect	Daily Doses of Divalproex	Events/ Randomized with Larger Dose	Events/ Randomized with Smaller Dose	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Attributable Events per 1000 Treated (95% CI)
Nausea	1000 mg vs. 500 mg	4/43	12/45	0.3 (0.1 to 1.0)	-0.17 (-0.33 to -0.02)	-174 (-329 to -18)
Nausea	1500 mg vs. 500 mg	15/44	12/45	1.3 (0.7 to 2.4)	0.07 (-0.12 to 0.26)	NS
Nausea	1500 mg vs. 1000 mg	15/44	4/43	3.7 (1.3 to 10.2)	0.25 (0.08 to 0.41)	248 (83 to 413)
Pain	1000 mg vs. 500 mg	3/43	4/45	0.8 (0.2 to 3.3)	-0.02 (-0.13 to 0.09)	NS
Pain	1500 mg vs. 500 mg	5/44	4/45	1.3 (0.4 to 4.5)	0.02 (-0.10 to 0.15)	NS
Pain	1500 mg vs. 1000 mg	5/44	3/43	1.6 (0.4 to 6.4)	0.04 (-0.08 to 0.16)	NS
Somnolence	1000 mg vs. 500 mg	3/43	3/45	1.0 (0.2 to 4.9)	0.00 (-0.10 to 0.11)	NS
Somnolence	1500 mg vs. 500 mg	8/44	3/45	2.7 (0.8 to 9.6)	0.12 (-0.02 to 0.25)	NS
Somnolence	1500 mg vs. 1000 mg	8/44	3/43	2.6 (0.7 to 9.2)	0.11 (-0.03 to 0.25)	NS
Tremor	1000 mg vs. 500 mg	3/43	0/45	7.3 (0.4 to 137.6)	0.07 (-0.02 to 0.16)	NS
Tremor	1500 mg vs. 500 mg	7/44	0/45	15.3 (0.9 to 260.6)	0.16 (0.05 to 0.27)	159 (46 to 272)
Tremor	1500 mg vs. 1000 mg	7/44	3/43	2.3 (0.6 to 8.2)	0.09 (-0.04 to 0.22)	NS
Vomiting	1000 mg vs. 500 mg	2/43	2/45	1.0 (0.2 to 7.1)	0.00 (-0.09 to 0.09)	NS
Vomiting	1500 mg vs. 500 mg	5/44	2/45	2.6 (0.5 to 12.5)	0.07 (-0.04 to 0.18)	NS
Vomiting	1500 mg vs. 1000 mg	5/44	2/43	2.4 (0.5 to 11.9)	0.07 (-0.05 to 0.18)	NS

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval; NS= not significant; Number needed to treat and number of attributable events were calculated for statistically significant differences

Appendix Table D131. Adverse effects with valproate vs. placebo for migraine prevention in adults, results from medium risk of bias randomized controlled clinical trials

Adverse Effects	Daily Dose	Reference	Events/ Randomized with Valproate	Events/ Randomized Placebo	Rate,% with Valproate [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Abdominal pain	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	2/43	1/43	4.7[2.3]	2.0 (0.2 to 21.2)	0.02 (-0.05 to 0.10)
Constipation	400 mg twice a day	Hering, 1992 ⁴⁸	0/32	1/32	0.0[3.1]	0.3 (0.0 to 7.9)	-0.03 (-0.11 to 0.05)
Diarrhea	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	1/43	0/43	2.3[0.0]	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.09)
Dizziness	400 mg twice a day	Hering, 1992 ⁴⁸	0/32	1/32	0.0[3.1]	0.3 (0.0 to 7.9)	-0.03 (-0.11 to 0.05)
Drowsiness	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	5/43	2/43	11.6[4.7]	2.5 (0.5 to 12.2)	0.07 (-0.04 to 0.18)
Dry mouth	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	1/43	0/43	2.3[0.0]	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.09)
Dyspepsia	400 mg twice a day	Hering, 1992 ⁴⁸	2/32	0/32	6.3[0.0]	5.0 (0.2 to 100.2)	0.06 (-0.04 to 0.16)
Dyspnea	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	1/43	0/43	2.3[0.0]	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.09)
Increased appetite	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	1/43	1/43	2.3[2.3]	1.0 (0.1 to 15.5)	0.00 (-0.06 to 0.06)
Mild weariness	400 mg twice a day	Hering, 1992 ⁴⁸	2/32	0/32	6.3[0.0]	5.0 (0.2 to 100.2)	0.06 (-0.04 to 0.16)
Nausea	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	5/43	2/43	11.6[4.7]	2.5 (0.5 to 12.2)	0.07 (-0.04 to 0.18)
Nausea	400 mg twice a day	Hering, 1992 ⁴⁸	2/32	0/32	6.3[0.0]	5.0 (0.2 to 100.2)	0.06 (-0.04 to 0.16)
Pain in neck/shoulders	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	1/43	0/43	2.3[0.0]	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.09)
Restless legs	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	1/43	0/43	2.3[0.0]	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.09)
Tinnitus	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	0/43	1/43	0.0[2.3]	0.3 (0.0 to 8.0)	-0.02 (-0.09 to 0.04)
Total	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	14/43	7/43	32.6[16.3]	2.0 (0.9 to 4.5)	0.16 (-0.02 to 0.34)
Tremor	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	1/43	0/43	2.3[0.0]	3.0 (0.1 to 71.7)	0.02 (-0.04 to 0.09)
Vertigo	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	3/43	0/43	7.0[0.0]	7.0 (0.4 to 131.6)	0.07 (-0.02 to 0.16)
Weight gain	1000mg to 1500 mg per day	Jensen, 1994 ⁴⁹	3/43	1/43	7.0[2.3]	3.0 (0.3 to 27.7)	0.05 (-0.04 to 0.13)

CI = confidence interval

Appendix Table D132. Adverse effects with propranolol vs. placebo, pooled results from randomized controlled clinical trials (random effects model)

Definition of the Outcome	Sample	Rate with Drug [Placebo]	Odds Ratio (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm (95% CI)	Attributable Events per 1000 Treated (95% CI)
Any adverse effects ^{50, 60, 61, 64}	414	28.4 [17.0]	1.7 (1.1 to 2.8)	0.09 (0.01 to 0.17)	11 (6 to 111)	88 (9 to 167)
Paresthesia ^{43, 52}	273	10.3 [4.5]	2.1 (0.7 to 6.3)	0.04 (-0.02 to 0.10)	NS	NS
Cold extremities ^{53, 62}	125	6.1 [1.7]	2.7 (0.4 to 17.6)	0.04 (-0.03 to 0.10)	NS	NS
Depression ^{53, 60, 61, 236}	411	5.3 [2.5]	2.3 (0.3 to 17.2)	0.03 (-0.02 to 0.09)	NS	NS
Diarrhea ^{53, 236}	169	11.4 [2.5]	4.6 (1.0 to 22.3)	0.09 (0.01 to 0.16)	11 (6 to 71)	89 (14 to 164)
Dreaming, abnormal. ^{60, 236}	306	4.6 [0.7]	7.8 (0.9 to 66.0)	0.04 (-0.06 to 0.14)	NS	NS
Fatigue ^{43, 52, 53, 60, 62, 236}	657	21.3 [11.0]	2.1 (0.8 to 5.8)	0.10 (-0.03 to 0.23)	NS	NS
Insomnia ^{43, 52, 53, 60, 62}	542	9.2 [6.0]	1.4 (0.7 to 2.8)	0.02 (-0.01 to 0.06)	NS	NS
Nausea ^{43, 52, 53, 60-62, 236}	694	9.3 [3.5]	2.3 (1.1 to 4.5)	0.04 (0.01 to 0.08)	23 (13 to 111)	43 (9 to 77)
Sleepiness ^{43, 236}	307	14.9 [2.8]	8.5 (2.5 to 29.0)	0.16 (-0.03 to 0.35)	NS	NS
Dizziness ^{52, 53, 60, 62}	349	5.4 [3.4]	1.6 (0.6 to 4.3)	0.02 (-0.02 to 0.06)	NS	NS

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval; NS= not significant; Number needed to treat and number of attributable events were calculated for statistically significant differences

Appendix Table D133. Adverse effects with timolol 10mg twice a day (results from randomized controlled clinical trials pooled with random effects model)

Outcome; Reference	Sample	Rate with Timolol [Placebo]	Odds Ratio (95% CI)	Absolute Risk Difference (95% CI)	Attributable Events per 1000 Treated (95% CI)
Total adverse effects^{60, 61}	183	38.0 [23.1]	1.9 (1.0 to 3.8)	0.14 (0.00 to 0.28)	137 (0 to 275)
Dizziness ^{60, 79}	238	5.6 [3.2]	1.8 (0.5 to 7.1)	0.03 (-0.02 to 0.08)	NS
Tiredness ^{60, 61, 79}	277	16.1 [9.8]	1.4 (0.7 to 3.0)	0.04 (-0.03 to 0.11)	NS
Insomnia ^{60, 79}	238	7.7 [3.2]	3.1 (0.8 to 11.6)	0.05 (-0.03 to 0.13)	NS
Nausea ^{60, 61}	182	1.7 [2.5]	0.5 (0.1 to 3.7)	-0.01 (-0.05 to 0.04)	NS

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

CI = confidence interval; NS= not significant; Number needed to treat and number of attributable events were calculated for statistically significant differences

Appendix Table D134. Adverse effects with timolol 10mg twice a day (results from randomized controlled clinical trials)

Adverse Effects	Reference Risk of Bias	Events/Randomized with Active Drug	Events/Randomized with Placebo	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Abnormal dreaming	Tfelt-Hansen, 1984 ⁶⁰ Medium	2/96	0/96	5.0 (0.2 to 102.8)	0.02 (-0.01 to 0.06)
Blurred vision	Standnes, 1982 ⁶¹ Medium	1/25	0/25	3.0 (0.1 to 70.3)	0.04 (-0.06 to 0.14)
Cold extremities	Standnes, 1982 ⁶¹ Medium	1/25	0/25	3.0 (0.1 to 70.3)	0.04 (-0.06 to 0.14)
Depression	Tfelt-Hansen, 1984 ⁶⁰ Medium	2/96	0/96	5.0 (0.2 to 102.8)	0.02 (-0.01 to 0.06)
Dyspnea	Standnes, 1982 ⁶¹ Medium	1/25	0/25	3.0 (0.1 to 70.3)	0.04 (-0.06 to 0.14)
Fatigue/tiredness	Tfelt-Hansen, 1984 ⁶⁰ Medium	18/96	8/48	1.1 (0.5 to 2.5)	0.02 (-0.11 to 0.15)
Gastroenteritis	Standnes, 1982 ⁶¹ Medium	1/25	0/25	3.0 (0.1 to 70.3)	0.04 (-0.06 to 0.14)
Increased weight	Standnes, 1982 ⁶¹ Medium	1/25	0/25	3.0 (0.1 to 70.3)	0.04 (-0.06 to 0.14)
Sleep disturbances	Tfelt-Hansen, 1984 ⁶⁰ Medium	4/96	1/48	2.0 (0.2 to 17.4)	0.02 (-0.04 to 0.08)
Tiredness	Standnes, 1982 ⁶¹ Medium	6/25	2/13	1.6 (0.4 to 6.7)	0.09 (-0.17 to 0.34)

Appendix Table D 135. Treatment discontinuation due to adverse effects with off label migraine preventive drugs vs. placebo, pooled with random effects model results from randomized controlled clinical trials

Active Drug	Reference	Events/ Randomized with Drug	Events/ Randomized with Placebo	Relative Risk (95% CI)	Relative Risk Weight (Inverse Variance)	Absolute Risk Difference (95% CI)	Absolute Risk Difference Weight (Inverse Variance)	Arcsine Transformed Risk Difference (95% CI)	Arcsine Transformed Risk Difference Weight
Amitriptyline	Couch, 2011 ¹¹¹	23/194	13/197	1.8 (0.9 to 3.4)	85.8	0.05 (-0.01 to 0.11)	70.37	0.09 (-0.01 to 0.19)	77.17
Amitriptyline	Couch, 1979 ¹⁰³	5/55	2/61	2.8 (0.6 to 13.7)	14.2	0.06 (-0.03 to 0.15)	29.63	0.12 (-0.06 to 0.31)	22.83
Amitriptyline	Pooled	28/249	15/258	1.9 (1.0 to 3.5)	100	0.05 (0.01 to 0.10)	100	0.10 (0.01 to 0.19)	100
Clonidine	Boisen, 1978 ¹⁴⁶	2/71	0/71	5.0 (0.2 to 102.3)	38.41	0.03 (-0.02 to 0.08)	36.3	0.17 (0.00 to 0.33)	44.23
Clonidine	Adam. 1978 ¹⁴⁸	2/96	1/96	2.0 (0.2 to 21.7)	61.59	0.01 (-0.03 to 0.05)	63.7	0.04 (-0.10 to 0.18)	55.77
Clonidine	Pooled	4/167	1/167	2.8 (0.4 to 18.5)	100	0.02 (-0.01 to 0.05)	100	0.10 (-0.02 to 0.22)	100
Femoxetine	Orholm, 1986 ¹¹³	4/31	2/34	2.2 (0.4 to 11.2)	52.65	0.07 (-0.07 to 0.21)	50.09	0.12 (-0.12 to 0.37)	52.37
Femoxetine	Orholm, 1985 ¹¹⁵	3/29	2/30	1.6 (0.3 to 8.6)	47.35	0.04 (-0.11 to 0.18)	49.91	0.07 (-0.19 to 0.32)	47.63
Femoxetine	Pooled	7/60	4/64	1.9 (0.6 to 6.1)	100	0.05 (-0.05 to 0.15)	100	0.10 (-0.08 to 0.27)	100
Gabapentin	NCT00742209 ¹⁹²	13/62	2/20	2.1 (0.5 to 8.5)	31.39	0.11 (-0.06 to 0.28)	21.89	0.18 (-0.07 to 0.43)	26.43
Gabapentin	Mathew, 2001 ⁸¹	16/98	4/45	1.8 (0.7 to 5.2)	57.25	0.07 (-0.04 to 0.19)	49.16	0.11 (-0.06 to 0.29)	53.91
Gabapentin	Wessely, 1987 ⁸⁴	2/23	1/22	1.9 (0.2 to 19.6)	11.36	0.04 (-0.10 to 0.19)	28.95	0.08 (-0.21 to 0.38)	19.66
Gabapentin	Pooled	31/183	7/87	1.9 (0.9 to 4.2)	100	0.07 (-0.01 to 0.15)	100	0.13 (0.00 to 0.26)	100
Lamotrigine	Steiner, 1997 ⁸⁷	7/18	3/40	5.2 (1.5 to 17.8)	54.39	0.31 (0.07 to 0.55)	43.22	0.40 (0.12 to 0.67)	46.23
Lamotrigine	Gupta, 2007 ⁴⁴	3/60	3/60	1.0 (0.2 to 4.8)	45.61	0.00 (-0.08 to 0.08)	56.78	0.00 (-0.18 to 0.18)	53.77
Lamotrigine	Pooled	10/78	6/100	2.4 (0.5 to 12.2)	100	0.14 (-0.17 to 0.44)	100	0.18 (-0.20 to 0.57)	100
Magnesium	Pfaffenrath, 1996 ¹⁹⁴	3/35	1/34	2.9 (0.3 to 26.7)	63.69	0.06 (-0.05 to 0.17)	39.24	0.13 (-0.11 to 0.36)	46.09

Appendix Table D135. Treatment discontinuation due to adverse effects with off label migraine preventive drugs vs. placebo, pooled with random effects model results from individual randomized controlled clinical trials (continued)

Active Drug	Reference	Events/ Randomized with Drug	Events/ Randomized with Placebo	Relative Risk (95% CI)	Relative Risk Weight (Inverse Variance)	Absolute Risk Difference (95% CI)	Absolute Risk Difference Weight (Inverse Variance)	Arcsine Transformed Risk Difference (95% CI)	Arcsine Transformed Risk Difference Weight
Magnesium	Peikert, 1996 ¹⁹⁵	3/43	0/38	6.2 (0.3 to 116.4)	36.31	0.07 (-0.02 to 0.16)	60.76	0.27 (0.05 to 0.49)	53.91
Magnesium	Pooled	6/78	1/72	3.8 (0.7 to 22.4)	100	0.06 (0.00 to 0.13)	100	0.20 (0.04 to 0.36)	100
Naproxen sodium	Welch, 1985 ^{237, 238}	2/46	1/46	2.0 (0.2 to 21.3)	64.25	0.02 (-0.05 to 0.09)	45.78	0.06 (-0.14 to 0.27)	53.49
Naproxen sodium	Ziegler, 1985 ²³⁹	1/40	0/40	3. 0(0.1 to 71.5)	35.75	0.03 (-0.04 to 0.09)	54.22	0.16 (-0.06 to 0.38)	46.51
Naproxen sodium	Pooled	3/86	1/86	2.3 (0.3 to 15.4)	100	0.02 (-0.03 to 0.07)	100	0.11 (-0.04 to 0.26)	100
Nimodipine	Havanka- Kanninen, 1985 ¹³²	0/33	1/33	0.3 (0.0 to 7.9)	17.11	-0.03 (-0.11 to 0.05)	66	-0.18 (-0.42 to 0.07)	42.61
Nimodipine	MINES, 1989 ¹³³	3/43	4/46	0.8 (0.2 to 3.4)	82.89	-0.02 (-0.13 to 0.09)	34	-0.03 (-0.24 to 0.18)	57.39
Nimodipine	Pooled	3/76	5/79	0.7 (0.2 to 2.6)	100	-0.03 (-0.09 to 0.04)	100	-0.09 (-0.25 to 0.07)	100

Active Drug	Degree of Freedom	P Value Relative Risk	I Squared Relative Risk	P Value Absolute Risk Difference	I Squared Absolute Risk Difference	P Value, Arcsine Transformed Risk Difference	I Squared, Arcsine Transformed Risk Difference
Amitriptyline	1	0.62	0.00%	0.01	60.30%	0.02	58.40%
Clonidine	1	0.64	0.00%	0.22	32.30%	0.24	26.90%
Femoxetine	1	0.77	0.00%	0.31	4.60%	0.31	2.90%
Gabapentin	2	0.99	0.00%	0.86	0.00%	0.67	0.00%
Lamotrigine	1	0.11	62.00%	0.92	0.00%	0.76	0.00%
Magnesium	1	0.69	0.00%	0.55	0.00%	0.26	22.90%
Naproxen	1	0.84	0.00%	0.75	0.00%	0.76	0.00%
Nimodipine	1	0.62	0.00%	0.83	0.00%	0.87	0.00%

Appendix Table D136. Adverse effects with antiepileptic drugs vs. placebo, pooled results from randomized controlled clinical trials (random effects model)

Drug	Outcome, Reference	Sample	Rate with Drug [Placebo]	Odds Ratio (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm (95% CI)	Attributable Events per 1000 Treated (95% CI)
Divalproex	Diarrhea ^{46, 47}	297	6.6 [3.6]	1.8 (0.6 to 5.2)	0.03 (-0.02 to 0.08)	NS	NS
Divalproex	Asthenia ⁴⁵⁻⁴⁷	404	17.3 [9.8]	2.1 (0.5 to 9.5)	0.11 (-0.07 to 0.30)	NS	NS
Divalproex	Sleepiness ⁴⁵⁻⁴⁷	405	15.6 [2.8]	4.9 (1.9 to 13.0)	0.13 (0.00 to 0.26)	NS	NS
Divalproex	Tremor^{45, 47}	166	14.0 [0.0]	8.5 (1.1 to 66.1)	0.14 (0.06 to 0.21)	7 (5 to 16)	137 (64 to 211)
Divalproex	Vomiting⁴⁵⁻⁴⁷	404	11.0 [1.4]	5.3 (1.5 to 18.4)	0.11 (0.02 to 0.20)	9 (5 to 63)	108 (16 to 200)
Divalproex	Infection ^{46, 47}	298	16.2 [14.3]	1.1 (0.6 to 2.0)	0.01 (-0.08 to 0.09)	NS	NS
Divalproex	Nausea ⁴⁵⁻⁴⁷	403	22.9 [9.5]	2.7 (1.2 to 6.0)	0.13 (-0.04 to 0.29)	NS	NS
Valproate	Nausea ^{48, 49}	150	9.3 [2.7]	3.2 (0.7 to 14.0)	0.07 (-0.01 to 0.14)	NS	NS
Gabapentin	Any adverse effects^{81, 192}	225	70.6 [54.4]	2.0 (1.1 to 3.6)	0.16 (0.02 to 0.30)	6 (3 to 56)	158 (18 to 297)
Gabapentin	Weight increase (gain) ^{81, 192}	321	5.2 [3.8]	1.5 (0.4 to 5.4)	0.01 (-0.03 to 0.06)	NS	NS
Gabapentin	Dizziness^{81, 192}	406	28.0 [7.5]	4.3 (1.4 to 12.9)	0.19 (0.05 to 0.34)	5 (3 to 20)	193 (51 to 335)
Gabapentin	Infection ^{81, 192}	225	8.7 [17.8]	0.4 (0.2 to 1.0)	-0.06 (-0.19 to 0.07)	NS	NS
Gabapentin	Sleepiness^{81, 192}	225	20.6 [7.6]	3.3 (1.2 to 8.9)	0.13 (0.04 to 0.22)	8 (5 to 24)	128 (41 to 216)

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
NS= not significant; Number needed to treat and number of attributable events were calculated for statistically significant differences

Appendix Table D137. Adverse effects with acetazolamide, 500 mg/day vs. placebo for migraine prevention in adults, results from low risk of bias randomized controlled clinical trial⁸⁰

Adverse effect	Events/ Randomized with Acetazolamide	Events/ Randomized with Placebo	Rate, % with Active Drug [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat (95% CI)	Attributable Events (95% CI)
Paresthesia	21/26	2/27	80.8 [7.4]	10.9 (2.8 to 41.9)	0.73 (0.55 to 0.91)	1 (1 to 2)	734 (553 to 914)
Fatigue, drowsiness, memory impairment, malaise, fasciculation	15/26	4/27	57.7 [14.8]	3.9 (1.5 to 10.2)	0.43 (0.20 to 0.66)	2 (2 to 5)	429 (196 to 661)
Gastrointestinal intolerance	3/26	2/27	11.5 [7.4]	1.6 (0.3 to 8.6)	0.04 (-0.12 to 0.20)	NS	NS
Hypokalemia	1/26	0/27	3.8 [0.0]	3.1 (0.1 to 73.1)	0.04 (-0.06 to 0.14)	NS	NS
Hyperuricemia	1/26	0/27	3.8 [0.0]	3.1 (0.1 to 73.1)	0.04 (-0.06 to 0.14)	NS	NS
Skin eruption	0/26	2/27	0.0 [7.4]	0.2 (0.0 to 4.1)	-0.07 (-0.19 to 0.04)	NS	NS
Fever and shivering	0/26	1/27	0.0 [3.7]	0.3 (0.0 to 8.1)	-0.04 (-0.13 to 0.06)	NS	NS
Dry mouth	1/26	1/27	3.8 [3.7]	1.0 (0.1 to 15.7)	0.00 (-0.10 to 0.10)	NS	NS
Breast tension	0/26	1/27	0.0 [3.7]	0.3 (0.0 to 8.1)	-0.04 (-0.13 to 0.06)	NS	NS
Rhinitis	1/26	2/27	3.8 [7.4]	0.5 (0.1 to 5.4)	-0.04 (-0.16 to 0.09)	NS	NS
Tinnitus	0/26	1/27	0.0 [3.7]	0.3 (0.0 to 8.1)	-0.04 (-0.13 to 0.06)	NS	NS
Miscellaneous	1/26	3/27	3.8 [11.1]	0.3 (0.0 to 3.1)	-0.07 (-0.21 to 0.07)	NS	NS

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence level; NS= not significant; Number needed to treat and number of attributable events were calculated for statistically significant differences

Appendix Table D138. Adverse effects with carbamazepine vs. placebo for migraine prevention in adults, results from medium risk of bias randomized controlled clinical trial⁸⁶

Adverse Effect	Events/ Randomized with Active Drug	Events/ Randomized with Placebo	Rate, % with Active Drug [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm (95% CI)	Attributable Events per 1000 Treated (95% CI)
Drowsiness	5/48	0/48	10.4 [0.0]	11.0 (0.6 to 193.6)	0.10 (0.01 to 0.20)	10 (5 to 88)	104 (11 to 197)
Vertigo or giddiness	23/48	2/48	47.9 [4.2]	11.5 (2.9 to 46.1)	0.44 (0.29 to 0.59)	2 (2 to 4)	438 (285 to 590)
Total	30/48	11/48	62.5 [22.9]	2.7 (1.6 to 4.8)	0.40 (0.21 to 0.58)	3 (2 to 5)	396 (214 to 577)
Necessitating reduction of dosage	6/48	0/48	12.5 [0.0]	13.0 (0.8 to 224.5)	0.13 (0.03 to 0.22)	8 (4 to 39)	125 (26 to 224)
Nausea	4/48	3/48	8.3 [6.3]	1.3 (0.3 to 5.6)	0.02 (-0.08 to 0.12)	NS	NS
Dry mouth	2/48	0/48	4.2 [0.0]	5.0 (0.2 to 101.5)	0.04 (-0.03 to 0.11)	NS	NS
Heavy eyes	2/48	0/48	4.2 [0.0]	5.0 (0.2 to 101.5)	0.04 (-0.03 to 0.11)	NS	NS
Constipation	2/48	0/48	4.2 [0.0]	5.0 (0.2 to 101.5)	0.04 (-0.03 to 0.11)	NS	NS
Vomiting	1/48	0/48	2.1 [0.0]	3.0 (0.1 to 71.9)	0.02 (-0.04 to 0.08)	NS	NS
Weight gain	1/48	1/48	2.1 [2.1]	1.0 (0.1 to 15.5)	0.00 (-0.06 to 0.06)	NS	NS
Sweating	1/48	0/48	2.1 [0.0]	3.0 (0.1 to 71.9)	0.02 (-0.04 to 0.08)	NS	NS
Transient rash	1/48	0/48	2.1 [0.0]	3.0 (0.1 to 71.9)	0.02 (-0.04 to 0.08)	NS	NS
Dysuria	1/48	0/48	2.1 [0.0]	3.0 (0.1 to 71.9)	0.02 (-0.04 to 0.08)	NS	NS
Blackened nose	0/48	1/48	0.0 [2.1]	0.3 (0.0 to 8.0)	-0.02 (-0.08 to 0.04)	NS	NS
Lack of drive	0/48	1/48	0.0 [2.1]	0.3 (0.0 to 8.0)	-0.02 (-0.08 to 0.04)	NS	NS
Flushing	0/48	1/48	0.0 [2.1]	0.3 (0.0 to 8.0)	-0.02 (-0.08 to 0.04)	NS	NS
Blunted feeling	0/48	1/48	0.0 [2.1]	0.3 (0.0 to 8.0)	-0.02 (-0.08 to 0.04)	NS	NS
Heavy head	0/48	1/48	0.0 [2.1]	0.3 (0.0 to 8.0)	-0.02 (-0.08 to 0.04)	NS	NS

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence level; NS= not significant; Number needed to treat and number of attributable events were calculated for statistically significant differences

Appendix Table D139. Adverse effects with gabapentin, titrated up to 2400 mg daily vs. placebo for migraine prevention in adults, results from medium risk of bias randomized controlled clinical trial⁸¹

Adverse Effect	Events/ Randomized with Active Drug	Events/ Randomized with Placebo	Rate, % with Active Drug [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm (95% CI)	Attributable Events per 1000 Treated (95% CI)
Dizziness	25/98	5/98	25.5 [11.1]	2.3 (0.9 to 5.6)	0.14 (0.02 to 0.27)	7 (4 to 56)	144 (18 to 270)
Somnolence	24/98	5/98	24.5 [11.1]	2.2 (0.9 to 5.4)	0.13 (0.01 to 0.26)	7 (4 to 117)	134 (9 to 259)
Asthenia	22/98	12/98	22.4 [26.7]	0.8 (0.5 to 1.5)	-0.04 (-0.20 to 0.11)	NS	NS
Infection	11/98	11/98	11.2 [24.4]	0.5 (0.2 to 1.0)	-0.13 (-0.27 to 0.01)	NS	NS
Weight gain	3/98	1/98	3.1 [2.2]	1.4 (0.1 to 12.9)	0.01 (-0.05 to 0.06)	NS	NS
Designated as probably, possibly, or definitely related to study drug (Total)	66/98	22/98	67.3 [48.9]	1.4 (1.0 to 1.9)	0.18 (0.01 to 0.36)	5 (3 to 87)	185 (12 to 358)

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence level ;NS= not significant; Number needed to treat and number of attributable events were calculated for statistically significant differences

Appendix Table D140. Treatment discontinuation due to bothersome adverse effects with lamotrigine, titrated up to 200 mg daily vs. placebo for migraine prevention in adults, results from low risk of bias randomized controlled clinical trial⁸⁷

Adverse Effect	Events/ Randomized with Active Drug	Events/ Randomized with Placebo	Rate, % with Active Drug [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95%CI)	Number Needed to Treat to Harm (95% CI)	Attributable Events per 1000 Treated (95% CI)
Rash	7/18	1/40	38.9 [3]	15.6 (2.1 to 117.3)	0.36 (0.13 to 0.59)	3 (2 to 7)	364 (134 to 594)
Dizziness	1/18	0/40	5.6 [0]	6.5 (0.3 to 151.7)	0.06 (-0.07 to 0.18)	NS	NS
Leucopenia	0/18	1/40	0.0 [3]	0.7 (0.0 to 16.9)	-0.03 (-0.12 to 0.07)	NS	NS
Dyspepsia	0/18	1/40	0.0 [3]	0.7 (0.0 to 16.9)	-0.03 (-0.12 to 0.07)	NS	NS
Nausea	0/18	1/40	0.0 [3]	0.7 (0.0 to 16.9)	-0.03 (-0.12 to 0.07)	NS	NS
Other	2/18	1/40	11.1 [3]	4.4 (0.4 to 45.9)	0.09 (-0.07 to 0.24)	NS	NS
Any	7/18	3/40	38.9 [8]	5.2 (1.5 to 17.8)	0.31 (0.07 to 0.55)	3 (2 to 13)	314 (74 to 553)

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

CI = confidence level; NS= not significant; Number needed to treat and number of attributable events were calculated for statistically significant differences

Appendix Table D141. Adverse effects with oxcarbazepine, titrated to a maximum tolerated dose of 1,200 mg/day vs. placebo for migraine prevention in adults, results from low risk of bias randomized controlled clinical trial⁸³

Adverse Effect	Events/ Randomized with Active Drug	Events/ Randomized with Placebo	Rate, % with Active Drug [Placebo]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm (95% CI)	Attributable Events per 1000 Treated (95% CI)
Patients with any adverse effects	68/85	55/85	80.0 [64.7]	1.2 (1.0 to 1.5)	0.15 (0.02 to 0.29)	7 (4 to 49)	153 (20 to 285)
Fatigue	17/85	6/85	20.0 [7.1]	2.8 (1.2 to 6.8)	0.13 (0.03 to 0.23)	8 (4 to 35)	129 (28 to 230)
Dizziness	15/85	6/85	17.6 [7.1]	2.5 (1.0 to 6.1)	0.11 (0.01 to 0.20)	9 (5 to 121)	106 (8 to 204)
Nausea	14/85	4/85	16.5 [4.7]	3.5 (1.2 to 10.2)	0.12 (0.03 to 0.21)	8 (5 to 37)	118 (27 to 208)
Somnolence	7/85	6/85	8.2 [7.1]	1.2 (0.4 to 3.3)	0.01 (-0.07 to 0.09)	NS	NS
Balance disorder	5/85	2/85	5.9 [2.4]	2.5 (0.5 to 12.5)	0.04 (-0.02 to 0.09)	NS	NS
Insomnia	5/85	6/85	5.9 [7.1]	0.8 (0.3 to 2.6)	-0.01 (-0.09 to 0.06)	NS	NS
Migraine	5/85	2/85	5.9 [2.4]	2.5 (0.5 to 12.5)	0.04 (-0.02 to 0.09)	NS	NS
Paresthesia	5/85	1/85	5.9 [1.2]	5.0 (0.6 to 41.9)	0.05 (-0.01 to 0.10)	NS	NS
Sinusitis	2/85	5/85	2.4 [5.9]	0.4 (0.1 to 2.0)	-0.04 (-0.09 to 0.02)	NS	NS

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence level; NS= not significant; Number needed to treat and number of attributable events were calculated for statistically significant differences

Appendix Table D142. Adverse effects with off label antidepressants vs. placebo, pooled results from randomized controlled clinical trials (random effects model)

Active Drug	Outcome, Reference	Sample	Rate with Drug [Placebo]	Odds Ratio (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm (95% CI)	Attributable Events per 1000 Treated (95% CI)
Amitriptyline	Total adverse effects ^{104, 111}	494	60.2 [28.8]	4.0 (2.2 to 7.3)	0.32 (0.18 to 0.47)	3 (2 to 6)	322 (175 to 469)
Amitriptyline	Dizziness ^{104, 111}	431	10.3 [5.1]	2.1 (1.0 to 4.4)	0.05 (0.00 to 0.10)	19 (10 to 500)	52 (2 to 102)
Amitriptyline	Depression ^{104, 111}	431	2.3 [1.4]	1.7 (0.4 to 7.3)	0.01 (-0.01 to 0.03)	NS	NS
Amitriptyline	Dry mouth ^{104, 111}	431	32.7 [6.9]	6.6 (3.6 to 12.0)	0.18 (-0.05 to 0.40)	NS	NS
Amitriptyline	Drowsiness ^{104, 111}	431	27.1 [9.2]	3.6 (2.1 to 6.3)	0.18 (0.11 to 0.25)	6 (4 to 9)	180 (109 to 251)
Amitriptyline	Weight increase (gain) ^{104, 111}		1.9 [1.8]	1.0 (0.2 to 4.4)	0.00 (-0.02 to 0.03)		
Amitriptyline	Constipation ^{104, 111}	431	11.2 [3.7]	3.2 (1.4 to 7.1)	0.07 (0.03 to 0.12)	14 (8 to 40)	74 (25 to 123)
Amitriptyline	Nausea ^{104, 111}	431	2.8 [2.3]	1.2 (0.4 to 4.1)	0.01 (-0.02 to 0.03)	NS	NS
Femoxetine	Adverse events: Any ^{113, 114}	124	23.0 [6.3]	4.4 (1.3 to 14.6)	0.17 (0.05 to 0.29)	6 (3 to 21)	167 (48 to 286)
Femoxetine	Nausea ^{113, 114}	124	3.3 [0.0]	3.2 (0.3 to 31.5)	0.03 (-0.03 to 0.09)	NS	NS
Fluoxetine	Adverse events ^{116, 117, 119}	195	56.9 [45.3]	2.1 (1.0 to 4.2)	0.12 (0.01 to 0.24)	8 (4 to 200)	121 (5 to 238)
Fluoxetine	Insomnia ^{117, 119}	163	20.4 [15.7]	1.5 (0.6 to 3.4)	0.06 (-0.03 to 0.15)	NS	NS

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

CI = confidence interval; NS= not significant; Number needed to treat and number of attributable events were calculated for statistically significant differences

Appendix Table D143. Strength of evidence of treatment discontinuation due to adverse effects with beta-blockers for migraine prevention in adults (evidence from randomized controlled clinical trials)

Reference	Drug	Risk of Bias	Directness	Consistency	Precision	Strength of Evidence
Forssman, 1982 ⁹⁵ Forssman, 1983 ⁹⁶	Atenolol	Medium	Yes	Not applicable	No	Low
van de Ven, 1997 ¹⁰¹	Bisoprolol	Medium	Yes	Not applicable	No	Low
Andersson, 1983 ⁹⁷	Metoprolol	Medium	Yes	Not applicable	No	Low
Freitag, 1984 ⁹⁸	Nadolol	Low	Yes	Not applicable	No	Low
Sjaastad, 1972 ⁸⁹	Pindolol (LB-46)	Medium	Yes	Not applicable	No	Low

Appendix Table D144. Treatment discontinuation due to adverse effects with beta-blockers for migraine prevention in adults, results from individual randomized controlled clinical trials

Reference Risk of Bias	Drug and Dose	Outcome	Events/ Randomized [Rate of Outcome with Drug, %]	Events/ Randomized [Rate of Outcome with Placebo, %]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Johannsson, 1987 ⁹⁹ Medium	Atenolol 100mg	Withdrawal due to side effects	0/72 [0.0%]	3/72 [4.2%]	0.1 (0.0 to 2.7)	-0.04 (-0.09 to 0.0)
Forssman, 1982 ⁹⁵ Forssman, 1983 ⁹⁶ Medium	Atenolol 100mg/day	Withdrawal due to mood alternations and increased tiredness	1/24 [4.2%]	0/24 [0.0%]	3.0 (0.1 to 70.2)	0.04 (-0.07 to 0.1)
Forssman, 1982 ⁹⁵ Forssman, 1983 ⁹⁶ Medium	Atenolol 100mg/day	Withdrawal due to intolerable increase of headache attack	0/24 [0.0%]	1/24 [4.2%]	0.3 (0.0 to 7.8)	-0.04 (-0.15 to 0.1)
van de Ven, 1997 ¹⁰¹ Medium	Bisoprolol 5mg/day Bisoprolol 10mg/day	Dropped out of the study due to adverse effects	4/74 [5.4%] 7/77 [9.1%]	2/37 [5.3%] 2/38 [5.3%]	1.0 (0.2 to 5.2) 1.7 (0.4 to 7.9)	0.00 (-0.09 to 0.1) 0.04 (-0.06 to 0.1)
Andersson, 1983 ⁹⁷ Medium	Metoprolol 200mg/day thereafter	Discontinued due to side-effects	1/34 [2.9%]	1/37 [2.7%]	1.1 (0.1 to 16.7)	0.00 (-0.07 to 0.1)
Freitag, 1984 ⁹⁸ Low	Nadolol 80mg to 240mg/day	Discontinued due to bradycardia	1/24 [4.2%]	0/8 [0.0%]	1.1 (0.0 to 24.2)	0.04 (-0.13 to 0.2)
Sjaastad, 1972 ⁸⁹ Medium	Pindolol (LB-46) 7.5 to 15mg	Discontinued due to side-effects	3/28 [10.7%]	0/28 [0.0%]	7.0 (0.4 to 129.5)	0.11 (-0.02 to 0.2)

Appendix Table D145. Adverse effects with beta-blockers for migraine prevention in adults (results from randomized controlled clinical trials)

Active Drug	Outcome, Reference	Sample	Rate with Drug [Placebo]	Odds Ratio (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm (95% CI)	Attributable Events per 1000 Treated (95% CI)
Atenolol	Tiredness, diffuse ^{62, 95}	118	5.1 [0.0]	4.2 (0.4 to 38.8)	0.04 (-0.02 to 0.11)	NS	NS
Metoprolol	Fatigue^{97, 102}	91	18.2 [4.3]	4.6 (0.9 to 24.4)	0.14 (0.02 to 0.27)	7 (4 to 67)	141 (15 to 268)
Metoprolol	Sleep disturbances^{97, 100}	225	9.9 [4.4]	2.3 (0.6 to 9.1)	0.05 (0.00 to 0.11)	19 (9 to 1000)	54 (1 to 106)
Metoprolol	Gastrointestinal disturbances ^{97, 102}	91	2.3 [12.8]	0.2 (0.0 to 1.3)	-0.10 (-0.20 to 0.01)	NS	NS

Bold = significant differences at 95% CI when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0; NS= not significant; Number needed to treat and number of attributable events were calculated for statistically significant differences

Appendix Table D146. Comparative safety of topiramate vs. onabotulinumtoxin A for migraine prevention in adults (results from individual randomized controlled clinical trials)

Adverse Effects	Reference Risk of Bias	Events/ Randomized with Topiramate	Events/ Randomized with Onabotulinumtoxin A	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Nausea	Cady, 2011 ¹⁶³ Medium	6/30	13/29	0.4 (0.2 to 1.0)	-0.25 (-0.48 to -0.02)
Mood swing	Cady, 2011 ¹⁶³ Medium	6/30	4/29	1.5 (0.5 to 4.6)	0.06 (-0.13 to 0.25)
Difficulty concentrating or with memory	Cady, 2011 ¹⁶³ Medium	11/30	13/29	0.8 (0.4 to 1.5)	-0.08 (-0.33 to 0.17)
Mild fatigue	Cady, 2011 ¹⁶³ Medium	15/30	16/29	0.9 (0.6 to 1.5)	-0.05 (-0.31 to 0.20)
Cognitive deficits (probable)	Mathew, 2009 ¹⁶¹ High	0/30	0/30	0.0 (0.0 to 0.0)	0.00 (0.00 to 0.00)
Dry mouth/thirst (definite)	Mathew, 2009 ¹⁶¹ High	1/30	0/30	3.0 (0.1 to 70.8)	0.03 (-0.05 to 0.12)
Sleepiness/tiredness/fatigue/dizziness (probable)	Mathew, 2009 ¹⁶¹ High	1/30	1/30	1.0 (0.1 to 15.3)	0.00 (-0.09 to 0.09)
Depression/mood disturbance (probable)	Mathew, 2009 ¹⁶¹ High	1/30	0/30	3.0 (0.1 to 70.8)	0.03 (-0.05 to 0.12)
Appetite/weight loss (probable)	Mathew, 2009 ¹⁶¹ High	1/30	0/30	3.0 (0.1 to 70.8)	0.03 (-0.05 to 0.12)
Night sweats (probable)	Mathew, 2009 ¹⁶¹ High	1/30	0/30	3.0 (0.1 to 70.8)	0.03 (-0.05 to 0.12)
Night sweats (definite)	Mathew, 2009 ¹⁶¹ High	2/30	0/30	5.0 (0.3 to 100.0)	0.07 (-0.04 to 0.17)
Blurred vision/vision problems (definite)	Mathew, 2009 ¹⁶¹ High	2/30	0/30	5.0 (0.3 to 100.0)	0.07 (-0.04 to 0.17)
Blurred vision/vision problems (probable)	Mathew, 2009 ¹⁶¹ High	2/30	0/30	5.0 (0.3 to 100.0)	0.07 (-0.04 to 0.17)
Sleepiness/tiredness/fatigue/dizziness (definite)	Mathew, 2009 ¹⁶¹ High	3/30	2/30	1.5 (0.3 to 8.3)	0.03 (-0.11 to 0.17)
Dry mouth/thirst (probable)	Mathew, 2009 ¹⁶¹ High	3/30	0/30	7.0 (0.4 to 129.9)	0.10 (-0.02 to 0.22)
Depression/mood disturbance (definite)	Mathew, 2009 ¹⁶¹ High	5/30	0/30	11.0 (0.6 to 190.5)	0.17 (0.03 to 0.31)
Appetite/weight loss (definite)	Mathew, 2009¹⁶¹ High	8/30	0/30	17.0 (1.0 to 281.9)	0.27 (0.10 to 0.43)
Paresthesia (probable)	Mathew, 2009¹⁶¹ High	11/30	0/30	23.0 (1.4 to 373.5)	0.37 (0.19 to 0.54)

Appendix Table D146. Comparative safety of topiramate vs. onabotulinumtoxin A for migraine prevention in adults (results from individual randomized controlled clinical trials) (continued)

Adverse Effects	Reference Risk of Bias	Events/ Randomized with Topiramate	Events/ Randomized with Onabotulinumtoxin A	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Paresthesia (definite)	Mathew, 2009 ¹⁶¹ High	14/30	3/30	4.7 (1.5 to 14.6)	0.37 (0.16 to 0.57)
Cognitive deficits (definite)	Mathew, 2009 ¹⁶¹ High	15/30	0/30	31.0 (1.9 to 495.6)	0.50 (0.32 to 0.68)
Drug-related adverse effects	Mathew, 2009 ¹⁶¹ High	25/30	18/30	1.4 (1.0 to 1.9)	0.23 (0.01 to 0.45)
Probable/possible drug-related	Mathew, 2009 ¹⁶¹ High	26/30	22/30	1.2 (0.9 to 1.5)	0.13 (-0.07 to 0.33)
All adverse effects	Mathew, 2009 ¹⁶¹ High	28/30	26/30	1.1 (0.9 to 1.3)	0.07 (-0.08 to 0.22)

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D147. Comparative safety of divalproex sodium vs. onabotulinumtoxin A for migraine prevention in adults (results from a single medium risk of bias randomized controlled clinical trial)¹⁶⁴

Adverse Effect	Events/ Randomized with Divalproex	Events/ Randomized with Onabotulinumtoxin A	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Ptosis, eyelid (possibly related to treatment)	0/29	8/30	0.1 (0.0 to 1.0)	-0.27 (-0.43 to -0.10)
Ptosis, eyebrow (possibly related to treatment)	0/29	5/30	0.1 (0.0 to 1.6)	-0.17 (-0.31 to -0.02)
Headache intensity/frequency increase (possibly related to treatment)	0/29	2/30	0.2 (0.0 to 4.1)	-0.07 (-0.17 to 0.04)
Vision disturbance (possibly related to treatment)	2/29	1/30	2.1 (0.2 to 21.6)	0.04 (-0.08 to 0.15)
Dizziness (possibly related to treatment)	2/29	0/30	5.2 (0.3 to 103.2)	0.07 (-0.04 to 0.18)
Infection, viral (possibly related to treatment)	2/29	0/30	5.2 (0.3 to 103.2)	0.07 (-0.04 to 0.18)
Numbness (possibly related to treatment)	2/29	0/30	5.2 (0.3 to 103.2)	0.07 (-0.04 to 0.18)
Pruritis (possibly related to treatment)	2/29	0/30	5.2 (0.3 to 103.2)	0.07 (-0.04 to 0.18)
Tinnitus (possibly related to treatment)	2/29	0/30	5.2 (0.3 to 103.2)	0.07 (-0.04 to 0.18)
Tremors (possibly related to treatment)	3/29	0/30	7.2 (0.4 to 134.2)	0.10 (-0.02 to 0.23)
Other gastrointestinal discomfort (possibly related to treatment)	3/29	0/30	7.2 (0.4 to 134.2)	0.10 (-0.02 to 0.23)
Sleepiness (possibly related to treatment)	4/29	0/30	9.3 (0.5 to 165.4)	0.14 (0.00 to 0.27)
Weight gain (possibly related to treatment)	4/29	1/30	4.1 (0.5 to 34.9)	0.10 (-0.04 to 0.25)
Fatigue (possibly related to treatment)	5/29	0/30	11.4 (0.7 to 196.7)	0.17 (0.03 to 0.32)
Hair loss (possibly related to treatment)	5/29	1/30	5.2 (0.6 to 41.6)	0.14 (-0.01 to 0.29)
Nausea (possibly related to treatment)	9/29	1/30	9.3 (1.3 to 68.9)	0.28 (0.10 to 0.46)
Related to treatment adverse effect	18/29	12/30	1.6 (0.9 to 2.6)	0.22 (-0.03 to 0.47)
Possibly related to treatment adverse effect	22/29	15/30	1.5 (1.0 to 2.3)	0.26 (0.02 to 0.50)

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0.
CI = confidence interval

Appendix Table D148. Comparative safety of amitriptyline vs. botulinum toxin type A for migraine prevention in adults (results from a single high risk of bias randomized controlled clinical trial)¹⁶²

Adverse Effect	Events/ Randomized with Amitriptyline	Events/ Randomized with Botulinum	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Constipation	14/37	0/35	27.5 (1.7 to 443.8)	0.38 (0.22 to 0.54)
Dry mouth	16/37	5/35	3.0 (1.2 to 7.4)	0.29 (0.09 to 0.49)
Somnolence	19/37	1/35	18.0 (2.5 to 127.2)	0.48 (0.31 to 0.66)
Weight gain	22/37	4/35	5.2 (2.0 to 13.6)	0.48 (0.29 to 0.67)

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D149. Treatment discontinuation due to adverse effects with migraine preventive drugs compared to each other, results from individual randomized controlled clinical trials

Active vs. Control Drug	Adverse Effect that Resulted in Treatment Discontinuation	Reference Risk of Bias	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Topiramate vs. Amitriptyline	Fatigue	Dodick, 2009 ¹⁷² Risk of bias Low	1.4 (0.4 to 5.0)	0.01 (-0.03 to 0.05)
Topiramate vs. Amitriptyline	Hypesthesia	Dodick, 2009 ¹⁷² Risk of bias Low	6.6 (0.3 to 127.7)	0.02 (-0.01 to 0.04)
Topiramate vs. Amitriptyline	Dizziness	Dodick, 2009 ¹⁷² Risk of bias Low	6.6 (0.3 to 127.7)	0.02 (-0.01 to 0.04)
Topiramate vs. Lamotrigine	Any adverse event	Gupta, 2007 ⁴⁴ Risk of bias Low	1.0 (0.2 to 4.8)	0.00 (-0.08 to 0.08)
Topiramate vs. Histamine	Any adverse event	Millan-Guerrero, 200¹⁶⁹ Risk of bias Low	21.0 (1.3 to 347.9)	0.22 (0.10 to 0.35)
Topiramate vs. Levetiracetam	Somnolence (drowsiness) and sedation	de Tommaso, 2007 ¹⁶⁸ Risk of bias Medium	3.4 (0.2 to 77.6)	0.08 (-0.11 to 0.26)
Propranolol vs. Nadolol	Any adverse event	Sudilovsky, 1987 ¹⁹¹ Risk of bias Medium	2.1 (0.4 to 11.1)	0.05 (-0.05 to 0.15)
Amitriptyline vs. Dihydroergotamine	Any adverse event	Bonuso, 1983 ¹⁵⁹ Risk of bias Medium	1.4 (0.3 to 7.7)	0.04 (-0.16 to 0.24)
Clomipramine vs. Metoprolol	Severe	Langohr, 1985¹⁸⁴ Risk of bias Medium	37.0 (2.3 to 600.9)	0.29 (0.17 to 0.40)
Venlafaxine vs. Amitriptyline	Any adverse event	Bulut, 2004 ¹⁰⁹ Risk of bias Medium	0.2 (0.0 to 1.6)	-0.15 (-0.32 to 0.01)
Metoprolol vs. Bisoprolol	Any adverse event	Worz, 1991 ¹⁸⁶ Risk of bias Medium	0.6 (0.2 to 1.8)	-0.04 (-0.12 to 0.05)
Metoprolol vs. Nebivolol	Any adverse event	Schellenberg, 2008 ¹⁸⁹ Risk of bias Medium	1.1 (0.1 to 16.6)	0.01 (-0.17 to 0.19)
Metoprolol vs. Aspirin	Drowsiness	Grottemeyer, 1990 ¹⁸⁵ Risk of bias Medium	5.0 (0.3 to 99.7)	0.07 (-0.04 to 0.18)
Metoprolol vs. Aspirin	Gastrointestinal side-effects	Grottemeyer, 1990 ¹⁸⁵ Risk of bias Medium	0.1 (0.0 to 1.6)	-0.18 (-0.33 to -0.03)
Metoprolol vs. Clonidine	Discontinued due to adverse event and/or lack of efficacy	Louis, 1985 ¹⁸³ Risk of bias Medium	0.1 (0.0 to 2.0)	-0.13 (-0.26 to 0.00)
Dihydroergocryptine vs. Dihydroergotamine	Gastric pain	Frediani, 1991 ²⁴⁰ Risk of bias Medium	0.2 (0.0 to 4.0)	-0.07 (-0.17 to 0.04)
Dihydroergocryptine vs. Dihydroergotamine	Nausea(severe)	Frediani, 1991 ²⁴⁰ Risk of bias Medium	0.2 (0.0 to 4.0)	-0.07 (-0.17 to 0.04)

Appendix Table D149. Treatment discontinuation due to adverse effects with migraine preventive drugs compared to each other, results from individual randomized controlled clinical trials (continued)

Active vs. Control Drug	Adverse Effect that Resulted in Treatment Discontinuation	Reference Risk of Bias	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Dihydroergocryptine vs. Dihydroergotamine	Skin rash(severe)	Frediani, 1991 ²⁴⁰ Risk of bias Medium	3.0 (0.1 to 70.8)	0.03 (-0.05 to 0.12)
Lisuride vs. Lisuride	Gastric pain and feeling badly	Bisceglia, 1990 ²⁴¹ Risk of bias Medium	0.3 (0.0 to 7.7)	-0.05 (-0.18 to 0.08)
Lisuride vs. Methysergide	Any adverse event	Hermann, 1977 ¹⁵³ Risk of bias Medium	0.4 (0.3 to 0.7)	-0.22 (-0.33 to -0.11)
Lisuride vs. Methysergide	Tiredness	Hermann, 1977 ¹⁵³ Risk of bias Medium	0.1 (0.0 to 2.6)	-0.02 (-0.06 to 0.01)
Lisuride vs. Methysergide	Dizziness	Hermann, 1977¹⁵³ Risk of bias Medium	0.2 (0.1 to 0.6)	-0.11 (-0.17 to -0.04)
Lisuride vs. Methysergide	Paresthesia	Hermann, 1977 ¹⁵³ Risk of bias Medium	0.2 (0.0 to 1.6)	-0.03 (-0.07 to 0.01)
Lisuride vs. Methysergide	Somnolence (Drowsiness)	Hermann, 1977 ¹⁵³ Risk of bias Medium	0.8 (0.2 to 2.8)	-0.01 (-0.06 to 0.04)
Lisuride vs. Methysergide	Tachycardia	Hermann, 1977 ¹⁵³ Risk of bias Medium	0.1 (0.0 to 1.9)	-0.03 (-0.07 to 0.00)
Lisuride vs. Methysergide	Vomiting	Hermann, 1977¹⁵³ Risk of bias Medium	0.1 (0.0 to 0.4)	-0.13 (-0.20 to -0.07)
Lisuride vs. Methysergide	Eye pain	Hermann, 1977 ¹⁵³ Risk of bias Medium	0.1 (0.0 to 2.6)	-0.02 (-0.06 to 0.01)
Lisuride vs. Methysergide	Gastro-intestinal	Hermann, 1977 ¹⁵³ Risk of bias Medium	0.6 (0.2 to 1.5)	-0.04 (-0.10 to 0.03)
Lisuride vs. Methysergide	Nausea	Hermann, 1977 ¹⁵³ Risk of bias Medium	0.3 (0.1 to 0.7)	-0.12 (-0.19 to -0.04)
Lisuride vs. Methysergide	Neuralgia	Hermann, 1977 ¹⁵³ Risk of bias Medium	0.1 (0.0 to 1.3)	-0.05 (-0.09 to -0.01)

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D150. Discontinuation due to treatment failure with topiramate versus other drugs for migraine prevention in adults

Topiramate, Daily Dose	Control Drug, Daily Dose	Reference Risk of Bias	Events/ Randomized [Rate, %] with Topiramate	Events/ Randomized [rate, %] with Control Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	2/178 [1.1]	0/169 [0.0]	4.7 (0.2 to 98.2)	0.01 (-0.01 to 0.03)
Topiramate 25mg BD	Lamotrigine 25mg BD	Gupta, 2007 ⁴⁴ Low	1/60 [1.7]	1/60 [1.7]	1.0 (0.1 to 15.6)	0.00 (-0.05 to 0.05)

CI = confidence interval

Appendix Table D151. Adverse effects with preventive drugs compared to each other, pooled with random effects models results from randomized controlled clinical trials

Active	Control	Definition of the Outcome, References	Sample	% with Active [Control]	Pooled Relative Risk (95% CI)	Pooled Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm (95% CI)	Attributable Events per 1000 Treated (95% CI)
Metoprolol	Bisoprolol	Adverse events ^{186, 187}	406	18.2 [22.7]	0.8 (0.5 to 1.2)	-0.04 (-0.12 to 0.04)	NS	NS
Timolol	Propranolol	Adverse events: Total ^{60, 61}	242	38.0 [33.9]	1.1 (0.8 to 1.6)	0.04 (-0.08 to 0.16)	NS	NS
Propranolol	Femoxetine	Gastric distress ^{77, 177}	107	1.9 [3.8]	0.6 (0.1 to 4.8)	-0.02 (-0.09 to 0.05)	NS	NS
Propranolol	Femoxetine	Palpitations ^{77, 177}	107	7.4 [1.9]	3.0 (0.5 to 18.0)	0.05 (-0.03 to 0.13)	NS	NS
Propranolol	Femoxetine	Exanthema ^{77, 177}	107	7.4 [3.8]	1.9 (0.3 to 10.6)	0.03 (-0.06 to 0.11)	NS	NS
Propranolol	Femoxetine	Dizziness ^{77, 177}	107	20.4 [7.5]	2.7 (0.9 to 8.1)	0.10 (-0.13 to 0.34)	NS	NS
Propranolol	Femoxetine	Tiredness^{77, 177}	107	31.5 [9.4]	3.3 (0.8 to 13.7)	0.23 (0.09 to 0.37)	4 (3 to 11)	230 (87 to 374)
Propranolol	Femoxetine	Sleep disturbances ^{77, 177}	107	11.1 [3.8]	2.7 (0.5 to 14.2)	0.06 (-0.08 to 0.19)	NS	NS
Propranolol	Femoxetine	Feeling unwell ^{77, 177}	107	5.6 [7.5]	0.8 (0.1 to 5.1)	-0.03 (-0.14 to 0.09)	NS	NS
Timolol	Propranolol	Depression ^{60, 61}	242	1.7 [3.3]	0.6 (0.1 to 2.6)	-0.02 (-0.06 to 0.03)	NS	NS
Timolol	Propranolol	Fatigue/tiredness ^{60, 61}	242	19.8 [11.6]	1.7 (0.9 to 3.2)	0.08 (-0.01 to 0.17)	NS	NS
Topiramate	Amitriptyline	Adverse events: Any ^{170, 172}	399	82.7 [87.3]	1.0 (0.9 to 1.0)	-0.04 (-0.11 to 0.02)	NS	NS
Topiramate	Valproate	Hair loss ^{167, 232}	134	0.0 [4.5]	0.3 (0.0 to 2.2)	-0.04 (-0.10 to 0.02)	NS	NS
Topiramate	Amitriptyline	Weight increase^{172, 242}	383	3.6 [18.7]	0.1 (0.0 to 3.7)	-0.14 (-0.19 to -0.09)	-7 (-11 to -5)	-140 (-192 to -88)
Topiramate	Amitriptyline	Paresthesia^{170, 172}	399	30.4 [4.1]	6.7 (3.4 to 13.5)	0.26 (0.19 to 0.33)	4 (3 to 5)	261 (192 to 331)
Topiramate	Amitriptyline	Weight decrease (loss)^{172, 242}	383	23.8 [4.0]	6.3 (2.9 to 13.4)	0.24 (0.06 to 0.42)	4 (2 to 16)	242 (61 to 423)
Topiramate	Valproate	Weight increase (gain) ^{167, 232}	134	0.0 [19.4]	0.1 (0.0 to 0.7)	-0.19 (-0.47 to 0.09)	NS	NS
Topiramate	Valproate	Somnolence ^{167, 232, 243}	210	13.1 [10.7]	0.7 (0.1 to 4.0)	-0.06 (-0.28 to 0.16)	NS	NS
Topiramate	Valproate	Paresthesia ^{167, 232, 243}	210	24.3 [4.9]	4.3 (0.3 to 56.0)	0.17 (-0.01 to 0.34)	NS	NS
Topiramate	Valproate	Weight decrease (loss)^{167, 232}	134	11.9 [0.0]	8.3 (1.1 to 65.1)	0.24 (0.06 to 0.42)	4 (2 to 16)	242 (61 to 423)
Metoprolol	Aspirin	Diastolic blood pressure ^{185, 188}	326	0.6 [0.0]	3.0 (0.1 to 73.0)	0.01 (-0.01 to 0.03)	NS	NS
Topiramate	Amitriptyline	Constipation ^{170, 172}	399	3.0 [13.6]	0.2 (0.0 to 1.5)	-0.25 (-0.65 to 0.16)	NS	NS
Topiramate	Amitriptyline	Hyperesthesia ¹⁷²	399	9.4 [10.8]	0.4 (0.0 to 29.7)	-0.23 (-0.82 to 0.37)	NS	NS
Topiramate	Valproate	Weight decrease (loss) ^{167, 170, 232}	134	11.9 [0.0]	6.3 (2.9 to 13.4)	0.11 (-0.02 to 0.24)	NS	NS

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval; NS= not significant; Number needed to treat and number of attributable events were calculated for statistically significant differences

Appendix Table D152. Comparative safety of topiramate for migraine prevention in adults (individual randomized controlled clinical trials)

Adverse Effect	Topiramate, Daily Dose	Control Drug, Daily Dose	Reference Risk of Bias	Events/ Randomized [Rate, %] with Topiramate	Events/ Randomized [Rate, %] with Control Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Abnormal vision	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	9/178 [5.1]	9/169 [5.3]	0.9 (0.4 to 2.3)	0.00 (-0.05 to 0.04)
Anorexia	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	12/178 [6.7]	8/169 [4.7]	1.4 (0.6 to 3.4)	0.02 (-0.03 to 0.07)
Anorexia	Topiramate 25mg BD	Lamotrigine 25mg BD	Gupta, 2007 ⁴⁴ Low	1/60 [1.7]	1/60 [1.7]	1.0 (0.1 to 15.6)	0.00 (-0.05 to 0.05)
Constipation	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	6/178 [3.4]	14/169 [8.3]	0.4 (0.2 to 1.0)	-0.05 (-0.10 to 0.00)
Constipation	Topiramate 200mg (Initiated at a dose of 25mg/day and increased in weekly increments of 25mg/day to a maximum dose of 200mg)	Amitriptyline 150mg (Initiated at a dose of 10mg/day and increased in weekly increments of 10-25mg/day to a maximum dose of 150mg/day)	Keskinbora, 2008 ¹⁷⁰ Medium	0/24 [0.0]	13/28 [45.4]	0.0 (0.0 to 0.7)	-0.46 (-0.65 to -0.27)
Coughing	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose	Dodick, 2009 ¹⁷² Low	9/178 [5.1]	7/169 [4.1]	1.2 (0.5 to 3.2)	0.01 (-0.03 to 0.05)

Appendix Table D152. Comparative safety of topiramate for migraine prevention in adults (individual randomized controlled clinical trials) (continued)

Adverse Effect	Topiramate, Daily Dose	Control Drug, Daily Dose	Reference Risk of Bias	Events/ Randomized [Rate, %] with Topiramate	Events/ Randomized [Rate, %] with Control Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
	titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))					
Difficulty with concentration/attention	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	12/178 [6.7]	5/169 [3.0]	2.3 (0.8 to 6.3)	0.04 (-0.01 to 0.08)
Distal paresthesia	Topiramate 100mg BD	Levetiracetam 1000mg BD	de Tommaso, 2007 ¹⁶⁸ Medium	7/13 [53.8]	0/15 [0.0]	17.1 (1.1 to 274.0)	0.54 (0.26 to 0.81)
Dizziness	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	15/178 [8.4]	18/169 [10.7]	0.8 (0.4 to 1.5)	-0.02 (-0.08 to 0.04)
Drowsiness	Topiramate 100mg BD	Levetiracetam 1000mg BD	de Tommaso, 2007 ¹⁶⁸ Medium	3/13 [23.1]	0/15 [0.0]	8.0 (0.5 to 141.8)	0.23 (-0.01 to 0.47)
Dry mouth	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	12/178 [6.7]	60/169 [35.5]	0.2 (0.1 to 0.3)	-0.29 (-0.37 to -0.21)
Dyspepsia	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose	Dodick, 2009 ¹⁷² Low	9/178 [5.1]	14/169 [8.3]	0.6 (0.3 to 1.4)	-0.03 (-0.08 to 0.02)

Appendix Table D152. Comparative safety of topiramate for migraine prevention in adults (individual randomized controlled clinical trials) (continued)

Adverse Effect	Topiramate, Daily Dose	Control Drug, Daily Dose	Reference Risk of Bias	Events/ Randomized [Rate, %] with Topiramate	Events/ Randomized [Rate, %] with Control Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
	titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))					
Fatigue	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	30/178 [16.9]	41/169 [24.3]	0.7 (0.5 to 1.1)	-0.07 (-0.16 to 0.01)
Gastrointestinal intolerance	Topiramate 25mg BD	Lamotrigine 25mg BD	Gupta, 2007 ⁴⁴ Low	3/60 [5.0]	2/60 [3.3]	1.5 (0.3 to 8.7)	0.02 (-0.05 to 0.09)
Giddiness	Topiramate 25mg BD	Lamotrigine 25mg BD	Gupta, 2007 ⁴⁴ Low	2/60 [3.3]	2/60 [3.3]	1.0 (0.1 to 6.9)	0.00 (-0.06 to 0.06)
Hair loss	Topiramate 50mg (25mg daily increment over 1 week to 50mg)	Sodium valproate 400mg (200mg daily increment over 1 week to 400mg)	Shaygannejad, 2006 ¹⁶⁷ Medium	0/32 [0.0]	1/32 [3.1]	0.3 (0.0 to 7.9)	-0.03 (-0.11 to 0.05)
Headache	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	9/178 [5.1]	0/169 [0.0]	18.0 (1.1 to 307.6)	0.05 (0.02 to 0.08)
Hyperosmia	Topiramate 200mg (Initiated at a dose of 25mg/day and increased in weekly increments of 25mg/day to a maximum dose of 200mg)	Amitriptyline 150mg (Initiated at a dose of 10mg/day and increased in weekly increments of 10-25mg/day to a maximum dose of 150mg/day)	Keskinbora, 2008 ¹⁷⁰ Medium	0/24 [0.0]	15/28 [54.6]	0.0 (0.0 to 0.6)	-0.54 (-0.73 to -0.35)
Hypoesthesia	Topiramate 100mg (The starting dosage was 25mg/d	Amitriptyline 100mg (The starting dosage was 25mg/d for	Dodick, 2009 ¹⁷² Low	19/178 [10.7]	6/169 [3.6]	3.0 (1.2 to 7.3)	0.07 (0.02 to 0.12)

Appendix Table D152. Comparative safety of topiramate for migraine prevention in adults (individual randomized controlled clinical trials) (continued)

Adverse Effect	Topiramate, Daily Dose	Control Drug, Daily Dose	Reference Risk of Bias	Events/ Randomized [Rate, %] with Topiramate	Events/ Randomized [Rate, %] with Control Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
	for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))					
Nausea	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	18/178 [10.1]	12/169 [7.1]	1.4 (0.7 to 2.9)	0.03 (-0.03 to 0.09)
Palpitations	Topiramate 25mg BD	Lamotrigine 25mg BD	Gupta, 2007 ⁴⁴ Low	0/60 [0.0]	0/60 [0.0]	0.0 (0.0 to 0.0)	0.00 (-0.03 to 0.03)
Paresthesia	Topiramate 200mg (Initiated at a dose of 25mg/day and increased in weekly increments of 25mg/day to a maximum dose of 200mg)	Amitriptyline 150mg (Initiated at a dose of 10mg/day and increased in weekly increments of 10-25mg/day to a maximum dose of 150mg/day)	Keskinbora, 2008 ¹⁷⁰ Medium	4/24 [15.0]	0/28 [0.0]	10.4 (0.6 to 184.6)	0.17 (0.01 to 0.32)
Paresthesia	Topiramate 200mg (Initiated at a dose of 25mg/day and increased in weekly increments of 25mg/day to a maximum dose of 200mg)	Amitriptyline 150mg (Initiated at a dose of 10mg/day and increased in weekly increments of 10-25mg/day to a maximum dose of 150mg/day)	Keskinbora, 2008¹⁷⁰ Medium	8/24 [35.0]	0/28 [0.0]	19.7 (1.2 to 324.8)	0.33 (0.14 to 0.52)
Paresthesia	Topiramate 200mg (Initiated at a dose of 25mg/day and increased in weekly increments of 25mg/day to a maximum dose of 200mg)	Amitriptyline 150mg (Initiated at a dose of 10mg/day and increased in weekly increments of 10-25mg/day to a maximum dose of 150mg/day)	Keskinbora, 2008 ¹⁷⁰ Medium	10/24 [40.0]	0/28 [0.0]	24.4 (1.5 to 395.1)	0.42 (0.22 to 0.62)

Appendix Table D152. Comparative safety of topiramate for migraine prevention in adults (individual randomized controlled clinical trials) (continued)

Adverse Effect	Topiramate, Daily Dose	Control Drug, Daily Dose	Reference Risk of Bias	Events/ Randomized [Rate, %] with Topiramate	Events/ Randomized [Rate, %] with Control Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Paresthesia	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	53/178 [29.8]	8/169 [4.7]	6.3 (3.1 to 12.8)	0.25 (0.18 to 0.32)
Paresthesia	Topiramate 50mg (25mg daily increment over 1 week to 50mg)	Sodium valproate 400mg (200mg daily increment over 1 week to 400mg)	Shaygannejad, 2006 ¹⁶⁷ Medium	3/32 [9.4]	0/32 [0.0]	7.0 (0.4 to 130.3)	0.09 (-0.02 to 0.21)
Paresthesia	Topiramate 25mg BD	Lamotrigine 25mg BD	Gupta, 2007 ⁴⁴ Low	3/60 [5.0]	2/60 [3.3]	1.5 (0.3 to 8.7)	0.02 (-0.05 to 0.09)
Paresthesia	Topiramate 25mg/day, gradually titrated up to 100mg/day	Zonisamide 50mg/day, gradually titrated up to 200mg/day	Mohammadiani nejad, 2011 ¹⁷³ Medium	9/40 [22.5]	0/40 [0.0]	19.0 (1.1 to 315.8)	0.23 (0.09 to 0.36)
Paresthesia and weight loss	Topiramate 50mg (25mg daily increment over 1 week to 50mg)	Sodium valproate 400mg (200mg daily increment over 1 week to 400mg)	Shaygannejad, 2006 ¹⁶⁷ Medium	8/32 [25.0]	0/32 [0.0]	17.0 (1.0 to 282.7)	0.25 (0.10 to 0.40)
Pharyngitis	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	8/178 [4.5]	11/169 [6.5]	0.7 (0.3 to 1.7)	-0.02 (-0.07 to 0.03)
Rash	Topiramate 25mg BD	Lamotrigine 25mg BD	Gupta, 2007 ⁴⁴ Low	0/60 [0.0]	2/60 [3.3]	0.2 (0.0 to 4.1)	-0.03 (-0.09 to 0.02)
Sedation and dizziness in the first days of therapy	Topiramate 100mg BD	Levetiracetam 1000mg BD	de Tommaso, 2007 ¹⁶⁸ Medium	0/13 [0.0]	5/15 [33.3]	0.1 (0.0 to 1.7)	-0.33 (-0.59 to -0.08)
Sinusitis	Topiramate 100mg (The starting	Amitriptyline 100mg (The starting	Dodick, 2009 ¹⁷² Low	14/178 [7.9]	18/169 [10.7]	0.7 (0.4 to 1.4)	-0.03 (-0.09 to 0.03)

Appendix Table D152. Comparative safety of topiramate for migraine prevention in adults (individual randomized controlled clinical trials) (continued)

Adverse Effect	Topiramate, Daily Dose	Control Drug, Daily Dose	Reference Risk of Bias	Events/ Randomized [Rate, %] with Topiramate	Events/ Randomized [Rate, %] with Control Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
	dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))					
Sleepiness and concentration difficulty	Topiramate 25mg BD	Lamotrigine 25mg BD	Gupta, 2007 ⁴⁴ Low	3/60 [5.0]	2/60 [3.3]	1.5 (0.3 to 8.7)	0.02 (-0.05 to 0.09)
Somnolence	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	21/178 [11.8]	30/169 [17.8]	0.7 (0.4 to 1.1)	-0.06 (-0.13 to 0.02)
Somnolence	Topiramate 50mg (25mg daily increment over 1 week to 50mg)	Sodium valproate 400mg (200mg daily increment over 1 week to 400mg)	Shaygannejad, 2006 ¹⁶⁷ Medium	0/32 [0.0]	1/32 [3.1]	0.3 (0.0 to 7.9)	-0.03 (-0.11 to 0.05)
Taste perversion	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	10/178 [5.6]	6/169 [3.6]	1.6 (0.6 to 4.3)	0.02 (-0.02 to 0.06)
Upper respiratory tract infection	Topiramate 100m g(The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	14/178 [7.9]	11/169 [6.5]	1.2 0.6 to 2.6)	0.01 (-0.04 to 0.07)
Viral infection	Topiramate 100mg (The starting	Amitriptyline 100mg (The starting	Dodick, 2009 ¹⁷² Low	14/178 [7.9]	11/169 [6.5]	1.2 (0.6 to 2.6)	0.01 (-0.04 to 0.07)

Appendix Table D152. Comparative safety of topiramate for migraine prevention in adults (individual randomized controlled clinical trials) (continued)

Adverse Effect	Topiramate, Daily Dose	Control Drug, Daily Dose	Reference Risk of Bias	Events/ Randomized [Rate, %] with Topiramate	Events/ Randomized [Rate, %] with Control Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
	dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))					
Weight gain	Topiramate 200mg(Initiated at a dose of 25mg/day and increased in weekly increments of 25mg/day to a maximum dose of 200mg)	Amitriptyline 150mg (Initiated at a dose of 10mg/day and increased in weekly increments of 10-25mg/day to a maximum dose of 150mg/day)	Keskinbora, 2008 ¹⁷⁰ Medium	0/24 [0.0]	8/28 [27.3]	0.1 (0.0 to 1.1)	-0.29 (-0.46 to -0.11)
Weight gain	Topiramate 50mg (25mg daily increment over 1 week to 50mg)	Sodium valproate 400mg (200mg daily increment over 1 week to 400mg)	Shaygannejad, 2006 ¹⁶⁷ Risk of bias Medium	0/32 [0.0]	11/32 [34.4]	0.0 (0.0 to 0.7)	-0.34 (-0.51 to -0.18)
Weight increase	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	0/178 [0.0]	23/169 [13.6]	0.0 (0.0 to 0.3)	-0.14 (-0.19 to -0.08)
Weight loss	Topiramate 50mg (25mg daily increment over 1 week to 50mg)	Sodium valproate 400mg (200mg daily increment over 1 week to 400mg)	Shaygannejad, 2006 ¹⁶⁷ Medium	6/32 [18.8]	0/32 [0.0]	13.0 (0.8 to 221.5)	0.19 (0.05 to 0.33)
Weight loss	Topiramate 100mg BD	Levetiracetam 1000mg BD	de Tommaso, 2007 ¹⁶⁸ Medium	8/13 [61.5]	0/15 [0.0]	19.4 (1.2 to 307.1)	0.62 (0.35 to 0.89)
<1% decrease to <1% increase from baseline	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or	Dodick, 2009 ¹⁷² Risk of bias Low	33/178 [18.7]	28/169 [16.5]	1.1 (0.7 to 1.8)	0.02 (-0.06 to 0.10)

Appendix Table D152. Comparative safety of topiramate for migraine prevention in adults (individual randomized controlled clinical trials) (continued)

Adverse Effect	Topiramate, Daily Dose	Control Drug, Daily Dose	Reference Risk of Bias	Events/ Randomized [Rate, %] with Topiramate	Events/ Randomized [Rate, %] with Control Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
	BID (or the maximum tolerated dose))	the maximum tolerated dose))					
≥1% loss of body weight during the study	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ^{1/2} Low	115/178 [64.4]	32/169 [19.0]	3.4 (2.5 to 4.7)	0.46 (0.36 to 0.55)
≥1% to <5% weight decrease from baseline	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made u to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ^{1/2} Low	61/178 [34.5]	27/169 [15.8]	2.1 (1.4 to 3.2)	0.18 (0.09 to 0.27)
≥1% to 5% increase in weight from baseline	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ^{1/2} Low	23/178 [12.9]	61/169 [36.1]	0.4 (0.2 to 0.6)	-0.23 (-0.32 to -0.14)
≥10% increase in weight from baseline	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ^{1/2} Low	1/178 [0.6]	15/169 [8.9]	0.1 (0.0 to 0.5)	-0.08 (-0.13 to -0.04)

Appendix Table D152. Comparative safety of topiramate for migraine prevention in adults (individual randomized controlled clinical trials) (continued)

Adverse Effect	Topiramate, Daily Dose	Control Drug, Daily Dose	Reference Risk of Bias	Events/ Randomized [Rate, %] with Topiramate	Events/ Randomized [Rate, %] with Control Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
≥10% weight decrease from baseline	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ^{1/2} Low	16/178 [8.8]	0/169 [0.0]	31.3 (1.9 to 518.3)	0.09 (0.05 to 0.13)
≥5% loss of body weight during the study	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ^{1/2} Low	53/178 [29.9]	5/169 [3.2]	10.1 (4.1 to 24.6)	0.27 (0.20 to 0.34)
≥5% to 10% increase in weight from baseline	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ^{1/2} Low	6/178 [3.5]	33/169 [19.6]	0.2 (0.1 to 0.4)	-0.16 (-0.23 to -0.10)
≥5% to <10% weight decrease from baseline	Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ^{1/2} Low	38/178 [21.1]	5/169 [3.2]	7.2 (2.9 to 17.9)	0.18 (0.12 to 0.25)

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D153. Adverse effects with migraine preventive drugs compared to each other, significant results from individual randomized controlled clinical trials

Active vs. Control Drug	Adverse Effect	Risk of Bias Reference	Sample	% with Active [Control] Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm (95% CI)	Attributable Events per 1000 Treated (95% CI)
Topiramate vs. Amitriptyline	Dry mouth	Low Dodick, 2009 ¹⁷²	347	6.7 [35.5]	0.2 (0.1 to 0.3)	-0.29 (-0.37 to -0.21)	-3 (-5 to -3)	-288 (-369 to -207)
Topiramate vs. Amitriptyline	Headache	Low Dodick, 2009 ¹⁷²	347	5.1 [0.0]	18.0 (1.1 to 307.6)	0.05 (0.02 to 0.08)	20 (12 to 60)	51 (17 to 84)
Topiramate vs. Propranolol	Paresthesia	Low Dodick, 2009 ¹⁷²	288	56.3 [11.8]	4.8 (3.0 to 7.6)	0.44 (0.35 to 0.54)	2 (2 to 3)	444 (348 to 541)
Topiramate vs. Levetiracetam	Paresthesia	Medium de Tommaso, 2007 ¹⁶⁸	28	53.8 [0.0]	17.1 (1.1 to 274.0)	0.54 (0.26 to 0.81)	2 (1 to 4)	538 (264 to 813)
Topiramate vs. Propranolol	Concentration/attention: Difficult	Low Diener, 2004 ⁴³	288	15.3 [4.9]	3.1 (1.4 to 7.1)	0.10 (0.04 to 0.17)	10 (6 to 28)	104 (36 to 173)
Topiramate vs. Propranolol	Weight decrease	Low Diener, 2004 ⁴³	288	9.0 [0.0]	27.0 (1.6 to 449.9)	0.09 (0.04 to 0.14)	11 (7 to 24)	90 (42 to 139)
Topiramate vs. Levetiracetam	Sedation and dizziness	Medium de Tommaso, 2007 ¹⁶⁸	28	0.0 [33.3]	0.1 (0.0 to 1.7)	-0.33 (-0.59 to -0.08)	-3 (-12 to -2)	-333 (-586 to -81)
Topiramate vs. Levetiracetam	Weight decrease (loss)	Medium de Tommaso, 2007 ¹⁶⁸	28	61.5 [0.0]	19.4 (1.2 to 307.1)	0.62 (0.35 to 0.89)	2 (1 to 3)	615 (346 to 885)
Propranolol LA (+ placebo) vs. Atenolol	Physical capacity: reduced	Medium Stensrud, 1980 ⁶²	70	17.1 [2.9]	6.0 (0.8 to 47.3)	0.14 (0.01 to 0.28)	7 (4 to 158)	143 (6 to 279)
Propranolol vs. Clonidine	Insomnia	Medium Kass, 1980 ⁶⁹	46	21.7 [0.0]	11.0 (0.6 to 188.1)	0.22 (0.04 to 0.39)	5 (3 to 25)	217 (40 to 395)
Propranolol vs. Femoxetine	Mental disorder	Medium Andersson, 1981 ¹⁷⁷	49	40.0 [4.2]	9.6 (1.3 to 69.4)	0.36 (0.15 to 0.57)	3 (2 to 7)	358 (150 to 566)
Propranolol vs. Nifedipine	Adverse events (Moderate-Severe):Any	High Albers, 1989 ⁷⁴	40	65.0 [90.0]	0.7 (0.5 to 1.0)	-0.25 (-0.50 to 0.00)	-4 (-328 to -2)	-250 (-497 to -3)
Propranolol vs. Nifedipine	Dizziness	High Albers, 1989 ⁷⁴	40	15.0 [65.0]	0.2 (0.1 to 0.7)	-0.50 (-0.76 to -0.24)	-2 (-4 to -1)	-500 (-761 to -239)
Propranolol vs. Nifedipine	Dizziness: Moderate-Severe	High Albers, 1989 ⁷⁴	40	5.0 [40.0]	0.1 (0.0 to 0.9)	-0.35 (-0.58 to -0.12)	-3 (-9 to -2)	-350 (-585 to -115)
Propranolol vs.	Fatigue: Total	High	40	45.0 [0.0]	19.0	0.45	2 (1 to 4)	450

Appendix Table D153. Adverse effects with migraine preventive drugs compared to each other, significant results from individual randomized controlled clinical trials (continued)

Active vs. Control Drug	Adverse Effect	Risk of Bias Reference	Sample	% with Active [Control] Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm (95% CI)	Attributable Events per 1000 Treated (95% CI)
Nifedipine		Albers, 1989 ⁷⁴			(1.2 to 305.9)	(0.23 to 0.67)		(227 to 673)
Propranolol vs. Nifedipine	Fatigue: Moderate-Severe	High Albers, 1989 ⁷⁴	40	45.0 [0.0]	19.0 (1.2 to 305.9)	0.45 (0.23 to 0.67)	2 (1 to 4)	450 (227 to 673)
Propranolol vs. Nifedipine	Shakiness: Total	High Albers, 1989 ⁷⁴	40	0.0 [20.0]	0.1 (0.0 to 1.9)	-0.20 (-0.39 to -0.01)	-5 (-78 to -3)	-200 (-387 to -13)
Propranolol vs. Nifedipine	Concentration decreased	High 2654067	40	0.0 [20.0]	0.1 (0.0 to 1.9)	-0.20 (-0.39 to -0.01)	-5 (-78 to -3)	-200 (-387 to -13)
Propranolol vs. Nifedipine	Tachycardia	High Albers, 1989 ⁷⁴	40	0.0 [30.0]	0.1 (0.0 to 1.3)	-0.30 (-0.51 to -0.09)	-3 (-11 to -2)	-300 (-508 to -92)
Propranolol vs. Nifedipine	Nausea	High Albers, 1989 ⁷⁴	40	0.0 [30.0]	0.1 (0.0 to 1.3)	-0.30 (-0.51 to -0.09)	-3 (-11 to -2)	-300 (-508 to -92)
Propranolol vs. Nifedipine	Warm, swollen red legs: Moderate-Severe	High Albers, 1989 ⁷⁴	40	0.0 [30.0]	0.1 (0.0 to 1.3)	-0.30 (-0.51 to -0.09)	-3 (-11 to -2)	-300 (-508 to -92)
Propranolol vs. Nifedipine	Warm, swollen red legs: Total	High Albers, 1989 ⁷⁴	40	0.0 [45.0]	0.1 (0.0 to 0.8)	-0.45 (-0.67 to -0.23)	-2 (-4 to -1)	-450 (-673 to -227)
Propranolol vs. Nifedipine	Facial flushing	High Albers, 1989 ⁷⁴	40	0.0 [30.0]	0.1 (0.0 to 1.3)	-0.30 (-0.51 to -0.09)	-3 (-11 to -2)	-300 (-508 to -92)
Propranolol vs. Nifedipine	Facial flushing: Moderate-Severe	High Albers, 1989 ⁷⁴	40	0.0 [20.0]	0.1 (0.0 to 1.9)	-0.2 (-0.39 to -0.01)	-5 (-78 to -3)	-200 (-387 to -13)
Metoprolol vs. Nebivolol	Adverse events: Moderate	Medium Schellenberg, 2008 ¹⁸⁹	30	85.7 [37.5]	2.3 (1.2 to 4.5)	0.48 (0.18 to 0.78)	2 (1 to 5)	482 (182 to 782)
Metoprolol vs. Nebivolol	Fatigue	Medium Schellenberg, 2008 ¹⁸⁹	30	78.6 [43.8]	1.8 (1.0 to 3.3)	0.35 (0.02 to 0.67)	3 (1 to 42)	348 (24 to 673)
Metoprolol vs. Nebivolol	Bradycardia	Medium Schellenberg, 2008 ¹⁸⁹	30	35.7 [6.3]	5.7 (0.8 to 43.2)	0.2 (0.02 to 0.57)	3 (2 to 59)	295 (17 to 572)
Metoprolol vs. Aspirin	Adverse events	Low Diener, 2001 ¹⁸⁸	270	73.3 [37.8]	1.9 (1.5 to 2.5)	0.36 (0.24 to 0.47)	3 (2 to 4)	356 (245 to 466)
Metoprolol vs. Aspirin	Autonomic nervous system disorders	Low Diener, 2001 ¹⁸⁸	270	8.1 [0.0]	23.0 (1.4 to 386.4)	0.08 (0.03 to 0.13)	12 (8 to 30)	81 (34 to 129)
Metoprolol vs. Aspirin	Body as a whole general disorders	Low Diener, 2001 ¹⁸⁸	270	8.1 [2.2]	3.7 (1.0 to 12.9)	0.06 (0.01 to 0.11)	17 (9 to 146)	59 (7 to 112)
Metoprolol vs. Aspirin	Psychiatric disorders	Low Diener, 2001 ¹⁸⁸	270	11.9 [1.5]	8.0 (1.9 to 34.1)	0.10 (0.05 to 0.16)	10 (6 to 22)	104 (45 to 162)

Appendix Table D153. Adverse effects with migraine preventive drugs compared to each other, significant results from individual randomized controlled clinical trials (continued)

Active vs. Control Drug	Adverse Effect	Risk of Bias Reference	Sample	% with Active [Control] Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm (95% CI)	Attributable Events per 1000 Treated (95% CI)
Metoprolol vs. Aspirin	Vascular disorders	Low Diener, 2001 ¹⁸⁸	270	3.7 [0.0]	11.0 (0.6 to 197.0)	0.04 (0.00 to 0.07)	27 (14 to 416)	37 (2 to 72)
Metoprolol vs. Aspirin	Skin and appendices disorders	Low Diener, 2001 ¹⁸⁸	270	6.7 [1.5]	4.5 (1.0 to 20.4)	0.05 (0.01 to 0.10)	19 (10 to 196)	52 (5 to 99)
Clomipramine vs. Metoprolol	Insomnia	Medium Langohr, 1985 ¹⁸⁴	126	23.8 [3.2]	7.5 (1.8 to 31.4)	0.21 (0.09 to 0.32)	5 (3 to 11)	206 (93 to 320)
Clomipramine vs. Metoprolol	Sweating	Medium Langohr, 1985 ¹⁸⁴	126	14.3 [1.6]	9.0 (1.2 to 69.0)	0.13 (0.04 to 0.22)	8 (5 to 28)	127 (35 to 219)
Clomipramine vs. Metoprolol	Constipation	Medium Langohr, 1985 ¹⁸⁴	126	9.5 [1.6]	6.0 (0.7 to 48.4)	0.08 (0.00 to 0.16)	13 (6 to 1716)	79 (1 to 158)
Femoxetine vs. propranolol	Dizziness	Medium Kangasniemi, 1983 ⁷⁷	48	41.7 [12.5]	3.3 (1.0 to 10.6)	0.29 (0.05 to 0.53)	3 (2 to 18)	292 (54 to 529)
Femoxetine vs. propranolol	Tiredness	Medium Kangasniemi, 1983 ⁷⁷	48	37.5 [4.2]	9.0 (1.2 to 65.6)	0.33 (0.12 to 0.54)	3 (2 to 8)	333 (124 to 543)
Fluoxetine vs. Amitriptyline	Adverse events, no detailed information	Medium Oguzhanoglu, 1999 ¹⁰⁷	47	40.0 [77.3]	0.5 (0.3 to 0.9)	-0.37 (-0.63 to -0.11)	-3 (-9 to -2)	-373 (-633 to -113)
Nortriptyline vs. Propranolol	Sleepiness (Somnolence)	Medium Domingues, 2009 ⁷⁵	49	25.0 [4.0]	6.3 (0.8 to 48.1)	0.21 (0.02 to 0.40)	5 (3 to 49)	210 (20 to 400)
Venlafaxine vs. Amitriptyline	Dry mouth	Medium Bulut, 2004 ¹⁰⁹	104	5.8 [69.2]	0.1 (0.0 to 0.3)	-0.63 (-0.78 to -0.49)	-2 (-2 to -1)	-635 (-775 to -494)
Venlafaxine vs. Amitriptyline	Memory loss	Medium Bulut, 2004 ¹⁰⁹	104	1.9 [17.3]	0.1 (0.0 to 0.8)	-0.15 (-0.26 to -0.04)	-6 (-22 to -4)	-154 (-263 to -44)
Venlafaxine vs. Amitriptyline	Sedation	Medium Bulut, 2004 ¹⁰⁹	104	11.5 [34.6]	0.3 (0.1 to 0.8)	-0.23 (-0.39 to -0.08)	-4 (-13 to -3)	-231 (-387 to -75)
Venlafaxine vs. Amitriptyline	Concentration difficult	Medium Bulut, 2004 ¹⁰⁹	104	5.8 [53.8]	0.1 (0.0 to 0.3)	-0.48 (-0.63 to -0.33)	-2 (-3 to -2)	-481 (-630 to -331)
Venlafaxine vs. Amitriptyline	Orthostatic hypotension	Medium Bulut, 2004 ¹⁰⁹	104	1.9 [30.8]	0.1 (0.0 to 0.5)	-0.29 (-0.42 to -0.16)	-3 (-6 to -2)	-288 (-419 to -158)
Venlafaxine vs. Amitriptyline	Weight increase (gain)	Medium Bulut, 2004 ¹⁰⁹	104	1.9 [15.4]	0.1 (0.0 to 1.0)	-0.13 (-0.24 to -0.03)	-7 (-34 to -4)	-135 (-240 to -30)
Venlafaxine vs. Amitriptyline	Weight decrease (Loss of weight)	Medium Bulut, 2004 ¹⁰⁹	104	9.6 [0.0]	11.0 (0.6 to 194.0)	0.10 (0.01 to 0.18)	10 (5 to 100)	96 (10 to 182)
Venlafaxine vs. Amitriptyline	Blurred vision	Medium Bulut, 2004 ¹⁰⁹	104	0.0 [13.5]	0.1 (0.0 to 1.1)	-0.13 (-0.23 to -0.04)	-7 (-27 to -4)	-135 (-232 to -37)

Appendix Table D153. Adverse effects with migraine preventive drugs compared to each other, significant results from individual randomized controlled clinical trials (continued)

Active vs. Control Drug	Adverse Effect	Risk of Bias Reference	Sample	% with Active [Control] Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	Number Needed to Treat to Harm (95% CI)	Attributable Events per 1000 Treated (95% CI)
Amitriptyline vs. Propranolol	Blurred vision	Medium Rafieian-Kopaei, 2005 ⁶⁴	105	66.7 [31.3]	2.1 (1.2 to 3.8)	0.35 (0.12 to 0.59)	3 (2 to 8)	354 (121 to 587)
Lisuride vs. Methysergide	Cold feeling	Medium Hermann, 1977 ¹⁵³	253	7.7 [0.0]	19.9 (1.2 to 335.6)	0.08 (0.03 to 0.12)	13 (8 to 34)	77 (29 to 125)
Lisuride vs. Methysergide	Muscle weakness	Medium Hermann, 1977 ¹⁵³	253	7.7 [0.0]	19.9 (1.2 to 335.6)	0.08 (0.03 to 0.12)	13 (8 to 34)	77 (29 to 125)

Appendix Table D154. Risk of any adverse effects with topiramate vs. amitriptyline for migraine prevention in adults

Topiramate, Daily Dose	Control Drug, Daily Dose	Reference Risk of Bias	Events/ Randomized [Rate, %] with Topiramate	Events/ Randomized [Rate, %] with Control Drug	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Topiramate + Amitriptyline Initial doses of topiramate 25mg/day and amitriptyline 10mg/day and this was followed by weekly increases of 25mg/day topiramate and 10mg/day amitriptyline	Amitriptyline 150mg (Initiated at a dose of 10mg/day and increased in weekly increments of 10- 25mg/day to a maximum dose of 150mg/day)	Keskinbor, 2008 ¹⁷⁰ Medium	9/23 [39.1]	22/28 [78.6]	0.5 (0.3 to 0.9)	-0.39 (-0.65 to -0.14)
Topiramate 200mg (Initiated at a dose of 25mg/day and increased in weekly increments of 25mg/day to a maximum dose of 200mg)	Amitriptyline 150mg (Initiated at a dose of 10mg/day and increased in weekly increments of 10- 25mg/day to a maximum dose of 150mg/day)	Keskinbor, 2008 ¹⁷⁰ Medium	15/24 [62.5]	22/28 [78.6]	0.8 (0.6 to 1.1)	-0.16 (-0.41 to 0.09)
Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	121/178 [68.0]	128/169 [75.7]	0.9 (0.8 to 1.0)	-0.08 (-0.17 to 0.02)
Topiramate 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25mg/d were made up to 50mg BID (or the maximum tolerated dose))	Amitriptyline 100mg (The starting dosage was 25mg/d for 7 days. Weekly dose titrations of 25m/d were made up to 50mg BID (or the maximum tolerated dose))	Dodick, 2009 ¹⁷² Low	152/178 [85.4]	150/169 [88.8]	1.0 (0.9 to 1.0)	-0.03 (-0.10 to 0.04)
Topiramate 200mg (Initiated at a dose of 25mg/day and increased in weekly increments of 25mg/day to a maximum dose of 200mg)	Topiramate + Amitriptyline Initial doses of topiramate 25mg/day and amitriptyline 10mg/day and this was followed by weekly increases of 25mg/day topiramate and 10mg/day amitriptyline	Keskinbora, 2008 ¹⁷⁰ Medium	15/24 [62.5]	9/23 [39.1]	1.6 (0.9 to 2.9)	0.23 (-0.04 to 0.51)

Bold = significant difference at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D155. Treatment discontinuation due to adverse effects with propranolol for migraine prevention in adults (results from randomized controlled clinical trials)

Active Treatment	Control Treatment	Reference Risk of Bias	Events/ Randomized with Active Treatment	Events/ Randomized with Control Treatment	Rate, % with Active [Control] Treatment	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Propranolol + Amitriptyline Propranolol: 160 mg; Amitriptyline: 75 mg	Abortive treatment with ergotamine and analgesics (control) Total ergotamine intake was restricted to 6 mg a week.	Mathew, 1981 ¹⁰⁵ Risk of bias High	2/41	4/45	5 [9]	0.5 (0.1 to 2.8)	-0.04 (-0.15 to 0.07)
Propranolol + Amitriptyline Propranolol: 160 mg; Amitriptyline: 75 mg	Abortive treatment with ergotamine and analgesics (control) Total ergotamine intake was restricted to 6 mg a week.	Mathew, 1981¹⁰⁵ Risk of bias High	2/47	9/49	4 [18]	0.2 (0.1 to 1.0)	-0.14 (-0.26 to -0.02)
Propranolol + Amitriptyline + Biofeedback Propranolol: 160 mg; Amitriptyline: 75 mg; Biofeedback: 10 x 1hr session of combined electromyographic and temperature regulation training; instructed to practice biofeedback at least once a day for minimum of 30 minutes	Abortive treatment with ergotamine and analgesics (control) Total ergotamine intake was restricted to 6 mg a week.	Mathew, 1981 ¹⁰⁵ Risk of bias High	4/46	9/49	9 [18]	0.5 (0.2 to 1.4)	-0.10 (-0.23 to 0.04)
Propranolol + Amitriptyline + Biofeedback Propranolol: 160 mg; Amitriptyline: 75 mg;	Abortive treatment with ergotamine and analgesics (control)	Mathew, 1981 ¹⁰⁵ Risk of bias High	3/38	4/45	8 [9]	0.9 (0.2 to 3.7)	-0.01 (-0.13 to 0.11)

Appendix Table D155. Treatment discontinuation due to adverse effects with propranolol for migraine prevention in adults (results from randomized controlled clinical trials) (continued)

Active Treatment	Control Treatment	Reference Risk of Bias	Events/ Randomized with Active Treatment	Events/ Randomized with Control Treatment	Rate, % with Active [Control] Treatment	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Biofeedback: 10 x 1hr session of combined electromyographic and temperature regulation training; instructed to practice biofeedback at least once a day for minimum of 30 minutes	Total ergotamine intake was restricted to 6 mg a week.						
Propranolol + Biofeedback Propranolol: 160 mg; Biofeedback: 10 x 1hr session of combined electromyographic and temperature regulation training; instructed to practice biofeedback at least once a day for minimum of 30 minutes	Abortive treatment with ergotamine and analgesics (control) Total ergotamine intake was restricted to 6 mg a week.	Mathew, 1981 ¹⁰⁵ Risk of bias High	2/39	4/45	5 [9]	0.6 (0.1 to 3.0)	-0.04 (-0.15 to 0.07)
Propranolol + Biofeedback Propranolol: 160 mg; Biofeedback: 10 x 1hr session of combined electromyographic and temperature regulation training; instructed to practice biofeedback at least once a day for minimum of 30 minutes	Abortive treatment with ergotamine and analgesics (control) Total ergotamine intake was restricted to 6 mg a week.	Mathew, 1981 ¹⁰⁵ Risk of bias High	3/43	9/49	7 [18]	0.4 (0.1 to 1.3)	-0.11 (-0.25 to 0.02)

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D156. Comparative effectiveness and safety of beta-blockers combined with behavioral therapy (orientation + relaxation training; migraine warning signs and triggers; effectively using migraine medication and reducing impact of migraines; stress management or biofeedback training; migraine management plan) vs. beta-blockers alone for migraine prevention in adults, results from individual low risk of bias randomized controlled clinical trial¹⁹³

Definition of the Outcome	Active Treatment	Control Treatment	Events Randomized with Active Treatment	Events/ Randomized with Control Treatment	Rate in Active Group,% [Control Group]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Clinically improved (≥50% reduction in migraines) at month 10	Behavioral migraine management + Placebo	Propranolol/nadolol	19/55	18/53	34.5 [34.0]	1.0 (0.6 to 1.7)	0.01 (-0.17 to 0.18)
Clinically improved (≥50% reduction in migraines) at month 10	Behavioral migraine management + Propranolol/nadolol	Propranolol/nadolol	53/69	18/53	76.8 [34.0]	2.3 (1.5 to 3.4)	0.43 (0.27 to 0.59)
Clinically improved (≥50% reduction in migraines) at month 10	Behavioral migraine management + placebo	Behavioral migraine management + Propranolol/nadolol	19/55	53/69	34.5 [76.8]	0.4 (0.3 to 0.7)	-0.42 (-0.58 to -0.26)
Dropped out	Behavioral migraine management + Placebo	Propranolol/nadolol	22/55	27/53	40.0 [50.9]	0.8 (0.5 to 1.2)	-0.11 (-0.30 to 0.08)
Dropped out	Behavioral migraine management + Propranolol/nadolol	Propranolol/nadolol	24/69	27/53	34.8 [50.9]	0.7 (0.4 to 1.0)	-0.16 (-0.34 to 0.01)
Dropped out	Behavioral migraine management + placebo	Behavioral migraine management + Propranolol/nadolol	22/55	24/69	40.0 [34.8]	1.2 (0.7 to 1.8)	0.05 (-0.12 to 0.22)
Dropped due to side - effects	Behavioral migraine management + Placebo	Propranolol/nadolol	5/55	7/53	9.1 [13.2]	0.7 (0.2 to 2.0)	-0.04 (-0.16 to 0.08)
Dropped due to side - effects	Behavioral migraine management + Propranolol/nadolol	Propranolol/nadolol	6/69	7/53	8.7 [13.2]	0.7 (0.2 to 1.8)	-0.05 (-0.16 to 0.07)
Dropped out due to side effects	Behavioral migraine management + placebo	Behavioral migraine management + Propranolol/nadolol	5/55	6/69	9.1 [8.7]	1.0 (0.3 to 3.2)	0.00 (-0.10 to 0.10)

Appendix Table 156. Comparative effectiveness and safety of beta-blockers combined with behavioral therapy (orientation +relaxation training; migraine warning signs and triggers; effectively using migraine medication, and reducing impact of migraines; stress management or biofeedback training; migraine management plan) vs. beta-blockers alone for migraine prevention in adults, results from individual low risk of bias randomized controlled clinical trial (continued)

Definition of the Outcome	Active Treatment	Control Treatment	Events Randomized with Active Treatment	Events/ Randomized with Control Treatment	Rate in Active Group,% [Control Group]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Dropped due to lack of efficacy	Behavioral migraine management + Propranolol/nadolol	Propranolol/nadolol	1/69	5/53	1.4 [9.4]	0.2 (0.0 to 1.3)	-0.08 (-0.16 to 0.00)
Dropped due to lack of efficacy	Behavioral migraine management + Placebo	Propranolol/nadolol	4/55	5/53	7.3 [9.4]	0.8 (0.2 to 2.7)	-0.02 (-0.13 to 0.08)
Dropped out due to lack of efficacy	Behavioral migraine management + placebo	Behavioral migraine management + Propranolol/nadolol	4/55	1/69	7.3 [1.4]	5.0 (0.6 to 43.6)	0.06 (-0.02 to 0.13)

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

CI = confidence interval

Appendix Table D157. Headache specific locus of control at month 16 with beta-blockers combined with behavioral therapy (orientation + relaxation training; migraine warning signs and triggers; effectively using migraine medication and reducing impact of migraines; stress management or biofeedback training; migraine management plan) vs. beta-blockers alone for migraine prevention in adults, results from individual medium risk of bias randomized controlled clinical trial²⁰⁷

Outcome	Active	Control	Randomized for Active [Control] Treatment	Mean [Standard Deviation] with Active Treatment	Mean [Standard Deviation] with Control Treatment	Mean Difference (95% CI)	Cohen Standardized Mean Difference (95% CI)
Mean Change HSLC (Headache Specific Locus of Control) at month 16	Placebo + Behavioral Migraine Management	Propranolol HCL/nadolol	55 [53]	21.4 [6.9]	26.4 [9.0]	-5.0 (-8.0 to -2.0)	-0.6 (-1.0 to -0.2)
Mean Change HSLC (Headache Specific Locus of Control) at month 16	Propranolol HCL/nadolol + Behavioral Migraine Management	Propranolol HCL/nadolol	69 [53]	21.1 [8.4]	26.4 [9.0]	-5.3 (-8.4 to -2.2)	-0.6 (-1.0 to -0.2)
Mean Change Professionals HSLC (Headache Specific Locus of Control) at month 16	Behavioral Migraine Management + Placebo	Propranolol HCL/nadolol + Behavioral Migraine Management	55 [69]	21.4 [6.9]	21.1 [8.4]	0.3 (-2.4 to 3.0)	0.0 (-0.3 to 0.4)
Mean Medical Professionals HSLC (Headache Specific Locus of Control) at month 16	Placebo + Behavioral Migraine Management	Propranolol HCL/nadolol	55 [53]	32.9 [5.8]	35.1 [6.7]	-2.2 (-4.6 to 0.2)	-0.4 (-0.7 to 0.0)
Mean Medical Professionals HSLC (Headache Specific Locus of Control) at month 16	Propranolol HCL/nadolol + Behavioral Migraine Management	Propranolol HCL/nadolol	69 [53]	31.6 [6.9]	35.1 [6.7]	-3.5 (-5.9 to -1.1)	-0.5 (-0.9 to -0.1)
Mean Medical Professionals HSLC (Headache Specific Locus of Control) at month 16	Behavioral Migraine Management + Placebo	Propranolol HCL/nadolol + Behavioral Migraine Management	55 [69]	32.9 [5.8]	31.6 [6.9]	1.3 (-0.9 to 3.5)	0.2 (-0.2 to 0.6)
Mean Internal HSLC (Headache Specific Locus of Control) at month 16	Placebo + Behavioral Migraine Management	Propranolol HCL/nadolol	55 [53]	63.4 [6.8]	57.7 [8.9]	5.7 (2.7 to 8.7)	0.7 (0.3 to 1.1)

Appendix Table 157. Headache Specific Locus of Control at month 16 with beta-blockers combined with behavioral therapy (orientation + relaxation training; migraine warning signs and triggers; effectively using migraine medication, and reducing impact of migraines; stress management or biofeedback training; migraine management plan) vs. beta-blockers alone for migraine prevention in adults, results from individual medium risk of bias randomized controlled clinical trial (continued)

Outcome	Active	Control	Randomized for Active [Control] Treatment	Mean [Standard Deviation] with Active Treatment	Mean [Standard Deviation] with Control Treatment	Mean Difference (95% CI)	Cohen Standardized Mean Difference (95% CI)
Mean Internal HSLC (Headache Specific Locus of Control) at month 16	Propranolol HCL/nadolol + Behavioral Migraine Management	Propranolol HCL/nadolol	69 [53]	63.9 [7.7]	57.7 [8.9]	6.2 (3.2 to 9.2)	0.8 (0.4 to 1.1)
Mean Internal Professionals HSLC (Headache Specific Locus of Control) at month 16	Behavioral Migraine Management + Placebo	Propranolol HCL/nadolol + Behavioral Migraine Management	55 [69]	63.4 [6.8]	63.9 [7.7]	-0.5 (-3.1 to 2.1)	-0.1 (-0.4 to 0.3)
Mean HSE (Headache Specific Locus of Control) at month 16	Placebo + Behavioral Migraine Management	Propranolol HCL/nadolol	55 [53]	143.4 [20.0]	127.5 [21.9]	15.9 (8.0 to 23.8)	0.8 (0.4 to 1.1)
Mean HSE (Headache Specific Locus of Control) at month 16	Propranolol HCL/nadolol + Behavioral Migraine Management	Propranolol HCL/nadolol	69 [53]	144.8 [23.6]	127.5 [21.9]	17.3 (9.2 to 25.4)	0.8 (0.4 to 1.1)
Mean HSE (Headache Specific Locus of Control) at month 16	Behavioral Migraine Management + Placebo	Propranolol HCL/nadolol + Behavioral Migraine Management	55 [69]	143.4 [20.0]	144.8 [23.6]	-1.4 (-9.1 to 6.3)	-0.1 (-0.4 to 0.3)

Bold = significant at 95% confidence limit when 95% CI of mean difference estimates do not include 0

CI = confidence interval

Appendix Table D158. Strength of evidence of comparative safety of beta-blockers for migraine prevention in adults (treatment discontinuation due to bothersome adverse effects in randomized controlled clinical trials)

Definition of the Outcome	Reference	Active Drug	Control Drug	Risk of Bias	Directness	Consistency	Precision	Strength of Evidence
Withdrew because of side effects and/or lack of efficacy	Louis, 1985 ¹⁸³	Metoprolol	Clonidine	Medium	Yes	Not applicable	No	Low
Discontinued due to side-effects	Worz, 1991 ¹⁸⁶	Metoprolol	Bisoprolol	Medium	Yes	Not applicable	No	Low
Patient withdrawal due to events	Schellenberg, 2008 ¹⁸⁹	Metoprolol	Nebivolol	Medium	Yes	Not applicable	No	Low
Drowsiness leading to withdrawal	Grotemeyer, 1990 ¹⁸⁵	Metoprolol	Aspirin	Medium	Yes	Not applicable	No	Low
Gastrointestinal side-effects leading to withdrawal	Grotemeyer, 1990 ¹⁸⁵	Metoprolol	Aspirin	Medium	Yes	Not applicable	No	Low
Discontinued treatment because of severe adverse reactions	Langohr, 1985 ¹⁸⁴	Clomipramine	Metoprolol	Medium	Yes	Not applicable	No	Low

Appendix Table D159. Comparative safety of beta-blockers for migraine prevention in adults, adverse effects in randomized controlled clinical trials

Adverse Effect	Reference Risk of Bias	Active Drug Dose	Control Drug Dose	Events/ Randomized [Rate of Outcome in Active Group, %]	Events/ Randomized [Rate of Outcome in Control Group, %]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Insomnia	Langohr, 1985 ¹⁸⁴ Medium	Clomipramine 100mg/day	Metoprolol 100mg/day	15/63 [23.8]	2/63 [3.2]	7.5 (1.8 to 31.4)	0.21 (0.09 to 0.32)
Sweating	Langohr, 1985 ¹⁸⁴ Medium	Clomipramine 100mg/day	Metoprolol 100mg/day	9/63 [14.3]	1/63 [1.6]	9.0 (1.2 to 69.0)	0.13 (0.04 to 0.22)
Tiredness	Langohr, 1985 ¹⁸⁴ Medium	Clomipramine 100mg/day	Metoprolol 100mg/day	7/63 [11.1]	9/63 [14.3]	0.8 (0.3 to 2.0)	-0.03 (-0.15 to 0.08)
Constipation	Langohr, 1985 ¹⁸⁴ Medium	Clomipramine 100mg/day	Metoprolol 100mg/day	6/63 [9.5]	1/63 [1.6]	6.0 (0.7 to 48.4)	0.08 (0.00 to 0.16)
Nausea	Langohr, 1985 ¹⁸⁴ Medium	Clomipramine 100mg/day	Metoprolol 100mg/day	5/63 [7.9]	2/63 [3.2]	2.5 (0.5 to 12.4)	0.05 (-0.03 to 0.13)
Dizziness	Langohr, 1985 ¹⁸⁴ Medium	Clomipramine 100mg/day	Metoprolol 100mg/day	4/63 [6.3]	1/63 [1.6]	4.0 (0.5 to 34.8)	0.05 (-0.02 to 0.12)
Loss of appetite	Langohr, 1985 ¹⁸⁴ Medium	Clomipramine 100mg/day	Metoprolol 100mg/day	3/63 [4.8]	1/63 [1.6]	3.0 (0.3 to 28.1)	0.03 (-0.03 to 0.09)
Restlessness	Langohr, 1985 ¹⁸⁴ Medium	Clomipramine 100mg/day	Metoprolol 100mg/day	2/63 [3.2]	2/63 [3.2]	1.0 (0.1 to 6.9)	0.00 (-0.06 to 0.06)
Adverse events	Worz, 1991 ¹⁸⁶ Medium	Metoprolol 50 to 100mg twice daily	Bisoprolol 5 to 10mg once daily	18/78 [23.1]	23/78 [29.5]	0.8 (0.5 to 1.3)	-0.06 (-0.20 to 0.07)
Dizziness	Worz, 1992 ¹⁸⁷ Medium	Metoprolol 50mg BID (max. 200mg daily after 4 weeks)	Bisoprolol 5mg/day (max. 10mg daily after 4 weeks)	4/125 [3.2]	8/125 [6.4]	0.5 (0.2 to 1.6)	-0.03 (-0.08 to 0.02)
Tiredness/fatigue	Worz, 1992 ¹⁸⁷ Medium	Metoprolol 50mg BID (max. 200mg daily after 4 weeks)	Bisoprolol 5mg/day (max. 10mg daily after 4 weeks)	7/125 [5.6]	3/125 [2.4]	2.3 (0.6 to 8.8)	0.03 (-0.02 to 0.08)
Sleep disturbances	Worz, 1992 ¹⁸⁷ Medium	Metoprolol 50mg BID (max. 200mg daily after 4 weeks)	Bisoprolol 5mg/day (max. 10mg daily after 4 weeks)	6/125 [4.8]	2/125 [1.6]	3.0 (0.6 to 14.6)	0.03 (-0.01 to 0.08)
Cardiovascular, hypotensive reactions	Worz, 1992 ¹⁸⁷ Medium	Metoprolol 50mg BID (max. 200mg daily after 4 weeks)	Bisoprolol 5mg/day (max. 10mg daily after 4 weeks)	1/125 [0.8]	6/125 [4.8]	0.2 (0.0 to 1.4)	-0.04 (-0.08 to 0.00)

Appendix Table 159. Comparative safety beta-blockers for migraine prevention in adults, adverse effects in randomized controlled clinical trials (continued)

Adverse Effect	Reference Risk of Bias	Active Drug Dose	Control Drug Dose	Events/ Randomized [Rate of Outcome in Active Group, %]	Events/ Randomized [Rate of Outcome in Control Group, %]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Gastrointestinal disturbances	Worz, 1992 ¹⁸⁷ Medium	Metoprolol 50mg BID (max. 200mg daily after 4 weeks)	Bisoprolol 5mg/day (max. 10mg daily after 4 weeks)	2/125 [1.6]	5/125 [4.0]	0.4 (0.1 to 2.0)	-0.02 (-0.06 to 0.02)
Adverse effects	Worz, 1992 ¹⁸⁷ Medium	Metoprolol 50mg BID (max. 200mg daily after 4 weeks)	Bisoprolol 5mg/day (max. 10mg daily after 4 weeks)	19/125 [15.2]	23/125 [18.4]	0.8 (0.5 to 1.4)	-0.03 (-0.12 to 0.06)
Patients with treatment-related events	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 - 16:142.5mg	Nebivolol 5mg daily	13/14 [92.9]	11/16 [68.8]	1.4 (0.9 to 1.9)	0.24 (-0.02 to 0.51)
Patients reporting mild events	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 - 16:142.5mg	Nebivolol 5mg daily	1/14 [7.1]	4/16 [25.0]	0.3 (0.0 to 2.3)	-0.18 (-0.43 to 0.07)
Patients reporting moderate events	Schellenberg, 2008¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 - 16:142.5mg	Nebivolol 5mg daily	12/14 [85.7]	6/16 [37.5]	2.3 (1.2 to 4.5)	0.48 (0.18 to 0.78)
Patients reporting severe events	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 - 16:142.5mg	Nebivolol 5mg daily	6/14 [42.9]	2/16 [12.5]	3.4 (0.8 to 14.3)	0.30 (0.00 to 0.61)
Fatigue	Schellenberg, 2008¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 - 16:142.5mg	Nebivolol 5mg daily	11/14 [78.6]	7/16 [43.8]	1.8 (1.0 to 3.3)	0.35 (0.02 to 0.67)
Bradycardia	Schellenberg, 2008¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 - 16:142.5mg	Nebivolol 5mg daily	5/14 [35.7]	1/16 [6.3]	5.7 (0.8 to 43.2)	0.29 (0.02 to 0.57)

Appendix Table 159. Comparative safety beta-blockers for migraine prevention in adults, adverse effects in randomized controlled clinical trials (continued)

Adverse Effect	Reference Risk of Bias	Active Drug Dose	Control Drug Dose	Events/ Randomized [Rate of Outcome in Active Group, %]	Events/ Randomized [Rate of Outcome in Control Group, %]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Hypotension	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 - 16:142.5mg	Nebivolol 5mg daily	2/14 [14.3]	1/16 [6.3]	2.3 (0.2 to 22.6)	0.08 (-0.14 to 0.30)
Supraventricular extrasystoles	Schellenberg, 2008 ¹⁸⁹ Medium	Metoprolol Week 1: 47.5mg, week 2: 95mg, week 3 - 16:142.5mg	Nebivolol 5mg daily	2/14 [14.3]	0/16 [0.0]	5.7 (0.3 to 108.9)	0.14 (-0.06 to 0.35)
At least one adverse effect	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	53/135 [39.3]	42/135 [31.1]	1.3 (0.9 to 1.8)	0.08 (-0.03 to 0.19)
Skin disorders	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	9/135 [6.7]	2/135 [1.5]	4.5 (1.0 to 20.4)	0.05 (0.01 to 0.10)
Muscular-skeletal system disorders	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	1/135 [0.7]	2/135 [1.5]	0.5 (0.0 to 5.4)	-0.01 (-0.03 to 0.02)
Central & peripheral nervous system disorders	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	4/135 [3.0]	3/135 [2.2]	1.3 (0.3 to 5.8)	0.01 (-0.03 to 0.05)
Autonomic nervous system disorders	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week	Aspirin 300mg/day	11/135 [8.1]	0/135 [0.0]	23.0 (1.4 to 386.4)	0.08 (0.03 to 0.13)

Appendix Table 159. Comparative safety beta-blockers for migraine prevention in adults, adverse effects in randomized controlled clinical trials (continued)

Adverse Effect	Reference Risk of Bias	Active Drug Dose	Control Drug Dose	Events/ Randomized [Rate of Outcome in Active Group, %]	Events/ Randomized [Rate of Outcome in Control Group, %]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
		and 200mg/day thereafter)					
Vision disorders	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	1/135 [0.7]	0/135 [0.0]	3.0 (0.1 to 73.0)	0.01 (-0.01 to 0.03)
Hearing and vestibular disorders	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	1/135 [0.7]	0/135 [0.0]	3.0 (0.1 to 73.0)	0.01 (-0.01 to 0.03)
Psychiatric disorders	Diener, 2001¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	16/135 [11.9]	2/135 [1.5]	8.0 (1.9 to 34.1)	0.10 (0.05 to 0.16)
Gastrointestinal system disorders	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	25/135 [18.5]	30/135 [22.2]	0.8 (0.5 to 1.3)	-0.04 (-0.13 to 0.06)
Liver and biliary system disorders	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	1/135 [0.7]	1/135 [0.7]	1.0 (0.1 to 15.8)	0.00 (-0.02 to 0.02)
Endocrine disorders	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	0/135 [0.0]	1/135 [0.7]	0.3 (0.0 to 8.1)	-0.01 (-0.03 to 0.01)

Appendix Table 159. Comparative safety beta-blockers for migraine prevention in adults, adverse effects in randomized controlled clinical trials (continued)

Adverse Effect	Reference Risk of Bias	Active Drug Dose	Control Drug Dose	Events/ Randomized [Rate of Outcome in Active Group, %]	Events/ Randomized [Rate of Outcome in Control Group, %]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Cardiovascular disorders, general	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	1/135 [0.7]	0/135 [0.0]	3.0 (0.1 to 73.0)	0.01 (-0.01 to 0.03)
Vascular (extracardiac) disorders	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	5/135 [3.7]	0/135 [0.0]	11.0 (0.6 to 197.0)	0.04 (0.00 to 0.07)
Respiratory system disorders	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	6/135 [4.4]	1/135 [0.7]	6.0 (0.7 to 49.2)	0.04 (0.00 to 0.07)
White blood cell disorders	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	2/135 [1.5]	0/135 [0.0]	5.0 (0.2 to 103.2)	0.01 (-0.01 to 0.04)
Urinary system disorders	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	2/135 [1.5]	4/135 [3.0]	0.5 (0.1 to 2.7)	-0.01 (-0.05 to 0.02)
Reproductive disorders, female	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	2/135 [1.5]	1/135 [0.7]	2.0 (0.2 to 21.8)	0.01 (-0.02 to 0.03)
Body as a whole general disorders	Diener, 2001¹⁸⁸ Low	Metoprolol 200mg/day	Aspirin 300mg/day	11/135 [8.1]	3/135 [2.2]	3.7 (1.0 to 12.9)	0.06 (0.01 to 0.11)

Appendix Table 159. Comparative safety beta-blockers for migraine prevention in adults, adverse effects in randomized controlled clinical trials (continued)

Adverse Effect	Reference Risk of Bias	Active Drug Dose	Control Drug Dose	Events/ Randomized [Rate of Outcome in Active Group, %]	Events/ Randomized [Rate of Outcome in Control Group, %]	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
		(100mg/day in the first week and 200mg/day thereafter)					
Non-medical	Diener, 2001 ¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	1/135 [0.7]	1/135 [0.7]	1.0 (0.1 to 15.8)	0.00 (-0.02 to 0.02)
Total adverse effects	Diener, 2001¹⁸⁸ Low	Metoprolol 200mg/day (100mg/day in the first week and 200mg/day thereafter)	Aspirin 300mg/day	99/135 [73.3]	51/135 [37.8]	1.9 (1.5 to 2.5)	0.36 (0.24 to 0.47)

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D160. Strength of evidence about treatment adherence and discontinuation due to adverse effects with antidepressant amitriptyline and spinal manipulation for migraine prevention in adults, individual medium risk of bias randomized controlled clinical trial²⁰⁴

Definition of the Outcome	Active Treatment	Control Treatment	Risk of Bias	Directness	Consistency	Precision	Strength of Evidence
Withdrawn due to side-effects	Spinal Manipulation	Amitriptyline	Medium	Yes	NA	No	Low
Withdrawn due to side-effects	Spinal Manipulation + Amitriptyline	Amitriptyline	Medium	Yes	NA	No	Low
Withdrawn due to side-effects	Spinal Manipulation	Spinal Manipulation + Amitriptyline	Medium	Yes	NA	No	Low

Appendix Table D161. Treatment adherence and discontinuation due to adverse effects with antidepressant amitriptyline and spinal manipulation for migraine prevention in adults, individual medium risk of bias randomized controlled clinical trial²⁰⁴

Outcome	Active Treatment	Control Treatment	Events/Randomized Rate, % with Active Treatment	Events/Randomized Rate, % with Control Treatment	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Withdrawn due to side-effects	Spinal Manipulation The spinal manipulation administered was a type described as high-velocity, low-amplitude, and short-lever arm.	Amitriptyline 100mg/day	0/7 0.05	7/77 10.05	0.1 (0.0 to 1.0)	-0.10 (-0.17 to -0.03)
Withdrawn due to side-effects	Spinal Manipulation + Amitriptyline 100mg/day	Amitriptyline 100mg/day	4/7 5.65	7/71 10.05	0.6 (0.2 to 1.8)	-0.04 (-0.13 to 0.04)
Withdrawn due to side-effects	Spinal Manipulation	Spinal Manipulation + Amitriptyline 100mg/day	0/4 0.05	4/77 5.65	0.1 (0.0 to 1.9)	-0.06 (-0.11 to 0.00)
Withdrawn	Spinal Manipulation + Amitriptyline 100mg/day	Amitriptyline 100mg/day	17/15 23.95	15/71 21.45	1.1 (0.6 to 2.1)	0.03 (-0.11 to 0.16)
Withdrawn	Spinal Manipulation	Amitriptyline 100mg/day	19/15 24.75	15/77 21.45	1.2 (0.6 to 2.1)	0.03 (-0.10 to 0.17)
Withdrawn	Spinal Manipulation	Amitriptyline + Spinal Manipulation	19/17 24.75	17/77 23.95	1.0 (0.6 to 1.8)	0.01 (-0.13 to 0.15)

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0
CI = confidence interval

Appendix Table D162. Indirect adjusted analysis of the comparative effects on the treatment discontinuation due to bothersome adverse effects with preventive drugs in adults, results from randomized controlled clinical trials (results with approved drugs and statistically significant results when off label drugs were compared with each other) (strength of evidence is low due to risk of bias and imprecision)

Active Drug, Reference	Control Drug, Reference	Odds Ratio with Active Drug vs. Placebo (95% CI)	Odds Ratio with Control Drug vs. Placebo (95% CI)	Odds Ratio of Active vs. Control Drug (95% CI)	Risk of Bias in Body of Evidence
Divalproex ^{45, 46}	Timolol ⁷⁹	1.3 (0.5 to 3.1)	5.2 (0.2 to 111.7)	0.2 (0.0 to 5.9)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Timolol ⁷⁹	2.0 (1.4 to 2.8)	5.2 (0.2 to 111.7)	0.4 (0.0 to 8.2)	Medium
Propranolol ^{50, 53}	Timolol ⁷⁹	2.4 (0.7 to 8.5)	5.2 (0.2 to 111.7)	0.5 (0.0 to 12.6)	Medium
Divalproex ^{45, 46}	Propranolol ^{50, 53}	1.3 (0.5 to 3.1)	2.4 (0.7 to 8.5)	0.5 (0.1 to 2.5)	Medium
Divalproex ^{45, 46}	Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	1.3 (0.5 to 3.1)	2.0 (1.4 to 2.8)	0.6 (0.2 to 1.7)	Medium
Propranolol ^{50, 53}	Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	2.4 (0.7 to 8.5)	2.0 (1.4 to 2.8)	1.2 (0.3 to 4.6)	Medium
Divalproex ^{45, 46}	Pindolol ⁸⁹	1.3 (0.5 to 3.1)	7.8 (0.4 to 158.9)	0.2 (0.0 to 3.7)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Pindolol ⁸⁹	2.0 (1.4 to 2.8)	7.8 (0.4 to 158.9)	0.3 (0.0 to 5.2)	Medium
Propranolol ^{50, 53}	Pindolol ⁸⁹	2.4 (0.7 to 8.5)	7.8 (0.4 to 158.9)	0.3 (0.0 to 8.0)	Medium
Divalproex ^{45, 46}	Carbamazepine ⁸⁶	1.3 (0.5 to 3.1)	3.1 (0.1 to 77.1)	0.4 (0.0 to 11.7)	Medium
Timolol ⁷⁹	Pindolol ⁸⁹	5.2 (0.2 to 111.7)	7.8 (0.4 to 158.9)	0.7 (0.0 to 49.0)	Medium
Divalproex ^{45, 46}	Nifedipine ¹²⁹	1.3 (0.5 to 3.1)	6.1 (0.6 to 56.4)	0.2 (0.0 to 2.3)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Carbamazepine ⁸⁶	2.0 (1.4 to 2.8)	3.1 (0.1 to 77.1)	0.6 (0.0 to 16.5)	Medium
Propranolol ^{50, 53}	Carbamazepine ⁸⁶	2.4 (0.7 to 8.5)	3.1 (0.1 to 77.1)	0.8 (0.0 to 25.0)	Medium
Timolol ⁷⁹	Acetazolamide ⁸⁰	5.2 (0.2 to 111.7)	6.6 (1.3 to 34.5)	0.8 (0.0 to 25.6)	Medium
Timolol ⁷⁹	Nifedipine ¹²⁹	5.2 (0.2 to 111.7)	6.1 (0.6 to 56.4)	0.9 (0.0 to 38.2)	Medium
Timolol ⁷⁹	Carbamazepine ⁸⁶	5.2 (0.2 to 111.7)	3.1 (0.1 to 77.1)	1.7 (0.0 to 145.7)	Medium
Divalproex ^{45, 46}	Acetazolamide ⁸⁰	1.3 (0.5 to 3.1)	6.6 (1.3 to 34.5)	0.2 (0.0 to 1.2)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Nifedipine ¹²⁹	2.0 (1.4 to 2.8)	6.1 (0.6 to 56.4)	0.3 (0.0 to 3.1)	Medium
Propranolol ^{50, 53}	Nifedipine ¹²⁹	2.4 (0.7 to 8.5)	6.1 (0.6 to 56.4)	0.4 (0.0 to 5.2)	Medium
Divalproex ^{45, 46}	Mg ^{194, 195}	1.3 (0.5 to 3.1)	4.1 (0.7 to 25.7)	0.3 (0.0 to 2.3)	Medium
Propranolol ^{50, 53}	Acetazolamide ⁸⁰	2.4 (0.7 to 8.5)	6.6 (1.3 to 34.5)	0.4 (0.0 to 2.9)	Medium
Divalproex ^{45, 46}	Tonabersat ¹²¹	1.3 (0.5 to 3.1)	2.2 (0.2 to 25.4)	0.6 (0.0 to 7.4)	Medium
Timolol ⁷⁹	Mg ^{194, 195}	5.2 (0.2 to 111.7)	4.1 (0.7 to 25.7)	1.3 (0.0 to 45.0)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Acetazolamide ⁸⁰	2.0 (1.4 to 2.8)	6.6 (1.3 to 34.5)	0.3 (0.1 to 1.6)	Medium
Divalproex ^{45, 46}	Clonidine ^{146, 148}	1.3 (0.5 to 3.1)	2.9 (0.4 to 19.3)	0.4 (0.1 to 3.5)	Medium
Divalproex ^{45, 46}	Lamotrigine ^{44, 87}	1.3 (0.5 to 3.1)	2.9 (0.4 to 21.6)	0.4 (0.1 to 4.0)	Medium
Divalproex ^{45, 46}	Tolfenamic Acid ²⁰²	1.3 (0.5 to 3.1)	2.1 (0.2 to 23.7)	0.6 (0.1 to 8.2)	Medium
Timolol ⁷⁹	Clonidine ^{146, 148}	5.2 (0.2 to 111.7)	2.9 (0.4 to 19.3)	1.8 (0.1 to 66.1)	Medium
Timolol ⁷⁹	Lamotrigine ^{44, 87}	5.2 (0.2 to 111.7)	2.9 (0.4 to 21.6)	1.8 (0.1 to 71.2)	Medium
Timolol ⁷⁹	Tonabersat ¹²¹	5.2 (0.2 to 111.7)	2.2 (0.2 to 25.4)	2.3 (0.1 to 115.8)	Medium
Timolol ⁷⁹	Tolfenamic Acid ²⁰²	5.2 (0.2 to 111.7)	2.1 (0.2 to 23.7)	2.5 (0.1 to 127.8)	Medium
Divalproex ^{45, 46}	Naproxen sodium ²³⁷⁻²³⁹	1.3 (0.5 to 3.1)	2.4 (0.3 to 16.6)	0.5 (0.1 to 4.5)	Medium
Propranolol ^{50, 53}	Mg ^{194, 195}	2.4 (0.7 to 8.5)	4.1 (0.7 to 25.7)	0.6 (0.1 to 5.4)	Medium
Divalproex ^{45, 46}	Metoprolol ⁹⁷	1.3 (0.5 to 3.1)	1.1 (0.1 to 18.2)	1.2 (0.1 to 22.0)	Medium

Appendix Table D162. Indirect adjusted analysis of the comparative effects on the treatment discontinuation due to bothersome adverse effects with preventive drugs in adults, results from randomized controlled clinical trials (results with approved drugs and statistically significant results when off label drugs were compared with each other) (strength of evidence is low due to risk of bias and imprecision) (continued)

Active Drug, Reference	Control Drug, Reference	Odds Ratio with Active Drug vs. Placebo (95% CI)	Odds Ratio with Control Drug vs. Placebo (95% CI)	Odds Ratio of Active vs. Control Drug (95% CI)	Risk of Bias in Body of Evidence
Timolol ⁷⁹	Naproxen sodium ²³⁷⁻²³⁹	5.2 (0.2 to 111.7)	2.4 (0.3 to 16.6)	2.2 (0.1 to 82.9)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Mg ^{194, 195}	2.0 (1.4 to 2.8)	4.1 (0.7 to 25.7)	0.5 (0.1 to 3.1)	Medium
Propranolol ^{50, 53}	Tonabersat ¹²¹	2.4 (0.7 to 8.5)	2.2 (0.2 to 25.4)	1.1 (0.1 to 16.5)	Medium
Propranolol ^{50, 53}	Tolfenamic Acid ²⁰²	2.4 (0.7 to 8.5)	2.1 (0.2 to 23.7)	1.2 (0.1 to 18.3)	Medium
Timolol ⁷⁹	Metoprolol ⁹⁷	5.2 (0.2 to 111.7)	1.1 (0.1 to 18.2)	4.8 (0.1 to 306.0)	Medium
Propranolol ^{50, 53}	Clonidine ^{146, 148}	2.4 (0.7 to 8.5)	2.9 (0.4 to 19.3)	0.8 (0.1 to 8.1)	Medium
Propranolol ^{50, 53}	Lamotrigine ^{44, 87}	2.4 (0.7 to 8.5)	2.9 (0.4 to 21.6)	0.8 (0.1 to 9.0)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Tonabersat ¹²¹	2.0 (1.4 to 2.8)	2.2 (0.2 to 25.4)	0.9 (0.1 to 10.2)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Tolfenamic Acid ²⁰²	2.0 (1.4 to 2.8)	2.1 (0.2 to 23.7)	1.0 (0.1 to 11.3)	Medium
Timolol ⁷⁹	Lisuride ¹⁵⁸	5.2 (0.2 to 111.7)	2.7 (0.9 to 8.0)	2.0 (0.1 to 50.7)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Lamotrigine ^{44, 87}	2.0 (1.4 to 2.8)	2.9 (0.4 to 21.6)	0.7 (0.1 to 5.3)	Medium
Timolol ⁷⁹	Tizanidine ²³⁴	5.2 (0.2 to 111.7)	2.1 (0.6 to 7.3)	2.4 (0.1 to 66.1)	Medium
Timolol ⁷⁹	Oxcarbazepine ⁸³	5.2 (0.2 to 111.7)	2.1 (0.6 to 7.3)	2.5 (0.1 to 67.6)	Medium
Timolol ⁷⁹	Bisoprolol ¹⁰¹	5.2 (0.2 to 111.7)	1.8 (0.4 to 9.1)	2.9 (0.1 to 92.9)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Clonidine ^{146, 148}	2.0 (1.4 to 2.8)	2.9 (0.4 to 19.3)	0.7 (0.1 to 4.7)	Medium
Propranolol ^{50, 53}	Naproxen sodium ²³⁷⁻²³⁹	2.4 (0.7 to 8.5)	2.4 (0.3 to 16.6)	1.0 (0.1 to 10.3)	Medium
Propranolol ^{50, 53}	Metoprolol ⁹⁷	2.4 (0.7 to 8.5)	1.1 (0.1 to 18.2)	2.2 (0.1 to 48.0)	Medium
Timolol ⁷⁹	Gabapentin ^{81, 84, 192}	5.2 (0.2 to 111.7)	2.1 (0.9 to 5.1)	2.5 (0.1 to 59.8)	Medium
Timolol ⁷⁹	Femoxetine ^{113, 115}	5.2 (0.2 to 111.7)	2.0 (0.5 to 7.1)	2.6 (0.1 to 73.3)	Medium
Divalproex ^{45, 46}	Lisuride ¹⁵⁸	1.3 (0.5 to 3.1)	2.7 (0.9 to 8.0)	0.5 (0.1 to 1.9)	Medium
Divalproex ^{45, 46}	Bisoprolol ¹⁰¹	1.3 (0.5 to 3.1)	1.8 (0.4 to 9.1)	0.7 (0.1 to 4.5)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Naproxen sodium ²³⁷⁻²³⁹	2.0 (1.4 to 2.8)	2.4 (0.3 to 16.6)	0.8 (0.1 to 6.0)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Metoprolol ⁹⁷	2.0 (1.4 to 2.8)	1.1 (0.1 to 18.2)	1.8 (0.1 to 30.7)	Medium
Timolol ⁷⁹	Amitriptyline ^{103, 111}	5.2 (0.2 to 111.7)	2.0 (1.1 to 3.9)	2.6 (0.1 to 58.9)	Medium
Divalproex ^{45, 46}	Tizanidine ²³⁴	1.3 (0.5 to 3.1)	2.1 (0.6 to 7.3)	0.6 (0.1 to 2.7)	Medium
Divalproex ^{45, 46}	Oxcarbazepine ⁸³	1.3 (0.5 to 3.1)	2.1 (0.6 to 7.3)	0.6 (0.1 to 2.8)	Medium
Divalproex ^{45, 46}	Femoxetine ^{113, 115}	1.3 (0.5 to 3.1)	2.0 (0.5 to 7.1)	0.6 (0.1 to 3.0)	Medium
Timolol ⁷⁹	Montelukast ²⁰³	5.2 (0.2 to 111.7)	0.9 (0.1 to 6.5)	5.8 (0.2 to 222.7)	Medium
Divalproex ^{45, 46}	Montelukast ²⁰³	1.3 (0.5 to 3.1)	0.9 (0.1 to 6.5)	1.4 (0.2 to 12.3)	Medium
Divalproex ^{45, 46}	Gabapentin ^{81, 84, 192}	1.3 (0.5 to 3.1)	2.1 (0.9 to 5.1)	0.6 (0.2 to 2.1)	Medium
Propranolol ^{50, 53}	Lisuride ¹⁵⁸	2.4 (0.7 to 8.5)	2.7 (0.9 to 8.0)	0.9 (0.2 to 4.8)	Medium
Propranolol ^{50, 53}	Bisoprolol ¹⁰¹	2.4 (0.7 to 8.5)	1.8 (0.4 to 9.1)	1.3 (0.2 to 10.4)	Medium
Timolol ⁷⁹	Fluoxetine ¹¹⁸	5.2 (0.2 to 111.7)	1.0 (0.2 to 4.3)	5.5 (0.2 to 165.6)	Medium
Propranolol ^{50, 53}	Tizanidine ²³⁴	2.4 (0.7 to 8.5)	2.1 (0.6 to 7.3)	1.1 (0.2 to 6.6)	Medium
Propranolol ^{50, 53}	Oxcarbazepine ⁸³	2.4 (0.7 to 8.5)	2.1 (0.6 to 7.3)	1.1 (0.2 to 6.7)	Medium

Appendix Table D162. Indirect adjusted analysis of the comparative effects on the treatment discontinuation due to bothersome adverse effects with preventive drugs in adults, results from randomized controlled clinical trials (results with approved drugs and statistically significant results when off label drugs were compared with each other) (strength of evidence is low due to risk of bias and imprecision) (continued)

Active Drug, Reference	Control Drug, Reference	Odds Ratio with Active Drug vs. Placebo (95% CI)	Odds Ratio with Control Drug vs. Placebo (95% CI)	Odds Ratio of Active vs. Control Drug (95% CI)	Risk of Bias in Body of Evidence
Divalproex ^{45, 46}	Methysergide ¹⁵⁴	1.3 (0.5 to 3.1)	0.5 (0.0 to 5.6)	2.5 (0.2 to 33.7)	Medium
Divalproex ^{45, 46}	Amitriptyline ^{103, 111}	1.3 (0.5 to 3.1)	2.0 (1.1 to 3.9)	0.6 (0.2 to 1.9)	Medium
Propranolol ^{50, 53}	Femoxetine ^{113, 115}	2.4 (0.7 to 8.5)	2.0 (0.5 to 7.1)	1.2 (0.2 to 7.4)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Bisoprolol ¹⁰¹	2.0 (1.4 to 2.8)	1.8 (0.4 to 9.1)	1.1 (0.2 to 5.8)	Medium
Timolol ⁷⁹	Methysergide ¹⁵⁴	5.2 (0.2 to 111.7)	0.5 (0.0 to 5.6)	10.6 (0.2 to 525.8)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Lisuride ¹⁵⁸	2.0 (1.4 to 2.8)	2.7 (0.9 to 8.0)	0.7 (0.2 to 2.3)	Medium
Divalproex ^{45, 46}	Fluoxetine ¹¹⁸	1.3 (0.5 to 3.1)	1.0 (0.2 to 4.3)	1.3 (0.2 to 7.6)	Medium
Propranolol ^{50, 53}	Gabapentin ^{81, 84, 192}	2.4 (0.7 to 8.5)	2.1 (0.9 to 5.1)	1.1 (0.2 to 5.3)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Tizanidine ²³⁴	2.0 (1.4 to 2.8)	2.1 (0.6 to 7.3)	0.9 (0.3 to 3.3)	Medium
Propranolol ^{50, 53}	Montelukast ²⁰³	2.4 (0.7 to 8.5)	0.9 (0.1 to 6.5)	2.7 (0.3 to 28.0)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Oxcarbazepine ⁸³	2.0 (1.4 to 2.8)	2.1 (0.6 to 7.3)	0.9 (0.3 to 3.4)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Femoxetine ^{113, 115}	2.0 (1.4 to 2.8)	2.0 (0.5 to 7.1)	1.0 (0.3 to 3.8)	Medium
Timolol ⁷⁹	Nimodipine ^{132, 133}	5.2 (0.2 to 111.7)	0.7 (0.2 to 2.7)	7.8 (0.3 to 227.8)	Medium
Propranolol ^{50, 53}	Amitriptyline ^{103, 111}	2.4 (0.7 to 8.5)	2.0 (1.1 to 3.9)	1.2 (0.3 to 4.9)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Montelukast ²⁰³	2.0 (1.4 to 2.8)	0.9 (0.1 to 6.5)	2.2 (0.3 to 16.4)	Medium
Propranolol ^{50, 53}	Methysergide ¹⁵⁴	2.4 (0.7 to 8.5)	0.5 (0.0 to 5.6)	4.8 (0.3 to 74.8)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Methysergide ¹⁵⁴	2.0 (1.4 to 2.8)	0.5 (0.0 to 5.6)	4.0 (0.3 to 46.1)	Medium
Propranolol ^{50, 53}	Fluoxetine ¹¹⁸	2.4 (0.7 to 8.5)	1.0 (0.2 to 4.3)	2.5 (0.4 to 17.9)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Gabapentin ^{81, 84, 192}	2.0 (1.4 to 2.8)	2.1 (0.9 to 5.1)	0.9 (0.4 to 2.4)	Medium
Divalproex ^{45, 46}	Nimodipine ^{132, 133}	1.3 (0.5 to 3.1)	0.7 (0.2 to 2.7)	1.9 (0.4 to 10.0)	Medium
Divalproex ^{45, 46}	Atenolol ⁹⁹	1.3 (0.5 to 3.1)	0.1 (0.0 to 2.7)	9.2 (0.4 to 206.0)	Medium
Divalproex ^{45, 46}	Dihydroergotamine ²³³	1.3 (0.5 to 3.1)	0.1 (0.0 to 2.7)	9.4 (0.4 to 213.7)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Fluoxetine ¹¹⁸	2.0 (1.4 to 2.8)	1.0 (0.2 to 4.3)	2.1 (0.4 to 9.6)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Amitriptyline ^{103, 111}	2.0 (1.4 to 2.8)	2.0 (1.1 to 3.9)	1.0 (0.5 to 2.0)	Medium
Timolol ⁷⁹	Atenolol ⁹⁹	5.2 (0.2 to 111.7)	0.1 (0.0 to 2.7)	38.1 (0.5 to 2739.1)	Medium
Propranolol ^{50, 53}	Nimodipine ^{132, 133}	2.4 (0.7 to 8.5)	0.7 (0.2 to 2.7)	3.6 (0.5 to 23.9)	Medium
Timolol ⁷⁹	Dihydroergotamine ²³³	5.2 (0.2 to 111.7)	0.1 (0.0 to 2.7)	39.1 (0.5 to 2833.1)	Medium
Propranolol ^{50, 53}	Atenolol ⁹⁹	2.4 (0.7 to 8.5)	0.1 (0.0 to 2.7)	17.4 (0.7 to 446.5)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Nimodipine ^{132, 133}	2.0 (1.4 to 2.8)	0.7 (0.2 to 2.7)	3.0 (0.7 to 12.6)	Medium
Propranolol ^{50, 53}	Dihydroergotamine ²³³	2.4 (0.7 to 8.5)	0.1 (0.0 to 2.7)	17.9 (0.7 to 463.0)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Atenolol ⁹⁹	2.0 (1.4 to 2.8)	0.1 (0.0 to 2.7)	14.3 (0.7 to 288.9)	Medium
Topiramate ^{19, 24, 28, 29, 31, 35, 42, 44}	Dihydroergotamine ²³³	2.0 (1.4 to 2.8)	0.1 (0.0 to 2.7)	14.7 (0.7 to 299.8)	Medium
Dihydroergotamine ²³³	Timolol ⁷⁹	0.1 (0.0 to 2.7)	5.2 (0.2 to 111.7)	0.0 (0.0 to 1.9)	Medium
Atenolol ⁹⁹	Timolol ⁷⁹	0.1 (0.0 to 2.7)	5.2 (0.2 to 111.7)	0.0 (0.0 to 1.9)	Medium
Nimodipine ^{132, 133}	Timolol ⁷⁹	0.7 (0.2 to 2.7)	5.2 (0.2 to 111.7)	0.1 (0.0 to 3.7)	Medium

Appendix Table D162. Indirect adjusted analysis of the comparative effects on the treatment discontinuation due to bothersome adverse effects with preventive drugs in adults, results from randomized controlled clinical trials (results with approved drugs and statistically significant results when off label drugs were compared with each other) (strength of evidence is low due to risk of bias and imprecision) (continued)

Active Drug, Reference	Control Drug, Reference	Odds Ratio with Active Drug vs. Placebo (95% CI)	Odds Ratio with Control Drug vs. Placebo (95% CI)	Odds Ratio of Active vs. Control Drug (95% CI)	Risk of Bias in Body of Evidence
Methysergide ¹⁵⁴	Timolol ⁷⁹	0.5 (0.0 to 5.6)	5.2 (0.2 to 111.7)	0.1 (0.0 to 4.7)	Medium
Montelukast ²⁰³	Timolol ⁷⁹	0.9 (0.1 to 6.5)	5.2 (0.2 to 111.7)	0.2 (0.0 to 6.6)	Medium
Metoprolol ⁹⁷	Timolol ⁷⁹	1.1 (0.1 to 18.2)	5.2 (0.2 to 111.7)	0.2 (0.0 to 13.4)	Medium
Fluoxetine ¹¹⁸	Timolol ⁷⁹	1.0 (0.2 to 4.3)	5.2 (0.2 to 111.7)	0.2 (0.0 to 5.6)	Medium
Femoxetine ^{113, 115}	Timolol ⁷⁹	2.0 (0.5 to 7.1)	5.2 (0.2 to 111.7)	0.4 (0.0 to 10.5)	Medium
Oxcarbazepine ⁸³	Timolol ⁷⁹	2.1 (0.6 to 7.3)	5.2 (0.2 to 111.7)	0.4 (0.0 to 11.0)	Medium
Bisoprolol ¹¹⁰¹	Timolol ⁷⁹	1.8 (0.4 to 9.1)	5.2 (0.2 to 111.7)	0.3 (0.0 to 11.0)	Medium
Naproxen sodium ²³⁷⁻²³⁹	Timolol ⁷⁹	2.4 (0.3 to 16.6)	5.2 (0.2 to 111.7)	0.5 (0.0 to 17.1)	Medium
Tolfenamic Acid ²⁰²	Timolol ⁷⁹	2.1 (0.2 to 23.7)	5.2 (0.2 to 111.7)	0.4 (0.0 to 19.8)	Medium
Tonabersat ¹²¹	Timolol ⁷⁹	2.2 (0.2 to 25.4)	5.2 (0.2 to 111.7)	0.4 (0.0 to 21.4)	Medium
Lamotrigine ^{44, 87}	Timolol ⁷⁹	2.9 (0.4 to 21.6)	5.2 (0.2 to 111.7)	0.6 (0.0 to 21.6)	Medium
Carbamazepine ⁸⁶	Timolol ⁷⁹	3.1 (0.1 to 77.1)	5.2 (0.2 to 111.7)	0.6 (0.0 to 50.2)	Medium
Amitriptyline ^{103, 111}	Timolol ⁷⁹	2.0 (1.1 to 3.9)	5.2 (0.2 to 111.7)	0.4 (0.0 to 8.9)	Medium
Gabapentin ^{81, 84, 192}	Timolol ⁷⁹	2.1 (0.9 to 5.1)	5.2 (0.2 to 111.7)	0.4 (0.0 to 9.8)	Medium
Tizanidine ²³⁴	Timolol ⁷⁹	2.1 (0.6 to 7.3)	5.2 (0.2 to 111.7)	0.4 (0.0 to 11.1)	Medium
Lisuride ¹⁵⁸	Timolol ⁷⁹	2.7 (0.9 to 8.0)	5.2 (0.2 to 111.7)	0.5 (0.0 to 13.2)	Medium
Clonidine ^{146, 148}	Timolol ⁷⁹	2.9 (0.4 to 19.3)	5.2 (0.2 to 111.7)	0.6 (0.0 to 20.4)	Medium
Mg ^{194, 195}	Timolol ⁷⁹	4.1 (0.7 to 25.7)	5.2 (0.2 to 111.7)	0.8 (0.0 to 28.0)	Medium
Pindolol ⁸⁹	Timolol ⁷⁹	7.8 (0.4 to 158.9)	5.2 (0.2 to 111.7)	1.5 (0.0 to 110.0)	Medium
Nifedipine ¹²⁹	Timolol ⁷⁹	6.1 (0.6 to 56.4)	5.2 (0.2 to 111.7)	1.2 (0.0 to 51.3)	Medium
Acetazolamide ⁸⁰	Timolol ⁷⁹	6.6 (1.3 to 34.5)	5.2 (0.2 to 111.7)	1.3 (0.0 to 41.2)	Medium
Dihydroergotamine ²³³	Acetazolamide ⁸⁰	0.1 (0.0 to 2.7)	6.6 (1.3 to 34.5)	0.0 (0.0 to 0.6)	Medium
Atenolol ⁹⁹	Acetazolamide ⁸⁰	0.1 (0.0 to 2.7)	6.6 (1.3 to 34.5)	0.0 (0.0 to 0.6)	Medium
Dihydroergotamine ²³³	Nifedipine ¹²⁹	0.1 (0.0 to 2.7)	6.1 (0.6 to 56.4)	0.0 (0.0 to 0.9)	Medium
Atenolol ⁹⁹	Nifedipine ¹²⁹	0.1 (0.0 to 2.7)	6.1 (0.6 to 56.4)	0.0 (0.0 to 0.9)	Medium
Nimodipine ^{132, 133}	Acetazolamide ⁸⁰	0.7 (0.2 to 2.7)	6.6 (1.3 to 34.5)	0.1 (0.0 to 0.9)	Medium
Nifedipine ¹²⁹	Atenolol ⁹⁹	6.1 (0.6 to 56.4)	0.1 (0.0 to 2.7)	44.2 (1.1 to 1831.0)	Medium
Nifedipine ¹²⁹	Dihydroergotamine ²³³	6.1 (0.6 to 56.4)	0.1 (0.0 to 2.7)	45.4 (1.1 to 1896.0)	Medium
Acetazolamide ⁸⁰	Nimodipine ^{132, 133}	6.6 (1.3 to 34.5)	0.7 (0.2 to 2.7)	9.9 (1.1 to 86.8)	Medium
Acetazolamide ⁸⁰	Atenolol ⁹⁹	6.6 (1.3 to 34.5)	0.1 (0.0 to 2.7)	48.3 (1.6 to 1459.9)	Medium
Acetazolamide ⁸⁰	Dihydroergotamine ²³³	6.6 (1.3 to 34.5)	0.1 (0.0 to 2.7)	49.6 (1.6 to 1513.0)	Medium

Table D163. Exploratory network Bayesian meta-analysis of treatment discontinuation due to bothersome adverse effects with preventive drugs in adults, results from randomized controlled clinical trials

Active Class	Active Drug	Control Class	Control Drugs	Risk of Bias Reference	Events/ Randomized In Active	Events/ Randomized In Control	Events/ Randomized In Control
Antidepressant	Amitriptyline	Ergot alkaloid	Dihydroergotamine	Medium Bonuso, 1983 ¹⁵⁹	3/21	2/20	NA/1
Antiepileptic	Topiramate	Antidepressant	Amitriptyline	Medium Keskinbora, 2008 ¹⁷⁰	2/24	4/28	NA/1
Antiepileptic	Topiramate	Antidepressant	Amitriptyline	Low Dodick, 2009 ¹⁷²	35/178	38/169	NA/1
Antiepileptic	Divalproex	Beta blocker	Propranolol	High Kaniecki, 1997 ⁶⁸	4/37	1/37	NA/1
Antiepileptic	Valproate	Calcium-channel antagonist	Cinnarizine	Low Togha, 2008 ¹⁹⁰	3/58	2/67	NA/1
Antiepileptic	Topiramate		Histamine	Low Millan-Guerrero, 2008 ¹⁶⁹	10/45	0/45	NA/1
Anti-epileptic	Topiramate	Anti-epileptic	Levetiracetam	Medium de Tommaso, 2007 ¹⁶⁸	1/13	0/15	NA/1
Beta blocker	Propranolol	Antidepressant	Femoxetine	Medium Kangasniemi, 1983 ⁷⁷	0/29	3/29	NA/1
Beta-blocker	Metoprolol	Antiadrenergics	Clonidine	Medium Louis, 1985 ¹⁸³	0/31	4/31	NA/1
Beta-blocker	Propranolol	Antidepressant Ergot alkaloid	Amitriptyline, Ergotamine	High Mathew, 1981 ¹⁰⁵	3/48	3/44	9/49
Beta-blocker	Metoprolol	Anti-depressant	Clomipramine	Medium Langohr, 1985 ¹⁸⁴	0/63	18/63	NA/1
Beta-blocker	Propranolol Hydrochloride	Beta blocker	Nadolol	Medium Sudilovsky, 1987 ¹⁹¹	4/44	2/47	NA/1
Beta-blocker	Propranolol	Dopaminergic agent	Dihydroergocryptine	High Micieli, 2001 ²⁴⁴	5/20	4/20	NA/1
Beta-blocker	Propranolol	Selective calcium channel blockers	Nifedipine	High Albers, 1989 ⁷⁴	5/20	13/20	NA/1
Placebo	Placebo	Antiadrenergics	Clonidine	Medium Adam, 1978 ¹⁴⁸	1/96	2/96	NA/1
Placebo	Placebo	Antiadrenergics	Clonidine	Medium Boisen, 1978 ¹⁴⁶	0/71	2/71	NA/1
Placebo	Placebo	Antidepressant	Amitriptyline	Medium Couch, 1979 ¹⁰³	2/61	5/55	NA/1

Table D163. Exploratory network Bayesian meta-analysis of treatment discontinuation due to bothersome adverse effects with preventive drugs in adults, results from randomized controlled clinical trials (continued)

Active Class	Active Drug	Control Class	Control Drugs	Risk of Bias Reference	Events/ Randomized In Active	Events/ Randomized In Control	Events/ Randomized In Control
Placebo	Placebo	Antidepressant	Amitriptyline	Medium Couch, 2011 ¹¹¹	13/197	23/194	NA/1
Placebo	Placebo	Antidepressant	Femoxetine	Medium Orholm, 1986 ¹¹³	2/34	4/31	NA/1
Placebo	Placebo	Antidepressant	Femoxetine	Medium Orholm, 1985 ¹¹⁵	2/30	3/29	NA/1
Placebo	Placebo	Antidepressant	Fluoxetine,	High Steiner, 1998 ¹¹⁸	4/26	4/27	NA/1
Placebo	Placebo	Antiepileptic	Acetazolamide	Low Vahedi, 2002 ⁸⁰	2/27	9/26	NA/1
Placebo	Placebo	Antiepileptic	Carbamazepine	Medium Rompel, 1970 ⁸⁶	0/48	1/48	NA/1
Placebo	Placebo	Antiepileptic	Divalproex	Medium Mathew, 1995 ⁴⁵	2/37	9/70	NA/1
Placebo	Placebo	Antiepileptic	Divalproex	Low Freitag, 2002 ⁴⁶	10/116	10/123	NA/1
Placebo	Placebo	Antiepileptic	Gabapentin	Medium Mathew, 2001 ⁸¹	4/45	16/98	NA/1
Placebo	Placebo	Antiepileptic	Gabapentin	Medium Wessely, 1987 ⁸⁴	1/22	2/23	NA/1
Placebo	Placebo	Antiepileptic	Gabapentin enacarbil	Low NCT00742209 ¹⁹²	2/20	13/62	NA/1
Placebo	Placebo	Antiepileptic	Lamotrigine	Low Steiner, 1997 ⁸⁷	3/40	7/18	NA/1
Placebo	Placebo	Antiepileptic	Oxcarbazepine	Low Silberstein, 2008 ⁸³	4/85	8/85	NA/1
Placebo	Placebo	Antiepileptic	Sodium valproate	Medium Jensen, 1994 ⁴⁹	2/43	4/43	NA/1
Placebo	Placebo	Antiepileptic	Topiramate	Medium Mei, 2004 ²⁴	2/57	3/58	NA/1
Placebo	Placebo	Antiepileptic	Topiramate	Low Mei, 2006 ²⁸	6/20	9/30	NA/1
Placebo	Placebo	Antiepileptic	Topiramate	Medium Silberstein, 2006 ²⁹	4/73	21/140	NA/1
Placebo	Placebo	Antiepileptic	Topiramate	Low Silberstein, 2007 ³¹	10/163	18/165	NA/1
Placebo	Placebo	Antiepileptic	Topiramate	Low Lainez, 2007 ³⁵	41/383	96/391	NA/1

Table D163. Exploratory network Bayesian meta-analysis of treatment discontinuation due to bothersome adverse effects with preventive drugs in adults, results from randomized controlled clinical trials (continued)

Active Class	Active Drug	Control Class	Control Drugs	Risk of Bias Reference	Events/ Randomized In Active	Events/ Randomized In Control	Events/ Randomized In Control
Placebo	Placebo	Antiepileptic	Topiramate	Low Lipton, 2011 ⁴²	18/197	21/188	NA/1
Placebo	Placebo	Antiepileptic	Topiramate	Low Edwards, 2003 ¹⁹	0/36	6/34	NA/1
Placebo	Placebo	Antiepileptic	Valproate	Medium Hering, 1992 ⁴⁸	2/32	1/32	NA/1
Placebo	Placebo	Antiepileptic Antiepileptic	Topiramate, Lamotrigine	Low Gupta, 2007 ⁴⁴	3/60	3/60	3/60
Placebo	Placebo	Beta-blocker	Atenolol	Medium Johannsson, 1987 ⁹⁹	3/72	0/72	NA/1
Placebo	Placebo	Beta-blocker	Bisoprolol	Medium van de Ven, 1997 ¹⁰¹	2/38	7/77	NA/1
Placebo	Placebo	Beta-blocker	Metoprolol	Medium Andersson, 1983 ⁹⁷	1/37	1/34	NA/1
Placebo	Placebo	Beta-blocker	Pindolol	Medium Sjaastad, 1972 ⁸⁹	0/28	3/28	NA/1
Placebo	Placebo	Beta-blocker	Propranolol	Medium Diamond, 1976 ⁵⁰	1/83	6/83	NA/1
Placebo	Placebo	Beta-blocker	Timolol	Medium Stellar, 1984 ⁷⁹	0/47	2/47	NA/1
Placebo	Placebo	Beta-blocker	Propranolol	Low Pradalier, 1989 ⁵³	5/24	9/31	NA/1
Placebo	Placebo	Ergot alkaloid	Dihydroergotamine	Medium Bousser, 1988 ²³³	3/45	0/45	NA/1
Placebo	Placebo	Ergot alkaloids	Lisuride	Medium Somerville, 1976 ¹⁵⁸	5/75	12/75	NA/1
Placebo	Placebo	Ergot alkaloids	Methysergide	Medium Whewell, 1966 ¹⁵⁴	2/74	1/74	NA/1
Placebo	Placebo	Magnesium	Magnesium	Low Peikert, 1996 ¹⁹⁵	0/38	3/43	NA/1
Placebo	Placebo	Magnesium	Magnesium	Low Pffaffenrath, 1996 ¹⁹⁴	1/34	3/35	NA/1
Placebo	Placebo	Muscle relaxant	Tizanidine	Medium Saper, 2002 ²³⁴	4/64	9/72	NA/1
Placebo	Placebo	NSAID	Naproxen sodium	High Ziegler, 1985 ²³⁹	0/40	1/40	NA/1
Placebo	Placebo	NSAID	Naproxen sodium	High Welch, 1985 ²³⁷ , ²³⁸ 7068	1/46	2/46	NA/1

Table D163. Exploratory network Bayesian meta-analysis of treatment discontinuation due to bothersome adverse effects with preventive drugs in adults, results from randomized controlled clinical trials (continued)

Active Class	Active Drug	Control Class	Control Drugs	Risk of Bias Reference	Events/ Randomized In Active	Events/ Randomized In Control	Events/ Randomized In Control
Placebo	Placebo	NSAID	Tolfenamic Acid	Medium Mikkelsen, 1982 ²⁰²	1/38	2/38	NA/1
Placebo	Placebo	Other	Tonabersat	Low Goadsby, 2009 ¹²¹	1/65	2/59	NA/1
Placebo	Placebo	Selective calcium channel blockers	Nifedipine	High McArthur, 1989 ¹²⁹	1/24	5/24	NA/1
Placebo	Placebo	Selective calcium channel blockers	Nimodipine	Low MINES, 1989 ¹³³	4/46	3/43	NA/1
Placebo	Placebo	Selective calcium channel blockers	Nimodipine	Medium Havanka- Kanninen, 1985 ¹³²	1/33	0/33	NA/1
Placebo	Placebo	Systemic Drugs	Montelukast	Low Brandes, 2004 ²⁰³	2/84	2/93	NA/1

Bold = significant differences at 95% confidence limit when 95% CI of odds ratio estimates do not include 1

Appendix Table D164. Decrease in frequency of migraine >50% with amitriptyline vs. placebo in adults with different baseline migraine frequency, results from medium risk of bias RCT¹¹¹

Baseline Migraine Frequency	Weeks of Treatment	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Baseline ≥17 Headaches per month	4	5.5 (0.7 to 40.5)	0.20 (0.04 to 0.37)
Baseline 1-16 Headaches per month	4	0.7 (0.3 to 1.5)	-0.04 (-0.10 to 0.03)
Baseline ≥17 Headaches per month	8	1.7 (0.5 to 5.4)	0.14 (-0.12 to 0.39)
Baseline 1-16 Headaches per month	8	1.0 (0.5 to 2.2)	0.00 (-0.08 to 0.08)
Baseline ≥17 Headaches per month	12	5.0 (0.7 to 34.3)	0.37 (0.11 to 0.63)
Baseline 1-16 Headaches per month	12	1.2 (0.6 to 2.5)	0.02 (-0.08 to 0.12)
Baseline ≥17 Headaches per month	16	1.8 (0.5 to 7.1)	0.16 (-0.16 to 0.48)
Baseline 1-16 Headaches per month	16	0.8 (0.4 to 1.8)	-0.03 (-0.13 to 0.07)

Bold = significant difference at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

CI = confidence interval

Appendix Table D165. Improvement of M score >50%* with amitriptyline vs. placebo in adults with different baseline M score and depressive symptoms, results from medium risk of bias RCT¹⁰³

Baseline Condition	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)
Baseline H<14	1.6 (1.0 to 2.5)	0.21 (0.00 to 0.43)
Baseline H>=14	1.5 (0.4 to 5.7)	0.13 (-0.29 to 0.54)
Baseline M<100	1.7 (0.9 to 3.0)	0.21 (-0.01 to 0.43)
Baseline M<100 AND H<14	1.5 (0.8 to 2.8)	0.16 (-0.08 to 0.40)
Baseline M<100 AND H>14	3.0 (0.8 to 11.3)	0.50 (-0.02 to 1)
Baseline M≥100	1.4 (0.7 to 2.9)	0.21 (-0.18 to 0.59)
Baseline M≥100 AND H<14	1.7 (1.0 to 3.1)	0.44 (0.10 to 0.79)
Baseline M≥100 AND H>14	0.3 (0.0 to 6.4)	-0.25 (-0.73 to 0.23)

M score = 2 (frequency*duration) Disabling+1 (frequency*duration) Severe; H SCORE=Hamilton Physician Depression Rating Scale (0-7 normal, 20 - severe depression)

Bold = significant difference at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

CI = confidence interval

Appendix Table D166. Prediction of $\geq 50\%$ in migraine days reduction per month with different doses of amitriptyline (50 vs. 25mg/day) for migraine prevention in adults, results from medium risk of bias RCT¹¹⁰

Predictor of Effect	Odds Ratio (95% CI)
Age (+1 year)	1.08 (0.99 to 1.17)
Age at onset of migraine (+1 year)	1.04 (0.94 to 1.16)
Amitriptyline ER 50 mg per day (versus not)	0.24 (0.06 to 1.04)
Duration of attack (+1 h)	1.04 (0.98 to 1.12)
Male gender (versus female)	2.1 (0.45 to 9.87)
Migraine days per month (+1 day)	2.35 (1.45 to 3.8)
Migraine with aura (versus without)	0.63 (0.13 to 3.12)
Number of drugs (+1 drug)	1.02 (0.67 to 1.55)
Pain intensity per attack (+1 score point)	0.69 (0.46 to 1.04)
Positive family history of migraine (versus negative)	2.35 (0.57 to 9.72)
Smoker (versus not)	2.23 (0.44 to 11.3)

Bold = significant difference at 95% confidence limit when 95% CI of odds ratio estimates do not include 1
CI = confidence interval

References for Appendix D

1. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. *Cephalalgia*. 2010 Jul;30(7):793-803. PMID 20647170.
2. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. *Cephalalgia*. 2010 Jul;30(7):804-14. PMID 20647171.
3. Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. *Neurology*. 2011 Oct 11;77(15):1465-72. PMID 21956721.
4. Saper JR, Mathew NT, Loder EW, et al. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. *Pain Med*. 2007 Sep;8(6):478-85. PMID 17716321.
5. Freitag FG, Diamond S, Diamond M, et al. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. *Headache*. 2008 Feb;48(2):201-9. PMID 18042229.
6. Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. *Headache*. 2000 Jun;40(6):445-50. PMID 10849039.
7. Elkind AH, O'Carroll P, Blumenfeld A, et al. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. *J Pain*. 2006 Oct;7(10):688-96. PMID 17018329.
8. Chankrachang S, Arayawichanont A, Pongvarin N, et al. Prophylactic botulinum type A toxin complex (Dysport(R)) for migraine without aura. *Headache*. 2011 Jan;51(1):52-63. PMID 21083558.
9. Petri S, Tolle T, Straube A, et al. Botulinum toxin as preventive treatment for migraine: a randomized double-blind study. *Eur Neurol*. 2009;62(4):204-11. PMID 19622887.
10. Mathew NT, Frishberg BM, Gawel M, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. *Headache*. 2005 Apr;45(4):293-307. PMID 15836565.
11. Silberstein SD, Stark SR, Lucas SM, et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. *Mayo Clin Proc*. 2005 Sep;80(9):1126-37. PMID 16178492.
12. Anand KS, Prasad A, Singh MM, et al. Botulinum toxin type A in prophylactic treatment of migraine. *Am J Ther*. 2006 May-Jun;13(3):183-7. PMID 16772757.
13. Cady R, Schreiber C. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. *Headache*. 2008 Jun;48(6):900-13. PMID 18047501.
14. Vo AH, Satori R, Jabbari B, et al. Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial.

Aviat Space Environ Med. 2007 May;78(5 Suppl):B113-8. PMID 17547312.

15. Aurora SK, Gawel M, Brandes JL, et al. Botulinum toxin type A prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. *Headache*. 2007 Apr;47(4):486-99. PMID 17445098.

16. Barrientos N, Chana P. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. *J. Headache Pain*. 2003;4(3):146-51.

17. Relja M, Poole AC, Schoenen J, et al. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. *Cephalalgia*. 2007 Jun;27(6):492-503. PMID 17428299.

18. Storey JR, Calder CS, Hart DE, et al. Topiramate in migraine prevention: a double-blind, placebo-controlled study. *Headache*. 2001 Nov-Dec;41(10):968-75. PMID 11903524.

19. Edwards KR, Potter DL, Wu SC, et al. Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials. *CNS Spectr*. 2003 Jun;8(6):428-32. PMID 12858132.

20. Silvestrini M, Bartolini M, Coccia M, et al. Topiramate in the treatment of chronic migraine. *Cephalalgia*. 2003 Oct;23(8):820-4. PMID 14510929.

21. Silberstein S. Efficacy and safety of topiramate in migraine prevention: a dose-ranging, placebo-controlled, double-blind, multicenter study. *Advanced Studies in Medicine*. 2003;3(6C):S565-8.

22. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. *JAMA*. 2004 Feb 25;291(8):965-73. PMID 14982912.

23. Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial. *Arch Neurol*. 2004 Apr;61(4):490-5. PMID 15096395.

24. Mei D, Capuano A, Vollono C, et al. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. *Neurol Sci*. 2004 Dec;25(5):245-50. PMID 15624081.

25. Bussone G, Diener HC, Pfeil J, et al. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. *Int J Clin Pract*. 2005 Aug;59(8):961-8. PMID 16033621.

26. Diamond M, Dahlof C, Papadopoulos G, et al. Topiramate improves health-related quality of life when used to prevent migraine. *Headache*. 2005 Sep;45(8):1023-30. PMID 16109116.

27. Silberstein SD, Loder E, Forde G, et al. The impact of migraine on daily activities: effect of topiramate compared with placebo. *Curr Med Res Opin*. 2006 Jun;22(6):1021-9. PMID 16846536.

28. Mei D, Ferraro D, Zelano G, et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. *Clin Neuropharmacol*. 2006 Sep-Oct;29(5):269-75. PMID 16960472.

29. Silberstein SD, Hulihan J, Karim MR, et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine

with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. *Clin Ther*. 2006 Jul;28(7):1002-11. PMID 16990078.

30. Brandes JL, Kudrow DB, Rothrock JF, et al. Assessing the ability of topiramate to improve the daily activities of patients with migraine. *Mayo Clin Proc*. 2006 Oct;81(10):1311-9. PMID 17036556.

31. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. *Headache*. 2007 Feb;47(2):170-80. PMID 17300356.

32. Lofland JH, Gagne JJ, Pizzi LT, et al. Impact of topiramate migraine prophylaxis on workplace productivity: results from two US randomized, double-blind, placebo-controlled, multicenter trials. *J Occup Environ Med*. 2007 Mar;49(3):252-7. PMID 17351510.

33. Limmroth V, Biondi D, Pfeil J, et al. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. *Headache*. 2007 Jan;47(1):13-21. PMID 17355489.

34. Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. *Cephalalgia*. 2007 Jul;27(7):814-23. PMID 17441971.

35. Lainez MJ, Freitag FG, Pfeil J, et al. Time course of adverse events most commonly associated with topiramate for migraine prevention. *Eur J Neurol*. 2007 Aug;14(8):900-6. PMID 17662012.

36. Freitag FG, Forde G, Neto W, et al. Analysis of pooled data from two pivotal

controlled trials on the efficacy of topiramate in the prevention of migraine. *J Am Osteopath Assoc*. 2007 Jul;107(7):251-8. PMID 17682112.

37. Dahlof C, Loder E, Diamond M, et al. The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. *Health Qual Life Outcomes*. 2007;5:56. PMID 17916258.

38. Diener HC, Agosti R, Allais G, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2007 Dec;6(12):1054-62. PMID 17988947.

39. Dodick DW, Silberstein S, Saper J, et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. *Headache*. 2007 Nov-Dec;47(10):1398-408. PMID 18052949.

40. Adelman J, Freitag FG, Lainez M, et al. Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials. *Pain Med*. 2008 Mar;9(2):175-85. PMID 18298700.

41. Silberstein S, Lipton R, Dodick D, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. *Headache*. 2009 Sep;49(8):1153-62. PMID 19719543.

42. Lipton RB, Silberstein S, Dodick D, et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. *Cephalalgia*. 2011 Jan;31(1):18-30. PMID 20974598.

43. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control. *J Neurol*. 2004 Aug;251(8):943-50. PMID 15316798.
44. Gupta P, Singh S, Goyal V, et al. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). *Headache*. 2007 Mar;47(3):402-12. PMID 17371357.
45. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. *Arch Neurol*. 1995 Mar;52(3):281-6. PMID 7872882.
46. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. *Neurology*. 2002 Jun 11;58(11):1652-9. PMID 12058094.
47. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. *Cephalalgia*. 1997 Apr;17(2):103-8. PMID 9137847.
48. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. *Cephalalgia*. 1992 Apr;12(2):81-4. PMID 1576648.
49. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. *Neurology*. 1994 Apr;44(4):647-51. PMID 8164818.
50. Diamond S, Medina JL. Double blind study of propranolol for migraine prophylaxis. *Headache*; 1976. p. 24-7.
51. Stensrud P, Sjaastad O. Short-term clinical trial of phopropranolol in racemic form (Inderal), D-propranolol and placebo in migraine. *Acta neurologica Scandinavica*; 1976. p. 229-32.
52. Forssman B, Henriksson KG, Johannsson V, et al. Propranolol for migraine prophylaxis. *Headache*; 1976. p. 238-45.
53. Pradalier A, Serratrice G, Collard M, et al. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. *Cephalalgia*. 1989 Dec;9(4):247-53. PMID 2692838.
54. Nadelmann JW, Stevens J, Saper JR. Propranolol in the prophylaxis of migraine. *Headache*; 1986. p. 175-82.
55. Sargent J, Solbach P, Damasio H, et al. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. *Headache*; 1985. p. 320-4.
56. Ahuja GK, Verma AK. Propranolol in prophylaxis of migraine. *Indian J Med Res*. 1985 Sep;82:263-5. PMID 3908306.
57. Malvea BP, Gwon N, Graham JR. Propranolol prophylaxis of migraine. *Headache*; 1973. p. 163-7.
58. Wideroe TE, Vigander T. Propranolol in the treatment of migraine. *Br Med J*. 1974 Jun 29;2(5921):699-701. PMID 4604977.
59. Palferman TG, Gibberd FB, Simmonds JP. Prophylactic propranolol in the treatment of headache. *Br J Clin Pract*. 1983 Jan;37(1):28-9. PMID 6340710.
60. Tfelt-Hansen P, Standnes B, Kangasneimi P, et al. Timolol vs propranolol vs placebo in common migraine

prophylaxis: a double-blind multicenter trial. *Acta Neurol Scand.* 1984 Jan;69(1):1-8. PMID 6367336.

61. Standnes B. The prophylactic effect of timolol versus propranolol and placebo in common migraine: Beta-blockers in migraine. *Cephalalgia*; 1982. p. 165-70.

62. Stensrud P, Sjaastad O. Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine. *Ups J Med Sci Suppl.* 1980;31:37-40. PMID 7006182.

63. al-Qassab HK, Findley LJ. Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study. *Cephalalgia.* 1993 Apr;13(2):128-31. PMID 8495455.

64. Rafieian-Kopaei M, Mehvari J, Shirzadeh H. Different profile of propranolol and amitriptyline effects on migraine prophylaxis. *International Journal of Pharmacology.* 2005;1:366-8.

65. Weber RB, Reinmuth OM. The treatment of migraine with propranolol. *Neurology*; 1972. p. 366-9.

66. Pradalier A, Serratrice G, Collard M, et al. Double-blind placebo controlled study of the use of long-acting propranolol in migraine prophylaxis. *Cephalalgia*; 1989. p. 367-8.

67. Kuritzky A, Hering R. Prophylactic treatment of migraine with long acting propranolol - a comparison with placebo. *Cephalalgia*; 1987. p. 457-8.

68. Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. *Arch Neurol.* 1997 Sep;54(9):1141-5. PMID 9311358.

69. Kass B, Nestvold K. Propranolol (Inderal) and clonidine (Catapressan) in the prophylactic treatment of migraine. A comparative trial. *Acta Neurol Scand.* 1980 Jun;61(6):351-6. PMID 6998250.

70. Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. *Cephalalgia.* 1984 Jun;4(2):91-6. PMID 6428749.

71. Gerber WD, Diener HC, Scholz E, et al. Responders and non-responders to metoprolol, propranolol and nifedipine treatment in migraine prophylaxis: a dose-range study based on time-series analysis. *Cephalalgia.* 1991 Feb;11(1):37-45. PMID 2036669.

72. Sudilovsky A, Elkind AH, Ryan RES, et al. Comparative efficacy of nadolol and propranolol in the management of migraine. *Headache*; 1987. p. 421-6.

73. Olerud B, Gustavsson CL, Furberg B. Nadolol and propranolol in migraine management. *Headache*; 1986. p. 490-3.

74. Albers GW, Simon LT, Hamik A, et al. Nifedipine versus propranolol for the initial prophylaxis of migraine. *Headache.* 1989 Apr;29(4):215-8. PMID 2654067.

75. Domingues RB, Silva AL, Domingues SA, et al. A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine. *Arq Neuropsiquiatr.* 2009 Dec;67(4):973-7. PMID 20069203.

76. Ziegler DK, Hurwitz A, Hassanein RS, et al. Migraine prophylaxis. A comparison of

propranolol and amitriptyline. *Arch Neurol*. 1987 May;44(5):486-9. PMID 3579659.

77. Kangasniemi PJ, Nyrke T, Lang AH, et al. Femoxetine - a new 5-HT uptake inhibitor - and propranolol in the prophylactic treatment of migraine. *Acta Neurol Scand*; 1983. p. 262-7.

78. Silberstein SD, Dodick DW, Lindblad AS, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. *Neurology*. 2012 Mar 27;78(13):976-84. PMID 22377815.

79. Stellar S, Ahrens SP, Meibohm AR, et al. Migraine prevention with timolol. A double-blind crossover study. *JAMA*. 1984 Nov 9;252(18):2576-80. PMID 6387197.

80. Vahedi K, Taupin P, Djomby R, et al. Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial. *J Neurol*. 2002 Feb;249(2):206-11. PMID 11985388.

81. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. *Headache*. 2001 Feb;41(2):119-28. PMID 11251695.

82. Ghose K, Niven B, Berry D. A double-blind crossover comparison of the effects of vigabatrin with placebo in the prevention of migraine headache. *J Headache Pain*. 2002;3:79-85.

83. Silberstein S, Saper J, Berenson F, et al. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. *Neurology*. 2008 Feb 12;70(7):548-55. PMID 18268247.

84. Wessely P, Baumgartner C, Klingler D, et al. Preliminary results of a double-blind study with the new migraine prophylactic

drug Gabapentin. *Cephalalgia*; 1987. p. 477-8.

85. Di Trapani G, Mei D, Marra C, et al. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. *Clin Ter*. 2000 May-Jun;151(3):145-8. PMID 10958046.

86. Rompel H, Bauermeister PW. Aetiology of migraine and prevention with carbamazepine (Tegretol): results of a double-blind, cross-over study. *S Afr Med J*. 1970 Jan 24;44(4):75-80. PMID 4905910.

87. Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. *Cephalalgia*. 1997 Apr;17(2):109-12. PMID 9137848.

88. Ekbom K, Lundberg PO. Clinical trial of LB-46 (d, 1-4-(2-hydroxy-3-isopropylaminopropoxy)indol. An adrenergic beta-receptor blocking agent in migraine prophylaxis. *Headache*; 1972. p. 15-7.

89. Sjaastad O, Stensrud P. Clinical trial of a beta-receptor blocking agent (LB 46) in migraine prophylaxis. *Acta neurologica Scandinavica*; 1972. p. 124-8.

90. Ekbom K. Alprenolol for migraine prophylaxis. *Headache*; 1975. p. 129-32.

91. Nanda RN, Johnson RH, Gray J, et al. A double blind trial of acebutolol for migraine prophylaxis. *Headache*; 1978. p. 20-2.

92. Briggs RS, Millac PA. Timolol in migraine prophylaxis. *Headache*. 1979 Nov;19(7):379-81. PMID 511540.

93. Ryan R, Ryan R, Sudilovsky A. Nadolol and placebo comparison study in the

prophylactic treatment of migraine.
Panminerva Med; 1982. p. 89-94.

94. Ryan R, Ryan R, Sudilovsky A. Nadolol:
Its use in the prophylactic treatment of
migraine. Headache; 1983. p. 26-31.

95. Forssman B. Atenolol for Migraine
Prophylaxis. Acta Neurologica
Scandinavica. 1982;65(S90):75-6.

96. Forssman B, Lindblad CJ, Zbornikova V.
Atenolol for migraine prophylaxis.
Headache; 1983. p. 188-90.

97. Andersson PG, Dahl S, Hansen JH, et al.
Prophylactic treatment of classical and non-
classical migraine with metoprolol--a
comparison with placebo. Cephalalgia. 1983
Dec;3(4):207-12. PMID 6640652.

98. Freitag FG, Diamond S. Nadolol and
placebo comparison study in the
prophylactic treatment of migraine. The
Journal of the American Osteopathic
Association; 1984. p. 343-7.

99. Johannsson V, Nilsson LR, Widelius T,
et al. Atenolol in migraine prophylaxis: a
double-blind cross-over multicenter study.
Headache; 1987. p. 372-4.

100. Kangasniemi P, Andersen AR,
Andersson PG, et al. Classic migraine:
effective prophylaxis with metoprolol.
Cephalalgia. 1987 Dec;7(4):231-8. PMID
3322569.

101. van de Ven LL, Franke CL, Koehler PJ.
Prophylactic treatment of migraine with
bisoprolol: a placebo-controlled study.
Cephalalgia. 1997 Aug;17(5):596-9. PMID
9251876.

102. Siniatchkin M, Andrasik F, Kropp P, et
al. Central mechanisms of controlled-release

metoprolol in migraine: a double-blind,
placebo-controlled study. Cephalalgia. 2007
Sep;27(9):1024-32. PMID 17680819.

103. Couch JR, Hassanein RS. Amitriptyline
in migraine prophylaxis. Arch Neurol. 1979
Nov;36(11):695-9. PMID 508127.

104. Gomersall JD, Stuart A. Amitriptyline
in migraine prophylaxis. Changes in pattern
of attacks during a controlled clinical trial. J
Neurol Neurosurg Psychiatry. 1973
Aug;36(4):684-90. PMID 4731336.

105. Mathew NT. Prophylaxis of migraine
and mixed headache. A randomized
controlled study. Headache. 1981
May;21(3):105-9. PMID 7021472.

106. Bank J. A comparative study of
amitriptyline and fluvoxamine in migraine
prophylaxis. Headache. 1994 Sep;34(8):476-
8. PMID 7960733.

107. Oguzhanoglu A, Sahiner T, Kurt T, et
al. Use of amitriptyline and fluoxetine in
prophylaxis of migraine and tension-type
headaches. Cephalalgia. 1999
Jun;19(5):531-2. PMID 10403070.

108. Krymchantowski AV, Silva MT,
Barbosa JS, et al. Amitriptyline versus
amitriptyline combined with fluoxetine in
the preventative treatment of transformed
migraine: a double-blind study. Headache.
2002 Jun;42(6):510-4. PMID 12167139.

109. Bulut S, Berilgen MS, Baran A, et al.
Venlafaxine versus amitriptyline in the
prophylactic treatment of migraine:
randomized, double-blind, crossover study.
Clin Neurol Neurosurg. 2004
Dec;107(1):44-8. PMID 15567552.

110. Lampl C, Huber G, Adl J, et al. Two
different doses of amitriptyline ER in the

prophylaxis of migraine: long-term results and predictive factors. *Eur J Neurol*. 2009 Aug;16(8):943-8. PMID 19456855.

111. Couch JR. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. *Headache*. 2011 Jan;51(1):33-51. PMID 21070231.

112. Couch JR, Hassanein RS. Migraine and depression: effect of amitriptyline prophylaxis. *Trans Am Neurol Assoc*; 1976. p. 234-7.

113. Orholm M, Honore PF, Zeeberg I. A randomized general practice group-comparative study of femoxetine and placebo in the prophylaxis of migraine. *Acta Neurol Scand*. 1986 Sep;74(3):235-9. PMID 3538753.

114. Zeeberg I, Orholm M, Nielsen JD, et al. Femoxetine in the prophylaxis of migraine: A randomized comparison with placebo. *Acta-Neurol-Scand*; 1981. p. 452-9.

115. Orholm M, Le Fevre P. Prophylactic treatment of migraine with femoxetine - a randomized comparison with placebo. *Cephalalgia*; 1985. p. 516-7.

116. Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. *Headache*. 1992 Feb;32(2):101-4. PMID 1551787.

117. Saper JR, Silberstein SD, Lake AE, 3rd, et al. Double-blind trial of fluoxetine: chronic daily headache and migraine. *Headache*. 1994 Oct;34(9):497-502. PMID 8002320.

118. Steiner TJ, Ahmed F, Findley LJ, et al. S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-

controlled study. *Cephalalgia*. 1998 Jun;18(5):283-6. PMID 9673809.

119. d'Amato CC, Pizza V, Marmolo T, et al. Fluoxetine for migraine prophylaxis: a double-blind trial. *Headache*. 1999 Nov-Dec;39(10):716-9. PMID 11279947.

120. Monro P, Swade C, Coppen A. Mianserin in the prophylaxis of migraine: a double-blind study. *Acta psychiatrica Scandinavica. Supplementum*; 1985. p. 98-103.

121. Goadsby PJ, Ferrari MD, Csanyi A, et al. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. *Cephalalgia*. 2009 Jul;29(7):742-50. PMID 19222510.

122. Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. *Headache*. 2005 Feb;45(2):144-52. PMID 15705120.

123. Tarlaci S. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. *Clin Neuropharmacol*. 2009 Sep-Oct;32(5):254-8. PMID 19667978.

124. Markley HG, Cheronis JC, Piepho RW. Verapamil in prophylactic therapy of migraine. *Neurology*; 1984. p. 973-6.

125. Stewart DJ, Gelston A, Hakim A. Effect of prophylactic administration of nimodipine in patients with migraine. *Headache*. 1988 May;28(4):260-2. PMID 3170182.

126. Leandri M, Rigardo S, Schizzi R, et al. Migraine treatment with nifedipine. *Cephalalgia*. 1990 Jun;10(3):111-6. PMID 2245455.

127. Gelmers HJ. Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine. *Headache*; 1983. p. 106-9.
128. (MINES) M-NESG. European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). *Headache*. 1989 Nov;29(10):633-8. PMID 2693405.
129. McArthur JC, Marek K, Pestronk A, et al. Nifedipine in the prophylaxis of classic migraine: a crossover, double-masked, placebo-controlled study of headache frequency and side effects. *Neurology*; 1989. p. 284-6.
130. Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. *JAMA*. 1983 Nov 11;250(18):2500-2. PMID 6355533.
131. Meyer JS, Hardenberg J. Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headaches. *Headache*; 1983. p. 266-77.
132. Havanka-Kanniainen H, Hokkanen E, Myllylä VV. Efficacy of nimodipine in the prophylaxis of migraine. *Cephalalgia : an international journal of headache*; 1985. p. 39-43.
133. (MINES) M-NESG. European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). *Headache*. 1989 Nov;29(10):639-42. PMID 2693406.
134. Ansell E, Fazzone T, Festenstein R, et al. Nimodipine in migraine prophylaxis. *Cephalalgia : an international journal of headache*; 1988. p. 269-72.
135. Shukla R, Garg RK, Nag D, et al. Nifedipine in migraine and tension headache: a randomised double blind crossover study. *J Assoc Physicians India*. 1995 Nov;43(11):770-2. PMID 8773038.
136. Schrader H, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. *BMJ*. 2001 Jan 6;322(7277):19-22. PMID 11141144.
137. Minervini MG, Pinto K. Captopril relieves pain and improves mood depression in depressed patients with classical migraine. *Cephalalgia*; 1987. p. 485-6.
138. Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. *JAMA*. 2003 Jan 1;289(1):65-9. PMID 12503978.
139. Diener HC, Gendolla A, Feuersenger A, et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. *Cephalalgia*. 2009 Sep;29(9):921-7. PMID 19250283.
140. Ryan RE, Sr., Ryan RE, Jr. The effects of clonidine in the prophylactic treatment of migraine. *Headache*; 1975. p. 199-212.
141. Ryan RE, Diamond S. Double blind study of clonidine and placebo for the prophylactic treatment of migraine. *Headache*; 1975. p. 202-10.
142. Shafar J, Tallett ER, Knowlson PA. Evaluation of clonidine in prophylaxis of migraine. Double-blind trial and follow-up. *Lancet*. 1972 Feb 19;1(7747):403-7. PMID 4110641.

143. Stensrud P, Sjaastad O. Clonidine (Catapresan)-double-blind study after long-term treatment with the drug in migraine. *Acta neurologica Scandinavica*; 1976. p. 233-6.
144. Martucci N, Manna V, Porto C, et al. Migraine and the noradrenergic control of vasomotricity: a study with alpha-2 stimulant and alpha-2 blocker drugs. *Headache*. 1985 Mar;25(2):95-100. PMID 3886600.
145. Denaro A, Martucci N, Ruggieri S, et al. Headache and noradrenergic involvement: the effects of alpha 2-stimulants and alpha 2-antagonists. *Acta Psychiatr Scand Suppl*. 1985;320:20-5. PMID 3901672.
146. Boisen E, Deth S, Hübbe P, et al. Clonidine in the prophylaxis of migraine. *Acta neurologica Scandinavica*; 1978. p. 288-95.
147. Wilkinson M. Preliminary report on the use of clonidine (Boehringer Ingelheim) in the treatment of migraine. *Research and clinical studies in headache*; 1970. p. 315-20.
148. Adam EI, Gore SM, Price WH. Double blind trial of clonidine in the treatment of migraine in a general practice. *J R Coll Gen Pract*. 1978 Oct;28(195):587-90. PMID 368333.
149. Bredfeldt RC, Sutherland JE, Kruse JE. Efficacy of transdermal clonidine for headache prophylaxis and reduction of narcotic use in migraine patients. A randomized crossover trial. *J Fam Pract*. 1989 Aug;29(2):153-6; discussion 7-8. PMID 2666565.
150. Kallanranta T, Hakkarainen H, Hokkanen E, et al. Clonidine in migraine prophylaxis. *Headache*; 1977. p. 169-72.
151. Das SM, Ahuja GK, Narainaswamy AS. Clonidine in prophylaxis of migraine. *Acta neurologica Scandinavica*; 1979. p. 214-7.
152. Martucci N, Manna V, Mattesi P, et al. Ergot derivatives in the prophylaxis of migraine: a multicentric study with a timed-release dihydroergotamine formulation. *Cephalalgia*. 1983 Aug;3(Suppl 1):151-5. PMID 6352046.
153. Herrmann WM, Horowski R, Dannehl K, et al. Clinical effectiveness of lisuride hydrogen maleate: a double-blind trial versus methysergide. *Headache*. 1977 May;17(2):54-60. PMID 324950.
154. Whewell J. Methysergide in prophylaxis of migraine: a clinical trial in general practice. *Br Med J*. 1966 Aug 13;2(5510):394-5. PMID 5331176.
155. Pradalier A, Lanteri-Minet M, Geraud G, et al. The PROMISE study: PROphylaxis of MIGraine with SEglor (dihydroergotamine mesilate) in French primary care. *CNS Drugs*. 2004;18(15):1149-63. PMID 15581385.
156. Neuman M, Demarez JP, Harmey JL, et al. Prevention of migraine attacks through the use of dihydroergotamine. *International journal of clinical pharmacology research*; 1986. p. 11-3.
157. Buscaino GA, Sorge F, Bussone G, et al. Preventive treatment of headache with slow-release dihydroergotamine: Comparison of dosage protocols. *Curr Ther Res Clin Exp*; 1991. p. 925-35.

158. Somerville BW, Herrmann WM. Migraine prophylaxis with lisuride. A double blind study of lisuride versus placebo. *Headache*; 1976. p. 85-6.
159. Bonuso S, Di Stasio E, Barone P, et al. Timed-release dihydroergotamine in the prophylaxis of mixed headache. A study versus amitriptyline. *Cephalalgia*; 1983. p. 175-8.
160. Millan-Guerrero RO, Isais-Millan S, Barreto-Vizcaino S, et al. Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study. *Eur J Neurol*. 2009 Jan;16(1):88-94. PMID 19087155.
161. Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxinA (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. *Headache*. 2009 Nov-Dec;49(10):1466-78. PMID 19912346.
162. Magalhaes E, Menezes C, Cardeal M, et al. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. *Clin Neurol Neurosurg*. 2010 Jul;112(6):463-6. PMID 20399553.
163. Cady RK, Schreiber CP, Porter JA, et al. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. *Headache*. 2011 Jan;51(1):21-32. PMID 21070228.
164. Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. *Headache*. 2008 Feb;48(2):210-20. PMID 18047502.
165. Freitag F, Taylor FR, Hamid MA, et al. Elimination of migraine-associated nausea in patients treated with rizatriptan orally disintegrating tablet (ODT): a randomized, double-blind, placebo-controlled study. *Headache*. 2008 Mar;48(3):368-77. PMID 18047500.
166. Bartolini M, Silvestrini M, Taffi R, et al. Efficacy of topiramate and valproate in chronic migraine. *Clin Neuropharmacol*. 2005 Nov-Dec;28(6):277-9. PMID 16340383.
167. Shaygannejad V, Janghorbani M, Ghorbani A, et al. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. *Headache*. 2006 Apr;46(4):642-8. PMID 16643559.
168. de Tommaso M, Marinazzo D, Nitti L, et al. Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine. *Clin Neurophysiol*. 2007 Oct;118(10):2297-304. PMID 17709295.
169. Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, et al. Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study. *Eur Neurol*. 2008;59(5):237-42. PMID 18264012.
170. Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. *Clin Neurol Neurosurg*. 2008 Dec;110(10):979-84. PMID 18620801.
171. Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine

prophylaxis. *Acta Neurol Scand.* 2008 Nov;118(5):301-5. PMID 18713156.

172. Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. *Clin Ther.* 2009 Mar;31(3):542-59. PMID 19393844.

173. Mohammadianinejad SE, Abbasi V, Sajedi SA, et al. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. *Clin Neuropharmacol.* 2011 Jul-Aug;34(4):174-7. PMID 21738025.

174. Behan PO, Reid M. Propranolol in the treatment of migraine. *Practitioner*; 1980. p. 201-4.

175. Carroll JD, Reidy M, Savundra PA, et al. Long-acting propranolol in the prophylaxis of migraine: a comparative study of two doses. *Cephalalgia.* 1990 Apr;10(2):101-5. PMID 2193712.

176. Kaushik R, Kaushik RM, Mahajan SK, et al. Biofeedback assisted diaphragmatic breathing and systematic relaxation versus propranolol in long term prophylaxis of migraine. *Complement Ther Med.* 2005 Sep;13(3):165-74. PMID 16150370.

177. Andersson PG, Petersen EN. Propranolol and femoxetine, a 5HT-uptake inhibitor, in migraine prophylaxis. A double-blind crossover study. *Acta Neurol Scand*; 1981. p. 280-8.

178. Havanka-Kanniainen H, Hokkanen E, Myllyla VV. Long acting propranolol in the prophylaxis of migraine. Comparison of the daily doses of 80 mg and 160 mg. *Headache*; 1988. p. 607-11.

179. Solomon GD. Verapamil and propranolol in migraine prophylaxis: a double-blind crossover study. *Headache*; 1986. p. 325.

180. Ryan RE, Sr. Comparative study of nadolol and propranolol in prophylactic treatment of migraine. *Am Heart J.* 1984 Oct;108(4 Pt 2):1156-9. PMID 6148878.

181. Olsson JE, Behring HC, Forssman B, et al. Metoprolol and propranolol in migraine prophylaxis: A double-blind multicentre study. *Acta Neurol Scand*; 1984. p. 160-8.

182. Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. *Cephalalgia.* 2002 Apr;22(3):209-21. PMID 12047461.

183. Louis P, Schoenen J, Hedman C. Metoprolol v. clonidine in the prophylactic treatment of migraine. *Cephalalgia.* 1985 Sep;5(3):159-65. PMID 3899370.

184. Langohr HD, Gerber WD, Koletzki E, et al. Clomipramine and metoprolol in migraine prophylaxis--a double-blind crossover study. *Headache.* 1985 Mar;25(2):107-13. PMID 3886599.

185. Grottemeyer KH, Scharafinski HW, Schlake HP, et al. Acetylsalicylic acid vs. metoprolol in migraine prophylaxis--a double-blind cross-over study. *Headache.* 1990 Oct;30(10):639-41. PMID 2272812.

186. Worz R, Reinhardt-Benmalek B, Grottemeyer KH, et al. Bisoprolol and metoprolol in the prophylactic treatment of migraine with and without aura - A randomized double-blind cross-over

multicenter study. *Cephalalgia*; 1991. p. 152-3.

187. Worz R, Reinhardt-Benmalek B, Foeh M, et al. Migraine prophylaxis with bisoprolol. *Headache Quarterly*; 1992. p. 64-72.

188. Diener HC, Hartung E, Chrubasik J, et al. A comparative study of oral acetylsalicylic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study. *Cephalalgia*. 2001 Mar;21(2):120-8. PMID 11422094.

189. Schellenberg R, Lichtenthal A, Wohling H, et al. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment? *Headache*. 2008 Jan;48(1):118-25. PMID 18184294.

190. Togha M, Rahmat Jirde M, Nilavari K, et al. Cinnarizine in refractory migraine prophylaxis: efficacy and tolerability. A comparison with sodium valproate. *J Headache Pain*. 2008 Apr;9(2):77-82. PMID 18286231.

191. Sudilovsky A, Elkind AH, Ryan RE, Sr., et al. Comparative efficacy of nadolol and propranolol in the management of migraine. *Headache*. 1987 Sep;27(8):421-6. PMID 3312113.

192. NCT00742209. Prevention Study in Adult Patients Suffering From Migraine Headaches. 2010.

193. Holroyd KA, Cottrell CK, O'Donnell FJ, et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled

trial. *BMJ*. 2010;341:c4871. PMID 20880898.

194. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine--a double-blind placebo-controlled study. *Cephalalgia*. 1996 Oct;16(6):436-40. PMID 8902254.

195. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. *Cephalalgia*. 1996 Jun;16(4):257-63. PMID 8792038.

196. Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. *JAMA*. 1990 Oct 3;264(13):1711-3. PMID 2204739.

197. Masel BE, Chesson AL, Peters BH, et al. Platelet antagonists in migraine prophylaxis. A clinical trial using aspirin and dipyridamole. *Headache*; 1980. p. 13-8.

198. Solomon GD, Freitag FG, Mehta N, et al. Fenoprofen calcium in migraine prophylaxis - a double-blind, placebo controlled study. *Cephalalgia*; 1987. p. 473-4.

199. Solomon GD, Kunkel RS. Flurbiprofen in the prophylaxis of migraine. *Cleve Clin J Med*. 1993 Jan-Feb;60(1):43-8. PMID 8443934.

200. Anthony M, Lance JW. Indomethacin in migraine. *Med J Aust*. 1968 Jan 13;1(2):56-7. PMID 4867513.

201. Visser WH, Malbecq W, Strohmaier K, et al. Preventive treatment of migraine headache with rofecoxib. In: Olesen J, Silberstein SD, Tfelt Hansen P, eds. *Preventive Pharmacotherapy of Headache*

Disorders. Oxford: Oxford University Press; 2004:44-9.

202. Mikkelsen BM, Falk JV. Prophylactic treatment of migraine with tolfenamic acid. A comparative double-blind crossover study between tolfenamic acid and placebo. *Acta neurologica Scandinavica*; 1982. p. 105-11.

203. Brandes JL, Visser WH, Farmer MV, et al. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study. *Headache*. 2004 Jun;44(6):581-6. PMID 15186302.

204. Nelson CF, Bronfort G, Evans R, et al. The efficacy of spinal manipulation, amitriptyline and the combination of both therapies for the prophylaxis of migraine headache. *J Manipulative Physiol Ther*. 1998 Oct;21(8):511-9. PMID 9798179.

205. Holroyd KA, France JL, Cordingley GE, et al. Enhancing the effectiveness of relaxation-thermal biofeedback training with propranolol hydrochloride. *J Consult Clin Psychol*. 1995 Apr;63(2):327-30. PMID 7751496.

206. Streng A, Linde K, Hoppe A, et al. Effectiveness and tolerability of acupuncture compared with metoprolol in migraine prophylaxis. *Headache*. 2006 Nov-Dec;46(10):1492-502. PMID 17115982.

207. Seng EK, Holroyd KA. Dynamics of changes in self-efficacy and locus of control expectancies in the behavioral and drug treatment of severe migraine. *Annals of behavioral medicine : a publication of the Society of Behavioral Medicine*; 2010. p. 235-47.

208. Wang LP, Zhang XZ, Guo J, et al. Efficacy of acupuncture for migraine prophylaxis: a single-blinded, double-

dummy, randomized controlled trial. *Pain*. 2011 Aug;152(8):1864-71. PMID 21616596.

209. Dahlof C. No clearcut longterm prophylactic effect of one month of treatment with propranolol in migraineurs. *Cephalalgia*; 1987. p. 459-60.

210. Lemstra M, Stewart B, Olszynski WP. Effectiveness of multidisciplinary intervention in the treatment of migraine: a randomized clinical trial. *Headache*. 2002 Oct;42(9):845-54. PMID 12390609.

211. Matchar DB, Harpole L, Samsa GP, et al. The headache management trial: a randomized study of coordinated care. *Headache*. 2008 Oct;48(9):1294-310. PMID 18547268.

212. Rothrock JF, Parada VA, Sims C, et al. The impact of intensive patient education on clinical outcome in a clinic-based migraine population. *Headache*. 2006 May;46(5):726-31. PMID 16643574.

213. Fritsche G, Frettlöh J, Hüppe M, et al. Prevention of medication overuse in patients with migraine. *Pain*; 2010. p. 404-13.

214. Sondergaard J, Foged A, Kragstrup J, et al. Intensive community pharmacy intervention had little impact on triptan consumption: a randomized controlled trial. *Scand J Prim Health Care*. 2006 Mar;24(1):16-21. PMID 16464810.

215. Hoffmann W, Herzog B, Muhlig S, et al. Pharmaceutical care for migraine and headache patients: a community-based, randomized intervention. *Ann Pharmacother*. 2008 Dec;42(12):1804-13. PMID 19001531.

216. Fritsche G, Diener H-C. Medication overuse headaches -- what is new? *Expert Opinion on Drug Safety*. 2002 Nov;1(4):331-8. PMID 12904133.
217. Guyuron B, Rose K, Kriegler JS, et al. Hourglass deformity after botulinum toxin type A injection. *Headache*. 2004 Mar;44(3):262-4. PMID 15012666.
218. Omoigui S, Irene S. Treatment of ptosis as a complication of botulinum toxin injection. *Pain Medicine*. 2005 Mar-Apr;6(2):149-51. PMID 15773880.
219. Villani V, Ciuffoli A, Prosperini L, et al. Zonisamide for migraine prophylaxis in topiramate-intolerant patients: an observational study. *Headache*. 2011 Feb;51(2):287-91. PMID 21284610.
220. Ashkenazi A, Benlifer A, Korenblit J, et al. Zonisamide for migraine prophylaxis in refractory patients. *Cephalalgia*. 2006 Oct;26(10):1199-202. PMID 16961786.
221. Pizza V, Busillo V, Agresta A, et al. Elderly patients with migraine: an open-label study on prophylaxis therapy with levetiracetam. *Cent Nerv Syst Agents Med Chem*. 2011 Mar 1;11(1):31-4. PMID 21250937.
222. Vukovic V, Lovrencic-Huzjan A, Bosnar-Puretic M, et al. The efficacy of gabapentin in migraine prophylaxis: an observational open label study. *Acta Clinica Croatica*. 2009 Jun;48(2):145-51. PMID 19928412.
223. Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term Safety of Depakote in Headache Prophylaxis Study Group. *Headache*. 1999 Oct;39(9):633-43. PMID 11284461.
224. Kinze S, Clauss M, Reuter U, et al. Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study. *Headache*. 2001 Sep;41(8):774-8. PMID 11576201.
225. Vijayan N, Spillane T. Valproic acid treatment of chronic daily headache. *Headache*. 1995 Oct;35(9):540-3. PMID 8530278.
226. Ghose K. Efficacy and safety of long-term sodium valproate therapy in the prophylaxis of migraine headache. *Headache Quarterly*. 1999;10(2):127-30.
227. Anthony M, Lance JW, Somerville B. A comparative trial of prindolol, clonidine and carbamazepine in the interval therapy of migraine. *Med J Aust*; 1972. p. 1343-6.
228. Rosen JA. Observations on the efficacy of propranolol for the prophylaxis of migraine. *Ann Neurol*. 1983 Jan;13(1):92-3. PMID 6338806.
229. Steardo L, Bonuso S, Di Stasio E, et al. Selective and non-selective beta-blockers: are both effective in prophylaxis of migraine? A clinical trial versus methysergide. *Acta Neurol (Napoli)*; 1982. p. 196-204.
230. Curran DA, Lance JW. Clinical Trial of Methysergide and Other Preparations in the Management of Migraine. *J Neurol Neurosurg Psychiatry*. 1964 Oct;27:463-9. PMID 14213477.
231. Kim MD, Lee G, Shin SW. Ergotamine-induced upper extremity ischemia: a case report. *Korean Journal of Radiology*. 2005 Apr-Jun;6(2):130-2. PMID 15968153.

232. Bavrasad R. Assessment of the middle-dose of topiramate in comparison with sodium valproate for migraine prophylaxis: a randomized double-blind study. *International Journal of Pharmacology*. 2010;6(5):670-5.
233. Bousser MG, Chick J, Fuseau E, et al. Combined low-dose acetylsalicylic acid and dihydroergotamine in migraine prophylaxis. A double-blind, placebo-controlled crossover study. *Cephalalgia : an international journal of headache*; 1988. p. 187-92.
234. Saper JR, Lake AE, 3rd, Cantrell DT, et al. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. *Headache*. 2002 Jun;42(6):470-82. PMID 12167135.
235. Diamond S, Solomon GD, Freitag FG, et al. Fenopropfen in the prophylaxis of migraine: a double-blind, placebo controlled study. *Headache*; 1987. p. 246-9.
236. Nadelmann JW, Phil M, Stevens J, et al. Propranolol in the prophylaxis of migraine. *Headache*. 1986 Apr;26(4):175-82. PMID 3519529.
237. Welch KMA, Ellis DJ, and Keenan PA. Successful migraine prophylaxis with naproxen sodium. *Neurology*; 1985.
238. Welch KM. Naproxen sodium in the treatment of migraine. *Cephalalgia*; 1986. p. 85-92.
239. Ziegler DK, Ellis DJ. Naproxen in prophylaxis of migraine. *Archives of neurology*; 1985. p. 582-4.
240. Frediani F, Grazzi L, Zanotti A, et al. Dihydroergocryptine versus dihydroergotamine in migraine prophylaxis: a double-blind clinical trial. *Cephalalgia*. 1991 Jul;11(3):117-21. PMID 1909603.
241. Bisceglia A, Cesarino F, Cerbo R, et al. Lisuride prophylactic treatment of migraine: A double blind study at two different dosages. *New Trends in Clinical Neuropharmacology*; 1990. p. 35-40.
242. Rodríguez-Leyva I. Topiramate versus amitriptyline in prophylactic treatment of migraine: a controlled clinical trial. *Revista Mexicana de Neurociencia*. 2010;11(5):338-42.
243. Afshari D, Rafizadeh S, Rezaei M. A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis. *Int J Neurosci*. 2012 Feb;122(2):60-8. PMID 21950578.
244. Micieli G, Cavallini A, Marcheselli S, et al. Alpha-dihydroergocryptine and predictive factors in migraine prophylaxis. *Int J Clin Pharmacol Ther*. 2001 Apr;39(4):144-51. PMID 11332869.